PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Alderson, AL; Novack, TA				Alderson, AL; Novack, TA			Reliable serial measurement of cognitive processes in rehabilitation: The cognitive log	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						cognition; neuropsychology; rehabilitation	TRAUMATIC BRAIN INJURY; GALVESTON ORIENTATION; AMNESIA TEST; STATE	Objective: To evaluate the reliability and utility of a brief quantitative measure of cognitive recovery, the Cognitive Log (Cog-Log), developed for daily use with rehabilitation inpatients to provide information about the recovery of higher neurocognitive processes including verbal recall, attention, working memory, motor sequencing, and response inhibition. Design: Descriptive study of the Cog-Log's normative scores, reliability (interrater, internal consistency), and validity as shown by its relationship to standard neuropsychologic measures. Setting: Inpatient rehabilitation hospital affiliated with a large university medical center. Participants: One hundred fifty neurorchabilitation inpatients with acquired brain injury; 83 young adults without acquired brain injury were included to provide normative data. Interventions: Not applicable. Main Outcome Measures: The Cog-Log; standardized neuropsychologic measures of memory (Wechsler Memory Scale-Revised, Rey Auditory Verbal Learning Test), language, attention (Wechsler Adult Intelligence Scale-Revised), and reasoning (Trail Making Test). Results: Reliability analysis showed strong interrater reliability across items (Spearman r,.749-1.0.0) and high internal consistency (Cronbach alpha =.778). Factor an alysis of the Cog-Log using principal components extraction revealed a unitary factor (eigenvalue=3.48). Cog-Log items designed to measure working. memory and immediate and delayed verbal memory were most strongly predictive of performance on similar standardized neuropsychologic measures administered on the same day. Conclusion: The Cog-Log appears to be a reliable and efficient tool for measuring ongoing neurocognitive recovery during inpatient rehabilitation.	Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA	Alderson, AL (corresponding author), Shepherd Ctr, 2020 Peachtree Rd NW, Atlanta, GA 30309 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07420] Funding Source: Medline		FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Israelian MK, 2000, REHABIL PSYCHOL, V45, P284, DOI 10.1037/0090-5550.45.3.284; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; *NO CAL NEUR GROUP, 1995, COGN NEUR COGN STAT; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635	9	26	26	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2003	84	5					668	672		10.1016/S0003-9993(03)04842-6			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	675NF	WOS:000182700900008	12736879				2021-06-18	
J	Emery, E				Emery, E			Intrathecal baclofen. Literature review of the results and complications	NEUROCHIRURGIE			French	Article; Proceedings Paper	53rd Annual Congress of the Societe-De-Neurochirurgie-De-Langue-Francaise	MAY 09-12, 2003	TOZEUR, TUNISIA	Soc Neurochirurgie Langue Francaise		spasticity; baclofen; intrathecal; results; functional gain; complication; quality of life	SEVERE SPINAL SPASTICITY; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN INJURY; TERM FOLLOW-UP; CEREBRAL-PALSY; INTRACTABLE SPASTICITY; FUNCTIONAL IMPROVEMENT; SUPRASPINAL SPASTICITY; ADMINISTERED BACLOFEN; CORD SPASTICITY	Intrathecally delivered baclofen has been used as a treatment for severe spasticity since 1984. A systematic literature review was conducted from 1984 to December 2002 to analyze the results of this treatment and to collect data on complications. Studies were included if the following criteria were met clear selection of patients suffering from spasticity of spinal or cerebral origin, clear measurements of outcome (Ashworth score, Spasm score and/or reflex score and/or functional scales), average follow-up of at least 6 months. Almost all the studies had open follow-up with no control groups (controls were used to examine the effect of test doses of baclofen rather than to assess long-term results). Studies often included heterogeneous patients groups with different causes of spasticity (spinal and/or cerebral etiology) and functional outcome was measured using different scales from one study to another. This literature review shows evidence that intrathecally administered baclofen is effective in reducing the positive signs of spasticity (tone, spasms, reflex activity). Significant reductions in spasm-related pain were noted. The reduction in spasticity led to improvement in ability to transfer and ease of nursing care in the majority of patients. Significant improvements were noted in terms of mobility. Benefits were most notable in bedridden patients who became able to sit in a wheelchair. Many benefited from improved wheelchair mobility, ability to sit down comfortably, and improvement in their ability to transfer. Such benefits were approved by all the patients as an improvement of their quality of life. Ambulatory patients could also benefit from an improved gait but were less often treated because they usually relied upon their spasticity for support during ambulation. Complications were rather rare and mainly were not life-threatening, although there was a high rate of catheter dysfunction (10 to 45 %) leading to reoperation. Wound complications were the leading cause of explantation in children with cerebral palsy. Despite the risks, patient satisfaction was high and was related to the improvement of the quality of life.	CHU Caen, Serv Neurochirurg, F-14033 Caen, France	Emery, E (corresponding author), CHU Caen, Serv Neurochirurg, Ave Cote Nacre, F-14033 Caen, France.						ABEL NA, 1994, ARCH PHYS MED REHAB, V75, P54; AKMAN MN, 1993, PARAPLEGIA, V31, P516, DOI 10.1038/sc.1993.84; ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418; Albright AL, 1996, J CHILD NEUROL, V11, pS29, DOI 10.1177/0883073896011001S05; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; Armstrong RW, 1997, J NEUROSURG, V87, P409, DOI 10.3171/jns.1997.87.3.0409; Azouvi P, 1996, ARCH PHYS MED REHAB, V77, P35, DOI 10.1016/S0003-9993(96)90217-8; Barnes MP, 2001, GERONTOLOGY, V47, P295, DOI 10.1159/000052817; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; BENNETT MI, 1994, PAIN, V56, P243, DOI 10.1016/0304-3959(94)90100-7; BROSETA J, 1990, STEREOT FUNCT NEUROS, V54-5, P147, DOI 10.1159/000100205; Burns AS, 2001, SPINAL CORD, V39, P413, DOI 10.1038/sj.sc.3101178; Butler C, 2000, DEV MED CHILD NEUROL, V42, P634, DOI 10.1017/S0012162200001183; CAMPBELL SK, 1995, PHYS THER, V75, P352, DOI 10.1093/ptj/75.5.352; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; CONCALVES J, 1994, STEREOT FUNCT NEUROS, V62, P108, DOI 10.1159/000098605; Dario A, 2001, FUNCT NEUROL, V16, P311; Dario A, 2002, ACTA NEUROL SCAND, V105, P83, DOI 10.1034/j.1600-0404.2002.1o042.x; DELHAAS EM, 1991, INT J CLIN PHARM TH, V29, P274; Denys P, 1998, ARCH PHYS MED REHAB, V79, P494, DOI 10.1016/S0003-9993(98)90061-2; Fakhoury T, 1998, ELECTROEN CLIN NEURO, V107, P339, DOI 10.1016/S0013-4694(98)00085-6; Galloway A, 2000, SPINAL CORD, V38, P126, DOI 10.1038/sj.sc.3100954; Gerszten PC, 1998, J NEUROSURG, V88, P1009, DOI 10.3171/jns.1998.88.6.1009; Gerszten PC, 1997, PEDIATR NEUROSURG, V27, P40, DOI 10.1159/000121223; Gilmartin R, 2000, J CHILD NEUROL, V15, P71, DOI 10.1177/088307380001500201; Gormley ME, 2001, EUR J NEUROL, V8, P127, DOI 10.1046/j.1468-1331.2001.00045.x; Green LB, 1999, ARCH PHYS MED REHAB, V80, P1600, DOI 10.1016/S0003-9993(99)90337-4; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Huch K, 1999, SPINAL CORD, V37, P648, DOI 10.1038/sj.sc.3100880; Huraibi HA, 2000, ANESTH ANALG, V91, P429, DOI 10.1097/00000539-200008000-00037; Ivanhoe C B, 2001, Phys Med Rehabil Clin N Am, V12, P923; KOFLER M, 1992, ELECTROEN CLIN NEURO, V83, P83, DOI 10.1016/0013-4694(92)90136-6; KOFLER M, 1994, NEUROLOGY, V44, P25, DOI 10.1212/WNL.44.1.25; Lazorthes Y, 1998, NEUROCHIRURGIE, V44, P201; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; Levin AB, 1995, STEREOT FUNCT NEUROS, V65, P147, DOI 10.1159/000098887; LOUBSER PG, 1991, PARAPLEGIA, V29, P48, DOI 10.1038/sc.1991.7; Marquardt G, 2002, J NEUROL NEUROSUR PS, V72, P275, DOI 10.1136/jnnp.72.2.275; Marquardt G, 1999, J NEUROL, V246, P619, DOI 10.1007/s004150050417; MCLEAN BN, 1993, BRIT J HOSP MED, V49, P262; Mertens P, 1995, ADV STER F, V11, P17; MEVTHALER JM, 2001, STROKE, V32, P2099; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1999, AM J PHYS MED REHAB, V78, P247, DOI 10.1097/00002060-199905000-00012; MEYTHALER JM, 1992, AM J PHYS MED REHAB, V71, P321, DOI 10.1097/00002060-199212000-00003; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; Middel B, 1997, J NEUROL NEUROSUR PS, V63, P204, DOI 10.1136/jnnp.63.2.204; MULLERSCHWEFE G, 1989, J NEUROSURG, V71, P273, DOI 10.3171/jns.1989.71.2.0273; Murphy NA, 2002, ARCH PHYS MED REHAB, V83, P1721, DOI 10.1053/apmr.2002.36068; NANCE P, 1995, CAN J NEUROL SCI, V22, P22, DOI 10.1017/S0317167100040452; Nielsen JF, 2002, CLIN NEUROL NEUROSUR, V104, P142, DOI 10.1016/S0303-8467(02)00009-4; Ochs GA, 1996, J NEUROL REHABIL, V10, P159; Ordia JI, 1996, J NEUROSURG, V85, P452, DOI 10.3171/jns.1996.85.3.0452; PARKE B, 1989, ARCH PHYS MED REHAB, V70, P30; PENN RD, 1985, LANCET, V2, P125; PENN RD, 1987, J NEUROSURG, V66, P181, DOI 10.3171/jns.1987.66.2.0181; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1984, LANCET, V1, P1078; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Pirotte B, 1995, ACTA NEUROL BELG, V95, P216; Rawicki B, 1999, J NEUROSURG, V91, P733, DOI 10.3171/jns.1999.91.5.0733; Reeves RK, 1998, ARCH PHYS MED REHAB, V79, P353, DOI 10.1016/S0003-9993(98)90021-1; Rifici C, 1994, Funct Neurol, V9, P29; SAHUQUILLO J, 1991, ACTA NEUROCHIR, V110, P166, DOI 10.1007/BF01400686; Saltuari L, 1992, Acta Neurol (Napoli), V14, P187; Sampson FC, 2002, J NEUROSURG, V96, P1052, DOI 10.3171/jns.2002.96.6.1052; Scheinberg AM, 2001, J PAEDIATR CHILD H, V37, P283, DOI 10.1046/j.1440-1754.2001.00676.x; Stempien L, 2000, AM J PHYS MED REHAB, V79, P536, DOI 10.1097/00002060-200011000-00010; Stewart-Wynne E G, 1991, Clin Exp Neurol, V28, P244; TEDDY P, 1992, BRIT J NEUROSURG, V6, P115, DOI 10.3109/02688699209002912; Van Schaeybroeck P, 2000, NEUROSURGERY, V46, P603, DOI 10.1097/00006123-200003000-00017; Zed PJ, 2000, J NEUROSURG, V92, P347, DOI 10.3171/jns.2000.92.2.0347; Zierski J, 1988, Acta Neurochir Suppl (Wien), V43, P94	75	26	30	0	1	MASSON EDITEUR	PARIS 06	120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE	0028-3770			NEUROCHIRURGIE	Neurochirurgie	MAY	2003	49	2-3	2				276	288					13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	679JM	WOS:000182917100017	12746703				2021-06-18	
J	Filipetti, P; Decq, P				Filipetti, P; Decq, P			Interest of anesthetic blocks for assessment of the spastic patient. A series of 815 motor blocks	NEUROCHIRURGIE			French	Article; Proceedings Paper	53rd Annual Congress of the Societe-De-Neurochirurgie-De-Langue-Francaise	MAY 09-12, 2003	TOZEUR, TUNISIA	Soc Neurochirurgie Langue Francaise		spasticity; local anesthetic block		Background - The purpose of the study was to emphasize the value of anesthetic blocks in the approach to the spastic patient. The report relates our experience concerning 566 patients (ranging in age from 4 to 72 years, mean 48 years) tested by 815 motor blocks performed within a "spasticity and dystonia evaluation" unit. The spasticity was mainly (lute to stroke (56%), cerebral palsy (21%) and traumatic brain injury (14%). Methods. - Motor blocks were performed with standardized procedure (specific needle, neurostimulator, localization technique), analytic and functional assessment. Results. - The anesthetic was mostly 1% non-adrenalized etidocaine, chosen for its onset and duration of action. Re-injections were few and side effects exeptional. Quality and motor blocks results were technique-dependent and required patient cooperation. The spasticity disappeared in blocked muscles. Tardieu and Ashworth modified scale showed constantly decreased spasticity (2 to 3 points) with better sensitivity for the Tardieu modified score. Local anesthetic blocks determined the relative contributions of overactivity and of muscle shortening in the generation of the pathologic posture, the muscle or muscles responsable for the spastic pattern and the level of active performance of the antagonistic muscle. New stability was evaluated by functional assessment of gait posture and prehension. Conclusion. - At the present time, anesthetic motor blocks represent a necessary and decisive stage procedure as regards spastic patient assessment. This method is particularly useful to anticipate a new functional balance and simulate treatment. Motor blocks provide acute knowledge of the pathological pattern and a better adjustment of therapeutic directions.	Hop Henri Mondor, Serv Neurochirurg, Grp Evaluat & Traitement Spast & Dystonie, F-94010 Creteil, France; Ctr Reg Specialise Arche, Le Mans, France	Filipetti, P (corresponding author), Hop Henri Mondor, Serv Neurochirurg, Grp Evaluat & Traitement Spast & Dystonie, F-94010 Creteil, France.						ARENDZEN JH, 1992, SCAND J REHABIL MED, V24, P75; ASHWORTH B, 1964, PRACTITIONER, V192, P540; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BONNET F, 1995, ACTUALITE ANESTHESIE, P157; BOYD RN, 1998, DEV MED CHILD NEUROL, V40, P7; DECQ P, 2000, NEUROTOMIES PERIPHER, V3; DUK HS, 2000, ARCH PHYS MED REHAB, V81, P910; FILIPETTI P, 1988, ANN READAPT MED PHYS, V41, P23; GAUTHIERLAFAYE P, 1994, PRECIS ANESTHESIE LO; KHALILI ALIA, 1966, CLIN ORTHOP RELAT RES, V47, P97; LECRON L, 1989, ANESTHESIE LOCO REGI; Liddell EGT, 1924, P R SOC LOND B-CONTA, V96, P212, DOI 10.1098/rspb.1924.0023; Liljestrand G, 1919, PFLUG ARCH GES PHYS, V176, P168, DOI 10.1007/BF01722339; MAHONEY F I, 1965, Md State Med J, V14, P61; PENN RD, 1985, LANCET, V2, P125; PIERROTDESEILLI.E, 2000, CLOSTRIDIUM, V3; PINZUR MS, 1985, J HAND SURG-AM, V10A, P547, DOI 10.1016/S0363-5023(85)80081-2; TARDIEU G., 1964, ARCH FRANC PEDIAT, V21, P25; TARDIEU G, 1954, REV NEUROL, V91, P143; Walshe FMR, 1924, BRAIN, V47, P159, DOI 10.1093/brain/47.2.159; YASUDA I, 1980, BRIT J ANAESTH, V52, P409, DOI 10.1093/bja/52.4.409; Zancolli ER., 1979, STRUCTURAL DYNAMIC B, Ved 2	22	26	27	0	4	MASSON EDITEUR	PARIS 06	120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE	0028-3770			NEUROCHIRURGIE	Neurochirurgie	MAY	2003	49	2-3	2				226	238					13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	679JM	WOS:000182917100011	12746697				2021-06-18	
J	Yunoki, M; Kawauchi, M; Ukita, N; Sugiura, T; Ohmoto, T				Yunoki, M; Kawauchi, M; Ukita, N; Sugiura, T; Ohmoto, T			Effects of lecithinized superoxide dismutase on neuronal cell loss in CA3 hippocampus after traumatic brain injury in rats	SURGICAL NEUROLOGY			English	Article						neuronal cell loss; superoxide dismutase; traumatic brain injury	POLYETHYLENE-GLYCOL; TIME-COURSE; EDEMA; LINES	BACKGROUND The protective effect of excitatory amino acid antagonists for CA3 hippocampal neuronal loss has been well documentated. From a clinical point of view, however, alternative therapies should also be explored because excitatory amino acid antagonists have relatively deleterious side effects. Administration of lecithinized superoxide dismutase (PC-SOD) has recently been demonstrated to reduce brain edema after traumatic brain injury (TBI) in the cerebral cortex. In this study, we investigated the effectiveness of PC-SOD on CA3 hippocampal cell loss by examining hematoxylin and eosin-stained sections. METHODS Rats were divided at random into three groups. The first group received 1 mL of saline (contusion + saline group, n = 5). Rats of the second group were treated with 3000 IU/kg of PC-SOD (contusion + SOD I group, n = 5), while the third group received 5000 IU/kg of PC-SOD (contusion + SOD 2 group, n = 5). All agents were administered intraperitoneally 1 minute after traumatic insult and every 24 hours until 2 or 3 days post-TBI. Animals were sacrificed 3 or 7 days after contusion injury. RESULTS PC-SOD prevented CA3 neuronal loss 3 days after TBI, and increased the number of surviving CA3 neurons 7 days after TBI. CONCLUSION Our findings suggest that PC-SOD may serve as a pharmacological agent in the treatment of neuronal loss after TBI. (C) 2003 Elsevier Science Inc.	Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 700, Japan	Yunoki, M (corresponding author), Okayama Univ, Sch Med, Dept Neurol Surg, 2-5-1 Shikata Cho, Okayama 700, Japan.						Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; CHOI D, 1981, J NEUROBIOL, V23, P1261; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; FUKUHARA T, 1994, NEUROSURGERY, V35, P924, DOI 10.1227/00006123-199411000-00018; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HE YY, 1993, AM J PHYSIOL, V265, pH252; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; IGARASHI R, 1994, J PHARMACOL EXP THER, V271, P1672; IGARASHI R, 1992, J PHARMACOL EXP THER, V262, P1214; Iijima T, 1998, J NEUROTRAUM, V15, P277, DOI 10.1089/neu.1998.15.277; KARLSSON K, 1989, LAB INVEST, V60, P659; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MAEDA T, 1996, NEUROTRAUMATOLOGY, V19, P162; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Nakauchi K, 1996, J NEUROTRAUM, V13, P573, DOI 10.1089/neu.1996.13.573; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; VERONESE FM, 1983, J PHARM PHARMACOL, V35, P757, DOI 10.1111/j.2042-7158.1983.tb02888.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Young W, 1992, J NEUROTRAUMA S1, V9, P9; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739	27	26	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	MAR	2003	59	3					156	161		10.1016/S0090-3019(02)01040-6			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	665JA	WOS:000182115400005	12681536				2021-06-18	
J	Baker, AM; Craig, BR; Lonergan, GJ				Baker, AM; Craig, BR; Lonergan, GJ			Homicidal commotio cordis: the final blow in a battered infant	CHILD ABUSE & NEGLECT			English	Article						homicide; commotio cordis; precordial	SUDDEN-DEATH; EXPERIMENTAL-MODEL; SPORTS ACTIVITIES; CARDIAC-ARREST; IMPACT; YOUNG	Objective: This report describes in detail the occurrence of inflicted commotio cordis (cardiac concussion) in a previously abused 7-week-old. Though inflicted commotio cordis has been reported in three toddlers, this is the first report in a young infant. Method: Following documentation of abuse in a living child, the case of a death of a prior sibling-previously regarded as natural-was re-opened for further investigation. Original autopsy materials were reviewed, and the body of the deceased child was exhumed. Results: Exhumation and second autopsy documented more than 50 fractures in the deceased child. When re-interviewed, the children's father admitted to causing the injuries in both children, and gave a textbook description of commotio cordis as the mechanism of death in the fatal case. Conclusions: Commotio cordis is a rare event in which a fatal dysrhythmia-usually ventricular fibrillation-is precipitated by a blow to the precordial chest. Previous reports have indicated that homicidal commotio cordis can occur in small children. This report demonstrates that commotio cordis can occur even in the very young, previously abused infant. Published by Elsevier Science Ltd.	Off Armed Forces Med Examiner, Rockville, MD USA; Armed Forces Ctr Child Protect, Bethesda, MD USA; Armed Forces Inst Pathol, Dept Radiol Pathol, Pediat Radiol Div, Washington, DC USA	Baker, AM (corresponding author), Hennepin Cty Med Examiners Off, 530 Chicago Ave, Minneapolis, MN 55415 USA.						ABRUNZO TJ, 1991, AM J DIS CHILD, V145, P1279, DOI 10.1001/archpedi.1991.02160110071023; Boglioli LR, 1998, PEDIATR CARDIOL, V19, P436, DOI 10.1007/s002469900347; Denton JS, 2000, J FORENSIC SCI, V45, P734; FRAZER M, 1984, AM J FOREN MED PATH, V5, P249, DOI 10.1097/00000433-198409000-00015; Link M S, 1999, Cardiol Rev, V7, P265, DOI 10.1097/00045415-199909000-00010; Link MS, 1998, NEW ENGL J MED, V338, P1805, DOI 10.1056/NEJM199806183382504; Link MS, 2001, J AM COLL CARDIOL, V37, P649, DOI 10.1016/S0735-1097(00)01142-6; Maron BJ, 1997, AM J CARDIOL, V79, P840, DOI 10.1016/S0002-9149(96)00887-9; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; Maron BJ, 1999, J CARDIOVASC ELECTR, V10, P114, DOI 10.1111/j.1540-8167.1999.tb00648.x; Maron BJ, 2002, AM J CARDIOL, V89, P210, DOI 10.1016/S0002-9149(01)02202-0; Michalodimitrakis EN, 1997, AM J FOREN MED PATH, V18, P282, DOI 10.1097/00000433-199709000-00010; Perron AD, 2001, AM J EMERG MED, V19, P406, DOI 10.1053/ajem.2001.24455	13	26	26	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134			CHILD ABUSE NEGLECT	Child Abuse Negl.	JAN	2003	27	1					125	130	PII S0145-2134(02)00511-2	10.1016/S0145-2134(02)00511-2			6	Family Studies; Psychology, Social; Social Work	Family Studies; Psychology; Social Work	635VG	WOS:000180419900009	12510035				2021-06-18	
J	Gottfried, JA; Sancar, F; Chatterjee, A				Gottfried, JA; Sancar, F; Chatterjee, A			Acquired mirror writing and reading: evidence for reflected graphemic representations	NEUROPSYCHOLOGIA			English	Article						reading; dysgraphia; dyslexia; traumatic brain injury	LEFT-HANDERS; DYSLEXIA; STIMULI; INFARCTION; ACTIVATION; REVERSALS; BEHAVIOR; CORTEX; FMRI	Mirror writing occurs when individual letters and whole word strings are produced in reverse direction. By analogy, mirror reading refers to the preference to read mirror reversed over normally written words. These phenomena appear rarely after brain damage and offer insight into the nervous system's organization of visual-spatial and visual-motor representations. We present the case of a 51-year-old patient with persistent mirror writing and reading following traumatic brain injury. She preferred to write in the mirror direction with either hand. She drew asymmetric pictures with the same directional bias as normal right-handed subjects, and she did not exhibit left-right confusion regarding other pictures. By contrast, on picture-word matching and lexical decision tasks, she was faster and more accurate with mirrored than normally written words. This pattern of performance suggests that her behavior was not accounted for by reflected motor programs, or by the mirroring of visual-spatial representations in general. Rather, we suggest that her behavior was produced by privileged access to mirrored graphemes. Furthermore, because she seemed better able to read irregular words in mirrored than in normal formats, we suggest that mirrored representations may exist at the whole word level and not simply at the letter level. (C) 2003 Elsevier Science Ltd. All rights reserved.	Hosp Univ Penn, Ctr Cognit Neurosci, Dept Neurol, Philadelphia, PA 19104 USA	Chatterjee, A (corresponding author), Hosp Univ Penn, Ctr Cognit Neurosci, Dept Neurol, 3 W Gates,3400 Spruce St, Philadelphia, PA 19104 USA.				NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC 04817] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 37539] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC004817] Funding Source: NIH RePORTER		ACHIM A, 1977, NEUROPSYCHOLOGIA, V15, P475, DOI 10.1016/0028-3932(77)90102-6; BERLUCCHI G, 1972, BRAIN RES, V37, P371, DOI 10.1016/0006-8993(72)90708-1; BRIGGS G G, 1975, Cortex, V11, P230; Bruning J.L., 1977, COMPUTATIONAL HDB ST; BUXBAUM LJ, 1993, NEUROPSYCHOLOGIA, V31, P1417, DOI 10.1016/0028-3932(93)90108-C; CHAN JL, 1988, NEUROLOGY, V38, P59, DOI 10.1212/WNL.38.1.59; CHIA LG, 1987, NEUROSURGERY PSYCHIA, P50; Coltheart, 1992, PSYCHOLINGUISTIC ASS; Corballis M. C., 1976, PSYCHOL LEFT RIGHT; CORBALLIS MC, 1970, PSYCHOL REV, V77, P451, DOI 10.1037/h0029805; CRITCHLEY M, 1928, MIRROR WRITING; DELIS DC, 1986, NEUROPSYCHOLOGIA, V24, P205, DOI 10.1016/0028-3932(86)90053-9; Dong Y, 2000, BRAIN, V123, P790, DOI 10.1093/brain/123.4.790; ELLIS AW, 1988, HUMAN COGNITIVE NEUR; FEINBERG T, 1985, CORTEX, V21, P261, DOI 10.1016/S0010-9452(85)80031-9; FISCHER FW, 1978, CORTEX, V14, P496, DOI 10.1016/S0010-9452(78)80025-2; Goebel R, 1998, NEUROREPORT, V9, P713, DOI 10.1097/00001756-199803090-00028; Gonzalez-Rothi L. J., 1984, BATTERY ADULT READIN; HEILMAN KM, 1980, J NEUROL NEUROSUR PS, V43, P774, DOI 10.1136/jnnp.43.9.774; HOWARD D, 1992, BRAIN, V115, P1769, DOI 10.1093/brain/115.6.1769; Karev GB, 1999, CORTEX, V35, P423, DOI 10.1016/S0010-9452(08)70810-4; LambonRalph MA, 1997, NEUROCASE, V3, P249; Mello N K, 1965, Science, V149, P1519; MELLO NK, 1966, PHYSIOL BEHAV, V1, P293, DOI 10.1016/0031-9384(66)90020-5; NOBLE J, 1966, NATURE, V211, P1263, DOI 10.1038/2111263a0; NOBLE J, 1968, BRAIN RES, V10, P120; ORAM MW, 1994, J COGNITIVE NEUROSCI, V6, P99, DOI 10.1162/jocn.1994.6.2.99; Orton ST, 1928, J AMER MED ASSOC, V90, P1095, DOI 10.1001/jama.1928.02690410007003; PARADOWSKI W, 1971, PERCEPT MOTOR SKILL, V32, P617, DOI 10.2466/pms.1971.32.2.617; PERRETT DI, 1985, PROC R SOC SER B-BIO, V223, P293, DOI 10.1098/rspb.1985.0003; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; Poldrack RA, 1998, CEREB CORTEX, V8, P1, DOI 10.1093/cercor/8.1.1; PRICE C, 1996, CEREBRAL CORTEX, V6; RODRIGUEZ R, 1989, BRAIN LANG, V37, P122, DOI 10.1016/0093-934X(89)90104-1; Schott GD, 1999, LANCET, V354, P2158, DOI 10.1016/S0140-6736(99)07016-6; SCHOTT GD, 1980, J NEUROL NEUROSUR PS, V43, P768, DOI 10.1136/jnnp.43.9.768; Southwood MH, 1999, BRAIN LANG, V67, P1, DOI 10.1006/brln.1998.2046; STREIFLER M, 1976, CORTEX, V12, P356, DOI 10.1016/S0010-9452(76)80039-1; TANKLE RS, 1983, BRAIN LANG, V19, P115, DOI 10.1016/0093-934X(83)90058-5; TRUEMAN RH, 1965, POSTGRAD MED, V38, P469, DOI 10.1080/00325481.1965.11695681; Turnbull OH, 1996, NEUROCASE, V2, P63, DOI 10.1093/neucas/2.1.63; WADE JB, 1991, J CLIN EXP NEUROPSYC, V13, P299, DOI 10.1080/01688639108401045; ZANGWILL OL, 1972, NEUROPSYCHOLOGIA, V10, P371, DOI 10.1016/0028-3932(72)90029-2	43	26	28	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2003	41	1					96	107	PII S0028-3932(02)00130-6	10.1016/S0028-3932(02)00130-6			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	622WD	WOS:000179669500008	12427568				2021-06-18	
J	Herrmann, B				Herrmann, B			Child physical abuse. Physical findings and medical diagnosis	MONATSSCHRIFT KINDERHEILKUNDE			German	Article						child physical abuse; non accidental injury; medical diagnosis; physical findings; shaken baby syndrome	SHAKEN-INFANT SYNDROME; HEMORRHAGES	Child physical abuse may result in dramatic short and longtime damage of children's physical and emotional well being. Even after excluding abusive head injury, neurobiological research has demonstrated structural changes of the brain resulting from chronic child abuse. This underscores the clinician's special responsibility to contribute a sound professional and scientific approach to the multi professional diagnosis and intervention in suspected child abuse cases. Various traumatic changes of the skin,the skeletal system, the brain and other parts of the body may be caused by inflicted injuries. The essential approach is to correlate the probability of a given finding with the history and comparing it to physical and physiological principles of pediatric traumatology. Suspicious findings require a rational diagnostic strategy and consideration of numerous differential diagnoses. The skeletal survey and ophthalmologic retinal exam are of utmost importance. Of concern are especially all serious injuries with an alleged trivial mechanism, missing, vague or changing patterns of explanation, injury patterns inadequate for age, delay of medical care and allegations by independent observers or even the child. Without an adequate accidental explanation the strongest indicators of physical abuse are shaken baby syndrome, retinal hemorrhages, complex skull fractures, epi- and metaphyseal fractures, multiple fractures in different stages of healing, multiple bruising in an uncommon distribution, patterned bruises or burns, immersion burns and intramural duodenal hematoma. Several controversies and new developments in abuse research have derived and need to be considered.	Arztl Kinderschutzambulanz, Kinderklin Klinikums, D-34125 Kassel, Germany	Herrmann, B (corresponding author), Arztl Kinderschutzambulanz, Kinderklin Klinikums, Monchebergstr 43, D-34125 Kassel, Germany.	b.herrmann@t-online.de					*AAP, 2001, PEDIATRICS, V107, P437; Alexander RC, 2001, CHILD ABUSE MED DIAG, P47; ARMBRUSTER S, 2002, THESIS U KLIN MAINZ; Ayoub C. C., 2002, CHILD MALTREATMENT, V7, P103, DOI 10.1177/1077559502007002001; Bays J., 2001, CHILD ABUSE MED DIAG, P177; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Glaser D, 2000, J CHILD PSYCHOL PSYC, V41, P97, DOI 10.1111/1469-7610.00551; HERMANN B, 2000, KINDESMISSHAND VERNA, V4, P123; HUYER D, 1994, APSAC ADVISOR, V7, P5; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jenny C., 2001, CHILD ABUSE MED DIAG, P23; Kairys SW, 2001, PEDIATRICS, V108, P206; *KIND ZENTR BERL, 2000, KIND HANDL; Kleinman PK., 1998, DIAGNOSTIC IMAGING C, V2; Krous HF, 1999, PEDIATR DEVEL PATHOL, V2, P497, DOI 10.1007/s100249900156; Levin AV, 2000, RECENT ADV PAEDIAT, P151; Lloyd B, 1998, BRIT MED J, V317, P1538, DOI 10.1136/bmj.317.7172.1538; NASHELSKY MB, 1995, AM J FOREN MED PATH, V16, P154, DOI 10.1097/00000433-199506000-00016; Sane SM, 2000, PEDIATRICS, V105, P1345; Schwartz AJ, 1996, PEDIATRICS, V97, P254; Sorantin E, 2002, MONATSSCHR KINDERH, V150, P1068, DOI 10.1007/s00112-002-0565-1; Southall DP, 1997, PEDIATRICS, V100, P735, DOI 10.1542/peds.100.5.735; Stephenson T, 1996, ARCH DIS CHILD, V74, P53, DOI 10.1136/adc.74.1.53; Taylor D, 1999, EYE, V13, P3; THYEN U, 1991, MONATSSCHR KINDERH, V139, P292	27	26	27	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0026-9298	1433-0474		MONATSSCHR KINDERH	Mon.schr. Kinderheilkd.	NOV	2002	150	11					1324	+		10.1007/s00112-002-0610-0			14	Pediatrics	Pediatrics	623ED	WOS:000179689600002					2021-06-18	
J	Park, ES; Park, CI; Kim, DY; Kim, YR				Park, ES; Park, CI; Kim, DY; Kim, YR			The effect of spasticity on cortical somatosensory-evoked potentials: Changes of cortical somatosensory-evoked potentials after botulinum toxin type A injection	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						botulinum toxin type A; cerebral palsy; evoked potentials, somatosensory; rehabilitation; spasticity	CEREBRAL-PALSY; CONTRACTION; DYSTONIA; MUSCLE; INHIBITION; RHIZOTOMY; MOVEMENT; CHILDREN; LIMB	Objective: To evaluate the changes in cortical somatosensory-evoked potentials (SEPs) after botulinum toxin type A injection to determine what effect spasticity has on cortical SEPs. Design: Intervention study and before-after trial. Setting: University-affiliated hospital in Korea. Participants: Twelve children with spastic hemiplegic cerebral palsy (CP), 7 children with spastic diplegic CP, and 8 patients with traumatic brain injury. Intervention: All participants had botulinum toxin type A injected into the muscles of the spastic limb. Main Outcome Measures: SEPs were recorded before and 7 days after the botulinum toxin type A injection. Spasticity of the affected spastic limb was also measured. The short latency and amplitude of waves in SEPs were measured. The SEP results were divided into 3 groups: flat (no evoked potential), abnormal (evoked but delayed in latency), and normal (clear waveform with normal latency). Results: The normal response of cortical SEP increased after injection. The SEPs exhibited more frequent improvement in the limbs, with greater improvement of spasticity in grade (>1.0 grade) and in patients of younger age (<3y) after injection (P<.05). Conclusion: The observed improvement of cortical SEPs with associated reduction of spasticity that occurred after the botulinum toxin type A injection indicates that spasticity itself can be considered a factor affecting cortical SEPs.	Yonsei Univ, Coll Med, Dept Rehabil, Seoul 120752, South Korea; Yonsei Univ, Severance Hosp, Rehabil Dept, Coll Med, Seoul 120752, South Korea; Yonsei Univ, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Res Inst Rehabil Med, Seoul 120752, South Korea; Yonsei Univ, Cerebral Palsy & Pediat Sect, Seoul 120752, South Korea	Kim, YR (corresponding author), Yonsei Univ, Severance Hosp, Rehabil Dept, Coll Med, CPO Box 8044, Seoul 120752, South Korea.	221419@hanmail.net	kim, deog young/Q-8498-2019	Park, Eun Sook/0000-0002-9144-3063; kim, deog young/0000-0001-7622-6311			AALFS CM, 1993, ELECTROEN CLIN NEURO, V89, P437, DOI 10.1016/0168-5597(93)90118-9; ABBRUZZESE G, 1981, J NEUROL NEUROSUR PS, V44, P942, DOI 10.1136/jnnp.44.10.942; APPLEGATE C, 1988, EXP BRAIN RES, V71, P183; Aymard C, 2000, BRAIN, V123, P1688, DOI 10.1093/brain/123.8.1688; CAHAN LD, 1987, APPL NEUROPHYSIOL, V50, P459; CHERON G, 1987, ELECTROEN CLIN NEURO, V67, P537, DOI 10.1016/0013-4694(87)90056-3; Chuang TY, 1999, AM J PHYS MED REHAB, V78, P2, DOI 10.1097/00002060-199901000-00002; DUMITRU D, 1993, AM J PHYS MED REHAB, V72, P75, DOI 10.1097/00002060-199304000-00004; FILIPPI GM, 1993, ACTA OTO-LARYNGOL, V113, P400, DOI 10.3109/00016489309135834; GANTCHEV G, 1994, INT J PSYCHOPHYSIOL, V17, P191, DOI 10.1016/0167-8760(94)90062-0; Giladi N, 1997, J NEUROL SCI, V152, P132, DOI 10.1016/S0022-510X(97)00151-2; Halliday A., 1993, EVOKED POTENTIALS CL; JONES SJ, 1989, ELECTROEN CLIN NEURO, V74, P36, DOI 10.1016/0168-5597(89)90049-X; Kanovsky P, 1998, MOVEMENT DISORD, V13, P108, DOI 10.1002/mds.870130122; KUNDI M, 1989, ARCH NEUROL-CHICAGO, V46, P524, DOI 10.1001/archneur.1989.00520410058024; Lin YY, 2000, NEUROIMAGE, V11, P334, DOI 10.1006/nimg.1999.0536; Modugno N, 1998, MUSCLE NERVE, V21, P1701, DOI 10.1002/(SICI)1097-4598(199812)21:12<1701::AID-MUS12>3.0.CO;2-K; Morita H, 1998, EXP BRAIN RES, V120, P143, DOI 10.1007/s002210050388; Nishihira Y, 1996, Electromyogr Clin Neurophysiol, V36, P21; Parise M, 1997, STEREOT FUNCT NEUROS, V69, P268, DOI 10.1159/000099886; PFEIFFER FE, 1989, MUSCLE NERVE, V12, P473, DOI 10.1002/mus.880120607; PRIORI A, 1995, BRAIN, V118, P801, DOI 10.1093/brain/118.3.801; Rossini PM, 1996, MUSCLE NERVE, V19, P191, DOI 10.1002/(SICI)1097-4598(199602)19:2<191::AID-MUS11>3.0.CO;2-Y; RUSHTON DN, 1981, BRAIN, V104, P465, DOI 10.1093/brain/104.3.465; Tinazzi M, 1998, NEUROLOGY, V50, P1655, DOI 10.1212/WNL.50.6.1655; Wissel J, 1999, NEUROPEDIATRICS, V30, P120, DOI 10.1055/s-2007-973475; WONG PKH, 1982, ELECTROEN CLIN NEURO, V54, P266, DOI 10.1016/0013-4694(82)90176-6	27	26	29	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2002	83	11					1592	1596		10.1053/apmr.2002.34623			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	612TP	WOS:000179091800016	12422331				2021-06-18	
J	Varma, MR; Dixon, CE; Jackson, EK; Peters, GW; Melick, JA; Griffith, RP; Vagni, VA; Clark, RSB; Jenkins, LW; Kochanek, PM				Varma, MR; Dixon, CE; Jackson, EK; Peters, GW; Melick, JA; Griffith, RP; Vagni, VA; Clark, RSB; Jenkins, LW; Kochanek, PM			Administration of adenosine receptor agonists or antagonists after controlled cortical impact in mice: effects on function and histopathology	BRAIN RESEARCH			English	Article						excitotoxicity; head injury; hippocampus; Morris water maze; neuroprotection; purine; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; EXCITATORY AMINO-ACIDS; HEAD-INJURY; KINDLED SEIZURES; RAT HIPPOCAMPUS; 2-CHLOROADENOSINE; METABOLISM; CELLS; INTRAPERITONEAL	Adenosine is an endogenous neuroprotectant via anti-excitotoxic effects at A(1) receptors, and blood flow promoting and anti-inflammatory effects at A(2a) receptors. Previous studies showed improved motor function after fluid percussion injury (FPI) in rats treated with the broad-spectrum adenosine receptor agonist 2-chloroadenosine (2-CA). We studied the effects of 2-CA, a specific A(1) agonist (2-chloro-N-6-cyclopentyladenosine, CCPA), and a specific A(1) antagonist (8-cyclopentyl-1,3-dipropylxanthine, DPCPX) on motor task and Morris water maze (MWM) performance, and histopathology (contusion volume, hippocampal cell counts) after controlled cortical impact (CCI) in mice. Each agent (12 nmol), or respective vehicle (saline or DMSO) was injected into dorsal hippocampus beneath the contusion immediately after CCI or craniotomy (sham). 2-CA treatment attenuated wire grip deficits after CCI (P<0.05 versus other treatments). DPCPX treatment exacerbated deficits on beam balance (P<0.05 versus sham). No treatment effect was seen on MWM performance, although there was a deleterious effect of the DMSO vehicle used for DPCPX. Contusion volume tended to be attenuated by 2-CA (P=0.08 versus saline) and increased after either DMSO or DPCPX (P<0.05 versus all groups). CA1 and CA3 counts were decreased in all groups versus sham. However, treatment with the selective A(1) agonist CCPA attenuated the CA3 cell loss (P<0.05 versus other treatment). We suggest that the beneficial effect of the broad spectrum adenosine receptor agonist 2-CA on motor function after CCI is not mediated solely by effects at the A(1) receptor. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318, P01NS038037] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38037, NS 30318] Funding Source: Medline		Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Boison D, 1999, EXP NEUROL, V160, P164, DOI 10.1006/exnr.1999.7209; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; Costenla AR, 1999, EXP EYE RES, V68, P367, DOI 10.1006/exer.1998.0645; DECKERT J, 1988, BRAIN RES, V446, P161, DOI 10.1016/0006-8993(88)91308-X; DEMENDONCA A, 1994, NEUROSCIENCE, V62, P385, DOI 10.1016/0306-4522(94)90373-5; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dunwiddie Thomas V., 1997, P359; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feeney D M, 1987, Brain Inj, V1, P27, DOI 10.3109/02699058709034441; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; Geiger Jonathan D., 1997, P55; Grant MB, 1999, CIRC RES, V85, P699, DOI 10.1161/01.RES.85.8.699; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HAMM RJ, 1992, J NEUROTRAUMA S1, V9, pS173; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Jacobson KA, 1996, TRENDS PHARMACOL SCI, V17, P108, DOI 10.1016/0165-6147(96)10002-X; Kaputlu I, 1998, ANAESTHESIA, V53, P496, DOI 10.1046/j.1365-2044.1998.00330.x; Kemp N, 1997, NEUROSCI LETT, V225, P189, DOI 10.1016/S0304-3940(97)00221-8; Kochanek PM, 2001, MAGNET RESON MED, V45, P924, DOI 10.1002/mrm.1123; KOCHANEK PM, 2001, SOC NEUR ABSTR, V27; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Melani A, 1999, STROKE, V30, P2448, DOI 10.1161/01.STR.30.11.2448; Miller LP, 1999, STROKE THERAPY, P131; Mirnajafi-Zadeh J, 2000, BRAIN RES, V858, P48, DOI 10.1016/S0006-8993(99)02425-7; MITCHELL HL, 1995, NEUROSURGERY, V36, P1003, DOI 10.1227/00006123-199505000-00017; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Navarro JF, 2000, METHOD FIND EXP CLIN, V22, P43, DOI 10.1358/mf.2000.22.1.795830; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Ochiishi T, 1999, J COMP NEUROL, V411, P301; Ongini E, 1997, ANN NY ACAD SCI, V825, P30, DOI 10.1111/j.1749-6632.1997.tb48412.x; Pourgholami MH, 1997, BRAIN RES, V775, P37, DOI 10.1016/S0006-8993(97)00769-5; Pourgholami MH, 1997, BRAIN RES, V751, P259, DOI 10.1016/S0006-8993(96)01406-0; Puccio AM, 2000, CRIT CARE MED, V28, pA205; RUNCKEL DN, 1980, CLIN CHEM, V26, P1745; Sebastiao AM, 1996, PROG NEUROBIOL, V48, P167, DOI 10.1016/0301-0082(95)00035-6; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; VONLUBITZ DKJ, 1997, PURINERGIC APPROACHE, P449; vonLubitz DKJE, 1997, ANN NY ACAD SCI, V825, P49; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Wiesner JB, 1999, J PHARMACOL EXP THER, V289, P1669; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YU L, 1991, BRAIN RES, V540, P307, DOI 10.1016/0006-8993(91)90525-Z	51	26	28	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 4	2002	951	2					191	201	PII S0006-8993(02)03161-X	10.1016/S0006-8993(02)03161-X			11	Neurosciences	Neurosciences & Neurology	602TB	WOS:000178519600006	12270497				2021-06-18	
J	Marklund, N; Sihver, S; Langstrom, B; Bergstrom, M; Hillered, L				Marklund, N; Sihver, S; Langstrom, B; Bergstrom, M; Hillered, L			Effect of traumatic brain injury and nitrone radical scavengers on relative changes in regional cerebral blood flow and glucose uptake in rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow (CBF); FDG; fluid percussion; glucose uptake; HMPAO; nitrone; rat; reactive oxygen species; traumatic brain injury (TBI)	COMPRESSION CONTUSION TRAUMA; EXPERIMENTAL HEAD-INJURY; BUTYL-NITRONE; LUMPED CONSTANT; TRAPPING AGENT; NITRIC-OXIDE; AMINO-ACIDS; S-PBN; MITOCHONDRIAL DYSFUNCTION; DELAYED TREATMENT	Changes in regional cerebral blood flow (rCBF) and glucose metabolism are commonly associated with traumatic brain injury (TBI). Reactive oxygen species (ROS) have been implicated as key contributors to the secondary injury process after TBI. Here, pretreatment with the nitrone radical scavengers (alpha-phenyl-N-tert-butyl nitrone (PBN) or its sulfonated analogue sodium 2-sulfophenyl-N-tert-butyl nitrone (S-PBN) were used as tools to study the. effects of ROS on rCBF and glucose metabolism after moderate (2.4-2.6 atm) lateral fluid percussion injury (FPI) in rats. S-PBN has a half-life in plasma of 9 min and does not penetrate the blood-brain barrier (BBB). In contrast, PBN has a half-life of 3 h and readily penetrates the BBB. Regional cerebral blood flow (rCBF) and glucose metabolism was estimated by using Tc-99m-HMPAO and [F-18]Fluoro-2-deoxyglucose (FDG) antoradiography, respectively, at 42 min (n = 37) and 12 h (n = 34) after the injury. Regions of interest were the parietal. cortex and hippocampus bilaterally. As expected, FPI produced an early (42-min) hypoperfusion in ipsilateral cortex and an increase in glucose metabolism in both cortex and hippocampus, giving way to a state of hypoperfusion and decreased glucose metabolism at 12 h postinjury. On the contralateral side, a hypoperfusion in the cortex and hippocampus was seen at 12 h only, but no significant changes in glucose metabolism. Both S-PBN and PBN attenuated the trauma-induced changes in rCBF and glucose metabolism. Thus, the early improvement in rCBF and glucose metabolism correlates with and may partly mediate the improved functional and morphological outcome after TBI in nitrone-treated rats.	Uppsala Univ, Dept Neurosci, Uppsala, Sweden; Uppsala Univ, Dept Neurosurg, Uppsala, Sweden; Uppsala Univ, Dept Med Pharmacol, Uppsala, Sweden; Uppsala Univ, Dept Med Sci, Uppsala, Sweden; Uppsala Univ, Dept Clin Chem, Uppsala, Sweden; Uppsala Univ, PET Ctr, Uppsala, Sweden	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Div Neurosurg, SE-75185 Uppsala, Sweden.			Marklund, Niklas/0000-0002-9797-5626			Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Beckman JS, 1996, ADV NEUROL, V71, P339; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRANSTON NM, 1974, EXP NEUROL, V45, P195, DOI 10.1016/0014-4886(74)90112-5; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; Carlsson C, 1975, Acta Anaesthesiol Scand Suppl, V57, P1; CHEN GM, 1990, FREE RADICAL RES COM, V9, P317, DOI 10.3109/10715769009145690; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; CHENG HY, 1993, FREE RADICAL BIO MED, V14, P243, DOI 10.1016/0891-5849(93)90021-L; Choi DW, 1997, NAT MED, V3, P1073, DOI 10.1038/nm1097-1073; CLARKE DD, 1999, NEUROCHEMISTRY MOL C, P637; CLOUGHHELFMAN C, 1991, FREE RADICAL RES COM, V15, P177, DOI 10.3109/10715769109049138; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; CSIBA L, 1985, BRAIN RES, V336, P167, DOI 10.1016/0006-8993(85)90430-5; DEVASKAR SU, 1991, ADV EXP MED BIOL, V293, P405; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Duncan R, 1996, J NUCL MED, V37, P661; Estevez AG, 1998, PROG BRAIN RES, V118, P269; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARRELL CL, 1991, P NATL ACAD SCI USA, V88, P5779, DOI 10.1073/pnas.88.13.5779; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GREENBERG JH, 1992, J CEREBR BLOOD F MET, V12, P70, DOI 10.1038/jcbfm.1992.9; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Hall ED, 1997, NEUROSURG CLIN N AM, V8, P195; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1996, NEUROTRAUMA, P1459; INANAMI O, 1995, FREE RADICAL RES, V23, P33, DOI 10.3109/10715769509064017; KAPOOR R, 1989, J NEUROCHEM, V53, P37, DOI 10.1111/j.1471-4159.1989.tb07292.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; LUCIGNANI G, 1990, EUR J NUCL MED, V16, P249, DOI 10.1007/BF00842776; Maples KR, 2001, FREE RADICAL RES, V34, P417, DOI 10.1080/10715760100300351; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Marshall JWB, 2001, STROKE, V32, P190, DOI 10.1161/01.STR.32.1.190; MATSUDA H, 1988, BRAIN DEV-JPN, V10, P13, DOI 10.1016/S0387-7604(88)80039-1; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629; Pazos AJ, 1999, BRAIN RES, V846, P186, DOI 10.1016/S0006-8993(99)02010-7; RACKER E, 1983, J BIOL CHEM, V258, P3702; ROSE IA, 1964, BIOCHEM BIOPH RES CO, V15, P33, DOI 10.1016/0006-291X(64)90098-1; SAHA GB, 1994, SEMIN NUCL MED, V24, P324, DOI 10.1016/S0001-2998(05)80022-4; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; SCHULZ JB, 1995, J CEREBR BLOOD F MET, V15, P948, DOI 10.1038/jcbfm.1995.120; Schulz JB, 1997, AM J PHYSIOL-HEART C, V272, pH1986; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SPENCE AM, 1990, J CEREBR BLOOD F MET, V10, P190, DOI 10.1038/jcbfm.1990.34; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Tabatabaie T, 1996, ARCH BIOCHEM BIOPHYS, V336, P290, DOI 10.1006/abbi.1996.0560; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P7, DOI 10.2176/nmc.33.7; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Yang Y, 2000, EXP NEUROL, V163, P39, DOI 10.1006/exnr.2000.7364; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU NC, 1995, MOL PHARMACOL, V48, P550; Zeller K, 1997, J CEREBR BLOOD F MET, V17, P204, DOI 10.1097/00004647-199702000-00010; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510	94	26	26	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2002	19	10					1139	1153		10.1089/08977150260337958			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	605MJ	WOS:000178681400004	12427324				2021-06-18	
J	Naunheim, R; McGurren, M; Standeven, J; Fucetola, R; Lauryssen, C; Deibert, E				Naunheim, R; McGurren, M; Standeven, J; Fucetola, R; Lauryssen, C; Deibert, E			Does the use of artificial turf contribute to head injuries?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; concussion; artificial turf		Background. A number of high-profile professional football players have suffered career-ending conclusions. The purpose of this article is to test the surfaces used by a professional team to determine their impact-attenuating properties. Methods: An accelerometer was dropped from a height of 48 inches onto three different playing fields in the St. Louis area: an indoor artificial turf practice field, a grass outdoor practice field, and the artificial turf field at a domed stadium. The accelerometer was dropped 20 times from a height of 48 inches onto each surface. Results: Statistical analysis of the peak Gs for impacts onto each surface indicate all three are statistically different. The artificial surface of the domed stadium was the hardest surface, with an average peak acceleration of 261 Gs compared with 183 Gs for the indoor artificial turf practice field and 246 Gs for the outdoor grass field. Conclusion. The surface used to play league games has the least impact attenuation of any field tested and may contribute to the high incidence of concussion in football players.	Washington Univ, Sch Med, Dept Emergency Med, St Louis, MO 63110 USA	Naunheim, R (corresponding author), Washington Univ, Sch Med, Dept Emergency Med, St Louis, MO 63110 USA.	naunheir@msnotes.wustl.edu					*ASTM, 1994, ANN BOOK ASTM STAND, V15, P7; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barth JT, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P81; EIBAND A, 1959, HUMAN TOLERANCE RA E, V69, P5; Gadd CW, 1966, P 10 STAPP CAR CRASH; Gennarelli TA, 1993, BIOMECHANICS IMPACT, P411; GOLDSMITH W, 1970, BIOMECHANICS ITS FDN, P585; GURDJIAN ES, 1961, SURG GYNECOL OBSTET, V113, P185; GURDJIAN ES, 1962, JAMA-J AM MED ASSOC, V182, P509, DOI 10.1001/jama.1962.03050440001001; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HADDAD B. F., 1955, NEUROLOGY, V5, P798; KIKUCHI A, 1993, BIOMECHANICS IMPACT, P361; LEWIS LM, 1993, J TRAUMA, V35, P932, DOI 10.1097/00005373-199312000-00020; *NFL PLAYERS ASS, 2000, 2000 NFL PLAYERS HLT; *SAE, 1966, SAE HDB; UNTERHARNSCHEID.F, 1993, BIOMECHANICS IMPACT, P407; Versace J., 1971, REV SEVERITY INDEX; ZEMPER ED, 1989, PHYSICIAN SPORTSMED, V17, P100, DOI 10.1080/00913847.1989.11709915	18	26	26	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2002	53	4					691	694		10.1097/00005373-200210000-00012			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	604JZ	WOS:000178618400016	12394868				2021-06-18	
J	Lippert-Gruner, M; Wedekind, C; Klug, N				Lippert-Gruner, M; Wedekind, C; Klug, N			Functional and psychosocial outcome one year after severe traumatic brain injury and early-onset rehabilitation therapy	JOURNAL OF REHABILITATION MEDICINE			English	Article						outcome; rehabilitation; traumatic brain injury; occupational reintegration; behavioural deficits	HEAD-INJURY	This study evaluates the impact of early-onset continuous rehabilitation treatment on the 1-year outcome of patients after severe traumatic brain injury. Immediately after recovery from mechanical ventilation, a total of 48 patients underwent a complex early rehabilitation treatment until they were discharged from hospital and local ambulant care was deemed sufficient. The follow-up examination took place 12 months after trauma. Data reveal that at 1 year 91.6% of the patients were completely or restrictedly independent of care and capable of carrying out activities of daily living, although they frequently were still suffering from marked behavioural and also from certain sensorimotor deficits. Only 45.8% of the patients were obviously able to work without restrictions or had returned to work. In those subjects who were not or only very restrictedly able to work, behavioural and speech deficits were significantly more frequent. Behavioural and speech deficits seem to represent the major cause that hinders professional reintegration. Rehabilitation therapy therefore should be specifically directed to improve these deficits.	Univ Cologne, Dept Neurosurg, DE-50924 Cologne, Germany	Lippert-Gruner, M (corresponding author), Univ Cologne, Dept Neurosurg, DE-50924 Cologne, Germany.						Anderson SI, 1996, BRAIN INJURY, V10, P115, DOI 10.1080/026990596124601; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Chua KSG, 1999, INT J REHABIL RES, V22, P189, DOI 10.1097/00004356-199909000-00005; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; CRAMON Y, 1988, NEUROPSYCHOLOGISCH R; CRAMON Y, 1993, NEUROPSYCHOLOGISCHE; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Frowein R A, 1992, Acta Neurochir Suppl (Wien), V55, P72; FROWEIN R A, 1975, Aktuelle Traumatologie, V5, P203; FROWEIN RA, 1978, ADV NEUROSURG, V5, P16; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; JENNETT B, 1976, LANCET, V1, P1031; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LIPPERTGRUNER M, 1999, BRAIN INJURY, V14, P585; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958	25	26	26	0	6	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	1650-1977			J REHABIL MED	J. Rehabil. Med.	SEP 1	2002	34	5					211	214		10.1080/165019702760279198			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	595HT	WOS:000178103600003	12392235	DOAJ Gold			2021-06-18	
J	Thanos, S; Indorf, L; Naskar, R				Thanos, S; Indorf, L; Naskar, R			In vivo FM: using conventional fluorescence microscopy to monitor retinal neuronal death in vivo	TRENDS IN NEUROSCIENCES			English	Article							CONFOCAL NEUROIMAGING ICON; IMAGED IN-VIVO; NERVE-CELLS; DYNAMICS; LINEAGE; PROBES; GROWTH; BRAIN; MICE	Post-traumatic death of mature retinal neurons occurs in glaucoma and after optic nerve injury. The death is a dynamic process that can be fully analyzed with methods that monitor changes over time. We have coupled the development of retrogradely transportable fluorescent dyes with modification of conventional epifluorescence microscopy to manipulate and visualize rat retinal neurons in vivo. The method is a relatively new concept and has potential for the monitoring of retinal conditions, such as glaucoma or optic nerve transection, and for evaluation of neuroprotective strategies in the near future.	Univ Munster, Hosp Eye, Dept Expt Ophthalmol, D-48149 Munster, Germany	Thanos, S (corresponding author), Univ Munster, Hosp Eye, Dept Expt Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.						BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Cullander C, 1999, METH MOL B, V122, P59; Dawson AJ, 2001, J COMP NEUROL, V434, P40, DOI 10.1002/cne.1163; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Engelmann R, 1999, METHOD ENZYMOL, V307, P563; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; FISHELL G, 1995, FASEB J, V9, P324; FRANK E, 1991, DEVELOPMENT, V111, P895; GARCIAVALENZUEL.E, 1993, J NEUROBIOL, V24, P431; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; Hollander H, 1966, Z Wiss Mikrosk, V67, P156; Jontes JD, 2000, NAT NEUROSCI, V3, P231; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; LICHTMAN JW, 1985, NATURE, V314, P357, DOI 10.1038/314357a0; Lichtman JW, 2001, NAT NEUROSCI, V4, P1215, DOI 10.1038/nn754; Meister M, 2001, J NEUROSCI, V21, P1351; Moritz OL, 1999, INVEST OPHTH VIS SCI, V40, P3276; NASKAR R, IN PRESS INVEST OPHT; PURVES D, 1987, TRENDS NEUROSCI, V10, P398, DOI 10.1016/0166-2236(87)90005-1; PURVES D, 1987, J NEUROSCI, V7, P1492; PURVES D, 1985, NATURE, V315, P404, DOI 10.1038/315404a0; Rousseau V, 1999, NEUROREPORT, V10, P3387, DOI 10.1097/00001756-199911080-00024; Sabel BA, 1997, NAT MED, V3, P244, DOI 10.1038/nm0297-244; THANOS S, 1994, TRENDS NEUROSCI, V17, P177, DOI 10.1016/0166-2236(94)90098-1	26	26	28	0	3	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0166-2236			TRENDS NEUROSCI	Trends Neurosci.	SEP	2002	25	9					441	444		10.1016/S0166-2236(02)02246-4			4	Neurosciences	Neurosciences & Neurology	587AM	WOS:000177618400006	12183199				2021-06-18	
J	Groswasser, Z; Reider-Groswasser, II; Schwab, K; Ommaya, AK; Pridgen, A; Brown, HR; Cole, R; Salazar, AM				Groswasser, Z; Reider-Groswasser, II; Schwab, K; Ommaya, AK; Pridgen, A; Brown, HR; Cole, R; Salazar, AM			Quantitative imaging in late TBI. Part II: cognition and work after closed and penetrating head injury: a report of the Vietnam head injury study	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; CT FINDINGS; VETERANS; RETURN; SCAN	Context: Functional outcome in relation to CT findings in traumatic brain injured (TBI) patients is not well established in relation to cognitive and vocational outcome. Objective: To investigate the possible correlation between relatively simple quantitative radiological measurements and cognitive and vocational outcome. Design: Retrospective analysis of quantitative assessment of CT studies in relation to post-injury cognitive changes and vocational outcome. Setting: US Army Medical Centre. Patients: 74 penetrating head injured (PHI) and 37 closed head injured (CHI) Vietnam war veterans. Outcome measures: The Armed Forces Qualification Test (AFQT); Disability score; Return to work. Results: Total brain volume loss, third ventricle width (3VW), ventricular score (VS), and septum-caudate distance (SCD) were significantly related to cognitive change and return to work in PHI patients. Volume loss and 3VW were the most valuable radiologic predictors of outcome in multivariate linear and logistic regression models for both CHI and PHI. Conclusion: 3VW on late CT scans following traumatic brain injury is a powerful predictor of overall long-term cognitive outcomes and potential for return to work.	Uniformed Serv Univ Hlth Sci, Dept Brain Injury Rehabil, Loewenstein Rehabil Hosp, HM Jackson Fdn Advancement Med Sci, IL-43100 Raanana, Israel; Def & Vet Head Injury Prog, Raanana, Israel; Tel Aviv Univ, Sect Sackler Fac Med, IL-69978 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Imaging, Tel Aviv, Israel	Groswasser, Z (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Brain Injury Rehabil, Loewenstein Rehabil Hosp, HM Jackson Fdn Advancement Med Sci, 278 Achza St,POB 3, IL-43100 Raanana, Israel.	zeevgros@ccsg.tau.ac.il					EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; GYLDENSTED C, 1977, NEURORADIOLOGY, V14, P183, DOI 10.1007/BF00496982; JONAS BS, 1987, P SECT SURV RES METH; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; Melamed S, 1982, PSYCHOSOCIAL RES REH, P59; REIDERGROSWASSE.I, BRAIN INJURY, V16, P517; ReiderGroswasser I, 1997, BRAIN INJURY, V11, P865, DOI 10.1080/026990597122936; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WHITENECK GG, 1994, ARCH PHYS MED REHAB, V75, P1073, DOI 10.1016/0003-9993(94)90080-9	19	26	27	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2002	16	8					681	690		10.1080/02699050110119835			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	583GP	WOS:000177399100004	12167193				2021-06-18	
J	Giese, A; Koops, E; Lohmann, F; Westphal, M				Giese, A; Koops, E; Lohmann, F; Westphal, M			Head injury by gunshots from blank cartridges	SURGICAL NEUROLOGY			English	Article						trauma; head injury; gun shot; blank cartridge; gas pistol	WOUNDS; GAS	BACKGROUND Blank cartridge handguns are generally underestimated in their capacity to inflict serious and potentially life threatening injuries. The predominant reasons for these injuries are suicide or suicide attempts, followed by accidental injuries. METHODS A series of 26 gas gunshots to the neurocranium is presented. The injury pattern relevant to neurosurgical practice is illustrated in a case summary of 7 selected cases and the clinical courses as well as outcomes are presented. RESULTS he injury pattern demonstrates that the energy density of the gas jet and the high temperatures of the exploding gas volume cause extensive soft tissue injuries, In close-range shots the gas jet takes on physical properties of a projectile. In these injuries impression fractures and dislocation of bone fragments are common. CONCLUSIONS Gas handguns, contrary to public opinion, are dangerous weapons and may inflict potentially fatal injuries to the neurocranium when fired at close range. These weapons are frequently used in criminal or careless activities predominantly by young males. Extensive CNS injuries including hematomas, subarachnoid hemorrhage, foreign body contamination, and increased intracranial pressure are frequently observed. (C) 2002 by Elsevier Science Inc.	Univ Hamburg, Hosp Eppendorf, Dept Neurosurg, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Forens Med, D-20246 Hamburg, Germany	Giese, A (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany.						AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; BOCK G, 1980, HDB FAUSTIEUERWAFFEN, V13, P114; BRUNNER RG, 1990, AM SURGEON, V56, P104; CLARK MA, 1984, AM J FOREN MED PATH, V5, P75, DOI 10.1097/00000433-198403000-00014; COONEY WP, 1982, J TRAUMA, V22, P112, DOI 10.1097/00005373-198202000-00006; EISELE JW, 1981, J FORENSIC SCI, V26, P480, DOI 10.1520/JFS11388J; ERTL M, 1993, IWM, V11, P312; JACOB B, 1990, AM J FOREN MED PATH, V11, P285, DOI 10.1097/00000433-199012000-00003; LANGNER M, 1995, WAFFEN VERSAMMLUNGEN, P261; MARJEWSKI, 1907, UEBER BEHANDLUNGE EX; MAXEINER H, 1989, Archiv fuer Kriminologie, V184, P84; OKSALA A, 1975, ACTA OPHTHALMOL, V53, P908; ORDOG GJ, 1993, J TRAUMA, V34, P358, DOI 10.1097/00005373-199303000-00009; Pollak S, 1988, Beitr Gerichtl Med, V46, P401; Pollak S, 1982, Beitr Gerichtl Med, V40, P493; PUSCHEL K, 2001, IN PRESS ARCH KRIMIN; ROHLFING H, 1916, THESIS BERLIN; ROTHSCHILD M, 1999, FREIVERKAUFLICHE SCH; Rothschild MA, 1998, INT J LEGAL MED, V111, P78, DOI 10.1007/s004140050118; Rothschild MA, 1999, FORENSIC SCI INT, V101, P151, DOI 10.1016/S0379-0738(99)00020-1; Rothschild MA, 1996, FORENSIC SCI INT, V83, P1, DOI 10.1016/0379-0738(96)02019-1; ROTHSCHILD MA, 1994, INT J LEGAL MED, V106, P274, DOI 10.1007/BF01225420; Rothschild MA, 1998, RECHTSMEDIZIN, V8, P77; ROUGE D, 1994, J FORENSIC SCI, V39, P650; SALZMANN, 1881, DTSCH MILITARARZTL Z, V10, P183; SCHRODER H, 1971, JR, V71, P205; Schyma C., 1999, RECHTSMEDIZIN, V9, P210, DOI [10.1007/s001940050112, DOI 10.1007/S001940050112]; SCHYMA C, 2000, VERSICHERUNGSMEDIZIN, V52, P141; Sellier KG, 1994, WOUND BALLISTICS SCI, p[17, 74, 103, 268]; Stahl C J, 1968, J Forensic Sci, V13, P442; SUWANJUTHA T, 1988, FORENSIC SCI INT, V37, P223, DOI 10.1016/0379-0738(88)90188-0; TAUSCH D, 1978, KRIMINALISTIK, V32, P451; TAUSCH D, 1974, Z RECHTSMED, V75, P71, DOI 10.1007/BF02114965; THORESEN S, 1984, Z RECHTSMED, V93, P65; Weimann W, 1927, ARCH KRIMINOL, V80, P40	35	26	28	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	APR	2002	57	4					268	277	PII S0090-3019(02)00643-2	10.1016/S0090-3019(02)00643-2			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	562XH	WOS:000176223900008	12173394				2021-06-18	
J	Sahuquillo, J; Biestro, A; Mena, MP; Amoros, S; Lung, M; Poca, MA; De Nadal, M; Baguena, M; Panzardo, H; Mira, JM; Garnacho, A; Lobato, RD				Sahuquillo, J; Biestro, A; Mena, MP; Amoros, S; Lung, M; Poca, MA; De Nadal, M; Baguena, M; Panzardo, H; Mira, JM; Garnacho, A; Lobato, RD			First tier therapeutic measures in the management of high intracranial pressure after severe head injury. Rationale and proposal for a protocol	NEUROCIRUGIA			Spanish	Article						clinical practice guidelines; evidence based medicine; severe head injuries; brain trauma; high intracranial pressure; management protocol	CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; INTRACEREBRAL HEMORRHAGE; CARE MANAGEMENT; BODY POSITION; CORTICOSTEROIDS; HYPOTHERMIA; GUIDELINES; VOLUME; MEDICINE	The management of severe head injuries in general and that of high intracranial pressure (ICP) in particular are among the most challenging tasks in neurocritical care. One of the difficulties still faced by clinicians is that of reducing variability among centers when implementing management protocols. The purpose of this paper is to propose a standardized protocol for the management of high ICP after severe head injury, consistent with recently published clinical practice guidelines and other clinical evidence such as that provided by the systematic reviews of the Cochrane Collaboration. Despite significant advances in neuromonitoring, deeper insight into the physiopathology of severe brain trauma and the many therapeutic options available, standardized protocols are still lacking. Recently published guidelines provide sketchy recommendations without details on how and when to apply different therapies. Consequently, great variability exists in daily clinical practice even though different centers apply the same evidence-based recommendations. In this paper we suggest a structured protocol in which each step is justified and integrated into an overall strategy for the management of severe head injuries. The most recent data from both the preliminary and definitive results of randomized clinical trials as well as from other sources are discussed. The main goal of this article is to provide neurotraumatology intensive care units with a unified protocol that can be easily modified as new evidence becomes available. This will reduce variation among centers when applying the same therapeutic measures. This goal will facilitate comparisons in outcomes among different centers and will also enable the implementation of more consistent clinical practice in centers involved in multicenter clinical trials.	Univ Barcelona, Hosp Gen Valle Hebron, Serv Neurocirugia, E-08036 Barcelona, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Unidad Invest Neurotraumatol, E-08036 Barcelona, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Unidad Ciudados Intens Neurotraumatol, E-08036 Barcelona, Spain; Hosp Clin Montevideo, Unidad Cuidados Intens, Montevideo, Uruguay; Hosp Santa Casa Misericordia, Serv Neurocirugia, Rio Grande Do Sul, Brazil; Hosp 12 Octubre, Serv Neurocirugia, E-28041 Madrid, Spain		sahuquillo@homemail.com	Mena, Mari-Pau/AAC-7966-2020; de Nadal, Miriam/J-8127-2017; Poca, Maria A./B-8475-2008; Garnacho, Angel/A-9309-2013; Sahuquillo, Juan/B-3577-2008	de Nadal, Miriam/0000-0002-4559-2463; Poca, Maria A./0000-0002-3831-0536; Sahuquillo, Juan/0000-0003-0713-5875; Lung, Mayli/0000-0002-2692-4370; Baguena, Marcelino/0000-0001-9598-4791; Mena Jaramillo, Maria de la Paz/0000-0001-9248-5997			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; ALI HH, 1971, BRIT J ANAESTH, V43, P478, DOI 10.1093/bja/43.5.478; ALI HH, 1971, BRIT J ANAESTH, V43, P473, DOI 10.1093/bja/43.5.473; *AM COLL EM PHYS, 1993, ANN EMERG MED, V22, P1101; Andrews Brian T., 1993, P227; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P103, DOI 10.1111/j.1399-6576.1995.tb04285.x; Bernard SA, 1999, CRIT CARE, V3, P167, DOI 10.1186/cc371; Biestro A, 1998, ACT NEUR S, V71, P5; BIESTRO AA, 1995, J NEUROSURG, V83, P627, DOI 10.3171/jns.1995.83.4.0627; Bloom Harold, 2000, HOW TO READ AND WHY; BRODERICK JP, 1994, STROKE, V25, P1081, DOI 10.1161/str.25.5.1081b; BRODERICK JP, 1990, J NEUROSURG, V72, P195, DOI 10.3171/jns.1990.72.2.0195; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock MR, 1996, J NEUROTRAUM, V13, P719; BULLOCK R, 1995, GUIDELINES MANAGEMEN; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut R M, 1995, New Horiz, V3, P581; CHESTNUT RM, 2000, HEAD INJURY, P229; Cold GE, 1996, ANESTHESIOLOGY, V85, P1499; Cook DJ, 1996, CRIT CARE MED, V24, P334, DOI 10.1097/00003246-199602000-00025; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; CROWLEY MP, 1995, MONITORING ANESTHESI, P605; CRUZ J, 1986, NEUROTRAUMA, V1, P55; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; DEARDEN NM, 1996, BLOOD PRESSURE MANIP; deBoisblanc BP, 1999, CRIT CARE MED, V27, P678, DOI 10.1097/00003246-199904000-00006; Dishart MK, 2000, DRUGS, V59, P79, DOI 10.2165/00003495-200059010-00005; DONNELLY A, 1999, ANESTHESIOLOGY CRITI; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GHAJAR JB, 1996, NEUROTRAUMA, P1007; GRANDE PO, 1998, PATHOPHYSIOLOGICAL P, P123; GREENFIELD JC, 1968, J CLIN INVEST, V47, P1672, DOI 10.1172/JCI105858; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT G, 1993, MED TEACH, V15, P147, DOI 10.3109/01421599309006708; HARIRI RJ, 1992, J NEUROSURG, V76, pA397; HARTL R, 1998, ACTA NEUROCHIR SUPP, V71, P420; HENNEMAN EA, 1995, CRIT CARE NURSE, P82; Jackson R, 1998, BRIT MED J, V317, P427; Jensen K, 1992, Acta Neurochir Suppl (Wien), V55, P47; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JOVELL AJ, 1995, FORMACION MED CONTIN, V2, P152; KOPMAN AF, 1984, ANESTHESIOLOGY, V61, P83, DOI 10.1097/00000542-198461010-00015; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McKinely BA, 1999, J TRAUMA, V46, P271, DOI 10.1097/00005373-199902000-00013; MCKINLEY BA, 2000, COMMUNICATION; MORGAN GE, 1996, CLIN ANAESTHESIOL, P102; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; NORDSTROM CH, 1998, PATHOPHYSIOLOGICAL P, P67; Ohlinger MJ, 1998, SURG NEUROL, V49, P217, DOI 10.1016/S0090-3019(97)00279-6; POCA MA, 1996, TRAUMATISMO CRANEOEN, P96; RAVUSSIN PA, 1994, ANN FR ANESTH, V13, P88, DOI 10.1016/S0750-7658(94)80191-6; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roberts I, 1999, BRIT MED J, V319, P1069; ROBERTS I, 2001, BARBITURATES ACUTE T; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Sahuquillo J, 1999, NEUROCIRUGIA, V10, P185; Sahuquillo J, 1997, NEUROCIRUGIA, V8, P260; Sahuquillo J, 2000, ACTA NEUROCHIR SUPPL, V76, P485; Sahuquillo J, 2001, NEUROCIRUGIA, V12, P23; SAHUQUILLO J, 2000, MANAGEMENT HEAD INJU, P109; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Schierhout G, 1997, J NEUROL NEUROSUR PS, V63, P1, DOI 10.1136/jnnp.63.1.1; Schierhout G, 2001, ANTIEPILEPTIC DRUGS; SCHIERHOUT G, 2000, MANNITOL ACUTE TRAUN; SERVADEI F, 1996, COMMUNICATION; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SIGNORINI DF, 2001, THERAPEUTIC HYPOTHER; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; TOLEDO RB, 1997, JANO, V53, P279; TUHRIM S, 1995, CRIT CARE MED, V23, P950, DOI 10.1097/00003246-199505000-00026; VIBYMOGENSEN J, 1993, INTENS CARE MED, V19, pS74, DOI 10.1007/BF01708805; Vincent JL, 1995, INTEGRATED APPROACH, P98; Yates D, 1999, J ACCID EMERG MED, V16, P83	80	26	27	0	2	ELSEVIER ESPANA SLU	BARCELONA	AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN	1130-1473	2340-6305		NEUROCIRUGIA	Neurocirugia	APR	2002	13	2					78	100					23	Neurosciences; Surgery	Neurosciences & Neurology; Surgery	555CB	WOS:000175774600002	12058608				2021-06-18	
J	Dault, MC; Dugas, C				Dault, MC; Dugas, C			Evaluation of a specific balance and coordination programme for individuals with a traumatic brain injury	BRAIN INJURY			English	Article							SWAY	The purpose of this study was to evaluate the effectiveness of an aerobic dancing training, designed to reduce postural imbalance and coordination deficits for individuals who had sustained a traumatic brain injury (TBI). A two group experimental design was conducted. A control group participated in a traditional muscular training (TMT) programme while participants in the experimental group were assigned to an aerobic dancing, Slide(TM) and Step(TM) training programme (specific training group (ST)). Participants were evaluated pre- and post-training. Balance was quantified using a force platform and coordination using a Peak Performance system to compare the velocity profiles of a modified Jumping jack test. Results showed that temporal variables were significantly different pre- and post-training for the ST group, but no changes were found in the TMT group. The results of the balance test indicated a significant reduction of postural sway area in the ST group but not in the TMT group. Overall, the combination workout with Step(TM) and Slide(TM) is more effective in reducing balance and coordination deficits when compared to muscular based training.	Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, Ottawa, ON K1N 8M5, Canada; Univ Quebec Trois Rivieres, Dept Sci Act Phys, Trois Rivieres, PQ GA9 5H7, Canada	Dault, MC (corresponding author), Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, 451 Smyth Rd, Ottawa, ON K1N 8M5, Canada.	mdault@uottawa.ca					Ashley MJ, 1995, TRAUMATIC BRAIN INJU; BERGEGO C, 1995, NEUROPSYCHOLOGIE TRA; BERROL C, 1990, Brain Injury, V4, P257; BERROL CF, 1985, AM J DANCE THER, V8, P46, DOI 10.1007/BF02251441; Buchner DM, 1997, AGING CLIN EXP RES, V9, P112, DOI 10.1007/BF03340136; Burton A. W., 1990, ADAPTED PHYSICAL ACT, V7, P126; COHADON F, 1988, SCAND J REHABIL MED, P75; DAULT MC, 1999, P 11 INT S AD PHYS E, P59; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; GILLBODY KM, 1997, PHYS THER, V77, P552; HAGAN M, 1992, PROGRAM SLIDE TRAINI; HOPKINS DR, 1990, GERONTOLOGIST, V30, P189, DOI 10.1093/geront/30.2.189; Horak FB, 1997, PHYS THER, V77, P517, DOI 10.1093/ptj/77.5.517; Leahy Patricia, 1994, P491; REESE S, 1991, NSCA J, V13, P22; SCHARFFOLSON M, 1991, MED SCI SPORTS EXERC, V23, P1311; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; VANIER M, 1993, CLINICIEN, V8, P105; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	22	26	26	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2002	16	3					231	244		10.1080/02699050110103300			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	526HP	WOS:000174124800005	11908477				2021-06-18	
J	Thees, C; Scholz, M; Schaller, C; Gass, A; Pavildis, C; Weyland, A; Hoeft, A				Thees, C; Scholz, M; Schaller, C; Gass, A; Pavildis, C; Weyland, A; Hoeft, A			Relationship between intracranial pressure and critical closing pressure in patients with neurotrauma	ANESTHESIOLOGY			English	Article							CEREBRAL PERFUSION-PRESSURE; CEREBROVASCULAR TONE; CIRCULATION; AUTOREGULATION; MANAGEMENT	Background: The driving pressure gradient for cerebral perfusion is the difference between mean arterial pressure (MAP) and critical closing pressure (CCP = zero flow pressure). Therefore, determination of the difference between MAP and CCP should provide an appropriate monitoring of the effective cerebral perfusion pressure (CPPeff). Based on this concept, the authors compared conventional measurements of cerebral perfusion pressure by MAP and intracranial pressure (CPPICP) with CPPeff. Methods: Simultaneous synchronized recordings of pressure waveforms of the radial artery and blood flow velocities of the middle cerebral artery were performed in 70 head trauma patients. CCP was calculated from pressure-flow velocity plots by linear extrapolation to zero flow. Results: Intracranial pressure measured by intraventricular probes and CCP ranged from 3 to 71 and 4 to 70 mmHg, respectively. Linear correlation between ICP and CCP was r = 0.91. CPPICP was 77 +/- 20 mm g and did not differ from CPPeff; linear correlation was r = 0.92. However, limits of agreement were only +/- 16.2 mmHg. Therefore, in 51.4% of the patients, CPPICP overestimated CPPeff by 19.8 mmHg at most. Conclusion: Assuming that CPPeff (MAP - CCP) takes into account more determinants of cerebral downstream pressure, in individual cases, the actual gold standard of CPP determination (MAP - ICP) might overestimate the CPPeff of therapeutic significance.	Univ Bonn, Klin & Poliklin Anaesthesiol & Specielle Intens M, Dept Anesthesia & Intens Care Med, D-53105 Bonn, Germany	Thees, C (corresponding author), Univ Bonn, Klin & Poliklin Anaesthesiol & Specielle Intens M, Dept Anesthesia & Intens Care Med, Sigmund Freud Str 25, D-53105 Bonn, Germany.						Aaslid R., 1986, INTRACRANIAL PRESSUR, P226; Aaslid R, 1992, TRANSCRANIAL DOPPLER, P49; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BURTON AC, 1951, AM J PHYSIOL, V164, P319; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; Czosnyka M, 1999, J NEUROL NEUROSUR PS, V66, P606, DOI 10.1136/jnnp.66.5.606; Dawson SL, 1999, J APPL PHYSIOL, V86, P675; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; EARLY CB, 1974, J NEUROSURG, V41, P590, DOI 10.3171/jns.1974.41.5.0590; MICHEL E, 1995, NEUROL RES, V17, P149, DOI 10.1080/01616412.1995.11740304; Michel E, 1997, J CEREBR BLOOD F MET, V17, P1127, DOI 10.1097/00004647-199710000-00015; PANERAI RB, 1995, NEUROPEDIATRICS, V26, P168, DOI 10.1055/s-2007-979748; Panerai RB, 1996, IEEE T BIO-MED ENG, V43, P779, DOI 10.1109/10.508541; PERMUTT S, 1963, J APPL PHYSIOL, V18, P924; Richards HK, 1999, ACTA NEUROCHIR, V141, P1221, DOI 10.1007/s007010050422; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SACHS I, 1997, ANGEW STAT ANWENDUNG, P84; Weyland A, 2000, J NEUROSURG ANESTH, V12, P210, DOI 10.1097/00008506-200007000-00002	19	26	26	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAR	2002	96	3					595	599		10.1097/00000542-200203000-00014			5	Anesthesiology	Anesthesiology	526NH	WOS:000174136200013	11873033				2021-06-18	
J	Melamed, H; Harris, MB; Awasthi, D				Melamed, Hooman; Harris, Mitchel B.; Awasthi, Deepak			Anatomic Considerations of Superior Laryngeal Nerve During Anterior Cervical Spine Procedures	SPINE			English	Article						superior laryngeal nerve; anterior cervical spine surgery		Study Design. Cadavers were dissected anatomically to identify the course of the superior laryngeal nerve relative to the spinal column. Objective. To illustrate the anatomic relation of the SLN with respect to its vulnerability during anterior cervical spine procedures. Summary of Background Data. There is ample literature referencing the superior laryngeal nerve with respect to head and neck surgery. Detailed descriptions of the anatomy of the recurrent laryngeal nerve are quite extensive in both the spine and head and neck literature. To the authors' best knowledge, no similar reports have delineated the anatomic relation of the superior laryngeal nerve in procedures on the anterior aspect of the cervical spine. Methods. Ten dissections were carried out on human cadavers to show the course of the superior laryngeal nerve. Particular attention was directed to the internal branch of the superior laryngeal nerve to show the overall anatomic relation relative to standard landmarks. These landmarks included the superior laryngeal and superior thyroid arteries, the split of the superior laryngeal nerve, and the intervertebral disc space. Results. The superior laryngeal nerve originates from the vagus nerve in the carotid sheath and bifurcates into internal and external branches. Distally, the internal branch of the superior laryngeal nerve courses in close proximity with the superior laryngeal artery and inserts within 1 cm superior to the superior laryngeal artery into the thyrohyoid membrane. With respect to the cervical spine, the distal of portion of the internal branch of the superior laryngeal nerve is located between the C3 and C4 vertebral bodies. Conclusions. The internal branch of the superior laryngeal nerve supplies innervation to the mucosa of the larynx and has an important sensory reflex that serves to protect the lungs from aspiration. Injury to this nerve can predispose the patient to life-threatening pneumonia. It is therefore imperative for the surgeon to recognize the location and course of this nerve to avoid injuring it. Injury most commonly occurs either by excessive retraction in different planes or by accidental ligation of the nerve.	[Melamed, Hooman] Louisiana State Univ, Dept Orthopaed Surg, New Orleans, LA USA; [Harris, Mitchel B.] Wake Forrest Univ, Dept Orthopaed Surg, Winston Salem, NC 27157 USA; [Awasthi, Deepak] Louisiana State Univ, Dept Neurosurg, New Orleans, LA USA	Harris, MB (corresponding author), Wake Forest Univ, Sch Med, Dept Orthopaed Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.	miharris@wfumc.edu					Blumin JH, 1999, LARYNGOSCOPE, V109, P1637, DOI 10.1097/00005537-199910000-00017; Cannon CR, 1999, OTOLARYNG HEAD NECK, V120, P769, DOI 10.1053/hn.1999.v120.a84675; DROULIAS C, 1976, AM SURGEON, V42, P635; DURHAM CF, 1964, SURG GYNECOL OBSTET, V118, P38; Dursun G, 1996, J VOICE, V10, P206, DOI 10.1016/S0892-1997(96)80048-8; Ebraheim NA, 1997, SPINE, V22, P2663; Eckley CA, 1998, J VOICE, V12, P340, DOI 10.1016/S0892-1997(98)80024-6; El-Guindy A, 2000, J LARYNGOL OTOL, V114, P268; HEENEMAN H, 1973, LARYNGOSCOPE, V83, P17, DOI 10.1288/00005537-197301000-00002; Jonas J, 2000, AM J SURG, V179, P234, DOI 10.1016/S0002-9610(00)00308-1; LENNQUIST S, 1987, SURGERY, V102, P999; Lu J, 2000, ORTHOPEDICS, V23, P841; Mortero RF, 2001, ANESTH ANALG, V92, P271; NAGAYAMA I, 1994, J LARYNGOL OTOL, V108, P417, DOI 10.1017/S0022215100126957; Sanders I, 1998, ANAT RECORD, V252, P646, DOI 10.1002/(SICI)1097-0185(199812)252:4<646::AID-AR15>3.0.CO;2-E; SantAmbrogio G, 1996, PULM PHARMACOL THER, V9, P309, DOI 10.1006/pulp.1996.0040; Stephens RE, 1999, CLIN ANAT, V12, P79, DOI 10.1002/(SICI)1098-2353(1999)12:2<79::AID-CA1>3.0.CO;2-W; Weisberg NK, 1997, OTOLARYNG HEAD NECK, V116, P317, DOI 10.1016/S0194-5998(97)70266-3	18	26	28	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	FEB 15	2002	27	4					E83	E86		10.1097/00007632-200202150-00005			4	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	V43MC	WOS:000209684500001	11840114				2021-06-18	
J	Natale, JE; Cheng, Y; Martin, LJ				Natale, JE; Cheng, Y; Martin, LJ			Thalamic neuron apoptosis emerges rapidly after cortical damage in immature mice	NEUROSCIENCE			English	Article						axotomy; brain injury; caspase-3; DNA damage; neuronal cell death; retrograde neurodegeneration	TRAUMATIC BRAIN INJURY; LATERAL GENICULATE-NUCLEUS; CELL-DEATH; RETROGRADE DEGENERATION; NERVOUS-SYSTEM; RAT; NEURODEGENERATION; CORTEX; TRANSPORT; ISCHEMIA	In adults and children, head trauma can have long-term neuropathological and functional consequences. The thalamus is a major site of remote neurodegeneration after cortical damage in adult humans and experimental animals, but less is known about thalamic responses to cortical injury in the immature brain. This study introduces an in vivo model of axotomy/target deprivation-induced neuronal apoptosis in the dorsal lateral geniculate nucleus of the thalamus produced by unilateral ablation of the occipital cortex in the immature mouse. We specifically examined whether occipital cortex ablation in the immature brain causes apoptotic death of projection neurons in the dorsal lateral geniculate nucleus. After unilateral occipital cortex aspiration, 10-day-old C57BL/6 mice were recovered for up to 28 days. Fluorogold-prelabeled thalamocortical projection neurons were apoptotic at 36-48 It after ablation. The structural progression of apoptosis in the immature lateral geniculate nucleus reveals typical chromatolytic morphology by 18-24 It, followed by cytoplasmic shrinkage and chromatin condensation characteristic of end-stage apoptosis after 36-48 It. Electron microscopy confirmed the presence of apoptosis. This study shows internucleosomal DNA fragmentation and expression of cleaved caspase-3 occurs rapidly, being noted first at 18 h, well before the peak of apoptotic cell death occurring at 36 h after cortical damage in the immature brain. From these data we suggest that axotomy/target deprivation-induced cell death in the immature brain may: (1) differ from that previously reported in adult mice with respect to the time required for progression to cell death; (2) be mediated by caspase-3 activation. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA; George Washington Univ, Sch Med, Childresn Res Inst, Ctr Res Neurosci, Washington, DC USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Natale, JE (corresponding author), Childrens Natl Med Ctr, Med Genet Res Ctr, 111 Michigan Ave,NW, Washington, DC 20010 USA.				NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG016282] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG16282] Funding Source: Medline		Agarwala S, 1998, J COMP NEUROL, V392, P252, DOI 10.1002/(SICI)1096-9861(19980309)392:2<252::AID-CNE7>3.0.CO;2-1; Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; Al-Abdulla NA, 1998, AM J PATHOL, V153, P447, DOI 10.1016/S0002-9440(10)65588-5; BARRON KD, 1973, J NEUROPATH EXP NEUR, V32, P218, DOI 10.1097/00005072-197304000-00004; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; Easton RM, 1997, J NEUROSCI, V17, P9656; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRICKE R, 1977, J COMP NEUROL, V173, P231, DOI 10.1002/cne.901730203; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; IIZAKA H, 1990, STROKE, V21, P790; LAVALLLE A, 1958, J EXPT ZOOLOGY, V137, P285; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953; Mufson EJ, 1999, PROG NEUROBIOL, V57, P451, DOI 10.1016/S0301-0082(98)00059-8; Nakajima W, 2000, J NEUROSCI, V20, P7994; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PARNAVELAS JG, 1977, J COMP NEUROL, V171, P481, DOI 10.1002/cne.901710405; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; RINK A, 1995, AM J PATHOL, V147, P1575; Rosen GD, 2000, INT MOUSE GENOME C, V14, P166; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; SCHMUED LC, 1986, BRAIN RES, V377, P147, DOI 10.1016/0006-8993(86)91199-6; Sobreviela T, 1996, J COMP NEUROL, V375, P417; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; 1998, NIH CONSENSUS STATEM, V16, P1	32	26	28	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2002	112	3					665	676	PII S0306-4522(02)00098-2	10.1016/S0306-4522(02)00098-2			12	Neurosciences	Neurosciences & Neurology	572JF	WOS:000176770200017	12074908				2021-06-18	
J	McMahon, MA; Noll, RB; Michaud, LJ; Johnson, JC				McMahon, MA; Noll, RB; Michaud, LJ; Johnson, JC			Sibling adjustment to pediatric traumatic brain injury: A case-controlled pilot study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavior; depressive symptoms; pediatric traumatic brain injury; self-concept; siblings	CHILDHOOD-CANCER; CHILDREN; FAMILY; PREDICTORS; ADAPTATION	Objective: To assess depressive symptoms, self-concept, and behavior in non-affected siblings of children with severe pediatric traumatic brain injury (TBI). Design: Cross-sectional study with case controls. Setting: Children's hospital tertiary care center. Participants: Twelve siblings of children consecutively admitted to an inpatient rehabilitation unit after a severe TBI. Case controls were randomly selected from the sibling's classmates. Main Outcome Measures: The Child Behavior Checklist (CBCL), the Teacher's Report Form of the CBCL (TRF-CBCL), the Self-Perception Profile for Children and the Children's Depression Inventory (CDI). Results: No statistical differences were found in depressive symptoms, self-concept, or behavior between the siblings and their classmates 3 to 18 months after injury: Poorer functional outcomes in the child with a TBI were found to correlate significantly with lower self-concept and more symptoms of depression in the siblings. Conclusions: Further research is needed to evaluate the potential impact on sibling adjustment after pediatric TBI.	Childrens Hosp, Med Ctr, Div Pediat Rehabil, Dept Pediat Rehabil, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Dept Hematol Oncol, Div Hematol Oncol, Cincinnati, OH 45229 USA; Univ Missouri, Biostat Off, Integrated Technol Serv, Columbia, MO USA	McMahon, MA (corresponding author), Childrens Hosp, Med Ctr, Div Pediat Rehabil, Dept Pediat Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Johnson, Jane/0000-0002-8825-5926			Achenbach TM, 1986, MANUAL TEACHERS REPO; ACHENBACH TM, 1986, MANUAL CHILD BEHAV C; AMSTEN A, 1989, EMERGENCE DISCIPLINE; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; CADMAN D, 1988, J DEV BEHAV PEDIATR, V9, P117; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gill D. J., 2000, REHABILITATION NURSI, V25, P48, DOI [DOI 10.1002/J.2048-7940.2000.TB01862.X, 10.1002/j.2048-7940.2000.tb01862.x]; Harter S., 1985, MANUAL SELF PERCEPTI; Houtzager BA, 1999, SUPPORT CARE CANCER, V7, P302, DOI 10.1007/s005200050268; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Kovacs M., 1992, MANUAL CHILDRENS DEP; KRAUS JF, 1987, PEDIATRICS, V79, P501; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; NOLL RB, 1995, J PEDIATR PSYCHOL, V20, P165, DOI 10.1093/jpepsy/20.2.165; Orsillo SM, 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199303000-00010, 10.1097/00001199-199303000-00010]; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; SAHLER OJZ, 1994, J DEV BEHAV PEDIATR, V15, P353; TEASDALE G, 1974, LANCET, V2, P81; *U BUFF, 1998, WEEFIM SYST CLIN GUI; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110	22	26	26	0	1	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2001	16	6					587	594		10.1097/00001199-200112000-00006			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	501AL	WOS:000172660800006	11732973				2021-06-18	
J	Rapoport, MJ; Feinstein, A				Rapoport, MJ; Feinstein, A			Age and functioning after mild traumatic brain injury: the acute picture	BRAIN INJURY			English	Article; Proceedings Paper	Annual Meeting of the Canadian-Association-of-Geriatric-Psychiatry	OCT   04, 2000	VICTORIA, CANADA	Canadian Assoc Geriat Psychiat			CLOSED-HEAD INJURY; GENERAL HEALTH QUESTIONNAIRE; FOLLOW-UP; NEUROBEHAVIORAL CONSEQUENCES; SUBSTANCE-ABUSE; OLDER ADULTS; SEQUELAE; STROKE; DEPRESSION; SURVIVAL	Hypothesis: There will be acute harbingers of poor outcome following mild traumatic brain injury (TBI) in the elderly. Participants: Twenty-six subjects age 60 and over were compared to 30 subjects aged 18-59, seen within 1 month, on average, following a mild TBI. Main outcome measures: Functioning was assessed using the Glasgow Outcome Scale (GOS), a global measure of outcome, as well as self-report measures of psychosocial functioning, physical symptoms and psychological distress. Results: Contrary to the hypothesis, the older group did better than their younger counterparts on the GOS (p=0.002), and reported less psychosocial impairment (p<0.0001), less psychological distress (p=0.002), and less physical symptoms (p=0.005). However, once employment was controlled for, these results only approached statistical significance. Discussion: The assumption that elderly subjects have a worse outcome following TBI needs to be reconsidered, at least within the acute recovery period. The importance of psychosocial factors as modifiers of outcome according to age are emphasized. Whether this finding holds true over a longer follow-up period is the subject of ongoing research.	Univ Toronto, Sunnybrook & Womens Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada	Rapoport, MJ (corresponding author), Univ Toronto, Sunnybrook & Womens Hlth Sci Ctr, Dept Psychiat, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Rapoport, Mark/AAD-8581-2020				AharonPeretz J, 1997, BRAIN INJURY, V11, P871; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Barnfield TV, 1998, BRAIN INJURY, V12, P951, DOI 10.1080/026990598122007; Bennun IS, 1999, MED SCI LAW, V39, P167, DOI 10.1177/002580249903900212; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BURVILL PW, 1995, BRIT J PSYCHIAT, V166, P320, DOI 10.1192/bjp.166.3.320; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DEPAULO JR, 1980, PSYCHOL MED, V10, P125, DOI 10.1017/S0033291700039659; DEPAULO JR, 1978, ANN NEUROL, V4, P225, DOI 10.1002/ana.410040306; Drubach D A, 1993, Md Med J, V42, P989; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; FIELDS RB, 1994, TXB GERIATRIC NEUROP, P479; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Herrmann N, 1998, STROKE, V29, P618, DOI 10.1161/01.STR.29.3.618; ISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460; JENNETT B, 1975, LANCET, V1, P480; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Koren D, 1999, AM J PSYCHIAT, V156, P367; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; RABINS PV, 1981, PSYCHOL MED, V11, P425, DOI 10.1017/S0033291700052259; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; ROBINSON RG, 1983, STROKE, V14, P736, DOI 10.1161/01.STR.14.5.736; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; *STAT CAN, 1996, NAT POP HLTH SURV; Tate PS, 1999, BRAIN INJURY, V13, P767; TURNER RJ, 1990, J NERV MENT DIS, V178, P343, DOI 10.1097/00005053-199006000-00001; Vingilis E, 1996, ACCIDENT ANAL PREV, V28, P637, DOI 10.1016/0001-4575(96)00036-X; Vollmer DG, 1991, J NEUROSURG S, V75, P37	40	26	26	1	5	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2001	15	10					857	864		10.1080/02699050110065303			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	483HF	WOS:000171627000002	11595082				2021-06-18	
J	Shi, R; Qiao, X; Emerson, N; Malcom, A				Shi, R; Qiao, X; Emerson, N; Malcom, A			Dimethylsulfoxide enhances CNS neuronal plasma membrane resealing after injury in low temperature or low calcium	JOURNAL OF NEUROCYTOLOGY			English	Article							MAMMALIAN SPINAL-CORD; CYTOCHEMICAL EVIDENCE; AXONAL DAMAGE; NERVE-FIBERS; BRAIN-INJURY; OPTIC-NERVE; IN-VITRO; HYPOTHERMIA; TRANSECTION; PERMEABILITY	The inability to repair the damaged membrane may be one of the key mechanisms underlying the severe neuronal degeneration and overall functional loss seen in in vivo spinal cord injury and traumatic axonal injury in blunt head trauma. Promoting membrane resealing following damage may therefore constitute a potential effective therapeutic intervention in treating head trauma and spinal cord injuries. In our previous studies, we have shown that the axolemma failed to reseal following transection in clinically related situations, such as low extracellular calcium and low temperature. Our current studies indicate that DMSO is capable of rendering significant improvement in guinea pig axonal membrane resealing following transection in both 0.5 mM [Ca2+](0) and 25degreesC situations. This was demonstrated physiologically by monitoring membrane potential recovery and anatomically by conducting HRP-exclusion assays 60 minutes after injury. Further, we have shown that the addition of DMSO in normal Krebs' solution (2 mM [Ca2+](0) and 37degreesC) resulted in a decrease in membrane repair following injury. This indicates that DMSO-mediated membrane repair is sensitive to temperature and calcium. This study suggests the role of DMSO in axonal membrane resealing in clinically relevant conditions and raises the possibility of using DMSO in combination with other more established therapies in spinal cord injury treatment.	Purdue Univ, Sch Vet Med, Inst Appl Neurol, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Shi, R (corresponding author), Purdue Univ, Sch Vet Med, Inst Appl Neurol, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	riyi@vet.purdue.edu					BADYLAK SF, 1986, AM J EMERG MED, V4, P313, DOI 10.1016/0735-6757(86)90299-8; Brown M, 1988, J Burn Care Rehabil, V9, P22, DOI 10.1097/00004630-198801000-00007; Bruck R, 1999, J HEPATOL, V31, P27, DOI 10.1016/S0168-8278(99)80160-3; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Cochran T, 1983, Curr Surg, V40, P435; CROALL DE, 1991, PHYSIOL REV, V71, P813; Eddleman CS, 1998, J NEUROSCI, V18, P4029; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; Garrett R, 1999, BIOCHEMISTRY; Gitler D, 1998, NEURON, V20, P1123, DOI 10.1016/S0896-6273(00)80494-8; GROSS GW, 1987, EXP BRAIN RES, V67, P52, DOI 10.1007/BF00269452; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HANSEBOUT RR, 1984, SPINE, V9, P508, DOI 10.1097/00007632-198407000-00020; HAYES KC, 1993, PARAPLEGIA, V31, P730, DOI 10.1038/sc.1993.115; Heimer L, 1989, NEUROANATOMICAL TRAC; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Kirpatovskii V I, 1995, Urol Nefrol (Mosk), P32; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; LUCAS JH, 1994, J NEUROTRAUM, V11, P35, DOI 10.1089/neu.1994.11.35; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Miyake K, 2001, J CELL SCI, V114, P3487; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Robertson CL, 2000, CRIT CARE MED, V28, P3218, DOI 10.1097/00003246-200009000-00017; ROEDERER E, 1983, J NEUROSCI, V3, P153; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SANGER JW, 1980, P NATL ACAD SCI-BIOL, V77, P5268, DOI 10.1073/pnas.77.9.5268; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; VINCENT C, 1990, MOL REPROD DEV, V26, P227, DOI 10.1002/mrd.1080260306; Westergren H, 2000, ACTA NEUROCHIR, V142, P567, DOI 10.1007/s007010050471; Winckler B, 1999, NATURE, V397, P698, DOI 10.1038/17806; XIE XY, 1991, J NEUROSCI, V11, P3257; YAWO H, 1985, J NEUROSCI, V5, P1626; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; Yu ZW, 1998, MOL MEMBR BIOL, V15, P59, DOI 10.3109/09687689809027519	51	26	27	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-4864			J NEUROCYTOL	J. Neurocytol.	SEP-OCT	2001	30	9-10					829	839		10.1023/A:1019645505848			11	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	582AX	WOS:000177328500006	12165673				2021-06-18	
J	Hausmann, R; Betz, P				Hausmann, R; Betz, P			Course of glial immunoreactivity for vimentin, tenascin and alpha 1-antichymotrypsin after traumatic injury to human brain	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						human brain injury; glial reaction; immunohistochemistry; wound age	EPITHELIAL MESENCHYMAL INTERACTIONS; FIBRILLARY ACIDIC PROTEIN; CENTRAL-NERVOUS-SYSTEM; REACTIVE ASTROCYTES; ENHANCED EXPRESSION; ALZHEIMERS-DISEASE; AMYLOID DEPOSITS; BETA-PROTEIN; MACROPHAGES; CELLS	In a total of 104 individuals who had sustained traumatic brain injury (TBI), the course of glial immunoreactivity was investigated at the injured cortical area during the first 30 weeks after the trauma, in order to provide data for a forensic wound age estimation. Glial cells were stained with antibodies against the intermediate filament protein vimentin, the extracellular matrix protein tenascin and the serine protease inhibitor (alpha1-antichymotrypsin (alpha1-ACT). Injury-induced glial staining reactions could be observed, at the earliest, after a post-infliction interval of 3.1 h for alpha1-ACT, 22 It for vimentin and 7 days for tenascin.	Univ Erlangen Nurnberg, Dept Legal Med, D-91054 Erlangen, Germany	Hausmann, R (corresponding author), Univ Erlangen Nurnberg, Dept Legal Med, Univ Str 22, D-91054 Erlangen, Germany.						ABRAHAM CR, 1993, BRAIN RES, V621, P222, DOI 10.1016/0006-8993(93)90110-9; ABRAHAM CR, 1990, NEUROBIOL AGING, V11, P123, DOI 10.1016/0197-4580(90)90045-2; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; AGUAYO AJ, 1981, J EXP BIOL, V95, P231; AUFDERHEIDE E, 1988, J CELL BIOL, V107, P2341, DOI 10.1083/jcb.107.6.2341; AUFDERHEIDE E, 1987, J CELL BIOL, V105, P599, DOI 10.1083/jcb.105.1.599; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BERKENBOSCH F, 1992, ANN NY ACAD SCI, V650, P186; BRODKEY JA, 1995, J NEUROSURG, V82, P106, DOI 10.3171/jns.1995.82.1.0106; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; GRAEBER MB, 1988, J NEUROCYTOL, V17, P573, DOI 10.1007/BF01189811; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; INAGUMA Y, 1988, DEV BIOL, V128, P245, DOI 10.1016/0012-1606(88)90288-6; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LAYWELL ED, 1992, P NATL ACAD SCI USA, V89, P2634, DOI 10.1073/pnas.89.7.2634; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MACKIE EJ, 1987, J CELL BIOL, V105, P2569, DOI 10.1083/jcb.105.6.2569; MAIER A, 1987, AM J ANAT, V180, P226, DOI 10.1002/aja.1001800303; OBLINGER MM, 1993, INT J DEV NEUROSCI, V11, P149, DOI 10.1016/0736-5748(93)90075-O; PASTERNACK JM, 1989, AM J PATHOL, V135, P827; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SHOJI M, 1991, AM J PATHOL, V138, P247; THESLEFF I, 1987, DEVELOPMENT, V101, P289; THOMAS WE, 1992, BRAIN RES REV, V17, P61; YAMAMOTO C, 1990, Okajimas Folia Anatomica Japonica, V67, P21	34	26	26	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0937-9827			INT J LEGAL MED	Int. J. Legal Med.	JUL	2001	114	6					338	342		10.1007/s004140000199			5	Medicine, Legal	Legal Medicine	457DY	WOS:000170122900006	11508799				2021-06-18	
J	Lewis, LM; Naunheim, R; Standeven, J; Lauryssen, C; Richter, C; Jeffords, B				Lewis, LM; Naunheim, R; Standeven, J; Lauryssen, C; Richter, C; Jeffords, B			Do football helmets reduce acceleration of impact in blunt head injuries?	ACADEMIC EMERGENCY MEDICINE			English	Article						football helmets; sports injuries; head injuries; acceleration	SOCCER PLAYERS; COLLEGE FOOTBALL; CONCUSSION	Several recent studies suggest that acceleration of the head at impact during sporting activities may have a detrimental effect on cognitive function. Reducing acceleration of impact in these sports could reduce neurologic sequelae. Objective: To measure the effectiveness of a regulation football helmet to reduce acceleration of impact for both low- and moderate-force impacts. Methods: An experimental paired study design was used. Male volunteers between 16 and 30 years of age headed soccer balls traveling approximately 35 miles per hour bareheaded and with a helmet. An intraoral accelerometer worn inside a plastic mouthpiece measured acceleration of the head. The helmet also had an accelerometer placed inside the padding. For more forceful impacts, cadaver heads, both with and without helmets, were instrumented with intraoral (IO) and intracranial (IC) accelerometers and struck with a pendulum device. Simultaneous IO and IC accelerations were measured and compared between helmeted and unhelmeted cadaver heads. The main outcome was mean peak acceleration of the head and/or brain associated with low- and moderate-force impacts with and without protective headgear. Results: Mean peak Gs, measured by the mouthpiece accelerometer, were significantly reduced when the participants heading soccer balls were wearing a helmet (7.7 Gs with vs 19.2 Gs without, p = 0.01). Wearing a helmet also significantly lowered the peak Gs measured intraorally and intracranially in cadavers subjected to moderate-force pendulum impacts: 28.7 Gs with vs 62.6 Gs without, p < 0.001; and 56.4 Gs with vs 81.6 Gs without, p < 0.001, respectively. Conclusions: A regulation football helmet substantially reduced the peak Cs associated with "heading" a soccer ball traveling at moderately high velocities. A helmet was also effective in reducing the peak acceleration both intraorally and intracranially for impacts significantly more forceful than heading a soccer ball.	Washington Univ, Sch Med, Emergency Med Div, St Louis, MO USA; Barnes Jewish Hosp, Human Performance Lab, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO USA	Lewis, LM (corresponding author), Washington Univ, Med Ctr, Div Emergency Med, Washington Univ Phys, Campus Box 8072,660 S Euclid Ave, St Louis, MO 63110 USA.						ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; *ASTM, 1997, F144697 ASTM, P923; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dietzen C J, 1999, Phys Med Rehabil Clin N Am, V10, P159; GIBBS N, 1993, AM J SPORT MED, V21, P696, DOI 10.1177/036354659302100510; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; LEWIS LM, 1993, ANN EMERG MED, V22, P900; Linn S, 1998, Inj Prev, V4, P122; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MCDERMOTT FT, 1982, MED J AUSTRALIA, V2, P30, DOI 10.5694/j.1326-5377.1982.tb124205.x; MURRAY WA, 1999, 2000 OFFICIAL RULES, P14; *NAT FOOTB LEAG, 1999, OFF RUL NFL, P58; OFFNER PJ, 1992, J TRAUMA, V32, P636, DOI 10.1097/00005373-199205000-00016; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; *US HOCK INC, 1999, 1999 2001 OFF RUL IC, P31; 2000, 2000 OFFICIAL RULES, P39	25	26	26	0	11	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JUN	2001	8	6					604	609		10.1111/j.1553-2712.2001.tb00171.x			6	Emergency Medicine	Emergency Medicine	441FM	WOS:000169220400002	11388933	Bronze			2021-06-18	
J	Hellawell, DJ; Pentland, B				Hellawell, DJ; Pentland, B			Relatives' reports of long term problems following traumatic brain injury or subarachnoid haemorrhage	DISABILITY AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; EARLY OPERATION; HEMORRHAGE; RECOVERY; RELIABILITY; IMPAIRMENT; ADJUSTMENT; COGNITION; OUTCOMES; MODERATE	Purpose: To describe and compare the late outcome of traumatic brain injury (TBI) and subarachnoid haemorrhage (SAH) in terms of the carers' perspectives, and their symptoms profiles. Method: Postal survey to surviving patients who had been discharged from a Regional Neurosurgical Unit five to seven years previously. There were 288 patients identified retrospectively from hospital records, of whom 209 (126 TBI and 83 SAH) were alive and traced at follow-up. The Glasgow Outcome Scale (GOS) and the Relatives Questionnaire (RQ) were used. Results: Relative's questionnaires were returned by 128 patients; 70 TBI and 58 SAH, giving response rates of 56 % and 70% respectively. In terms of outcome, there was a high degree of similarity between groups. On the GOS, approximately half of each group were classified as moderately disabled (49 % and 48 % of the TBI and SAH groups respectively); a quarter remained severely disabled (27 % and 22%); and the remaining quarter were adjudged to have made a good recovery (24 % and 29 %). There was a considerable overlap in terms of the most commonly reported symptoms. Cognitive and physical problems tended to be more commonly reported by relatives of the TBI patients, whilst emotional and subjective symptoms were reported equally in both patient groups. Conclusions: The effects of TBI and SAH persist for many years post-injury, leading to considerable disability and increased dependency. Although the demographic details and mechanisms of injury in these two patient groups differ, there is a high degree of similarity in the pattern of sequelae reported by carers.	Univ Edinburgh, Rehabil Studies Unit, Edinburgh EH8 9YL, Midlothian, Scotland	Pentland, B (corresponding author), Astley Ainslie Hosp, Scottish Injury Rehabil Serv, Grange Loan, Edinburgh EH9 2HL, Midlothian, Scotland.						Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; ANDERSON SI, 1994, CLIN REHABIL, V8, P301; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1984, CLOSED HEAD INJURY P; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dombovy ML, 1998, BRAIN INJURY, V12, P887; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; Hellawell DJ, 2000, DISABIL REHABIL, V22, P446, DOI 10.1080/09638280050045910; Hellawell DJ, 1999, CLIN REHABIL, V13, P333, DOI 10.1191/026921599669500092; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; HUTTER BO, 1995, BRIT J NEUROSURG, V9, P465, DOI 10.1080/02688699550041106; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1975, LANCET, V1, P480; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LINDBERG M, 1996, CLIN REHABIL, V10, P69; LINDSAY K, 1991, NEUROLOGY NEUROSURGE; LJUNGGREN B, 1985, J NEUROSURG, V62, P673, DOI 10.3171/jns.1985.62.5.0673; MCKENNA P, 1989, BRIT MED J, V299, P485, DOI 10.1136/bmj.299.6697.485; MCKENNA P, 1989, NEUROSURGERY, V24, P361, DOI 10.1227/00006123-198903000-00009; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PONSFORD JL, 1996, RECOVERY TRAUMATIC B, V15, P219; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SIBBALD B, 1994, BRIT J GEN PRACT, V44, P297; SONESSON B, 1987, NEUROSURGERY, V21, P279, DOI 10.1227/00006123-198709000-00001; SORYAL I, 1992, CLIN REHABIL, V6, P103; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437	40	26	26	0	3	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.	MAY 10	2001	23	7					300	305		10.1080/769979114			6	Rehabilitation	Rehabilitation	428RC	WOS:000168473800005	11354583				2021-06-18	
J	Levine, DA; Platt, SL; Foltin, GL				Levine, DA; Platt, SL; Foltin, GL			Scooter injuries in children	PEDIATRICS			English	Article						scooter; children; injury prevention; protective gear	LINE	Objective. To describe a series of non-motorized scooter-related injuries to children to increase public awareness and encourage prevention of such injuries. Design. A descriptive study of a consecutive series of patients. Setting. The pediatric emergency service of a municipal hospital. Participants. All children <18 years old who presented to the Pediatric Emergency Service (PES) with a scooter-related injury from July through September 2000. Methods. Patients were identified by review of the PES medical records. Charts were reviewed for patient data including age, place of injury, use of protective gear, adult supervision, injury sustained, medical management, and disposition. Results. There were 15 children treated in the PES for scooter-related injuries. The mean age was 7.8 years, 73% were male. Approximately 90% of injuries occurred as a result of falling off a scooter. Irregular pavement caused 3 falls and tandem riding caused 2 falls. Inability to use the foot brake caused 1 collision, and 1 child was hit by a motor vehicle while crossing the street. Injuries occurred in a park (33%), on a sidewalk (47%), in a home (13%), and on the street (7%). Adult supervision was present in half of the cases. Only 2 children were wearing helmets at the time of injury; none wore protective padding. Five children (33%) suffered head trauma; 1 lost consciousness, and 2 suffered amnesia. Three children required a head computed tomography scan, and 1 required cervical spine radiographs. All radiographs were negative. None of these 5 children were wearing helmets. Seven children (47%) sustained facial injuries, and 4 of these children required laceration repair. Seven children (47%) sustained extremity trauma, including 1 laceration and 6 fractures (1 supracondylar, 1 distal radius, 2 radius/ulnar, 1 tibia/fibula, and 1 patella). Four fractures involved the upper extremity. Four fractures were managed by closed reduction; 2 required operative repair. One child required splinting of an avulsed tooth. Three of the children (20%) were admitted. The 5 children with head trauma were observed and released. Conclusion. The use of nonmotorized scooters by children may result in serious injury, particularly in the young child. Although not life-threatening, these injuries require significant medical intervention and may result in permanent functional and cosmetic deformity. These injuries are potentially preventable with the proper use of protective gear and supervision. Public and parental awareness and education are essential to prevent additional injuries.	NYU, Sch Med, Bellevue Hosp Ctr, Dept Pediat,Pediat Emergency Serv, New York, NY 10016 USA; NYU, Sch Med, Bellevue Hosp Ctr, Dept Emergency Med Surg, New York, NY 10016 USA	Levine, DA (corresponding author), NYU, Sch Med, Bellevue Hosp Ctr, Dept Pediat,Pediat Emergency Serv, 27th St & 1st Ave,Room 1 S 6, New York, NY 10016 USA.	mlevine336@aol.com					CASS DT, 1990, MED J AUSTRALIA, V153, P140, DOI 10.5694/j.1326-5377.1990.tb136832.x; Osberg JS, 1998, ARCH PEDIAT ADOL MED, V152, P985; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; Schieber RA, 1996, NEW ENGL J MED, V335, P1630, DOI 10.1056/NEJM199611283352202; Thompson DC, 2000, COCHRANE DATABASE SY, V2; US Consumer Product Safety Commission, 2000, NAT EL INJ SURV SYST; Wesson D, 2000, J PEDIATR SURG, V35, P688, DOI 10.1053/jpsu.2000.5944	7	26	26	0	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAY	2001	107	5							e64	10.1542/peds.107.5.e64			3	Pediatrics	Pediatrics	427NA	WOS:000168411100001	11331714	Bronze			2021-06-18	
J	Claassen, J; Hansen, HC				Claassen, J; Hansen, HC			Early recovery after closed traumatic head injury: Somatosensory evoked potentials and clinical findings	CRITICAL CARE MEDICINE			English	Article						somatosensory evoked potentials; traumatic diffuse axonal; closed head injury; recovery; diffuse axonal head injury; outcome prediction	DIFFUSE AXONAL INJURY; BRAIN-FUNCTION; PROGNOSTIC IMPLICATIONS; INTRACRANIAL-PRESSURE; COMA; CT; DYSFUNCTION; CONDUCTION; RESPONSES; SEPS	Objective: To determine the ability of somatosensory evoked potentials (SEP) compared with clinical findings to monitor and predict recovery in patients suffering from closed head injury with predominantly diffuse axonal injury (DAI). Design: Prospective cohort study. Setting: Neurologic intensive care unit (ICU) of a university hospital. Patients: Serial SEP recordings were obtained from 31 consecutive patients with closed head injury. The first SEP was recorded within 48 hrs after trauma, followed by recordings after another 2 days, after which the time interval for each consecutive recording was doubled. Clinical examinations were performed every 6 hrs during the ICU stay and daily after transfer to a general neurologic ward. Interventions: None. Measurements and Main Results: Twenty-three of 31 patients demonstrated pathologic SEP findings at initial examination. Of these patients, 11 recovered clinically, two remained vegetative, and ten died. In all 11 patients with clinical recovery, SEP also recovered. In 8 of 31 patients, initial SEPs were normal and remained normal until discharge, all eight had a good outcome. Initial SEP findings were related with outcome at 6 months (p = .02), and follow-up studies increased the predictive value of SEP studies (p = .009). Other factors related to outcome included age, severity of DAI, and length of ICU/hospital stay. In the 11 patients with SEP and clinical recovery, early (day 2) and late (greater than or equal to2 months) recovery was documented. Early and reliable SEP indicators of improvement included N20-P25-Amplitudes (mean recovery, 8.5 days) and central conduction time (9.6 days). Pupillary light reaction (6.4 days), Babinski reflex (12.4 days), and Glasgow Coma Score (9.6 days) were the most valuable clinical findings. Recovery of the Glasgow Coma Score frequently coincided with reduction of sedatives. In most patients, recovery was detected with SEP before clinical recovery (7/11 patients, time difference 1 wk). Conclusions: Initial SEP findings correlate with long-term outcome in patients with closed head injury with DAl. Initial bilaterally absent cortical responses in the SEP reliably predicted death, whereas completely normal SEP findings predicted good longterm outcome. Early recovery after DAl can be detected with serial SEP recordings despite sedative medications. Electrophysiologic recovery frequently precedes clinical recovery.	Univ Hamburg Hosp, Neurol Intens Care Unit, Dept Neurol, D-2000 Hamburg, Germany	Claassen, J (corresponding author), Univ Hamburg Hosp, Neurol Intens Care Unit, Dept Neurol, D-2000 Hamburg, Germany.		Claassen, Jan/AAA-5451-2020				ABBRUZZESE G, 1981, J NEUROL NEUROSUR PS, V44, P942, DOI 10.1136/jnnp.44.10.942; ALLISON T, 1983, ELECTROEN CLIN NEURO, V55, P619, DOI 10.1016/0013-4694(83)90272-9; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Cheung DS, 1999, EMERG MED CLIN N AM, V17, P9, DOI 10.1016/S0733-8627(05)70044-4; CUSUMANO S, 1992, ELECTROEN CLIN NEURO, V84, P499, DOI 10.1016/0168-5597(92)90039-E; DAWSON GD, 1947, J NEUROL NEUROSUR PS, V10, P141, DOI 10.1136/jnnp.10.4.141; DELATORRE JC, 1977, EXP NEUROL, V60, P304; DUBOIS M, 1981, ELECTROEN CLIN NEURO, V52, P157, DOI 10.1016/0013-4694(81)90163-2; GANES T, 1988, ELECTROEN CLIN NEURO, V69, P6, DOI 10.1016/0013-4694(88)90030-2; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gennarelli TA, 1993, HEAD INJURY, P137; GOLDIE WD, 1981, NEUROLOGY, V31, P248, DOI 10.1212/WNL.31.3.248; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GUTLING E, 1994, ELECTROEN CLIN NEURO, V92, P568, DOI 10.1016/0168-5597(94)90141-4; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; Ito H, 1997, Ann Nucl Med, V11, P167; JONES SJ, 1993, EVOKED POTENTIALS CL, P421; Kane NM, 1998, ELECTROEN CLIN NEURO, V106, P244, DOI 10.1016/S0013-4694(97)00141-7; KEREN O, 1991, Brain Injury, V5, P233, DOI 10.3109/02699059109008094; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KOCHS E, 1991, EUR J ANAESTH, V8, P257; KONASIEWICZ SJ, 1994, J TRAUMA, V37, P370, DOI 10.1097/00005373-199409000-00006; KONASIEWICZ SJ, 1994, CAN J NEUROL SCI, V21, P219, DOI 10.1017/S0317167100041196; LEANDRI M, 1981, J NEUROL NEUROSUR PS, V44, P718, DOI 10.1136/jnnp.44.8.718; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; MANZANO GM, 1995, EVOKED POTENTIAL, V96, P229, DOI 10.1016/0168-5597(94)00271-F; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mayer S, 2000, MERRITTS NEUROLOGY, P401; Mayer S A, 1999, J Stroke Cerebrovasc Dis, V8, P183, DOI 10.1016/S1052-3057(99)80025-1; MICHELOYANNIS J, 1989, ACTA NEUROL SCAND, V79, P146, DOI 10.1111/j.1600-0404.1989.tb03727.x; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NARAYAN RK, 1995, PRINCIPLES NEUROSURG; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; PINTO F, 1990, ACTA ANAESTH SCAND, V34, P389, DOI 10.1111/j.1399-6576.1990.tb03108.x; RIFFEL B, 1994, DIAGNOSTIK PROGNOSTI, P22; RUMPL E, 1988, J CLIN NEUROPHYSIOL, V5, P237, DOI 10.1097/00004691-198807000-00002; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SHAW NA, 1986, J NEUROL SCI, V73, P145, DOI 10.1016/0022-510X(86)90126-7; TEASDALE G, 1974, LANCET, V2, P81; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x	47	26	29	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAR	2001	29	3					494	502		10.1097/00003246-200103000-00005			9	Critical Care Medicine	General & Internal Medicine	411WM	WOS:000167522400004	11373410				2021-06-18	
J	Movsesyan, VA; Yakovlev, AG; Fan, L; Faden, AI				Movsesyan, VA; Yakovlev, AG; Fan, L; Faden, AI			Effect of serine protease inhibitors on posttraumatic brain injury and neuronal apoptosis	EXPERIMENTAL NEUROLOGY			English	Article						brain trauma; serine protease; TPCK; neuronal death; apoptosis	CELL-DEATH; NEUROBLASTOMA-CELLS; OXIDATIVE STRESS; NMDA RECEPTORS; NERVOUS-SYSTEM; IN-VITRO; RAT; CULTURES; INVOLVEMENT; CONTRIBUTES	N-Tosyl-L-phenylalanyl chloromethyl ketone (TPCK), an inhibitor of chymotrypsin-like serine protease (CSP), prevents DNA fragmentation and apoptotic cell death in certain blood cell lines and was reported to reduce hippocampal neuronal damage caused by cerebral ischemia, We examined the role of CSP on recovery after lateral fluid percussion-induced traumatic brain injury (TBI) in rats, as well as on cell survival in various in vitro models of neuronal cell death. TBI caused significant time-dependent upregulation of CSP activity, but not trypsin-like serine protease activity in injured cortex, Intracerebroventricular administration of TPCK to rats after TBI did not significantly affect deficits of spatial learning but exacerbated motor dysfunction after injury, Moreover, TPCK did not prevent apoptotic neuronal cell death caused by serum/K+ deprivation or by application of staurosporine or etoposide in cultured rat cerebellar granule cells, rat cortical neurons, or in the human neuroblastoma SH-SY5Y cell line. Instead, at doses from 10 to 100 muM, TPCK was cytotoxic in all cultures tested. Similar results were obtained in cultures treated with another CSP inhibitor, 3,4-dichloroisocoumarin. Cell death caused by CSP inhibitors was neither caspase-dependent nor associated with oligonucleosomal DNA fragmentation. Taken together, these data do not support a neuroprotective role for CSP inhibitors. Rather, they suggest that CSPs may serve an endogenous neuroprotective role, possibly by modulating necrotic cell death, (C) 2001 Academic Press.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurosci, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurosci, 3900 Reservoir Rd NW,Res Bldg,Room EP12, Washington, DC 20007 USA.						Atabay C, 1996, J NEUROSCI RES, V43, P465; Back SA, 1999, J NEUROSCI METH, V91, P47, DOI 10.1016/S0165-0270(99)00062-X; Boix J, 1998, EXP CELL RES, V238, P422, DOI 10.1006/excr.1997.3852; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; Davies BJ, 1998, J BIOL CHEM, V273, P23004, DOI 10.1074/jbc.273.36.23004; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Faden AI, 1999, ANN NEUROL, V46, P496; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hara A, 1998, J CEREBR BLOOD F MET, V18, P819, DOI 10.1097/00004647-199808000-00001; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Komatsu N, 1998, J BIOCHEM-TOKYO, V124, P1038, DOI 10.1093/oxfordjournals.jbchem.a022197; Martins LM, 1998, BLOOD, V92, P3042, DOI 10.1182/blood.V92.9.3042.421k55_3042_3049; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; NAKAJIMA M, 1994, BRAIN RES, V641, P350, DOI 10.1016/0006-8993(94)90165-1; Nath R, 1997, BIOCHEM MOL BIOL INT, V43, P197; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RINK A, 1995, AM J PATHOL, V147, P1575; ROBICHON A, 1991, ENDOCRINOLOGY, V128, P1974, DOI 10.1210/endo-128-4-1974; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; SINENSKY MC, 1995, TOXICOL LETT, V75, P101; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Turgeon VL, 1997, BRAIN RES REV, V25, P85, DOI 10.1016/S0165-0173(97)00015-5; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; Yakovlev AG, 1999, NUCLEIC ACIDS RES, V27, P1999, DOI 10.1093/nar/27.9.1999; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	31	26	26	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	FEB	2001	167	2					366	375		10.1006/exnr.2000.7567			10	Neurosciences	Neurosciences & Neurology	400BG	WOS:000166848300017	11161625				2021-06-18	
J	Mautes, AEM; Muller, M; Cortbus, F; Schwerdtfeger, K; Maier, B; Holanda, M; Nacimiento, A; Marzi, I; Steudel, WI				Mautes, AEM; Muller, M; Cortbus, F; Schwerdtfeger, K; Maier, B; Holanda, M; Nacimiento, A; Marzi, I; Steudel, WI		HOTBIG	Alterations of norepinephrine levels in plasma and CSF of patients after traumatic brain injury in relation to disruption of the blood-brain barrier	ACTA NEUROCHIRURGICA			English	Article						blood-brain/CSF barrier (BBB); catecholamines; cerebral spinal fluid (CSF); clinical study; traumatic brain injury (TBI)	HEAD-INJURY; PRESSURE; OXIDASE; FLOW; RAT; CATECHOLAMINES; MICROVESSELS; METABOLISM; ADRENALINE; RELEVANCE	Background. In injured brain tissue with a disrupted blood-brain barrier (BBB) catecholamines such as norepinephrine (NE) are known to enhance glucose consumption and cerebral blood flow but may lead to an energy-depletion increasing the risk of ischemia. Therefore it is of great interest whether the exogenous administration of NE used mainly to maintain an adequate cerebral perfusion pressure influences CSF NE levels or not, and whether elevated plasma or CSF levels of NE can influence the actual clinical condition. We addressed this issue by measuring the levels of NE in CSF and plasma and correlating them with the actual clinical condition of the patients. Methods. In 29 patients with severe TBI (<8 points on the Glasgow Coma Scale: GCS) NE levels were analysed by high performance liquid chromatography (HPLC) in paired blood and CSF specimens which were collected from days 1 to 14 after severe TBI (total number of pairs = 121). The integrity of the BBB was evaluated by determining the CSF/serum albumin ratio. The clinical condition of the patients was assessed by GCS. Results. Elevated plasma and CSF NE: levels were observed in 50% of all samples, most consistently in patients treated with NE. NE elevation in CSF was independent of whether or not the BBB remained intact. There was no correlation between GCS and the levels of NE in CSF or plasma either in samples from the treated or the untreated group. Interpretation. Exogenous administration of NE seems to increase NE levels in plasma and CSF. However, in this group of patients with severe TBI there was no clinical evidence that exogenous administration of NE was detrimental to the traumatized patients.	Univ Saarland, Sch Med, Neurosurg Res Lab, Dept Neurosurg, D-66421 Homburg, Germany; Univ Saarland, Sch Med, Dept Trauma Surg, D-66421 Homburg, Germany; Univ Saarland, Sch Med, Dept Neurol, D-66421 Homburg, Germany	Mautes, AEM (corresponding author), Univ Saarland, Sch Med, Neurosurg Res Lab, Dept Neurosurg, Kirrberger Str, D-66421 Homburg, Germany.						BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BUSTO R, 1985, ANN NEUROL, V18, P329, DOI 10.1002/ana.410180310; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; DAHLGREN N, 1980, BRAIN RES, V184, P143, DOI 10.1016/0006-8993(80)90593-4; EISENBERG HM, 1983, INTRACRANIAL PRESSUR, V5, P549; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HARDEBO JE, 1980, ANN NEUROL, V8, P1, DOI 10.1002/ana.410080102; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; JOHANSSON B, 1970, ACTA NEUROPATHOL, V16, P117, DOI 10.1007/BF00687666; LAI FM, 1978, ARCH INT PHARMACOD T, V233, P227; LASBENNES F, 1983, J CEREBR BLOOD F MET, V3, P521, DOI 10.1038/jcbfm.1983.80; LASBENNES F, 1988, BRAIN RES, V454, P205, DOI 10.1016/0006-8993(88)90819-0; Levin BE, 1998, BRAIN RES, V808, P317, DOI 10.1016/S0006-8993(98)00839-7; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Miller J D, 1972, Prog Brain Res, V35, P411; RAPOPORT S, 1976, BLOOD BRAIN BARRIER, P4386; REIBER H, 1987, CLIN CHIM ACTA, V163, P43; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SEELIG JM, 1986, INTRACRANIAL PRESSUR, V6, P675; Strittmatter M, 1997, HEADACHE, V37, P211, DOI 10.1046/j.1526-4610.1997.3704211.x; VORBRODT AW, 1988, PROG HISTOCHEM CYTOC, V18, P1; WEILMALHERBE H, 1959, SCIENCE, V129, P1226, DOI 10.1126/science.129.3357.1226; WERDAN K, 1992, SCH INT MED, V80, P133; Zwetnow N N, 1970, Acta Physiol Scand Suppl, V339, P1	30	26	27	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2001	143	1					51	58		10.1007/s007010170138			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	402CA	WOS:000166967400022	11345718				2021-06-18	
J	Dijkstra, S; Geisert, EE; Gispen, WH; Bar, PR; Joosten, EAJ				Dijkstra, S; Geisert, EE; Gispen, WH; Bar, PR; Joosten, EAJ			Up-regulation of CD81 (target of the antiproliferative antibody; TAPA) by reactive microglia and astrocytes after spinal cord injury in the rat	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						gliosis; nerve regeneration; central nervous system; Schwann cells; spinal cord injuries	PROTEIN-TYROSINE PHOSPHORYLATION; CELL-ADHESION; AXONAL REGENERATION; HUMAN PLATELETS; NERVOUS-SYSTEM; ADULT-RAT; IN-VITRO; EXPRESSION; LESION; BRAIN	We examined the expression of CD81 (also known as TAPA, or target of the antiproliferative antibody) after traumatic spinal cord injury in the rat. CD81, a member of the tetraspanin family of proteins, is thought to be involved in reactive gliosis. This is based on the antiproliferative and antiadhesive effects of antibodies against CD81 on cultured astrocytes, as well as its up-regulation after penetrating brain injury. CD81 expression following dorsal hemisection of the spinal cord was determined immunohistochemically at time points ranging from 1 day to 2 months postlesion (p.l.). In the unlesioned cord a low background level of CD81 was observed, with the exception of the ependyma of the central canal and the pia mater, which were strongly CD81-positive. One day p.l., CD81 was diffusely up-regulated in the spinal cord parenchyma surrounding the lesion site. From 3 days onward, intensely CD81-positive round cells entered the lesion site, completely filling it by 7 days p.l. Staining with the microglial markers OX-42 and Iba1 revealed that these cells were reactive microglia/ macrophages. At this time, no significant CD81 expression by GFAP-positive reactive astrocytes was noted. From the second week onward, CD81 was gradually down-regulated; i.e., its spatial distribution became more restricted. The CD81-positive microglia/macrophages disappeared from the lesion site, leaving behind large cavities. After 2 months, astrocytes that formed the wall of these cavities were strongly CD81-positive. In addition, CD81 was present on reactive astrocytes in the dorsal funiculus distal from the lesion in degenerated white matter tracts. In conclusion, the spatiotemporal expression pattern of CD81 by reactive microglia and astrocytes indicates that CD81 is involved in the glial response to spinal cord injury. (C) 2000 Wiley-Liss, Inc.	Univ Utrecht, Med Ctr, Lab Expt Neurol, Dept Expt Neurol,RMI Neurosci, NL-3508 GA Utrecht, Netherlands; Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA	Dijkstra, S (corresponding author), Univ Utrecht, Med Ctr, Lab Expt Neurol, Dept Expt Neurol,RMI Neurosci, Room G02314,POB 85500, NL-3508 GA Utrecht, Netherlands.		bar, peter/A-2897-2009				ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; ANTON ES, 1995, J NEUROSCI, V15, P584; Bartholdi D, 1998, GLIA, V23, P278, DOI 10.1002/(SICI)1098-1136(199807)23:3<278::AID-GLIA10>3.0.CO;2-Q; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Brook GA, 1998, J NEUROSCI RES, V53, P51, DOI 10.1002/(SICI)1097-4547(19980701)53:1<51::AID-JNR6>3.0.CO;2-I; Clarke K, 1998, Mol Vis, V4, P3; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Elkabes S, 1996, J NEUROSCI, V16, P2508; GEISERT EE, 1991, NEUROSCI LETT, V133, P262, DOI 10.1016/0304-3940(91)90584-G; Geisert EE, 1996, J NEUROSCI, V16, P5478; GIELING RG, 1998, EUR J NEUROSCI S, V10; GIULIAN D, 1993, ADV NEUROL, V59, P315; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; Houweling DA, 1998, EXP NEUROL, V153, P49, DOI 10.1006/exnr.1998.6867; IRWIN MH, 1993, NEUROSCI LETT, V154, P57, DOI 10.1016/0304-3940(93)90170-P; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; JOOSTEN EAJ, 1995, J NEUROSCI RES, V41, P481, DOI 10.1002/jnr.490410407; KAPRIELIAN Z, 1995, J NEUROSCI, V15, P562; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; KOSHINAGA M, 1995, J NEUROTRAUM, V12, P209, DOI 10.1089/neu.1995.12.209; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Maecker HT, 1997, FASEB J, V11, P428; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Miyake M, 1996, CANCER RES, V56, P1244; Morin-Richaud C, 1998, BRAIN RES, V783, P85, DOI 10.1016/S0006-8993(97)01282-1; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Pasterkamp RJ, 1998, J NEUROSCI, V18, P9962; Peduzzi JD, 1999, EXP NEUROL, V160, P460, DOI 10.1006/exnr.1999.7234; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Reier P J, 1988, Adv Neurol, V47, P87; SCHICK MR, 1993, J IMMUNOL, V151, P1918; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Serru V, 2000, BBA-PROTEIN STRUCT M, V1478, P159, DOI 10.1016/S0167-4838(00)00022-4; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sullivan CD, 1998, J COMP NEUROL, V396, P366; Todd SC, 1998, BBA-GENE STRUCT EXPR, V1399, P101, DOI 10.1016/S0167-4781(98)00087-6; Watanabe T, 1999, J NEUROTRAUM, V16, P255, DOI 10.1089/neu.1999.16.255; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; YATOMI Y, 1993, FEBS LETT, V322, P285, DOI 10.1016/0014-5793(93)81587-P	49	26	26	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	DEC 11	2000	428	2					266	277		10.1002/1096-9861(20001211)428:2<266::AID-CNE6>3.0.CO;2-0			12	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	371ML	WOS:000165182700006	11064366				2021-06-18	
J	Beschorner, R; Engel, S; Mittelbronn, M; Adjodah, D; Dietz, K; Schluesener, HJ; Meyermann, R				Beschorner, R; Engel, S; Mittelbronn, M; Adjodah, D; Dietz, K; Schluesener, HJ; Meyermann, R			Differential regulation of the monocytic calcium-binding peptides macrophage-inhibiting factor related protein-8 (MRP8/S100A8) and allograft inflammatory factor-1 (AIF-1) following human traumatic brain injury	ACTA NEUROPATHOLOGICA			English	Article						allograft-inflammatory factor-1; microglia response factor-1; macrophage-inhibiting factor related-protein-8/S 100A8; traumatic brain injury; human	FACTOR-I; ACTIVATED MACROPHAGES; MICROGLIAL CELLS; EXPRESSION; LESIONS; MRP14; ENCEPHALOMYELITIS; POLYPEPTIDE; CONTUSION; NEURITIS	Intracellular calcium (Ca2+) has been shown to function as second messenger and to be associated with activation of different cell types including microglia. Previously, in human focal cerebral infarctions an early expression of macrophage-related protein-8 (MRP8/ S100A8), a member of the Ca2+-binding S100-protein family, in microglia has been reported. On the other hand, a delayed activation of microglia was observed following traumatic brain injury (TBI). We therefore examined immunohistochemically microglial expression of MRP8 and allograft inflammatory factor-1 (AIF-1), identical to microglial response factor-1 (mrf-1) and ionized calcium binding adaptor molecule-1 (iba1) in human brains after TBI and in control brains. Both, MRP8 and AIF-1 are Ca2+-binding peptides which have been associated with microglial activation in experimental models and in human cerebral infarctions. Detection of AIF-1 in controls confirmed constitutive expression of this peptide in a subset of microglial cells. After TBI, the density of AIF-1(+) microglia did not increase significantly. Lesional expression of AIF-1 did not significantly differ from other brain regions. Furthermore, following TBI, we found no significant differences in the density of AIF-1+ microglia as compared to controls. Microglial MRP8 expression was not detectable in controls and within the first 3 days post TBI, but increased rapidly after 3 days post TBI, suggesting a subpopulation of microglial cells to be AIF-1(-)/MRP8(+). We conclude that the delayed expression of MRP8 and the lack of AIF-1 up-regulation in microglia after TBI is in contrast to ischemic brain lesions and might reflect different activation cascades of microglia.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Univ Tubingen, Dept Med Biometry, D-72076 Tubingen, Germany	Beschorner, R (corresponding author), Univ Tubingen, Inst Brain Res, Calwerstr 3, D-72076 Tubingen, Germany.		Dietz, Klaus/R-9268-2016; Beschorner, Rudi/M-6397-2014	Dietz, Klaus/0000-0001-8503-9737; Mittelbronn, Michel/0000-0002-2998-052X; Beschorner, Rudi/0000-0003-1109-915X			Abe M, 1999, J NEUROL, V246, P358, DOI 10.1007/s004150050363; Autieri MV, 1996, BIOCHEM BIOPH RES CO, V228, P29, DOI 10.1006/bbrc.1996.1612; Chen ZW, 1997, P NATL ACAD SCI USA, V94, P13879, DOI 10.1073/pnas.94.25.13879; ENGEL S, 1996, NACTA NEUROCHIR WI S, V66, P89; ENGEL S, 2000, IN PRESS ACTA NEUROP; GILCHRIST JSC, 1994, MOL CELL BIOCHEM, V135, P79, DOI 10.1007/BF00925963; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; LAGASSE E, 1992, BLOOD, V79, P1907; LAN HY, 1995, J HISTOCHEM CYTOCHEM, V43, P97, DOI 10.1177/43.1.7822770; Lugering N, 1998, Z GASTROENTEROL, V36, P173; MAHNKE K, 1995, J LEUKOCYTE BIOL, V57, P63; MATTIACE LA, 1990, AM J PATHOL, V136, P1101; McLarnon JG, 1997, NEUROSCIENCE, V78, P1217, DOI 10.1016/S0306-4522(96)00680-X; Moller T, 1997, J NEUROSCI, V17, P615; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Postler E, 2000, J NEUROIMMUNOL, V104, P85, DOI 10.1016/S0165-5728(99)00222-2; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; ROTH J, 1994, BIOCHEM J, V301, P655, DOI 10.1042/bj3010655; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schluesener HJ, 1999, ACTA NEUROPATHOL, V97, P119, DOI 10.1007/s004010050964; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; Streit Wolfgang J., 1995, P85; Tanaka S, 1998, J NEUROSCI, V18, P6358; UTANS U, 1995, J CLIN INVEST, V95, P2954, DOI 10.1172/JCI118003; Utans U, 1996, TRANSPLANTATION, V61, P1387, DOI 10.1097/00007890-199605150-00018; Wege H, 1998, ADV EXP MED BIOL, V440, P437	31	26	26	0	6	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	DEC	2000	100	6					627	634		10.1007/s004010000232			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	365ZY	WOS:000089981400006	11078214	Green Published			2021-06-18	
J	Coolidge, FL; Segal, DL; Stewart, SE; Ellett, JAC				Coolidge, FL; Segal, DL; Stewart, SE; Ellett, JAC			Neuropsychological dysfunction in children with borderline personality disorder features: A preliminary investigation	JOURNAL OF RESEARCH IN PERSONALITY			English	Article							DIMENSIONS; TWIN	Borderline personality disorder (BPD) is often linked to neuropsychological deficits, yet few studies have examined BPD or its features and concomitant neuropsychological dysfunction in childhood. This study examined children with borderline features (n = 21) using the Coolidge Personality and Neuropsychological Inventory for Children and compared them to controls (n = 21) with features of at least one personality disorder, but not BPD. As hypothesized, the BPD group scored significantly higher than the control group on the Attention Deficit/Hyperactivity Disorder, Executive Functions Deficits, Mild Neurocognitive Disorder, Conduct Disorder. and Oppositional Defiant Disorder scales. It appears that behavioral disturbances associated with BPD are linked strongly with neuropsychological dysfunction. Because none of the children with BPD features in the present sample had a history of traumatic brain injury (TBI), it appears likely that TBI in the histories of adult BPD patients may not be the cause of BPD, but traits such as anger and impulsivity in BPD may cause TBI. Clinical implications and future research directions are discussed. (C) 2000 Academic Press.	Univ Colorado, Dept Psychol, Colorado Springs, CO 80933 USA	Coolidge, FL (corresponding author), Univ Colorado, Dept Psychol, POB 7150, Colorado Springs, CO 80933 USA.			Ellett, Julie/0000-0002-7034-5691			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDRULONIS PA, 1981, PSYCHIAT CLIN N AM, V4, P47; ANDRULONIS PA, 1982, J NERV MENT DIS, V170, P670, DOI 10.1097/00005053-198211000-00006; BEMPORAD JR, 1982, AM J PSYCHIAT, V139, P596; Coolidge F.L., 1992, J PERSONALITY CLIN S, V8, P7; COOLIDGE FL, 1994, INDIAN J PSYCHOL ISS, V2, P1; COOLIDGE FL, 1990, J PERSONALITY CLIN S, V6, P225; COOLIDGE FL, 1999, M SOC PERS ASS NEW O; COOLIDGE FL, 1998, COOLIDGE PERSONALITY; COOLIDGE FL, 2000, COOLIDGE PERSONALITY; FRIEDMAN MC, 1998, THESIS U COLOARDO CO; GARDNER D, 1987, J NERV MENT DIS, V175, P177, DOI 10.1097/00005053-198703000-00009; GIOIA GA, 1999, M AM PSYCH ASS BOST; HECHTMAN L, 1994, J PSYCHIATR NEUROSCI, V19, P193; HOLM S, 1979, SCAND J STAT, V6, P65; Jang KL, 1996, ACTA PSYCHIAT SCAND, V94, P438, DOI 10.1111/j.1600-0447.1996.tb09887.x; KERNBERG PF, 1983, PSYCHIAT HOSP, V13, P137; KIMBLE CR, 1997, ROLE SEXUAL ABUSE ET, P165; KREUTZER JS, 1999, M AM PSYCH ASS BOST; LEWIS M, 1976, J AM ACAD CHILD PSY, V15, P131, DOI 10.1016/S0002-7138(09)62265-2; LIVESLEY WJ, 1993, AM J PSYCHIAT, V150, P1826; MURRAY ME, 1979, AM J PSYCHOTHER, V33, P391; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; PHILBRICK PB, 1990, THESIS U COLARDO COL; QUITKIN F, 1976, ARCH GEN PSYCHIAT, V33, P845; REILMAN BJ, 1993, THESIS U COLARDO COL; Rosnow R.L., 1996, BEGINNING BEHAV RES; Sherman DK, 1997, J AM ACAD CHILD PSY, V36, P745, DOI 10.1097/00004583-199706000-00010; SILVER CH, 1999, M AM PSYCH ASS BOST; SOLOFF PH, 1983, COMPR PSYCHIAT, V24, P574, DOI 10.1016/0010-440X(83)90026-3; SPREEN O, 1989, J CLIN EXP NEUROPSYC, V11, P117, DOI 10.1080/01688638908400880; VANREEKUM R, 1993, CAN J PSYCHIAT S1, V38, P4; VERHULST FC, 1984, ACTA PAEDOPSYCHIATR, V50, P161	33	26	27	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0092-6566			J RES PERS	J. Res. Pers.	DEC	2000	34	4					554	561		10.1006/jrpe.2000.2298			8	Psychology, Social	Psychology	376ME	WOS:000165460700010					2021-06-18	
J	Bentzer, P; Davidsson, H; Grande, PO				Bentzer, P; Davidsson, H; Grande, PO			Microdialysis-based long-term measurements of energy-related metabolites in the rat brain following a fluid percussion trauma	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion injury; glucose; lactate; lactate/pyruvate ratio; microdialysis	CEREBRAL EXTRACELLULAR GLUCOSE; EXPERIMENTAL HEAD-INJURY; LACTATE CONCENTRATIONS; SKELETAL-MUSCLE; AMINO-ACIDS; DAMAGE; HYPERLACTATEMIA; HYPOXIA; SEPSIS	The aim of the study was to evaluate an experimental approach based on a fluid percussion rat trauma model in combination with the microdialysis technique for the analysis of cerebral interstitial biochemical alterations following head trauma, and to test the hypothesis that the previously observed acute accumulation of lactate and increase in the lactate pyruvate ratio may persist for several days following trauma. We analyzed how lactate, pyruvate, and glucose were altered in the cortex adjacent to the contusion and in the contralateral side of the brain following a traumatic brain injury. The results were compared with those from sham-operated animals. The lactate concentration in the cortex adjacent to the contusion was 0.73 +/- 0.13 mmol/L and 0.71 +/- 0.08 mmol/L 24 and 48 h posttrauma, respectively, and 0.42 +/- 0.07 mmol/L in the sham group (p < 0.05). The lactate/pyruvate ratio of 18.3 +/- 2.3 in the cortex adjacent to the contusion 24 h posttrauma was higher than corresponding value of 10.3 +/- 1.5 in the sham group (p < 0.05). The lactate/pyruvate ratio 48 h posttrauma did not differ from that in the sham group. Interstitial glucose in the cortex adjacent to the contusion and the sham group were similar. Microdialysis measurements from the contralateral side did not differ from those in the sham group. We conclude that the previously oh. served acute alterations in brain metabolism persist for at least 48 h posttrauma. Further, the measured parameters from the contralateral side can be used as controls since they did not differ from the sham group. Combining microdialysis with a fluid percussion trauma model may be a tool to explore secondary brain injury mechanisms and evaluate new therapies for the treatment of traumatic brain injury.	Lund Univ, Dept Physiol Sci, SE-22362 Lund, Sweden	Bentzer, P (corresponding author), Lund Univ, Dept Physiol Sci, Solvegatan 19, SE-22362 Lund, Sweden.	peter.bentzer@mphy.lu.se					Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; HARADA M, 1992, ANESTHESIOLOGY, V77, P728, DOI 10.1097/00000542-199210000-00017; HOTCHKISS RS, 1992, JAMA-J AM MED ASSOC, V267, P1503, DOI 10.1001/jama.267.11.1503; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SIESJO BK, 1978, BRAIN ENERGY METABOL, P192; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; Vary TC, 1999, JPEN-PARENTER ENTER, V23, P213, DOI 10.1177/0148607199023004213; Vary TC, 1998, J SURG RES, V80, P44, DOI 10.1006/jsre.1998.5324; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	27	26	28	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2000	17	5					441	447		10.1089/neu.2000.17.441			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	316BB	WOS:000087146500007	10833063				2021-06-18	
J	Adkins, SB; Figler, RA				Adkins, SB; Figler, RA			Hip pain in athletes	AMERICAN FAMILY PHYSICIAN			English	Article							STRESS-FRACTURES; INJURIES; OSTEOARTHRITIS; KNEE; PELVIS; SPORTS	Hip pain in athletes involves a wide differential diagnosis. Adolescents and young adults are at particular risk for various apophyseal and epiphyseal injuries due to lack of ossification of these cartilaginous growth plates. Older athletes are more likely to present with tendinitis in these areas because their growth plates have closed. Several bursae in the hip area are prone to inflammation. The trochanteric bursa is the most commonly injured, and the lesion is easily identified by palpation of the area. Iliotibial band syndrome presents with similar lateral hip pain and may be identified by provocative testing (Ober's test). A methodical physical examination that specifically tests the various muscle groups that move the hip joint can help determine a more specific diagnosis for the often vague complaint of hip pain. A number of hip conditions are more prevalent in athletes of certain ages. Transient synovitis is a common diagnosis in the very young, Legg-Calve-Perthes disease causes bony disruption of the femoral head in prepubescents, and slipped capital femoral epiphysis is seen most commonly in obese adolescent males. Femoral neck stress fractures are seen in adult athletes, especially those involved in endurance sports, and can progress to necrosis of the femoral head if not found early. Older athletes may be limited by degenerative joint disease but nonetheless should be encouraged to stay active.	E Carolina Univ, Sch Med, Dept Family Med, Family Med Residency Program, Greenville, NC 27858 USA	Adkins, SB (corresponding author), E Carolina Univ, Sch Med, Dept Family Med, Family Med Residency Program, Greenville, NC 27858 USA.						Boyd KT, 1997, SPORTS MED, V24, P273, DOI 10.2165/00007256-199724040-00005; COFFEY J, 1978, PEDIAT XRAY DIAGNOSI; EDEESON J, 1994, J BONE JOINT SURG, V76, P993; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1343, DOI 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9; FULLERTON LR, 1990, SPORTS MED, V9, P192, DOI 10.2165/00007256-199009030-00006; Guidera K J, 1995, Adv Pediatr, V42, P501; HOLLINGWORTH P, 1995, BRIT J RHEUMATOL, V34, P78; Lane NE, 1998, J RHEUMATOL, V25, P334; METZMAKER JN, 1985, AM J SPORT MED, V13, P349, DOI 10.1177/036354658501300510; NATTIV A, 1994, CLIN SPORT MED, V13, P405; PALETTA GA, 1995, CLIN SPORT MED, V14, P591; PRATHER JL, 1977, J BONE JOINT SURG AM, V59, P869, DOI 10.2106/00004623-197759070-00006; Rich Brent S E, 1992, Phys Sportsmed, V20, P104, DOI 10.1080/00913847.1992.11947506; Spector TD, 1996, ARTHRITIS RHEUM, V39, P988, DOI 10.1002/art.1780390616; Stanitski, 1994, J Am Acad Orthop Surg, V2, P96; Stiell IG, 1997, JAMA-J AM MED ASSOC, V278, P2075, DOI 10.1001/jama.278.23.2075; Tandeter HB, 1997, AM FAM PHYSICIAN, V55, P2721; Vingard E, 1998, AM J SPORT MED, V26, P78, DOI 10.1177/03635465980260013101	18	26	28	1	4	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA	0002-838X			AM FAM PHYSICIAN	Am. Fam. Physician	APR 1	2000	61	7					2109	2118					10	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	304FZ	WOS:000086474100014	10779252				2021-06-18	
J	Shum, DHK; Harris, D; O'Gorman, JG				Shum, DHK; Harris, D; O'Gorman, JG			Effects of severe traumatic brain injury on visual memory	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY	The study aimed to clarify the effects of severe traumatic brain injury (TBI) on visual memory. Three groups of participants (14 late-recovery and 14 early-recovery TBI individuals and 18 controls) were administered the following: The Shum Visual Learning Test (SVLT), a test that measures the ability to remember visual patterns, an electronic maze test, a test that measures the ability to remember spatial positions, and the Rey Auditory Verbal Learning Test (RAVLT), a test of verbal memory and learning. The individuals with TBI (late- and early-recovery) were found to be impaired on the SVLT and the RAVLT but not on the electronic maze. Specifically, on the SVLT, they were found to learn at a slower rate and make more false-positive errors than the controls. The advantages of the SVLT over visual memory tests used in previous studies and the significance of findings of the present study were discussed.	Griffith Univ, Neuropsychol Unit, Brisbane, Qld, Australia; Griffith Univ, Sch Appl Psychol, Brisbane, Qld, Australia	Shum, DHK (corresponding author), Griffith Univ, Sch Appl Psychol, Nathan, Qld 4111, Australia.		Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			BOWDEN SC, 1994, AUST PSYCHOL, V29, P34, DOI 10.1080/00050069408257317; BOWDEN SC, 1988, J CLIN EXP NEUROPSYC, V10, P157, DOI 10.1080/01688638808408232; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P224; BROOKS DN, 1976, CORTEX, V10, P224; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CULLUM CM, 1990, TRAUMATIC BRAIN INJU, P129; DELIS DC, 1989, HDB NEUROPSYCHOLOGY, V3, P3; EADIE K, 1995, J CLIN EXP NEUROPSYC, V17, P731, DOI 10.1080/01688639508405163; GEFFEN GM, 1994, BRAIN INJURY, V8, P405, DOI 10.3109/02699059409150992; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HEILBRONNER RL, 1992, CLIN NEUROPSYCHOL, V6, P105; KIMURA D, 1963, ARCH NEUROL-CHICAGO, V8, P48; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; Lee G.P., 1989, PSYCHOL ASSESSMENT J, V1, DOI [https://doi.org/10.1037/1040-3590.1.3.192, DOI 10.1037/1040-3590.1.3.192]; MAPOU RL, 1992, HDB HEAD TRAUMA EARL, V75, P75; Mayes A., 1992, HDB NEUROPSYCHOLOGIC, P73; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; NEWCOMBE F, 1987, NEUROPSYCHOLOGIA, V25, P149, DOI 10.1016/0028-3932(87)90127-8; REID DB, 1993, J CLIN PSYCHOL, V49, P245, DOI 10.1002/1097-4679(199303)49:2<245::AID-JCLP2270490219>3.0.CO;2-1; Rey A, 1964, EXAMEN CLIN PSYCHOL; SHUM DHK, IN PRESS CLIN NEUROP; VANDERPLAS JM, 1959, J EXP PSYCHOL, V57, P147, DOI 10.1037/h0048723; VANZOMEREN AH, 1990, HDB CLIN NEUROLOGY, V13, P397; Walsh K. W, 1991, UNDERSTANDING BRAIN; Wechsler D., 1987, WECHSLER MEMORY SCAL; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]	28	26	26	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	2000	22	1					25	39		10.1076/1380-3395(200002)22:1;1-8;FT025			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	287BE	WOS:000085484000003	10649543				2021-06-18	
J	Smith, JS; Fulop, ZL; Levinsohn, SA; Darrell, RS; Stein, DG				Smith, JS; Fulop, ZL; Levinsohn, SA; Darrell, RS; Stein, DG			Effects of the novel NMDA receptor antagonist gacyclidine on recovery from medial frontal cortex contusion injury in rats	NEURAL PLASTICITY			English	Article						gacyclidine; contusion; medial frontal cortex; trauma; Morris water maze; recovery of function; inflammation; NMDA-receptor antagonist	TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; GROWTH-HORMONE SECRETION; D-ASPARTATE RECEPTORS; BLOOD-FLOW; NONCOMPETITIVE BLOCKADE; NEUROCHEMICAL SEQUELAE; GLUTAMATE ANTAGONISTS; FUNCTIONAL RECOVERY; CORTICAL CONTUSION	Gacyclidine, a novel, noncompetitive NMDA receptor,antagonist, was injected (i.v.) into rats at three different doses to determine if the drug could promote behavioral recovery and reduce the behavioral and anatomical impairments that occur after bilateral contusions of the medial frontal cortex (MFC), In the Morris water maze, contused rats treated with gacyclidine at a dosage of 0.1 mg/kg performed better than their vehicle-treated conspecifics. Rats given gacyclidine at either 0.3 or 0.03 mg/kg performed better than brain-injured controls, but not as well as those treated:with 0.1 mg/kg, Counts of surviving neurons in the nucleus basalis magnocellularis (NBM) and the medial dorsal nucleus (MDN) of the thalamus were used to determine whether gacyclidine treatment attenuated secondary cell death. In both the NBM and the MDN, the counts revealed fewer surviving neurons in untreated contused rats than in gacyclidine-treated rats. Increases in the size and number of microglia and astrocytes were observed in the striatum of gacyclidine-treated contused brains. Although most consequences of MFC contusions were attenuated, we still observed increases in ventricle dilation and thinning of the cortex. In fact, the ventricles of rats treated with 0.1 mg/kg of gacyclidine were larger than those of their vehicle treated counterparts, although we observed no behavioral impairment.	Emory Univ, Brain Res Lab, Dept Neurol, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Brain Res Lab, Dept Neurol, 575 Rollins Way, Atlanta, GA 30322 USA.	dgstein@gsas.emory.edu	Stein, Donald/AAJ-5139-2020	Smith, Jeffrey/0000-0001-5499-4475			ARSLAN M, 1992, LIFE SCI, V50, P295, DOI 10.1016/0024-3205(92)90337-O; ASSOULINE JG, 1987, DEV BRAIN RES, V31, P103, DOI 10.1016/0165-3806(87)90087-3; ATTELLA MJ, 1992, BEHAV NEURAL BIOL, V57, P157, DOI 10.1016/0163-1047(92)90665-Q; BALASINGAM V, 1994, J NEUROSCI, V14, P846; Bissonnette JM, 1997, J PHYSIOL-LONDON, V501, P415, DOI 10.1111/j.1469-7793.1997.415bn.x; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Bullock R, 1995, ANN NY ACAD SCI, V765, P272, DOI 10.1111/j.1749-6632.1995.tb16584.x; Conti F, 1996, GLIA, V17, P254, DOI 10.1002/(SICI)1098-1136(199607)17:3<254::AID-GLIA7>3.0.CO;2-0; Conti F, 1997, MOL NEUROBIOL, V14, P1, DOI 10.1007/BF02740618; CULLCANDY S, 1995, CURR BIOL, V5, P841, DOI 10.1016/S0960-9822(95)00168-0; DEKKER AJAM, 1991, NEUROSCI BIOBEHAV R, V15, P299, DOI 10.1016/S0149-7634(05)80008-9; DRIAN MJ, 1991, J NEUROSCI RES, V29, P133, DOI 10.1002/jnr.490290116; ESPANOL MT, 1994, ACTA NEUROCHIR, P58; Estienne MJ, 1996, J ANIM SCI, V74, P597; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fox RM, 1996, NEUROTOXICOLOGY, V17, P705; Fulop ZL, 1997, INT J NEUROSCI, V90, P203, DOI 10.3109/00207459709000639; GALLYAS F, 1970, ACTA NEUROPATHOL, V16, P35, DOI 10.1007/BF00686961; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; GOLDING EM, 1995, MOL CHEM NEUROPATHOL, V24, P137, DOI 10.1007/BF02962139; GRAY JA, 1983, NEUROSCI BIOBEHAV R, V7, P119, DOI 10.1016/0149-7634(83)90014-3; HAGLID KG, 1991, J NEUROCHEM, V56, P1957, DOI 10.1111/j.1471-4159.1991.tb03453.x; HANKER G, 1980, SCIENCE, V209, P809; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; IRLE E, 1990, BRAIN RES REV, V15, P181, DOI 10.1016/0165-0173(90)90001-5; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KOLB B, 1982, BEHAV BRAIN RES, V6, P365, DOI 10.1016/0166-4328(82)90018-3; KURODA Y, 1994, NEUROSURGERY, V35, P106, DOI 10.1227/00006123-199407000-00016; Leggate J R, 1988, Br J Neurosurg, V2, P327, DOI 10.3109/02688698809001003; LEONARD CM, 1969, BRAIN RES, V12, P321, DOI 10.1016/0006-8993(69)90003-1; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lu XW, 1997, NEUROCHEM RES, V22, P705, DOI 10.1023/A:1027354110563; Maione S, 1998, PHARMACOL BIOCHEM BE, V59, P233, DOI 10.1016/S0091-3057(97)00337-7; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MEYER FB, 1990, J CEREBR BLOOD F MET, V10, P895, DOI 10.1038/jcbfm.1990.146; Miller RD, 1996, J NEUROL SCI, V136, P37, DOI 10.1016/0022-510X(95)00309-P; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; MURPHY S, 1987, NEUROSCIENCE, V22, P381, DOI 10.1016/0306-4522(87)90342-3; Myseros JS, 1995, ANN NY ACAD SCI, V765, P262, DOI 10.1111/j.1749-6632.1995.tb16583.x; Nordqvist ACS, 1997, NEUROREPORT, V8, P455, DOI 10.1097/00001756-199701200-00016; O'Brien M D, 1982, Exp Brain Res, VSuppl 5, P196; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PAXINOS G, 1986, RAT BRAIN; PEARCE B, 1991, ANN NY ACAD SCI, V633, P432; Pinilla L, 1996, J ENDOCRINOL INVEST, V19, P353, DOI 10.1007/BF03344969; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUDGE JS, 1985, BRAIN RES, V31, P161; SAUER D, 1988, NEUROSCI LETT, V91, P327, DOI 10.1016/0304-3940(88)90701-X; SLUKA KA, 1994, PAIN, V59, P95, DOI 10.1016/0304-3959(94)90052-3; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Stein DG, 1991, J NEUROTRAUM, V8, P281, DOI 10.1089/neu.1991.8.281; STEVENS MK, 1990, J CEREBR BLOOD F MET, V10, P77, DOI 10.1038/jcbfm.1990.10; VACA K, 1992, EXP NEUROL, V118, P62, DOI 10.1016/0014-4886(92)90023-J; WALTZ W, 1989, PROG NEUROBIOL, V33, P309; WATSON RE, 1986, PEPTIDES, V7, P155, DOI 10.1016/0196-9781(86)90076-8; WILKIN GP, 1991, ANN NY ACAD SCI, V633, P475	66	26	26	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-5904	1687-5443		NEURAL PLAST	Neural. Plast.		2000	7	1-2					73	91		10.1155/NP.2000.73			19	Neurosciences	Neurosciences & Neurology	260BP	WOS:000083928700009	10709216	DOAJ Gold, Green Published			2021-06-18	
J	Rousseau, V; Engelmann, R; Sabel, BA				Rousseau, V; Engelmann, R; Sabel, BA			Restoration of vision III: soma swelling dynamics predicts neuronal death or survival after optic nerve crush in vivo	NEUROREPORT			English	Article						axonal injury; cell death; ICON microscopy; neuron survival; plasticity; recovery; retinal ganglion cells; vision	ADULT-RATS; INJURY; MICROSCOPY; RECOVERY; MODEL; CAT	PREDICTING neuron death or survival after axonal injury is important in neurotrauma research. We now used in vivo confocal neuroimaging microscopy to repeatedly visualize retinal ganglion cells after optic nerve crush and studied their morphological alterations and ultimate fate. An intracollicular injection of a retrograde fluorescent tracer was made before or after optic nerve crush. Retinal ganglion cell sizes were then determined at different time points up to post-surgery day 75. Cell death was inevitable when soma swelling was fast and massive (86% above baseline or higher), but when it was slower and moderate (32% above baseline) long-term neuron survival could be predicted with high accuracy as early as post-operative day 5. Moderate swelling continued until day 15 (64%) and after about 3 weeks these cells started shrinking again, as a sign of recovery. We propose that moderate soma swelling is an adaptive rather than pathogenic posttraumatic reaction to axonal injury. NeuroReport 10:3387-3391 (C) 1999 Lippincott Williams & Wilkins.	Univ Magdeburg, Inst Med Psychol, D-39120 Magdeburg, Germany; Leibniz Inst Neurobiol, D-39118 Magdeburg, Germany	Sabel, BA (corresponding author), Univ Magdeburg, Inst Med Psychol, Leipzigerstr 44, D-39120 Magdeburg, Germany.		Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543			BERARDI N, 1999, IN PRESS RESTOR NEUR, V15; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; CHINO MY, 1999, IN PRESS RESTOR NEUR, V15; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; EYSEL UT, 1985, EXP NEUROL, V88, P757, DOI 10.1016/0014-4886(85)90086-X; EYSEL UT, 1999, IN PRESS RESTOR NEUR, V15; FINE A, 1988, TRENDS NEUROSCI, V11, P346, DOI 10.1016/0166-2236(88)90056-2; FROST D, 1999, IN PRESS RESTOR NEUR, V15; Gennarelli T.A., 1986, MECHANISMS SECONDARY, P15; Kasten E, 1998, NAT MED, V4, P1083, DOI 10.1038/2079; KASTEN E, 1999, IN PRESS RESTOR NEUR, V15; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; PAYNE B, 1999, IN PRESS RESTOR NEUR, V15; Sabel BA, 1997, NAT MED, V3, P244, DOI 10.1038/nm0297-244; Sabel BA, 1997, ADV NEUROL, V73, P251; SABEL BA, 1999, IN PRESS RESTOR NEUR, V15; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SHOTTON DM, 1989, J CELL SCI, V94, P175; SILVEIRA LCL, 1994, J NEUROCYTOL, V23, P75, DOI 10.1007/BF01183863; STEWARD O, 1982, INT REV NEUROBIOL, V23, P197, DOI 10.1016/S0074-7742(08)60626-1; Tetzlaff W, 1990, Restor Neurol Neurosci, V1, P189, DOI 10.3233/RNN-1990-13403; ULFHAKE B, 1991, J NEUROSCI METH, V40, P39, DOI 10.1016/0165-0270(91)90115-G; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; WHITNALL MH, 1983, BRAIN RES, V272, P49, DOI 10.1016/0006-8993(83)90363-3	24	26	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	NOV 8	1999	10	16					3387	3391		10.1097/00001756-199911080-00024			5	Neurosciences	Neurosciences & Neurology	257QH	WOS:000083792700025	10599850				2021-06-18	
J	Gerwick, L; Demers, NE; Bayne, CJ				Gerwick, L; Demers, NE; Bayne, CJ			Modulation of stress hormones in rainbow trout by means of anesthesia, sensory deprivation and receptor blockade	COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY			English	Article						stress; anesthesia; antagonist; catecholamine; cortisol; Oncorhynchus; spleen; trout; 2-phenoxyethanol	CORTISOL; PHAGOCYTES; SALMON; BURST	Sympathetic activation leading to increased levels of blood catecholamines, and stimulation of the hypothalamic-pituitary-inter-renal axis leading to increased cortisol, are difficult to avoid when handling animals. Yet, in research on effects of acute stress, elicitation of such responses must be minimized in the control groups. The work examines means to achieve a mimmally disturbed stale in rainbow trout (Oncorhynchus mykiss). Level of arousal was determined by adrenaline and cortisol concentrations in plasma, and by the spleen:somatic index. Fish were prepared for bleeding by rapid capture and concussion, by infusion of anesthetic into the undisturbed home tank, by confinement in black boxes, or by being fed alpha- and P-receptor antagonists. Even when done quickly, netting and concussion yielded fish with ca. 200-pmol adrenaline/ml plasma. Cortisol was elevated(to > 10 ng/ml) within 30 s of stress initiation. Surreptitious infusion of anesthetic (2-phenoxyethanol, PE) into tanks yielded fish with lower adrenaline levels (means 19.34 and 19.58 pmols/ml in home tank and black boxes, respectively). Among fish given phentolamine and propranolol, spleen:somatic indices and plasma adrenaline were higher than in diet controls, whether undisturbed or stressed, indicative of successful receptor blockade. Since careful infusion of 2-PE yielded the lowest adrenaline levels, and requires no special apparatus, it is the method of choice for obtaining minimally stressed fish. (C) 1999 Elsevier Science Inc. All rights reserved.	Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA	Gerwick, L (corresponding author), Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA.	gerwickl@bcc.orst.edu			NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES-00210, ES-03850] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P50ES003850, P30ES000210, P30ES003850] Funding Source: NIH RePORTER		BAYNE CJ, 1991, J LEUKOCYTE BIOL, V50, P554; BAYNE CJ, 1991, J FISH BIOL, V38, P609, DOI 10.1111/j.1095-8649.1991.tb03147.x; BERNARD C, 1959, HOMEOSTASIS ORIGINS; Cannon W.B., 1915, BODILY CHANGES PAIN; Demers NE, 1997, DEV COMP IMMUNOL, V21, P363, DOI 10.1016/S0145-305X(97)00009-8; DEMERS NE, 1994, MODULATORS FISH IMMU, V1; FLORY C M, 1989, Brain Behavior and Immunity, V3, P331, DOI 10.1016/0889-1591(89)90032-9; FLORY CM, 1990, DEV COMP IMMUNOL, V14, P283, DOI 10.1016/0145-305X(90)90019-B; GAMPERL AK, 1994, J FISH BIOL, V45, P313; IWAMA GK, 1989, CAN J ZOOL, V67, P2065, DOI 10.1139/z89-294; KIECOLTGLASER JK, 1992, PSYCHOSOM MED, V54, P680, DOI 10.1097/00006842-199211000-00008; MATTHEWS KA, 1995, PSYCHOSOM MED, V57, P564, DOI 10.1097/00006842-199511000-00009; MAULE AG, 1989, J ENDOCRINOL, V120, P135, DOI 10.1677/joe.0.1200135; NALIBOFF BD, 1995, BRAIN BEHAV IMMUN, V9, P207, DOI 10.1006/brbi.1995.1020; PEARSON MP, 1991, FISH PHYSIOL BIOCHEM, V9, P39, DOI 10.1007/BF01987610; POTTINGER TG, 1993, J FISH BIOL, V43, P121, DOI 10.1111/j.1095-8649.1993.tb00415.x; REDDING JM, 1984, GEN COMP ENDOCR, V56, P146, DOI 10.1016/0016-6480(84)90071-6; Ruis MAW, 1997, J AQUAT ANIM HEALTH, V9, P190, DOI 10.1577/1548-8667(1997)009&lt;0190:EOASOB&gt;2.3.CO;2; SCHRECK CB, 1996, FISH IMMUNE SYSTEM, V15; SELYE H, 1973, AM SCI, V61, P692; SELYE H, 1950, BRIT MED J, V1, P1383, DOI 10.1136/bmj.1.4667.1383; Thomas P, 1990, AM FISHERIES SOC S, V8, P9; Wedemeyer G.A., 1990, P451	23	26	27	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1095-6433	1531-4332		COMP BIOCHEM PHYS A	Comp. Biochem. Physiol. A-Mol. Integr. Physiol.	NOV	1999	124	3					329	334		10.1016/S1095-6433(99)00126-9			6	Biochemistry & Molecular Biology; Physiology; Zoology	Biochemistry & Molecular Biology; Physiology; Zoology	264LF	WOS:000084183200009	10665382	Green Published			2021-06-18	
J	Driesse, MJ; Kros, JM; Avezaat, CJJ; Valerio, D; Vecht, CJ; Bout, A; Smitt, PAES				Driesse, MJ; Kros, JM; Avezaat, CJJ; Valerio, D; Vecht, CJ; Bout, A; Smitt, PAES			Distribution of recombinant adenovirus in the cerebrospinal fluid of nonhuman primates	HUMAN GENE THERAPY			English	Article							MONKEY AIRWAY EPITHELIUM; BLOOD-BRAIN-BARRIER; GENE-TRANSFER; IMMUNE-RESPONSE; RAT MODEL; VECTORS; METHOTREXATE; EXPRESSION; THERAPY; LUNG	Gene therapy by administration of vectors into the cerebrospinal fluid (CSF) may be used in treatment of leptomeningeal metastases (cancer gene therapy) as well as in treatment of neurodegenerative disorders, traumatic injury, and chronic pain. Recombinant adenoviruses are attractive vectors for intra-CSF administration because they can efficiently transfer genes into the nonreplicating cells of the central nervous system (CNS). In addition, they can be produced in high titers and, because no producers cells are introduced, the risk of CSF obstruction by clustering cells is circumvented. However, successful application requires favorable distribution dynamics, high transduction efficiency, and long-lasting transgene expression. In this study we examined the distribution of a recombinant adenovirus containing the lacZ gene after administration into the CSF of nonhuman primates. After intraventricular and suboccipital administration, homogeneous distribution of the vector along the meninges covering the brain and spinal cord was obtained, as demonstrated by extensive and intense blue staining of cells, predominantly in the arachnoid and pia mater. In one animal we also found beta-galactosidase activity in the cervical paraspinal fat and in one of the deep cervical lymph nodes, indicating drainage of the vector or vector products with CSF into cervical lymph. This route of vector clearance from the CNS may result in antigenic presentation and an effective immune response and may explain the sixfold higher serum antibody titers after intrathecal injection of adenovirus as compared with intranasal application in Fischer rats. We conclude that distribution dynamics of recombinant adenovirus after intra-CSP administration are excellent. However, because of the immune response elicited by the virus, even after administration to the CNS, development of immunomodulating strategies remains a challenge.	Univ Rotterdam Hosp, Dept Neurooncol, Dept Neurosurg, NL-3008 AE Rotterdam, Netherlands; Univ Rotterdam Hosp, Dept Pathol, NL-3008 AE Rotterdam, Netherlands; Leiden Univ, Dept Mol Cell Biol, NL-2301 CA Leiden, Netherlands; IntroGene BV, NL-2301 CA Leiden, Netherlands	Driesse, MJ (corresponding author), Univ Rotterdam Hosp, Dept Neurooncol, Dept Neurosurg, POB 5201, NL-3008 AE Rotterdam, Netherlands.						BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; BLANEY SM, 1995, J CLIN ONCOL, V13, P177, DOI 10.1200/JCO.1995.13.1.177; BOUT A, 1993, EXP LUNG RES, V19, P193, DOI 10.3109/01902149309031719; BOUT A, 1994, GENE THER, V1, P385; BOUT A, 1994, HUM GENE THER, V5, P3, DOI 10.1089/hum.1994.5.1-3; BRADBURY MWB, 1990, FERNS FOUND SERIES, V14, P403; CSERR HF, 1992, J NEUROIMMUNOL, V41, P195, DOI 10.1016/0165-5728(92)90070-2; CSERR HF, 1992, IMMUNOL TODAY, V13, P507, DOI 10.1016/0167-5699(92)90027-5; DEJONG JC, 1993, J CLIN MICROBIOL, V31, P1562, DOI 10.1128/JCM.31.6.1562-1569.1993; ERLICH SS, 1986, J NEUROSURG, V64, P466, DOI 10.3171/jns.1986.64.3.0466; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Fishman RA., 1992, CEREBROSPINAL FLUID; Fortunati E, 1996, BBA-GENE STRUCT EXPR, V1306, P55, DOI 10.1016/0167-4781(95)00217-0; Furlan R, 1998, HUM GENE THER, V9, P2605, DOI 10.1089/hum.1998.9.17-2605; GORDON LB, 1992, J NEUROIMMUNOL, V40, P81, DOI 10.1016/0165-5728(92)90215-7; Gravel C, 1997, NAT MED, V3, P765, DOI 10.1038/nm0797-765; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; LE GLS, 1993, SCIENCE, V259, P988; MCCOMB JG, 1990, FERNS FOUND SERIES, V14, P421; MCCULLY CL, 1990, LAB ANIM SCI, V40, P520; MILHORAT TH, 1970, J NEUROSURG, V32, P522, DOI 10.3171/jns.1970.32.5.0522; Morral N, 1997, HUM GENE THER, V8, P1275, DOI 10.1089/hum.1997.8.10-1275; Ohashi T, 1997, P NATL ACAD SCI USA, V94, P1287, DOI 10.1073/pnas.94.4.1287; Posner JB, 1995, NEUROLOGIC COMPLICAT, P143; PRECIOUS B, 1985, VIROLOGY PRACTICAL A, P157; SHAPIRO WR, 1975, NEW ENGL J MED, V293, P161, DOI 10.1056/NEJM197507242930402; Smith JG, 1998, GENE THERAPY NEUROLO, P147; SNIDER RS, 1961, STEREOTACTIC ATLAS M; Stevenson PG, 1997, J VIROL, V71, P145, DOI 10.1128/JVI.71.1.145-151.1997; Vincent AJPE, 1997, NEUROSURGERY, V41, P442, DOI 10.1097/00006123-199708000-00023; Vincent AJPE, 1996, J NEUROSURG, V85, P648, DOI 10.3171/jns.1996.85.4.0648	33	26	28	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1043-0342			HUM GENE THER	Hum. Gene Ther.	SEP 20	1999	10	14					2347	2354		10.1089/10430349950016997			8	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	239JT	WOS:000082765500008	10515454				2021-06-18	
J	Glass, TF; Fabian, MJ; Schweitzer, JB; Weinberg, JA; Proctor, KG				Glass, TF; Fabian, MJ; Schweitzer, JB; Weinberg, JA; Proctor, KG			Secondary neurologic injury resulting from nonhypotensive hemorrhage combined with mild traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral contusion; hemorrhage; secondary brain injury; swine; traumatic brain injury	CEREBRAL BLOOD-FLOW; ISCHEMIA; METABOLISM; RATS; PROPOFOL; OXYGEN; SHOCK; MODEL; RESUSCITATION; HYPOTENSION	Although the emergency physician often treats patients with multiple injuries, there are relatively few clinically relevant models that mimic these situations. To describe the changes after a hemorrhagic insult superimposed on traumatic brain injury (TBI), anesthetized and ventilated juvenile pigs were assigned to 35% hemorrhage (35H), TBI (via fluid percussion); TBI + 35H, and TBI + 40H (40% hemorrhage). Animals were resuscitated with shed blood and crystalloid. Hemodynamic, metabolic, behavioral, and histologic parameters were assessed for 48 h. In TBI, mean arterial pressure (MAP) was not significantly different from baseline. For TBI + 40H, MAP fell by 60% (p < 0.05). This was corrected with resuscitation. Interestingly, TBI + 35H did not show a fall in MAP, while in 35H, MAP was reduced similarly to the TBI + 40H group. ICP was elevated only initially in the TBI group. In TBI + 40H and TBI + 35H, ICP increased markedly with resuscitation, remaining elevated for 60 min. ICP remained at baseline with 35 H. Hemorrhagic focal cerebal contusions at the gray-white interface we:re observed in 3/5 of TBI + 40H and 5/7 of TBI + 35H. Despite the presence of subarachnoid hemorrhage (SAH) in all the animals in the TBI alone group, none of these animals demonstrated grossly discernible intraparenchymal injury. There was no evidence of intracranial injury in the 35H group. Only in animals receiving a secondary insult of hemorrhage following the primary TBI were cerebral contusions found. These experiments demonstrate the evolution of cerebral contusions as a form of secondary neurologic injury following resuscitation from traumatic brain injury and hemorrhage, even in the absence of significant blood pressure changes.	Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; Lebonheur Childrens Hosp & Med Ctr, Memphis, TN USA; Childrens Hosp, Med Ctr, Div Pediat Emergency Med, Cincinnati, OH 45229 USA	Glass, TF (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA.	glast0@chmcc.org					ABRAHAM E, 1995, CRIT CARE MED, V23, P1319, DOI 10.1097/00003246-199508000-00004; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Boswell WC, 1996, SOUTHERN MED J, V89, P218, DOI 10.1097/00007611-199602000-00012; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CIPOLLE MD, 1993, CRIT CARE CLIN, V9, P261; COLLINS T, 1995, SCI AM SCI MED   NOV, P28; Conti AC, 1998, J NEUROSCI, V18, P5663; DELMAESTRO RF, 1979, ACTA U UPSAL, V304, pV1; DeWitt D S, 1995, New Horiz, V3, P376; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; FABIAN TC, 1994, ANN SURG, V220, P552, DOI 10.1097/00000658-199410000-00013; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; HANNON JP, 1990, LAB ANIM SCI, V40, P293; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Lang E W, 1995, New Horiz, V3, P400; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; MILLEN JE, 1980, J APPL PHYSIOL, V49, P856; MILLEN JE, 1983, J APPL PHYSIOL, V54, P666; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; *NAT I DIS REH RES, 1995, NAT PED TRAUM REG BI; Pepperman ML, 1997, PAEDIATR ANAESTH, V7, P143, DOI 10.1046/j.1460-9592.1997.d01-56.x; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; ROBERTSON CS, 1995, NEW HORIZONS, V3, P210; ROUMEN RMH, 1995, CRIT CARE MED, V23, P474, DOI 10.1097/00003246-199503000-00010; Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016; SCHWEITZER JB, 1993, ACTA NEUROPATHOL, V85, P503; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; Smith D H, 1995, New Horiz, V3, P562; Stoffel M, 1997, ACT NEUR S, V70, P91; TREVISANI GT, 1994, J TRAUMA, V37, P452, DOI 10.1097/00005373-199409000-00021; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Wei JN, 1998, BRAIN RES, V791, P146, DOI 10.1016/S0006-8993(98)00089-4; Weinbroum AA, 1997, INTENS CARE MED, V23, P1258, DOI 10.1007/s001340050495; WEISS SJ, 1986, ACTA PHYSIOL SCAND, V126, P9; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	50	26	26	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	1999	16	9					771	782		10.1089/neu.1999.16.771			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	241EL	WOS:000082869700003	10521137				2021-06-18	
J	Elmaraghy, AW; Aksenov, S; Byrick, RJ; Richards, RR; Schemitsch, EH				Elmaraghy, AW; Aksenov, S; Byrick, RJ; Richards, RR; Schemitsch, EH			Pathophysiological effect of fat embolism in a canine model of pulmonary contusion	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							RESPIRATORY-DISTRESS SYNDROME; MULTIPLE TRAUMA; FEMORAL-SHAFT; FRACTURES; FIXATION; DOGS	Background The objective of this study was to determine the individual and combined effects of pulmonary contusion and fat embolism on the hemodynamics and pulmonary pathophysiology in a canine model of acute traumatic pulmonary injury, Methods: After a thoracotomy, twenty-one skeletally mature dogs were randomly assigned to one of three groups, Unilateral, pulmonary contusion alone was produced in Group 1 (seven dogs); pulmonary contusion and fat embolism, in Group 2 (seven dogs); and fat embolism alone, in Group 3 (seven dogs). Pulmonary contusion was produced by standardized compression of the left lung with a piezoelectric force transducer, Fat embolism was produced by femoral and tibial reaming followed by pressurization of the intramedullary canals. Cardiac output, systolic blood pressure, peak airway pressure, pulmonary arterial pressure, pulmonary capillary wedge pressure, partial pressure of arterial oxygen, and partial pressure of carbon dioxide were monitored for all groups. From these data, several outcome parameters were calculated: total thoracic compliance, alveolar-arterial oxygen gradient, and ratio of partial pressure of arterial oxygen to fractional inspired oxygen concentration. All of the dogs were killed after eight hours, and tissue samples were obtained from the brain, kidneys, and lungs for histological analysis, Lung samples were assigned scores for pulmonary edema (the presence of fluid in the: alveoli) and inflammation (the presence of neutrophils or hyaline membranes, or both). The percentage of the total area occupied by fat was determined. Results: Pulmonary contusion alone caused a significant increase in the alveolar-arterial oxygen gradient but only after seven hours (p = 0.034), Fat embolism alone caused a significant transient decrease in systolic blood pressure (p = 0.001) and a significant transient increase in pulmonary arterial pressure (p = 0.01) and pulmonary capillary wedge pressure (p = 0.015), Fat embolism alone also caused a significant sustained decrease in the ratio of partial pressure of arterial oxygen to fractional inspired oxygen concentration (p = 0.0001) and a significant increase in the alveolar-arterial oxygen gradient (p = 0.0001). The combination of pulmonary contusion and fat embolism caused a significant transient increase in pulmonary capillary wedge pressure (p = 0.0013) as well as a significant sustained decrease in partial pressure of arterial oxygen (p = 0.0001) and a significant decrease in systolic blood pressure (p = 0.001) that lasted for an hour. Pulmonary contusion followed by fat embolism caused a significant increase in peak airway pressure (p = 0.015), alveolar-arterial oxygen gradient (p = 0.0001), and pulmonary arterial pressure (p = 0.01), and these effects persisted for five hours. Total thoracic compliance was decreased 6.4 percent by pulmonary contusion alone, 4.6 percent by fat embolism alone, and 23.5 percent by pulmonary contusion followed by fat embolism. The ratio of partial pressure of arterial oxygen to fractional inspired oxygen concentration was decreased 23.7 percent by pulmonary contusion alone, 52.3 percent by fat embolism alone, and 65.8 percent by pulmonary contusion followed by fat embolism. The mean pulmonary edema score was significantly higher with the combined injury than with either injury alone (p = 0.0001), None of the samples from the lungs demonstrated inflammation. Fat embolism combined with pulmonary contusion resulted in a significantly greater mean percentage of the area occupied by fat in the noncontused right lung than in the contused left lung (p = 0.001); however, no significant difference between the right and left lungs could be detected with fat embolism alone, The mean percentage of the glomerular and cerebral areas occupied by fat was greater with fat embolism combined with pulmonary contusion than with fat embolism alone (p = 0.0001 and p = 0.01, respectively). Conclusions: The combination of pulmonary contusion and fat embolism leads to more substantial pulmonary dysfunction than does either form of injury alone. The histological results suggest that the early effects seen following the combination of pulmonary contusion and fat embolism are mediated not by inflammatory changes but by redistribution of pulmonary perfusion by mechanical mechanisms, Clinical Relevance: The redistribution of pulmonary perfusion that occurs as a result of pulmonary contusion may potentiate both the pulmonary and the systemic complications associated with fat emboli if intramedullary nailing adds an embolic load to the venous circulation. The optimum timing and method of fracture fixation may depend not only on the time elapsed since the injury but also on the severity and stage of the associated pulmonary contusion.	Univ Toronto, St Michaels Hosp, Dept Surg, Div Orthopaed Surg,Musculoskeletal Res Lab, Toronto, ON M5C 1R6, Canada; Univ Toronto, St Michaels Hosp, Dept Anaesthesia, Toronto, ON M5C 1R6, Canada	Elmaraghy, AW (corresponding author), Univ Toronto, St Michaels Hosp, Dept Surg, Div Orthopaed Surg,Musculoskeletal Res Lab, 55 Queen St E,Suite 800, Toronto, ON M5C 1R6, Canada.		Schemitsch, Emil/G-5706-2017	Schemitsch, Emil/0000-0002-6435-9069			Alexander RH, 1993, ADV TRAUMA LIFE SUPP, P11; BENUMOF JL, 1975, J APPL PHYSIOL, V38, P846; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BONE LB, 1992, SKELETAL TRAUMA, P127; BYRICK RJ, 1994, AM J RESP CRIT CARE, V150, P1416, DOI 10.1164/ajrccm.150.5.7952570; CLARK GC, 1988, J TRAUMA, V28, P298, DOI 10.1097/00005373-198803000-00004; Cohn SM, 1996, J TRAUMA, V41, P565, DOI 10.1097/00005373-199609000-00036; CRAVEN KD, 1979, J APPL PHYSIOL, V47, P729; Duwelius PJ, 1997, J BONE JOINT SURG AM, V79A, P194, DOI 10.2106/00004623-199702000-00005; FABIAN TC, 1993, NEW ENGL J MED, V329, P961, DOI 10.1056/NEJM199309233291313; GORIS RJA, 1982, J TRAUMA, V22, P895, DOI 10.1097/00005373-198211000-00002; HULMAN G, 1995, J PATHOL, V176, P3, DOI 10.1002/path.1711760103; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; KADIRI YZ, 1980, CAN ANAESTH SOC J, V27, P216, DOI 10.1007/BF03007431; KERSTELL J, 1971, AM J SURG, V121, P712, DOI 10.1016/0002-9610(71)90053-5; KISHIKAWA M, 1991, J TRAUMA, V31, P1203, DOI 10.1097/00005373-199109000-00002; LEWIS FR, 1982, SURG CLIN N AM, V62, P97; LHOWE DW, 1994, ORTHOP CLIN N AM, V25, P573; LINDEQUE BGP, 1987, J BONE JOINT SURG BR, V69, P128; MALIK AB, 1983, PHYSIOL REV, V63, P1114; OPPENHEIMER L, 1979, J APPL PHYSIOL, V47, P718; PAHUD B, 1987, J BONE JOINT SURG BR, V69, P391; PAPE HC, 1993, J TRAUMA, V34, P540, DOI 10.1097/00005373-199304000-00010; PAPE HC, 1993, J TRAUMA, V35, P709, DOI 10.1097/00005373-199311000-00010; PELL ACH, 1993, NEW ENGL J MED, V329, P926, DOI 10.1056/NEJM199309233291305; PELTIER LF, 1988, CLIN ORTHOP RELAT R, P263; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PETTY TL, 1978, WESTERN J MED, V128, P399; Schemitsch EH, 1997, J BONE JOINT SURG AM, V79A, P984, DOI 10.2106/00004623-199707000-00004; SCOPA M, 1994, J TRAUMA, V36, P906, DOI 10.1097/00005373-199406000-00030; Shepard G H, 1969, Ann Thorac Surg, V7, P110; Trinkle J K, 1973, Ann Thorac Surg, V16, P568; WEIGELT JA, 1984, MULTIPLY INJURED PAT, P42; WOZASEK GE, 1994, J TRAUMA, V37, P249, DOI 10.1097/00005373-199408000-00017; WOZASEK GE, 1994, J TRAUMA, V36, P202, DOI 10.1097/00005373-199402000-00010	35	26	27	0	1	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	AUG	1999	81A	8					1155	1164		10.2106/00004623-199908000-00011			10	Orthopedics; Surgery	Orthopedics; Surgery	228ER	WOS:000082124600011	10466648				2021-06-18	
J	Thornton, KE				Thornton, KE			Exploratory investigation into mild brain injury and discriminant analysis with high frequency bands (32-64 Hz)	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; QUANTITATIVE EEG	QEEG variables (five activation, two relationship variables, 19 locations and five bands up to 64 Hertz) were collected under eyes dosed condition (under both 32 and 64 Hertz conditions) on 91 subjects, consisting of 32 mild brain-injured subjects (no loss of consciousness greater than 20 minutes) and 52 normals over the age of 14. An additional seven subjects who were unconscious seater than 20 minutes were available for analysis. Previous discriminant function analysis developed by Thatcher et at. was employed on the eyes closed 32 Hertz condition to ascertain its robustness for time periods greater than 1 year and for significant periods of unconsciousness. A separate discriminant for subjects was developed, employing only frontal high frequency coherence figures. The Thatcher discriminant could reliably (79%) identify all subjects up to 43 years post accident. The high frequency discriminant effectively identified 87% of the brain injured across an time periods (without significant loss of consciousness) and 100% of subjects within 1 year of accident. The combination of the discriminants resulted in a 100% accuracy rate for the 39 brain injured subjects for which discriminate values were available.	Ctr Hlth Psychol, S Plainfield, NJ USA	Thornton, KE (corresponding author), Ctr Hlth Psychol, 24 Highland Ave, Metuchen, NJ 08840 USA.			thornton, kirtley/0000-0002-3303-4747			DUFFY FH, 1994, CLIN ELECTROENCEPHAL, V25, pR6, DOI 10.1177/155005949402500403; HOOSHMAND H, 1989, CLIN ELECTROENCEPHAL, V20, P235, DOI 10.1177/155005948902000411; HUGHES JR, 1999, IN PRESS J NEUROPSYC; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; PAULSON MJ, 1970, J CLIN PSYCHOL, V26, P453, DOI 10.1002/1097-4679(197010)26:4<453::AID-JCLP2270260415>3.0.CO;2-V; RANDOLPH C, 1988, NEUROPSYCHOBIOLOGY, V20, P43, DOI 10.1159/000118471; Roland P. E., 1993, BRAIN ACTIVATION; TABANO MT, 1988, ELECTROENCEPHALOGRAP, V70, P185; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0	10	26	27	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1999	13	7					477	488		10.1080/026990599121395			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	215GT	WOS:000081374100002	10462146				2021-06-18	
J	Ippolito, E; Formisano, R; Farsetti, P; Caterini, R; Penta, F				Ippolito, E; Formisano, R; Farsetti, P; Caterini, R; Penta, F			Excision for the treatment of periarticular ossification of the knee in patients who have a traumatic brain injury	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							HETEROTOPIC OSSIFICATION	Background: Patients who are comatose after a traumatic brain injury often have heterotopic periarticular ossification that can be treated with excision to improve the range of motion of the joint; Methods: Areas of periarticular ossification were resected at an average of twenty-three months after recovery from a coma in seven knees of five patients who had a traumatic brain injury. Before the procedure, all of the knees were fixed in a flexed position that ranged from 10 to 40 degrees and they had a painful are of motion that ranged from 20 to 70 degrees of flexion, None of the patients could walk, and some of them could barely sit in a wheelchair. At the end of the operation, the are of motion was markedly improved in all of the knees (0 to 130 degrees in three knees, 0 to 120 degrees in three, and 10 to 120 degrees in one). In an attempt to prevent postoperative loss of motion and recurrence of the ossification, continuous passive motion was applied to the involved knee: for six weeks before a full rehabilitation program was started. The latest follow-up evaluation was at an average of thirty-four months (range, twenty-five to sixty months). Results: At the time of follow-up, all of the patients could walk and all of the knees were pain-free. One knee had an are of flexion of 0 to 90 degrees; two, an arc of 10 to 100 degrees; one, an are of 5 to 110 degrees; two, an are of 0 to 120 degrees; and one, an are of 0 to 130 degrees. Ossification did not recur in any of the knees. Conclusions: Patients,vith good neuromuscular control had the best general functional result, The routine use of a continuous-passive-motion machine was associated with no recurrence of ossification, and there was some late loss of motion after its use was discontinued.	Univ Roma Tor Vergata, Dept Orthopaed Surg, I-00173 Rome, Italy; Ist Ric & Cura Carattere Sci Santa Lucia, Postcoma Neurorehabil Unit, I-00179 Rome, Italy	Ippolito, E (corresponding author), Univ Roma Tor Vergata, Dept Orthopaed Surg, Via Ric Sci 135, I-00173 Rome, Italy.						Charnley G, 1996, INJURY, V27, P125, DOI 10.1016/0020-1383(95)00180-8; GACON G, 1978, REV CHIR ORTHOP, V64, P375; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; McAuliffe JA, 1997, J BONE JOINT SURG AM, V79A, P749, DOI 10.2106/00004623-199705000-00015; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; ROBERTS JB, 1979, J BONE JOINT SURG AM, V61, P760, DOI 10.2106/00004623-197961050-00018; ROSEN MA, 1992, AM J SPORT MED, V20, P122, DOI 10.1177/036354659202000205; VEVERELI PA, 1995, CLIN ORTHOPAEDICS, V321, P208	10	26	28	0	1	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	JUN	1999	81A	6					783	789		10.2106/00004623-199906000-00005			7	Orthopedics; Surgery	Orthopedics; Surgery	207JE	WOS:000080933100005	10391543				2021-06-18	
J	Johnstone, B; Schopp, LH; Harper, J; Koscuilek, J				Johnstone, B; Schopp, LH; Harper, J; Koscuilek, J			Neuropsychological impairments, vocational outcomes, and financial costs for individuals with traumatic brain injury receiving state vocational rehabilitation services	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							PREMORBID INTELLIGENCE; EMPLOYMENT; WORK; RETURN; PROGRAM; SCHOOL; ISSUES; TESTS; LIFE	Objective: To determine the relationship among neuropsychological variables, vocational outcomes, and vocational costs for Missouri Division of Vocational Rehabilitation (MO-DVR) clients with traumatic brain injury (TBI). Design: Clients referred for neuropsychological evaluations were followed until DVR case closure. Subjects were grouped according to the following DVR status at case closure: Successfully Employed, Services Interrupted, and No Services Provided. Spearman correlations with Bonferroni corrections were calculated to determine relationships among variables, and Kruskal-Wallis nonparametric one-way analyses of variance (ANOVAs) were conducted to evaluate differences in DVR group status in terms of neuropsychological variables and DVR costs. Setting: All evaluations were completed through a Midwestern university neuropsychology laboratory. Patients: 110 consecutively referred DVR clients with nonacute TBI referred for neuropsychological evaluation. Main outcome measures: Absolute level (ie, raw/standard scores) of neuropsychological functioning and relative degree of decline in: intelligence (WAIS-R), memory (WMS-R General and Delayed Memory Indices), attention (WMS-R Attention Index), speed of processing (Trails A), and cognitive flexibility (Trails B); DVR costs at closure. Results: 1) Surprisingly, the Successfully Employed group had significantly greater neuropsychological impairments; 2) Greater decline in delayed memory was associated with higher DVR costs (r = -0.30, P < .05); and 3) More indices of relative decline were significantly correlated with vocational outcomes (5/6) than were indices of absolute functioning (3/6). Conclusions: DVR is effective in providing services to individuals with the most significant neuropsychological deficits; it is important to consider both absolute level of functioning and relative decline in functioning when evaluating TBI.	Univ Missouri, Sch Med, Dept Phys Med & Rehabil, Columbia, MO 65212 USA; Univ Missouri, Dept Educ & Counseling Psychol, Columbia, MO 65212 USA	Johnstone, B (corresponding author), Univ Missouri, Sch Med, Dept Phys Med & Rehabil, DC046-00,1 Hosp Dr, Columbia, MO 65212 USA.			Johnstone, Brick/0000-0001-8845-9649			Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Bistany D. V., 1994, BRAIN INJURY NEUROPS, P245; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; CHEREK L, 1995, NEUROREHABILITATION, V5, P87, DOI 10.3233/NRE-1995-5108; COOK J, 1990, REHABILITATION ADULT, P493; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Crawford J. R., 1992, HDB NEUROPSYCHOLOGIC, P21; DODRILL CB, 1984, J CONSULT CLIN PSYCH, V52, P520, DOI 10.1037/0022-006X.52.4.520; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; FROMMAUCH D, 1983, J CLIN NEUROPSYCHOL, V5, P221, DOI 10.1080/01688638308401171; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GOODALL P, 1994, J HEAD TRAUMA REHAB, V9, P61; GOUVIER D, 1986, NEUROPSYCHOLOGY HDB, P278; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hannay HJ, 1998, ARCH CLIN NEUROPSYCH, V13, P157, DOI 10.1016/S0887-6177(98)00003-1; Hartman D E, 1991, Arch Clin Neuropsychol, V6, P147, DOI 10.1016/0887-6177(91)90030-D; HARTMAN DE, 1989, ARCH CLIN NEUROPSYCH, V4, P285; Heaton R.K., 1991, COMPREHENSIVE NORMS; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JASTAK S, 1984, WRAT R WIDE RANGE AC; Johnstone B, 1996, J Int Neuropsychol Soc, V2, P282; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Johnstone B, 1997, ARCH CLIN NEUROPSYCH, V12, P523, DOI 10.1016/S0887-6177(97)00034-6; Johnstone B, 1997, NEUROREHABILITATION, V8, P57, DOI 10.3233/NRE-1997-8108; JOHNSTONE B, 1995, NEUROREHABILITATION, V5, P75, DOI 10.3233/NRE-1995-5107; Johnstone B, 1997, ARCH CLIN NEUROPSYCH, V12, P591, DOI 10.1016/S0887-6177(97)00002-4; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; LANDRUM PK, 1998, OUTCOME ORIENTED REH; MALEC J, 1991, NEUROPSYCHOLOGY, V5, P29; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; Reitan R, 1986, TRAIL MAKING TEST MA; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Wechsler D., 1987, MANUAL WECHSLER MEMO; WECHSTER D, 1981, WECHSLER ADULT INTEL; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEST M, 1991, ARCH PHYS MED REHAB, V72, P127; Wilkinson G.S., 1993, WRAT 3 WIDE RANGE AC	45	26	26	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1999	14	3					220	232		10.1097/00001199-199906000-00003			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	203XY	WOS:000080734500003	10381975				2021-06-18	
J	Prigatano, GP				Prigatano, GP			Impaired awareness, finger tapping, and rehabilitation outcome after brain injury	REHABILITATION PSYCHOLOGY			English	Article; Proceedings Paper	106th Annual Convention of the American-Psychological-Association	AUG, 1998	SAN FRANCISCO, CALIFORNIA	Amer Psychol Assoc			CLOSED HEAD-INJURY; BEHAVIORAL LIMITATIONS; NEUROPSYCHOLOGICAL REHABILITATION; FUNCTIONAL REORGANIZATION; RECOVERY; DYSFUNCTION; INFARCTION	Speed of finger tapping after traumatic brain injury has been related to the problem of impaired self-awareness as well as to rehabilitation outcome. This article summarizes selected literature that documents the potentially rich information this "simple" task can provide. It supports Leonard Diller's emphasis on using developmentally sensitive tasks that allow for simple inferences to be applied to issues of diagnosis and rehabilitation after brain injury.	Barrow Neurol Inst, Dept Clin Neuropsychol, St Josephs Hosp & Med Ctr, Phoenix, AZ 85013 USA	Prigatano, GP (corresponding author), Barrow Neurol Inst, Dept Clin Neuropsychol, St Josephs Hosp & Med Ctr, Phoenix, AZ 85013 USA.						Anton G., 1896, MITTEILUNGEN VEREINS, V33, P41; Anton G., 1898, WIEN KLIN WOCHENSCHR, V11, P227; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; DIKMEN S, 1980, J NERV MENT DIS, V168, P236, DOI 10.1097/00005053-198004000-00008; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DILLER L, 1964, BRAIN DAMAGE CHILDRE, P27; DOYLE AC, 1986, S HOLMES COMPLETE NO, V2; FINLAYSON MAJ, 1976, PERCEPT MOTOR SKILL, V43, P475, DOI 10.2466/pms.1976.43.2.475; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Halstead WC, 1947, BRAIN INTELLIGENCE; HEATON RK, 1978, J NERV MENT DIS, V166, P408, DOI 10.1097/00005053-197806000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Muller G., 1991, DEMENTIA, V2, P169; OBOYLE MW, 1994, CORTEX, V30, P519, DOI 10.1016/S0010-9452(13)80347-4; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Prigatano G. P., 1997, CLIN NEUROPSYCHOL, V11, P1; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1999, ARCH PHYS MED REHAB, V80, P77, DOI 10.1016/S0003-9993(99)90311-8; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1997, ARCH PHYS MED REHAB, V78, P847, DOI 10.1016/S0003-9993(97)90198-2; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1991, AWARENESS DEFICITY B; PRIGATANO GP, IN PRESS PRINCIPLES; Schacter DL., 1991, AWARENESS DEFICIT BR, P17; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Spreen O., 1991, COMPENDIUM NEUROPSYC; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WEILLER C, 1993, ANN NEUROL, V33, P181; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; WESSEL K, 1995, BRAIN, V118, P379, DOI 10.1093/brain/118.2.379	39	26	26	0	3	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	1999	44	2					145	159		10.1037/0090-5550.44.2.145			15	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	198ED	WOS:000080409000002					2021-06-18	
J	Aloni, A; Keren, O; Cohen, M; Rosentul, N; Romm, M; Groswasser, Z				Aloni, A; Keren, O; Cohen, M; Rosentul, N; Romm, M; Groswasser, Z			Incidence of sexual dysfunction in TBI patients during the early post-traumatic in-patient rehabilitation phase	BRAIN INJURY			English	Article							HEAD-INJURY	Objective: The aim of the study is to find whether sexuality acid intimacy dysfunction are already present at the early rehabilitation phase of TBI patients. Methods: Forty-four consequent severe TBI patients. were studied. The GCS and the duration of unconsciousness determined the initial severity of the injury. Patients' function regarding motor, language, cognition and behaviour were assessed by an interdisciplinary team. Sexuality and intimacy were evaluated by using a special closed questionnaire. Results: Regarding self confidence 81% of patients described themselves as having high or average self confidences; 78% described themselves as having high or average feeling of being sexually appealing; mood level was average or high in 80% of patients. Only 7.7% of patients reported having sexual dysfunction at that phase of rehabilitation. Conclusions: Sexual dysfunction in Severe TBI patients is uncommon at the early post-traumatic phase. It is suggested that sexual dysfunction appearing during later stages of recovery is most probably related to reactive behavioural changes.	Loewenstein Rehabil Hosp, IL-43100 Raanana, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Groswasser, Z (corresponding author), Loewenstein Rehabil Hosp, 278 Achuza St,POB 3, IL-43100 Raanana, Israel.						Benyakar M, 1988, Brain Inj, V2, P351, DOI 10.3109/02699058809150907; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Groswasser Z, 1998, J HEAD TRAUMA REHAB, V13, P69, DOI 10.1097/00001199-199802000-00009; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; KATZ N, 1989, AM J OCCUP THER, V43, P184, DOI 10.5014/ajot.43.3.184; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; KREUTZER SJ, 1989, BRAIN INJURY, V3, P177; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; ZASLER ND, 1995, PHYS MED REHABIL STA, V9, P361	12	26	26	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1999	13	2					89	97		10.1080/026990599121755			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	167HQ	WOS:000078626800002	10079954				2021-06-18	
J	London, L; Nell, V; Thompson, ML; Myers, JE				London, L; Nell, V; Thompson, ML; Myers, JE			Health status among farm workers in the western cape - Collateral evidence from a study of occupational hazards	SOUTH AFRICAN MEDICAL JOURNAL			English	Article							SOUTH-AFRICA; EXPOSURE	Motivation. Farm workers are a marginalised occupational group whose poor living and working conditions may place them at increased risk for occupational and non-occupational morbidity and mortality. Research into the health status of farm workers has been neglected in the past. Aims and objectives. As part of an investigation into the neurological and neurobehavioural effects of exposure to organophosphate insecticides, this study describes the demographics, life histories, risk factors for chronic illness End selected indicators of general health status among:a group of farm workers in the Western Cape. Study design. Cross-sectional study conducted in the deciduous fruit farming industry in 1993. Subjects. 164 pesticide applicators and 83 non-spraying controls (all men) from 73 farms, frequency matched for age and education. Measurements. A structured questionnaire, venous blood for serum and erythrocyte cholinesterase, albumin, gamma glutamyl transferase and haemoglobin assessment, and weight measurement. Results. Most farm workers were children of farm workers had lived and worked on farms for most of their lives. study found substantial levels of illiteracy (21 - 44%, depending on the definition) and innumeracy (4%) and evidence of a significant morbidity burden: high levels of alcohol intake and ongoing reported application of the 'dop' system, high levels of head injury (70% of subjects) and evidence of substantial adult, undernutrition. Protective equipment was relatively well distributed and used, although certain work activities (such as acting as a human marker) continue to pose substantial exposure hazards. There were no differences in respect of cholinesterase levels between spray applicators and controls, although past poisoning was reported by 9% of subjects. Conclusion. Farm workers appear to be a closed community with a high disease burden. Their health needs pose substantial challenges to the public health authorities.	Univ Cape Town, Occupat & Environm Hlth Res Unit, Dept Community Hlth, ZA-7700 Rondebosch, South Africa; Univ S Africa, Hlth Psychol Unit, Johannesburg, South Africa; Univ Washington, Dept Biostat, Seattle, WA 98195 USA	London, L (corresponding author), Univ Cape Town, Occupat & Environm Hlth Res Unit, Dept Community Hlth, ZA-7700 Rondebosch, South Africa.		London, Leslie/G-6061-2011				Bailie R, 1998, S AFR MED J, V88, P1105; BALL A, 1990, S AFR LAB B, V14, P52; Bourne L T, 1993, Cent Afr J Med, V39, P238; BRIDGEMAN DHM, 1992, S AFRICAS LEADING ED; COYE MJ, 1988, OCCUPATIONAL HLTH RE; DAVIES W, 1990, WE CRY OUR LAND FARM; DEGRAAFF JF, 1990, 14 U STELL RES UN SO; DONALDSON A, 1994, DEV SO AFRICA, V11, P131; DUTOIT A, 1992, FARM FAMILY PATERNAL; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; *FARMW RES RES PRO, 1997, STAT S AFR FARMW 199; GROENEWALD CJ, 1986, COMMUNITY DEV FARMS, V9; KEENAN J, 1987, S AFRICAN REV, V4, P581; KNEDEL M, 1967, KLIN WOCHENSCHR, V45, P325, DOI 10.1007/BF01747115; KRITZINGER A, 1995, LABOUR SITUATION S A; LANZ SH, 1994, WOMEN FARMS REPORT W; LOEWENSEN R, 1990, RES WORKSH PEST SAF; Loewenson R., 1986, Health Policy and Planning, V1, P48, DOI 10.1093/heapol/1.1.48; London L, 1997, ENVIRON RES, V73, P132, DOI 10.1006/enrs.1997.3715; LONDON L, 1995, OCCUP ENVIRON MED, V52, P57, DOI 10.1136/oem.52.1.57; LONDON L, 1994, S AFR MED J, V84, P273; London L, 1995, S AFR J SCI, V91, P515; LONDON L, 1995, EPIDEMIOLOGY S, V6, pS107; LONDON L, 1995, THESIS U CAPE TOWN D; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; Merchant James, 1995, P267; National Center for Health Statistics, 1994, TRAUMA REV, V2, P1; Naude JT, 1998, S AFR MED J, V88, P1102; REES D, 1993, SCAND J WORK ENV HEA, V19, P236, DOI 10.5271/sjweh.1478; *S AFR MED RES COU, 1993, GUID ETH MED RES; Segal Lauren, 1991, BRUTAL HARVEST ROOTS; SEKIMPI DK, 1992, OCCUPATIONAL HLTH DE, P31; SETZER ML, 1971, AM J PSYCHIAT, V127, P1653; STEYN K, 1990, S AFR MED J, V78, P68; WALDMAN PL, 1993, THESIS U CAP TOWN DE; WEIDEPOEL L, 1984, LEARNING LIT PROJECT; WHITTAKER S, 1987, THESIS U CAPE TOWN; *WHO, 1982, DECL HELS PROP INT G; WOLMARANS P, 1988, S AFR MED J, V73, P12	39	26	28	0	2	MED ASSOC S AFRICA	JOHANNESBURG	MED HOUSE CENTRAL SQ 7430 PINELANDS  PRIV BAG X1, JOHANNESBURG, SOUTH AFRICA	0038-2469			S AFR MED J	S. Afr. Med. J.	SEP	1998	88	9					1096	1101					6	Medicine, General & Internal	General & Internal Medicine	131NY	WOS:000076583200035	9798496				2021-06-18	
J	Britton, KR				Britton, KR			Medroxyprogesterone in the treatment of aggressive hypersexual behaviour in traumatic brain injury	BRAIN INJURY			English	Article								Sexual function is among the many areas affected by traumatic brain injury. The most common change is decreased sexual performance and satisfaction, for the brain injured person and the sexual partner. Hypersexuality, especially inappropriate sexual, comments and gestures, is also a common result of traumatic brain injury. A. case of hypersexuality in a severely disabled brain injured man is presented. He was successfully treated with medroxyprogesterone acetate after failure of multiple other treatment strategies. The literature is reviewed. An evaluation and treatment strategy for sexual dysfunction post traumatic brain injury is presented.	Univ Minnesota, Vet Adm Med Ctr, Minneapolis, MN 55415 USA	Britton, KR (corresponding author), Univ Minnesota, Vet Adm Med Ctr, 701 Pk Ave, Minneapolis, MN 55415 USA.						ANGLE DK, 1991, COMMUNITY LIVING SKI; BERLIN F, 1987, CURRENTS AFFECTIVE I, V6, P5015; BLACKENBY W, 1989, PHYSICAL MED REHABIL, V3; COLE T, 1990, KRUSENS HDB PHYSICAL, P1000; COOPER AJ, 1987, J CLIN PSYCHIAT, V48, P368; DEBOSKY D, 1991, ED FAMILIES HEAD INJ; GRABER B, 1982, J FORENSIC SCI, V27, P125; JENIKE MA, 1989, GERIATRIC PSYCHIAT P; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; MILLER BL, 1986, J NEUROL NEUROSUR PS, V49, P867, DOI 10.1136/jnnp.49.8.867; O'Hara CC, 1991, REHABILITATION BRAIN; ROSENTHAL M, 1983, REHABILITATION ADULT; SACHS P, 1988, TREATING FAMILIES BR; VALENTICH M, 1986, SEX DISABIL, V7, P28; WEHMAN P, 1990, VOCATIONAL REHABILIT; WHYTE J, 1993, REHABILITATION MED P, P849; WOOD R, 1988, J HEAD TRAUMA REHAB, V3, P53; Wood RLL, 1990, NEUROBEHAVIORAL SEQU; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163	19	26	27	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1998	12	8					703	707		10.1080/026990598122269			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	108AN	WOS:000075243800007	9724841				2021-06-18	
J	Nelson, LD; Drebing, C; Satz, P; Uchiyama, C				Nelson, LD; Drebing, C; Satz, P; Uchiyama, C			Personality change in head trauma: A validity study of the Neuropsychology Behavior and Affect Profile	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							RELATIVES VIEW; INJURY; INDIVIDUALS; SEQUELAE	This study represets the first attempt to cross validate and report on the Neuropsychology Behavior and Affect Profile (NBAP) using closed head injury (CHI) participants. The NBAP is designed to measure emotional functioning before and following a brain event. Two CHI samples, differing primarily by method of ascertainment, were compared to a group of normal controls. Results provided support for concurrent and predictive validity the NBAP across both CHI samples. Significantly higher levels postinjury emotional functioning in clinic-referred CHI patients compared to CHI individuals not seeking treatment (strictly research participants) was demonstrated. A surprising finding was that pre-injury emotional levels of clinic-referred subjects were rated as less severe than that of controls. Based on this finding, the possibility of a gradient effect was discussed in which raters appeared to place selectively greater weight on current condition, while simultaneously making premorbid levels less severe than they really were. Results were discussed in the context of study limitations and directions further research. (C) 1998 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Univ Calif Irvine, Med Ctr, Dept Neurol, Orange, CA 92868 USA; Edith Nourse Rogers Mem VA Med Ctr, Bedford, MA USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA	Nelson, LD (corresponding author), Univ Calif Irvine, Med Ctr, Dept Neurol, 101 City Dr,Route 81,Bldg 53,Room 225, Orange, CA 92868 USA.						Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Bond M R, 1975, Ciba Found Symp, P141; Borod J. C., 1993, NEUROPSYCHOLOGY, V7, P427; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; FINSET A, 1988, CEREBRAL HEMISPHERE, P51; Gass CS, 1997, ARCH CLIN NEUROPSYCH, V12, P199, DOI 10.1016/S0887-6177(96)00032-7; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; Lees-Haley P. R., 1992, FORENSIC REPORTS, V5, P385; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; NELSON L, 1995, AM J MENT RETARD, V99, P616; Nelson L., 1994, MANUAL NEUROPSYCHOLO; Nelson LD, 1995, PSYCHOL ASSESSMENT, V7, P404, DOI 10.1037/1040-3590.7.3.404; NELSON LD, 1994, J CLIN EXP NEUROPSYC, V16, P796, DOI 10.1080/01688639408402693; Nelson LD, 1991, PSYCHOL ASSESSMENT, V3, P55; NELSON LD, 1989, J CONSULT CLIN PSYCH, V1, P266; NELSON LD, 1993, PSYCHOL ASSESSMENT, V5, P374; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Prigatano G. P., 1991, AWARENESS DEFICIT BR; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Ramachandran VS, 1996, NATURE, V382, P501, DOI 10.1038/382501a0; Satz P, 1993, NEUROPSYCHOLOGY, V7, P553	25	26	27	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	1998	13	6					549	560		10.1016/S0887-6177(97)00052-8			12	Psychology, Clinical; Psychology	Psychology	100JH	WOS:000074812700007	14590639	Bronze			2021-06-18	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Blood-free magnesium concentration declines following graded experimental traumatic brain injury	SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION			English	Article						head injury; ion-selective electrodes; ionised magnesium; trauma	IONIZED MAGNESIUM; AXONAL INJURY; RATS; CATECHOLAMINES; CALCIUM	Traumatic brain injury has been shown to result in a decrease in brain-free magnesium concentration that is associated with the development of neurologic motor deficits. Although these changes have been well characterized in the brain, changes in free magnesium homeostasis have not been characterized in other fluid compartments. The current experiments use ion selective electrodes to measure alterations in blood-free magnesium concentration following graded experimental brain injury in rats and to compare these changes with subsequent neurologic outcome. After severe impact-acceleration-induced injury, blood-free magnesium levels significantly declined (p<0.05) by 25% and remained depressed for at least 4 days after injury. After moderate injury, the decline in blood-free magnesium was less than that observed in the severe injury group, with respect to both degree of decline and duration of decline. The post-traumatic blood-free magnesium concentration correlated to observed motor deficits as assessed by rotarod evaluation (p<0.001). We conclude that blood-free magnesium levels may be a prognostic indicator of outcome following severe traumatic brain injury.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia	Heath, DL (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			Altura Bella T., 1994, Scandinavian Journal of Clinical and Laboratory Investigation, V54, P53, DOI 10.3109/00365519409095211; CAVALIERE F, 1985, RECENT PROGR MED, V76, P561; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; Elin RJ, 1996, SCAND J CLIN LAB INV, V56, P203, DOI 10.3109/00365519609088641; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1996, NEUROSCI RES COMMUN, V18, P163; HENROTTE JG, 1995, ANN NUTR METAB, V39, P285, DOI 10.1159/000177874; HENROTTE JG, 1985, J AM COLL NUTR, V4, P165, DOI 10.1080/07315724.1985.10720073; Howarth Frank C., 1994, Magnesium Research, V7, P187; JOBORN H, 1985, CLIN ENDOCRINOL, V23, P219, DOI 10.1111/j.1365-2265.1985.tb00217.x; KING LR, 1973, ANN SURG, V177, P126, DOI 10.1097/00000658-197301000-00022; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; Ritter C, 1996, SCAND J CLIN LAB INV, V56, P275, DOI 10.3109/00365519609088647; SEELIG MS, 1994, J AM COLL NUTR, V13, P429; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; Zoppi F, 1996, SCAND J CLIN LAB INV, V56, P259, DOI 10.3109/00365519609088646	23	26	26	0	0	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0036-5513			SCAND J CLIN LAB INV	Scand. J. Clin. Lab. Invest.	APR	1998	58	2					161	166		10.1080/00365519850186751			6	Medicine, Research & Experimental	Research & Experimental Medicine	ZH381	WOS:000073102800010	9587169				2021-06-18	
J	Anderson, RM; Opeskin, K				Anderson, RM; Opeskin, K			Timing of early changes in brain trauma	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						brain; physical injury; timing of changes	DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD-INJURY; DAMAGE	One hundred and fourteen fatal cases of brain trauma were examined prospectively; in 100 of these cases, death occurred within 48 hours of injury. The methods of injury included motor vehicle accidents (MVA), gunshot wounds, blunt instrument injuries, and falls. All cases showed subarachnoid and parenchymal hemorrhages. Paraffin sections were studied with hematoxylin and eosin (H&E) stain and also with special stains in selected slides. The cases were examined histologically before having exact clinical knowledge of the time of death. Eosinophilic neurons were noted in many cases surviving <1 hour after injury and increased in frequency and severity with time. These were most commonly seen in areas of contusion, the hippocampus, and the arterial boundary zones of the cerebral cortex. Neuronal incrustation was seen from 3 to 48 hours postinjury in areas of contusion. Axonal swelling and spheroids were seen in the white matter in areas of laceration and hemorrhage at 1 hour postinjury in many cases and continuing through all time periods. Glial swelling was seen in the subpial and subependymal regions and around hemorrhages from very early to 48 hours postinjury. Polymorphonuclear leukocytes (granulocytes) were present in the tissues at all time periods with increasing frequency over time. They were also found surrounding corpora amylacea in cases with <1 hour survival. Axonal swelling, eosinophilia of neurons, and incrustation of neurons were noted at earlier time periods than previously reported in the literature. Determining the time of injury based on histologic evidence is difficult. We believe that the data reported here will allow more accurate appreciation of timing of the early interval between brain trauma and death.	Victorian Inst Forens Med, Melbourne, Vic 3006, Australia	Anderson, RM (corresponding author), Victorian Inst Forens Med, 57-83 Kavanagh St, Melbourne, Vic 3006, Australia.						Adams J H, 1988, Curr Top Pathol, V76, P1; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, RECENT ADV NEUROPATH, P165; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brown A W, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P155; Cammermeyer J., 1972, STRUCTURE FUNCTION N, V6, P131; Clark ER, 1936, AM J ANAT, V59, P123, DOI 10.1002/aja.1000590106; COURVILLE CB, 1945, PATHOLOGY CENTRAL NE, P28; CROOKS DA, 1992, MED SCI LAW, V32, P109, DOI 10.1177/106002809203200204; Gallyas Ferenc, 1994, Neurobiology (Budapest), V2, P245; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; KITAMURA O, 1994, INT J LEGAL MED, V107, P69, DOI 10.1007/BF01225492; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LOBERG EM, 1989, MED SCI LAW, V29, P109, DOI 10.1177/002580248902900205; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Nishino Hitoo, 1994, Neurobiology (Budapest), V2, P223; OEHMICHEN M, 1980, Z RECHTSMED, V84, P79, DOI 10.1007/BF02114577; OPESKIN K, 1994, BIOTECH HISTOCHEM, V69, P253, DOI 10.3109/10520299409106297; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1	24	26	27	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0195-7910			AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	MAR	1998	19	1					1	9		10.1097/00000433-199803000-00001			9	Medicine, Legal; Pathology	Legal Medicine; Pathology	ZB026	WOS:000072427400001	9539384				2021-06-18	
J	Wenden, FJ; Crawford, S; Wade, DT; King, NS; Moss, NEG				Wenden, FJ; Crawford, S; Wade, DT; King, NS; Moss, NEG			Assault, post-traumatic amnesia and other variables related to outcome following head injury	CLINICAL REHABILITATION			English	Article							EPIDEMIOLOGY; DISABILITY; ADMISSION; MILD	Objective: To estimate how many patients who sustain a head injury might benefit from intervention and support each year and to consider whether relationships can be found between demographic data relating to patients' circumstances at the time of head injury, and their outcomes six months later. Design: Data collected on 625 patients through follow-up interviews and assessments by the Oxford Head Injury Service for a randomized controlled trial of intervention conducted in 1993-94. Setting: A mixed rural and urban Health District with a population of approximately 560 000. Patients: Patients were aged between 16 and 65 years and resident in Oxfordshire. They presented over 13 months to accident and emergency departments, or were admitted to hospital. All were diagnosed as having suffered a head injury. Outcome measures: The Rivermead Head Injury Follow Up Questionnaire and the Rivermead Post Concussion Symptoms Questionnaire. Results: Data are given on age, sex, social circumstances, employment, cause of injury, severity of associated injuries, post-traumatic amnesia (PTA), anticonvulsants, postconcussion symptoms and activities of everyday life. Outcome at six months was significantly worse for those who had been assaulted as against all other causes of injury combined (p = 0.0001); and/or had been admitted to hospital (p = 0.0001); and/or had sustained more severe additional injuries (p = 0.04); and/or had experienced any PTA (p = 0.00001). The minimum incidence of such injuries in those aged 16-65, calculated for Oxfordshire, is 292 per annum (74/100 000 aged 16-65 per year). Conclusions: In the general population 52/100 000 patients per annum will experience more serious head injuries as indicated by hospital admission and/or one or more fractures and/or any length of PTA and/or having been assaulted. This group may benefit from monitoring and support and their needs should be considered when planning services.	Rivermead Rehabil Ctr, Oxford Head Injury Serv, Oxford OX1 4XD, England	Wenden, FJ (corresponding author), Rivermead Rehabil Ctr, Oxford Head Injury Serv, Abingdon Rd, Oxford OX1 4XD, England.			Wade, Derick/0000-0002-1188-8442			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BRIGGS M, 1984, BRIT MED J, V288, P983; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1976, LANCET, V1, P1031; Jennett B, 1990, HDB CLIN NEUROLOGY, V13; JOHNSON R, 1987, INJURY, V18, P7, DOI 10.1016/0020-1383(87)90374-3; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1990, HDB CLIN NEUROLOGY, V13; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Moss NE, 1996, DISABIL REHABIL, V18, P169, DOI 10.3109/09638289609166296; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; 1994, OFFICE POP CENS SURV	27	26	26	0	1	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON, ENGLAND NW1 3BH	0269-2155			CLIN REHABIL	Clin. Rehabil.	FEB	1998	12	1					53	63		10.1191/026921598675567949			11	Rehabilitation	Rehabilitation	ZC019	WOS:000072531400008	9549026				2021-06-18	
J	Warren, WL; Bailes, JE				Warren, WL; Bailes, JE			On the field evaluation of athletic head injuries	CLINICS IN SPORTS MEDICINE			English	Article								This article reviews the diagnosis and management of athletic-related head injury. Cerebral concussion, diffuse; axonal injury, brain contusion, and the spectrum of intracranial hematoma is discussed. Emphasis is placed on the need to evaluate when it is prevented from further participation.	Allegheny Gen Hosp, Dept Neurosurg, Pittsburgh, PA 15212 USA; Orlando Reg Healthcare Syst, Orlando, FL USA	Warren, WL (corresponding author), Allegheny Gen Hosp, Dept Neurosurg, 320 East North Ave, Pittsburgh, PA 15212 USA.						ALVES WM, 1996, NEUROTRAUMA, P913; *AM COLL SURG, 1993, ADV TRAUM LIF SUPP M; *BRAIN TRAUM FDN, 1995, GUID MAN SEV HEAD IN; BRUNO LA, 1987, CLIN SPORTS MED, V6, P1; BUCKLEY WE, 1988, AM J SPORTS MED, V16, P1; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CLEMETT RS, 1980, NZ MED J, V92, P663; FICK DS, 1995, POSTGRAD MED, V97, P2; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P12; GRAHAM DI, NEUROTRAUMA, P46; JAFFE R, 1986, PRIMARY CARE, V13, P1; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P20; LEHMAN LB, 1988, AFP, V38, P4; LEHMAN LB, 1990, CLIN SPORTS MED, V9, P2; LINDSAY KW, 1980, BRIT MED J, V281, P20; MCLATCHIE G, 1994, BRIT MED J, V308, P1624; MUELLER FO, 1987, CLIN SPORTS MED, V6, P1; PATTERSON D, 1987, CLIN SPORTS MED, V6, P1; PLUM F, 1982, DIAGNOSIS STUPOR COM, P119; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P4; SONZOGNI JJ, 1993, CLIN SPORTS MED, V12, P2; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P24; TYSVAER A, 1989, AM J SPORTS MED, V17, P4; VEGSO JJ, 1987, CLIN SPORT MED, V6, P1; Wekesa M, 1996, BRIT J SPORT MED, V30, P61, DOI 10.1136/bjsm.30.1.61; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; WILBERGER JE, 1993, SPORTS MED, V15, P5	29	26	26	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0278-5919			CLIN SPORT MED	Clin. Sports Med.	JAN	1998	17	1					13	+		10.1016/S0278-5919(05)70057-0			15	Sport Sciences	Sport Sciences	YU153	WOS:000071687600003	9475967				2021-06-18	
J	Zink, BJ; Stern, SA; Wang, X; Chudnofsky, CC				Zink, BJ; Stern, SA; Wang, X; Chudnofsky, CC			Effects of ethanol in an experimental model of combined traumatic brain injury and hemorrhagic shock	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	SAEM Annual Meeting	MAY, 1996	DENVER, COLORADO	Soc Acad Emergency Med		alcohol; ethanol; injury; shock; hemorrhage; brain; trauma	CEREBRAL BLOOD-FLOW; FREE-RADICAL MECHANISMS; NERVOUS-SYSTEM TRAUMA; SEVERE HEAD-INJURIES; OXYGEN DELIVERY; ALCOHOL-INTOXICATION; RESPONSES; METABOLISM; ARTERIOLES; REDUCTION	Objectives: Given that clinical and laboratory studies suggest that ethanol and hemorrhagic shock (HS) potentiate traumatic brain injury (TBI), the authors studied the effects of ethanol in a model of combined TBI and HS. Methods: A controlled porcine model of combined TBI and HS was evaluated for the effect of ethanol on survival time, hemodynamic function, and cerebral tissue perfusion. Anesthetized swine (17-24 kg) were instrumented, splenectomized, and subjected to fluid percussion TBI with concurrent 25-mL/kg graded hemorrhage over 30 minutes. Two groups were studied: control (n = 11) and ethanol (n = 11). Ethanol, 3.5 g/kg intragastric, was given 100 minutes prior to TBI/HS. Systemic and cerebral physiologic and metabolic parameters were monitored for 2 hours without resuscitation. Regional cerebral blood flow (rCBF) and renal blood flow were measured with dye-labeled microspheres. Data were analyzed with 2-sample t-test and repeated-measures ANOVA. Results: Ethanol levels at the time of injury were 162 +/- 68 mg/dL. Average TBI was 2.65 +/- 0.35 atm. Survival time was significantly shorter in the ethanol group (60 +/- 27 min vs 94 +/- 28 min, p = 0.011). The ethanol group had significantly lower mean arterial pressure, cerebral perfusion pressure, and cerebral venous O-2 saturation in the postinjury period. Cerebral O-2 extraction ratios and cerebral venous lactate levels were significantly higher in the ethanol group. A trend toward lower postinjury rCBF in all brain regions was observed in the ethanol group. Conclusion: In this TBI/HS model, ethanol administration decreased survival time, impaired the hemodynamic response, and worsened measures of cerebral tissue perfusion.	Univ Michigan, Med Ctr, Dept Surg, Sect Emergency Med, Ann Arbor, MI 48109 USA	Zink, BJ (corresponding author), Univ Michigan, Med Ctr, Dept Surg, Sect Emergency Med, TC B134,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	bzink@umich.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [K08AA000184] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [1 KO8 AA00184-01A2] Funding Source: Medline		ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; BEARD JD, 1973, Q J STUD ALCOHOL, V34, P1303; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CREWS F, 1993, RES MONOGRAPH, V22, P355; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DILUZIO NR, 1969, EXP MOL PATHOL, V11, P38, DOI 10.1016/0014-4800(69)90069-0; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; DURCAN MJ, 1989, PHARMACOL BIOCHEM BE, V32, P667, DOI 10.1016/0091-3057(89)90015-4; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; EISENHOFER G, 1984, BRIT J CLIN PHARMACO, V18, P581, DOI 10.1111/j.1365-2125.1984.tb02507.x; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FADEN AI, 1989, SCIENCE, V244, P789; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GETTLER DT, 1963, ANN SURG, V158, P151, DOI 10.1097/00000658-196308000-00001; GOLDSTEIN D, 1983, PHARM ALCOHOL, P164; GORDIS E, 1989, ALCOHOL ALERT NAT I, V3, P1; GORDON EL, 1995, J CEREBR BLOOD F MET, V15, P532, DOI 10.1038/jcbfm.1995.66; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HORTON JW, 1986, SURGERY, V100, P520; ISRAEL RS, 1988, ANN EMERG MED, V17, P560; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; KNEUSSL MP, 1986, AM REV RESPIR DIS, V133, P1024; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KUPARI M, 1983, EUR HEART J, V4, P463, DOI 10.1093/oxfordjournals.eurheartj.a061503; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LIEBER CS, 1984, MED CLIN N AM, V68, P3, DOI 10.1016/S0025-7125(16)31238-X; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARX J, 1990, Emergency Medicine Clinics of North America, V8, P929; Mayhan WG, 1996, ALCOHOL CLIN EXP RES, V20, P538, DOI 10.1111/j.1530-0277.1996.tb01089.x; MAYHAN WG, 1995, STROKE, V26, P2097, DOI 10.1161/01.STR.26.11.2097; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; Mihic S. J., 1996, PHARM TOXIC, P51; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MURR R, 1989, CEREBRAL MICROCIRCUL, V16, P61; NEWSOME HH, 1988, J TRAUMA, V28, P1, DOI 10.1097/00005373-198801000-00001; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; Nordmann R, 1996, PHARM TOXIC, P329; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PITTS LH, 1990, HDB CLIN NEUROLOGY, V13, P65; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; REVES JG, 1972, Q J STUD ALCOHOL, V33, P464; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SCALEA TM, 1994, CRIT CARE MED, V22, P1610; Schmoker JD, 1996, J NEUROTRAUM, V13, P67, DOI 10.1089/neu.1996.13.67; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SELIGMAN ML, 1977, LIPIDS, V12, P945, DOI 10.1007/BF02533316; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SIGGINS GR, 1996, PHARM TOXIC, P175; Smith DH, 1996, NEUROTRAUMA, P1445; Suzuki K., 1990, NAGOYA MED J, V34, P159; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YUAN XQ, 1991, CIRC SHOCK, V35, P231; ZHANG A, 1993, EUR J PHARM-ENVIRON, V248, P229, DOI 10.1016/0926-6917(93)90049-V; ZINK BJ, 1988, ANN EMERG MED, V17, P15, DOI 10.1016/S0196-0644(88)80496-7; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; ZINK BJ, 1988, CIRC SHOCK, V24, P19	70	26	30	0	2	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JAN	1998	5	1					9	17		10.1111/j.1553-2712.1998.tb02568.x			9	Emergency Medicine	Emergency Medicine	YQ544	WOS:000071398400003	9444336	Bronze			2021-06-18	
J	Schmid, I; Wechsler, B				Schmid, I; Wechsler, B			Behaviour of Japanese quail (Coturnix japonica) kept in semi-natural aviaries	APPLIED ANIMAL BEHAVIOUR SCIENCE			English	Article						Japanese quail; housing; time budget; social behaviour; egg laying behaviour	WELFARE	In caged Japanese quail (Coturnix japonica), there are several welfare problems such as head injuries caused by aggressive pecking and head-banging as a consequence of escape responses. The present study is aimed at improving the knowledge of the behaviour elf this farm animal species for the design of adequate housing systems. From May to October, eight groups of eight or nine quails of a domestic strain were housed in aviaries (19.1 m(2)) containing natural soil and vegetation. There were two groups with hens only and six groups of varied sex ratio. A time budget analysis showed that the quails spent 35% of the observation time on passive behaviour, 24% on locomotory behaviour, 8% on exploratory/foraging behaviour, 14% on comfort behaviour and 4% on ingestive behaviour. The percentage of time the quails stayed in cover (average 48%) was significantly higher than the proportion of the floor area that was severed with plants and artificial shelters. On the other hand, the time spent on elevated structures (average 0.5%) was significantly lower than expected. Based on data of spatial proximity 'close relationships' of a given hen with a cock were identified, Most of these relationships broke up after the end of the reproductive period. Aggressive behaviour was rare in groups without cocks. In heterosexual groups, 67% of the aggressive interactions were observed between cocks. The percentage of eggs found in cover (average 91%) was significantly higher than expected. The hens also laid significantly more eggs than expected in the corners and within a zone of 0.1 m along the border of the aviaries. In the discussion, recommendations are made for the design of housing systems that are adapted to the behaviour of domestic quails. (C) 1997 Elsevier Science B.V.	Univ Bern, Inst Zool, Abt Sozial & Nutzierethol, Ethol Stn Hasli, CH-3032 Hinterkappelen, Switzerland	Schmid, I (corresponding author), Univ Bern, Inst Zool, Abt Sozial & Nutzierethol, Ethol Stn Hasli, Wohlenstr 50A, CH-3032 Hinterkappelen, Switzerland.		Wechsler, Beat/D-7897-2013	Wechsler, Beat/0000-0002-9022-5988			ALTMANN J, 1974, BEHAVIOUR, V49, P227, DOI 10.1163/156853974X00534; APPLEBY MC, 1991, WORLD POULTRY SCI J, V47, P109, DOI 10.1079/WPS19910013; BAUMGARTNER J, 1994, WORLD POULTRY SCI J, V50, P227; Cooper D. M., 1987, UFAW HDB CARE MANAGE, P678; DAWKINS MS, 1989, APPL ANIM BEHAV SCI, V24, P77, DOI 10.1016/0168-1591(89)90126-3; GERKEN M, 1987, BRIT POULTRY SCI, V28, P23, DOI 10.1080/00071668708416933; Gerken M, 1993, 4 EUR S POULTR WELF, P158; Kovach J. K., 1975, The behaviour of domestic animals,, P437; Kovach J.K., 1974, APPL ANIM ETHOL, V1, P77, DOI [10.1016/0304-3762(74)90010-8, DOI 10.1016/0304-3762(74)90010-8]; LUCOTTE G, 1978, THESIS U ORLEANS; Nichols C. R., 1992, Gibier Faune Sauvage, V9, P743; ORCUTT FS, 1976, AUK, V93, P135; RATNAMOHAN N, 1985, VET RES COMMUN, V9, P1, DOI 10.1007/BF02215123; SCHEIN MW, 1983, APPL ANIM ETHOL, V10, P375, DOI 10.1016/0304-3762(83)90186-4; Siegel S., 1988, NONPARAMETRIC STAT B; STATKIEWICZ WR, 1980, ANIM BEHAV, V28, P462, DOI 10.1016/S0003-3472(80)80053-4; STEVENS VERNON C., 1961, JOUR WILDLIFE MANAGEMENT, V25, P99, DOI 10.2307/3797004; TAKATSUKASA N, 1967, BIRDS NIPPON, P177; Wakasugi N., 1984, EVOLUTION DOMESTICAT, P319; WILKINSON L, 1992, SYSTAT SYSTEM STAT S; Yamashina Y., 1961, Journal of the Bombay Natural History Society, V58, P216	21	26	27	1	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0168-1591			APPL ANIM BEHAV SCI	Appl. Anim. Behav. Sci.	DEC	1997	55	1-2					103	112		10.1016/S0168-1591(97)00039-7			10	Agriculture, Dairy & Animal Science; Behavioral Sciences; Veterinary Sciences	Agriculture; Behavioral Sciences; Veterinary Sciences	YP628	WOS:000071297800009					2021-06-18	
J	Max, JE; Sharma, A; Qurashi, MI				Max, JE; Sharma, A; Qurashi, MI			Traumatic brain injury in a child psychiatry inpatient population: A controlled study	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; children and adolescents; psychiatric inpatients	HEAD-INJURIES; SEQUELAE	Objective: To extend our findings from child psychiatry outpatients to child psychiatry inpatients regarding the similarity of children with a history of traumatic brain injury (TBI), particularly mild TBI, to matched children without such a history. Method: This is a chart review of patients consecutively admitted to a child psychiatry inpatient unit over a 5-year period. Children with TBI were matched by age, sex, race, and social class to children with no history of TBI. Axis I and II diagnoses and diagnostic clusters and use of special education services and IQ scores were compared. Results: Fifty-six (8.1%) of 694 consecutive patients admitted had a definite TBI. Not one of more than 50 variables compared between TBI and control subjects was significantly different. Conclusion: In a child psychiatry inpatient unit, patients with a history of TBI were virtually indistinguishable from matched children without TBI. Caution should be exercised before attributing the child's problems, especially long-term problems, to the TBI unless the injury was severe or the child is exhibiting related phobic or posttraumatic stress symptomatology.	UNIV IOWA,DEPT PSYCHIAT,IOWA CITY,IA 52242							ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BENDER L, 1956, PSYCHOPATHOLOGY CHIL, P66; Black P, 1981, BRAIN DYSFUNCTION CH, P171; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; MAX JE, 1997, J AM ACAD CHILD ADOL, V36, P96; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; OTTO U, 1960, Acta Paedopsychiatr, V27, P6; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; *SPSS INC, 1995, SPSS WIND PROF STAT; TEASDALE G, 1974, LANCET, V2, P81	17	26	27	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	NOV	1997	36	11					1595	1601		10.1016/S0890-8567(09)66570-9			7	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	YC340	WOS:A1997YC34000023	9394945				2021-06-18	
J	Yunoki, M; Kawauchi, M; Ukita, N; Noguchi, Y; Nishio, S; Ono, Y; Asari, S; Ohmoto, T; Asanuma, M; Ogawa, N				Yunoki, M; Kawauchi, M; Ukita, N; Noguchi, Y; Nishio, S; Ono, Y; Asari, S; Ohmoto, T; Asanuma, M; Ogawa, N			Effects of lecithinized superoxide dismutase on traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						superoxide dismutase; lecithinization; reactive oxygen species; traumatic brain injury; mRNA; brain edema	POLYETHYLENE-GLYCOL; LIPID-PEROXIDATION; CELL-LINES; REPERFUSION; INDUCTION; ISCHEMIA; BINDING; TISSUES; ENZYME; EDEMA	Only small amounts of superoxide dismutase (SOD) are present in the extracellular space to scavenge excess amounts of superoxide anions (O2(-)) released after traumatic brain injury (TBI). Experiments were performed in rats with cerebral contusion produced by weight-drop technique. We investigated the effects of exogenous lecithinized SOD (PC-SOD) on accumulation of O2(-) produced in our model, by measuring the level of SOD activity (using the NBT-reducing method) and the expression of copper, zinc-SOD (Cu, Zn-SOD) mRNA (by Northern blot analysis). As determined by tissue-specific gravity, administration of PC-SOD reduced brain edema in the periphery of the lesion 6 h after contusion. SOD activity increased in the peripheral region at 30 min after contusion, but returned to normal levels at 6 h after TBI. Administration of PC-SOD increased SOD activity up to 6 h after TBI. The expression of Cu, Zn-SOD mRNA increased in the core region, peripheral portion, and contralateral hemisphere up to 6 h after TBI, then was suppressed in all three regions by PC-SOD. Our results confirm the important role of O2(-) in the development of brain edema after TBI and indicate that PC-SOD diminishes brain edema through a protective effect against O2(-).	OKAYAMA UNIV,SCH MED,INST MOL & CELLULAR MED,DEPT NEUROSCI,OKAYAMA 700,JAPAN	Yunoki, M (corresponding author), OKAYAMA UNIV,SCH MED,INST MOL & CELLULAR MED,DEPT NEUROL SURG,2-5-1 SHIKATA CHO,OKAYAMA 700,JAPAN.						ASANUMA M, 1995, MOL BRAIN RES, V33, P29, DOI 10.1016/0169-328X(95)00102-X; CHEN LY, 1995, AM HEART J, V129, P211, DOI 10.1016/0002-8703(95)90000-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELABAR JM, 1987, EUR J BIOCHEM, V166, P181, DOI 10.1111/j.1432-1033.1987.tb13500.x; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; FUKUHARA T, 1994, NEUROSURGERY, V35, P924, DOI 10.1227/00006123-199411000-00018; Haber F., 1934, P ROY SOC          A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/rspa.1934.0221]; HE YY, 1993, AM J PHYSIOL, V265, pH252; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; IGARASHI R, 1994, J PHARMACOL EXP THER, V271, P1672; IGARASHI R, 1992, J PHARMACOL EXP THER, V262, P1214; KARLSSON K, 1989, LAB INVEST, V60, P659; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MATSUYAMA T, 1993, J CEREBR BLOOD F MET, V13, P135, DOI 10.1038/jcbfm.1993.16; MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NADASY GL, 1989, ACTA PHYSIOL HUNG, V74, P267; Nakauchi K, 1996, J NEUROTRAUM, V13, P573, DOI 10.1089/neu.1996.13.573; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; OGAWA N, 1994, BRAIN RES, V646, P337, DOI 10.1016/0006-8993(94)90102-3; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; UYAMA O, 1992, STROKE, V23, P75, DOI 10.1161/01.STR.23.1.75; VERONESE FM, 1983, J PHARM PHARMACOL, V35, P757, DOI 10.1111/j.2042-7158.1983.tb02888.x; YANG YJ, 1991, MOL CHEM NEUROPATHOL, V14, P11, DOI 10.1007/BF03160994	33	26	26	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1997	14	10					739	746		10.1089/neu.1997.14.739			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YE057	WOS:A1997YE05700005	9383092				2021-06-18	
J	Obrenovitch, TP; Urenjak, J; Zilkha, E				Obrenovitch, TP; Urenjak, J; Zilkha, E			Effects of increased extracellular glutamate levels on the local field potential in the brain of anaesthetized rats	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						glutamate; excitotoxicity; glutamate-uptake; microdialysis; L-trans-pyrrolidine-2,4-dicarboxylate; glutamate receptors	D-ASPARTATE RECEPTORS; INTRACEREBRAL MICRODIALYSIS; ANOXIC DEPOLARIZATION; MOUSE CORTEX; IN-VIVO; SODIUM; INHIBITION; ISCHEMIA; RELEASE; ACTIVATION	1 It is generally considered that glutamate-mediated transmission can be altered from a physiological to neurotoxic action when extracellular glutamate levels become excessive subsequent to impaired uptake and/or excessive release. However, high extracellular glutamate does not consistently correlate with neuronal dysfunction and death in vivo. The purpose of this study was to examine in situ the local depolarizations, as indicated by negative shifts of the extracellular field (d.c.) potential, produced by local inhibition of high-affinity glutamate uptake, with or without co-application of exogenous glutamate, in three brain regions of anaesthetized rats. 2 Microdialysis probes incorporating an electrode were used to apply exogenous glutamate and/or its uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylate (L-trans-PDC), and to monitor the resulting changes in extracellular glutamate and d.c. potential at the sites of application within the cortex, striatum and hippocampus. 3 Perfusion of 1 to 10 mM L-trans-PDC markedly and concentration-dependently increased extracellular glutamate levels (by up to 1700% of basal level in the parietal cortex). Despite their large magnitude, glutamate changes were associated with minor negative shifts of the d.c. potential (<2 mV), which were not suppressed by the N-methyl-D-aspartate (NMDA)-channel blocker, dizocilpine (MK-801, 2 mg kg(-1), i.v.), or the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate-receptor antagonist, 6-nitro-7-sulphamoylbenzo(f)quinoxaline-2,3-dione (NBQX, 30 mg kg(-1), i.p.). L-trans-PDC had virtually identical concentration-dependent effects on dialysate glutamate in the hippocampus and striatum, but those induced in the cortex were around 40% larger (P<0.002). In contrast, the associated depolarizations were around twice as large in the striatum and cortex as in the hippocampus (P<0.002). Finally, co-application of L-trans-PDC did not enhance the d.c. potential changes evoked by perfusion of 5 or 20 mM glutamate. 4 As the neurotoxic potency of glutamate agonists is considered to be linked to excessive opening of glutamate-operated ion channels, these results challenge the notion that high extracellular glutamate levels may be the key to excitotoxicity in neurological disorders. In particular, they do not support the hypothesis that high extracellular glutamate causes the sudden negative shifts of the d.c. potential associated with ischaemia (i.e. anoxic depolarization), traumatic brain injury and spreading depression. Impaired uptake and excessive release of glutamate may well lead to excitotoxicity, but only at the synaptic level, not by spreading through the interstitial fluid.	INST NEUROL, GOUGH COOPER DEPT NEUROL SURG, LONDON WC1N 3BG, ENGLAND; PFIZER LTD, CENT RES, DISCOVERY BIOL, SANDWICH CT13 9NJ, KENT, ENGLAND							BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; CARLA V, 1992, NEUROSCI LETT, V146, P21, DOI 10.1016/0304-3940(92)90162-Z; CHIZH BA, 1994, BRIT J PHARMACOL, V112, P843, DOI 10.1111/j.1476-5381.1994.tb13156.x; CHOI DW, 1987, J NEUROSCI, V7, P369; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; Desai M. A., 1995, Society for Neuroscience Abstracts, V21, P1112; ERIKSSON G, 1995, GLIA, V15, P152, DOI 10.1002/glia.440150207; GARTHWAITE G, 1992, EUR J NEUROSCI, V4, P353, DOI 10.1111/j.1460-9568.1992.tb00882.x; GRIFFITHS R, 1994, BIOCHEM PHARMACOL, V47, P267, DOI 10.1016/0006-2952(94)90016-7; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; MARRANNES R, 1989, ACTA PHYSL SCAN S582, V136, P75; MARTIN DC, 1995, BIOCHEM PHARMACOL, V49, P809, DOI 10.1016/0006-2952(94)00519-R; MASSIEU L, 1995, J NEUROCHEM, V64, P2262; McCulloch J, 1993, Acta Neurochir Suppl (Wien), V57, P73; MELDRUM BS, 1994, NEUROLOGY, V44, P14; MILLER S, 1994, EUR J PHARM-MOLEC PH, V269, P235, DOI 10.1016/0922-4106(94)90091-4; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OBRENOVITCH TP, 1994, BRIT J PHARMACOL, V113, P1295, DOI 10.1111/j.1476-5381.1994.tb17139.x; OBRENOVITCH TP, 1995, J NEUROPHYSIOL, V73, P2107; OBRENOVITCH TP, 1993, J NEUROSCI METH, V47, P139, DOI 10.1016/0165-0270(93)90030-U; Obrenovitch TP, 1996, ACT NEUR S, V66, P50; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; OBRENOVITCH TP, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P23; OBRENOVITCH TP, 1993, J NEUROCHEM, V61, P178, DOI 10.1111/j.1471-4159.1993.tb03553.x; Obrenovitch TP, 1996, J NEUROCHEM, V66, P2446; RAUEN T, 1992, FEBS LETT, V312, P15, DOI 10.1016/0014-5793(92)81401-7; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SARANTIS M, 1993, J PHYSIOL-LONDON, V459, pP246; SMITH AD, 1994, J NEUROSCI METH, V54, P75, DOI 10.1016/0165-0270(94)90161-9; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; THOMPSON SM, 1986, J NEUROPHYSIOL, V56, P507; THOMSEN C, 1994, J NEUROCHEM, V63, P2038; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; Urenjak J, 1997, N-S ARCH PHARMACOL, V355, P36; Urenjak J, 1997, LIFE SCI, V61, P523, DOI 10.1016/S0024-3205(97)00412-8; Urenjak J, 1996, PHARMACOL REV, V48, P21; Urenjak J, 1996, BRIT J PHARMACOL, V117, pP67; URENJAK J, 1995, BRIT J PHARMACOL, V116, pP339; WALDMEIER PC, 1993, N-S ARCH PHARMACOL, V348, P478; XIE YX, 1994, BRAIN RES, V652, P216, DOI 10.1016/0006-8993(94)90230-5; XIE YX, 1995, J CEREBR BLOOD F MET, V15, P587, DOI 10.1038/jcbfm.1995.72; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	48	26	27	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	SEP	1997	122	2					372	378		10.1038/sj.bjp.0701372			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	XW039	WOS:A1997XW03900026	9313949	Green Published, Bronze			2021-06-18	
J	Brooks, CA; Gabella, B; Hoffman, R; Sosin, D; Whiteneck, G				Brooks, CA; Gabella, B; Hoffman, R; Sosin, D; Whiteneck, G			Traumatic brain injury: Designing and implementing a population-based follow-up system	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEALTH; SCALE	Craig Hospital and the Colorado Department of Public Health and Environment began designing a population-based followup system for persons with traumatic brain injury (TBI) in 1994. With funding from the Centers for Disease Control and Prevention, the Colorado TBI Follow-up System addresses the issue, ''What happens to persons with TBI after they are dis charged from the hospital?'' Two methods of data collection are used, medical record review and annual telephone surveys to gather long-term outcomes. The design calls for following all persons hospitalized with severe TBI (defined as any person with inpatient rehabilitation and/or with an Abbreviated Injury Scale [AIS] score for the head of 3 or greater) and a 20% random sample of persons hospitalized with less severe TBI. An expert panel was used to select variables for retrospective abstracting and prospective interviewing. Information obtained from medical records includes data verifying eligibility, diagnoses, radiological results, circumstances of injury, and severity of injury, as well as demographic data. The interview instrument includes questions and scales related to health status, disability, handicap, quality of life, and service utilization. Both methods of data collection have been pilot-tested and are now used routinely in the Colorado TBI Follow-up System. (C) 1997 by the American Congress of Rehabilitation Medicine.	COLORADO DEPT PUBL HLTH & ENVIRONM,DENVER,CO; CTR DIS CONTROL & PREVENT,ATLANTA,GA	Brooks, CA (corresponding author), CRAIG HOSP RES,3425 S CLARKSON ST,ENGLEWOOD,CO 80110, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/CCU812447] Funding Source: Medline		BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BENYISHAY Y, 1987, J HEAD TRAUMA REHABI, V2, P224; BERKMAN PL, 1971, AM J EPIDEMIOL, V94, P105, DOI 10.1093/oxfordjournals.aje.a121301; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111, DOI DOI 10.1159/000264678; BRESLAU N, 1985, PSYCHIAT RES, V15, P219, DOI 10.1016/0165-1781(85)90079-4; *CDC, 1997, MMWR MORB MORTAL WLD, V6, P8; Derogatis LR, 1975, BRIEF SYMPTOM INVENT; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; GRANGER CV, 1994, AM J PHYS MED REHAB, V73, P51, DOI 10.1097/00002060-199473010-00012; GREENSPAN A, 1996, FIREARM INJURY OUTCO; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; *J HOPK U, 1993, INJ SEV SCOR ICDMAP; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; McDowell I., 1987, MEASURING HLTH GUIDE; *NAT CTR HLTH STAT, 1995, VIT HLTH STAT, V10; *NAT MULT SCLER SO, 1987, MIN REC DIS MULT SCL; POLLARD WE, 1976, MED CARE, V14, P146, DOI 10.1097/00005650-197602000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RADOSEVICH DM, 1995, UPDATE NEWSLETTER HL, V2, P2; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; *SOC TEACH FAM MED, 240890038 HRSA DHHS, P18; Truelle J L, 1990, Brain Inj, V4, P305, DOI 10.3109/02699059009026181; WARE JG, 1992, MED CARE, V30, P470; *WAYN STAT U, 1996, TRAUM BRAIN INJ MOD; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WOOD V, 1969, J GERONTOL, V24, P465, DOI 10.1093/geronj/24.4.465	28	26	27	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1997	78	8		4			S26	S30		10.1016/S0003-9993(97)90152-0			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	XR538	WOS:A1997XR53800005	9270485				2021-06-18	
J	Smith, GA; Bowman, MJ; Luria, JW; Shields, BJ				Smith, GA; Bowman, MJ; Luria, JW; Shields, BJ			Babywalker-related injuries continue despite warning labels and public education	PEDIATRICS			English	Article						babywalker; pediatric trauma; falls; injury prevention	WALKER-RELATED INJURIES; INFANT WALKER; BABY WALKERS; CHILDREN; HAZARD	Objective. To describe the epidemiology of babywalker-related injuries to children treated in a pediatric emergency department despite current prevention efforts, and to investigate the beliefs of parents regarding babywalker use. Design. A descriptive study of a consecutive series of patients. Setting. The emergency department of a large, academic children's hospital. Participants. Children treated for babywalker-related injuries during the 3-year period of March 1993 through February 1996. Results. There were 271 children treated for babywalker-related injuries. The mean age was 9.2 months, and 62% of patients were boys. Ninety-six percent of children were injured when they fell down stairs in their babywalker. The number of stairs that a child fell down was significantly associated with skull fracture and admission to the hospital, and a fall down more than 10 stairs had a relative risk (RR) of skull fracture = 3.28 (95% confidence interval, 1.35 < RR < 7.98). There were 159 children with conlusions/abrasions (58.6%), 35 concussions/head injuries (12.9%), 33 lacerations (12.2%), 26 skull fractures (9.6%), 9 epistaxis (3.3%), 4 nonskull fractures (1.5%), 4 avulsed teeth (1.5%), and 1 burn (0.4%). Three of the skull fractures were depressed, and three also had accompanying intracranial hemorrhage. Ten patients (3.7%) were admitted to the hospital, and all had skull fractures resulting from falls down stairs. Supervision was present in 78% of cases, including supervision by an adult in 69% of cases. Forty-five percent of families kept the walker, and 32% used the walker again for the study patient or another child after the injury episode. Fifty-nine percent of parents acknowledged that they were aware of the potential dangers of babywalkers before the injury event. Fifty-six percent of parents favored a national ban on the sale of walkers, and 20% were opposed. Conclusion. Despite the currently used prevention strategies, including adult supervision, warning labels, care giver education programs, and stairway gates, serious injuries associated with babywalkers continue to occur to young children. The US Consumer Product Safety Commission should promulgate a rule, similar to the voluntary standard adopted in Canada, regarding design requirements for babywalkers that will prevent their passage through household doorways at the head of stairs. The manufacture and sale of mobile babywalkers that do not meet this new standard should be banned in the US. A recall or trade-in campaign should be conducted nationally to decrease the number of existing babywalkers.		Smith, GA (corresponding author), OHIO STATE UNIV, CHILDRENS HOSP,COLL MED,DEPT PEDIAT, DIV EMERGENCY MED, 700 CHILDRENS DR, COLUMBUS, OH 43205 USA.						*AM MED ASS BOARD, 1991, AM J DIS CHILD, V145, P933; Baker S P, 1981, J Public Health Policy, V2, P235, DOI 10.2307/3342369; BIRCHALL MA, 1988, BRIT MED J, V296, P1641, DOI 10.1136/bmj.296.6637.1641; BIRCHALL MA, 1988, BURNS, V14, P244, DOI 10.1016/0305-4179(88)90049-6; BOYLE WE, 1995, PEDIATRICS, V95, P778; CHIAVIELLO CT, 1994, PEDIATRICS, V93, P974; COATS TJ, 1991, ARCH EMERG MED, V8, P52; COURY DL, 1992, AM J DIS CHILD, V146, P507; CROUCHMAN M, 1986, DEV MED CHILD NEUROL, V28, P757; DEAN AG, 1990, EPILNFO; DIMARIO FJ, 1990, CLIN PEDIATR, V29, P405, DOI 10.1177/000992289002900709; FAZEN LE, 1982, PEDIATRICS, V70, P106; GLEADHILL DNS, 1987, ARCH DIS CHILD, V62, P491, DOI 10.1136/adc.62.5.491; HOLM VA, 1983, AM J DIS CHILD, V137, P1189, DOI 10.1001/archpedi.1983.02140380049016; INWOOD S, 1989, CAN NURSE, V4, P14; JAMES W, 1988, CAN MED ASSOC J, V139, P73; JOFFE M, 1988, PEDIATRICS, V82, P457; JOHNSON C F, 1990, Pediatric Emergency Care, V6, P58, DOI 10.1097/00006565-199003000-00017; KAUFFMAN IB, 1977, PERCEPT MOTOR SKILL, V45, P1323, DOI 10.2466/pms.1977.45.3f.1323; KAVANAGH CA, 1982, AM J DIS CHILD, V136, P205, DOI 10.1001/archpedi.1982.03970390019005; KOSER M, 1995, ARCH PEDIAT ADOL MED, V149, P1275, DOI 10.1001/archpedi.1995.02170240093016; LANGRUNTZ H, 1983, CAN MED ASSOC J, V129, P482; Marcella S, 1990, Conn Med, V54, P127; MAYR J, 1994, EUR J PEDIATR, V153, P531, DOI 10.1007/BF01957011; MEYER M, 1988, BURNS, V14, P145, DOI 10.1016/0305-4179(88)90222-7; MILLAR R, 1975, INJURY, V7, P8, DOI 10.1016/0020-1383(75)90051-0; Morrison CD, 1996, PEDIATR EMERG CARE, V12, P180, DOI 10.1097/00006565-199606000-00008; PARTINGTON MD, 1991, ANN EMERG MED, V20, P652, DOI 10.1016/S0196-0644(05)82386-8; RIEDER MJ, 1986, PEDIATRICS, V78, P488; Sendut I H, 1995, Med J Malaysia, V50, P192; SHEEHAN KM, 1995, PEDIATR EMERG CARE, V11, P27, DOI 10.1097/00006565-199502000-00008; STOFFMAN JM, 1984, CAN MED ASSOC J, V131, P573; TRINKOFF A, 1993, PUBLIC HEALTH REP, V108, P784; WELLMAN S, 1984, CLIN PEDIATR, V23, P98, DOI 10.1177/000992288402300206; 1994, FED REGISTER, V59, P39306	35	26	28	0	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	AUG	1997	100	2							e1	10.1542/peds.100.2.e1			5	Pediatrics	Pediatrics	XP050	WOS:A1997XP05000016	9233972	Bronze			2021-06-18	
J	Zafonte, RD; Mann, NR; Millis, SR; Wood, DL; Lee, CY; Black, KL				Zafonte, RD; Mann, NR; Millis, SR; Wood, DL; Lee, CY; Black, KL			Functional outcome after violence related traumatic brain injury	BRAIN INJURY			English	Article							CRANIOCEREBRAL GUNSHOT WOUNDS; GLASGOW-COMA-SCALE; ADULT CIVILIANS; HEAD-INJURY; VIETNAM; POPULATION; MANAGEMENT; MORTALITY; NEUROLOGY; PROGNOSIS	Violent injuries have become an increasingly prevalent cause of traumatic brain injury (TBI). These injuries can be classified as either penetrating or non-penetrating in nature. While much of the research on violence has been within a military population, there exists a marked difference between military and civilian injuries. Prior work has reported relatively poor outcomes for those individuals who have suffered penetrating TBIs, but little has been done to assess specific functional outcome parameters in survivors. We examined 25 subjects that had sustained blunt injuries and 25 cases with penetrating injuries as a result of a violent act. Cases were matched by initial Glasgow Coma Scale (GCS), age and educational level. Mean GCS for this study sample was 8.8. The following outcome variables were assessed at rehabilitation admission and discharge and at 1 year post injury: Disability Rating Scale (DRS), Rancho Los Amigos Scale (LCFS), Functional Independence Measure (FIM) (ambulation, expression items), length of stay, and cost of care. Student's t-tests were performed to assess for differences between the two groups. No significant differences were noted between the groups for any of the outcome variables. Although penetrating injuries may have a higher initial mortality, those who survive to come to rehabilitation appear to have similar outcomes to those patients with nonpenetrating violence related injuries.	WAYNE STATE UNIV,REHABIL INST MICHIGAN,DETROIT,MI							ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; CAREY ME, 1974, J NEUROSURG, V41, P542, DOI 10.3171/jns.1974.41.5.0542; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; COWEN T, ARCH PHYSICAL MED RE, V76, P797; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1985, NEUROSURGERY, V16, P754, DOI 10.1227/00006123-198506000-00002; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; MILLIS SR, 1995, BRAIN INJURY, V9, P509, DOI 10.3109/02699059509008210; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SALAZAR AM, 1986, NEUROLOGY, V36, P459, DOI 10.1212/WNL.36.4.459; SCHAWB K, 1993, NEUROLOGY, V43, P95; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; SWEENEY J, 1983, PHYS THER, V12, P2018	18	26	27	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUN	1997	11	6					403	407					5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WZ726	WOS:A1997WZ72600002	9171926				2021-06-18	
J	Evers, P; Johnston, GR; Wallace, LJ; Lipowitz, AJ; King, VL				Evers, P; Johnston, GR; Wallace, LJ; Lipowitz, AJ; King, VL			Long-term results of treatment of traumatic coxofemoral joint dislocation in dogs: 64 cases (1973-1992)	JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article							PELVIC OSTEOTOMY; HIP DISLOCATION; FEMORAL-HEAD; LUXATION; REPAIR; EXCISION; NECK; CAT	Objective-To determine long-term results of various treatments for traumatic coxofemoral joint dislocation in dogs. Design-Retrospective case series. Animals-64 dogs that underwent closed reduction and bandage stabilization, extracapsular suture stabilization, transacetabular pinning, toggle pinning, DeVita pinning, or femoral head and neck excision. Procedure-Follow-up evaluations included owner evaluation (64 dogs), physical evaluation (23), and radiography (19). Follow-up time ranged from 8 to 156 months. Results-Owner evaluation scores after closed reduction were significantly better than scores after DeVita pinning, extracapsular suture stabilization, and femoral head and neck excision. On physical examination, 6 of 23 dogs were lame on the side of the previous dislocation. Signs of pain and crepitation were evident during palpation of 12 and 8 of 25 joints, respectively. Thirteen of 21 joints had radiographic evidence of degenerative joint disease. There was a greater progression of degenerative joint disease in previously dislocated joints than in unaffected joints. There were not any significant differences between treatments in regard to results of physical and radiographic evaluation. Time between trauma and treatment and existence of concomitant injuries did not influence follow-up results, but there was a significant association between body weight and radiographic evaluation score. Clinical Implications-Concomitant injuries do not appear to justify a worse prognosis in dogs with traumatic coxofemoral joint dislocation, nor does a delay in treatment of > 3 days. Gait abnormalities and degenerative joint disease might develop in the long term. Proper body weight should be maintained regardless of treatment.	UNIV MINNESOTA,VET TEACHING HOSP,DEPT SMALL ANIM CLIN SCI,ST PAUL,MN 55108; UNIV MINNESOTA,VET TEACHING HOSP,DEPT CLIN & POPULAT SCI,ST PAUL,MN 55108							ALLEN SW, 1986, COMP CONT EDUC PRACT, V8, P457; BASHER AWP, 1986, VET SURG, V15, P356, DOI 10.1111/j.1532-950X.1986.tb00243.x; BEALE BS, 1991, VET COMP ORTHOPAED T, V38, P28; BENNETT D, 1980, J SMALL ANIM PRACT, V21, P373, DOI 10.1111/j.1748-5827.1980.tb01264.x; BONE DL, 1984, VET SURG, V13, P263, DOI 10.1111/j.1532-950X.1984.tb00807.x; Braden T. D., 1988, Veterinary and Comparative Orthopaedics and Traumatology, V1, P26; BRINKER WO, 1990, HDB SMALL ANIMAL ORT, P285; BRINKER WO, 1990, HDB SMALL ANIMAL ORT, P345; BRINKER WO, 1990, HDB SMALL ANIMAL ORT, P76; BURNS J, 1987, VET MED-US, V82, P694; CORLEY EA, 1985, J AM VET MED ASSOC, V187, P805; Dallman M. J., 1984, Journal of Veterinary Orthopedics, V3, P7; DAVIS MA, 1989, AM J EPIDEMIOL, V130, P278, DOI 10.1093/oxfordjournals.aje.a115334; De Vita J, 1952, P AM VET MED ASS 89, P191; DeAngelis M., 1973, Journal of the American Animal Hospital Association, V9, P175; DUFF SRI, 1982, VET REC, V111, P140, DOI 10.1136/vr.111.7.140; EHMER EE, 1934, N AM VET         DEC, P31; ELKINS AD, 1991, J AM ANIM HOSP ASSOC, V27, P53; ELKINS AD, 1981, CALIF VET, V10, P19; FLYNN MF, 1994, VET SURG, V23, P311, DOI 10.1111/j.1532-950X.1994.tb00490.x; FRY PD, 1974, J SMALL ANIM PRACT, V15, P661, DOI 10.1111/j.1748-5827.1974.tb05648.x; GARRETT JC, 1979, J BONE JOINT SURG AM, V61, P2, DOI 10.2106/00004623-197961010-00002; GUTHRIE S, 1989, J SMALL ANIM PRACT, V30, P639, DOI 10.1111/j.1748-5827.1989.tb01497.x; HAMMER DL, 1980, J AM VET MED ASSOC, V177, P1018; HEFFRON LE, 1979, J SMALL ANIM PRACT, V20, P603, DOI 10.1111/j.1748-5827.1979.tb06669.x; Herron M. R., 1979, Journal of Veterinary Orthopedics, V1, P30; HUNT CA, 1985, J AM VET MED ASSOC, V187, P828; JOHNSON JA, 1994, VET COMP ORTHOPAED, V7, P56; JOHNSON ME, 1987, VET SURG, V16, P346, DOI 10.1111/j.1532-950X.1987.tb00965.x; KATCHERIAN G, 1990, CANINE PRACT, V15, P7; KNOWLES AT, 1953, J AM VET MED ASSOC, V123, P508; Lawson DD, 1964, J SMALL ANIM PRACT, V6, P57; LEEDS EB, 1979, J VET ORTHOP, V1, P37; LEIGHTON RL, 1985, VET MED-US, V80, P53; LIPOWITZ AJ, 1993, SMALL ANIMAL ORTHOPE, P198; LIPPINCOTT CL, 1987, VET CLIN N AM-SMALL, V17, P857, DOI 10.1016/S0195-5616(87)50081-X; Manley PA, 1993, TXB SMALL ANIMAL SUR, P1786; MANN FA, 1987, VET SURG, V16, P223, DOI 10.1111/j.1532-950X.1987.tb00943.x; MCLAUGHLIN RM, 1991, VET SURG, V20, P291, DOI 10.1111/j.1532-950X.1991.tb01270.x; OTTENSCHOT TRF, 1986, TIJDSCHR DIERGENEESK, V111, P1229; PETTIT GD, 1956, CALIF VET        MAR, P14; ROY RG, 1992, VET SURG, V21, P475, DOI 10.1111/j.1532-950X.1992.tb00084.x; Schwarz E J, 1972, Mod Vet Pract, V53, P52; SHUTTLEWORTH A C, 1950, Vet Rec, V62, P365; STADER O, 1955, N AM VET         DEC, P1026; STEAD AC, 1970, J SMALL ANIM PRACT, V11, P591, DOI 10.1111/j.1748-5827.1970.tb05620.x; TIRGARI M, 1978, J AM ANIM HOSP ASSOC, V14, P757	47	26	26	0	9	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360	0003-1488			J AM VET MED ASSOC	J. Am. Vet. Med. Assoc.	JAN 1	1997	210	1					59	&					7	Veterinary Sciences	Veterinary Sciences	VZ462	WOS:A1997VZ46200021	8977650				2021-06-18	
J	ChathamShowalter, PE				ChathamShowalter, PE			Carbamazepine for combativeness in acute traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							BEHAVIOR	Psychiatrists increasingly consult on the treatment of acute traumatic brain injury (TBI) when combativeness compromises safe critical care. The author discusses use of carbamazepine for 7 combative patients with multiple trauma including TBI. This cohort had a clinical decrease in combativeness within 4 days after carbamazepine, compared with this Level I trauma center's experience of prolonged combative periods without its use.		ChathamShowalter, PE (corresponding author), LEHIGH VALLEY HOSP CTR,DEPT PSYCHIAT,CONSULTAT LIAISON DIV,ALLENTOWN,PA 18103, USA.						GUALTIERI CT, 1991, J CLIN PSYCHOPHARM, V11, P280, DOI 10.1097/00004714-199108000-00027; MATLES JA, 1990, J NEUROPSYCHIATRY CL, V2, P159; Mellow A M, 1993, J Geriatr Psychiatry Neurol, V6, P205; SCHIFF HB, 1982, AM J PSYCHIAT, V139, P1346; SMALL JG, 1991, ARCH GEN PSYCHIAT, V48, P915; STUPPAECK CH, 1992, ALCOHOL ALCOHOLISM, V27, P153; YUDOFSKY S, 1981, AM J PSYCHIAT, V138, P218; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Yudofsky SC, 1987, TXB NEUROPSYCHIATRY, P179; 1981, RANCHO LOS AMIGOS CO	10	26	26	0	0	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1996	8	1					96	99					4	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	TR911	WOS:A1996TR91100016	8845710				2021-06-18	
J	Englander, JS; Cifu, DX; Wright, J; Zafonte, R; Mann, N; Yablon, S; Ivanhoe, C				Englander, JS; Cifu, DX; Wright, J; Zafonte, R; Mann, N; Yablon, S; Ivanhoe, C			The impact of acute complications, fractures, and motor deficits on functional outcome and length of stay after traumatic brain injury: A multicenter analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						fractures; functional outcomes; length of stay; medical complications; motor weakness	HEAD-INJURY; REHABILITATION; SEVERITY	Objective: To determine the influence of acute respiratory complications, gastrointestinal procedures, fractures, and motor deficits on length of stay (LOS) and functional outcome following traumatic brain injury (TBI). Design: Prospective multicenter analysis of consecutive admissions to designated TBI Model Systems of Care. Setting: Four National institute for Disability and Rehabilitation Research (NIDRR) TBI Model Systems centers for coordinated acute and rehabilitation care. Participants: 637 adults with TBI were enrolled in the study from February 1989 through June 1995. One-year follow cv-up data were available on 270 subjects. Main Outcome Measures: Acute and rehabilitation LOS, Disability Rating Scale (DRS) score, and Functional Independence Measure (FIM)) score. Results: Gastrostomies or jejunostomies were placed in 44% of individuals and were associated with swallowing and feeding problems at rehabilitation admission and discharge. Respiratory complications occurred in 39% of individuals and were associated with increased acute and rehabilitation LOS (P <.0005). Pelvic and lower extremity fractures occurred in 21% of individuals, and upper extremity fractures occurred in 11%; both were associated with increased acute and rehabilitation LOS. Only lower extremity fractures were associated with the need for physical assistance with functional activities at rehabilitation admission and discharge. Less-than-antigravity strength and moderate to severe incoordination were associated with the need for physical assistance with mobility and self-care at admission, at discharge, and at 1-year follow-up. AU of these associations diminished over time. Conclusions: Medical complications associated with TBI and resultant motor impairment negatively affect functioning at time of rehabilitation admission and discharge. These effects diminish by 1 year post injury.	STANFORD UNIV,SCH MED,STANFORD,CA; VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,RICHMOND,VA; WAYNE STATE UNIV,DETROIT,MI; BAYLOR COLL MED,HOUSTON,TX 77030	Englander, JS (corresponding author), SANTA CLARA VALLEY MED CTR,DEPT PHYS MED & REHABIL,751 S BASCOM AVE,SAN JOSE,CA 95128, USA.			Cifu, David/0000-0003-1600-9387			BENNETT BR, 1989, J TRAUMA, V29, P556, DOI 10.1097/00005373-198905000-00003; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; EIDE PK, 1992, ACTA NEUROL SCAND, V86, P194, DOI 10.1111/j.1600-0404.1992.tb05065.x; GOBIET W, 1995, ZBL CHIR, V120, P544; GROSSWASSER Z, 1990, BRAIN INJURY, V4, P247; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hamilton B., 1987, REHABILITATION OUTCO; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; MYSIW W J, 1990, Brain Injury, V4, P247, DOI 10.3109/02699059009026174; SIEGEL JH, 1990, ARCH SURG-CHICAGO, V125, P498; SPLAINGARD ML, 1989, ARCH PHYS MED REHAB, V70, P318; *TRAUM BRAIN INJ M, 1994, TRAUM BRAIN INJ MOD; WONG PP, 1994, BRAIN INJURY, V8, P509, DOI 10.3109/02699059409151003	16	26	26	0	2	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1996	11	5					15	26		10.1097/00001199-199610000-00003			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VP053	WOS:A1996VP05300003					2021-06-18	
J	Moonis, M; Swearer, JM; Blumstein, SE; Kurowski, K; Licho, R; Kramer, P; Mitchell, A; Osgood, DL; Drachman, DA				Moonis, M; Swearer, JM; Blumstein, SE; Kurowski, K; Licho, R; Kramer, P; Mitchell, A; Osgood, DL; Drachman, DA			Foreign accent syndrome following a closed head injury: Perfusion deficit on single photon emission tomography with normal magnetic resonance imaging	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						foreign accent syndrome; caudate nucleus; frontal gyrus	APHASIA	Foreign accent syndrome is a rare speech disorder characterized by the emergence of an apparent foreign accent after an anterior left-hemispheric lesion. We report a case where the patient experienced foreign accent syndrome without other significant neurological deficits, consequent to a minor head injury. Results of single photon emission tomography (SPECT) studies suggest abnormal function of the left dorsolateral inferior frontal gyrus (sparing Broca's area) and the caudate nucleus as the underlying functional/anatomic basis of the syndrome, and acoustic analysis showed prosodic and vowel anomalies that contributed to the listener's perception of a ''foreign accent.''	UNIV MASSACHUSETTS,SCH MED,DEPT NUCL MED,WORCESTER,MA 01655; BROWN UNIV,DEPT COGNIT & LINGUIST SCI,PROVIDENCE,RI 02912	Moonis, M (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT NEUROL,SCH MED,55 LAKE AVE N,WORCESTER,MA 01655, USA.						ARDILA A, 1988, APHASIOLOGY, V2, P493, DOI 10.1080/02687038808248955; Aronson A. E., 1990, CLIN VOICE DISORDERS; BEHRENS SJ, 1987, PHOENTIC APPROACHES, P81; BLUMSTEIN SE, 1987, BRAIN LANG, V31, P215, DOI 10.1016/0093-934X(87)90071-X; COMALLI PE, 1962, J GENET PSYCHOL, V100, P47, DOI 10.1080/00221325.1962.10533572; Damasio A., 1979, CLIN NEUROPSYCHOLOGY, P360; DELIS D, 1987, CALIFORNIA VERBAL LE; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; GRAFFRADFORD NR, 1986, BRAIN LANG, V28, P86, DOI 10.1016/0093-934X(86)90093-3; GURD JM, 1988, NEUROPSYCHOLOGIA, V26, P237, DOI 10.1016/0028-3932(88)90077-2; INGRAM JCL, 1992, J PHONETICS, V20, P457, DOI 10.1016/S0095-4470(19)30650-3; Lieberman P., 1967, INTONATION PERCEPTIO; MONRADKROHN GH, 1947, BRAIN, V70, P405, DOI 10.1093/brain/70.4.405; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; PETERSON GE, 1952, J ACOUST SOC AM, V24, P175, DOI 10.1121/1.1906875; Ross E, 1985, PRINCIPLES BEHAV NEU, P239; SCHIFF HB, 1983, ARCH NEUROL-CHICAGO, V40, P720, DOI 10.1001/archneur.1983.04050110038005; SWEETING PM, 1982, J SPEECH HEAR RES, V25, P129, DOI 10.1044/jshr.2501.129; TAKAYAMA Y, 1993, NEUROLOGY, V43, P1361, DOI 10.1212/WNL.43.7.1361; Wechsler D, 1974, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WHITTY CWM, 1964, J NEUROL NEUROSUR PS, V27, P507, DOI 10.1136/jnnp.27.6.507	22	26	26	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	OCT	1996	9	4					272	279					8	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	VG776	WOS:A1996VG77600009					2021-06-18	
J	Ritter, AM; Robertson, CS; Goodman, JC; Contant, CF; Grossman, RG				Ritter, AM; Robertson, CS; Goodman, JC; Contant, CF; Grossman, RG			Evaluation of a carbohydrate-free diet for patients with severe head injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral ischemia; head injury; hyperglycemia	ENERGY PHOSPHATE-METABOLISM; TOTAL PARENTERAL-NUTRITION; TRAUMATIC BRAIN INJURY; CEREBRAL-ISCHEMIA; VASOGENIC EDEMA; RAT-BRAIN; HYPERGLYCEMIA; INFARCTION; HYPOXIA; CHLORIDE	Hyperglycemia, which may be caused or exacerbated by conventional diets, may worsen the neurological outcome from severe head injury, especially if secondary ischemic insults occur. The purpose of this study was to evaluate an experimental diet intended to replace systemic caloric and protein requirements without producing hyperglycemia. In initial studies in the laboratory, 5 experimental diets were employed in a middle cerebral artery temporary occlusion model. The effects of the diets on blood biochemistry and on infarction volume were compared in fasted animals and in animals fed a control diet. Animals fed the experimental diets had a significantly lower preischemia blood glucose concentration, a higher blood concentration of ketone bodies, and a smaller infarct volume than the animals fed a control diet. One diet chosen from the laboratory study was then evaluated in a clinical study as a randomized, open-label trial. Twenty severely head-injured patients were randomly assigned to be fed the experimental diet, EN-9305, or the control diet, Osmolyte HN, for the first 2 weeks after injury. Both treatment groups had similar blood glucose concentrations, averaging 6.33 +/- 0.21 mu mol/mL (114 +/- 4 mg/dL), on day 1 prior to starting the assigned diet. Blood glucose concentration increased in the control diet group to a peak of 8.37 +/- 0.94 mu mol/mL (151 +/- 17 mg/dL) on day 7 as the infusion rate of the diet was increased to the final rate. In the experimental diet group, the blood glucose concentration remained unchanged from fasting levels as the diet was advanced. Blood lactate concentration was lower, and blood ketone body concentrations were higher in the patients fed the experimental diet. Urinary nitrogen balance was better in the experimental diet group, but measures of visceral protein sparing, including serum albumin, plasma retinol binding protein, and total lymphocyte count, were not significantly different in the 2 treatment groups. Measures of cerebral anaerobic metabolism, including CSF lactate concentration and cerebral lactate production, were not significantly different in the 2 treatment groups. These studies suggest that a carbohydrate-free diet such as EN-9305 might have advantages for patients with severe head injury by replacing systemic caloric and protein requirements without producing hyperglycemia.	BAYLOR COLL MED,DEPT NEUROSURG,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS26716] Funding Source: Medline		BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BRINT S, 1988, J CEREBR BLOOD F MET, V8, P474, DOI 10.1038/jcbfm.1988.88; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; CHONG WK, 1989, J CHROMATOGR-BIOMED, V487, P147, DOI 10.1016/S0378-4347(00)83017-0; COMBS DJ, 1989, J NEUROSURG, V70, P623, DOI 10.3171/jns.1989.70.4.0623; EISENBERG HM, 1983, INTRACRANIAL PRESSUR, V5, P549; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; ISAYAMA K, 1991, STROKE, V22, P1394, DOI 10.1161/01.STR.22.11.1394; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KIRSCH JR, 1980, STROKE, V11, P506, DOI 10.1161/01.STR.11.5.506; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LUNDY EF, 1984, STROKE, V15, P547, DOI 10.1161/01.STR.15.3.547; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; MICHAUD LJ, 1991, J TRAUMA, V31, P1365; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MYERS RE, 1976, J NEUROPATH EXP NEUR, V35, P301, DOI 10.1097/00005072-197605000-00011; Pentelenyi T, 1979, Acta Neurochir Suppl (Wien), V28, P103; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROBERTSON C, 1992, STROKE, V23, P564, DOI 10.1161/01.STR.23.4.564; ROBERTSON CS, 1992, J NEUROTRAUM, V9, P398; Rogers A. E., 1979, LABORATORY RAT, V1, P123, DOI [10.1016/B978-0-12-074901-0.50013-7, DOI 10.1016/B978-0-12-074901-0.50013-7]; ROSNER MJ, 1993, INTRACRANIAL PRESSUR, V8, P686; SIEMKOWICZ E, 1981, ACTA NEUROL SCAND, V64, P207; SIEMKOWICZ E, 1978, ACTA NEUROL SCAND, V58, P1; WATERS DC, 1986, J NEUROSURG, V64, P460, DOI 10.3171/jns.1986.64.3.0460; YIP PK, 1991, NEUROLOGY, V67, P76; YOUNG B, 1987, J NEUROSURG, V67, P76, DOI 10.3171/jns.1987.67.1.0076; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	36	26	29	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1996	13	8					473	485		10.1089/neu.1996.13.473			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VH009	WOS:A1996VH00900005	8880611				2021-06-18	
J	Britt, LD; Zolfaghari, D; Kennedy, E; Pagel, KJ; Minghini, A				Britt, LD; Zolfaghari, D; Kennedy, E; Pagel, KJ; Minghini, A			Incidence and prophylaxis of deep vein thrombosis in a high risk trauma population	AMERICAN JOURNAL OF SURGERY			English	Article								BACKGROUND: Pelvic fractures, lower extremity injuries, acute head or spinal injury, and extended bedrest place trauma patients at an increased risk for deep vein thrombosis (DVT) and pulmonary embolism (PE). We reviewed patients with traumatic brain injuries (TBI), spinal cord injuries (SCI), and lower extremity fractures (LEF) to examine our DVT and PE incidence and evaluate the success of our DVT and PE prophylaxis. METHODS: From January 1, 1994 to March 1, 1995, the records of trauma patients with TBI, SCI, and LEF who were admitted to the trauma service and transferred to an inpatient rehabilitation facility were reviewed. RESULTS: Twenty-two patients had a TBI, 16 patients with SCI, and 12 patients with LEF. Forty-nine of the 50 patients received DVT prophylaxis, with 7 inferior vena cava (IVC) filters placed. The DVT incidence was 6% and the PE incidence was 2%. CONCLUSION: The 6% incidence of DVT was lower than expected due to diligent DVT prophylaxis and appropriate screening of symptomatic patients for clinically significant DVT. The 2% incidence of PE was also lower than expected, most likely due to our lower DVT incidence and the use of IVC filters. The lower DVT and PE incidence verifies our success at DVT and PE prophylaxis.	EASTERN VIRGINIA MED SCH,DEPT PHYS MED & REHABIL,NORFOLK,VA 23507	Britt, LD (corresponding author), EASTERN VIRGINIA MED SCH,DEPT SURG,825 FAIRFAX AVE,SUITE 610,NORFOLK,VA 23507, USA.						COON WW, 1977, ANN SURG, V186, P149, DOI 10.1097/00000658-197708000-00006; KUDSK KA, 1989, AM J SURG, V158, P515, DOI 10.1016/0002-9610(89)90182-7; OMALLEY KF, 1990, J TRAUMA, V30, P6; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; Shackford SR, 1988, J INTENSIVE CARE MED, V3, P87, DOI DOI 10.1177/088506668800300205; 1986, JAMA-J AM MED ASSOC, P256	7	26	28	0	0	CAHNERS PUBL CO	NEW YORK	249 WEST 17 STREET, NEW YORK, NY 10011	0002-9610			AM J SURG	Am. J. Surg.	JUL	1996	172	1					13	14		10.1016/S0002-9610(96)00079-7			2	Surgery	Surgery	UY817	WOS:A1996UY81700004	8686794				2021-06-18	
J	Ford, MR; Khalil, M				Ford, MR; Khalil, M			Evoked potential findings in mild traumatic brain injury .1. Middle latency component augmentation and cognitive component attenuation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED HEAD-INJURY; P300; DYSFUNCTION; CONCUSSION; RESPONSES; SYMPTOMS; RECOVERY; SEQUELAE	Objective: To compare evoked potential (EP) and electroencephalogram (EEG) recordings from patients with suspected mild traumatic brain injury (TBI) versus normal controls using computerized EP and EEG analysis procedures. Design: Matched two-group comparison design, with a second matched replication group, and a second group of normals. Setting: Private, ambulatory, non-emergency facility specializing in assessment, pain management, and rehabilitation of spine and related injuries. Patients and Other Participants: Patients were 54 consecutive referrals for computerized EP/EEG evaluation with histories of primarily motor vehicle accidents and symptoms consistent with mild TBI. Normal controls were 27 screened volunteers. Patients were arbitrarily divided into two groups and matched to the controls on the basis of age and gender. Main Outcome Measures: Outcome measures not included in this phase of investigation. Auditory and visual EPs were obtained in resting and P300 task sessions (in which subjects counted the number of randomly occurring target stimuli). The paucity of existing Literature did not permit prediction of all critical EP or EEG variables. Results: Middle latency EP components tie, after brain stem responses yet before long latency, cognitive components) showed amplitude increases (auditory P1, P2, and N2, and visual P2, 50-220 milliseconds poststimulus). Long latency cognitive components (auditory and visual P300 and N3, 290-700 milliseconds) showed amplitude decreases. Similar findings were present in the replication group of patients and in comparison to a second group of normal controls. Conclusions: Significant and reliable EP differences were present in patients whose histories and symptoms were consistent with mild TBI.	AUSTIN NEUROL INST PA,FUNCT NEUROIMAGING LAB,AUSTIN,TX							Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; EVANS RW, 1992, PHYSICAL MED REHABIL; EVANS RW, 1992, NEUROLOGIC CLIN NEUR; Ford Martin R., 1993, Brain Topography, V6, P43, DOI 10.1007/BF01234126; FORD MR, 1990, J CLIN EXP NEUROPSYC, V12, P52; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GREENBERG RP, 1982, J NEUROSURG, V56, P1, DOI 10.3171/jns.1982.56.1.0001; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P154, DOI 10.1177/155005948101200402; RAPPAPORT M, 1991, CLIN ELECTROENCEPHAL, V22, P199, DOI 10.1177/155005949102200407; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P167, DOI 10.1177/155005948101200403; RAPPAPORT M, 1994, J HEAD TRAUMA REHAB, V9, P94; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; WARD AA, 1966, HEAD INJURY C U CHIC; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; YOUNG WB, 1994, SEMIN NEUROL, V14, P46, DOI 10.1055/s-2008-1041058; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	35	26	26	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1996	11	3					1	15		10.1097/00001199-199606000-00004			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UP774	WOS:A1996UP77400004					2021-06-18	
J	Reeder, KP; Rosenthal, M; Lichtenberg, P; Wood, D				Reeder, KP; Rosenthal, M; Lichtenberg, P; Wood, D			Impact of age on functional outcome following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							DISABILITY RATING-SCALE; GLASGOW-COMA-SCALE; IMPAIRED CONSCIOUSNESS; HEAD-INJURY; RELIABILITY; RECOVERY	Objective: To examine whether increasing age is associated with poorer rehabilitation outcome. It was hypothesized that older individuals would benefit less from rehabilitation since increasing age is associated with greater morbidity and mortality. Design: Retrospective analysis of data collected at the beginning and end of inpatient medical rehabilitation. No experimental manipulation was performed. Injury severity, demographic information, initial level of functioning, and age were used in a hierarchical regression analysis to predict level of independent functioning. Setting: inpatient traumatic brain injury units at four model system programs. Patients: 365 patients with traumatic brain injuries (39 mild, 67 moderate, 259 severe; 78% male; mean age = 34 years). Interventions: All subjects participated in a comprehensive rehabilitation program including sen-ices from rehabilitation medicine, neuropsychology, nursing, social work, physical therapy, occupational therapy, speech and language pathology, vocational rehabilitation, and therapeutic recreation. Main Outcome Measures: Functional Independence Measure (FIM) and Disability Rating Scale (DRS). Results: After controlling for injury etiology, injury severity, and other demographic information, age had no statistically significant predictive value for functional outcome. Level of functioning on admission, independent of other factors, was the strongest predictor of functioning at discharge. Conclusions: Although increasing age has been strongly associated with higher rates of morbidity and mortality, it did not affect the level of functional improvement individuals achieved during inpatient rehabilitation. Hence, there does not appear to be justification for limiting access to rehabilitation solely on the: basis of advanced age.	WAYNE STATE UNIV,DEPT PHYS MED & REHABIL,DETROIT,MI 48202	Reeder, KP (corresponding author), REHABIL INST MICHIGAN,261 MACK BLVD,SUITE 555,DETROIT,MI 48201, USA.						Cambria S, 1979, J Neurosurg Sci, V23, P121; DAVIS CS, 1988, J AM GERIATR SOC, V36, P225, DOI 10.1111/j.1532-5415.1988.tb01805.x; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL K, FUNCTIONAL ASSESSMEN; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; JENNETT B, 1975, LANCET, V1, P480; JOHNSTONE AJ, 1993, BRAIN INJURY, V7, P501, DOI 10.3109/02699059309008177; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; NOVACK TA, 1992, J HEAD TRAUMA REHAB, V6, P69; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENTHAL M, 1992, NEUROREHABILITATION, V2, P1; ROSENTHAL M, 1993, J HEAD TRAUMA REHABI, V8; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; Tabachnick B.G., 1989, USING MULTIVARIATE S; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; Vollmer DG, 1991, J NEUROSURG S, V75, P37; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456	31	26	26	1	18	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1996	11	3					22	31		10.1097/00001199-199606000-00006			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UP774	WOS:A1996UP77400006					2021-06-18	
J	vanBalen, HGG; Mulder, T; Keyser, A				vanBalen, HGG; Mulder, T; Keyser, A			Towards a disability-oriented epidemiology of traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						epidemiology; functional recovery; traumatic brain injury	SICKNESS IMPACT PROFILE; HEALTH-STATUS MEASURE; HEAD-INJURY; FAMILY	The aim of this study was to investigate the value of using a disability-oriented approach to the epidemiology of traumatic brain injury (TBI) in order to improve health administration by preventing long-term sequelae. The epidemiology of disease was established by a registration system of inpatients which covers more than 99% of all hospital admissions in The Netherlands. Some international differences and national trends are discussed. The disability-related epidemiology was investigated by means of structured interviews, 3-7 years after the injury, in a clustered sample of 51 patients with major TBI according to the ICD-9-CM. The survey included evaluation scales such as the Sickness Impact Profile, the Barthel Index, and a Disability Rating Questionnaire. Concerning the disease-related epidemiological data, the overwhelming majority of all TBI patients went home, which suggests good recovery. Nevertheless, the disability-oriented research revealed long-term situational, cognitive and behavioural disabilities in at least 67% of the major-TBI population, whereas only 10% received any rehabilitation services at all after the acute-care period. It is concluded that preventive measures and a comprehensive service for brain injury survivors should be based both on disease and disability-oriented data.		vanBalen, HGG (corresponding author), ST MAARTENS CLIN,DEPT RES & DEV,POB 9011,6500 GM NIJMEGEN,NETHERLANDS.						Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGNER M, 1976, INT J HEALTH SERV, V6, P393, DOI 10.2190/RHE0-GGH4-410W-LA17; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; CAVENESS WF, 1979, ADV NEUROL, V20, P1; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; *CTR BUR STAT, 1994, STAT JB 1994 GRAV; FIELD JH, 1975, EPIDEMIOLOGY HEAD IN; HORTON AM, 1984, CURRENT TOPICS REHAB, P77; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; Kraus J, 1989, HEAD INJURY, P1; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISHMAN WA, 1987, ORGANIC PSYCHIATRY; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MAHONEY F I, 1965, Md State Med J, V14, P61; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCLELLAND RJ, 1988, BRIT J PSYCHIAT, V153, P141; MINDERHOUD JM, 1984, TRAUMATISCH HERSENLE; Morris JN, 1964, USES OF EPIDEMIOLOGY; ODDY M, 1989, CLIN REHABIL, V3, P253; Pentland B, 1990, Int Disabil Stud, V12, P86; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; RELLER J, 1984, PICKING PIECES; *SIG ZORG, 1993, TOEL KLIN; SNIVELY SA, 1991, J HEAD TRAUMA REHAB, V6, P11; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; STURMANS F, 1975, EPIDEMIOLOGIE MED ST; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; van Balen HG, 1992, MENSEN TRAUMATISCH H; VANBALEN HGG, 1990, P 5 EUR REG C REH IN, P82; VANBALEN HGG, 1993, S NEUROREHABILITATIO, P90; VANZOMEREN AH, 1990, HDB CLIN NEUROLOGY, V13, P397; Wade D T, 1988, Int Disabil Stud, V10, P64; WADE DT, 1991, CLIN REHABIL, V5, P141; WEHMAN P, 1990, VOCATIONAL REHABILIT, P1; WEHMAN P, 1990, VOCATIONAL REHABILIT; WILLER B, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P18; WINTEMUTE GJ, 1991, J HEAD TRAUMA REHAB, V6, P38; World Health Organization, 1980, INT CLASS IMP DIS HA	45	26	26	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0963-8288			DISABIL REHABIL	Disabil. Rehabil.	APR	1996	18	4					181	190		10.3109/09638289609166298			10	Rehabilitation	Rehabilitation	UG134	WOS:A1996UG13400004	8744906	Green Published			2021-06-18	
J	Gansler, DA; Covall, S; McGrath, N; OscarBerman, M				Gansler, DA; Covall, S; McGrath, N; OscarBerman, M			Measures of prefrontal dysfunction after closed head injury	BRAIN AND COGNITION			English	Article							DIFFUSE AXONAL INJURY; COMPARATIVE NEUROPSYCHOLOGY; KORSAKOFFS SYNDROME; DELAYED ALTERNATION; PERFORMANCE; ATROPHY	Tasks sensitive to frontal lobe dysfunction (delayed response, delayed alternation, object alternation, and Wisconsin Card Sort) were administered to 20 patients with post-acute closed-head injury (CHI). Time since injury varied (6 to 280 months; mean, 48 months), as did length of coma (2 hr to 120 days; mean, 38 days). Compared to normal controls, CHI patients showed no deficits on delayed response tasks, but were impaired on delayed alternation, object alternation, and the Wisconsin Card Sort Test. Analyses of the performance profiles of the CHI patients suggested that they may have difficulty in establishing set (a consequence of damage to the orbitofrontal system). (C) 1996 Academic Press, Inc.	TUFTS UNIV,SCH MED,DEPT PSYCHIAT,MEDFORD,MA 02155; BOSTON UNIV,SCH MED,DEPT REHABIL MED,BOSTON,MA 02215; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02215; BOSTON UNIV,SCH MED,DIV PSYCHIAT,BOSTON,MA 02215	Gansler, DA (corresponding author), VET AFFAIRS MED CTR,PSYCHOL SERV 116B,150 S HUNTINGTON AVE,BOSTON,MA 02130, USA.			Berman, Marlene Oscar/0000-0003-0100-8883	NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA07112] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R37AA007112, R01AA007112] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1984, RECENT ADV HISTOPATH, V12; ADAMS JH, 1984, GREENFIELDS NEUROPAT; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DENCKER SJ, 1960, ARCH GEN PSYCHIAT, V2, P569; ELAWAR M, 1991, BRAIN COGNITION, V16, P121, DOI 10.1016/0278-2626(91)90001-O; FREEDMAN M, 1986, CAN J NEUROL SCI, V13, P410; FREEDMAN M, 1990, BRAIN COGNITION, V14, P134, DOI 10.1016/0278-2626(90)90025-J; FREEDMAN M, 1994, UNPUB FRONTAL LOBE F; GELLERMANN LW, 1933, J GENET PSYCHOL, V42, P207; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRANT DA, 1948, J EXP PSYCHOL, V38, P2404; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Klove H, 1972, Scand J Rehabil Med, V4, P55; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; OSCARBERMAN M, 1982, NEUROPSYCHOLOGIA, V20, P187, DOI 10.1016/0028-3932(82)90009-4; OSCARBERMAN M, 1980, NEUROPSYCHOLOGIA, V18, P513, DOI 10.1016/0028-3932(80)90153-0; OSCARBERMAN M, 1980, NEUROPSYCHOLOGIA, V18, P499, DOI 10.1016/0028-3932(80)90152-9; OSCARBERMAN M, 1984, NEUROPSYCHOLOGY MEMO; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Reynolds C. R., 1983, CLIN NEUROPSYCHOLOGY, V5, P111; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Warren JM., 1964, FRONTAL GRANULAR COR; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	36	26	26	0	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0278-2626			BRAIN COGNITION	Brain Cogn.	MAR	1996	30	2					194	204		10.1006/brcg.1996.0012			11	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	UA078	WOS:A1996UA07800003	8811997				2021-06-18	
J	Curl, RM; Fraser, RT; Cook, RG; Clemmons, D				Curl, RM; Fraser, RT; Cook, RG; Clemmons, D			Traumatic brain injury vocational rehabilitation: Preliminary findings for the coworker as trainer project	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						functional skills training; traumatic brain injury; vocational rehabilitation intervention	EMPLOYMENT	Persons with severe traumatic brain injury (TBI) who return to work represent a group of consumers who may require high levels of interdisciplinary support and long-term maintenance. The coworker model, previously demonstrated to be effective for youths with cognitive and behavioral deficits, was modified for use with new and returning workers with a severe TBI, even at professional levels of employment. Preliminary results show that coworker trainers learned to apply the basic teaching sequence and basic organizational tools. Individual coworker salary subsidies to date have been under $400. Although natural supports of this type may not be required for a majority of individuals experiencing TBI, they appear to be extremely assistive for approximately one third of all project participants.	UNIV WASHINGTON,VACAT SERV EPILEPSY CTR,SEATTLE,WA 98195; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NEUROL SURG,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT REHABIL MED,SEATTLE,WA 98104	Curl, RM (corresponding author), MINOT STATE UNIV,N DAKOTA CTR DISABIL,DEPT PSYCHOL,500 UNIV AVE W,MINOT,ND 58707, USA.						CALLAHAN M, 1992, NATURAL SUPPORTS SCH; CURL R, 1990, PUT PERSON WORK MANU; CURL RM, 1991, ID G008400604 UT STA; CURL RM, 1990, 87 TECHN REP; CURL RM, 1987, PUT PERSON WORK COWO; CURL RM, 1987, TRAINER WORKER IMPLE; CURL RM, 1993, J VOCATIONAL REHABIL, V3, P72; CURL RM, 1991, ID H078C80034 US OFF; DEMCHAK MA, 1987, EDUC TRAIN MENT RET, V22, P205; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; FRASER R, 1990, SUMMARY NIDRR STUDIE; FRASER RT, IN PRESS NEURO REHAB; HAGNER D, 1992, NATURAL SUPPORTS SCH; LIKINS M, 1989, J APPL BEHAV ANAL, V22, P381, DOI 10.1901/jaba.1989.22-381; MCCONAUGHY EK, 1989, REHABIL PSYCHOL, V34, P3, DOI 10.1037//0090-5550.34.1.3; MCCONAUGHY EK, 1987, 13TH ANN CONV ASS BE; NISBET J, 1988, J ASSOC PERS SEVERE, V13, P260; REPP AC, 1987, RES DEV DISABIL, V8, P331, DOI 10.1016/0891-4222(87)90011-4; ROGAN P, 1993, J ASSOC PERS SEVERE, V18, P275, DOI 10.1177/154079699301800410; WALLS RT, 1980, AM J MENT DEF, V84, P495; WALLS RT, 1979, EDUC TRAIN MENT RET, V14, P120; WALLS RT, 1982, AM J MENT DEF, V87, P309; WALLS RT, 1981, AM J MENT DEF, V85, P357; Wehman P., 1990, COMMUNITY INTEGRATIO; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27	26	26	26	1	4	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1996	11	1					75	85		10.1097/00001199-199602000-00009			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TU021	WOS:A1996TU02100009					2021-06-18	
J	HAYES, RL; YANG, K; WHITSON, JS; POSMANTUR, R				HAYES, RL; YANG, K; WHITSON, JS; POSMANTUR, R			CYTOSKELETAL DERANGEMENTS FOLLOWING CENTRAL-NERVOUS-SYSTEM INJURY - MODULATION BY NEUROTROPHIC GENE TRANSFECTION	JOURNAL OF NEUROTRAUMA			English	Article						CYTOSKELETON; TRAUMATIC BRAIN INJURY; NEUROFILAMENTS; MAP2; CALPAIN; NEUROTROPHINS	TRAUMATIC BRAIN INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; CALCIUM-ACTIVATED PROTEOLYSIS; CONTROLLED CORTICAL IMPACT; MIDDLE CEREBRAL-ARTERY; NEUROFILAMENT PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; FOREBRAIN ISCHEMIA; GROWTH-FACTOR; RAT	This paper reviews important new evidence indicating that traumatic brain injury can produce more widespread derangements to the neuronal cytoskeleton than previously recognized. Although cytoskeletal derangements in axons have long been documented, recent data suggest that traumatic brain injury can produce structural derangements to dendrites and cell bodies as well. Many of these investigations have employed in vivo models to provide important insights into mechanisms possibly mediating the acute loss of cytoskeletal proteins, including disturbances in calcium homeostasis and activation of calcium-dependent proteolytic enzymes. However, we have little understanding of processes mediating the recovery of cytoskeletal proteins following injury. This paper provides recent evidence from in vitro models of central nervous system injury that neurotrophic proteins can enhance the recovery of the neuronal cytoskeleton. Neurotrophin-based therapy could employ either administration of exogenous neurotrophic proteins and/or transfection of cDNA for appropriate neurotrophins.		HAYES, RL (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT NEUROSURG, 6431 FANNIN ST, SUITE 7148, HOUSTON, TX 77030 USA.						Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; ARAI A, 1991, BRAIN RES, V555, P276, DOI 10.1016/0006-8993(91)90352-V; BARINAGA M, 1994, SCIENCE, V264, P772, DOI 10.1126/science.8171331; BEATTIE MS, 1988, PHARM APPROACHES TRE, P43; CLARK EA, 1991, J NEUROCHEM, V57, P802, DOI 10.1111/j.1471-4159.1991.tb08222.x; CORK LC, 1986, J NEUROPATH EXP NEUR, V45, P56, DOI 10.1097/00005072-198601000-00005; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DAUTIGNY A, 1988, BIOCHEM BIOPH RES CO, V154, P1099, DOI 10.1016/0006-291X(88)90254-9; DIETZEL I, 1986, ADV NEUROL, V44, P619; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FANG XJ, 1989, HEPATOLOGY, V10, P781; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FORNO LS, 1986, NEUROSCI LETT, V64, P253, DOI 10.1016/0304-3940(86)90337-X; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GIORDANO T, 1991, EXP CELL RES, V992, P993; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HAYES RL, 1995, NEUROSCI LETT, V191, P121, DOI 10.1016/0304-3940(95)11561-X; HEFTI F, 1986, J NEUROSCI, V6, P2155; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HORWITZ M S, 1990, P1679; HUG P, 1991, BIOCHIM BIOPHYS ACTA, V1097, P1, DOI 10.1016/0925-4439(91)90016-3; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; IP NY, 1993, J NEUROSCI, V13, P3394; JENSEN AM, 1990, J NEUROSCI, V10, P1165; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON PA, 1992, MOL BRAIN RES, V12, P95, DOI 10.1016/0169-328X(92)90072-J; JULIEN JP, 1982, J BIOL CHEM, V257, P467; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KUDO T, 1993, STROKE, V24, P259, DOI 10.1161/01.STR.24.2.259; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LI AP, 1992, IN VITRO CELL DEV-AN, V28A, P373; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MATTSON MP, 1989, BRAIN RES, V478, P337, DOI 10.1016/0006-8993(89)91514-X; NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6-649; NAKAMURA M, 1992, EXP BRAIN RES, V89, P31; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NIXON RA, 1984, J NEUROCHEM, V43, P507, DOI 10.1111/j.1471-4159.1984.tb00928.x; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OGATA N, 1989, J NEUROSURG, V70, P103, DOI 10.3171/jns.1989.70.1.0103; PERLMUTTER LS, 1988, SYNAPSE, V2, P79, DOI 10.1002/syn.890020111; PIETRINI V, 1993, CLIN NEUROPATHOL, V12, P1; POLTORAK M, 1988, BRAIN RES, V475, P328, DOI 10.1016/0006-8993(88)90621-X; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POSMANTUR R, 1995, IN PRESS J NEUROPATH; POSMANTUR R, 1994, NEUROTRAUMA SOC ABST; ROESSLER BJ, 1994, NEUROSCI LETT, V167, P5, DOI 10.1016/0304-3940(94)91015-4; SAMBROOK J, 1989, MOL CLONING, V18, P32; SAUTTER J, 1991, BRAIN RES, V565, P23, DOI 10.1016/0006-8993(91)91732-G; SCHLAEPFER WW, 1985, PROG BRAIN RES, V63, P185; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; SHAW G, 1986, BIOESSAYS, V4, P161, DOI 10.1002/bies.950040406; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274, DOI 10.1073/pnas.82.12.4274; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; THOMPSON TA, 1993, IN VITRO CELL DEV-AN, V29, P165, DOI 10.1007/BF02630949; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROOST D, 1992, ACTA NEUROPATHOL, V84, P664, DOI 10.1007/BF00227744; ULRICH J, 1987, PATHOL IMMUNOPATH R, V6, P273, DOI 10.1159/000157058; WANG S, 1994, J NEUROCHEM, V62, P739; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WHITSON JS, 1995, IN PRESS BRAIN RES; WOLF D, 1988, MOL BIOL MED, V5, P43; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YANG K, 1994, NEUROSCI LETT, V182, P287, DOI 10.1016/0304-3940(94)90818-4; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG K, 1994, NEUROSCI LETT, V182, P291, DOI 10.1016/0304-3940(94)90819-2	83	26	27	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					933	941		10.1089/neu.1995.12.933			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600020	8594223				2021-06-18	
J	SCHMIDT, SH; OORTMARBURGER, D; MEIJMAN, TF				SCHMIDT, SH; OORTMARBURGER, D; MEIJMAN, TF			EMPLOYMENT AFTER REHABILITATION FOR MUSCULOSKELETAL IMPAIRMENTS - THE IMPACT OF VOCATIONAL-REHABILITATION AND WORKING ON A TRIAL BASIS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; DISABILITY; RETURN; CONTEXT; POLICY	Objective: To investigate to what extent vocational rehabilitation and working on a trial basis have an impact on employment after rehabilitation. Design: Follow-up survey, conducted in 1991, among all patients, aged 14 to 64, who were treated between 1984 and 1987. Setting: An out-clinic department of a rehabilitation center in the west of The Netherlands. Subjects: 395 patients (59% of the original sample) participated in the study. They suffer from musculoskeletal impairments due to back pain (41%), brain injury (20%), neurological disorder (12%), trauma to the upper and/or lower extremities (8%), rheumatoid arthritis (7%), or other disorders (12%). No differences were found between those who did and those who did not respond with regard to age, gender, marital status, disorder, work experience, and participation in vocational rehabilitation. Main Outcome Measure: Odds ratio of having a paid job after rehabilitation. Results: Participation in vocational rehabilitation and working on a trial basis depends on age, gender, work experience, and disorder. When statistically controlled for these variables vocational rehabilitation (odds ratio 1.96; 95% confidence interval 1.12 to 3.42) and working on a trial basis (odds ratio 3.26; 95% confidence interval 1.74 to 6.11) proved to have a significant impact on employment after rehabilitation. Conclusions: The findings suggest that rehabilitation programs that aim specifically at promoting employment for people with disabilities are effective, in particular when they take place in both a laboratory and a natural setting. The validity of this suggestion must be further tested by means of an experimental design. (C) 1995 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV GRONINGEN,DEPT EXPTL & OCCUPAT PSYCHOL,9700 AB GRONINGEN,NETHERLANDS	SCHMIDT, SH (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,INST SOCIAL MED,INST WORK & HLTH,MEIBERGDREEF 15,1105 AZ AMSTERDAM,NETHERLANDS.						BEEK KWH, 1992, ESB, V77, P560; Cornes P, 1987, Int Rehabil Med, V8, P138; CREWE N, 1987, INDEPENDENT LIVING P; DEVIVO MJ, 1987, ARCH PHYS MED REHAB, V68, P494; DOMARACKI JW, 1992, RES DEV DISABIL, V13, P363, DOI 10.1016/0891-4222(92)90011-T; EKLUND M, 1991, SCAND J REHABIL MED, V23, P73; Fawber HL, 1987, J HEAD TRAUMA REHAB, V2, P27; FOX DM, 1989, MILBANK Q, V67, P1; FRASER RT, 1983, EPILEPSIA, V24, P734, DOI 10.1111/j.1528-1157.1983.tb04636.x; GALVIN DE, 1986, REHABIL LIT, V47, P218; GEURTS D, 1992, LAAT MIJ MAAR WERKEN; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HARDERING J, 1990, REHABILITATION STUTT, V31, P40; HEARNE PG, 1991, MILBANK Q, V69, P121; HOSMER DW, 1989, APPLIED LOGISTIC REG, V87, P109; LONSDALE S, 1992, SOCIAL SECURITY 50 Y, V3, P73; MCLOUGHLIN CS, 1987, GETTING EMPLOYED STA; Oliver M, 1993, DISABLING BARRIERS E, P267; POPE AM, 1991, DISABILITY AM NATION; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAVAUD JF, 1992, SOC SCI MED, V35, P951, DOI 10.1016/0277-9536(92)90234-H; REVELL WG, 1978, REHABIL LIT, V39, P226; SANDSTROM J, 1986, SCAND J REHABIL MED, V18, P29; SAXON JP, 1983, J REHABIL, V49, P69; Schmidt S H, 1986, Tijdschr Gerontol Geriatr, V17, P183; SCHMIDT SH, 1988, REVALIDATIE ARBEID; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STRAATON KV, 1992, ARTHRITIS RHEUM, V35, P503, DOI 10.1002/art.1780350503; TATE DG, 1992, AM J PHYS MED REHAB, V71, P92, DOI 10.1097/00002060-199204000-00006; VANDENELSHOUT S, 1993, SOC EC MNDSTAT S1, V10, P4; VANDERGOOT D, 1987, REHABIL COUNS BULL, V30, P243; VANSONSBEEK JLA, 1991, STAT MAG, V11, P47; VEERMAN TJ, 1994, SMA, V49, P79; VROOMAN JC, 1990, EC STAT BERICHTEN, V75, P942; WALKER A, 1981, DISABILITY BRITAIN M; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEST J, 1991, MILBANK Q, V69, P3, DOI 10.2307/3350156; WEST J, 1991, MILBANK Q, V69, pR11; YELIN E, 1986, MILBANK Q, V64, P622, DOI 10.2307/3349928; YELIN E, 1989, MILBANK Q, V67, P114, DOI 10.2307/3350238; YELIN EH, 1991, MILBANK Q, V69, P129, DOI 10.2307/3350161; 1989, 23 INT SOC SEC ASS R; 1992, HANDELINGEN TWEEDE K, P13; 1989, 22 INT SOC SEC ASS R; 1985, TARGETS HLTH ALL TAR	45	26	27	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1995	76	10					950	954		10.1016/S0003-9993(95)80073-5			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	RY975	WOS:A1995RY97500012	7487437				2021-06-18	
J	MCLEAN, AJ				MCLEAN, AJ			BRAIN INJURY WITHOUT HEAD IMPACT	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		TRAUMATIC BRAIN INJURY; NONIMPACT INJURY; POSTMORTEM ANALYSIS	CEREBRAL CONCUSSION	The proposition that acceleration of the brain without direct impact to the head can result in brain injury is examined by reviewing a series of 414 road users who were fatally injured in the vicinity of Adelaide, South Australia. The series comprises 170 pedestrians, 10 pedal cyclists, 143 motorcyclists, and 91 vehicle occupants, In each case a member of the research team attended the autopsy to look for evidence of impact on the body, particularly to the head or face, The brain was examined by a neuropathologist and the type and pattern of injury was recorded, The circumstances of the crash were investigated, including an examination of the crash site and the vehicles involved and, where relevant, interviews with witnesses, In cases involving a motorcyclist the helmet worn was retrieved by the police and assigned to the research unit for examination, Particular attention was paid to the identification of objects causing injury to the head or face and also to objects impacted by a helmet, Brain injury was recorded as a cause of death in 55% of the 403 cases for which there was a dear classification of cause of death, Brain injury, at any level of severity, was identified by a neuropathologist in 86 percent of the 414 fatally injured road users in the sample, including 24 cases that were examined microscopically, There were no cases in which there was an injury to the brain in the absence of evidence of an impact to the head.		MCLEAN, AJ (corresponding author), UNIV ADELAIDE,NHMRC,RD ACCIDENT RES UNIT,ADELAIDE,SA 5005,AUSTRALIA.						BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDSMITH W, 1966, HEAD INJURY C P, P350; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Thiabault LE, 1990, 34 ANN P ASS ADV AUT, V34, P337	8	26	27	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					621	625		10.1089/neu.1995.12.621			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000013	8683613				2021-06-18	
J	NEWTON, RA				NEWTON, RA			BALANCE ABILITIES IN INDIVIDUALS WITH MODERATE AND SEVERE TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article								Balance characteristics, latency, amplitude, and symmetry were measured in 23 moderate and 23 severe traumatic brain-injured (TBI) patients. Patients received two graded forward and two graded backward linear perturbations. Although within normal limits, latency was high. Patients were able to appropriately grade force in relation to the size of the perturbation. Standing posture prior to and during perturbation was recorded by the amount of force generation through each lower extremity. Some individuals used an asymmetrical balance response following perturbations, whereas others shifted to a more symmetrical weight-bearing balance response. TBI patients may be prone to instability due to a combination of long latency of onset of the balance response coupled with asymmetrical stance patterns during recovery from an unexpected linear perturbation.		NEWTON, RA (corresponding author), TEMPLE UNIV,COLL ALLIED HLTH PROFESS,DEPT PHYS THERAPY,3307 N BROAD ST,PHILADELPHIA,PA 19140, USA.						DIENER HC, 1988, J NEUROPHYSIOL, V59, P1888; FREGLY AR, 1968, AEROSPACE MED, V39, P277; HORAK FB, 1986, J NEUROPHYSIOL, V55, P1369; JENNETT B, 1975, LANCET, V1, P480; NASHNER LM, 1990, 1989 P BAL S APTA NA, P5; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Romberg M. H., 1853, MANUAL NERVOUS DIS M, P395; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; VORHEES RL, 1989, LARYNGOSCOPE, V99, P995; WINTER DA, 1990, MED PROG TECHNOL, V16, P31	10	26	26	0	3	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1995	9	5					445	451		10.3109/02699059509008204			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RJ331	WOS:A1995RJ33100003	7550216				2021-06-18	
J	YELON, JA; HARRIGAN, N; EVANS, JT				YELON, JA; HARRIGAN, N; EVANS, JT			BICYCLE TRAUMA - A 5-YEAR EXPERIENCE	AMERICAN SURGEON			English	Article; Proceedings Paper	62nd Annual Scientific Meeting of the Southeastern Surgical Conference	FEB 06-10, 1994	LAKE BUENA VISTA, FL				INJURIES; ACCIDENTS; CHILDHOOD	The medical records of 84 patients who were admitted to the hospital following injuries sustained during bicycle collisions (BC) between January 1986 and December 1991 were retrospectively reviewed. BC most commonly occurred during summer months in the afternoon and early evening. The average patient age was 21.3 years, with more men injured than women (83% vs 17%). Forty-four individuals were struck by a motor vehicle, 36 fell from their cycles, and two were struck by another cyclist. The average ISS for the group was 13.1. Fifteen per cent of the patients had a documented positive toxicology screen; all patients tested positive for ethanol, with an average blood alcohol level of 201 mg/dL. An additional 17% of patients had polychemical intoxication. Orthopedic injuries were the most commonly encountered (59.5%), with lower extremity fractures being most common (52%). Neurologic injuries accounted for 35.7% of injuries, with closed head injuries being most common. Twenty-four patients sustained visceral injuries: 50% thoracic, 25% genitourinary, and 25% abdominal. Of the thoracic injuries, 83% had parenchymal lung injuries, and half had skeletal chest injury. No patient had a vascular lesion within the chest, owing to the minimal deceleration incurred during these injuries. The genitourinary injuries (n = 6) were all urethral injuries that occurred with ejections from the bicycle. No patient had any form of protective gear. The overall average length of stay was 9.15 days, with 30.9% requiring ICU admission. Although bicycling remains a popular recreational activity as well as mode of transportation, few locals mandate protective legislation. Because of the high percentage of orthopedic and CNS injuries, helmets and protective padding might be a reasonable requirement for cyclists in public areas.		YELON, JA (corresponding author), NASSAU CTY MED CTR,DEPT SURG,2201 HEMPSTEAD TURNPIKE,E MEADOW,NY 11554, USA.						BODTKER S, 1990, Ugeskrift for Laeger, V152, P2412; FIFE D, 1983, J TRAUMA, V23, P745, DOI 10.1097/00005373-198308000-00011; GREENSHER J, 1988, PEDIATR ANN, V17, P114, DOI 10.3928/0090-4481-19880201-08; GUCHON DM, 1975, J TRAUMA, V15, P504; ILLINGWORTH CM, 1981, INJURY, V13, P7, DOI 10.1016/0020-1383(81)90083-8; KIBURZ D, 1986, AM J SPORT MED, V14, P416, DOI 10.1177/036354658601400516; KRUSE DL, 1980, AM J SPORT MED, V8, P342, DOI 10.1177/036354658000800509; MCKENNA PJ, 1991, J TRAUMA, V31, P392, DOI 10.1097/00005373-199103000-00015; MELLION MB, 1991, SPORTS MED, V11, P52, DOI 10.2165/00007256-199111010-00004; NIXON J, 1987, BRIT MED J, V294, P1267, DOI 10.1136/bmj.294.6582.1267; PLESS IB, 1987, AM J PUBLIC HEALTH, V77, P358, DOI 10.2105/AJPH.77.3.358; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; 1991, MMWR-MORBID MORTAL W, V36, P269; 1990, NY STATE J MED, V90, P426; 1991, ACCIDENT FACTS, P62	16	26	26	0	3	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352	0003-1348			AM SURGEON	Am. Surg.	MAR	1995	61	3					202	205					4	Surgery	Surgery	QM985	WOS:A1995QM98500004	7887529				2021-06-18	
J	HUNT, J; HILL, D; BESSER, M; WEST, R; RONCAL, S				HUNT, J; HILL, D; BESSER, M; WEST, R; RONCAL, S			OUTCOME OF PATIENTS WITH NEUROTRAUMA - THE EFFECT OF A REGIONALIZED TRAUMA SYSTEM	AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY			English	Article						NEUROTRAUMA; OUTCOMES; REGIONALIZATION; TRAUMA CENTER	SEVERE HEAD-INJURY; IMPACT; MANAGEMENT; EXPERIENCE; MODEL; TEAM; CARE	A system of regionalized trauma care was introduced to Sydney in early 1992. This study was carried out to assess the effect of regionalization on the outcome of patients suffering major head injury within the central Sydney area. A prospective before and after study extending over 3 years and centred on the time of designation of Royal Prince Alfred Hospital (RPAH) as a trauma centre, was the methodology used. The study group consisted of all patients admitted with head injury (Glasgow Coma Score < 9; admission systolic brood pressure > 90 mmHg; Injury Severity Score > 15) to RPAH from the central Sydney area. Outcome criteria include survival rates, transfer numbers, and time to definitive neurosurgical care. Fifty patients were entered during the first 18 months of the study, and 38 during the second 18 months. Fifteen in the first group required evacuation of intracranial mass lesions, as did nine in the second group. The overall mortality fell from 42 to 26% (P=0.13). During the study period there were 77 primary retrievals and 20 required evacuation of mass lesions. The median time from injury to commencement of operation in these patients was 2 h 13 min (range 1 h 3 min-5 h 35 min). There were 11 transfers, four requiring craniotomy. The median time from injury to surgery was 7 h 24 min (range 3 h 2 min-10 h 25 min; P < 0.01). A trend towards a decreased mortality following regionalization, as well as a statistical difference (P < 0.01) in the time taken for primary retrieval patients to undergo craniotomy when compared to transferred patients has been shown. This evidence, in conjunction with the decrease in transferred patients post-regionalization, helps validate regionalization in the setting of major neurotrauma.	UNIV SYDNEY,SYDNEY,NSW,AUSTRALIA	HUNT, J (corresponding author), ROYAL PRINCE ALFRED HOSP,DIV SURG,MISSENDEN RD,CAMPERDOWN,NSW 2050,AUSTRALIA.						BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; CALES RH, 1983, ANN EMERG MED, V13, P1; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DEANE SA, 1989, AUST NZ J SURG, V59, P373; DEANE SA, 1990, J TRAUMA, V30, P806, DOI 10.1097/00005373-199007000-00007; FRIEDMAN AH, 1991, TXB SURGERY BIOL BAS, P1252; HILL DA, 1993, AUST NZ J SURG, V63, P940, DOI 10.1111/j.1445-2197.1993.tb01723.x; HILL DA, 1992, AUST NZ J SURG, V62, P204, DOI 10.1111/j.1445-2197.1992.tb05464.x; HILL DA, 1993, MED TEACH, V15, P179, DOI 10.3109/01421599309006712; KANE G, 1992, J TRAUMA, V32, P576, DOI 10.1097/00005373-199205000-00007; KLAUBER MR, 1985, J NEUROSURG, V57, P528; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; MARCH H, 1989, BRIT J NEUROSURG, V3, P13; MCDERMOTT FT, 1994, AUST NZ J SURG, V64, P147, DOI 10.1111/j.1445-2197.1994.tb02168.x; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; ROY PD, 1987, CAN J SURG, V30, P17; SELECKI BR, 1986, AUST NZ J SURG, V56, P529, DOI 10.1111/j.1445-2197.1986.tb07095.x; SIMPSON D, 1986, AUST NZ J SURG, V56, P527, DOI 10.1111/j.1445-2197.1986.tb07094.x; TEASDALE G, 1976, LANCET, V1, P1031; WEST JG, 1983, ARCH SURG-CHICAGO, V118, P740	21	26	26	0	0	BLACKWELL SCIENCE PUBL AUSTR	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON 3053, AUSTRALIA	0004-8682			AUST NZ J SURG	Aust. N. Z. J. Surg.	FEB	1995	65	2					83	86		10.1111/j.1445-2197.1995.tb07266.x			4	Surgery	Surgery	QF429	WOS:A1995QF42900004	7857235				2021-06-18	
J	SCOTT, DE; WU, WT; SLUSSER, J; DEPTO, A; HANSEN, S				SCOTT, DE; WU, WT; SLUSSER, J; DEPTO, A; HANSEN, S			NEURAL REGENERATION AND NEURONAL MIGRATION FOLLOWING INJURY .1. THE ENDOCRINE HYPOTHALAMUS AND NEUROHYPOPHYSEAL SYSTEM	EXPERIMENTAL NEUROLOGY			English	Article							NITRIC-OXIDE SYNTHASE; 3RD CEREBRAL VENTRICLE; RAT-BRAIN; NADPH DIAPHORASE; MEDIAN-EMINENCE; MAGNOCELLULAR NEURONS; INCREASED EXPRESSION; POSTERIOR PITUITARY; ELECTRON-MICROSCOPY; SUPRAOPTIC NUCLEUS	Central to this investigation are several basic hypotheses that are designed to test the role of nitric oxide (NO) in the complex process of central regeneration and plasticity in a well established model system of the mammalian brain. We have employed histochemical techniques at the light and ultrastructural level coupled with correlative scanning electron microscopy, immunoelectron microscopy, and in situ hybridization in order to determine the functional significance of the increased expression of nitric oxide synthase (NOS) in neurons of the supraoptic (SON) and paraventricular (PVN) nuclei which accompanies regeneration of their axotomized neurites following hypophysectomy. The aim of this investigation was to determine the potential role and temporal up-regulation of NOS in this basic regenerative process and to establish the ultrastructural and neuroanatomical correlates during critical periods of regeneration and regrowth of SON and PVN axons following hypophysectomy in the endocrine hypothalamus of the rat. Our data support the hypothesis that NO may serve as a second messenger molecule that may act in some fashion to govern not only the process of central regeneration and regrowth of magnocellular (SON/PVN) axons into the median eminence, neural stem, and neural lobe (the neurohypophyseal system) but may also influence the regeneration of neurites into new neuroanatomical domains such as the adjacent lumen of the third cerebral ventricle. We have demonstrated a distinct temporal relationship between injury (axotomy) of SON/PVN axons and the establishment of new neurovascular zones following hypophysectomy with the up-regulation of NOS, This up-regulation appears to correlate well with successful regeneration in the mammalian neurohypophyseal system. We have also successfully inhibited axonal regeneration with the use of nitroarginine, a competitive antagonist of NO. NOS up-regulation attendant to regeneration of SON and PVN axons may have inestimable clinical implications, particularly with respect to closed head injury and cerebral contusion that involves the mechanical shearing of the infundibular stalk. In addition, this investigation has reaffirmed that large numbers of bona fide neurons migrate and emerge upon the floor of the adjacent third cerebral ventricle shortly following hypophysectomy (within 2 weeks). The origin and mechanisms of neuronal migration and plasticity following hypophysectomy are the subject of interpretation and discussion in this investigation. (C) 1995 Academic Press, Inc.	EASTERN VIRGINIA MED SCH,DEPT SURG,INST DIABET,NORFOLK,VA 23501; EASTERN VIRGINIA MED SCH,DEPT INTERNAL MED,NORFOLK,VA 23501	SCOTT, DE (corresponding author), EASTERN VIRGINIA MED SCH,DEPT ANAT & NEUROBIOL,DIV NEUROSURG,NORFOLK,VA 23501, USA.						ADAMS JH, 1968, J COMP NEUROL, V135, P121; BARNES PRJ, 1990, CELL TISSUE RES, V260, P211, DOI 10.1007/BF00297508; BEAGLEY GH, 1992, BRAIN RES BULL, V28, P613, DOI 10.1016/0361-9230(92)90111-A; BECK E, 1969, NEUROENDOCRINOLOGY, V5, P161, DOI 10.1159/000121858; BILLENSTIEN DC, 1955, ENDOCRINOLOGY, V56, P704, DOI 10.1210/endo-56-6-704; BLOTTNER D, 1992, J COMP NEUROL, V316, P45, DOI 10.1002/cne.903160105; BRIGHTMAN MW, 1955, ANAT REC, V121, P268; BURD GD, 1985, J COMP NEUROL, V240, P143, DOI 10.1002/cne.902400204; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DELLMANN HD, 1993, J NEURAL TRANSP PLAS, V4, P127, DOI 10.1155/NP.1993.127; EDELMAN GM, 1987, NEURAL DARWINISM; GAINER H, 1977, J CELL BIOL, V73, P366, DOI 10.1083/jcb.73.2.366; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GASH D, 1980, CELL TISSUE RES, V211, P191; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; HOFER H, 1955, VORH DTSCH ZOOL GES, V8, P202; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; LAYCHOCK SG, 1991, ENDOCRINOLOGY, V129, P3043, DOI 10.1210/endo-129-6-3043; LEBEAU JM, 1991, J NEUROSCI RES, V28, P299, DOI 10.1002/jnr.490280217; LEVEQUE TF, 1959, ENDOCRINOLOGY, V6, P909; LIUZZI F, 1991, SURGICAL MANAGEMENT, V1042, P331; LIUZZI FJ, 1993, EXP NEUROL, V12, P275; MARCIANO FF, 1989, BRAIN RES, V483, P135, DOI 10.1016/0006-8993(89)90044-9; MARZBAN F, 1992, BRAIN RES BULL, V28, P757, DOI 10.1016/0361-9230(92)90256-W; MCKENNA OC, 1979, J COMP NEUROL, V184, P127, DOI 10.1002/cne.901840108; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONROE BG, 1966, J ULTRASTRUCT RES, V14, P405; NOTTEBOHM F, 1985, ANN NY ACAD SCI, V457, P143, DOI 10.1111/j.1749-6632.1985.tb20803.x; PLOTSKY PM, 1987, ENDOCRINOLOGY, V120, P1361, DOI 10.1210/endo-120-4-1361; POULAIN DA, 1982, NEUROSCIENCE, V7, P773, DOI 10.1016/0306-4522(82)90044-6; RAISMAN G, 1973, BRAIN RES, V55, P245, DOI 10.1016/0006-8993(73)90294-1; RIOCH D, 1940, RES NERV MENT DIS PR, P3; ROBINSON AG, 1983, NEUROENDOCRINOLOGY, V36, P347, DOI 10.1159/000123479; SAGAR SM, 1987, BRAIN RES, V400, P348, DOI 10.1016/0006-8993(87)90633-0; SANDMAN CA, 1984, SCIENCE, V224, P1355, DOI 10.1126/science.6729458; SCHARRER EA, 1929, Z VERGL PHYSIOL, V7, P1; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SCOTT DE, 1984, BRAIN RES BULL, V12, P453, DOI 10.1016/0361-9230(84)90161-8; SCOTT DE, 1972, Z ZELLFORSCH MIK ANA, V132, P203, DOI 10.1007/BF00307011; SCOTT DE, 1978, CELL TISSUE RES, V190, P317; SCOTT DE, 1986, BRAIN RES BULL, V17, P367, DOI 10.1016/0361-9230(86)90240-6; SCOTT DE, 1982, FRONT HORM RES, V9, P15; SHEPARD GM, 1988, DEV NEUROBIOL, V2, P197; SILVERMAN AJ, 1983, ANNU REV NEUROSCI, V6, P357, DOI 10.1146/annurev.ne.06.030183.002041; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SNYDER SH, 1992, SCI AM, V226, P68; STILLMAN MA, 1977, ENDOCRINOLOGY, V101, P42, DOI 10.1210/endo-101-1-42; THORNGRE.KG, 1973, CALC TISS RES, V11, P281, DOI 10.1007/BF02547228; TODA N, 1990, BIOCHEM BIOPH RES CO, V170, P308, DOI 10.1016/0006-291X(90)91275-W; TWEEDLE CD, 1987, NEUROSCIENCE, V20, P241, DOI 10.1016/0306-4522(87)90016-9; VALSTCHANOFF JG, 1993, J COMP NEUROL, V331, P111; VIGHTEICHMANN I, 1974, ADV ANATOMY EMBRYOLO, P1; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; WHITNALL MH, 1988, J COMP NEUROL, V275, P13, DOI 10.1002/cne.902750103; WICKHAM MG, 1973, STAIN TECHNOL, V48, P63, DOI 10.3109/10520297309116583; WU W, 1989, BRAIN RES BULL, V22, P399, DOI 10.1016/0361-9230(89)90067-1; WU WT, 1993, EXP NEUROL, V121, P279, DOI 10.1006/exnr.1993.1097; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050	62	26	28	0	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	1995	131	1					23	38		10.1016/0014-4886(95)90004-7			16	Neurosciences	Neurosciences & Neurology	QN056	WOS:A1995QN05600003	7534719				2021-06-18	
J	MCHENRY, MA; MINTON, JT; WILSON, RL; POST, YV				MCHENRY, MA; MINTON, JT; WILSON, RL; POST, YV			INTELLIGIBILITY AND NONSPEECH OROFACIAL STRENGTH AND FORCE CONTROL FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF SPEECH AND HEARING RESEARCH			English	Article; Proceedings Paper	1992 American-Speech-Language-Hearing-Association Annual Convention	NOV, 1992	SAN ANTONIO, TX	Amer Speech Language Hearing Assoc		OROFACIAL STRENGTH; FORCE CONTROL; INTELLIGIBILITY; TRAUMATIC BRAIN INJURY	AMYOTROPHIC-LATERAL-SCLEROSIS; LOWER LIPS; POSITION CONTROL; FINE FORCE; MAXIMUM	Objective measures of nonspeech orofacial strength and force control were obtained for 20 individuals with traumatic brain injury. The dynamic and static force generating abilities of the upper lip, lower lip, tongue, and jaw were assessed. Based on sentence intelligibility scores, the subjects were divided into two groups, more and less intelligible. Force measures included reaction time, slope, derivative, peak overshoot, and first- and second-half mean hold and standard deviation. Groups differed only in the ability to sustain the 2 N force level with the tongue. Other potential contributors to the differences in intelligibility are discussed.		MCHENRY, MA (corresponding author), GALVESTON INST HUMAN COMMUN,TRANSIT LEARNING COMMUNITY,1528 POSTOFFICE ST,GALVESTON,TX 77553, USA.						ABBS JH, 1985, SPEECH SCI RECENT AD, P155; AMERMAN JD, 1993, J SPEECH HEAR RES, V36, P460, DOI 10.1044/jshr.3603.460; BARLOW S M, 1989, Journal of Voice, V3, P283, DOI 10.1016/S0892-1997(89)80050-5; BARLOW SM, 1985, J SPEECH HEAR RES, V28, P373, DOI 10.1044/jshr.2803.373; BARLOW SM, 1983, J SPEECH HEAR RES, V26, P616, DOI 10.1044/jshr.2604.616; BARLOW SM, 1986, EXP NEUROL, V94, P699, DOI 10.1016/0014-4886(86)90248-7; BARLOW SM, 1986, J SPEECH HEAR RES, V29, P163, DOI 10.1044/jshr.2902.163; BARLOW SM, 1990, J SPEECH HEAR RES, V33, P660, DOI 10.1044/jshr.3304.660; BARLOW SM, 1991, J COMPUTER USERS SPE, V7, P211; DWORKIN JP, 1986, J COMMUN DISORD, V19, P115, DOI 10.1016/0021-9924(86)90015-8; DWORKIN JP, 1980, J SPEECH HEAR RES, V23, P828, DOI 10.1044/jshr.2304.828; FRICK T, 1978, REV EDUC RES, V48, P157, DOI 10.3102/00346543048001157; GENTIL M, 1990, SPEECH PRODUCTION SP, P1; KEARNS KP, 1988, J SPEECH HEAR RES, V31, P131, DOI 10.1044/jshr.3101.131; KENT JF, 1992, J SPEECH HEAR RES, V35, P723, DOI 10.1044/jshr.3504.723; KENT RD, 1987, J SPEECH HEAR DISORD, V52, P367, DOI 10.1044/jshd.5204.367; LUSCHEI ES, 1991, DYSARTHRIA AND APRAXIA OF SPEECH, P3; MCHENRY M, 1994, MOTOR SPEECH DISORDE, P135; MCNEIL MR, 1990, J SPEECH HEAR RES, V33, P255, DOI 10.1044/jshr.3302.255; Muller E. M., 1985, Mathematics and computers in biomedical applications, P363; MULLER EM, 1977, AM SPEECH HEARING AS; ROBIN DA, 1992, J SPEECH HEAR RES, V35, P1239, DOI 10.1044/jshr.3506.1239; ROBIN DA, 1991, DYSARTHRIA APRAXIA S, P3; SMITHERAN JR, 1981, J SPEECH HEAR DISORD, V46, P138, DOI 10.1044/jshd.4602.138; STIERWALT JG, 1994, C MOTOR SPEECH SEDON; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Yorkston K., 1984, COMPUTERIZED ASSESSM; 1989, MINITAB VERSION 7 2	28	26	28	0	1	AMER SPEECH-LANG-HEARING ASSN	ROCKVILLE	10801 ROCKVILLE PIKE RD, ROCKVILLE, MD 20852-3279	0022-4685			J SPEECH HEAR RES	J. Speech Hear. Res.	DEC	1994	37	6					1271	1283		10.1044/jshr.3706.1271			13	Language & Linguistics; Rehabilitation	Linguistics; Rehabilitation	PX191	WOS:A1994PX19100005	7877286				2021-06-18	
J	HAMMELL, KRW				HAMMELL, KRW			PSYCHOSOCIAL OUTCOME FOLLOWING SPINAL-CORD INJURY	PARAPLEGIA			English	Article						SPINAL CORD INJURIES; HEAD INJURIES; PSYCHOLOGICAL OUTCOME; SOCIAL OUTCOME; QUALITY OF LIFE; REHABILITATION		Studies have indicated that loss of social contact remains the primary complaint of people with head injuries many years after discharge. In an attempt to disentangle specific and nonspecific effects of head injury a study was undertaken to compare a group of 15 men with severe closed head injuries and their wives, with a group of 15 men with complete, traumatic spinal cord injuries and their partners (n = 60). Time since discharge extended from 4 months to several years. This paper focuses primarily upon the results and implication of the responses from the group of men with spinal cord injuries and their partners. The Interview Schedule for Social Interaction was correlated with the Leeds Scale for the Self Assessment of Anxiety and Depression. All groups reported low availability and adequacy of social integration and exhibited high levels of depression. The group of men with spinal cord injuries had the lowest scores for the availability of social integration, indicating that the social isolation which has previously been identified amongst people with head injuries may not be attributable solely to brain damage.1	UNIV SOUTHAMPTON,REHABIL RES UNIT,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND								0	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0031-1758			PARAPLEGIA	Paraplegia	NOV	1994	32	11					771	779					9	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	PV770	WOS:A1994PV77000009	7885720				2021-06-18	
J	JORDAN, FM; MURDOCH, BE				JORDAN, FM; MURDOCH, BE			SEVERE CLOSED-HEAD INJURY IN CHILDHOOD - LINGUISTIC OUTCOMES INTO ADULTHOOD	BRAIN INJURY			English	Article							CHILDREN; SEQUELAE	The language functioning of a group of adults who had sustained a severe closed-head injury in childhood was evaluated. The subjects were administered a battery of language assessments including measures of syntax, semantics and pragmatics, as well as a measure of metalinguistic ability. Performance of the experimental group was compared with that of a control group matched for age, sex and educational level. Results indicated that all areas of language competence assessed (syntax, semantics, pragmatics) appeared to be compromised by the childhood closed-head injury.				Murdoch, Bruce E/C-1397-2012				CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CROKER A, 1991, ED IMPLICATIONS CHIL; Dunn L., 1981, PEABODY PICTURE VOCA; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Ewing-Cobbs L., 1985, SPEECH LANGUAGE EVAL, P97; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; GAIDOLFI E, 1980, ITALIAN J NEUROLOGIC, V39, P213; HAMMILL DD, 1987, TEST ADOLESCENT LANG, V2; JORDAN F M, 1990, Brain Injury, V4, P27; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; Kaplan E., 1983, BOSTON NAMING TEST; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Spreen O, 1969, NEUROSENSORY CTR COM; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; WILG EH, 1989, TEST LANGUAGE COMPET; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	22	26	26	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					501	508		10.3109/02699059409151002			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200002	7527267				2021-06-18	
J	JONES, R; HUX, K; MORTONANDERSON, KA; KNEPPER, L				JONES, R; HUX, K; MORTONANDERSON, KA; KNEPPER, L			AUDITORY-STIMULATION EFFECT ON A COMATOSE SURVIVOR OF TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SCALE		UNIV NEBRASKA,DEPT SPECIAL EDUC & COMMUN DISORDERS,318E BARKLEY MEM CTR,LINCOLN,NE 68583; MADONNA REHABIL CTR,LINCOLN,NE							ANSELL BJ, 1991, J SPEECH HEAR RES, V24, P1017; BERGIN AE, 1970, J ABNORM PSYCHOL, V76, P13, DOI 10.1037/h0029634; HAGEN C, 1981, TOP LANG DISORD, V14, P73; Johnson D, 1989, Nurs Times, V85, P25; KATER KM, 1989, W J NURS RES, V1, P20; LUCAS B, 1992, HEADLINES        JUL, P16; McCain LJ, 1979, QUASIEXPERIMENTATION, P233; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; MOORE J, 1980, RECOVERY FUNCTION TH, P1; PLUM F, 1980, DIAGNOSIS STUPOR COM, P373; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenzwelg M., 1980, RECOVERY FUNCTION TH, P127; SISSON R, 1990, HEART LUNG, V19, P373; SMITH GJ, 1985, HEAD INJURY REHABILI, P275; TEASDALE G, 1974, LANCET, V2, P81; TICE R, 1991, DIGIT O SCOPE COMPUT; WHYTE J, 1989, TRAUMATIC BRAIN INJU, P13; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112; WOOD R L, 1991, Brain Injury, V5, P401, DOI 10.3109/02699059109008113; Yorkston K. M., 1988, CLIN MANAGEMENT DYSA	20	26	28	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1994	75	2					164	171					8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	MW994	WOS:A1994MW99400007	8311672				2021-06-18	
J	MUIZELAAR, JP				MUIZELAAR, JP			CEREBRAL ISCHEMIA-REPERFUSION INJURY AFTER SEVERE HEAD-INJURY AND ITS POSSIBLE TREATMENT WITH POLYETHYLENEGLYCOL-SUPEROXIDE DISMUTASE	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	SYMP ON NEUROTRAUMA : CONCEPTS, CURRENT PRACTICE AND EMERGING THERAPIES	JUN 11-12, 1992	DEARBORN, MI	WAYNE STATE UNIV SCH MED, DEPT EMERGENCY MED		BRAIN INJURY; ISCHEMIA-REPERFUSION		Oxygen radical-mediated mechanisms play a role both in cerebral ischemia-reperfusion injury and in traumatic brain injury. Moreover, my work with measurements of cerebral blood flow with the Xe-133 method and the stable xenon-computed tomography method and through measurements of arteriovenous difference of oxygen indicates that ischemia and ischemia-reperfusion are also part of traumatic brain injury but only in the first few hours after injury. The contributions of the research laboratories at the Medical College of Virginia, Richmond, to the understanding of the role of oxygen free radicals in traumatic brain injury are discussed. Finally, a trial of the oxygen radical scavenger polyethyleneglycol-superoxide dismutase in human beings with severe head injuries shows that death and vegetative state occurred twice as often in the 26 patients receiving placebo compared with the group of 26 patients receiving a 10,000 U/kg bolus of polyethyleneglycol-superoxide dismutase (43%, respectively; 20% at three months; P < .03).		MUIZELAAR, JP (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,BOX 631,MCV STN,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587, R01NS029412] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587, NS-1-54600-1768, NS-29412-01A1] Funding Source: Medline			0	26	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUN	1993	22	6					1014	1021		10.1016/S0196-0644(05)82744-1			8	Emergency Medicine	Emergency Medicine	LE338	WOS:A1993LE33800010	8503521				2021-06-18	
J	HARMANLI, O; KOYFMAN, Y				HARMANLI, O; KOYFMAN, Y			TRAUMATIC ATLANTO OCCIPITAL DISLOCATION WITH SURVIVAL - A CASE-REPORT AND REVIEW OF THE LITERATURE	SURGICAL NEUROLOGY			English	Article						ATLANTO OCCIPITAL DISLOCATION; MAGNETIC RESONANCE IMAGING	ATLANTOOCCIPITAL DISLOCATION; JUNCTION; INJURIES; CHILDREN; SPINE	The number of patients who have survived traumatic atlanto-occipital dislocation, the usual outcome of which is death from brain stem transection, has increased in the past two decades due to improvements in on-scene resuscitation and transportation. This case of survival after traumatic atlanto-occipital dislocation is of interest because the patient had a complete neurologic recovery and a magnetic resonance imaging (MRI) study was obtained to confirm the diagnosis and rule out associated injuries.	MED CTR DELAWARE,DEPT SURG,NEWARK,DE 19713							ALKER GJ, 1978, ORTHOP CLIN N AM, V9, P1003; Blackwood NJ, 1908, ANN SURG, V47, P654, DOI 10.1097/00000658-190805000-00003; BOOLS JC, 1986, AM J NEURORADIOL, V7, P901; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; CLARK CR, 1988, SPINE, V13, P742, DOI 10.1097/00007632-198807000-00006; COLLATO PM, 1986, J BONE JOINT SURG AM, V61, P1106; DIBENEDETTO T, 1990, SPINE, V15, P595, DOI 10.1097/00007632-199006000-00031; DUBLIN AB, 1980, J NEUROSURG, V52, P541, DOI 10.3171/jns.1980.52.4.0541; EISHMONT FJ, 1978, J BONE JOINT SURG AM, V60, P397; EWARTS CM, 1970, J BONE JOINT SURG AM, V52, P1653; FARTHING J W, 1948, N C Med J, V9, P34; FRUIN AH, 1977, J NEUROSURG, V46, P663, DOI 10.3171/jns.1977.46.5.0663; GABRIELS.TO, 1966, AMER J ROENTGENOL RA, V97, P624, DOI 10.2214/ajr.97.3.624; GOLDBERG AL, 1991, J COMPUT ASSIST TOMO, V15, P174, DOI 10.1097/00004728-199101000-00034; GROBOVSCHEK M, 1983, NEURORADIOLOGY, V25, P173, DOI 10.1007/BF00455738; JEVTICH V, 1989, SPINE, V14, P123, DOI 10.1097/00007632-198901000-00027; KAUFMAN RA, 1987, AM J NEURORADIOL, V8, P995; KAUFMAN RA, 1982, AM J NEURORADIOL, V3, P415; LEE C, 1984, AM J NEURORADIOL, V5, P775; LEE C, 1987, AM J NEURORADIOL, V8, P19; LEVINE AM, 1989, CLIN ORTHOP RELAT R, V239, P53; PAGE CP, 1973, J NEUROSURG, V39, P394, DOI 10.3171/jns.1973.39.3.0394; PANG D, 1980, NEUROSURGERY, V7, P503, DOI 10.1227/00006123-198011000-00017; PAPADOPOULOS SM, 1991, NEUROSURGERY, V28, P574, DOI 10.1227/00006123-199104000-00015; POWERS B, 1979, NEUROSURGERY, V4, P12, DOI 10.1097/00006123-197901000-00004; PUTNAM WE, 1986, J AM OSTEOPATH ASSOC, V86, P798; RAMSAY AH, 1986, INJURY, V17, P412, DOI 10.1016/0020-1383(86)90084-7; RASOOL MN, 1987, S AFR MED J, V72, P295; ROCKSWOLD GL, 1979, MINN MED, V62, P151; TEPPER SL, 1990, AM J FOREN MED PATH, V11, P193, DOI 10.1097/00000433-199009000-00003; TRAYNELIS VC, 1986, J NEUROSURG, V65, P863, DOI 10.3171/jns.1986.65.6.0863; VANDENBOUT AH, 1986, SPINE, V11, P174, DOI 10.1097/00007632-198603000-00017; WATRIDGE CB, 1985, NEUROSURGERY, V17, P345, DOI 10.1227/00006123-198508000-00021; WERNE SVEN, 1957, ACTA ORTHOPAED SCAND SUPPL, V23, P1; WHOLEY MH, 1958, RADIOLOGY, V71, P350, DOI 10.1148/71.3.350; WOODRING JH, 1981, AM J ROENTGENOL, V137, P21, DOI 10.2214/ajr.137.1.21	36	26	28	0	0	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0090-3019			SURG NEUROL	Surg. Neurol.	APR	1993	39	4					324	330		10.1016/0090-3019(93)90015-S			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	LD877	WOS:A1993LD87700015	8488454				2021-06-18	
J	FADEN, AI; TZENDZALIAN, PA				FADEN, AI; TZENDZALIAN, PA			PLATELET-ACTIVATING-FACTOR ANTAGONISTS LIMIT GLYCINE CHANGES AND BEHAVIORAL DEFICITS AFTER BRAIN TRAUMA	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article						AMINO ACIDS; CATIONS; CEREBRAL EDEMA; PHOSPHOLIPIDS; RECEPTOR ANTAGONISTS	AMINO-ACIDS; EXTRACELLULAR LEVELS; NMDA-RECEPTORS; GERBIL BRAIN; BLOOD-FLOW; INJURY; RATS; ISCHEMIA; REPERFUSION	Tissue damage after traumatic brain injury (TBI) results in part from delayed biochemical changes initiated by the insult. Platelet-activating factor (PAF) is an alkylphospholipid that has been implicated in tissue damage after cerebral ischemia. PAF is toxic to certain neuronal cell lines in culture, reduces cerebral blood flow, alters the blood-brain barrier, and can enhance phospholipid hydrolysis. The recent development of receptor antagonists to PAF permits examination of its possible role in delayed tissue injury after neurotrauma. Treatment with the PAF receptor antagonists BN 52021 and WEB 2170 before injury significantly enhanced neurological recovery after fluid percussion-induced TBI in rats. Pretreatment with WEB 2170 also significantly limited alterations in tissue water content and tissue glycine levels after trauma, and reduced posttraumatic levels of extracellular glycine in ipsilateral hippocampus. These findings implicate PAF in the pathophysiology of TBI, through actions at PAF receptors. A possible role for glycine in this process is suggested.	GEORGETOWN UNIV,MED CTR,SCH MED,DEPT PHARMACOL,WASHINGTON,DC 20007	FADEN, AI (corresponding author), GEORGETOWN UNIV,MED CTR,SCH MED,DEPT NEUROL,OFF DEAN RES,MED DENT BLDG NW 101,3900 RESERVOIR RD,WASHINGTON,DC 20007, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01NS27849-02] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR903623] Funding Source: Medline		BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1986, ADV INFLAMMAT RES, V12, P135; BUCHANAN DC, 1988, ANN NY ACAD SCI, P427; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEMEDIUK P, 1989, J NEUROCHEM, V52, P1529, DOI 10.1111/j.1471-4159.1989.tb09204.x; DOMINGO MT, 1988, BIOCHEM BIOPH RES CO, V151, P730, DOI 10.1016/S0006-291X(88)80341-3; FADEN A I, 1989, Society for Neuroscience Abstracts, V15, P1112; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P451; FAULER J, 1989, BIOCHIM BIOPHYS ACTA, V1013, P80, DOI 10.1016/0167-4889(89)90131-6; FRANCESCANGELI E, 1989, BIOCHEM BIOPH RES CO, V161, P107, DOI 10.1016/0006-291X(89)91567-2; FRERICHS KU, 1990, CEREBROVAS BRAIN MET, V2, P148; GLOBUS MYT, 1991, J NEUROCHEM, V57, P470, DOI 10.1111/j.1471-4159.1991.tb03775.x; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEUER HO, 1990, J PHARMACOL EXP THER, V255, P962; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; Kochanek P, 1991, J NEUROTRAUM, V8, P19, DOI 10.1089/neu.1991.8.19; KOCHANEK PM, 1988, J CEREBR BLOOD F MET, V8, P546, DOI 10.1038/jcbfm.1988.95; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KUMAR R, 1988, BIOCHIM BIOPHYS ACTA, V963, P375, DOI 10.1016/0005-2760(88)90304-9; LINDSBERG P J, 1989, Society for Neuroscience Abstracts, V15, P805; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PANETTA T, 1987, BIOCHEM BIOPH RES CO, V149, P580, DOI 10.1016/0006-291X(87)90407-4; TOKUMURA A, 1987, BIOCHEM BIOPH RES CO, V145, P415, DOI 10.1016/0006-291X(87)91338-6; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	30	26	30	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0002-9513			AM J PHYSIOL	Am. J. Physiol.	OCT	1992	263	4	2				R909	R914					6	Physiology	Physiology	JU806	WOS:A1992JU80600073	1415805				2021-06-18	
J	MCINTOSH, TK				MCINTOSH, TK			PHARMACOLOGICAL STRATEGIES IN THE TREATMENT OF EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL BLOOD-FLOW; SPINAL-CORD INJURY; INTRACELLULAR FREE MG-2+; OPIOID RECEPTOR AGONIST; EXCITATORY AMINO-ACIDS; CENTRAL NERVOUS-SYSTEM; MOTOR CORTEX INJURY; DYNORPHIN-A 1-13; TRAUMATIC BRAIN; ENDOGENOUS OPIOIDS	Although the mechanisms underlying secondary or delayed damage after traumatic injury to the central nervous system (CNS) are poorly understood, delayed neuronal injury may result from pathologic changes in the brain's endogenous neurochemistry. These neurochemical changes may include the overactivation of neurotransmitter release systems, changes in presynaptic or postsynaptic receptor binding, or the pathologic release or synthesis of autodestructive injury factors. Identification of such factors and the timing of the neurochemical cascade after CNS injury provides a window of opportunity for treatment with pharmacologic agents that modify synthesis, release, receptor binding, or physiologic activity with subsequent limitation of damage and disability. Over the past decade, a number of experimental studies have reported that modification of postinjury events by pharmacologic manipulation can promote functional recovery in a variety of animal models of CNS injury. This article summarizes the recent work suggesting that endogenous opioid peptides, catecholamines, and magnesium all play a role in the pathophysiologic cascade after brain injury and that pharmacologic manipulation of these endogenous systems may improve functional outcome after brain injury.		MCINTOSH, TK (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT SURG L1096,SURG RES CTR,FARMINGTON,CT 06030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818] Funding Source: NIH RePORTER		Aikawa J., 1981, MAGNESIUM ITS BIOL S; ALTURA BM, 1984, SCIENCE, V223, P1315, DOI 10.1126/science.6701524; ALTURA BT, 1982, MAGNESIUM EXP CLIN R, V1, P277; BASKIN DS, 1985, NEUROPEPTIDES, V5, P307, DOI 10.1016/0143-4179(85)90014-9; BECKER DP, 1985, CENTRAL NERVOUS SYST, P229; BOYESON M G, 1984, Society for Neuroscience Abstracts, V10, P68; Cavaliere F, 1985, Recenti Prog Med, V76, P563; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; CLARK AF, 1980, J BIOL CHEM, V255, P6556; CLIFTON GL, 1985, CENTRAL NERVOUS SYST, P139; COHN M, 1962, J BIOL CHEM, V237, P176; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; COX B, 1982, LIFE SCI, V31, P1655; CROCKARD HA, 1977, J NEUROSURG, V46, P784, DOI 10.3171/jns.1977.46.6.0784; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DELGADO TJ, 1986, J CEREBR BLOOD F MET, V6, P600, DOI 10.1038/jcbfm.1986.107; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DEVLIN T, 1990, J PHARMACOL EXP THER, V253, P749; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; EISENBERG H, 1983, INTRACRANIAL PRESSUR, P549; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FAGG G, 1985, TRENDS NEUROSCI, V2, P207; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; GARFINKEL L, 1985, Magnesium, V4, P60; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GLOBUS MYT, 1989, J CEREBR BLOOD F MET, V9, P892, DOI 10.1038/jcbfm.1989.123; GORDON K, 1990, J NEUROCHEM, V54, P605, DOI 10.1111/j.1471-4159.1990.tb01914.x; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HALLE D, 1990, IN PRESS STROKE; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; HOLADAY JW, 1980, BRAIN RES, V189, P295, DOI 10.1016/0006-8993(80)90032-3; Hossman K, 1976, DYNAMICS BRAIN EDEMA, P219; HOSSMANN KA, 1977, BRAIN HEART INFARCT, P107; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; JENNETT B, 1981, CONT NEUROLOGY SERIE, V20; KHACHATURIAN H, 1985, TRENDS NEUROSCI, V8, P111, DOI 10.1016/0166-2236(85)90048-7; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LONG JB, 1987, BRAIN RES, V436, P374, DOI 10.1016/0006-8993(87)91683-0; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1167; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1158; LONG JB, 1989, BRAIN RES, V10, P1; LYETH BG, 1990, J NEUROTRAUM, V9, P143; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; McINTOSH T., 1988, NEUROL NEUR, P653; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, J CEREB BLOOD FLOW S, V11, pS734; MCINTOSH TK, 1987, J CEREB BLOOD FLOW M, V7, pS620; MCINTOSH TK, 1988, PHARM APPROACH TREAT, P89; MCINTOSH TK, 1988, AM J PHYSIOL, V257, pR785; MCINTOSH TK, 1988, PERSPECTIVES SHOCK R, P415; MCINTOSH TK, 1989, J CEREB BLOOD FLO S1, V9, pS78; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; NIGAM R, 1986, ESSENTIAL FATTY ACID, V233, P1; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PAPPIUS HM, 1987, J NEUROCHEM, V49, P321, DOI 10.1111/j.1471-4159.1987.tb03433.x; PAPPIUS HM, 1988, J CEREBR BLOOD F MET, V8, P324, DOI 10.1038/jcbfm.1988.67; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PERRY DC, 1990, NEUR ABSTR, V16, P242; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROBINSON SE, 1988, NEUR ABSTR, V2, P1254; Romhanyi R, 1990, J NEUROTRAUM, V9, P164; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSNER MJ, 1985, CENTRAL NERVOUS SYST, P405; ROSNER MJ, 1982, HEAD INJURY BASIC CL, P103; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; SADEE W, 1982, J NEUROCHEM, V39, P659, DOI 10.1111/j.1471-4159.1982.tb07943.x; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SCHOENFELD TA, 1977, PHYSIOL BEHAV, V18, P951, DOI 10.1016/0031-9384(77)90206-2; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; SILVIA RC, 1987, BRAIN RES, V403, P52, DOI 10.1016/0006-8993(87)90121-1; SVENDGAARD NA, 1987, J CEREBR BLOOD F MET, V7, P21, DOI 10.1038/jcbfm.1987.4; SVENDGAARD NA, 1986, J CEREBR BLOOD F MET, V6, P650, DOI 10.1038/jcbfm.1986.120; Tandian D, 1990, J NEUROTRAUM, V9, P174; TANG AH, 1985, LIFE SCI, V37, P1475, DOI 10.1016/0024-3205(85)90178-X; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; VINK R, 1988, J NEUROTRAUM, V5, P105; WEAVER MS, 1988, NEUR ABSTR, V14, P1451; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEST M, 1981, BRAIN RES, V225, P271, DOI 10.1016/0006-8993(81)90835-0; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061; ZUKIN RS, 1961, LIFE SCI, V29, P2681	131	26	26	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S201	S209					9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600019	1588609				2021-06-18	
J	WIRSEN, A; STENBERG, G; ROSEN, I; INGVAR, DH				WIRSEN, A; STENBERG, G; ROSEN, I; INGVAR, DH			QUANTIFIED EEG AND CORTICAL EVOKED-RESPONSES IN PATIENTS WITH CHRONIC TRAUMATIC FRONTAL LESIONS	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						FRONTAL TRAUMA; QUANTIFIED EEG; SEP; P300; LESION VOLUME; OUTCOME	EVENT-RELATED POTENTIALS; CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; ENDOGENOUS POTENTIALS; HIPPOCAMPAL-FORMATION; CLINICAL-APPLICATION; SCHIZOPHRENIA; METABOLISM; STIMULI; MEMORY	Eighteen frontal trauma patients and 17 age-matched control subjects had quantified EEGs and measurements of sensory (SEP) and auditory evoked potentials (P300) using a Biologic Brain Atlas Ill system. The findings were compared to the conventional paper EEG, and to the frontal lesion volumes, severity of head injury, and outcome variables. The quantified EEG confirmed the pathological findings detected by visual inspection, but some regional abnormalities were more easily detected by topographic mapping. The regional distribution of pathological slowing corresponded well with the morphological lesions in most patients. The modal frequency of EEG correlated both with lesion volume and injury severity and with the outcome variables. There were no pathological findings in the SEPs, and all but one patient had clearly distinguishable P300 responses. There was a significant reduction in P300 amplitude in the frontal patients at the anterior, but not at the posterior electrodes. The topographical distribution of the P300 changes corresponded well with the morphological lesions. Our findings indicate that the P300 potential is, in part, dependent upon the prefrontal cortical areas. The present study thus supports P300 investigations which have shown amplitude reduction in other disorders (e.g., schizophrenia) with a presumed prefrontal dysfunction.		WIRSEN, A (corresponding author), UNIV LUND HOSP,DEPT CLIN NEUROPHYSIOL,S-22185 LUND,SWEDEN.		Stenberg, Georg/B-9375-2009	Stenberg, Georg/0000-0002-3246-2790			ALTER I, 1990, Brain Injury, V4, P19, DOI 10.3109/02699059009026144; Aminoff M.J., 1986, ELECTRODIAGNOSIS CLI, P21; BARTFAI A, 1986, PRELIMINARY SWEDISH; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; COURCHESNE E, 1975, ELECTROEN CLIN NEURO, V39, P131, DOI 10.1016/0013-4694(75)90003-6; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DUFFY FH, 1981, ELECTROEN CLIN NEURO, V51, P455, DOI 10.1016/0013-4694(81)90221-2; Duffy FH, 1986, TOPOGRAPHIC MAPPING; FAUX SF, 1988, BIOL PSYCHIAT, V23, P776, DOI 10.1016/0006-3223(88)90066-2; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GURDJIAN ES, 1958, HEAD INJURIES MECHAN; HALGREN E, 1980, SCIENCE, V210, P803, DOI 10.1126/science.7434000; HALGREN E, 1986, EVOKED POTENTIAL, P269; HILLYARD SA, 1983, ANNU REV PSYCHOL, V34, P33, DOI 10.1146/annurev.ps.34.020183.000341; HILLYARD SA, 1973, SCIENCE, V182, P177, DOI 10.1126/science.182.4108.177; INGVAR DH, 1976, ELECTROEN CLIN NEURO, V41, P268, DOI 10.1016/0013-4694(76)90119-X; INGVAR DH, 1979, PHARMAKOPSYCH NEURO, V12, P200, DOI 10.1055/s-0028-1094611; ISRAEL J. B., 1980, PSYCHOPHYSIOLOGY, V17, P259; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KILOH LG, 1981, CLIN ELECTROENCEPHAL; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Levander S, 1987, AUTOMATED PSYCHOL TE; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MAEDER P, 1991, ACTA RADIOL, V32, P271; MAURER K, 1988, Z EEG EMG, V19, P21; MAURER K, 1988, Z EEG EMG, V19, P26; NAGATA K, 1986, TOPOGRAPHIC MAPPING, P357; Niedermeyer E, 1982, ELECTROENCEPHALOGRAP, P71; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OKADA YC, 1983, ELECTROEN CLIN NEURO, V55, P417, DOI 10.1016/0013-4694(83)90130-X; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P85, DOI 10.1016/0168-5597(84)90026-1; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P104, DOI 10.1016/0168-5597(84)90027-3; Picton T.W., 1988, HUMAN EVENT RELATED, VVolume 1, P361; RUMPL E, 1982, ELECTROENCEPHALOGRAP, P291; SHIRAHATA N, 1985, J COMPUT ASSIST TOMO, V9, P861, DOI 10.1097/00004728-198509000-00004; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WIRSEN A, 1991, NEUROPSYCHOLOGY, V5, P151; WIRSEN A, 1991, UNPUB DIFFUSE NEUROP; WIRSEN A, 1991, UNPUB PROBLEM RECRUI; WIRSEN A, 1991, UNPUB NORMAL RCBF AC	50	26	26	0	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.	MAR-APR	1992	84	2					127	138		10.1016/0168-5597(92)90017-6			12	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	HL143	WOS:A1992HL14300004	1372227				2021-06-18	
J	SCHER, AT				SCHER, AT			SPINAL-CORD CONCUSSION IN RUGBY PLAYERS	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article								During an analysis of a group of 40 rugby players who had sustained cervical spinal cord injury, 9 players were identified who had sustained only transient paralysis. These players showed no radiologic evidence of any injury to the cervical spine. We did a retrospective analysis of the clinical and radiological findings in this group of rugby players. The cervical spine radiographs were analyzed for evidence of spinal stenosis, congenital anomalies, and degenerative disk disease. Using the ratio method of assessment for spinal stenosis, we found spinal canal narrowing maximally at C-3 and C-4 in five of the nine players. In the remaining four players, one showed evidence of osteoarthritic change at two levels while another had congenital fusion of two vertebral bodies. In two players, no radiologic evidence of any abnormality was detected. The mechanism of transient disturbance of the spinal cord function after trauma is discussed here.		SCHER, AT (corresponding author), UNIV STELLENBOSCH,DEPT RADIOL,TYGERBERG 7505,SOUTH AFRICA.							0	26	26	0	1	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154	0363-5465			AM J SPORT MED	Am. J. Sports Med.	SEP-OCT	1991	19	5					485	488		10.1177/036354659101900511			4	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	GG868	WOS:A1991GG86800011	1962714				2021-06-18	
J	NOUCHI, I; ITO, O; HARAZONO, Y; KOBAYASHI, K				NOUCHI, I; ITO, O; HARAZONO, Y; KOBAYASHI, K			EFFECTS OF CHRONIC OZONE EXPOSURE ON GROWTH, ROOT RESPIRATION AND NUTRIENT-UPTAKE OF RICE PLANTS	ENVIRONMENTAL POLLUTION			English	Article							PHASEOLUS-VULGARIS L; SULFUR-DIOXIDE; NET PHOTOSYNTHESIS; NITROGEN-DIOXIDE; YIELD; RADISH; REDUCTIONS; INJURY; IMPACT; LEAF	To clarify the response of growth and root functions to low concentrations of ozone (O3), rice plants (Oryza sativa L.) were exposed to O3 at 0.0 (control), 0.05 and 0.10 ppm for 8 weeks from vegetative to early heading stages. Exposure to 0.05 ppm O3 tended to slightly stimulate the dry weight of whole plants up to 5 weeks and then slightly decrease the dry weight of whole plants. However, these effects were statistically significant only at 6 weeks. Exposure to 0.10 ppm O3 reduced the dry weight of whole plants by 50% at 5 and 6 weeks, and thereafter the reduction of the dry weight of whole plants was gradually alleviated. Those changes in dry weight can be accounted for by a decrease or increase in the relative growth rate (RGR). The changes in the RGR caused by 0.05 and 0.10 ppm O3 could be mainly attributed to the effect of O3 on the net assimilation rate. Root/shoot ratio was lowered by both 0.05 and 0.10 ppm O3 throughout the exposure period. The root/shoot ratio which had severely decreased at 0.10 ppm O3 in the first half period of exposure (1-4 weeks) became close to the control in the latter part of exposure (5-8 weeks). Time-course changes in NH4-N root uptake rate were similar to those in the root/shoot ratio especially for 0.10 ppm O3. On the other hand, root respiration increased from the middle to later periods. Since it is to be supposed that plants grown under stressed conditions change the ratio of plant organ weight to achieve balance between the proportion of shoots to roots in the plant and their activity for maintaining plant growth, these changes in root/shoot ratio and nitrogen uptake rate under long-term exposure can be considered to be an adaptive response to maintain rice growth under O3 stress.		NOUCHI, I (corresponding author), NATL INST AGROENVIRONM SCI,TSUKUBA,IBARAKI 305,JAPAN.						AMUNDSON RG, 1987, PHYTOPATHOLOGY, V77, P75, DOI 10.1094/Phyto-77-75; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ASAKAWA F, 1981, JPN J SOIL SCI PLANT, V51, P201; ATKINSON CJ, 1988, NEW PHYTOL, V10, P173; Baba I, 1956, EXPT METHODS CROP SC, P157; BENNETT JP, 1976, J AM SOC HORTIC SCI, V101, P638; BROWN KA, 1988, ENVIRON POLLUT, V55, P55, DOI 10.1016/0269-7491(88)90159-5; CHAYKIN S, 1969, ANAL BIOCHEM, V31, P375, DOI 10.1016/0003-2697(69)90278-4; COOLEY DR, 1987, ENVIRON POLLUT, V47, P95, DOI 10.1016/0269-7491(87)90040-6; DAVIDSON RL, 1969, ANN BOT-LONDON, V33, P561, DOI 10.1093/oxfordjournals.aob.a084308; ENDRESS AG, 1985, AGR ECOSYST ENVIRON, V13, P9, DOI 10.1016/0167-8809(85)90097-0; FUHRER J, 1989, ENVIRON POLLUT, V60, P273, DOI 10.1016/0269-7491(89)90109-7; HEAGLE AS, 1979, PHYTOPATHOLOGY, V69, P21, DOI 10.1094/Phyto-69-21; Heck W.W., 1988, ASSESSMENT CROP LOSS; HECK WW, 1983, ENVIRON SCI TECHNOL, V17, pA572, DOI 10.1021/es00118a716; HECK WW, 1984, JAPCA J AIR WASTE MA, V34, P810, DOI 10.1080/00022470.1984.10465815; HOFSTRA G, 1981, ATMOS ENVIRON, V15, P483, DOI 10.1016/0004-6981(81)90178-5; HORSMAN DC, 1980, AUST J PLANT PHYSIOL, V7, P511, DOI 10.1071/PP9800511; ITO O, 1985, J EXP BOT, V36, P652, DOI 10.1093/jxb/36.4.652; KATS G, 1985, AGR ECOSYST ENVIRON, V14, P103, DOI 10.1016/0167-8809(85)90088-X; KOBAYASHI K, 1988, ENVIRON POLLUT, V53, P437, DOI 10.1016/0269-7491(88)90066-8; Koziol M. J., 1984, GASEOUS AIR POLLUTAN; Murphy J., 1962, ANAL CHIM ACTA, V27, P678, DOI DOI 10.1016/S0003-2670(00)88444-5; OKANO K, 1985, ENVIRON POLLUT A, V38, P361, DOI 10.1016/0143-1471(85)90107-2; OSHIMA RJ, 1978, J AM SOC HORTIC SCI, V103, P348; OSHIMA RJ, 1979, J ENVIRON QUAL, V8, P575; RADFORD PJ, 1967, CROP SCI, V7, P171, DOI 10.2135/cropsci1967.0011183X000700030001x; REICH PB, 1985, SCIENCE, V230, P566, DOI 10.1126/science.230.4725.566; REICH PB, 1985, ENVIRON POLLUT A, V39, P39, DOI 10.1016/0143-1471(85)90061-3; REICH PB, 1986, J ENVIRON QUAL, V15, P31, DOI 10.2134/jeq1986.00472425001500010008x; Reich PB, 1987, TREE PHYSIOL, V3, P63, DOI 10.1093/treephys/3.1.63; REINERT RA, 1982, PLANT DIS, V66, P122, DOI 10.1094/PD-66-122; REINERT RA, 1980, J ENVIRON QUAL, V10, P240; SATOH S, 1983, STUDIES COMBINED EFF, V2; SHIMIZU H, 1981, Environment Control in Biology, V19, P137; TINGEY DT, 1973, CAN J PLANT SCI, V53, P875, DOI 10.4141/cjps73-169; TINGEY DT, 1971, J AM SOC HORTIC SCI, V96, P369; WALMSLEY L, 1980, ENVIRON POLLUT A, V23, P165, DOI 10.1016/0143-1471(80)90044-6	38	26	45	2	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0269-7491			ENVIRON POLLUT	Environ. Pollut.		1991	74	2					149	164		10.1016/0269-7491(91)90111-9			16	Environmental Sciences	Environmental Sciences & Ecology	GH011	WOS:A1991GH01100006	15092071				2021-06-18	
J	BROTHERTON, FA; THOMAS, LL; WISOTZEK, IE; MILAN, MA				BROTHERTON, FA; THOMAS, LL; WISOTZEK, IE; MILAN, MA			SOCIAL SKILLS TRAINING IN THE REHABILITATION OF PATIENTS WITH TRAUMATIC CLOSED HEAD-INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA; GEORGIA STATE UNIV, DEPT PSYCHOL, ATLANTA, GA 30303 USA							ANDRASIK F, 1985, HDB SOCIAL SKILLS TR, P418; ASCHER LM, 1980, HDB BEHAV INTERVENTI, P266; Bellack A. S., 1979, RES PRACTICE SOCIAL; Ben-Yishay Y, 1983, REHABILITATION HEAD, P367; CURRAN JP, 1977, PSYCHOL BULL, V84, P140; DEUTSCH RD, 1979, RES COMMUN PSYCH PSY, V4, P415; DUNN M, 1981, BEHAV THER, V12, P153, DOI 10.1016/S0005-7894(81)80068-8; HERSEN M, 1976, J APPL BEHAV ANAL, V9, P239, DOI 10.1901/jaba.1976.9-239; Hersen M, 1976, SINGLE CASE EXPT DES; Jennett B, 1981, MANAGEMENT HEAD INJU; KOLKO DJ, 1985, BEHAV MODIF, V9, P165, DOI 10.1177/01454455850092003; KOLKO DJ, 1981, BEHAV ASSESS, V3, P383; LABATE LL, 1985, HDB SOCIAL SKILLS TR; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LIBET JM, 1973, J CONSULT CLIN PSYCH, V40, P304, DOI 10.1037/h0034530; MUIR CA, 1983, REHABILITATION HEAD, P381; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PHILLIPS EL, 1985, HDB SOCIAL SKILLS TR, P3; ROSENTHAL M, 1983, REHABILITATION HEAD; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; ZAHARA DJ, 1984, CLIN PSYCHOL REV, V4, P477, DOI 10.1016/0272-7358(84)90022-9	23	26	26	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1988	69	10					827	832					6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	Q5535	WOS:A1988Q553500001	3178449				2021-06-18	
J	STONE, L; KEENAN, MAE				STONE, L; KEENAN, MAE			PERIPHERAL-NERVE INJURIES IN THE ADULT WITH TRAUMATIC BRAIN INJURY	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article									RANCHO LOS AMIGOS HOSP, ADULT HEAD TRAUMA SERV, DOWNEY, CA 90242 USA; UNIV SO CALIF, SCH MED, DEPT ORTHOPAED SURG, LOS ANGELES, CA 90033 USA	STONE, L (corresponding author), RANCHO LOS AMIGOS HOSP, HEAD TRAUMA SERV, 7601 E IMPERIAL HIGHWAY, DOWNEY, CA 90242 USA.		Keenan, Mary Ann/ABB-1551-2020				ANDERSON DW, 1980, J NEUROSURG, V53, pS1; BOOTH BJ, 1983, PHYS THER, V63, P1960, DOI 10.1093/ptj/63.12.1960; BRAUN RM, 1973, J BONE JOINT SURG AM, VA 55, P580, DOI 10.2106/00004623-197355030-00015; CHAN RC, 1980, NEUROSURGERY, V7, P545, DOI 10.1227/00006123-198012000-00001; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; FEINDEL W, 1958, Can J Surg, V1, P287; FROIMSON AI, 1980, J HAND SURG-AM, V5, P391, DOI 10.1016/S0363-5023(80)80183-3; GARLAND DE, 1978, CLIN ORTHOP RELAT R, P111; GARLAND DE, 1983, PHYS THER, V63, P2004, DOI 10.1093/ptj/63.12.2004; GARLAND DE, 1984, ARCH PHYS MED REHAB, V65, P243; GARLAND DE, 1981, CLIN ORTHOP RELAT R, V155, P162; GELBERMAN RH, 1981, J BONE JOINT SURG AM, V63, P380, DOI 10.2106/00004623-198163030-00009; Heiden J.S., 1979, NEURAL TRAUMA, P181; HERBISON GJ, 1983, ARCH PHYS MED REHAB, V64, P201; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; KATZ JORDAN, 1967, ARCH PHYS MED REHABIL, V48, P97; KEENAN MAE, 1988, J HAND SURG-AM, V13A, P120, DOI 10.1016/0363-5023(88)90214-6; KEENAN MAE, 1987, J HEAD TRAUMA REHAB, V2, P62; KHALILI AA, 1967, J AMER MED ASSOC, V200, P1155, DOI 10.1001/jama.200.13.1155; KHALILI ALI A., 1964, ARCH PHYS MED REHABIL, V45, P513; Kimura J., 1983, ELECTRODIAGNOSIS DIS; KINGSTON WJ, 1985, SEMIN NEUROL, V5, P260, DOI 10.1055/s-2008-1041523; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MALKMUS D, 1980, REHABILITATION HEAD, P2; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MOONEY V, 1969, CLIN ORTHOP RELAT R, P122; MORITZ U, 1973, SCAND J REHABIL MED, V5, P160; PHALEN GS, 1970, J AMER MED ASSOC, V212, P1365, DOI 10.1001/jama.212.8.1365; RHOADES ME, 1978, CLIN ORTHOP RELAT R, P104; WILBOURN AJ, 1985, NEUROL CLIN, V3, P511, DOI 10.1016/S0733-8619(18)31019-3; Woltman HW, 1930, AM J MED SCI, V179, P528, DOI 10.1097/00000441-193004000-00008	32	26	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	AUG	1988		233					136	144					9	Orthopedics; Surgery	Orthopedics; Surgery	P7178	WOS:A1988P717800017	3402119				2021-06-18	
J	NOWAK, P; COHN, AM; GUIDICE, MA				NOWAK, P; COHN, AM; GUIDICE, MA			AIRWAY COMPLICATIONS IN PATIENTS WITH CLOSED-HEAD INJURIES	AMERICAN JOURNAL OF OTOLARYNGOLOGY			English	Article									WAYNE STATE UNIV,SCH MED,DEPT OTOLARYNGOL,DETROIT,MI 48201								0	26	26	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0196-0709			AM J OTOLARYNG	Am. J. Otolaryngol.	MAR-APR	1987	8	2					91	96		10.1016/S0196-0709(87)80030-3			6	Otorhinolaryngology	Otorhinolaryngology	G9294	WOS:A1987G929400004	3592081				2021-06-18	
J	RICHARDSON, JTE; BARRY, C				RICHARDSON, JTE; BARRY, C			THE EFFECTS OF MINOR CLOSED HEAD-INJURY UPON HUMAN-MEMORY - FURTHER EVIDENCE ON THE ROLE OF MENTAL-IMAGERY	COGNITIVE NEUROPSYCHOLOGY			English	Article										RICHARDSON, JTE (corresponding author), BRUNEL UNIV,DEPT PSYCHOL,UXBRIDGE UB8 3PH,MIDDX,ENGLAND.			Richardson, John/0000-0002-6267-0603			Baddeley A.D, 1976, PSYCHOL MEMORY; BAHRICK HP, 1968, J EXP PSYCHOL, V78, P417, DOI 10.1037/h0026458; BEGG I, 1973, CAN J PSYCHOL, V27, P159, DOI 10.1037/h0082465; Bower G.H., 1972, COGNITION LEARNING M; BOWER GH, 1970, J VERB LEARN VERB BE, V9, P529, DOI 10.1016/S0022-5371(70)80096-2; BOWER GH, 1970, AM SCI, V58, P496; BROOKS D N, 1974, Cortex, V10, P224; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; COHEN ME, 1978, B PSYCHONOMIC SOC, V12, P317; COHEN RL, 1968, J VERB LEARN VERB BE, V7, P653, DOI 10.1016/S0022-5371(68)80121-5; COHEN RL, 1970, Q J EXP PSYCHOL, V22, P450, DOI 10.1080/14640747008401918; CONKEY RC, 1938, ARCH PSYCHOL, V33; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; CROVITZ HF, 1979, CORTEX, V15, P225, DOI 10.1016/S0010-9452(79)80027-1; CROVITZ HF, 1979, CORTEX, V15, P131, DOI 10.1016/S0010-9452(79)80013-1; DEFFENBACHER KA, 1981, PERCEIVING REMEMBERI; DEMPSTER FN, 1974, J EXP PSYCHOL, V103, P400, DOI 10.1037/h0037162; ELLIS HD, 1975, BRIT J PSYCHOL, V66, P409, DOI 10.1111/j.2044-8295.1975.tb01477.x; ELLIS HD, 1981, PERCEIVING REMEMBERI; FODOR IE, 1972, J NEUROL NEUROSUR PS, V35, P818, DOI 10.1136/jnnp.35.6.818; GASPARRINI B, 1979, Journal of Clinical Neuropsychology, V1, P137, DOI 10.1080/01688637908414447; GLASGOW RE, 1977, J CLIN PSYCHOL, V33, P1049, DOI 10.1002/1097-4679(197710)33:4<1049::AID-JCLP2270330429>3.0.CO;2-V; GOLDSTEIN AG, 1979, B PSYCHONOMIC SOC, V13, P15, DOI 10.3758/BF03334999; GOLDSTEIN AG, 1976, B PSYCHONOMIC SOC, V7, P407, DOI 10.3758/BF03337231; GOLDSTEIN AG, 1971, PERCEPT PSYCHOPHYS, V9, P237, DOI 10.3758/BF03212641; GOLDSTEIN AG, 1981, PERCEIVING REMEMBERI; GRIFFITH D, 1978, B PSYCHONOMIC SOC, V12, P347; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; GRONWALL D, 1974, LANCET, V2, P605; GUPTON T, 1970, J EXP PSYCHOL, V86, P461, DOI 10.1037/h0030178; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HUNTER IML, 1977, J MENTAL IMAGERY, V1, P65; JANSSEN W, 1976, NATURE MENTAL IMAGE; JONES MK, 1974, NEUROPSYCHOLOGIA, V12, P21, DOI 10.1016/0028-3932(74)90023-2; Kucera H, 1967, COMPUTATIONAL ANAL P; KURTZ KH, 1953, J EXP PSYCHOL, V45, P157, DOI 10.1037/h0061022; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; LEVIN HS, 1977, CORTEX, V13, P119, DOI 10.1016/S0010-9452(77)80003-8; LEVIN HS, 1976, DIS NERV SYST, V37, P68; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEWINSOHN PM, 1977, J CONSULT CLIN PSYCH, V45, P717, DOI 10.1037/0022-006X.45.5.717; LIDVALL HF, 1974, ACTA NEUROLOGICA S56, V50; MALPASS RS, 1973, PERCEPT PSYCHOPHYS, V14, P285, DOI 10.3758/BF03212392; MORRIS P, 1977, ADULT LEARNING PSYCH; MORRIS PE, 1974, J VERB LEARN VERB BE, V13, P310, DOI 10.1016/S0022-5371(74)80067-8; MORRIS PE, 1974, BRIT J PSYCHOL, V65, P7, DOI 10.1111/j.2044-8295.1974.tb02765.x; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAIVIO A, 1973, COGNITIVE PSYCHOL, V5, P176, DOI 10.1016/0010-0285(73)90032-7; PAIVIO A, 1972, FUNCTION NATURE IMAG; Paivio A., 1978, HDB PERCEPTION, V8; PAIVIO A, 1968, J EXPT PSYCHOL MON 2, V76; Paivio A., 1971, IMAGERY VERBAL PROCE; Paivio A., 1967, PSYCHON SCI, V8, P65; PARKER SA, 1976, ACTA NEUROCHIR, V34, P71, DOI 10.1007/BF01405864; PATTEN BM, 1972, ARCH NEUROL-CHICAGO, V26, P25, DOI 10.1001/archneur.1972.00490070043006; PELLEGRINO JW, 1975, J EXPT PSYCHOL HUMAN, V1, P95, DOI DOI 10.1037/0278-7393.1.2.95; Poon L. W., 1980, NEW DIRECTIONS MEMOR; Richardson J. T. E., 1980, MENTAL IMAGERY HUMAN; RICHARDSON JT, 1974, J VERB LEARN VERB BE, V13, P709, DOI 10.1016/S0022-5371(74)80057-5; RICHARDSON JTE, 1984, COGN NEUROPSYCHOL, V1, P217, DOI 10.1080/02643298408252023; RICHARDSON JTE, 1979, BRIT J SOC CLIN PSYC, V18, P319, DOI 10.1111/j.2044-8260.1979.tb00342.x; RICHARDSON JTE, 1984, CORTEX, V20, P413, DOI 10.1016/S0010-9452(84)80009-X; RICHARDSON JTE, 1978, PERCEPT MOTOR SKILL, V47, P967, DOI 10.2466/pms.1978.47.3.967; RICHARDSON JTE, 1978, Q J EXP PSYCHOL, V30, P471, DOI 10.1080/00335557843000061; RICHARDSON JTE, 1976, BRIT J PSYCHOL, V67, P487, DOI 10.1111/j.2044-8295.1976.tb01537.x; RICHARDSON JTE, 1979, CORTEX, V15, P145, DOI 10.1016/S0010-9452(79)80016-7; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SAVINO PJ, 1980, NEUROLOGY, V30, P963, DOI 10.1212/WNL.30.9.963; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHEEHAN PW, 1972, FUNCTION NATURE IMAG; Shepherd J, 1981, PERCEIVING REMEMBERI; THOMSEN IV, 1977, SCAND J REHABIL MED, V9, P73; Thorndike EL., 1944, TEACHERS WORD BOOK 3; TULVING E, 1973, PSYCHOL REV, V80, P352, DOI 10.1037/h0020071; *UK OFF POP CENS S, 1970, 1970 CLASS OCC; WARREN MW, 1977, MEM COGNITION, V5, P362, DOI 10.3758/BF03197584; WINER BJ, 1962, STATISTICAL PRINCIPL; YIN RK, 1970, NEUROPSYCHOLOGIA, V8, P395, DOI 10.1016/0028-3932(70)90036-9; YIN RK, 1969, J EXP PSYCHOL, V81, P141, DOI 10.1037/h0027474; YUILLE JC, 1968, J EXP PSYCHOL, V78, P436, DOI 10.1037/h0026457	84	26	26	0	0	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0264-3294			COGNITIVE NEUROPSYCH	Cogn. Neuropsychol.		1985	2	2					149	168		10.1080/02643298508252864			20	Psychology; Psychology, Experimental	Psychology	AKH49	WOS:A1985AKH4900002					2021-06-18	
J	NEWCOMBE, F				NEWCOMBE, F			THE PSYCHOLOGICAL CONSEQUENCES OF CLOSED HEAD-INJURY - ASSESSMENT AND REHABILITATION	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article										NEWCOMBE, F (corresponding author), RADCLIFFE INFIRM,NEUROPSYCHOL UNIT,NEUROSCI GRP,OXFORD OX2 6HE,ENGLAND.							0	26	26	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0020-1383			INJURY	Injury-Int. J. Care Inj.		1982	14	2					111	136		10.1016/0020-1383(82)90046-8			26	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	PJ320	WOS:A1982PJ32000001	6754607				2021-06-18	
J	FAAS, FH; OMMAYA, AK				FAAS, FH; OMMAYA, AK			BRAIN TISSUE ELECTROLYTES AND WATER CONTENT IN EXPERIMENTAL CONCUSSION IN MONKEY	JOURNAL OF NEUROSURGERY			English	Article																ALEU FP, 1963, J NEUROPATH EXP NEUR, V22, P403, DOI 10.1097/00005072-196307000-00003; Alexander L, 1938, ARCH NEURO PSYCHIATR, V40, P877, DOI 10.1001/archneurpsyc.1938.02270110031002; BOURKE RS, 1965, AM J PHYSIOL, V208, P682; BRADBURY BW, 1965, J PHYSIOL-LONDON, V181, P151; CAVENESS WF, 1966, HEAD INJURY       ED, P439; CAVENESS WF, 1966, HEAD INJURY       ED, P142; CAVENESS WF, 1966, HEAD INJURY       ED, P444; CAVENESS WF, 1966, HEAD INJURY       ED, P249; CAVENESS WF, 1966, HEAD INJURY       ED, P397; CAVENESS WF, 1966, HEAD INJURY C P   ED, P276; CAVENESS WF, 1966, HEAD INJURY C P   ED, P254; CAVENESS WF, 1966, HEAD INJURY       ED, P448; COTLOVE E, 1963, ANAL CHEM, V35, P101, DOI 10.1021/ac60194a031; COTLOVE E, 1958, J LAB CLIN MED, V51, P461; EICHELBERGER L, 1949, AM J PHYSIOL, V156, P129; FISHER RG, 1966, HEAD INJURY, P249; Flamm E S, 1966, Surg Forum, V17, P414; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; HERSCHKO.N, 1965, BRAIN, V88, P557, DOI 10.1093/brain/88.3.557; ISHII S, 1966, HEAD INJURY, P276; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KURZE T, 1966, HEAD INJURY C P, P254; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; MCLAURIN RL, 1966, HEAD INJURY C P, P142; Nelson S, 1966, HEAD INJURY, P444; Ommaya A K, 1966, Ann R Coll Surg Engl, V39, P317; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; PAPPIUS H. M., 1965, PROGR BRAIN RES, V15, P135; Pappius HM, 1963, ACTA NEUROPATH BERL, V2, P451; Pilcher C, 1937, ARCH SURG-CHICAGO, V35, P512, DOI 10.1001/archsurg.1937.01190150095009; PILCHER C, 1941, SURG GYNECOL OBSTET, V72, P755; POPE A, 1966, HEAD INJURY, P439; REED DJ, 1964, ARCH NEUROL-CHICAGO, V10, P604, DOI 10.1001/archneur.1964.00460180070007; Shapiro P, 1939, ARCH SURG-CHICAGO, V38, P443, DOI 10.1001/archsurg.1939.01200090048005; SPIEGEL EA, 1946, P ASS RES NERV MENT, V26, P84; STEINWALL O, UNPUBLISHED OBSERVAT; STERN WE, 1964, AM J PHYSIOL, V206, P1, DOI 10.1152/ajplegacy.1964.206.1.1; STERN WE, 1965, NEUROLOGY, V15, P902, DOI 10.1212/WNL.15.10.902; TOWER DB, 1966, HEAD INJURY, P448; VANHARRE.A, 1966, AM J PHYSIOL, V210, P251; VANHARREVELD A, 1966, HEAD INJURY, P397; VANHARREVELD A, 1966, BRAIN TISSUE ELECTRO; White JC, 1943, ANN SURG, V119, P619, DOI 10.1097/00000658-194310000-00010; WHITE JC, ARCHS SURG CHICAGO, V44, P1	45	26	26	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.		1968	28	2					137	+		10.3171/jns.1968.28.2.0137			1	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	A6851	WOS:A1968A685100008	4966169				2021-06-18	
J	Chesnut, R; Aguilera, S; Buki, A; Bulger, E; Citerio, G; Cooper, DJ; Arrastia, RD; Diringer, M; Figaji, A; Gao, GY; Geocadin, R; Ghajar, J; Harris, O; Hoffer, A; Hutchinson, P; Joseph, M; Kitagawa, R; Manley, G; Mayer, S; Menon, DK; Meyfroidt, G; Michael, DB; Oddo, M; Okonkwo, D; Patel, M; Robertson, C; Rosenfeld, JV; Rubiano, AM; Sahuquillo, J; Servadei, F; Shutter, L; Stein, D; Stocchetti, N; Taccone, FS; Timmons, S; Tsai, E; Ullman, JS; Vespa, P; Videtta, W; Wright, DW; Zammit, C; Hawryluk, GWJ				Chesnut, Randall; Aguilera, Sergio; Buki, Andras; Bulger, Eileen; Citerio, Giuseppe; Cooper, D. Jamie; Arrastia, Ramon Diaz; Diringer, Michael; Figaji, Anthony; Gao, Guoyi; Geocadin, Romer; Ghajar, Jamshid; Harris, Odette; Hoffer, Alan; Hutchinson, Peter; Joseph, Mathew; Kitagawa, Ryan; Manley, Geoffrey; Mayer, Stephan; Menon, David K.; Meyfroidt, Geert; Michael, Daniel B.; Oddo, Mauro; Okonkwo, David; Patel, Mayur; Robertson, Claudia; Rosenfeld, Jeffrey V.; Rubiano, Andres M.; Sahuquillo, Juan; Servadei, Franco; Shutter, Lori; Stein, Deborah; Stocchetti, Nino; Taccone, Fabio Silvio; Timmons, Shelly; Tsai, Eve; Ullman, Jamie S.; Vespa, Paul; Videtta, Walter; Wright, David W.; Zammit, Christopher; Hawryluk, Gregory W. J.			A management algorithm for adult patients with both brain oxygen and intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC)	INTENSIVE CARE MEDICINE			English	Article						Brain injury; Head trauma; Algorithm; Protocol; Consensus; Intracranial pressure; Brain oxygen; Tiers; Seattle; SIBICC; PbtO2	GUIDELINES; TRIAL	Background Current guidelines for the treatment of adult severe traumatic brain injury (sTBI) consist of high-quality evidence reports, but they are no longer accompanied by management protocols, as these require expert opinion to bridge the gap between published evidence and patient care. We aimed to establish a modern sTBI protocol for adult patients with both intracranial pressure (ICP) and brain oxygen monitors in place. Methods Our consensus working group consisted of 42 experienced and actively practicing sTBI opinion leaders from six continents. Having previously established a protocol for the treatment of patients with ICP monitoring alone, we addressed patients who have a brain oxygen monitor in addition to an ICP monitor. The management protocols were developed through a Delphi-method-based consensus approach and were finalized at an in-person meeting. Results We established three distinct treatment protocols, each with three tiers whereby higher tiers involve therapies with higher risk. One protocol addresses the management of ICP elevation when brain oxygenation is normal. A second addresses management of brain hypoxia with normal ICP. The third protocol addresses the situation when both intracranial hypertension and brain hypoxia are present. The panel considered issues pertaining to blood transfusion and ventilator management when designing the different algorithms. Conclusions These protocols are intended to assist clinicians in the management of patients with both ICP and brain oxygen monitors but they do not reflect either a standard-of-care or a substitute for thoughtful individualized management. These protocols should be used in conjunction with recommendations for basic care, management of critical neuroworsening and weaning treatment recently published in conjunction with the Seattle International Brain Injury Consensus Conference.	[Chesnut, Randall] Univ Washington, Harborview Med Ctr, Dept Neurol Surg, 325 Ninth Ave,Mailstop 359766, Seattle, WA 98109 USA; [Chesnut, Randall] Univ Washington, Harborview Med Ctr, Dept Orthopaed Surg, 325 Ninth Ave,Mailstop 359766, Seattle, WA 98109 USA; [Aguilera, Sergio] Almirante Nef Naval Hosp, Vina Del Mar, Chile; [Aguilera, Sergio] Univ Valparaiso, Valparaiso, Chile; [Buki, Andras] Sch Med, Dept Neurosurg, Ifjusag Utja 20, H-7624 Pecs, Hungary; [Buki, Andras] Szentagothai Res Ctr, Ifjusag Utja 20, H-7624 Pecs, Hungary; [Buki, Andras] Univ Pecs, Pecs, Hungary; [Bulger, Eileen] Univ Washington, Harborview Med Ctr, Dept Surg, 325 Ninth Ave, Seattle, WA 98104 USA; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Citerio, Giuseppe] San Gerardo Hosp, ASST, Dept Emergency & Intens Care, Neurointens Care, Monza, Italy; [Cooper, D. Jamie] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Intens Care Med, Monash, Australia; [Cooper, D. Jamie] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Arrastia, Ramon Diaz] Univ Penn, Perelman Sch Med, Penn Presbyterian Med Ctr, 51 North 39th St, Philadelphia, PA 19104 USA; [Diringer, Michael] Washington Univ, Sch Med, Dept Neurol, Barnes Jewish Hosp, 1 Barnes Jewish Hosp Plaza, St Louis, MO 63110 USA; [Figaji, Anthony] Univ Cape Town, Div Neurosurg, Groote Schuur Hosp, H53 Old Main Bldg,Main Rd, ZA-7925 Observatory, South Africa; [Figaji, Anthony] Univ Cape Town, Inst Neurosci, Groote Schuur Hosp, H53 Old Main Bldg,Main Rd, ZA-7925 Observatory, South Africa; [Gao, Guoyi] Shandong Jiaotong Univ, Renji Hosp, Shanghai Inst Head Trauma, Sch Med,Dept Neurosurg, 1630 Dongfang Rd, Shanghai 200127, Peoples R China; [Geocadin, Romer] Johns Hopkins Univ, Sch Med, 1800 Orleans St Sheikh Zayed Tower, Baltimore, MD 21287 USA; [Ghajar, Jamshid] Stanford Neurosci Hlth Ctr, 213 Quarry Rd 4th Fl MC 5958, Palo Alto, CA 94304 USA; [Harris, Odette] Dept Neurosurg, Pasteur Dr,Room R205,Edwards Bldg,MC 5327, Stanford, CA 94305 USA; [Hoffer, Alan] Case Western Reserve Univ, Sch Med, Dept Neurol Surg, 11100 Euclid Ave,HAN 5042, Cleveland, OH 44106 USA; [Hutchinson, Peter] Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Hutchinson, Peter] Univ Cambridge, Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Joseph, Mathew] Christian Med Coll & Hosp, Dept Neurol Sci, Ida Scudder Rd, Vellore, Tamil Nadu, India; [Kitagawa, Ryan] McGovern Med Sch UTHlth, Vivian L Smith Dept Neurosurg, 6400 Fannin St,Suite 2800, Houston, TX 77030 USA; [Manley, Geoffrey] Univ Calif San Francisco, San Francisco Gen Hosp, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Manley, Geoffrey] Trauma Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Mayer, Stephan] Henry Ford Hosp, Neurol, K-11,2799 W Grand Blvd, Detroit, MI 48202 USA; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Hills Rd,Box 93, Cambridge CB2 0QQ, England; [Menon, David K.] Addenbrookes Hosp, Hills Rd,Box 93, Cambridge CB2 0QQ, England; [Meyfroidt, Geert] Univ Hosp Leuven, Dept & Lab Intens Care Med, Herestr 49,Box 7003 63, B-3000 Louvain, Belgium; [Meyfroidt, Geert] Katholieke Univ Leuven, Herestr 49,Box 7003 63, B-3000 Louvain, Belgium; [Michael, Daniel B.] Oakland Univ, William Beaumont Sch Med, Beaumont Hlth, Michigan Head & Spine Inst, Southfield, MI USA; [Oddo, Mauro] Univ Lausanne, CHUV Lausanne Univ Hosp, Dept Intens Care Med, Fac Biol & Med, Lausanne, Switzerland; [Okonkwo, David] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; [Patel, Mayur] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Robertson, Claudia] Baylor Coll Med, One Baylor Plaza, Houston, TX 77030 USA; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic, Australia; [Rubiano, Andres M.] El Bosque Univ, INUB MEDITECH Res Grp, Neurosci Inst, Bogota, Colombia; [Rubiano, Andres M.] MEDITECH Fdn, Clin Res, Calle 7-A 44-95, Cali 760036, Colombia; [Sahuquillo, Juan] Univ Hosp Vall Hebron, Barcelona, Spain; [Servadei, Franco] Humanitas Univ, Dept Neurosurg, Milan, Italy; [Servadei, Franco] Res Hosp, Milan, Italy; [Servadei, Franco] World Federat Neurosurg Soc, Nyon, Switzerland; [Shutter, Lori] Univ Pittsburgh, Med Ctr, 3550 Terrace St,Room 646, Pittsburgh, PA 15261 USA; [Stein, Deborah] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, 1001 Potrero Ave,Ward 3A, San Francisco, CA 94110 USA; [Stein, Deborah] Univ Calif San Francisco, Ctr Trauma, 1001 Potrero Ave,Ward 3A, San Francisco, CA 94110 USA; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplantat, Milan, Italy; [Stocchetti, Nino] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Neurosci Intens Care Unit, Milan, Italy; [Taccone, Fabio Silvio] Univ Libre Bruxelles ULB, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Timmons, Shelly] Penn State Univ, Milton S Hershey Med Ctr, Dept Neurol Surg, 30 Hope Dr,Suite 1200,Bldg B, Hershey, PA 17033 USA; [Tsai, Eve] Univ Ottawa, Suruchi Bhargava Chair Spinal Cord & Brain Regene, Ottawa Hosp, Neurosci Unit C2, Civ Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada; [Ullman, Jamie S.] Shore Univ Hosp, Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Neurosurg, 300 Community Dr,9 Tower, Manhasset, NY USA; [Vespa, Paul] UCLA Med Ctr, Ronald Reagan UCLA Med Ctr, Santa Monica, CA USA; [Videtta, Walter] Posadas Hosp, Buenos Aires, DF, Argentina; [Wright, David W.] Emory Univ, Sch Med, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA; [Zammit, Christopher] Univ Rochester, Med Ctr, Sch Med & Dent, 601 Elmwood Ave,Box 655C, Rochester, NY 14642 USA; [Hawryluk, Gregory W. J.] Univ Manitoba, Neurosurg Sect, GB1,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada	Hawryluk, GWJ (corresponding author), Univ Manitoba, Neurosurg Sect, GB1,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	ghawryluk@hsc.mb.ca	Sahuquillo, Juan/B-3577-2008; Cooper, D. James/G-7961-2013; Tsai, Eve/D-7007-2014	Sahuquillo, Juan/0000-0003-0713-5875; Cooper, D. James/0000-0002-5872-9051; Figaji, Anthony/0000-0002-3357-6490; Tsai, Eve/0000-0002-8152-349X; Shutter, Lori/0000-0002-1390-0628			Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Hawryluk GWJ, 2019, INTENS CARE MED, V45, DOI 10.1007/s00134-019-05805-9; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hendrickson P, 2018, WORLD NEUROSURG, V110, pE952, DOI 10.1016/j.wneu.2017.11.142; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, pS1, DOI 10.1097/PCC.0000000000001735; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, P269, DOI 10.1097/PCC.0000000000001737; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Okonkwo DO, 2017, CRIT CARE MED, V45, P1907, DOI 10.1097/CCM.0000000000002619; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360	11	25	25	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAY	2020	46	5					919	929		10.1007/s00134-019-05900-x			11	Critical Care Medicine	General & Internal Medicine	LK9CU	WOS:000531156300006	31965267	Green Published, Other Gold			2021-06-18	
J	Ekstrand, J; Krutsch, W; Spreco, A; van Zoest, W; Roberts, C; Meyer, T; Bengtsson, H				Ekstrand, Jan; Krutsch, Werner; Spreco, Armin; van Zoest, Wart; Roberts, Craig; Meyer, Tim; Bengtsson, Hakan			Time before return to play for the most common injuries in professional football: a 16-year follow-up of the UEFA Elite Club Injury Study	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						soccer; injuries; return to play; epidemiology	HAMSTRING INJURIES; MUSCLE INJURIES; CONSENSUS STATEMENT; SPORT; RISK; CONCUSSION	Objectives The objective was to describe the typical duration of absence following the most common injury diagnoses in professional football. Methods Injuries were registered by medical staff members of football clubs participating in the Union of European Football Association Elite Club Injury Study. Duration of absence due to an injury was defined by the number of days that passed between the date of the injury occurrence and the date when the medical team allowed the player to return to full participation. In total, 22942 injuries registered during 494 team-seasons were included in the study. Results The 31 most common injury diagnoses constituted a total of 78 % of all reported injuries. Most of these injuries were either mild (leading to a median absence of 7 days or less, 6440 cases = 42%) or moderate (median absence: 7-28 days, 56% = 8518 cases) while only few (2% = 311 cases) were severe (median absence of >28 days). The mean duration of absence from training and competition was significantly different (p < 0.05) between index injuries and re-injuries for six diagnoses (Achilles tendon pain, calf muscle injury, groin adductor pain, hamstring muscle injuries and quadriceps muscle injury) with longer absence following re-injuries for all six diagnoses Conclusions The majority of all time loss due to injuries in professional football stems from injuries with an individual absence of up to 4 weeks. This article can provide guidelines for expected time away from training and competition for the most common injury types as well as for its realistic range.	[Ekstrand, Jan; Bengtsson, Hakan] Linkoping Univ, Dept Med & Hlth Sci, S-58221 Linkoping, Sweden; [Ekstrand, Jan] Aspetar Orthopaed & Sports Med Hosp, Doha, Qatar; [Krutsch, Werner] Univ Klinikum Regensburg, Dept Trauma Surg, Regensburg, Germany; [Spreco, Armin] Linkoping Univ, Athlet Res Ctr, Dept Med & Hlth Sci, Linkoping, Sweden; [van Zoest, Wart] St Anna Hosp, Dept Orthopaed Surg, Eindhoven, Netherlands; [Roberts, Craig] AFC Bournemouth, Bournemouth, Dorset, England; [Meyer, Tim] Univ Saarland, Inst Sports & Prevent Med, Saarbrucken, Germany	Ekstrand, J (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, S-58221 Linkoping, Sweden.	jan.ekstrand@telia.com			UEFA; Swedish Football Association; Swedish Research Council for Sport Science	The Football Research Group was established in Linkoping, Sweden, in cooperation with Linkoping University. It was supported by grants from UEFA, the Swedish Football Association, and the Swedish Research Council for Sport Science.	Ardern CL, 2016, BRIT J SPORT MED, V50, P853, DOI 10.1136/bjsports-2016-096278; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bahr R, 2018, BRIT J SPORT MED, V52, P1018, DOI 10.1136/bjsports-2017-098160; Cohen SB, 2011, SPORTS HEALTH, V3, P423, DOI 10.1177/1941738111403107; Comin J, 2013, AM J SPORT MED, V41, P111, DOI 10.1177/0363546512463679; Dijkstra HP, 2017, BRIT J SPORT MED, V51, P419, DOI 10.1136/bjsports-2016-096209; Ekstrand J, 2016, BRIT J SPORT MED, V50, P709, DOI 10.1136/bjsports-2016-096333; Ekstrand J, 2016, BRIT J SPORT MED, V50, P731, DOI 10.1136/bjsports-2015-095359; Ekstrand J, 2013, BRIT J SPORT MED, V47, P732, DOI 10.1136/bjsports-2013-092394; Ekstrand J, 2012, BRIT J SPORT MED, V46, P112, DOI 10.1136/bjsports-2011-090155; Ekstrand J, 2011, AM J SPORT MED, V39, P1226, DOI 10.1177/0363546510395879; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Gajhede-Knudsen M, 2013, BRIT J SPORT MED, V47, P763, DOI 10.1136/bjsports-2013-092271; Grindem H, 2016, BRIT J SPORT MED, V50, P804, DOI 10.1136/bjsports-2016-096031; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Hagglund M, 2005, SCAND J MED SCI SPOR, V15, P21, DOI 10.1111/j.1600-0838.2004.00395.x; Hallen A, 2014, J SPORT SCI, V32, P1229, DOI 10.1080/02640414.2014.905695; Koulouris G, 2007, AM J SPORT MED, V35, P1500, DOI 10.1177/0363546507301258; Kristenson K, 2013, BRIT J SPORT MED, V47, P775, DOI 10.1136/bjsports-2013-092266; Krutsch W, 2018, UNFALLCHIRURG, V121, P433, DOI 10.1007/s00113-018-0487-6; McCall A, 2017, BRIT J SPORT MED, V51, P702, DOI 10.1136/bjsports-2016-096752; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McLendon LA, 2016, PEDIATR NEUROL, V62, P9, DOI 10.1016/j.pediatrneurol.2016.03.009; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Orchard J, 2005, CLIN J SPORT MED, V15, P436, DOI 10.1097/01.jsm.0000188206.54984.65; van Melick N, 2016, BRIT J SPORT MED, V50, P1506, DOI 10.1136/bjsports-2015-095898; Wangensteen A, 2016, AM J SPORT MED, V44, P2112, DOI 10.1177/0363546516646086	27	25	24	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2020	54	7					421	426		10.1136/bjsports-2019-100666			6	Sport Sciences	Sport Sciences	LB2ZI	WOS:000524506500010	31182429	Green Published, Other Gold			2021-06-18	
J	Hornby, TG; Reisman, DS; Ward, IG; Scheets, PL; Miller, A; Haddad, D; Fox, EJ; Fritz, NE; Hawkins, K; Henderson, CE; Hendron, KL; Holleran, CL; Lynskey, JE; Walter, A				Hornby, T. George; Reisman, Darcy S.; Ward, Irene G.; Scheets, Patricia L.; Miller, Allison; Haddad, David; Fox, Emily J.; Fritz, Nora E.; Hawkins, Kelly; Henderson, Christopher E.; Hendron, Kathryn L.; Holleran, Carey L.; Lynskey, James E.; Walter, Amber		Locomotor CPG Appraisal Team	Clinical Practice Guideline to Improve Locomotor Function Following Chronic Stroke, Incomplete Spinal Cord Injury, and Brain Injury	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						clinical practice guidelines; locomotor function; rehabilitation	BODY-WEIGHT SUPPORT; ANKLE-FOOT ORTHOSIS; QUALITY-OF-LIFE; RHYTHMIC AUDITORY-STIMULATION; PRESERVED EJECTION FRACTION; RANDOMIZED CONTROLLED-TRIAL; CHRONIC HEMIPARETIC STROKE; WALKING TRAINING-PROGRAM; VIRTUAL-REALITY GAMES; TRAUMATIC BRAIN	Background: Individuals with acute-onset central nervous system (CNS) injury, including stroke, motor incomplete spinal cord injury, or traumatic brain injury, often experience lasting locomotor deficits, as quantified by decreases in gait speed and distance walked over a specific duration (timed distance). The goal of the present clinical practice guideline was to delineate the relative efficacy of various interventions to improve walking speed and timed distance in ambulatory individuals greater than 6 months following these specific diagnoses. Methods: A systematic review of the literature published between 1995 and 2016 was performed in 4 databases for randomized controlled clinical trials focused on these specific patient populations, at least 6 months postinjury and with specific outcomes of walking speed and timed distance. For all studies, specific parameters of training interventions including frequency, intensity, time, and type were detailed as possible. Recommendations were determined on the basis of the strength of the evidence and the potential harm, risks, or costs of providing a specific training paradigm, particularly when another intervention may be available and can provide greater benefit. Results: Strong evidence indicates that clinicians should offer walking training at moderate to high intensities or virtual reality-based training to ambulatory individuals greater than 6 months following acute-onset CNS injury to improve walking speed or distance. In contrast, weak evidence suggests that strength training, circuit (ie, combined) training or cycling training at moderate to high intensities, and virtual reality-based balance training may improve walking speed and distance in these patient groups. Finally, strong evidence suggests that body weight-supported treadmill training, robotic-assisted training, or sitting/standing balance training without virtual reality should not be performed to improve walking speed or distance in ambulatory individuals greater than 6 months following acute-onset CNS injury to improve walking speed or distance. Discussion: The collective findings suggest that large amounts of task-specific (ie, locomotor) practice may be critical for improvements in walking function, although only at higher cardiovascular intensities or with augmented feedback to increase patient's engagement. Lower-intensity walking interventions or impairment-based training strategies demonstrated equivocal or limited efficacy. Limitations: As walking speed and distance were primary outcomes, the research participants included in the studies walked without substantial physical assistance. This guideline may not apply to patients with limited ambulatory function, where provision of walking training may require substantial physical assistance. The guideline suggests that task-specific walking training should be performed to improve walking speed and distance in those with acute-onset CNS injury although only at higher intensities or with augmented feedback. Future studies should clarify the potential utility of specific training parameters that lead to improved walking speed and distance in these populations in both chronic and subacute stages following injury. Disclaimer: These recommendations are intended as a guide for clinicians to optimize rehabilitation outcomes for persons with chronic stroke, incomplete spinal cord injury, and traumatic brain injury to improve walking speed and distance.	[Hornby, T. George; Henderson, Christopher E.] Indiana Univ, Dept Phys Med & Rehabil, Indianapolis, IN 46204 USA; [Hornby, T. George] Northwestern Univ, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Reisman, Darcy S.; Miller, Allison] Univ Delaware, Dept Phys Therapy, Newark, DE USA; [Ward, Irene G.; Miller, Allison; Haddad, David] Kessler Inst Rehabil, W Orange, NJ USA; [Ward, Irene G.] Univ Med & Dent New Jersey, Newark, NJ USA; [Scheets, Patricia L.] Infin Rehab, Wilsonville, OR USA; [Fox, Emily J.; Hendron, Kathryn L.] Univ Florida, Dept Phys Therapy, Gainesville, FL USA; [Fox, Emily J.; Hawkins, Kelly] Brooks Rehabil Ctr, Jacksonville, FL USA; [Fritz, Nora E.] Wayne State Univ, Dept Phys Therapy, Detroit, MI USA; [Hendron, Kathryn L.] Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA; [Holleran, Carey L.] Washington Univ, Program Phys Therapy, St Louis, MO 63110 USA; [Lynskey, James E.] AT Still Univ, Dept Phys Therapy, Mesa, AZ 85206 USA; [Walter, Amber] Sheltering Arms Hosp, Mechanicsville, VA USA	Hornby, TG (corresponding author), Rehabil Hosp Indiana, Locomotor Recovery Lab, 4141 Shore Dr, Indianapolis, IN 46254 USA.	tghornby@iu.edu	Fritz, Nora/ABG-6696-2020; Hornby, Thomas/AAS-1131-2020		American Physical Therapy Association (APTA) Practice Division; Academy of Neurologic Physical Therapy (ANPT)	The American Physical Therapy Association (APTA) Practice Division and the Academy of Neurologic Physical Therapy (ANPT) provided funding to support the development and preparation of this document. Neither association influenced the recommendations put forth by this guideline.	About the CMS Innovation Center, CMS INN CTR CTR MED; Ada L, 2003, ARCH PHYS MED REHAB, V84, P1486, DOI 10.1016/S0003-9993(03)00349-6; Ada L, 2010, STROKE, V41, P1237, DOI 10.1161/STROKEAHA.109.569483; Alexeeva N, 2011, J SPINAL CORD MED, V34, P362, DOI 10.1179/2045772311Y.0000000018; [Anonymous], 2018, SPINAL CORD INJURY S; Aruin AS, 2012, TOP STROKE REHABIL, V19, P556, DOI 10.1310/tsr1906-556; Awad LN, 2016, NEUROREHAB NEURAL RE, V30, P661, DOI 10.1177/1545968315619696; Awad LN, 2015, NEUROREHAB NEURAL RE, V29, P499, DOI 10.1177/1545968314554625; Balasubramanian CK, 2014, STROKE RES TREAT, V2014, DOI 10.1155/2014/591013; Bang Dae-Hyouk, 2016, J Phys Ther Sci, V28, P2381, DOI 10.1589/jpts.28.2381; Bang DH, 2016, NEUROREHABILITATION, V38, P343, DOI 10.3233/NRE-161325; Bang DH, 2014, J PHYS THER SCI, V26, P1689, DOI 10.1589/jpts.26.1689; Bang DH, 2013, CLIN REHABIL, V27, P1118, DOI 10.1177/0269215513501528; BARBEAU H, 1987, MED BIOL ENG COMPUT, V25, P341, DOI 10.1007/BF02447435; Barbeau H, 2003, ARCH PHYS MED REHAB, V84, P1458, DOI 10.1016/S0003-9993(03)00361-7; Bayouk JF, 2006, INT J REHABIL RES, V29, P51, DOI 10.1097/01.mrr.0000192100.67425.84; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Bethoux F, 2014, NEUROREHAB NEURAL RE, V28, P688, DOI 10.1177/1545968314521007; Biering-Sorensen B, 2009, MUSCLE NERVE, V40, P499, DOI 10.1002/mus.21391; Billinger SA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-014-0519-8; Billinger SA, 2014, STROKE, V45, P2532, DOI 10.1161/STR.0000000000000022; Bland DC, 2011, BRAIN INJURY, V25, P664, DOI 10.3109/02699052.2011.576306; Bobath B., 1990, ADULT HEMIPLEGIA EVA; Bochkezanian V, 2015, SPINAL CORD, V53, P418, DOI 10.1038/sc.2015.48; Bonan IV, 2004, ARCH PHYS MED REHAB, V85, P274, DOI 10.1016/j.apmr.2003.06.016; Bourbonnais D, 2002, AM J PHYS MED REHAB, V81, P890, DOI 10.1097/00002060-200212000-00002; Bowden MG, 2006, STROKE, V37, P872, DOI 10.1161/01.STR.0000204063.75779.8d; Boyne P, 2016, PHYS THER, V96, P1533, DOI 10.2522/ptj.20150277; Brogardh C, 2012, ARCH PHYS MED REHAB, V93, P253, DOI 10.1016/j.apmr.2011.09.005; Brown TH, 2005, J HEAD TRAUMA REHAB, V20, P402, DOI 10.1097/00001199-200509000-00002; Buesing C, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0062-0; Centers for Medicare & Medicaid Innovation, BUNDL PAYM CAR IMPR; Cha J, 2007, J NEUROTRAUM, V24, P1000, DOI 10.1089/neu.2006.0233; Cha Y, 2014, NEUROREHABILITATION, V35, P681, DOI 10.3233/NRE-141182; Chen IH, 2014, NEUROREHAB NEURAL RE, V28, P45, DOI 10.1177/1545968313497102; Cho KH, 2015, TOHOKU J EXP MED, V236, P273, DOI 10.1620/tjem.236.273; Cho KH, 2014, GAIT POSTURE, V39, P523, DOI 10.1016/j.gaitpost.2013.09.003; Cho KH, 2013, AM J PHYS MED REHAB, V92, P371, DOI 10.1097/PHM.0b013e31828cd5d3; Chun JY, 2016, ANN REHABIL MED-ARM, V40, P972, DOI 10.5535/arm.2016.40.6.972; Chung E, 2014, RESTOR NEUROL NEUROS, V32, P313, DOI 10.3233/RNN-130353; Clark DJ, 2013, NEUROREHAB NEURAL RE, V27, P335, DOI 10.1177/1545968312469833; CMS Takes Action to Modernize Medicare Home Health, 2019, CMS TAK ACT MOD MED; Colombo G, 2000, J REHABIL RES DEV, V37, P693; Colombo G, 2001, SPINAL CORD, V39, P252, DOI 10.1038/sj.sc.3101154; Combs SA, 2013, DISABIL REHABIL, V35, P860, DOI 10.3109/09638288.2012.717575; Combs-Miller SA, 2014, CLIN REHABIL, V28, P873, DOI 10.1177/0269215514520773; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Cramer SC, 2011, BRAIN, V134, P1591, DOI 10.1093/brain/awr039; CROZIER KS, 1992, PARAPLEGIA, V30, P762, DOI 10.1038/sc.1992.147; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; Danks KA, 2016, J NEUROL PHYS THER, V40, P232, DOI 10.1097/NPT.0000000000000143; Danks KA, 2016, ARCH PHYS MED REHAB, V97, pS185, DOI 10.1016/j.apmr.2016.01.039; Darekar A, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0035-3; de Leon RD, 1998, J NEUROPHYSIOL, V79, P1329; de Leon RD, 1998, J NEUROPHYSIOL, V80, P83; Dean CM, 2010, J PHYSIOTHER, V56, P97, DOI 10.1016/S1836-9553(10)70039-4; Dean CM, 2000, ARCH PHYS MED REHAB, V81, P409, DOI 10.1053/mr.2000.3839; Dean CM, 1997, STROKE, V28, P722, DOI 10.1161/01.STR.28.4.722; Dhamoon MS, 2007, STROKE, V38, P1752, DOI 10.1161/STROKEAHA.106.480988; Dietz V, 2014, BRAIN, V137, P654, DOI 10.1093/brain/awt262; Diong J, 2013, AM J PHYS MED REHAB, V92, P565, DOI 10.1097/PHM.0b013e318274605a; Diong JHL, 2012, MUSCLE NERVE, V46, P237, DOI 10.1002/mus.23356; Dobkin BH, 2009, CURR OPIN NEUROL, V22, P563, DOI 10.1097/WCO.0b013e3283314b11; Druzbicki M, 2015, J REHABIL MED, V47, P419, DOI 10.2340/16501977-1949; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Duncan PW, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-39; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; Duncan PW, 2000, NEUROPHARMACOLOGY, V39, P835, DOI 10.1016/S0028-3908(00)00003-4; Duncan PW, 2011, AM PHYS THER ASS COM; Esquenazi A, 2013, PM&R, V5, P280, DOI 10.1016/j.pmrj.2012.10.009; Everaert DG, 2013, NEUROREHAB NEURAL RE, V27, P579, DOI 10.1177/1545968313481278; Field-Fote EC, 2011, PHYS THER, V91, P48, DOI 10.2522/ptj.20090359; FINCH L, 1991, PHYS THER, V71, P842, DOI 10.1093/ptj/71.11.842; Flansbjer UB, 2008, J REHABIL MED, V40, P42, DOI 10.2340/16501977-0129; Forrester LW, 2016, J NEUROENG REHABIL, V13, DOI 10.1186/s12984-016-0158-1; Freivogel S, 2008, BRAIN INJURY, V22, P625, DOI 10.1080/02699050801941771; Fritz SL, 2013, TOP STROKE REHABIL, V20, P218, DOI 10.1310/tsr2003-218; Gama GL, 2015, AM J PHYS MED REHAB, V94, P718, DOI 10.1097/PHM.0000000000000240; Geidl W, 2018, NEUROL INT, V10, P13, DOI 10.4081/ni.2018.6993; Gil-Gomez JA, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-30; Globas C, 2012, NEUROREHAB NEURAL RE, V26, P85, DOI 10.1177/1545968311418675; Goodman RN, 2014, J REHABIL RES DEV, V51, P213, DOI 10.1682/JRRD.2013.02.0050; Gordon CD, 2013, STROKE, V44, P1179, DOI 10.1161/STROKEAHA.111.000642; Gottschall JS, 2005, J APPL PHYSIOL, V99, P23, DOI 10.1152/japplphysiol.01190.2004; Gottschall JS, 2003, J APPL PHYSIOL, V94, P1766, DOI 10.1152/japplphysiol.00670.2002; Gracies JM, 2017, NEUROLOGY, V89, P2245, DOI 10.1212/WNL.0000000000004687; Gracies JM, 2015, LANCET NEUROL, V14, P992, DOI 10.1016/S1474-4422(15)00216-1; Hafer-Macko CE, 2008, J REHABIL RES DEV, V45, P261, DOI 10.1682/JRRD.2007.02.0040; Hesse S, 2013, NEUROREHABILITATION, V33, P77, DOI 10.3233/NRE-130930; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; Hesse S, 1999, BIOMED TECH, V44, P194, DOI 10.1515/bmte.1999.44.7-8.194; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; Holleran CL, 2018, J NEUROL PHYS THER, V42, P94, DOI 10.1097/NPT.0000000000000217; Holleran CL, 2015, J NEUROL PHYS THER, V39, P95, DOI 10.1097/NPT.0000000000000077; Holleran CL, 2014, NEUROREHAB NEURAL RE, V28, P643, DOI 10.1177/1545968314521001; Holleran CL, 2016, COMMUNITY MOBILITY M; Hornby TG, 2008, STROKE, V39, P1786, DOI 10.1161/STROKEAHA.107.504779; Hornby TG, 2016, NEUROREHAB NEURAL RE, V30, P440, DOI 10.1177/1545968315604396; Hornby TG, 2012, PHYS THER, V92, P1278, DOI 10.2522/ptj.20110310; Hornby TG, 2011, TOP STROKE REHABIL, V18, P293, DOI 10.1310/tsr1804-293; Howlett OA, 2015, ARCH PHYS MED REHAB, V96, P934, DOI 10.1016/j.apmr.2015.01.013; Hui-Chan Christina W Y, 2009, Hong Kong Med J, V15, P42; In T, 2016, MED SCI MONITOR, V22, P4046, DOI 10.12659/MSM.898157; Israel JF, 2006, PHYS THER, V86, P1466, DOI 10.2522/ptj.20050266; Ivey FM, 2015, J STROKE CEREBROVASC, V24, P2539, DOI 10.1016/j.jstrokecerebrovasdis.2015.07.002; Jacobs PL, 2004, SPORTS MED, V34, P727, DOI 10.2165/00007256-200434110-00003; Jaffe DL, 2004, J REHABIL RES DEV, V41, P283, DOI 10.1682/JRRD.2004.03.0283; Jayaraman A, 2013, J NEUROL PHYS THER, V37, P112, DOI 10.1097/NPT.0b013e31828390a1; Jeong YG, 2016, TOP STROKE REHABIL, V23, P406, DOI 10.1080/10749357.2016.1168592; Jin H, 2013, NEUROREHABILITATION, V32, P327, DOI 10.3233/NRE-130852; Jin H, 2012, DISABIL REHABIL, V34, P1665, DOI 10.3109/09638288.2012.658952; Johannsen L, 2010, NEUROREHAB NEURAL RE, V24, P243, DOI 10.1177/1545968309347679; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Kang HK, 2012, CLIN REHABIL, V26, P246, DOI 10.1177/0269215511419383; Kang TW, 2016, J STROKE CEREBROVASC, V25, P848, DOI 10.1016/j.jstrokecerebrovasdis.2015.11.037; Katch VL, 2011, ESSENTIALS EXERCISE; Kendrick D, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009848.pub2; Kilinc M, 2016, TOP STROKE REHABIL, V23, P17, DOI 10.1179/1945511915Y.0000000011; Kim C M, 2001, J Stroke Cerebrovasc Dis, V10, P265, DOI 10.1053/jscd.2001.123775; Kim H, 2015, INT J REHABIL RES, V38, P156, DOI 10.1097/MRR.0000000000000103; Kim JH, 2009, AM J PHYS MED REHAB, V88, P693, DOI 10.1097/PHM.0b013e3181b33350; Kim JH, 2013, NEUROREHABILITATION, V33, P565, DOI 10.3233/NRE-130991; Kim N, 2016, J EXPT STROKE TRANSL, V9, P1, DOI DOI 10.3343/ALM.2016.36.1.67; Kim N, 2015, J PHYS THER SCI, V27, P655, DOI 10.1589/jpts.27.655; Kim Sung-Jin, 2016, J Phys Ther Sci, V28, P2596; Kimberley TJ, 2010, J REHABIL RES DEV, V47, P851, DOI 10.1682/JRRD.2010.02.0019; Kitzman DW, 2010, CIRC-HEART FAIL, V3, P659, DOI 10.1161/CIRCHEARTFAILURE.110.958785; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kluding PM, 2013, STROKE, V44, P1660, DOI 10.1161/STROKEAHA.111.000334; Knarr BA, 2013, MUSCLE NERVE, V48, P971, DOI 10.1002/mus.23835; Krishnan S, 2018, DISABIL REHABIL, V40, P1401, DOI 10.1080/09638288.2017.1297855; Kuys S, 2006, PHYSIOTHER RES INT, V11, P219, DOI 10.1002/pri.344; Labruyere R, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-4; Lam T, 2015, J REHABIL RES DEV, V52, P113, DOI 10.1682/JRRD.2014.03.0090; Lang Catherine E, 2007, J Neurol Phys Ther, V31, P3; Lang CE, 2009, ARCH PHYS MED REHAB, V90, P1692, DOI 10.1016/j.apmr.2009.04.005; Lau RWK, 2012, MED SCI SPORT EXER, V44, P1409, DOI 10.1249/MSS.0b013e31824e4f8c; Laver K, 2013, AUST OCCUP THER J, V60, P93, DOI [10.1111/1440-1630.12018, 10.1111/1440-1630.12087]; Laver K, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-64; Laver K, 2011, J REHABIL MED, V43, P354, DOI 10.2340/16501977-0678; Lee CH, 2014, HONG KONG PHYSIOTHER, V32, P51, DOI 10.1016/j.hkpj.2014.04.002; Lee SSM, 2015, CLIN BIOMECH, V30, P269, DOI 10.1016/j.clinbiomech.2015.01.004; Lee SW, 2013, CLIN REHABIL, V27, P921, DOI 10.1177/0269215513485100; Lee YH, 2015, AM J PHYS MED REHAB, V94, P687, DOI 10.1097/PHM.0000000000000233; Levin MF, 2015, PHYS THER, V95, P415, DOI 10.2522/ptj.20130579; Lewis GN, 2012, DISABIL REHABIL, V34, P1880, DOI 10.3109/09638288.2012.670036; Liao LR, 2016, MED SCI SPORT EXER, V48, P1227, DOI 10.1249/MSS.0000000000000909; Llorens R, 2015, CLIN REHABIL, V29, P261, DOI 10.1177/0269215514543333; Lohse KR, 2018, ARCH PHYS MED REHAB, V99, P1424, DOI 10.1016/j.apmr.2017.12.024; Lucareli PR, 2011, SPINAL CORD, V49, P1001, DOI 10.1038/sc.2011.37; Luft AR, 2008, STROKE, V39, P3341, DOI 10.1161/STROKEAHA.108.527531; Macko R F, 2005, Top Stroke Rehabil, V12, P45; Macko RF, 2005, STROKE, V36, P2206, DOI 10.1161/01.STR.0000181076.91805.89; Madhavan S, 2011, CLIN NEUROPHYSIOL, V122, P1588, DOI 10.1016/j.clinph.2011.01.011; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Mehrholz J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002840.pub3; Mehrholz J, 2013, STROKE, V44, pE127, DOI 10.1161/STROKEAHA.113.003061; Mehrholz J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006676.pub3; Michael KM, 2005, ARCH PHYS MED REHAB, V86, P1552, DOI 10.1016/j.apmr.2004.12.026; Middleton A, 2015, J AGING PHYS ACTIV, V23, P314, DOI 10.1123/japa.2013-0236; Middleton A, 2014, TOP STROKE REHABIL, V21, P462, DOI 10.1310/tsr2106-462; Mirelman A, 2009, STROKE, V40, P169, DOI 10.1161/STROKEAHA.108.516328; Moore JL, 2018, J NEUROL PHYS THER, V42, P174, DOI 10.1097/NPT.0000000000000229; Moore JL, 2010, STROKE, V41, P129, DOI 10.1161/STROKEAHA.109.563247; Moore SA, 2016, ARCH PHYS MED REHAB, V97, P596, DOI 10.1016/j.apmr.2015.12.018; Mudge S, 2009, ARCH PHYS MED REHAB, V90, P1989, DOI 10.1016/j.apmr.2009.07.015; Munari D, 2016, EUR J PHYS REHAB MED, V54, P408; Nadeau S, 1999, CLIN BIOMECH, V14, P125, DOI 10.1016/S0268-0033(98)00062-X; Nadeau S, 2011, PROG BRAIN RES, V192, P161, DOI 10.1016/B978-0-444-53355-5.00011-7; Newham DJ, 2001, DISABIL REHABIL, V23, P379; OLNEY SJ, 1994, PHYS THER, V74, P872, DOI 10.1093/ptj/74.9.872; Ouellette MM, 2004, STROKE, V35, P1404, DOI 10.1161/01.STR.0000127785.73065.34; Pak S, 2008, TOP STROKE REHABIL, V15, P177, DOI 10.1310/tsr1503-177; Pandey A, 2015, CIRC-HEART FAIL, V8, P33, DOI 10.1161/CIRCHEARTFAILURE.114.001615; Pang MYC, 2005, J AM GERIATR SOC, V53, P1667, DOI 10.1111/j.1532-5415.2005.53521.x; Paoloni M, 2010, NEUROREHAB NEURAL RE, V24, P254, DOI 10.1177/1545968309349940; Park HJ, 2011, CLIN REHABIL, V25, P451, DOI 10.1177/0269215510389200; Park IM, 2013, J PHYS THER SCI, V25, P379, DOI 10.1589/jpts.25.379; Park J, 2015, NEUROREHABILITATION, V37, P193, DOI 10.3233/NRE-151252; Park YH, 2013, J EXERC REHABIL, V9, P489, DOI 10.12965/jer.130066; Patten C, 2004, J REHABIL RES DEV, V41, P293, DOI 10.1682/JRRD.2004.03.0293; Patterson SL, 2007, ARCH PHYS MED REHAB, V88, P115, DOI 10.1016/j.apmr.2006.10.025; Peurala SH, 2005, ARCH PHYS MED REHAB, V86, P1557, DOI 10.1016/j.apmr.2005.02.005; Plummer P, 2007, NEUROREHAB NEURAL RE, V21, P137, DOI 10.1177/1545968306295559; Pohl M, 2002, STROKE, V33, P553, DOI 10.1161/hs0202.102365; Pollock A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001920.pub2; Prajapati SK, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/612458; Resnick B, 2008, TOP STROKE REHABIL, V15, P494, DOI 10.1310/tsr1505-494; Ribeiro T, 2013, EUR J PHYS REHAB MED, V49, P451; Roger VL, 2012, CIRCULATION, V125, P188, DOI 10.1161/CIR.0b013e3182456d46; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Rose D, 2011, NEUROREHAB NEURAL RE, V25, P140, DOI 10.1177/1545968310384270; Rycroft-Malone J, 2008, J NURS MANAGE, V16, P404, DOI 10.1111/j.1365-2834.2008.00859.x; Rydwik E, 2006, CLIN REHABIL, V20, P645, DOI 10.1191/0269215506cre986oa; Saraf P, 2010, PHYS THER, V90, P224, DOI 10.2522/ptj.20090064; Schmidt R.A., 1999, MOTOR CONTROL LEARNI, V3rd ed; Scrivener K, 2012, J REHABIL MED, V44, P824, DOI 10.2340/16501977-1028; Severinsen K, 2014, AM J PHYS MED REHAB, V93, P29, DOI 10.1097/PHM.0b013e3182a518e1; Sharp KG, 2014, ARCH PHYS MED REHAB, V95, P615, DOI 10.1016/j.apmr.2013.11.016; Sheikh M, 2016, CLIN REHABIL, V30, P1088, DOI 10.1177/0269215515611467; Shields RK, 2002, J ORTHOP SPORT PHYS, V32, P65, DOI 10.2519/jospt.2002.32.2.65; Shiffman RN, 2012, J AM MED INFORM ASSN, V19, P94, DOI 10.1136/amiajnl-2011-000172; Shumway-Cook A, 2003, J AM GERIATR SOC, V51, P393, DOI 10.1046/j.1532-5415.2003.51114.x; Shumway-Cook A, 2002, PHYS THER, V82, P670, DOI 10.1093/ptj/82.7.670; SNF PPS Payment Model Research, 2019, SNF PPS PAYM MOD RES; Song GB, 2015, J PHYS THER SCI, V27, P2057, DOI 10.1589/jpts.27.2057; Song HS, 2015, J PHYS THER SCI, V27, P187, DOI 10.1589/jpts.27.187; States RA, 2009, J NEUROL PHYS THER, V33, P179, DOI 10.1097/NPT.0b013e3181c29a8c; States RA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006075.pub2; Stein J, 2014, AM J PHYS MED REHAB, V93, P987, DOI 10.1097/PHM.0000000000000119; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Sullivan KJ, 2002, ARCH PHYS MED REHAB, V83, P683, DOI 10.1053/apmr.2002.32488; Suputtitada Areerat, 2004, Journal of the Medical Association of Thailand, V87, pS107; Takao T, 2015, J PHYS THER SCI, V27, P159, DOI 10.1589/jpts.27.159; Tang A, 2016, J REHABIL MED, V48, P841, DOI 10.2340/16501977-2163; Tang A, 2014, INT J STROKE, V9, P883, DOI 10.1111/ijs.12156; Taylor RS, 2004, AM J MED, V116, P682, DOI 10.1016/j.amjmed.2004.01.009; Teixeira-Salmela LF, 1999, ARCH PHYS MED REHAB, V80, P1211, DOI 10.1016/S0003-9993(99)90018-7; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Ucar DE, 2014, NEUROREHABILITATION, V34, P447, DOI 10.3233/NRE-141054; Vahlberg B, 2017, DISABIL REHABIL, V39, P1615, DOI 10.1080/09638288.2016.1206631; van de Port IGL, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-43; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; VISINTIN M, 1989, CAN J NEUROL SCI, V16, P315, DOI 10.1017/S0317167100029152; Werner C, 2002, STROKE, V33, P2895, DOI 10.1161/01.STR.0000035734.61539.f6; WERNIG A, 1995, EUR J NEUROSCI, V7, P823, DOI 10.1111/j.1460-9568.1995.tb00686.x; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Wevers L, 2009, STROKE, V40, P2450, DOI 10.1161/STROKEAHA.108.541946; Winding KM, 2018, DIABETES OBES METAB, V20, P1131, DOI 10.1111/dom.13198; WINSTEIN CJ, 1989, ARCH PHYS MED REHAB, V70, P755; Won SH, 2015, J PHYS THER SCI, V27, P2581, DOI 10.1589/jpts.27.2581; Wu M, 2016, AM J PHYS MED REHAB, V95, P911, DOI 10.1097/PHM.0000000000000517; Wu M, 2014, ARCH PHYS MED REHAB, V95, P799, DOI 10.1016/j.apmr.2013.12.021; Wu M, 2012, ARCH PHYS MED REHAB, V93, P782, DOI 10.1016/j.apmr.2011.12.018; Xu TM, 2018, ARCH PHYS MED REHAB, V99, P563, DOI 10.1016/j.apmr.2017.06.032; Yagura H, 2006, ARCH PHYS MED REHAB, V87, P529, DOI 10.1016/j.apmr.2005.11.035; Yang C. H, 2016, J EXP STROKE TRANSL, V9, P1; Yang JF, 2014, NEUROREHAB NEURAL RE, V28, P314, DOI 10.1177/1545968313508473; Yang YR, 2008, GAIT POSTURE, V28, P201, DOI 10.1016/j.gaitpost.2007.11.007; Yang YR, 2007, GAIT POSTURE, V25, P185, DOI 10.1016/j.gaitpost.2006.03.007; Yang YR, 2006, CLIN REHABIL, V20, P860, DOI 10.1177/0269215506070701; Yavuzer G, 2006, CLIN REHABIL, V20, P960, DOI 10.1177/0269215506070315; Yen CL, 2008, NEUROREHAB NEURAL RE, V22, P22, DOI 10.1177/1545968307301875; Yom C, 2015, J PHYS THER SCI, V27, P845, DOI 10.1589/jpts.27.845; You YY, 2012, J PHYS THER SCI, V24, P571, DOI 10.1589/jpts.24.571; Zbogar D, 2017, SPINAL CORD, V55, P172, DOI 10.1038/sc.2016.129; Zbogar D, 2017, ARCH PHYS MED REHAB, V98, P2449, DOI 10.1016/j.apmr.2017.05.009; Zorner B, 2010, J NEUROTRAUM, V27, P241, DOI 10.1089/neu.2009.0901	249	25	26	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	JAN	2020	44	1					49	100		10.1097/NPT.0000000000000303			52	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	KL0WC	WOS:000513152300008	31834165				2021-06-18	
J	Soleman, J; Lutz, K; Schaedelin, S; Kamenova, M; Guzman, R; Mariani, L; Fandino, J				Soleman, Jehuda; Lutz, Katharina; Schaedelin, Sabine; Kamenova, Maria; Guzman, Raphael; Mariani, Luigi; Fandino, Javier			Subperiosteal vs Subdural Drain After Burr-Hole Drainage of Chronic Subdural Hematoma: A Randomized Clinical Trial (cSDH-Drain-Trial)	NEUROSURGERY			English	Article						Burr-hole drainage; Chronic subdural hematoma; Subdural drain; Subperiosteal drain; Traumatic brain injury	SUBGALEAL; TREPANATION; MANAGEMENT; SYSTEM	BACKGROUND: The use of a subdural drain (SDD) after burr-hole drainage of chronic subdural hematoma (cSDH) reduces recurrence at 6 mo. Subperiosteal drains (SPDs) are considered safer, since they are not positioned in direct contact to cortical structures, bridging veins, or hematoma membranes. OBJECTIVE: To investigate whether the recurrence rate after insertion of a SPD is noninferior to the insertion of a more commonly used SDD. METHODS: Multicenter, prospective, randomized, controlled, noninferiority trial analyzing patients undergoing burr-hole drainage for cSDH aged 18 yr and older. After hematoma evacuation, patients were randomly assigned to receive either a SDD (SDD-group) or a SPD (SPD-group). The primary endpoint was recurrence indicating a reoperation within 12 mo, with a noninferiority margin of 3.5%. Secondary outcomes included clinical and radiological outcome, morbidity and mortality rates, and length of stay. RESULTS: Of 220 randomized patients, all were included in the final analysis (120 SPD and 100 SDD). Recurrence rate was lower in the SPD group (8.33%, 95% confidence interval [CI] 4.28-14.72) than in the SDD group (12.00%, 95% CI 6.66-19.73), with the treatment difference (3.67%, 95% CI -12.6-5.3) not meeting predefined noninferiority criteria. The SPD group showed significantly lower rates of surgical infections (P=.0406) and iatrogenic morbidity through drain placement (P=.0184). Length of stay and mortality rates were comparable in both groups. CONCLUSION: Although the noninferiority criteria were not met, SPD insertion led to lower recurrence rates, fewer surgical infections, and lower drain misplacement rates. These findings suggest that SPD may be warranted in routine clinical practice	[Soleman, Jehuda; Lutz, Katharina; Fandino, Javier] Kantonsspital Aarau, Dept Neurosurg, Aarau, Switzerland; [Soleman, Jehuda; Kamenova, Maria; Guzman, Raphael; Mariani, Luigi] Univ Hosp Basel, Dept Neurosurg, Spitalstr 21, CH-4031 Basel, Switzerland; [Schaedelin, Sabine] Univ Hosp Basel, Clin Trial Unit, Basel, Switzerland	Soleman, J (corresponding author), Univ Hosp Basel, Dept Neurosurg, Spitalstr 21, CH-4031 Basel, Switzerland.	jehuda.soleman@gmail.com	Soleman, Jehuda/D-8083-2017	Soleman, Jehuda/0000-0003-1900-9286; Guzman, Raphael/0000-0001-9620-0581	Research Foundation Kantonsspital Aarau	Funded by the Research Foundation Kantonsspital Aarau. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Abouzari M, 2007, NEUROSURGERY, V61, P794, DOI 10.1227/01.NEU.0000298908.94129.67; Agency EM, 1998, ICH TOP E 9 STAT PRI; Almenawer SA, 2014, ANN SURG, V259, P449, DOI 10.1097/SLA.0000000000000255; Baechli H, 2004, NEUROSURG REV, V27, P263, DOI 10.1007/s10143-004-0337-6; Bellut D, 2012, WORLD NEUROSURG, V77, P111, DOI 10.1016/j.wneu.2011.05.036; Chih ANW, 2017, MALAYS J MED SCI, V24, P21, DOI 10.21315/mjms2017.24.1.3; Gazzeri R, 2007, ACTA NEUROCHIR, V149, P487, DOI 10.1007/s00701-007-1139-8; Ishfaq A, 2017, JCPSP-J COLL PHYSICI, V27, P419, DOI 2656; Kaliaperumal C, 2012, ACTA NEUROCHIR, V154, P2083, DOI 10.1007/s00701-012-1483-1; MARKWALDER TM, 1981, J NEUROSURG, V55, P390, DOI 10.3171/jns.1981.55.3.0390; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Oral S, 2015, NORTH CLIN ISTANB, V2, P115, DOI 10.14744/nci.2015.06977; Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802; Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6; Sjavik K, 2020, J NEUROSURG, V133, P1113, DOI 10.3171/2016.12.JNS161713; Soleman J, 2014, TRAUMATIC BRAIN INJU, DOI [10.5772/57336, DOI 10.5772/57336]; Soleman J, 2017, SWISS MED WKLY, V147, DOI 10.4414/smw.2017.14398; Soleman J, 2017, WORLD NEUROSURG, V104, P528, DOI 10.1016/j.wneu.2017.04.134; Soleman J, 2016, JMIR RES PROTOC, V5, DOI 10.2196/resprot.5339; Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937; Yadav Yad Ram, 2016, Asian J Neurosurg, V11, P214, DOI 10.4103/1793-5482.145096; Zumofen D, 2009, NEUROSURGERY, V64, P1116, DOI 10.1227/01.NEU.0000345633.45961.BB	22	25	26	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	2019	85	5					E825	E833		10.1093/neuros/nyz095			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	JI6HX	WOS:000493569500008	31194877				2021-06-18	
J	Beqiri, E; Smielewski, P; Robba, C; Czosnyka, M; Cabeleira, MT; Tas, J; Donnelly, J; Outtrim, JG; Hutchinson, P; Menon, D; Meyfroidt, G; Depreitere, B; Aries, MJ; Ercole, A				Beqiri, Erta; Smielewski, Peter; Robba, Chiara; Czosnyka, Marek; Cabeleira, Manuel Teixeira; Tas, Jeanette; Donnelly, Joseph; Outtrim, Joanne G.; Hutchinson, Peter; Menon, David; Meyfroidt, Geert; Depreitere, Bart; Aries, Marcel J.; Ercole, Ari			Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure: the COGiTATE phase II study protocol	BMJ OPEN			English	Article						autoregulation; Optimal CPP; COGiTATE; precision medicine; individualised TBI management; intensive care	AUTOREGULATION; REACTIVITY; BEDSIDE; CARE	Introduction Individualising therapy is an important challenge for intensive care of patients with severe traumatic brain injury (TBI). Targeting a cerebral perfusion pressure (CPP) tailored to optimise cerebrovascular autoregulation has been suggested as an attractive strategy on the basis of a large body of retrospective observational data. The objective of this study is to prospectively assess the feasibility and safety of such a strategy compared with fixed thresholds which is the current standard of care from international consensus guidelines. Methods and analysis CPPOpt Guided Therapy: Assessment of Target Effectiveness (COGiTATE) is a prospective, multicentre, non-blinded randomised, controlled trial coordinated from Maastricht University Medical Center, Maastricht (The Netherlands). The other original participating centres are Cambridge University NHS Foundation Trust, Cambridge (UK), and University Hospitals Leuven, Leuven (Belgium). Adult severe TBI patients requiring intracranial pressure monitoring are randomised within the first 24 hours of admission in neurocritical care unit. For the control arm, the CPP target is the Brain Trauma Foundation guidelines target (60-70 mm Hg); for the intervention group an automated CPP target is provided as the CPP at which the patient's cerebrovascular reactivity is best preserved (CPPopt). For a maximum of 5 days, attending clinicians review the CPP target 4-hourly. The main hypothesis of COGiTATE are: (1) in the intervention group the percentage of the monitored time with measured CPP within a range of 5 mm Hg above or below CPPopt will reach 36%; (2) the difference in between groups in daily therapy intensity level score will be lower or equal to 3. Ethics and dissemination Ethical approval has been obtained for each participating centre. The results will be presented at international scientific conferences and in peer-reviewed journals.	[Beqiri, Erta; Smielewski, Peter; Czosnyka, Marek; Cabeleira, Manuel Teixeira; Donnelly, Joseph; Hutchinson, Peter] Univ Cambridge, Clin Neurosci, Cambridge, England; [Beqiri, Erta] Univ Milan, Physiol & Transplantat, Milan, Italy; [Robba, Chiara] Univ Genoa, Anaesthesia & Intens Care, Policlin San Martino, IRCCS Oncol & Neurosci, Genoa, Italy; [Tas, Jeanette; Aries, Marcel J.] Maastricht Univ, Med Ctr, Intens Care, Maastricht, Netherlands; [Outtrim, Joanne G.; Menon, David; Ercole, Ari] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Meyfroidt, Geert; Depreitere, Bart] Univ Ziekenhuizen Leuven, Intens Geneeskunde, Leuven, Belgium	Beqiri, E (corresponding author), Univ Cambridge, Clin Neurosci, Cambridge, England.; Beqiri, E (corresponding author), Univ Milan, Physiol & Transplantat, Milan, Italy.	erta.beqiri@gmail.com	Depreitere, Bart/AAA-9846-2020; Ercole, Ari/B-6288-2009; Robba, Chiara/AAS-7421-2020	Depreitere, Bart/0000-0002-7458-0648; Ercole, Ari/0000-0001-8350-8093; beqiri, erta/0000-0002-8108-0000	European Society of Intensive Care Medicine small investigator award	This study was supported by European Society of Intensive Care Medicine small investigator award (N/A: awarded to MJA).	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Dias C, 2015, NEUROCRIT CARE, V23, P92, DOI 10.1007/s12028-014-0103-8; Donnelly J, 2015, EXPERT REV NEUROTHER, V15, P169, DOI 10.1586/14737175.2015.996552; Ercole A, 2018, ACTA NEUROCHIR SUPPL, V126, P55, DOI 10.1007/978-3-319-65798-1_12; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Kelly S, 2018, ACTA NEUROCHIR SUPPL, V126, P317, DOI 10.1007/978-3-319-65798-1_62; Liu XY, 2017, J NEUROTRAUM, V34, P3081, DOI 10.1089/neu.2017.5003; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Menon DK, 2017, HAND CLINIC, V140, P239, DOI 10.1016/B978-0-444-63600-3.00014-3; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; R Core Team, 2013, R LANG ENV STAT COMP; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 2017, LANCET NEUROL, V16, P452, DOI 10.1016/S1474-4422(17)30118-7; Zuercher P, 2016, J NEUROTRAUM, V33, P1768, DOI 10.1089/neu.2015.4266; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	19	25	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open	SEP	2019	9	9							e030727	10.1136/bmjopen-2019-030727			7	Medicine, General & Internal	General & Internal Medicine	JO7XE	WOS:000497787600311	31542757	DOAJ Gold, Green Published			2021-06-18	
J	Beaudouin, F; der Funten, KA; Tross, T; Reinsberger, C; Meyer, T				Beaudouin, Florian; der Fuenten, Karen Aus; Troess, Tobias; Reinsberger, Claus; Meyer, Tim			Head injuries in professional male football (soccer) over 13 years: 29% lower incidence rates after a rule change (red card)	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							UEFA CHAMPIONS LEAGUE; ELITE FOOTBALL; CONSENSUS STATEMENT; MUSCLE INJURIES; CONCUSSION; MECHANISMS; PLAYERS; PATTERNS; SPORT	Background Absolute numbers of head injuries in football (soccer) are considerable because of its high popularity and the large number of players. In 2006 a rule was changed to reduce head injuries. Players were given a red card (sent off) for intentional elbow-head contact. Aims To describe the head injury mechanism and examine the effect of the rule change. Methods Based on continuously recorded data from the German football magazine "kicker", a database of all head injuries in the 1st German Male Bundesliga was generated comprising seasons 2000/01-2012/13. Injury mechanisms were analysed from video recordings. Injury incidence rates (IR) and 95% confidence intervals (95% CI) as well as incidence rate ratios (IRR) to assess differences before and after the rule change were calculated. Results 356 head injuries were recorded (IR 2.22, 95% CI 2.00 to 2.46 per 1000 match hours). Contact with another player caused most head injuries, more specifically because of head-head (34%) or elbow-head (17%) contacts. After the rule change, head injuries were reduced by 29% (IRR 0.71, 95% CI 0.57 to 0.86, p=0.002). Lacerations/abrasions declined by 42% (95% CI 0.39 to 0.85), concussions by 29% (95% CI 0.46 to 1.09), contusions by 18% (95% CI 0.43 to 1.55) and facial fractures by 16% (95% CI 0.55 to 1.28). Conclusions This rule change appeared to reduce the risk of head injuries in men's professional football.	[Beaudouin, Florian; der Fuenten, Karen Aus; Troess, Tobias; Meyer, Tim] Saarland Univ, FIFA Med Ctr Excellence, Inst Sports & Prevent Med, Saarbrucken, Germany; [Reinsberger, Claus] Univ Paderborn, Inst Sports Med, Paderborn, Germany	Beaudouin, F (corresponding author), Saarland Univ, Inst Sports & Prevent Med, Bldg B 8-2, D-66123 Saarbrucken, Germany.	florian.beaudouin@uni-saarland.de			German Federal Institute of Sports Science	This study was funded by the German Federal Institute of Sports Science.	Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Bjorneboe J, 2013, BRIT J SPORT MED, V47, P508, DOI 10.1136/bjsports-2012-091522; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Camargo AV, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.01729; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Ekstrand J, 2011, BRIT J SPORT MED, V45, P553, DOI 10.1136/bjsm.2009.060582; Ekstrand J, 2013, BRIT J SPORT MED, V47, P732, DOI 10.1136/bjsports-2013-092394; Ekstrand J, 2011, AM J SPORT MED, V39, P1226, DOI 10.1177/0363546510395879; Funten KAD, 2014, J ATHL TRAINING, V49, P786, DOI 10.4085/1062-6050-49.3.51; Fuller CW, 2004, AM J SPORT MED, V32, p43S, DOI 10.1177/0363546503261248; Fuller CW, 2007, BRIT J SPORT MED, V41, pI20, DOI 10.1136/bjsm.2007.037267; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Hagglund M, 2006, BRIT J SPORT MED, V40, P767, DOI 10.1136/bjsm.2006.026609; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Junge A, 2013, BRIT J SPORT MED, V47, P782, DOI 10.1136/bjsports-2013-092205; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Leventer L, 2016, INT J SPORTS MED, V37, P898, DOI 10.1055/s-0042-108201; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Niedfeldt MW, 2011, CURR SPORT MED REP, V10, P324, DOI 10.1249/JSR.0b013e318237be53; Nilsson M, 2013, CLIN J SPORT MED, V23, P255, DOI 10.1097/JSM.0b013e31827ee6f8; Pappachan B, 2006, J ORAL MAXIL SURG, V64, P1023, DOI 10.1016/j.joms.2006.03.021; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Tscholl P, 2007, BRIT J SPORT MED, V41, pI8, DOI 10.1136/bjsm.2007.036871; Tscholl P, 2007, BRIT J SPORT MED, V41, pI15, DOI 10.1136/bjsm.2007.036889; Walden M, 2005, BRIT J SPORT MED, V39, P542, DOI 10.1136/bjsm.2004.014571; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182	32	25	25	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2019	53	15					948	+		10.1136/bjsports-2016-097217			6	Sport Sciences	Sport Sciences	IM3ME	WOS:000477896500007	28646098				2021-06-18	
J	Rehman, SU; Ikram, M; Ullah, N; Alam, SI; Park, HY; Badshah, H; Choe, K; Kim, MO				Rehman, Shafiq Ur; Ikram, Muhammad; Ullah, Najeeb; Alam, Sayed Ibrar; Park, Hyun Young; Badshah, Haroon; Choe, Kyonghwan; Kim, Myeong Ok			Neurological Enhancement Effects of Melatonin against Brain Injury-Induced Oxidative Stress, Neuroinflammation, and Neurodegeneration via AMPK/CREB Signaling	CELLS			English	Article						rmTBI melatonin; AMPK; CREB; neurodegeneration; amyloid beta; synaptic dysfunction	AMYLOID PRECURSOR PROTEIN; TRANSCRIPTIONAL REGULATION; AMPK ACTIVATION; KINASE; APOPTOSIS; PATHWAY; BETA; DEGENERATION; MECHANISMS; INHIBITION	Oxidative stress and energy imbalance strongly correlate in neurodegenerative diseases. Repeated concussion is becoming a serious public health issue with uncontrollable adverse effects in the human population, which involve cognitive dysfunction and even permanent disability. Here, we demonstrate that traumatic brain injury (TBI) evokes oxidative stress, disrupts brain energy homeostasis, and boosts neuroinflammation, which further contributes to neuronal degeneration and cognitive dysfunction in the mouse brain. We also demonstrate that melatonin (an anti-oxidant agent) treatment exerts neuroprotective effects, while overcoming oxidative stress and energy depletion and reducing neuroinflammation and neurodegeneration. Male C57BL/6N mice were used as a model for repetitive mild traumatic brain injury (rmTBI) and were treated with melatonin. Protein expressions were examined via Western blot analysis, immunofluorescence, and ELISA; meanwhile, behavior analysis was performed through a Morris water maze test, and Y-maze and beam-walking tests. We found elevated oxidative stress, depressed phospho-5'AMP-activated protein kinase (p-AMPK) and phospho- CAMP-response element-binding (p-CREB) levels, and elevated p-NF-kappa B in rmTBI mouse brains, while melatonin treatment significantly regulated p-AMPK, p-CREB, and p-NF-kappa B in the rmTBI mouse brain. Furthermore, rmTBI mouse brains showed a deregulated mitochondrial system, abnormal amyloidogenic pathway activation, and cognitive functions which were significantly regulated by melatonin treatment in the mice. These findings provide evidence, for the first time, that rmTBI induces brain energy imbalance and reduces neuronal cell survival, and that melatonin treatment overcomes energy depletion and protects against brain damage via the regulation of p-AMPK/p-CREB signaling pathways in the mouse brain.	[Rehman, Shafiq Ur; Ikram, Muhammad; Ullah, Najeeb; Alam, Sayed Ibrar; Badshah, Haroon; Kim, Myeong Ok] Gyeongsang Natl Univ, Coll Nat Sci, Div Life Sci & Appl Life Sci BK 21plus, Jinju 52828, South Korea; [Ullah, Najeeb] Khyber Med Univ, Inst Basic Med Sci, Peshawar 25100, Khyber Pakhtunk, Pakistan; [Park, Hyun Young; Choe, Kyonghwan] Maastricht Univ, Med Ctr, Sch Mental Hlth & Neurosci, Alzheimer Ctr Limburg, NL-6229 ER Maastricht, Netherlands	Kim, MO (corresponding author), Gyeongsang Natl Univ, Coll Nat Sci, Div Life Sci & Appl Life Sci BK 21plus, Jinju 52828, South Korea.	mokim@gnu.ac.kr	Ikram, Muhammad/Z-5563-2019	Ikram, Muhammad/0000-0001-5226-4081	Brain Research Program through the National Research Foundation (NRF) of Korea - Ministry of Science, ICT [2016M3C7A1904391]	This research work was supported by the Brain Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Science, ICT (2016M3C7A1904391).	Ahmad A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060850; Ahmad A, 2019, METABOLISM, V90, P31, DOI 10.1016/j.metabol.2018.10.004; Alam SI, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020271; Ali T, 2018, MOL NEUROBIOL, V55, P6076, DOI 10.1007/s12035-017-0798-6; Ali T, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1157-x; Ali T, 2017, MOL NEUROBIOL, V54, P6490, DOI 10.1007/s12035-016-0136-4; Ali T, 2015, J PINEAL RES, V59, P47, DOI 10.1111/jpi.12238; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Badshah H, 2016, J NEUROIMMUNE PHARM, V11, P48, DOI 10.1007/s11481-015-9623-z; Bonnefont-Rousselot D, 2010, TOXICOLOGY, V278, P55, DOI 10.1016/j.tox.2010.04.008; Borriello M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050385; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Cai ZY, 2012, J ALZHEIMERS DIS, V29, P89, DOI 10.3233/JAD-2012-111649; Calvo JR, 2013, J PINEAL RES, V55, P103, DOI 10.1111/jpi.12075; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cenini G., 2019, OXIDATIVE MED CELL L, V2019; Ceolotto G, 2007, ARTERIOSCL THROM VAS, V27, P2627, DOI 10.1161/ATVBAHA.107.155762; Chang JC, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060564; Chen D, 2012, ACTA NEUROCHIR, V154, P1469, DOI 10.1007/s00701-012-1328-y; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Domise M, 2016, EXPERIENTIA SUPPL, V107, P153, DOI 10.1007/978-3-319-43589-3_7; Fiorelli S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040356; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2018, NEUROLOGY, V90, pE1771, DOI 10.1212/WNL.0000000000005522; Ghosh M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0463-9; Hill JL, 2016, J NEUROCHEM, V139, P106, DOI 10.1111/jnc.13726; Hong Y, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020135; Ikram M., 2019, MOL NEUROBIOL; Ikram M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051082; Jo M. G., 2018, MOL NEUROBIOL, P1; Ju TC, 2014, BBA-MOL BASIS DIS, V1842, P1668, DOI 10.1016/j.bbadis.2014.06.012; Kerr NA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010069; Khan A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050680; Khan A, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01383; Kho AR, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050405; Kim JE, 2008, J PHARMACOL SCI, V106, P394, DOI 10.1254/jphs.FP0071857; Kim MJ, 2017, NANOMED-NANOTECHNOL, V13, P2533, DOI 10.1016/j.nano.2017.06.022; Kitagawa K, 2007, FEBS J, V274, P3210, DOI 10.1111/j.1742-4658.2007.05890.x; Lahiri DK, 1999, J PINEAL RES, V26, P137, DOI 10.1111/j.1600-079X.1999.tb00575.x; Li CW, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00614; Lin Y. W., 2018, INT J MOL MED; Liou CJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050447; Liu XZ, 2013, J PINEAL RES, V55, P14, DOI 10.1111/jpi.12045; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McGuire J. L., 2018, MOL PSYCHIAT; Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634; Merlo L, 2014, J NEUROTRAUM, V31, P1375, DOI 10.1089/neu.2014.3385; Muhammad T, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030648; Nguyen TLA, 2007, J BIOL CHEM, V282, P20854, DOI 10.1074/jbc.M703060200; Ogeturk M, 2008, TOXICOL IND HEALTH, V24, P201, DOI 10.1177/0748233708093725; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ou ZR, 2018, BRAIN BEHAV IMMUN, V69, P351, DOI 10.1016/j.bbi.2017.12.009; Park JJ, 2019, ACS APPL POLYM MATER, V1, P27, DOI 10.1021/acsapm.8b00019; Peixoto CA, 2017, EXP NEUROL, V298, P31, DOI 10.1016/j.expneurol.2017.08.013; Qin LM, 2016, J NEUROCHEM, V136, P918, DOI 10.1111/jnc.13497; Rehman SU, 2018, IEEE I C ELECT CIRC, P45; Rehman SU, 2018, CEREB CORTEX, V28, P2854, DOI 10.1093/cercor/bhx164; Saito M., 2019, INT J DEV NEUROSCI; Singleton Q, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010063; Subedi L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020194; Thanan R, 2015, INT J MOL SCI, V16, P193, DOI 10.3390/ijms16010193; Thomson DM, 2008, J APPL PHYSIOL, V104, P429, DOI 10.1152/japplphysiol.00900.2007; Toyoda T, 2004, AM J PHYSIOL-ENDOC M, V287, pE166, DOI 10.1152/ajpendo.00487.2003; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu HJ, 2017, CELL MOL NEUROBIOL, V37, P1173, DOI 10.1007/s10571-017-0461-9; Xu J, 2017, ONCOTARGET, V8, P112477, DOI 10.18632/oncotarget.22055; Yamada KH, 2012, J BIOL CHEM, V287, P13182, DOI 10.1074/jbc.M111.302612; Yan P, 2019, INT J NEUROPSYCHOPH, V22, P303, DOI 10.1093/ijnp/pyz001; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Zeke A, 2016, MICROBIOL MOL BIOL R, V80, P793, DOI 10.1128/MMBR.00043-14; ZHOU P, 2019, CELLS-BASEL, V8, DOI DOI 10.3390/cells8030213; Zihl J, 2015, J CLIN MED, V4, P1051, DOI 10.3390/jcm4051051	73	25	26	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2073-4409		CELLS-BASEL	Cells	JUL	2019	8	7							760	10.3390/cells8070760			23	Cell Biology	Cell Biology	IN8AC	WOS:000478902000025	31330909	DOAJ Gold, Green Published			2021-06-18	
J	Alverson, WA; O'Rourke, JJF; Soble, JR				Alverson, W. Alex; O'Rourke, Justin J. F.; Soble, Jason R.			The Word Memory Test genuine memory impairment profile discriminates genuine memory impairment from invalid performance in a mixed clinical sample with cognitive impairment	CLINICAL NEUROPSYCHOLOGIST			English	Article						Performance validity; cognitive impairment; neuropsychological assessment; psychometrics; Word Memory Test (WMT)	SYMPTOM VALIDITY TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; RELIABLE DIGIT SPAN; DEMENTIA PROFILE; HIGH SPECIFICITY; TRIAL 1; SENSITIVITY; ACCURACY; SCORES	Objective: The Word Memory Test (WMT) is a memory-based performance validity test (PVT) with adjusted interpretive criteria (Genuine Memory Impairment Profile; GMIP) proposed for those with cognitive impairment (CI). The GMIP has been criticized for poor discriminability; thus, this study sought to validate the GMIP in a mixed clinical sample. Analyses aimed to demonstrate enhanced detection of invalid neuropsychological test performance while minimizing false positives in a sample including patients with mild CI. Method: Data included 116 Veterans who completed the WMT and four criterion PVTs during clinical evaluation. This sample was 37.1% valid-CI, 33.6% valid-unimpaired, and 29.3% invalid per criterion PVTs. Group differences in WMT performance and diagnostic accuracy were assessed. Results: WMT performance significantly differed between validity groups (Wilk's Lambda = .40, F[6, 109] = 27.62, p < .001, eta(2)(p) = .60) with invalid participants scoring significantly lower across all WMT indices, with larger effect sizes for the effort subtests (eta(2)(p) = .44-.55) than memory subtests (eta(2)(p) = .16-.32). CI also had a significant effect on WMT performance (Wilk's Lambda = .65, F[6, 75] = 6.66, p < .001, eta(2)(p) = .35). Those with CI scored lower across all indices, with larger effect sizes for the memory subtests (eta(2)(p) = .29-.30) relative to effort subtests (eta(2)(p) = .18-.20). Standard WMT pass/fail criteria were sensitive (.97), but had unacceptable specificity (. 66). GMIP sensitivity (.94) and specificity (.91) were robust with a DOR of 171.43. Conclusions: WMT indices were more significantly affected by performance validity than memory. However, with CI, GMIP criteria is essential to improve diagnostic accuracy and reduce false positive errors when identifying invalid performance.	[Alverson, W. Alex; O'Rourke, Justin J. F.; Soble, Jason R.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA; [Soble, Jason R.] Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL USA; [Soble, Jason R.] Univ Illinois, Coll Med, Dept Neurol, Chicago, IL USA	Alverson, WA (corresponding author), South Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	William.Alverson@VA.gov					Allen MD, 2007, BRAIN INJURY, V21, P1425, DOI 10.1080/02699050701769819; Allen MD, 2011, PSYCHOL INJ LAW, V4, P140, DOI 10.1007/s12207-011-9105-4; Arnett P., 2013, SECONDARY INFLUENCES; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Bain K. M., ASSESSMENT, DOI [10.1177/107319111772517, DOI 10.1177/107319111772517]; Barhon LI, 2015, APPL NEUROPSYCH-ADUL, V22, P114, DOI 10.1080/23279095.2013.863775; Boone K., 2002, DOT COUNTING TEST; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; DSM-V American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; Eichstaedt KE, 2014, CLIN NEUROPSYCHOL, V28, P941, DOI 10.1080/13854046.2014.942374; Fazio RL, 2015, ARCH CLIN NEUROPSYCH, V30, P293, DOI 10.1093/arclin/acv024; Fischer JE, 2003, INTENS CARE MED, V29, P1043, DOI 10.1007/s00134-003-1761-8; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Gervais R.O., 2001, J FORENSIC NEUROPSYC, V2, DOI [DOI 10.1300/J151V02N02_01, https://doi.org/10.1300/J151v02n02_01]; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P., 2005, WORD MEMORY TEST WIN; Green P., 2004, MED SYMPTOM VALIDITY; Green P, 2003, WORD MEMORY TEST WIN; Green P., 1996, WORD MEMORY TEST USE; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Howe L, 2009, CLIN NEUROPSYCHOL, V23, P329, DOI 10.1080/13854040801945060; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Pearson NCS., 2009, ADV CLIN SOLUTIONS W; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rienstra A, 2013, ARCH CLIN NEUROPSYCH, V28, P463, DOI 10.1093/arclin/act026; Robinson JS, 2018, ARCH CLIN NEUROPSYCH, V33, P238, DOI 10.1093/arclin/acx069; Schroeder RW, 2019, CLIN NEUROPSYCHOL, V33, P466, DOI 10.1080/13854046.2018.1484517; Singhal A, 2009, ARCH CLIN NEUROPSYCH, V24, P721, DOI 10.1093/arclin/acp074; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tombaugh TN, 1996, TEST MEMORY MALINGER; Webber TA, 2018, CLIN NEUROPSYCHOL, V32, P657, DOI 10.1080/13854046.2017.1415374; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083	48	25	25	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 17	2019	33	8			SI		1420	1435		10.1080/13854046.2019.1599071		APR 2019	16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	JH1IM	WOS:000465948000001	31002017				2021-06-18	
J	Lee, SW; Vaccari, JPD; Truettner, JS; Dietrich, WD; Keane, RW				Lee, Stephanie W.; Vaccari, Juan Pablo de Rivero; Truettner, Jessie S.; Dietrich, W. Dalton; Keane, Robert W.			The role of microglial inflammasome activation in pyroptotic cell death following penetrating traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Inflammasome; ASC; Pyroptosis; Microglia; Infiltrating leukocytes; Traumatic brain injury; Penetrating traumatic brain injury; PTBI; Penetrating ballistic-brain injury; PBBI	CIVILIAN GUNSHOT WOUNDS; GASDERMIN D; RAT MODEL; UNITED-STATES; ASC; NEUROINFLAMMATION; HEAD; NEUROPROTECTION; INHIBITION; PREDICTORS	BackgroundTraumatic brain injury remains a significant cause of death and disability in the USA. Currently, there are no effective therapies to mitigate disability except for surgical interventions necessitating a need for continued research into uncovering novel therapeutic targets. In a recent study, we used a rodent model of penetrating traumatic brain injury known as penetrating ballistic-like brain injury (PBBI) to examine the role of innate immunity in post-traumatic secondary injury mechanisms. We previously reported that the inflammasome, a multiprotein complex composed of apoptosis-associated speck-like protein containing card and caspase-1, plays a role in secondary cell death mechanisms after PBBI, including inflammatory cell death (pyroptosis).MethodsIn the current study, we used flow cytometry analysis to evaluate activated microglia and CD11b-positive leukocytes after PBBI and assessed inflammasome activation and pyroptosis of specific cellular populations. Sprague-Dawley male rats underwent PBBI or sham-operated procedures and ipsilateral cortical regions processed for flow cytometry and cellular analysis. Flow cytometry results were compared using one-way ANOVA followed by Tukey's multiple comparisons.ResultsAt 48h following PBBI, there was an increase in activated microglia and infiltrating leukocytes compared to sham controls that were associated with increased caspase-1 activity. Using a florescent probe to identify caspase-1 activity and a fluorescent assay to determine cell viability, evidence for pyroptosis in CD11b+ cells was also determined. Finally, while post-traumatic treatment with an anti-ASC antibody had no effect on the number of activated microglia and infiltrating leukocytes, antibody treatment decreased caspase-1 activity in both resident microglia and infiltrating leukocytes and reduced pyroptotic CD11b+ cell death.ConclusionsThese results provide evidence for inflammasome activation in microglia and infiltrating leukocytes after penetrating traumatic brain injury and a role for pyroptotic cell death in the pathophysiology. In addition to inhibiting neuronal cell death, therapeutic treatments targeting inflammasome activation may also provide beneficial effects by reducing the potentially detrimental consequences of activated microglia and infiltrating CD11b+ leukocytes following penetrating traumatic brain injury.	[Lee, Stephanie W.; Vaccari, Juan Pablo de Rivero; Truettner, Jessie S.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA	Keane, RW (corresponding author), Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA.	swlee@med.miami.edu; rkeane@miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS089443, RO1 NS042133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089443, R01NS042133] Funding Source: NIH RePORTER	This work was supported by NIH awards RO1 NS089443 and RO1 NS042133.	Aarabi B, 2014, J NEUROSURG, V120, P1138, DOI 10.3171/2014.1.JNS131869; Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Bakir A, 2005, NEUROL MED-CHIR, V45, P281, DOI 10.2176/nmc.45.281; Beaman V, 2000, ANN EMERG MED, V35, P258, DOI 10.1016/S0196-0644(00)70077-1; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Broderick L, 2015, ANNU REV PATHOL-MECH, V10, P395, DOI 10.1146/annurev-pathol-012414-040431; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Cartagena CM, 2013, NEUROMOL MED, V15, P504, DOI 10.1007/s12017-013-8236-z; Cartagena CM, 2013, J MOL NEUROSCI, V49, P301, DOI 10.1007/s12031-012-9828-z; Cernak I, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00209; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Defense and Veterans Brain Injury Center, 2018, DOD WORLDW NUMB TRAU; Deng-Bryant Y, 2015, RESTOR NEUROL NEUROS, V33, P189, DOI 10.3233/RNN-140455; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Du LL, 2017, MOL NEUROBIOL, V54, P1992, DOI 10.1007/s12035-016-9758-9; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; FORD AL, 1995, J IMMUNOL, V154, P4309; Franklin BS, 2014, NAT IMMUNOL, V15, P727, DOI 10.1038/ni.2913; Gajavelli S, 2015, J CEREBR BLOOD F MET, V35, P773, DOI 10.1038/jcbfm.2014.243; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gressot LV, 2014, J NEUROSURG, V121, P645, DOI 10.3171/2014.5.JNS131872; Greter M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00249; Hanisch UK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00065; He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139; Hellwig S, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00071; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Jha MK, 2016, BIOCHEM PHARMACOL, V103, P1, DOI 10.1016/j.bcp.2015.11.003; Ji KA, 2007, GLIA, V55, P1577, DOI 10.1002/glia.20571; Joseph B, 2014, J AM COLL SURGEONS, V218, P58, DOI 10.1016/j.jamcollsurg.2013.08.018; Kabba J. A., 2017, CELL MOL NEUROBIOL, P1; Kerr NA, 2018, J NEUROTRAUM, V35, P2067, DOI 10.1089/neu.2017.5430; Kim JY, 2015, ONCOTARGET, V6, P44161, DOI 10.18632/oncotarget.6592; Lee SW, 2018, J NEUROTRAUM, V35, P1681, DOI 10.1089/neu.2017.5530; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Liu YG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.460; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu A, 2014, CELL, V156, P1193, DOI 10.1016/j.cell.2014.02.008; Lu XCM, 2016, THER HYPOTHERMIA TEM, V6, P30, DOI 10.1089/ther.2015.0017; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Oehmichen M, 2000, J NEUROTRAUM, V17, P155, DOI 10.1089/neu.2000.17.155; Oehmichen M, 2001, FORENSIC SCI INT, V115, P189, DOI 10.1016/S0379-0738(00)00335-2; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; Perfetto SP, 2006, J IMMUNOL METHODS, V313, P199, DOI 10.1016/j.jim.2006.04.007; Qiu Z, 2017, OXID MED CELL LONGEV, V2017; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Rathkey JK, 2017, J BIOL CHEM, V292, P14649, DOI 10.1074/jbc.M117.797217; Sarkar S, 2017, NPJ PARKINSON DIS, V3, DOI 10.1038/s41531-017-0032-2; Shi FS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-73; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Taabazuing CY, 2017, CELL CHEM BIOL, V24, P507, DOI 10.1016/j.chembiol.2017.03.009; Tan MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.348; Torres-Platas SG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-12; Truettner JS, 2018, J NEUROTRAUM, V35, P940, DOI 10.1089/neu.2017.5303; Truettner JS, 2017, J CEREBR BLOOD F MET, V37, P2952, DOI 10.1177/0271678X16680003; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2; Venegas C, 2017, NATURE, V552, P355, DOI 10.1038/nature25158; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yao CP, 2008, BRAIN INJURY, V22, P723, DOI 10.1080/02699050802304706	77	25	28	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	FEB 8	2019	16								27	10.1186/s12974-019-1423-6			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	HK7EK	WOS:000458150700002	30736791	DOAJ Gold, Green Published			2021-06-18	
J	Abdullah, A; Zhang, M; Frugier, T; Bedoui, S; Taylor, JM; Crack, PJ				Abdullah, Amar; Zhang, Moses; Frugier, Tony; Bedoui, Sammy; Taylor, Juliet M.; Crack, Peter J.			STING-mediated type-I interferons contribute to the neuroinflammatory process and detrimental effects following traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						STING; Type-I interferon; Traumatic brain injury; Neuroinflammation; Autophagy	TUMOR-NECROSIS-FACTOR; TUBERCULOSIS DNA; FACTOR-ALPHA; CELL-DEATH; AUTOPHAGY; ACTIVATION; EXPRESSION; RECEPTORS; PATHWAY; IFN	Background: Traumatic brain injury (TBI) represents a major cause of disability and death worldwide with sustained neuroinflammation and autophagy dysfunction contributing to the cellular damage. Stimulator of interferon genes (STING)-induced type-I interferon (IFN) signalling is known to be essential in mounting the innate immune response against infections and cell injury in the periphery, but its role in the CNS remains unclear. We previously identified the type-I IFN pathway as a key mediator of neuroinflammation and neuronal cell death in TBI. However, the modulation of the type-I IFN and neuroinflammatory responses by STING and its contribution to autophagy and neuronal cell death after TBI has not been explored. Methods: C57BL/6J wild-type (WT) and STING(-/-) mice (8-10-week-old males) were subjected to controlled cortical impact (CCI) surgery and brains analysed by QPCR, Western blot and immunohistochemical analyses at 2 h or 24 h. STING expression was also analysed by QPCR in post-mortem human brain samples. Results: A significant upregulation in STING expression was identified in late trauma human brain samples that was confirmed in wild-type mice at 2 h and 24 h after CCI. This correlated with an elevated pro-inflammatory cytokine profile with increased TNF-alpha, IL-6, IL-1 beta and type-I IFN (IFN-alpha and IFN-beta) levels. This expression was suppressed in the STING(-/-) mice with a smaller lesion volume in the knockout animals at 24 h post CCI. Wild-type mice also displayed increased levels of autophagy markers, LC3-II, p62 and LAMP2 after TBI; however, STING(-/-) mice showed reduced LAMP2 expression suggesting a role for STING in driving dysfunctional autophagy after TBI. Conclusion: Our data implicates a detrimental role for STING in mediating the TBI-induced neuroinflammatory response and autophagy dysfunction, potentially identifying a new therapeutic target for reducing cellular damage in TBI.	[Abdullah, Amar; Zhang, Moses; Frugier, Tony; Taylor, Juliet M.; Crack, Peter J.] Univ Melbourne, Dept Pharmacol & Therapeut, Neuropharmacol Lab, Melbourne, Vic 3010, Australia; [Bedoui, Sammy] Peter Doherty Inst, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia	Taylor, JM; Crack, PJ (corresponding author), Univ Melbourne, Dept Pharmacol & Therapeut, Neuropharmacol Lab, Melbourne, Vic 3010, Australia.	aabdullah@student.unimelb.edu.au; juliett@unimelb.edu.au; pcrack@unimelb.edu.au	Crack, Peter/ABE-2065-2020	Crack, Peter/0000-0002-5030-0330; Taylor, Juliet/0000-0002-4596-6760; BEDOUI, SAMMY/0000-0002-7443-0543	National Health and Medical Research Council (NHMRC) of AustraliaNational Health and Medical Research Council of Australia	This study was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia to PJC and JMT.	Blaauboer SM, 2014, J IMMUNOL, V192, P492, DOI 10.4049/jimmunol.1301812; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Burdette DL, 2013, NAT IMMUNOL, V14, P19, DOI 10.1038/ni.2491; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Cai X, 2014, MOL CELL, V54, P289, DOI 10.1016/j.molcel.2014.03.040; Chen MX, 2016, MOL CELL, V64, P105, DOI 10.1016/j.molcel.2016.08.025; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845; de Weerd NA, 2007, J BIOL CHEM, V282, P20053, DOI 10.1074/jbc.R700006200; de Weerd NA, 2012, IMMUNOL CELL BIOL, V90, P483, DOI 10.1038/icb.2012.9; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMc1303158, 10.1056/NEJMra1205406]; Field R, 2010, BRAIN BEHAV IMMUN, V24, P996, DOI 10.1016/j.bbi.2010.04.004; Frugier T, 2012, J NEUROPATH EXP NEUR, V71, P242, DOI 10.1097/NEN.0b013e3182496149; Gehrke N, 2015, CELL DEATH DIFFER, V22, P826, DOI 10.1038/cdd.2014.178; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Gough DJ, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000361; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Jeremiah N, 2014, J CLIN INVEST, V124, P5516, DOI 10.1172/JCI79100; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Karve IP, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0128-15.2016; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kim DY, 2015, J NEUROTRAUM, V32, P1815, DOI 10.1089/neu.2014.3728; Klarquist J, 2014, J IMMUNOL, V193, P6124, DOI 10.4049/jimmunol.1401869; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Liu CF, 2016, ONCOTARGET, V7, P46972, DOI 10.18632/oncotarget.10503; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Main BS, 2016, GLIA, V64, P1590, DOI 10.1002/glia.23028; Mathur V, 2017, NEURON, V96, P1290, DOI 10.1016/j.neuron.2017.11.032; Minter MR, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0341-4; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Nazmi A, 2012, SCI REP-UK, V2, DOI 10.1038/srep00347; Ning S, 2011, GENES IMMUN, V12, P399, DOI 10.1038/gene.2011.21; Paludan SR, 2013, IMMUNITY, V38, P870, DOI 10.1016/j.immuni.2013.05.004; Petrasek J, 2013, P NATL ACAD SCI USA, V110, P16544, DOI 10.1073/pnas.1308331110; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Prabakaran T, 2018, EMBO J, V37, DOI 10.15252/embj.201797858; Qiao JT, 2018, METABOLISM, V81, P13, DOI 10.1016/j.metabol.2017.09.010; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Schmeisser H, 2014, J INTERF CYTOK RES, V34, P71, DOI 10.1089/jir.2013.0128; Schmeisser H, 2013, AUTOPHAGY, V9, P683, DOI 10.4161/auto.23921; Seki E, 2008, HEPATOLOGY, V48, P322, DOI 10.1002/hep.22306; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013; Taylor JM, 2014, NEUROBIOL AGING, V35, P1012, DOI 10.1016/j.neurobiolaging.2013.10.089; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; Vitner EB, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0570-2; Vogan K, 2014, NAT GENET, V46, P933, DOI [10.1038/ng.3082, DOI 10.1038/NG.3082]; Watson RO, 2015, CELL HOST MICROBE, V17, P811, DOI 10.1016/j.chom.2015.05.004; Watson RO, 2012, CELL, V150, P803, DOI 10.1016/j.cell.2012.06.040; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Woo SR, 2013, J IMMUNOL, V190; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu X, 2018, NEUROBIOL DIS, V117, P15, DOI 10.1016/j.nbd.2018.05.016; Zhang JY, 2018, J NEUROTRAUM, V35, P802, DOI 10.1089/neu.2016.4871; Zhang MY, 2017, CELL MOL NEUROBIOL, V37, P291, DOI 10.1007/s10571-016-0369-9; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	75	25	26	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	NOV 21	2018	15								323	10.1186/s12974-018-1354-7			17	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	HB3HQ	WOS:000450942200002	30463579	DOAJ Gold, Green Published			2021-06-18	
J	Carnevale, JA; Segar, DJ; Powers, AY; Shah, M; Doberstein, C; Drapcho, B; Morrison, JF; Williams, JR; Collins, S; Monteiro, K; Asaad, WF				Carnevale, Joseph A.; Segar, David J.; Powers, Andrew Y.; Shah, Meghal; Doberstein, Cody; Drapcho, Benjamin; Morrison, John F.; Williams, John R.; Collins, Scott; Monteiro, Kristina; Asaad, Wael F.			Blossoming contusions: identifying factors contributing to the expansion of traumatic intracerebral hemorrhage	JOURNAL OF NEUROSURGERY			English	Article						intraparenchymal hemorrhage; traumatic brain injury; hemorrhagic progression of contusion; volumetric progression; intracerebral hemorrhage; trauma	BRAIN-INJURY; HEAD-INJURY; FRACTURE FIXATION; RISK-FACTORS; CEREBRAL CONTUSIONS; ETHANOL; PROGRESSION; ANTIPLATELET; AGGREGATION; PREDICTORS	OBJECTIVE Traumatic brain injury (TBI) remains a significant cause of neurological morbidity and mortality. Each year, more than 1.7 million patients present to the emergency department with TBI. The goal of this study was to evaluate the prognosis of traumatic cerebral intraparenchymal hemorrhage (tIPH), to develop subclassifications of these injuries that relate to prognosis, and to provide a more comprehensive assessment of hemorrhagic progression contusion (HPC) by analyzing the rate at which tIPH " blossom" (i.e., expansion), depending on a variety of intrinsic and modifiable factors. METHODS In this retrospective study, 726 patients (age range 0-100 years) were admitted to a level 1 trauma center with tIPH during an 8-year period (2005-2013). Of these patients, 491 underwent both admission and follow-up head CT (HCT) within 72 hours. The change in tIPH volume over time, the expansion rate, was recorded for all 491 patients. Effects of prehospital and in-hospital variables were examined using ordinal response logistic regression analyses. These variables were further examined using multivariate linear regression analysis to accurately predict the extent to which a hemorrhage will progress. RESULTS Of the 491 (67.6%) patients who underwent both admission and follow-up HCT, 368 (74.9%) patients experienced HPC. These hemorrhages expanded on average by 61.6% (4.76 ml) with an average expansion rate of 0.71 ml per hour. On univariate analysis, certain patient characteristics were significantly (p < 0.05) related to HPC, including age (> 60 years), admission Glasgow Coma Scale score, blood alcohol level, international normalized ratio, absolute platelet count, transfusion of platelets, concomitant anticoagulation and antiplatelet medication, the initial tIPH volume on admission HCT, and ventriculostomy. Increased expansion rate was significantly associated with patient disposition to hospice or death (p < 0.001). To determine which factors most accurately predict overall patient disposition, an ordinal-response logistic regression identified systolic blood pressure, Injury Severity Score, admission Glasgow Coma Scale score, follow-up scan volume, transfusion of platelets, and ventriculostomy as predictors of patient discharge disposition following tIPH. A multivariate logistic regression identified several prehospital and in-hospital variables (age, Injury Severity Score, blood alcohol level, initial scan volume, concomitant epidural hematoma, presence of subarachnoid hemorrhage, transfusion of platelets, and ventriculostomy) that predicted the volumetric expansion of tIPH. Among these variables, the admission tIPH volume by HCT proved to be the factor most predictive of HPC. CONCLUSIONS Several factors contribute to the rate at which traumatic cerebral contusions blossom in the acute posttraumatic period. Identifying the intrinsic and modifiable aspects of cerebral contusions can help predict the rate of expansion and highlight potential therapeutic interventions to improve TBI-associated morbidity and mortality.	[Carnevale, Joseph A.; Segar, David J.; Powers, Andrew Y.; Shah, Meghal; Drapcho, Benjamin; Williams, John R.; Monteiro, Kristina; Asaad, Wael F.] Brown Univ, Warren Alpert Med Sch, Dept Neurosurg, Providence, RI 02912 USA; [Segar, David J.] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA; [Morrison, John F.] SUNY Buffalo, Dept Neurosurg, Buffalo, NY USA; [Doberstein, Cody] Haverford Coll, Haverford, PA 19041 USA; [Williams, John R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Collins, Scott] Rhode Isl Hosp, Dept Diagnost Imaging, Providence, RI USA; [Asaad, Wael F.] Rhode Isl Hosp, Norman Prince Neurosci Inst, Providence, RI USA	Carnevale, JA (corresponding author), NewYork Presbyterian Hosp, Weill Cornell Med, Brain & Spine Ctr, New York, NY 10010 USA.	joseph_carnevale@alumni.brown.edu		Carnevale, Joseph Anthony/0000-0002-9477-9996; Collins, Scott/0000-0002-8117-164X			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Allison RZ, 2017, NEUROCRIT CARE, V26, P80, DOI 10.1007/s12028-016-0303-5; Bullock MR, 2007, GUIDELINES MANAGEMEN; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Carnevale Joseph, 2016, Neurosurgery, V63 Suppl 1, P195, DOI 10.1227/01.neu.0000489815.75476.e0; Cepeda S, 2015, J NEUROTRAUM, V32, P1246, DOI 10.1089/neu.2014.3808; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Creutzfeldt CJ, 2009, J STROKE CEREBROVASC, V18, P221, DOI 10.1016/j.jstrokecerebrovasdis.2008.10.007; Ehrlich D, 2014, PLATELETS, V25, P16, DOI 10.3109/09537104.2013.764979; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; Flierl MA, 2010, J ORTHOP TRAUMA, V24, P107, DOI 10.1097/BOT.0b013e3181b6bdfc; Folkerson LE, 2015, SURGERY, V158, P655, DOI 10.1016/j.surg.2015.02.029; Giannoudis PV, 2002, AM J SURG, V183, P261, DOI 10.1016/S0002-9610(02)00783-3; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Grotz MRW, 2004, INJURY, V35, P1077, DOI 10.1016/j.injury.2004.05.025; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; JAKUBOWSKI JA, 1988, ARTERIOSCLEROSIS, V8, P436, DOI 10.1161/01.ATV.8.4.436; Jamjoom BA, 2012, NEUROSCIENCES, V17, P111; Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241; Kim H, 2015, J NEUROTRAUM, V32, P950, DOI 10.1089/neu.2014.3697; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Marumo M, 2010, ALCOHOL, V44, P343, DOI 10.1016/j.alcohol.2010.02.002; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; MEHTA P, 1987, THROMB RES, V48, P653, DOI 10.1016/0049-3848(87)90431-2; Mendelow AD, 2015, J NEUROTRAUM, V32, P1312, DOI 10.1089/neu.2014.3644; MIKHAILIDIS DP, 1990, ALCOHOL, V7, P171, DOI 10.1016/0741-8329(90)90080-V; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pape HC, 2009, J AM ACAD ORTHOP SUR, V17, P541, DOI 10.5435/00124635-200909000-00001; Rosado JA, 2006, ARCH BIOCHEM BIOPHYS, V452, P9, DOI 10.1016/j.abb.2006.05.011; Rundhaug NP, 2015, J NEUROSURG, V122, P211, DOI 10.3171/2014.9.JNS14322; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sanus GZ, 2004, NEUROSURG QUART, V14, P97, DOI 10.1097/01.wnq.0000127718.06183.12; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; Yuan F, 2012, J NEUROTRAUM, V29, P2137, DOI 10.1089/neu.2011.2233	42	25	27	1	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2018	129	5					1305	1316		10.3171/2017.7.JNS17988			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HE4XT	WOS:000453373600026	29303442				2021-06-18	
J	Niu, XL; Zheng, SM; Liu, HT; Li, SY				Niu, Xiaoli; Zheng, Simin; Liu, Hongtao; Li, Siyuan			Protective effects of taurine against inflammation, apoptosis, and oxidative stress in brain injury	MOLECULAR MEDICINE REPORTS			English	Article						apoptosis; brain injury; inflammation; neurons; taurine	CENTRAL-NERVOUS-SYSTEM; MITOCHONDRIAL DYSFUNCTION; IN-VITRO; NEURONS; BLOOD; ACCUMULATION; EXPRESSION; CELLS; TUMOR; ACID	The protective effect of taurine against inflammation, apoptosis and oxidative stress in traumatic brain injury was investigated in the present study. Taurine is a non-proteogenic and essential amino acid in animals. It plays a critical nutritional role in brain cell growth, differentiation, and development. Taurine is involved in regeneration and neuroprotection in the injured nervous system, and is an effective antioxidant against lead-, cadmium-, and exercise-induced oxidative stress. Astrocytes and neuron cells were co-cultured and cells were treated with different concentrations of taurine (100, 200 and 300 mg/l) for 72 h, and the levels of reactive oxygen species, malondialdehyde, reduced glutathione, glutathione peroxidase, superoxide dismutase, catalase, acetylcholinesterase, tumor necrosis factor-alpha, interleukin-6, caspase-3, p53, B-cell lymphoma 2 and Bcl-2-associated X protein were determined. These inflammatory, apoptotic, and oxidative stress markers were substantially increased in injured cells, and returned to normal levels following taurine supplementation. Thus, taurine supplementation may be effective against oxidative stress, apoptosis, and inflammation in injured brain cells.	[Niu, Xiaoli; Zheng, Simin; Liu, Hongtao; Li, Siyuan] Xi An Jiao Tong Univ, Dept Anesthesiol, Affiliated Hosp 2, 157 West 5th Rd, Xian 710004, Shaanxi, Peoples R China	Li, SY (corresponding author), Xi An Jiao Tong Univ, Dept Anesthesiol, Affiliated Hosp 2, 157 West 5th Rd, Xian 710004, Shaanxi, Peoples R China.	lowesiomew@yahoo.com			Key Research and Development Project of Shaanxi Province [2017SF-180]	The present study was supported by the Key Research and Development Project of Shaanxi Province (grant no. 2017SF-180).	Afshari J Tavakkol, 2005, BMC Pregnancy Childbirth, V5, P14, DOI 10.1186/1471-2393-5-14; Birdsall T C, 1998, Altern Med Rev, V3, P128; Boda D, 2014, FARMACIA, V62, P704; Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326; Collins  C., 1996, OCCUPATIONAL THERAPY, P395; Dominy J, 2004, J NEUROCHEM, V89, P1195, DOI 10.1111/j.1471-4159.2004.02410.x; El Idrissi A, 2003, ADV EXP MED BIOL, V526, P515; Erden Inal M, 2003, J AM AGING ASSOC, V26, P55, DOI DOI 10.1007/S11357-003-0005-8; Foos TM, 2002, NEUROCHEM RES, V27, P21, DOI 10.1023/A:1014890219513; Gong H, 2017, FARMACIA, V65, P1; Heidari R, 2016, TOXICOL REP, V3, P870, DOI 10.1016/j.toxrep.2016.04.002; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101; Kaddour T., 2016, J ACUTE DIS, V5, P470, DOI DOI 10.1016/J.JOAD.2016.08.028; Katano H, 1999, NEUROREPORT, V10, P2439, DOI 10.1097/00001756-199908200-00002; Keelan J, 1999, BRAIN RES, V821, P124, DOI 10.1016/S0006-8993(99)01084-7; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Leon R, 2009, J NEUROSCI RES, V87, P1185, DOI 10.1002/jnr.21926; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lobos E, 2005, ENDOCRINOLOGY, V146, P1922, DOI 10.1210/en.2004-0925; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Madakkannu B, 2017, TOXICOL REP, V4, P484, DOI 10.1016/j.toxrep.2017.09.001; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Medhat D, 2017, BIOMED PHARMACOTHER, V91, P1006, DOI 10.1016/j.biopha.2017.05.043; Nakajima Y, 2010, J NEUROTRAUM, V27, P403, DOI 10.1089/neu.2009.1044; Negrei C, 2012, FARMACIA, V60, P767; Olive MF, 2002, AMINO ACIDS, V23, P345, DOI 10.1007/s00726-002-0203-1; Prentice H, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/964518; Rak K, 2014, NEUROREPORT, V25, P1250, DOI 10.1097/WNR.0000000000000254; Schaffer SW, 2014, AMINO ACIDS, V46, P21, DOI 10.1007/s00726-012-1378-8; Schuller-Levis GB, 2003, FEMS MICROBIOL LETT, V226, P195, DOI 10.1016/S0378-1097(03)00611-6; Shaheen TI, 2016, BIOMED PHARMACOTHER, V83, P865, DOI 10.1016/j.biopha.2016.07.052; Shimada K, 2015, ADV EXP MED BIOL, V803, P581, DOI 10.1007/978-3-319-15126-7_47; Sun M, 2015, J NEUROTRAUM, V32, P66, DOI 10.1089/neu.2012.2432; Sun M, 2012, AMINO ACIDS, V42, P1735, DOI 10.1007/s00726-011-0885-3; Sun M, 2011, AMINO ACIDS, V40, P1419, DOI 10.1007/s00726-010-0751-8; Sun QR, 2014, BIOCHEM BIOPH RES CO, V447, P485, DOI 10.1016/j.bbrc.2014.04.019; Tataranu LG, 2017, FARMACIA, V65, P766; Tsuboyama-Kasaoka N, 2006, ENDOCRINOLOGY, V147, P3276, DOI 10.1210/en.2005-1007; Vlodavsky E, 2017, J CEREBR BLOOD F MET, V37, P166, DOI 10.1177/0271678X15621068; Wang Q, 2016, AMINO ACIDS, V48, P2169, DOI 10.1007/s00726-016-2244-x; Wang X, 2001, J CEREB BLOOD FLOW M, V21, pS264; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yanagita T, 2008, LIPIDS HEALTH DIS, V7, DOI 10.1186/1476-511X-7-38; Yang YJ, 2013, ACTA BIOCH BIOPH SIN, V45, P359, DOI 10.1093/abbs/gmt034; Zhang M, 2004, AMINO ACIDS, V26, P203, DOI 10.1007/s00726-003-0002-3; Zhu KJ, 2014, WORLD J GASTROENTERO, V20, P9585, DOI 10.3748/wjg.v20.i28.9585	48	25	27	1	16	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	NOV	2018	18	5					4516	4522		10.3892/mmr.2018.9465			7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	GV9PW	WOS:000446493000038	30221665	Other Gold, Green Published			2021-06-18	
J	Fakhri, S; Dargahi, L; Abbaszadeh, F; Jorjani, M				Fakhri, Sajad; Dargahi, Leila; Abbaszadeh, Fatemeh; Jorjani, Masoumeh			Astaxanthin attenuates neuroinflammation contributed to the neuropathic pain and motor dysfunction following compression spinal cord injury	BRAIN RESEARCH BULLETIN			English	Article						Astaxanthin; Spinal cord injury; Neuroinflammation; Glutamate signaling; Sensory-motor function; Rat	GLUN2B-CONTAINING NMDA RECEPTORS; MIGRATION-INHIBITORY FACTOR; GLUTAMATE-INDUCED APOPTOSIS; OXIDATIVE STRESS; BRAIN-INJURY; IN-VITRO; HIPPOCAMPAL-NEURONS; DNA FRAGMENTATION; TRAUMATIC BRAIN; CELL APOPTOSIS	Spinal cord injury (SCI) is a debilitating condition in which inflammatory responses in the secondary phase of injury leads to long lasting sensory-motor dysfunction. The medicinal therapy of SCI complications is still a clinical challenge. Understanding the molecular pathways underlying the progress of damage will help to find new therapeutic candidates. Astaxanthin (AST) is a ketocarotenoid which has shown anti-inflammatory effects in models of traumatic brain injury. In the present study, we examined its potential in the elimination of SCI damage through glutamatergic-phospo p38 mitogen-activated protein kinase (p-p38MAPK) signaling pathway. Inflammatory response, histopathological changes and sensory-motor function were also investigated in a severe compression model of SCI in male rats. The results of acetone drop and inclined plane tests indicated the promising role of AST in improving sensory and motor function of SCI rats. AST decreased the expression of n-methyl-D-aspartate receptor subunit 2B (NR2B) and p-p38MAPK as inflammatory signaling mediators as well as tumor necrosis factor-alpha (TNF-alpha) as an inflammatory cytokine, following compression SCI. The histopathological study culminated in preserved white mater and motor neurons beyond the injury level in rostral and caudal parts. The results show the potential of AST to inhibit glutamate-initiated signaling pathway and inflammatory reactions in the secondary phase of SCI, and suggest it as a promising candidate to enhance functional recovery after SCI.	[Fakhri, Sajad; Jorjani, Masoumeh] Shahid Beheshti Univ Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran; [Dargahi, Leila] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran, Iran; [Abbaszadeh, Fatemeh; Jorjani, Masoumeh] Shahid Beheshti Univ Med Sci, Neurobiol Res Ctr, Tehran, Iran	Jorjani, M (corresponding author), Shahid Beheshti Univ Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran.; Jorjani, M (corresponding author), Shahid Beheshti Univ Med Sci, Sch Med, Neurobiol Res Ctr, Tehran, Iran.	msjorjani@sbmu.ac.ir	fakhri, sajad/E-9333-2019; Dargahi, Leila/K-4693-2017	Dargahi, Leila/0000-0001-7777-5435	Neuroscience Research Center of Shahid Beheshti University of Medical Sciences, IRAN [S-N-56-1397]	The current research was performed as part of a Ph.D. thesis project of Sajad Fakhri and was supported by the Neuroscience Research Center (Grant No. S-N-56-1397) of Shahid Beheshti University of Medical Sciences, IRAN.	Ambati RR, 2014, MAR DRUGS, V12, P128, DOI 10.3390/md12010128; Araujo IM, 2010, NEUROCHEM RES, V35, P1966, DOI 10.1007/s11064-010-0323-z; Augusti PR, 2012, J CLIN BIOCHEM NUTR, V51, P42, DOI 10.3164/jcbn.11-74; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Balietti M, 2016, J SCI FOOD AGR, V96, P615, DOI 10.1002/jsfa.7131; Bank M, 2015, ARCH PHYS MED REHAB, V96, P633, DOI 10.1016/j.apmr.2014.10.021; Baralic I, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/783761; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Borbely Z, 2017, BRAIN RES BULL, V131, P150, DOI 10.1016/j.brainresbull.2017.04.007; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Brecht S, 2001, MOL BRAIN RES, V94, P25, DOI 10.1016/S0006-8993(01)02767-6; Cheriyan T, 2014, SPINAL CORD, V52, P588, DOI 10.1038/sc.2014.91; Choi DC, 2012, EXP NEUROL, V236, P268, DOI 10.1016/j.expneurol.2012.05.014; Choi SK, 2008, J MICROBIOL BIOTECHN, V18, P1990, DOI 10.4014/jmb.0800.489; David BT, 2013, NEUROBIOL DIS, V54, P194, DOI 10.1016/j.nbd.2012.12.012; Dong LY, 2013, MAR DRUGS, V11, P960, DOI 10.3390/md11030960; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Dowdall T, 2005, PHARMACOL BIOCHEM BE, V80, P93, DOI 10.1016/j.pbb.2004.10.016; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Elmarakby AA, 2012, CARDIOVASC THER, V30, P49, DOI 10.1111/j.1755-5922.2010.00218.x; Evans J, 2015, MICROVASC RES, V98, P145, DOI 10.1016/j.mvr.2014.04.011; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Gruener H, 2018, SPINAL CORD, V56, P176, DOI 10.1038/s41393-017-0014-6; Guo SX, 2015, MAR DRUGS, V13, P2105, DOI 10.3390/md13042105; Higuera-Ciapara I, 2006, CRIT REV FOOD SCI, V46, P185, DOI 10.1080/10408690590957188; Hook MA, 2017, J NEUROTRAUM, V34, P632, DOI 10.1089/neu.2016.4507; Hu Y, 2011, CARBON NANOTUBES - GROWTH AND APPLICATIONS, P3; Hui KY, 2014, CANCER LETT, V354, P189, DOI 10.1016/j.canlet.2014.08.009; Ikeda Y, 2008, J NEUROCHEM, V107, P1730, DOI 10.1111/j.1471-4159.2008.05743.x; Jiang Q, 2000, BRAIN RES, V857, P71, DOI 10.1016/S0006-8993(99)02364-1; Jiang X, 2018, NEUROSCI LETT, V662, P36, DOI 10.1016/j.neulet.2017.09.064; Kakulas BA, 1998, SPINAL CORD MONITORING, P395; Kauppila T, 2000, EXP NEUROL, V161, P740, DOI 10.1006/exnr.1999.7287; Khoei HH, 2019, TOXIN REV, V38, P223, DOI 10.1080/15569543.2018.1444641; Kidd P, 2011, ALTERN MED REV, V16, P355; Kim SY, 2002, NEUROREPORT, V13, P2483, DOI 10.1097/00001756-200212200-00021; Kiss JP, 2012, NEUROCHEM INT, V60, P170, DOI 10.1016/j.neuint.2011.12.005; Koda M, 2004, ACTA NEUROPATHOL, V108, P31, DOI 10.1007/s00401-004-0853-z; Kong XY, 2017, J CELL MOL MED, V21, P941, DOI 10.1111/jcmm.13034; Kuedo Z, 2016, MOLECULES, V21, DOI 10.3390/molecules21030382; Kwon BK, 2011, J NEUROTRAUM, V28, P1525, DOI 10.1089/neu.2010.1296; Kwon BK, 2011, J NEUROTRAUM, V28, P1589, DOI 10.1089/neu.2009.1150; Lancelot E, 1998, PROG BRAIN RES, V116, P331, DOI 10.1016/S0079-6123(08)60446-X; Lerch JK, 2014, SEMIN IMMUNOL, V26, P409, DOI 10.1016/j.smim.2014.03.004; Lin XT, 2017, EUR J PHARMACOL, V806, P43, DOI 10.1016/j.ejphar.2017.04.008; Luo Y, 2015, MOL MED REP, V12, P7132, DOI 10.3892/mmr.2015.4274; Masoudi A, 2017, BEHAV BRAIN RES, V329, P104, DOI 10.1016/j.bbr.2017.04.026; MESTRE C, 1994, J PHARMACOL TOX MET, V32, P197, DOI 10.1016/1056-8719(94)90087-6; Nakae A., 2011, BIOMED RES INT; Nakajima Y, 2008, J PHARM PHARMACOL, V60, P1365, DOI 10.1211/jpp/60.10.0013; Nakano M, 2008, J NUTR SCI VITAMINOL, V54, P329, DOI 10.3177/jnsv.54.329; Nakao R, 2010, ANTICANCER RES, V30, P2721; Naseri K, 2013, J MOL NEUROSCI, V49, P470, DOI 10.1007/s12031-012-9840-3; O'Shea TM, 2017, J CLIN INVEST, V127, P3265, DOI 10.1172/JCI90608; Ohgami K, 2003, INVEST OPHTH VIS SCI, V44, P2694, DOI 10.1167/iovs.02-0822; Pan L, 2017, BRAIN RES BULL, V130, P211, DOI 10.1016/j.brainresbull.2017.01.024; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Rami A, 2000, BRAIN RES, V866, P299, DOI 10.1016/S0006-8993(00)02301-5; Rao AR, 2010, J AGR FOOD CHEM, V58, P8553, DOI 10.1021/jf101187k; Ray SK, 2000, BRAIN RES, V852, P326, DOI 10.1016/S0006-8993(99)02148-4; Samini F, 2013, PHARMACOL BIOCHEM BE, V110, P238, DOI 10.1016/j.pbb.2013.07.019; Schelman WR, 2004, MOL BRAIN RES, V128, P160, DOI 10.1016/j.molbrainres.2004.06.011; Schwab ME, 1996, PHYSIOL REV, V76, P319; Sedy J, 2008, NEUROSCI BIOBEHAV R, V32, P550, DOI 10.1016/j.neubiorev.2007.10.001; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Sharma K, 2018, NEUROSCI LETT, V674, P162, DOI 10.1016/j.neulet.2018.03.030; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Sifi N, 2016, INFLAMM RES, V65, P623, DOI 10.1007/s00011-016-0945-y; Song Xue-Song, 2005, Shengli Xuebao, V57, P139; Speranza L, 2012, MAR DRUGS, V10, P890, DOI 10.3390/md10040890; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Suzuki Y, 2006, EXP EYE RES, V82, P275, DOI 10.1016/j.exer.2005.06.023; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Vegh D, 2017, BRAIN RES BULL, V135, P157, DOI 10.1016/j.brainresbull.2017.10.011; Vizi ES, 2013, BRAIN RES BULL, V93, P32, DOI 10.1016/j.brainresbull.2012.10.005; Wu HJ, 2015, MAR DRUGS, V13, P5750, DOI 10.3390/md13095750; Xue Y, 2017, BRAIN RES BULL, V131, P221, DOI 10.1016/j.brainresbull.2017.04.019; Yan TT, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4512309; Ye QY, 2013, MAR DRUGS, V11, P1019, DOI 10.3390/md11041019; Zhang Fei-E, 2005, Shengli Xuebao, V57, P545; Zhang XS, 2014, MAR DRUGS, V12, P4291, DOI 10.3390/md12084291; Zhang YM, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-49	83	25	26	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	OCT	2018	143						217	224		10.1016/j.brainresbull.2018.09.011			8	Neurosciences	Neurosciences & Neurology	HD8NL	WOS:000452813700023	30243665				2021-06-18	
J	Echemendia, RJ; Bruce, JM; Meeuwisse, W; Hutchison, MG; Comper, P; Aubry, M				Echemendia, Ruben J.; Bruce, Jared M.; Meeuwisse, Willem; Hutchison, Michael G.; Comper, Paul; Aubry, Mark			Can visible signs predict concussion diagnosis in the National Hockey League?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Concussion Signs; Video analyses; Concussion Diagnoses; Ice Hockey	TEMPORAL WINDOW; VULNERABILITY	Background Early identification and evaluation of concussions is critical. We examined the utility of using visible signs (VS) of concussion in predicting subsequent diagnosis of concussion in NHL players. Methods VS of concussion were identified through video review. Coders were trained to detect and record specific visual signs while viewing videos of NHL regular season games. 2460 games were reviewed by at least two independent coders across two seasons. The reliability, sensitivity and specificity of these VS were examined. Results VS were reliably coded with inter-rater agreement rates ranging from 73% to 98.9%. 1215 VS were identified in 861 events that occurred in 735 games. 47% of diagnosed concussions were associated with a VS but 53% of diagnosed concussions had no VS. Of the VS, only loss of consciousness, motor incoordination, and blank/vacant look had positive likelihood ratios greater than 1, indicating a positive association with concussion diagnoses. Slow to get up and clutching of the head were observed frequently but had low positive predictive values. Sensitivity decreased and specificity increased when multiple VS occurred together. Conclusions Non-medical personnel can be trained to reliably identify events in which VS occur and to reliably identify specific VS within each of those events. VS can be useful to detect concussion early but they are not enough since more than half of physician diagnosed concussions occurred without the presence of a visual sign. The results underscore the complexity of this injury and highlight the need for comprehensive approaches to injury detection.	[Echemendia, Ruben J.] Concuss Care Clin, Univ Orthoped Ctr, 101 Regent Court, State Coll, PA 16801 USA; [Echemendia, Ruben J.; Bruce, Jared M.] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Meeuwisse, Willem] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Comper, Paul] Toronto Rehabil Inst, Toronto, ON, Canada; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada	Echemendia, RJ (corresponding author), Concuss Care Clin, Univ Orthoped Ctr, 101 Regent Court, State Coll, PA 16801 USA.	rechemendia@comcast.net	Echemendia, Ruben/R-6939-2019				Broglio S, 2014, OXFORD HDB SPORTS RE; Cantu R, 2014, OXFORD HDB SPORTS RE; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Makdissi M, 2016, J SCI MED SPORT, V19, P859, DOI 10.1016/j.jsams.2016.02.015; McCrory P, 2014, OXFORD HDB SPORTS RE; McCrory P, 2013, PM&R, V5, P255, DOI 10.1016/j.pmrj.2013.02.012; McCrory Paul, 2009, Scand J Med Sci Sports, V19, P452, DOI 10.1111/j.1600-0838.2009.00978.x; NHL Concussion Working Group, 2011, NHL CONC EV MAN PROT; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8	13	25	25	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2018	52	17					1149	1154		10.1136/bjsports-2016-097090			6	Sport Sciences	Sport Sciences	GS4GO	WOS:000443598200014	28377445				2021-06-18	
J	Mentiplay, BF; Banky, M; Clark, RA; Kahn, MB; Williams, G				Mentiplay, Benjamin F.; Banky, Megan; Clark, Ross A.; Kahn, Michelle B.; Williams, Gavin			Lower limb angular velocity during walking at various speeds	GAIT & POSTURE			English	Article						Gait; Angular velocity; Kinematics; Biomechanics; Mobility	TOTAL KNEE ARTHROPLASTY; TRAUMATIC BRAIN-INJURY; HIP-JOINT CENTER; CEREBRAL-PALSY; GAIT ANALYSIS; NEUROLOGIC REHABILITATION; OLDER-PEOPLE; SPASTICITY; CHILDREN; STROKE	Background: Although it is well established that lower limb joint angles adapt to walking at various speeds, limited research has examined the modifications in joint angular velocity. There is currently no normative dataset for joint angular velocity during walking, which would be useful to allow comparisons for patient cohorts. Additionally, understanding normal joint angular velocity may assist clinical assessment and treatment procedures to incorporate methods that replicate the movement speed of the lower limb joints during walking. Research Question: This study aimed to examine lower limb joint angles and angular velocities in a healthy population walking at various gait speeds. Methods: Thirty-six healthy adult participants underwent three-dimensional gait analysis while walking at various speeds during habitual and slowed walking. The peak joint angles and angular velocities during important phases of the gait cycle were examined for the hip, knee and ankle in the sagittal plane. Data were grouped in 0.2 m/s increments from a walking speed of 0.4 m/s to 1.6 m/s to represent the range of walking speeds reported in studies of people with gait impairments. Results: For joint angles and angular velocities, the shape of the gait traces were consistent regardless of the walking speed. However as walking speed increased, so did the peak joint angles and angular velocities for the hip, knee and ankle. The largest angular velocity occurred when the knee joint extended at the terminal swing phase of gait. For the ankle and hip joints, the largest angular velocity occurred during the push-off phase. Significance: This study examined how lower limb joint angular velocities change with various walking speeds. These data can be used as a comparator for data from clinical cohorts, and has the potential to be used to match clinical assessment and treatment methods to joint angular velocity during walking.	[Mentiplay, Benjamin F.; Banky, Megan; Kahn, Michelle B.; Williams, Gavin] Epworth HealthCare, Dept Physiotherapy, Richmond, Vic, Australia; [Mentiplay, Benjamin F.] La Trobe Univ, La Trobe Sport & Exercise Med Res Ctr, Bundoora, Vic 3086, Australia; [Mentiplay, Benjamin F.] Murdoch Childrens Res Inst, Victorian Infant Brain Studies, Melbourne, Vic, Australia; [Banky, Megan; Clark, Ross A.; Kahn, Michelle B.] Univ Sunshine Coast, Sch Hlth & Sport Sci, Sippy Downs, Qld, Australia; [Williams, Gavin] Univ Melbourne, Dept Physiotherapy, Melbourne, Vic, Australia	Mentiplay, BF (corresponding author), La Trobe Univ, La Trobe Sport & Exercise Med Res Ctr, Bundoora, Vic 3086, Australia.	b.mentiplay@latrobe.edu.au	Clark, Ross/K-7613-2019; Clark, Ross A/R-5664-2018; Mentiplay, Benjamin/A-2279-2019	Clark, Ross/0000-0002-7291-8553; Clark, Ross A/0000-0002-7291-8553; Mentiplay, Benjamin/0000-0002-4360-8310	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [1090415]	Author RAC is supported by a RD Wright Biomedical Fellowship (#1090415) from the National Health and Medical Research Council.	Afilalo J, 2010, J AM COLL CARDIOL, V56, P1668, DOI 10.1016/j.jacc.2010.06.039; Akman MN, 1999, SPINAL CORD, V37, P638, DOI 10.1038/sj.sc.3100892; Baker R., 2003, ALL YOU EVER WANTED; Banky M, 2017, BRAIN INJURY, V31, P440, DOI 10.1080/02699052.2016.1271455; Bean JF, 2002, J AM GERIATR SOC, V50, P461; Beaulieu ML, 2010, GAIT POSTURE, V32, P269, DOI 10.1016/j.gaitpost.2010.05.007; Carse B, 2013, PHYSIOTHERAPY, V99, P347, DOI 10.1016/j.physio.2013.03.001; Collins TD, 2009, GAIT POSTURE, V30, P173, DOI 10.1016/j.gaitpost.2009.04.004; Cuoco A, 2004, J GERONTOL A-BIOL, V59, P1200, DOI 10.1093/gerona/59.11.1200; Damiano DL, 2006, GAIT POSTURE, V23, P1, DOI 10.1016/j.gaitpost.2004.10.007; Dietz V, 2007, LANCET NEUROL, V6, P725, DOI 10.1016/S1474-4422(07)70193-X; Harrington ME, 2007, J BIOMECH, V40, P595, DOI 10.1016/j.jbiomech.2006.02.003; Hendrey G, 2018, ARCH PHYS MED REHAB, V99, P2430, DOI 10.1016/j.apmr.2018.04.032; Hof A., 1996, GAIT POSTURE, V4, P222, DOI 10.1016/0966-6362(95)01057-2; Liu MQ, 2008, J BIOMECH, V41, P3243, DOI 10.1016/j.jbiomech.2008.07.031; Lord SE, 2004, ARCH PHYS MED REHAB, V85, P234, DOI 10.1016/j.apmr.2003.05.002; Lu TW, 1999, J BIOMECH, V32, P129, DOI 10.1016/S0021-9290(98)00158-4; McGinley JL, 2009, GAIT POSTURE, V29, P360, DOI 10.1016/j.gaitpost.2008.09.003; Mentiplay BF, 2018, GAIT POSTURE, V64, P75, DOI 10.1016/j.gaitpost.2018.05.033; Pohl PS, 2000, CLIN REHABIL, V14, P601, DOI 10.1191/0269215500cr367oa; Pua YH, 2017, SEMIN ARTHRITIS RHEU, V46, P544, DOI 10.1016/j.semarthrit.2016.10.012; Pua YH, 2013, ARCH PHYS MED REHAB, V94, P503, DOI 10.1016/j.apmr.2012.10.008; Richards C, 1996, GAIT POSTURE, V4, P12, DOI 10.1016/0966-6362(96)01063-6; Roberts M., 2017, PHYS THER REHABIL, V4, P6, DOI [10.7243/2055-2386-4-6, DOI 10.7243/2055-2386-4-6]; SAHRMANN SA, 1977, ANN NEUROL, V2, P460, DOI 10.1002/ana.410020604; Salter K, 2016, TOP STROKE REHABIL, V23, P366, DOI 10.1080/10749357.2016.1160656; Sangeux M, 2014, GAIT POSTURE, V40, P20, DOI 10.1016/j.gaitpost.2014.01.024; Schwartz MH, 2008, J BIOMECH, V41, P1639, DOI 10.1016/j.jbiomech.2008.03.015; Scianni A, 2009, AUST J PHYSIOTHER, V55, P81, DOI 10.1016/S0004-9514(09)70037-6; Sinclair J, 2013, J HUM KINET, V39, P25, DOI 10.2478/hukin-2013-0065; Sofuwa O, 2005, ARCH PHYS MED REHAB, V86, P1007, DOI 10.1016/j.apmr.2004.08.012; Stansfield BW, 2001, J PEDIATR ORTHOPED, V21, P395, DOI 10.1097/00004694-200105000-00026; Thewlis D, 2013, J APPL BIOMECH, V29, P112, DOI 10.1123/jab.29.1.112; Tuzson AE, 2003, ARCH PHYS MED REHAB, V84, P1363, DOI 10.1016/S0003-9993(03)00199-0; Umberger BR, 2007, J EXP BIOL, V210, P3255, DOI 10.1242/jeb.000950; van Kan GA, 2009, J NUTR HEALTH AGING, V13, P881; Williams G, 2015, BRAIN INJURY, V29, P1232, DOI 10.3109/02699052.2015.1035328; Williams G, 2015, J HEAD TRAUMA REHAB, V30, pE49, DOI 10.1097/HTR.0000000000000094; Williams G, 2014, AM J PHYS MED REHAB, V93, P828, DOI 10.1097/PHM.0000000000000139; Williams G, 2014, AM J PHYS MED REHAB, V93, P511, DOI 10.1097/PHM.0000000000000058; WINTER DA, 1983, J MOTOR BEHAV, V15, P302; Wren TAL, 2008, GAIT POSTURE, V27, P530, DOI 10.1016/j.gaitpost.2007.07.006; Zeni JA, 2008, GAIT POSTURE, V27, P710, DOI 10.1016/j.gaitpost.2007.07.007	43	25	26	3	60	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	SEP	2018	65						190	196		10.1016/j.gaitpost.2018.06.162			7	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	GQ6YO	WOS:000441877300032					2021-06-18	
J	Miao, HS; Li, RM; Han, C; Lu, XZ; Zhang, H				Miao, Hongsheng; Li, Runming; Han, Cong; Lu, Xiuzhen; Zhang, Hang			Minocycline promotes posthemorrhagic neurogenesis via M2 microglia polarization via upregulation of the TrkB/BDNF pathway in rats	JOURNAL OF NEUROPHYSIOLOGY			English	Article						ICH; microglial polarization; minocycline; neurogenesis; TrkB/BDNF pathway	EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; TRAUMATIC BRAIN-INJURY; CANNABINOID RECEPTOR 2; INTRAVENTRICULAR HEMORRHAGE; EXPERIMENTAL STROKE; NEUROTROPHIC FACTOR; M1/M2 POLARIZATION; ACTIVATION; INFLAMMATION; MODEL	Intracerebral hemorrhage (ICH) is a devastating disease worldwide with increasing mortality. The present study investigated whether minocycline was neuroprotective and induced M2 microglial polarization via upregulation of the TrkB/BDNF pathway after ICH. ICH was induced via injection of autologous blood into 150 Sprague-Dawley rats. A selective TrkB antagonist [N2-2-2-oxoazepan-3-yl amino] carbonyl phenyl benzo (b) thiophene-2-carboxamide (ANA 12)] and agonist [N-[2-(5-hydroxy-1H-indol-3-yl) ethyl]2-oxopiperidine-3-carboxamide (HIOC)] were used to investigate the mechanism of minocycline-induced neuroprotection. Minocycline improved ICH-induced neurological deficits and reduced M1 microglia marker protein (CD68, CD16) expression as well as M2 microglial polarization (CD206 and arginase 1 protein). Minocycline administration enhanced microglia-neuron cross talk and promoted the proliferation of neuronal progenitor cells, such as DCX- and Tuj-1-positive cells, 24 h after ICH. Minocycline also increased M2 microglia-derived brain-derived neurotrophic factors (BDNF) and the upstream TrkB pathway. ANA 12 reversed the neuroprotective effects of minocycline. HIOC exhibited the same effects as minocycline and accelerated neurogenesis after ICH. This study demonstrated for the first time that minocycline promoted M2 microglia polarization via upregulation of the TrkB/BDNF pathway and promoted neurogenesis after ICH. This study contributes to our understanding of the therapeutic potential of minocycline in ICH. NEW & NOTEWORTHY The present study gives several novel points: 1) Minocycline promotes neurogenesis after intracerebral hemorrhage in rats. 2) Minocycline induces activated M1 microglia into M2 neurotrophic phenotype. 3) M2 microglia secreting BDNF remodel the damaged neurocircuit.	[Miao, Hongsheng; Han, Cong; Lu, Xiuzhen] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Neurosurg, Sch Med, Shanghai, Peoples R China; [Li, Runming; Zhang, Hang] 205 Hosp Peoples Liberat Army China, Dept Neurosurg, Jingzhou, Peoples R China	Miao, HS (corresponding author), Shanghai Jiao Tong Univ, Dept Neurosurg, Shanghai Gen Hosp, 650 Xinsongjiang Rd, Shanghai 210620, Peoples R China.	miaohongsheng1973@yeah.net			National Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81601356]	This work was supported by the National Science Foundation of China (NSFC, no. 81601356).	Ahn SY, 2013, STROKE, V44, P497, DOI 10.1161/STROKEAHA.112.679092; Alam MA, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00094; Baker RG, 2011, CELL METAB, V13, P11, DOI 10.1016/j.cmet.2010.12.008; Cai ZY, 2010, NEUROSCI BULL, V26, P28, DOI 10.1007/s12264-010-0818-2; CASH E, 1993, CELL IMMUNOL, V147, P129, DOI 10.1006/cimm.1993.1053; Chang JJ, 2017, EUR J NEUROL, V24, P1384, DOI 10.1111/ene.13403; Chen QW, 2015, STROKE, V46, P2902, DOI 10.1161/STROKEAHA.115.009713; Daly LT, 2016, PLAST RECONSTR SURG, V138, p856E, DOI 10.1097/PRS.0000000000002633; Dang G, 2017, TRANSL STROKE RES, V8, P174, DOI 10.1007/s12975-016-0505-3; Deonarine K, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-11; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Fagan SC, 2011, TRANSL STROKE RES, V2, P202, DOI 10.1007/s12975-011-0072-6; Fouda AY, 2017, STROKE, V48, P2885, DOI 10.1161/STROKEAHA.117.018658; Gemma C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00229; Gustafsson E, 2003, STROKE, V34, P2710, DOI 10.1161/01.STR.0000096025.35225.36; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hahn JN, 2016, J IMMUNOL, V197, P3850, DOI 10.4049/jimmunol.1600436; Hankey GJ, 2017, LANCET, V389, P641, DOI 10.1016/S0140-6736(16)30962-X; Hanlon LA, 2016, J NEUROPATH EXP NEUR, V75, P214, DOI 10.1093/jnen/nlv021; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Hess David C, 2010, Rev Neurol Dis, V7 Suppl 1, pS7; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Huang WC, 2010, ANAT CELL BIOL, V43, P325, DOI 10.5115/acb.2010.43.4.325; Jiang B, 2017, TRANSL STROKE RES, V8, P183, DOI 10.1007/s12975-016-0506-2; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim KH, 2013, J EXP NEUROSCI, V7, P85, DOI 10.4137/JEN.S11269; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Lan X, 2017, BRAIN BEHAV IMMUN, V61, P326, DOI 10.1016/j.bbi.2016.12.012; Lei CY, 2015, STROKE, V46, P500, DOI 10.1161/STROKEAHA.114.006825; Li L, 2015, TRANSL STROKE RES, V6, P467, DOI 10.1007/s12975-015-0425-7; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Pan J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0270-3; Pang T, 1820, BIOCHIM BIOPHYS ACTA, P503; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Perego C, 2016, NEUROBIOL DIS, V96, P284, DOI 10.1016/j.nbd.2016.09.017; Ploughman M, 2009, STROKE, V40, P1490, DOI 10.1161/STROKEAHA.108.531806; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Quirie A, 2013, EUR J NEUROSCI, V37, P1193, DOI 10.1111/ejn.12111; Shi W, 2011, ACTA NEUROCHIR SUPPL, V110, P61, DOI 10.1007/978-3-7091-0356-2_12; Soliman S, 2015, TRANSL STROKE RES, V6, P309, DOI 10.1007/s12975-015-0408-8; Strahan JA, 2017, DEV NEUROBIOL, V77, P753, DOI 10.1002/dneu.22457; Tang J, 2016, MOL NEUROBIOL, V53, P1935, DOI 10.1007/s12035-015-9154-x; Tang JJ, 2015, NEUROBIOL DIS, V78, P126, DOI 10.1016/j.nbd.2015.01.009; Tao YH, 2016, BRAIN BEHAV IMMUN, V58, P118, DOI 10.1016/j.bbi.2016.05.020; Wan S, 2016, TRANSL STROKE RES, V7, P478, DOI 10.1007/s12975-016-0472-8; Zhao F, 2011, STROKE, V42, P3587, DOI 10.1161/STROKEAHA.111.623926; Zhao H, 2015, TRANSL STROKE RES, V6, P407, DOI 10.1007/s12975-015-0428-4	50	25	31	1	21	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	SEP	2018	120	3					1307	1317		10.1152/jn.00234.2018			11	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	GX3UY	WOS:000447653800002	29790836	Bronze			2021-06-18	
J	Fowler, JH; McQueen, J; Holland, PR; Manso, Y; Marangoni, M; Scott, F; Chisholm, E; Scannevin, RH; Hardingham, GE; Horsburgh, K				Fowler, Jill H.; McQueen, Jamie; Holland, Philip R.; Manso, Yasmina; Marangoni, Martina; Scott, Fiona; Chisholm, Emma; Scannevin, Robert H.; Hardingham, Giles E.; Horsburgh, Karen			Dimethyl fumarate improves white matter function following severe hypoperfusion: Involvement of microglia/macrophages and inflammatory mediators	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Electrophysiology; cerebrovascular disease; inflammation; microglia; white matter	CHRONIC CEREBRAL HYPOPERFUSION; TRAUMATIC BRAIN-INJURY; OLIGODENDROCYTE PROGENITOR CELLS; SMALL-VESSEL DISEASE; RAT-BRAIN; MULTIPLE-SCLEROSIS; COGNITIVE IMPAIRMENT; CORPUS-CALLOSUM; ACID ESTERS; SPINAL-CORD	The brain's white matter is highly vulnerable to reductions in cerebral blood flow via mechanisms that may involve elevated microgliosis and pro-inflammatory pathways. In the present study, the effects of severe cerebral hypoperfusion were investigated on white matter function and inflammation. Male C57Bl/6J mice underwent bilateral common carotid artery stenosis and white matter function was assessed at seven days with electrophysiology in response to evoked compound action potentials (CAPs) in the corpus callosum. The peak latency of CAPs and axonal refractoriness was increased following hypoperfusion, indicating a marked functional impairment in white matter, which was paralleled by axonal and myelin pathology and increased density and numbers of microglia/macrophages. The functional impairment in peak latency was significantly correlated with increased microglia/macrophages. Dimethyl fumarate (DMF; 100mg/kg), a drug with anti-inflammatory properties, was found to reduce peak latency but not axonal refractoriness. DMF had no effect on hypoperfusion-induced axonal and myelin pathology. The density of microglia/macrophages was significantly increased in vehicle-treated hypoperfused mice, whereas DMF-treated hypoperfused mice had similar levels to that of sham-treated mice. The study suggests that increased microglia/macrophages following cerebral hypoperfusion contributes to the functional impairment in white matter that may be amenable to modulation by DMF.	[Fowler, Jill H.; McQueen, Jamie; Holland, Philip R.; Manso, Yasmina; Marangoni, Martina; Scott, Fiona; Chisholm, Emma; Horsburgh, Karen] Univ Edinburgh, Ctr Neuroregenerat, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland; [McQueen, Jamie; Hardingham, Giles E.] Univ Edinburgh, Ctr Integrat Physiol, Edinburgh, Midlothian, Scotland; [Holland, Philip R.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Basic & Clin Neurosci, London, England; [Manso, Yasmina] Dev Neurobiol & Regenerat Lab, Parc Cient Barcelona, Barcelona, Spain; [Marangoni, Martina] Univ Florence, Dept Hlth Sci, Florence, Italy; [Scannevin, Robert H.] Biogen, Cambridge, MA USA; [Hardingham, Giles E.] Univ Edinburgh, UK Dementia Res Inst, Edinburgh, Midlothian, Scotland; [Horsburgh, Karen] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland	Fowler, JH; Horsburgh, K (corresponding author), Univ Edinburgh, Ctr Neuroregenerat, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.	Jill.Fowler@ed.ac.uk; Karen.Horsburgh@ed.ac.uk		Hardingham, Giles/0000-0002-7629-5314; Marangoni, Martina/0000-0003-0706-6566; Horsburgh, Karen/0000-0002-9620-3691; Manso Sanz, Yasmina/0000-0002-5788-4180; Fowler, Jill/0000-0003-3204-1221; Holland, Philip Robert/0000-0003-3345-4853; McQueen, Jamie/0000-0001-7172-7504; Scannevin, Robert/0000-0002-5749-2785	Alzheimer's Society; Alzheimer Research UKAlzheimer's Research UK (ARUK); BiogenBiogen; Wellcome TrustWellcome TrustEuropean Commission; University of Edinburgh Centre for Cognitive Aging and Cognitive Epidemiology (CCACE), part of the Lifelong Health and Wellbeing Initiative [(G0700704/84698]; CCACE PhD studentship; Alzheimer's Society Fellowship [297]; Alzheimer's Research UK Senior Fellowship [ARUK-SRF2013-4]; Alzheimers Research UKAlzheimer&apos;s Research UK (ARUK) [ARUK-SRF2013-4] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0902044, UKDRI-4001, MR/K026992/1] Funding Source: researchfish	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Alzheimer's Society, Alzheimer Research UK, Biogen, Wellcome Trust and The University of Edinburgh Centre for Cognitive Aging and Cognitive Epidemiology (CCACE), part of the Lifelong Health and Wellbeing Initiative (G0700704/84698). J.M. was supported by a CCACE PhD studentship, J.H.F. was funded by an Alzheimer's Society Fellowship (Grant 297) and is currently funded by an Alzheimer's Research UK Senior Fellowship (Grant ARUK-SRF2013-4).	Ahuja M, 2016, J NEUROSCI, V36, P6332, DOI 10.1523/JNEUROSCI.0426-16.2016; Al-Jaderi Z, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00278; Baltan S, 2008, J NEUROSCI, V28, P1479, DOI 10.1523/JNEUROSCI.5137-07.2008; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brennan MS, 2016, ANTIOXID REDOX SIGN, V24, P1058, DOI 10.1089/ars.2015.6622; Chen L, 2015, SCI REP-UK, V5, DOI 10.1038/srep14308; Cho H, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0452-z; Cho KO, 2006, J NEUROSCI RES, V83, P285, DOI 10.1002/jnr.20727; Coltman R, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.09.005; Corcoba A., 2015, INT J NEUROPSYCHOPH, V19; Crawford DK, 2009, NEUROSCIENCE, V164, P1407, DOI 10.1016/j.neuroscience.2009.09.069; Crawford DK, 2009, J NEUROSCI METH, V182, P25, DOI 10.1016/j.jneumeth.2009.05.013; de Groot JC, 2002, ANN NEUROL, V52, P335, DOI 10.1002/ana.10294; Ellrichmann G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016172; Fernando MS, 2006, STROKE, V37, P1391, DOI 10.1161/01.STR.0000221308.94473.14; Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081; Goncharenko K, 2014, J NEUROPHYSIOL, V112, P2067, DOI 10.1152/jn.00037.2013; Hamner MA, 2015, J NEUROSCI, V35, P15599, DOI 10.1523/JNEUROSCI.2544-15.2015; Han RR, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0559-x; Holland PR, 2015, J CEREBR BLOOD F MET, V35, P1005, DOI 10.1038/jcbfm.2015.12; Holland PR, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.11.009; Hou X, 2015, NEUROSCIENCE, V297, P118, DOI 10.1016/j.neuroscience.2015.03.033; Iniaghe LO, 2015, NEUROBIOL DIS, V82, P349, DOI 10.1016/j.nbd.2015.07.001; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Jing X, 2015, NEUROSCIENCE, V286, P131, DOI 10.1016/j.neuroscience.2014.11.047; KIM JS, 1995, J NEUROIMMUNOL, V56, P127, DOI 10.1016/0165-5728(94)00138-E; Kunze R, 2015, EXP NEUROL, V266, P99, DOI 10.1016/j.expneurol.2015.02.022; Lambertsen KL, 2004, J NEUROPATH EXP NEUR, V63, P942, DOI 10.1093/jnen/63.9.942; Lastres-Becker I, 2016, ANTIOXID REDOX SIGN, V25, P61, DOI 10.1089/ars.2015.6549; Lee KM, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0652-1; Lin RH, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0733-1; Linker RA, 2011, BRAIN, V134, P678, DOI 10.1093/brain/awq386; Liu QH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084802; Liu YZ, 2015, J NEUROSURG, V123, P915, DOI 10.3171/2014.11.JNS132348; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Matute C, 2012, ASN NEURO, V4, P89, DOI 10.1042/AN20110060; McQueen J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087227; Michell-Robinson MA, 2016, ANN CLIN TRANSL NEUR, V3, P27, DOI 10.1002/acn3.270; Miki K, 2009, J NEUROSCI RES, V87, P1270, DOI 10.1002/jnr.21925; Miljkovic D, 2015, J IMMUNOL, V194, P2493, DOI 10.4049/jimmunol.1402302; Mirabelli-Badenier M, 2011, THROMB HAEMOSTASIS, V105, P409, DOI 10.1160/TH10-10-0662; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Moharregh-Khiabani D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011769; Moore S, 2013, NEUROSCIENCE, V245, P166, DOI 10.1016/j.neuroscience.2013.04.017; Moore S, 2014, J NEUROSCI RES, V92, P1621, DOI 10.1002/jnr.23440; Morsali D, 2013, BRAIN, V136, P1067, DOI 10.1093/brain/awt041; Murray KN, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00018; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Parodi B, 2015, ACTA NEUROPATHOL, V130, P279, DOI 10.1007/s00401-015-1422-3; Patel R, 2013, BRAIN PATHOL, V23, P462, DOI 10.1111/bpa.12029; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Pitarokoili K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143416; Prins ND, 2005, BRAIN, V128, P2034, DOI 10.1093/brain/awh553; Prins ND, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2015.10; Pryor J, 2006, SPINAL CORD, V44, P653, DOI 10.1038/sj.sc.3101901; Redford EJ, 1997, BRAIN, V120, P2149, DOI 10.1093/brain/120.12.2149; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2016, EXP NEUROL, V283, P188, DOI 10.1016/j.expneurol.2016.06.011; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reimer MM, 2011, J NEUROSCI, V31, P18185, DOI 10.1523/JNEUROSCI.4936-11.2011; Ritter J, 2013, J NEUROSCI, V33, P8990, DOI 10.1523/JNEUROSCI.5528-12.2013; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Schilling S, 2006, CLIN EXP IMMUNOL, V145, P101, DOI 10.1111/j.1365-2249.2006.03094.x; Schulze-Topphoff U, 2016, P NATL ACAD SCI USA, V113, P4777, DOI 10.1073/pnas.1603907113; Sun J, 2013, BRAIN RES, V1491, P225, DOI 10.1016/j.brainres.2012.11.006; Takami S, 1997, NEUROSCI LETT, V227, P173, DOI 10.1016/S0304-3940(97)00338-8; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; Tanaka K, 2001, NEUROREPORT, V12, P2169, DOI 10.1097/00001756-200107200-00025; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; Tsai TH, 2015, J HYPERTENS, V33, P1001, DOI 10.1097/HJH.0000000000000529; Ueno M, 2002, J CEREBR BLOOD F MET, V22, P97, DOI 10.1097/00004647-200201000-00012; Ueno Y, 2015, J CEREBR BLOOD F MET, V35, P382, DOI 10.1038/jcbfm.2014.210; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang JP, 2016, MOL NEUROBIOL, V53, P6057, DOI 10.1007/s12035-015-9512-8; Wang Y, 2016, PROG NEUROBIOL, V141, P45, DOI [10.1016/j.pneurobio.2016.04.00, 10.1016/j.pneurobio.2016.04.005]; Washida K, 2010, STROKE, V41, P1798, DOI 10.1161/STROKEAHA.110.583948; Wiesner D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076670; Wilms H, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-30; Yamagami S, 1999, J LEUKOCYTE BIOL, V65, P744; Yamazaki Y, 2010, NEUROSCIENTIST, V16, P11, DOI 10.1177/1073858409334425; Yao Y, 2016, TRANSL STROKE RES, V7, P535, DOI 10.1007/s12975-016-0496-0; Yoshizaki K, 2008, EXP NEUROL, V210, P585, DOI 10.1016/j.expneurol.2007.12.005; Yuan BQ, 2017, MOL CELL NEUROSCI, V78, P52, DOI 10.1016/j.mcn.2016.08.003; Zechariah A, 2013, STROKE, V44, P1690, DOI 10.1161/STROKEAHA.111.000240; Zhang JD, 2013, J NEUROSCI RES, V91, P240, DOI 10.1002/jnr.23150; Zhao XR, 2015, STROKE, V46, P1923, DOI 10.1161/STROKEAHA.115.009398	89	25	25	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2018	38	8					1354	1370		10.1177/0271678X17713105			17	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	GP2OQ	WOS:000440674900008	28606007	Green Published, Other Gold			2021-06-18	
J	Kerr, ZY; Comstock, RD; Dompier, TP; Marshall, SW				Kerr, Zachary Y.; Comstock, R. Dawn; Dompier, Thomas P.; Marshall, Stephen W.			The First Decade of Web-Based Sports Injury Surveillance (2004-2005 Through 2013-2014): Methods of the National Collegiate Athletic Association Injury Surveillance Program and High School Reporting Information Online	JOURNAL OF ATHLETIC TRAINING			English	Article							UNITED-STATES; CONSENSUS STATEMENT; SOCCER INJURIES; DATA-COLLECTION; FOOTBALL DATA; RISK-FACTORS; EPIDEMIOLOGY; SYSTEM; CONCUSSION; PREVENTION	Objective: To describe the methods of the National Collegiate Athletic Association (NCAA) Injury Surveillance Program (ISP) and High School Reporting Information Online (HS RIO) system as a complement to the sport-specific manuscripts that will follow. Background: The NCAA-ISP and HS RIO collect injury and exposure data from samples of collegiate and high school sports programs, respectively. The NCAA-ISP, which the NCAA has maintained since 1982, was relaunched as a Web-based platform at the beginning of the 2004-2005 academic year. In 2005, the HS RIO was introduced to capture data on high school athletes and modeled after the NCAA-ISP. Relevant data are shared with the NCAA and high school sport and policy committees to develop evidence-based rules and programs that help protect the health and safety of student-athletes. Description: The NCAA-ISP and HS RIO monitor participation in school-sanctioned competitions and practices that occur from the first preseason practice to the final postseason contest for more than 25 sports. For this series of publications in the Journal of Athletic Training, injury information on 13 sports at the collegiate level during the 2004-2005 through 2013-2014 academic years and the high school level during the 2005-2006 through 2013-2014 academic years was evaluated. Conclusions: Athletic trainers have been a vital source of data collection over the past decade to help produce the largest datasets of collegiate and high school sports injuries. Such data have helped various sport and policy committees advance protocols that aim to increase sports safety. This series of publications will aid by continuing to provide data to stakeholders in the sports community.	[Kerr, Zachary Y.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Marshall, Stephen W.] Univ North Carolina Chapel Hill, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Comstock, R. Dawn] Univ Colorado Anschutz, Colorado Sch Publ Hlth, Program Injury Prevent Educ & Res, Dept Epidemiol, Aurora, CO USA; [Comstock, R. Dawn] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Dompier, Thomas P.] Lebanon Valley Coll, Dept Athlet Training, Annville, PA USA; [Marshall, Stephen W.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA	Kerr, ZY (corresponding author), Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym CB 8700, Chapel Hill, NC 27599 USA.	zkerr@email.unc.edu			NCAA; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Center for Research Resources awardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2 RR025754]; National Federation of State High School Associations (Indianapolis, IN); National Operating Committee on Standards for Athletic Equipment (Overland Park, KS); DonJoy Orthotics (Vista, CA); EyeBlack (Potomac, MD)	The NCAA-ISP data were provided by the Datalys Center for Sports Injury Research and Prevention, Inc. The Injury Surveillance Program was funded by the NCAA. Funding for HS RIO was provided in part by the Centers for Disease Control and Prevention grants R49/CE000674-01 and R49/CE001172-01 and the National Center for Research Resources award KL2 RR025754. The authors also acknowledge the research funding contributions of the National Federation of State High School Associations (Indianapolis, IN), National Operating Committee on Standards for Athletic Equipment (Overland Park, KS), DonJoy Orthotics (Vista, CA), and EyeBlack (Potomac, MD). The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the funding organizations. We thank the many ATs who have volunteered their time and efforts to submit data to HS RIO and the NCAA-ISP. Their efforts are greatly appreciated and have had a tremendously positive effect on the safety of high school and collegiate student-athletes.	[Anonymous], 1997, MMWR Recomm Rep, V46, P1; Borowski LA, 2008, AM J SPORT MED, V36, P2328, DOI 10.1177/0363546508322893; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; Cross KM, 2013, AM J SPORT MED, V41, P742, DOI 10.1177/0363546513475342; Dick R, 2007, J ATHL TRAINING, V42, P173; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Dragoo JL, 2013, KNEE, V20, P191, DOI 10.1016/j.knee.2012.07.006; Dragoo JL, 2012, AM J SPORT MED, V40, P2066, DOI 10.1177/0363546512454653; Dragoo JL, 2012, AM J SPORT MED, V40, P990, DOI 10.1177/0363546512442336; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Fuller CW, 2006, SCAND J MED SCI SPOR, V16, P83, DOI 10.1111/j.1600-0838.2006.00528.x; Howard AF, 2014, J ADOLESCENT HEALTH, V55, P627, DOI 10.1016/j.jadohealth.2014.05.013; Hunt KJ, 2013, CLIN J SPORT MED, V23, P278, DOI 10.1097/JSM.0b013e31827ee829; Kerr ZY, 2017, NEUROL CLIN, V35, P409, DOI 10.1016/j.ncl.2017.03.001; Kerr ZY, 2015, MMWR-MORBID MORTAL W, V64, P1330, DOI 10.15585/mmwr.mm6448a2; Kerr ZY, 2015, J ATHL TRAINING, V50, P870, DOI 10.4085/1062-6050-50.7.02; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kerr ZY, 2011, CLIN PEDIATR, V50, P594, DOI 10.1177/0009922810390513; Kerr ZY, 2011, CLIN J SPORT MED, V21, P101, DOI 10.1097/JSM.0b013e31820bd1b6; Kucera KL, 2011, J ATHL TRAINING, V46, P489; Last JM, 2001, DICT EPIDEMIOLOGY; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; National Collegiate Athletic Association, STUD ATHL PART 1981; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Robinson TW, 2014, PEDIATRICS, V133, P272, DOI 10.1542/peds.2013-2279; Stovitz SD, 2012, BRIT J SPORT MED, V46, P960, DOI 10.1136/bjsports-2011-090693; Swenson DM, 2013, MED SCI SPORT EXER, V45, P462, DOI 10.1249/MSS.0b013e318277acca; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	35	25	25	0	7	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	AUG	2018	53	8					729	737		10.4085/1062-6050-143-17			9	Sport Sciences	Sport Sciences	GW7OJ	WOS:000447157700004	30024769	Green Published, Bronze			2021-06-18	
J	Gugliandolo, E; D'Amico, R; Cordaro, M; Fusco, R; Siracusa, R; Crupi, R; Impellizzeri, D; Cuzzocrea, S; Di Paola, R				Gugliandolo, Enrico; D'Amico, Ramona; Cordaro, Marika; Fusco, Roberta; Siracusa, Rosalba; Crupi, Rosalie; Impellizzeri, Daniela; Cuzzocrea, Salvatore; Di Paola, Rosanna			Neuroprotective Effect of Artesunate in Experimental Model of Traumatic Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; neuroin flammation; neurodegeneration; artesunate; artemisin	CONTROLLED CORTICAL IMPACT; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; POSTTRAUMATIC NEURODEGENERATION; NLRP3 INFLAMMASOME; IN-VIVO; EXPRESSION; MICE; ACTIVATION; ARTEMISININ	Traumatic brain injuries (TBI) are an important public health challenge. In addition, subsequent events at TBI can compromise the quality of life of these patients. In fact, TBI is associated with several complications for both long and short term, some evidence shows how TBI is associated with a decline in cognitive functions such as the risk of developing dementia, cerebral atrophy, and Parkinson disease. After the direct damage from TBI, a key role in TBI injury is played by the inflammatory response and oxidative stress, that contributes to tissue damage and to neurodegenerative processes, typical of secondary injury, after TBI. Given the complex series of events that are involved after TBI injury, a multitarget pharmacological approach is needed. Artesunate is a more stable derivative of its precursor artemisin, a sesquiterpene lactone obtained from a Chinese plant Artemisia annua, a plant used for centuries in traditional Chinese medicine. artesunate has been shown to be a pluripotent agent with different pharmacological actions. therefore, in this experimental model of TBI we evaluated whether the treatment with artesunate at the dose of 30mg\Kg, had an efficacy in reducing the neuroinflammatory process after TBI injury, and in inhibiting the NLRP3 inflammasome pathway, which plays a key role in the inflammatory process. We also assessed whether treatment with artesunate was able to exert a neuroprotective action by modulating the release of neurotrophic factors. our results show that artesunate was able to reduce the TBI-induced lesion, it also showed an anti-inflammatory action through the inhibition of Nf-kappa b, release of proinflammatory cytokines IL-1 beta and TNF-alpha and through the inhibition NLRP3 inflammasome complex, furthermore was able to reduce the activation of astrocytes and microglia (GFAP, Iba-1). Finally, our results show that the protective effects of artesunate also occur through the modulation of neurotrophic factors (BDNF, GDNF, NT-3) that play a key role in neuronal survival.	[Gugliandolo, Enrico; D'Amico, Ramona; Cordaro, Marika; Fusco, Roberta; Siracusa, Rosalba; Crupi, Rosalie; Impellizzeri, Daniela; Cuzzocrea, Salvatore; Di Paola, Rosanna] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Messina, Italy; [Cuzzocrea, Salvatore] St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63103 USA	Cuzzocrea, S (corresponding author), Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Messina, Italy.	salvator@unime.it	Cordaro, Marika/K-7329-2016; Gugliandolo, Enrico/AAB-9972-2019; D'Amico, Ramona/AAC-9061-2019; FUSCO, Roberta/AAC-1745-2019; di paola, rosanna/U-4356-2019	Cordaro, Marika/0000-0002-3980-0043; Gugliandolo, Enrico/0000-0001-6840-3154; D'Amico, Ramona/0000-0003-0389-3871; FUSCO, Roberta/0000-0003-0223-1403; di paola, rosanna/0000-0001-6725-8581; Impellizzeri, Daniela/0000-0001-9492-3161; Crupi, Rosalia/0000-0002-7629-3132; Siracusa, Rosalba/0000-0001-7868-2505			Alafuzoff I, 2008, BRAIN PATHOL, V18, P484, DOI 10.1111/j.1750-3639.2008.00147.x; Beccafico S, 2015, CARCINOGENESIS, V36, P1071, DOI 10.1093/carcin/bgv098; Berger TG, 2005, ONCOL REP, V14, P1599; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Campolo M, 2018, METHODS MOL BIOL, V1727, P385, DOI 10.1007/978-1-4939-7571-6_30; Campolo M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0196-1; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Carbo-Gas M, 2014, ADDICT BIOL, V19, P61, DOI 10.1111/adb.12042; Cheng C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020932; Clemmer L, 2011, ANTIMICROB AGENTS CH, V55, P1383, DOI 10.1128/AAC.01277-10; Cordaro M, 2016, J NEUROTRAUM, V33, P132, DOI 10.1089/neu.2014.3460; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Efferth T, 2010, CRIT REV TOXICOL, V40, P405, DOI 10.3109/10408441003610571; Elliott EI, 2015, IMMUNOL REV, V265, P35, DOI 10.1111/imr.12286; Esposito E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041880; Esposito E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-66; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Guevara AB, 2015, J HEAD TRAUMA REHAB, V30, pE26, DOI 10.1097/HTR.0000000000000046; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Impellizzeri D, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00458; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Jennings JS, 2008, MINI-REV MED CHEM, V8, P689, DOI 10.2174/138955708784567377; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Li B, 2010, INT IMMUNOPHARMACOL, V10, P344, DOI 10.1016/j.intimp.2009.12.006; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Minnich JE, 2010, RESTOR NEUROL NEUROS, V28, P293, DOI 10.3233/RNN-2010-0528; Miranda AS, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-388; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mueller FJ, 2005, E SCHERING RES FDN W, V53, P83; Nosten F, 2007, AM J TROP MED HYG, V77, P181, DOI 10.4269/ajtmh.2007.77.181; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Patsouris D, 2008, CELL METAB, V8, P301, DOI 10.1016/j.cmet.2008.08.015; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RINK A, 1995, AM J PATHOL, V147, P1575; Rosenthal PJ, 2008, NEW ENGL J MED, V358, P1829, DOI 10.1056/NEJMct0709050; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Vazquez-Sanroman D, 2013, BEHAV BRAIN RES, V243, P118, DOI 10.1016/j.bbr.2012.12.047; Wang DJ, 2015, INFLAMMATION, V38, P1925, DOI 10.1007/s10753-015-0172-7; Woodrow CJ, 2005, POSTGRAD MED J, V81, P71, DOI 10.1136/pgmj.2004.028399; Zhao MF, 2016, MOL MED REP, V13, P13, DOI 10.3892/mmr.2015.4551; Zhou DJ, 2011, J INFECT DIS, V203, P1647, DOI 10.1093/infdis/jir163; Zuo SL, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1489050	59	25	26	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JUL 31	2018	9								590	10.3389/fneur.2018.00590			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GO8MY	WOS:000440346000001	30108544	DOAJ Gold, Green Published			2021-06-18	
J	Gold, EM; Vasilevko, V; Hasselmann, J; Tiefenthaler, C; Hoa, D; Ranawaka, K; Cribbs, DH; Cummings, BJ				Gold, Eric M.; Vasilevko, Vitaly; Hasselmann, Jonathan; Tiefenthaler, Casey; Hoa, Danny; Ranawaka, Kasuni; Cribbs, David H.; Cummings, Brian J.			Repeated Mild Closed Head Injuries Induce Long-Term White Matter Pathology and Neuronal Loss That Are Correlated With Behavioral Deficits	ASN NEURO			English	Article						animal models; behavioral assessment; cognitive function; concussion; inflammation; traumatic brain injury; closed head injury	TRAUMATIC BRAIN-INJURY; NEURAL STEM-CELLS; DENDRITIC SPINE LOSS; MOUSE MODEL; UNITED-STATES; TRACT ABNORMALITIES; FUNCTIONAL RECOVERY; PLUS-MAZE; RAT MODEL; HUMAN TAU	An estimated 5.3 million Americans are living with a disability from a traumatic brain injury (TBI). There is emerging evidence of the detrimental effects from repeated mild TBIs (rmTBIs). rmTBI manifests its own unique set of behavioral and neuropathological changes. A subset of individuals exposed to rmTBI develop permanent behavioral and pathological consequences, defined postmortem as chronic traumatic encephalopathy. We have combined components of two classic rodent models of TBI, the controlled cortical impact model and the weight drop model, to develop a repeated mild closed head injury (rmCHI) that produces long-term deficits in several behaviors that correlate with neuropathological changes. Mice receiving rmCHI performed differently from 1-hit or sham controls on the elevated plus maze; these deficits persist up to 6 months postinjury (MPI). rmCHI mice performed worse than 1-hit and control sham mice at 2 MPI and 6 MPI on the Morris water maze. Mice receiving rmCHI exhibited significant atrophy of the corpus callosum at both 2 MPI and 6 MPI, as assessed by stereological volume analysis. Stereological analysis also revealed significant loss of cortical neurons in comparison with 1-hit and controls. Moreover, both of these pathological changes correlated with behavioral impairments. In human tau transgenic mice, rmCHI induced increases in hyperphosphorylated paired helical filament 1 tau in the hippocampus. This suggests that strategies to restore myelination or reduce neuronal loss may ameliorate the behavioral deficits observed following rmCHI and that rmCHI may model chronic traumatic encephalopathy in human tau mice.	[Gold, Eric M.; Hasselmann, Jonathan; Tiefenthaler, Casey; Hoa, Danny; Ranawaka, Kasuni; Cummings, Brian J.] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA; [Gold, Eric M.; Tiefenthaler, Casey; Hoa, Danny; Ranawaka, Kasuni; Cummings, Brian J.] Univ Calif Irvine, Sue & Bill Gross Stem Cell Ctr, Room 2026 Gross Hall,845 Hlth Sci Rd, Irvine, CA 92697 USA; [Vasilevko, Vitaly; Hasselmann, Jonathan; Cribbs, David H.; Cummings, Brian J.] Univ Calif Irvine, UCI Inst Memory Impairments & Neurol Disorders, Irvine, CA USA; [Cummings, Brian J.] Univ Calif Irvine, Dept Phys Med & Rehabil, Irvine, CA USA	Cummings, BJ (corresponding author), Univ Calif Irvine, Sue & Bill Gross Stem Cell Ctr, Room 2026 Gross Hall,845 Hlth Sci Rd, Irvine, CA 92697 USA.	Cummings@uci.edu	Cummings, Brian J/C-9180-2012	Cummings, Brian J/0000-0003-3628-5290; Hasselmann, Jonathan/0000-0003-2630-9850; Ranawaka, Ranawaka Kasuni/0000-0003-0881-4087	California Institute for Regenerative Medicine (CIRM): Early Translational Award [TR2-01767]; Department of DefenseUnited States Department of Defense [W81XWH-15-1-0435 (MR 141282)]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 AG00096-30, T32 NS082174-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS082174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000096] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The preceding studies were supported by a grant from the California Institute for Regenerative Medicine (CIRM): Early Translational Award TR2-01767 awarded to B. J. C., a grant from the Department of Defense, W81XWH-15-1-0435 (MR 141282), to Cathy Cahill and B. J. C., and Predoctoral Fellowships from the National Institutes of Health for "Training in the Neurobiology of Aging" (T32 AG00096-30) and for "Training Program in Stem Cell Translational Medicine for Neurological Disorders" (T32 NS082174-01) awarded to E. M. G.	Abisambra JF, 2014, J ALZHEIMERS DIS, V40, P495, DOI 10.3233/JAD-131019; Acabchuk R., 2016, CONCUSSION, V1, P1; Anderson AJ, 2011, REGEN MED, V6, P367, DOI [10.2217/RME.11.22, 10.2217/rme.11.22]; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Arciniegas DB, 2014, PSYCHIAT CLIN N AM, V37, P31, DOI 10.1016/j.psc.2013.12.001; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bennett R. E., 2014, J NEUROTRAUM, V17, P1; Beretta S, 2017, CELL TRANSPLANT, V26, P1247, DOI 10.1177/0963689717714107; Bond-Lamberty B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150599; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Chabrier MA, 2014, NEUROBIOL DIS, V64, P107, DOI 10.1016/j.nbd.2014.01.007; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Cummings BJ, 2007, BEHAV BRAIN RES, V177, P232, DOI 10.1016/j.bbr.2006.11.042; Dagher NN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0366-9; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flygt J, 2017, RESTOR NEUROL NEUROS, V35, P251, DOI 10.3233/RNN-160675; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Gerberding JL, 2003, REP C MILD TRAUM BRA; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Haus DL, 2016, EXP NEUROL, V281, P1, DOI 10.1016/j.expneurol.2016.04.008; Henderson VC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001489; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kirby BB, 2006, NAT NEUROSCI, V9, P1506, DOI 10.1038/nn1803; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; Laskowski RA, 2015, BRAIN NEUROTRAUMA MO, P35; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Main B. S., 2017, JOVE-J VIS EXP, P124; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; MOSER E, 1993, J NEUROSCI, V13, P3916; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Mul JD, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0201-16.2016; Multani N, 2016, J NEUROL, V263, P1332, DOI 10.1007/s00415-016-8141-0; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Nichols JN, 2016, BEHAV BRAIN RES, V298, P111, DOI 10.1016/j.bbr.2015.10.052; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Petit-Demouliere B, 2005, PSYCHOPHARMACOLOGY, V177, P245, DOI 10.1007/s00213-004-2048-7; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; RODGERS RJ, 1995, PHARMACOL BIOCHEM BE, V52, P297, DOI 10.1016/0091-3057(95)00138-M; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wang EY, 2012, J NEUROTRAUM, V29, P295, DOI 10.1089/neu.2011.2043; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Wojnarowicz MW, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00240	81	25	25	2	19	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1759-0914			ASN NEURO	ASN Neuro	JUN 22	2018	10								1759091418781921	10.1177/1759091418781921			25	Neurosciences	Neurosciences & Neurology	GK2NE	WOS:000435967100001	29932344	DOAJ Gold, Green Published			2021-06-18	
J	Erdodi, LA; Sagar, S; Seke, K; Zuccato, BG; Schwartz, ES; Roth, RM				Erdodi, Laszlo A.; Sagar, Sanya; Seke, Kristian; Zuccato, Brandon G.; Schwartz, Eben S.; Roth, Robert M.			The Stroop Test as a Measure of Performance Validity in Adults Clinically Referred for Neuropsychological Assessment	PSYCHOLOGICAL ASSESSMENT			English	Article						Stroop task; performance validity; embedded validity indicators	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; RECOGNITION MEMORY TEST; COMPLEX FIGURE TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; NEGATIVE RESPONSE BIAS; CARD SORTING TEST; WORD CHOICE TEST; SYMPTOM VALIDITY; TEST-II	This study was designed to develop performance validity indicators embedded within the Delis-Kaplan Executive Function Systems (D-KEFS) version of the Stroop task. Archival data from a mixed clinical sample of 132 patients (50% male; M-Age = 43.4; M-Education = 14.1) clinically referred for neuropsychological assessment were analyzed. Criterion measures included the Warrington Recognition Memory Test-Words and 2 composites based on several independent validity indicators. An age-corrected scaled score <= 6 on any of the 4 trials reliably differentiated psychometrically defined credible and noncredible response sets with high specificity (.87-.94) and variable sensitivity (.34 -.71). An inverted Stroop effect was less sensitive (.14 -.29), but comparably specific (.85-90) to invalid performance. Aggregating the newly developed D-KEFS Stroop validity indicators further improved classification accuracy. Failing the validity cutoffs was unrelated to self-reported depression or anxiety. However, it was associated with elevated somatic symptom report. In addition to processing speed and executive function, the D-KEFS version of the Stroop task can function as a measure of performance validity. A multivariate approach to performance validity assessment is generally superior to univariate models.	[Erdodi, Laszlo A.; Sagar, Sanya; Zuccato, Brandon G.] Univ Windsor, Dept Psychol, Windsor, ON, Canada; [Seke, Kristian] Univ Windsor, Brain Cognit Neurosci Program, Windsor, ON, Canada; [Schwartz, Eben S.] Waukesha Mem Hosp, Waukesha, WI USA; [Roth, Robert M.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Lebanon, NH 03766 USA	Erdodi, LA (corresponding author), 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com		Sagar, Sanya/0000-0001-7381-0803			Arentsen TJ, 2013, CLIN NEUROPSYCHOL, V27, P1060, DOI 10.1080/13854046.2013.803603; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Baker DA, 2014, CLIN NEUROPSYCHOL, V28, P116, DOI 10.1080/13854046.2013.858184; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Blaskewitz N, 2009, APPL NEUROPSYCHOL, V16, P54, DOI 10.1080/09084280802644227; BLONDER LX, 1989, BRAIN COGNITION, V9, P244, DOI 10.1016/0278-2626(89)90034-1; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; COMALLI PE, 1962, J GENET PSYCHOL, V100, P47, DOI 10.1080/00221325.1962.10533572; Considine CM, 2011, ARCH CLIN NEUROPSYCH, V26, P445, DOI 10.1093/arclin/acr041; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Egeland J, 2007, APPL NEUROPSYCHOL, V14, P113, DOI 10.1080/09084280701319953; Erdodi L. A., 2016, APPL NEUROPSYCHOL, V22, P851; Erdodi L, 2017, APPL NEUROPSYCH-ADUL, V24, P264, DOI 10.1080/23279095.2016.1154856; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Erdodi LA, 2014, APPL NEUROPSYCH-ADUL, V21, P43, DOI 10.1080/09084282.2012.724036; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Golden C., 2002, MANUAL ADULT STROOP; Green P., 2013, CLIN PRACTICE FORENS; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, ARCH PHYS MED REHAB, V90, P1117, DOI 10.1016/j.apmr.2009.01.018; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Guise BJ, 2014, J NEUROPSYCHOL, V8, P20, DOI 10.1111/jnp.12002; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Lansbergen MM, 2007, NEUROPSYCHOLOGY, V21, P251, DOI 10.1037/0894-4105.21.2.251; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Lippa SM, 2010, ARCH CLIN NEUROPSYCH, V25, P146, DOI 10.1093/arclin/acq001; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; MacLeod CM, 2000, TRENDS COGN SCI, V4, P383, DOI 10.1016/S1364-6613(00)01530-8; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Osimani A, 1997, J NEUROL NEUROSUR PS, V62, P617, DOI 10.1136/jnnp.62.6.617; Pearson NCS., 2009, ADV CLIN SOLUTIONS W; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; SAYKIN AJ, 1995, EPILEPSIA, V36, P1071, DOI 10.1111/j.1528-1157.1995.tb00464.x; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; Schutte C, 2015, PSYCHOL INJ LAW, V8, P100, DOI 10.1007/s12207-015-9225-3; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Vallabhajosula B, 2001, J AM ACAD PSYCHIATRY, V29, P207; Whiteside D, 2010, CLIN NEUROPSYCHOL, V24, P315, DOI 10.1080/13854040903482822; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	78	25	26	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	JUN	2018	30	6					755	766		10.1037/pas0000525			12	Psychology, Clinical	Psychology	GH5YS	WOS:000433515100005	29470092				2021-06-18	
J	Jullienne, A; Salehi, A; Affeldt, B; Baghchechi, M; Haddad, E; Avitua, A; Walsworth, M; Enjalric, I; Hamer, M; Bhakta, S; Tang, JP; Zhang, JH; Pearce, WJ; Obenaus, A				Jullienne, Amandine; Salehi, Arjang; Affeldt, Bethann; Baghchechi, Mohsen; Haddad, Elizabeth; Avitua, Angela; Walsworth, Mark; Enjalric, Isabelle; Hamer, Mary; Bhakta, Sonali; Tang, Jiping; Zhang, John H.; Pearce, William J.; Obenaus, Andre			Male and Female Mice Exhibit Divergent Responses of the Cortical Vasculature to Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; heme oxygenase-1; sex difference; vasculature; Wnt/beta-catenin	SEX-DIFFERENCES; INFLAMMATORY RESPONSE; VONWILLEBRAND-FACTOR; GENDER-DIFFERENCES; IMPACT INJURY; HEAD-INJURY; ESTROGEN; NEURODEGENERATION; PROGESTERONE; RECOVERY	We previously reported that traumatic brain injuries (TBI) alter the cerebrovasculature near the injury site in rats, followed by revascularization over a 2-week period. Here, we tested our hypothesis that male and female adult mice have differential cerebrovascular responses following a moderate controlled cortical impact (CCI). Using in vivo magnetic resonance imaging (MRI), a new technique called vessel painting, and immunohistochemistry, we found no differences between males and females in lesion volume, neurodegeneration, blood-brain barrier (BBB) alteration, and microglia activation. However, females exhibited more astrocytic hypertrophy and heme-oxygenase-1 (HO-1) induction at 1 day post-injury (dpi), whereas males presented with increased endothelial activation and expression of beta-catenin, shown to be involved in angiogenesis. At 7dpi, we observed an increase in the number of vessels and an enhancement in vessel complexity in the injured cortex of males compared with females. Cerebrovasculature recovers differently after CCI, suggesting biological sex should be considered when designing new therapeutic agents.	[Jullienne, Amandine; Salehi, Arjang; Affeldt, Bethann; Baghchechi, Mohsen; Haddad, Elizabeth; Avitua, Angela; Walsworth, Mark; Enjalric, Isabelle; Hamer, Mary; Bhakta, Sonali; Obenaus, Andre] Loma Linda Univ, Dept Basic Sci, Loma Linda, CA 92350 USA; [Tang, Jiping; Zhang, John H.; Pearce, William J.] Loma Linda Univ, Dept Physiol & Pharmacol, Loma Linda, CA 92350 USA; [Zhang, John H.] Loma Linda Univ, Dept Anesthesiol, Loma Linda, CA 92350 USA; [Zhang, John H.] Loma Linda Univ, Dept Neurosurg, Loma Linda, CA 92350 USA; [Pearce, William J.] Loma Linda Univ, Ctr Perinatal Biol, Loma Linda, CA 92350 USA; [Obenaus, Andre] Univ Calif Irvine, Dept Pediat, Hewitt Hall,Room 2066, Irvine, CA 92697 USA	Obenaus, A (corresponding author), Univ Calif Irvine, Dept Pediat, Hewitt Hall,Room 2066, Irvine, CA 92697 USA.	obenausa@uci.edu	Bhakta, Sonali/K-6996-2019; Jullienne, Amandine/H-3081-2019	Jullienne, Amandine/0000-0001-9458-055X; Pearce, William/0000-0002-5331-5677; Haddad, Elizabeth/0000-0002-7622-9085	NIH Program Project grant from NINDS [POINS082184]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD083132] Funding Source: NIH RePORTER	We would like to thank Saburi Eliamani for acquiring the MRI data. This study was supported by a NIH Program Project grant from NINDS (POINS082184, Project 3).	Acaz-Fonseca E., 2015, GLIA; Ahnstedt H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062698; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Arias C, 2009, HORM BEHAV, V55, P257, DOI 10.1016/j.yhbeh.2008.10.016; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Barreto GE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00132; Bhalla RC, 1997, AM J PHYSIOL-HEART C, V272, pH1996; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Caplan HW, 2017, J NEUROSCI RES, V95, P509, DOI 10.1002/jnr.23854; Chenu C, 2017, ARTERIOSCL THROM VAS, V37, P909, DOI 10.1161/ATVBAHA.117.309219; Chisholm NC, 2016, NEUROBIOL DIS, V85, P245, DOI 10.1016/j.nbd.2015.03.028; Cordeau P, 2008, STROKE, V39, P935, DOI 10.1161/STROKEAHA.107.501460; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cosgrove KP, 2007, BIOL PSYCHIAT, V62, P847, DOI 10.1016/j.biopsych.2007.03.001; Covassin T, 2003, J ATHL TRAINING, V38, P238; Donovan V, 2012, NEUROIMAGE-CLIN, V1, P18, DOI 10.1016/j.nicl.2012.08.001; Dulak J, 2004, ANTIOXID REDOX SIGN, V6, P858, DOI 10.1089/1523086041797980; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ghosh N, 2014, MED IMAGE ANAL, V18, P1059, DOI 10.1016/j.media.2014.05.002; Ghosh N, 2011, J MAGN RESON IMAGING, V33, P772, DOI 10.1002/jmri.22488; Gunther M, 2015, ACTA NEUROCHIR, V157, P649, DOI 10.1007/s00701-014-2331-2; Haast RAM, 2012, J CEREBR BLOOD F MET, V32, P2100, DOI 10.1038/jcbfm.2012.141; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Hirschberg R, 2008, FUTUR NEUROL, V3, P483, DOI 10.2217/14796708.3.4.483; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hughes S, 2014, METHODS MOL BIOL, V1135, P127, DOI 10.1007/978-1-4939-0320-7_12; Immonen R, 2010, J CEREBR BLOOD F MET, V30, P1318, DOI 10.1038/jcbfm.2010.15; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Krasinski K, 1997, CIRCULATION, V95, P1768; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Mannix R, 2014, J NEUROSURG, V121, P1337, DOI 10.3171/2014.8.JNS14715; McCarthy MM, 2012, J NEUROSCI, V32, P2241, DOI 10.1523/JNEUROSCI.5372-11.2012; Meyer MR, 2006, HYPERTENSION, V47, P1019, DOI 10.1161/01.HYP.0000223064.62762.0b; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; Obenaus A., 2015, ENCY MENTAL HLTH, P329; Obenaus A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00161-4; Ossei-Gerning N, 1998, THROMB HAEMOSTASIS, V79, P736; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pearce WJ, 2016, AM J PHYSIOL-REG I, V311, pR1093, DOI 10.1152/ajpregu.00240.2016; Perez-Barcena J, 2015, J NEUROL SCI, V353, P38, DOI 10.1016/j.jns.2015.03.044; Randi AM, 2017, J THROMB HAEMOST, V15, P13, DOI 10.1111/jth.13551; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Salehi A, 2018, J CEREBR BLOOD F MET, V38, P274, DOI 10.1177/0271678X17744124; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; SARJI KE, 1975, THROMB RES, V7, P885, DOI 10.1016/0049-3848(75)90092-4; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Scott EL, 2013, BRAIN RES, V1514, P63, DOI 10.1016/j.brainres.2012.12.015; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Shansky RM, 2016, J NEUROSCI, V36, P11817, DOI 10.1523/JNEUROSCI.1390-16.2016; Sharp FR, 2013, TRANSL STROKE RES, V4, P685, DOI 10.1007/s12975-013-0271-4; Sieveking DP, 2010, J EXP MED, V207, P345, DOI 10.1084/jem.20091924; SPORN LA, 1989, J CELL BIOL, V108, P1283, DOI 10.1083/jcb.108.4.1283; Toth B, 2003, ARCH SURG-CHICAGO, V138, P1375, DOI 10.1001/archsurg.138.12.1375; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wang LF, 2016, SCI REP-UK, V6, DOI 10.1038/srep26358; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zhang XM, 2008, NEUROTOXICOLOGY, V29, P406, DOI 10.1016/j.neuro.2008.01.006; Zheng MZ, 2016, ACTA NEUROCHIR SUPPL, V121, P367, DOI 10.1007/978-3-319-18497-5_63; Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385	79	25	25	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	14					1646	1658		10.1089/neu.2017.5547		MAY 2018	13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GK9FP	WOS:000431584200001	29648973	Green Published			2021-06-18	
J	Liu, B; Gao, JM; Li, F; Gong, QH; Shi, JS				Liu, Bo; Gao, Jian-Mei; Li, Fei; Gong, Qi-Hai; Shi, Jing-Shan			Gastrodin Attenuates Bilateral Common Carotid Artery Occlusion-Induced Cognitive Deficits via Regulating A beta-Related Proteins and Reducing Autophagy and Apoptosis in Rats	FRONTIERS IN PHARMACOLOGY			English	Article						gastrodin; cognitive deficits; hippocampus; A beta-related proteins; autophagy; apoptosis	CHRONIC CEREBRAL HYPOPERFUSION; AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; MEMORY IMPAIRMENT; CELLS; MODEL; MICE; ACTIVATION	Gastrodin (GAS), an active constituent extracted from Gastrodia elata Blume, is used to treat ischemic stroke, epilepsy, dizziness, and dementia for centuries in China. This study examined its effects on vascular dementia (VD) and the underlying molecular mechanisms. VD was established by ligation of bilateral common carotid artery occlusion (BCCAO). A total of 7 days after BCCAO surgery, GAS (15, 30, and 60 mg/kg) was orally administered for 28 consecutive days to evaluate therapeutic effects. Cognitive function was tested by the Morris water maze. The neuronal morphological changes were examined via Hematoxylin-Eosin staining. Flow cytometry was used for evaluating apoptosis in the hippocampi. The target protein expression was examined by Western blot. The results showed that BCCAO induced cognitive impairment, hippocampus CA1 and CA3 pyramidal neuron damage, beta-amyloid (A beta) deposition, excessive autophagy, and apoptosis. GAS treatment significantly improved BCCAO-induced cognitive deficits and hippocampus neuron damage. Molecular analysis revealed that GAS exerted the protective effect via reducing the levels of A beta 140/42, APP, and beta-site APP-cleaving enzyme 1 expression, and increasing Ab-related protein, a disintegrin and metalloprotease 10, and insulin degrading enzyme expression. Meanwhile, GAS inhibited excessive autophagy via decreasing Beclin-1, LC3-II, and p62 levels. Furthermore, GAS inhibited apoptosis through the downregulation of Bax and upregulation of Bcl-2. Moreover, P38 MAPK signaling pathway was involved in the process. Our findings demonstrate that GAS was effective in the treatment of BCCAOinduced VD via targeting A beta-related protein formation and inhibiting autophagy and apoptosis of hippocampus neurons.	[Liu, Bo] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai, Peoples R China; [Liu, Bo; Gao, Jian-Mei; Li, Fei; Gong, Qi-Hai; Shi, Jing-Shan] Zunyi Med Univ, Minist Educ, Key Lab Basic Pharmacol, Zunyi, Peoples R China; [Liu, Bo; Gao, Jian-Mei; Li, Fei; Gong, Qi-Hai; Shi, Jing-Shan] Zunyi Med Univ, Minist Educ, Joint Int Res Lab Ethnomed, Zunyi, Peoples R China	Shi, JS (corresponding author), Zunyi Med Univ, Minist Educ, Key Lab Basic Pharmacol, Zunyi, Peoples R China.; Shi, JS (corresponding author), Zunyi Med Univ, Minist Educ, Joint Int Res Lab Ethnomed, Zunyi, Peoples R China.	shijingshan2018@163.com	shan, Shi Jing/AAX-7736-2020; Qihai, Gong/AAM-9343-2021	shan, Shi Jing/0000-0002-2537-1751; 	Brainstorm Project on Social Development by Department of Science and Technology of Guizhou Province [JZ (2014) 2015]	The present study was supported by the Brainstorm Project on Social Development by Department of Science and Technology of Guizhou Province [Grant No. JZ (2014) 2015].	Cai ZY, 2017, NEUROCHEM RES, V42, P3446, DOI 10.1007/s11064-017-2391-9; Choi BR, 2011, STROKE, V42, P2595, DOI 10.1161/STROKEAHA.111.620179; Corrigan F, 2012, J NEUROCHEM, V122, P208, DOI 10.1111/j.1471-4159.2012.07761.x; Corrigan F, 2012, BRAIN RES, V1451, P87, DOI 10.1016/j.brainres.2012.02.045; Erisgin Z, 2017, BRATISL MED J, V118, P107, DOI 10.4149/BLL_2017_022; Gao CT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121338; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004; Han HH, 2015, NEUROREPORT, V26, P723, DOI 10.1097/WNR.0000000000000424; Han R, 2014, ACTA PHARMACOL SIN, V35, P1323, DOI 10.1038/aps.2014.62; Hu M, 2017, BEHAV BRAIN RES, V325, P79, DOI 10.1016/j.bbr.2016.11.053; Jang JH, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/309261; Jeong S, 2017, MOL CELLS, V40, P613, DOI [10.14348/molcells.2017.0096b, 10.14348/molcells.2017.0096]; Jiang GL, 2014, NEUROCHEM INT, V75, P79, DOI 10.1016/j.neuint.2014.06.003; Jiang Q, 2013, FEBS LETT, V587, P2420, DOI 10.1016/j.febslet.2013.06.011; Jin M, 2018, NEUROCHEM RES, V43, P904, DOI 10.1007/s11064-018-2496-9; Jiwa NS, 2010, J NEUROCHEM, V115, P814, DOI 10.1111/j.1471-4159.2010.06958.x; Kim G, 2018, INT J OBESITY, V42, P542, DOI 10.1038/ijo.2017.222; Kukreja L, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-16; Li M, 2016, J MOL NEUROSCI, V60, P21, DOI 10.1007/s12031-016-0758-z; Li WX, 2015, PHARMACOL BIOCHEM BE, V138, P40, DOI 10.1016/j.pbb.2015.09.001; Liu B, 2016, MOL MED REP, V14, P4144, DOI 10.3892/mmr.2016.5785; Liu Y, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00024; Maloney B, 2011, GENE, V488, P1, DOI 10.1016/j.gene.2011.06.004; Meineck Myriam, 2016, Medicines (Basel), V3, DOI 10.3390/medicines3040030; Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2; Nagatani K, 2012, SHOCK, V37, P645, DOI 10.1097/SHK.0b013e31824ed57c; Reijmer YD, 2016, J CEREBR BLOOD F MET, V36, P40, DOI 10.1038/jcbfm.2015.88; Schutte B, 1998, J NEUROSCI METH, V86, P63, DOI 10.1016/S0165-0270(98)00147-2; Shin JY, 2014, AUTOPHAGY, V10, P32, DOI 10.4161/auto.26508; Smith EE, 2017, CLIN SCI, V131, P1059, DOI 10.1042/CS20160607; Song B, 2013, NEURAL REGEN RES, V8, P2449, DOI 10.3969/j.issn.1673-5374.2013.26.006; Stargardt A, 2013, AGING CELL, V12, P499, DOI 10.1111/acel.12074; Wang XS, 2016, PHYTOTHER RES, V30, P386, DOI 10.1002/ptr.5538; Won JS, 2013, J ALZHEIMERS DIS, V34, P621, DOI 10.3233/JAD-121786; Xiong ZL, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00238; Xu Y, 2014, MED MICROBIOL IMMUN, V203, P73, DOI 10.1007/s00430-013-0316-z; Xue Q, 2015, PHOTODIAGN PHOTODYN, V12, P84, DOI 10.1016/j.pdpdt.2014.12.001; Yang P, 2013, BIOCHEM PHARMACOL, V85, P1124, DOI 10.1016/j.bcp.2013.01.020; Yuksel M, 2017, BIOCHIMIE, V138, P82, DOI 10.1016/j.biochi.2017.04.012; Zhang DZ, 2017, J ADV TRANSPORT, DOI 10.1155/2017/6350562; Zhang H, 2012, J NEUROCHEM, V120, P9, DOI 10.1111/j.1471-4159.2011.07519.x; Zhang J., 2016, MET ENG COM, V3, P1, DOI DOI 10.1016/J.NEUR0SCIENCE.2016.03.024; Zhang RG, 2014, NEUROCHEM RES, V39, P172, DOI 10.1007/s11064-013-1203-0; Zhang Y, 2016, EXP THER MED, V12, P3729, DOI 10.3892/etm.2016.3849; Zhao TF, 2018, IUBMB LIFE, V70, P60, DOI 10.1002/iub.1704; Zhu Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep42660; Zhu ZY, 2013, J NEUROSCI, V33, P13138, DOI 10.1523/JNEUROSCI.4790-12.2013; Zou WY, 2018, MOL NEUROBIOL, V55, P776, DOI 10.1007/s12035-016-0351-z	49	25	25	0	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	APR 26	2018	9								405	10.3389/fphar.2018.00405			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GE1BQ	WOS:000430952200001	29755351	DOAJ Gold, Green Published			2021-06-18	
J	Gallagher, V; Kramer, N; Abbott, K; Alexander, J; Breiter, H; Herrold, A; Lindley, T; Mjaanes, J; Reilly, J				Gallagher, Virginia; Kramer, Natalie; Abbott, Kristin; Alexander, John; Breiter, Hans; Herrold, Amy; Lindley, Tory; Mjaanes, Jeffrey; Reilly, James			The Effects of Sex Differences and Hormonal Contraception on Outcomes after Collegiate Sports-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						concussion; HC; mild traumatic brain injury; sex differences	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; GENDER-DIFFERENCES; INTERNATIONAL-CONFERENCE; RECOVERY-TIME; EPIDEMIOLOGY; SYMPTOMS; LEVONORGESTREL; PERFORMANCE; DEPRESSION	There is conflicting evidence regarding whether females are more adversely affected after concussion than males. Further, recent research suggests that hormonal contraceptive (HC) use may affect symptom severity and duration post-concussion. The objective of this study was to examine the effects of sex and HC use on outcomes following concussion among collegiate varsity athletes. We hypothesized that females would have longer length of recovery (LOR), and that peak symptom severity would be associated with longer LOR in both males and females. Among females, we hypothesized that non-HC users would have longer LOR and higher peak symptom severity than HC users. Ninety collegiate student-athletes were included in this study (40 males, 50 females; 24 HC users, 25 non-HC users). Demographic, injury, and recovery information was abstracted via retrospective record review. LOR was defined as days between injury and clearance for full return to play by team physician. Peak symptom severity score (Sport Concussion Assessment Tool [SCAT] 2 or 3) was used in analyses. Study results revealed that males had shorter LOR than females (F[1, 86] = 5.021, p < 0.05, d = 0.49), but had comparable symptom severity scores. Symptom severity was strongly related to LOR for males (r = 0.513, p < 0.01) but not females (r = -0.003, p > 0.05). Among females, non-HC users demonstrated higher symptom severity than HC users (F[1,47] = 5.142, p < 0.05, d = 0.70). No significant differences between female HC users and non-HC users on LOR were observed. This study provides evidence for differential concussion outcomes between male and female collegiate athletes and between HC users and nonusers among females.	[Gallagher, Virginia; Breiter, Hans; Herrold, Amy; Reilly, James] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Warren Wright Adolescent Ctr, Chicago, IL 60611 USA; [Kramer, Natalie; Abbott, Kristin; Alexander, John; Lindley, Tory; Mjaanes, Jeffrey] Northwestern Univ, Hlth Serv, Evanston, IL USA; [Herrold, Amy] Edward Hines Jr VA Hosp, Hines, IL USA	Gallagher, V (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Warren Wright Adolescent Ctr, Chicago, IL 60611 USA.	Va.t.gallagher@gmail.com			RRD VA [IK2 RX000949] Funding Source: Medline; Veterans AffairsUS Department of Veterans Affairs [IK2RX000949] Funding Source: NIH RePORTER		Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brotfain E, 2016, CURR NEUROPHARMACOL, V14, P641, DOI 10.2174/1570159X14666160309123554; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Choi JC, 2006, ANESTHESIOLOGY, V105, P120, DOI 10.1097/00000542-200607000-00021; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Fillingim RB, 1997, PSYCHOSOM MED, V59, P512, DOI 10.1097/00006842-199709000-00008; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; GASPARD UJ, 1983, CONTRACEPTION, V27, P577, DOI 10.1016/0010-7824(83)90023-9; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kilcoyne KG, 2014, SPORTS HEALTH, V6, P402, DOI 10.1177/1941738113491545; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P837, DOI 10.1136/bjsports-2017-097878; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Mihalik JP, 2009, J SCI MED SPORT, V12, P383, DOI 10.1016/j.jsams.2008.05.003; MISHELL DR, 1972, AM J OBSTET GYNECOL, V114, P923, DOI 10.1016/0002-9378(72)90098-1; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; National Collegiate Athletic Association, 2017, SPORT SPONS PART DEM; Niemeier JP, 2014, J WOMENS HEALTH, V23, P573, DOI 10.1089/jwh.2013.4535; NILSSON CG, 1980, CONTRACEPTION, V21, P225, DOI 10.1016/0010-7824(80)90003-7; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Safran DG, 1997, SOC SCI MED, V45, P711, DOI 10.1016/S0277-9536(96)00405-4; Sheard M, 2009, BRIT J EDUC PSYCHOL, V79, P189, DOI 10.1348/000709908X304406; Smith F., 2007, J GEOGR HIGH ED, V28, P167; Stone S, 2017, SPORTS HEALTH, V9, P41, DOI 10.1177/1941738116672184; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	47	25	26	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2018	35	11					1242	1247		10.1089/neu.2017.5453		MAR 2018	6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GG7EW	WOS:000428591300001	29336208				2021-06-18	
J	Buckley, TA; Munkasy, BA; Clouse, BP				Buckley, Thomas A.; Munkasy, Barry A.; Clouse, Brandy P.			Sensitivity and Specificity of the Modified Balance Error Scoring System in Concussed Collegiate Student Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; efficacy; postural control; diagnostic accuracy; mild traumatic brain injury	MANAGEMENT PRACTICE PATTERNS; TRAUMATIC BRAIN-INJURY; TRAINERS	Objective: To assess the efficacy of the modified Balance En-or Scoring System (mBESS) compared with the Balance Error Scoring System (BESS) in an acutely concussed population. Design: Prospective observational study. Setting: University athletic training room. Patients: Thirty-five collegiate student-athletes (18 Female, 18.9 +/- 0.8 year old, height: 1.71 +/- 0.12 m, weight: 76.3 +/- 24.1 kg) with diagnosed concussions and baseline BESS/mBESS tests. Interventions: All participants completed the BESS and mBESS on the day after the concussion (acute) and were retested daily until their BESS score achieved baseline value (recovery). Main Outcome Measures: The number of errors committed during the BESS and mBESS at each time point were recorded. The sensitivity and specificity of the BESS and mBESS compared with the baseline test was calculated for acute and recovery as well as the mBESS compared with the BESS. Results: At acute, the sensitivity of the BESS and mBESS were 60.0% and 71.4%, respectively. Relative to mBESS baseline, 60% of participants were misclassified at either acute or recovery. Conclusions: The mBESS had higher sensitivity at acute and identified lingering deficits at BESS recovery. Use of the mBESS is likely to produce different results than the BESS; however, the clinical implications of this warrant further investigation.	[Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, 541 South Coll Ave, Newark, DE 19716 USA; [Buckley, Thomas A.] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE USA; [Munkasy, Barry A.] Georgia Southern Univ, Sch Hlth & Kinesiol, Statesboro, GA USA; [Clouse, Brandy P.] Georgia Southern Univ, Dept Intercollegiate Athlet, Statesboro, GA USA	Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, 541 South Coll Ave, Newark, DE 19716 USA.	TBuckley@UDel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R15NS070744-01A1]	This project was funded, in part, by an NIH/NINDS grant (1R15NS070744-01A1). All authors of this article were primary investigators on the grant. The funding agency had no role in the development of the manuscript, the interpretation of the results, or the decision where to submit the manuscript.	Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P61, DOI 10.1016/j.jshs.2016.01.007; Buckley TA, 2015, J ATHL TRAINING, V50, P879, DOI 10.4085/1062-6050-50.7.04; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Luoto TM, 2014, J NEUROTRAUM, V31, P728, DOI 10.1089/neu.2013.3174; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf	11	25	25	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2018	28	2					174	176		10.1097/JSM.0000000000000426			3	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	GP1HC	WOS:000440564900014	28454123				2021-06-18	
J	Scharfen, J; Peters, JM; Holling, H				Scharfen, Jana; Peters, Judith Marie; Holling, Heinz			Retest effects in cognitive ability tests: A meta-analysis	INTELLIGENCE			English	Article						Meta-analysis; Cognitive ability; Intelligence; Retest effect	MILLER ANALOGIES TEST; LONG-TERM RETENTION; WORKING-MEMORY; OLDER-ADULTS; EFFECT SIZE; CONCUSSION ASSESSMENT; SPATIAL ORIENTATION; SELECTION SETTINGS; STRUCTURAL-CHANGES; INHIBITORY CONTROL	Retest effects are referred to as the increase in test scores due to the repeated administration of cognitive ability tests. This meta-analysis attempts to update and extend previous meta-analyses by examining the size of retest effects and its determinants in a high number of cognitive ability tests for up to four test administrations. Strict inclusion and exclusion criteria were applied regarding study design, participant age and health status, and cognitive ability tests. An extensive literature search detected 174 samples from 122 studies, which resulted in 786 test outcomes and an overall sample size of 153,185. A comprehensive longitudinal multilevel meta-analysis revealed significant retest effects and no further score gains after the third test administration. Moderator analyses for multiple retests indicated that cognitive ability operation and content, equivalence of test forms, retest interval and participant age have a significant influence on the size of the retest effect. Implications for future research and retesting practice are discussed.	[Scharfen, Jana; Peters, Judith Marie; Holling, Heinz] Westfalische Wilhelms Univ Munster, Inst Psychol, Fliednerstr 21, D-48149 Munster, Germany	Scharfen, J (corresponding author), Westfalische Wilhelms Univ Munster, Inst Psychol, Fliednerstr 21, D-48149 Munster, Germany.	jana.scharfen@uni-muenster.de; holling@uni-muenster.de	Holling, Heinz/K-3728-2017	Holling, Heinz/0000-0002-0311-3970; Scharfen, Jana/0000-0003-1285-6319	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [HO 1286/6-4]	This work was supported by the Deutsche Forschungsgemeinschaft [HO 1286/6-4].	ACKERMAN PL, 1987, PSYCHOL BULL, V102, P3, DOI 10.1037/0033-2909.102.1.3; Albers F, 2009, DIAGNOSTICA, V55, P71, DOI 10.1026/0012-1924.55.2.71; Allalouf A, 1998, J EDUC MEAS, V35, P31, DOI 10.1111/j.1745-3984.1998.tb00526.x; ANASTASI A, 1981, AM PSYCHOL, V36, P1086, DOI 10.1037/0003-066X.36.10.1086; Arendasy ME, 2017, INTELLIGENCE, V62, P89, DOI 10.1016/j.intell.2017.03.003; Arendasy ME, 2013, INTELLIGENCE, V41, P181, DOI 10.1016/j.intell.2013.02.004; Arthur W, 2010, INT J SELECT ASSESS, V18, P1, DOI 10.1111/j.1468-2389.2010.00476.x; Au J, 2015, PSYCHON B REV, V22, P366, DOI 10.3758/s13423-014-0699-x; BADDELEY AD, 1968, PSYCHON SCI, V10, P341; Ball K, 2007, J GERONTOL B-PSYCHOL, V62, P19, DOI 10.1093/geronb/62.special_issue_1.19; Bartels C, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-118; BECKER BJ, 1990, REV EDUC RES, V60, P373, DOI 10.3102/00346543060003373; BECKER BJ, 1988, BRIT J MATH STAT PSY, V41, P257, DOI 10.1111/j.2044-8317.1988.tb00901.x; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Bennett G.K., 1990, DIFFERENTIAL APTITUD; Benton A., 1976, MULTILINGUAL APHASIA; BORS DA, 1993, CAN J EXP PSYCHOL, V47, P763, DOI 10.1037/h0084956; Braver TS, 2002, NEUROSCI BIOBEHAV R, V26, P809, DOI 10.1016/S0149-7634(02)00067-2; Broglio SP, 2007, J ATHL TRAINING, V42, P509; BRYK AS, 1988, AM J EDUC, V97, P65, DOI 10.1086/443913; Buehner M, 2005, INTELLIGENCE, V33, P251, DOI 10.1016/j.intell.2005.01.002; Buschkuhl M, 2007, THESIS; Calamia M, 2013, CLIN NEUROPSYCHOL, V27, P1077, DOI 10.1080/13854046.2013.809795; Calamia M, 2012, CLIN NEUROPSYCHOL, V26, P543, DOI 10.1080/13854046.2012.680913; CARPENTER PA, 1990, PSYCHOL REV, V97, P404, DOI 10.1037/0033-295X.97.3.404; Carroll J. B., 1993, HUMAN COGNITIVE ABIL; Cattell R.B., 1987, INTELLIGENCE ITS STR; Childers TL, 2000, J BUS RES, V47, P109, DOI 10.1016/S0148-2963(98)00055-1; Colom R, 2012, INTELLIGENCE, V40, P479, DOI 10.1016/j.intell.2012.05.004; Cook T.D., 1979, QUASIEXPERIMENTATION; Cooper H, 2009, HDB RES SYNTHESIS ME; Cooper H., 2017, RES SYNTHESIS METAAN; Cowan N, 2005, COGNITIVE PSYCHOL, V51, P42, DOI 10.1016/j.cogpsych.2004.12.001; Coyle TR, 2006, INTELLIGENCE, V34, P15, DOI 10.1016/j.intell.2005.04.001; Crone EA, 2009, DEVELOPMENTAL SCI, V12, P55, DOI 10.1111/j.1467-7687.2008.00743.x; Dahlin E, 2008, PSYCHOL AGING, V23, P720, DOI 10.1037/a0014296; de Oliveira RS, 2014, EINSTEIN-SAO PAULO, V12, P149, DOI 10.1590/S1679-45082014AO2954; DERSIMONIAN R, 1983, HARVARD EDUC REV, V53, P1; Do B.-R., 2011, THESIS; Donner Y, 2015, PSYCHON B REV, V22, P1308, DOI 10.3758/s13423-015-0811-x; Dunlop PD, 2011, INT J SELECT ASSESS, V19, P217, DOI 10.1111/j.1468-2389.2011.00549.x; Ekstrom R.B., 1976, MANUAL KIT FACTOR RE; Enge S, 2014, J EXP PSYCHOL LEARN, V40, P987, DOI 10.1037/a0036165; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Eysenck MW, 2007, EMOTION, V7, P336, DOI 10.1037/1528-3542.7.2.336; Flanagan J. C., 1962, DESIGN STUDY AM YOUT; French J. W., 1963, KIF REFERENCE TESTS; Freund PA, 2011, INTELLIGENCE, V39, P233, DOI 10.1016/j.intell.2011.02.009; GIBBONS RD, 1993, J EDUC STAT, V18, P271, DOI 10.3102/10769986018003271; Gil-Gouveia R., 2015, ACTA NEUROLOGICA SCA; Grissom N, 2009, NEUROBIOL LEARN MEM, V92, P215, DOI 10.1016/j.nlm.2008.07.001; Guthke J., 2001, PERSPEKTIVEN INTELLI; Halford GS, 2007, TRENDS COGN SCI, V11, P236, DOI 10.1016/j.tics.2007.04.001; Hasegawa H, 1997, JPN J PSYCHOL, V68, P417, DOI 10.4992/jjpsy.68.417; Hausknecht JP, 2007, J APPL PSYCHOL, V92, P373, DOI 10.1037/0021-9010.92.2.373; Hausknecht JP, 2002, J APPL PSYCHOL, V87, P243, DOI 10.1037//0021-9010.87.2.243; Hayes TR, 2015, INTELLIGENCE, V48, P1, DOI 10.1016/j.intell.2014.10.005; Hedges LV, 2010, RES SYNTH METHODS, V1, P39, DOI 10.1002/jrsm.5; HOLLAND BS, 1988, PSYCHOL BULL, V104, P145, DOI 10.1037/0033-2909.104.1.145; HOLLING H, 2004, INTELLIGENZDIAGNOSTI; HOLM S, 1979, SCAND J STAT, V6, P65; HUBER O, 1980, ACTA PSYCHOL, V45, P187, DOI 10.1016/0001-6918(80)90031-1; Hulsheger UR, 2007, INT J SELECT ASSESS, V15, P3, DOI 10.1111/j.1468-2389.2007.00363.x; Hunter J.E., 2004, METHODS METAANALYSIS; Ishak KJ, 2007, CLIN TRIALS, V4, P525, DOI 10.1177/1740774507083567; Iuliano E, 2015, EXP GERONTOL, V70, P105, DOI 10.1016/j.exger.2015.07.008; Jaber MY, 2013, COMPUT IND ENG, V64, P866, DOI 10.1016/j.cie.2012.12.005; Jager A, 1982, DIAGNOSTICA, V28, P195; JR Anderson., 1981, COGNITIVE SKILLS THE, P1; Karch D, 2013, DTSCH ARZTEBL INT, V110, P643, DOI 10.3238/arztebl.2013.0643; Kelly ME, 2014, AGEING RES REV, V15, P28, DOI 10.1016/j.arr.2014.02.004; Klauer KJ, 2008, REV EDUC RES, V78, P85, DOI 10.3102/0034654307313402; Klauer KJ, 2014, Z PADAGOG PSYCHOL, V28, P5, DOI 10.1024/1010-0652/a000123; Konstantopoulos S., 2011, RES SYNTH METHODS, V17, P279; Kozhevnikov M, 2001, MEM COGNITION, V29, P745, DOI 10.3758/BF03200477; KUBINGER KD, 2003, SCHLUSSELBEGRIFFE PS; KULIK JA, 1984, AM EDUC RES J, V21, P435, DOI 10.3102/00028312021002435; KYLLONEN PC, 1990, INTELLIGENCE, V14, P389, DOI 10.1016/S0160-2896(05)80012-1; LADER MH, 1964, J NEUROL NEUROSUR PS, V27, P210, DOI 10.1136/jnnp.27.3.210; Lampit A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001756; LANE RG, 1966, J APPL PSYCHOL, V50, P409, DOI 10.1037/h0023817; Langenecker SA, 2007, J CLIN EXP NEUROPSYC, V29, P842, DOI 10.1080/13803390601147611; Lievens F, 2005, PERS PSYCHOL, V58, P981, DOI 10.1111/j.1744-6570.2005.00713.x; Lievens F, 2007, J APPL PSYCHOL, V92, P1672, DOI 10.1037/0021-9010.92.6.1672; Lo AHY, 2012, J NEUROPSYCHOL, V6, P212, DOI 10.1111/j.1748-6653.2011.02023.x; Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846; Lyall S. M., 2016, PLOS ONE, V11; Maerlender AC, 2016, J CLIN EXP NEUROPSYC, V38, P869, DOI 10.1080/13803395.2016.1168781; Matton N, 2009, INTELLIGENCE, V37, P412, DOI 10.1016/j.intell.2009.03.011; Mehlsen M, 2009, PSYCHO-ONCOL, V18, P248, DOI 10.1002/pon.1398; Meneghetti C, 2016, PSYCHOL RES-PSYCH FO, V80, P113, DOI 10.1007/s00426-014-0644-7; MESSICK S, 1981, PSYCHOL BULL, V89, P191, DOI 10.1037/0033-2909.89.2.191; MILLMAN J, 1965, EDUC PSYCHOL MEAS, V25, P707, DOI 10.1177/001316446502500304; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Musekiwa A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164898; NEVO B, 1976, MEAS EVAL GUID, V9, P16, DOI 10.1080/00256307.1976.12022706; Ng E, 2015, LEARN INDIVID DIFFER, V40, P141, DOI 10.1016/j.lindif.2015.04.007; Nguyen HT, 2015, J OCCUP ENVIRON MED, V57, P676, DOI 10.1097/JOM.0000000000000424; Nijenhuis J., 2007, INTELLIGENCE, V35, P238; Oelhafen S, 2013, NEUROPSYCHOLOGIA, V51, P2781, DOI 10.1016/j.neuropsychologia.2013.08.012; Olenick J, 2016, INT J SELECT ASSESS, V24, P324, DOI 10.1111/ijsa.12151; Ones D. S., 2005, HDB SELECTION, P143; Pereira DR, 2015, ARCH CLIN NEUROPSYCH, V30, P424, DOI 10.1093/arclin/acv028; PETERS M, 1995, BRAIN COGNITION, V28, P39, DOI 10.1006/brcg.1995.1032; Powers KL, 2013, PSYCHON B REV, V20, P1055, DOI 10.3758/s13423-013-0418-z; Puddey IB, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-48; R Core Team, 2018, R LANG ENV STAT COMP; Randall JG, 2017, HUM RESOUR MANAGE R, V27, P536, DOI 10.1016/j.hrmr.2016.10.002; Randall JG, 2016, J PERS PSYCHOL, V15, P45, DOI 10.1027/1866-5888/a000149; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Raven J, 1962, COLOURED PROGR MATRI; Raven J. C, 1936, STANDARD PROGR MATRI; Raven J.C., 1962, ADV PROGR MATRICES S; Reeve CL, 2009, INTELLIGENCE, V37, P34, DOI 10.1016/j.intell.2008.05.003; Reeve CL, 2005, INTELLIGENCE, V33, P535, DOI 10.1016/j.intell.2005.05.003; Robinson SJ, 2013, AVIAT SPACE ENVIR MD, V84, P592, DOI 10.3357/ASEM.3391.2013; Roediger HL, 2011, TRENDS COGN SCI, V15, P20, DOI 10.1016/j.tics.2010.09.003; Roediger HL, 2006, PSYCHOL SCI, V17, P249, DOI 10.1111/j.1467-9280.2006.01693.x; Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643; Salminen T, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00166; Salthouse TA, 2004, DEV PSYCHOL, V40, P813, DOI 10.1037/0012-1649.40.5.813; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; Salthouse TA, 2008, NEUROPSYCHOLOGY, V22, P800, DOI 10.1037/a0013091; Sandberg P, 2014, AGING NEUROPSYCHOL C, V21, P577, DOI 10.1080/13825585.2013.839777; SARASON IG, 1960, J EXP PSYCHOL, V59, P185, DOI 10.1037/h0047062; Schellig D., 1997, BLOCK TAPPING TEST; Schleicher DJ, 2010, J APPL PSYCHOL, V95, P603, DOI 10.1037/a0018920; SCHUERGER JM, 1989, J CLIN PSYCHOL, V45, P294, DOI 10.1002/1097-4679(198903)45:2<294::AID-JCLP2270450218>3.0.CO;2-N; Scott G, 2004, CREATIVITY RES J, V16, P361, DOI 10.1207/s15326934crj1604_1; Shaffer D. D. R., 2010, DEV PSYCHOL CHILDHOO; Sharma VK, 2014, J CLIN DIAGN RES, V8, P10, DOI [10.7860/JCDR/2014/7256.3668, 10.7660/JCDP/201477256.3668]; SHEPARD RN, 1976, SCIENCE, V191, P952, DOI 10.1126/science.1251207; Soveri A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081693; SPIELBERGER CD, 1959, J APPL PSYCHOL, V43, P259, DOI 10.1037/h0042419; Sun JZ, 2016, HUM BRAIN MAPP, V37, P3375, DOI 10.1002/hbm.23246; Suss HM, 2002, INTELLIGENCE, V30, P261, DOI 10.1016/S0160-2896(01)00100-3; Thurstone L. L., 1959, TEST ADM MANUAL SPAC; Thurstone L. L., 1938, PRIMARY MENTAL ABILI; Thurstone T. G., 1963, PRIMARY MENTAL ABILI; Thurstone TG, 1958, MANUAL SRA PRIMARY M; Toril P, 2014, PSYCHOL AGING, V29, P706, DOI 10.1037/a0037507; Trikalinos TA, 2012, CLIN TRIALS, V9, P610, DOI 10.1177/1740774512453218; Uttal DH, 2013, PSYCHOL BULL, V139, P352, DOI 10.1037/a0028446; van Eersel M. E. A., 2015, PLOS ONE, V10, P1; Van Iddekinge CH, 2011, J APPL PSYCHOL, V96, P941, DOI 10.1037/a0023562; VANDENBERG SG, 1978, PERCEPT MOTOR SKILL, V47, P599, DOI 10.2466/pms.1978.47.2.599; VENKATESAN M, 1986, J PUBLIC POLICY MARK, V5, P29, DOI 10.1177/074391568600500102; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Villado AJ, 2016, J BUS PSYCHOL, V31, P233, DOI 10.1007/s10869-015-9408-7; Wang P, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00720; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1958, MEASUREMENT APPRAISA; Woehlke A. B., 1963, PERS PSYCHOL, P198; Zachary R., 1986, SHIPLEY I LIVING SCA; Zehnder F, 2009, RESTOR NEUROL NEUROS, V27, P507, DOI 10.3233/RNN-2009-0491	157	25	25	3	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0160-2896	1873-7935		INTELLIGENCE	Intelligence	MAR-APR	2018	67						44	66		10.1016/j.intell.2018.01.003			23	Psychology, Multidisciplinary	Psychology	FY1AM	WOS:000426544000006					2021-06-18	
J	Vogelaar, CF; Mandal, S; Lerch, S; Birkner, K; Birkenstock, J; Buhler, U; Schnatz, A; Raine, CS; Bittner, S; Vogt, J; Kipnis, J; Nitsch, R; Zipp, F				Vogelaar, Christina F.; Mandal, Shibajee; Lerch, Steffen; Birkner, Katharina; Birkenstock, Jerome; Buehler, Ulrike; Schnatz, Andrea; Raine, Cedric S.; Bittner, Stefan; Vogt, Johannes; Kipnis, Jonathan; Nitsch, Robert; Zipp, Frauke			Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation	SCIENCE TRANSLATIONAL MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; T-CELLS; IN-VIVO; NOGO-A; FUNCTIONAL RECOVERY; NEURITE OUTGROWTH; AXON REGENERATION; NERVOUS-SYSTEM	Ongoing axonal degeneration is thought to underlie disability in chronic neuroinflammation, such as multiple sclerosis (MS), especially during its progressive phase. Upon inflammatory attack, axons undergo pathological swelling, which can be reversible. Because we had evidence for beneficial effects of T helper 2 lymphocytes in experimental neurotrauma and discovered interleukin-4 receptor (IL-4R) expressed on axons in MS lesions, we aimed at unraveling the effects of IL-4 on neuroinflammatory axon injury. We demonstrate that intrathecal IL-4 treatment during the chronic phase of several experimental autoimmune encephalomyelitis models reversed disease progression without affecting inflammation. Amelioration of disability was abrogated upon neuronal deletion of IL-4R. We discovered direct neuronal signaling via the IRS1-PI3K-PKC pathway underlying cytoskeletal remodeling and axonal repair. Nasal IL-4 application, suitable for clinical translation, was equally effective in improving clinical outcome. Targeting neuronal IL-4 signaling may offer new therapeutic strategies to halt disability progression in MS and possibly also neurodegenerative conditions.	[Vogelaar, Christina F.; Mandal, Shibajee; Lerch, Steffen; Birkner, Katharina; Birkenstock, Jerome; Buehler, Ulrike; Bittner, Stefan; Zipp, Frauke] Johannes Gutenberg Univ Mainz, Dept Neurol, Focus Program Translat Neurosci FTN, Univ Med Ctr, D-55131 Mainz, Germany; [Vogelaar, Christina F.; Mandal, Shibajee; Lerch, Steffen; Birkner, Katharina; Birkenstock, Jerome; Buehler, Ulrike; Bittner, Stefan; Zipp, Frauke] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy FZI, Rhine Main Neurosci Network Rmn2, D-55131 Mainz, Germany; [Schnatz, Andrea; Vogt, Johannes] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Rhine Main Neurosci Network Rmn2, Inst Microanat & Neurobiol,Focus Program Translat, D-55131 Mainz, Germany; [Raine, Cedric S.] Albert Einstein Coll Med, Dept Pathol, Neuropathol, Bronx, NY 10461 USA; [Kipnis, Jonathan] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Gutenberg Res Fellowship Grp Neuroimmunol, Focus Program Translat Neurosci FTN, D-55131 Mainz, Germany; [Kipnis, Jonathan] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy FZI, Rhine Main Neurosci Network Rmn2, D-55131 Mainz, Germany; [Kipnis, Jonathan] Univ Virginia, Sch Med, Dept Neurosci, Ctr Brain Immunol & Glia, Charlottesville, VA 22908 USA; [Nitsch, Robert] Westfal Wilhelms Univ Munster, Univ Med Ctr, Inst Translat Neurosci, Albert Schweitzer Campus, D-48149 Munster, Germany	Zipp, F (corresponding author), Johannes Gutenberg Univ Mainz, Dept Neurol, Focus Program Translat Neurosci FTN, Univ Med Ctr, D-55131 Mainz, Germany.; Zipp, F (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy FZI, Rhine Main Neurosci Network Rmn2, D-55131 Mainz, Germany.	frauke.zipp@unimedizin-mainz.de	Nitsch, Robert/AAI-9129-2021; Vogt, Johannes/O-4289-2019; Vogelaar, Christina Francisca/AAA-8484-2021; Vogt, Johannes/K-2278-2015; Zipp, Frauke/C-9968-2015	Vogelaar, Christina Francisca/0000-0002-9683-7336; Vogt, Johannes/0000-0003-2439-8247; MANDAL, SHIBAJEE/0000-0002-6112-6972; Bittner, Stefan/0000-0003-2179-3655; Zipp, Frauke/0000-0002-1231-1928; Birkenstock, Jerome/0000-0002-3418-9847; Schnatz, Andrea/0000-0003-4855-8663	German Research Foundation (DFG)German Research Foundation (DFG) [CRC 1080, CRC-TR-128]; Progressive MS Alliance [PA-1604-08492]; NIH/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS096967]	This work was supported by the German Research Foundation (DFG; CRC 1080 to J.K. and F.Z. and CRC-TR-128 to F.Z.), Progressive MS Alliance (PA-1604-08492, BRAVEinMS to F.Z.), and NIH/National Institute of Neurological Disorders and Stroke (NS096967 to J.K.).	2004 Allen Institute for Brain Science, 2004, ALL MOUS BRAIN ATL; Arrant AE, 2017, BRAIN, V140, P1447, DOI 10.1093/brain/awx060; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Broberg EK, 2004, NEUROSCI LETT, V364, P173, DOI 10.1016/j.neulet.2004.04.059; Butti E, 2008, GENE THER, V15, P504, DOI 10.1038/gt.2008.10; Carlton SM, 2002, J COMP NEUROL, V448, P102, DOI 10.1002/cne.10250; Carter LM, 2008, J NEUROSCI, V28, P14107, DOI 10.1523/JNEUROSCI.2217-08.2008; Casanova E, 2001, GENESIS, V31, P37, DOI 10.1002/gene.1078; Chevalier-Larsen E, 2006, BBA-MOL BASIS DIS, V1762, P1094, DOI 10.1016/j.bbadis.2006.04.002; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Cummings BS, 2004, CURR PROTOC PHARM, V12, P12, DOI DOI 10.1002/04711; DeLuca GC, 2004, BRAIN, V127, P1009, DOI 10.1093/brain/awh118; Ellwardt E, 2016, TRENDS IMMUNOL, V37, P154, DOI 10.1016/j.it.2015.12.008; Ferreira R, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00153; Francos-Quijorna I, 2016, GLIA, V64, P2079, DOI 10.1002/glia.23041; Franklin RJM, 2012, NAT REV NEUROL, V8, P624, DOI 10.1038/nrneurol.2012.200; Freeley M, 2011, CELL SIGNAL, V23, P753, DOI 10.1016/j.cellsig.2010.10.013; Friese MA, 2014, NAT REV NEUROL, V10, P225, DOI 10.1038/nrneurol.2014.37; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Hasan M, 2016, NEUROSCIENCE, V319, P168, DOI 10.1016/j.neuroscience.2016.01.045; Heller N., 2012, ALLERGIC DIS HIGHLIG, P43; Herrero-Herranz E, 2008, NEUROBIOL DIS, V30, P162, DOI 10.1016/j.nbd.2008.01.001; Holahan MR, 2015, RES REP BIOCHEM, V5, P137, DOI 10.2147/RRBC.S73846; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Huebner EA, 2011, J BIOL CHEM, V286, P18026, DOI 10.1074/jbc.M110.208108; Inobe J, 1996, ANN NY ACAD SCI, V778, P390, DOI 10.1111/j.1749-6632.1996.tb21153.x; Keating P, 2009, IMMUNOL CELL BIOL, V87, P534, DOI 10.1038/icb.2009.37; Kipnis J, 2016, SCIENCE, V353, P766, DOI 10.1126/science.aag2638; Kurland DB, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0599-2; Lang DM, 2017, J COMP NEUROL, V525, P936, DOI 10.1002/cne.24112; Larochelle C, 2016, TRENDS NEUROSCI, V39, P325, DOI 10.1016/j.tins.2016.02.001; Larsson C, 2006, CELL SIGNAL, V18, P276, DOI 10.1016/j.cellsig.2005.07.010; Liu XB, 2012, EPILEPSIA, V53, P45, DOI 10.1111/j.1528-1167.2012.03474.x; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Lu Ruirui, 2013, Methods Mol Biol, V1020, P215, DOI 10.1007/978-1-62703-459-3_14; Metz I, 2007, BRAIN, V130, P1254, DOI 10.1093/brain/awl370; Mi S, 2007, NAT MED, V13, P1228, DOI 10.1038/nm1664; Mueller TD, 2002, BBA-MOL CELL RES, V1592, P237, DOI 10.1016/S0167-4889(02)00318-X; Nicholson-Fish JC, 2016, NEUROCHEM RES, V41, P534, DOI 10.1007/s11064-015-1663-5; Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324; Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301-0082(97)00043-9; Paolillo A, 1999, NEUROLOGY, V53, P751, DOI 10.1212/WNL.53.4.751; Paterka M, 2017, J AUTOIMMUN, V76, P108, DOI 10.1016/j.jaut.2016.09.008; Payne NL, 2012, CELL ADHES MIGR, V6, P179, DOI 10.4161/cam.20341; Pollinger B, 2009, J EXP MED, V206, P1303, DOI 10.1084/jem.20090299; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; Rommer PS, 2014, CLIN EXP IMMUNOL, V175, P397, DOI 10.1111/cei.12206; Siffrin V, 2010, IMMUNITY, V33, P424, DOI 10.1016/j.immuni.2010.08.018; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; Steward O, 2004, J COMP NEUROL, V472, P463, DOI 10.1002/cne.20090; Vogt J, 2009, ANN NEUROL, V66, P310, DOI 10.1002/ana.21719; Walsh JT, 2015, J CLIN INVEST, V125, P699, DOI [10.1172/JCI176210, 10.1172/JCI76210]; Wang XJ, 2013, BRAIN RES, V1518, P9, DOI 10.1016/j.brainres.2013.04.042; Williams PR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6683; Wright KT, 2007, BIOCHEM BIOPH RES CO, V354, P559, DOI 10.1016/j.bbrc.2007.01.013; Xiao C, 2013, J ALZHEIMERS DIS, V35, P777, DOI 10.3233/JAD-122419; Zipp F, 2013, JAMA NEUROL, V70, P1569, DOI 10.1001/jamaneurol.2013.4391	59	25	25	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	FEB 28	2018	10	430							eaao2304	10.1126/scitranslmed.aao2304			12	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	FX7SS	WOS:000426291800002	29491183	Bronze			2021-06-18	
J	Undurti, A; Colasurdo, EA; Sikkema, CL; Schultz, JS; Peskind, ER; Pagulayan, KF; Wilkinson, CW				Undurti, Arundhati; Colasurdo, Elizabeth A.; Sikkema, Carl L.; Schultz, Jaclyn S.; Peskind, Elaine R.; Pagulayan, Kathleen F.; Wilkinson, Charles W.			Chronic Hypopituitarism Associated with Increased Postconcussive Symptoms Is Prevalent after Blast-Induced Mild Traumatic Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; blast; concussion; pituitary; military; posttraumatic stress disorder; growth hormone deficiency; veterans	GROWTH-HORMONE DEFICIENCY; QUALITY-OF-LIFE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; ANTERIOR-PITUITARY DYSFUNCTION; GH DEFICIENCY; LONG-TERM; IGF-I; POSTTRAUMATIC HYPOPITUITARISM; SCREENING-TEST; YOUNG-ADULTS	The most frequent injury sustained by US service members deployed to Iraq or Afghanistan is mild traumatic brain injuries (mTBI), or concussion, by far most often caused by blast waves from improvised explosive devices or other explosive ordnance. TBI from all causes gives rise to chronic neuroendocrine disorders with an estimated prevalence of 25-50%. The current study expands upon our earlier finding that chronic pituitary gland dysfunction occurs with a similarly high frequency after blast-related concussions. We measured circulating hormone levels and accessed demographic and testing data from two groups of male veterans with hazardous duty experience in Iraq or Afghanistan. Veterans in the mTBI group had experienced one or more blast-related concussion. Members of the deployment control (DC) group encountered similar deployment conditions but had no history of blast-related mTBI. 12 of 39 (31%) of the mTBI participants and 3 of 20 (15%) veterans in the DC group screened positive for one or more neuroendocrine disorders. Positive screens for growth hormone deficiency occurred most often. Analysis of responses on self-report questionnaires revealed main effects of both mTBI and hypopituitarism on postconcussive and posttraumatic stress disorder (PTSD) symptoms. Symptoms associated with pituitary dysfunction overlap considerably with those of PTSD. They include cognitive deficiencies, mood and anxiety disorders, sleep problems, diminished quality of life, deleterious changes in metabolism and body composition, and increased cardiovascular mortality. When such symptoms are due to hypopituitarism, they may be alleviated by hormone replacement. These findings suggest consideration of routine post-deployment neuroendocrine screening of service members and veterans who have experienced blast-related mTBI and are reporting postconcussive symptoms.	[Undurti, Arundhati; Peskind, Elaine R.; Pagulayan, Kathleen F.; Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Colasurdo, Elizabeth A.; Sikkema, Carl L.; Schultz, Jaclyn S.; Wilkinson, Charles W.] US Dept Vet Affairs, VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98174 USA; [Peskind, Elaine R.; Pagulayan, Kathleen F.] US Dept Vet Affairs, VA Puget Sound Hlth Care Syst, VISN Northwest Network Mental Illness Res Educ &, Seattle, WA USA; [Undurti, Arundhati] Vancouver Clin, Vancouver, WA USA	Wilkinson, CW (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.; Wilkinson, CW (corresponding author), US Dept Vet Affairs, VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98174 USA.	wilkinso@uw.edu	Pagulayan, Kati/AAR-9225-2020; Wilkinson, Charles W/N-5969-2017	Wilkinson, Charles/0000-0002-5390-0294	United States Department of Defense Congressionally Directed Medical Research Programs Concept Award [W81XWH-11-1-0278]; United States Department of Veterans Affairs (USDVA) Rehabilitation Research and Development Service Merit Award [5 I01 RX 000509]; USDVA Clinical Science Research and Development Service Career Development Award [IK2CX000516]; USDVA Rehabilitation Research and Development Service Merit Award [B77421]; Geriatric Research, Education and Clinical Center; Research and Development Service of the VA Puget Sound Health Care System; VA Northwest Network Mental Illness Research, Education and Clinical Center; University of Washington Alzheimer's Disease Research CenterUniversity of Washington [NIA AG05136]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005136] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000521, I01RX001612, IK2CX000516, I01RX000509] Funding Source: NIH RePORTER	United States Department of Defense Congressionally Directed Medical Research Programs Concept Award Number W81XWH-11-1-0278 and United States Department of Veterans Affairs (USDVA) Rehabilitation Research and Development Service Merit Award #5 I01 RX 000509 to CW, USDVA Clinical Science Research and Development Service Career Development Award #IK2CX000516 to KP, USDVA Rehabilitation Research and Development Service Merit Award #B77421 to EP, the Geriatric Research, Education and Clinical Center, and the Research and Development Service of the VA Puget Sound Health Care System; the VA Northwest Network Mental Illness Research, Education and Clinical Center; and the University of Washington Alzheimer's Disease Research Center NIA AG05136.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Ajmal A, 2014, PSYCHOSOMATICS, V55, P29, DOI 10.1016/j.psym.2013.08.008; American Psychiatric Association, 1994, DSM 4 DIAGN STAT MAN, P828; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Baxter D, 2013, ANN NEUROL, V74, P527, DOI 10.1002/ana.23958; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Behan LA, 2007, HORM RES, V68, P18, DOI 10.1159/000110466; Ben-Shlomo A, 2011, PITUITARY, 3RD EDITION, P21, DOI 10.1016/B978-0-12-380926-1.10002-1; Blair JC, 2010, BRIT J NEUROSURG, V24, P10, DOI 10.3109/02688690903536637; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blevins JE, 2015, PHYSIOL BEHAV, V152, P438, DOI 10.1016/j.physbeh.2015.05.023; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Brambilla M, 2016, DRUG DEVELOP RES, V77, P479, DOI 10.1002/ddr.21343; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Campbell A, 2010, PERS SOC PSYCHOL REV, V14, P281, DOI 10.1177/1088868310363594; Campbell I, 2007, STAT MED, V26, P3661, DOI 10.1002/sim.2832; Capozzi A, 2015, GYNECOL ENDOCRINOL, V31, P506, DOI 10.3109/09513590.2015.1017810; Carboni L, 2012, INT J NEUROPSYCHOPH, V15, P645, DOI 10.1017/S1461145711000824; Ceanga M, 2010, NEUROSCI LETT, V477, P15, DOI 10.1016/j.neulet.2010.04.024; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Colao A, 2008, CLIN ENDOCRINOL, V69, P347, DOI 10.1111/j.1365-2265.2008.03292.x; Corneli G, 2008, J ENDOCRINOL INVEST, V31, P689, DOI 10.1007/BF03346416; Corneli G, 2007, EUR J ENDOCRINOL, V157, P701, DOI 10.1530/EJE-07-0384; Detillion CE, 2004, PSYCHONEUROENDOCRINO, V29, P1004, DOI 10.1016/j.psyneuen.2003.10.003; Di Simplicio M, 2016, J PSYCHOPHARMACOL, V30, P1156, DOI 10.1177/0269881116641872; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; First M. B., 2002, STRUCTURED CLIN INTE, P1; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Guerrero AF, 2010, MIL MED, V175, P574, DOI 10.7205/MILMED-D-09-00189; Hadjadj S, 2007, ANN ENDOCRINOL-PARIS, V68, P449, DOI 10.1016/j.ando.2007.08.004; Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Hoencamp R, 2014, INJURY, V45, P1028, DOI 10.1016/j.injury.2014.02.012; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Ioachimescu AG, 2015, PITUITARY, V18, P535, DOI 10.1007/s11102-014-0606-5; Juul A, 1997, J CLIN ENDOCR METAB, V82, P1195, DOI 10.1210/jc.82.4.1195; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2014, J NEUROTRAUM, V31, P1161, DOI 10.1089/neu.2013.3212; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2015, EUR J ENDOCRINOL, V172, P753, DOI 10.1530/EJE-14-1069; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Kozlowski AJ, 2013, ARCH PHYS MED REHAB, V94, P589, DOI 10.1016/j.apmr.2012.08.199; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Krewer C, 2016, J NEUROTRAUM, V33, P1544, DOI 10.1089/neu.2015.4109; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lagraoui M, 2017, BRAIN BEHAV IMMUN, V61, P96, DOI 10.1016/j.bbi.2016.12.005; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lincoln GA, 2002, J NEUROENDOCRINOL, V14, P36, DOI 10.1046/j.0007-1331.2001.00734.x; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Maghnie M, 2005, EUR J ENDOCRINOL, V152, P589, DOI 10.1530/eje.1.01873; Masel Brent E, 2005, Pituitary, V8, P263, DOI 10.1007/s11102-006-6052-2; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Montgomery J, 2004, J CLIN PSYCHIAT, V65, P1491, DOI 10.4088/JCP.v65n1108; Mossberg KA, 2008, J CLIN ENDOCR METAB, V93, P2581, DOI 10.1210/jc.2008-0368; Naja WJ, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0819-1; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Park KD, 2010, BRAIN INJURY, V24, P1330, DOI 10.3109/02699052.2010.506863; Pavlovic D, 2010, EUR J NEUROL, V17, P696, DOI 10.1111/j.1468-1331.2009.02910.x; Peuskens J, 2014, CNS DRUGS, V28, P421, DOI 10.1007/s40263-014-0157-3; Pfeifer AC, 2016, SCHMERZ, V30, P457, DOI 10.1007/s00482-016-0164-z; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Richardson J T, 1994, Stat Methods Med Res, V3, P107, DOI 10.1177/096228029400300202; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Romano A, 2016, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00497; Rosario ER, 2013, J HEAD TRAUMA REHAB, V28, P390, DOI 10.1097/HTR.0b013e318250eac6; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; Ruxton GD, 2006, BEHAV ECOL, V17, P688, DOI 10.1093/beheco/ark016; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Schultz JS, 2017, SOC BEH NEUR 21 ANN; Silva PPB, 2015, J NEUROTRAUM, V32, P1789, DOI 10.1089/neu.2015.3998; Steward KA, 2017, ARCH CLIN NEUROPSYCH, V32, P98, DOI 10.1093/arclin/acw081; Svensson J, 2007, GROWTH HORM IGF RES, V17, P67, DOI 10.1016/j.ghir.2006.11.002; Szeto A, 2017, AM J PHYSIOL-ENDOC M, V312, pE183, DOI 10.1152/ajpendo.00346.2016; Tanriverdi F, 2011, J ENDOCRINOL INVEST, V34, P541, DOI 10.3275/7805; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2015, NEUROPSYCH DIS TREAT, V11, P1835, DOI 10.2147/NDT.S65814; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tomlinson JW, 2001, LANCET, V357, P425, DOI 10.1016/S0140-6736(00)04006-X; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; VANCAUTER E, 1992, J CLIN ENDOCR METAB, V74, P1441, DOI 10.1210/jc.74.6.1441; Vanya M, 2017, PSYCHIAT RES, V247, P288, DOI 10.1016/j.psychres.2016.12.007; Venegas J., 2011, ENCY CLIN NEUROPSYCH, P2693; Voss JD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0506-z; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; Xin Q, 2017, NEUROCHEM INT, V103, P57, DOI 10.1016/j.neuint.2016.12.021; Young L, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00089; Zgaljardic DJ, 2011, CLIN ENDOCRINOL, V74, P365, DOI 10.1111/j.1365-2265.2010.03935.x	109	25	26	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	FEB 19	2018	9								72	10.3389/fneur.2018.00072			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FW6HD	WOS:000425418100002	29515515	DOAJ Gold, Green Published			2021-06-18	
J	Zeng, XJ; Li, P; Ning, YL; Zhao, Y; Peng, Y; Yang, N; Zhao, ZA; Chen, JF; Zhou, YG				Zeng, Xu-Jia; Li, Ping; Ning, Ya-Lei; Zhao, Yan; Peng, Yan; Yang, Nan; Zhao, Zi-Ai; Chen, Jiang-Fan; Zhou, Yuan-Guo			Impaired autophagic flux is associated with the severity of trauma and the role of A(2A)R in brain cells after traumatic brain injury	CELL DEATH & DISEASE			English	Article							CORTICAL IMPACT MODEL; NEURODEGENERATIVE DISEASES; MOUSE; MICE; RECEPTORS; APOPTOSIS; PATHWAYS; DEATH; NEUROPROTECTION; DEGRADATION	Recent studies have shown that after traumatic brain injury (TBI), the number of autophagosomes is markedly increased in brain cells surrounding the wound; however, whether autophagy is enhanced or suppressed by TBI remains controversial. In our study, we used a controlled cortical impact system to establish models of mild, moderate and severe TBI. In the mild TBI model, the levels of autophagy-related protein 6 (Beclin1) and autophagy-related protein 12 (ATG12)-autophagy-related protein 5 (ATG5) conjugates were increased, indicating the enhanced initiation of autophagy. Furthermore, the level of the autophagic substrate sequestosome 1 (SQSTM1) was decreased in the ipsilateral cortex. This result, together with the results observed in tandem mRFP-GFP-LC3 adeno-associated virus (AAV)-infected mice, indicates that autophagosome clearance was also increased after mild TBI. Conversely, following moderate and severe TBI, there was no change in the initiation of autophagy, and autophagosome accumulation was observed. Next, we used chloroquine (CQ) to artificially impair autophagic flux in the injured cortex of the mild TBI model and found that the severity of trauma was obviously exacerbated. In addition, autophagic flux and trauma severity were significantly improved in adenosine A(2A) receptor (A(2A)R) knockout (KO) mice subjected to moderate TBI. Thus, A(2A)R may be involved in regulating the impairment of autophagic flux in response to brain injury. Our findings suggest that whether autophagy is increased after TBI is associated with whether autophagic flux is impaired, and the impairment of autophagic flux exacerbates the severity of trauma. Furthermore, A(2A)R may be a target for alleviating the impairment in autophagic flux after TBI.	[Zeng, Xu-Jia; Li, Ping; Ning, Ya-Lei; Zhao, Yan; Peng, Yan; Yang, Nan; Zhao, Zi-Ai; Zhou, Yuan-Guo] Third Mil Med Univ, Mol Biol Ctr, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China; [Zeng, Xu-Jia; Li, Ping; Ning, Ya-Lei; Zhao, Yan; Peng, Yan; Yang, Nan; Zhao, Zi-Ai; Zhou, Yuan-Guo] Third Mil Med Univ, State Key Lab Trauma Burn & Combined Injury, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China; [Zeng, Xu-Jia; Li, Ping; Ning, Ya-Lei; Zhao, Yan; Peng, Yan; Yang, Nan; Zhao, Zi-Ai; Zhou, Yuan-Guo] Third Mil Med Univ, Res Inst Surg, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China; [Zeng, Xu-Jia; Li, Ping; Ning, Ya-Lei; Zhao, Yan; Peng, Yan; Yang, Nan; Zhao, Zi-Ai; Zhou, Yuan-Guo] Third Mil Med Univ, Daping Hosp, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China; [Chen, Jiang-Fan] Boston Univ, Dept Neurol & Pharmacol, Sch Med, Boston, MA 02118 USA	Zhou, YG (corresponding author), Third Mil Med Univ, Mol Biol Ctr, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China.; Zhou, YG (corresponding author), Third Mil Med Univ, State Key Lab Trauma Burn & Combined Injury, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China.; Zhou, YG (corresponding author), Third Mil Med Univ, Res Inst Surg, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China.; Zhou, YG (corresponding author), Third Mil Med Univ, Daping Hosp, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China.	yuanguo.zhou@gmail.com	Li, ping/J-6507-2019		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471109]	This work was supported by a grant from the National Natural Science Foundation of China (81471109).	Alfinito PD, 2003, J NEUROSCI, V23, P10982; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bao H. J., 2014, NEUROCHEM RES, V40, P29; Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405; Butler D, 2006, AUTOPHAGY, V2, P234, DOI 10.4161/auto.2729; Chen JF, 2014, INT REV NEUROBIOL, V119, P1, DOI 10.1016/B978-0-12-801022-8.00001-5; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Cunha GMA, 2006, NEUROSCIENCE, V141, P1775, DOI 10.1016/j.neuroscience.2006.05.024; Dai SS, 2013, J EXP MED, V210, P839, DOI 10.1084/jem.20122196; Dall'lgna OP, 2003, BRIT J PHARMACOL, V138, P1207, DOI 10.1038/sj.bjp.0705185; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014; Hu QH, 2016, SCI REP-UK, V6, DOI 10.1038/srep18959; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ichimura Y, 2008, AUTOPHAGY, V4, P1063, DOI 10.4161/auto.6826; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Ke JJ, 2015, J CARDIOVASC PHARM, V66, P25, DOI 10.1097/FJC.0000000000000239; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2006, NATURE, V441, P819, DOI 10.1038/441819a; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Laurent C, 2016, MOL PSYCHIATR, V21, P97, DOI 10.1038/mp.2014.151; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li W, 2009, EXP NEUROL, V215, P69, DOI 10.1016/j.expneurol.2008.09.012; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu YW, 2016, SCI REP-UK, V6, DOI 10.1038/srep33614; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Martini-Stoica H, 2016, TRENDS NEUROSCI, V39, P221, DOI 10.1016/j.tins.2016.02.002; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Nixon RA, 2011, NEUROBIOL DIS, V43, P38, DOI 10.1016/j.nbd.2011.01.021; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Petullo D, 1999, LIFE SCI, V64, P1099, DOI 10.1016/S0024-3205(99)00038-7; Pierri M, 2005, NEUROPHARMACOLOGY, V48, P517, DOI 10.1016/j.neuropharm.2004.11.009; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shao L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9917; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Simoes AP, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-204; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wolfe DM, 2013, EUR J NEUROSCI, V37, P1949, DOI 10.1111/ejn.12169; Zhang L, 2016, CELL MOL NEUROBIOL, V36, P131, DOI 10.1007/s10571-015-0227-1; Zhang MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087241; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhao MF, 2016, MOL MED REP, V13, P13, DOI 10.3892/mmr.2015.4551	51	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	FEB 14	2018	9								252	10.1038/s41419-018-0316-4			16	Cell Biology	Cell Biology	FZ2LP	WOS:000427410000033	29449536	DOAJ Gold, Green Published			2021-06-18	
J	Sun, DW; Wang, WY; Wang, XT; Wang, Y; Xu, XT; Ping, F; Du, Y; Jiang, W; Cui, DR				Sun, Dawei; Wang, Wenying; Wang, Xintao; Wang, Yan; Xu, Xiaotao; Ping, Feng; Du, Yu; Jiang, Wei; Cui, Derong			bFGF plays a neuroprotective role by suppressing excessive autophagy and apoptosis after transient global cerebral ischemia in rats	CELL DEATH & DISEASE			English	Article							FIBROBLAST-GROWTH-FACTOR; HIPPOCAMPAL NEURONAL DEATH; BRAIN-INJURY; CELL-DEATH; ALZHEIMERS-DISEASE; ACTIVATION; RECOVERY; MEMORY; DAMAGE; STRESS	Transient global cerebral ischemia (tGCI) is a cerebrovascular disorder that can cause apoptotic neuronal damage and functional deficits. Basic fibroblast growth factor (bFGF) was reported to be highly expressed in the central nervous system (CNS) and to exert neuroprotective effects against different CNS diseases. However, the effects of bFGF on tGCI have not been studied intensively. This study was conducted to investigate the effect of bFGF and its underlying mechanism in an animal model of tGCI. After intracerebroventricular (i.c.v.) injection of bFGF, functional improvement was observed, and the number of viable neurons increased in the ischemia-vulnerable hippocampal CA1 region. Apoptosis was induced after tGCI and could be attenuated by bFGF treatment via inhibition of p53 mitochondrial translocation. In addition, autophagy was activated during this process, and bFGF could inhibit activation of autophagy through the mTOR pathway. Rapamycin, an activator of autophagy, was utilized to explore the relationship among bFGF, apoptosis, and autophagy. Apoptosis deteriorated after rapamycin treatment, which indicated that excessive autophagy could contribute to the apoptosis process. In conclusion, these results demonstrate that bFGF could exert neuroprotective effects in the hippocampal CA1 region by suppressing excessive autophagy via the mTOR pathway and inhibiting apoptosis by preventing p53 mitochondrial translocation. Furthermore, our results suggest that bFGF may be a promising therapeutic agent to for treating tGCI in response to major adverse events, including cardiac arrest, shock, extracorporeal circulation, traumatic hemorrhage, and asphyxiation.	[Sun, Dawei; Wang, Wenying; Wang, Xintao; Wang, Yan; Xu, Xiaotao; Ping, Feng; Jiang, Wei; Cui, Derong] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Anesthesiol, Shanghai 200233, Peoples R China; [Du, Yu] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Neurol, Shanghai 200233, Peoples R China	Jiang, W; Cui, DR (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Anesthesiol, Shanghai 200233, Peoples R China.; Jiang, W; Cui, DR (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Neurol, Shanghai 200233, Peoples R China.	jiangw@sjtu.edu.cn; cuishuning118@163.com		Sun, Dawei/0000-0002-6631-8527	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81671879]; Shanghai Municipal Commission of Health and Family Planning [201740118]; Medicine-Engineering Joint Foundation of Shanghai Jiaotong University [YG2016MS17]	This work was supported by the National Natural Science Foundation of China (No. 81671879), grant (No. 201740118) from Shanghai Municipal Commission of Health and Family Planning and the Medicine-Engineering Joint Foundation of Shanghai Jiaotong University (No. YG2016MS17).	Bendel O, 2005, J CEREBR BLOOD F MET, V25, P1586, DOI 10.1038/sj.jcbfm.9600153; Block F, 1999, PROG NEUROBIOL, V58, P279, DOI 10.1016/S0301-0082(98)00085-9; Bogousslavsky J, 2002, CEREBROVASC DIS, V14, P239, DOI 10.1159/000065683; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Buccafusco JJ, 2009, FRONT NEUROSCI, P1; Chen DY, 2011, NATURE, V469, P491, DOI 10.1038/nature09667; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cui DR, 2013, NEUROSCIENCE, V246, P117, DOI 10.1016/j.neuroscience.2013.04.054; Cui DR, 2016, SCI REP-UK, V6, DOI 10.1038/srep27642; Endo H, 2006, J NEUROSCI, V26, P7974, DOI 10.1523/JNEUROSCI.0897-06.2006; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Ham PB, 2017, PROG NEUROBIOL, V157, P92, DOI 10.1016/j.pneurobio.2016.06.006; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Klionsky DJ, 2011, AUTOPHAGY, V7, P1273, DOI 10.4161/auto.7.11.17661; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee JY, 2014, NEUROPHARMACOLOGY, V79, P161, DOI 10.1016/j.neuropharm.2013.11.011; Lu Q, 2016, MOL NEUROBIOL, V53, P5344, DOI 10.1007/s12035-015-9455-0; Matsuse D, 2011, TISSUE ENG PT A, V17, P1993, DOI [10.1089/ten.TEA.2010.0585, 10.1089/ten.tea.2010.0585]; Meng QL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033053; Moscovitch M, 2016, ANNU REV PSYCHOL, V67, P105, DOI 10.1146/annurev-psych-113011-143733; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Nguyen TH, 2013, NAT CHEM, V5, P221, DOI [10.1038/nchem.1573, 10.1038/NCHEM.1573]; Niizuma K, 2009, STROKE, V40, P618, DOI 10.1161/STROKEAHA.108.524447; Papadakis M, 2013, NAT MED, V19, P351, DOI 10.1038/nm.3097; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; Puyal J, 2013, PROG NEUROBIOL, V105, P24, DOI 10.1016/j.pneurobio.2013.03.002; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Schimanski LA, 2004, NEUROSCI BIOBEHAV R, V28, P463, DOI 10.1016/j.neubiorev.2004.04.002; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; Speidel D, 2010, TRENDS CELL BIOL, V20, P14, DOI 10.1016/j.tcb.2009.10.002; Spencer SJ, 2008, STROKE, V39, P975, DOI 10.1161/STROKEAHA.107.497016; Sun HS, 2009, NAT NEUROSCI, V12, P1300, DOI 10.1038/nn.2395; Chung TN, 2017, CRIT CARE MED, V45, pE508, DOI 10.1097/CCM.0000000000002289; Tang DW, 2010, BIOMATERIALS, V31, P9320, DOI 10.1016/j.biomaterials.2010.08.058; Thorburn A, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001967; Wang JY, 2008, STROKE, V39, P983, DOI 10.1161/STROKEAHA.107.499079; Wang P, 2012, AUTOPHAGY, V8, P77, DOI 10.4161/auto.8.1.18274; Wang ZG, 2012, TOXICOL LETT, V212, P137, DOI 10.1016/j.toxlet.2012.05.006; Wang ZX, 2016, MOL NEUROBIOL, V53, P1905, DOI 10.1007/s12035-015-9143-0; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; Wu Dafang, 2005, NeuroRx, V2, P120, DOI 10.1007/BF03206648; Xing SH, 2012, AUTOPHAGY, V8, P63, DOI 10.4161/auto.8.1.18217; Zechel S, 2010, NEUROSCIENTIST, V16, P357, DOI 10.1177/1073858410371513; Zhang C, 2014, INT J PHARMACEUT, V461, P192, DOI 10.1016/j.ijpharm.2013.11.049; Zhang HY, 2013, CNS NEUROSCI THER, V19, P20, DOI 10.1111/cns.12013; Zhang XN, 2014, AUTOPHAGY, V10, P1801, DOI 10.4161/auto.32136; Zhao YN, 2017, ONCOTARGET, V8, P23353, DOI 10.18632/oncotarget.15058; Zhao YZ, 2016, J CONTROL RELEASE, V224, P165, DOI 10.1016/j.jconrel.2016.01.017; Zhou XY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.34; Zuo W, 2014, NEUROPHARMACOLOGY, V86, P103, DOI 10.1016/j.neuropharm.2014.07.002	52	25	34	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	FEB 7	2018	9								172	10.1038/s41419-017-0229-7			14	Cell Biology	Cell Biology	FZ2IN	WOS:000427401400014	29416039	DOAJ Gold, Green Published			2021-06-18	
J	Woldetensay, YK; Belachew, T; Tesfaye, M; Spielman, K; Biesalski, HK; Kantelhardt, EJ; Scherbaum, V				Woldetensay, Yitbarek Kidane; Belachew, Tefera; Tesfaye, Markos; Spielman, Kathryn; Biesalski, Hans Konrad; Kantelhardt, Eva Johanna; Scherbaum, Veronika			Validation of the Patient Health Questionnaire (PHQ-9) as a screening tool for depression in pregnant women: Afaan Oromo version	PLOS ONE			English	Article							MIDDLE-INCOME COUNTRIES; TRAUMATIC BRAIN-INJURY; MENTAL-DISORDERS; CULTURAL-FACTORS; VALIDITY; SYMPTOMS; SCALE; EPIDEMIOLOGY; DIAGNOSIS; ADULTS	Background Semantic, technical, content, criterion and conceptual equivalence must be examined in order to validate a psychological rating scale in a new cultural setting. Few validation studies have been conducted in sub-Saharan Africa for scales seeking to detect depression in pregnant women. The aim of this study is to validate the 9-item Patient Health Questionnaire (PHQ-9) as a screening instrument for depression among Afaan Oromo speaking pregnant Ethiopian women. Methods A random sample of 246 pregnant women were recruited in Seka Chekorsa District, Ethiopia during their first, second or third trimester. One week later, 29 participants were selected to answer the questionnaire for a second time to evaluate test retest reliability. The Mini International Neuropsychiatric Interview (MINI-Plus) scale was used as a gold standard to evaluate validity. PHQ-9 was compared with MINI-Plus and sensitivity, specificity, accuracy, positive likelihood ratio, negative likelihood ratio and Receiver Operating Characteristic Curves (ROC) for PHQ-9 were calculated. Rasch analysis was also carried out using Win-steps version 3.81.0. Results The reliability coefficient, Cronbach's alpha, for the PHQ-9 total score was 0.84. Both the agreement and consistency Intra-class Correlation coefficients (ICC) for the one-week test-retest reliability were 0.98. The cut-off point of a summed score of eight resulted in a sensitivity of 80.8% and a specificity of 79.5%. The calculated area under the curve (AUC) for the PHQ-9 score versus the MINI-Plus was excellent, 0.88 (SE = 0.04; CI = 0.81-0.95). The PHQ-9 meets the criteria established by Linacre for rating scale effectiveness. Conclusions The PHQ-9 proved to be a reliable and valid instrument that may be used to screen major depressive disorders among Afaan Oromo speaking Ethiopian pregnant women.	[Woldetensay, Yitbarek Kidane; Biesalski, Hans Konrad; Scherbaum, Veronika] Univ Hohenheim, Inst Biol Chem & Nutr 140a, Stuttgart, Germany; [Woldetensay, Yitbarek Kidane; Biesalski, Hans Konrad; Scherbaum, Veronika] Univ Hohenheim, Food Secur Ctr, Stuttgart, Germany; [Woldetensay, Yitbarek Kidane; Belachew, Tefera; Tesfaye, Markos] Jimma Univ, Coll Hlth Sci, Dept Populat & Family Hlth, Jimma, Ethiopia; [Spielman, Kathryn] Tufts Univ, Freidman Sch Nutr Sci & policy, Boston, MA 02111 USA; [Kantelhardt, Eva Johanna] Martin Luther Univ Halle Wittenberg, Fac Med, Dept Gynecol, Halle, Germany; [Kantelhardt, Eva Johanna] Martin Luther Univ Halle Wittenberg, Fac Med, Inst Med Epidemiol Biostat & Informat, Halle, Germany	Woldetensay, YK (corresponding author), Univ Hohenheim, Inst Biol Chem & Nutr 140a, Stuttgart, Germany.; Woldetensay, YK (corresponding author), Univ Hohenheim, Food Secur Ctr, Stuttgart, Germany.; Woldetensay, YK (corresponding author), Jimma Univ, Coll Hlth Sci, Dept Populat & Family Hlth, Jimma, Ethiopia.	yitbarek.woldetensay@gmail.com	Tesfaye, Markos/H-9297-2019; Belachew, Tefera/AAO-5877-2020	Woldetensay, Yitbarek/0000-0001-7697-4918; Tesfaye, Markos/0000-0002-3351-701X	Empowering New Generations to Improve Nutrition and Economic opportunities (ENGINE) program	This study was funded by Empowering New Generations to Improve Nutrition and Economic opportunities (ENGINE) program. The funder had no role in the analysis and interpretation of the evidence or in writing the paper or in the decision to submit for publication.; This study was funded by Empowering New Generations to Improve Nutrition and Economic opportunities (ENGINE) program. The sponsor had no role in the analysis and interpretation of the evidence or in writing the paper or in the decision to submit for publication. We would like to thank Mr. Yohannes Kebede, Mr. Geda Tolera, Mr. Muktar Beshir, for translating the English version of the instruments into Afaan Oromo and Mr. Gemechis Mekonnen for back translating the Afaan Oromo version back to English Language for consistency check. We thank Mr. Matios Seboka and Mr. Gutema for administering the MINI-Plus instrument. The authors are grateful to Dr. Charlotte Hanlone for her valuable comments on the study protocol. We are also grateful to all the women who volunteered for the study and to the enumerators for their co-operation and support.	Adewuya AO, 2006, J AFFECT DISORDERS, V96, P89, DOI 10.1016/j.jad.2006.05.021; Akena D, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-187; Ali GC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156939; Altman D. G., 1999, PRACTICAL STAT MED R; ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814; Bond T.G., 2007, APPL RASCH MODEL FUN; Bowling KJ, 1998, MODERN EPIDEMIOLOGY; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Comrey A., 1992, 1 COURSE FACTOR ANAL; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; Costello A.B., 2005, PRACTICAL ASSESSMENT, V10, P1; De Jonge P, 2007, PSYCHOSOM MED, V69, P735, DOI 10.1097/PSY.0b013e31815743ca; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fisher J, 2012, B WORLD HEALTH ORGAN, V90, P139, DOI 10.2471/BLT.11.091850; FLAHERTY JA, 1988, J NERV MENT DIS, V176, P257; Gelaye B, 2016, LANCET PSYCHIAT, V3, P973, DOI 10.1016/S2215-0366(16)30284-X; Gelaye B, 2013, PSYCHIAT RES, V210, P653, DOI 10.1016/j.psychres.2013.07.015; Gothwal VK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101295; Hanlon C, 2008, J AFFECT DISORDERS, V108, P251, DOI 10.1016/j.jad.2007.10.023; Huang FY, 2006, J GEN INTERN MED, V21, P547, DOI 10.1111/j.1525-1497.2006.00409.x; Kalpakjian CZ, 2009, J SPINAL CORD MED, V32, P147, DOI 10.1080/10790268.2009.11760766; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEFF JP, 1973, BRIT J PSYCHIAT, V123, P299, DOI 10.1192/bjp.123.3.299; LERNER J, 1968, INT J SOC PSYCHIATR, V14, P145, DOI 10.1177/002076406801400209; Linacre J. M, 2005, USERS GUIDE WINSTEPS; Linacre John M, 2002, J Appl Meas, V3, P85; Manea L, 2012, CAN MED ASSOC J, V184, pE191, DOI 10.1503/cmaj.110829; Medical Outcomes Trust, 1997, TRUST B, V5; Monahan PO, 2009, J GEN INTERN MED, V24, P189, DOI 10.1007/s11606-008-0846-z; Omoro SAO, 2006, INT J PSYCHIAT MED, V36, P367, DOI 10.2190/8W7Y-0TPM-JVGV-QW6M; Patel V, 2001, BRIT MED BULL, V57, P33, DOI 10.1093/bmb/57.1.33; Patel V, 2007, BRIT MED BULL, V81-82, P81, DOI 10.1093/bmb/ldm010; Patel V, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000159; Reckase M.D., 1979, J EDUC STAT, V4, P207, DOI 10.3102/10769986004003207; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; Sheehan DV, 1998, J CLIN PSYCHIAT S20, V59, pS22; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Walker ER, 2012, SEIZURE-EUR J EPILEP, V21, P437, DOI 10.1016/j.seizure.2012.04.009; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.0.CO;2-E; Williams RT, 2009, REHABIL PSYCHOL, V54, P198, DOI 10.1037/a0015529; Yonkers KA, 2009, GEN HOSP PSYCHIAT, V31, P327, DOI 10.1016/j.genhosppsych.2009.03.005; Zhou H., 2011, STAT INFERENCES YOUD	42	25	26	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2018	13	2							e0191782	10.1371/journal.pone.0191782			15	Multidisciplinary Sciences	Science & Technology - Other Topics	FV1EC	WOS:000424302800024	29408928	DOAJ Gold, Green Published			2021-06-18	
J	Alshareef, A; Giudice, JS; Forman, J; Salzar, RS; Panzer, MB				Alshareef, Ahmed; Giudice, J. Sebastian; Forman, Jason; Salzar, Robert S.; Panzer, Matthew B.			A Novel Method for Quantifying Human In Situ Whole Brain Deformation under Rotational Loading Using Sonomicrometry	JOURNAL OF NEUROTRAUMA			English	Article						brain deformation; FE validation; sonomicrometry; TBI	HEAD; INJURY; DISPLACEMENT; MECHANICS	Traumatic brain injuries (TBI) are one of the least understood injuries to the body. Finite element (FE) models of the brain have been crucial for understanding concussion and for developing injury mitigation systems; however, the experimental brain deformation data currently used to validate these models are limited. The objective of this study was to develop a methodology for the investigation of in situ three-dimensional brain deformation during pure rotational loading of the head, using sonomicrometry. Sonomicrometry uses ultrasonic pulses to measure the dynamic distances between piezoelectric crystals implanted in any sound-transmitting media. A human cadaveric head-neck specimen was acquired 14h postmortem and was instrumented with an array of 32 small sonomicrometry crystals embedded in the head: 24 crystals were implanted in the brain, and 8 were fixed to the inner skull. A dynamic rotation was then applied to the head using a closed-loop controlled test device. Four pulses with different severity levels were applied around three orthogonal anatomical axes of rotation. A repeated test of the highest severity rotation was conducted in each axis to assess repeatability. All tests were completed within 56h postmortem. Overall, the combined experimental and sonomicrometry methods were demonstrated to reliably and repeatedly capture three-dimensional dynamic deformation of an intact human brain. These methods provide a framework for using sonomicrometry to acquire multidimensional experimental data required for FE model development and validation, and will lend insight into the deformations sustained by the brain during impact.	[Alshareef, Ahmed; Giudice, J. Sebastian; Forman, Jason; Salzar, Robert S.; Panzer, Matthew B.] Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA	Panzer, MB (corresponding author), Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA.	mbp2q@virginia.edu		Alshareef, Ahmed/0000-0003-4512-1618; Giudice, Sebastian/0000-0003-1074-4890	National Highway Traffic Safety Administration [DTNH221500022/0002]	This study was sponsored by the National Highway Traffic Safety Administration under contract number DTNH221500022/0002. The authors acknowledge the assistance and support of Kasia Rawska, Kevin Kong, Hongnan Lin, Kevin Kopp, Sara Heltzel, Ted Miller, Jim Bolton, Brian Overby, and Joey White.	Azhari H., 2010, BASICS BIOMEDICAL UL, P313, DOI DOI 10.1002/9780470561478.APP1/SUMMARY; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Dione D, 1997, P ANN INT IEEE EMBS, V19, P848, DOI 10.1109/IEMBS.1997.757790; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fomovsky GM, 2012, J MOL CELL CARDIOL, V52, P1083, DOI 10.1016/j.yjmcc.2012.02.012; Gabler L.F., 2017, J BIOMECH ENG; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; Gehre C., 2009, P 21 INT TECHN C ENH; Gennarelli T.A., 1972, STAPP CAR CRASH J, P296; Gennarelli Thomas A, 1987, P 31 STAPP CAR CRASH, DOI [10.4271/872197, DOI 10.4271/872197]; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Holbourn AHS, 1943, LANCET, V2, P438; Holmes JW, 2004, J APPL PHYSIOL, V97, P1453, DOI 10.1152/japplphysiol.00834.2003; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Knutsen AK, 2014, J BIOMECH, V47, P3475, DOI 10.1016/j.jbiomech.2014.09.010; KREMKAU FW, 1981, J ACOUST SOC AM, V70, P29, DOI 10.1121/1.386578; Mallory A.E., 2014, THESIS, pUniversity; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Meoli D, 1998, PROCEEDINGS OF THE IEEE 24TH ANNUAL NORTHEAST BIOENGINEERING CONFERENCE, P64, DOI 10.1109/NEBC.1998.664878; Meyer SA, 1997, IEEE T BIO-MED ENG, V44, P1061, DOI 10.1109/10.641333; Newman J A, 2000, Stapp Car Crash J, V44, P215; Nusholtz G.S., 1984, 841657 SAE, P41; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; Robbins D.H., 1983, P 32 STAPP CAR CRASH, P199; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sanchez E.J., 2017, J NEUROTRAUMA; Sarazan RD, 2009, ADV PHYSIOL EDUC, V33, P144, DOI 10.1152/advan.90208.2008; Sipes NS, 2005, J BIOMECH, V38, P2486, DOI 10.1016/j.jbiomech.2004.10.017; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Society of Automotive Engineers (SAE), 1995, J2111 SAE; Stalnaker IL., 1977, 770921 SAE, P303; Stonecash R.M., 2005, THESIS; Sugawara O, 1996, SPINE, V21, P2089, DOI 10.1097/00007632-199609150-00006; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; VANTRIGT P, 1981, AM J PHYSIOL, V240, pH664; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	40	25	25	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2018	35	5					780	789		10.1089/neu.2017.5362		JAN 2018	10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FX4ZY	WOS:000423522600001	29179620				2021-06-18	
J	Caccese, JB; Buckley, TA; Tierney, RT; Arbogast, KB; Rose, WC; Glutting, JJ; Kaminski, TW				Caccese, Jaclyn B.; Buckley, Thomas A.; Tierney, Ryan T.; Arbogast, Kristy B.; Rose, William C.; Glutting, Joseph J.; Kaminski, Thomas W.			Head and neck size and neck strength predict linear and rotational acceleration during purposeful soccer heading	SPORTS BIOMECHANICS			English	Article						Concussion; subconcussion; mild traumatic brain injury; paediatric	SEGMENT DYNAMIC STABILIZATION; CONCUSSION; FOOTBALL; CHILDREN; PLAYERS; IMPACTS; SPINE	There is increasing societal concern about the long-term effects of repeated impacts from soccer heading, but there is little information about ways to reduce head impact severity. The purpose of this study was to identify factors that contribute to head acceleration during soccer heading. One-hundred soccer players completed 12 controlled soccer headers. Peak linear (PLA) and rotational (PRA) accelerations were measured using a triaxial accelerometer and gyroscope. Head acceleration contributing factors were grouped into 3 categories: size (head mass, neck girth), strength (sternocleidomastoid, upper trapezius) and technique [kinematics (trunk, head-to-trunk range-of-motion), sternocleidomastoid and upper trapezius activity]. Multiple regression analyses indicated size variables explained 22.1% of the variance in PLA and 23.3% of the variance in PRA; strength variables explained 13.3% of the variance in PLA and 17.2% of the variance in PRA; technique variables did not significantly predict PLA or PRA. These findings suggest that head and neck size and neck strength predict PLA and PRA. Anthropometric and neck strength measurements should be considered when determining an athlete's readiness to begin soccer heading.	[Caccese, Jaclyn B.; Buckley, Thomas A.; Rose, William C.; Kaminski, Thomas W.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA; [Tierney, Ryan T.] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Glutting, Joseph J.] Univ Delaware, Sch Educ, Newark, DE USA	Caccese, JB (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA.	jcaccese@udel.edu	Caccese, Jaclyn B./AAH-4571-2020; Buckley, Thomas A/B-7525-2016	Caccese, Jaclyn B./0000-0003-2329-3603; Buckley, Thomas A/0000-0002-0515-0150; Arbogast, Kristy/0000-0002-1694-4562			Arbogast KB, 2009, STAPP CAR CRASH JO, V53, P329; Babbs C F, 2001, ScientificWorldJournal, V1, P281; Caccese JB, 2016, SPORTS MED, V46, P1591, DOI 10.1007/s40279-016-0544-7; Cummiskey B, 2017, P I MECH ENG P-J SPO, V231, P144, DOI 10.1177/1754337116658395; Dezman ZDW, 2013, SPORTS HEALTH, V5, P320, DOI 10.1177/1941738113480935; Falla D, 2002, CLIN NEUROPHYSIOL, V113, P57, DOI 10.1016/S1388-2457(01)00708-8; Federation Internationale de Football Association, 2007, FIFA BIG COUNT 2006, P31; Funk J, 2009, 2009010251 SAE, DOI [10.4271/2009-01-0251, DOI 10.4271/2009-01-0251]; Grinberg LT, 2016, J ALZHEIMERS DIS, V54, P169, DOI 10.3233/JAD-160312; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Gutierrez GM, 2014, PEDIATR EXERC SCI, V26, P33, DOI 10.1123/pes.2013-0102; Hales C, 2014, NEUROLOGY, V83, P2307, DOI 10.1212/WNL.0000000000001081; Hermens H. J., 1999, ROESSINGH RES DEV, V8, P13; Higgins MJ, 2009, P I MECH ENG P-J SPO, V223, P117, DOI 10.1243/17543371JSET15; JENSEN RK, 1986, J BIOMECH, V19, P359, DOI 10.1016/0021-9290(86)90012-6; Karton C., 2016, ISBS C P ARCH TSUK J, V34; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; Mansell J, 2005, J ATHL TRAINING, V40, P310; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Parnell D, 2018, SPORT SOC, V21, DOI 10.1080/17430437.2016.1207787; Peterson-Kendall F, 2005, MUSCLES TESTING FUNC; PLAGENHOEF S, 1983, RES Q EXERCISE SPORT, V54, P169, DOI 10.1080/02701367.1983.10605290; Rooney M., 2010, ULTIMATE WARRIOR WOR; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Seacrist T, 2012, J BIOMECH, V45, P99, DOI 10.1016/j.jbiomech.2011.09.016; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; Tarnutzer A. A., BRIT J SPORTS MED; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Yang YT, 2016, JAMA PEDIATR, V170, P413, DOI 10.1001/jamapediatrics.2016.0338	31	25	25	2	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1476-3141	1752-6116		SPORT BIOMECH	Sport. Biomech.		2018	17	4					462	476		10.1080/14763141.2017.1360385			15	Engineering, Biomedical; Sport Sciences	Engineering; Sport Sciences	GV1AM	WOS:000445798400004	29037111				2021-06-18	
J	Houck, Z; Asken, B; Clugston, J; Perlstein, W; Bauer, R				Houck, Zac; Asken, Breton; Clugston, James; Perlstein, William; Bauer, Russell			Socioeconomic Status and Race Outperform Concussion History and Sport Participation in Predicting Collegiate Athlete Baseline Neurocognitive Scores	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Neurocognitive; Baseline; Concussion; Socioeconomic Status; Neurobiopsychosocial; Collegiate student-athletes	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; DEFICIT HYPERACTIVITY DISORDER; AFRICAN-AMERICAN; HEALTH RESEARCH; READING LEVEL; UNITED-STATES; EDUCATION; FOOTBALL; AGE; IQ	Objectives: The purpose of this study was to assess the contribution of socioeconomic status (SES) and other multivariate predictors to baseline neurocognitive functioning in collegiate athletes. Methods: Data were obtained from the Concussion Assessment, Research and Education (CARE) Consortium. Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) baseline assessments for 403 University of Florida student-athletes (202 males; age range: 18-23) from the 2014-2015 and 2015-2016 seasons were analyzed. ImPACT composite scores were consolidated into one memory and one speed composite score. Hierarchical linear regressions were used for analyses. Results: In the overall sample, history of learning disability (beta = -0.164; p = .001) and attention deficit-hyperactivity disorder (beta = -0.102; p = .038) significantly predicted worse memory and speed performance, respectively. Older age predicted better speed performance (beta = .176; p < .001). Black/African American race predicted worse memory (beta = -0.113; p = .026) and speed performance (beta = -.242; p < .001). In football players, higher maternal SES predicted better memory performance (beta = 0.308; p = .007); older age predicted better speed performance (beta = 0.346; p = .001); while Black/African American race predicted worse speed performance (beta = -0.397; p < .001). Conclusions: Baseline memory and speed scores are significantly influenced by history of neurodevelopmental disorder, age, and race. In football players, specifically, maternal SES independently predicted baseline memory scores, but concussion history and years exposed to sport were not predictive. SES, race, and medical history beyond exposure to brain injury or subclinical brain trauma are important factors when interpreting variability in cognitive scores among collegiate athletes. Additionally, sport-specific differences in the proportional representation of various demographic variables (e.g., SES and race) may also be an important consideration within the broader biopsychosocial attributional model.	[Houck, Zac; Asken, Breton; Perlstein, William; Bauer, Russell] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; [Clugston, James] Univ Florida, Dept Community Hlth & Family Med, Gainesville, FL 32610 USA	Houck, Z (corresponding author), Univ Florida, 1225 Ctr Dr,Room 3151, Gainesville, FL 32610 USA.	zhouck@phhp.ufl.edu		Asken, Breton/0000-0001-8419-142X; Clugston, James/0000-0002-2103-1039	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Department of DefenseUnited States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	This publication was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded, in part by the National Collegiate Athletic Association (NCAA) and the Department of Defense. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Ford Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award NO W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense (DHP funds). No conflict of interest exists among authors.	Alosco ML, 2014, BRAIN INJURY, V28, P472, DOI 10.3109/02699052.2014.887145; Andersson HW, 1996, PSYCHOL REP, V79, P3, DOI 10.2466/pr0.1996.79.1.3; [Anonymous], 2015, COLL SPORT RAC GEND; Asken BM, 2016, NEUROPSYCHOL REV, V26, P340, DOI 10.1007/s11065-016-9327-z; Bailey CM, 2010, CLIN J SPORT MED, V20, P272, DOI 10.1097/JSM.0b013e3181e8f8d8; Blom G., 1958, STAT ESTIMATES TRANS; Bradley RH, 2001, CHILD DEV, V72, P1868, DOI 10.1111/1467-8624.t01-1-00383; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cook N.E., 2017, CLIN NEUROPSYCHOL, P1; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Darling-Hammond L, 2004, DUBOIS REV SOCIAL SC, V1, P213; Derogatis L., 2000, BRIEF SYMPTOM INVENT; Dotson VM, 2008, CLIN NEUROPSYCHOL, V22, P989, DOI 10.1080/13854040701679017; Dotson VM, 2009, J INT NEUROPSYCH SOC, V15, P580, DOI 10.1017/S1355617709090821; Duncan G.J., 2003, CHILD CARE HLTH DEV, V27, P97; DUNCAN GJ, 1994, CHILD DEV, V65, P296, DOI 10.1111/j.1467-8624.1994.tb00752.x; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Gerrard PB, 2017, ARCH CLIN NEUROPSYCH, V32, P117, DOI 10.1093/arclin/acw097; GOTTFRIED AW, 1985, MERRILL PALMER QUART, V31, P85; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Jones NS, 2014, CLIN J SPORT MED, V24, P284, DOI 10.1097/JSM.0000000000000031; Kaplan GA, 2001, INT J EPIDEMIOL, V30, P256, DOI 10.1093/ije/30.2.256; Kontos AP, 2010, ARCH CLIN NEUROPSYCH, V25, P734, DOI 10.1093/arclin/acq068; KORENMAN S, 1995, CHILD YOUTH SERV REV, V17, P127, DOI 10.1016/0190-7409(95)00006-X; Krieger N, 1997, ANNU REV PUBL HEALTH, V18, P341, DOI 10.1146/annurev.publhealth.18.1.341; Larrabee GJ, 2013, CLIN NEUROPSYCHOL, V27, P215, DOI 10.1080/13854046.2013.769634; Littleton AC, 2015, ARCH CLIN NEUROPSYCH, V30, P683, DOI 10.1093/arclin/acv043; Lovell MR., 2000, IMPACT IMMEDIATE POS; Maerlender A, 2013, CLIN NEUROPSYCHOL, V27, P290, DOI 10.1080/13854046.2012.744098; Manly JJ, 2004, APPL NEUROPSYCHOL, V11, P37, DOI 10.1207/s15324826an1101_5; Manly JJ, 2002, J INT NEUROPSYCH SOC, V8, P341, DOI 10.1017/S1355617702813157; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McCrory P., 2017, BRIT J SPORTS MED; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Pastor P.N., 2009, DIAGNOSED ATTENTION; Shuttleworth-Edwards AB, 2004, J CLIN EXP NEUROPSYC, V26, P903, DOI 10.1080/13803390490510824; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Williams DR, 1997, ANN EPIDEMIOL, V7, P322, DOI 10.1016/S1047-2797(97)00051-3	41	25	25	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2018	24	1					1	10		10.1017/S1355617717000716			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	FR6BL	WOS:000419150300001	28791942				2021-06-18	
J	Mohamed, AZ; Cumming, P; Srour, H; Gunasena, T; Uchida, A; Haller, CN; Nasrallah, F				Mohamed, Abdalla Z.; Cumming, Paul; Srour, Hussein; Gunasena, Tamara; Uchida, Aya; Haller, Courtney Nicole; Nasrallah, Fatima		Dept Def Alzheimers Dis	Amyloid pathology fingerprint differentiates post-traumatic stress disorder and traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Traumatic brain injury; Post-traumatic stress disorder; Alzheimer's disease; Amyloid; PET; Department of Defense Alzheimer's Disease; Neuroimaging Initiative (DOD-ADNI)	PRECLINICAL ALZHEIMERS-DISEASE; HIPPOCAMPAL VOLUME; FLORBETAPIR-PET; BETA; DEMENTIA; RISK; METAANALYSIS; VETERANS; TAU; ASSOCIATION	Introduction: Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) are risk factors for early onset of Alzheimer's disease (AD) and may accelerate the progression rate of AD pathology. As amyloid-beta (A beta) plaques are a hallmark of AD pathology, we hypothesized that TBI and PTSD might increase A beta accumulation in the brain. Methods: We examined PET and neuropsychological data from Vietnam War veterans compiled by the US Department of Defense Alzheimer's Disease Neuroimaging Initiative, to examine the spatial distribution of A beta in male veterans' who had experienced a TBI and/or developed PTSD. Subjects were classified into controls, TBI only, PTSD only, and TBI with PTSD (TBI_PTSD) groups and data were analyzed using both voxel-based and ROI-based approaches. Results: Compared to controls, all three clinical groups showed a pattern of mainly increased referenced standard uptake values (SUVR) for the amyloid tracer [F-18]-AV45 PET, with rank order PTSD > TBI_PTSD > TBI > Control, and same rank order was seen in the deficits of cognitive functions. SUVR increase was observed in widespread cortical regions of the PTSD group; in white matter of the TBI_PTSD group; and cerebellum and precuneus area of the TBI group, in contrast with controls. The [F-18]-AV45 SUVR correlated negatively with cerebrospinal fluid (CSF) amyloid levels and positively with the CSF tau concentrations. Conclusion: These results suggest that both TBI and PTSD are substantial risk factors for cognition decline and increased A beta deposition resembling that in AD. In addition, both PTSD and TBI_PTSD have a different pathways of A beta accumulation.	[Mohamed, Abdalla Z.; Srour, Hussein; Nasrallah, Fatima] Univ Queensland, Queensland Brain Inst, Bldg 79,Upland Rd, Brisbane, Qld 4072, Australia; [Cumming, Paul] Queensland Univ Technol, Sch Psychol & Counselling, Brisbane, Qld 4059, Australia; [Cumming, Paul] Queensland Univ Technol, IHBI, Brisbane, Qld 4059, Australia; [Cumming, Paul] QIMR Berghofer Inst, Brisbane, Qld 4006, Australia; [Gunasena, Tamara; Uchida, Aya; Haller, Courtney Nicole] Univ Queensland, Sch Med, Brisbane, Qld 4072, Australia	Nasrallah, F (corresponding author), Univ Queensland, Queensland Brain Inst, Bldg 79,Upland Rd, Brisbane, Qld 4072, Australia.	f.nasrallah@uq.edu.au	Mohamed, Abdalla Z/AAL-8721-2020; Nasrallah, Fatima/N-3398-2016	Mohamed, Abdalla Z/0000-0003-4499-672X; Nasrallah, Fatima/0000-0002-7385-9559; Cumming, Paul/0000-0002-0257-9621	Motor Accident Insurance Commission (MAIC), The Queensland Government, Australia [2014000857]; Wesley Hospital Medical Research Foundation, Brisbane, Australia; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 AG024904]; DOD-ADNI (Department of Defense)United States Department of Defense [W81XWH-12-2-0012]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); AbbVieAbbVie; Alzheimer's AssociationAlzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; BiogenBiogen; Bristol-Myers Squibb CompanyBristol-Myers Squibb; CereSpir, Inc.; Cogstate; Eisai Inc.Eisai Co Ltd; Elan Pharmaceuticals, Inc.; Eli Lilly and CompanyEli Lilly; EuroImmun; F. Hoffmann-La Roche LtdHoffmann-La Roche; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG024904] Funding Source: NIH RePORTER	This research was supported by Motor Accident Insurance Commission (MAIC), The Queensland Government, Australia (grant number: 2014000857). In addition, PC acknowledges grant support from the Wesley Hospital Medical Research Foundation (2016-19), Brisbane, Australia.; Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD-ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.	Aisen PS, 2010, ALZHEIMERS DEMENT, V6, P239, DOI 10.1016/j.jalz.2010.03.006; Alway Y, 2016, DEPRESS ANXIETY, V33, P19, DOI 10.1002/da.22396; Amen DG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129659; Anderson V, 2012, DISABIL REHABIL, V34, P1639, DOI 10.3109/09638288.2012.656789; Andersson J. L. R., 2007, NONLINEAR REGISTRATI, V22; Apostolova LG, 2010, NEUROBIOL AGING, V31, P1284, DOI 10.1016/j.neurobiolaging.2010.05.003; Balan S, 2013, DRUG ALCOHOL DEPEN, V133, P228, DOI 10.1016/j.drugalcdep.2013.04.030; Bendlin BB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037720; Block SR, 2017, COGN AFFECT BEHAV NE, V17, P422, DOI 10.3758/s13415-016-0488-2; Byun BH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006441; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chetelat G, 2013, NEUROIMAGE-CLIN, V2, P356, DOI 10.1016/j.nicl.2013.02.006; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; Cohen BE, 2013, J CLIN PSYCHIAT, V74, P1063, DOI 10.4088/JCP.12m08291; Csernansky JG, 2006, AM J PSYCHIAT, V163, P2164, DOI 10.1176/appi.ajp.163.12.2164; Devi L, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-34; Farias ST, 2008, NEUROPSYCHOLOGY, V22, P531, DOI 10.1037/0894-4105.22.4.531; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Grabner G., 2006, SYMMETRIC ATLASING M, P58; Greenberg MS, 2014, ALZHEIMERS DEMENT, V10, pS155, DOI 10.1016/j.jalz.2014.04.008; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hefter D, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00022; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ikonomovic MD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0399-z; Isamah N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013642; Ito K, 2012, J PHARMACOKINET PHAR, V39, P601, DOI 10.1007/s10928-012-9271-3; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson KA, 2013, ALZHEIMERS DEMENT, V9, pE1, DOI [10.1016/j.jalz.2013.06.001, 10.1016/j.jalz.2013.01.002, 10.1016/j.jalz.2012.10.007]; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Justice NJ, 2015, J NEUROSCI, V35, P2612, DOI 10.1523/JNEUROSCI.3333-14.2015; Kempuraj D, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00703; Kerbler GM, 2015, NEUROIMAGE-CLIN, V7, P105, DOI 10.1016/j.nicl.2014.11.015; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Landau SM, 2012, ANN NEUROL, V72, P578, DOI 10.1002/ana.23650; Lebois LAM, 2016, EXP NEUROL, V284, P141, DOI 10.1016/j.expneurol.2016.04.019; Lepage C, 2018, BRAIN IMAGING BEHAV, V12, P870, DOI 10.1007/s11682-017-9744-5; Li Wei, 2017, Alzheimers Dement (Amst), V6, P196, DOI 10.1016/j.dadm.2017.01.008; Lindauer RJL, 2005, PSYCHOL MED, V35, P1421, DOI 10.1017/S0033291705005246; Liu G, 2015, CURR ALZHEIMER RES, V12, P648, DOI 10.2174/1567205011666141107153634; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Marmar CR, 2015, JAMA PSYCHIAT, V72, P875, DOI 10.1001/jamapsychiatry.2015.0803; Masters CL, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006262; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Morris E, 2016, EUR J NUCL MED MOL I, V43, P374, DOI 10.1007/s00259-015-3228-x; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Morris MC, 2012, CLIN PSYCHOL REV, V32, P301, DOI 10.1016/j.cpr.2012.02.002; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nemmi F., 2014, EUR J NUCL MED MOL I, V1408-1418; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Qureshi SU, 2010, J AM GERIATR SOC, V58, P1627, DOI 10.1111/j.1532-5415.2010.02977.x; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rothman SM, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.07.005; Ruigrok ANV, 2014, NEUROSCI BIOBEHAV R, V39, P34, DOI 10.1016/j.neubiorev.2013.12.004; Saint-Aubert L, 2013, EJNMMI RES, V3, DOI 10.1186/2191-219X-3-43; Schuff N, 2008, PSYCHIAT RES-NEUROIM, V162, P147, DOI 10.1016/j.pscychresns.2007.04.011; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Sekiguchi A, 2013, MOL PSYCHIATR, V18, P618, DOI 10.1038/mp.2012.51; Skinner J, 2012, BRAIN IMAGING BEHAV, V6, P489, DOI 10.1007/s11682-012-9166-3; Spreen O., 1998, COMPENDIUM NEUROPSYC, P75; Toledo JB, 2013, ACTA NEUROPATHOL, V126, P683, DOI 10.1007/s00401-013-1148-z; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Tsolaki M, 2009, HELL J NUCL MED, V12, P41; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; van Rooij S. J. H., 2015, PSYCHOL MED, V1-10; Vlassenko AG, 2012, BBA-MOL BASIS DIS, V1822, P370, DOI 10.1016/j.bbadis.2011.11.005; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; Weiner Michael W, 2017, Alzheimers Dement (N Y), V3, P177, DOI 10.1016/j.trci.2017.02.005; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Woodward SH, 2009, ARCH GEN PSYCHIAT, V66, P1373, DOI 10.1001/archgenpsychiatry.2009.160; Xue C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120270; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	82	25	25	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2018	19						716	726		10.1016/j.nicl.2018.05.016			11	Neuroimaging	Neurosciences & Neurology	GQ7PL	WOS:000441936300073	30009128	DOAJ Gold, Green Published			2021-06-18	
J	Steward, KA; Kennedy, R; Novack, TA; Crowe, M; Marson, DC; Triebel, KL				Steward, Kayla A.; Kennedy, Richard; Novack, Thomas A.; Crowe, Michael; Marson, Daniel C.; Triebel, Kristen L.			The Role of Cognitive Reserve in Recovery From Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive reserve; longitudinal studies; neuropsychology; rehabilitation; traumatic brain injury	ADULT READING WTAR; WECHSLER TEST; PREMORBID INTELLIGENCE; HEAD-INJURY; SEVERITY; VALIDITY; REHABILITATION; PERFORMANCE; EDUCATION; OUTCOMES	Objective: To examine whether cognitive reserve (CR) attenuates the initial impact of traumatic brain injury (TBI) on cognitive performance (neural reserve) and results in faster cognitive recovery rates in the first year postinjury (neural compensation), and whether the advantage of CR differs on the basis of the severity of TBI. Setting: Inpatient/outpatient clinics at an academic medical center. Participants: Adults with mild TBI (mTBI; n = 28), complicated mild TBI (cmTBI; n = 24), and moderate to severe TBI (msevTBI; n = 57), and demographically matched controls (n = 66). Design: Retrospective, longitudinal cohort assessed at 1, 6, and 12 months postinjury. Main Measures: Outcomes were 3 cognitive domains: processing speed/executive function, verbal fluency, and memory. Premorbid IQ, estimated with the Wechsler Test of Adult Reading, served as CR proxy. Results: Higher premorbid IQ was associated with better performance on cognitive domains at 1 month postinjury, and the effect of IQ was similarly beneficial for all groups. Cognitive recovery rate was moderated only by TBI severity; those with more severe TBI had faster recovery in the first year. Conclusion: Results support only the neural reserve theory of CR within a TBI population and indicate that CR is neuroprotective, regardless of the degree of TBI. Higher premorbid CR does not allow for more rapid adaptation and recovery from injury.	[Steward, Kayla A.; Crowe, Michael] Univ Alabama Birmingham, Dept Psychol, Campbell Hall 415,1530 3rd Ave South, Birmingham, AL 35294 USA; [Kennedy, Richard] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA; [Novack, Thomas A.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Marson, Daniel C.; Triebel, Kristen L.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL USA	Steward, KA (corresponding author), Univ Alabama Birmingham, Dept Psychol, Campbell Hall 415,1530 3rd Ave South, Birmingham, AL 35294 USA.	ksteward@uab.edu	triebel, kristen/A-6569-2019	triebel, kristen/0000-0001-9161-7847	National Institute on Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1R01HD053074]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD053074] Funding Source: NIH RePORTER	This work was supported by the National Institute on Child Health and Human Development (grant 1R01HD053074) (Dr Marson, PI). The authors thank the following contributors: Sandra Caldwell, MA (UAB Department of Physical Medicine and Rehabilitation, data collection); UAB Neuropsychology Laboratory Staff (data collection); Pat R. Pritchard, MD (UAB Department of Surgery, referring study participants); and Sarah Nafziger, MD(UAB Department of Emergency Medicine, referring study participants).	Brasure M, 2012, AHRQ COMP EFFECTIVEN; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Delis D. C., 2000, CVLT II CALIFORNIA V; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dwan TM, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00056; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Garcia-Molina A, 2013, MED CLIN-BARCELONA, V140, P527, DOI 10.1016/j.medcli.2012.09.047; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Jeon IC, 2008, J KOREAN NEUROSURG S, V44, P295, DOI 10.3340/jkns.2008.44.5.295; Kalmar K, 2008, ARCH PHYS MED REHAB, V89, P942, DOI 10.1016/j.apmr.2008.01.008; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Mathias JL, 2007, BRIT J CLIN PSYCHOL, V46, P457, DOI 10.1348/014466507X190197; Mathias JL, 2015, NEUROSCI BIOBEHAV R, V55, P573, DOI 10.1016/j.neubiorev.2015.06.001; McGurn B, 2004, NEUROLOGY, V62, P1184, DOI 10.1212/01.WNL.0000103169.80910.8B; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Orme DR, 2004, REHABIL PSYCHOL, V49, P250, DOI 10.1037/0090-5550.49.3.250; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Prescott R, 2006, APPL MIXED MODELS ME; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Singer J.D., 2003, APPL LONGITUDINAL DA; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Spreen O., 1998, COMPENDIUM NEUROPSYC; Steffener J, 2012, BBA-MOL BASIS DIS, V1822, P467, DOI 10.1016/j.bbadis.2011.09.012; Stern Y, 2005, CEREB CORTEX, V15, P394, DOI 10.1093/cercor/bhh142; Stern Y, 2006, ALZ DIS ASSOC DIS, V20, pS69, DOI 10.1097/00002093-200607001-00010; Steward KA, 2017, ARCH CLIN NEUROPSYCH, V32, P98, DOI 10.1093/arclin/acw081; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; Triebel KL, 2012, NEUROLOGY, V78, P1472, DOI 10.1212/WNL.0b013e3182553c38; Wechsler D, 1997, WMS III WECHSLER MEM; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; Wechsler D., 2001, WECHSLER TEST ADULT; Whitney KA, 2010, APPL NEUROPSYCHOL, V17, P196, DOI 10.1080/09084282.2010.499787; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolfson D., 1993, HALSTEAD REITAN NEUR	47	25	25	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2018	33	1					E18	E27		10.1097/HTR.0000000000000325			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GB0QS	WOS:000428752300003	28520675	Green Accepted			2021-06-18	
J	Vergara, VM; Mayer, AR; Kiehl, KA; Calhoun, VD				Vergara, Victor M.; Mayer, Andrew R.; Kiehl, Kent A.; Calhoun, Vince D.			Dynamic functional network connectivity discriminates mild traumatic brain injury through machine learning	NEUROIMAGE-CLINICAL			English	Article						Traumatic brain injury; Magnetic resonance imaging; Dynamic functional network connectivity	DEFAULT-MODE NETWORK; FMRI DATA; TIME; MRI; ABNORMALITIES; DISRUPTION; REST	Mild traumatic brain injury (mTBI) can result in symptoms that affect a person's cognitive and social abilities. Improvements in diagnostic methodologies are necessary given that current clinical techniques have limited accuracy and are solely based on self-reports. Recently, resting state functional network connectivity (FNC) has shown potential as an important imaging modality for the development of mTBI biomarkers. The present work explores the use of dynamic functional network connectivity (dFNC) for mTBI detection. Forty eight mTBI patients (24 males) and age-gender matched healthy controls were recruited. We identified a set of dFNC states and looked at the possibility of using each state to classify subjects in mTBI patients and healthy controls. A linear support vector machine was used for classification and validated using leave-one-out cross validation. One of the dFNC states achieved a high classification performance of 92% using the area under the curve method. A series of t-test analysis revealed significant dFNC increases between cerebellum and sensorimotor networks. This significant increase was detected in the same dFNC state useful for classification. Results suggest that dFNC can be used to identify optimal dFNC states for classification excluding those that does not contain useful features.	[Vergara, Victor M.; Mayer, Andrew R.; Kiehl, Kent A.; Calhoun, Vince D.] Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA; [Vergara, Victor M.; Mayer, Andrew R.; Kiehl, Kent A.; Calhoun, Vince D.] Lovelace Biomed & Environm Res Inst, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA; [Calhoun, Vince D.] Univ New Mexico, Dept ECE, Albuquerque, NM 87131 USA; [Mayer, Andrew R.; Kiehl, Kent A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Psychiat & Behav Sci, Albuquerque, NM 87131 USA	Vergara, VM (corresponding author), Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	vvergara@mrn.org; amayer@mrn.org; kkiehl@mrn.org; vcalhoun@mrn.org	Kiehl, Kent A./AAK-3290-2020	Vergara, Victor/0000-0001-9404-0924	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21NS064464/3R21 NS064464/1 R01 NS098494-01A1, P20GM103472/1R01EB006841/R01REB020407]; National Science FoundationNational Science Foundation (NSF) [1539067]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB020407] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS098494] Funding Source: NIH RePORTER	The authors thank Joseph Ling, Jill Fries, Vikram Rao, Prashanth Nyalakanti, and Sandeep Panta for help with preprocessing the data. This work was funded by the following NIH grants: R21NS064464/3R21 NS064464/1 R01 NS098494-01A1 to A.M. and P20GM103472/1R01EB006841/R01REB020407 and National Science Foundation (#1539067) to V.C.	Allen EA, 2014, CEREB CORTEX, V24, P663, DOI 10.1093/cercor/bhs352; Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Arenth PM, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318289ede5; Ben-Hur A, 2001, ADV NEUR IN, V13, P367; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun VD, 2008, HUM BRAIN MAPP, V29, P828, DOI 10.1002/hbm.20581; Calhoun Vince D, 2012, IEEE Rev Biomed Eng, V5, P60, DOI 10.1109/RBME.2012.2211076; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Friston KJ., 2003, NEUROSCIENCE DATABAS, P237, DOI [10.1007/978-1-4615-1079-6_16, DOI 10.1007/978-1-4615-1079-6_16]; Gonzalez-Castillo J, 2017, NEUROIMAGE; Hahn T, 2015, JAMA PSYCHIAT, V72, P68, DOI 10.1001/jamapsychiatry.2014.1741; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Himberg J, 2003, 2003 IEEE XIII WORKSHOP ON NEURAL NETWORKS FOR SIGNAL PROCESSING - NNSP'03, P259, DOI 10.1109/NNSP.2003.1318025; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hutchison RM, 2013, NEUROIMAGE, V80, P360, DOI 10.1016/j.neuroimage.2013.05.079; Iraji A, 2016, NEUROIMAGE-CLIN, V12, P100, DOI 10.1016/j.nicl.2016.06.012; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Ma S, 2011, IEEE T BIO-MED ENG, V58, P3406, DOI 10.1109/TBME.2011.2167149; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Miller RL, 2016, IEEE T BIO-MED ENG, V63, P2525, DOI 10.1109/TBME.2016.2600637; Mooneyham BW, 2017, J COGNITIVE NEUROSCI, V29, P495, DOI 10.1162/jocn_a_01066; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Palacios EM, 2017, J NEUROTRAUM, V34, P1546, DOI 10.1089/neu.2016.4752; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Sakoglu U, 2010, MAGN RESON MATER PHY, V23, P351, DOI 10.1007/s10334-010-0197-8; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; TEASDALE G, 1974, LANCET, V2, P81; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; Vergara VM, 2017, J NEUROTRAUM, V34, P1045, DOI 10.1089/neu.2016.4526; Whelan R, 2014, NATURE, V512, P185, DOI 10.1038/nature13402; Yaesoubi M, 2015, NEUROIMAGE, V120, P133, DOI 10.1016/j.neuroimage.2015.07.002; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	51	25	25	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2018	19						30	37		10.1016/j.nicl.2018.03.017			8	Neuroimaging	Neurosciences & Neurology	GQ7PL	WOS:000441936300004	30034999	DOAJ Gold, Green Published			2021-06-18	
J	Dimitriadis, SI; Antonakakis, M; Simos, P; Fletcher, JM; Papanicolaou, AC				Dimitriadis, Stavros I.; Antonakakis, Marios; Simos, Panagiotis; Fletcher, Jack M.; Papanicolaou, Andrew C.			Data-Driven Topological Filtering Based on Orthogonal Minimal Spanning Trees: Application to Multigroup Magnetoencephalography Resting-State Connectivity	BRAIN CONNECTIVITY			English	Article						brain networks; network topology; optimization of information flow; resting state; topological filtering		In the present study, a novel data-driven topological filtering technique is introduced to derive the backbone of functional brain networks relying on orthogonal minimal spanning trees (OMSTs). The method aims to identify the essential functional connections to ensure optimal information flow via the objective criterion of global efficiency minus the cost of surviving connections. The OMST technique was applied to multichannel, resting-state neuromagnetic recordings from four groups of participants: healthy adults (n=50), adults who have suffered mild traumatic brain injury (n=30), typically developing children (n=27), and reading-disabled children (n=25). Weighted interactions between network nodes (sensors) were computed using an integrated approach of dominant intrinsic coupling modes based on two alternative metrics (symbolic mutual information and phase lag index), resulting in excellent discrimination of individual cases according to their group membership. Classification results using OMST-derived functional networks were clearly superior to results using either relative power spectrum features or functional networks derived through the conventional minimal spanning tree algorithm.	[Dimitriadis, Stavros I.] Cardiff Univ, Sch Med, Div Psychol Med & Clin Neurosci, Cardiff, S Glam, Wales; [Dimitriadis, Stavros I.] Cardiff Univ, Sch Psychol, Brain Res Imaging Ctr CUBRIC, Cardiff, S Glam, Wales; [Dimitriadis, Stavros I.] Cardiff Univ, Sch Psychol, Cardiff, S Glam, Wales; [Dimitriadis, Stavros I.] Cardiff Univ, Sch Psychol, Brain Res Imaging Ctr CUBRIC, Neuroinformat Grp, Cardiff, S Glam, Wales; [Dimitriadis, Stavros I.] Cardiff Univ, Sch Med, MRC Ctr Neuropsychiat Genet & Genom, Cardiff, S Glam, Wales; [Antonakakis, Marios] Westfalian Wilhelms Univ Muenster, Inst Biomagnetism & Biosignal Anal, Munster, Germany; [Simos, Panagiotis] Univ Crete, Sch Med, Iraklion, Greece; [Simos, Panagiotis] Fdn Res & Technol, Inst Comp Sci, Iraklion, Greece; [Fletcher, Jack M.] Univ Houston, Dept Psychol, Houston, TX USA; [Papanicolaou, Andrew C.] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA; [Papanicolaou, Andrew C.] Le Bonheur Childrens Hosp, Neurosci Inst, Memphis, TN USA	Dimitriadis, SI (corresponding author), Cardiff Univ, Brain Res Imaging Ctr CUBRIC, Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales.	dimitriadiss@cardiff.ac.uk	Antonakakis, Marios/ABD-8218-2020	Simos, Panagiotis/0000-0002-0116-8564	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P50 HD052117]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/K004360/1]; MARIE-CURIE COFUND EU-UK FELLOWSHIP; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P50HD052117] Funding Source: NIH RePORTER	This research was supported, in part, by grant P50 HD052117 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NICHD or the National Institutes of Health. S.I.D. was supported, in part, by MRC grant MR/K004360/1 (Behavioural and Neurophysiological Effects of Schizophrenia Risk Genes: A Multilocus, Pathway Based Approach) and by a MARIE-CURIE COFUND EU-UK FELLOWSHIP.	Abraham A, 2017, NEUROIMAGE, V147, P736, DOI 10.1016/j.neuroimage.2016.10.045; Antonakakis M, 2016, INT J PSYCHOPHYSIOL, V102, P1, DOI 10.1016/j.ijpsycho.2016.02.002; Antonakakis M, 2015, IEEE ENG MED BIO, P7426, DOI 10.1109/EMBC.2015.7320108; Aru J, 2015, CURR OPIN NEUROBIOL, V31, P51, DOI 10.1016/j.conb.2014.08.002; Basar E, 2016, INT J PSYCHOPHYSIOL, V103, P185, DOI 10.1016/j.ijpsycho.2015.02.018; Bassett DS, 2006, NEUROSCIENTIST, V12, P512, DOI 10.1177/1073858406293182; Bastos AM, 2016, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00175; Borg I., 2005, MODERN MULTIDIMENSIO, P207; Bullmore ET, 2011, ANNU REV CLIN PSYCHO, V7, P113, DOI 10.1146/annurev-clinpsy-040510-143934; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Buzsaki G., 2006, RHYTHMS BRAIN; Buzsaki Gyorgy, 2012, Dialogues Clin Neurosci, V14, P345; Canolty RT, 2010, TRENDS COGN SCI, V14, P506, DOI 10.1016/j.tics.2010.09.001; Dansereau C, 2017, NEUROIMAGE, V149, P220, DOI 10.1016/j.neuroimage.2017.01.072; Deco G, 2017, NEUROIMAGE, V152, P538, DOI 10.1016/j.neuroimage.2017.03.023; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Dimitriadis SI, 2013, NEUROIMAGE, V83, P307, DOI 10.1016/j.neuroimage.2013.06.036; Dimitriadis SI, 2016, 20 INT C BIOM SEOUL; Dimitriadis S, 2016, IEEE T NEUR SYS REH, V24, P1017, DOI 10.1109/TNSRE.2016.2516107; Dimitriadis Stavros I, 2016, Alzheimers Dement (N Y), V2, P241, DOI 10.1016/j.trci.2016.08.004; Dimitriadis SI, 2017, FRONT NEUROINFORM, V11, DOI 10.3389/fninf.2017.00028; Dimitriadis SI, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00454; Dimitriadis SI, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00163; Dimitriadis SI, 2015, NEUROIMAGE-CLIN, V9, P519, DOI 10.1016/j.nicl.2015.09.011; Dimitriadis SI, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00350; Dimitriadis SI, 2015, ANN BIOMED ENG, V43, P977, DOI 10.1007/s10439-014-1143-0; Dimitriadis SI, 2010, J NEUROSCI METH, V193, P145, DOI 10.1016/j.jneumeth.2010.08.027; Dunkley BT, 2015, NEUROIMAGE-CLIN, V7, P611, DOI 10.1016/j.nicl.2015.02.020; Engel AK, 2013, NEURON, V80, P867, DOI 10.1016/j.neuron.2013.09.038; Escudero J, 2011, ANN BIOMED ENG, V39, P2274, DOI 10.1007/s10439-011-0312-7; Fotopoulou F, 2014, INT CONF FRONT HAND, P749, DOI 10.1109/ICFHR.2014.131; Fouss F, 2012, NEURAL NETWORKS, V31, P53, DOI 10.1016/j.neunet.2012.03.001; Hammond DK, 2013, IEEE GLOB CONF SIG, P419, DOI 10.1109/GlobalSIP.2013.6736904; Janson S, 2004, THEOR COMPUT SCI, V326, P213, DOI 10.1016/j.tcs.2004.06.023; Jirsa V, 2013, FRONT COMPUT NEUROSC, V7, DOI 10.3389/fncom.2013.00078; Khazaee A, 2017, BEHAV BRAIN RES, V322, P339, DOI 10.1016/j.bbr.2016.06.043; King JR, 2013, CURR BIOL, V23, P1914, DOI 10.1016/j.cub.2013.07.075; Kruskal J.B., 1956, P AM MATH SOC, V7, P48, DOI [DOI 10.1090/S0002-9939-1956-0078686-7, 10.1090/S0002-9939-1956-0078686-7]; Llinas RR, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00320; Meier J, 2015, BRAIN CONNECT, V5, P575, DOI 10.1089/brain.2014.0330; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; PRIM RC, 1957, AT&T TECH J, V36, P1389, DOI 10.1002/j.1538-7305.1957.tb01515.x; Robinson SE, 2015, NEUROPSYCHOPHARMACOL, V40, P251, DOI 10.1038/npp.2014.217; Roux F, 2013, J NEUROSCI, V33, P17827, DOI 10.1523/JNEUROSCI.5778-12.2013; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Shew WL, 2009, J NEUROSCI, V29, P15595, DOI 10.1523/JNEUROSCI.3864-09.2009; Stam CJ, 2007, HUM BRAIN MAPP, V28, P1178, DOI 10.1002/hbm.20346; Stam CJ, 2014, NAT REV NEUROSCI, V15, P683, DOI 10.1038/nrn3801; Stamoulis C, 2015, J COGNITIVE NEUROSCI, V27, P2512, DOI 10.1162/jocn_a_00877; Telesford QK, 2011, BRAIN CONNECT, V1, P295, DOI [10.1089/brain.2011.0055, 10.1089/brain.2011.0038]; Tewarie P, 2015, NEUROIMAGE, V104, P177, DOI 10.1016/j.neuroimage.2014.10.015; van den Heuvel MP, 2017, NEUROIMAGE, V152, P437, DOI 10.1016/j.neuroimage.2017.02.005; van Wijk BCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013701; VanVeen BD, 1997, IEEE T BIO-MED ENG, V44, P867, DOI 10.1109/10.623056; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550	56	25	25	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	2158-0014	2158-0022		BRAIN CONNECT	Brain Connect.	DEC	2017	7	10					661	670		10.1089/brain.2017.0512			10	Neurosciences	Neurosciences & Neurology	VJ2VM	WOS:000570278500005	28891322	Green Published, Green Accepted			2021-06-18	
J	Schreiber, JE; Palmer, SL; Conklin, HM; Mabbott, DJ; Swain, MA; Bonner, MJ; Chapieski, ML; Huang, L; Zhang, H; Gajjar, A				Schreiber, Jane E.; Palmer, Shawna L.; Conklin, Heather M.; Mabbott, Donald J.; Swain, Michelle A.; Bonner, Melanie J.; Chapieski, Mary L.; Huang, Lu; Zhang, Hui; Gajjar, Amar			Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study	NEURO-ONCOLOGY			English	Article						brain tumor; medulloblastoma; neuropsychological outcomes; posterior fossa syndrome	CEREBELLAR MUTISM SYNDROME; TRAUMATIC BRAIN-INJURY; COGNITIVE-AFFECTIVE SYNDROME; TUMOR RESECTION; EXECUTIVE FUNCTION; WORKING-MEMORY; NEUROCOGNITIVE CONSEQUENCES; PEDIATRIC MEDULLOBLASTOMA; RHESUS-MONKEY; FOLLOW-UP	Background. Patients treated for medulloblastoma who experience posterior fossa syndrome (PFS) demonstrate increased risk for neurocognitive impairment at one year post diagnosis. The aim of the study was to examine longitudinal trajectories of neuropsychological outcomes in patients who experienced PFS compared with patients who did not. Methods. Participants were 36 patients (22 males) who experienced PFS and 36 comparison patients (21 males) who were matched on age at diagnosis and treatment exposure but did not experience PFS. All patients underwent serial evaluation of neurocognitive functioning spanning 1 to 5 years post diagnosis. Results. The PFS group demonstrated lower estimated mean scores at 1, 3, and 5 years post diagnosis on measures of general intellectual ability, processing speed, broad attention, working memory, and spatial relations compared with the non-PFS group. The PFS group exhibited estimated mean scores that were at least one standard deviation below the mean for intellectual ability, processing speed, and broad attention across all time points and for working memory by 5 years post diagnosis. Processing speed was stable over time. Attention and working memory declined over time. Despite some change over time, caregiver ratings of executive function and behavior problem symptoms remained within the average range. Conclusion. Compared with patients who do not experience PFS, patients who experience PFS exhibit greater neurocognitive impairment, show little recovery over time, and decline further in some domains. Findings highlight the particularly high risk for long-term neurocognitive problems in patients who experience PFS and the need for close follow-up and intervention.	[Schreiber, Jane E.; Palmer, Shawna L.; Conklin, Heather M.] St Jude Childrens Res Hosp, Dept Psychol, 262 Danny Thomas Pl,MS 740, Memphis, TN 38105 USA; [Huang, Lu; Zhang, Hui] St Jude Childrens Res Hosp, Dept Biostat, 332 N Lauderdale St, Memphis, TN 38105 USA; [Gajjar, Amar] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Mabbott, Donald J.] Hosp Sick Children, Dept Psychol, Toronto, ON, Canada; [Swain, Michelle A.] Lady Cilento Childrens Hosp, South Brisbane, Qld, Australia; [Bonner, Melanie J.] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA; [Chapieski, Mary L.] Texas Childrens Hosp, Dept Pediat Med, Houston, TX 77030 USA	Schreiber, JE (corresponding author), St Jude Childrens Res Hosp, Dept Psychol, 262 Danny Thomas Pl,MS 740, Memphis, TN 38105 USA.	Jane.schreiber@stjude.org	Conklin, Heather M/N-2696-2018; Gajjar, Amar/N-8059-2018	Zhang, Hui/0000-0001-6825-5649	National Cancer Institute through a Cancer Center Support (CORE) grant [P30-CA21765]; Noyes Brain Tumor Foundation; Musicians Against Childhood Cancer (MACC); American Lebanese Syrian Associated Charities (ALSAC)American Lebanese Syrian Associated Charities (ALSAC)	This work was supported in part by the National Cancer Institute through a Cancer Center Support (CORE) grant (P30-CA21765), the Noyes Brain Tumor Foundation, Musicians Against Childhood Cancer (MACC), and the American Lebanese Syrian Associated Charities (ALSAC).	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Catsman-Berrevoets CE, 2010, CORTEX, V46, P933, DOI 10.1016/j.cortex.2009.10.007; CHANG CH, 1969, RADIOLOGY, V93, P1351, DOI 10.1148/93.6.1351; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Conklin HM, 2010, J CLIN ONCOL, V28, P4465, DOI 10.1200/JCO.2010.28.4026; De Ruiter MA, 2013, DEV MED CHILD NEUROL, V55, P408, DOI 10.1111/dmcn.12020; De Smet HJ, 2007, EUR J PAEDIATR NEURO, V11, P193, DOI 10.1016/j.ejpn.2007.01.007; De Smet HJ, 2009, NEUROPSYCHOLOGY, V23, P694, DOI 10.1037/a0016106; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gudrunardottir T, 2016, CHILD NERV SYST, V32, P1195, DOI 10.1007/s00381-016-3093-3; Gudrunardottir T, 2011, CHILD NERV SYST, V27, P355, DOI 10.1007/s00381-010-1328-2; GURNEY JG, 1995, CANCER, V75, P2186, DOI 10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-F; Huber JF, 2006, CHILD NERV SYST, V22, P132, DOI 10.1007/s00381-005-1223-4; Huber JF, 2007, J CHILD NEUROL, V22, P848, DOI 10.1177/0883073807303995; Knight SJ, 2014, J PEDIATR PSYCHOL, V39, P501, DOI 10.1093/jpepsy/jsu009; Korah MP, 2010, INT J RADIAT ONCOL, V77, P106, DOI 10.1016/j.ijrobp.2009.04.058; Law N, 2017, J NEUROPSYCHOL, V11, P174, DOI 10.1111/jnp.12082; Law N, 2015, HUM BRAIN MAPP, V36, P2615, DOI 10.1002/hbm.22795; Law N, 2012, NEURO-ONCOLOGY, V14, P1294, DOI 10.1093/neuonc/nos160; Levisohn L, 2000, BRAIN, V123, P1041, DOI 10.1093/brain/123.5.1041; Miller NG, 2010, AM J NEURORADIOL, V31, P288, DOI 10.3174/ajnr.A1821; Moxon-Emre I, 2014, J CLIN ONCOL, V32, P1760, DOI 10.1200/JCO.2013.52.3290; Mulhern RK, 2005, J CLIN ONCOL, V23, P5511, DOI 10.1200/JCO.2005.00.703; Mulhern RK, 2001, J CLIN ONCOL, V19, P472, DOI 10.1200/JCO.2001.19.2.472; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Palmer SL, 2013, J CLIN ONCOL, V31, P3494, DOI 10.1200/JCO.2012.47.4775; Palmer SL, 2010, NEURO-ONCOLOGY, V12, P1311, DOI 10.1093/neuonc/noq094; Patay Z, 2014, AM J NEURORADIOL, V35, P797, DOI 10.3174/ajnr.A3762; Robertson PL, 2006, J NEUROSURG, V105, P444, DOI 10.3171/ped.2006.105.6.444; Robinson KE, 2013, J INT NEUROPSYCH SOC, V19, P44, DOI 10.1017/S1355617712000987; SCHMAHMANN JD, 1995, NEUROSCI LETT, V199, P175, DOI 10.1016/0304-3940(95)12056-A; Schmahmann JD, 1997, INT REV NEUROBIOL, V41, P31, DOI 10.1016/S0074-7742(08)60346-3; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; Schmahmann JD, 1997, J NEUROSCI, V17, P438; Schreiber JE, 2014, NEURO-ONCOLOGY, V16, P1129, DOI 10.1093/neuonc/nou006; Slomine B, 2009, DEV DISABIL RES REV, V15, P133, DOI 10.1002/ddrr.56; Steinbok P, 2003, PEDIATR NEUROSURG, V39, P179, DOI 10.1159/000072468; Steinlin M, 2003, BRAIN, V126, P1998, DOI 10.1093/brain/awg195; Steinlin M, 2008, CEREBELLUM, V7, P607, DOI 10.1007/s12311-008-0083-3; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wolfe-Christensen C, 2007, PEDIATR BLOOD CANCER, V49, P723, DOI 10.1002/pbc.21084; Woodcock R, 2001, WOODCOCK JOHNSON 3 E; Zeltzer PM, 1999, J CLIN ONCOL, V17, P832, DOI 10.1200/JCO.1999.17.3.832	46	25	26	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1522-8517	1523-5866		NEURO-ONCOLOGY	Neuro-Oncology	DEC	2017	19	12					1673	1682		10.1093/neuonc/nox135			10	Oncology; Clinical Neurology	Oncology; Neurosciences & Neurology	FO9JQ	WOS:000417204200019	29016818	Green Published, Bronze			2021-06-18	
J	Zeiler, FA; Donnelly, J; Menon, DK; Smielewski, P; Zweifel, C; Brady, K; Czosnyka, M				Zeiler, Frederick A.; Donnelly, Joseph; Menon, David K.; Smielewski, Peter; Zweifel, Christian; Brady, Ken; Czosnyka, Marek			Continuous Autoregulatory Indices Derived from Multi-Modal Monitoring: Each One Is Not Like the Other	JOURNAL OF NEUROTRAUMA			English	Article						autoregulation; autoregulation index; co-variance; multi-modal monitoring	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; NEAR-INFRARED SPECTROSCOPY; CEREBROVASCULAR REACTIVITY; INTRACRANIAL-PRESSURE; NEUROCRITICAL CARE; OXYGEN-PRESSURE; HEAD-INJURY; OSCILLATIONS; EXPERIENCE	We assess the relationships between various continuous measures of autoregulatory capacity in a cohort of adults with traumatic brain injury (TBI). We assessed relationships between autoregulatory indices derived from intracranial pressure (ICP: PRx, PAx, RAC), transcranial Doppler (TCD: Mx, Sx, Dx), brain tissue-oxygenation (ORx), and spatially resolved near infrared spectroscopy (NIRS resolved: TOx, THx). Relationships between indices were assessed using Pearson correlation coefficient, Friedman test, principal component analysis (PCA), agglomerative hierarchal clustering (AHC) and k-means cluster analysis (KMCA). All analytic techniques were repeated for a range of temporal resolutions of data, including minute-by-minute averages, moving means of 30 samples, and grand mean for each patient. Thirty-seven patients were studied. The PRx displayed strong association with PAx/RAC across all the analytical techniques: Pearson correlation (r = 0.682/r = 0.677, p < 0.0001), PCA, AHC, and KMCA in the grand mean data sheet. Most TCD-based indices (Mx, Dx) were correlated and co-clustered on PCA, AHC, and KMCA. The Sx was found to be more closely associated with ICP-derived indices on Pearson correlation, PCA, AHC, and KMCA. The NIRS indices displayed variable correlation with each other and with indices derived from ICP and TCD signals. Of interest, TOx and THx co-cluster with ICP-based indices on PCA and AHC. The ORx failed to display any meaningful correlations with other indices in neither of the analytical method used. Thirty-minute moving average and minute-by-minute data set displayed similar results across all the methods. The RAC, Mx, and Sx were the strongest predictors of outcome at six months. Continuously updating autoregulatory indices are not all correlated with one another. Caution must be advised when utilizing less commonly described autoregulation indices (i.e., ORx) for the clinical assessment of autoregulatory capacity, because they appear to not be related to commonly measured/establish indices, such as PRx. Further prospective validation is required.	[Zeiler, Frederick A.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Dept Surg, Winnipeg, MB R3A 1R9, Canada; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Clinician Investigator Program, Winnipeg, MB, Canada; [Donnelly, Joseph; Smielewski, Peter; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Sect Brain Phys, Cambridge, England; [Zweifel, Christian] Cantonal Hosp Chur, Dept Neurosurg, Basel, Switzerland; [Brady, Ken] Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA	Zeiler, FA (corresponding author), Univ Manitoba, Rady Fac Hlth Sci, Dept Surg, Winnipeg, MB R3A 1R9, Canada.	umzeiler@myumanitoba.ca	Donnelly, Joseph/N-6803-2019; Donnelly, Joseph/E-9235-2018	Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Zeiler, Frederick/0000-0003-1737-0510	Cambridge Commonwealth Trust Scholarship; Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery; University of Manitoba Clinician Investigator Program; R. Samuel McLaughlin Research and Education Award; Manitoba Medical Service Foundation; University of Manitoba Faculty of Medicine Dean's Fellowship Fund; National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award; European Union Framework Program 7 grant (CENTER-TBI) [602150]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This work was made possible through salary support through the Cambridge Commonwealth Trust Scholarship, the Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery, the University of Manitoba Clinician Investigator Program, R. Samuel McLaughlin Research and Education Award, the Manitoba Medical Service Foundation, and the University of Manitoba Faculty of Medicine Dean's Fellowship Fund.; These studies were supported by the National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award to DKM. Authors were also supported by a European Union Framework Program 7 grant (CENTER-TBI; Grant Agreement No. 602150).	Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Crawley M.J., 2013, R BOOK, P809; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 2003, ACT NEUR S, V86, P581; Czosnyka M, 2002, ACT NEUR S, V81, P117; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2000, ACT NEUR S, V76, P483; Czosnyka M, 1999, J NEUROL NEUROSUR PS, V66, P606, DOI 10.1136/jnnp.66.5.606; Czosnyka M, 2014, NEUROCRIT CARE, V21, P95, DOI 10.1007/s12028-014-0046-0; Dengler J, 2013, NEUROCRIT CARE, V19, P74, DOI 10.1007/s12028-012-9686-0; Dias C, 2015, NEUROCRIT CARE, V23, P92, DOI 10.1007/s12028-014-0103-8; Diedler J, 2011, ANESTH ANALG, V113, P849, DOI 10.1213/ANE.0b013e3182285dc0; Easley RB, 2013, NEUROL RES, V35, P344, DOI 10.1179/1743132812Y.0000000145; Eide PK, 2007, NEUROL RES, V29, P578, DOI 10.1179/016164107X172167; Gao L, 2016, J NEUROTRAUM, V33, P2011, DOI 10.1089/neu.2015.4228; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Highton D, 2012, CRIT CARE, V16, pS106; Highton D, 2015, ANESTH ANALG, V121, P198, DOI 10.1213/ANE.0000000000000790; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Lang EW, 2015, NEUROCRIT CARE, V23, P85, DOI 10.1007/s12028-014-0074-9; Le Roux P, 2014, NEUROCRIT CARE, V21, P1, DOI 10.1007/s12028-014-0041-5; Menzel M, 2003, J NEUROSURG ANESTH, V15, P33, DOI 10.1097/00008506-200301000-00006; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; Pandey M., 2015, BIOSTATISTICS BASIC, P454; Smielewski P, 2009, J NEUROTRAUM, V26, pA47; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Zweifel C, 2014, MED ENG PHYS, V36, P638, DOI 10.1016/j.medengphy.2014.03.002; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	32	25	25	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2017	34	22					3070	3080		10.1089/neu.2017.5129			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FL9GC	WOS:000414560000002	28571485				2021-06-18	
J	Kamimori, GH; Reilly, LA; LaValle, CR; Da Silva, UBO				Kamimori, G. H.; Reilly, L. A.; LaValle, C. R.; Da Silva, U. B. Olaghere			Occupational overpressure exposure of breachers and military personnel	SHOCK WAVES			English	Article						Breachers; Breaching; Blast exposure; Overpressure; Impulse; Blast gauge; K equation; Minimum safe distance	CHRONIC TRAUMATIC ENCEPHALOPATHY; LOW-LEVEL BLAST; FOOTBALL-LEAGUE PLAYER; BRAIN-INJURY; BIOMARKER	Military and law enforcement personnel may be routinely and repetitively exposed to low-level blast (LLB) overpressure during training and in operations. This repeated exposure has been associated with symptoms similar to that reported for sports concussion. This study reports LLB exposure for various military and law enforcement sources in operational training environments. Peak overpressure and impulse data are presented from indoor breaching, outdoor breaching, shotgun door breaching, small arms discharge, and mortar and artillery fire missions. Data were collected using the Black Box Biometrics (B3) Blast Gauge sensors. In all cases, sensors were attached to the operators and, where possible, also statically mounted to walls or other fixed structures. Peak overpressures from below 1 psi (7 kPa) to over 12 psi (83 kPa) were recorded; all values reported are uncorrected for incidence angle to the blast exposure source. The results of these studies indicate that the current minimum safe distance calculations are often inaccurate for both indoor and outdoor breaching scenarios as true environmental exposure can consistently exceed the 4 psi (28 kPa) incident safe threshold prescribed by U.S. Army doctrine. While ballistic (shotgun) door breaching and small arms firing only expose the operator to low peak exposure levels, the sheer number of rounds fired during training may result in an excessive cumulative exposure. Mortar and artillery crew members received significantly different overpressure and impulse exposures based on their position (job) relative to the weapon. As both the artillery and mortar crews commonly fire hundreds of rounds during a single training session they are also likely to receive high cumulative exposures. These studies serve to provide the research community with estimates for typical operator exposure across a range of operational scenarios or in the discharge of various weapons systems.	[Kamimori, G. H.; Reilly, L. A.; LaValle, C. R.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Dept, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Da Silva, U. B. Olaghere] Naval Med Res Ctr, Neurotrauma Dept, 503 Robert Grant Ave, Silver Spring, MD 20910 USA	Reilly, LA (corresponding author), Walter Reed Army Inst Res, Blast Induced Neurotrauma Dept, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	lucas.a.reilly3.ctr@mail.mil		Olaghere da Silva, Uade/0000-0003-1755-4985; LaValle, Christina/0000-0003-1529-4761	Office of the Assistant Secretary of Defense for Health Affairs; Broad Agency Announcement Award [W81XWH-16-2-0001, JCP-5, RAD3]; Environmental Sensors in Training (ESiT) program; Washington County (OR) Sheriff's Department, 35th Engineers (Fort Leonard Wood, MO); Las Vegas (NV) Special Weapons and Tactics, Infantry Mortar Leaders Course (Fort Benning, GA); Big Deuce (Fort Sill, OK)	This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, Broad Agency Announcement Award No. W81XWH-16-2-0001, JCP-5, RAD3 and the Environmental Sensors in Training (ESiT) program. Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70-25. Thanks to the staff of the Walter Reed Army Institute of Research and Naval Medical Research Center for their assistance in the completion of the studies described herein and the preparation of this manuscript. We would like to acknowledge the support of the units involved in these studies: Washington County (OR) Sheriff's Department, 35th Engineers (Fort Leonard Wood, MO), Las Vegas (NV) Special Weapons and Tactics, Infantry Mortar Leaders Course (Fort Benning, GA) and the Big Deuce (Fort Sill, OK). The authors would like to thank Anthony Misistia for his additional contributions to the project and submission of the final manuscript.	[Anonymous], 2016, HEADQ DEP ARM PUBL; Baker AJ, 2011, J TRAUMA, V71, pS472, DOI 10.1097/TA.0b013e318232e7da; Branch M., 2013, TECH REP; Capo-Aponte JE, 2015, J REHABIL RES DEV, V52, P273, DOI 10.1682/JRRD.2014.09.0204; Carr W, 2016, MIL MED, V181, P28, DOI 10.7205/MILMED-D-15-00137; Carr W, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00049; Cranz C., 1916, TXB BALLISTICS; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; FEMA, 2004, BUILD DES HOM SEC; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Guard, 2015, US INT AMM TECHN GUI; HIRSCH FG, 1968, ANN NY ACAD SCI, V152, P147, DOI 10.1111/j.1749-6632.1968.tb11972.x; Hopkinson, 1915, BRIT ORDNANCE BOARD, P13565; Kamimori G.H., 2015, WATER MITIGATION BLA; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Lakis N, 2013, NEUROL RES, V35, P290, DOI 10.1179/1743132813Y.0000000177; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thiel K.J., 2016, 201606 USAARL	27	25	25	3	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-1287	1432-2153		SHOCK WAVES	Shock Waves	NOV	2017	27	6					837	847		10.1007/s00193-017-0738-4			11	Mechanics	Mechanics	FN4BE	WOS:000415946600003					2021-06-18	
J	Medcalf, RL				Medcalf, R. L.			Fibrinolysis: from blood to the brain	JOURNAL OF THROMBOSIS AND HAEMOSTASIS			English	Article; Proceedings Paper	26th Congress of the International-Society-on-Thrombosis-and-Haemostasis (ISTH)	JUL 08-13, 2017	Berlin, GERMANY	Int Soc Thrombosis & Haemostasis		blood brain barrier; fibrinolysis; plasminogen; plasminogen activators; stroke; traumatic brain injury	TISSUE-PLASMINOGEN-ACTIVATOR; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; ACUTE ISCHEMIC-STROKE; TRANEXAMIC ACID; T-PA; INTRACRANIAL HEMORRHAGE; PROTEOLYTIC ACTIVITY; THERAPEUTIC WINDOW; LATE-PHASE	We all know about classical fibrinolysis, how plasminogen activation by either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA) promotes fibrin breakdown, and how this process was harnessed for the therapeutic removal of blood clots. While this is still perfectly true and still applicable to thromboembolic conditions today, another dimension to this system came to light over two decades ago that implicated the plasminogen activating system in a context far removed from the dissolution of blood clots. This unsuspected area related to brain biology where t-PA was linked to a plethora of activities in the CNS, some of which do not necessarily require plasmin generation. Indeed, t-PA either directly or via plasmin, has been shown to not only have key roles in modulating astrocytes, neurons, microglia, and pericytes, but also to have profound effects in a number of CNS conditions, including ischaemic stroke, severe traumatic brain injury and also in neurodegenerative disorders. While compelling insights have been obtained from various animal models, the clinical relevance of aberrant expression of these components in the CNS, although strongly implied, are only just emerging. This review will cover these areas and will also discuss how the use of thrombolytic agents and anti-fibrinolytic drugs may potentially have impacts outside of their clinical intention, particularly in the CNS.	[Medcalf, R. L.] Monash Univ, Australian Ctr Blood Dis, Level 6,Burnet Bldg,89 Commercial Rd, Melbourne, Vic 3004, Australia	Medcalf, RL (corresponding author), Monash Univ, Australian Ctr Blood Dis, Level 6,Burnet Bldg,89 Commercial Rd, Melbourne, Vic 3004, Australia.	robert.medcalf@monash.edu	Medcalf, Robert L/E-9632-2011	Medcalf, Robert/0000-0001-6885-3892			Armstead WM, 2006, NAT NEUROSCI, V9, P1150, DOI 10.1038/nn1757; ASTRUP T, 1947, NATURE, V159, P681, DOI 10.1038/159681b0; ASTRUP T, 1953, P SOC EXP BIOL MED, V84, P605, DOI 10.3181/00379727-84-20727; ASTRUP T, 1956, BLOOD, V11, P781, DOI 10.1182/blood.V11.9.781.781; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Bardehle S, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00354; Baron A, 2010, CELL DEATH DIFFER, V17, P860, DOI 10.1038/cdd.2009.172; Barthel D, 2012, J BIOL CHEM, V287, P18831, DOI 10.1074/jbc.M111.323287; Basham ME, 2001, J NEUROCHEM, V77, P318, DOI 10.1046/j.1471-4159.2001.t01-1-00239.x; Benchenane K, 2007, J CELL SCI, V120, P578, DOI 10.1242/jcs.03354; Bier OG, 1932, CR SOC BIOL, V110, P129; BIGGS R, 1947, LANCET, V252, P402; Borg RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131216; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Calabresi P, 2000, EUR J NEUROSCI, V12, P1002, DOI 10.1046/j.1460-9568.2000.00991.x; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; Centonze D, 2002, EUR J NEUROSCI, V16, P713, DOI 10.1046/j.1460-9568.2002.02106.x; Chatterjee S, 2014, JAMA-J AM MED ASSOC, V311, P2414, DOI 10.1001/jama.2014.5990; Cops EJ, 2013, EXP NEUROL, V249, P8, DOI 10.1016/j.expneurol.2013.08.001; Das R, 2014, BLOOD, V124, P679, DOI 10.1182/blood-2014-01-549659; Dastre A., 1893, ARCH, V5, P661; Diebel LN, 2017, J TRAUMA ACUTE CARE, V82, P1080, DOI 10.1097/TA.0000000000001445; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Draxler DF, 2017, SEMIN THROMB HEMOST, V43, P143, DOI 10.1055/s-0036-1586227; Draxler DF, 2015, TRANSFUS MED REV, V29, P102, DOI 10.1016/j.tmrv.2014.09.006; FANTL P, 1948, AUST J EXP BIOL MED, V26, P521, DOI 10.1038/icb.1948.54; FANTL P, 1950, BRIT J EXP PATHOL, V31, P131; Fredriksson L, 2017, SEMIN THROMB HEMOST, V43, P154, DOI 10.1055/s-0036-1586229; Gaberel T, 2013, NEUROPHARMACOLOGY, V67, P267, DOI 10.1016/j.neuropharm.2012.11.023; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Grummisch JA, 2016, MOL CELL NEUROSCI, V74, P25, DOI 10.1016/j.mcn.2016.03.005; Gurwitz JH, 1998, ANN INTERN MED, V129, P597, DOI 10.7326/0003-4819-129-8-199810150-00002; Haile WB, 2012, J CEREBR BLOOD F MET, V32, P57, DOI 10.1038/jcbfm.2011.106; Hao ZF, 2006, BLOOD, V108, P200, DOI 10.1182/blood-2005-12-4884; Hijazi N, 2015, BLOOD, V125, P2558, DOI 10.1182/blood-2014-08-588442; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Hultman K, 2014, J THROMB HAEMOST, V12, P701, DOI 10.1111/jth.12553; Ishiguro M, 2012, NEUROSCIENCE, V220, P302, DOI 10.1016/j.neuroscience.2012.06.015; Jimenez JJ, 2007, CRIT CARE, V11, DOI 10.1186/cc6173; Katzenberger RJ, 2015, FLY, V9, P68, DOI 10.1080/19336934.2015.1085623; KONDO M, 1976, GASTROENTEROLOGY, V71, P631; KRYSTOSEK A, 1981, P NATL ACAD SCI-BIOL, V78, P7810, DOI 10.1073/pnas.78.12.7810; Kvajo M, 2004, J NEUROSCI, V24, P9734, DOI 10.1523/JNEUROSCI.3306-04.2004; Later AFL, 2013, CYTOKINE, V61, P438, DOI 10.1016/j.cyto.2012.10.033; Later AFL, 2013, J THORAC CARDIOV SUR, V145, P1611, DOI 10.1016/j.jtcvs.2012.11.042; Lei H, 2008, INVEST OPHTH VIS SCI, V49, P42, DOI 10.1167/iovs.07-0776; Li JX, 2006, J NEUROSCI, V26, P7839, DOI 10.1523/JNEUROSCI.1624-06.2006; Li JX, 2013, P NATL ACAD SCI USA, V110, pE2410, DOI 10.1073/pnas.1305010110; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Lu WQ, 2002, DEVELOPMENT, V129, P2043; MACFARLANE RG, 1946, LANCET, V251, P562; Machovich R, 1990, Blood Coagul Fibrinolysis, V1, P79, DOI 10.1097/00001721-199003000-00011; Machovich R, 1997, ARCH BIOCHEM BIOPHYS, V344, P343, DOI 10.1006/abbi.1997.0221; Macrez R, 2011, STROKE, V42, P2315, DOI 10.1161/STROKEAHA.110.606293; Macrez R, 2010, STROKE, V41, P2950, DOI 10.1161/STROKEAHA.110.592360; Madani R, 1999, EMBO J, V18, P3007, DOI 10.1093/emboj/18.11.3007; Marcos-Contreras OA, 2016, BLOOD, V128, P2423, DOI 10.1182/blood-2016-03-705384; MARKUS G, 1979, J BIOL CHEM, V254, P1211; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Matys T, 2003, NAT MED, V9, P371, DOI 10.1038/nm0403-371; Medcalf RL, 2015, BLOOD, V125, P2457, DOI 10.1182/blood-2015-02-629808; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Nicole O, 2001, NAT MED, V7, P59; Niego B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177332; Niego B, 2014, J CEREBR BLOOD F MET, V34, P1283, DOI 10.1038/jcbfm.2014.99; Niego B, 2012, BLOOD, V119, P4752, DOI 10.1182/blood-2011-07-369512; Noel M, 2011, P NATL ACAD SCI USA, V108, P5069, DOI 10.1073/pnas.1017608108; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; PLOW EF, 1975, J CLIN INVEST, V56, P30, DOI 10.1172/JCI108076; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Reust DL, 2010, ANESTH ANALG, V110, P694, DOI 10.1213/ANE.0b013e3181c7eb27; Robinson SD, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00404; Rodier M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092416; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; Samson AL, 2008, J NEUROCHEM, V107, P1091, DOI 10.1111/j.1471-4159.2008.05687.x; Samson AL, 2012, CELL REP, V2, P889, DOI 10.1016/j.celrep.2012.08.026; Samson AL, 2009, BLOOD, V114, P1937, DOI 10.1182/blood-2009-02-203448; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Schuster V, 1997, BLOOD, V90, P958, DOI 10.1182/blood.V90.3.958.958_958_966; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shaw MA, 2017, J NEUROSCI, V37, P3776, DOI 10.1523/JNEUROSCI.2932-15.2017; Shibuya M, 2005, J NEUROL SCI, V238, P31, DOI 10.1016/j.jns.2005.06.003; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Silva MMCG, 2012, J THROMB HAEMOST, V10, P2354, DOI 10.1111/j.1538-7836.2012.04925.x; Simao F, 2017, BLOOD, V129, P2280, DOI 10.1182/blood-2016-09-740670; SOREQ H, 1981, BRAIN RES, V216, P361, DOI 10.1016/0006-8993(81)90138-4; Stanley D, 2016, NAT MED, V22, P1277, DOI 10.1038/nm.4194; Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787; Su EJ, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00385; Suzuki Y, 2007, J THROMB HAEMOST, V5, P1732, DOI 10.1111/j.1538-7836.2007.02628.x; Suzuki Y, 2009, BLOOD, V114, P3352, DOI 10.1182/blood-2009-02-203919; Syrovets T, 2012, J LEUKOCYTE BIOL, V92, P509, DOI 10.1189/jlb.0212056; Tait RC, 1996, THROMB HAEMOSTASIS, V76, P1004; TAKASHIMA S, 1969, BRIT J EXP PATHOL, V50, P533; THEURING F, 1995, FIBRINOLYSIS, V9, P277, DOI 10.1016/S0268-9499(95)80016-6; Tillett WS, 1933, J EXP MED, V58, P485, DOI 10.1084/jem.58.4.485; TOVI D, 1973, ACTA NEUROL SCAND, V49, P152; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Turner RJ, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00056; Vermeij JD, 2016, CEREBROVASC DIS, V42, P361, DOI 10.1159/000446160; VONKAULLA KN, 1953, P SOC EXP BIOL MED, V83, P692; Wahlgren N, 2017, J INTERN MED, V281, P273, DOI 10.1111/joim.12576; Walsh M, 2017, SEMIN THROMB HEMOST, V43, P200, DOI 10.1055/s-0036-1597900; Westendorp WF, 2015, LANCET, V385, P1519, DOI 10.1016/S0140-6736(14)62456-9; Witting PK, 2008, THROMB RES, V122, P674, DOI 10.1016/j.thromres.2007.12.013; Wu F, 2012, J NEUROSCI, V32, P9848, DOI 10.1523/JNEUROSCI.1241-12.2012; Wu XW, 2017, SHOCK, V47, P500, DOI 10.1097/SHK.0000000000000758; Yao Y, 2011, J CELL SCI, V124, P1486, DOI 10.1242/jcs.082834; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Yepes M, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3339/fncel.2015.00304, 10.3389/fncel.2015.00304]; Yu H, 2001, EUR J NEUROSCI, V14, P799, DOI 10.1046/j.0953-816x.2001.01700.x; ZANKER KS, 1978, J NEUROL SCI, V38, P67, DOI 10.1016/0022-510X(78)90246-0; Zeng B, 2002, THROMB HAEMOSTASIS, V88, P805; Zhang ZG, 2002, CIRCULATION, V106, P740, DOI 10.1161/01.CIR.0000023942.10849.41; Zhao XJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180822; ZISAPEL N, 1982, BRAIN RES, V248, P129, DOI 10.1016/0006-8993(82)91154-4	120	25	27	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1538-7933	1538-7836		J THROMB HAEMOST	J. Thromb. Haemost.	NOV	2017	15	11					2089	2098		10.1111/jth.13849			10	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	FL7YI	WOS:000414466400003	28925023	Other Gold			2021-06-18	
J	Brenner, LA; Stearns-Yoder, KA; Hoffberg, AS; Penzenik, ME; Starosta, AJ; Hernandez, TD; Hadidi, DA; Lowry, CA				Brenner, Lisa A.; Stearns-Yoder, Kelly A.; Hoffberg, Adam S.; Penzenik, Molly E.; Starosta, Amy J.; Hernandez, Theresa D.; Hadidi, Daniel A.; Lowry, Christopher A.			Growing literature but limited evidence: A systematic review regarding prebiotic and probiotic interventions for those with traumatic brain injury and/or posttraumatic stress disorder	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Bifidobacteria; Lactobacilli; Persistent post-concussive symptoms; Posttraumatic stress disorder; Prebiotic; Probiotic; PTSD; Synbiotic; TBI; Traumatic brain injury; Systematic review	LACTOBACILLUS-HELVETICUS R0052; BIFIDOBACTERIUM-LONGUM R0175; ANXIETY-LIKE BEHAVIOR; IN-VITRO; MODULATION; MEDICINE; PTSD; COMPLEMENTARY; RESILIENCE; SOLDIERS	Traumatic brain injury (TBI) is highly prevalent among a wide range of populations, including civilians, military personnel, and Veterans. TBI sequelae may be further exacerbated by symptoms associated with frequently occurring comorbid psychiatric conditions, including posttraumatic stress disorder (PTSD). This is particularly true among the population of military personnel from recent conflicts in Iraq and Afghanistan, with a history of mild TBI (mTBI) and PTSD. The need for efficacious treatments for TBI and comorbid PTSD is significant, and evidence-based interventions for these frequently co-occurring conditions are limited. Based on findings suggesting that inflammation may be an underlying mechanism of both conditions, anti-inflammatory/immunoregulatory agents, including probiotics, may represent a novel strategy to treat TBI and/or PTSD-related symptoms. The focus of this systematic review was to identify and evaluate existing research regarding prebiotic and probiotic interventions for the populations of individuals with a history of TBI and/or PTSD. Only 4 studies were identified (3 severe TBI, 1 PTSD, 0 co-occurring TBI and PTSD). Although findings suggested some promise, work in this area is nascent and results to date do not support some claims within the extensive coverage of probiotics in the popular press. Published by Elsevier Inc.	[Brenner, Lisa A.; Stearns-Yoder, Kelly A.; Hoffberg, Adam S.; Penzenik, Molly E.; Starosta, Amy J.; Hernandez, Theresa D.; Hadidi, Daniel A.; Lowry, Christopher A.] Rocky Mt Mental Illness Res Educ & Clin Ctr MIREC, Denver, CO USA; [Brenner, Lisa A.; Hernandez, Theresa D.; Hadidi, Daniel A.; Lowry, Christopher A.] Univ Colorado, Dept Phys Med & Rehabil, Anschutz Med Campus, Aurora, CO USA; [Brenner, Lisa A.] Univ Colorado, Dept Psychiat & Neurol, Anschutz Med Campus, Aurora, CO USA; [Brenner, Lisa A.; Stearns-Yoder, Kelly A.; Lowry, Christopher A.] Mil & Vet Microbiome Consortium Res & Educ MVM Co, Denver, CO USA; [Hernandez, Theresa D.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA; [Hernandez, Theresa D.; Hadidi, Daniel A.; Lowry, Christopher A.] Univ Colorado, Ctr Neurosci, Anschutz Med Campus, Aurora, CO USA; [Lowry, Christopher A.] Univ Colorado, Dept Integrat Physiol, Boulder, CO 80309 USA; [Lowry, Christopher A.] Univ Colorado, Ctr Neurosci, Boulder, CO 80309 USA	Brenner, LA (corresponding author), Rocky Mt MIRECC, Eastern Colorado Hlth Care Syst, 1055 Clermont St, Denver, CO 80220 USA.	lisa.brenner@va.gov	Brenner, Lisa A./AAG-2442-2019; Starosta, Amy/AAV-1665-2020	Hoffberg, Adam/0000-0002-7036-936X			Abbott Laboratories Inc., PROD INF TWOCAL HN; Abbott Laboratories Inc., PROD INF PIVOT 1 5 C; Allen AP, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.191; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; Barnes Patricia M, 2004, Adv Data, P1; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Bercik P, 2011, NEUROGASTROENT MOTIL, V23, P1132, DOI 10.1111/j.1365-2982.2011.01796.x; Bercik P, 2010, GASTROENTEROLOGY, V139, P2102, DOI 10.1053/j.gastro.2010.06.063; Betthauser LM, 2014, MED CARE, V52, pS50, DOI 10.1097/MLR.0000000000000219; Bramley H, 2016, SPORTS MED ARTHROSC, V24, P123, DOI 10.1097/JSA.0000000000000111; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Centers for Disease Control and Prevention, TRAUM BRAIN INJ CONC; ClinicalTrials. gov, BIOL SIGN PROB THOS; Davis LMG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025200; de Arruda ISF, 2004, CLIN SCI, V106, P287, DOI 10.1042/CS20030251; Defense and Veterans Brain Injury Center, 2016, DOD WORLDW TBI NUMB; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Field R, 2010, BRAIN BEHAV IMMUN, V24, P996, DOI 10.1016/j.bbi.2010.04.004; GIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/jn/125.6.1401; Gocan AG, 2012, HORM MOL BIOL CLIN I, V10, P301, DOI 10.1515/hmbci-2011-0135; Hartling L, 2010, DEV TESTING TOOL CLA; Hernandez TD, 2016, BRAIN RES, V1640, P139, DOI 10.1016/j.brainres.2016.01.025; Higgins JP, 2008, COCHRANE HDB SYSTEMA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge C, 2015, JAMA INTERN MED, V175, P53, DOI 10.1001/jamainternmed.2014.3375; Jones ML, 2012, EUR J CLIN NUTR, V66, P1234, DOI 10.1038/ejcn.2012.126; Karl JP, 2017, AM J PHYSIOL-GASTR L, V312, pG559, DOI 10.1152/ajpgi.00066.2017; Likotrafiti E, 2014, ANAEROBE, V27, P50, DOI 10.1016/j.anaerobe.2014.03.009; Lowry Christopher A, 2016, Curr Environ Health Rep, V3, P270, DOI 10.1007/s40572-016-0100-5; Lozano D., 2015, NEUROPSYCH DIS TREAT, V11, P106; Mahajan Girish Badrinath, 2012, Front Biosci (Elite Ed), V4, P240; Matchar D.B., 2012, METHODS GUIDE MED TE; McFadden KL, 2011, J NEUROTRAUM, V28, P21, DOI 10.1089/neu.2010.1515; Messaoudi M, 2011, GUT MICROBES, V2, P256, DOI 10.4161/gmic.2.4.16108; Messaoudi M, 2011, BRIT J NUTR, V105, P755, DOI 10.1017/S0007114510004319; Miller AH, 2015, JAMA PSYCHIAT, V72, P527, DOI 10.1001/jamapsychiatry.2015.22; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Painter TJ, 2015, INT J SURG, V21, P70, DOI 10.1016/j.ijsu.2015.07.008; Pena JA, 2005, INFECT IMMUN, V73, P912, DOI 10.1128/IAI.73.2.912-920.2005; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Reber SO, 2016, PSYCHONEUROENDOCRINO, V74, P221, DOI 10.1016/j.psyneuen.2016.08.031; Reber SO, 2016, P NATL ACAD SCI USA, V113, pE3130, DOI 10.1073/pnas.1600324113; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Rodgers KM, 2014, J NEUROTRAUM, V31, P487, DOI [10.1089/NEU.2013.3090, 10.1089/neu.2013.3090]; Rodgers KM, 2012, J NEUROTRAUM, V29, P1886, DOI 10.1089/neu.2011.2273; Rook GAW, 2004, SPRINGER SEMIN IMMUN, V25, P237, DOI 10.1007/s00281-003-0148-9; Savignac HM, 2015, BEHAV BRAIN RES, V287, P59, DOI 10.1016/j.bbr.2015.02.044; Savignac HM, 2014, NEUROGASTROENT MOTIL, V26, P1615, DOI 10.1111/nmo.12427; Schottenbauer MA, 2008, PSYCHIATRY, V71, P134, DOI 10.1521/psyc.2008.71.2.134; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Tan M., 2009, MC TIMES        1218; Tan M, 2011, CRIT CARE, V15, DOI 10.1186/cc10579; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tillisch K, 2013, GASTROENTEROLOGY, V144, P1394, DOI 10.1053/j.gastro.2013.02.043; Tubelius Py, 2005, Environ Health, V4, P25, DOI 10.1186/1476-069X-4-25; VA Health Services Research & Development, EV BAS SYNTH PROGR; Viswanathan M., 2013, ASSESSING RISK BIAS, P2013; Viswanathan M., METHODS GUIDE EFFECT, P2008; Viswanathan M, 2012, J CLIN EPIDEMIOL, V65, P163, DOI 10.1016/j.jclinepi.2011.05.008; World Health Organization, GUID EV PROB FOOD; Zeng H, 2015, TRENDS IMMUNOL, V36, P3, DOI 10.1016/j.it.2014.08.003	63	25	25	1	39	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	OCT	2017	65						57	67		10.1016/j.bbi.2017.06.003			11	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	FC6YD	WOS:000406986700007	28606462				2021-06-18	
J	Liu, DC; Li, Z; Zhang, XX; Zhao, LP; Jia, JP; Sun, F; Wang, YX; Ma, DQ; Wei, WB				Liu, Dachuan; Li, Zhen; Zhang, Xuxiang; Zhao, Liping; Jia, Jianping; Sun, Fei; Wang, Yaxing; Ma, Daqing; Wei, Wenbin			Assessment of intracranial pressure with ultrasonographic retrobulbar optic nerve sheath diameter measurement	BMC NEUROLOGY			English	Article						B-scan ultrasonography; Optic nerve sheath diameter; Intracranial pressure	TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; HYPERTENSION; ULTRASOUND	Background: Ultrasonograpic retrobulbar optic nerve sheath diameter (ONSD) measurement is considered to be an alternative noninvasive method to estimate intracranial pressure, but the further validation is urgently needed. The aim of the current study was to investigate the association of the ultrasonographic ONSD and intracranial pressure (ICP) in patients. Methods: One hundred and ten patients whose intracranial pressure measured via lumbar puncture were enrolled in the study. Their retrobulbar ONSD with B-scan ultrasound was determined just before lumber puncture. The correlation between the ICP and the body mass index (BMI), ONSD or age was established respectively with the Pearson correlation coefficient analysis. The discriminant analysis was used to obtain a discriminant formula for predicting ICP with the ONSD. BMI. gender and age. Another 20 patients were recruited for further validation the efficiency of this discriminant equation. Results: The mean ICP was 215.3 +/- 81.2 mmH(2)O. ONSD was 5.70 +/- 0.80 mm in the right eye and 5.80 +/- 0.77 mm in the left eye. A significant correlation was found between ICP and BMI (r = 0.554, p < 0.001), the mean ONSD (r = 0.61, P < 0.001), but not with age (r = -0.131, p = 0.174) and gender (r = 0.03, p = 0.753). Using receiver operating characteristic (ROC) curve analysis, the critical value for the risk mean-ONSD was 5.6 mm from the ROC curve, with the sensitivity of 86.2% and specificity of 73.1%. With 200 mmH(2)O as the cutoff point for a high or low ICP, stepwise discriminant was applied, the sensitivity and specificity of ONSD predicting ICP was 84.5%-85.7% and 86.5%-92.3%. Conclusions: Ophthalmic ultrasound measurement of ONSD may be a good surrogate of invasive ICP measurement. This non-invasive method may be an alternative approach to predict the ICP value of patients whose ICP measurement via lumbar puncture are in high risk. The discriminant formula, which incorporated the factor of BMI, had similar sensitivity and higher specificity than the ROC curve.	[Liu, Dachuan; Wei, Wenbin] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Tongren Hosp,Beijing Ophthalmol & Visual, Beijing 100730, Peoples R China; [Liu, Dachuan; Li, Zhen; Zhang, Xuxiang; Zhao, Liping] Capital Med Univ, Dept Ophthalmol, Xuanwu Hosp, Beijing, Peoples R China; [Jia, Jianping] Capital Med Univ, Dept Neurol, Xuanwu Hosp, Beijing, Peoples R China; [Sun, Fei] Beijing Geriatr Healthcare Ctr, Beijing, Peoples R China; [Wang, Yaxing] Beijing Inst Ophthalmol, Beijing, Peoples R China; [Ma, Daqing] Imperial Coll London, Anaesthet Pain Med & Intens Care, Dept Surg & Canc, Fac Med, London, England; [Ma, Daqing] Chelsea & Westminster Hosp, London, England	Wei, WB (corresponding author), Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Tongren Hosp,Beijing Ophthalmol & Visual, Beijing 100730, Peoples R China.	weiwenbintr@163.com		Jia, Jianping/0000-0003-4624-0336; Ma, Daqing/0000-0003-1235-0537	Beijing Municipal Science & Technology CommissionBeijing Municipal Science & Technology Commission [Z111107067311016, Z151100003915127]	This study was supported by Beijing Municipal Science & Technology Commission No. Z111107067311016 and Z151100003915127. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amini A, 2013, AM J EMERG MED, V31, P236, DOI 10.1016/j.ajem.2012.06.025; Atsumi Hideki, 2014, Tokai J Exp Clin Med, V39, P34; Bauerle J, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-187; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Frumin E, 2014, WEST J EMERG MED, V15, P217, DOI 10.5811/westjem.2013.9.16191; Gjerris F, 2004, CLIN NEUROL NEUROSUR, P179; HANSEN HC, 1994, NEURO-OPHTHALMOLOGY, V14, P345, DOI 10.3109/01658109409024061; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Kalantari H, 2013, AM J EMERG MED, V31, P1595, DOI 10.1016/j.ajem.2013.07.028; Kimberly HH, 2008, CRIT CARE, V12, DOI 10.1186/cc7008; Li Z, 2014, J CLIN ULTRASOUND ME, V14, P160; Li Z, 2014, OPHTHALMOL CHN, V23, P347; LIU D, 1993, AM J OPHTHALMOL, V116, P548, DOI 10.1016/S0002-9394(14)73195-2; Maude RR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081013; Qayyum H, 2013, EUR J EMERG MED, V20, P91, DOI 10.1097/MEJ.0b013e32835105c8; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Rickert K., 2003, OPERATIVE TECHNIQUES, V5, P170, DOI [10.1016/S1524-153X(03)70010-4, DOI 10.1016/S1524-153X(03)70010-4]; Sekhon MS, 2014, INTENS CARE MED, V40, P1267, DOI 10.1007/s00134-014-3392-7; Shimbles S, 2005, PHYSIOL MEAS, V26, P1085, DOI 10.1088/0967-3334/26/6/017; Speck V, 2011, NEUROCRIT CARE, V14, P208, DOI 10.1007/s12028-010-9459-6; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Tamburrelli C., 1993, OPHTHALMIC ECHOGRAPH, P101; Xie XB, 2013, CRIT CARE, V17, DOI 10.1186/cc12841; Zeng T, 2010, CHIN J TRAUMATOL, V13, P146, DOI 10.3760/cma.j.issn.1008-1275.2010.03.003	29	25	30	1	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	SEP 29	2017	17								188	10.1186/s12883-017-0964-5			7	Clinical Neurology	Neurosciences & Neurology	FI6CU	WOS:000412078700001	28962603	DOAJ Gold, Green Published			2021-06-18	
J	Cherry, JD; Stein, TD; Tripodis, Y; Alvarez, VE; Huber, BR; Au, R; Kiernan, PT; Daneshvar, DH; Mez, J; Solomon, TM; Alosco, ML; McKee, AC				Cherry, Jonathan D.; Stein, Thor D.; Tripodis, Yorghos; Alvarez, Victor E.; Huber, Bertrand R.; Au, Rhoda; Kiernan, Patrick T.; Daneshvar, Daniel H.; Mez, Jesse; Solomon, Todd M.; Alosco, Michael L.; McKee, Ann C.			CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer's disease	PLOS ONE			English	Article							NATIONAL INSTITUTE; NEUROPATHOLOGIC ASSESSMENT; ASSOCIATION GUIDELINES; BRAIN-INJURY; TAU; CRITERIA; RELIABILITY; MICROGLIA; DIAGNOSIS; CONSENSUS	CCL11, a protein previously associated with age-associated cognitive decline, is observed to be increased in the brain and cerebrospinal fluid (CSF) in chronic traumatic encephalopathy (CTE) compared to Alzheimer's disease (AD). Using a cohort of 23 deceased American football players with neuropathologically verified CTE, 50 subjects with neuropathologically diagnosed AD, and 18 non-athlete controls, CCL11 was measured with ELISA in the dorsolateral frontal cortex (DLFC) and CSF. CCL11 levels were significantly increased in the DLFC in subjects with CTE (fold change = 1.234, p < 0.050) compared to non-athlete controls and AD subjects with out a history of head trauma. This increase was also seen to correlate with years of exposure to American football (beta = 0.426, p = 0.048) independent of age (beta = -0.046, p = 0.824). Preliminary analyses of a subset of subjects with available post-mortem CSF showed a trend for increased CCL11 among individuals with CTE (p = 0.069) mirroring the increase in the DLFC. Furthermore, an association between CSF CCL11 levels and the number of years exposed to football (beta = 0.685, p = 0.040) was observed independent of age (beta = -0.103, p = 0.716). Finally, a receiver operating characteristic (ROC) curve analysis demonstrated CSF CCL11 accurately distinguished CTE subjects from non-athlete controls and AD subjects (AUC = 0.839, 95% CI 0.62 - 1.058, p = 0.028). Overall, the current findings provide preliminary evidence that CCL11 may be a novel target for future CTE biomarker studies.	[Cherry, Jonathan D.; Stein, Thor D.; Alvarez, Victor E.; Huber, Bertrand R.; Kiernan, Patrick T.; Daneshvar, Daniel H.; Mez, Jesse; Solomon, Todd M.; Alosco, Michael L.; McKee, Ann C.] Boston Univ, Sch Med, Boston Univ Alzheimers Dis, Boston, MA 02118 USA; [Cherry, Jonathan D.; Stein, Thor D.; Alvarez, Victor E.; Huber, Bertrand R.; Kiernan, Patrick T.; Daneshvar, Daniel H.; Mez, Jesse; Solomon, Todd M.; Alosco, Michael L.; McKee, Ann C.] Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA; [Cherry, Jonathan D.; Stein, Thor D.; Alvarez, Victor E.; Huber, Bertrand R.; Au, Rhoda; Mez, Jesse; Alosco, Michael L.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Cherry, Jonathan D.; Alvarez, Victor E.; Huber, Bertrand R.; McKee, Ann C.] VA Boston Healthcare Syst, Boston, MA 02130 USA; [Stein, Thor D.; Alvarez, Victor E.; McKee, Ann C.] Dept Vet Affairs Med Ctr, Bedford, MA USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Au, Rhoda] Boston Univ, Sch Med, Framingham Heart Study, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	Cherry, JD (corresponding author), Boston Univ, Sch Med, Boston Univ Alzheimers Dis, Boston, MA 02118 USA.; Cherry, JD (corresponding author), Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA.; Cherry, JD (corresponding author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.; Cherry, JD (corresponding author), VA Boston Healthcare Syst, Boston, MA 02130 USA.	Jdcherry@bu.edu		Stein, Thor/0000-0001-6954-4477; Tripodis, Yorghos/0000-0003-2190-7608; Daneshvar, Daniel/0000-0003-3691-9513	Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and DevelopmentUS Department of Veterans Affairs [I01-CX001038]; Alzheimer's AssociationAlzheimer's Association [NIRG-305779]; Veterans Affairs Biorepository [CSP 501]; National Institute of AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1RF1AG054156-01]; National Institute of Aging Boston University AD Center [P30AG13846, 0572063345-5]; Department of Defense Peer Reviewed Alzheimer's Research Program [DoD-PRARP 13267017]; National Heart, Lung, and Blood Institute, Framingham Heart Study, (NHLBI/NIH) [N01-HC-25195, R01AG08122]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1F32NS096803-01]; Concussion Legacy Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG046377, RF1AG057902, P30AG013846, RF1AG054156] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award (I01-CX001038 to TDS); Alzheimer's Association (NIRG-305779 to TDS); Veterans Affairs Biorepository (CSP 501 to ACM); National Institute of Aging (1RF1AG054156-01); National Institute of Aging Boston University AD Center (P30AG13846; supplement 0572063345-5 to ACM); Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP #13267017 to ACM); National Heart, Lung, and Blood Institute, Framingham Heart Study, (NHLBI/NIH #N01-HC-25195 and R01AG08122 to RA); NINDS (1F32NS096803-01 to MLA); Concussion Legacy Foundation to ACM. This work was also supported by unrestricted gifts from the Andlinger Foundation and WWE to ACM. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bachstetter AD, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0209-z; Baruch K, 2013, P NATL ACAD SCI USA, V110, P2264, DOI 10.1073/pnas.1211270110; Belkhelfa M, 2014, J INTERFERON CYTOKIN; Bigio EH, 2008, J NEUROPATH EXP NEUR, V67, P635, DOI 10.1097/NEN.0b013e31817d751c; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Bogoslovsky T, 2016, DIAGNOSTICS, V6, DOI 10.3390/diagnostics6040037; BROWNELL B, 1970, J NEUROL NEUROSUR PS, V33, P338, DOI 10.1136/jnnp.33.3.338; Cairns NJ, 2007, ACTA NEUROPATHOL, V114, P5, DOI 10.1007/s00401-007-0237-2; Castellano JM, 2015, JAMA NEUROL, V72, P1191, DOI 10.1001/jamaneurol.2015.1616; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Dickson DW, 2010, INT J CLIN EXP PATHO, V3, P1; Flynn G, 2003, J NEUROIMMUNOL, V136, P84, DOI 10.1016/S0165-5728(03)00009-2; Furukawa T, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000138; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Huber A. K., 2016, CLIN IMMUNOL; Huber AK, 2014, NEUROLOGY, V83, P1500, DOI 10.1212/WNL.0000000000000908; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Kanaan NM, 2016, J NEUROPATH EXP NEUR, V75, P19, DOI 10.1093/jnen/nlv001; Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505; Kovac A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-139; Leung R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064971; Litvan I, 1996, J NEUROPATH EXP NEUR, V55, P97, DOI 10.1097/00005072-199601000-00010; Love S., 2008, GREENFIELDS NEUROPAT, V8th; Mackenzie IRA, 2010, ACTA NEUROPATHOL, V119, P1, DOI 10.1007/s00401-009-0612-2; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKeith IG, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P417; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Mielke MM, 2014, CLIN EPIDEMIOL, V6, P37, DOI 10.2147/CLEP.S37929; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1147, DOI 10.1097/00005072-199911000-00004; Okamura N, 2016, AGEING RES REV, V30, P107, DOI 10.1016/j.arr.2015.12.010; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Parajuli B, 2015, GLIA, V63, P2274, DOI 10.1002/glia.22892; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shahim P, 2017, JAMA NEUROL; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Szmydynger-Chodobska J, 2012, J CEREBR BLOOD F MET, V32, P93, DOI 10.1038/jcbfm.2011.111; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; van der Meer P, 2000, EXP MOL PATHOL, V69, P192, DOI 10.1006/exmp.2000.2336; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P509, DOI 10.1007/s00401-007-0311-9; VONSATTEL JPG, 1995, J NEUROPATH EXP NEUR, V54, P42; Westin K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030525; Wild Edward, 2011, PLoS Curr, V3, pRRN1231, DOI 10.1371/currents.RRN1231; Wyss-Coray T, 2016, NATURE, V539, P180, DOI 10.1038/nature20411; Yang LP, 2007, MOL VIS, V13, P1083; Zhu C, 2016, MOL NEUROBIOL	63	25	25	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2017	12	9							e0185541	10.1371/journal.pone.0185541			14	Multidisciplinary Sciences	Science & Technology - Other Topics	FI1DL	WOS:000411671000062	28950005	DOAJ Gold, Green Published			2021-06-18	
J	Esquenazi, A; Lee, S; Wikoff, A; Packel, A; Toczylowski, T; Feeley, J				Esquenazi, Alberto; Lee, Stella; Wikoff, Amanda; Packel, Andrew; Toczylowski, Theresa; Feeley, John			A Comparison of Locomotor Therapy Interventions: Partial-Body Weight - Supported Treadmill, Lokomat, and G-EO Training in People With Traumatic Brain Injury	PM&R			English	Article							WALKING; IMPAIRMENT; GAIT; REHABILITATION	Background: Literature in the application of gait training techniques in persons with traumatic brain injury (TBI) is limited. Current techniques require multiple staff and are physically demanding. The use of a robotic locomotor training may provide improved training capacity for this population. Objective: To examine the impact of 3 different modes of locomotor therapy on gait velocity and spatiotemporal symmetry using an end effector robot (G-EO); a robotic exoskeleton (Lokomat), and manual assisted partial-body weightesupported treadmill training (PBWSTT) in participants with traumatic brain injury. Design: Randomized, prospective study. Setting: Tertiary rehabilitation hospital. Participants: A total of 22 individuals with >= 12 months chronic TBI with hemiparetic pattern able to walk overground without assistance at velocities between 0.2 and 0.6 m/s. Intervention: Eighteen sessions of 45 minutes of assigned locomotor training. Outcome Measures: Overground walking self-selected velocity (SSV), maximal velocity (MV), spatiotemporal asymmetry ratio, 6-Minute Walk Test (6MWT), and mobility domain of Stroke Impact Scale (MSIS). Results: Severity in walking dysfunction was similar across groups as determined by walking velocity data. At baseline, participants in the Lokomat group had a baseline velocity that was slightly slower compared with the other groups. Training elicited a statistically significant median increase in SSV for all groups compared with pretraining (Lokomat, P = .04; G-EO, P = .03; and PBWSTT, P = .02) and MV excluding the G-EO group (Lokomat, P = .04; PBWSTT, P =.03 and G-EO, P = .15). There were no pre-post significant differences in swing time, stance time, and step length asymmetry ratios at SSV or MV for any of the interventions. Mean rank in the change of SSV and MV was not statistically significantly different between groups. Participants in the G-EO and PBWSTT groups significantly improved their 6MWT posttraining (P = .04 and.03, respectively). The MSIS significantly improved only for the Lokomat group (P = .04 and.03). The data did not elicit between-groups significant differences for 6MWT and MSIS. There was less use of staff for Lokomat than G-EO. Conclusions: Locomotor therapy using G-EO, Lokomat, or PBWSTT in individuals with chronic TBI increased SSV and MV without significant changes in gait symmetry. Staffing needed for therapy provision was the least for the Lokomat. A larger study may further elucidate changes in gait symmetry and other training parameters.	[Esquenazi, Alberto; Lee, Stella; Wikoff, Amanda; Packel, Andrew; Toczylowski, Theresa; Feeley, John] MossRehab Gait & Mot Anal Lab, 60 Township Line Rd, Elkins Pk, PA 19027 USA	Esquenazi, A (corresponding author), MossRehab Gait & Mot Anal Lab, 60 Township Line Rd, Elkins Pk, PA 19027 USA.	aesquena@einstein.edu	Packel, Andrew/AAJ-4840-2021	Packel, Andrew/0000-0002-5048-1661	MossRehab	Disclosures related to this publication: grant, MossRehab (money to institution)	Balasubramanian CK, 2007, ARCH PHYS MED REHAB, V88, P43, DOI 10.1016/j.apmr.2006.10.004; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Behrman AL, 2006, PHYS THER, V86, P1406, DOI 10.2522/ptj.20050212; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; Brown AW, 2007, BRAIN INJURY, V21, P673, DOI 10.1080/02699050701468925; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Esquenazi A, 2016, CLIN APPL ROBOTICS T; Esquenazi A, 1995, GAIT ANAL THEORY APP, P412; Esquenazi A, 2013, PM&R, V5, P280, DOI 10.1016/j.pmrj.2012.10.009; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Hillier SL, 1997, BRAIN INJURY, V11, P661; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Johnk K, 1999, RESTOR NEUROL NEUROS, V14, P143; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Mehrholz J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002840.pub3; National Database, 2016, NAT DAT 2016 PROF PE; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Peters DM, 2014, ARCH PHYS MED REHAB, V95, P1454, DOI 10.1016/j.apmr.2014.04.006; Rosenthal R., 1994, HDB RES SYNTHESIS, P231; Sacco K, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00146; SCHMIDT RA, 1998, MOTOR CONTROL LEARNI; Taylor A, 1980, P INT C REH ENG TOR; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Williams G, 2011, J NEUROTRAUM, V28, P281, DOI 10.1089/neu.2010.1649; Wilson DJ, 2002, BRAIN INJURY, V16, P259, DOI 10.1080/02699050110103922	28	25	25	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	SEP	2017	9	9					839	846		10.1016/j.pmrj.2016.12.010			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	FL7PN	WOS:000414440500001	28093370				2021-06-18	
J	Koch, SBJ; van Zuiden, M; Nawijn, L; Frijling, JL; Veltman, DJ; Olff, M				Koch, Saskia B. J.; van Zuiden, Mirjam; Nawijn, Laura; Frijling, Jessie L.; Veltman, Dick J.; Olff, Miranda			Decreased uncinate fasciculus tract integrity in male and female patients with PTSD: a diffusion tensor imaging study	JOURNAL OF PSYCHIATRY & NEUROSCIENCE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; WHITE-MATTER MICROSTRUCTURE; VENTROMEDIAL PREFRONTAL CORTEX; TRAUMATIC BRAIN-INJURY; FUNCTIONAL CONNECTIVITY; AMYGDALA; EXTINCTION; HIPPOCAMPAL; VETERANS; ANXIETY	Background: Posttraumatic stress disorder (PTSD) is a disabling psychiatric disorder that has been associated with lower white matter integrity of tracts connecting the prefrontal cortex with limbic regions. However, previous diffusion tensor imaging (DTI) findings have been inconsistent, showing high variability in the exact location and direction of effects. Methods: We performed probabilistic tractography of the bilateral uncinate fasciculus, cingulum and superior longitudinal fasciculus (both temporal and parietal projections) in male and female police officers with and without PTSD. Results: We included 38 (21 men) police officers with and 39 (20 men) without PTSD in our analyses. Compared with trauma-exposed controls, patients with PTSD showed significantly higher mean diffusivity of the right uncinate fasciculus, the major white matter tract connecting the amygdala to the prefrontal cortex (p = 0.012). No other significant between-group or group x sex differences were observed. Mean diffusivity of the right uncinate fasciculus was positively associated with anxiety symptoms (r = 0.410, p = 0.013) in patients with PTSD as well as with amygdala activity (r = 0.247, p = 0.038) and ventromedial prefrontal cortex (vmPFC) activity (r = 0.283, p = 0.016) in all participants in response to happy and neutral faces. Limitations: Our specific sample of trauma-exposed police officers limits the generalizability of our findings to other PTSD patient groups (e.g., civilian trauma). Conclusion: Patients with PTSD showed diminished structural connectivity between the amygdala and vmPFC, which was correlated with higher anxiety symptoms and increased functional activity of these brain regions. Our findings provide additional evidence for the prevailing neurocircuitry model of PTSD, postulating that ineffective communication between the amygdala and vmPFC underlies decreased top-down control over fear responses.	[Koch, Saskia B. J.; van Zuiden, Mirjam; Nawijn, Laura; Frijling, Jessie L.; Olff, Miranda] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, Meibergdreef 5, NL-1105 AZ Amsterdam, Netherlands; [Koch, Saskia B. J.; Nawijn, Laura; Frijling, Jessie L.] Acad Med Ctr, Brain Imaging Ctr, Amsterdam, Netherlands; [Veltman, Dick J.] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands; [Olff, Miranda] Arq Psychotrauma Expert Ctr, Diemen, Netherlands; [Koch, Saskia B. J.] Radboud Univ Nijmegen, Ctr Cognit Neuroimaging, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands	Koch, SBJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Psychiat, Meibergdreef 5, NL-1105 AZ Amsterdam, Netherlands.	saskia_koch@hotmail.com	Olff, Miranda/S-6235-2019; Koch, Saskia B.J. B.J./W-9894-2018	Koch, Saskia B.J. B.J./0000-0002-3628-6712; Nawijn, Laura/0000-0001-7183-8933; van Zuiden, Mirjam/0000-0002-1225-2702	ZonMw, the Netherlands organization for Health Research and DevelopmentNetherlands Organization for Health Research and DevelopmentNetherlands Government [40-00812-98-10041]; Academic Medical Center Research Council [110614]	The authors thank all individuals who participated in this study. The authors thank all personnel of the PDC police outpatient clinic for their valuable help with recruitment of the patients with PTSD. The study is supported by grants from ZonMw, the Netherlands organization for Health Research and Development (grant no. 40-00812-98-10041) and the Academic Medical Center Research Council (110614).	Abe O, 2006, PSYCHIAT RES-NEUROIM, V146, P231, DOI 10.1016/j.pscychresns.2006.01.004; Admon R, 2013, HUM BRAIN MAPP, V34, P2808, DOI 10.1002/hbm.22100; Alvarez RP, 2008, J NEUROSCI, V28, P6211, DOI 10.1523/JNEUROSCI.1246-08.2008; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Bierer LM, 2015, PSYCHONEUROENDOCRINO, V51, P567, DOI 10.1016/j.psyneuen.2014.11.007; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bremner JD, 2007, J NERV MENT DIS, V195, P211, DOI 10.1097/01.nmd.0000243824.84651.6c; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Caan MWA, 2010, LECT NOTES COMPUT SC, V6361, P167; Carlier I, 1992, PSYCHIAT FENNICA S, V23, P59; Costanzo ME, 2016, NEUROSCI LETT, V618, P66, DOI 10.1016/j.neulet.2016.02.041; Cox SR, 2015, NEUROBIOL AGING, V36, P257, DOI 10.1016/j.neurobiolaging.2014.06.022; Daniels JK, 2013, DEPRESS ANXIETY, V30, P207, DOI 10.1002/da.22044; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; de Vries GJ, 2009, J TRAUMA STRESS, V22, P259, DOI 10.1002/jts.20429; Fani N, 2012, NEUROPSYCHOPHARMACOL, V37, P2740, DOI 10.1038/npp.2012.146; First Michael B, 2012, STRUCTURED CLIN INTE; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Hagmann P, 2006, RADIOGRAPHICS, V26, pS205, DOI 10.1148/rg.26si065510; Hariri AR, 2002, NEUROIMAGE, V17, P317, DOI 10.1006/nimg.2002.1179; Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9; Hsu JL, 2008, NEUROIMAGE, V39, P566, DOI 10.1016/j.neuroimage.2007.09.017; Isaac L, 2015, BIOL PSYCHOL, V105, P20, DOI 10.1016/j.biopsycho.2014.12.011; Jovanovic T, 2009, PSYCHIAT RES, V167, P151, DOI 10.1016/j.psychres.2007.12.014; Kalisch R, 2006, J NEUROSCI, V26, P9503, DOI 10.1523/JNEUROSCI.2021-06.2006; Kennis M, 2015, NEUROPSYCHOPHARMACOL, V40, P2434, DOI 10.1038/npp.2015.94; Kim MJ, 2011, BEHAV BRAIN RES, V223, P403, DOI 10.1016/j.bbr.2011.04.025; Kim MJ, 2009, J NEUROSCI, V29, P11614, DOI 10.1523/JNEUROSCI.2335-09.2009; Kim MJ, 2005, NEUROREPORT, V16, P1049, DOI 10.1097/00001756-200507130-00004; Kim SJ, 2006, NEUROPSYCHOBIOLOGY, V54, P120, DOI 10.1159/000098262; Koch SBJ, 2016, NEUROPSYCHOPHARMACOL, V41, P1495, DOI 10.1038/npp.2015.299; Kranz GS, 2014, J NEUROSCI, V34, P15466, DOI 10.1523/JNEUROSCI.2488-14.2014; Kuhn S, 2013, BIOL PSYCHIAT, V73, P70, DOI 10.1016/j.biopsych.2012.06.029; Li WJ, 2014, HUM BRAIN MAPP, V35, P238, DOI 10.1002/hbm.22168; Liberzon I, 2016, NEURON, V92, P14, DOI 10.1016/j.neuron.2016.09.039; Lissek S, 2015, INT J PSYCHOPHYSIOL, V98, P594, DOI 10.1016/j.ijpsycho.2014.11.006; Liu YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119998; Milad MR, 2007, BIOL PSYCHIAT, V62, P446, DOI 10.1016/j.biopsych.2006.10.011; MORELL P, 1980, SCI AM, V242, P88, DOI 10.1038/scientificamerican0580-88; Olabarriaga SD, 2010, IEEE T INF TECHNOL B, V14, P979, DOI 10.1109/TITB.2010.2046742; Pacheco J, 2009, J NEUROSCI, V29, P6229, DOI 10.1523/JNEUROSCI.0896-09.2009; Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Schmahmann JD, 2006, FIBER PATHWAYS BRAIN; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Sekiguchi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083967; Sexton CE, 2014, J NEUROSCI, V34, P15425, DOI 10.1523/JNEUROSCI.0203-14.2014; Shahand S, 2015, CONCURR COMP-PRACT E, V27, P489, DOI 10.1002/cpe.3281; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Shvil E, 2014, NEUROBIOL LEARN MEM, V113, P101, DOI 10.1016/j.nlm.2014.02.003; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Spielberg JM, 2015, BIOL PSYCHIAT, V78, P210, DOI 10.1016/j.biopsych.2015.02.013; Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069; Sun YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083473; Swartz JR, 2014, NEUROIMAGE, V86, P212, DOI 10.1016/j.neuroimage.2013.08.018; Tromp DPM, 2012, ARCH GEN PSYCHIAT, V69, P925, DOI 10.1001/archgenpsychiatry.2011.2178; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Weiss DS., 2007, CROSS CULTURAL ASSES, P219; Yendiki Anastasia, 2011, Front Neuroinform, V5, P23, DOI 10.3389/fninf.2011.00023; Zhang L, 2011, J AFFECT DISORDERS, V133, P294, DOI 10.1016/j.jad.2011.03.040; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zuurbier LA, 2013, EMOTION, V13, P385, DOI 10.1037/a0031163	67	25	25	0	10	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	1180-4882	1488-2434		J PSYCHIATR NEUROSCI	J. Psychiatry Neurosci.	SEP	2017	42	5					331	342		10.1503/jpn.160129			12	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	FE8BW	WOS:000408431600007	28452713	Bronze, Green Published			2021-06-18	
J	Leeper, CM; Neal, MD; McKenna, CJ; Gaines, BA				Leeper, Christine M.; Neal, Matthew D.; McKenna, Christine J.; Gaines, Barbara A.			Trending Fibrinolytic Dysregulation Fibrinolysis Shutdown in the Days After Injury Is Associated With Poor Outcome in Severely Injured Children	ANNALS OF SURGERY			English	Article; Proceedings Paper	137th Annual Meeting of the American-Surgical-Association (ASA)	APR 20-22, 2017	Philadelphia, PA	Amer Surg Assoc		coagulopathy; massive transfusion; pediatric; trauma; traumatic brain injury	ADMISSION RAPID THROMBELASTOGRAPHY; ACUTE TRAUMATIC COAGULOPATHY; PRINCIPAL COMPONENT ANALYSIS; PEDIATRIC TRAUMA; MORTALITY; CHILDREN; COAGULATION; TIME; HYPERFIBRINOLYSIS; PREVALENCE	Objective: To trend fibrinolysis after injury and determine the influence of traumatic brain injury (TBI) and massive transfusion on fibrinolysis status. Background: Admission fibrinolytic derangement is common in injured children and adults, and is associated with poor outcome. No studies examine fibrinolysis days after injury. Methods: Prospective study of severely injured children at a level 1 pediatric trauma center. Rapid thromboelastography was obtained on admission and daily for up to 7 days. Standard definitions of hyperfibrinolysis (HF; LY30 >= 3), fibrinolysis shutdown (SD; LY30 <= 0.8), and normal (LY30 = 0.9-2.9) were applied. Antifibrinolytic use was documented. Outcomes were death, disability, and thromboembolic complications. Wilcoxon rank-sum and Fisher exact tests were performed. Exploratory subgroups included massively transfused and severe TBI patients. Results: In all, 83 patients were analyzed with median (interquartile ranges) age 8 (4-12) and Injury Severity Score 22 (13-34), 73.5% blunt mechanism, 47% severe TBI, 20.5% massively transfused. Outcomes were 14.5% mortality, 43.7% disability, and 9.8% deep vein thrombosis. Remaining in or trending to SD was associated with death (P = 0.007), disability (P = 0.012), and deep vein thrombosis (P = 0.048). Median LY30 was lower on post-trauma day (PTD) 1 to PTD4 in patients with poor compared with good outcome; median LY30 was lower on PTD1 to PTD3 in TBI patients compared with non-TBI patients. HF without associated shutdown was not related to poor outcome, but extreme HF (LY30 >30%, n = 3) was lethal. Also, 50% of massively transfused patients in hemorrhagic shock demonstrated SD physiology on admission. All with HF (fc31.2%) corrected after hemostatic resuscitation without tranexamic acid. Conclusions: Fibrinolysis shutdown is common postinjury and predicts poor outcomes. Severe TBI is associated with sustained shutdown. Empiric anti-fibrinolytics for children should be questioned; thromboelastography-directed selective use should be considered for documented HF.	[Leeper, Christine M.; Neal, Matthew D.; Gaines, Barbara A.] Univ Pittsburgh, Dept Surg, Med Ctr, Div Gen Surg & Trauma, Pittsburgh, PA USA; [Leeper, Christine M.; McKenna, Christine J.; Gaines, Barbara A.] UPMC, Childrens Hosp Pittsburgh, 7th Floor,Fac Pavil,One Childrens Hosp Dr, Pittsburgh, PA 15224 USA	Leeper, CM (corresponding author), UPMC, Childrens Hosp Pittsburgh, 7th Floor,Fac Pavil,One Childrens Hosp Dr, Pittsburgh, PA 15224 USA.	leepercm@upmc.edu			University of Pittsburgh Clinical and Translational Science InstituteUniversity of Pittsburgh [UL1 TR000005]; Vascular Medicine Institute; Hemophilia Center of Western Pennsylvania; Institute for Transfusion Medicine; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER	This publication was made possible by grant number UL1 TR000005 (University of Pittsburgh Clinical and Translational Science Institute), the Vascular Medicine Institute, the Hemophilia Center of Western Pennsylvania, and the Institute for Transfusion Medicine.	Affonseca CA, 2007, J PEDIAT-BRAZIL, V83, P274, DOI [10.1590/S0021-75572007000400014, 10.2223/JPED.1639]; Calkins CM, 2002, J TRAUMA, V53, P1058, DOI 10.1097/00005373-200212000-00005; Centers for Disease Control and Prevention, 2014, C TRAUM BRAIN INJ US; Centers for Disease Control and Prevention, 2015, 10 LEAD CAUS DEATH A; Chapman MP, 2015, J TRAUMA ACUTE CARE, V79, P925, DOI 10.1097/TA.0000000000000871; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Chin TL, 2014, SURGERY, V156, P570, DOI 10.1016/j.surg.2014.04.030; Christiaans SC, 2014, SHOCK, V41, P476, DOI 10.1097/SHK.0000000000000151; Eckert MJ, 2014, J TRAUMA ACUTE CARE, V77, P852, DOI 10.1097/TA.0000000000000443; Gonzalez E, 2016, ANN SURG, V263, P1051, DOI 10.1097/SLA.0000000000001608; HARDAWAY RM, 1962, ANN SURG, V155, P325; Hendrickson JE, 2012, J PEDIATR-US, V160, P204, DOI 10.1016/j.jpeds.2011.08.019; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Kunitake RC, 2017, J TRAUMA ACUTE CARE, V82, P302, DOI 10.1097/TA.0000000000001313; Kutcher ME, 2013, J TRAUMA ACUTE CARE, V74, P1223, DOI 10.1097/TA.0b013e31828b7fa1; Leeper CM, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26415; Leeper CM, 2017, J TRAUMA ACUTE CARE, V82, P27, DOI 10.1097/TA.0000000000001308; Leeper CM, 2016, J TRAUMA ACUTE CARE, V81, P34, DOI 10.1097/TA.0000000000001002; Leeper CM, 2016, J TRAUMA ACUTE CARE, V80, P711, DOI 10.1097/TA.0000000000000954; Leeper CM, 2017, AC SURG C LAS VEG NV; Liras IN, 2017, J AM COLL SURGEONS, V224, P625, DOI 10.1016/j.jamcollsurg.2016.12.046; Liras IN, 2015, SURGERY, V158, P812, DOI 10.1016/j.surg.2015.05.004; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; Meizoso JP, 2017, J AM COLL SURGEONS, V224, P575, DOI 10.1016/j.jamcollsurg.2016.12.018; Moore HB, 2016, 58 ANN M AM SOC HEAM; Moore HB, 2016, J AM COLL SURGEONS, V222, P347, DOI 10.1016/j.jamcollsurg.2016.01.006; Moore HB, 2014, J TRAUMA ACUTE CARE, V77, P811, DOI 10.1097/TA.0000000000000341; Neff LP, 2015, J TRAUMA ACUTE CARE, V78, P22, DOI 10.1097/TA.0000000000000488; Patregnani JT, 2012, PEDIATR CRIT CARE ME, V13, P273, DOI 10.1097/PCC.0b013e31822f1727; Rizoli S, 2013, J TRAUMA ACUTE CARE, V74, P1229; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Suominen P, 1998, INJURY, V29, P425; Vogel AM, 2013, J PEDIATR SURG, V48, P1371, DOI 10.1016/j.jpedsurg.2013.03.036; Whittaker B, 2013, SHOCK, V39, P421, DOI 10.1097/SHK.0b013e31828e08cb	35	25	26	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	SEP	2017	266	3					508	515		10.1097/SLA.0000000000002355			8	Surgery	Surgery	FD2UR	WOS:000407390800013	28650356				2021-06-18	
J	Theadom, A; Barker-Collo, S; Jones, K; Kahan, M; Ao, BT; McPherson, K; Starkey, N; Feigin, V				Theadom, Alice; Barker-Collo, Suzanne; Jones, Kelly; Kahan, Michael; Ao, Braden Te; McPherson, Kathryn; Starkey, Nicola; Feigin, Valery		BIONIC4you Res Grp	Work Limitations 4 Years After Mild Traumatic Brain Injury: A Cohort Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain concussion; Brain injuries, traumatic; Employment; Longitudinal studies; Rehabilitation; Work	QUALITY-OF-LIFE; NEW-ZEALAND; QUESTIONNAIRE; EMPLOYMENT; ADULTS	Objective: To explore employment status, work limitations, and productivity loss after mild traumatic brain injury (TBI). Design: Inception cohort study over 4 years. Setting: General community. Participants: Adults (N=245; >16y at the time of injury) who experienced a mild TBI and who were employed prior to their injury. Interventions: Not applicable. Main Outcome Measures: Details of the injury, demographic information, and preinjury employment status were collected from medical records and self-report. Symptoms and mood were assessed 1 month postinjury using the Rivermead Post-Concussion Symptom Questionnaire and the Hospital Anxiety and Depression Scale. Postinjury employment status and work productivity were assessed 4 years postinjury using the Work Limitations Questionnaire. Results: Four years after mild TBI, 17.3% of participants had exited the workforce (other than for reasons of retirement or to study) or had reduced their working hours compared with preinjury. A further 15.5% reported experiencing limitations at work because of their injury. Average work productivity loss was 3.6%. The symptom of taking longer to think 1 month postinjury significantly predicted work productivity loss 4 years later ((beta=.47, t=3.79, P <=.001). Conclusions: Although changes in employment status and difficulties at work are likely over time, the results indicate increased unemployment rates, work limitations, and productivity loss in the longer term after a mild TBI. Identification of cognitive difficulties 1 month after TBI in working aged adults and subsequent interventions to address these difficulties are required to facilitate work productivity. (C) 2016 by the American Congress of Rehabilitation Medicine	[Theadom, Alice; Jones, Kelly; Feigin, Valery] Auckland Univ Technol, Sch Publ Hlth & Psychosocial Studies, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Barker-Collo, Suzanne] Univ Auckland, Sch Psychol, Auckland, New Zealand; [Kahan, Michael] Waikato Occupat Serv, Hamilton, New Zealand; [Ao, Braden Te] Auckland Univ Technol, Sch Publ Hlth & Psychosocial Studies, Dept Biostat & Epidemiol, Auckland, New Zealand; [McPherson, Kathryn] Hlth Res Council New Zealand, Auckland, New Zealand; [Starkey, Nicola] Univ Waikato, Sch Psychol, Hamilton, New Zealand	Theadom, A (corresponding author), Natl Inst Stroke & Appl Neurosci, Sch Rehabil & Occupat Studies, Fac Hlth & Environm Sci, AUT North Shore Campus,AA254C,90 Akoranga Dr, Auckland 1142, New Zealand.	alice.theadom@aut.ac.nz	Starkey, Nicola/AAJ-3795-2020; Jones, Kelly/I-5199-2019; Feigin, Valery/AAF-2313-2019	Starkey, Nicola/0000-0002-4370-8186; Barber, P Alan/0000-0003-2469-9023; Feigin, Valery L./0000-0002-6372-1740; McPherson, Kath/0000-0003-0487-8497; Te Ao, Braden/0000-0002-1050-200X	Health Research Council of New ZealandHealth Research Council of New Zealand [09/063A, 11/192, 13/408]	Supported by the Health Research Council of New Zealand (grant nos. 09/063A, 11/192, and 13/408).	Barra LJ, 2016, CLIN EXP RHEUMATOL, V34, pS111; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lerner D, 2001, MED CARE, V39, P72, DOI 10.1097/00005650-200101000-00009; Lerner D., 2002, QUAL LIFE RES, V28, P9; Lerner DJ, 1998, WORK LIMITATIONS QUE; McGrath C, 2017, CANCER NURS, V40, P160, DOI 10.1097/NCC.0000000000000359; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Sengupta I, 2010, WORKERS COMPENSATION; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Te Ao B, 2014, NEUROLOGY, V83, P1645, DOI 10.1212/WNL.0000000000000933; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; Theadom A, 2015, J NEUROTRAUM, V32, P674, DOI 10.1089/neu.2014.3579; Trewin D, 2006, AISTR MZ STANDARD CL; van Vilsteren M, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0562-x; Vikane E, 2016, BEHAV NEUROL, V2016, DOI 10.1155/2016/8026414; Waljas M, 2014, J HEAD TRAUMA REHAB, V29, P443, DOI 10.1097/HTR.0000000000000002; Walsh JA, 2014, J RHEUMATOL, V41, P1670, DOI 10.3899/jrheum.140259; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	25	25	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2017	98	8					1560	1566		10.1016/j.apmr.2017.01.010			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	FD1OF	WOS:000407305900008	28188778	Green Accepted			2021-06-18	
J	Dillahunt-Aspillaga, C; Nakase-Richardson, R; Hart, T; Powell-Cope, G; Dreer, LE; Eapen, BC; Barnett, SD; Mellick, D; Haskin, A; Silva, MA				Dillahunt-Aspillaga, Christina; Nakase-Richardson, Risa; Hart, Tessa; Powell-Cope, Gail; Dreer, Laura E.; Eapen, Blessen C.; Barnett, Scott D.; Mellick, Dave; Haskin, Adam; Silva, Marc A.			Predictors of Employment Outcomes in Veterans With Traumatic Brain Injury: A VA Traumatic Brain Injury Model Systems Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						employment; return to work; service members; traumatic brain injury; unemployment; veterans	POSTTRAUMATIC-STRESS-DISORDER; VOCATIONAL-REHABILITATION; DISABILITY COMPENSATION; COGNITIVE RECOVERY; RACIAL-DIFFERENCES; FUNCTIONAL STATUS; ENDURING FREEDOM; SERVICE MEMBERS; PAIN DIAGNOSES; IRAQI FREEDOM	Objectives: To examine the length of time to return to work (RTW) among service members and veterans (SM/V) with traumatic brain injury (TBI) and to identify variables predictive of RTW. Setting: Department of Veterans Affairs Polytrauma Rehabilitation Centers (VA PRC). Participants: SM/V enrolled in the VA PRC Traumatic Brain Injury Model Systems database who were of 18 to 60 years of age and admitted with the diagnosis of TBI. Design: Prospective observational cohort study. Main OutcomeMeasures: Employment status at 1-year postinjury follow-up; Time to Employment (ie, number of days it took to RTW) as documented during 1-year postinjury follow-up. Results: The final sample (n = 293) included male (96%) SM/V with severe TBI (69%). Approximately 21% of the sample participants were employed at 1 year postinjury. Younger individuals who self-identified as nonminority returned to work sooner. Significant associations were observed for time to employment for cause of injury and injury severity. Conclusions: Few SM/V with moderate to severe TBI returned to work at 1 year postinjury. Predictors such as younger age at the time of injury, minority status, and severity of TBI affected time to and probability of RTW. Findings from this study have important implications for rehabilitation planning and service delivery across the continuum of recovery.	[Dillahunt-Aspillaga, Christina] Univ S Florida, Rehabil & Mental Hlth Counseling Program, Tampa, FL USA; [Dillahunt-Aspillaga, Christina; Nakase-Richardson, Risa; Powell-Cope, Gail; Barnett, Scott D.; Silva, Marc A.] James A Haley Vet Hosp, HSR&D Ctr Innovat Disabil & Rehabil Res CINDRR, Tampa, FL USA; [Nakase-Richardson, Risa; Barnett, Scott D.; Haskin, Adam; Silva, Marc A.] Def & Vet Brain Injury Ctr, Def Ctr Excellence Psychol Hlth, Tampa, FL USA; [Nakase-Richardson, Risa; Barnett, Scott D.; Haskin, Adam; Silva, Marc A.] Def & Vet Brain Injury Ctr, Def Ctr Traumat Brain Injury, Tampa, FL USA; [Nakase-Richardson, Risa; Barnett, Scott D.; Silva, Marc A.] James A Haley Vet Hosp, MHBS, Tampa, FL USA; [Nakase-Richardson, Risa] Univ S Florida, Dept Med, Tampa, FL USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Eapen, Blessen C.] South Texas Vet Hlth Care Syst, Polytrauma Rehabil Ctr, San Antonio, TX USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA; [Mellick, Dave] Craig Hosp, Traumat Brain Injury Model Syst Natl Data & Stat, Englewood, CO USA; [Haskin, Adam] Gen Dynam Hlth Solut, Tampa, FL USA; [Silva, Marc A.] Univ S Florida, Dept Psychol, Tampa, FL USA	Dillahunt-Aspillaga, C (corresponding author), HSR&D Ctr Innovat Disabil & Rehabil Res, 8900 Grand Oak Circle, Tampa, FL 33637 USA.	cdillahuntas@usf.edu	Silva, Marc A./J-1874-2019	Silva, Marc A./0000-0002-3879-6054	Department of Veterans AffairsUS Department of Veterans Affairs; Department of Education, National Institute on Disability, Independent Living, and Rehabilitation Research; VHA Central Office VA TBI Model System Program of Research; General Dynamics Health Solutions from the Defense and Veterans Brain Injury Center, US Army Medical Research and Material Command (USAMRMC), U.S. Department of Veterans Affairs [W91YTZ-13-C-0015, 1 I50 HX001233-01, W81XWH-13-2-0095]; U.S. Department of Defense Congressionally Directed Medical Research Programs	The Polytrauma Rehabilitation Center Traumatic Brain Injury (TBI) Model System collaboration is funded through an Interagency Agreement between the Department of Veterans Affairs and the Department of Education, National Institute on Disability, Independent Living, and Rehabilitation Research. This research is sponsored by VHA Central Office VA TBI Model System Program of Research, and Subcontract from General Dynamics Health Solutions (W91YTZ-13-C-0015) from the Defense and Veterans Brain Injury Center, US Army Medical Research and Material Command (USAMRMC), U.S. Department of Veterans Affairs grants (1 I50 HX001233-01, W81XWH-13-2-0095), and U.S. Department of Defense Congressionally Directed Medical Research Programs.	Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Adler DA, 2011, PSYCHIAT SERV, V62, P39, DOI 10.1176/ps.62.1.pss6201_0039; Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Bahadur S, 2016, J ROY ARMY MED CORPS, V162, P120, DOI 10.1136/jramc-2014-000393; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cohen SI, 2013, WORK, V44, P213, DOI 10.3233/WOR-2012-1417; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Corrigan JD, 2014, J NEUROTRAUM, V31, P1000, DOI 10.1089/neu.2013.3145; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P160, DOI 10.1097/HTR.0000000000000090; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85; Daggett VS, 2013, J REHABIL RES DEV, V50, P327, DOI 10.1682/JRRD.2011.09.0168; Defense and Veterans Brain Injury Center, 2016, WORLDW NUMB TBI; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dillahunt-Aspillaga C, 2014, PLOS ONE, V9, P1; Dillahunt-Aspillaga C, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/924027; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Drew D, 2001, PSYCHIATR SERV, V52, P1479, DOI 10.1176/appi.ps.52.11.1479; Ettenhofer ML, 2012, MIL MED, V177, P1272, DOI 10.7205/MILMED-D-12-00095; Fadyl JK, 2009, J HEAD TRAUMA REHAB, V24, P195, DOI 10.1097/HTR.0b013e3181a0d458; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Finnanger TG, 2013, BRAIN INJURY, V27, P1606, DOI 10.3109/02699052.2013.831127; French LM, 2011, CLIN MANUAL MANAGEME, P383; Gary KW, 2010, J VOCAT REHABIL, V33, P65, DOI 10.3233/JVR-2010-0516; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Golding H, 2009, J REHABIL RES DEV, V46, pVII, DOI 10.1682/JRRD.2009.06.0081; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hankins AB, 2015, J OCCUP REHABIL, V25, P599, DOI 10.1007/s10926-015-9568-3; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P467, DOI 10.1097/00001199-200611000-00002; Hart T, 2010, J VOCAT REHABIL, V32, P135, DOI 10.3233/JVR-2010-0505; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Janak J.C., 2015, TRAUMATIC BRAIN INJU, P6, DOI [10.2217/fmeb2013.13.296, DOI 10.2217/FMEB2013.13.296]; Kennedy CH, 2012, ARCH CLIN NEUROPSYCH, V27, P817, DOI 10.1093/arclin/acs092; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Lamberty GJ, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e31829a64d1; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; Lew HL, 2013, J REHABIL RES DEV, V50, pXI, DOI 10.1682/JRRD.2013.09.0212; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; McCulloch KL, 2015, J HEAD TRAUMA REHAB, V30, P56, DOI 10.1097/HTR.0000000000000104; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1861, DOI 10.1016/j.apmr.2013.05.027; Odgaard L, 2017, J HEAD TRAUMA REHAB, V32, pE57, DOI 10.1097/HTR.0000000000000239; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Pogoda TK, 2016, J HEAD TRAUMA REHAB, V31, P191, DOI 10.1097/HTR.0000000000000092; Ponsford J, 2013, NEUROREHABILITATION, V32, P803, DOI 10.3233/NRE-130904; Ponsford JL, 2016, J NEUROTRAUM, V33, P997, DOI 10.1089/neu.2015.4025; Ponsford JL, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000033; Radford K, 2013, BRAIN INJURY, V27, P507, DOI 10.3109/02699052.2013.766929; Resnik L, 2012, J REHABIL RES DEV, V49, P87, DOI 10.1682/JRRD.2010.06.0107; Rueda S, 2012, AM J PUBLIC HEALTH, V102, P541, DOI 10.2105/AJPH.2011.300401; Saltychev M, 2013, BRAIN INJURY, V27, P1516, DOI 10.3109/02699052.2013.831131; SAS Institute I, 2011, SAS 9 2; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2014, SOC ISS POLICY REV, V8, P33, DOI 10.1111/sipr.12001; Scherer MR, 2013, PHYS THER, V93, P1254, DOI 10.2522/ptj.20120143; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Stergiou-Kita M, 2011, J OCCUP REHABIL, V21, P374, DOI 10.1007/s10926-010-9282-0; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Trudel TM, 2007, J REHABIL RES DEV, V44, P1007, DOI 10.1682/JRRD.2006.12.0167; Tsai J, 2013, J OCCUP REHABIL, V23, P504, DOI 10.1007/s10926-013-9419-z; Twamley EW, 2013, J REHABIL RES DEV, V50, P663, DOI 10.1682/JRRD.2012.08.0137; Tyerman A, 2012, NEUROREHABILITATION, V31, P51, DOI 10.3233/NRE-2012-0774; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE55, DOI 10.1097/HTR.0000000000000140; Xiong C, 2016, DISABIL HEALTH J, V9, P439, DOI 10.1016/j.dhjo.2015.12.002; Zasler ND, 2012, BRAIN INJURY MED PRI	90	25	25	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2017	32	4					271	282		10.1097/HTR.0000000000000275			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FA2KB	WOS:000405269200015	28060203				2021-06-18	
J	Liu, XY; Donnelly, J; Czosnyka, M; Aries, MJH; Brady, K; Cardim, D; Robba, C; Cabeleira, M; Kim, DJ; Haubrich, C; Hutchinson, PJ; Smielewski, P				Liu, Xiuyun; Donnelly, Joseph; Czosnyka, Marek; Aries, Marcel J. H.; Brady, Ken; Cardim, Danilo; Robba, Chiara; Cabeleira, Manuel; Kim, Dong-Joo; Haubrich, Christina; Hutchinson, Peter J.; Smielewski, Peter			Cerebrovascular pressure reactivity monitoring using wavelet analysis in traumatic brain injury patients: A retrospective study	PLOS MEDICINE			English	Article							DYNAMIC CEREBRAL AUTOREGULATION; ARTERIAL-BLOOD-PRESSURE; PERFUSION-PRESSURE; COHERENCE ANALYSIS; INTRACRANIAL-PRESSURE; HEART-RATE; AGE; CIRCULATION; TRANSFORM	Background After traumatic brain injury (TBI), the ability of cerebral vessels to appropriately react to changes in arterial blood pressure (pressure reactivity) is impaired, leaving patients vulnerable to cerebral hypo-or hyperperfusion. Although, the traditional pressure reactivity index (PRx) has demonstrated that impaired pressure reactivity is associated with poor patient outcome, PRx is sometimes erratic and may not be reliable in various clinical circumstances. Here, we introduce a more robust transform-based wavelet pressure reactivity index (wPRx) and compare its performance with the widely used traditional PRx across 3 areas: its stability and reliability in time, its ability to give an optimal cerebral perfusion pressure (CPPopt) recommendation, and its relationship with patient outcome. Methods and findings Five hundred and fifteen patients with TBI admitted in Addenbrooke's Hospital, United Kingdom (March 23rd, 2003 through December 9th, 2014), with continuous monitoring of arterial blood pressure (ABP) and intracranial pressure (ICP), were retrospectively analyzed to calculate the traditional PRx and a novel wavelet transform-based wPRx. wPRx was calculated by taking the cosine of the wavelet transform phase-shift between ABP and ICP. A time trend of CPPopt was calculated using an automated curve-fitting method that determined the cerebral perfusion pressure (CPP) at which the pressure reactivity (PRx or wPRx) was most efficient (CPPopt_PRx and CPPopt_wPRx, respectively). There was a significantly positive relationship between PRx and wPRx (r = 0.73), and wavelet wPRx was more reliable in time (ratio of between-hour variance to total variance, wPRx 0.957 +/- 0.0032 versus PRx and 0.949 +/- 0.047 for PRx, p = 0.002). The 2-hour interval standard deviation of wPRx (0.19 +/- 0.07) was smaller than that of PRx (0.30 +/- 0.13, p < 0.001). wPRx performed better in distinguishing between mortality and survival (the area under the receiver operating characteristic [ROC] curve [AUROC] for wPRx was 0.73 versus 0.66 for PRx, p = 0.003). The mean difference between the patients' CPP and their CPPopt was related to outcome for both calculation methods. There was a good relationship between the 2 CPPopts (r = 0.814, p < 0.001). CPPopt_wPRx was more stable than CPPopt_ PRx (within patient standard deviation 7.05 +/- 3.78 versus 8.45 +/- 2.90; p < 0.001). Key limitations include that this study is a retrospective analysis and only compared wPRx with PRx in the cohort of patients with TBI. Prior prospective validation is required to better assess clinical utility of this approach. Conclusions wPRx offers several advantages to the traditional PRx: it is more stable in time, it yields a more consistent CPPopt recommendation, and, importantly, it has a stronger relationship with patient outcome. The clinical utility of wPRx should be explored in prospective studies of critically injured neurological patients.	[Liu, Xiuyun; Donnelly, Joseph; Czosnyka, Marek; Aries, Marcel J. H.; Cardim, Danilo; Robba, Chiara; Cabeleira, Manuel; Hutchinson, Peter J.; Smielewski, Peter] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Aries, Marcel J. H.] Maastricht Univ, Med Ctr, Dept Intens Care, Maastricht, Netherlands; [Brady, Ken] Baylor Coll Med, Houston, TX 77030 USA; [Robba, Chiara] Univ Genoa, Dept Neurosci, Genoa, Italy; [Kim, Dong-Joo] Korea Univ, Dept Brain & Cognit Engn, Seoul, South Korea; [Haubrich, Christina] Univ Aachen, Fac Med, Aachen, Germany	Liu, XY (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England.	xl334@cam.ac.uk	Liu, Xiuyun/V-4427-2017; Donnelly, Joseph/E-9235-2018; Donnelly, Joseph/N-6803-2019; Cardim, Danilo Augusto/B-8447-2012; Robba, Chiara/AAS-7421-2020	Liu, Xiuyun/0000-0001-9540-4865; Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Cardim, Danilo Augusto/0000-0002-9261-1321; Brady, Ken/0000-0002-3260-0233; Cabeleira, Manuel/0000-0002-1710-6544	Gates Cambridge Scholarship (University of Cambridge)University of Cambridge; Woolf Fisher Scholarship (the Woolf Fisher Trust, NZ); Cambridge Commonwealth, European & International Trust Scholarship (University of Cambridge); National Institute for Health Research (NIHR) ProfessorshipNational Institute for Health Research (NIHR); NIHR Cambridge Bran Repair Centre; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G1002277, G0601025] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013] Funding Source: researchfish	XL is a recipient of Gates Cambridge Scholarship (University of Cambridge, https://www.gatescambridge.org/). JD is funded by Woolf Fisher Scholarship (the Woolf Fisher Trust, NZ, http://www.woolffishertrust.co.nz/). DC is supported by a Cambridge Commonwealth, European & International Trust Scholarship (University of Cambridge, https://www.cambridgetrust.org/). PJH is supported by a National Institute for Health Research (NIHR) Professorship and the NIHR Cambridge Bran Repair Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Addison P., 2002, BIOMEDICAL INSTRUMEN; Addison P. S., 2002, ILLUSTRATED WAVELET, P353; [Anonymous], 2015, C P IEEE ENG MED BIO, V8, P5960; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Carey BJ, 2003, STROKE, V34, P1871, DOI 10.1161/01.STR.0000081981.99908.F3; Cooper PR, 1993, HEAD INJURY; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Donnelly J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1293-6; Donnelly J, 2015, EXPERT REV NEUROTHER, V15, P169, DOI 10.1586/14737175.2015.996552; FLEG JL, 1986, AM J CARDIOL, V57, pC33, DOI 10.1016/0002-9149(86)91025-8; GRIBBIN B, 1971, CIRC RES, V29, P424, DOI 10.1161/01.RES.29.4.424; Grinsted A, 2004, NONLINEAR PROC GEOPH, V11, P561, DOI 10.5194/npg-11-561-2004; JENNETT B, 1975, LANCET, V1, P480; KANNEL WB, 1978, B NEW YORK ACAD MED, V54, P573; Keissar K, 2009, PHILOS T R SOC A, V367, P1393, DOI 10.1098/rsta.2008.0273; Kvandal P, 2013, J CLIN MONIT COMPUT, V27, P375, DOI 10.1007/s10877-013-9484-z; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Obuchowski NA, 2003, RADIOLOGY, V229, P3, DOI 10.1148/radiol.2291010898; Panerai RB, 2002, PHYSIOL MEAS, V23, P59, DOI 10.1088/0967-3334/23/1/306; Robin AX, 2012, PACKAGE PROC, P1, DOI DOI 10.1186/1471-2105-12-77; Soul JS, 2007, PEDIATR RES, V61, P467, DOI 10.1203/pdr.0b013e31803237f6; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tian FH, 2016, NEUROIMAGE-CLIN, V11, P124, DOI 10.1016/j.nicl.2016.01.020; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Toledo E, 2003, AM J PHYSIOL-REG I, V284, pR1079, DOI 10.1152/ajpregu.00287.2002; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Wagner M, 2012, AM J NEURORADIOL, V33, P2081, DOI 10.3174/ajnr.A3138; Yam AT, 2005, J CLIN NEUROSCI, V12, P643, DOI 10.1016/j.jocn.2004.08.017	34	25	25	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	JUL	2017	14	7							e1002348	10.1371/journal.pmed.1002348			19	Medicine, General & Internal	General & Internal Medicine	FC1QA	WOS:000406611200018	28742798	DOAJ Gold, Green Published			2021-06-18	
J	Echemendia, RJ; Meeuwisse, W; McCrory, P; Davis, GA; Putukian, M; Leddy, J; Makdissi, M; Sullivan, SJ; Broglio, SP; Raftery, M; Schneider, K; Kissick, J; McCrea, M; Dvorak, J; Sills, AK; Aubry, M; Engebretsen, L; Loosemore, M; Fuller, G; Kutcher, J; Ellenbogen, R; Guskiewicz, K; Patricios, J; Herring, S				Echemendia, Ruben J.; Meeuwisse, Willem; McCrory, Paul; Davis, Gavin A.; Putukian, Margot; Leddy, John; Makdissi, Michael; Sullivan, S. John; Broglio, Steven P.; Raftery, Martin; Schneider, Kathryn; Kissick, James; McCrea, Michael; Dvorak, Jiri; Sills, Allen K.; Aubry, Mark; Engebretsen, Lars; Loosemore, Mike; Fuller, Gordon; Kutcher, Jeffrey; Ellenbogen, Richard; Guskiewicz, Kevin; Patricios, Jon; Herring, Stanley			The Concussion Recognition Tool 5th Edition (CRT5): Background and rationale	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; SPORT HELD; ZURICH	The Concussion Recognition Tool 5 (CRT5) is the most recent revision of the Pocket Sport Concussion Assessment Tool 2 that was initially introduced by the Concussion in Sport Group in 2005. The CRT5 is designed to assist non-medically trained individuals to recognise the signs and symptoms of possible sport-related concussion and provides guidance for removing an athlete from play/sport and to seek medical attention. This paper presents the development of the CRT5 and highlights the differences between the CRT5 and prior versions of the instrument.	[Echemendia, Ruben J.] Univ Orthoped Ctr, Dept Concuss Care Clin, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA; [Meeuwisse, Willem] Univ Calgary, Fac Kinesiol, Sports Injury Prevent Res Ctr, Calgary, AB, Canada; [McCrory, Paul] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Davis, Gavin A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Davis, Gavin A.; Makdissi, Michael] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Putukian, Margot] Princeton Univ, Dept Athlet Med, Princeton, NJ 08544 USA; [Leddy, John] Univ Buffalo, Concuss Management Clin, UBMD Orthopaed & Sports Med, Buffalo, NY USA; [Leddy, John] SUNY Buffalo, Dept Orthopaed, Buffalo, NY USA; [Sullivan, S. John] Univ Otago, Sch Physiotherapy, Dunedin, New Zealand; [Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA; [Raftery, Martin] World Rugby, Dublin, Ireland; [Schneider, Kathryn] Ctr Fac Kinesiol, Sport Injury Prevent Res, Calgary, AB, Canada; [Schneider, Kathryn] Alberta Childrens Hosp Res Inst Child & Maternal, Cumming Sch Med, Calgary, AB, Canada; [Schneider, Kathryn] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Kissick, James] Carleton Univ, Sport Med Clin, Ottawa, ON, Canada; [Kissick, James] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [Kissick, James] Int Paralymp Comm Med Comm, Ottawa, ON, Canada; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Dvorak, Jiri] Schulthess Clin, Neurol Dept, Zurich, Switzerland; [Sills, Allen K.] Vanderbilt Univ, Dept Neurosurg, Franklin, TN USA; [Aubry, Mark] Int Ice Hockey Federat, Zurich, Switzerland; [Engebretsen, Lars] Oslo Univ Hosp, Med & Sci Dept, Oslo, Norway; [Loosemore, Mike] Univ Coll Hosp, Inst Sport Exercise & Hlth, London, England; [Fuller, Gordon] Univ Sheffield, Ctr Urgent & Emergency Care Res, Sheffield, S Yorkshire, England; [Kutcher, Jeffrey] Sports Neurol Clin, Brighton, MI USA; [Ellenbogen, Richard] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Guskiewicz, Kevin] Univ N Carolina, Sports Med Res Lab, Chapel Hill, NC USA; [Patricios, Jon] Univ Pretoria, Fac Hlth Sci, Johannesburg, South Africa; [Patricios, Jon] Univ Witwatersrand, Dept Emergency Med, Johannesburg, South Africa; [Herring, Stanley] Dept Rehabil Med, Seattle, WA USA; [Herring, Stanley] Dept Orthopaed, Seattle, WA USA; [Herring, Stanley] Dept Sports Med & Neurol Surg, Seattle, WA USA	Echemendia, RJ (corresponding author), Univ Orthoped Ctr, Concuss Care Clin, 101 Regent Ct, State Coll, PA 16801 USA.	rechemendia@comcast.net	McCrory, Paul/Q-8688-2019; Echemendia, Ruben/R-6939-2019	Patricios, Jon/0000-0002-6829-4098; Fuller, Gordon Ward/0000-0001-8532-3500; Schneider, Kathryn/0000-0002-5951-5899; McCrory, Paul/0000-0003-4850-0568; Davis, Gavin/0000-0001-8293-4496	National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2015-04-005] Funding Source: researchfish		Davis GA, 2017, BRIT J SPORTS MED; Echemendia R, 2017, BRIT J SPORTS MED; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721	6	25	25	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2017	51	11					870	871		10.1136/bjsports-2017-097508			2	Sport Sciences	Sport Sciences	EW3QP	WOS:000402416500006	28446450	Green Accepted			2021-06-18	
J	Tigchelaar, S; Streijger, F; Sinha, S; Flibotte, S; Manouchehri, N; So, K; Shortt, K; Okon, E; Rizzuto, MA; Malenica, I; Courtright-Lim, A; Eisen, A; Van Keuren-Jensen, K; Nislow, C; Kwon, BK				Tigchelaar, Seth; Streijger, Femke; Sinha, Sunita; Flibotte, Stephane; Manouchehri, Neda; So, Kitty; Shortt, Katelyn; Okon, Elena; Rizzuto, Michael A.; Malenica, Ivana; Courtright-Lim, Amanda; Eisen, Andrew; Van Keuren-Jensen, Kendall; Nislow, Corey; Kwon, Brian K.			Serum MicroRNAs Reflect Injury Severity in a Large Animal Model of Thoracic Spinal Cord Injury	SCIENTIFIC REPORTS			English	Article							SYSTEMIC INFLAMMATORY RESPONSE; TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; STRUCTURAL BIOMARKERS; CIRCULATING MICRORNAS; BLOOD BIOMARKERS; CLINICAL-TRIALS; PORCINE MODEL; EXPRESSION; MIRNA	Therapeutic development for spinal cord injury is hindered by the difficulty in conducting clinical trials, which to date have relied solely on functional outcome measures for patient enrollment, stratification, and evaluation. Biological biomarkers that accurately classify injury severity and predict neurologic outcome would represent a paradigm shift in the way spinal cord injury clinical trials could be conducted. MicroRNAs have emerged as attractive biomarker candidates due to their stability in biological fluids, their phylogenetic similarities, and their tissue specificity. Here we characterized a porcine model of spinal cord injury using a combined behavioural, histological, and molecular approach. We performed next-generation sequencing on microRNAs in serum samples collected before injury and then at 1, 3, and 5 days post injury. We identified 58, 21, 9, and 7 altered miRNA after severe, moderate, and mild spinal cord injury, and SHAM surgery, respectively. These data were combined with behavioural and histological analysis. Overall miRNA expression at 1 and 3 days post injury strongly correlates with outcome measures at 12 weeks post injury. The data presented here indicate that serum miRNAs are promising candidates as biomarkers for the evaluation of injury severity for spinal cord injury or other forms of traumatic, acute, neurologic injury.	[Tigchelaar, Seth; Streijger, Femke; Manouchehri, Neda; So, Kitty; Shortt, Katelyn; Okon, Elena; Rizzuto, Michael A.; Kwon, Brian K.] Univ British Columbia, ICORD, Vancouver, BC, Canada; [Sinha, Sunita; Flibotte, Stephane; Nislow, Corey] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Malenica, Ivana; Courtright-Lim, Amanda; Van Keuren-Jensen, Kendall] Translat Genom, Phoenix, AZ USA; [Eisen, Andrew] Acorda Therapeut, Ardsley, NY USA; [Kwon, Brian K.] Univ British Columbia, Vancouver Spine Surg Inst, Dept Orthoped, Vancouver, BC, Canada	Kwon, BK (corresponding author), Univ British Columbia, ICORD, Vancouver, BC, Canada.; Kwon, BK (corresponding author), Univ British Columbia, Vancouver Spine Surg Inst, Dept Orthoped, Vancouver, BC, Canada.	brian.kwon@ubc.ca	Malenica, Ivana/J-2007-2019	Malenica, Ivana/0000-0002-7404-8088; Tigchelaar, Seth/0000-0002-2207-9034; Rizzuto, Michael/0000-0001-7743-4454; Okon, Elena/0000-0001-8568-5771	veterinarian staff and animal care technicians at the Centre for Comparative Medicine (CCM), UBC; Brain Canada Foundation; Rick Hansen Institute,; Acorda Therapeutics	The authors gratefully acknowledge the expertise and support of the veterinarian staff and animal care technicians at the Centre for Comparative Medicine (CCM), UBC. C.N. is the Canada Research Chair in Translational Genomics. B.K.K. is the Canada Research Chair in Spinal Cord Injury and Dvorak Chair in Spinal Trauma. The authors also acknowledge grant-funding support from the Brain Canada Foundation and the Rick Hansen Institute, and also a collaborative research agreement with Acorda Therapeutics to conduct this research.	Aanes H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089158; Andrews S, 2010, FASTQC QUALITY CONTR; [Anonymous], 2014, J Spinal Cord Med, V37, P243, DOI 10.1179/1079026814Z.000000000260; Bao F, 2012, J NEUROTRAUM, V29, P1626, DOI 10.1089/neu.2011.2190; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Beveridge NJ, 2008, HUM MOL GENET, V17, P1156, DOI 10.1093/hmg/ddn005; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Boon H, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12622; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Burgos K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094839; Burgos KL, 2013, RNA, V19, P712, DOI 10.1261/rna.036863.112; BYRNES JJ, 1975, BIOCHEMISTRY-US, V14, P796, DOI 10.1021/bi00675a023; De Biase A, 2005, PHYSIOL GENOMICS, V22, P368, DOI 10.1152/physiolgenomics.00081.2005; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dillies MA, 2013, BRIEF BIOINFORM, V14, P671, DOI 10.1093/bib/bbs046; Eguchi A, 2014, J HEPATOL, V60, P1063, DOI 10.1016/j.jhep.2013.12.026; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Gris D, 2008, EXP NEUROL, V211, P259, DOI 10.1016/j.expneurol.2008.01.033; Hachisuka S, 2014, SPINAL CORD, V52, P596, DOI 10.1038/sc.2014.86; Hu JR, 2013, J PHARMACOL SCI, V121, P343, DOI 10.1254/jphs.12235SC; Jee MK, 2012, BRAIN, V135, P1237, DOI 10.1093/brain/aws047; Jickling GC, 2011, NEUROTHERAPEUTICS, V8, P349, DOI 10.1007/s13311-011-0050-4; Jing L, 2015, SCI REP-UK, V5, DOI 10.1038/srep11953; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Kuhle J, 2015, J NEUROL NEUROSUR PS, V86, P273, DOI 10.1136/jnnp-2013-307454; Kwon B. K., 2016, J NEUROTRAUMA; Kwon BK, 2011, CLIN CHEM LAB MED, V49, P425, DOI 10.1515/CCLM.2011.068; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; Langmead Ben, 2010, Curr Protoc Bioinformatics, VChapter 11, DOI 10.1002/0471250953.bi1107s32; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Lee JHT, 2013, J NEUROTRAUM, V30, P142, DOI 10.1089/neu.2012.2386; Lee RS, 2012, J CLIN NEUROSCI, V19, P1338, DOI 10.1016/j.jocn.2012.02.015; Lehmann-Werman R, 2016, P NATL ACAD SCI USA, V113, pE1826, DOI 10.1073/pnas.1519286113; Li XQ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0246-3; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Ma YD, 2015, INT J CLIN EXP PATHO, V8, P1682; Marques JT, 2010, NAT STRUCT MOL BIOL, V17, P24, DOI 10.1038/nsmb.1735; Martin M, 2011, CUTADAPT REMOVES ADA, V17; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Nakanishi K, 2010, SPINAL CORD, V48, P192, DOI 10.1038/sc.2009.89; Nieto-Diaz M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00053; Ning B, 2014, INT J BIOL SCI, V10, P997, DOI 10.7150/ijbs.9058; Paczynska P, 2015, BMC GENET, V15, DOI 10.1186/s12863-015-0166-3; Pouw MH, 2014, SPINAL CORD, V52, P428, DOI 10.1038/sc.2014.26; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Streijger F, 2015, J NEUROTRAUM, V32, P908, DOI 10.1089/neu.2014.3707; Sun ZF, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-423; Theis T., 2016, MOL NEUROBIOL; van Rossum IA, 2010, J ALZHEIMERS DIS, V20, P881, DOI 10.3233/JAD-2010-091606; Wernersson R, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-70; Whiteley W, 2012, STROKE, V43, P86, DOI 10.1161/STROKEAHA.111.634089; Wohl SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep35423; Wu D, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00035; Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012; Yu YM, 2011, EUR J NEUROSCI, V33, P1587, DOI 10.1111/j.1460-9568.2011.07643.x; Yunta M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034534; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang LF, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000716	62	25	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAY 3	2017	7								1376	10.1038/s41598-017-01299-x			14	Multidisciplinary Sciences	Science & Technology - Other Topics	ET7PX	WOS:000400490600001	28469141	DOAJ Gold, Green Published			2021-06-18	
J	Diaz, MF; Vaidya, AB; Evans, SM; Lee, HJ; Aertker, BM; Alexander, AJ; Price, KM; Ozuna, JA; Liao, GP; Aroom, KR; Xue, HS; Gu, L; Omichi, R; Bedi, S; Olson, SD; Cox, CS; Wenzel, PL				Diaz, Miguel F.; Vaidya, Abishek B.; Evans, Siobahn M.; Lee, Hyun J.; Aertker, Benjamin M.; Alexander, Alexander J.; Price, Katherine M.; Ozuna, Joyce A.; Liao, George P.; Aroom, Kevin R.; Xue, Hasen; Gu, Liang; Omichi, Rui; Bedi, Supinder; Olson, Scott D.; Cox, Charles S.; Wenzel, Pamela L.			Biomechanical Forces Promote Immune Regulatory Function of Bone Marrow Mesenchymal Stromal Cells	STEM CELLS			English	Article						Biomechanical force; Mesenchymal stromal cells; Immunomodulation; Inflammation; Shear stress; Traumatic brain injury	FLUID SHEAR-STRESS; ACTIVATED MICROGLIAL/MACROPHAGE RESPONSE; TRAUMATIC BRAIN-INJURY; STEM-CELLS; HEME OXYGENASE-1; GENE-EXPRESSION; BLOOD-FLOW; INTERLEUKIN-10; INFLAMMATION; MACROPHAGES	Mesenchymal stromal cells (MSCs) are believed to mobilize from the bone marrow in response to inflammation and injury, yet the effects of egress into the vasculature on MSC function are largely unknown. Here we show that wall shear stress (WSS) typical of fluid frictional forces present on the vascular lumen stimulates antioxidant and anti-inflammatory mediators, as well as chemokines capable of immune cell recruitment. WSS specifically promotes signaling through NFB-COX2-prostaglandin E-2 (PGE(2)) to suppress tumor necrosis factor- (TNF-) production by activated immune cells. Ex vivo conditioning of MSCs by WSS improved therapeutic efficacy in a rat model of traumatic brain injury, as evidenced by decreased apoptotic and M1-type activated microglia in the hippocampus. These results demonstrate that force provides critical cues to MSCs residing at the vascular interface which influence immunomodulatory and paracrine activity, and suggest the potential therapeutic use of force for MSC functional enhancement. Stem Cells2017;35:1259-1272	[Diaz, Miguel F.; Vaidya, Abishek B.; Evans, Siobahn M.; Lee, Hyun J.; Aertker, Benjamin M.; Alexander, Alexander J.; Price, Katherine M.; Ozuna, Joyce A.; Liao, George P.; Aroom, Kevin R.; Xue, Hasen; Gu, Liang; Omichi, Rui; Bedi, Supinder; Olson, Scott D.; Cox, Charles S.; Wenzel, Pamela L.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Childrens Regenerat Med Program, Dept Pediat Surg, Houston, TX 77030 USA; [Diaz, Miguel F.; Vaidya, Abishek B.; Evans, Siobahn M.; Lee, Hyun J.; Alexander, Alexander J.; Price, Katherine M.; Ozuna, Joyce A.; Gu, Liang; Omichi, Rui; Cox, Charles S.; Wenzel, Pamela L.] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Ctr Stem Cell & Regenerat Med, Houston, TX 77030 USA; [Alexander, Alexander J.; Price, Katherine M.; Ozuna, Joyce A.] Rice Univ, Dept BioSci, Houston, TX USA; [Omichi, Rui] Tokushima Univ, Sch Med, Fac Med, Tokushima, Japan	Wenzel, PL (corresponding author), Univ Texas Hlth Sci Ctr Houston, Childrens Regenerat Med Program, Ctr Stem Cell & Regenerat Med, Dept Pediat Surg,McGovern Med Sch,Brown Fdn Inst, 1825 Pressler St,SRB 637A, Houston, TX 77030 USA.	pamela.l.wenzel@uth.tmc.edu	Vaidya, Abishek/AAR-4515-2021; Wenzel, Pamela/AAJ-1944-2021; Stefanadis, Christodoulos/ABH-2232-2020	Wenzel, Pamela/0000-0002-4530-015X; Alexander, Alexander/0000-0002-0590-6536; Vaidya, Abishek/0000-0001-8458-7950; Gu, Liang/0000-0001-6130-8752; Aroom, Kevin/0000-0003-1504-0585; Olson, Scott/0000-0001-8032-3755; Stefanadis, Christodoulos/0000-0001-5974-6454	State of Texas Emerging Technology Fund; American Society of Hematology Scholar Award; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01DK092365]; Mission Connect: a Program of the TIRR Foundation [014-121, 016-118]; Ruth L. Kirschstein National Research Service Award from the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T35DK007676]; Cancer Prevention and Research Institute of Texas [RP110776]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K01DK092365, T35DK007676] Funding Source: NIH RePORTER	We wish to thank Zhengmei Mao for imaging support and Naama Toledano Furman for flow cytometry. This work was supported by grants from the State of Texas Emerging Technology Fund, American Society of Hematology Scholar Award, National Institutes of Health K01DK092365, and Mission Connect: a Program of the TIRR Foundation (014-121, 016-118) to P.L.W. L.G. is the recipient of a Ruth L. Kirschstein National Research Service Award T35DK007676 from the National Institutes of Health. Flow cytometry instrumentation was supported in part through the Cancer Prevention and Research Institute of Texas (RP110776).	Achille V, 2011, J CELL BIOCHEM, V112, P1817, DOI 10.1002/jcb.23100; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536; Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028; Chabannes D, 2007, BLOOD, V110, P3691, DOI 10.1182/blood-2007-02-075481; Chamberlain G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025663; Cox CS, 2017, STEM CELLS, V35, P1065, DOI 10.1002/stem.2538; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cunningham KS, 2005, LAB INVEST, V85, P9, DOI 10.1038/labinvest.3700215; Dahlen E, 1998, J IMMUNOL, V160, P3585; DAVIES PF, 1986, P NATL ACAD SCI USA, V83, P2114, DOI 10.1073/pnas.83.7.2114; Davies PF, 1997, ANNU REV PHYSIOL, V59, P527, DOI 10.1146/annurev.physiol.59.1.527; Di Francesco L, 2009, CIRC RES, V104, P506, DOI 10.1161/CIRCRESAHA.108.191114; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; English K, 2013, IMMUNOL CELL BIOL, V91, P19, DOI 10.1038/icb.2012.56; Gimbrone MA, 2016, CIRC RES, V118, P620, DOI 10.1161/CIRCRESAHA.115.306301; Glossop JR, 2009, GENE EXPR PATTERNS, V9, P381, DOI 10.1016/j.gep.2009.01.001; Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003; Knippenberg M, 2005, TISSUE ENG, V11, P1780, DOI 10.1089/ten.2005.11.1780; Kreke MR, 2008, TISSUE ENG PT A, V14, P529, DOI 10.1089/tea.2007.0068; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee HJ, 2013, DIFFERENTIATION, V86, P92, DOI 10.1016/j.diff.2013.06.004; Li Nan, 2015, Methods Mol Biol, V1212, P183, DOI 10.1007/7651_2014_95; Liao GP, 2015, PEDIATR CRIT CARE ME, V16, P245, DOI 10.1097/PCC.0000000000000324; Liao GP, 2014, J SURG RES, V190, P628, DOI 10.1016/j.jss.2014.05.011; Lu H, 2004, ANAL CHEM, V76, P5257, DOI 10.1021/ac049837t; Mendez-Ferrer S, 2015, ANN NY ACAD SCI, V1335, P32, DOI 10.1111/nyas.12641; Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262; Moll G, 2015, STEM CELLS DEV, V24, P2269, DOI 10.1089/scd.2015.0120; Mougiakakos D, 2011, BLOOD, V117, P4826, DOI 10.1182/blood-2010-12-324038; Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Papaioannou Theodoros G, 2005, Hellenic J Cardiol, V46, P9; Prockop DJ, 2013, STEM CELLS, V31, P2042, DOI 10.1002/stem.1400; Rozenberg A, 2016, STEM CELL TRANSL MED, V5, P1506, DOI 10.5966/sctm.2015-0243; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Sheikh S, 2003, BLOOD, V102, P2828, DOI 10.1182/blood-2003-01-0080; Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004; Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997; Sun YY, 2012, J ELECTRON MATER, V41, P519, DOI 10.1007/s11664-011-1800-0; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Topper JN, 1999, MOL MED TODAY, V5, P40, DOI 10.1016/S1357-4310(98)01372-0; Valles G, 2015, BIOMATERIALS, V37, P124, DOI 10.1016/j.biomaterials.2014.10.028; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Wagner J, 2009, CURR OPIN BIOTECH, V20, P531, DOI 10.1016/j.copbio.2009.08.009; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Wan M, 2012, STEM CELLS, V30, P2498, DOI 10.1002/stem.1208; Winkler IG, 2010, BLOOD, V116, P375, DOI 10.1182/blood-2009-07-233437; Xia ZW, 2007, AM J PATHOL, V171, P1904, DOI 10.2353/ajpath.2007.070096; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001; Yang YH, 2016, STEM CELLS, V34, P2525, DOI 10.1002/stem.2405; Yuan L, 2013, STEM CELLS DEV, V22, P2384, DOI 10.1089/scd.2012.0717	54	25	27	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	MAY	2017	35	5					1259	1272		10.1002/stem.2587			14	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	ET1HC	WOS:000400017200013	28181347	Bronze, Green Accepted			2021-06-18	
J	May, M; Milders, M; Downey, B; Whyte, M; Higgins, V; Wojcik, Z; Amin, S; O'Rourke, S				May, Michelle; Milders, Maarten; Downey, Bruce; Whyte, Maggie; Higgins, Vanessa; Wojcik, Zuzana; Amin, Sophie; O'Rourke, Suzanne			Social Behavior and Impairments in Social Cognition Following Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain injury; Social behavior; Models of social cognition; Impairment; Cognitive function	CLOSED-HEAD-INJURY; EMOTION RECOGNITION; NEUROPSYCHOLOGY BEHAVIOR; EXECUTIVE DYSFUNCTION; DYSEXECUTIVE SYNDROME; FUNCTIONAL OUTCOMES; PREFRONTAL LESIONS; FACIAL EXPRESSION; SELF-AWARENESS; MIND	Objectives: The negative effect of changes in social behavior following traumatic brain injury (TBI) are known, but much less is known about the neuropsychological impairments that may underlie and predict these changes. The current study investigated possible associations between post-injury behavior and neuropsychological competencies of emotion recognition, understanding intentions, and response selection, that have been proposed as important for social functioning. Methods: Forty participants with TBI and 32 matched healthy participants completed a battery of tests assessing the three functions of interest. In addition, self- and proxy reports of pre- and post-injury behavior, mood, and community integration were collected. Results: The TBI group performed significantly poorer than the comparison group on all tasks of emotion recognition, understanding intention, and on one task of response selection. Ratings of current behavior suggested significant changes in the TBI group relative to before the injury and showed significantly poorer community integration and interpersonal behavior than the comparison group. Of the three functions considered, emotion recognition was associated with both post-injury behavior and community integration and this association could not be fully explained by injury severity, time since injury, or education. Conclusions: The current study confirmed earlier findings of associations between emotion recognition and post-TBI behavior, providing partial evidence for models proposing emotion recognition as one of the pre- requisites for adequate social functioning.	[May, Michelle] Murdostoun Brain Injury Rehabil & Neurol Care Ctr, Murdostoun, Wishaw, Scotland; [Milders, Maarten] Vrije Univ Amsterdam, Amsterdam, Netherlands; [Downey, Bruce; Whyte, Maggie; Wojcik, Zuzana] Natl Hlth Serv Grampian, Aberdeen, Scotland; [Higgins, Vanessa] Univ Aberdeen, Aberdeen, Scotland; [Amin, Sophie] Momentum Skills, Aberdeen, Scotland; [O'Rourke, Suzanne] Univ Edinburgh, Edinburgh, Midlothian, Scotland	Milders, M (corresponding author), Vrije Univ Amsterdam, Dept Clin Neuropsychol, Van der Boechorststr 1, NL-1081 BT Amsterdam, Netherlands.	m.v.milders@vu.nl		O'Rourke, Suzanne/0000-0003-4027-675X			Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Anderson-Parente JK, 1990, COGNITIVE REHABILITA, P22; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Ben-David BM, 2011, J INT NEUROPSYCH SOC, V17, P354, DOI 10.1017/S135561771000175X; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Benton A. L., 1994, CONTRIBUTIONS NEUROP; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bivona U, 2014, J HEAD TRAUMA REHAB, V29, P157, DOI 10.1097/HTR.0b013e3182864f0b; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Cannon BJ, 2000, ARCH CLIN NEUROPSYCH, V15, P327; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Chaytor N, 2007, BRAIN INJURY, V21, P615, DOI 10.1080/02699050701426949; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; Corrigan PW, 1997, PSYCHIATRY, V60, P309, DOI 10.1080/00332747.1997.11024809; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Ekman P., 1976, PICTURES FACIAL AFFE; Eslinger PJ, 2011, J NEUROPSYCH CLIN N, V23, P74, DOI 10.1176/appi.neuropsych.23.1.74; Geraci A, 2010, BRAIN INJURY, V24, P978, DOI 10.3109/02699052.2010.487477; Golan O, 2006, J AUTISM DEV DISORD, V36, P169, DOI 10.1007/s10803-005-0057-y; Golden C., 1978, STROOP COLOUR WORD T; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Gregory C, 2002, BRAIN, V125, P752, DOI 10.1093/brain/awf079; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hannay HJ, 2004, NEUROPSYCHOLOGICAL A, P160; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Henry JD, 2015, CURR OPIN PSYCHIATR, V28, P133, DOI 10.1097/YCO.0000000000000139; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Katsifaraki M, 2014, BRAIN INJURY, V28, P1389, DOI 10.3109/02699052.2014.919538; Kelley E, 2014, J HEAD TRAUMA REHAB, V29, P147, DOI 10.1097/HTR.0b013e31826db6b9; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kosty JA, 2013, NEUROL RES, V35, P277, DOI 10.1179/1743132813Y.0000000168; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Mah LWY, 2005, J NEUROPSYCH CLIN N, V17, P66, DOI 10.1176/appi.neuropsych.17.1.66; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McDonald S, 2016, APHASIOLOGY, V30, P801, DOI 10.1080/02687038.2015.1070948; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; McLellan T, 2013, BRAIN INJURY, V27, P1032, DOI 10.3109/02699052.2013.794965; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Nelson LD, 1998, ARCH CLIN NEUROPSYCH, V13, P549, DOI 10.1016/S0887-6177(97)00052-8; Neumann D, 2015, J HEAD TRAUMA REHAB, V30, pE12, DOI 10.1097/HTR.0000000000000054; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; O'Sullivan M., 1976, 4 FACTOR TEST SOCIAL; Ochsner KN, 2008, BIOL PSYCHIAT, V64, P48, DOI 10.1016/j.biopsych.2008.04.024; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Osborne-Crowley K, 2016, NEUROPSYCHOLOGY, V30, P820, DOI 10.1037/neu0000293; Osborne-Crowley K, 2016, J INT NEUROPSYCH SOC, V22, P303, DOI 10.1017/S1355617715001277; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Salter K, 2008, BRAIN INJURY, V22, P820, DOI 10.1080/02699050802425428; Shany-Ur T, 2011, CURR OPIN NEUROL, V24, P550, DOI 10.1097/WCO.0b013e32834cd42a; Spikman JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065581; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P4, DOI 10.1097/HTR.0b013e3182048e98; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Ubukata S, 2014, NEUROPSYCH DIS TREAT, V10, P2061, DOI 10.2147/NDT.S68156; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Vollm BA, 2006, NEUROIMAGE, V29, P90, DOI 10.1016/j.neuroimage.2005.07.022; Wechsler D., 1998, MANUAL WECHSLER ADUL; Wessa M, 2007, AM J PSYCHIAT, V164, P638, DOI 10.1176/appi.ajp.164.4.638; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Williams C, 2013, J HEAD TRAUMA REHAB, V28, pE21, DOI 10.1097/HTR.0b013e318267b0ab; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P113, DOI 10.1080/13803390902806543; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood RL, 2001, BRAIN DAM B, P3; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	84	25	25	0	16	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2017	23	5					400	411		10.1017/S1355617717000182			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	EU4BD	WOS:000400973900003	28399953				2021-06-18	
J	Velosky, AG; Tucker, LB; Fu, AH; Liu, J; McCabe, JT				Velosky, Alexander G.; Tucker, Laura B.; Fu, Amanda H.; Liu, Jiong; McCabe, Joseph T.			Cognitive performance of male and female C57BL/6J mice after repetitive concussive brain injuries	BEHAVIOURAL BRAIN RESEARCH			English	Article						Sex differences; Traumatic brain injury; Learning and memory; Cognition; Behavior	CHRONIC TRAUMATIC ENCEPHALOPATHY; MOUSE MODEL; SEX-DIFFERENCES; HEAD-INJURY; NEUROBEHAVIORAL CHANGES; STEROID-HORMONES; CORPUS-CALLOSUM; WHITE-MATTER; HIGH-SCHOOL; GENDER	In contact sports, repetitive concussive brain injury (rCBI) is the prevalent form of head injury seen in athletes. The need for effective treatment is urgent as rCBI has been associated with a host of cognitive, behavioral and neurological complaints. There has been a growing trend in the use of female animals in pre-clinical research, but few studies have investigated possible sex differences following rCBI. The goal of the current study was to determine any differences between male and female C57BL/6J mice on assessments of learning and memory after repetitive concussive injury. Following rCBI by impact to the scalp, male mice exhibited longer righting reflexes during acute recovery. In both sexes, there were no evident histopathological changes observed in the underlying cerebral cortex or hippocampus. Reactive astrogliosis was elevated in the corpus callosum and optic tract, and astrogliosis was slightly less in the optic tract of female mice. rCBI mice exhibited impairment during the learning phase of the Morris water maze (MWM), but female mice, in comparison to male mice, were observed to have superior spatial memory during standard MWM probe trials. Female mice were overall more active, evidenced by greater distances traveled in the y-maze and greater swim speeds in the MWM. The results of this study demonstrate sex differences in cognitive performance following rCBI and support previous research suggesting the neuroprotective role of sex in brain injury. Published by Elsevier B.V.	[Velosky, Alexander G.; Tucker, Laura B.; Fu, Amanda H.; Liu, Jiong; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, FE Hebert Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Tucker, Laura B.; Fu, Amanda H.; McCabe, Joseph T.] Ctr Neurosci & Regenerat Med, Preclin Studies Core, Bethesda, MD USA	McCabe, JT (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, FE Hebert Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Joseph.McCabe@usuhs.edu	McCabe, Joseph/J-6293-2014	McCabe, Joseph/0000-0002-1159-7442; Tucker, Laura/0000-0002-5984-6399	The Center for Neuroscience and Regenerative Medicine [60855-300600-7.01]	This work was supported by The Center for Neuroscience and Regenerative Medicine, 60855-300600-7.01.	Acaz-Fonseca E, 2016, PROG NEUROBIOL, V144, P5, DOI 10.1016/j.pneurobio.2016.06.002; Alstott J, 2009, BEHAV BRAIN RES, V196, P214, DOI 10.1016/j.bbr.2008.09.001; Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Briggs DI, 2016, AM J PATHOL, V186, P2869, DOI 10.1016/j.ajpath.2016.07.013; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Chakrabarti M, 2016, REV NEUROSCIENCE, V27, P271, DOI 10.1515/revneuro-2015-0032; Collins TJ, 2007, BIOTECHNIQUES, V43, P25; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Demarest TG, 2015, J BIOENERG BIOMEMBR, V47, P173, DOI 10.1007/s10863-014-9583-7; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Franklin KB, 2008, MOUSE BRAIN STEREOTA; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Gilmer LK, 2008, J NEUROTRAUM, V25, P593, DOI 10.1089/neu.2007.0477; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hall ANB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159442; Hylin MJ, 2013, J NEUROTRAUM, V30, P716, DOI 10.1089/neu.2012.2717; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McCullough LD, 2014, BIOL SEX DIFFER, V5, DOI 10.1186/s13293-014-0015-5; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Morgan MA, 2002, BEHAV BRAIN RES, V132, P85, DOI 10.1016/S0166-4328(01)00398-9; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Ngun TC, 2011, FRONT NEUROENDOCRIN, V32, P227, DOI 10.1016/j.yfrne.2010.10.001; Nichols JN, 2016, BEHAV BRAIN RES, V298, P111, DOI 10.1016/j.bbr.2015.10.052; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; O'Leary TP, 2013, BEHAV GENET, V43, P34, DOI 10.1007/s10519-012-9572-8; Ogawa S, 2003, ENDOCRINOLOGY, V144, P230, DOI 10.1210/en.2002-220519; Ratnu VS, 2017, J NEUROSCI RES, V95, P301, DOI 10.1002/jnr.23886; Reyes-Haro D, 2013, BIOL RES, V46, P27, DOI 10.4067/S0716-97602013000100004; Safinia Cyrus, 2016, J Vasc Interv Neurol, V9, P34; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Soltani Z, 2016, J PHYSIOL BIOCHEM, V72, P33, DOI 10.1007/s13105-015-0453-5; Sorge RE, 2014, NAT METHODS, V11, P629, DOI [10.1038/NMETH.2935, 10.1038/nmeth.2935]; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Van Swearingen AED, 2013, PSYCHOPHARMACOLOGY, V225, P707, DOI 10.1007/s00213-012-2860-4; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178; Zhou J, 2013, P NATL ACAD SCI USA, V110, pE2714, DOI 10.1073/pnas.1310233110	56	25	25	0	29	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAY 1	2017	324						115	124		10.1016/j.bbr.2017.02.017			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	EP9JY	WOS:000397691100015	28214540	Green Published, Other Gold			2021-06-18	
J	Xu, SX; Zhong, AQ; Ma, HN; Li, D; Hu, Y; Xu, YZ; Zhang, JP				Xu, Shixin; Zhong, Aiqin; Ma, Huining; Li, Dan; Hu, Yue; Xu, Yingzhi; Zhang, Junping			Neuroprotective effect of salvianolic acid B against cerebral ischemic injury in rats via the CD40/NF-kappa B pathway associated with suppression of platelets activation and neuroinflammation	BRAIN RESEARCH			English	Article						Cerebral ischemia/reperfusion injury; Platelets activation; Inflammation; Salvianolic acid B	NF-KAPPA-B; INFLAMMATORY GENE-EXPRESSION; TRAUMATIC BRAIN-INJURY; ARTERY OCCLUSION; MICROCIRCULATORY DISTURBANCE; ANTIPLATELET THERAPY; REPERFUSION INJURY; STROKE; ADHESION; INFARCT	Neuroinflammation plays a critical role in the pathogenesis of ischemia/reperfusion (I/R) injury. Activated platelets are increasingly regarded as initiators and/or amplifiers of inflammatory processes in cerebral I/R injury. Salvianolic acid B (SAB) is the most abundant bioactive compound of Salviae miltiorrhizae, a well-known Chinese herb used to promote blood circulation and eliminating blood stasis. S. miltiorrhizae has been used clinically in Asia for the treatment of ischemic cerebrovascular diseases. In the present study, a rat model of transient middle cerebral artery occlusion (tMCAO) was established to investigate the neuroprotective effects and mechanisms of SAB treatment against focal cerebral I/R insult. The results showed that SAB treatment (3 mg/kg, 6 mg/kg and 12 mg/kg, i.p.) dose-dependently decreased I/R-induced neurological deficits at 24, 48, and 72 h after reperfusion and decreased plasma-soluble P-selectin and soluble CD40 ligand as early as 6 h after onset of I/12 insult. At 24 h after reperfusion, SAB treatment significantly reduced neuronal and DNA damage in the hippocampal CA1 region and decreased neural cell loss in the ischemic core. The I/R-induced pro-inflammatory mediator mRNA and protein overexpression in the penumbra cortex, including ICAM-1, IL-1 beta, IL-6, IL-8, and MCP-1, were significantly inhibited by SAB in a dose-dependent manner. Further studies suggested SAB treatment attenuated CD40 expression and NF-kappa B activation, which involved NF-kappa B/p65 phosphorylation and h kappa B alpha phosphorylation and degradation. In conclusion, our findings indicated that the neuroprotective effects of SAB post cerebral I/R injury are associated with the inhibition of both platelets activation and production of pro-inflammatory mediators and the downregulation of the CD40/NF-kappa B pathway. (C) 2017 Elsevier B.V. All rights reserved.	[Xu, Shixin; Li, Dan] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Med Expt Ctr, 314 An Shan Xi Rd, Tianjin 300193, Peoples R China; [Zhong, Aiqin; Xu, Yingzhi; Zhang, Junping] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Geriatr, 314 An Shan Xi Rd, Tianjin 300193, Peoples R China; [Ma, Huining; Hu, Yue] Tianjin Univ Tradit Chinese Med, 312 An Shan Xi Rd, Tianjin 300193, Peoples R China	Xu, SX (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Med Expt Ctr, 314 An Shan Xi Rd, Tianjin 300193, Peoples R China.; Zhang, JP (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Geriatr, 314 An Shan Xi Rd, Tianjin 300193, Peoples R China.	shixinxu1973@outlook.com; tjzhtcm@163.com		Xu, Shixin/0000-0003-2270-2911	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81373850]; Tianjin Natural Science FoundationNatural Science Foundation of Tianjin [13JCZDJC31500]	This work was supported by the National Natural Science Foundation of China (No. 81373850) and Tianjin Natural Science Foundation (No. 13JCZDJC31500).	Adams HP, 2008, STROKE, V39, P87, DOI 10.1161/STROKEAHA.106.476648; Andre P, 2002, CIRCULATION, V106, P896, DOI 10.1161/01.CIR.0000028962.04520.01; Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Berger C, 2004, BRAIN RES, V998, P237, DOI 10.1016/j.brainres.2003.11.049; Berti R, 2002, J CEREBR BLOOD F MET, V22, P1068, DOI 10.1097/00004647-200209000-00004; Chen KQ, 2006, CELL MOL IMMUNOL, V3, P163; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Chen YH, 2000, ACTA PHARMACOL SIN, V21, P463; Cheng TO, 2007, INT J CARDIOL, V121, P9, DOI 10.1016/j.ijcard.2007.01.004; Davidson DC, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-144; De Meyer Simon F, 2011, Exp Transl Stroke Med, V3, P9, DOI 10.1186/2040-7378-3-9; del Zoppo GJ, 1998, NEUROLOGY, V51, pS9, DOI 10.1212/WNL.51.3_Suppl_3.S9; Garcia-Bonilla L, 2011, BRAIN RES, V1373, P211, DOI 10.1016/j.brainres.2010.12.005; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Han JY, 2008, PHARMACOL THERAPEUT, V117, P280, DOI 10.1016/j.pharmthera.2007.09.008; Harari OA, 2010, ANN NY ACAD SCI, V1207, P32, DOI 10.1111/j.1749-6632.2010.05735.x; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hong KS, 2014, J CLIN NEUROL, V10, P189, DOI 10.3988/jcn.2014.10.3.189; Hu P, 2005, CHEM PHARM BULL, V53, P677, DOI 10.1248/cpb.53.677; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Ishikawa M, 2005, CIRCULATION, V111, P1690, DOI 10.1161/01.CIR.0000160349.42665.0C; Ishikawa M, 2004, J CEREBR BLOOD F MET, V24, P907, DOI 10.1097/01.WCB.0000132690.96836.7F; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Ji XY, 2000, ACTA PHARMACOL SIN, V21, P1089; Jiang Y.F., 2014, CHIN J INTEGR MED; Jin R, 2013, J CARDIOVASC TRANSL, V6, P834, DOI 10.1007/s12265-013-9508-6; Kim DY, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-25; Kitagawa K, 1998, J CEREBR BLOOD F MET, V18, P1336, DOI 10.1097/00004647-199812000-00008; Kleinig TJ, 2009, CURR OPIN NEUROL, V22, P294, DOI 10.1097/WCO.0b013e32832b4db3; Kleinschnitz C, 2007, CIRCULATION, V115, P2323, DOI 10.1161/CIRCULATIONAHA.107.691279; Lee JH, 2007, BRAIN RES, V1152, P182, DOI 10.1016/j.brainres.2007.03.035; Lindsberg PJ, 1996, CIRCULATION, V94, P939, DOI 10.1161/01.CIR.94.5.939; Liu L., 2014, THROMB RES; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Ma C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014692; Matsumoto T, 1997, LAB INVEST, V77, P119; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Nagai N, 2015, INT J MOL SCI, V16, P29329, DOI 10.3390/ijms161226166; Nagy B, 2012, CURR MED CHEM, V19, P518, DOI 10.2174/092986712798918770; Nieswandt B, 2011, J THROMB HAEMOST, V9, P92, DOI 10.1111/j.1538-7836.2011.04361.x; Nieswandt B, 2011, J PHYSIOL-LONDON, V589, P4115, DOI 10.1113/jphysiol.2011.212886; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Ramirez SH, 2010, J NEUROSCI, V30, P9454, DOI 10.1523/JNEUROSCI.5796-09.2010; Ruehl ML, 2002, NEUROL RES, V24, P226, DOI 10.1179/016164102101199738; Sandercock PAG, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000029.pub3; Schneider A, 1999, NAT MED, V5, P554; Schwaninger M, 2006, BIOCHEM SOC T, V34, P1291, DOI 10.1042/BST0341291; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Steinhubl SR, 2007, HEMATOL ONCOL CLIN N, V21, P115, DOI 10.1016/j.hoc.2006.11.015; Steinhubl SR, 2007, VASC MED, V12, P113, DOI 10.1177/1358863X07077462; Stoll G, 2008, BLOOD, V112, P3555, DOI 10.1182/blood-2008-04-144758; Stoll G, 2010, ANN NY ACAD SCI, V1207, P149, DOI 10.1111/j.1749-6632.2010.05730.x; Tang MK, 2006, BEHAV PHARMACOL, V17, P493, DOI 10.1097/00008877-200609000-00015; Tian JW, 2009, BRAIN RES, V1263, P114, DOI 10.1016/j.brainres.2009.01.034; Tomizawa A, 2015, THROMB RES, V136, P1224, DOI 10.1016/j.thromres.2015.09.013; Tuttolomondo A, 2010, ATHEROSCLEROSIS, V208, P290, DOI 10.1016/j.atherosclerosis.2009.07.032; Vemuganti R, 2004, STROKE, V35, P179, DOI 10.1161/01.STR.0000106479.53235.3E; Wang Y, 2010, CHINESE MED J-PEKING, V123, P3612, DOI 10.3760/cma.j.issn.0366-6999.2010.24.020; Whitehead SN, 2007, STROKE, V38, P381, DOI 10.1161/01.STR.0000254464.05561.72; Williams AJ, 2006, NEUROCHEM INT, V49, P106, DOI 10.1016/j.neuint.2006.03.018; Wu B, 2007, STROKE, V38, P1973, DOI 10.1161/STROKEAHA.106.473165; Wu YP, 2008, THROMB RES, V123, P298, DOI 10.1016/j.thromres.2008.05.020; Xu SX, 2015, THROMB RES, V135, P137, DOI 10.1016/j.thromres.2014.10.034; Yang LJ, 2015, THROMB RES, V136, P1310, DOI 10.1016/j.thromres.2015.10.039; Zhang JX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102506; Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630; Zhu HB, 2013, EUR J PHARMACOL, V714, P23, DOI 10.1016/j.ejphar.2013.05.043	70	25	31	1	27	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 15	2017	1661						37	48		10.1016/j.brainres.2017.02.011			12	Neurosciences	Neurosciences & Neurology	ER2TP	WOS:000398647000004	28214521				2021-06-18	
J	Guida, F; Boccella, S; Iannotta, M; De Gregorio, D; Giordano, C; Belardo, C; Romano, R; Palazzo, E; Scafuro, MA; Serra, N; de Novellis, V; Rossi, F; Maione, S; Luongo, L				Guida, Francesca; Boccella, Serena; Iannotta, Monica; De Gregorio, Danilo; Giordano, Catia; Belardo, Carmela; Romano, Rosaria; Palazzo, Enza; Scafuro, Maria A.; Serra, Nicola; de Novellis, Vito; Rossi, Francesco; Maione, Sabatino; Luongo, Livio			Palmitoylethanolamide Reduces Neuropsychiatric Behaviors by Restoring Cortical Electrophysiological Activity in a Mouse Model of Mild Traumatic Brain Injury	FRONTIERS IN PHARMACOLOGY			English	Article						traumatic brain injury; Palmitoylethanolamide; medial prefrontal cortex; mice depression; aggressive; behavior; in vivo electrophysiology	MEDIAL PREFRONTAL CORTEX; LONG-TERM POTENTIATION; NEURONS; AMYGDALA; PAIN; INFLAMMATION; INTERLEUKIN-1-BETA; INTERNEURONS; HIPPOCAMPAL; PLASTICITY	Traumatic brain injury (TBI) represents a major public health problem, which is associated with neurological dysfunction. In severe or moderate cases of TBI, in addition to its high mortality rate, subjects may encounter diverse behavioral dysfunctions. Previous reports suggest that an association between TBI and chronic pain syndromes tends to be more common in patients with mild forms of brain injury. Despite causing minimal brain damage, mild TBI (mTBI) often leads to persistent psychologically debilitating symptoms, which can include anxiety, various forms of memory and learning deficits, and depression. At present, no effective treatment options are available for these symptoms, and little is known about the complex cellular activity affecting neuronal activity that occurs in response to TBI during its late phase. Here, we used a mouse model to investigate the effect of Palmitoylethanolamide (PEA) on both the sensorial and neuropsychiatric dysfunctions associated with mTBI through behavioral, electrophysiological, and biomolecular approaches. Fourteen-day mTBI mice developed anxious, aggressive, and reckless behavior, whilst depressive-like behavior and impaired social interactions were observed from the 60th day onward. Altered behavior was associated with changes in interleukin 1 beta (IL-1 beta) expression levels and neuronal firing activity in the medial prefrontal cortex. Compared with vehicle, PEA restored the behavioral phenotype and partially normalized the biochemical and functional changes occurring at the supraspinal level. In conclusion, our findings reveal some of the supraspinal modifications responsible for the behavioral alterations associated with mTBI and suggest PEA as a pharmacological tool to ameliorate neurological dysfunction induced by the trauma.	[Guida, Francesca; Boccella, Serena; Iannotta, Monica; De Gregorio, Danilo; Giordano, Catia; Belardo, Carmela; Romano, Rosaria; Palazzo, Enza; de Novellis, Vito; Rossi, Francesco; Maione, Sabatino; Luongo, Livio] Univ Campania Luigi Vanvitelli Ex SUN, Dept Expt Med, Sect Pharmacol L Donatelli, Naples, Italy; [Guida, Francesca; Maione, Sabatino; Luongo, Livio] CNR, Inst Biomol Chem, Endocannabinoid Res Grp, Pozzuoli, Italy; [Scafuro, Maria A.] Univ Campania Luigi Vanvitelli Ex SUN, Dept Anesthesiol Surg & Emergency, Naples, Italy; [Serra, Nicola] Univ Campania Luigi Vanvitelli Ex SUN, Dept Radiol, Naples, Italy; [Luongo, Livio] Young Pain YAP Italian Grp, Naples, Italy	Maione, S; Luongo, L (corresponding author), Univ Campania Luigi Vanvitelli Ex SUN, Dept Expt Med, Sect Pharmacol L Donatelli, Naples, Italy.; Maione, S; Luongo, L (corresponding author), CNR, Inst Biomol Chem, Endocannabinoid Res Grp, Pozzuoli, Italy.; Luongo, L (corresponding author), Young Pain YAP Italian Grp, Naples, Italy.	sabatino.maione@unina2.it; livio.luongo@gmail.com		DE GREGORIO, DANILO/0000-0002-8623-0661; Maione, Sabatino/0000-0003-3850-6704; Serra, Nicola/0000-0001-8086-6362	fund "Ricerca di Ateneo"	This study is supported by the fund "Ricerca di Ateneo" 2014 of LL.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Ahmad A, 2012, BRAIN BEHAV IMMUN, V26, P1310, DOI 10.1016/j.bbi.2012.07.021; Apps R, 2015, NAT REV NEUROSCI, V16, P642, DOI 10.1038/nrn4028; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Arciniegas DB, 2011, INT J PSYCHOPHYSIOL, V82, P41, DOI 10.1016/j.ijpsycho.2011.03.004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byom L, 2017, INT J LANG COMM DIS, V52, P501, DOI 10.1111/1460-6984.12289; Constantinidis C, 2002, J NEUROPHYSIOL, V88, P3487, DOI 10.1152/jn.00188.2002; Cordaro M, 2016, MOL PHARMACOL, V90, P549, DOI 10.1124/mol.116.105668; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Cuzzocrea S, 2012, FASEB J, V26; D'Agostino G, 2015, MOL METAB, V4, P528, DOI 10.1016/j.molmet.2015.04.005; del Rey A, 2013, BRAIN BEHAV IMMUN, V33, P15, DOI 10.1016/j.bbi.2013.05.011; FAGNI L, 1987, EXP BRAIN RES, V65, P513; Feliciano DP, 2014, NEUROSCI LETT, V583, P55, DOI 10.1016/j.neulet.2014.09.030; Floresco SB, 2007, J NEUROSCI, V27, P2045, DOI 10.1523/JNEUROSCI.5474-06.2007; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gabbott PLA, 2006, NEUROSCIENCE, V139, P1039, DOI 10.1016/j.neuroscience.2006.01.026; Gao X, 2016, SCI REP-UK, V6, DOI 10.1038/srep22490; Giordano C, 2012, CEREB CORTEX, V22, P2495, DOI 10.1093/cercor/bhr328; Guida F, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0139-5; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Ishikawa A, 2003, J NEUROSCI, V23, P9987; Jung MW, 1998, CEREB CORTEX, V8, P437, DOI 10.1093/cercor/8.5.437; Kelso ML, 2014, CURR PHARM DESIGN, V20, P4284; Lampa J, 2012, P NATL ACAD SCI USA, V109, P12728, DOI 10.1073/pnas.1118748109; Laviolette SR, 2006, J NEUROSCI, V26, P6458, DOI 10.1523/JNEUROSCI.0707-06.2006; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; LoVerme J, 2005, LIFE SCI, V77, P1685, DOI 10.1016/j.lfs.2005.05.012; Luongo L, 2013, CNS NEUROL DISORD-DR, V12, P45, DOI 10.2174/1871527311312010009; Luongo L, 2013, NEUROPHARMACOLOGY, V66, P317, DOI 10.1016/j.neuropharm.2012.05.047; Mann Aniv, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P209, DOI 10.1515/jbcpp-2015-0092; Mannelli LD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128080; Martinez-Vargas M, 2013, INT J MOL SCI, V14, P23341, DOI 10.3390/ijms141223341; Mayeux J, 2017, J NEUROTRAUM, V34, P436, DOI 10.1089/neu.2016.4452; Mori F, 2014, NEUROMOL MED, V16, P38, DOI 10.1007/s12017-013-8249-7; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nistico R, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0162; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; PEREZJARANAY JM, 1991, BRAIN RES, V564, P97, DOI 10.1016/0006-8993(91)91357-7; Rowe RK, 2016, MOL PAIN, V12, DOI 10.1177/1744806916647055; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Shultz SR, 2017, NEUROSCI BIOBEHAV R, V76, P396, DOI 10.1016/j.neubiorev.2016.09.014; Simone Donald A., 2008, Shengli Xuebao, V60, P635; Skaper SD, 2013, MOL NEUROBIOL, V48, P340, DOI 10.1007/s12035-013-8487-6; Solorzano C, 2009, P NATL ACAD SCI USA, V106, P20966, DOI 10.1073/pnas.0907417106; Tierney PL, 2004, EUR J NEUROSCI, V20, P514, DOI 10.1111/j.1460-9568.2004.03501.x; Tong LQ, 2012, J NEUROSCI, V32, P17714, DOI 10.1523/JNEUROSCI.1253-12.2012; Vialou V, 2014, J NEUROSCI, V34, P3878, DOI 10.1523/JNEUROSCI.1787-13.2014; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	54	25	26	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	MAR 6	2017	8								95	10.3389/fphar.2017.00095			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EM5ZU	WOS:000395393400001	28321191	DOAJ Gold, Green Published			2021-06-18	
J	Takizawa, T; Shibata, M; Kayama, Y; Shimizu, T; Toriumi, H; Ebine, T; Unekawa, M; Koh, A; Yoshimura, A; Suzuki, N				Takizawa, Tsubasa; Shibata, Mamoru; Kayama, Yohei; Shimizu, Toshihiko; Toriumi, Haruki; Ebine, Taeko; Unekawa, Miyuki; Koh, Anri; Yoshimura, Akihiko; Suzuki, Norihiro			High-mobility group box I is an important mediator of microglial activation induced by cortical spreading depression	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cortical spreading depression; microglia; high-mobility group box I; Toll-like receptors; cathepsin D	PROLONGED MIGRAINE AURA; TRAUMATIC BRAIN-INJURY; RECEPTOR 4; NEUROVASCULAR CHANGES; DEPOLARIZATIONS; HMGB1; APOPTOSIS; ISCHEMIA; LOCALIZATION; HEMORRHAGE	Single episodes of cortical spreading depression (CSD) are believed to cause typical migraine aura, whereas clusters of spreading depolarizations have been observed in cerebral ischemia and subarachnoid hemorrhage. We recently demonstrated that the release of high-mobility group box I (HMGBI) from cortical neurons after CSD in a rodent model is dependent on the number of CSD episodes, such that only multiple CSD episodes can induce significant HMGBI release. Here, we report that only multiple CSD inductions caused microglial hypertrophy (activation) accompanied by a greater impact on the transcription activity of the HMGBI receptor genes, TLR2 and TLR4, while the total number of cortical microglia was not affected. Both an HMGBI-neurtalizing antibody and the HMGBI inhibitor glycyrrhizin abrogated multiple CSD-induced microglial hypertrophy. Moreover, multiple CSD inductions failed to induce microglial hypertrophy in TLR2/4 double knockout mice. These results strongly implicate the HMGBI-TLR2/4 axis in the activation of microglia following multiple CSD inductions. Increased expression of the lysosomal acid hydrolase cathepsin D was detected in activated microglia by immunostaining, suggesting that lysosomal phagocytic activity may be enhanced in multiple CSD-activated microglia.	[Takizawa, Tsubasa; Shibata, Mamoru; Kayama, Yohei; Shimizu, Toshihiko; Toriumi, Haruki; Ebine, Taeko; Unekawa, Miyuki; Koh, Anri; Suzuki, Norihiro] Keio Univ, Sch Med, Dept Neurol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan; [Yoshimura, Akihiko] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo, Japan	Shibata, M (corresponding author), Keio Univ, Sch Med, Dept Neurol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	mshibata@a7.keio.jp	Yoshimura, Akihiko/K-5515-2013; Suzuki, Norihiro/J-5125-2013; Shibata, Mamoru/L-8537-2013; Shimizu, Toshihiko/M-4870-2013; Unekawa, Miyuki/M-2415-2013	Suzuki, Norihiro/0000-0002-0399-6590; Shibata, Mamoru/0000-0002-2416-4259; Takizawa, Tsubasa/0000-0003-2605-7200	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26460706, 22390132]; Takeda Science FoundationTakeda Science Foundation (TSF); Pfizer Inc.Pfizer [WS1878886]; Keio University Doctorate Student	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by JSPS KAKENHI (grant numbers 26460706 to MS and 22390132 to NS), a grant from the Takeda Science Foundation to MS, a research grant from Pfizer Inc. to NS (WS1878886), and Keio University Doctorate Student Grant- in- Aid Program to TT.	Andersson A, 2008, J LEUKOCYTE BIOL, V84, P1248, DOI 10.1189/jlb.1207844; Ayata C, 2006, ANN NEUROL, V59, P652, DOI 10.1002/ana.20778; Ayata C, 2015, PHYSIOL REV, V95, P953, DOI 10.1152/physrev.00027.2014; Casano AM, 2015, DEV CELL, V32, P469, DOI 10.1016/j.devcel.2015.01.018; Casula M, 2011, NEUROSCIENCE, V179, P233, DOI 10.1016/j.neuroscience.2011.02.001; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Eichler FS, 2008, ANN NEUROL, V63, P729, DOI 10.1002/ana.21391; Eikermann-Haerter K, 2015, ANN NEUROL, V78, P193, DOI 10.1002/ana.24449; GEHRMANN J, 1995, J NEUROPATH EXP NEUR, V54, P680, DOI 10.1097/00005072-199509000-00010; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; Gong G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089450; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222; Iizuka T, 2015, J NEUROL NEUROSUR PS, V86, P344, DOI 10.1136/jnnp-2014-307731; Iizuka T, 2012, J NEUROL NEUROSUR PS, V83, P205, DOI 10.1136/jnnp-2011-300843; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; Kim JB, 2008, J NEUROSCI RES, V86, P1125, DOI 10.1002/jnr.21555; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.00216.x; Lourbopoulos A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00054; Luo XG, 2012, TRANSL NEURODEGENER, V1, DOI 10.1186/2047-9158-1-9; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; Pietrobon D, 2014, NAT REV NEUROSCI, V15, P379, DOI 10.1038/nrn3770; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Rajbhandari L, 2014, GLIA, V62, P1982, DOI 10.1002/glia.22719; Sato H, 2013, NEUROSCIENCE, V248, P345, DOI 10.1016/j.neuroscience.2013.06.010; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Takizawa T, 2016, CEPHALALGIA, V36, P44, DOI 10.1177/0333102415580100; Trotta T, 2014, J NEUROIMMUNOL, V268, P1, DOI 10.1016/j.jneuroim.2014.01.014; Unekawa M, 2015, J CEREBR BLOOD F MET, V35, P689, DOI 10.1038/jcbfm.2014.250; VERHAEGEN M, 1992, BRAIN RES, V581, P153, DOI 10.1016/0006-8993(92)90355-D; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; White CA, 1998, INT IMMUNOL, V10, P935, DOI 10.1093/intimm/10.7.935; Yang QW, 2011, J CEREBR BLOOD F MET, V31, P593, DOI 10.1038/jcbfm.2010.129; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334	43	25	26	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2017	37	3					890	901		10.1177/0271678X16647398			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	EL5KQ	WOS:000394660400013	27142867	Green Published, Bronze			2021-06-18	
J	Hopp, S; Nolte, MW; Stetter, C; Kleinschnitz, C; Siren, AL; Albert-Weissenberger, C				Hopp, Sarah; Nolte, Marc W.; Stetter, Christian; Kleinschnitz, Christoph; Siren, Anna-Leena; Albert-Weissenberger, Christiane			Alleviation of secondary brain injury, posttraumatic inflammation, and brain edema formation by inhibition of factor XIIa	JOURNAL OF NEUROINFLAMMATION			English	Article						Focal brain lesion; Brain edema; Factor XII	COAGULATION-FACTOR-XII; KALLIKREIN-KININ SYSTEM; RECEPTOR B1 PROTECTS; IN-VIVO; IMMUNE-RESPONSE; HEAD-INJURY; MICE; BRADYKININ; DAMAGE; ACTIVATION	Background: Traumatic brain injury (TBI) is a devastating neurological condition and a frequent cause of permanent disability. Posttraumatic inflammation and brain edema formation, two pathological key events contributing to secondary brain injury, are mediated by the contact-kinin system. Activation of this pathway in the plasma is triggered by activated factor XII. Hence, we set out to study in detail the influence of activated factor XII on the abovementioned pathophysiological features of TBI. Methods: Using a cortical cryogenic lesion model in mice, we investigated the impact of genetic deficiency of factor XII and inhibition of activated factor XII with a single bolus injection of recombinant human albumin-fused Infestin-4 on the release of bradykinin, the brain lesion size, and contact-kinin system-dependent pathological events. We determined protein levels of bradykinin, intracellular adhesion molecule-1, CC-chemokine ligand 2, and interleukin-1 beta by enzyme-linked immunosorbent assays and mRNA levels of genes related to inflammation by quantitative real-time PCR. Brain lesion size was determined by tetrazolium chloride staining. Furthermore, protein levels of the tight junction protein occludin, integrity of the blood-brain barrier, and brain water content were assessed by Western blot analysis, extravasated Evans Blue dye, and the wet weight-dry weight method, respectively. Infiltration of neutrophils and microglia/activated macrophages into the injured brain lesions was quantified by immunohistological stainings. Results: We show that both genetic deficiency of factor XII and inhibition of activated factor XII in mice diminish brain injury-induced bradykinin release by the contact-kinin system and minimize brain lesion size, blood-brain barrier leakage, brain edema formation, and inflammation in our brain injury model. Conclusions: Stimulation of bradykinin release by activated factor XII probably plays a prominent role in expanding secondary brain damage by promoting brain edema formation and inflammation. Pharmacological blocking of activated factor XII could be a useful therapeutic principle in the treatment of TBI-associated pathologic processes by alleviating posttraumatic inflammation and brain edema formation.	[Hopp, Sarah; Kleinschnitz, Christoph] Univ Hosp Wurzburg, Dept Neurol, Wurzburg, Germany; [Hopp, Sarah; Stetter, Christian; Siren, Anna-Leena; Albert-Weissenberger, Christiane] Univ Hosp Wurzburg, Dept Neurosurg, Josef Schneider Str 11, Wurzburg, Germany; [Nolte, Marc W.] CSL Behring GmbH, Marburg, Germany; [Kleinschnitz, Christoph] Univ Duisburg Essen, Dept Neurol, Essen, Germany	Albert-Weissenberger, C (corresponding author), Univ Hosp Wurzburg, Dept Neurosurg, Josef Schneider Str 11, Wurzburg, Germany.	Albert_C2@ukw.de	Siren, Anna-Leena/AAE-1374-2019	Siren, Anna-Leena/0000-0002-2217-0081; Kleinschnitz, Christoph/0000-0002-1650-8875	Else Kroner-Fresenius Foundation, Germany,; CSL Behring GmbH, Germany; German Federal Ministry of Education and Research under the framework of EU-ERA-NET NEURON CnsAFlame [BMBF 01EW1502]; Interdisciplinary Clinical Research Center (IZKF) Wurzburg [A-226, E-313]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SFB 688, TP A13]; University of Wurzburg	This work was supported by the Else Kroner-Fresenius Foundation, Germany, CSL Behring GmbH, Germany, the German Federal Ministry of Education and Research under the framework of EU-ERA-NET NEURON CnsAFlame (BMBF 01EW1502B), the Interdisciplinary Clinical Research Center (IZKF) Wurzburg (A-226 and E-313), and the Deutsche Forschungsgemeinschaft (SFB 688, TP A13). This publication was supported by the Open Access Publication Fund of the University of Wurzburg.	Albert-Weissenberger C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00345; Albert-Weissenberger C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00269; Albert-Weissenberger C, 2013, PROG NEUROBIOL, V101, P65, DOI 10.1016/j.pneurobio.2012.11.004; Albert-Weissenberger C, 2012, J CEREBR BLOOD F MET, V32, P1747, DOI 10.1038/jcbfm.2012.62; Bjorkqvist J, 2014, THROMB HAEMOSTASIS, V112, P868, DOI 10.1160/TH14-04-0311; Bockmann S, 2000, J LEUKOCYTE BIOL, V68, P587; De Meyer SF, 2016, STROKE, V47, P1165, DOI 10.1161/STROKEAHA.115.011238; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gill P, 2015, J ALLERGY CLIN IMMUN, V135, P1424, DOI 10.1016/j.jaci.2015.04.019; Hopp S, 2016, ANN NEUROL, V79, P970, DOI 10.1002/ana.24655; Kilkenny C, 2010, J PHARMACOL PHARMACO, V1, P94, DOI 10.4103/0976-500X.72351; Kunz M, 2013, J NEUROTRAUM, V30, P1638, DOI 10.1089/neu.2012.2774; Langer HF, 2009, J CELL MOL MED, V13, P1211, DOI 10.1111/j.1582-4934.2009.00811.x; Langhauser F, 2012, BLOOD, V120, P4082, DOI 10.1182/blood-2012-06-440057; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P381, DOI 10.1007/978-3-211-85578-2_73; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Negraes PD, 2015, CELL TRANSPLANT, V24, P613, DOI 10.3727/096368915X687778; Pauer HU, 2004, THROMB HAEMOSTASIS, V92, P503, DOI 10.1160/TH04-04-0250; Raslan Furat, 2012, Exp Transl Stroke Med, V4, P6, DOI 10.1186/2040-7378-4-6; Raslan F, 2010, J CEREBR BLOOD F MET, V30, P1477, DOI 10.1038/jcbfm.2010.28; Renne T, 2005, J EXP MED, V202, P271, DOI 10.1084/jem.20050664; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322; Wagner DD, 2003, ARTERIOSCL THROM VAS, V23, P2131, DOI 10.1161/01.ATV.0000095974.95122.EC; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zweckberger K, 2009, NEUROSCI LETT, V454, P115, DOI 10.1016/j.neulet.2009.02.014	31	25	25	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 20	2017	14								39	10.1186/s12974-017-0815-8			10	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	EP1OQ	WOS:000397154600001	28219400	DOAJ Gold, Green Published			2021-06-18	
J	Tucker, LB; McCabe, JT				Tucker, Laura B.; McCabe, Joseph T.			Behavior of Male and Female C57BL/6J Mice Is More Consistent with Repeated Trials in the Elevated Zero Maze than in the Elevated Plus Maze	FRONTIERS IN BEHAVIORAL NEUROSCIENCE			English	Article						anxiety; memory; sex differences; behavior; one-trial tolerance	ANXIETY-LIKE BEHAVIOR; TRAUMATIC BRAIN-INJURY; RECEPTOR BETA KNOCKOUT; SEX-DIFFERENCES; ANIMAL-MODELS; TYPE-1 5-ALPHA-REDUCTASE; SOCIAL BEHAVIORS; INBRED STRAINS; DRUG DISCOVERY; BASE-LINE	The elevated plus maze (EPM) and elevated zero maze (EZM) are behavioral tests that are widely employed to assess anxiety-like behaviors in rats and mice following experimental manipulations, or to test the effects of pharmacological agents. Both tests are based on approach/avoidance conflict, with rodents perceived as less anxious being more willing to explore the brighter, open and elevated regions of the apparatus as opposed to remaining in the darkened and enclosed regions. The goal of this research was to compare, under identical laboratory conditions, the behavior of male and female C57BL/6J mice in EZM and EPM during repeated trials. Mice were tested either daily or weekly, exclusively in the EPM or EZM, for a total of five exposures. During the first trial, the mazes were explored equally as measured by the total distance traveled during the test session. However, mice tested in the EZM spent nearly twice the amount of time in the anxiogenic regions (open quadrants) as the mice tested in the EPM spent in the open arms of that apparatus. After the first trial in the EPM, amounts of ambulation and percent time in the open arms decreased significantly (independent of inter-trial interval) which has been well-described in previous research as the one-trial tolerance phenomenon. In contrast, behavior in the EZM remained comparatively stable for several trials when the animals were tested weekly or daily. Sex differences were limited to activity levels, with females being more active than males. In conclusion, the design of the EZM encourages greater exploration of the anxiogenic regions of the apparatus, and may also be a more suitable test than the EPM for experimental designs in which assessment of anxiety-related behaviors is needed at more than one time point following experimental manipulations.	[Tucker, Laura B.; McCabe, Joseph T.] Ctr Neurosci & Regenerat Med, Preclin Studies Core, Bethesda, MD 20894 USA; [Tucker, Laura B.; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, FE Hebert Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	McCabe, JT (corresponding author), Ctr Neurosci & Regenerat Med, Preclin Studies Core, Bethesda, MD 20894 USA.; McCabe, JT (corresponding author), Uniformed Serv Univ Hlth Sci, FE Hebert Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA.	Joseph.McCabe@usuhs.edu	; McCabe, Joseph/J-6293-2014	Tucker, Laura/0000-0002-5984-6399; McCabe, Joseph/0000-0002-1159-7442	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [60855-300600-7.01]	This work was supported by The Center for Neuroscience and Regenerative Medicine, 60855-300600-7.01.	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Amani M, 2013, NEUROPHARMACOLOGY, V73, P87, DOI 10.1016/j.neuropharm.2013.04.056; An XL, 2011, EXP ANIM TOKYO, V60, P111, DOI 10.1538/expanim.60.111; ARCHER J, 1975, BEHAV BIOL, V14, P451, DOI 10.1016/S0091-6773(75)90636-7; Blokland A, 2012, BEHAV BRAIN RES, V228, P16, DOI 10.1016/j.bbr.2011.11.042; Bolivar VJ, 2000, BEHAV GENET, V30, P285, DOI 10.1023/A:1026545316455; Braun AA, 2011, PHARMACOL BIOCHEM BE, V97, P406, DOI 10.1016/j.pbb.2010.09.013; Cook MN, 2002, BEHAV GENET, V32, P113, DOI 10.1023/A:1015249706579; Cook MN, 2001, BEHAV NEUROSCI, V115, P468, DOI 10.1037/0735-7044.115.2.468; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; Cryan JF, 2011, BRIT J PHARMACOL, V164, P1129, DOI 10.1111/j.1476-5381.2011.01362.x; Ennaceur A, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.223; FILE SE, 1990, PSYCHOPHARMACOLOGY, V102, P98, DOI 10.1007/BF02245751; Frye CA, 2004, BRAIN RES, V1004, P116, DOI 10.1016/j.brainres.2004.01.020; Galeeva A, 2001, BEHAV BRAIN RES, V119, P41, DOI 10.1016/S0166-4328(00)00341-7; Gangitano D, 2009, GENES BRAIN BEHAV, V8, P398, DOI 10.1111/j.1601-183X.2009.00476.x; Gioiosa L, 2007, HORM BEHAV, V52, P307, DOI 10.1016/j.yhbeh.2007.05.006; Gomes KS, 2009, PROG NEURO-PSYCHOPH, V33, P1261, DOI 10.1016/j.pnpbp.2009.07.015; Griebel G, 2013, NAT REV DRUG DISCOV, V12, P667, DOI 10.1038/nrd4075; Haller J, 2013, NEUROSCI BIOBEHAV R, V37, P2318, DOI 10.1016/j.neubiorev.2012.09.001; Hendershott TR, 2016, BEHAV BRAIN RES, V314, P215, DOI 10.1016/j.bbr.2016.08.004; Holmes A, 1998, PHARMACOL BIOCHEM BE, V60, P473, DOI 10.1016/S0091-3057(98)00008-2; Holmes A, 1999, NEUROSCI BIOBEHAV R, V23, P971, DOI 10.1016/S0149-7634(99)00030-5; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Kokras N, 2014, BRIT J PHARMACOL, V171, P4595, DOI 10.1111/bph.12710; Koonce CJ, 2013, BEHAV BRAIN RES, V253, P232, DOI 10.1016/j.bbr.2013.07.025; Koonce CJ, 2012, BEHAV BRAIN RES, V226, P376, DOI 10.1016/j.bbr.2011.09.028; LEE C, 1990, PSYCHOPHARMACOLOGY, V102, P507, DOI 10.1007/BF02247133; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; Milner LC, 2008, GENES BRAIN BEHAV, V7, P496, DOI 10.1111/j.1601-183X.2007.00385.x; O'Leary TP, 2013, BEHAV GENET, V43, P34, DOI 10.1007/s10519-012-9572-8; Olesen KM, 2011, HORM BEHAV, V60, P318, DOI 10.1016/j.yhbeh.2011.06.005; Painsipp E, 2007, NEUROSCIENCE, V150, P522, DOI 10.1016/j.neuroscience.2007.09.024; Pearson BL, 2015, PHYSIOL BEHAV, V146, P98, DOI 10.1016/j.physbeh.2015.03.035; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Prendergast BJ, 2014, NEUROSCI BIOBEHAV R, V40, P1, DOI 10.1016/j.neubiorev.2014.01.001; RODGERS RJ, 1993, PSYCHOPHARMACOLOGY, V113, P237, DOI 10.1007/BF02245704; Rodgers RJ, 1997, BRAZ J MED BIOL RES, V30, P289, DOI 10.1590/S0100-879X1997000300002; Rodgers RJ, 2002, GENES BRAIN BEHAV, V1, P242, DOI 10.1034/j.1601-183X.2002.10406.x; RODGERS RJ, 1993, PHYSIOL BEHAV, V54, P729, DOI 10.1016/0031-9384(93)90084-S; RODGERS RJ, 1992, PSYCHOPHARMACOLOGY, V106, P102, DOI 10.1007/BF02253596; Roy V, 2009, PSYCHOPHARMACOLOGY, V203, P131, DOI 10.1007/s00213-008-1378-2; Schneider P, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00043; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; Tarantino LM, 2000, MAMM GENOME, V11, P555, DOI 10.1007/s003350010107; TREIT D, 1993, PHARMACOL BIOCHEM BE, V44, P463, DOI 10.1016/0091-3057(93)90492-C; Tucker LB, 2017, J NEUROTRAUM, V34, P890, DOI 10.1089/neu.2016.4508; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Voikar V, 2001, PHYSIOL BEHAV, V72, P271, DOI 10.1016/S0031-9384(00)00405-4; Walf AA, 2008, BEHAV NEUROSCI, V122, P974, DOI 10.1037/a0012749; Walf AA, 2009, BEHAV BRAIN RES, V196, P254, DOI 10.1016/j.bbr.2008.09.016; Zhou H, 2015, PHARMACOL BIOCHEM BE, V135, P40, DOI 10.1016/j.pbb.2015.05.009	52	25	25	0	7	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5153			FRONT BEHAV NEUROSCI	Front. Behav. Neurosci.	JAN 26	2017	11								13	10.3389/fnbeh.2017.00013			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	EI7CT	WOS:000392655700001	28184191	DOAJ Gold, Green Published			2021-06-18	
J	Liu, ZK; Ng, CF; Shiu, HT; Wong, HL; Wong, CW; Li, KK; Zhang, JF; Lam, PK; Poon, WS; Lau, CBS; Leung, PC; Ko, CH				Liu, Zhi-Ke; Ng, Chun-Fai; Shiu, Hoi-Ting; Wong, Hing-Lok; Wong, Chun-Wai; Li, Kai-Kai; Zhang, Jin-Fang; Lam, Ping-Kuen; Poon, Wai-Sang; Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay			A traditional Chinese formula composed of Chuanxiong Rhizoma and Gastrodiae Rhizoma (Da Chuanxiong Formula) suppresses inflammatory response in LPS -induced RAW 264.7 cells through inhibition of NF-kappa B pathway	JOURNAL OF ETHNOPHARMACOLOGY			English	Article						Chuanxiong Rhizoma; Gastrodiae Rhizoma; Da Chuanxiong Formula; Anti-inflammation; NF-kappa B	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE; CLUSTER HEADACHE; MEMORY DEFICITS; RATS; TETRAMETHYLPYRAZINE; CYCLOOXYGENASE-2; EXPRESSION; CYTOKINES	Ethnopharmacological relevance: Da Chuanxiong Formula (DCXF) which origins from Jin Dynasty is a famous classical 2-herb Chinese medicinal prescription. It is composed of dried rhizomes of Ligusticum chuanxiong (Chuanxiong Rhizoma, CR) and Gastrodia elata (Gastrodiae Rhizoma, GR) at the ratio of 4:1 (w/w). It has been used to treat headache which is caused by wind pathogen and blood stasis for thousands of years in China. Aim of study: The present study was performed to investigate the anti-inflammatory effect of DCXF and elucidate its underlying molecular mechanisms using LPS-stimulated RAW 264.7 cells. Materials and methods: The anti-inflammatory effect of DCXF was evaluated using LPS-stimulated RAW 264.7 cells. Generation of nitric oxide (NO) and prostaglandin E-2 (PGE(2)) were measured by the Griess colorimetric method and enzyme-linked immunosorbent assay (ELISA), respectively. The gene expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) were detected by reverse transcription-polymerase chain reaction (RT-PCR). Furthermore, the effect of DCXF on NF-kappa B activation was measured by western blot assay. Results: Treatment with DCXF significantly suppressed the productions of NO and PGE(2) through inhibitions of iNOS and COX-2 expressions in LPS-stimulated RAW 264.7 cells. DCXF significantly decreased I kappa B alpha phosphorylation, inhibited p65 expression and reduced p-p65 level. These results suggested the anti-inflammatory effect of DCXF was associated with the reduction of inflammatory mediators through inhibition of NF-kappa B pathway. Conclusions: These results indicated that DCXF inhibited inflammation in LPS-stimulated RAW 264.7 cells through inactivation of NF-kappa B pathway.	[Liu, Zhi-Ke; Ng, Chun-Fai; Shiu, Hoi-Ting; Wong, Hing-Lok; Wong, Chun-Wai; Li, Kai-Kai; Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay] Chinese Univ Hong Kong, Inst Chinese Med, Sci Ctr East Block, Shatin, Hong Kong, Peoples R China; [Liu, Zhi-Ke; Ng, Chun-Fai; Shiu, Hoi-Ting; Wong, Hing-Lok; Wong, Chun-Wai; Li, Kai-Kai; Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay] Chinese Univ Hong Kong, State Key Lab Phytochem & Plant Resources West Ch, Shatin, Hong Kong, Peoples R China; [Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen 518057, Peoples R China; [Zhang, Jin-Fang] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Orthopaed & Traumatol, Shatin, Hong Kong, Peoples R China; [Lam, Ping-Kuen; Poon, Wai-Sang] Chinese Univ Hong Kong, Dept Surg, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China	Leung, PC; Ko, CH (corresponding author), Chinese Univ Hong Kong, Inst Chinese Med, Sci Ctr East Block, Shatin, Hong Kong, Peoples R China.	liuzhikebee@163.com; ncf0000@hotmail.com; hoitingshiu@gmail.com; vhlwong@yahoo.com; cwwong_eric@cuhk.edu.hk; likaicuhk@gmail.com; zhangjf06@cuhk.edu.hk; lampingkuen@yahoo.com.hk; wpoon@surgery.cuhk.edu.hk; claralau@cuhk.edu.hk; pingcleung@cuhk.edu.hk; gohey@yahoo.com	Poon, Wai Sang/F-1558-2011; Lau, Clara Bik-San/AAF-3989-2020	Lau, Clara Bik-San/0000-0002-7409-1270	Food and Health Bureau, Hong Kong, Special Administration Region, Health and Medical Research Fund [12134111]	The research was financially supported by the Food and Health Bureau, Hong Kong, Special Administration Region, Health and Medical Research Fund (no. 12134111).	Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Antonova M, 2013, CURR OPIN NEUROL, V26, P269, DOI 10.1097/WCO.0b013e328360864b; Blatteis CM, 2005, PROSTAG OTH LIPID M, V76, P1, DOI 10.1016/j.prostaglandins.2005.01.001; Bredt DS, 1999, FREE RADICAL RES, V31, P577, DOI 10.1080/10715769900301161; Brietzke E, 2012, MED HYPOTHESES, V78, P601, DOI 10.1016/j.mehy.2012.01.036; Chavarria A, 2004, AUTOIMMUN REV, V3, P251, DOI 10.1016/j.autrev.2003.09.006; China Pharmacopoeia Committee, 2010, PHARMACOPOEIA PEOPLE; Cimino PJ, 2008, CURR MED CHEM, V15, P1863, DOI 10.2174/092986708785132915; Dai JN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021891; Ferreiro DU, 2010, BIOCHEMISTRY-US, V49, P1560, DOI 10.1021/bi901948j; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Fung A, 2012, BRAIN RES, V1446, P144, DOI 10.1016/j.brainres.2012.01.061; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Guo JM, 2013, J ETHNOPHARMACOL, V150, P649, DOI 10.1016/j.jep.2013.09.020; Guo JM, 2011, FITOTERAPIA, V82, P441, DOI 10.1016/j.fitote.2010.12.002; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; He Li, 2004, Sichuan Da Xue Xue Bao Yi Xue Ban, V35, P821; Hu YK, 2014, NEUROPATHOLOGY, V34, P370, DOI 10.1111/neup.12115; John S, 2014, HEADACHE, V54, P572, DOI 10.1111/head.12306; Kao TK, 2013, EXP NEUROL, V247, P188, DOI 10.1016/j.expneurol.2013.04.010; Kim YM, 1997, BIOCHEM BIOPH RES CO, V236, P655, DOI 10.1006/bbrc.1997.7031; Koh PO, 2013, SYNAPSE, V67, P390, DOI 10.1002/syn.21649; Korhonen Riku, 2005, Current Drug Targets - Inflammation and Allergy, V4, P471, DOI 10.2174/1568010054526359; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Legler DF, 2010, INT J BIOCHEM CELL B, V42, P198, DOI 10.1016/j.biocel.2009.09.015; Li Y., 2015, J ETHNOPHARMACOL; Lin LC, 2007, ANAL CHIM ACTA, V590, P173, DOI 10.1016/j.aca.2007.03.035; Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nagy G, 2007, IMMUNOL LETT, V111, P1, DOI 10.1016/j.imlet.2007.04.013; Ng CF, 2016, J ETHNOPHARMACOL, V185, P87, DOI 10.1016/j.jep.2016.03.018; Niu J. X., 2011, J EMERGENCY TRADITIO, V20, P833; Olesen J, 2010, NEUROTHERAPEUTICS, V7, P183, DOI 10.1016/j.nurt.2010.03.006; Olesen J, 2008, PHARMACOL THERAPEUT, V120, P157, DOI 10.1016/j.pharmthera.2008.08.003; Peng Z, 2013, PHYSIOL RES, V62, P537, DOI 10.33549/physiolres.932507; Peng ZW, 2015, NEUROCHEM RES, V40, P661, DOI 10.1007/s11064-015-1513-5; Predonzani Andrea, 2015, World J Exp Med, V5, P64, DOI 10.5493/wjem.v5.i2.64; Pu QH, 2015, LIFE SCI, V121, P46, DOI 10.1016/j.lfs.2014.11.016; Steinberg A, 2012, CURR PAIN HEADACHE R, V16, P185, DOI 10.1007/s11916-012-0250-6; Sun SC, 2008, TRENDS IMMUNOL, V29, P469, DOI 10.1016/j.it.2008.07.003; Tsai TH, 2001, INT J PHARMACEUT, V216, P61, DOI 10.1016/S0378-5173(01)00572-5; Waeber C, 2005, NEUROLOGY, V64, pS9, DOI 10.1212/WNL.64.10_suppl_2.S9; Wang HN, 2014, BEHAV BRAIN RES, V266, P153, DOI 10.1016/j.bbr.2014.02.046; Wang L., 2013, SCI WORLD J, V2013, P1, DOI DOI 10.1002/AS12.454.WILEY0NLINELIBRARY.C0M; Wang XN, 2014, NEUROCHEM RES, V39, P1458, DOI 10.1007/s11064-014-1335-x; Wienecke T, 2009, CEPHALALGIA, V29, P509, DOI 10.1111/j.1468-2982.2008.01748.x; Wu K, 2014, J ETHNOPHARMACOL, V151, P1133, DOI 10.1016/j.jep.2013.12.027; Yang HW, 2008, CURR PHARM DESIGN, V14, P1443, DOI 10.2174/138161208784480144; [姚干 Yao Gan], 2004, [中成药, Chinese Traditional Patent Medicine], V26, P314; Yeo SJ, 2003, J BIOL CHEM, V278, P40590, DOI 10.1074/jbc.M306280200; Yuste JE, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00322; Zhao Y., 2008, INFORM TRADITIONAL C, V25, P67; Zhou Y., 2003, HENAN TRADIT CHIN ME, V23, P22; Zhu MD, 2014, BRAIN RES BULL, V109, P54, DOI 10.1016/j.brainresbull.2014.10.002; 周明眉, 2008, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V24, P6; 周明眉, 2009, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V25, P9	57	25	29	1	43	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-8741			J ETHNOPHARMACOL	J. Ethnopharmacol.	JAN 20	2017	196						20	28		10.1016/j.jep.2016.12.014			9	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	EJ9ER	WOS:000393529900003	27965052				2021-06-18	
J	Vergara, VM; Mayer, AR; Damaraju, E; Hutchison, K; Calhoun, VD				Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Hutchison, Kent; Calhoun, Vince D.			The effect of preprocessing pipelines in subject classification and detection of abnormal resting state functional network connectivity using group ICA	NEUROIMAGE			English	Article							TRAUMATIC BRAIN-INJURY; DEFAULT-MODE NETWORK; CEREBRAL-CORTEX; SMOKING CUES; HEAD MOTION; TIME-SERIES; FMRI DATA; BOLD; IDENTIFICATION; ACTIVATION	Resting state functional network connectivity (rsFNC) derived from functional magnetic resonance (fMRI) imaging is emerging as a possible biomarker to identify several brain disorders. Recently it has been pointed out that methods used to preprocess head motion variance might not fully remove all unwanted effects in the data. Proposed processing pipelines locate the treatment of head motion effects either close to the beginning or as one of the final steps. In this work, we assess several preprocessing pipelines applied in group independent component analysis (gICA) methods to study the rsFNC of the brain. The evaluation method utilizes patient/control classification performance based on linear support vector machines and leave-one-out cross validation. In addition, we explored group tests and correlation with severity measures in the patient population. We also tested the effect of removing high frequencies via filtering. Two real data cohorts were used: one consisting of 48 mTBI and one composed of 21 smokers, both with their corresponding matched controls. A simulation procedure was designed to test the classification power of each pipeline. Results show that data preprocessing can change the classification performance. In real data, regressing motion variance before gICA produced clearer group differences and stronger correlation with nicotine dependence. (C) 2016 Elsevier Inc. All rights reserved.	[Vergara, Victor M.; Mayer, Andrew R.; Calhoun, Vince D.] Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA; [Damaraju, Eswar; Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87106 USA; [Hutchison, Kent] Univ Colorado, Dept Psychol, Boulder, CO 80302 USA; [Hutchison, Kent] Univ Colorado, Dept Neurosci, Boulder, CO 80302 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Vergara, VM (corresponding author), Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	vvergara@mrn.org			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24HD050836/R21NS064464/R21NS064464, P20GM103472/R01EB006841/R01EB020407]; NSFNational Science Foundation (NSF) [1539067]; Office of Integrative ActivitiesNational Science Foundation (NSF)NSF - Office of the Director (OD) [1539067] Funding Source: National Science Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB006841, R01EB020407] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA040487] Funding Source: NIH RePORTER	The authors thank Joseph Ling, Jill Fries, Vikram Rao, Prashanth Nyalakanti, and Sandeep Panta for help with preprocessing the data. We also appreciate the advice provided by Professor Eric Erhart to improve our statistical analysis. This work was funded by NIH grants R24HD050836/R21NS064464/R21NS064464 (to A.M.), and P20GM103472/R01EB006841/R01EB020407 and NSF grant 1539067 (to V.D.C.).	Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Boubela RN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00168; Calhoun V. D., 2011, FRONT PSYCHOL, V2; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun Vince D, 2012, IEEE Rev Biomed Eng, V5, P60, DOI 10.1109/RBME.2012.2211076; Chai XQJ, 2011, NEUROPSYCHOPHARMACOL, V36, P2009, DOI 10.1038/npp.2011.88; Chanraud S, 2011, CEREB CORTEX, V21, P2272, DOI 10.1093/cercor/bhq297; Chen JYE, 2015, NEUROIMAGE, V107, P207, DOI 10.1016/j.neuroimage.2014.12.012; Claus ED, 2013, NEUROPSYCHOPHARMACOL, V38, P2363, DOI 10.1038/npp.2013.134; Cordes D, 2001, AM J NEURORADIOL, V22, P1326; Damaraju E., 2014, 4 BIENN C REST STAT; Das P, 2014, NEUROIMAGE, V98, P73, DOI 10.1016/j.neuroimage.2014.04.062; Due DL, 2002, AM J PSYCHIAT, V159, P954, DOI 10.1176/appi.ajp.159.6.954; Ely AV, 2015, APPETITE, V95, P126, DOI 10.1016/j.appet.2015.06.022; Erhardt EB, 2011, HUM BRAIN MAPP, V32, P2075, DOI 10.1002/hbm.21170; FAGERSTROM K O, 1990, Ear Nose and Throat Journal, V69, P763; First MB., 2002, STRUCTURED CLIN INTE; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Friston KJ., 2003, NEUROSCIENCE DATABAS, P237, DOI [10.1007/978-1-4615-1079-6_16, DOI 10.1007/978-1-4615-1079-6_16]; Garrity A. G., 2007, ABERRANT DEFAULT MOD; Grouiller F, 2011, BRAIN, V134, P2867, DOI 10.1093/brain/awr156; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Konova AB, 2015, BRAIN RES, V1628, P147, DOI 10.1016/j.brainres.2015.02.002; Kundu P, 2012, NEUROIMAGE, V60, P1759, DOI 10.1016/j.neuroimage.2011.12.028; Lee HL, 2013, NEUROIMAGE, V65, P216, DOI 10.1016/j.neuroimage.2012.10.015; Lee MH, 2013, AM J NEURORADIOL, V34, P1866, DOI 10.3174/ajnr.A3263; Liu F, 2015, BRAIN STRUCT FUNCT, V220, P101, DOI 10.1007/s00429-013-0641-4; Ma S, 2011, IEEE T BIO-MED ENG, V58, P3406, DOI 10.1109/TBME.2011.2167149; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McClernon FJ, 2009, PSYCHOPHARMACOLOGY, V204, P25, DOI 10.1007/s00213-008-1436-9; Mowinckel AM, 2012, NEUROIMAGE, V63, P1364, DOI 10.1016/j.neuroimage.2012.08.004; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Niazy RK, 2011, PROG BRAIN RES, V193, P259, DOI 10.1016/B978-0-444-53839-0.00017-X; Olsen A, 2015, CEREB CORTEX, V25, P2170, DOI 10.1093/cercor/bhu023; Pariyadath V, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00425; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Rachakonda S., 2011, ALTERED TOPOLOGICAL; Rocca MA, 2013, NEUROTHERAPEUTICS, V10, P511, DOI 10.1007/s13311-013-0189-2; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schmidt A, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.28; Sheline YI, 2013, BIOL PSYCHIAT, V74, P340, DOI 10.1016/j.biopsych.2012.11.028; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Strangman GE, 2009, NEUROREHAB NEURAL RE, V23, P226, DOI 10.1177/1545968308324225; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Yaesoubi M, 2015, NEUROIMAGE, V120, P133, DOI 10.1016/j.neuroimage.2015.07.002; Yuan K, 2016, BRAIN STRUCT FUNCT, V221, P1427, DOI 10.1007/s00429-014-0982-7; Zeng LL, 2014, HUM BRAIN MAPP, V35, P1630, DOI 10.1002/hbm.22278	56	25	27	1	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN 15	2017	145		B		SI		365	376		10.1016/j.neuroimage.2016.03.038			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EG3WU	WOS:000390976200020	27033684	Green Accepted			2021-06-18	
J	Dobney, DM; Grilli, L; Kocilowicz, H; Beaulieu, C; Straub, M; Friedman, D; Gagnon, I				Dobney, Danielle M.; Grilli, Lisa; Kocilowicz, Helen; Beaulieu, Christine; Straub, Meghan; Friedman, Debbie; Gagnon, Isabelle			Evaluation of an active rehabilitation program for concussion management in children and adolescents	BRAIN INJURY			English	Article						Brain concussion; mild traumatic brain injury; exercise therapy	TRAUMATIC-BRAIN-INJURY; SPORTS-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; POSTCONCUSSION SYNDROME; AGREEMENT STATEMENT; SEX-DIFFERENCES; BASE-LINE; SYMPTOMS; CONSENSUS; RECOVERY	Objective: To estimate the extent to which post-concussion symptoms were influenced by participation In an Active Rehabilitation (AR) program (aerobic exercise, coordination drills, visualization and education) for children and adolescents who are slow to recover from concussion. A secondary exploratory objective included examining the influence of sex on symptom evolution.& para;& para;Methods: Analysis of prospectively collected data was performed on 277 youth who Initiated an AR program, between three and four weeks post-injury at a Concussion Clinic in a tertiary care paediatric teaching hospital.& para;& para;Main outcome measure. Post-concussion symptom scale (PCSS) from Sport Concussion Assessment Tool- 3 (SCAT 3).& para;& para;Results: Children and adolescents participating in an active rehabilitation program displayed Improved post- concussion symptom severity at follow-up (median = 9.5) compared to pre-intervention (median = 18) (p < .05). Patients demonstrated Improved physical, cognitive, emotional and sleep-related post-concussion symptoms (p < .05). Female sex was associated with an increased post-concussion symptom severity at follow-up.& para;& para;Conclusions: Youth experiencing persisting symptoms three to four weeks post-concussion demonstrated Improved post-concussion symptoms scores (physical, cognitive, emotional and sleep related) with participation in an active rehabilitation program.	[Dobney, Danielle M.] McGill Univ, Fac Med, Sch Phys & Occupat Therapy, 3654 Prom Sir William Osler, Montreal, PQ H3G 1Y5, Canada; [Grilli, Lisa; Kocilowicz, Helen; Beaulieu, Christine; Straub, Meghan; Friedman, Debbie] McGill Univ, Hlth Ctr, Montreal Childrens Hosp, Trauma Ctr, Montreal, PQ, Canada; [Friedman, Debbie] McGill Univ, Fac Med, Dept Pediat, Canadian Hosp Injury Reporting & Prevent Program, Montreal, PQ, Canada; [Gagnon, Isabelle] McGill Univ, Montreal Univ Hlth Ctr, Montreal Childrens Hosp, Sch Phys & Occupat Therapy, Montreal, PQ, Canada	Dobney, DM (corresponding author), McGill Univ, Fac Med, Sch Phys & Occupat Therapy, 3654 Prom Sir William Osler, Montreal, PQ H3G 1Y5, Canada.	danielle.dobney@mail.mcgill.ca			Fonds de recherche du Quebec - Sante (FRQS)Fonds de la Recherche en Sante du Quebec; Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	The authors acknowledge funding from Fonds de recherche du Quebec - Sante (FRQS) and Canadian Institutes of Health Research (CIHR).	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; DiFazio M, 2015, CLIN PEDIATR; Echemendia RJ, 2015, BRAIN INJURY, V29, P185, DOI 10.3109/02699052.2014.965212; Gagnon I, 2015, SCANDINAVIAN J MED S; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2015, BRAIN INJURY, V29, P195, DOI 10.3109/02699052.2014.965210; Hugentobler JA, 2015, INT J SPORTS PHYS TH, V10, P676; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2012, MILD TRAUMATIC BRAIN, P281; Kurowski BG, 2016, J HEAD TRAUMA REHABI; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P., 2009, S AFRICAN J SPORTS M, V21; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mychasiuk R, 2016, EUR J NEUROSCI, V44, P2407, DOI 10.1111/ejn.13360; Pardini D., 2004, BR J SPORTS MED, V38, P661; Roemmich JN, 2006, MED SCI SPORT EXER, V38, P1014, DOI 10.1249/01.mss.0000218123.81079.49; Schneider KJ, 2013, BRIT J SPORT MED, V47, P1; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Terwilliger VK, 2016, J NEUROTRAUM, V33, P761, DOI 10.1089/neu.2015.4082; Verschuren O, 2011, DEV MED CHILD NEUROL, V53, P861, DOI 10.1111/j.1469-8749.2011.03989.x; Hunt AW, 2016, J ATHL TRAINING, V51, P749, DOI 10.4085/1062-6050-51.11.12; Winkler R, 2015, J HEAD TRAUMA REHABI; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	35	25	25	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	13-14					1753	1759		10.1080/02699052.2017.1346294			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FO2MD	WOS:000416612500007	29058559				2021-06-18	
J	Erdodi, LA; Rai, JK				Erdodi, Laszlo A.; Rai, Jaspreet K.			A single error is one too many: Examining alternative cutoffs on Trial 2 of the TOMM	BRAIN INJURY			English	Article						Test of Memory Malingering; performance validity assessment; alternative cutoffs	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; COMPLEX FIGURE TEST; CARD SORTING TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; WORD MEMORY TEST; CLASSIFICATION ACCURACY; PERFORMANCE VALIDITY; RESPONSE BIAS; CROSS-VALIDATION	Objective: This study investigated the potential of alternative, more liberal cutoffs on Trial 2 of the Test of Memory Malingering (TOMM) to improve classification accuracy relative to the standard cutoffs (44). Method: The sample consisted of 152 patients (49.3% male) with psychiatric conditions (PSY) and traumatic brain injury (TBI) referred for neuropsychological assessment in a medico-legal setting (M-Age = 44.4, M-Education = 11.9 years). Classification accuracy for various TOMM Trial 2 cutoffs was computed against three criterion measures.Results: Patients with TBI failed TOMM Trial 2 cutoffs at higher rates than patients with PSY. Trial 2 49 achieved acceptable combinations of sensitivity (0.38-0.67) and specificity (0.89-0.96) in all but one comparison group. Trial 2 48 improved specificity (0.94-0.98) with minimal loss in sensitivity. The standard cutoff (44) disproportionally traded sensitivity (0.15-0.50) for specificity (0.96-1.00).Conclusions: One error on TOMM Trial 2 constitutes sufficient evidence to question the credibility of a response set. However, the confidence in classifying a score as invalid continues to increase with each additional error. Even at the most liberal conceivable cutoff (49), the TOMM detected only about half of the patients who failed other criterion measures. Therefore, it should never be used in isolation to determine performance validity.	[Erdodi, Laszlo A.; Rai, Jaspreet K.] Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada	Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com					Armistead-Jehle P, 2015, APPL NEUROPSYCH-ADUL, V22, P415, DOI 10.1080/23279095.2014.953678; Armistead-Jehle P, 2011, APPL NEUROPSYCHOL, V18, P284, DOI 10.1080/09084282.2011.595455; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bigler ED, BRAIN INJ, V28, P1623; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Blaskewitz N, 2009, APPL NEUROPSYCHOL, V16, P54, DOI 10.1080/09084280802644227; Boone K. B., 2013, CLIN PRACTICE FORENS; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Cappa KA, 2011, HEALTH PSYCHOL, V30, P542, DOI 10.1037/a0025220; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Considine CM, 2011, ARCH CLIN NEUROPSYCH, V26, P445, DOI 10.1093/arclin/acr041; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Duncan A, 2005, ASSESSMENT, V12, P123, DOI 10.1177/1073191105275512; Erdodi LA, 2016, PSYCHOL ASSESSM, DOI 10.1037/pas0000319; Erdodi LA, 2016, J CLIN EXP NEUROPSYC, DOI [10.1080/13803395.2016. 1230181, DOI 10.1080/13803395.2016]; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P327, DOI 10.1080/23279095.2017.1298600; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green, 2004, GREENS MED SYMPTOM V; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2003, GREENS WORD MEMORY T; Green P., 2008, GREENS NONVERBAL MED; Green P, 2011, APPL NEUROPSYCHOL, V18, P18, DOI 10.1080/09084282.2010.523365; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Hartman DE, 2002, ARCH CLIN NEUROPSYCH, V17, P709, DOI 10.1016/S0887-6177(01)00172-X; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Larrabee, 2012, FORENSIC NEUROPSYCHO, P116; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lichtenstein JD, 2016, CHILD NEUROPSYCHOL, DOI [10.1080/09297049.2015. 1135422, DOI 10.1080/09297049.2015]; Love CM, 2014, ASSESSMENT, V21, P618, DOI 10.1177/1073191114528028; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Schroeder RW, 2013, ARCH CLIN NEUROPSYCH, V28, P21, DOI 10.1093/arclin/acs094; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Slick D., 1997, VSVT VICTORIA SYMPTO; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith K, 2014, CLIN NEUROPSYCHOL, V28, P1048, DOI 10.1080/13854046.2014.931465; Sugarman MA, 2016, APPL NEUROPSYCH-ADUL, V23, P105, DOI 10.1080/23279095.2015.1014557; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sweet J. J., 2007, ASSESSMENT FEIGNED C, P152; Sweet JJ, 2013, BEHAV SCI LAW, V31, P756, DOI 10.1002/bsl.2088; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1996, TEST MEMORY MALINGER; Trueblood W., 1994, J CLIN EXPT NEUROPSY, V4, P697, DOI DOI 10.1080/01688639408402671	68	25	25	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	10					1362	1368		10.1080/02699052.2017.1332386			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FN4GH	WOS:000415961800014	28657355				2021-06-18	
J	Jiang, C; Zuo, FF; Wang, YJ; Lu, H; Yang, QW; Wang, J				Jiang, Chao; Zuo, Fangfang; Wang, Yuejuan; Lu, Hong; Yang, Qingwu; Wang, Jian			Progesterone Changes VEGF and BDNF Expression and Promotes Neurogenesis After Ischemic Stroke	MOLECULAR NEUROBIOLOGY			English	Article						Brain-derived neurotrophic factor; Cerebral ischemia; Neurogenesis; Progesterone; Vascular endothelial growth factor	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; ENDOTHELIAL GROWTH-FACTOR; NEUROTROPHIC FACTOR EXPRESSION; NEURAL STEM-CELLS; ADULT-RAT; AGED RATS; INTRACEREBRAL HEMORRHAGE; STIMULATES NEUROGENESIS; INFLAMMATORY RESPONSE	Studies have shown that progesterone enhances functional recovery after ischemic stroke, but the underlying mechanisms are not completely understood. Therefore, we investigated the effect of progesterone on vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), and neurogenesis in a rodent stroke model. Rats underwent permanent middle cerebral artery occlusion (pMCAO) and then received intraperitoneal injections of progesterone (15 mg/kg) or vehicle at 1 h followed by subcutaneous injections at 6, 24, and 48 h. We examined VEGF and BDNF expression by Western blotting and/or immunostaining and microvessel density by lectin immunostaining. Neurogenesis in the subventricular zone was determined by immunostaining of Ki67 and doublecortin, and double BrdU/Nestin immunostaining. We calculated brain water content with the wet-dry weight method on day 3 and assessed neurologic deficits with the modified neurological severity score on days 1, 3, 7, and 14. Progesterone-treated rats showed a significant decrease in VEGF expression, but an increase in BDNF expression, compared with that of vehicle-treated pMCAO rats on day 3 post-occlusion. Progesterone did not alter the microvessel density, but it reduced brain water content compared with that in vehicle-treated rats on day 3 post-occlusion. Progesterone treatment increased the numbers of newly generated neurons in the subventricular zone and doublecortin-positive cells in the peri-infarct region on day 7 post-occlusion. In addition, progesterone improved neurologic function on days 7 and 14 post-occlusion. Our data suggest that the enhancement of endogenous BDNF and subsequent neurogenesis could partially underlie the neuroprotective effects of progesterone.	[Jiang, Chao; Zuo, Fangfang; Wang, Yuejuan] Zhengzhou Univ, Dept Neurol, Affiliated Hosp 5, Zhengzhou 450052, Henan, Peoples R China; [Jiang, Chao; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Baltimore, MD 21205 USA; [Lu, Hong] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 450000, Peoples R China; [Yang, Qingwu] Third Mil Med Univ, Xinqiao Hosp, Dept Neurol, Chongqing 400044, Peoples R China	Jiang, C (corresponding author), Zhengzhou Univ, Dept Neurol, Affiliated Hosp 5, Zhengzhou 450052, Henan, Peoples R China.; Jiang, C; Wang, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Baltimore, MD 21205 USA.	chaojzzu@126.com; jwang79@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81301006]; American Heart AssociationAmerican Heart Association [13GRNT15730001]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078026, R01AT007317]	This work was supported by grants from the National Natural Science Foundation of China (81301006), American Heart Association grant 13GRNT15730001, and the National Institutes of Health (R01NS078026, R01AT007317). We thank Claire Levine for assistance with this manuscript.	Cekic M, 2012, RESTOR NEUROL NEUROS, V30, P115, DOI 10.3233/RNN-2011-0628; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Chen K, 2007, MOL CELL NEUROSCI, V36, P108, DOI 10.1016/j.mcn.2007.06.004; Coughlan T, 2009, INT J NEUROSCI, V119, P1718, DOI 10.1080/00207450903116430; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Fournier NM, 2012, BEHAV BRAIN RES, V227, P440, DOI 10.1016/j.bbr.2011.04.022; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Greenberg ME, 2009, J NEUROSCI, V29, P12764, DOI 10.1523/JNEUROSCI.3566-09.2009; Ishrat T, 2012, NEUROSCIENCE, V210, P442, DOI 10.1016/j.neuroscience.2012.03.008; Jiang C, 2013, BEHAV BRAIN RES, V250, P222, DOI 10.1016/j.bbr.2013.05.011; Jiang C, 2011, INT IMMUNOPHARMACOL, V11, P1925, DOI 10.1016/j.intimp.2011.08.001; Jiang C, 2009, INFLAMM RES, V58, P619, DOI 10.1007/s00011-009-0032-8; Jiang SZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086407; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kaur P, 2007, J NEUROSCI RES, V85, P2441, DOI 10.1002/jnr.21370; Khaibullina AA, 2004, DEV BRAIN RES, V148, P59, DOI 10.1016/j.devbrainres.2003.09.022; Klein RL, 1999, NEUROSCIENCE, V90, P815, DOI 10.1016/S0306-4522(98)00537-5; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Lacroix-Fralish ML, 2006, NEURON GLIA BIOL, V2, P227, DOI 10.1017/S1740925X07000385; Li J, 2011, J CEREBR BLOOD F MET, V31, P413, DOI 10.1038/jcbfm.2010.181; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Minnerup J, 2012, INT J MOL SCI, V13, P11753, DOI 10.3390/ijms130911753; Morita K, 2008, J MOL NEUROSCI, V34, P193, DOI 10.1007/s12031-007-9034-6; Moyse E, 2006, AUTON NEUROSCI-BASIC, V126, P50, DOI 10.1016/j.autneu.2006.03.006; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; Pencea V, 2001, J NEUROSCI, V21, P6706; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schabitz WR, 2007, STROKE, V38, P2165, DOI 10.1161/STROKEAHA.106.477331; Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016; Schumacher M, 2008, CURR OPIN PHARMACOL, V8, P740, DOI 10.1016/j.coph.2008.10.002; Stein DG, 2012, HORM BEHAV, DOI [10.1016/j.yhbeh.2012.1005.1004, DOI 10.1016/J.YHBEH.2012.1005.1004]; Suh H, 2009, ANNU REV CELL DEV BI, V25, P253, DOI 10.1146/annurev.cellbio.042308.113256; Vandromme M, 2008, CRIT CARE, V12, DOI 10.1186/cc6899; Wang JP, 2015, BRAIN BEHAV IMMUN, V45, P98, DOI 10.1016/j.bbi.2014.12.015; Wang JP, 2010, BEHAV BRAIN RES, V209, P119, DOI 10.1016/j.bbr.2010.01.026; Wojtal K, 2006, PHARMACOL REP, V58, P335; Won S, 2014, J CEREBR BLOOD F MET, V34, P72, DOI 10.1038/jcbfm.2013.163; Wu H, 2015, NEUROBIOL AGING, V36, P1439, DOI 10.1016/j.neurobiolaging.2014.12.029; Wu T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-22; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yao RQ, 2009, BRAIN RES BULL, V79, P69, DOI 10.1016/j.brainresbull.2008.12.010; Yousuf S, 2014, J CEREBR BLOOD F MET, V34, P297, DOI 10.1038/jcbfm.2013.198; Zan L, 2014, NEUROSCIENCE, V262, P118, DOI 10.1016/j.neuroscience.2013.12.060; Zan LK, 2011, NEUROCHEM INT, V58, P872, DOI 10.1016/j.neuint.2011.02.014; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhao XC, 2015, BRAIN BEHAV IMMUN, V46, P293, DOI 10.1016/j.bbi.2015.02.011	58	25	25	0	17	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JAN	2017	54	1					571	581		10.1007/s12035-015-9651-y			11	Neurosciences	Neurosciences & Neurology	EI0AO	WOS:000392133900047		Green Accepted			2021-06-18	
J	Manskow, US; Friborg, O; Roe, C; Braine, M; Damsgard, E; Anke, A				Manskow, Unn Sollid; Friborg, Oddgeir; Roe, Cecilie; Braine, Mary; Damsgard, Elin; Anke, Audny			Patterns of change and stability in caregiver burden and life satisfaction from 1 to 2 years after severe traumatic brain injury: A Norwegian longitudinal study	NEUROREHABILITATION			English	Article						Caregiver burden; life satisfaction; traumatic brain injury; social network	QUALITY-OF-LIFE; CLOSED-HEAD-INJURY; FAMILY CAREGIVERS; NATIONAL COHORT; RELATIVES; HEALTH; MULTICENTER; SCALE; CARE; PREDICTORS	OBJECTIVE: To assess burden and life satisfaction in family members of patients with severe traumatic brain injury (sTBI) at 1 and 2 years post-injury, examine if change in burden can be predicted by family member and patient demographics, patient's functional status, family members social network or level of burden at 1 year. METHODS: Prospective national multicenter study. Self-report from family members, patient data collected from a national cohort study on patients with sTBI. 80 family members participated. MAIN OUTCOME MEASURE: The Caregiver Burden Scale (CBS), life satisfaction. RESULTS: Total burden increased between years 1 and 2 post-injury (P = 0.04). Thirty percent of the family members reported an increased burden, 55% were stable, and 15% had a decrease in burden between the two follow-up times. Logistic regression analyses revealed that experiencing loneliness was an independent predictor of increased burden from 1 to 2 years post-injury (OR = 4.35, P < 0.05). Life Satisfaction was lower at the 2 year follow-up than at 1 year (p = 0.03). CONCLUSIONS: The results demonstrate a need for long-term follow-up of patients and family members that focuses on professional support to relieve burden and risk of loneliness or social isolation. This group may benefit from additional follow-up interventions tailored to their needs.	[Manskow, Unn Sollid; Anke, Audny] Univ Hosp North Norway, Dept Rehabil, Sykehusvegen 38, N-9038 Tromso, Norway; [Manskow, Unn Sollid; Damsgard, Elin] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Hlth & Care Sci, Tromso, Norway; [Friborg, Oddgeir] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Psychol, Tromso, Norway; [Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, Oslo, Norway; [Braine, Mary] Univ Salford, Fac Hlth & Social Care, Sch Nursing & Midwifery, Salford, Lancs, England; [Anke, Audny] Arctic Univ Norway, Fac Hlth Sci, Dept Clin Med, Tromso, Norway	Manskow, US (corresponding author), Univ Hosp North Norway, Dept Rehabil, Sykehusvegen 38, N-9038 Tromso, Norway.	unn.manskow@gmail.com		Anke, Audny/0000-0002-2491-2560; Friborg, Oddgeir/0000-0001-6629-0782	North Norwegian Health Authorities [8744/SFP1108-13]	This study was supported by grants from the North Norwegian Health Authorities (grant no. 8744/SFP1108-13).	Adelman RD, 2014, JAMA-J AM MED ASSOC, V311, P1052, DOI 10.1001/jama.2014.304; Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andren S, 2005, SCAND J CARING SCI, V19, P157, DOI 10.1111/j.1471-6712.2005.00328.x; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; Anke A, 2015, J HEAD TRAUMA REHAB, V30, pE38, DOI 10.1097/HTR.0000000000000080; Association for the Advancement of Automotive Medicine (AAAM), 2005, ABBR INJ SCAL AIS 20; Bayen E, 2016, J HEAD TRAUMA REHAB, V31, pE59, DOI 10.1097/HTR.0000000000000079; Bayen E, 2013, J HEAD TRAUMA REHAB, V28, P408, DOI 10.1097/HTR.0b013e31825413cf; Becker F, 2014, NEUROREHABILITATION, V34, P87, DOI 10.3233/NRE-131015; Bergstrom AL, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-1; Boycott N, 2013, J HEAD TRAUMA REHAB, V28, P106, DOI 10.1097/HTR.0b013e31823fe07e; Braine ME, 2011, J NEUROSCI NURS, V43, P156, DOI 10.1097/JNN.0b013e3182135bb2; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cacioppo JT, 2014, COGNITION EMOTION, V28, P3, DOI 10.1080/02699931.2013.837379; Copay AG, 2007, SPINE J, V7, P541, DOI 10.1016/j.spinee.2007.01.008; Dahlrup B, 2011, CLIN INTERV AGING, V6, P9, DOI 10.2147/CIA.S14237; Diener E, 2003, ANNU REV PSYCHOL, V54, P403, DOI 10.1146/annurev.psych.54.101601.145056; Doser K, 2016, BRAIN INJURY, V30, P334, DOI 10.3109/02699052.2015.1114143; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Elmstahl S, 1996, ARCH PHYS MED REHAB, V77, P177, DOI 10.1016/S0003-9993(96)90164-1; Fayers PM, 2007, J CLIN EPIDEMIOL, V60, P1034, DOI 10.1016/j.jclinepi.2007.03.005; Fayers PM, 2002, LANCET, V359, P187, DOI 10.1016/S0140-6736(02)07466-4; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Fujita F, 2005, J PERS SOC PSYCHOL, V88, P158, DOI 10.1037/0022-3514.88.1.158; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Godwin EE, 2013, BRAIN INJURY, V27, P637, DOI 10.3109/02699052.2012.750745; Gottlieb BH, 2010, J PSYCHOSOM RES, V69, P511, DOI 10.1016/j.jpsychores.2009.10.001; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; Kasuya RT, 2000, POSTGRAD MED, V108, P119, DOI 10.3810/pgm.2000.12.1324; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Livingston LA, 2010, NEUROREHABILITATION, V27, P73, DOI 10.3233/NRE-2010-0582; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Manskow US, 2015, J HEAD TRAUMA REHAB, V30, P411, DOI 10.1097/HTR.0000000000000085; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; Nicholson NR, 2012, J PRIM PREV, V33, P137, DOI 10.1007/s10935-012-0271-2; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Norup A, 2015, NEUROREHABILITATION, V36, P203, DOI 10.3233/NRE-151208; Norup A, 2012, BRAIN INJURY, V26, P1192, DOI 10.3109/02699052.2012.672790; Norup A, 2010, BRAIN INJURY, V24, P81, DOI 10.3109/02699050903508200; O'Neill L J, 1998, Br J Nurs, V7, P842; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perlesz A, 1998, INT J REHABIL RES, V21, P339, DOI 10.1097/00004356-199812000-00001; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Ramkumar NA, 2010, NEUROREHABILITATION, V27, P105, DOI 10.3233/NRE-2010-0585; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Simpson G, 2013, CLIN REHABIL, V27, P367, DOI 10.1177/0269215512457961; Sundstrom Terje, 2005, Tidsskr Nor Laegeforen, V125, P1310; TEASDALE G, 1974, LANCET, V2, P81; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	61	25	25	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2017	40	2					211	222		10.3233/NRE-161406			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ER7FW	WOS:000398976700006	27935561				2021-06-18	
J	Winkler, EA; Yue, JK; Ferguson, AR; Temkin, NR; Stein, MB; Barber, J; Yuh, EL; Sharma, S; Satris, GG; McAllister, TW; Rosand, J; Sorani, MD; Lingsma, HF; Tarapore, PE; Burchard, EG; Hui, DL; Eng, C; Wang, KKW; Mukherjee, P; Okonkwo, DO; Diaz-Arrastia, R; Manley, GT				Winkler, Ethan A.; Yue, John K.; Ferguson, Adam R.; Temkin, Nancy R.; Stein, Murray B.; Barber, Jason; Yuh, Esther L.; Sharma, Sourabh; Satris, Gabriela G.; McAllister, Thomas W.; Rosand, Jonathan; Sorani, Marco D.; Lingsma, Hester F.; Tarapore, Phiroz E.; Burchard, Esteban G.; Hui, Donglei; Eng, Celeste; Wang, Kevin K. W.; Mukherjee, Pratik; Okonkwo, David O.; Diaz-Arrastia, Ramon; Manley, Geoffrey T.		TRACK-TBI Investigators	COMT Val(158)Met polymorphism is associated with post-traumatic stress disorder and functional outcome following mild traumatic brain injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Traumatic brain injury; Genetic factors; PTSD; Outcome measures; Human studies	CATECHOL-O-METHYLTRANSFERASE; COMMON DATA ELEMENTS; PSYCHIATRIC-DISORDERS; PSYCHOLOGICAL HEALTH; GENE POLYMORPHISMS; GENOTYPE; RESILIENCE; RISK; SCHIZOPHRENIA; ABNORMALITIES	Mild traumatic brain injury (mTBI) results in variable clinical trajectories and outcomes. The source of variability remains unclear, but may involve genetic variations, such as single nucleotide polymorphisms (SNPs). A SNP in catechol-o-methyltransferase (COMT) is suggested to influence development of post traumatic stress disorder (PTSD), but its role in TBI remains unclear. Here, we utilize the Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot (TRACK-TBI Pilot) study to investigate whether the COMT Val(158)Met polymorphism is associated with PTSD and global functional outcome as measured by the PTSD Checklist - Civilian Version and Glasgow Outcome Scale Extended (GOSE), respectively. Results in 93 predominately Caucasian subjects with mTBI show that the COMT Met(158) allele is associated with lower incidence of PTSD (univariate odds ratio (OR) of 0.25, 95% CI [0.09-0.69]) and higher GOSE scores (univariate OR 2.87, 95% CI [1.20-6.861) 6-months following injury. The COMT Val(158)Met genotype and PTSD association persists after controlling for race (multivariable OR of 0.29, 95% CI [0.10-0.83]) and pre-existing psychiatric disorders/substance abuse (multivariable OR of 0.32, 95% CI [0.11-0.97]). PTSD emerged as a strong predictor of poorer outcome on GOSE (multivariable OR 0.09, 95% CI 10.03-0.26]), which persists after controlling for age, GCS, and race. When accounting for PTSD in multivariable analysis, the association of COMT genotype and GOSE did not remain significant (multivariable OR 1.73, 95% CI [0.69-4.35]). Whether COMT genotype indirectly influences global functional outcome through PTSD remains to be determined and larger studies in more diverse populations are needed to confirm these findings. (C) 2016 Elsevier Ltd. All rights reserved.	[Winkler, Ethan A.; Yue, John K.; Ferguson, Adam R.; Sharma, Sourabh; Satris, Gabriela G.; Sorani, Marco D.; Tarapore, Phiroz E.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Winkler, Ethan A.; Yue, John K.; Ferguson, Adam R.; Sharma, Sourabh; Satris, Gabriela G.; Sorani, Marco D.; Tarapore, Phiroz E.; Mukherjee, Pratik; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Temkin, Nancy R.] Univ Washington, Dept Neurol Surg & Biostat, Seattle, WA 98195 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family & Preventat Med, San Diego, CA 92103 USA; [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Rosand, Jonathan] Harvard Med Sch, Dept Neurol, Boston, MA USA; [Rosand, Jonathan] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA; [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Burchard, Esteban G.; Hui, Donglei; Eng, Celeste] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32610 USA; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Ferguson, Adam/0000-0001-7102-1608; Temkin, Nancy/0000-0002-6392-5292; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Wang, Kevin/0000-0002-9343-6473	DOD USAMRAAUnited States Department of Defense [W81XWH-13-1-0441];  [NIH RC2 NS069409];  [NIH RC2 NS069409-02S1];  [NIH U01 NS086090-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, RC2NS069409] Funding Source: NIH RePORTER	This work was supported by the following grants: NIH RC2 NS069409, NIH RC2 NS069409-02S1, NIH U01 NS086090-01, DOD USAMRAA W81XWH-13-1-0441.	Agren T, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.5; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Association AP, 1994, DIAGN STAT MAN MENT; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Brady KT, 2000, J CLIN PSYCHIAT, V61, P22; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589; Clark R, 2013, J PSYCHIATR RES, V47, P1849, DOI 10.1016/j.jpsychires.2013.08.013; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Davidson J, 2015, NEUROSCIENTIST, V21, P424, DOI 10.1177/1073858414543150; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dickinson D, 2009, NEUROSCIENCE, V164, P72, DOI 10.1016/j.neuroscience.2009.05.014; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flashman L.A., 2004, J NEUROPSYCHIATRY CL, V16, P238; Gatt JM, 2015, J PSYCHIATR RES, V60, P1, DOI 10.1016/j.jpsychires.2014.09.014; Graham DP, 2013, J PSYCHIATR RES, V47, P835, DOI 10.1016/j.jpsychires.2013.02.006; Hapke U, 2006, EUR ARCH PSY CLIN N, V256, P299, DOI 10.1007/s00406-006-0654-6; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Heinz A, 2006, REV NEUROSCIENCE, V17, P359; Hill Shirley Y, 2013, Adv J Mol Imaging, V3, P43; Ho BC, 2005, MOL PSYCHIATR, V10, P287, DOI 10.1038/sj.mp.4001616; Hong SB, 2015, HUM BRAIN MAPP, V36, P367, DOI 10.1002/hbm.22634; Humphreys KL, 2014, J CHILD ADOL PSYCHOP, V24, P454, DOI 10.1089/cap.2014.0077; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Kang JI, 2013, NEUROPSYCHOBIOLOGY, V68, P174, DOI 10.1159/000353257; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Klucken T, 2015, HUM BRAIN MAPP, V36, P1093, DOI 10.1002/hbm.22688; Kolassa IT, 2010, BIOL PSYCHIAT, V67, P304, DOI 10.1016/j.biopsych.2009.10.009; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Lonsdorf TB, 2009, PSYCHOL SCI, V20, P198, DOI 10.1111/j.1467-9280.2009.02280.x; LOTTA T, 1995, BIOCHEMISTRY-US, V34, P4202, DOI 10.1021/bi00013a008; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Valente NLM, 2011, J MOL NEUROSCI, V43, P516, DOI 10.1007/s12031-010-9474-2; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Mier D, 2010, MOL PSYCHIATR, V15, P918, DOI 10.1038/mp.2009.36; Ohnishi T, 2006, BRAIN, V129, P399, DOI 10.1093/brain/awh702; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Raczka KA, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.10; Sandweiss DA, 2011, ARCH GEN PSYCHIAT, V68, P496, DOI 10.1001/archgenpsychiatry.2011.44; Stein DJ, 2006, CNS SPECTRUMS, V11, P745, DOI 10.1017/S1092852900014863; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tunbridge EM, 2006, BIOL PSYCHIAT, V60, P141, DOI 10.1016/j.biopsych.2005.10.024; Wang YJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/293687; Waters RJ, 2013, J NEUROTRAUM, V30, P1710, DOI 10.1089/neu.2012.2792; Weathers F, 1993, 9 ANN CONV INT SOC T; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilker S, 2014, NEUROBIOL LEARN MEM, V112, P75, DOI 10.1016/j.nlm.2013.08.015; Willmott C, 2014, J NEUROTRAUM, V31, P1507, DOI 10.1089/neu.2013.3308; Willmott C, 2013, BRAIN INJURY, V27, P1281, DOI 10.3109/02699052.2013.809553; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Witte AV, 2012, BRAIN RES BULL, V88, P418, DOI 10.1016/j.brainresbull.2011.11.012; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	61	25	25	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	JAN	2017	35						109	116		10.1016/j.jocn.2016.09.017			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EI2YS	WOS:000392356700024	27769642	Green Accepted			2021-06-18	
J	Shen, L; Wang, Z; Su, ZZ; Qiu, S; Xu, J; Zhou, Y; Yan, A; Yin, R; Lu, B; Nie, XH; Zhao, SF; Yan, RF				Shen, Liang; Wang, Zhuo; Su, Zhongzhou; Qiu, Sheng; Xu, Jie; Zhou, Yue; Yan, Ai; Yin, Rui; Lu, Bin; Nie, Xiaohu; Zhao, Shufa; Yan, Renfu			Effects of Intracranial Pressure Monitoring on Mortality in Patients with Severe Traumatic Brain Injury: A Meta-Analysis	PLOS ONE			English	Article							CEREBRAL PERFUSION-PRESSURE; INTENSIVE-CARE; MANAGEMENT; CHILDREN; REACTIVITY; MODERATE; IMPACT; TRIAL	Background The Brain Trauma Foundation (BTF) guidelines published in 2007 suggest some indications for intracranial pressure (ICP) monitoring in severe traumatic brain injury (TBI). However, some studies had not shown clinical benefit in patients with severe TBI; several studies had even reported that ICP monitoring was associated with an increased mortality rate. The effect of ICP monitoring has remained controversial, regardless of the ICP monitoring guidelines. Here we performed a meta-analysis of published studies to assess the effects of ICP monitoring in patients with severe TBI. Methods We searched three comprehensive databases, the Cochrane Library, PUBMED, and EMBASE, for studies without limitations published up to September 2015. Mortality, ICU LOS, and hospital LOS were analyzed with Review Manager software according to data from the included studies. Results Eighteen eligible studies involving 25229 patients with severe TBI were included in our meta-analysis. The results indicated no significant reduction in the ICP monitored group in mortality (hospitalized before 2007), hospital mortality (hospitalized before 2007), mortality in randomized controlled trials. However, overall mortality, mortality (hospitalized after 2007), hospital mortality (hospitalized after 2007), mortality in observational studies (hospitalized after 2007), 2-week mortality, 6-month mortality, were reduced in ICP monitored group. Patients with an increased ICP were more likely to require ICP monitoring. Conclusion Superior survival was observed in severe TBI patients with ICP monitoring since the third edition of "Guidelines for the Management of Severe Traumatic Brain Injury," which included "Indications for intracranial pressure monitoring," was published in 2007.	[Shen, Liang; Su, Zhongzhou; Qiu, Sheng; Xu, Jie; Zhou, Yue; Yan, Ai; Yin, Rui; Lu, Bin; Nie, Xiaohu; Zhao, Shufa; Yan, Renfu] Huzhou Cent Hosp, Dept Neurosurg, Huzhou, Zhejiang, Peoples R China; [Wang, Zhuo] Huzhou Univ, Coll Nursing, Dept Med Coll, Huzhou, Zhejiang, Peoples R China	Yan, RF (corresponding author), Huzhou Cent Hosp, Dept Neurosurg, Huzhou, Zhejiang, Peoples R China.	20125232086@suda.edu.cn					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Agrawal D, 2015, J NEUROTRAUMA; Alali AS, 2015, J NEUROSURG-PEDIATR, V16, P523, DOI 10.3171/2015.3.PEDS14507; Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Biersteker HAR, 2012, CRIT CARE MED, V40, P1914, DOI 10.1097/CCM.0b013e3182474bde; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bratton SI, GUIDELINES MANAGEMEN, VVIII; Carney N, 2016, NEUROSURGERY; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dawes AJ, 2015, J TRAUMA ACUTE CARE, V78, P492, DOI 10.1097/TA.0000000000000559; Dings J, 1996, ZBL NEUROCHIR, V57, P177; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Gao L, 2013, WORLD NEUROSURG, V80, P879, DOI 10.1016/j.wneu.2013.01.020; Griesdale DEG, 2010, CAN J NEUROL SCI, V37, P43, DOI 10.1017/S031716710000963X; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; Haddad S, 2011, ANAESTH INTENS CARE, V39, P1043, DOI 10.1177/0310057X1103900610; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Kim DR, 2014, J KOREAN NEUROSURG S, V55, P26, DOI 10.3340/jkns.2014.55.1.26; Korley FK, 2015, J HEAD TRAUMA REHABI; Koskinen LOD, 2014, NEUROSCIENCE, V283, P245, DOI 10.1016/j.neuroscience.2014.06.039; Kostic Aleksandar, 2011, Med Pregl, V64, P461; Kukreti V, 2014, J PEDIATR NEUROSCI, V9, P207, DOI 10.4103/1817-1745.147572; Lang EW, 2016, ACTA NEUROCHIR SUPPL, V122, P221, DOI 10.1007/978-3-319-22533-3_44; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Rosso A, 2007, WIEN KLIN WOCHENSCHR, V119, P29, DOI 10.1007/s00508-006-0761-4; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Soeken KL, 2003, NURS RES, V52, P57, DOI 10.1097/00006199-200301000-00009; Su SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087432; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Tang A, 2015, J SURG RES, V194, P565, DOI 10.1016/j.jss.2014.11.017; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Wells GA., NEWCASTLE OTTAWA SCA; Yuan Q, 2015, CRIT CARE MED, V43, P1405, DOI 10.1097/CCM.0000000000000965; Yuan Q, 2015, J NEUROSURG, V122, P574, DOI 10.3171/2014.10.JNS1460; Zhou ZR, 2013, J CANCER RES CLIN, V139, P783, DOI 10.1007/s00432-013-1383-7; Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048	48	25	27	5	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2016	11	12							e0168901	10.1371/journal.pone.0168901			15	Multidisciplinary Sciences	Science & Technology - Other Topics	EG7JB	WOS:000391222000083	28030638	DOAJ Gold, Green Published			2021-06-18	
J	Naeser, MA; Martin, PI; Ho, MD; Krengel, MH; Bogdanova, Y; Knight, JA; Yee, MK; Zafonte, R; Frazier, J; Hamblin, MR; Koo, BB				Naeser, Margaret A.; Martin, Paula I.; Ho, Michael D.; Krengel, Maxine H.; Bogdanova, Yelena; Knight, Jeffrey A.; Yee, Megan K.; Zafonte, Ross; Frazier, Judith; Hamblin, Michael R.; Koo, Bang-Bon			Transcranial, Red/Near-Infrared Light-Emitting Diode Therapy to Improve Cognition in Chronic Traumatic Brain Injury	PHOTOMEDICINE AND LASER SURGERY			English	Article						traumatic brain injury; TBI; photobiomodulation; PBM; TBI treatment; cognitive dysfunction; light-emitting diodes; LED; postconcussion syndrome; sports head injury; PTSD; LLLT	POSTTRAUMATIC-STRESS-DISORDER; LEVEL LASER THERAPY; COLLEGIATE FOOTBALL PLAYERS; DEFAULT MODE NETWORK; INTRINSIC CONNECTIVITY NETWORKS; CONTROLLED CORTICAL IMPACT; ALTERED WORKING-MEMORY; DIFFUSE AXONAL INJURY; FUNCTIONAL CONNECTIVITY; HEAD-INJURY	Objective: We review the general topic of traumatic brain injury (TBI) and our research utilizing transcranial photobiomodulation (tPBM) to improve cognition in chronic TBI using red/near-infrared (NIR) light-emitting diodes (LEDs) to deliver light to the head. tPBM improves mitochondrial function increasing oxygen consumption, production of adenosine triphosphate (ATP), and improving cellular energy stores. Nitric oxide is released from the cells increasing regional blood flow in the brain. Review of published studies: In our previously published study, 11 chronic TBI patients with closed-head TBI caused by different accidents (motor vehicle accident, sports-related, improvised explosive device blast injury) and exhibiting long-lasting cognitive dysfunction received 18 outpatient treatments (Monday, Wednesday, Friday for 6 weeks) starting at 10 months to 8 years post-TBI. LED therapy is nonthermal, painless, and noninvasive. An LED-based device classified as nonsignificant risk (FDA cleared) was used. Each LED cluster head (5.35 cm diameter, 500mW, 22.2 mW/cm(2)) was applied for 9 min 45 sec (13 J/cm(2)) using 11 locations on the scalp: midline from front-to-back hairline and bilaterally on frontal, parietal, and temporal areas. Testing was performed before and after transcranial LED (tLED; at 1 week, 1 month, and at 2 months after the 18th treatment) and showed significant improvements in executive function and verbal memory. There were also fewer post-traumatic stress disorder (PTSD) symptoms reported. Ongoing studies: Ongoing, current studies involve TBI patients who have been treated with tLED using either 26 J/cm(2) per LED location on the head or treated with intranasal only (iLED) using red (633 nm) and NIR (810 nm) diodes placed into the nostrils. The NIR iLED is hypothesized to deliver photons to the hippocampus, and the red 633 nm iLED is believed to increase melatonin. Results have been similar to the previously published tLED study. Actigraphy sleep data showed increased time asleep (on average one additional hour per night) after the 18th tLED or iLED treatment. LED treatments may be performed in the home. Sham-controlled studies with veterans who have cognitive dysfunction from Gulf War Illness, blast TBI, and TBI/PTSD are currently ongoing.	[Naeser, Margaret A.; Martin, Paula I.; Ho, Michael D.; Krengel, Maxine H.; Bogdanova, Yelena; Knight, Jeffrey A.; Yee, Megan K.] VA Boston Healthcare Syst 12A, 150 So Huntington Ave, Boston, MA 02130 USA; [Naeser, Margaret A.; Martin, Paula I.; Ho, Michael D.; Krengel, Maxine H.; Yee, Megan K.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Bogdanova, Yelena; Knight, Jeffrey A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Knight, Jeffrey A.] VA Boston Healthcare Syst, Behav Sci Div, Natl Ctr PTSD, Boston, MA USA; [Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Zafonte, Ross] Harvard Med Sch, Dept Dermatol, Boston, MA USA; [Zafonte, Ross] Spaulding Rehabil Hosp, Charlestown, MA USA; [Frazier, Judith] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Hamblin, Michael R.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Hamblin, Michael R.] Spaulding Rehabil Hosp, TBI Res Program, Charlestown, MA USA; [Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA USA; [Koo, Bang-Bon] Boston Univ, Ctr Biomed Imaging, Boston, MA 02215 USA	Naeser, MA (corresponding author), VA Boston Healthcare Syst 12A, 150 So Huntington Ave, Boston, MA 02130 USA.	mnaeser@bu.edu	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605; Ho, Michael/0000-0002-6648-7806	PTSD; Army Medical Department Advanced Medical Technology Initiative; Veterans AffairsUS Department of Veterans Affairs [I21RX001773] Funding Source: NIH RePORTER	Additional pilot clinical studies with tLED are being carried out at the VA Boston Healthcare System. Dr. Jeffrey Knight at the National Center for PTSD has received VA funding to carry out a pilot study using real versus sham tLED to see whether PBM can reduce symptoms of PTSD and improve cognitive function in veterans who had suffered TBI. Dr. Yelena Bogdanova is conducting a similar study of real versus sham tLED and iLED to improve sleep and cognition in veterans who have sustained TBI. Dr. Margaret Naeser is conducting a trial with VA funding to test whether real versus sham tLED and iLED can improve cognitive function in veterans suffering from Gulf War Illness. Dr. Carole Palumbo is testing the ability of tLED and iLED applied to active duty soldiers who have suffered blast TBI with funding from the Army Medical Department Advanced Medical Technology Initiative. Dr. Palumbo is an investigator at the U.S. Army Institute of Environmental Medicine.	Aimbire F, 2005, LASER MED SCI, V20, P11, DOI 10.1007/s10103-005-0339-9; Albertini R, 2007, INFLAMM RES, V56, P228, DOI 10.1007/s00011-007-6211-6; Avci P, 2014, LASER SURG MED, V46, P144, DOI 10.1002/lsm.22170; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Boelen DHE, 2011, J NEUROPSYCHOL, V5, P73, DOI 10.1348/174866410X516434; Bogdanova Y., 2014, ARCH PHYS MED REHAB, V95, pe77; Bogdanova Y, 2015, J HEAD TRAUMA REHAB, V30, pE101; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Castano AP, 2007, LASER SURG MED, V39, P543, DOI 10.1002/lsm.20516; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Daniels JK, 2013, PSYCHOL TRAUMA-US, V5, P142, DOI 10.1037/a0026946; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faraguna U, 2008, J NEUROSCI, V28, P4088, DOI 10.1523/JNEUROSCI.5510-07.2008; Faul M., 2013, TRAUMATIC BRAIN INJU; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gilbert KS, 2015, CLIN PSYCHOL REV, V40, P195, DOI 10.1016/j.cpr.2015.05.008; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hanson ND, 2011, NEUROPSYCHOPHARMACOL, V36, P2589, DOI 10.1038/npp.2011.220; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang YY, 2013, J BIOPHOTONICS, V6, P829, DOI 10.1002/jbio.201200157; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krewer C, 2016, J NEUROTRAUM, V33, P1544, DOI 10.1089/neu.2015.4109; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Levin HS, 2013, J NEUROTRAUM, V30, P625, DOI 10.1089/neu.2012.2627; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2012, LANCET NEUROL, V11, P12, DOI 10.1016/S1474-4422(11)70267-8; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2011, INT J PSYCHOPHYSIOL, V82, P107, DOI 10.1016/j.ijpsycho.2011.06.022; McAllister TW, 2011, J NEUROPSYCH CLIN N, V23, P277, DOI 10.1176/appi.neuropsych.23.3.277; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McAllister TW., 2002, J NEUROPSYCHIATRY CL, V14, P116; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Menon V, 2011, TRENDS COGN SCI, V15, P483, DOI 10.1016/j.tics.2011.08.003; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Mi XQ, 2004, PHOTOMED LASER SURG, V22, P477, DOI 10.1089/pho.2004.22.477; Migliario M, 2014, LASER MED SCI, V29, P1463, DOI 10.1007/s10103-014-1556-x; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Naeser M, 2012, PROCD SOC BEHV, V61, P138, DOI 10.1016/j.sbspro.2012.10.116; Naeser MA, 2015, PROC SPIE, V9467, DOI 10.1117/12.2176345; Naeser MA, 2014, J NEUROTRAUM, V31, P1008, DOI 10.1089/neu.2013.3244; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Nawashiro H, 2012, PHOTOMED LASER SURG, V30, P231, DOI 10.1089/pho.2011.3044; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Provenzale JM, 2010, AM J ROENTGENOL, V194, P16, DOI 10.2214/AJR.09.3687; Raichle ME, 2015, ANNU REV NEUROSCI, V38, P433, DOI 10.1146/annurev-neuro-071013-014030; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao V, 2014, BRAIN INJURY, V28, P20, DOI 10.3109/02699052.2013.847210; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Saltmarche AE, PHOTOMED LA IN PRESS; Saper CB, 2001, TRENDS NEUROSCI, V24, P726, DOI 10.1016/S0166-2236(00)02002-6; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Sompol P, 2006, J MOL NEUROSCI, V29, P279, DOI 10.1385/JMN:29:3:279; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P917, DOI 10.1017/S1355617712000458; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tuby H, 2006, LASER SURG MED, V38, P682, DOI 10.1002/lsm.20377; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xuan WJ, 2015, J BIOPHOTONICS, V8, P502, DOI 10.1002/jbio.201400069; Xuan WJ, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.10.108003; Zafonte R, 2009, PROG BRAIN RES, V177, P293, DOI 10.1016/S0079-6123(09)17720-8; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; ZHANG YH, 1994, INFECT IMMUN, V62, P4140, DOI 10.1128/IAI.62.10.4140-4144.1994; Zhao JX, 2012, J ATHL TRAINING, V47, P673, DOI 10.4085/1062-6050-47.6.08	131	25	25	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1549-5418	1557-8550		PHOTOMED LASER SURG	Photomed. Laser Surg.	DEC	2016	34	12					610	626		10.1089/pho.2015.4037			17	Surgery	Surgery	EH5ZN	WOS:000391852000004	28001756				2021-06-18	
J	Gioia, GA; Glang, AE; Hooper, SR; Brown, BE				Gioia, Gerard A.; Glang, Ann E.; Hooper, Stephen R.; Brown, Brenda Eagan			Building Statewide Infrastructure for the Academic Support of Students With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						academic outcomes; intervention strategies; mild TBI; school management; statewide infrastructure	SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; KNOWLEDGE; EDUCATION; SYMPTOMS; CHILDREN; PATHOPHYSIOLOGY; STATEMENT; RECOVERY; REST	Objectives: To focus attention on building statewide capacity to support students with mild traumatic brain injury (mTBI)/concussion. Method: Consensus-building process with a multidisciplinary group of clinicians, researchers, policy makers, and state Department of Education personnel. Results: The white paper presents the group's consensus on the essential components of a statewide educational infrastructure to support the management of students with mTBI. The nature and recovery process of mTBI are briefly described specifically with respect to its effects on school learning and performance. State and local policy considerations are then emphasized to promote implementation of a consistent process. Five key components to building a statewide infrastructure for students with mTBI are described including (1) definition and training of the interdisciplinary school team, (2) professional development of the school and medical communities, (3) identification, assessment, and progress monitoring protocols, (4) a flexible set of intervention strategies to accommodate students' recovery needs, and (5) systematized protocols for active communication among medical, school, and family team members. The need for a research to guide effective program implementation is stressed. Conclusion: This guiding framework strives to assist the development of support structures for recovering students with mTBI to optimize academic outcomes. Until more evidence is available on academic accommodations and other school-based supports, educational systems should follow current best practice guidelines.	[Gioia, Gerard A.] Childrens Natl Med Ctr, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Ste 350, Rockville, MD 20850 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Pediat & Psychiat & Behav Sci, Washington, DC USA; [Glang, Ann E.] Univ Oregon, Ctr Brain Injury Res & Training, Eugene, OR 97403 USA; [Glang, Ann E.] ORCAS, Eugene, OR USA; [Hooper, Stephen R.] Univ N Carolina, Sch Med, Dept Allied Hlth Sci, Chapel Hill, NC USA; [Brown, Brenda Eagan] Brain Injury Assoc Penn, BrainSTEPS State Program, Carlisle, PA USA	Gioia, GA (corresponding author), Childrens Natl Med Ctr, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Ste 350, Rockville, MD 20850 USA.	ggioia@cnmc.org	Hooper, Stephen/X-8171-2019				Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Becker MH, 1974, HLTH ED MONOGR, V2; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Centers for Disease Control and Prevention, HEADS SCH KNOW YOUR; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061865; Davies SC, 2013, CONCUSSION AWARENESS; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Demorest RA, 2005, PEDIATRICS, V115, P28, DOI 10.1542/peds.2004-0266; Dettmer J, 2014, J HEAD TRAUMA REHAB, V29, P224, DOI 10.1097/HTR.0b013e3182a1cd68; Diaz AL, 2012, CONCUSSIONS ROLE SCH; Eagan Brown B, 2013, BRAINSTEPS CONCUSSIO; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Evans K, 2009, CONT ISSUES COMMUN S, V36, P166; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2016, J CHILD NEUROL, V31, P93, DOI 10.1177/0883073814555604; Gioia GA, 2015, BRAIN INJURY, V29, P195, DOI 10.3109/02699052.2014.965210; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Glang A, 2008, NEUROREHABILITATION, V23, P477; Glang AE, 2015, J ADOLESCENT HEALTH, V56, P91, DOI 10.1016/j.jadohealth.2014.08.011; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Henehan M, 2003, CLIN J SPORT MED, V13, P285, DOI 10.1097/00042752-200309000-00003; Heyer GL, 2015, J PEDIATR-US, V166, P594, DOI 10.1016/j.jpeds.2014.09.038; Hooper S., 2006, EXCEPTIONALITY, V14, P171, DOI DOI 10.1207/s15327035ex1403_5; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Institute of Medicine and National Research Council, 2013, SPORTS REL CONC YOUT; Institute of Medicine's Committee on Sports-Related Concussions in Youth, 2013, SPORTS RELATED CONCU; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly JP, 1997, NEUROLOGY, V48, P581; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Lin AC, 2015, SPORTS HEALTH, V7, P124, DOI 10.1177/1941738115571570; Lincoln AE, 2011, AM J SPORTS MED; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; Mazmanian PE, 2009, CHEST, V135, p49S, DOI 10.1378/chest.08-2518; McAvoy K, 2009, REAP BENEFITS GOOD C; McAvoy K, 2012, BRAIN INJ PROF, V9, P26; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Mckinlay A, 2011, BRAIN INJURY, V25, P761, DOI 10.3109/02699052.2011.579935; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Nygren-de Boussard Catharina, 2014, Arch Phys Med Rehabil, V95, pS257, DOI 10.1016/j.apmr.2013.10.009; O'Brien LM, 2009, CHILD ADOL PSYCH CL, V18, P813, DOI 10.1016/j.chc.2009.04.008; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Popoli DM, 2014, CLIN PEDIATR, V53, P217, DOI 10.1177/0009922813499070; PREMI J, 1994, ACAD MED, V69, P800, DOI 10.1097/00001888-199410000-00002; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Smits PBA, 2002, BMJ-BRIT MED J, V324, P153, DOI 10.1136/bmj.324.7330.153; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Zemek R., 2014, GUIDELINES DIAGNOSIN; Zirkel PA, 2015, J SCH NURS, V31, P99, DOI 10.1177/1059840514521465; Zonfrillo MR, 2014, J NEUROTRAUM, V31, P722, DOI 10.1089/neu.2013.3088; Zuckerbraun NS, 2014, PEDIATRICS, V133, P635, DOI 10.1542/peds.2013-2600	86	25	25	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2016	31	6					397	406		10.1097/HTR.0000000000000205			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EC0IW	WOS:000387784800011	26709582				2021-06-18	
J	Mathew, MJ; Deepika, A; Shukla, D; Devi, BI; Ramesh, VJ				Mathew, Manish Joseph; Deepika, Akhil; Shukla, Dhaval; Devi, Bhagavatula Indira; Ramesh, Venkatapura J.			Paroxysmal sympathetic hyperactivity in severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Paroxysmal sympathetic hyperactivity; Dysautonomia; Disability	INTENSIVE-CARE-UNIT; AUTONOMIC INSTABILITY; DIAGNOSTIC-CRITERIA; DYSAUTONOMIA; DYSTONIA; SEIZURES	Paroxysmal sympathetic hyperactivity (PSH) is a less-known complication of traumatic brain injury (TBI). This study was done to assess the clinical features and outcome of patients who develop PSH following severe TBI. A prospective observational study was done on patients, admitted in the intensive care unit, for treatment of severe TBI. The clinical characteristics and outcome of patients, with and without PSH, was compared. At the time of discharge, patients were assessed with the Disability Rating Scale (DRS), and at 6 months with the Glasgow Outcome Score Extended (GOSE). The incidence of PSH was 8 % (29/343). Tachycardia, hypertension, and sweating were seen in all of the patients. Tachypnea was seen in 24 (82.8 %), hyperthermia in 28 (96.6 %), and posturing in 13 (44.8 %) patients. Thirteen (44.8 %) patients had all six symptoms of PSH. Follow-up data were available for 23 (79.3 %) patients. At the end of 6 months, 14 (60.9 %) patients had died, seven (30.4 %) were severely disabled, and two (8.7 %) were moderately disabled. There was a significant correlation of GOSE with the number of symptoms of PSH (Spearman's rho = 0.502, p = 0.015). The patients with PSH had significantly higher DRS scores at discharge, 25.3 vs. 19.9, p < 0.001; higher mortality at 6 months 60.9 vs. 30.4 %, p < 0.001; and higher proportions with unfavorable outcome. Presence of PSH in patients with severe TBI was associated with prolonged hospital stay, poorer DRS at discharge, more deaths, and unfavorable outcome. The number of symptoms of PSH had a significant effect on outcome at 6 months.	[Mathew, Manish Joseph; Shukla, Dhaval; Devi, Bhagavatula Indira] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India; [Deepika, Akhil] Natl Inst Mental Hlth & Neurosci, Clin Neurosci, Bangalore, Karnataka, India; [Ramesh, Venkatapura J.] Natl Inst Mental Hlth & Neurosci, Neuroanesthesiol & Neuroctit Care, Bangalore, Karnataka, India	Shukla, D (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India.	neurodhaval@rediffmail.com	Ramesh, Venkatapura J/H-1147-2013	MATHEW, MANISH JOSEPH/0000-0002-8566-5954; Shukla, Dhaval/0000-0001-7613-1929			Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; Deepika A, 2015, AUTON NEUROSCI-BASIC, V193, P149, DOI 10.1016/j.autneu.2015.08.003; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Fernandez-Ortega JF, 2004, REV NEUROLOGIA, V39, P715, DOI 10.33588/rn.3908.2004034; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Goddeau RP, 2007, NEUROCRIT CARE, V7, P217, DOI 10.1007/s12028-007-0066-0; Hinson HE, 2012, CURR OPIN CRIT CARE, V18, P139, DOI 10.1097/MCC.0b013e3283513290; Perkes IE, 2011, BRAIN INJURY, V25, P925, DOI 10.3109/02699052.2011.589797; Pozzi M, 2015, J HEAD TRAUMA REHAB, V30, P357, DOI 10.1097/HTR.0000000000000084; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Sander A., 2002, EXTENDED GLASGOW OUT; Srinivasan S, 2007, CLIN AUTON RES, V17, P378, DOI 10.1007/s10286-007-0428-x; Wright J., 2000, DISABILITY RATING SC	18	25	30	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2016	158	11					2047	2052		10.1007/s00701-016-2934-x			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EA1OR	WOS:000386362200003	27581717				2021-06-18	
J	Reynolds, BB; Patrie, J; Henry, EJ; Goodkin, HP; Broshek, DK; Wintermark, M; Druzgal, TJ				Reynolds, Bryson B.; Patrie, James; Henry, Erich J.; Goodkin, Howard P.; Broshek, Donna K.; Wintermark, Max; Druzgal, T. Jason			Quantifying Head Impacts in Collegiate Lacrosse	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries/concussion; female sports; lacrosse; biomechanics; subconcussion	INJURY SURVEILLANCE SYSTEM; VIDEO INCIDENT ANALYSIS; HIGH-SCHOOL FOOTBALL; STATES HIGH-SCHOOL; UNITED-STATES; DESCRIPTIVE EPIDEMIOLOGY; IN-VIVO; CONCUSSION; SPORTS; EXPOSURE	Background: Concussion and repetitive head impact in sports has increased interest and concern for clinicians, scientists, and athletes. Lacrosse is the fastest growing sport in the United States, but the burden of head impact in lacrosse is unknown. Purpose: The goal of this pilot study was to quantify head impact associated with practicing and playing collegiate lacrosse while subjects were fitted with wearable accelerometers. Study Design: Descriptive epidemiology study. Methods: In a single year, a collegiate cohort of 14 women's and 15 men's lacrosse players wore mastoid-patch accelerometers to measure the frequency and severity of head impacts during official practices and games. Average impact severity, mean number of impacts, and cumulative acceleration were evaluated, stratified by sport and event type. Results: Men's and women's collegiate lacrosse players did not significantly differ in the number of head impacts received during games (11.5 for men vs 9.2 for women) or practices (3.1 vs 3.1). Men's lacrosse players had significantly higher average head acceleration per impact during games compared with women (21.1g vs 14.7g) but not during practices (21.3g vs 18.1g). For both men and women, more impacts occurred during games than during practices (men, 11.5 vs 3.1; women, 9.2 vs 3.1), but impact severity did not significantly differ between events for either sport (men, 21.1g vs 21.3g; women, 14.7g vs 18.1g). Conclusion: The study data suggest a higher impact burden during games compared with practices, but this effect is driven by the quantity rather than severity of impacts. In contrast, sex-based effects in impact burden are driven by average impact severity rather than quantity. Data collected from larger multisite trials and/or different age groups could be used to inform ongoing debates, including headgear and practice regulations, that might appreciably affect the burden of head impacts in lacrosse. Clinical Relevance: While most head impacts do not result in a clinical diagnosis of concussion, evidence indicates that subconcussive head impacts may increase susceptibility to concussion and contribute to long-term neurodegeneration.	[Reynolds, Bryson B.; Patrie, James; Henry, Erich J.; Goodkin, Howard P.; Broshek, Donna K.; Wintermark, Max; Druzgal, T. Jason] Univ Virginia, POB 800170, Charlottesville, VA 22908 USA; [Wintermark, Max] Stanford Univ, Palo Alto, CA 94304 USA	Druzgal, TJ (corresponding author), Univ Virginia, POB 800170, Charlottesville, VA 22908 USA.	tjd4m@virginia.edu		Reynolds, Bryson/0000-0001-9196-1461; Druzgal, Jason/0000-0001-7240-9487; Goodkin, Howard/0000-0003-0528-4949	University of Virginia Health System Research Award; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2 T32 GM 8328-21]; University of Virginia Department of Radiology and Medical Imaging; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008328] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: Financial support was provided by a University of Virginia Health System Research Award, NIH 2 T32 GM 8328-21, and the University of Virginia Department of Radiology and Medical Imaging. Access to the xPatch impact sensors was obtained through a research agreement with X2 Biosystems. M.W. is a member of the advisory board of the GA NFL project.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Caswell SV, 2012, AM J SPORT MED, V40, P756, DOI 10.1177/0363546512436647; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Crisco JJ, 2015, J APPL BIOMECH, V31, P122, DOI [10.1123/jab.2014-0102, 10.1123/JAB.2014-0102]; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Dick R, 2007, J ATHL TRAINING, V42, P262; Dick R, 2007, J ATHL TRAINING, V42, P255; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Huber P.J., 1967, P 5 BERK S MATH STAT, V1; Johnson BD, 2014, CONCUSSIONS ATHLETIC, P331, DOI DOI 10.1007/978-1-4939-0295-8_19; King D, 2016, SPORTS MED, V46, P151, DOI 10.1007/s40279-015-0423-7; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Swartz EE, 2015, J ATHL TRAINING, V50, P1219, DOI 10.4085/1062-6050-51.1.06; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; Yard EE, 2006, J ATHL TRAINING, V41, P441	49	25	25	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2016	44	11					2947	2956		10.1177/0363546516648442			10	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	EB4RE	WOS:000387359900006	27281278	Green Accepted			2021-06-18	
J	Caccese, JB; Lamond, LC; Buckley, TA; Kaminski, TW				Caccese, Jaclyn B.; Lamond, Lindsey C.; Buckley, Thomas A.; Kaminski, Thomas W.			Reducing purposeful headers from goal kicks and punts may reduce cumulative exposure to head acceleration	RESEARCH IN SPORTS MEDICINE			English	Article						Soccer; concussion; subconcussion; repetitive head impacts	FEMALE SOCCER PLAYERS; POSTURAL CONTROL; YOUTH SOCCER; CONCUSSION; INJURY; GENDER	The purpose of this study was to measure peak linear and rotational head acceleration in women's collegiate soccer and explore the variations in acceleration across different strategic scenarios. Game videos from 14 games were used to identify the strategic scenario in which the athlete headed the ball. Strategic scenarios included: bounce, secondary header, punt, throw-in, goal kick, corner kick, and kick. Peak linear and rotational accelerations were measured using the Smart Impact Monitor (Triax Technologies Inc., Norwalk, CT). Goal kick (38.8 +/- 19.4g, p=0.001, ss=8.9; 9.3 +/- 3.9krad/s(2), p=0.004, ss=1.9) and punt (36.0 +/- 15.1g, p=0.055, ss=6.3; 10.1 +/- 4.8krad/s(2), p=0.002, ss=2.5) impacts resulted in higher linear and rotational head accelerations than the base variable, kick (30.0 +/- 19.5g; 7.5 +/- 4.1krad/s(2)). This suggests that limiting headers from goal kicks and punts in younger athletes who are still learning proper heading technique may limit cumulative linear and rotational accelerations.	[Caccese, Jaclyn B.; Buckley, Thomas A.; Kaminski, Thomas W.] Univ Delaware, Biomech & Movement Sci Interdisciplinary Program, 541 S Coll Ave, Newark, DE 19716 USA; [Caccese, Jaclyn B.; Lamond, Lindsey C.; Buckley, Thomas A.; Kaminski, Thomas W.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA	Caccese, JB (corresponding author), Univ Delaware, Biomech & Movement Sci Interdisciplinary Program, 541 S Coll Ave, Newark, DE 19716 USA.	jcaccese@udel.edu	Buckley, Thomas A/B-7525-2016; Caccese, Jaclyn B./AAH-4571-2020	Buckley, Thomas A/0000-0002-0515-0150; Caccese, Jaclyn B./0000-0003-2329-3603			Babwah T, 2014, RES SPORTS MED, V22, P334, DOI 10.1080/15438627.2014.945644; Babwah TJ, 2014, RES SPORTS MED, V22, P327, DOI 10.1080/15438627.2014.944304; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Broglio SP, 2016, J ATHL TRAINING, V51, P511, DOI 10.4085/1062-6050-51.7.04; Caccese J. B., 2016, INT RES SCI SOCCER; Caccese JB, 2016, SPORTS MED, V46, P1591, DOI 10.1007/s40279-016-0544-7; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chrisman SPD, 2016, J CHILD NEUROL, V31, P971, DOI 10.1177/0883073816634857; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Dorminy M, 2015, BRAIN INJURY, V29, P1158, DOI 10.3109/02699052.2015.1035324; Federation Internationale de Football Association, 2007, FIFA BIG COUNT 2006; Greig M, 2014, RES SPORTS MED, V22, P368, DOI 10.1080/15438627.2014.944300; Hammes D, 2015, RES SPORTS MED, V23, P215, DOI 10.1080/15438627.2015.1005295; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Irick E., 2015, SPORTS SPONSORSHIP P; Karton C, 2016, MEASUREMENT ACCURACY; King D, 2016, SPORTS MED, V46, P151, DOI 10.1007/s40279-015-0423-7; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Oeur R. A., 2016, IMPACT FREQUENCY VAL; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; Rieder C, 2011, ARCH CLIN NEUROPSYCH, V26, P583, DOI 10.1093/arclin/acr055; Ruestow PS, 2015, J OCCUP ENVIRON HYG, V12, P875, DOI 10.1080/15459624.2015.1072632; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Self BP, 2006, ENG SPORT 6, V6, P81; US Youth Soccer Association, 2014, KEY STAT MEMB STAT; Yang YT, 2016, JAMA PEDIATR, V170, P413, DOI 10.1001/jamapediatrics.2016.0338; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	36	25	25	1	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1543-8627	1543-8635		RES SPORTS MED	Res. Sports Med.	OCT-DEC	2016	24	4			SI		407	415		10.1080/15438627.2016.1230549			9	Sport Sciences	Sport Sciences	EB8NX	WOS:000387648900011	27598519				2021-06-18	
J	Shultz, EL; Hoskinson, KR; Keim, MC; Dennis, M; Taylor, HG; Bigler, ED; Rubin, KH; Vannatta, K; Gerhardt, CA; Stancin, T; Yeates, KO				Shultz, Emily L.; Hoskinson, Kristen R.; Keim, Madelaine C.; Dennis, Maureen; Taylor, H. Gerry; Bigler, Erin D.; Rubin, Kenneth H.; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Yeates, Keith Owen			Adaptive Functioning Following Pediatric Traumatic Brain Injury: Relationship to Executive Function and Processing Speed	NEUROPSYCHOLOGY			English	Article						pediatrics; traumatic brain injury; adaptive functioning	QUALITY-OF-LIFE; HEAD-INJURY; CHILDHOOD; CHILDREN; OUTCOMES; PREDICTORS; MEDIATOR; BEHAVIOR; RATINGS; SAMPLE	Objective: Pediatric traumatic brain injury (TBI) may affect children's ability to perform everyday tasks (i.e., adaptive functioning). Guided by the American Association for Intellectual and Developmental Disabilities (AAIDD) model, we explored the association between TBI and adaptive functioning at increasing levels of specificity (global, AAIDD domains, and subscales). We also examined the contributions of executive function and processing speed as mediators of TBI's effects on adaptive functioning. Method: Children (ages 8-13) with severe TBI (STBI; n = 19), mild-moderate TBI (MTBI; n = 50), or orthopedic injury (OI; n = 60) completed measures of executive function (TEA-Ch) and processing speed (WISC-IV) an average of 2.7 years postinjury (SD = 1.2; range: 1-5.3). Parents rated children's adaptive functioning (ABAS-II, BASC-2, CASP). Results: STBI had lower global adaptive functioning (eta(2) = .04-.08) than the MTBI and OI groups, which typically did not differ. Deficits in the STBI group were particularly evident in the social domain, with specific deficits in social participation, leisure, and social adjustment (eta(2) = .06-.09). Jointly, executive function and processing speed were mediators of STBI's effects on global adaptive functioning and in conceptual and social domains. In the STBI group, executive function mediated social functioning, and processing speed mediated social participation. Conclusions: Children with STBI experience deficits in adaptive functioning, particularly in social adjustment, with less pronounced deficits in conceptual and practical skills. Executive function and processing speed may mediate the effects of STBI on adaptive functioning. Targeting adaptive functioning and associated cognitive deficits for intervention may enhance quality of life for pediatric TBI survivors.	[Shultz, Emily L.; Hoskinson, Kristen R.; Keim, Madelaine C.; Vannatta, Kathryn; Gerhardt, Cynthia A.] Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA; [Hoskinson, Kristen R.; Vannatta, Kathryn; Gerhardt, Cynthia A.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Dennis, Maureen] Hosp Sick Kids, Toronto, ON, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Magnet Resonance Imaging MRI Res Facil, Provo, UT 84602 USA; [Rubin, Kenneth H.] Univ Maryland, Dept Human Dev & Quantitat Methodol, College Pk, MD 20742 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Yeates, Keith Owen] Univ Calgary, Alberta Childrens Hosp, Res Inst, Dept Psychol, Calgary, AB T2N 1N4, Canada; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada; [Dennis, Maureen] Hosp Sick Children, Dept Psychol, Toronto, ON, Canada	Hoskinson, KR (corresponding author), Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA.; Hoskinson, KR (corresponding author), Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.	Kristen.hoskinson@nationwidechildrens.org	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020; Hoskinson, Kristen/AAL-9162-2020; Rubin, Kenneth H/M-5276-2018	Hoskinson, Kristen/0000-0003-4044-9753; Rubin, Kenneth H/0000-0002-2608-2484; Moscato, Emily/0000-0002-0207-0251; Yeates, Keith/0000-0001-7680-2892	National Institute of Child HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5 R01 HD048946]; Human Development; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	Erin D. Bigler co-directs the BYU Neurological Assessment lab, which provides forensic consulation. This research was supported in part by grant 5 R01 HD048946 from the National Institute of Child Health and Human Development to Keith Owen Yeates.	Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Chapman S.B, 1995, TRAUMATIC HEAD INJUR, P95; DEEGAN J, 1978, EDUC PSYCHOL MEAS, V38, P873, DOI 10.1177/001316447803800404; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Fritz MS, 2007, PSYCHOL SCI, V18, P233, DOI 10.1111/j.1467-9280.2007.01882.x; Gale SD, 2010, J HEAD TRAUMA REHAB, V25, P15, DOI 10.1097/HTR.0b013e3181c39960; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hayes A.F., 2018, INTRO MEDIATION MODE, V2nd ed.; Heverly-Fitt S, 2014, J INT NEUROPSYCH SOC, V20, P684, DOI 10.1017/S1355617714000393; Howard I, 2005, ETHNIC DIS, V15, pS51; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T., 1999, TEA CH TEST EVERYDAY; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Reynolds C.R., 2004, BEHAV ASSESSMENT SYS; Robinson KE, 2014, J NEUROTRAUM, V31, P1835, DOI 10.1089/neu.2014.3422; Schalock R. L., 2010, INTELLECTUAL DISABIL; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Toplak ME, 2013, J CHILD PSYCHOL PSYC, V54, P131, DOI 10.1111/jcpp.12001; Wechsler D., 2003, WECHSLER INTELLIGENC; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2014, CLIN PSYCHOL SCI, V2, P97, DOI 10.1177/2167702613499734	42	25	26	1	22	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2016	30	7					830	840		10.1037/neu0000288			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	DY9FX	WOS:000385440400007	27182708	Green Accepted, Bronze			2021-06-18	
J	Yuan, J; Wang, AH; He, Y; Si, ZH; Xu, S; Zhang, SC; Wang, K; Wang, DW; Liu, YM				Yuan, Jing; Wang, Aihua; He, Yan; Si, Zhihua; Xu, Shan; Zhang, Shanchao; Wang, Kun; Wang, Dawei; Liu, Yiming			Cordycepin attenuates traumatic brain injury-induced impairments of blood-brain barrier integrity in rats	BRAIN RESEARCH BULLETIN			English	Article						Cordycepin; Traumatic brain injury; Blood-brain barrier integrity; Neuroprotective; Anti-oxidative; Anti-inflammatory	CEREBRAL-ISCHEMIA; TIGHT JUNCTION; OCCLUDIN; PATHWAY; MICE; PERMEABILITY; DYSFUNCTION; DEFICITS; STRESS	Loss of blood-brain barrier (BBB) integrity is a downstream event caused by traumatic brain injury (TBI). BBB integrity is affected by certain physiological conditions, including inflammation and oxidative stress. Cordycepin is a susbtance with anti-inflammatory and anti-oxidative effects. Therefore, it is necessary to investigate whether cordycepin affects TBI-induced impairments of BBB integrity. Using TBI rats as the in vivo model and applying multiple techniques, including stroke severity evaluation, Evans blue assessment, quantitative real-time PCR, Western blotting and ELISA, we investigated the dose-dependent protective effects of cordycepin on the TBI-induced impairments of BBB integrity. Cordycepin treatment attenuated the TBI-induced impairments in a dose-dependent manner, and played a role in protecting BBB integrity. Cordycepin was able to alleviate TBI-induced loss of tight junction proteins zonula occludens protein-1 (ZO-1) and occludin, which are important for BBB integrity. Moreover, cordycepin suppressed pro-inflammatory factors, including IL-1 beta, iNOS, MPO and MMP-9, and promoted anti-inflammation-associated factors arginase 1 and IL-10. Furthermore, cordycepin inhibited NADPH oxidase (NOX) expression and activity following TBI, probably through NOX1, but not NOX2 and NOX4. Cordycepin has protective effects against brain damages induced by TBI. The protection of cordycepin on BBB integrity was probably achieved through recovery of tight junction proteins, inhibition of local inflammation, and prevention of NOX activity. (C) 2016 Elsevier Inc. All rights reserved.	[Yuan, Jing; Wang, Aihua; He, Yan; Si, Zhihua; Xu, Shan; Zhang, Shanchao] Shandong Univ, Qianfoshan Hosp, Dept Neurol, 16766 Jingshi Rd, Jinan 250014, Peoples R China; [Wang, Kun] Shandong Univ, Qianfoshan Hosp, Dept Gen Surg, 16766 Jingshi Rd, Jinan 250014, Peoples R China; [Wang, Dawei] Shandong Univ, Shandong Prov Hosp, Dept Orthoped, 324 Jingwu Rd, Jinan 250021, Peoples R China; [Liu, Yiming] Shandong Univ, Qilu Hosp, Dept Neurol, 107 West Wenhua Rd, Jinan 250012, Peoples R China	Wang, K (corresponding author), Shandong Univ, Qianfoshan Hosp, Dept Gen Surg, 16766 Jingshi Rd, Jinan 250014, Peoples R China.; Wang, DW (corresponding author), Shandong Univ, Shandong Prov Hosp, Dept Orthoped, 324 Jingwu Rd, Jinan 250021, Peoples R China.; Liu, YM (corresponding author), Shandong Univ, Qilu Hosp, Dept Neurol, 107 West Wenhua Rd, Jinan 250012, Peoples R China.	qywangkun1981@sohu.com; wangdwsd@126.com; yimingliusdql@yeah.net		Wang, Dawei/0000-0002-6151-5839	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81201392]	This work was supported by National Natural Science Foundation of China (81201392).	Alluri H, 2015, METAB BRAIN DIS, V30, P1093, DOI 10.1007/s11011-015-9651-7; Balda MS, 2000, J CELL BIOCHEM, V78, P85, DOI 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.3.CO;2-6; Carone D, 2015, BRAIN RES, V1615, P31, DOI 10.1016/j.brainres.2015.04.025; Carron SF, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00047; Chen JW, 2008, BRAIN, V131, P1123, DOI 10.1093/brain/awn004; Chen W, 2015, EXP BRAIN RES, V233, P2823, DOI 10.1007/s00221-015-4352-3; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Fouda Abdelrahman Y, 2013, Exp Transl Stroke Med, V5, P12, DOI 10.1186/2040-7378-5-12; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; Hirase T, 2001, J BIOL CHEM, V276, P10423, DOI 10.1074/jbc.M007136200; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Huang J, 2013, STROKE, V44, P190, DOI 10.1161/STROKEAHA.112.670299; Jin ML, 2014, NEUROTOXICOLOGY, V41, P102, DOI 10.1016/j.neuro.2014.01.005; Lacaz-Vieira F, 1999, J MEMBRANE BIOL, V168, P289, DOI 10.1007/s002329900518; Liu WJ, 2014, BRAIN RES, V1573, P17, DOI 10.1016/j.brainres.2014.05.022; Liu WL, 2008, J NEUROCHEM, V107, P1196, DOI 10.1111/j.1471-4159.2008.05664.x; Ma L, 2015, NUTR RES, V35, P431, DOI 10.1016/j.nutres.2015.04.011; Park ES, 2014, CARDIOVASC TOXICOL, V14, P1, DOI 10.1007/s12012-013-9232-0; Pazar A, 2016, J PINEAL RES, V60, P74, DOI 10.1111/jpi.12292; Ramesh T, 2012, EXP GERONTOL, V47, P979, DOI 10.1016/j.exger.2012.09.003; Shao AW, 2014, CNS NEUROSCI THER, V20, P182, DOI 10.1111/cns.12194; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Tuli HS, 2013, LIFE SCI, V93, P863, DOI 10.1016/j.lfs.2013.09.030; Wang K, 2015, NEUROSCI LETT, V591, P53, DOI 10.1016/j.neulet.2015.02.016; Wang YL, 2014, J NEUROCHEM, V129, P827, DOI 10.1111/jnc.12695; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8; Yu Q, 2015, CELL PHYSIOL BIOCHEM, V36, P1539, DOI 10.1159/000430317	28	25	27	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	OCT	2016	127						171	176		10.1016/j.brainresbull.2016.09.010			6	Neurosciences	Neurosciences & Neurology	ED7YH	WOS:000389088100021	27646481				2021-06-18	
J	Rom, S; Zuluaga-Ramirez, V; Reichenbach, NL; Dykstra, H; Gajghate, S; Pacher, P; Persidsky, Y				Rom, Slava; Zuluaga-Ramirez, Viviana; Reichenbach, Nancy L.; Dykstra, Holly; Gajghate, Sachin; Pacher, Pal; Persidsky, Yuri			PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier	JOURNAL OF NEUROINFLAMMATION			English	Article						Leukocyte-endothelial interaction; VLA-4; LFA-1; Actin cytoskeleton; PARP-1	NF-KAPPA-B; POLY(ADP-RIBOSE) POLYMERASE-1 INHIBITOR; MICROVASCULAR ENDOTHELIAL-CELLS; FOCAL CEREBRAL-ISCHEMIA; CANNABINOID RECEPTOR 2; TRANSENDOTHELIAL MIGRATION; MULTIPLE-SCLEROSIS; NEUROINFLAMMATORY CONDITIONS; VASCULAR-DISEASE; OXIDATIVE STRESS	Background: Blood-brain barrier (BBB) dysfunction/disruption followed by leukocyte infiltration into the brain causes neuroinflammation and contributes to morbidity in multiple sclerosis, encephalitis, traumatic brain injury, and stroke. The identification of pathways that decreases the inflammatory potential of leukocytes would prevent such injury. Poly(ADP-ribose) polymerase 1 (PARP) controls various genes via its interaction with myriad transcription factors. Selective PARP inhibitors have appeared lately as potent anti-inflammatory tools. Their effects are outside the recognized PARP functions in DNA repair and transcriptional regulation. In this study, we explored the idea that selective inhibition of PARP in leukocytes would diminish their engagement of the brain endothelium. Methods: Cerebral vascular changes and leukocyte-endothelium interactions were surveyed by intravital videomicroscopy utilizing a novel in vivo model of localized aseptic meningitis when TNFa was introduced intracerebrally in wild-type (PARP(+/+)) and PARP-deficient (PARP(-/-)) mice. The effects of selective PARP inhibition on primary human monocytes ability to adhere to or migrate across the BBB were also tested in vitro, employing primary human brain microvascular endothelial cells (BMVEC) as an in vitro model of the BBB. Results: PARP suppression in monocytes diminished their adhesion to and migration across BBB in vitro models and prevented barrier injury. In monocytes, PARP inactivation decreased conformational activation of integrins that plays a key role in their tissue infiltration. Such changes were mediated by suppression of activation of small Rho GTPases and cytoskeletal rearrangements in monocytes. In vitro observations were confirmed in vivo showing diminished leukocyte-endothelial interaction after selective PARP suppression in leukocytes accompanied by BBB protection. PARP knockout animals demonstrated a substantial diminution of inflammatory responses in brain microvasculature and a decrease in BBB permeability. Conclusions: These results suggest PARP inhibition in leukocytes as a novel approach to BBB protection in the setting of endothelial dysfunction caused by inflammation-induced leukocyte engagement.	[Rom, Slava; Zuluaga-Ramirez, Viviana; Reichenbach, Nancy L.; Dykstra, Holly; Gajghate, Sachin; Persidsky, Yuri] Temple Univ, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA; [Rom, Slava; Persidsky, Yuri] Temple Univ, Lewis Katz Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19140 USA; [Pacher, Pal] NIAAA, Lab Cardiovasc Physiol & Tissue Injury, NIH, Bethesda, MD 20852 USA	Rom, S; Persidsky, Y (corresponding author), Temple Univ, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA.; Rom, S; Persidsky, Y (corresponding author), Temple Univ, Lewis Katz Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19140 USA.	srom@temple.edu; yuri.persidsky@tuhs.temple.edu	Rom, Slava/AAF-6872-2020; Pacher, Pal/B-6378-2008	Pacher, Pal/0000-0001-7036-8108; Rom, Slava/0000-0002-1050-1955	 [MH65151];  [AA015913];  [DA013429];  [NS087385];  [ZIAAA000375]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R29AI042404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH106967, R01MH065151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R37AA015913, R01AA015913, ZIAAA000375, U01AA023552] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P30DA013429] Funding Source: NIH RePORTER	The work performed in the authors' laboratories is supported by grants from MH65151 (YP), AA015913 (YP), DA013429 (YP), NS087385 (SR), and ZIAAA000375 (PP). The fund agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad SF, 2015, MOL IMMUNOL, V63, P394, DOI 10.1016/j.molimm.2014.09.009; Ahmad SF, 2014, CYTOKINE, V68, P76, DOI 10.1016/j.cyto.2014.04.006; Alevriadou BR, 2003, AM J PHYSIOL-CELL PH, V285, pC250, DOI 10.1152/ajpcell.00189.2003; Allport JR, 1997, J EXP MED, V186, P517, DOI 10.1084/jem.186.4.517; Alon R, 2005, J CELL BIOL, V171, P1073, DOI 10.1083/jcb.200503155; Aoyagi-Scharber M, 2014, ACTA CRYSTALLOGR F, V70, P1143, DOI 10.1107/S2053230X14015088; Ba XQ, 2011, AM J PATHOL, V178, P946, DOI 10.1016/j.ajpath.2010.12.004; Bai P, 2015, TRENDS ENDOCRIN MET, V26, P75, DOI 10.1016/j.tem.2014.11.003; Barthel SR, 2008, J LEUKOCYTE BIOL, V83, P1, DOI 10.1189/jlb.0607344; Bernas MJ, 2010, NAT PROTOC, V5, P1265, DOI 10.1038/nprot.2010.76; Bolomini-Vittori M, 2009, NAT IMMUNOL, V10, P185, DOI 10.1038/ni.1691; Canan S, 2011, METHODS MOL BIOL, V780, P463, DOI 10.1007/978-1-61779-270-0_28; Cavone L, 2011, MULT SCLER J, V17, P794, DOI 10.1177/1352458511399113; Cernuda-Morollon E, 2006, CIRC RES, V98, P757, DOI 10.1161/01.RES.0000210579.35304.d3; Chamorro A, 2006, STROKE, V37, P291, DOI 10.1161/01.STR.0000200561.69611.f8; Chigaev A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00242; Chigaev A, 2009, J BIOL CHEM, V284, P14337, DOI 10.1074/jbc.M901178200; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; del Zoppo GJ, 2009, NEUROSCIENCE, V158, P972, DOI 10.1016/j.neuroscience.2008.08.028; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Evans R, 2011, BLOOD, V117, P3331, DOI 10.1182/blood-2010-06-289140; Farez MF, 2009, NAT IMMUNOL, V10, P958, DOI 10.1038/ni.1775; Ferreira AM, 2006, MICROCIRCULATION, V13, P439, DOI 10.1080/10739680600776062; Fu Y, 2015, NAT REV NEUROL, V11, P524, DOI 10.1038/nrneurol.2015.144; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Goldey GJ, 2014, NAT PROTOC, V9, P2515, DOI 10.1038/nprot.2014.165; Gorina R, 2014, J IMMUNOL, V192, P324, DOI 10.4049/jimmunol.1300858; Haider L, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/725370; Hogg N, 2011, NAT REV IMMUNOL, V11, P416, DOI 10.1038/nri2986; Horvath B, 2012, BRIT J PHARMACOL, V165, P2462, DOI 10.1111/j.1476-5381.2011.01381.x; Hottiger MO, 2015, EXPERT OPIN THER TAR, V19, P1149, DOI 10.1517/14728222.2015.1073262; Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Kauppinen TM, 2005, J NEUROSCI RES, V81, P190, DOI 10.1002/jnr.20525; Kebir H, 1862, BIOCHIM BIOPHYS ACTA, V2015, P472; Knowland D, 2014, NEURON, V82, P603, DOI 10.1016/j.neuron.2014.03.003; Koedel U, 2002, J CEREBR BLOOD F MET, V22, P39, DOI 10.1097/00004647-200201000-00005; Larochelle C, 2011, FEBS LETT, V585, P3770, DOI 10.1016/j.febslet.2011.04.066; Lenzser G, 2007, J CEREBR BLOOD F MET, V27, P1318, DOI 10.1038/sj.jcbfm.9600437; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Lim YC, 2000, MICROCIRCULATION, V7, P201, DOI 10.1038/sj.mn.7300103; Liu LL, 2012, HUM IMMUNOL, V73, P439, DOI 10.1016/j.humimm.2012.02.002; Luissint AC, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-23; Martinez-Zamudio RI, 2014, BRAIN BEHAV, V4, P552, DOI 10.1002/brb3.239; Martire S, 2015, MECH AGEING DEV, V146, P53, DOI 10.1016/j.mad.2015.04.001; Mathews MT, 2008, ARTERIOSCL THROM VAS, V28, P711, DOI 10.1161/ATVBAHA.107.156406; Milzani A, 1997, ARCH BIOCHEM BIOPHYS, V339, P267, DOI 10.1006/abbi.1996.9847; Mizuno K, 2013, CELL SIGNAL, V25, P457, DOI 10.1016/j.cellsig.2012.11.001; Moroni F, 2008, CURR OPIN PHARMACOL, V8, P96, DOI 10.1016/j.coph.2007.10.005; Mukhopadhyay P, 2014, HEPATOLOGY, V59, P1998, DOI 10.1002/hep.26763; Nakagawa Y, 2015, ONCOTARGET, V6, P3825, DOI 10.18632/oncotarget.2868; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pasqualetti G, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0531-7; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Persidsky Y, 2015, AM J PATHOL, V185, P1548, DOI 10.1016/j.ajpath.2015.03.001; Prat A, 2002, ARCH NEUROL-CHICAGO, V59, P391, DOI 10.1001/archneur.59.3.391; Qiu W, 2014, ACTA CRYSTALLOGR D, V70, P2740, DOI 10.1107/S1399004714017660; Ramirez SH, 2008, J IMMUNOL, V180, P1854, DOI 10.4049/jimmunol.180.3.1854; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Rolfe BE, 2005, ATHEROSCLEROSIS, V183, P1, DOI 10.1016/j.atherosclerosis.2005.04.023; Rom S, 2015, J CEREBR BLOOD F MET, V35, P1957, DOI 10.1038/jcbfm.2015.154; Rom S, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00878; Rom S, 2015, J CEREBR BLOOD F MET, V35, P28, DOI 10.1038/jcbfm.2014.167; Rom S, 2013, AM J PATHOL, V183, P1548, DOI 10.1016/j.ajpath.2013.07.033; Rom S, 2012, AM J PATHOL, V181, P1414, DOI 10.1016/j.ajpath.2012.06.018; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; Samstag Y, 2003, J LEUKOCYTE BIOL, V73, P30, DOI 10.1189/jlb.0602272; Sanchez-Martin L, 2004, J BIOL CHEM, V279, P16194, DOI 10.1074/jbc.M400905200; Shimizu Y, 2001, AM J RESP CRIT CARE, V163, P210, DOI 10.1164/ajrccm.163.1.2001089; Stevens SL, 2002, BRAIN RES, V932, P110, DOI 10.1016/S0006-8993(02)02292-8; Tobin MK, 2014, J CEREBR BLOOD F MET, V34, P1573, DOI 10.1038/jcbfm.2014.130; Ana MT, 2014, FREE RADICAL BIO MED, V75, pS19, DOI 10.1016/j.freeradbiomed.2014.10.633; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; van Buul JD, 2004, ARTERIOSCL THROM VAS, V24, P824, DOI 10.1161/01.ATV.0000122854.76267.5c; Venter G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097378; Veres B, 2003, BIOCHEM PHARMACOL, V65, P1373, DOI 10.1016/S0006-2952(03)00077-7; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Vuong B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0448-8; Wahlberg E, 2012, NAT BIOTECHNOL, V30, P283, DOI 10.1038/nbt.2121; Woska JR, 2001, J LEUKOCYTE BIOL, V70, P329; Zhang CX, 2004, AM J PHYSIOL-HEART C, V287, pH659, DOI 10.1152/ajpheart.00162.2004; Zohrabian VM, 2009, ANTICANCER RES, V29, P119; Zuluaga-Ramirez V, 2015, FLUIDS BARRIERS CNS, V12, DOI 10.1186/s12987-015-0021-y	86	25	25	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	SEP 27	2016	13								254	10.1186/s12974-016-0729-x			16	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DX8EJ	WOS:000384620600001	27677851	DOAJ Gold, Green Published			2021-06-18	
J	Albrecht, JS; Hirshon, JM; McCunn, M; Bechtold, KT; Rao, V; Simoni-Wastila, L; Smith, GS				Albrecht, Jennifer S.; Hirshon, Jon Mark; McCunn, Maureen; Bechtold, Kathleen T.; Rao, Vani; Simoni-Wastila, Linda; Smith, Gordon S.			Increased Rates of Mild Traumatic Brain Injury Among Older Adults in US Emergency Departments, 2009-2010	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						emergency departments; mild traumatic brain injury; NHAMCS; older adults	ACCURACY; MORTALITY; OUTCOMES; VISITS; RISK	Objective: To estimate rates of emergency department (ED) visits for mild traumatic brain injury (TBI) among older adults. We defined possible mild TBI cases to assess underdiagnoses. Design: Cross-sectional. Setting: National sample of ED visits in 2009-2010 captured by the National Hospital Ambulatory Medical Care Survey. Participants: Aged 65 years and older. Measurements: Mild TBI defined by International Classification of Diseases, Ninth Revision, Clinical Modification, codes (800.0x-801.9x, 803. xx, 804. xx, 850. xx-854.1x, 950.1x-950.3x, 959.01) and a Glasgow Coma Scale score of 14 or more or missing, excluding those admitted to the hospital. Possible mild TBI was defined similarly among those without mild TBI and with a fall or motor vehicle collision as cause of injury. We calculated rates of mild TBI and examined factors associated with a diagnosis of mild TBI. Results: Rates of ED visits for mild TBI were 386 per 100 000 among those aged 65 to 74 years, 777 per 100 000 among those aged 75 to 84 years, and 1205 per 100 000 among those older than 84 years. Rates for women (706/100 000) were higher than for men (516/100 000). Compared with a possible mild TBI, a diagnosis of mild TBI was more likely in the West (odds ratio = 2.31; 95% confidence interval, 1.02-5.24) and less likely in the South/Midwest (odds ratio = 0.52; 95% confidence interval, 0.29-0.96) than in the Northeast. Conclusions: This study highlights an upward trend in rates of ED visits for mild TBI among older adults.	[Albrecht, Jennifer S.; Hirshon, Jon Mark; Smith, Gordon S.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA; [Hirshon, Jon Mark] Univ Maryland, Sch Med, Dept Emergency Med, Baltimore, MD 21201 USA; [McCunn, Maureen] Univ Maryland, Sch Med, Dept Anesthesiol, Div Trauma Anesthesiol,R Adams Cowley Shock Traum, Baltimore, MD 21201 USA; [McCunn, Maureen] Univ Maryland, Sch Med, Dept Anesthesiol, Div Surg Crit Care,R Adams Cowley Shock Trauma Ct, Baltimore, MD 21201 USA; [Bechtold, Kathleen T.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Rao, Vani] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA; [Simoni-Wastila, Linda] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA; [Hirshon, Jon Mark; Smith, Gordon S.] Univ Maryland, Natl Study Ctr Trauma & Emergency Med Serv, Shock Trauma & Anesthesiol Res STAR Organized Res, Baltimore, MD 21201 USA	Albrecht, JS (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA.	jalbrecht@epi.umaryland.edu		Albrecht, Jennifer/0000-0003-4838-2274; Smith, Gordon/0000-0002-2911-3071	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12HD43489-13, R01AA18707]; DODUnited States Department of Defense [W81XWH-13-1-0469]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD043489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA018707] Funding Source: NIH RePORTER	Dr Albrecht is supported by NIH grant K12HD43489-13. Dr Rao is supported by DOD grant W81XWH-13-1-0469. Dr Smith is supported by NIH grant R01AA18707.	Albrecht JS, 2015, J HEAD TRAUMA REHAB, V30, pE62, DOI 10.1097/HTR.0000000000000035; Albrecht JS, 2014, JAMA INTERN MED, V174, P1244, DOI 10.1001/jamainternmed.2014.2534; American College of Emergency Physicians/Centers for Disease Control and Prevention Panel to Revise the 2002 Clinical Policy, 2008, ANN EMERG MED, V52, P714; [Anonymous], AMB HLTH CAR SURV; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Buck PW, 2011, HEALTH SOC WORK, V36, P299, DOI 10.1093/hsw/36.4.299; Centers for Disease Control and Prevention, 2014, RAT TBI REL EM DEP V; Centers for Disease Control and Prevention, 2001, RAT TBI REL EM DEP V; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Gillespie LD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007146.pub3; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kamel H, 2013, J STROKE CEREBROVASC, V22, pE142, DOI 10.1016/j.jstrokecerebrovasdis.2012.09.016; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Marr AL., 2004, CENTRAL NERVOUS SYST; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Moyer VA, 2012, ANN INTERN MED, V157, P197, DOI 10.7326/0003-4819-157-3-201208070-00462; National Center for Injury Prevention and Control Report to Congress on Mild Traumatic Brain Injury in the United States, 2003, REP C MILD TRAUM BRA; Papa L, 2012, CURR GERIATR REP, V1, P135, DOI 10.1007/s13670-012-0019-0; Pape TLB, 2013, PM&R, V5, P856, DOI 10.1016/j.pmrj.2013.06.007; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Scheetz LJ, 2011, AACN ADV CRIT CARE, V22, P128, DOI 10.1097/NCI.0b013e3182122c93; Song YJ, 2010, NEW ENGL J MED, V363, P45, DOI 10.1056/NEJMsa0910881; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; SVARSTAD BL, 1987, MED CARE, V25, P1089, DOI 10.1097/00005650-198711000-00007; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thompson HJ, 2012, RES GERONTOL NURS, V5, P17, DOI 10.3928/19404921-20111206-02; Vincent GK, 2010, NEXT 4 DECADES OLDER; Welch HG, 2011, JAMA-J AM MED ASSOC, V305, P1113, DOI 10.1001/jama.2011.307	40	25	25	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2016	31	5					E1	E7		10.1097/HTR.0000000000000190			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DX2ZY	WOS:000384243600001	26479396	Green Accepted			2021-06-18	
J	Faul, M; Xu, LK; Sasser, SM				Faul, Mark; Xu, Likang; Sasser, Scott M.			HOSPITALIZED TRAUMATIC BRAIN INJURY: LOW TRAUMA CENTER UTILIZATION AND HIGH INTERFACILITY TRANSFERS AMONG OLDER ADULTS	PREHOSPITAL EMERGENCY CARE			English	Article						TBI; Traumatic Brain Injury; Field triage; Brain Trauma Foundation Guidelines; Field Triage Guidelines; ambulance; transport; older adults; children	LEVEL I; DIRECT TRANSPORT; OUTCOMES; GUIDELINES; IMPACT; MORTALITY; TRENDS; TRIAGE	Objective: Guidelines suggest that Traumatic Brain Injury (TBI) related hospitalizations are best treated at Level I or II trauma centers because of continuous neurosurgical care in these settings. This population-based study examines TBI hospitalization treatment paths by age groups. Methods: Trauma center utilization and transfers by age groups were captured by examining the total number of TBI hospitalizations from National Inpatient Sample (NIS) and the number of TBI hospitalizations and transfers in the Trauma Data Bank National Sample Population (NTDB-NSP). TBI cases were defined using diagnostic codes. Results: Of the 351,555 TBI related hospitalizations in 2012, 47.9% (n = 168,317) were directly treated in a Level I or II trauma center, and an additional 20.3% (n = 71,286) were transferred to a Level I or II trauma center. The portion of the population treated at a trauma center (68.2%) was significantly lower than the portion of the U.S. population who has access to a major trauma center (90%). Further, nearly half of all transfers to a Level I or II trauma center were adults aged 55 and older (p < 0.001) and that 20.2% of pediatric patients arrive by non-ambulatory means. Conclusion: Utilization of trauma center resources for hospitalized TBIs may be low considering the established lower mortality rate associated with treatment at Level I or II trauma centers. The higher transfer rate for older adults may suggest rapid decline amid an unrecognized initial need for a trauma center care. A better understanding of hospital destination decision making is needed for patients with TBI.	[Faul, Mark] Ctr Dis Control & Prevent, 4770 Buford Highway, Atlanta, GA 30341 USA; Greenville Hlth Syst, Dept Emergency Med, Greenville, SC USA	Faul, M (corresponding author), Ctr Dis Control & Prevent, 4770 Buford Highway, Atlanta, GA 30341 USA.	mfaul@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline		American College of Surgeons, 2006, RES OPT CAR INJ PAT; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barber MA, 2012, J TRAUMA ACUTE CARE, V73, P558, DOI 10.1097/TA.0b013e318265cb75; Berlot G, 2009, EUR J EMERG MED, V16, P312, DOI 10.1097/MEJ.0b013e32832d3aa1; Brewer ES, 2011, J TRAUMA, V70, pE1, DOI 10.1097/TA.0b013e3181e5e286; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chisholm KM, 2010, AM J FOREN MED PATH, V31, P350, DOI 10.1097/PAF.0b013e3181f69c87; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; Dillingham TR, 1998, ARCH PHYS MED REHAB, V79, P279, DOI 10.1016/S0003-9993(98)90007-7; Esposito TJ, 2006, J TRAUMA, V61, P1380, DOI 10.1097/01.ta.0000242862.68899.04; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Faul M, 2015, WEST J EMERG MED, V16, P98, DOI 10.5811/westjem.2014.10.22837; Garwe T, 2011, J TRAUMA, V70, P1118, DOI 10.1097/TA.0b013e3181e243b8; Goble S, 2009, J TRAUMA, V67, P637, DOI 10.1097/TA.0b013e3181b84294; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Joosse P, 2012, J TRAUMA ACUTE CARE, V72, P487, DOI 10.1097/TA.0b013e318226ed59; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lane P, 2003, ACAD EMERG MED, V10, P244, DOI 10.1111/j.1553-2712.2003.tb01998.x; Mahapatra AK, 2012, TXB TRAUMATIC BRAIN, P40; Mann NC, 1999, J TRAUMA, V47, pS25, DOI 10.1097/00005373-199909001-00007; Marion DW, 1997, NE J MED, V336, P541; Newgard CD, 2014, PREHOSP EMERG CARE, V18, P461, DOI 10.3109/10903127.2014.912707; Pitts LH, 1998, J TRAUMA, V44, P989; Qato DM, 2008, JAMA-J AM MED ASSOC, V300, P2867, DOI 10.1001/jama.2008.892; Rinker CF, 1998, J TRAUMA, V44, P984, DOI 10.1097/00005373-199806000-00009; Roudsari B, 2012, AM J ROENTGENOL, V198, P985, DOI 10.2214/AJR.11.6976; Ryb GE, 2011, J TRAUMA, V71, P742, DOI 10.1097/TA.0b013e31822ba010; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; SAS Institute Inc, 2013, SAS VERS 9 3; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Scheetz LJ, 2012, J EMERG MED, V43, P1020, DOI 10.1016/j.jemermed.2011.09.036; Smith NL, 1999, ARCH INTERN MED, V159, P1574, DOI 10.1001/archinte.159.14.1574; Staudenmayer KL, 2013, J AM COLL SURGEONS, V217, P569, DOI 10.1016/j.jamcollsurg.2013.06.017; Tauber M, 2009, J TRAUMA, V67, P521, DOI 10.1097/TA.0b013e3181a7c184; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	42	25	25	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	SEP-OCT	2016	20	5					594	600		10.3109/10903127.2016.1149651			7	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	DW8OI	WOS:000383915000007	26986195	Green Accepted			2021-06-18	
J	Kataria, H; Lutz, D; Chaudhary, H; Schachner, M; Loers, G				Kataria, Hardeep; Lutz, David; Chaudhary, Harshita; Schachner, Melitta; Loers, Gabriele			Small Molecule Agonists of Cell Adhesion Molecule L1 Mimic L1 Functions In Vivo	MOLECULAR NEUROBIOLOGY			English	Article						Cell adhesion molecule L1; Spinal cord injury; Femoral nerve injury; Neurite outgrowth; Neuronal survival; Small molecule	TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; IMMUNOGLOBULIN SUPERFAMILY; NEURITE OUTGROWTH; MICE DEFICIENT; SPINAL-CORD; ISCHEMIA-REPERFUSION; POLYSIALIC ACID; NERVE INJURY; RECOVERY	Lack of permissive mechanisms and abundance of inhibitory molecules in the lesioned central nervous system of adult mammals contribute to the failure of functional recovery after injury, leading to severe disabilities in motor functions and pain. Peripheral nerve injury impairs motor, sensory, and autonomic functions, particularly in cases where nerve gaps are large and chronic nerve injury ensues. Previous studies have indicated that the neural cell adhesion molecule L1 constitutes a viable target to promote regeneration after acute injury. We screened libraries of known drugs for small molecule agonists of L1 and evaluated the effect of hit compounds in cell-based assays in vitro and in mice after femoral nerve and spinal cord injuries in vivo. We identified eight small molecule L1 agonists and showed in cell-based assays that they stimulate neuronal survival, neuronal migration, and neurite outgrowth and enhance Schwann cell proliferation and migration and myelination of neurons in an L1-dependent manner. In a femoral nerve injury mouse model, enhanced functional regeneration and remyelination after application of the L1 agonists were observed. In a spinal cord injury mouse model, L1 agonists improved recovery of motor functions, being paralleled by enhanced remyelination, neuronal survival, and monoaminergic innervation, reduced astrogliosis, and activation of microglia. Together, these findings suggest that application of small organic compounds that bind to L1 and stimulate the beneficial homophilic L1 functions may prove to be a valuable addition to treatments of nervous system injuries.	[Kataria, Hardeep; Lutz, David; Chaudhary, Harshita; Loers, Gabriele] Univ Klinikum Hamburg Eppendorf, Inst Biosynth Neuraler Strukturen, Zentrum Mol Neurobiol Hamburg, Falkenried 94, D-20251 Hamburg, Germany; [Schachner, Melitta] Rutgers State Univ, Keck Ctr Collaborat Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA; [Schachner, Melitta] Rutgers State Univ, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA; [Schachner, Melitta] Shantou Univ, Ctr Neurosci, Coll Med, 22 Xin Ling Rd, Shantou 515041, Guangdong, Peoples R China	Schachner, M (corresponding author), Rutgers State Univ, Keck Ctr Collaborat Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.; Schachner, M (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.; Schachner, M (corresponding author), Shantou Univ, Ctr Neurosci, Coll Med, 22 Xin Ling Rd, Shantou 515041, Guangdong, Peoples R China.	schachner@stu.edu.cn	Kataria, Hardeep/AAI-8411-2020	Kataria, Hardeep/0000-0001-8413-0600	New Jersey Commission for Spinal Cord Research; Li Kashing Foundation at the Shantou University Medical College	We thank Eva Kronberg and Ulrike Wolters for excellent animal caretaking and Ute Bork for genotyping of mice, Dagmar Drexler and Barbara Holstermann for help with electron microscopy, and Torsten Renz and Fritz Kutschera for technical support. Melitta Schachner is supported by the New Jersey Commission for Spinal Cord Research and the Li Kashing Foundation at the Shantou University Medical College.	APPEL F, 1995, J NEUROBIOL, V28, P297, DOI 10.1002/neu.480280304; Ball Susan G, 2013, Drugs Context, V2013, P212245, DOI 10.7573/dic.212245; Barbin G, 2004, NEURON GLIA BIOL, V1, P65, DOI [10.1017/S1740925X04000092, 10.1017/s1740925x04000092]; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BRUSHART TME, 1988, J NEUROSCI, V8, P1026; Buffet M, 2003, FUND CLIN PHARMACOL, V17, P217, DOI 10.1046/j.1472-8206.2003.00173.x; Calabrese F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037916; Casacalenda N, 2002, AM J PSYCHIAT, V159, P1354, DOI 10.1176/appi.ajp.159.8.1354; Chen J, 2005, J NEUROTRAUM, V22, P896, DOI 10.1089/neu.2005.22.896; Chen J, 2007, BRAIN, V130, P954, DOI 10.1093/brain/awm049; Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6; Chenu F, 2009, INT J NEUROPSYCHOPH, V12, P475, DOI 10.1017/S1461145708009218; CRISMON ML, 1994, ANN PHARMACOTHER, V28, P744, DOI 10.1177/106002809402800612; Cui XZ, 2011, BRAIN BEHAV, V1, P73, DOI 10.1002/brb3.15; Cui YF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017126; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Dityatev A, 2008, NEURON GLIA BIOL, V4, P197, DOI 10.1017/S1740925X09990111; Djogo N, 2013, NEUROBIOL DIS, V56, P104, DOI 10.1016/j.nbd.2013.04.014; Du QH, 2013, PHARM BIOL, V51, P1347, DOI 10.3109/13880209.2013.792849; Ferguson IA, 2001, EUR J NEUROSCI, V13, P1059, DOI 10.1046/j.1460-9568.2001.01482.x; Godenschwege TA, 2006, CURR BIOL, V16, P12, DOI 10.1016/j.cub.2005.11.062; Guan HJ, 2010, CEREB CORTEX, V20, P2684, DOI 10.1093/cercor/bhq016; Guseva D, 2011, EXP NEUROL, V229, P339, DOI 10.1016/j.expneurol.2011.02.018; He XW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046223; Hu ZY, 2013, BRAIN RES, V1491, P204, DOI 10.1016/j.brainres.2012.11.004; Husi H, 2000, NAT NEUROSCI, V3, P661; Irintchev A, 2005, EUR J NEUROSCI, V22, P802, DOI 10.1111/j.1460-9568.2005.04274.x; Irintchev A, 2012, NEUROSCIENTIST, V18, P452, DOI 10.1177/1073858411419047; Itoh K, 2005, MOL CELL NEUROSCI, V29, P245, DOI 10.1016/j.mcn.2005.02.014; Kalus I, 2003, J BIOL CHEM, V278, P10381, DOI 10.1074/jbc.M208351200; Kamiguchi H, 1997, J NEUROSCI RES, V49, P1, DOI 10.1002/(SICI)1097-4547(19970701)49:1<1::AID-JNR1>3.0.CO;2-H; Lanzilli G, 2012, INFLAMMATION, V35, P240, DOI 10.1007/s10753-011-9310-z; Lavdas AA, 2011, CURR GENE THER, V11, P90; Lavdas AA, 2010, EXP NEUROL, V221, P206, DOI 10.1016/j.expneurol.2009.10.024; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; Li JH, 2013, INT UROL NEPHROL, V45, P679, DOI 10.1007/s11255-013-0410-6; Liu K, 2011, ANNU REV NEUROSCI, V34, P131, DOI 10.1146/annurev-neuro-061010-113723; Loers G, 2005, J NEUROCHEM, V92, P1463, DOI 10.1111/j.1471-4159.2004.02983.x; Loers G, 2014, BIOCHEM J, V460, P437, DOI 10.1042/BJ20131677; Loers G, 2014, J NEUROCHEM, V128, P88, DOI 10.1111/jnc.12408; Loers G, 2012, J NEUROSCI, V32, P3917, DOI 10.1523/JNEUROSCI.6165-11.2012; Lundborg G, 2007, ACTA PHYSIOL, V189, P207, DOI 10.1111/j.1748-1716.2006.01653.x; Lutz D., 2015, MOL NEUROBIOL; Lutz D, 2014, J BIOL CHEM, V289, P13503, DOI 10.1074/jbc.M113.530238; Lutz D, 2014, J NEUROCHEM, V128, P713, DOI 10.1111/jnc.12473; Maness PF, 2007, NAT NEUROSCI, V10, P19, DOI 10.1038/nn1827; Maretzky T, 2005, MOL CELL BIOL, V25, P9040, DOI 10.1128/MCB.25.20.9040-9053.2005; Matsumoto-Miyai K, 2003, J NEUROSCI, V23, P7727; Mehanna A, 2010, MOL THER, V18, P34, DOI 10.1038/mt.2009.235; Mehanna A, 2009, BRAIN, V132, P1449, DOI 10.1093/brain/awp128; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; Montag-Sallaz M, 2002, MOL CELL BIOL, V22, P7967, DOI 10.1128/MCB.22.22.7967-7981.2002; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; NORMAN TR, 1989, J NEURAL TRANSM-GEN, P53; Pasinetti GM, 2015, BBA-MOL BASIS DIS, V1852, P1202, DOI 10.1016/j.bbadis.2014.10.006; Picazo O, 2010, CELL MOL NEUROBIOL, V30, P675, DOI 10.1007/s10571-009-9490-3; Poynard T, 2001, ALIMENT PHARM THER, V15, P355, DOI 10.1046/j.1365-2036.2001.00937.x; RATHJEN FG, 1984, EMBO J, V3, P1; Reidy M, 2006, J BIOMED MATER RES A, V77A, P542, DOI 10.1002/jbm.a.30590; Rocha-Gonzalez HI, 2008, CNS NEUROSCI THER, V14, P234, DOI 10.1111/j.1755-5949.2008.00045.x; Roonprapunt C, 2013, J NEUROTRAUM, V20, P871; Saghatelyan AK, 2004, MOL CELL NEUROSCI, V26, P191, DOI 10.1016/j.mcn.2004.01.008; Sandi C, 2007, NEUROENDOCRINOLOGY, V85, P158, DOI 10.1159/000101535; Schulz F, 2013, NANOSCALE, V5, P10605, DOI 10.1039/c3nr02707d; Shipton OA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0163; Simova O, 2006, ANN NEUROL, V60, P430, DOI 10.1002/ana.20948; Simpson SM, 2012, PHARMACOL BIOCHEM BE, V102, P109, DOI 10.1016/j.pbb.2012.03.027; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Skaper Stephen D, 2012, Methods Mol Biol, V846, P13, DOI 10.1007/978-1-61779-536-7_2; Tsoory MM, 2010, J NEUROSCI RES, V88, P369, DOI 10.1002/jnr.22203; Vega-Rivera NM, 2013, NEUROSCIENCE, V250, P102, DOI 10.1016/j.neuroscience.2013.06.058; Venero C, 2002, NEUROSCIENCE, V115, P1211, DOI 10.1016/S0306-4522(02)00543-2; Wang HQ, 2014, NEUROPHARMACOLOGY, V86, P9, DOI 10.1016/j.neuropharm.2014.06.018; Wei CH, 2012, EXP MOL MED, V44, P413, DOI 10.3858/emm.2012.44.7.050; Welzl H, 2003, NEWS PHYSIOL SCI, V18, P147, DOI 10.1152/nips.01422.2002; Witheford M, 2013, GLIA, V61, P1873, DOI 10.1002/glia.22564; WOOD PM, 1990, J NEUROSCI, V10, P3635; Woodbury A, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00130; Xu G, 2004, NEUROREPORT, V15, P2167, DOI 10.1097/00001756-200410050-00004; Zhang P, 2013, NEUROSCI LETT, V534, P123, DOI 10.1016/j.neulet.2012.11.052; Zhang Y, 2008, RESTOR NEUROL NEUROS, V26, P81; Zhong ZG, 1997, J NEUROCHEM, V68, P2291; Zhou LJ, 2012, J BIOL CHEM, V287, P25927, DOI 10.1074/jbc.M112.377465	83	25	25	1	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	SEP	2016	53	7					4461	4483		10.1007/s12035-015-9352-6			23	Neurosciences	Neurosciences & Neurology	DS3JI	WOS:000380678600017	26253722				2021-06-18	
J	Lemarchant, S; Dunghana, H; Pomeshchik, Y; Leinonen, H; Kolosowska, N; Korhonen, P; Kanninen, KM; Garcia-Berrocoso, T; Montaner, J; Malm, T; Koistinaho, J				Lemarchant, Sighild; Dunghana, Hiramani; Pomeshchik, Yuriy; Leinonen, Henri; Kolosowska, Natalia; Korhonen, Paula; Kanninen, Katja M.; Garcia-Berrocoso, Teresa; Montaner, Joan; Malm, Tarja; Koistinaho, Jari			Anti-Inflammatory Effects of ADAMTS-4 in a Mouse Model of Ischemic Stroke	GLIA			English	Article						ADAMTS-4; stroke; microglia; astrocyte; neuroinflammation	SPINAL-CORD-INJURY; CHONDROITIN SULFATE PROTEOGLYCAN; PROMOTES FUNCTIONAL RECOVERY; FIBROBLAST-LIKE SYNOVIOCYTES; CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; ABC PROMOTES; KAPPA-B; DIFFERENTIAL REGULATION; MACROPHAGE ACTIVATION	ADAMTS-4 (a disintegrin and metalloproteinase with thrombospondin motifs type 4) is a metalloprotease capable to degrade chondroitin sulfate proteoglycans leading to cartilage destruction during arthritis or to neuroplasticity during spinal cord injury (SCI). Although ADAMTS-4 is an inflammatory-regulated enzyme, its role during inflammation has never been investigated. The aim of this study was to investigate the role of ADAMTS-4 in neuroinflammation. First, we evidenced an increase of ADAMTS-4 expression in the ischemic brain hemisphere of mouse and human patients suffering from ischemic stroke. Then, we described that ADAMTS-4 has predominantly an anti-inflammatory effect in the CNS. Treatment of primary microglia or astrocyte cultures with low doses of a human recombinant ADAMTS-4 prior to LPS exposure decreased NO production and the synthesis/release of pro-inflammatory cytokines including NOS2, CCL2, TNF-alpha, IL-1 beta and MMP-9. Accordingly, when cell cultures were transfected with silencing siRNA targeting ADAMTS-4 prior to LPS exposure, the production of NO and the synthesis/release of pro-inflammatory cytokines were increased. Finally, the feasibility of ADAMTS-4 to modulate neuroinflammation was investigated in vivo after permanent middle cerebral artery occlusion in mice. Although ADAMTS-4 treatment did not influence the lesion volume, it decreased astrogliosis and macrophage infiltration, and increased the number of microglia expressing arginase-1, a marker of alternatively activated cells with inflammation inhibiting functions. Additionally, ADAMTS-4 increased the production of IL-10 and IL-6 in the peri-ischemic area. By having anti-inflammatory and neuroregenerative roles, ADAMTS-4 may represent an interesting target to treat acute CNS injuries, such as ischemic stroke, SCI or traumatic brain injury.	[Lemarchant, Sighild; Dunghana, Hiramani; Pomeshchik, Yuriy; Leinonen, Henri; Kolosowska, Natalia; Korhonen, Paula; Kanninen, Katja M.; Malm, Tarja; Koistinaho, Jari] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Bioctr Kuopio, POB 1627, Kuopio, Finland; [Garcia-Berrocoso, Teresa; Montaner, Joan] Univ Autonoma Barcelona, Neurovasc Res Lab, VHIR, Barcelona, Spain	Lemarchant, S (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, POB 1627, Kuopio 70211, Finland.	sighild.lemarchant@uef.fi	Leinonen, Henri/V-2684-2019; Montaner, Joan/D-3063-2015	Leinonen, Henri/0000-0002-0388-832X; Montaner, Joan/0000-0003-4845-2279; GARCIA-BERROCOSO, TERESA/0000-0001-8072-8533; Pomeshchik, Yuriy/0000-0002-1412-7403; Dhungana, Hiramani/0000-0003-3738-5410; Malm, Tarja/0000-0002-9530-7472	Academy of FinlandAcademy of FinlandEuropean Commission; ERANET-Neuron research program "ProteA: Proteases before, during and after stroke"	Grant sponsor: Academy of Finland and the ERANET-Neuron research program "ProteA: Proteases before, during and after stroke," 2012-2015.	Amantea D, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00147; Ashlin TG, 2013, CYTOKINE, V64, P234, DOI 10.1016/j.cyto.2013.06.315; Bartus K, 2014, J NEUROSCI, V34, P4822, DOI 10.1523/JNEUROSCI.4369-13.2014; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bradbury EJ, 2011, BRAIN RES BULL, V84, P306, DOI 10.1016/j.brainresbull.2010.06.015; Cai P, 2015, STROKE, V46, P2647, DOI 10.1161/STROKEAHA.115.009526; Casse F, 2012, J NEUROSCI, V32, P5186, DOI 10.1523/JNEUROSCI.5296-11.2012; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Cross AK, 2006, BRAIN RES, V1088, P19, DOI 10.1016/j.brainres.2006.02.136; Demircan K, 2013, NEUROSCI LETT, V544, P25, DOI 10.1016/j.neulet.2013.02.064; Denorme F, 2016, BLOOD, V127, P2337, DOI 10.1182/blood-2015-08-662650; Didangelos A, 2014, J NEUROSCI, V34, P16424, DOI 10.1523/JNEUROSCI.2927-14.2014; Franco R, 2015, PROG NEUROBIOL, V131, P65, DOI 10.1016/j.pneurobio.2015.05.003; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Gherardini L, 2015, CEREB CORTEX, V25, P202, DOI 10.1093/cercor/bht217; Goldring MB, 2011, CURR OPIN RHEUMATOL, V23, P471, DOI 10.1097/BOR.0b013e328349c2b1; Haddock G, 2006, MULT SCLER J, V12, P386, DOI 10.1191/135248506ms1300oa; Hamel MG, 2005, J NEUROCHEM, V93, P1533, DOI 10.1111/j.1471-4159.2005.03144.x; Hamel MG, 2008, EXP NEUROL, V210, P428, DOI 10.1016/j.expneurol.2007.11.014; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Hill JJ, 2012, P NATL ACAD SCI USA, V109, P9155, DOI 10.1073/pnas.1205697109; Hobohm C, 2005, J NEUROSCI RES, V80, P539, DOI 10.1002/jnr.20459; Howell MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047226; Hsu YP, 2012, INT J EXP PATHOL, V93, P70, DOI 10.1111/j.1365-2613.2011.00802.x; Huh JE, 2012, J ETHNOPHARMACOL, V143, P779, DOI 10.1016/j.jep.2012.06.041; Jha MK, 2016, BIOCHEM PHARMACOL, V103, P1, DOI 10.1016/j.bcp.2015.11.003; Koh TJ, 2013, METHODS MOL BIOL, V1037, P507, DOI 10.1007/978-1-62703-505-7_30; Korhonen P, 2015, BRAIN BEHAV IMMUN, V49, P322, DOI 10.1016/j.bbi.2015.06.013; Krstic D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047793; Lemarchant S, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0078-3; Lemarchant S, 2014, NEUROBIOL DIS, V66, P28, DOI 10.1016/j.nbd.2014.02.005; Lemarchant S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-133; Malm T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0229-9; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Marzolo MP, 2000, J NEUROSCI RES, V60, P401, DOI 10.1002/(SICI)1097-4547(20000501)60:3<401::AID-JNR15>3.0.CO;2-L; Mimata Y, 2012, INT J RHEUM DIS, V15, P36, DOI 10.1111/j.1756-185X.2011.01656.x; Murray KN, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00018; Novak ML, 2013, AM J PATHOL, V183, P1352, DOI 10.1016/j.ajpath.2013.06.034; Pihlaja R, 2011, GLIA, V59, P1643, DOI 10.1002/glia.21212; Pocivavsek A, 2009, GLIA, V57, P444, DOI 10.1002/glia.20772; Reid MJ, 2009, NEUROSCI LETT, V452, P252, DOI 10.1016/j.neulet.2009.01.058; Ren PP, 2013, ANN THORAC SURG, V95, P570, DOI 10.1016/j.athoracsur.2012.10.084; Rolova T, 2014, NEUROBIOL DIS, V64, P16, DOI 10.1016/j.nbd.2013.12.003; Sasaki M, 2001, MOL BRAIN RES, V89, P158, DOI 10.1016/S0169-328X(01)00046-8; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Seguin CA, 2006, MATRIX BIOL, V25, P409, DOI 10.1016/j.matbio.2006.07.002; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; Skaper SD, 2014, CNS NEUROL DISORD-DR, V13, P1654; Soleman S, 2012, BRAIN, V135, P1210, DOI 10.1093/brain/aws027; Tauchi R, 2012, NEUROSCI LETT, V517, P1, DOI 10.1016/j.neulet.2012.03.002; Tauchi R, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-53; Tian Y, 2013, AM J PATHOL, V182, P2310, DOI 10.1016/j.ajpath.2013.02.037; Wagsater D, 2008, ATHEROSCLEROSIS, V196, P514, DOI 10.1016/j.atherosclerosis.2007.05.018; Wang LX, 2013, ANN NEUROL, V73, P189, DOI 10.1002/ana.23762; Yamamoto K, 2014, J BIOL CHEM, V289, P6462, DOI 10.1074/jbc.M113.545376; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang C, 2009, AM J PATHOL, V174, P586, DOI 10.2353/ajpath.2009.080661; Zhao BQ, 2009, BLOOD, V114, P3329, DOI 10.1182/blood-2009-03-213264; Zuo J, 1998, EXP NEUROL, V154, P654, DOI 10.1006/exnr.1998.6951; Zuo J, 2002, EXP NEUROL, V176, P221, DOI 10.1006/exnr.2002.7922	61	25	31	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	SEP	2016	64	9					1492	1507		10.1002/glia.23017			16	Neurosciences	Neurosciences & Neurology	DY2OG	WOS:000384931300003	27301579				2021-06-18	
J	Madsen, PM; Clausen, BH; Degn, M; Thyssen, S; Kristensen, LK; Svensson, M; Ditzel, N; Finsen, B; Deierborg, T; Brambilla, R; Lambertsen, KL				Madsen, Pernille M.; Clausen, Bettina H.; Degn, Matilda; Thyssen, Stine; Kristensen, Lotte K.; Svensson, Martina; Ditzel, Nicholas; Finsen, Bente; Deierborg, Tomas; Brambilla, Roberta; Lambertsen, Kate L.			Genetic ablation of soluble tumor necrosis factor with preservation of membrane tumor necrosis factor is associated with neuroprotection after focal cerebral ischemia	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Tumor necrosis factor; microglia; macrophages; neuroprotection; behavior; cytokines; chemokines	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MICROGLIAL-MACROPHAGE SYNTHESIS; FACTOR-ALPHA GENE; TNF RECEPTOR 2; ARTERY OCCLUSION; INFLAMMATORY RESPONSES; TRANSMEMBRANE TNF; INFARCT VOLUME; DEFICIENT MICE	Microglia respond to focal cerebral ischemia by increasing their production of the neuromodulatory cytokine tumor necrosis factor, which exists both as membrane-anchored tumor necrosis factor and as cleaved soluble tumor necrosis factor forms. We previously demonstrated that tumor necrosis factor knockout mice display increased lesion volume after focal cerebral ischemia, suggesting that tumor necrosis factor is neuroprotective in experimental stroke. Here, we extend our studies to show that mice with intact membrane-anchored tumor necrosis factor, but no soluble tumor necrosis factor, display reduced infarct volumes at one and five days after stroke. This was associated with improved functional outcome after experimental stroke. No changes were found in the mRNA levels of tumor necrosis factor and tumor necrosis factor-related genes (TNFR1, TNFR2, TACE), pro-inflammatory cytokines (IL-1, IL-6) or chemokines (CXCL1, CXCL10, CCL2); however, protein expression of TNF, IL-1, IL-6 and CXCL1 was reduced in membrane-anchored tumor necrosis factor(/) compared to membrane-anchored tumor necrosis factor(wt/wt) mice one day after experimental stroke. This was paralleled by reduced MHCII expression and a reduction in macrophage infiltration in the ipsilateral cortex of membrane-anchored tumor necrosis factor(/) mice. Collectively, these findings indicate that membrane-anchored tumor necrosis factor mediates the protective effects of tumor necrosis factor signaling in experimental stroke, and therapeutic strategies specifically targeting soluble tumor necrosis factor could be beneficial in clinical stroke therapy.	[Madsen, Pernille M.; Clausen, Bettina H.; Thyssen, Stine; Kristensen, Lotte K.; Finsen, Bente; Lambertsen, Kate L.] Univ Southern Denmark, Inst Mol Med, Dept Neurobiol Res, Winsloewpk 25,2, DK-5000 Odense C, Denmark; [Madsen, Pernille M.; Brambilla, Roberta] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA; [Degn, Matilda] Glostrup Cty Hosp, Dept Diagnost, Mol Sleep Lab, Glostrup, Denmark; [Svensson, Martina; Deierborg, Tomas] Lund Univ, Dept Expt Med Sci, Expt Neuroinflammat Lab, Lund, Sweden; [Ditzel, Nicholas] Odense Univ Hosp, KMEB, Mol Endocrinol, Odense, Denmark	Lambertsen, KL (corresponding author), Univ Southern Denmark, Inst Mol Med, Dept Neurobiol Res, Winsloewpk 25,2, DK-5000 Odense C, Denmark.; Brambilla, R (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA.	r.brambilla@miami.edu; klambertsen@health.sdu.dk	Deierborg, Tomas/P-6345-2015; Lambertsen, Kate L./I-8676-2014	Deierborg, Tomas/0000-0002-3651-3444; Madsen, pernille/0000-0003-0558-2460; Clausen, Bettina Hjelm/0000-0003-3302-2022; Lambertsen, Kate L./0000-0001-9276-4902; Degn, Matilda/0000-0003-3093-3525; Finsen, Bente/0000-0002-8323-9329	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS084303-01A1]; Miami Project To Cure Paralysis; Lundbeck FoundationLundbeckfonden [R67-A6383, R54-A5539]; Carlsberg FoundationCarlsberg Foundation [2007_01_0176]; Novo Nordisk FoundationNovo Nordisk Foundation [R153-A12550, R168-A14120]; Fonden til Laegevidenskabens Fremme; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094522] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institute of Health grant NS084303-01A1 (RB); The Miami Project To Cure Paralysis (RB); The Lundbeck Foundation (BHC (R67-A6383) and KLL (R54-A5539)); The Carlsberg Foundation (2007_01_0176), The Novo Nordisk Foundation (R153-A12550 & R168-A14120), and Fonden til Laegevidenskabens Fremme (KLL).	Alexopoulou L, 2006, EUR J IMMUNOL, V36, P2768, DOI 10.1002/eji.200635921; Ando T, 1999, NEUROIMMUNOMODULAT, V6, P319, DOI 10.1159/000026391; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Bach A, 2012, P NATL ACAD SCI USA, V109, P3317, DOI 10.1073/pnas.1113761109; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Barker V, 2001, NAT NEUROSCI, V4, P1194, DOI 10.1038/nn755; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Baune BT, 2008, AM J MED GENET B, V147B, P1056, DOI 10.1002/ajmg.b.30712; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Brambilla R, 2011, BRAIN, V134, P2736, DOI 10.1093/brain/awr199; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Cabal-Hierro L, 2012, CELL SIGNAL, V24, P1297, DOI 10.1016/j.cellsig.2012.02.006; Castellanos M, 2002, STROKE, V33, P982, DOI 10.1161/hs0402.105339; Chen ZG, 2013, BRAIN BEHAV IMMUN, V30, P45, DOI 10.1016/j.bbi.2013.01.083; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Clausen BH, 2006, EXP BRAIN RES, V175, P60, DOI 10.1007/s00221-006-0526-3; Clausen BH, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-46; Clausen BH, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0203-6; Clausen BH, 2005, NEUROSCIENCE, V132, P879, DOI 10.1016/j.neuroscience.2005.01.031; Cui GL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-235; Cunningham CL, 2013, J NEUROSCI, V33, P4216, DOI 10.1523/JNEUROSCI.3441-12.2013; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/0304-3940(96)13116-5; Dziewulska D, 2003, CLIN NEUROPATHOL, V22, P35; Edelblum KL, 2008, J BIOL CHEM, V283, P29485, DOI 10.1074/jbc.M801269200; Fischer R, 2014, GLIA, V62, P272, DOI 10.1002/glia.22605; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; Gimsa U, 2012, CYTOKINE, V59, P72, DOI 10.1016/j.cyto.2012.04.001; Golan H, 2004, SYNAPSE, V53, P6, DOI 10.1002/syn.20032; Golan H, 2004, CEREB CORTEX, V14, P97, DOI 10.1093/cercor/bhg108; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Gu L, 2013, AM J MED SCI, V345, P227, DOI 10.1097/MAJ.0b013e31825f92da; Gu L, 2013, INT J NEUROSCI, V123, P1, DOI 10.3109/00207454.2012.725118; Hallenbeck JM, 2002, NAT MED, V8, P1363, DOI 10.1038/nm1202-1363; Hill JK, 1999, BRAIN RES, V820, P45, DOI 10.1016/S0006-8993(98)01140-8; Holtmann MH, 2004, CURR MOL MED, V4, P439, DOI 10.2174/1566524043360636; Intiso D, 2004, NEUROL SCI, V24, P390, DOI 10.1007/s10072-003-0194-z; Lambertsen KL, 2007, NEUROSCIENCE, V144, P934, DOI 10.1016/j.neuroscience.2006.10.046; Lambertsen KL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-123; Lambertsen KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047744; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014; Lambertsen KL, 2004, J NEUROPATH EXP NEUR, V63, P942, DOI 10.1093/jnen/63.9.942; Lambertsen KL, 2002, J CEREBR BLOOD F MET, V22, P785, DOI 10.1097/00004647-200207000-00004; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Lewitus GM, 2014, J NEUROSCI, V34, P6146, DOI 10.1523/JNEUROSCI.3481-13.2014; Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; LIU T, 1993, NEUROSCI LETT, V164, P125, DOI 10.1016/0304-3940(93)90873-J; Lyck L, 2007, EUR J NEUROSCI, V26, P1749, DOI 10.1111/j.1460-9568.2007.05763.x; Maier O, 2013, BIOCHEM BIOPH RES CO, V440, P336, DOI 10.1016/j.bbrc.2013.09.083; Mazzotta G, 2004, EUR J NEUROL, V11, P377, DOI 10.1111/j.1468-1331.2004.00798.x; McAfoose J, 2009, PSYCHONEUROENDOCRINO, V34, P615, DOI 10.1016/j.psyneuen.2008.10.006; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; MOLLER A, 1995, NEUROL RES, V17, P353; Naude PJW, 2014, BEHAV BRAIN RES, V258, P43, DOI 10.1016/j.bbr.2013.10.006; Novrup HG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0159-6; Olleros ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031469; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Patel A, 2010, BRAIN BEHAV IMMUN, V24, P1276, DOI 10.1016/j.bbi.2010.05.005; Patel JR, 2012, ACTA NEUROPATHOL, V124, P847, DOI 10.1007/s00401-012-1034-0; Perez-Polo JR, 2015, J NEUROSCI RES, V93, P549, DOI 10.1002/jnr.23513; Pettigrew LC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-47; Pradillo JM, 2005, J CEREBR BLOOD F MET, V25, P193, DOI 10.1038/sj.jcbfm.9600019; Probert L, 2015, NEUROSCIENCE, V302, P2, DOI 10.1016/j.neuroscience.2015.06.038; Quintana A, 2005, J NEUROSCI RES, V82, P701, DOI 10.1002/jnr.20680; Ruuls SR, 2001, IMMUNITY, V15, P533, DOI 10.1016/S1074-7613(01)00215-1; Sairanen T, 2001, STROKE, V32, P1750, DOI 10.1161/01.STR.32.8.1750; Saunders BM, 2005, J IMMUNOL, V174, P4852, DOI 10.4049/jimmunol.174.8.4852; Simen BB, 2006, BIOL PSYCHIAT, V59, P775, DOI 10.1016/j.biopsych.2005.10.013; Sotgiu S, 2006, EUR J NEUROL, V13, P505, DOI 10.1111/j.1468-1331.2006.01280.x; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Sumbria RK, 2012, J CEREBR BLOOD F MET, V32, P1933, DOI 10.1038/jcbfm.2012.97; Taoufik E, 2008, NEURODEGENER DIS, V5, P32, DOI 10.1159/000109936; Taoufik E, 2008, P NATL ACAD SCI USA, V105, P6185, DOI 10.1073/pnas.0801447105; Taoufik E, 2007, J NEUROSCI, V27, P6633, DOI 10.1523/JNEUROSCI.1091-07.2007; Taoufik E, 2011, BRAIN, V134, P2722, DOI 10.1093/brain/awr203; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Torres D, 2005, AM J PATHOL, V167, P1677, DOI 10.1016/S0002-9440(10)61250-3; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Ventre J, 1997, DIABETES, V46, P1526, DOI 10.2337/diabetes.46.9.1526; Veroni C, 2010, MOL CELL NEUROSCI, V45, P234, DOI 10.1016/j.mcn.2010.06.014; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; WANG XK, 1995, STROKE, V26, P661, DOI 10.1161/01.STR.26.4.661; Wang XK, 1998, J NEUROCHEM, V71, P1194; Wirenfeldt M, 2007, AM J PATHOL, V171, P617, DOI 10.2353/ajpath.2007.061044; Yamada K, 2000, J NEUROIMMUNOL, V111, P131, DOI 10.1016/S0165-5728(00)00375-1; Zaremba J, 2001, Folia Morphol (Warsz), V60, P91; Zaremba J, 2001, ACTA NEUROL SCAND, V104, P288, DOI 10.1034/j.1600-0404.2001.00053.x	95	25	25	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2016	36	9					1553	1569		10.1177/0271678X15610339			17	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	DV5UU	WOS:000382996800007	26661199	Bronze, Green Published			2021-06-18	
J	Bambakidis, T; Dekker, SE; Sillesen, M; Liu, BL; Johnson, CN; Jin, G; de Vries, HE; Li, YQ; Alam, HB				Bambakidis, Ted; Dekker, Simone E.; Sillesen, Martin; Liu, Baoling; Johnson, Craig N.; Jin, Guang; de Vries, Helga E.; Li, Yongqing; Alam, Hasan B.			Resuscitation with Valproic Acid Alters Inflammatory Genes in a Porcine Model of Combined Traumatic Brain Injury and Hemorrhagic Shock	JOURNAL OF NEUROTRAUMA			English	Article						genomics; inflammation; in vivo studies; therapeutic approaches for the treatment of central nervous system injury; traumatic brain injury	CLOSED-HEAD INJURY; LARGE ANIMAL-MODEL; PHARMACOLOGICAL RESUSCITATION; NORMAL SALINE; TNF-ALPHA; EXPRESSION; STRATEGIES; ACTIVATION; DEFICIENT; PHENOTYPE	Traumatic brain injury and hemorrhagic shock (TBI+HS) elicit a complex inflammatory response that contributes to secondary brain injury. There is currently no proven pharmacologic treatment for TBI+HS, but modulation of the epigenome has been shown to be a promising strategy. The aim of this study was to investigate whether valproic acid (VPA), a histone deacetylase inhibitor, modulates the expression of cerebral inflammatory gene profiles in a large animal model of TBI+HS. Ten Yorkshire swine were subjected to computer-controlled TBI+HS (40% blood volume). After 2 h of shock, animals were resuscitated with Hextend (HEX) or HEX+VPA (300 mg/kg, n = 5/group). Six hours after resuscitation, brains were harvested, RNA was isolated, and gene expression profiles were measured using a porcine microarray. Ingenuity Pathway Analysis (R) (IPA), gene ontology (GO), Parametric Gene Set Enrichment Analysis (PGSEA), and DAVID (Database for Annotation, Visualization, and Integrated Discovery) were used for pathway analysis. Key microarray findings were verified using real-time polymerase chain reaction (PCR). IPA analysis revealed that VPA significantly down-regulated the complement system (p < 0.001), natural killer cell communication (p < 0.001), and dendritic cell maturation (p < 0.001). DAVID analysis indicated that a cluster of inflammatory pathways held the highest rank and gene enrichment score. Real-time PCR data confirmed that VPA significantly down-expressed genes that ultimately regulate nuclear factor-kB (NF-kB)-mediated production of cytokines, such as TYROBP, TREM2, CCR1, and IL-1 beta. This high-throughput analysis of cerebral gene expression shows that addition of VPA to the resuscitation protocol significantly modulates the expression of inflammatory pathways in a clinically realistic model of TBI+HS.	[Bambakidis, Ted; Dekker, Simone E.; Liu, Baoling; Jin, Guang; Li, Yongqing; Alam, Hasan B.] Univ Michigan Hosp, Dept Surg, Ann Arbor, MI 48109 USA; [Dekker, Simone E.] Vrije Univ Amsterdam, Med Ctr, Inst Cardiovasc Res, Dept Anesthesiol, Amsterdam, Netherlands; [Sillesen, Martin] Copenhagen Univ Hosp, Dept Surg Gastroenterol, Copenhagen, Denmark; [Johnson, Craig N.] Univ Michigan, DNA Sequencing Core, Ann Arbor, MI 48109 USA; [de Vries, Helga E.] Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands	Alam, HB (corresponding author), Univ Michigan Hosp, Dept Gen Surg, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Sillesen, Martin/0000-0001-9494-5475; Johnson, Craig/0000-0003-3955-7394			Abraham RT, 2004, NAT REV IMMUNOL, V4, P301, DOI 10.1038/nri1330; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bambakidis T, 2015, J SURG RES, V196, P159, DOI 10.1016/j.jss.2015.02.036; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bouchon A, 2001, J EXP MED, V194, P1111, DOI 10.1084/jem.194.8.1111; Brown AL, 2006, J LEUKOCYTE BIOL, V80, P433, DOI 10.1189/jlb.0206112; Dekker SE, 2014, J TRAUMA ACUTE CARE, V77, P906, DOI 10.1097/TA.0000000000000345; Dekker SE, 2014, SURGERY, V156, P556, DOI 10.1016/j.surg.2014.04.016; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fukudome EY, 2012, SURGERY, V152, P254, DOI 10.1016/j.surg.2012.03.013; Fukudome EY, 2010, J SURG RES, V163, P118, DOI 10.1016/j.jss.2010.04.013; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hamerman JA, 2005, NAT IMMUNOL, V6, P579, DOI 10.1038/ni1204; Han Zhe, 2014, J Pharm Pract, V27, P487; Helming L, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159665; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Ichiyama T, 2000, BRAIN RES, V857, P246, DOI 10.1016/S0006-8993(99)02439-7; Imam A, 2015, J NEUROTRAUM, V32, P307, DOI 10.1089/neu.2014.3535; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kiialainen A, 2005, NEUROBIOL DIS, V18, P314, DOI 10.1016/j.nbd.2004.09.007; Kim K, 2012, RESUSCITATION, V83, P243, DOI 10.1016/j.resuscitation.2011.07.029; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Lee MMK, 2009, J LEUKOCYTE BIOL, V86, P1319, DOI 10.1189/jlb.0209052; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li YQ, 2012, ADV EXP MED BIOL, V710, P107, DOI 10.1007/978-1-4419-5638-5_11; Liu ZC, 2014, SHOCK, V41, P104, DOI 10.1097/SHK.0000000000000074; Luer MS, 1996, PHARMACOTHERAPY, V16, P830; Ma J, 2015, MOL NEUROBIOL, V51, P820, DOI 10.1007/s12035-014-8811-9; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Okkenhaug K, 2007, TRENDS IMMUNOL, V28, P80, DOI 10.1016/j.it.2006.12.007; Paradowska-Gorycka A, 2013, HUM IMMUNOL, V74, P730, DOI 10.1016/j.humimm.2013.02.003; Piccio L, 2007, EUR J IMMUNOL, V37, P1290, DOI 10.1002/eji.200636837; Ritchie ME, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-261; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shein SL, 2014, J NEUROTRAUM, V31, P1386, DOI 10.1089/neu.2013.2985; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P1, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tomasello E, 2005, EUR J IMMUNOL, V35, P1670, DOI 10.1002/eji.200425932; Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Zhang Z, 2008, CELL MOL LIFE SCI, V65, P4055, DOI 10.1007/s00018-008-8521-4	53	25	26	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2016	33	16					1514	1521		10.1089/neu.2015.4163			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DU6ED	WOS:000382305900005	26905959				2021-06-18	
J	Kramer, AH; Deis, N; Ruddell, S; Couillard, P; Zygun, DA; Doig, CJ; Gallagher, C				Kramer, Andreas H.; Deis, Nathan; Ruddell, Stacy; Couillard, Philippe; Zygun, David A.; Doig, Christopher J.; Gallagher, Clare			Decompressive Craniectomy in Patients with Traumatic Brain Injury: Are the Usual Indications Congruent with Those Evaluated in Clinical Trials?	NEUROCRITICAL CARE			English	Article						Decompressive craniectomy; Transtentorial herniation; Midline shift; Pupillary light reflex; Cerebral edema; Intracranial pressure	REFRACTORY INTRACRANIAL HYPERTENSION; MIDDLE-CEREBRAL-ARTERY; SEVERE HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; RANDOMIZED-TRIAL; PRACTICAL SCALE; HEMICRANIECTOMY; CLASSIFICATION; PREDICTORS; MANAGEMENT	In patients with traumatic brain injury (TBI), multicenter randomized controlled trials have assessed decompressive craniectomy (DC) exclusively as treatment for refractory elevation of intracranial pressure (ICP). DC reliably lowers ICP but does not necessarily improve outcomes. However, some patients undergo DC as treatment for impending or established transtentorial herniation, irrespective of ICP. We performed a population-based cohort study assessing consecutive patients with moderate-severe TBI. Indications for DC were compared with enrollment criteria for the DECRA and RESCUE-ICP trials. Of 644 consecutive patients, 51 (8 %) were treated with DC. All patients undergoing DC had compressed basal cisterns, 82 % had at least temporary preoperative loss of a parts per thousand yen1 pupillary light reflex (PLR), and 80 % had > 5 mm of midline shift. Most DC procedures (67 %) were "primary," having been performed concomitantly with evacuation of a space-occupying lesion. ICP measurements influenced the decision to perform DC in 18 % of patients. Only 10 and 16 % of patients, respectively, would have been eligible for the DECRA and RESCUE-ICP trials. DC improved basal cistern compression in 76 %, and midline shift in 94 % of patients. Among patients with a parts per thousand yen1 absent PLR at admission, DC was associated with lower mortality (46 vs. 68 %, p = 0.03), especially when the admission Marshall CT score was 3-4 (p = 0.0005). No patients treated with DC progressed to brain death. Variables predictive of poor outcome following DC included loss of PLR(s), poor motor score, midline shift a parts per thousand yen11 mm, and development of perioperative cerebral infarcts. DC is most often performed for clinical and radiographic evidence of herniation, rather than for refractory ICP elevation. Results of previously completed randomized trials do not directly apply to a large proportion of patients undergoing DC in practice.	[Kramer, Andreas H.; Deis, Nathan; Ruddell, Stacy; Couillard, Philippe; Doig, Christopher J.; Gallagher, Clare] Univ Calgary, Dept Crit Care Med, Foothills Med Ctr, 3132 Hosp Dr NW, Calgary, AB T2N 2T9, Canada; [Kramer, Andreas H.; Deis, Nathan; Couillard, Philippe; Gallagher, Clare] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Kramer, Andreas H.; Couillard, Philippe; Gallagher, Clare] Hotchkiss Brain Inst, Calgary, AB, Canada; [Zygun, David A.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Doig, Christopher J.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada	Kramer, AH (corresponding author), Univ Calgary, Dept Crit Care Med, Foothills Med Ctr, 3132 Hosp Dr NW, Calgary, AB T2N 2T9, Canada.; Kramer, AH (corresponding author), Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.; Kramer, AH (corresponding author), Hotchkiss Brain Inst, Calgary, AB, Canada.	andreas.kramer@albertahealthservices.ca	Doig, Christopher/AAC-7949-2020	Doig, Christopher/0000-0002-8576-9139			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Al-Jishi A, 2011, CAN J NEUROL SCI, V38, P612, DOI 10.1017/S0317167100012154; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dandaleh NS, 2012, J CLIN NEUROSCI, V19, P1236, DOI 10.1016/j.jocn.2011.11.025; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; Fujimoto K, 2015, J NEUROSURG, V23, P1; HORNIG CR, 1994, STROKE, V25, P372, DOI 10.1161/01.STR.25.2.372; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; JENNETT B, 1975, LANCET, V1, P480; Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mendelow AD, 2015, J NEUROTRAUM, V32, P1312, DOI 10.1089/neu.2014.3644; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; Munch E, 2000, NEUROSURGERY, V47, P315; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nirula R, 2014, J TRAUMA ACUTE CARE, V76, P944, DOI 10.1097/TA.0000000000000194; Saade Nelson, 2014, Rev. Col. Bras. Cir., V41, P256, DOI 10.1590/0100-69912014004006; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Sturiale CL, 2012, J NEUROTRAUM, V29, P2723, DOI 10.1089/neu.2012.2556; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1974, LANCET, V2, P81; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Trauma Foundation, 2007, J NEUROTRAUM, pS; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Yuan Q, 2013, BRIT J NEUROSURG, V27, P483, DOI 10.3109/02688697.2013.763897	35	25	26	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2016	25	1					10	19		10.1007/s12028-015-0232-8			10	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	DR8LZ	WOS:000380150700003	26732269				2021-06-18	
J	McDevitt, J; Appiah-Kubi, KO; Tierney, R; Wright, WG				McDevitt, J.; Appiah-Kubi, K. O.; Tierney, R.; Wright, W. G.			Vestibular and Oculomotor Assessments May Increase Accuracy of Subacute Concussion Assessment	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						near point convergence; optokinetic stimulation; gaze stabilization test; concussion; mild TBI; BESS; SOT	SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; HUMAN OPTOKINETIC NYSTAGMUS; SENSORY ORGANIZATION TEST; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; POSTURAL STABILITY; FOOTBALL PLAYERS; GAZE STABILIZATION; PERIPHERAL RETINA	In this study, we collected and analyzed preliminary data for the internal consistency of a new condensed model to assess vestibular and oculomotor impairments following a concussion. We also examined this model's ability to discriminate concussed athletes from healthy controls. Each participant was tested in a concussion assessment protocol that consisted of the Neurocom's Sensory Organization Test (SOT), Balance Error Scoring System exam, and a series of 8 vestibular and oculomotor assessments. Of these 10 assessments, only the SOT, near point convergence, and the signs and symptoms (S/S) scores collected following optokinetic stimulation, the horizontal eye saccades test, and the gaze stabilization test were significantly correlated with health status, and were used in further analyses. Multivariate logistic regression for binary outcomes was employed and these beta weights were used to calculate the area under the receiver operating characteristic curve (area under the curve). The best model supported by our findings suggest that an exam consisting of the 4 SOT sensory ratios, near point convergence, and the optokinetic stimulation signs and symptoms score are sensitive in discriminating concussed athletes from healthy controls (accuracy = 98.6 %, AUC = 0.983). However, an even more parsimonious model consisting of only the optokinetic stimulation and gaze stabilization test S/S scores and near point convergence was found to be a sensitive model for discriminating concussed athletes from healthy controls (accuracy = 94.4 %, AUC = 0.951) without the need for expensive equipment. Although more investigation is needed, these findings will be helpful to health professionals potentially providing them with a sensitive and specific battery of simple vestibular and oculomotor assessments for concussion management.	[McDevitt, J.] East Stroudsburg Univ, Athlet Training, East Stroudsburg, PA USA; [Appiah-Kubi, K. O.; Wright, W. G.] Temple Univ, Phys Therapy, 3307N Broad St, Philadelphia, PA 19130 USA; [Tierney, R.] Temple Univ, Kinesiol, Philadelphia, PA 19122 USA; [Wright, W. G.] Temple Univ, Bioengn, Philadelphia, PA 19122 USA	Wright, WG (corresponding author), Temple Univ, Phys Therapy, 3307N Broad St, Philadelphia, PA 19130 USA.	wrightw@temple.edu	Appiah-Kubi, Kwadwo/ABF-9527-2020	Appiah-Kubi, Kwadwo/0000-0001-6566-9758	Department of DefenseUnited States Department of Defense [W81XWH-13-C-0189]	This study was funded, in part, by the Department of Defense, Army Rapid Innovation Fund Award No. W81XWH-13-C-0189 (WGW).	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Baker C.S., 2014, PHYSL REP, V2, P1; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Christman SP, 2013, BRAIN INJURY, V27, P1; Ciuffreda KJ, 2009, OPTOM VIS DEV, V40, P16; COHEN B, 1977, J PHYSIOL-LONDON, V270, P321, DOI 10.1113/jphysiol.1977.sp011955; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Field A., 1998, BRIT PSYCHOL SOC MAT, V6, P13; FORDSMITH CD, 1995, ARCH PHYS MED REHAB, V76, P77, DOI 10.1016/S0003-9993(95)80047-6; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goebel JA, 2007, OTOL NEUROTOL, V28, P68, DOI 10.1097/01.mao.0000244351.42201.a7; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harriss DJ, 2015, INT J SPORTS MED, V36, P1121, DOI 10.1055/s-0035-1565186; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; HOWARD IP, 1984, VISION RES, V24, P969, DOI 10.1016/0042-6989(84)90072-5; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Kaufman DR, 2014, PHYS THER SPORT, V15, P181, DOI 10.1016/j.ptsp.2013.10.002; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; LONGRIDGE NS, 1984, OTOLARYNG HEAD NECK, V92, P671, DOI 10.1177/019459988409200614; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Murray N, 2014, J ATHL TRAINING, V49, P540, DOI 10.4085/1062-6050-49.3.32; NeuroCom, DIV NAT SETT STAND B; Phillips J, 2015, J EYE MOVEMENT RES, V8; Rabago CA, 2011, J NEUROL PHYS THER, V35, P185, DOI 10.1097/NPT.0b013e318235d7e6; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Rine RM, 2013, NEUROLOGY, V80, pS25, DOI 10.1212/WNL.0b013e3182872c6a; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Teel EF, 2013, J SCI MED SPORT, V16, P190, DOI 10.1016/j.jsams.2012.09.007; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Treleaven J, 2011, MANUAL THER, V16, P252, DOI 10.1016/j.math.2010.11.002; VANDIE GC, 1986, BRAIN RES, V383, P185, DOI 10.1016/0006-8993(86)90019-3; Ward BK, 2010, J VESTIBUL RES-EQUIL, V20, P363, DOI 10.3233/VES-2010-0371; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; Wrisley DM, 2007, ARCH PHYS MED REHAB, V88, P1049, DOI 10.1016/j.apmr.2007.05.003	51	25	26	0	24	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	AUG	2016	37	9					738	747		10.1055/s-0042-100470			10	Sport Sciences	Sport Sciences	DS4UP	WOS:000380777400010	27176886				2021-06-18	
J	Mohr, NM; Harland, KK; Shane, DM; Miller, SL; Torner, JC				Mohr, Nicholas M.; Harland, Karisa K.; Shane, Dan M.; Miller, Sarah L.; Torner, James C.			Potentially Avoidable Pediatric Interfacility Transfer Is a Costly Burden for Rural Families: A Cohort Study	ACADEMIC EMERGENCY MEDICINE			English	Article							CARE; TELEMEDICINE; CHILDREN	Objectives: Interhospital transfer is a common strategy to provide high-quality regionalized care in rural emergency departments (EDs), but several reports have highlighted problems with selection of children for transfer. The purpose of this study is to characterize the burden of potentially avoidable transfer (PAT) and to estimate the medical and family-oriented costs associated with PAT. Methods: This study was a cohort study of all children treated in Iowa EDs between 2004 and 2013. PAT was defined as a child who was transferred and then either discharged from the receiving ED or admitted for <= 1 day, without having any separately billed procedures performed. Costs of care were estimated from 1) medical costs, 2) ambulance transfer, and 3) family costs (travel and lodging). Results: Over 10 years, 2,117,317 children were included (1% transferred to another hospital). Only 63% were transferred to a designated children's hospital, and PATs were identified in 39% of all transfers. PAT was associated with $909 in additional cost. The conditions most strongly associated with PAT were seizure (additional cost $1,138), fracture ($814), isolated traumatic brain injury without extra-axial bleeding ($1,455), respiratory infection ($556), and wheezing ($804). Few of these charges are attributable to nonmedical family costs ($21). Conclusions: Potentially avoidable pediatric interhospital transfer is common and is responsible for significant healthcare-related costs. Future work should focus on improving selection of children who benefit from interhospital transfer for high-yield conditions, to reduce the costly and distressing burden that PAT places on rural patients and their families. (C) 2016 by the Society for Academic Emergency Medicine	[Mohr, Nicholas M.; Harland, Karisa K.; Miller, Sarah L.] Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA; [Shane, Dan M.; Torner, James C.] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA	Mohr, NM (corresponding author), Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA.	nicholas-mohr@uiowa.edu	Mohr, Nicholas/N-1112-2017	Mohr, Nicholas/0000-0003-0497-5828; Miller, Sarah/0000-0002-2726-962X; Harland, Karisa/0000-0001-9482-8447	Children's Miracle Network; University of Iowa Carver College of Medicine; University of Iowa Stead Family Department of Pediatrics; University of Iowa Department of Emergency Medicine; Emergency Medicine Foundation; Federal Office of Rural Health Policy	This project was supported by a grant from the Children's Miracle Network, the University of Iowa Carver College of Medicine, the University of Iowa Stead Family Department of Pediatrics, and the University of Iowa Department of Emergency Medicine. Dr. Mohr is additionally supported by a grant from the Emergency Medicine Foundation and a grant from the Federal Office of Rural Health Policy.	[Anonymous], 2010, PED CAR RUR HOSP EM; Basco WT, 2013, PEDIATRICS, V132, P390, DOI 10.1542/peds.2013-1517; DeLia D, 2016, J PUBLIC HEALTH DENT, V76, P1, DOI 10.1111/jphd.12103; Feudtner C, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e99; Gattu RK, 2014, PEDIATR EMERG CARE, V30, P26, DOI 10.1097/PEC.0000000000000061; Goudie A, 2014, PEDIATRICS, V133, pE1525, DOI 10.1542/peds.2013-3795; Groth H, 2013, WEST J EMERG MED, V14, P186, DOI 10.5811/westjem.2012.8.12783; Hernandez M, 2016, TELEMED E-HEALTH, V22, P51, DOI 10.1089/tmj.2015.0043; Krug SE, 2007, PEDIATRICS, V119, P161, DOI 10.1542/peds.2006-2900; Lagu T, 2012, CRIT CARE MED, V40, P754, DOI 10.1097/CCM.0b013e318232db65; Li J, 2012, PEDIATRICS, V130, P83, DOI 10.1542/peds.2011-1819; Miyamoto S, 2014, CHILD ABUSE NEGLECT, V38, P1533, DOI 10.1016/j.chiabu.2014.04.015; Ogola GO, 2016, J TRAUMA ACUTE CARE, V80, P265, DOI 10.1097/TA.0000000000000911; Sullivan AF, 2013, INT J EMERG MED, V6, DOI 10.1186/1865-1380-6-13; Wiebe RA, 2000, PEDIATRICS, V105, P647; Yang NH, 2015, MED DECIS MAKING; Yang Nikki H, 2015, Pediatr Crit Care Med, V16, pe59, DOI 10.1097/PCC.0000000000000337	17	25	25	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	AUG	2016	23	8					885	894		10.1111/acem.12972			10	Emergency Medicine	Emergency Medicine	DW1BQ	WOS:000383378200006	27018337				2021-06-18	
J	Mustafa, G; Hou, JM; Tsuda, S; Nelson, R; Sinharoy, A; Wilkie, Z; Pandey, R; Caudle, RM; Neubert, JK; Thompson, FJ; Bose, P				Mustafa, Golam; Hou, Jiamei; Tsuda, Shigeharu; Nelson, Rachel; Sinharoy, Ankita; Wilkie, Zachary; Pandey, Rahul; Caudle, Robert M.; Neubert, John K.; Thompson, Floyd J.; Bose, Prodip			Trigeminal neuroplasticity underlies allodynia in a preclinical model of mild closed head traumatic brain injury (cTBI)	NEUROPHARMACOLOGY			English	Article						Closed head TBI; Facial allodynia; Trigeminal sensitization; Operant conditioning	SUBSTANCE-P; SPINAL-CORD; LOCUS-COERULEUS; NEUROKININ-1 RECEPTOR; GABAERGIC NEURONS; OROFACIAL PAIN; POSTTRAUMATIC HEADACHES; FUNCTIONAL NEUROANATOMY; CENTRAL SENSITIZATION; DOWN-REGULATION	Post-traumatic headache (PTH) following TBI is a common and often persisting pain disability. PTH is often associated with a multimodal central pain sensitization on the skin surface described as allodynia. However, the particular neurobiology underlying cTBI-induced pain disorders are not known. These studies were performed to assess trigeminal sensory sensitization and to determine if sensitization measured behaviorally correlated with detectable changes in portions of the trigeminal sensory system (TSS), particularly trigeminal nucleus, thalamus, and sensory cortex. Thermal stimulation is particularly well suited to evaluate sensitization and was used in these studies. Recent advances in the use of reward/conflict paradigms permit use of operant measures of behavior, versus reflex-driven response behaviors, for thermal sensitization studies. Thus, to quantitate facial thermal sensitization (allodynia) in the setting of acute TBI, the current study utilized an operant orofacial pain reward/conflict testing paradigm to assess facial thermal sensitivity in uninjured control animals compared with those two weeks after cTBI in a rodent model. Significant reductions in facial contact/lick behaviors were observed in the TBI animals using either cool or warm challenge temperatures compared with behaviors in the normal animals. These facial thermal sensitizations correlated with detectable changes in multiple levels of the TSS. The immunohistochemical (IHC) studies revealed significant alterations in the expression of the serotonin (5 HT), neurokinin 1 receptor (NK1R), norepinephrine (NE), and gamma-aminobutyric acid (GABA) in the caudal trigeminal nucleus, thalamic VPL/VPM nucleus, and sensory cortex of the orofacial pain pathways. There was a strong correlation between increased expression of certain IHC markers and increased behavioral markers for facial sensitization. The authors conclude that TBI-induced changes observed in the TSS are consistent with the expression of generalized facial allodynia following cTBI. To our knowledge, this is the first report of orofacial sensitization correlated with changes in selected neuromodulators/neurotransmitters in the TSS following experimental mild TBI. Published by Elsevier Ltd.	[Mustafa, Golam; Hou, Jiamei; Nelson, Rachel; Sinharoy, Ankita; Wilkie, Zachary; Pandey, Rahul; Thompson, Floyd J.; Bose, Prodip] North Florida South Georgia Vet Hlth Syst, Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr Excellence, Gainesville, FL 32608 USA; [Mustafa, Golam; Hou, Jiamei; Tsuda, Shigeharu; Thompson, Floyd J.; Bose, Prodip] Univ Florida, Coll Vet Med, Dept Physiol Sci, Gainesville, FL 32610 USA; [Thompson, Floyd J.] Univ Florida, Coll Med, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA; [Caudle, Robert M.] Univ Florida, Coll Dent, Dept Oral & Maxillofacial Surg, Gainesville, FL 32610 USA; [Neubert, John K.] Univ Florida, Coll Dent, Dept Orthodont, Gainesville, FL 32610 USA; [Bose, Prodip] Univ Florida, Coll Med, Dept Neurol, McKnight Brain Inst, Gainesville, FL 32610 USA	Bose, P (corresponding author), North Florida South Georgia Vet Hlth Syst, Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr Excellence, Gainesville, FL 32608 USA.	pkbose@ufl.edu		Sinharoy, Ankita/0000-0002-6911-196X; Caudle, Robert/0000-0002-2394-4114; Wilkie, Zachary/0000-0002-4331-9770	United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service [B6570R, B78071, B1005-R]; Veterans AffairsUS Department of Veterans Affairs [I01RX001005] Funding Source: NIH RePORTER	This work was supported by Merit Review Award # B6570R, B78071, B1005-R, from the United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service.	Abbadie C, 1997, J NEUROSCI, V17, P8049; Aicher SA, 2012, J CHEM NEUROANAT, V43, P103, DOI 10.1016/j.jchemneu.2011.11.002; Alwis DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052169; Anderson EM, 2013, JOVE-J VIS EXP, DOI 10.3791/50336; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Awawdeh LA, 2002, EUR J ORAL SCI, V110, P185, DOI 10.1034/j.1600-0447.2002.21236.x; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bernstein AI, 2013, TOXICOL LETT, V219, P93, DOI 10.1016/j.toxlet.2013.03.003; Bernstein AI, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-2; BERVOETS K, 1990, EUR J PHARMACOL, V191, P185, DOI 10.1016/0014-2999(90)94146-O; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bose P, 2005, EXP NEUROL, V191, P13, DOI 10.1016/j.expneurol.2004.08.028; Bose P, 2013, J NEUROTRAUM, V30, P1177, DOI 10.1089/neu.2012.2740; Bose PK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00258; Boulenguez P, 2010, NAT MED, V16, P302, DOI 10.1038/nm.2107; Bowles WR, 2003, J ENDODONT, V29, P265, DOI 10.1097/00004770-200304000-00009; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burstein R, 2010, ANN NEUROL, V68, P81, DOI 10.1002/ana.21994; Cai YQ, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-70; Chai BY, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-78; CHERYCROZE S, 1983, PAIN, V17, P109, DOI 10.1016/0304-3959(83)90137-9; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Cook GA, 2014, MIL MED, V179, P1083, DOI 10.7205/MILMED-D-13-00435; Couto LB, 2006, J CHEM NEUROANAT, V32, P28, DOI 10.1016/j.jchemneu.2006.03.003; Cramer SW, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-36; Defrin R, 2002, BRAIN, V125, P501, DOI 10.1093/brain/awf055; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Denadai-Souza A, 2009, EUR J PAIN, V13, P812, DOI 10.1016/j.ejpain.2008.09.012; DOUGHERTY PM, 1991, PAIN, V47, P85, DOI 10.1016/0304-3959(91)90015-P; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; Egea J, 2012, PFLUG ARCH EUR J PHY, V463, P449, DOI 10.1007/s00424-011-1063-x; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Guven H, 2013, NEUROL SCI, V34, P1397, DOI 10.1007/s10072-012-1249-9; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Haggman-Henrikson B, 2011, SWED DENT J, V35, P123; Hirata A, 2006, J NEUROSCI, V26, P4426, DOI 10.1523/JNEUROSCI.5298-05.2006; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Holzer P, 2004, EUR J PHARMACOL, V500, P231, DOI 10.1016/j.ejphar.2004.07.028; Hou JM, 2014, J NEUROTRAUM, V31, P1088, DOI 10.1089/neu.2013.3096; Jasmin L, 2002, P NATL ACAD SCI USA, V99, P1029, DOI 10.1073/pnas.012598599; Jensen O K, 2001, Ugeskr Laeger, V163, P5029; JONES BE, 1991, PROG BRAIN RES, V88, P15; Lagraize SC, 2010, NEUROSCIENCE, V171, P1341, DOI 10.1016/j.neuroscience.2010.09.040; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Lazarov N. E., 2012, NEUROCHEMICAL ANATOM; Lee M, 2011, GLIA, V59, P152, DOI 10.1002/glia.21087; Lipton JW, 2008, NEUROPHARMACOLOGY, V55, P851, DOI 10.1016/j.neuropharm.2008.06.062; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Mansikka H, 2000, EXP NEUROL, V162, P343, DOI 10.1006/exnr.1999.7336; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCCORMICK DA, 1991, J PHYSIOL-LONDON, V442, P235, DOI 10.1113/jphysiol.1991.sp018791; Millan MJ, 1995, BEHAV BRAIN RES, V73, P69; MILLHORN DE, 1988, BRAIN RES, V461, P169, DOI 10.1016/0006-8993(88)90736-6; Miremami JD, 2014, SOMATOSENS MOT RES, V31, P127, DOI 10.3109/08990220.2014.897602; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Murphy Niall P, 2014, Curr Top Behav Neurosci, V20, P121, DOI 10.1007/7854_2014_332; Mustafa G, 2013, PAIN, V154, P2547, DOI 10.1016/j.pain.2013.07.041; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Neubert JK, 2005, PAIN, V116, P386, DOI 10.1016/j.pain.2005.05.011; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Okubo M, 2013, J NEUROSCI, V33, P5152, DOI 10.1523/JNEUROSCI.3390-12.2013; Perez CT, 2013, J NEUROPHYSIOL, V110, P286, DOI 10.1152/jn.01006.2012; Pinal CS, 1998, PERSPECT DEV NEUROBI, V5, P109; Rivera C, 1999, NATURE, V397, P251; Rodd HD, 2000, EUR J ORAL SCI, V108, P467, DOI 10.1034/j.1600-0722.2000.00924.x; Samuels ER, 2008, CURR NEUROPHARMACOL, V6, P254, DOI 10.2174/157015908785777193; SASA M, 1986, BRAIN RES, V377, P337, DOI 10.1016/0006-8993(86)90877-2; SASA M, 1979, J PHARMACOL EXP THER, V210, P311; SASA M, 1974, BRAIN RES, V80, P443, DOI 10.1016/0006-8993(74)91029-4; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Song BB, 2007, BRAIN RES, V1158, P57, DOI 10.1016/j.brainres.2007.05.006; STAMP JA, 1995, BRAIN RES, V677, P39, DOI 10.1016/0006-8993(95)00119-B; Sterling M, 2003, PAIN, V104, P509, DOI 10.1016/S0304-3959(03)00078-2; TAIWO YO, 1992, NEUROSCIENCE, V48, P485, DOI 10.1016/0306-4522(92)90508-Y; Takeda M, 2005, PAIN, V116, P375, DOI 10.1016/j.pain.2005.05.007; Takeda M, 2012, J PERIPHER NERV SYST, V17, P169, DOI 10.1111/j.1529-8027.2012.00404.x; Teodoro FC, 2013, NEUROPEPTIDES, V47, P199, DOI 10.1016/j.npep.2012.10.005; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Tsuruoka M, 2003, BRAIN RES, V993, P146, DOI 10.1016/j.brainres.2003.09.023; Vierck CJ, 2015, NEUROSCI BIOBEHAV R, V51, P223, DOI 10.1016/j.neubiorev.2015.01.022; Viggiano A, 2004, EUR J PHARMACOL, V496, P87, DOI 10.1016/j.ejphar.2004.06.019; Wasner GL, 2008, CLIN NEUROPHYSIOL, V119, P2389, DOI 10.1016/j.clinph.2008.07.223; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; Wu LA, 2009, NEUROSCI LETT, V457, P36, DOI 10.1016/j.neulet.2009.03.107; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Zhang H, 2007, J NEUROSCI, V27, P12067, DOI 10.1523/JNEUROSCI.0496-07.2007	89	25	25	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	AUG	2016	107						27	39		10.1016/j.neuropharm.2016.03.016			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	DQ1HZ	WOS:000378953400004	26972829	Green Accepted			2021-06-18	
J	Hall, ANB; Joseph, B; Brelsfoard, JM; Saatman, KE				Hall, Amanda N. Bolton; Joseph, Binoy; Brelsfoard, Jennifer M.; Saatman, Kathryn E.			Repeated Closed Head Injury in Mice Results in Sustained Motor and Memory Deficits and Chronic Cellular Changes	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; MOUSE MODEL; AXONAL INJURY; BEHAVIORAL IMPAIRMENTS; COGNITIVE IMPAIRMENT; ASTROCYTE ACTIVATION; OPTIC-NERVE; MILD; CONCUSSION	Millions of mild traumatic brain injuries (TBIs) occur every year in the United States, with many people subject to multiple head injuries that can lead to chronic behavioral dysfunction. We previously reported that mild TBI induced using closed head injuries (CHI) repeated at 24h intervals produced more acute neuron death and glial reactivity than a single CHI, and increasing the length of time between injuries to 48h reduced the cumulative acute effects of repeated CHI. To determine whether repeated CHI is associated with behavioral dysfunction or persistent cellular damage, mice receiving either five CHI at 24h intervals, five CHI at 48h intervals, or five sham injuries at 24h intervals were evaluated across a 10 week period after injury. Animals with repeated CHI exhibited motor coordination and memory deficits, but not gait abnormalities when compared to sham animals. At 10wks post-injury, no notable neuron loss or glial reactivity was observed in the cortex, hippocampus, or corpus callosum. Argyrophilic axons were found in the pyramidal tract of some injured animals, but neither silver stain accumulation nor inflammatory responses in the injury groups were statistically different from the sham group in this region. However, argyrophilic axons, microgliosis and astrogliosis were significantly increased within the optic tract of injured animals. Repeated mild CHI also resulted in microgliosis and a loss of neurofilament protein 200 in the optic nerve. Lengthening the inter-injury interval from 24h to 48h did not effectively reduce these behavioral or cellular responses. These results suggest that repeated mild CHI results in persistent behavioral dysfunction and chronic pathological changes within the visual system, neither of which was significantly attenuated by lengthening the inter-injury interval from 24h to 48h.	[Hall, Amanda N. Bolton; Joseph, Binoy; Brelsfoard, Jennifer M.; Saatman, Kathryn E.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40506 USA; [Hall, Amanda N. Bolton; Saatman, Kathryn E.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40506 USA; [Saatman, Kathryn E.] Univ Kentucky, Coll Med, Dept Neurosurg, Lexington, KY 40506 USA	Saatman, KE (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40506 USA.; Saatman, KE (corresponding author), Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40506 USA.; Saatman, KE (corresponding author), Univ Kentucky, Coll Med, Dept Neurosurg, Lexington, KY 40506 USA.	k.saatman@uky.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32 NS077889, F31 NS087878-02, P30 NS051220]; Kentucky Spinal Cord and Head Injury Trust [14-13A, 9-13]	This study was supported by the National Institute of Neurological Disorders and Stroke T32 NS077889 and National Institute of Neurological Disorders and Stroke F31 NS087878-02 (ANBH); National Institute of Neurological Disorders and Stroke P30 NS051220, Kentucky Spinal Cord and Head Injury Trust 14-13A, Kentucky Spinal Cord and Head Injury Trust 9-13 (KES). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amende Ivo, 2005, J Neuroeng Rehabil, V2, P20, DOI 10.1186/1743-0003-2-20; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Balaratnasingam C, 2010, INVEST OPHTH VIS SCI, V51, P3019, DOI 10.1167/iovs.09-4692; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Febinger HY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0386-5; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GRONWALL D, 1975, LANCET, V2, P995; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Huynh T, 2006, AM SURGEON, V72, P1162; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kraft AW, 2013, FASEB J, V27, P187, DOI 10.1096/fj.12-208660; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Macauley SL, 2011, J NEUROSCI, V31, P15575, DOI 10.1523/JNEUROSCI.3579-11.2011; Madathil SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067204; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2005, BRIT J SPORT MED, V39, pI58, DOI 10.1136/bjsm.2005.020776; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nichols JN, 2016, BEHAV BRAIN RES, V298, P111, DOI 10.1016/j.bbr.2015.10.052; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Piccin D, 2011, STEM CELLS, V29, P528, DOI 10.1002/stem.589; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Schoch KM, 2012, EXP NEUROL, V236, P371, DOI 10.1016/j.expneurol.2012.04.022; Selwyn RG, 2015, J NEUROTRAUMA; Semple BD, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00069; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Spires TL, 2006, AM J PATHOL, V168, P1598, DOI 10.2353/ajpath.2006.050840; Springer JE, 2010, J NEUROTRAUM, V27, P139, DOI 10.1089/neu.2009.0952; Syed A T, 2007, Int J Health Sci (Qassim), V1, P131; Tellier A, 1999, BRAIN INJURY, V13, P463; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Viswanathan S, 1999, INVEST OPHTH VIS SCI, V40, P1124; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Xu L, 2014, EXP NEUROL; Zhang J, 2015, J CEREBR BLOOD F MET, V35, P443, DOI 10.1038/jcbfm.2014.216	79	25	26	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2016	11	7							e0159442	10.1371/journal.pone.0159442			23	Multidisciplinary Sciences	Science & Technology - Other Topics	DR8TD	WOS:000380169300067	27427961	DOAJ Gold, Green Published			2021-06-18	
J	Murray, CE; Lundgren, K; Olson, LN; Hunnicutt, G				Murray, Christine E.; Lundgren, Kristine; Olson, Loreen N.; Hunnicutt, Gwen			Practice Update: What Professionals Who Are Not Brain Injury Specialists Need to Know About Intimate Partner Violence-Related Traumatic Brain Injury	TRAUMA VIOLENCE & ABUSE			English	Article						traumatic brain injury; intimate partner violence; domestic violence; battering; victimization	BATTERED WOMEN; HEAD-INJURY; HELP-SEEKING; RECOVERY; REHABILITATION; PERFORMANCE; CONCUSSION; OUTCOMES; MODEL; SCALE	There is growing recognition of the risk for traumatic brain injury (TBI) among victims and survivors of intimate partner violence (IPV). A wide range of physically abusive behaviors may lead to injuries to the head or neck and place an individual at risk for a TBI. The purpose of this article is to consolidate current research and present practical guidelines for professionals, who are not brain injury specialists, but work with clients who may have sustained a TBI in the context of IPV. Recommendations are provided for TBI risk screening, making appropriate referrals, and providing services in light of a potential TBI.	[Murray, Christine E.] Univ N Carolina, Dept Counseling & Educ Dev, Greensboro, NC 27412 USA; [Lundgren, Kristine] Univ N Carolina, Dept Commun Sci & Disorders, Greensboro, NC 27412 USA; [Olson, Loreen N.] Univ N Carolina, Dept Commun Studies, Greensboro, NC 27412 USA; [Hunnicutt, Gwen] Univ N Carolina, Sociol & Womens & Gender Studies, Greensboro, NC 27412 USA	Murray, CE (corresponding author), Univ N Carolina, 224A Curry Bldg, Greensboro, NC 27412 USA.	cemurray@uncg.edu	Hunnicutt, Gwen/AAS-1272-2020				Almeida RV, 1999, J MARITAL FAM THER, V25, P313, DOI 10.1111/j.1752-0606.1999.tb00250.x; Arosarena OA, 2009, ARCH FACIAL PLAST S, V11, P48, DOI 10.1001/archfacial.2008.507; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brain Injury Association of America, 2014, AB BRAIN INJ; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Centers for Disease Control and Prevention, 2014, INJ PREV CONTR TRAUM; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Crowe A, 2015, PARTN ABUSE, V6, P157, DOI 10.1891/1946-6560.6.2.157; Dams-O'Connor K, 2010, PSYCHIAT CLIN N AM, V33, P893, DOI 10.1016/j.psc.2010.08.002; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Faul M., 2010, EMERGENCY DEP VISITS; Giza CC, 2001, J ATHL TRAINING, V36, P228; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; GRONWALL D, 1975, LANCET, V2, P995; Hoofien D, 2001, BRAIN INJURY, V15, P189; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P434; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mayo Clinic, 2014, DIS COND TRAUM BRAIN; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mechanic MB, 2008, VIOLENCE AGAINST WOM, V14, P1148, DOI 10.1177/1077801208323792; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Murray CE, 2013, RESPONDING TO FAMILY VIOLENCE: A COMPREHENSIVE, RESEARCH-BASED GUIDE FOR THERAPISTS, P1; Murray CE, 2015, J FAM VIOLENCE, V30, P381, DOI 10.1007/s10896-015-9674-1; Novack TA, 2000, BRAIN INJURY, V14, P987; Overstreet NM, 2013, BASIC APPL SOC PSYCH, V35, P109, DOI 10.1080/01973533.2012.746599; Picard M., 1991, HELPS; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Roberts AR, 2005, J SOC SERV RES, V32, P33, DOI 10.1300/J079v32n01_03; Ruff RM, 1999, BRAIN INJURY, V13, P943; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Straus MA, 1996, J FAM ISSUES, V17, P283, DOI 10.1177/019251396017003001; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Tanielian T, 2008, INVISIBLE WOUNDS WAR; TEASDALE G, 1974, LANCET, V2, P81; Tinius TP, 2003, ARCH CLIN NEUROPSYCH, V18, P439, DOI 10.1016/S0887-6177(02)00144-0; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wenner K., 2012, NY TIMES; Wong JYH, 2014, TRAUMA VIOLENCE ABUS, V15, P22, DOI 10.1177/1524838013496333	51	25	25	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1524-8380	1552-8324		TRAUMA VIOLENCE ABUS	Trauma Violence Abus.	JUL	2016	17	3					298	305		10.1177/1524838015584364			8	Criminology & Penology; Family Studies; Social Work	Criminology & Penology; Family Studies; Social Work	DN5HP	WOS:000377097500005	25951838				2021-06-18	
J	Zhou, ZL; Mo, BL; Qiu, SJ; Chao, D; Shi, BC; Shuai, H; Shun, Y; Hui, Z				Zhou Zhilai; Mo Biling; Qiu Sujun; Chao, Dong; Shi Benchao; Shuai, Huang; Shun, Yao; Hui, Zhang			Preconditioning in lowered oxygen enhances the therapeutic potential of human umbilical mesenchymal stem cells in a rat model of spinal cord injury	BRAIN RESEARCH			English	Article						Spinal cord injury; Umbilical cord; Physioxic; Mesenchymal stem cells; Transplantation	TRAUMATIC BRAIN-INJURY; MARROW STROMAL CELLS; FUNCTIONAL RECOVERY; TRANSPLANTATION; HYPOXIA; PROLIFERATION; STROKE; BLOOD; HEMORRHAGE; THERAPIES	Human umbilical cord mesenchymal stem cells (UCMSCs) have recently been shown to hold great therapeutic potential for the treatment of spinal cord injury (SCI). However, the number of engrafted cells has been shown to decrease dramatically post-transplantation. Physioxia is known to enhance the paracrine properties and immune modulation of stem cells, a notion that has been applied in many clinical settings. We therefore hypothesized that preconditioning of UCMSCs in physioxic environment would enhance the regenerative properties of these cells in the treatment of rat SCI. UCMSCs were pretreated with either atmospheric normoxia (21% O-2, N-UCMSC) or physioxia (5% O-2. P-UCMSC). The MSCs were characterized using flow cytometry, immunocytochemistry, and real-time polymerase chain reaction. Furthermore, 10(5) N-UCMSC or P-UCMSC were injected into the injured spinal cord immediately after SCI, and locomotor function as well as cellular, molecular and pathological changes were compared between the groups. We found that N-UCMSC and P-UCMSC displayed similar surface protein expression. P-UCMSC grew faster, while physioxia up-regulated the expression of trophic and growth factors, including hepatocyte growth factor (HGF), brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor(VEGF), in UCMSCs. Compared to N-UCMSC, treatment with P-UCMSC was associated with marked changes in the SCI environment, with a significant increase in axonal preservation and a decrease in the number of caspase-3+ cells and ED-1+ macrophages. These changes were accompanied by improved functional recovery. Thus, the present study indicated that preculturing UCMSCs under 5% lowered oxygen physioxic conditions prior to transplantation improves their therapeutic potential for the treatment of SCI in rats. (C) 2016 Elsevier B.V. All rights reserved.	[Zhou Zhilai; Qiu Sujun; Chao, Dong; Shi Benchao; Shuai, Huang; Shun, Yao; Hui, Zhang] Southern Med Univ, Zhujiang Hosp, Dept Orthoped, 253 Gongye Rd, Guangzhou 510282, Guangdong, Peoples R China; [Mo Biling] Guangzhou Med Univ, Liwan Hosp, Dept Cardiol, Guangzhou, Guangdong, Peoples R China	Hui, Z (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Orthoped, 253 Gongye Rd, Guangzhou 510282, Guangdong, Peoples R China.	13312959@qq.com; zzlspine@foxmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81400996]; Natural Science Foundation of Guangdong Province, ChinaNational Natural Science Foundation of Guangdong Province [2014A030310100]; Science and Technology Plan Projects of Guangdong Province, China [2011B031800282]	This work was supported by the National Natural Science Foundation of China (No. 81400996), the Natural Science Foundation of Guangdong Province, China (No. 2014A030310100) and the Science and Technology Plan Projects of Guangdong Province, China (No. 2011B031800282).	Ahn SY, 2013, STROKE, V44, P497, DOI 10.1161/STROKEAHA.112.679092; Amsalem Y, 2007, CIRCULATION, V116, pI38, DOI 10.1161/CIRCULATIONAHA.106.680231; Barcia RN, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/583984; Bicknese AR, 2002, CELL TRANSPLANT, V11, P261; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; Cheng HB, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0253-7; Drela K, 2014, CYTOTHERAPY, V16, P881, DOI 10.1016/j.jcyt.2014.02.009; Ejtehadifar M, 2015, ADV PHARM BULL, V5, P141, DOI 10.15171/apb.2015.021; Gong W, 2012, CELL TRANSPLANT, V21, P207, DOI 10.3727/096368911X586756; Han K.H., 2015, CELL BIOL INT; Hu SL, 2010, CRIT CARE MED, V38, P2181, DOI 10.1097/CCM.0b013e3181f17c0e; Jeong SR, 2012, EXP NEUROL, V233, P312, DOI 10.1016/j.expneurol.2011.10.021; Lan YW, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0081-6; Lavrentieva A, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-18; Lee HJ, 2015, STEM CELLS, V33, P2182, DOI 10.1002/stem.2020; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; Lindenmair Andrea, 2012, Cells, V1, P1061, DOI 10.3390/cells1041061; Liu JJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126715; Ma T, 2009, BIOTECHNOL PROGR, V25, P32, DOI 10.1002/btpr.128; MILLER WM, 1987, J CELL PHYSIOL, V132, P524, DOI 10.1002/jcp.1041320315; Nakamura Y, 2007, STEM CELLS, V25, P612, DOI 10.1634/stemcells.2006-0168; Nascimento DS, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt394; Parekkadan B, 2010, ANNU REV BIOMED ENG, V12, P87, DOI 10.1146/annurev-bioeng-070909-105309; Rosova I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007-1104; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Sahni V, 2010, NAT REV NEUROL, V6, P363, DOI 10.1038/nrneurol.2010.73; Sasaki M, 2009, J NEUROSCI, V29, P14932, DOI 10.1523/JNEUROSCI.2769-09.2009; Schira J, 2012, BRAIN, V135, P431, DOI 10.1093/brain/awr222; Sun JM, 2015, EXP NEUROL, V272, P78, DOI 10.1016/j.expneurol.2015.03.011; Theus MH, 2008, EXP NEUROL, V210, P656, DOI 10.1016/j.expneurol.2007.12.020; Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9; van der Bogt KEA, 2009, TRANSPLANTATION, V87, P642, DOI 10.1097/TP.0b013e31819609d9; Wang XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118951; Wei L, 2012, NEUROBIOL DIS, V46, P635, DOI 10.1016/j.nbd.2012.03.002; Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336; Yang DM, 2012, BRAIN RES, V1444, P1, DOI 10.1016/j.brainres.2012.01.024; Yu SP, 2013, TRANSL STROKE RES, V4, P76, DOI 10.1007/s12975-012-0251-0; Zacharek A, 2010, STROKE, V41, P524, DOI 10.1161/STROKEAHA.109.568881; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhou ZL, 2012, BRAIN RES, V1481, P79, DOI 10.1016/j.brainres.2012.08.051	41	25	29	0	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 1	2016	1642						426	435		10.1016/j.brainres.2016.04.025			10	Neurosciences	Neurosciences & Neurology	DP7EI	WOS:000378661600048	27085204				2021-06-18	
J	Santoro, A; Raso, GM; Taliani, S; Da Pozzo, E; Simorini, F; Costa, B; Martini, C; Laneri, S; Sacchi, A; Cosimelli, B; Calignano, A; Da Settimo, F; Meli, R				Santoro, Anna; Raso, Giuseppina Mattace; Taliani, Sabrina; Da Pozzo, Eleonora; Simorini, Francesca; Costa, Barbara; Martini, Claudia; Laneri, Sonia; Sacchi, Antonia; Cosimelli, Barbara; Calignano, Antonio; Da Settimo, Federico; Meli, Rosaria			TSPO-ligands prevent oxidative damage and inflammatory response in C6 glioma cells by neurosteroid synthesis	EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						N,N-dialkyl-2-phenylindol-3-ylglyoxylamides; Pregnenolone; Aminoglutethimide; Oxidative stress; Inflammation; C6 glioma cells	PERIPHERAL BENZODIAZEPINE-RECEPTOR; TRANSLOCATOR-PROTEIN TSPO; ACUTE REGULATORY PROTEIN; 18 KDA TSPO; TRAUMATIC BRAIN-INJURY; CHOLESTEROL TRANSPORT; NERVOUS-SYSTEM; GLIAL-CELLS; NEURODEGENERATIVE DISEASES; MICROGLIAL ACTIVATION	Translocator protein 18 kDa (TSPO) is predominantly located in the mitochondrial outer membrane, playing an important role in steroidogenesis, inflammation, cell survival and proliferation. Its expression in central nervous system, mainly in glial cells, has been found to be upregulated in neuropathology, and brain injury. In this study, we investigated the anti-oxidative and anti-inflammatory effects of a group of TSPO ligands from the N, N-dialkyl-2-phenylindol-3-ylglyoxylamide class (PIGAs), highlighting the involvement of neurosteroids in their pharmacological effects. To this aim we used a well-known in vitro model of neurosteroidogenesis: the astrocytic C6 glioma cell line, where TSPO expression and localization, as well as cell response to TSPO ligand treatment, have been established. All PIGAs reduced L-buthionine-(S, R)-sulfoximine (BSO)-driven cell cytotoxicity and lipid peroxidation. Moreover, an anti-inflammatory effect was observed due to the reduction of inducible nitric oxide synthase and cyclooxygenase-2 induction in LPS/IFN gamma challenged cells. Both effects were blunted by aminoglutethimide (AMG), an inhibitor of pregnenolone synthesis, suggesting neurosteroids' involvement in PIGA protective mechanism. Finally, pregnenolone evaluation in PIGA exposed cells revealed an increase in its synthesis, which was prevented by AMG pre-treatment. These findings indicate that these TSPO ligands reduce oxidative stress and pro-inflammatory enzymes in glial cells through the de novo synthesis of neurosteroids, suggesting that these compounds could be potential new therapeutic tools for the treatment of inflammatory-based neuropathologies with beneficial effects possibly comparable to steroids, but potentially avoiding the negative side effects of long-term therapies with steroid hormones. (C) 2016 Elsevier B.V. All rights reserved.	[Santoro, Anna; Raso, Giuseppina Mattace; Laneri, Sonia; Sacchi, Antonia; Cosimelli, Barbara; Calignano, Antonio; Meli, Rosaria] Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, I-80131 Naples, Italy; [Santoro, Anna; Raso, Giuseppina Mattace; Laneri, Sonia; Sacchi, Antonia; Cosimelli, Barbara; Calignano, Antonio; Meli, Rosaria] Univ Pisa, I-56126 Pisa, Italy; [Taliani, Sabrina; Da Pozzo, Eleonora; Simorini, Francesca; Costa, Barbara; Martini, Claudia; Da Settimo, Federico] Univ Pisa, Dept Pharm, I-56126 Pisa, Italy	Meli, R (corresponding author), Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, I-80131 Naples, Italy.	meli@unina.it	Da Pozzo, Eleonora/AAW-8186-2020; Calignano, Antonio/K-2542-2018; TALIANI, SABRINA/AAO-7850-2020; Martini, Claudia/AAC-4089-2019	Da Pozzo, Eleonora/0000-0003-4762-8949; Martini, Claudia/0000-0001-9379-3027; SIMORINI, Francesca/0000-0002-6745-6489; Mattace Raso, Giuseppina/0000-0002-5254-139X; Santoro, Anna/0000-0002-2276-5659; Meli, Rosaria/0000-0002-6246-6813			Agis-Balboa RC, 2006, P NATL ACAD SCI USA, V103, P14602, DOI 10.1073/pnas.0606544103; Akk G, 2007, MOL PHARMACOL, V71, P461, DOI 10.1124/mol.106.029942; Austin CJD, 2013, INT J BIOCHEM CELL B, V45, P1212, DOI 10.1016/j.biocel.2013.03.004; Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Barresi E, 2015, J MED CHEM, V58, P6081, DOI 10.1021/acs.jmedchem.5b00689; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Barron AM, 2013, J NEUROSCI, V33, P8891, DOI 10.1523/JNEUROSCI.1350-13.2013; Batarseh A, 2010, MOL CELL ENDOCRINOL, V327, P1, DOI 10.1016/j.mce.2010.06.013; Beinlich A, 2000, BIOCHEM PHARMACOL, V60, P397, DOI 10.1016/S0006-2952(00)00325-7; Belelli D, 2006, NEUROSCIENCE, V138, P821, DOI 10.1016/j.neuroscience.2005.07.021; BESSLER H, 1992, J NEUROIMMUNOL, V38, P19, DOI 10.1016/0165-5728(92)90086-Z; Biggio G, 2007, PHARMACOL THERAPEUT, V116, P140, DOI 10.1016/j.pharmthera.2007.04.005; Borowicz Kinga K, 2011, Front Endocrinol (Lausanne), V2, P50, DOI 10.3389/fendo.2011.00050; Bose HS, 2002, ENDOCR RES, V28, P295, DOI 10.1081/ERC-120016800; Cagnin A, 2001, BRAIN, V124, P2014, DOI 10.1093/brain/124.10.2014; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Charalampopoulos I, 2008, TRENDS ENDOCRIN MET, V19, P300, DOI 10.1016/j.tem.2008.07.004; Chelli B, 2004, BIOCHEM PHARMACOL, V68, P125, DOI 10.1016/j.bcp.2004.03.008; Chelli B, 2005, CHEMBIOCHEM, V6, P1082, DOI 10.1002/cbic.200400350; Chen C, 2014, ENDOCRINOLOGY, V155, P2976, DOI 10.1210/en.2013-1844; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Choi HB, 2002, J NEUROCHEM, V83, P546, DOI 10.1046/j.1471-4159.2002.01122.x; Costa B, 2011, PSYCHONEUROENDOCRINO, V36, P463, DOI 10.1016/j.psyneuen.2010.07.021; Da Pozzo E, 2015, BIOCHEM SOC T, V43, P559, DOI 10.1042/BST20150028; Da Settimo F, 2008, J MED CHEM, V51, P5798, DOI 10.1021/jm8003224; Ding Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2236; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Esposito E, 2010, N-S ARCH PHARMACOL, V381, P93, DOI 10.1007/s00210-009-0466-0; Gavish M, 1999, PHARMACOL REV, V51, P629; Gazouli M, 2002, J PHARMACOL EXP THER, V303, P627, DOI 10.1124/jpet.102.039388; Girard C, 2008, P NATL ACAD SCI USA, V105, P20505, DOI 10.1073/pnas.0811201106; Goya L, 1996, INT J DEV NEUROSCI, V14, P409, DOI 10.1016/0736-5748(96)00026-3; Guennoun R, 2015, J STEROID BIOCHEM, V146, P48, DOI 10.1016/j.jsbmb.2014.09.001; Hauet T, 2005, MOL ENDOCRINOL, V19, P540, DOI 10.1210/me.2004-0307; Hauet T, 2002, ENDOCR RES, V28, P395, DOI 10.1081/ERC-120016814; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Jung-Testas I, 1998, J STEROID BIOCHEM, V65, P243, DOI 10.1016/S0960-0760(97)00191-X; Kannan S, 2009, J CHILD NEUROL, V24, P1190, DOI 10.1177/0883073809338063; Keller EA, 2004, DEV BRAIN RES, V153, P13, DOI 10.1016/j.devbrainres.2004.07.009; Klegeris A, 2000, BIOCHEM PHARMACOL, V59, P1305, DOI 10.1016/S0006-2952(00)00252-5; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6; Leaver KR, 2012, ACS CHEM NEUROSCI, V3, P114, DOI 10.1021/cn200099e; Li W, 2007, BIOCHEM PHARMACOL, V73, P491, DOI 10.1016/j.bcp.2006.10.025; Liu GJ, 2014, BRAIN PATHOL, V24, P631, DOI 10.1111/bpa.12196; Madrigal Jose L. M., 2006, CNS & Neurological Disorders-Drug Targets, V5, P561; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; MANGOURA D, 1989, NEUROCHEM RES, V14, P941, DOI 10.1007/BF00965927; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Mathieu AP, 2002, J MOL ENDOCRINOL, V29, P327, DOI 10.1677/jme.0.0290327; Meli R, 2001, J NEUROCHEM, V79, P556, DOI 10.1046/j.1471-4159.2001.00617.x; Midzak A, 2015, BIOCHEM SOC T, V43, P572, DOI 10.1042/BST20150061; Nogawa S, 1997, J NEUROSCI, V17, P2746; Papadopoulos V, 2006, NEUROSCIENCE, V138, P749, DOI 10.1016/j.neuroscience.2005.05.063; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Papadopoulos V, 2007, MOL CELL ENDOCRINOL, V265, P59, DOI 10.1016/j.mce.2006.12.004; Papadopoulos V, 2015, MOL CELL ENDOCRINOL, V408, P90, DOI 10.1016/j.mce.2015.03.014; Papadopoulos V, 2012, BEST PRACT RES CL EN, V26, P771, DOI 10.1016/j.beem.2012.05.002; PARKER KK, 1980, SCIENCE, V208, P179, DOI 10.1126/science.6102413; Primofiore G, 2004, J MED CHEM, V47, P1852, DOI 10.1021/jm030973k; Raso GM, 2011, J NEUROENDOCRINOL, V23, P591, DOI 10.1111/j.1365-2826.2011.02152.x; Raso GM, 2006, NEUROSCI LETT, V396, P121, DOI 10.1016/j.neulet.2005.11.022; Repalli Jayanthi, 2014, Curr Aging Sci, V7, P168; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Ryu JK, 2005, NEUROBIOL DIS, V20, P550, DOI 10.1016/j.nbd.2005.04.010; Sasso O, 2010, EUR NEUROPSYCHOPHARM, V20, P195, DOI 10.1016/j.euroneuro.2009.09.003; Selleri S, 2005, BIOORGAN MED CHEM, V13, P4821, DOI 10.1016/j.bmc.2005.05.015; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Taliani S, 2007, J MED CHEM, V50, P404, DOI 10.1021/jm061137o; Taliani S, 2011, CURR TOP MED CHEM, V11, P860, DOI 10.2174/156802611795165142; Thomson M, 2003, BIOESSAYS, V25, P252, DOI 10.1002/bies.10243; Torres SR, 2000, EUR J PHARMACOL, V408, P199, DOI 10.1016/S0014-2999(00)00760-3; Veenman L, 2012, CURR MOL MED, V12, P398; Veenman L, 2008, J BIOENERG BIOMEMBR, V40, P199, DOI 10.1007/s10863-008-9142-1; Veenman L, 2007, CURR PHARM DESIGN, V13, P2385; Veiga S, 2005, J NEUROSCI RES, V80, P129, DOI 10.1002/jnr.20430; Venneti S, 2006, PROG NEUROBIOL, V80, P308, DOI 10.1016/j.pneurobio.2006.10.002; Wilms H, 2003, NEUROBIOL DIS, V14, P417, DOI 10.1016/j.nbd.2003.07.002	82	25	25	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0928-0987	1879-0720		EUR J PHARM SCI	Eur. J. Pharm. Sci.	JUN 10	2016	88						124	131		10.1016/j.ejps.2016.04.006			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DM9AI	WOS:000376655200011	27094781				2021-06-18	
J	Baum, J; Entezami, P; Shah, K; Medhkour, A				Baum, Justin; Entezami, Pouya; Shah, Kavit; Medhkour, Azedine			Predictors of Outcomes in Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Outcomes; Traumatic brain injury	ACUTE LUNG INJURY; MULTIPLE-ORGAN FAILURE; RESPIRATORY-DISTRESS-SYNDROME; GLASGOW COMA SCALE; CONCOMITANT INJURIES; HEAD-INJURY; EXTRACRANIAL INJURIES; MAJOR CAUSE; MORTALITY; IMPACT	INTRODUCTION: The purpose of this study was to retrospectively evaluate patients treated for traumatic brain injuries (TBI) to determine how multiple organ trauma (MOT) and lung injuries sustained at the time of initial injury affect outcome. METHODS: A single institution retrospective review of all patients diagnosed with TBI at a level I trauma center from 2000 to 2014 was conducted. Clinical outcome was based on Glasgow Outcome Scale at hospital discharge. Lung injury was defined as the presence of pulmonary contusions, pneumothorax, hemothorax, rib fractures, or diaphragmatic rupture proven by x-ray or computed tomography scan. MOT was defined as trauma to one body region with an Abbreviated Injury Scale (AIS) score >= 3 plus trauma to 2 additional body regions with AIS scores > 1. Regression analysis was conducted with SPSS 21. RESULTS: There were 409 patients reviewed. The majority of patients were male (73%), average age was 46 years (range, 16-94 years), average Glasgow Coma Scale (GCS) score was 7, and 71% had a severe TBI (GCS <= 8). Thirty percent of patients had poor outcome (Glasgow Outcome Scale = 1-2) Regression analysis indicated age (odds ratio [OR] 1.03, P < 0.001), initial GCS (OR 0.88, P < 0.001), Injury Severity Score (OR 1.03, P = 0.021), and head AIS >= 5 (OR 0.55, P = 0.019) were significant independent predictors of poor outcome. Sex, MOT, lung injury, and lung injury severity were not significant predictors of outcome. CONCLUSIONS: Age, GCS, Injury Severity Score, and critical head injuries (AIS >= 5) were significant tools in predicting outcome in this patient cohort. MOT and traumatic lung injury may cause significant damage to a patient suffering from a severe TBI, but these injuries do not predict mortality in this patient population.	[Baum, Justin; Entezami, Pouya; Shah, Kavit; Medhkour, Azedine] Univ Toledo, Med Ctr, Div Neurosurg, 2801 W Bancroft St, Toledo, OH 43606 USA	Medhkour, A (corresponding author), Univ Toledo, Med Ctr, Div Neurosurg, 2801 W Bancroft St, Toledo, OH 43606 USA.	Azedine.Medhkour@utoledo.edu	Shah, Kavit/ABC-6493-2020	Shah, Kavit/0000-0001-8378-8224			Andruszkow H, 2013, CLIN ORTHOP RELAT R, V471, P2899, DOI 10.1007/s11999-013-3031-6; Arbabi S, 2014, J TRAUMA ACUTE CARE, V76, P927; Asilioglu N, 2011, J PEDIAT-BRAZIL, V87, P325, DOI [10.2223/JPED.2097, 10.1590/S0021-75572011000400009]; Baker CC, 2001, J TRAUMA, V51, P841; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Frohlich M, 2014, J TRAUMA ACUTE CARE, V76, P921, DOI 10.1097/TA.0000000000000199; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Ho KM, 2010, CRIT CARE MED, V38, P1562, DOI 10.1097/CCM.0b013e3181e2ccd8; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775; Kemp CD, 2008, AM SURGEON, V74, P866; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Leitgeb J, 2013, ARCH ORTHOP TRAUM SU, V133, P659, DOI 10.1007/s00402-013-1710-0; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; Leong BK, 2013, DISABIL REHABIL, V35, P1546, DOI 10.3109/09638288.2012.748832; Li N, 2011, NEUROCRIT CARE, V14, P377, DOI 10.1007/s12028-011-9511-1; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Nast-Kolb D, 2001, J TRAUMA, V51, P835, DOI 10.1097/00005373-200111000-00003; Nayak NV, 2013, J TRAUMA ACUTE CARE, V75, P273, DOI 10.1097/TA.0b013e3182905eb4; Oddo M, 2010, NEUROSURGERY, V67, P338, DOI 10.1227/01.NEU.0000371979.48809.D9; Oliveira RARA, 2012, ARQ NEURO-PSIQUIAT, V70, P604, DOI 10.1590/S0004-282X2012000800009; Orliaguet C, 2000, ANN FR ANESTH, V19, P164; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI 10.1586/ERS.10.92; Raj R, 2014, CRIT CARE, V18, DOI 10.1186/cc13814; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; Sharma S, 2013, J TRAUMA ACUTE CARE, V74, P890, DOI 10.1097/TA.0b013e3182827253; Stewart TC, 2013, J TRAUMA ACUTE CARE, V75, P836, DOI 10.1097/TA.0b013e3182a685b0; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; TEASDALE G, 1974, LANCET, V2, P81; Valle EJ, 2014, J TRAUMA ACUTE CARE, V77, P243, DOI 10.1097/TA.0000000000000307; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Ward PA, 1999, ARCH SURG-CHICAGO, V134, P666, DOI 10.1001/archsurg.134.6.666; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2003, J CRIT CARE, V18, P238, DOI 10.1016/j.jcrc.2003.10.007	47	25	25	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2016	90						525	529		10.1016/j.wneu.2015.12.012			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DS1MS	WOS:000380360500066	26721615				2021-06-18	
J	Feng, Y; Cui, Y; Gao, JL; Li, R; Jiang, XH; Tian, YX; Wang, KJ; Li, MH; Zhang, HA; Cui, JZ				Feng, Yan; Cui, Ying; Gao, Jun-Ling; Li, Ran; Jiang, Xiao-Hua; Tian, Yan-Xia; Wang, Kai-Jie; Li, Ming-Hang; Zhang, Hong-Ao; Cui, Jian-Zhong			Neuroprotective effects of resveratrol against traumatic brain injury in rats: Involvement of synaptic proteins and neuronal autophagy	MOLECULAR MEDICINE REPORTS			English	Article						neuroprotective; resveratrol; traumatic brain injury; synaptic proteins; autophagy	CONTROLLED CORTICAL IMPACT; CELL-DEATH; MODEL; MICE; PATHOPHYSIOLOGY; SYNAPTOGENESIS; HEMORRHAGE; EXPRESSION; APOPTOSIS; PROTECTS	Traumatic brain injury (TBI) involves primary and secondary injury cascades that underlie delayed neuronal dysfunction and death, leading to long-term cognitive deficits, and effective therapeutic strategies targeting neuronal death remain elusive. The present study aimed to determine whether the administration of resveratrol (100 mg/kg) was able to significantly enhance functional recovery in a rat model of TBI and whether resveratrol treatment was able to upregulate synaptic protein expression and suppress post-TBI neuronal autophagy. The results demonstrated that daily treatment with resveratrol attenuated TBI-induced brain edema and improved spatial cognitive function and neurological impairment in rats. The expression of synaptic proteins was downregulated following TBI and this phenomenon was partly reversed by treatment with resveratrol. In addition, resveratrol was observed to significantly reduce the levels of the autophagic marker proteins, microtubule-associated protein light chain 3-II and Beclin1, in the hippocampus compared with the TBI group. Therefore, these results suggest that resveratrol may represent a novel therapeutic strategy for TBI, and that this protection may be associated with the upregulation of synaptophysin, postsynaptic density protein 95 and the suppression of neuronal autophagy.	[Feng, Yan] Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China; [Cui, Ying; Wang, Kai-Jie; Cui, Jian-Zhong] Tangshan Workers Hosp, Dept Neurosurg, 27 Wen Hua Rd, Tangshan 063000, Hebei, Peoples R China; [Gao, Jun-Ling; Li, Ran; Jiang, Xiao-Hua; Tian, Yan-Xia; Li, Ming-Hang; Zhang, Hong-Ao] North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Gao, Jun-Ling; Li, Ran; Jiang, Xiao-Hua; Tian, Yan-Xia] North China Univ Sci & Technol, Tangshan Key Lab Preclin & Basic Res Chron Dis, Hebei Key Lab Chron Dis, Tangshan 063000, Hebei, Peoples R China	Cui, JZ (corresponding author), Tangshan Workers Hosp, Dept Neurosurg, 27 Wen Hua Rd, Tangshan 063000, Hebei, Peoples R China.	jzhcuidr2001@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2014105079]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (grant no. H2014105079).	Alayev A, 2014, CELL CYCLE, V13, P371, DOI 10.4161/cc.27355; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bao HJ, 2015, NEUROCHEM RES, V40, P89, DOI 10.1007/s11064-014-1469-x; BROCK TO, 1987, J NEUROSCI, V7, P931; Bursch W, 2000, J CELL SCI, V113, P1189; Chen P, 2007, MOL PHARMACOL, V72, P40, DOI 10.1124/mol.107.034942; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cordaro M, 2015, J NEUROTRAUMA; Cucciolla V, 2007, CELL CYCLE, V6, P2495, DOI 10.4161/cc.6.20.4815; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Delmas D, 2005, MOL NUTR FOOD RES, V49, P377, DOI 10.1002/mnfr.200400098; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; Ehrlich I, 2007, P NATL ACAD SCI USA, V104, P4176, DOI 10.1073/pnas.0609307104; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Jing CH, 2012, NEUROSCIENCE, V213, P144, DOI 10.1016/j.neuroscience.2012.03.055; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Liu CJ, 2011, BRAIN RES, V1374, P100, DOI 10.1016/j.brainres.2010.11.061; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meng HD, 2006, BRAIN RES, V1124, P197, DOI 10.1016/j.brainres.2006.09.086; Pozuelo-Rubio M, 2011, AUTOPHAGY, V7, P240, DOI 10.4161/auto.7.2.14286; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004; Sakata Y, 2010, EXP NEUROL, V224, P325, DOI 10.1016/j.expneurol.2010.03.032; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Semchenko V V, 2006, Neurosci Behav Physiol, V36, P613, DOI 10.1007/s11055-006-0065-1; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6	37	25	27	0	10	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	JUN	2016	13	6					5248	5254		10.3892/mmr.2016.5201			7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	DO7UR	WOS:000377989000096	27122047	Bronze			2021-06-18	
J	Papadimitriou, KI; Wang, C; Rogers, ML; Gowers, SAN; Leong, CL; Boutelle, MG; Drakakis, EM				Papadimitriou, Konstantinos I.; Wang, Chu; Rogers, Michelle L.; Gowers, Sally A. N.; Leong, Chi L.; Boutelle, Martyn G.; Drakakis, Emmanuel M.			High-Performance Bioinstrumentation for Real-Time Neuroelectrochemical Traumatic Brain Injury Monitoring	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						analog-to-digital conversion; bioinstrumentation; biosensors; microdialysis; microfluidics; traumatic brain injury	SPREADING DEPOLARIZATIONS; ONLINE MICRODIALYSIS; ISCHEMIA; DEPRESSION; STROKE	Traumatic brain injury (TBI) has been identified as an important cause of death and severe disability in all age groups and particularly in children and young adults. Central to TBIs devastation is a delayed secondary injury that occurs in 30-40% of TBI patients each year, while they are in the hospital Intensive Care Unit (ICU). Secondary injuries reduce survival rate after TBI and usually occur within 7 days post-injury. State-of-art monitoring of secondary brain injuries benefits from the acquisition of high-quality and time-aligned electrical data i.e., ElectroCorticoGraphy (ECoG) recorded by means of strip electrodes placed on the brains surface, and neurochemical data obtained via rapid sampling microdialysis and microfluidics-based biosensors measuring brain tissue levels of glucose, lactate and potassium. This article progresses the field of multi-modal monitoring of the injured human brain by presenting the design and realization of a new, compact, medical-grade amperometry, potentiometry and ECoG recording bioinstrumentation. Our combined TBI instrument enables the high-precision, real-time neuroelectrochemical monitoring of TBI patients, who have undergone craniotomy neurosurgery and are treated sedated in the ICU. Electrical and neurochemical test measurements are presented, confirming the high-performance of the reported TBI bioinstrumentation.	[Papadimitriou, Konstantinos I.; Wang, Chu; Rogers, Michelle L.; Gowers, Sally A. N.; Leong, Chi L.; Boutelle, Martyn G.; Drakakis, Emmanuel M.] Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England; [Papadimitriou, Konstantinos I.; Drakakis, Emmanuel M.] Bioinspired VLSI Circuits & Syst Grp, London, England; [Wang, Chu; Rogers, Michelle L.; Gowers, Sally A. N.; Leong, Chi L.; Boutelle, Martyn G.] Biomed Sensors Grp, London, England	Boutelle, MG; Drakakis, EM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England.; Drakakis, EM (corresponding author), Bioinspired VLSI Circuits & Syst Grp, London, England.; Boutelle, MG (corresponding author), Biomed Sensors Grp, London, England.	m.boutelle@imperial.ac.uk; e.drakakis@imperial.ac.uk		Leong, Chi Leng/0000-0002-2654-1345; Papadimitriou, Konstantinos I./0000-0002-0995-4834; Rogers, Michelle/0000-0002-1434-2322; Gowers, Sally/0000-0002-2407-2266	Wellcome Trust / UK Department of Health Healthcare Innovation Challenge Fund [HICF-0510-080]	We thank the Wellcome Trust / UK Department of Health Healthcare Innovation Challenge Fund (HICF-0510-080) for finding. The authors would also like to thank Dr. Toby Jeffcote for sharing his expertise on ECoG measurements in TBI and Professor Antony Strong for kindly providing us with the artificial ECoG/SD signal.	[Anonymous], 2010, LANCET NEUROL, V9, P331, DOI 10.1016/S1474-4422(10)70069-7; Asano E, 2005, EPILEPSIA, V46, P1086, DOI 10.1111/j.1528-1167.2005.05205.x; Bhatia R, 2006, NEUROSURGERY, V58, P313, DOI 10.1227/01.NEU.0000208963.42378.83; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; Glaros KN, 2013, IEEE T BIOMED CIRC S, V7, P363, DOI 10.1109/TBCAS.2012.2200677; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2009, J NEUROPHYSIOL, V102, P2563, DOI 10.1152/jn.00345.2009; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Jeffcote T, 2014, NEUROCRIT CARE, V20, P21, DOI 10.1007/s12028-013-9938-7; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P391, DOI 10.1152/jn.1944.7.6.391; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Liu M. M, 2006, DEMYSTIFYING SWITCHE, V1; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Oliveira-Ferreira AI, 2010, J CEREBR BLOOD F MET, V30, P1504, DOI 10.1038/jcbfm.2010.40; Park J., 2003, PRACTICAL DATA ACQUI; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Rogers ML, 2013, ANAL BIOANAL CHEM, V405, P3881, DOI 10.1007/s00216-013-6770-z; Rogers M, 2011, PHYS CHEM CHEM PHYS, V13, P5298, DOI 10.1039/c0cp02810j; Rogers ML, 2013, ACS CHEM NEUROSCI, V4, P799, DOI 10.1021/cn400047x; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2005, CRIT CARE MED, V33, P2147, DOI 10.1097/01.CCM.0000179029.95415.51; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Whitfield PC, 2009, HEAD INJURY: A MULTIDISCIPLINARY APPROACH, P1, DOI 10.1017/CBO9780511576515; Woitzik J, 2012, J CEREBR BLOOD F MET, V32, P203, DOI 10.1038/jcbfm.2011.169; Yue XC, 2008, IEEE T BIOMED CIRC S, V2, P66, DOI 10.1109/TBCAS.2008.925639	35	25	25	0	20	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAY 19	2016	10								212	10.3389/fnhum.2016.00212			15	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	DM0TV	WOS:000376059600001	27242477	DOAJ Gold, Green Published			2021-06-18	
J	Nezhadi, A; Sheibani, V; Esmaeilpour, K; Shabani, M; Esmaeili-Mahani, S				Nezhadi, Akram; Sheibani, Vahid; Esmaeilpour, Khadijeh; Shabani, Mohammad; Esmaeili-Mahani, Saeed			Neurosteroid allopregnanolone attenuates cognitive dysfunctions in 6-OHDA-induced rat model of Parkinson's disease	BEHAVIOURAL BRAIN RESEARCH			English	Article						Parkinson's disease; Allopregnanolone; 6-OHDA; Cognitive behaviors; Learning and memory	TRAUMATIC BRAIN-INJURY; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; FUNCTIONAL DEFICITS; GENE-EXPRESSION; DORSAL STRIATUM; MESSENGER-RNA; WATER MAZE; PROGESTERONE; BDNF	Cognitive deficits have an extensive influence on the quality of life of the Parkinson's disease (PD) patients. Previous studies have shown that lack of steroid hormones have an important role in the development of PD. Therefore, in this study the effects of neurosteroid allopregnanolone (Allo) on the PD-induced cognitive disorders were assessed. To simulate PD, 6-hydroxydopamine (6-OHDA) was injected into the rat's substantia nigra. Alio (5 and 20 mg/kg, orally) were administered on the day after the 6-OHDA injection and continued during the entire treatment period (two months). Cognitive behaviors were assessed by Moris water maze (MWM), novel object recognition (NOR) and object location tasks. The data indicated that Allo significantly improved the 6-OHDA-induced cognitive impairment which revealed by the reduction of time spent to find out platform (escape latency) and the increase of retention time in MWM test and also with increase in the exploration index in NOR and object location tasks. Present study strongly supports the pro-cognitive property of allopregnanolone in PD. (c) 2016 Elsevier B.V. All rights reserved.	[Nezhadi, Akram; Sheibani, Vahid; Esmaeilpour, Khadijeh; Shabani, Mohammad; Esmaeili-Mahani, Saeed] Kerman Univ Med Sci, Inst Neuropharmacol, Kerman Neurosci Res Ctr, Lab Mol Neurosci, Kerman, Iran; [Esmaeili-Mahani, Saeed] Shahid Bahonar Univ Kerman, Fac Sci, Dept Biol, POB 76135-133, Kerman, Iran	Esmaeili-Mahani, S (corresponding author), Shahid Bahonar Univ Kerman, Fac Sci, Dept Biol, POB 76135-133, Kerman, Iran.	semahani@yahoo.com	sheibani, vahid/ABB-5259-2020	sheibani, vahid/0000-0003-4321-6103; Esmaeili Mahani, Saeed/0000-0001-5550-9806; Nezhadi, Akram/0000-0002-3821-9441; Esmaeilpour, Khadije/0000-0002-5349-9285; Shabani, Mohammad/0000-0002-2082-5849	Kerman Neuroscience Research Center, Kerman University of Medical Sciences [93/37]	This work was supported by funds from Kerman Neuroscience Research Center (#93/37), Kerman University of Medical Sciences. The authors would like to thank the editor and two anonymous reviewers for their critical comments on an earlier version of this manuscript.	Adeosun SO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050040; Allen SJ, 2013, PHARMACOL THERAPEUT, V138, P155, DOI 10.1016/j.pharmthera.2013.01.004; Arancibia S, 2008, NEUROBIOL DIS, V31, P316, DOI 10.1016/j.nbd.2008.05.012; Baulieu E., 2001, NEUROSTEROIDS BRAIN; Calabresi P, 2000, TRENDS NEUROSCI, V23, pS57, DOI 10.1016/S1471-1931(00)00017-3; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; Carlini V.P., 2011, OBJECT RECOGNITION, DOI [10.5772/613, DOI 10.5772/613]; Chao OY, 2011, NEUROSCIENCE, V196, P228, DOI 10.1016/j.neuroscience.2011.08.043; Chao Y.-H., 2013, INVESTIGATION ALTERN; Charalampopoulos I, 2008, TRENDS ENDOCRIN MET, V19, P300, DOI 10.1016/j.tem.2008.07.004; Cools R, 2002, BRAIN, V125, P584, DOI 10.1093/brain/awf052; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Da Cunha C, 2002, CELL MOL NEUROBIOL, V22, P227, DOI 10.1023/A:1020736131907; Dagher A, 2001, BRAIN, V124, P1020, DOI 10.1093/brain/124.5.1020; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Duvoisin R.C., 2016, ADV NEUROL, V60, P306; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Findley L, 2003, MOVEMENT DISORD, V18, P1139, DOI 10.1002/mds.10507; Franklin TB, 2006, PSYCHONEUROENDOCRINO, V31, P38, DOI 10.1016/j.psyneuen.2005.05.008; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; Frye CA, 2010, PHYSIOL BEHAV, V99, P218, DOI 10.1016/j.physbeh.2009.09.006; Fukui K., 2006, ANN NY ACAD SCI, V959, P275; Gibbs RB, 1999, BRAIN RES, V844, P20, DOI 10.1016/S0006-8993(99)01880-6; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Grobin AC, 2006, NEUROSCIENCE, V138, P809, DOI 10.1016/j.neuroscience.2005.12.026; Haik KL, 2008, EXP CLIN PSYCHOPHARM, V16, P178, DOI 10.1037/1064-1297.16.2.178; Hajali V, 2015, NEUROBIOL LEARN MEM, V123, P140, DOI 10.1016/j.nlm.2015.05.008; HANSEN S, 1991, PHARMACOL BIOCHEM BE, V39, P71, DOI 10.1016/0091-3057(91)90399-M; Hritcu L, 2014, PROG NEURO-PSYCHOPH, V51, P126, DOI 10.1016/j.pnpbp.2014.01.016; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Janvin CC, 2007, COGNITIVE IMPAIRMENT; Klein RL, 1999, BRAIN RES, V847, P314, DOI 10.1016/S0006-8993(99)02116-2; LENNARD SN, 1995, MOL REPROD DEV, V42, P131, DOI 10.1002/mrd.1080420202; LENNARD SN, 1995, J REPROD FERTIL, V103, P169, DOI 10.1530/jrf.0.1030169; Lindenbach D, 2015, NEUROSCIENCE, V310, P12, DOI 10.1016/j.neuroscience.2015.09.018; Luchetti S, 2010, BRAIN PATHOL, V20, P945, DOI 10.1111/j.1750-3639.2010.00396.x; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Menza M, 2009, MOVEMENT DISORD, V24, P1325, DOI 10.1002/mds.22586; Nezhadi Akram, 2011, Pathophysiology, V18, P317, DOI 10.1016/j.pathophys.2011.05.004; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Ryan L, 2010, HIPPOCAMPUS, V20, P11, DOI 10.1002/hipo.20607; RYBICKI BA, 1993, MOVEMENT DISORD, V8, P87, DOI 10.1002/mds.870080116; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SHULTS CW, 1995, NEUROREPORT, V6, P1109, DOI 10.1097/00001756-199505300-00009; Singh C, 2012, NEUROBIOL AGING, V33, P1493, DOI 10.1016/j.neurobiolaging.2011.06.008; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Sriraksa N, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/823206; Sun CY, 2012, CURR ALZHEIMER RES, V9, P473, DOI 10.2174/156720512800492567; SWANSON LW, 1982, BRAIN RES BULL, V9, P321, DOI 10.1016/0361-9230(82)90145-9; TANDBERG E, 1995, MOVEMENT DISORD, V10, P541, DOI 10.1002/mds.870100503; van den Pol AN, 2004, NAT NEUROSCI, V7, P7, DOI 10.1038/nn0104-7; Wang JM, 2008, BRAIN RES REV, V57, P398, DOI 10.1016/j.brainresrev.2007.08.010; Weintraub D, 2004, J AM GERIATR SOC, V52, P784, DOI 10.1111/j.1532-5415.2004.52219.x; Wooten GF, 2004, J NEUROL NEUROSUR PS, V75, P637, DOI 10.1136/jnnp.2003.020982; 1988, BRAIN RES, V31, P47	59	25	25	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAY 15	2016	305						258	264		10.1016/j.bbr.2016.03.019			7	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	DK0OZ	WOS:000374613400032	26970579				2021-06-18	
J	Hilz, MJ; Liu, M; Koehn, J; Wang, RH; Ammon, F; Flanagan, SR; Hosl, KM				Hilz, Max J.; Liu, Mao; Koehn, Julia; Wang, Ruihao; Ammon, Fabian; Flanagan, Steven R.; Hoesl, Katharina M.			Valsalva maneuver unveils central baroreflex dysfunction with altered blood pressure control in persons with a history of mild traumatic brain injury	BMC NEUROLOGY			English	Article						Mild traumatic brain injury; Central autonomic network; Valsalva maneuver; Blood pressure overshoot; Sympathetic dysregulation; Baroreflex dysfunction	HEART-RATE-VARIABILITY; REGRESSIVE SPECTRAL-ANALYSIS; BARORECEPTOR SENSITIVITY; AUTONOMIC DYSFUNCTION; HYPERTENSIVE PATIENTS; FREQUENCY-DOMAIN; PROGNOSTIC VALUE; MORTALITY; DEATH; ADULTS	Background: Patients with a history of mild TBI (post-mTBI-patients) have an unexplained increase in long-term mortality which might be related to central autonomic dysregulation (CAD). We investigated whether standardized baroreflex-loading, induced by a Valsalva maneuver (VM), unveils CAD in otherwise healthy post-mTBI-patients. Methods: In 29 healthy persons (31.3 +/- 12.2 years; 9 women) and 25 post-mTBI-patients (35.0 +/- 13.2 years, 7 women, 4-98 months post-injury), we monitored respiration (RESP), RR-intervals (RRI) and systolic blood pressure (BP) at rest and during three VMs. At rest, we calculated parameters of total autonomic modulation [RRI-coefficient-of-variation (CV), RRI-standard-deviation (RRI-SD), RRI-total-powers], of sympathetic [RRI-low-frequency-powers (LF), BP-LF-powers] and parasympathetic modulation [square-root-of-mean-squared-differences-of-successive-RRIs (RMSSD), RRI-high-frequency-powers (HF)], the index of sympatho-vagal balance (RRI LF/HF-ratios), and baroreflex sensitivity (BRS). We calculated Valsalva-ratios (VR) and times from lowest to highest RRIs after strain (VR-time) as indices of parasympathetic activation, intervals from highest systolic BP-values after strain-release to the time when systolic BP had fallen by 90 % of the differences between peak-phase-IV-BP and baseline-BP (90 %-BP-normalization-times), and velocities of BP-normalization (90 %-BP-normalization-velocities) as indices of sympathetic withdrawal. We compared patient-and control-parameters before and during VM (Mann-Whitney-U-tests or t-tests; significance: P < 0.05). Results: At rest, RRI-CVs, RRI-SDs, RRI-total-powers, RRI-LF-powers, BP-LF-powers, RRI-RMSSDs, RRI-HF-powers, and BRS were lower in patients than controls. During VMs, 90 %-BP-normalization-times were longer, and 90 %-BP-normalization-velocities were lower in patients than controls (P < 0.05). Conclusions: Reduced autonomic modulation at rest and delayed BP-decrease after VM-induced baroreflex-loading indicate subtle CAD with altered baroreflex adjustment to challenge. More severe autonomic challenge might trigger more prominent cardiovascular dysregulation and thus contribute to increased mortality risk in post-mTBI-patients.	[Hilz, Max J.; Liu, Mao; Koehn, Julia; Wang, Ruihao; Ammon, Fabian] Univ Erlangen Nurnberg, Dept Neurol, Schwabachanlage 6, D-91054 Erlangen, Germany; [Flanagan, Steven R.] NYU, Dept Rehabil Med, Sch Med, 240 East 38th St, New York, NY 10016 USA; [Hoesl, Katharina M.] Paracelsus Med Univ Nuremberg, Dept Psychiat & Psychotherapy, Prof Ernst Nathan Str 1, D-90419 Nurnberg, Germany	Hilz, MJ (corresponding author), Univ Erlangen Nurnberg, Dept Neurol, Schwabachanlage 6, D-91054 Erlangen, Germany.	max.hilz@uk-erlangen.de	Liu, Mao/AAI-1391-2019	Liu, Mao/0000-0002-1948-0337; Wang, Ruihao/0000-0003-4792-5572; Flanagan, Steven/0000-0001-9005-5897	International Brain Research Foundation, IBRF, Flanders, NJ, USA	The study was partially funded by the International Brain Research Foundation, IBRF, Flanders, NJ, USA.	Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; BENARROCH EE, 1993, CLIN AUTONOMIC DISOR, P209; BENARROCH EE, 1997, CENTRAL AUTONOMIC NE; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Black M, 2002, J CLIN PATHOL, V55, P44, DOI 10.1136/jcp.55.1.44; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Buccelletti F, 2009, EUR REV MED PHARMACO, V13, P299; Camm AJ, 1996, EUR HEART J, V17, P354; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Cencetti S, 1999, HEART, V82, P365, DOI 10.1136/hrt.82.3.365; Cerutti S, 2001, AUTON NEUROSCI-BASIC, V90, P3, DOI 10.1016/S1566-0702(01)00261-2; Chida K, 1994, Funct Neurol, V9, P65; Christou DD, 2003, HYPERTENSION, V41, P1219, DOI 10.1161/01.HYP.0000072011.17095.AE; Colivicchi F, 2005, STROKE, V36, P1710, DOI 10.1161/01.STR.0000173400.19346.bd; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dauphinot V, 2013, INT J CARDIOL, V168, P4010, DOI 10.1016/j.ijcard.2013.06.080; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Drawz PE, 2013, AM J NEPHROL, V38, P517, DOI 10.1159/000357200; Eckberg DL, 1992, HUMAN BAROREFLEXES H; EWING DJ, 1980, Q J MED, V49, P95; Ewing DJ, 1993, CLIN AUTONOMIC DISOR, P297; Ewing DJ, 1992, AUTONOMIC FAILURE, P312; Ferrettia G, 2009, J HYPERTENS, V27, P551, DOI 10.1097/HJH.0b013e328322ca2f; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Fernandez-Ortega JF, 2012, J NEUROTRAUM, V29, P1364, DOI 10.1089/neu.2011.2033; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gulli G, 2005, CLIN AUTON RES, V15, P207, DOI 10.1007/s10286-005-0273-8; Hallman DM, 2015, INT J ENV RES PUB HE, V12, P14811, DOI 10.3390/ijerph121114811; Hassett LM, 2008, COCHRANE DB SYST REV, V2; Hilz MJ, 2008, STROKE, V39, P2421, DOI 10.1161/STROKEAHA.108.518613; Hilz MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132139; Hilz MJ, 2014, AUTON NEUROSCI-BASIC, V183, P83, DOI 10.1016/j.autneu.2014.02.004; Hilz MJ, 2011, J HYPERTENS, V29, P2387, DOI 10.1097/HJH.0b013e32834c31db; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Hilz MJ, 2010, J HYPERTENS, V28, P1438, DOI 10.1097/HJH.0b013e328336a077; Hilz MJ, 2011, STROKE, V42, P1528, DOI 10.1161/STROKEAHA.110.607721; Hilz MJ, 2001, ANN NEUROL, V49, P575, DOI 10.1002/ana.1006; Hilz MJ, 2002, NEUROMUSCULAR FUNCTI, P1899; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huikuri HV, 1996, CIRCULATION, V94, P122, DOI 10.1161/01.CIR.94.2.122; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Johansson M, 2007, J HYPERTENS, V25, P163, DOI 10.1097/01.hjh.0000254377.18983.eb; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Katarzynska-Szymanska A, 2013, BRIT J CLIN PHARMACO, V75, P1516, DOI 10.1111/bcp.12027; Kiviniemi AM, 2014, AM J CARDIOL, V114, P571, DOI 10.1016/j.amjcard.2014.05.032; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Krause M, 2009, PEDIATR DIABETES, V10, P255, DOI 10.1111/j.1399-5448.2008.00447.x; La Rovere MT, 1998, LANCET, V351, P478; Lanfranchi PA, 2002, AM J PHYSIOL-REG I, V283, pR815, DOI 10.1152/ajpregu.00051.2002; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Low P.A., 1997, CLIN AUTONOMIC DISOR; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Malliani A., 2005, EUR J INTERN MED, V16, P12, DOI [10.1016/j.ejim.2004.06.016, DOI 10.1016/J.EJIM.2004.06.016]; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; McMillan TM, 2014, J NEUROL NEUROSUR PS, V85, P1214, DOI 10.1136/jnnp-2013-307279; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mirizzi G, 2013, INT J CARDIOL, V169, pE9, DOI 10.1016/j.ijcard.2013.08.120; Montano N, 2009, NEUROSCI BIOBEHAV R, V33, P71, DOI 10.1016/j.neubiorev.2008.07.006; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; OPPENHEIMER SM, 1991, BRAIN RES, V550, P115, DOI 10.1016/0006-8993(91)90412-O; Ormezzano O, 2008, J HYPERTENS, V26, P1373, DOI 10.1097/HJH.0b013e3283015e5a; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; Palma JA, 2014, NEUROLOGY, V83, P261, DOI 10.1212/WNL.0000000000000605; Parati G, 2001, ANN NY ACAD SCI, V940, P469; Ponikowski P, 1997, AM J CARDIOL, V79, P1645, DOI 10.1016/S0002-9149(97)00215-4; Reimann M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012187; Robinson TG, 2003, STROKE, V34, P705, DOI 10.1161/01.STR.0000058493.94875.9F; Rosengard-Barlund M, 2009, DIABETOLOGIA, V52, P1164, DOI 10.1007/s00125-009-1340-9; Rudiger H, 1999, COMPUT METH PROG BIO, V58, P1; Rudiger H, 2001, AUTON NEUROSCI-BASIC, V93, P71, DOI 10.1016/S1566-0702(01)00326-5; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sapoznikov D, 2011, MED BIOL ENG COMPUT, V49, P1045, DOI 10.1007/s11517-011-0806-3; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Soares-Miranda L, 2014, CIRCULATION, V129, P2100, DOI 10.1161/CIRCULATIONAHA.113.005361; Spallone V, 2011, DIABETES-METAB RES, V27, P639, DOI 10.1002/dmrr.1239; Sung CW, 2016, PSYCHOPHYSIOLOGY, V53, P455, DOI 10.1111/psyp.12575; Sung CW, 2016, CLIN NEUROPHYSIOL, V127, P1629, DOI 10.1016/j.clinph.2015.08.006; Sykora M, 2008, CRIT CARE MED, V36, P3074, DOI 10.1097/CCM.0b013e31818b306d; Sykora M, 2012, STROKE, V43, P714, DOI 10.1161/STROKEAHA.111.632778; Sykora M, 2009, STROKE, V40, pE678, DOI 10.1161/STROKEAHA.109.565838; Sykora M, 2009, STROKE, V40, P737, DOI 10.1161/STROKEAHA.108.519967; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; Tang SC, 2015, J NEUROL NEUROSUR PS, V86, P95, DOI 10.1136/jnnp-2014-308389; Toschi-Dias E, 2013, AM J PHYSIOL-HEART C, V304, pH1038, DOI 10.1152/ajpheart.00848.2012; Vinik AI, 2003, DIABETES CARE, V26, P1553, DOI 10.2337/diacare.26.5.1553; Vogel ER, 2005, NEUROLOGY, V65, P1533, DOI 10.1212/01.wnl.0000184504.13173.ef; Voss A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118308; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yperzeele L, 2015, INT J STROKE, V10, P796, DOI 10.1111/ijs.12573; Ziemssen T, 2013, J NEURAL TRANSM, V120, pS27, DOI 10.1007/s00702-013-1054-5	99	25	26	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	MAY 4	2016	16								61	10.1186/s12883-016-0584-5			12	Clinical Neurology	Neurosciences & Neurology	DL6RX	WOS:000375767500004	27146718	DOAJ Gold, Green Published			2021-06-18	
J	Hart, T; Fann, JR; Chervoneva, I; Juengst, SB; Rosenthal, JA; Krellman, JW; Dreer, LE; Kroenke, K				Hart, Tessa; Fann, Jesse R.; Chervoneva, Inna; Juengst, Shannon B.; Rosenthal, Joseph A.; Krellman, Jason W.; Dreer, Laura E.; Kroenke, Kurt			Prevalence, Risk Factors, and Correlates of Anxiety at 1 Year After Moderate to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Anxiety; Brain injuries; Quality of Life; Rehabilitation	BEHAVIORAL ACTIVATION; PSYCHIATRIC-DISORDERS; PRIMARY-CARE; PARTICIPATION ASSESSMENT; MODEL SYSTEMS; DEPRESSION; OUTCOMES; REHABILITATION; SATISFACTION; HEALTH	Objective: To determine at 1 year after moderate to severe traumatic brain injury the (1) rate of clinically significant anxiety; (2) rates of specific symptoms of anxiety; (3) risk factors for anxiety; and (4) associations of anxiety with other 1-year outcomes, including participation and quality of life. Design: Prospective longitudinal observational study. Setting: Inpatient rehabilitation centers, with data capture at injury and 1-year follow-up. Participants: Persons with moderate to severe traumatic brain injury who were enrolled in the Traumatic Brain Injury Model Systems database (N = 1838). Interventions: Not applicable. Main Outcome Measures: The 7-item Generalized Anxiety Disorder Scale, Patient Health Questionnaire (9-item screen for depression), PIM, Participation Assessment with Recombined Tools-Objective, and Satisfaction with Life Scale. Results: Clinically significant anxiety was reported by 21% of the participants. Of these, >80% reported interference with daily activities, with the most common symptoms being excessive worry and irritability. A common pattern was comorbid anxiety and depression, with smaller proportions reporting either disorder alone. Anxiety had large effect sizes with respect to life satisfaction and cognitive disability and medium to small effect sizes relative to societal participation and self-care. Middle age, black race, lower socioeconomic status, preinjury mental health treatment, and at least 1 traumatic brain injury prior to the index injury were all risk factors for later anxiety. Conclusions: Anxiety should be screened, fully evaluated, and treated after moderate to severe traumatic brain injury. Worry and irritability might be treated with pharmacologic agents or relatively simple behavioral interventions, which should be further researched in this population. (C) 2016 by the American Congress of Rehabilitation Medicine	[Hart, Tessa] Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA; [Fann, Jesse R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Chervoneva, Inna] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pharmacol & Expt Therapeut, Div Biostat, Philadelphia, PA 19107 USA; [Juengst, Shannon B.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Rosenthal, Joseph A.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Krellman, Jason W.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA; [Kroenke, Kurt] Vet Adm Hlth Serv, Res & Dev Ctr Hlth Informat & Commun, Indianapolis, IN USA; [Kroenke, Kurt] Indiana Univ, Dept Med, Indianapolis, IN USA; [Kroenke, Kurt] Regenstrief Inst Inc, Indianapolis, IN USA	Hart, T (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu	Juengst, Shannon B/AAC-5891-2019	Juengst, Shannon/0000-0003-4709-545X; Kroenke, Kurt/0000-0002-0114-4669	National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [90DP0037, 90DP0040, 90DP0038, 90DP0041]	Supported by the National Institute on Disability, Independent Living, and Rehabilitation Research (grant nos. 90DP0037, 90DP0040, 90DP0038, and 90DP0041).	Baird BM, 2010, SOC INDIC RES, V99, P183, DOI 10.1007/s11205-010-9584-9; Bell KR, 2015, CONTEMP CLIN TRIALS, V40, P54, DOI 10.1016/j.cct.2014.11.001; Beninato M, 2006, ARCH PHYS MED REHAB, V87, P32, DOI 10.1016/j.apmr.2005.08.130; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Demakis GJ, 2010, APPL NEUROPSYCHOL, V17, P183, DOI 10.1080/09084282.2010.499752; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dimidjian S, 2011, ANNU REV CLIN PSYCHO, V7, P1, DOI 10.1146/annurev-clinpsy-032210-104535; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Gignac MAM, 2013, SOC SCI MED, V81, P87, DOI 10.1016/j.socscimed.2012.12.013; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2014, J CLIN EXP NEUROPSYC, V36, P1, DOI 10.1080/13803395.2013.863832; Gros DF, 2012, BEHAV MODIF, V36, P580, DOI 10.1177/0145445512448097; Hammond FM, 2014, J HEAD TRAUMA REHAB, V29, P391, DOI 10.1097/01.HTR.0000438116.56228.de; Hart T, 2007, J HEAD TRAUMA REHAB, V22, P122, DOI 10.1097/01.HTR.0000265100.37059.44; Hart T, 2015, CONTEMP CLIN TRIALS, V40, P180, DOI 10.1016/j.cct.2014.12.005; Hart T, 2014, J NEUROTRAUM, V31, P610, DOI 10.1089/neu.2013.3041; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Jakupcak M, 2010, J TRAUMA STRESS, V23, P491, DOI 10.1002/jts.20543; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004; Kroenke K, 2012, J PRIM HEALTH CARE, V4, P4, DOI 10.1071/HC12004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lowe B, 2008, GEN HOSP PSYCHIAT, V30, P191, DOI 10.1016/j.genhosppsych.2008.01.001; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Mallya S, 2015, J NEUROTRAUM, V32, P411, DOI 10.1089/neu.2014.3504; Perrin PB, 2014, ARCH PHYS MED REHAB, V95, P2288, DOI 10.1016/j.apmr.2014.07.409; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Rosengren L, 2015, ACTA NEUROL SCAND, V132, P164, DOI 10.1111/ane.12380; Rubin D.B., 1997, MULTIPLE IMPUTATION; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Strine TW, 2008, PSYCHIAT SERV, V59, P1383, DOI 10.1176/appi.ps.59.12.1383; United States Department of Health and Human Services, 1998, NAT HOUS SURV DRUG A; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	51	25	25	1	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2016	97	5					701	707		10.1016/j.apmr.2015.08.436			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DL4UM	WOS:000375633300006	26707456				2021-06-18	
J	Orr, CA; Albaugh, MD; Watts, R; Garavan, H; Andrews, T; Nickerson, JP; Gonyea, J; Hipko, S; Zweber, C; Logan, K; Hudziak, JJ				Orr, Catherine A.; Albaugh, Matthew D.; Watts, Richard; Garavan, Hugh; Andrews, Trevor; Nickerson, Joshua P.; Gonyea, Jay; Hipko, Scott; Zweber, Cole; Logan, Katherine; Hudziak, James J.			Neuroimaging Biomarkers of a History of Concussion Observed in Asymptomatic Young Athletes	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; head trauma; MRI; neuroplasticity	TRAUMATIC BRAIN-INJURY; WHITE-MATTER INTEGRITY; INDEPENDENT COMPONENT ANALYSIS; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; DIFFUSION KURTOSIS; DEFAULT NETWORK; SPORT; ENCEPHALOPATHY; CONNECTIVITY	Participation in contact sports places athletes at elevated risk for repeated head injuries and is associated with negative mental health outcomes later in life. The current study identified changes observable on neuroimaging that persisted beyond the apparent resolution of acute symptoms of concussion. Sixteen young adult ice hockey players with a remote history of concussion but no subjective complaints were compared against 13 of their teammates with no history of concussion. Participants completed a detailed phenotypic assessment and a neuroimaging battery including diffusion kurtosis imaging and resting-state functional magnetic resonance imaging. Athletes with a history of concussion performed no differently from those without on phenotypic assessment, but showed significantly elevated fractional anisotropy (FA) in the left genu and anterior corona radiata relative to those without. Post hoc analyses revealed that elevated FA was associated with increased microstructural complexity perpendicular to the primary axon (radial kurtosis). Athletes with concussion history also showed significant differences in the organization of the default mode network (DMN) characterized by stronger temporal coherence in posterior DMN, decreased temporal coherence in anterior DMN, and increased functional connectivity outside the DMN. In the absence of deficits on detailed phenotypic assessment, athletes with a history of concussion displayed changes to the microstructural architecture of the cerebral white matter and to the functional connectivity of the brain at rest. Some of these changes are consistent with those previously associated with persisting deficits and complaints, but we also report novel, complementary changes that possibly represent compensatory mechanisms.	[Orr, Catherine A.; Albaugh, Matthew D.; Zweber, Cole; Logan, Katherine; Hudziak, James J.] Univ Vermont, Vermont Ctr Children Youth & Families, Burlington, VT USA; [Watts, Richard; Andrews, Trevor; Nickerson, Joshua P.] Univ Vermont, Dept Radiol, Burlington, VT USA; [Garavan, Hugh] Univ Vermont, Dept Psychiat, Burlington, VT USA; [Garavan, Hugh] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA; [Watts, Richard; Andrews, Trevor; Nickerson, Joshua P.; Gonyea, Jay; Hipko, Scott] Univ Vermont, MRI Ctr Biomed Imaging, Burlington, VT USA; [Andrews, Trevor] Philips Healthcare, Cleveland, OH USA; [Hudziak, James J.] Erasmus Univ, Sophia Childrens Hosp, Rotterdam, Netherlands; [Hudziak, James J.] Washington Univ, Dept Child Psychiat, St Louis, MO USA	Hudziak, JJ (corresponding author), Univ Vermont, Coll Med, Vermont Ctr Children Youth & Families, Univ Hlth Ctr Campus,1 South Prospect St, Burlington, VT 05401 USA.	james.hudziak@uvm.edu	Meijer, Anna/K-5118-2016; Albaugh, Matthew D/R-4349-2016; Albaugh, Matthew/ABB-5839-2020	Albaugh, Matthew/0000-0002-5971-6658; Andrews, Trevor/0000-0003-0331-1798			Achenbach T.M., 2003, RATINGS RELATIONS DS; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Andersson J.L., 2007, TR07JA2 FMRIB U OXF; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Calhoun VD, 2004, MAGN RESON IMAGING, V22, P1181, DOI 10.1016/j.mri.2004.09.004; Calhoun VD, 2006, HUM BRAIN MAPP, V27, P47, DOI 10.1002/hbm.20166; Cheung MM, 2009, NEUROIMAGE, V45, P386, DOI 10.1016/j.neuroimage.2008.12.018; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Di Martino A, 2014, MOL PSYCHIATR, V19, P659, DOI 10.1038/mp.2013.78; Ducharme S, 2011, BIOL PSYCHIAT, V70, P283, DOI 10.1016/j.biopsych.2011.03.015; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Groves AR, 2011, NEUROIMAGE, V54, P2198, DOI 10.1016/j.neuroimage.2010.09.073; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hammeke TA, 2013, J INT NEUROPSYCH SOC, V19, P863, DOI 10.1017/S1355617713000702; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hui ES, 2008, NEUROIMAGE, V42, P122, DOI 10.1016/j.neuroimage.2008.04.237; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Korngold C, 2013, J AM ACAD PSYCHIATRY, V41, P430; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li X., 2012, ENG MED BIOL SOC EMB; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Lovell MR., 2000, IMPACT IMMEDIATE POS; Luo L, 2012, BRAIN CONNECT, V2, P33, DOI 10.1089/brain.2011.0026; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Parmet Sharon, 2003, JAMA, V290, P2628, DOI 10.1001/jama.290.19.2628; Patel DR, 2013, ADOLESCENCE SPORTS; Qin SZ, 2014, BIOL PSYCHIAT, V75, P892, DOI 10.1016/j.biopsych.2013.10.006; Rabinowitz AR, 2014, ANNU REV PSYCHOL, V65, P301, DOI 10.1146/annurev-psych-010213-115103; Rivara FP, 2014, JAMA-J AM MED ASSOC, V311, P239, DOI 10.1001/jama.2013.282985; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tabesh A, 2011, MAGN RESON MED, V65, P823, DOI 10.1002/mrm.22655; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Yan CG, 2013, NEUROIMAGE, V76, P183, DOI 10.1016/j.neuroimage.2013.03.004; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhuo J., 2012, ORG HUM BRAIN MAPP A; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	67	25	25	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 1	2016	33	9					803	810		10.1089/neu.2014.3721			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DK7SA	WOS:000375124800001	26413910				2021-06-18	
J	Hobbs, JG; Young, JS; Bailes, JE				Hobbs, Jonathan G.; Young, Jacob S.; Bailes, Julian E.			Sports-related concussions: diagnosis, complications, and current management strategies	NEUROSURGICAL FOCUS			English	Article						concussion; mild traumatic brain injury; chronic traumatic encephalopathy; subconcussion	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; STATES HIGH-SCHOOL; KING-DEVICK TEST; CEREBRAL CONCUSSION; AXONAL INJURY; CEREBROSPINAL-FLUID; POSTURAL CONTROL; TEMPORAL WINDOW; COGNITIVE IMPAIRMENT	Sports-related concussions (SRCs) are traumatic events that affect up to 3.8 million athletes per year. The initial diagnosis and management is often instituted on the field of play by coaches, athletic trainers, and team physicians. SRCs are usually transient episodes of neurological dysfunction following a traumatic impact, with most symptoms resolving in 7-10 days; however, a small percentage of patients will suffer protracted symptoms for years after the event and may develop chronic neurodegenerative disease. Rarely, SRCs are associated with complications, such as skull fractures, epidural or subdural hematomas, and edema requiring neurosurgical evaluation. Current standards of care are based on a paradigm of rest and gradual return to play, with decisions driven by subjective and objective information gleaned from a detailed history and physical examination. Advanced imaging techniques such as functional MRI, and detailed understanding of the complex pathophysiological process underlying SRCs and how they affect the athletes acutely and long-term, may change the way physicians treat athletes who suffer a concussion. It is hoped that these advances will allow a more accurate assessment of when an athlete is truly safe to return to play, decreasing the risk of secondary impact injuries, and provide avenues for therapeutic strategies targeting the complex biochemical cascade that results from a traumatic injury to the brain.	[Hobbs, Jonathan G.; Young, Jacob S.] Univ Chicago, Pritzker Sch Med, Dept Surg, Neurosurg Sect, Chicago, IL 60637 USA; [Bailes, Julian E.] Univ Chicago, Pritzker Sch Med, Dept Neurosurg, NorthShore Univ HealthSyst, Evanston, IL USA	Hobbs, JG (corresponding author), Univ Chicago, Dept Surg, Neurosurg Sect, MC 3026,J341,5841 S Maryland Ave, Chicago, IL 60637 USA.	jonathan.hobbs@uchospitals.edu	Young, Jacob/AAE-6194-2020				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Bigler ED, 2012, NEUROSCI LETT, V509, P1, DOI 10.1016/j.neulet.2011.12.009; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cheng X, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/760758; Chrisman SPD, 2014, J ADOLESCENT HEALTH, V54, P582, DOI 10.1016/j.jadohealth.2013.10.006; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kakuda T, 2002, BIOL PHARM BULL, V25, P1513, DOI 10.1248/bpb.25.1513; Kakuda T, 2011, PHARMACOL RES, V64, P162, DOI 10.1016/j.phrs.2011.03.010; Kalimo H, 1981, Acta Neuropathol Suppl, V7, P20; Karantzoulis S, 2013, NEUROPSYCHOL REV, V23, P350, DOI 10.1007/s11065-013-9243-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; King D, 2015, J NEUROL SCI, V357, P75, DOI 10.1016/j.jns.2015.06.069; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lardner AL, 2014, NUTR NEUROSCI, V17, P145, DOI 10.1179/1476830513Y.0000000079; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Ley EJ, 2011, J SURG RES, V170, P253, DOI 10.1016/j.jss.2011.03.006; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mandel SA, 2011, J ALZHEIMERS DIS, V25, P187, DOI 10.3233/JAD-2011-101803; Mansell JL, 2010, BRAIN INJURY, V24, P1070, DOI 10.3109/02699052.2010.494589; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; May KH, 2014, INT J SPORTS PHYS TH, V9, P242; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2011, J NEUROPSYCH CLIN N, V23, P277, DOI 10.1176/appi.neuropsych.23.3.277; McClain R, 2015, PRIMARY CARE, V42, P77, DOI 10.1016/j.pop.2014.09.005; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2001, BRIT J SPORT MED, V35, P380, DOI 10.1136/bjsm.35.6.380; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Petraglia AL, 2012, NEUROSURGERY, V70, P1520, DOI 10.1227/NEU.0b013e31824cebe8; Petraglia Anthony L, 2011, Surg Neurol Int, V2, P146, DOI 10.4103/2152-7806.85987; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Quintana A, 2008, DEV NEUROBIOL, V68, P195, DOI 10.1002/dneu.20584; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Rezai-Zadeh K, 2008, BRAIN RES, V1214, P177, DOI 10.1016/j.brainres.2008.02.107; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Seidman DH, 2015, J NEUROL SCI, V356, P97, DOI 10.1016/j.jns.2015.06.021; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Sweeney TE, 2015, WORLD J EMERG SURG, V10, DOI 10.1186/s13017-015-0017-6; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Ventura RE, 2015, SEMIN NEUROL, V35, P599, DOI 10.1055/s-0035-1563567; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yu CH, 2011, J VET SCI, V12, P299, DOI 10.4142/jvs.2011.12.3.299; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	155	25	25	0	42	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	APR	2016	40	4							E5	10.3171/2016.1.FOCUS15617			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI4NL	WOS:000373476500011	27032922	Bronze			2021-06-18	
J	Seli, P				Seli, Paul			The Attention-Lapse and Motor Decoupling accounts of SART performance are not mutually exclusive	CONSCIOUSNESS AND COGNITION			English	Article						The Sustained Attention to Response Task; SART; Mind wandering; Motor decoupling; Inattention; Attention lapses	DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; SUSTAINED-ATTENTION; RESPONSE-TASK; FAILURES; ADHD	There is an ongoing debate about the mechanisms purported to underlie performance in the Sustained-Attention-to-Response Task (SART). Whereas the Attention-Lapse account posits that SART errors result from attentional disengagement, the Motor Decoupling account proposes that SART errors result from failures to inhibit a fast, prepotent motor response, despite adequate attention to the task. That SART performance might be fully accounted for by motor decoupling is problematic for a Attention-Lapse account, and for the use of the SART as an index of attention lapses. To test whether SART performance is in fact fully accounted for by motor decoupling, I examined the relation between SART performance and attention lapses while controlling for motor decoupling. The results were clear: The SART was associated with attention lapses independently of motor decoupling. Thus, the present study suggests that both accounts are correct and that the SART is a valid measure of attention lapses. (C) 2016 Elsevier Inc. All rights reserved.	[Seli, Paul] Harvard Univ, Dept Psychol, William James Hall,33 Kirkland St, Cambridge, MA 02138 USA	Seli, P (corresponding author), Harvard Univ, Dept Psychol, William James Hall,33 Kirkland St, Cambridge, MA 02138 USA.	paulseli@fas.harvard.edu			Natural Sciences and Engineering Research Council of Canada (NSERC) Post-Doctoral FellowshipNatural Sciences and Engineering Research Council of Canada (NSERC)	This research was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) Post-Doctoral Fellowship to Paul Seli.	Bellgrove MA, 2006, CORTEX, V42, P838, DOI 10.1016/S0010-9452(08)70426-X; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chan RCK, 2009, COGN BEHAV NEUROL, V22, P180, DOI 10.1097/WNN.0b013e3181b7ef84; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Head J, 2014, EXP BRAIN RES, V232, P565, DOI 10.1007/s00221-013-3765-0; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Jonker TR, 2013, CONSCIOUS COGN, V22, P1468, DOI 10.1016/j.concog.2013.10.005; Kline RB., 2016, PRINCIPLES PRACTICE, V4; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Manly T., 2000, CLIN NEUROPSYCHOLOGI, V3, P167; Marquez CMS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00333; Molenberghs P, 2009, NEUROPSYCHOLOGIA, V47, P2866, DOI 10.1016/j.neuropsychologia.2009.06.012; Peebles D, 2004, PROCEEDINGS OF THE SIXTH INTERNATIONAL CONFERENCE ON COGNITIVE MODELING, P231; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Seli P., 2014, PSYCHOL RES, P1; Seli P., PSYCHONOMIC IN PRESS, DOI 10.3758/s13423-015-0979-0; Seli P., 2013, FRONTIERS PSYCHOL; Seli P, 2013, BEHAV RES METHODS, V45, P355, DOI 10.3758/s13428-012-0266-1; Seli P, 2012, CAN J EXP PSYCHOL, V66, P44, DOI 10.1037/a0025111; Seli P, 2012, CONSCIOUS COGN, V21, P277, DOI 10.1016/j.concog.2011.09.017; Smallwood J, 2004, CONSCIOUS COGN, V13, P789, DOI 10.1016/j.concog.2004.07.004; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Smilek D, 2010, NEUROPSYCHOLOGIA, V48, P2564, DOI 10.1016/j.neuropsychologia.2010.05.002; Van der Linden D, 2005, WORK STRESS, V19, P23, DOI 10.1080/02678370500065275; Wilson KM, 2015, CONSCIOUS COGN, V33, P406, DOI 10.1016/j.concog.2015.02.014	28	25	25	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8100	1090-2376		CONSCIOUS COGN	Conscious. Cogn.	APR	2016	41						189	198		10.1016/j.concog.2016.02.017			10	Psychology, Experimental	Psychology	DI7BF	WOS:000373653400019	26946296				2021-06-18	
J	Yue, JK; Winkler, EA; Burke, JF; Chan, AK; Dhall, SS; Berger, MS; Manley, GT; Tarapore, PE				Yue, John K.; Winkler, Ethan A.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Berger, Mitchel S.; Manley, Geoffrey T.; Tarapore, Phiroz E.			Pediatric sports-related traumatic brain injury in United States trauma centers	NEUROSURGICAL FOCUS			English	Article						concussion; mortality; pediatric; sports; outcome; traumatic brain injury	HIGH-SCHOOL; HEAD-INJURY; DATA-BANK; FOOTBALL PLAYERS; CONCUSSION; CHILDREN; EPIDEMIOLOGY; POPULATION; PREDICTORS; MANAGEMENT	OBJECTIVE Traumatic brain injury (TBI) in children is a significant public health concern estimated to result in over 500,000 emergency department (ED) visits and more than 60,000 hospitalizations in the United States annually. Sports activities are one important mechanism leading to pediatric TBI. In this study, the authors characterize the demographics of sports-related TBI in the pediatric population and identify predictors of prolonged hospitalization and of increased morbidity and mortality rates. METHODS Utilizing the National Sample Program of the National Trauma Data Bank (NTDB), the authors retrospectively analyzed sports-related TBI data from children (age 0-17 years) across 5 sports categories: fall or interpersonal contact (FIC), roller sports, skiing/snowboarding, equestrian sports, and aquatic sports. Multivariable regression analysis was used to identify predictors of prolonged length of stay (LOS) in the hospital or intensive care unit (ICU), medical complications, inpatient mortality rates, and hospital discharge disposition. Statistical significance was assessed at alpha < 0.05, and the Bonferroni correction (set at significance threshold p = 0.01) for multiple comparisons was applied in each outcome analysis. RESULTS From 2003 to 2012, in total 3046 pediatric sports-related TBIs were recorded in the NTDB, and these injuries represented 11,614 incidents nationally after sample weighting. Fall or interpersonal contact events were the greatest contributors to sports-related TBI (47.4%). Mild TBI represented 87.1% of the injuries overall. Mean (+/- SEM) LOSs in the hospital and ICU were 2.68 +/- 0.07 days and 2.73 +/- 0.12 days, respectively. The overall mortality rate was 0.8%, and the prevalence of medical complications was 2.1% across all patients. Severities of head and extracranial injuries were significant predictors of prolonged hospital and ICU LOSs, medical complications, failure to discharge to home, and death. Hypotension on admission to the ED was a significant predictor of failure to discharge to home (OR 0.05, 95% CI 0.03-0.07, p < 0.001). Traumatic brain injury incurred during roller sports was independently associated with prolonged hospital LOS compared with FIC events (mean increase 0.54 +/- 0.15 days, p < 0.001). CONCLUSIONS In pediatric sports-related TBI, the severities of head and extracranial traumas are important predictors of patients developing acute medical complications, prolonged hospital and ICU LOSs, in-hospital mortality rates, and failure to discharge to home. Acute hypotension after a TBI event decreases the probability of successful discharge to home. Increasing TBI awareness and use of head-protective gear, particularly in high-velocity sports in older age groups, is necessary to prevent pediatric sports-related TBI or to improve outcomes after a TBI.	[Yue, John K.; Winkler, Ethan A.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Berger, Mitchel S.; Manley, Geoffrey T.; Tarapore, Phiroz E.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Yue, John K.; Winkler, Ethan A.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Manley, Geoffrey T.; Tarapore, Phiroz E.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA	Tarapore, PE (corresponding author), San Francisco Gen Hosp, 1001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94110 USA.	taraporep@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722			Agran PF, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.3.e45; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; American College of Surgeons, 2013, NAT TRAUM DAT BANK N; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bekelis K, 2015, ANN SURG, V261, P579, DOI 10.1097/SLA.0000000000000672; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Buller DB, 2003, J TRAUMA, V55, P939, DOI 10.1097/01.TA.0000078694.53320.CA; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gassner R, 2004, J ORAL MAXIL SURG, V62, P399, DOI 10.1016/j.joms.2003.05.013; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilliam Jerene M, 2007, J Agromedicine, V12, P11; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Glass T, 2015, AM J EMERG MED, V33, P1458, DOI 10.1016/j.ajem.2015.06.069; Grubenhoff JA, 2011, BRAIN INJURY, V25, P943, DOI 10.3109/02699052.2011.597043; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Haring RS, 2015, BRAIN INJURY, V29, P989, DOI 10.3109/02699052.2015.1033014; Hendricks K J, 2001, Inj Prev, V7, P307, DOI 10.1136/ip.7.4.307; Hendricks KJ, 2005, J SAFETY RES, V36, P149, DOI 10.1016/j.jsr.2005.01.002; Hubler Crystal L, 2002, J Emerg Nurs, V28, P284, DOI 10.1067/men.2002.124797; Kannan Nithya, 2014, Int J Crit Illn Inj Sci, V4, P131, DOI 10.4103/2229-5151.134152; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Lam WH, 1999, PAEDIATR ANAESTH, V9, P377; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; Majidi S, 2013, AM J EMERG MED, V31, P1215, DOI 10.1016/j.ajem.2013.05.026; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Rose SC, 2015, PEDIATR NEUROL, V53, P108, DOI 10.1016/j.pediatrneurol.2015.04.003; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schoenfeld AJ, 2013, SPINE J, V13, P1766, DOI 10.1016/j.spinee.2013.03.024; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Smith GA, 2004, CLIN PEDIATR, V43, P335, DOI 10.1177/000992280404300404; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stocchetti N, 2010, MINERVA ANESTESIOL, V76, P1052; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; U. S. Consumer Product Safety Commission: NationalBike Helmet Use Survey, NAT BIK HELM USE SUR; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Winkler EA, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15613; Winkler EA, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15270	56	25	26	0	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	APR	2016	40	4							E3	10.3171/2016.1.FOCUS15612			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI4NL	WOS:000373476500008	27032920	Bronze			2021-06-18	
J	Rich, MC; Keene, CN; Neher, MD; Johnson, K; Yu, ZX; Ganivet, A; Holers, VM; Stahel, PF				Rich, Megan C.; Keene, Chesleigh N.; Neher, Miriam D.; Johnson, Krista; Yu, Zhao-Xue; Ganivet, Antoine; Holers, V. Michael; Stahel, Philip F.			Site-targeted complement inhibition by a complement receptor 2-conjugated inhibitor (mTT30) ameliorates post-injury neuropathology in mouse brains	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Neuroinflammation; Site-targeted complement inhibition; CR2-conjugated pharmacological compounds; Secondary brain injury	CLOSED-HEAD INJURY; MEMBRANE ATTACK COMPLEX; ALTERNATIVE PATHWAY; MICE LACKING; FACTOR-B; ACTIVATION; SYSTEM; C3; INFLAMMATION; IMMUNITY	Intracerebral complement activation after severe traumatic brain injury (TBI) leads to a cascade of neuroinflammatory pathological sequelae that propagate host-mediated secondary brain injury and adverse outcomes. There are currently no specific pharmacological agents on the market to prevent or mitigate the development of secondary cerebral insults after TBI. A novel chimeric CR2-fH compound (mTT30) provides targeted inhibition of the alternative complement pathway at the site of tissue injury. This experimental study was designed to test the neuroprotective effects of mTT30 in a mouse model of closed head injury. The administration of 500 mu g mTT30 i.v. at 1 h, 4 h and 24 h after head injury attenuated complement C3 deposition in injured brains, reduced the extent of neuronal cell death, and decreased post-injury microglial activation, compared to vehicle-injected placebo controls. These data imply that site-targeted alternative pathway complement inhibition may represent a new promising therapeutic avenue for the future management of severe TBI. (C) 2016 Published by Elsevier Ireland Ltd.	[Rich, Megan C.; Keene, Chesleigh N.; Neher, Miriam D.; Ganivet, Antoine; Stahel, Philip F.] Denver Hlth Med Ctr, Dept Orthopaed Surg, Denver, CO 80204 USA; [Rich, Megan C.; Keene, Chesleigh N.; Neher, Miriam D.; Ganivet, Antoine; Stahel, Philip F.] Univ Colorado, Sch Med, 777 Bannock St, Denver, CO 80204 USA; [Johnson, Krista; Yu, Zhao-Xue] Alex Pharmaceut, Cheshire, CT 06410 USA; [Holers, V. Michael] Univ Colorado, Sch Med, Dept Med, Aurora, CO 80045 USA; [Holers, V. Michael] Univ Colorado, Sch Med, Dept Immunol, Aurora, CO 80045 USA; [Stahel, Philip F.] Univ Colorado, Sch Med, Dept Neurosurg, 777 Bannock St, Denver, CO 80204 USA; [Stahel, Philip F.] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed Surg, 777 Bannock St, Denver, CO 80204 USA; [Stahel, Philip F.] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Neurosurg, 777 Bannock St, Denver, CO 80204 USA	Stahel, PF (corresponding author), Univ Colorado, Sch Med, Dept Neurosurg, 777 Bannock St, Denver, CO 80204 USA.; Stahel, PF (corresponding author), Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed Surg, 777 Bannock St, Denver, CO 80204 USA.; Stahel, PF (corresponding author), Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Neurosurg, 777 Bannock St, Denver, CO 80204 USA.	philip.stahel@dhha.org			Colorado Traumatic Brain Injury Trust Fund	This study was supported by a project grant from the Colorado Traumatic Brain Injury Trust Fund to P.F.S.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Bellander BM, 2010, EXP BRAIN RES, V205, P103, DOI 10.1007/s00221-010-2342-z; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Ehrnthaller C, 2011, MOL MED, V17, P317, DOI 10.2119/molmed.2010.00149; Elvington A, 2012, J IMMUNOL, V189, P4640, DOI 10.4049/jimmunol.1201904; Elvington M, 2015, CLIN EXP IMMUNOL, V179, P500, DOI 10.1111/cei.12464; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Gasque P, 1996, J IMMUNOL, V156, P2247; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Holers V.M., 2015, IMMUNOBIOLOGY; Holers VM, 2007, MOL IMMUNOL, V44, P64, DOI 10.1016/j.molimm.2006.07.003; Holers VM, 2013, ADV EXP MED BIOL, V735, P137, DOI 10.1007/978-1-4614-4118-2_9; Hu XZ, 2012, NEUROSCI LETT, V531, P35, DOI 10.1016/j.neulet.2012.10.012; Huang YX, 2008, J IMMUNOL, V181, P8068, DOI 10.4049/jimmunol.181.11.8068; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Moriyama M, 2011, J NEUROSCI, V31, P3981, DOI 10.1523/JNEUROSCI.3617-10.2011; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; Neher MD, 2014, SOUTH MED J, V107, P248, DOI 10.1097/SMJ.0000000000000086; Neher MD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-95; Neher MD, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-90; Orsini F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00380; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Woodruff TM, 2010, NEUROMOL MED, V12, P179, DOI 10.1007/s12017-009-8085-y	37	25	25	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 23	2016	617						188	194		10.1016/j.neulet.2016.02.025			7	Neurosciences	Neurosciences & Neurology	DI5LB	WOS:000373539400032	26892188				2021-06-18	
J	Olson, DM; Fishel, M				Olson, DaiWai M.; Fishel, Megan			The Use of Automated Pupillometry in Critical Care	CRITICAL CARE NURSING CLINICS OF NORTH AMERICA			English	Article						Multimodal monitoring; Neurologic assessment; Pupillometer; Cranial nerve assessment	TRAUMATIC BRAIN-INJURY; INFRARED PUPILLOMETRY; HEAD-INJURY; PUPIL SIZE; COMA SCALE; 4 SCORE; DIAMETER; PATIENT; UNIT	The neurologic examination (neuroexamination) is one of the most powerful tools available to nurses and physicians caring for patients with neurologic or neurosurgical illness. Assessing cranial nerve function is one of the most vital components of the neuroexamination. The pupillary light reflex helps to evaluate the status of the second and third cranial nerves and is one of the most well-known elements of the cranial nerve examination. Automated pupillometers have been developed that provide objective measures of size of the pupil and the responsiveness of the pupil to light (neuropupillary index).	[Olson, DaiWai M.; Fishel, Megan] Univ Texas Southwestern, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	Olson, DM (corresponding author), Univ Texas Southwestern, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	DaiWai.Olson@UTSouthwestern.edu	Olson, DaiWai/I-5932-2019	Olson, DaiWai/0000-0002-9280-078X			Bader MK, 2010, AANN CORE CURRICULUM; Blumenfeld H, 2002, NEUROANATOMY CLIN CA; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Campbell W. W., 2005, DEJONGS NEUROLOGIC E; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Chen JW, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-548; Clark A, 2006, EMERG MED J, V23, P440, DOI 10.1136/emj.2005.030247; Du R, 2005, NEUROSURGERY, V57, P198, DOI 10.1227/01.NEU.0000163425.79170.CB; Fountas KN, 2006, NEUROCRIT CARE, V5, P55, DOI 10.1385/NCC:5:1:55; GOEBERT HW, 1970, SURG CLIN N AM, V50, P427; Greenberg MS., 2010, HDB NEUROSURGERY, V7th; Greenberg MS, 2006, HDB NEUROSURGERY; HESS EH, 1960, SCIENCE, V132, P349, DOI 10.1126/science.132.3423.349; Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3; Litvan I, 2000, NEUROLOGY, V54, P530, DOI 10.1212/WNL.54.2.530; Loewenfeld I.E., 1993, PUPIL ANATOMY PHYSL; Mahdavi Z, 2015, CRIT CARE NURS CLIN, V27, P213, DOI 10.1016/j.cnc.2015.02.002; Manley GT, 2002, J NEUROSURG ANESTH, V14, P223, DOI 10.1097/00008506-200207000-00009; Mazzoni P, 2006, MERRITTS NEUROLOGY H; McMullen W H, 1917, Br J Ophthalmol, V1, P593, DOI 10.1136/bjo.1.10.593; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; Olson DM, 2005, AACN ADV CRIT CARE, V16, P441, DOI 10.1097/00044067-200510000-00003; Olson DM, 2015, NEUROCRIT CARE; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; Rebolleda G, 2013, ARCH SOC ESP OFTALMO, V88, P125, DOI [10.1016/j.oftal.2013.02.014, DOI 10.1016/J.0FTAL.2013.02.014]; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; Schallenberg M, 2010, J REFRACT SURG, V26, P134, DOI 10.3928/1081597X-20100121-09; Singhal NS, 2014, J CRIT CARE, V29, P627, DOI 10.1016/j.jcrc.2014.02.014; Song Z, 2012, CLIN NEUROL NEUROSUR, V114, P634, DOI 10.1016/j.clineuro.2011.12.029; TEASDALE G, 1974, LANCET, V2, P81; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wilson S F, 1988, J Neurosci Nurs, V20, P189; Wilson-Pauwels L, 1988, CRANIAL NERVES ANATO; Worthley L I, 2000, Crit Care Resusc, V2, P7; Zafar SF, 2014, J CRIT CARE, V29, P599, DOI 10.1016/j.jcrc.2014.01.012	35	25	25	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0899-5885	1558-3481		CRIT CARE NURS CLIN	Crit. Care Nurs. Clin. N. Am.	MAR	2016	28	1					101	+		10.1016/j.cnc.2015.09.003			8	Nursing	Nursing	DD1TR	WOS:000369705200010	26873763				2021-06-18	
J	Shah, FA; Gim, SA; Sung, JH; Jeon, SJ; Kim, MO; Koh, PO				Shah, Fawad-Ali; Gim, Sang-Ah; Sung, Jin-Hee; Jeon, Seong-Jun; Kim, Myeong-Ok; Koh, Phil-Ok			Identification of proteins regulated by curcumin in cerebral ischemia	JOURNAL OF SURGICAL RESEARCH			English	Article						Curcumin; Stroke; Proteomics	TRAUMATIC BRAIN-INJURY; C-TERMINAL HYDROLASE; SYNAPTIC PLASTICITY; REPERFUSION INJURY; OXIDATIVE STRESS; ARTERY OCCLUSION; UBIQUITIN; RATS; MECHANISMS; PYRIDOXAL	Background: Curcumin is known to have a neuroprotective effect against cerebral ischemia. The objective of this study was to identify various proteins that are differentially expressed by curcumin treatment in focal cerebral ischemia using a proteomic approach. Methods: Adult male rats were treated with vehicle or curcumin 1 h after middle cerebral artery occlusion. Brain tissues were collected 24 h after the onset of middle cerebral artery occlusion, and cerebral cortices proteins were identified by two-dimensional gel electrophoresis and mass spectrometry. Results: We detected several proteins with altered expression levels between vehicle- and curcumin-treated animals. Among these proteins, ubiquitin carboxy-terminal hydrolase L1, isocitrate dehydrogenase, adenosylhomocysteinase, and eukaryotic initiation factor 4A were decreased in the vehicle-treated animal, and curcumin treatment attenuated the injury-induced decreases of these proteins. Conversely, pyridoxal phosphate phosphatase was increased in the vehicle-treated animal, and curcumin treatment prevented decreases in this protein. The identified altered proteins are associated with cellular metabolism and differentiation. Conclusions: The results of this study suggest that curcumin exerts a neuroprotective effect by regulating the expression of various proteins in focal cerebral ischemia. (C) 2016 Elsevier Inc. All rights reserved.	[Shah, Fawad-Ali; Gim, Sang-Ah; Sung, Jin-Hee; Jeon, Seong-Jun; Koh, Phil-Ok] Gyeongsang Natl Univ, Life Sci Res Inst, Coll Vet Med, Dept Anat, Jinju, South Korea; [Shah, Fawad-Ali; Kim, Myeong-Ok] Gyeongsang Natl Univ, Div Life Sci & Appl Life Sci, Jinju, South Korea	Koh, PO (corresponding author), Gyeongsang Natl Univ, Coll Vet Med, Dept Anat, 900 Gajwa Dong, Jinju 660701, South Korea.	pokoh@gnu.ac.kr		Shah, Fawad Ali/0000-0002-5415-2179	Basic Science Research Program through National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [NRF-2013R1A1A2007300]	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2013R1A1A2007300).	Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; Baxter P, 2003, BBA-PROTEINS PROTEOM, V1647, P36, DOI 10.1016/S1570-9639(03)00045-1; Bubber P, 2005, ANN NEUROL, V57, P695, DOI 10.1002/ana.20474; Castillo J, 2000, STROKE, V31, P852, DOI 10.1161/01.STR.31.4.852; Chu KY, 2012, DIABETOLOGIA, V55, P128, DOI 10.1007/s00125-011-2323-1; Costa-Mattioli M, 2009, PROG MOL BIOL TRANSL, V90, P293, DOI 10.1016/S1877-1173(09)90008-4; Ge PF, 2007, STROKE, V38, P3230, DOI 10.1161/STROKEAHA.107.487108; Gong B, 2006, CELL, V126, P775, DOI 10.1016/j.cell.2006.06.046; Guo LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070565; Hartong DT, 2008, NAT GENET, V40, P1230, DOI 10.1038/ng.223; Hwang IK, 2007, EXP NEUROL, V206, P114, DOI 10.1016/j.expneurol.2007.04.005; Jang YM, 2003, J BIOL CHEM, V278, P50040, DOI 10.1074/jbc.M309619200; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Meijer HA, 2013, SCIENCE, V340, P82, DOI 10.1126/science.1231197; Ouh In-Ohk, 2013, Lab Anim Res, V29, P156, DOI 10.5625/lar.2013.29.3.156; PALMER JL, 1979, J BIOL CHEM, V254, P1217; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Parsyan A, 2011, NAT REV MOL CELL BIO, V12, P235, DOI 10.1038/nrm3083; PATEL BT, 1986, BRAIN RES, V370, P250, DOI 10.1016/0006-8993(86)90480-4; Sanderson TH, 2013, MOL NEUROBIOL, V47, P9, DOI 10.1007/s12035-012-8344-z; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Sun JH, 2008, BIOCHEM BIOPH RES CO, V366, P539, DOI 10.1016/j.bbrc.2007.11.176; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Tu XK, 2014, INFLAMMATION, V37, P1544, DOI 10.1007/s10753-014-9881-6; Wang Q, 2005, J NEUROSCI RES, V82, P138, DOI 10.1002/jnr.20610; Wardas J, 2002, POL J PHARMACOL, V54, P313; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Yamashima T, 2001, NUTR NEUROSCI, V4, P389, DOI 10.1080/1028415X.2001.11747375; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Zhao J, 2008, BRAIN RES, V1229, P224, DOI 10.1016/j.brainres.2008.06.117; Zhao J, 2010, NEUROCHEM RES, V35, P374, DOI 10.1007/s11064-009-0065-y	34	25	26	1	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAR	2016	201	1					141	148		10.1016/j.jss.2015.10.025			8	Surgery	Surgery	DD0GU	WOS:000369599200018	26850195				2021-06-18	
J	Willigenburg, NW; Borchers, JR; Quincy, R; Kaeding, CC; Hewett, TE				Willigenburg, Nienke W.; Borchers, James R.; Quincy, Richard; Kaeding, Christopher C.; Hewett, Timothy E.			Comparison of Injuries in American Collegiate Football and Club Rugby: A Prospective Cohort Study	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						epidemiology; rugby; American football; head injury; concussion; ACL injury	SURVEILLANCE SYSTEM; EPIDEMIOLOGY; PATTERNS; UNION	Background: American football and rugby players are at substantial risk of injury because of the full-contact nature of these sports. Methodological differences between previous epidemiological studies hamper an accurate comparison of injury rates between American football and rugby. Purpose: To directly compare injury rates in American collegiate football and rugby, specified by location, type, mechanism, and severity of injury, as reported by licensed medical professionals. Study Design: Cohort study; Level of evidence, 2. Methods: Licensed medical professionals (athletic trainer or physician) associated with the football and rugby teams of a National Collegiate Athletic Association Division I university reported attendance and injury details over 3 autumn seasons. Injuries were categorized by the location, type, mechanism, and severity of injury, and the injury rate was calculated per 1000 athlete-exposures (AEs). Injury rate ratios (IRRs) were calculated to compare overall, game, and practice injury rates within and between sports. Results: The overall injury rate was 4.9/1000 AEs in football versus 15.2/1000 AEs in rugby: IRR = 3.1 (95% CI, 2.3-4.2). Game injury rates were higher than practice injury rates: IRR = 6.5 (95% CI, 4.5-9.3) in football and IRR = 5.1 (95% CI, 3.0-8.6) in rugby. Injury rates for the shoulder, wrist/hand, and lower leg and for sprains, fractures, and contusions in rugby were >4 times as high as those in football (all P 0.006). Concussion rates were 1.0/1000 AEs in football versus 2.5/1000 AEs in rugby. Most injuries occurred via direct player contact, especially during games. The rate of season-ending injuries (>3 months of time loss) was 0.8/1000 AEs in football versus 1.0/1000 AEs in rugby: IRR = 1.3 (95% CI, 0.4-3.4). Conclusion: Overall injury rates were substantially higher in collegiate rugby compared with football. Similarities between sports were observed in the most common injury types (sprains and concussions), locations (lower extremity and head), and mechanisms (direct player contact). Upper extremity injuries were more common in rugby, and the rate of season-ending injuries was similar between sports.	[Willigenburg, Nienke W.; Borchers, James R.; Quincy, Richard; Kaeding, Christopher C.; Hewett, Timothy E.] Ohio State Univ, Columbus, OH 43210 USA; [Hewett, Timothy E.] Mayo Clin, Dept Orthoped, 200 First St SW, Rochester, MN 55905 USA; [Willigenburg, Nienke W.; Borchers, James R.; Kaeding, Christopher C.; Hewett, Timothy E.] Ohio State Univ, Sports Hlth & Performance Inst, Columbus, OH 43210 USA; [Willigenburg, Nienke W.] OLVG, Dept Orthopaed Surg, JointRes, Amsterdam, Netherlands; [Borchers, James R.] Ohio State Univ, Dept Family Med, Columbus, OH 43210 USA; [Quincy, Richard; Kaeding, Christopher C.] Ohio State Univ, Dept Orthopaed, Columbus, OH 43210 USA	Hewett, TE (corresponding author), Mayo Clin, Dept Orthoped, 200 First St SW, Rochester, MN 55905 USA.; Hewett, TE (corresponding author), Ohio State Univ, Sports Hlth & Performance Inst, Columbus, OH 43210 USA.	hewett.timothy@mayo.edu	Borchers, James/E-2778-2011		National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01-AR049735, R01-AR055563, R01-AR056259]; Sports Health and Performance Institute at The Ohio State University; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR055563, R01AR056259, R01AR049735] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: Funding support was received from National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases grants (R01-AR049735, R01-AR055563, and R01-AR056259 to T.E.H.) and from the Sports Health and Performance Institute at The Ohio State University.	Albright JP, 2004, AM J SPORT MED, V32, P1394, DOI 10.1177/0363546504264159; [Anonymous], 2013 14 HIGH SCH ATH; [Anonymous], SPORTS SPONS PART RA; Chadwick S, 2010, EC IMPACT REPORT GLO; Dean A., OPENEPI OPEN SOURCE; Dick R, 2007, J ATHL TRAINING, V42, P221; Dick R, 2007, J ATHL TRAINING, V42, P173; Feeley BT, 2008, AM J SPORT MED, V36, P1597, DOI 10.1177/0363546508316021; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hwang JTG, 2001, STAT SINICA, V11, P807; Kerr HA, 2008, BRIT J SPORT MED, V42, P595, DOI 10.1136/bjsm.2007.035881; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1; Willigenburg NW, 2014, ANN SPORTS MED RES, V1, P1005	14	25	26	0	30	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2016	44	3					753	760		10.1177/0363546515622389			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DF9CQ	WOS:000371658300031	26786902				2021-06-18	
J	Alsalaheen, B; Haines, J; Yorke, A; Diebold, J				Alsalaheen, B.; Haines, J.; Yorke, A.; Diebold, J.			King-Devick Test reference values and associations with balance measures in high school American football players	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						Concussion; head injury; normative values; adolescents; visual; screening; reliability; validity; minimum detectable change	VISUAL SCREENING TOOL; ICE HOCKEY PLAYERS; RUGBY LEAGUE; CONCUSSION; ADOLESCENTS; YOUTH	The King-Devick test appears to be a promising tool in screening for concussions. However, limited evidence exists on the baseline associations between the K-D test and age and baseline screening tools used after concussion. Additionally, there are no published reference values for the K-D test in high school football players. The K-D test, the Balance Error Scoring System, and the Limits of Stability (LOS) test were administered to 157 high school football players. Additionally, a subsample of 62 participants completed the test twice to examine the reliability of K-D test. There was no relationship between the K-D test and the BESS, or the reaction time and directional control of LOS test. Students aged between 16 and 18years demonstrated faster K-D test performance compared to students between 13 and 15years of age. However, there was no association between K-D test and history of concussion. The reliability of the K-D test was (ICC2,1=0.89), and the minimal detectable change was 6.10s. Normative reference values for high school football players are presented in this study.	[Alsalaheen, B.; Haines, J.; Yorke, A.; Diebold, J.] Univ Michigan, Dept Phys Therapy, Flint, MI 48502 USA	Alsalaheen, B (corresponding author), Univ Michigan, Phys Therapy Dept, 2157 William S White Bldg,303 E Kearsley St, Flint, MI 48502 USA.	alsalahe@umich.edu	Yorke, Amy/Q-4091-2019	Yorke, Amy/0000-0003-4998-0313	Dr. Ben F. Bryer Foundation Medical Research Fund; University of Michigan-Flint's Research and Creative Activity (RCA) Award	This project was funded by Dr. Ben F. Bryer Foundation Medical Research Fund, and by the University of Michigan-Flint's Research and Creative Activity (RCA) Award. We thank Mitch Smelis, AT, ATC and Kirk Cabanilla AT, ATC for their assistance in recruitment.	Allum J H J, 2012, Front Neurol, V3, P83, DOI 10.3389/fneur.2012.00083; Alsalaheen B, 2015, ARCH PHYS MED REHAB, V96, P2194, DOI 10.1016/j.apmr.2015.08.418; Alsalaheen BA, 2016, CLIN J SPORT MED, V26, P46, DOI 10.1097/JSM.0000000000000185; Baumgartner T.A., 1999, MEASUREMENT EVALUATI; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Iverson G.L., 2003, IMMEDIATE POSTCONCUS; Khan S, 2013, NEUROREHABILITATION, V32, P437, DOI 10.3233/NRE-130866; King D, 2015, J NEUROL SCI, V357, P75, DOI 10.1016/j.jns.2015.06.069; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Vartiainen MV, 2015, SCAND J MED SCI SPOR, V25, pe327, DOI 10.1111/sms.12307	22	25	25	0	16	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	FEB	2016	26	2					235	239		10.1111/sms.12628			5	Sport Sciences	Sport Sciences	DB9TU	WOS:000368860600013	26648587				2021-06-18	
J	Osborn, AJ; Mathias, JL; Fairweather-Schmidt, AK				Osborn, A. J.; Mathias, J. L.; Fairweather-Schmidt, A. K.			Prevalence of Anxiety Following Adult Traumatic Brain Injury: A Meta-Analysis Comparing Measures, Samples and Postinjury Intervals	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; anxiety; generalized anxiety disorder; prevalence; meta-analysis	QUALITY-OF-LIFE; II PSYCHIATRIC-DISORDERS; HEAD-INJURY; DSM-IV; DEPRESSION SCALE; HOSPITAL ANXIETY; AXIS-I; PSYCHOSOCIAL ADJUSTMENT; POSTCONCUSSION SYNDROME; DIAGNOSTIC INTERVIEW	Objective: Anxiety following a traumatic brain injury (TBI) is a common problem; however, disparate prevalence estimates limit the clinical utility of research. The purpose of the current study was to examine how differences in methodological variables and sample characteristics impact on the prevalence of anxiety. Method: Data from 41 studies that examined either the prevalence of generalized anxiety disorder (GAD) diagnoses or clinically significant "cases" of self-reported anxiety following adult, nonpenetrating TBI were analyzed, and the impact of diagnostic criteria, measure, postinjury interval and injury severity was evaluated. Results: Overall, 11% of people were diagnosed with GAD and 37% reported clinically significant levels of anxiety following TBI. Prevalence estimates varied for different diagnostic criteria (range: 2%-19%), interview schedules (range: 2%-28%), and self-report measures (range: 36%-50%). GAD and "cases" of anxiety were most prevalent 2 to 5 years postinjury. The rates of GAD increased with injury severity (mild: 11%, severe 15%), but "cases" decreased (mild: 53%, severe: 38%), although neither difference was significant. Conclusions: Anxiety is common after a TBI and ongoing monitoring and treatment should be provided. Methodological and sample characteristics should be clear and well-defined, as differences across studies (e.g., how anxiety is conceptualized, which measure is used, time since injury, injury severity) impact prevalence rates.	[Osborn, A. J.; Mathias, J. L.; Fairweather-Schmidt, A. K.] Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia; [Fairweather-Schmidt, A. K.] Flinders Univ S Australia, Sch Psychol, Adelaide, SA, Australia	Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au		Mathias, Jane/0000-0001-8957-8594			Al-Adawi S, 2007, BRAIN INJURY, V21, P385, DOI 10.1080/02699050701311059; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; Alway Y, 2012, NEUROPSYCHOL REHABIL, V22, P374, DOI 10.1080/09602011.2011.648757; American Psychiatric Association, 2000, HDB PSYCHIAT MEASURE; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 2001, DIAGN STAT MAN MENT; Andruszkow H, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-26; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Aziz Mohamed A, 2004, J Psychiatr Pract, V10, P307, DOI 10.1097/00131746-200409000-00004; Baxter AJ, 2014, DEPRESS ANXIETY, V31, P506, DOI 10.1002/da.22230; Beaupre M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/924692; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Bertisch HC, 2013, REHABIL PSYCHOL, V58, P429, DOI 10.1037/a0034554; Borenstein M., 2009, INTRO METAANALYSIS; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Boyles AL, 2011, EPIDEMIOLOGY, V22, P746, DOI 10.1097/EDE.0b013e318225ba48; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; Cantor JB, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e318270f91e; Chalton LD, 2009, BRAIN INJURY, V23, P77, DOI 10.1080/02699050802635273; Chen HN, 2010, COMMUN STAT-SIMUL C, V39, P860, DOI 10.1080/03610911003650383; Clarke LA, 2012, BRAIN INJURY, V26, P298, DOI 10.3109/02699052.2012.654588; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Downing MG, 2013, J HEAD TRAUMA REHAB, V28, P171, DOI 10.1097/HTR.0b013e31828b4f63; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; Fairweather-Schmidt AK, 2012, SOC PSYCH PSYCH EPID, V47, P515, DOI 10.1007/s00127-011-0369-5; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First MB., 1997, STRUCTURED CLIN INTE; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2014, J CLIN EXP NEUROPSYC, V36, P1, DOI 10.1080/13803395.2013.863832; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Gregorio GW, 2014, J HEAD TRAUMA REHAB, V29, pE43, DOI 10.1097/HTR.0b013e318292fb00; Haller H, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-128; HAMMELL KRW, 1994, INT J REHABIL RES, V17, P319; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; HASIN DS, 1987, J PSYCHIAT RES, V21, P7, DOI 10.1016/0022-3956(87)90005-7; Hawthorne G, 2011, J CLIN NEUROSCI, V18, P197, DOI 10.1016/j.jocn.2010.06.015; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; HEDGES LV, 1982, PSYCHOL BULL, V92, P490, DOI 10.1037/0033-2909.92.2.490; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hopkins WG, 2002, NEW VIEW STAT SCALE; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kit KA, 2007, REHABIL PSYCHOL, V52, P25, DOI 10.1037/0090-5550.52.1.25; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Koponen S, 2005, PSYCHOSOM MED, V67, P807, DOI 10.1097/01.psy.0000181278.92249.e5; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koponen S, 2011, BRAIN INJURY, V25, P1029, DOI 10.3109/02699052.2011.607783; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kurtz JE, 2007, J PERS ASSESS, V88, P66, DOI 10.1207/s15327752jpa8801_09; Landau J., 2008, FAMILIES SYSTEMS HLT, V26, P69, DOI DOI 10.1037/1091-7527.26.1.69; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; Lipsey M.W., 2001, APPL SOCIAL RES METH, V49; Ma HP, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004205; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mathias JL, 2013, BRAIN INJURY, V27, P887, DOI 10.3109/02699052.2013.793398; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mathias JL, 2014, J NEUROTRAUM, V31, P658, DOI 10.1089/neu.2013.3160; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McLean CP, 2011, J PSYCHIATR RES, V45, P1027, DOI 10.1016/j.jpsychires.2011.03.006; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mendlowicz MV, 2000, AM J PSYCHIAT, V157, P669, DOI 10.1176/appi.ajp.157.5.669; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; Orwin R. G., 1983, J EDUC STAT, V8, P157, DOI [10.3102/10769986008002157., DOI 10.2307/1164923]; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Ponsford J., 2003, Z NEUROPSYCHOL, V14, P155, DOI DOI 10.1024/1016-264X.14.3.155; Ponsford J., 2014, J HEAD TRAUMA REHABI; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Powell T, 2012, DISABIL REHABIL, V34, P1461, DOI 10.3109/09638288.2011.644384; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Richman WL, 1999, J APPL PSYCHOL, V84, P754, DOI 10.1037/0021-9010.84.5.754; Rickels K, 2001, J CLIN PSYCHIAT, V62, P4; Rieger E., 2008, ABNORMAL PSYCHOL LEA; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; ROSENTHAL R, 1995, PSYCHOL BULL, V118, P183, DOI 10.1037/0033-2909.118.2.183; Ruddle JA., 2011, SOCIAL CARE NEURODIS, V2, P200, DOI [10.1108/20420911111188452, DOI 10.1108/20420911111188452]; Schnieders J, 2012, J HEAD TRAUMA REHAB, V27, P404, DOI 10.1097/HTR.0b013e3182306341; Senathi-Raja D, 2010, J HEAD TRAUMA REHAB, V25, P330, DOI 10.1097/HTR.0b013e3181ccc893; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Skilbeck C, 2013, NEUROPSYCHOL REHABIL, V23, P234, DOI 10.1080/09602011.2012.747968; Slade T, 2001, SOC PSYCH PSYCH EPID, V36, P45, DOI 10.1007/s001270050289; Smith H.E., 1992, CLIN REHABIL, V6, P31; SNAITH RP, 1976, BRIT J PSYCHIAT, V128, P156, DOI 10.1192/bjp.128.2.156; Spielberger C.D., 1970, STATE TRAIT ANXIETY; Spitz G, 2013, J HEAD TRAUMA REHAB, V28, P116, DOI 10.1097/HTR.0b013e3182452f4f; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sumpter RE, 2006, BRAIN INJURY, V20, P93, DOI 10.1080/02699050500394090; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Williams J, 2012, HDB ASSESSMENT CHILD; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; Wing J. K., 1974, DESCRIPTION CLASSIFI; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589; Wise EK, 2012, ARCH PHYS MED REHAB, V93, P1319, DOI 10.1016/j.apmr.2012.05.009; Wittchen HU, 2001, J CLIN PSYCHIAT, V62, P15; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; World Health Organization, 1992, ICD 10 CLASS MENT BE; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	141	25	25	1	22	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	FEB	2016	30	2					247	261		10.1037/neu0000221			15	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	DD6YM	WOS:000370070600010	26146855				2021-06-18	
J	Talavage, TM; Nauman, EA; Leverenz, LJ				Talavage, Thomas M.; Nauman, Eric A.; Leverenz, Larry J.			The Role of Medical Imaging in the Recharacterization of Mild Traumatic Brain Injury Using Youth Sports as a Laboratory	FRONTIERS IN NEUROLOGY			English	Article						concussion; traumatic brain injury; functional MRI; magnetic resonance imaging; magnetic resonance spectroscopy; subconcussive	HIGH-SCHOOL FOOTBALL; DEFAULT-MODE NETWORK; HEAD IMPACTS; CEREBROVASCULAR REACTIVITY; FUNCTIONAL CONNECTIVITY; WORKING-MEMORY; PROFESSIONAL FOOTBALL; TEMPORAL-LOBE; WHITE-MATTER; CONCUSSION	The short-and long-term impact of mild traumatic brain injury (TBI) is an increasingly vital concern for both military and civilian personnel. Such injuries produce significant social and financial burdens and necessitate improved diagnostic and treatment methods. Recent integration of neuroimaging and biomechanical studies in youth collision-sport athletes has revealed that significant alterations in brain structure and function occur even in the absence of traditional clinical markers of "concussion." While task performance is maintained, athletes exposed to repetitive head accelerations exhibit structural changes to the underlying white matter, altered glial cell metabolism, aberrant vascular response, and marked changes in functional network behavior. Moreover, these changes accumulate with accrued years of exposure, suggesting a cumulative trauma mechanism that may culminate in categorization as "concussion" and long-term neurological deficits. The goal of this review is to elucidate the role of medical imaging in recharacterizing TBI, as a whole, to better identify at-risk individuals and improve the development of preventative and interventional approaches.	[Talavage, Thomas M.] Purdue Univ, Weldon Sch Biomed Engn, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Nauman, Eric A.] Purdue Univ, Weldon Sch Biomed Engn, Sch Mech Engn, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA	Talavage, TM (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA.	tmt@purdue.edu	Meijer, Anna/K-5118-2016		BrainScope, LLC; General Electric HealthcareGE Healthcare; Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health	This work was supported in part by grants from BrainScope, LLC; General Electric Healthcare; and the Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Ahmed Niyaz, 2005, Ann Clin Microbiol Antimicrob, V4, P17, DOI 10.1186/1476-0711-4-17; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bailes J, 2015, DEV NEUROPSYCHOL, V40, P59, DOI 10.1080/87565641.2015.1018090; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bartsch A, 2012, J NEUROSURG, V116, P222, DOI 10.3171/2011.9.JNS111059; Baslow MH, 2007, BRAIN LANG, V102, P153, DOI 10.1016/j.bandl.2006.06.119; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Birn RM, 2008, HUM BRAIN MAPP, V29, P740, DOI 10.1002/hbm.20577; BISHOP PJ, 1984, AM J SPORT MED, V12, P233, DOI 10.1177/036354658401200313; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Cooley J., 2014, IMPACT CODY LEHE; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Graner J, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00016; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Handwerker DA, 2007, HUM BRAIN MAPP, V28, P846, DOI 10.1002/hbm.20307; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Hoge CW, 2011, NEW ENGL J MED, V365, P860, DOI 10.1056/NEJMc1107891; Hui OY, 2008, J NEUROTRAUM, V25, P19, DOI 10.1089/neu.2007.0340; Ibe O, 2005, FUNDAMENTALS APPL PR; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kastrup A, 2001, MAGN RESON IMAGING, V19, P13, DOI 10.1016/S0730-725X(01)00227-2; Kulkarni P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125748; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Liu Y, 2008, BRAIN, V131, P945, DOI 10.1093/brain/awn018; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Maerlender A, 2015, DEV NEUROPSYCHOL, V40, P69, DOI 10.1080/87565641.2015.1014089; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCabe MA, 2012, AM J NURS, V112, P33, DOI 10.1097/01.NAJ.0000421019.77542.65; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Meier TB, 2015, J SCI MED SPORT, V18, P507, DOI 10.1016/j.jsams.2014.07.008; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Miller JJ, 2011, BIG SCRUM TEDDY ROSS; Mummery CJ, 2000, ANN NEUROL, V47, P36; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Nauman EA, 2015, DEV NEUROPSYCHOL, V40, P85, DOI 10.1080/87565641.2015.1016161; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Ouyang H, 2010, J NEUROTRAUM, V27, P1109, DOI 10.1089/neu.2010.1271; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Ragland JD, 2002, NEUROPSYCHOLOGY, V16, P370, DOI 10.1037//0894-4105.16.3.370; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Shenk TE, 2015, DEV NEUROPSYCHOL, V40, P63, DOI 10.1080/87565641.2015.1014088; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Substance Abuse and Mental Health Services Administration, 2014, RES 2013 NAT SURV DR; Supekar K, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000100; Svaldi DO, 2015, DEV NEUROPSYCHOL, V40, P80, DOI 10.1080/87565641.2014.973959; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	91	25	26	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JAN 19	2016	6								273	10.3389/fneur.2015.00273			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DE2AZ	WOS:000370429900001	26834695	DOAJ Gold, Green Published			2021-06-18	
J	Cotton, RT; Pearce, CW; Young, PG; Kota, N; Leung, AC; Bagchi, A; Qidwai, SM				Cotton, R. T.; Pearce, C. W.; Young, P. G.; Kota, N.; Leung, A. C.; Bagchi, A.; Qidwai, S. M.			Development of a geometrically accurate and adaptable finite element head model for impact simulation: the Naval Research Laboratory-Simpleware Head Model	COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING			English	Article						head impact; blast; traumatic brain injury; simulation; finite element; meshing	CORTICAL BONE; BRAIN MOTION; INJURY; MECHANISMS	This study demonstrates a novel model generation methodology that addresses several limitations of conventional finite element head models (FEHM). By operating chiefly in image space, new structures can be incorporated or merged, and the mesh either decimated or refined both locally and globally. This methodology is employed in the development of a highly bio-fidelic FEHM from high-resolution scan data. The model is adaptable and presented here in a form optimised for impact and blast simulations. The accuracy and feasibility of the model are successfully demonstrated against a widely used experimental benchmark in impact loading and through the investigation of potential brain injury under blast overpressure loading.	[Cotton, R. T.; Pearce, C. W.] Simpleware Ltd, Exeter EX4 3PL, Devon, England; [Young, P. G.] Univ Exeter, Coll Engn Math & Phys Sci, Exeter, Devon, England; [Kota, N.] Leidos Corp, MCET Dept, Arlington, VA USA; [Leung, A. C.; Bagchi, A.; Qidwai, S. M.] US Naval Res Lab, Multifunct Mat Branch, Washington, DC USA	Cotton, RT (corresponding author), Simpleware Ltd, Bradninch Hall,Castle St, Exeter EX4 3PL, Devon, England.	r.cotton@simpleware.com			Office of Naval Research (ONR) through US Naval Research Laboratory's Basic Research Program; Department of Defense (DoD) High Performance Computing Modernization Program (HPCMP); Air Force Research Laboratory (AFRL)United States Department of DefenseUS Air Force Research Laboratory; Major Shared Resource Center (MSRC) [416, 231]	This work was supported by the Office of Naval Research (ONR) through the US Naval Research Laboratory's Basic Research Program, and the Department of Defense (DoD) High Performance Computing Modernization Program (HPCMP) using the Air Force Research Laboratory (AFRL) Major Shared Resource Center (MSRC) under project 416, subproject 231.	ABAQUS, 2012, ABAQUS DOC; Alves JM, 1996, IEEE T BIO-MED ENG, V43, P249, DOI 10.1109/10.486282; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Dewey JM., 2010, 21 INT S MIL ASP BLA; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Johnson TPM, 2010, ACTA BIOMATER, V6, P4073, DOI 10.1016/j.actbio.2010.04.017; Kang HS, 1997, SAE TRANSACTIONS, V106, P3849; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kota N, 2014, J BIOMECH; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Li YA, 2010, J APPL BIOMATER BIOM, V8, P191, DOI 10.5301/JABB.2010.6095; Lim J, 2011, INT J IMPACT ENG, V38, P130, DOI 10.1016/j.ijimpeng.2010.09.003; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Mehta BV, 1997, J DIGIT IMAGING, V10, P203, DOI 10.1007/BF03168701; Mercer C, 2006, ACTA BIOMATER, V2, P59, DOI 10.1016/j.actbio.2005.08.004; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Nahum AM., 1977, P 21 STAPP CAR CRASH, P339, DOI [10.4271/770922., DOI 10.4271/770922]; NASA, 1995, ANTHR BIOM MAN SYST, V1; Nie X, 2011, J APPL MECH-T ASME, V78, DOI 10.1115/1.4002580; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Peterson J, 2002, ANAT REC, V268, P7, DOI 10.1002/ar.10131; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwartz-Dabney CL, 2002, J DENT RES, V81, P613, DOI 10.1177/154405910208100907; Sigal IA, 2004, INVEST OPHTH VIS SCI, V45, P4378, DOI 10.1167/iovs.04-0133; Sigal IA, 2009, BIOMECH MODEL MECHAN, V8, P85, DOI 10.1007/s10237-008-0120-7; Simpleware Ltd, 2013, REF GUID SCANIP SOFT; Song B, 2007, J BIOMECH, V40, P2999, DOI 10.1016/j.jbiomech.2007.02.001; Takhounts EG, 2008, STAPP CAR C, V52, P1; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; TROTTER M, 1960, J BONE JOINT SURG AM, V42, P50, DOI 10.2106/00004623-196042010-00005; US Centers for Disease Control and Prevention, 2010, GET STATS TRAUM BRAI; US Department of Veterans Affairs, TRAUM BRAIN INJ GUID; Ward SR, 2005, J BIOMECH, V38, P2317, DOI 10.1016/j.jbiomech.2004.10.001; Young PG, 2008, PHILOS T R SOC A, V366, P3155, DOI 10.1098/rsta.2008.0090; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	41	25	25	1	27	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-5842	1476-8259		COMPUT METHOD BIOMEC	Comput. Methods Biomech. Biomed. Eng.	JAN 2	2016	19	1					101	113		10.1080/10255842.2014.994118			13	Computer Science, Interdisciplinary Applications; Engineering, Biomedical	Computer Science; Engineering	CV0FF	WOS:000363923600002	25563692	Green Accepted			2021-06-18	
J	Grinberg, LT; Anghinah, R; Nascimento, CF; Amaro, E; Leite, RP; Martin, MDM; Naslavsky, MS; Takada, LT; Jacob, W; Pasqualucci, CA; Nitrini, R				Grinberg, Lea T.; Anghinah, Renato; Nascimento, Camila Fernandes; Amaro, Edson, Jr.; Leite, Renata P.; Martin, Maria da Graca M.; Naslavsky, Michel S.; Takada, Leonel T.; Jacob Filho, Wilson; Pasqualucci, Carlos A.; Nitrini, Ricardo			Chronic Traumatic Encephalopathy Presenting as Alzheimer's Disease in a Retired Soccer Player	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; autopsy; chronic post-traumatic encephalopathy; dementia; humans; soccer	HIPPOCAMPAL SCLEROSIS; BRAIN-INJURY; PATHOLOGY; DEMENTIA	The relationship between soccer and chronic traumatic encephalopathy (CTE) is not well established. We report clinicopathological correlations in an 83-year-old retired center-back soccer player, with no history of concussion, manifesting typical Alzheimer-type dementia. Examination revealed mixed pathology including widespread CTE, moderate Alzheimer's disease, hippocampal sclerosis, and TDP-43 proteinopathy. This case adds to a few CTE cases described in soccer players. Furthermore, it corroborates that CTE may present clinically as typical Alzheimer-type dementia. Further studies investigating the extent to which soccer is a risk for CTE are needed.	[Grinberg, Lea T.] Univ Calif San Francisco, Memory & Aging Ctr, San Francisco, CA 94143 USA; [Grinberg, Lea T.; Nascimento, Camila Fernandes; Pasqualucci, Carlos A.] Univ Sao Paulo, Sch Med, Dept Pathol, LIM 22, Sao Paulo, Brazil; [Grinberg, Lea T.] Hosp Albert Einstein, Sao Paulo, Brazil; [Anghinah, Renato; Takada, Leonel T.; Nitrini, Ricardo] Univ Sao Paulo, Sch Med, Dept Neurol, Av Dr 15 Eneas Carvalho Aguiar, BR-05403000 Sao Paulo, SP, Brazil; [Amaro, Edson, Jr.] Univ Sao Paulo, Sch Med, Inst Radiol, Sao Paulo, Brazil; [Leite, Renata P.; Jacob Filho, Wilson] Univ Sao Paulo, Sch Med, Div Geriatr, Sao Paulo, Brazil; [Naslavsky, Michel S.] Univ Sao Paulo, Human Genome Res Ctr, Sao Paulo, Brazil	Nitrini, R (corresponding author), Univ Sao Paulo, Sch Med, Dept Neurol, Av Dr 15 Eneas Carvalho Aguiar, BR-05403000 Sao Paulo, SP, Brazil.	rnitrini@uol.com.br	Nascimento, Camila/ABC-6200-2020; Naslavsky, Michel/U-6595-2019; Amaro, Edson/B-6653-2009; Nitrini, Ricardo/B-8703-2013; Naslavsky, Michel S/L-1772-2015; Takada, Leonel/H-7124-2013	Nascimento, Camila/0000-0002-8170-7635; Naslavsky, Michel/0000-0002-9068-1713; Amaro, Edson/0000-0002-5889-1382; Nitrini, Ricardo/0000-0002-5721-1525; Naslavsky, Michel S/0000-0002-9068-1713; Takada, Leonel/0000-0002-0121-9253	University of Sao Paulo Medical School [LIM-22];  [NIH P01-AG1972403];  [P50-AG023501]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG040311, P50AG023501] Funding Source: NIH RePORTER	The authors thank the patient's family for the brain donation and the Brazilian Brain Bank. We also thank Dr. Custodio M. Ribeiro for his help during patient's terminal illness, and Dr. Daniel Perl and Dr. Ann McKee for reviewing the neuropathological slides. LTG is supported by institutional grants NIH P01-AG1972403 and P50-AG023501. This study received funding from LIM-22, University of Sao Paulo Medical School.	Amador-Ortiz C, 2007, ANN NEUROL, V61, P435, DOI 10.1002/ana.21154; Bellini G, 2015, BELLINI 1 CAPIT CAMP; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Carthery-Goulart MT, 2009, REV SAUDE PUBL, V43, P631, DOI 10.1590/S0034-89102009005000031; Fredericks Carolyn A, 2015, Neurol Clin Pract, V5, P475; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Hales C, 2014, NEUROLOGY, V83, P2307, DOI 10.1212/WNL.0000000000001081; Junge A, 2015, BRIT J SPORT MED, V49, P599, DOI 10.1136/bjsports-2014-094469; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Koerte IK, 2016, BRAIN IMAGING BEHAV, V10, P792, DOI 10.1007/s11682-015-9442-0; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Nelson PT, 2013, ACTA NEUROPATHOL, V126, P161, DOI 10.1007/s00401-013-1154-1; Schneider JA, 2007, NEUROLOGY, V69, P2197, DOI 10.1212/01.wnl.0000271090.28148.24; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364	24	25	26	2	29	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	54	1					169	174		10.3233/JAD-160312			6	Neurosciences	Neurosciences & Neurology	DW7NS	WOS:000383838400017	27472879	Green Accepted			2021-06-18	
J	Huang, MX; Risling, M; Baker, DG				Huang, Mingxiong; Risling, Marten; Baker, Dewleen G.			The role of biomarkers and MEG-based imaging markers in the diagnosis of post-traumatic stress disorder and blast-induced mild traumatic brain injury	PSYCHONEUROENDOCRINOLOGY			English	Article						Traumatic brain injury (TBI); Blast; Concussion; PTSD; Magnetoencephalogram; Diffusion tensor imaging (DTI); Military; Veteran	DIFFUSE AXONAL INJURY; OPERATION IRAQI FREEDOM; HEAD-INJURY; WAR VETERANS; DELTA WAVES; MILITARY PERSONNEL; BLOOD-FLOW; PTSD; ENCEPHALOPATHY; SYMPTOMS	Background: Pervasive use of improvised explosive devices (IEDs), rocket-propelled grenades, and land mines in the recent conflicts in Iraq and Afghanistan has brought traumatic brain injury (TBI) and its impact on health outcomes into public awareness. Blast injuries have been deemed signature wounds of these wars. War-related TBI is not new, having become prevalent during WWI and remaining medically relevant in WWII and beyond. Medicine's past attempts to accurately diagnose and disentangle the pathophysiology of war-related TBI parallels current lines of inquiry and highlights limitations in methodology and attribution of symptom etiology, be it organic, psychological, or behavioral. New approaches and biomarkers are needed. Preclinical: Serological biomarkers and biomarkers of injury obtained with imaging techniques represent cornerstones in the translation between experimental data and clinical observations. Experimental models for blast related TBI and PTSD can generate critical data on injury threshold, for example for white matter injury from acceleration. Carefully verified and validated models can be evaluated with gene expression arrays and proteomics to identify new candidates for serological biomarkers. Such models can also be analyzed with diffusion MRI and microscopy in order to identify criteria for detection of diffuse white matter injuries, such as DAI (diffuse axonal injury). The experimental models can also be analyzed with focus on injury outcome in brain stem regions, such as locus coeruleus or nucleus raphe magnus that can be involved in response to anxiety changes. Clinical: Mild (and some moderate) TBI can be difficult to diagnose because the injuries are often not detectable on conventional MRI or CT. There is accumulating evidence that injured brain tissues in TBI patients generate abnormal low-frequency magnetic activity (ALFMA, peaked at 1-4 Hz) that can be measured and localized by magnetoencephalography (MEG). MEG imaging detects TBI abnormalities at the rates of 87% for the mild TBI, group (blast-induced plus non-blast causes) and 100% for the moderate group. Among the mild TBI patients, the rates of abnormalities are 96% and 77% for the blast and non-blast TBI groups, respectively. There is emerging evidence based on fMRI and MEG studies showing hyper-activity in the amygdala and hypo-activity in prefrontal cortex in individuals with PTSD. MEG signal may serve as a sensitive imaging marker for mTBI, distinguishable from abnormalities generated in association with PTSD. More work is needed to fully describe physiological mechanisms of post-concussive symptoms. Published by Elsevier Ltd.	[Huang, Mingxiong] VA San Diego Healthcare Syst, Serv Radiol, San Diego, CA USA; [Huang, Mingxiong] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Huang, Mingxiong] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA; [Risling, Marten] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Baker, Dewleen G.] Vet Affairs Ctr Excellence Stress & Mental Hlth C, San Diego, CA USA; [Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA	Huang, MX (corresponding author), UCSD Radiol Imaging Lab, San Diego, CA 92121 USA.	mxhuang@ucsd.edu	Baker, Dewleen/O-4957-2019	Baker, Dewleen/0000-0002-1736-9838	Veterans Affairs Health Service Research and Development [SDR 09-0128]; Department of Veterans AffairsUS Department of Veterans Affairs [101-CX000499, NURC-022-10F]; VA Center of Excellence for Stress and Mental Health San Diego, CA, USA; Swedish Defense FoT Research; Veterans AffairsUS Department of Veterans Affairs [I01CX000499] Funding Source: NIH RePORTER	We gratefully acknowledge the fiscal support for our work. Acknowledgements include Veterans Affairs Health Service Research and Development project SDR 09-0128 (DGB), the Marine Corps (MXH, DGB), and the Navy Bureau of Medicine and Surgery (MXH, DGB), Merit Review Grants from the Department of Veterans Affairs (MXH, DGB, 101-CX000499, NURC-022-10F) as well as support of the VA Center of Excellence for Stress and Mental Health San Diego, CA, USA (DGB) and the Swedish Defense FoT Research funding program. We also thank the anonymous reviewers' constructive suggestions that substantially strengthen this study.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Agoston Denes V, 2012, Front Neurol, V3, P3, DOI 10.3389/fneur.2012.00003; Anderson AK, 2003, J NEUROSCI, V23, P5627; [Anonymous], 2007, LANCET, V370, P1879; Baayen JC, 2003, BRAIN TOPOGR, V16, P85, DOI 10.1023/B:BRAT.0000006332.71345.b7; Baker DG, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110134; BALL GJ, 1977, ELECTROEN CLIN NEURO, V43, P346, DOI 10.1016/0013-4694(77)90258-9; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Baxter D, 2013, ANN NEUROL, V74, P527, DOI 10.1002/ana.23958; Bigler ED, 2004, STUD NEUROPSYCHOL DE, P71; Birnie M, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-303; Bryant RA, 2005, BIOL PSYCHIAT, V58, P111, DOI 10.1016/j.biopsych.2005.03.021; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; CELANDER H, 1955, ACTA PHYSIOL SCAND, V33, P6, DOI 10.1111/j.1748-1716.1955.tb01188.x; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chung YA, 2006, CLIN NEUROPHYSIOL, V117, P637, DOI 10.1016/j.clinph.2005.10.020; Clemedson C.J., 1949, ACTA PHYSL SCAND S61, V18; CLEMEDSON CARL-JOHAN, 1955, JOUR AVIATION MED, V26, P373; Corcoran KA, 2001, J NEUROSCI, V21, P1720; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; de Jongh A, 2003, NEUROIMAGE, V20, P2291, DOI 10.1016/j.neuroimage.2003.07.030; de Kloet CS, 2006, J PSYCHIATR RES, V40, P550, DOI 10.1016/j.jpsychires.2005.08.002; DECKER DA, 1972, ELECTROEN CLIN NEURO, V33, P303, DOI 10.1016/0013-4694(72)90157-5; Dolcos F, 2004, NEURON, V42, P855, DOI 10.1016/S0896-6273(04)00289-2; Eulion JF, 1942, NEW ENGL J MED, V226, P1; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goldstein LE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0064-3; Gunther M., 2015, ACTA NEUROCHIR WIEN; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hoffman SW, 2009, CLIN NEUROPSYCHOL, V23, P1400, DOI 10.1080/13854040903369433; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2014, JAMA-J AM MED ASSOC, V312, P1685, DOI 10.1001/jama.2014.6670; Hoge CW, 2011, NEW ENGL J MED, V365, P860, DOI 10.1056/NEJMc1107891; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2014, NEUROIMAGE, V84, P585, DOI 10.1016/j.neuroimage.2013.09.022; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hughes KC, 2011, EXPERT REV NEUROTHER, V11, P275, DOI [10.1586/ern.10.198, 10.1586/ERN.10.198]; Jacobo A-M, 2014, INT J AUTOMOTIVE ENG, V5, P31; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Jin C., 2013, P 4 INT SC WORKSH DA, P1, DOI DOI 10.1109/MWSYM.2013.6697734; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kamnaksh A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04809; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kawa L, 2015, J NEUROTRAUM, V32, P1190, DOI 10.1089/neu.2014.3669; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Krystal JH, 2009, BRAIN RES, V1293, P13, DOI 10.1016/j.brainres.2009.03.044; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lakis N, 2013, NEUROL RES, V35, P290, DOI 10.1179/1743132813Y.0000000177; Leahy RM, 1998, ELECTROEN CLIN NEURO, V107, P159, DOI 10.1016/S0013-4694(98)00057-1; Lee KYK, 2011, NEUROIMAGE, V54, pS30, DOI 10.1016/j.neuroimage.2010.05.042; Lewine J D, 1995, Neuroimaging Clin N Am, V5, P575; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McFarlane AC, 2010, J AFFECT DISORDERS, V127, P365, DOI 10.1016/j.jad.2010.05.002; McGaugh JL, 2004, ANNU REV NEUROSCI, V27, P1, DOI 10.1146/annurev.neuro.27.070203.144157; Myers CS, 1915, LANCET, V1, P316; NAGATA K, 1985, NEUROSURGERY, V17, P613, DOI 10.1227/00006123-198510000-00014; Naviaux RK, 2014, MITOCHONDRION, V16, P7, DOI 10.1016/j.mito.2013.08.006; O'Neil M.E., 2013, COMPLICATIONS MILD T; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL., 1998, CNS SPECTRUMS, V3, P30, DOI [10.1017/S1092852900007306, DOI 10.1017/S1092852900007306]; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Roitman P, 2013, J TRAUMA STRESS, V26, P727, DOI 10.1002/jts.21862; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Schaul N, 1998, ELECTROEN CLIN NEURO, V106, P101, DOI 10.1016/S0013-4694(97)00111-9; SCHAUL N, 1978, BRAIN RES, V143, P475, DOI 10.1016/0006-8993(78)90358-X; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seifman MA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00237; Selden NR, 1998, BRAIN, V121, P2249, DOI 10.1093/brain/121.12.2249; Semple WE, 2000, PSYCHIATRY, V63, P65, DOI 10.1080/00332747.2000.11024895; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83; Shin LM, 2004, HIPPOCAMPUS, V14, P292, DOI 10.1002/hipo.10183; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; TEASDALE G, 1974, LANCET, V2, P81; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; van Liempt S, 2013, PSYCHONEUROENDOCRINO, V38, P155, DOI 10.1016/j.psyneuen.2012.05.015; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vieth JB, 1996, BRAIN TOPOGR, V8, P215, DOI 10.1007/BF01184772; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yan XD, 2013, NEUROSCI LETT, V547, P1, DOI 10.1016/j.neulet.2013.04.032; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	107	25	26	0	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4530			PSYCHONEUROENDOCRINO	Psychoneuroendocrinology	JAN	2016	63						398	409		10.1016/j.psyneuen.2015.02.008			12	Endocrinology & Metabolism; Neurosciences; Psychiatry	Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry	CZ9MT	WOS:000367422400050	25769625				2021-06-18	
J	Karve, IP; Zhang, M; Habgood, M; Frugier, T; Brody, KM; Sashindranath, M; Ek, CJ; Chappaz, S; Kile, B; Wright, D; Wang, H; Johnston, L; Daglas, M; Ates, RC; Medcalf, RL; Taylor, JM; Crack, PJ				Karve, Ila P.; Zhang, Moses; Habgood, Mark; Frugier, Tony; Brody, Kate M.; Sashindranath, Maithili; Ek, C. Joakim; Chappaz, Stephane; Kile, Ben T.; Wright, David; Wang, Hong; Johnston, Leigh; Daglas, Maria; Ates, Robert C.; Medcalf, Robert L.; Taylor, Juliet M.; Crack, Peter J.			Ablation of Type-1 IFN Signaling in Hematopoietic Cells Confers Protection Following Traumatic Brain Injury	ENEURO			English	Article						neuroinflammation; traumatic brain injury; type-1 interferon	PROINFLAMMATORY CYTOKINE; INFLAMMATORY RESPONSE; POSITIVE FEEDBACK; INTERFERON-ALPHA; WHITE-MATTER; SPINAL-CORD; ACTIVATION; EXPRESSION; ASTROCYTES; MOUSE	Type-1 interferons (IFNs) are pleiotropic cytokines that signal through the type-1 IFN receptor (IFNAR1). Recent literature has implicated the type-1 IFNs in disorders of the CNS. In this study, we have investigated the role of type-1 IFNs in neuroinflammation following traumatic brain injury (TBI). Using a controlled cortical impact model, TBI was induced in 8-to 10-week-old male C57BL/6J WT and IFNAR1(-/-) mice and brains were excised to study infarct volume, inflammatory mediator release via quantitative PCR analysis and immune cell profile via immunohistochemistry. IFNAR1(-/-) mice displayed smaller infarcts compared with WT mice after TBI. IFNAR1(-/-) mice exhibited an altered anti-inflammatory environment compared with WT mice, with significantly reduced levels of the proinflammatory mediators TNF alpha, IL-1 beta and IL-6, an up-regulation of the anti-inflammatory mediator IL-10 and an increased activation of resident and peripheral immune cells after TBI. WT mice injected intravenously with an anti-IFNAR1 blocking monoclonal antibody (MAR1) 1 h before, 30 min after or 30 min and 2 d after TBI displayed significantly improved histological and behavioral outcome. Bone marrow chimeras demonstrated that the hematopoietic cells are a peripheral source of type-1 IFNs that drives neuroinflammation and a worsened TBI outcome. Type-1 IFN mRNA levels were confirmed to be significantly altered in human postmortem TBI brains. Together, these data demonstrate that type-1 IFN signaling is a critical pathway in the progression of neuroinflammation and presents a viable therapeutic target for the treatment of TBI.	[Karve, Ila P.; Zhang, Moses; Habgood, Mark; Frugier, Tony; Brody, Kate M.; Ek, C. Joakim; Ates, Robert C.; Taylor, Juliet M.; Crack, Peter J.] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic 3010, Australia; [Sashindranath, Maithili; Daglas, Maria; Medcalf, Robert L.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; [Chappaz, Stephane; Kile, Ben T.] Walter & Eliza Hall Inst Med Res, ACRF Chem Biol Div, Parkville, Vic 3052, Australia; [Wright, David; Wang, Hong; Johnston, Leigh] Florey Inst Neurosci & Mental Hlth, Florey Imaging, Parkville, Vic 3052, Australia	Crack, PJ (corresponding author), Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic 3010, Australia.	pcrack@unimelb.edu.au	Kile, Benjamin T/F-6593-2011; Crack, Peter/ABE-2065-2020; Medcalf, Robert L/E-9632-2011; Sashindranath, Maithili/AAI-7408-2021; Johnston, Leigh A/D-7102-2014	Kile, Benjamin T/0000-0002-8836-8947; Crack, Peter/0000-0002-5030-0330; Sashindranath, Maithili/0000-0002-9712-4784; Johnston, Leigh A/0000-0002-5032-4674; Chappaz, Stephane/0000-0003-0574-7544; Wright, David/0000-0002-7535-8651; Brody, Kate/0000-0003-0884-8893; Frugier, Tony/0000-0002-1275-5158	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [628391, 1044714]; Australian Research CouncilAustralian Research Council; Rebecca Cooper Foundation	This work was supported by National Health and Medical Research Council of Australia Project Grant 628391 (PJC) and Project Grant 1044714 (PJC, JMT), an Australian Research Council Future Fellowship (PJC) and the Rebecca Cooper Foundation.	Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Chen ZH, 2012, J NEUROSCI, V32, P11706, DOI 10.1523/JNEUROSCI.0730-12.2012; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Crack PJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-37; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Dai PH, 2011, J VIROL, V85, P10814, DOI 10.1128/JVI.00104-11; de Weerd NA, 2007, J BIOL CHEM, V282, P20053, DOI 10.1074/jbc.R700006200; Downes CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057948; Field R, 2010, BRAIN BEHAV IMMUN, V24, P996, DOI 10.1016/j.bbi.2010.04.004; Frugier T, 2012, J NEUROPATH EXP NEUR, V71, P242, DOI 10.1097/NEN.0b013e3182496149; Frugier T, 2011, CELL MOL NEUROBIOL, V31, P569, DOI 10.1007/s10571-011-9650-0; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Fukuda S, 1996, HUM MUTAT, V7, P123, DOI 10.1002/(SICI)1098-1004(1996)7:2<123::AID-HUMU6>3.3.CO;2-V; Gough DJ, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000361; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Henry T, 2007, J EXP MED, V204, P987, DOI 10.1084/jem.20062665; Honda K, 2005, INT IMMUNOL, V17, P1367, DOI 10.1093/intimm/dxh318; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Khorooshi R, 2010, J IMMUNOL, V185, P1258, DOI 10.4049/jimmunol.0901753; Kim KK, 2009, J BIOL CHEM, V284, P31052, DOI 10.1074/jbc.M109.052969; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Li P, 2011, BLOOD, V117, P2847, DOI 10.1182/blood-2010-07-294272; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Mikita J, 2011, MULT SCLER J, V17, P2, DOI 10.1177/1352458510379243; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Paintlia MK, 2013, J BIOL CHEM, V288, P3831, DOI 10.1074/jbc.M112.405654; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Taylor JM, 2014, NEUROBIOL AGING, V35, P1012, DOI 10.1016/j.neurobiolaging.2013.10.089; Terai K, 2001, BRAIN RES, V900, P48, DOI 10.1016/S0006-8993(01)02202-8; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang RG, 2011, GLIA, V59, P946, DOI 10.1002/glia.21167; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Yu YJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002230; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012	49	25	25	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	2373-2822			ENEURO	eNeuro	JAN-FEB	2016	3	1								10.1523/ENEURO.0128-15.2016			18	Neurosciences	Neurosciences & Neurology	EH7AS	WOS:000391925700016	27022620	DOAJ Gold, Green Published			2021-06-18	
J	Krause-Titz, UR; Warneke, N; Freitag-Wolf, S; Barth, H; Mehdorn, HM				Krause-Titz, U. R.; Warneke, N.; Freitag-Wolf, S.; Barth, H.; Mehdorn, H. M.			Factors influencing the outcome (GOS) in reconstructive cranioplasty	NEUROSURGICAL REVIEW			English	Article						Cranioplasty; Complications; Glasgow Outcome Scale; Hydrocephalus; Seizures; Decompressive craniectomy	CEREBRAL-ARTERY INFARCTION; DECOMPRESSIVE CRANIECTOMY; BRAIN-INJURY; BLOOD-FLOW; HEMICRANIECTOMY; RISK; HYDROCEPHALUS; MULTICENTER; EPILEPSY; SEIZURES	After performing a decompressive craniectomy, a cranioplastic surgery is usually warranted. The complications of this reconstructive procedure may differ from the initial operation. The authors of this study report on their experience to define patient-specific and procedural risk factors for possible complications following cranioplasty influencing the outcome (Glasgow Outcome Scale (GOS)), mobility, shunt dependency, and seizures. A retrospective analysis of 263 patients of all ages and both sexes who had undergone cranioplasty after craniectomy for traumatic brain injury (including chronic subdural hematoma), subarachnoidal hemorrhage (including intracerebral hemorrhage), ischemic stroke, and tumor surgery in one single center in 12 years from January 2000 to March 2012 has been carried out. A multiple logistic regression analysis was performed to identify potential risk factors (age, gender, used cranioplasty material, initial diagnosis, clipped or coil-embolized subarachnoidal hemorrhage (SAH) patients, time interval, complications especially hydrocephalus and seizures, mobility) upon the prognosis described as a dichotomized Glasgow Outcome Scale. Two hundred forty-eight patients met the study criteria. The overall complication rate after cranioplastic surgery was 18.5 % (46 patients). Complications included: surgical site infection, epidural hematoma, hydrocephalus with or without former SAH, and new-onset seizures. Logistic regression analysis identified significant correlation between a low GOS (2 or 3) and postoperative seizures (OR 2.37, CI 1.35-4.18, p < 0.05), shunt-depending hydrocephalus (OR 5.83, CI 3.06-11.11, p < 0.05), and age between 51 and 70 years (OR 2.4, 95 % CI 1.09-5.29, p = 0.029). However, gender, time interval between craniectomy and cranioplasty, initial diagnosis, and used cranioplasty material had no significant influence on post-cranioplasty complications as surgical site infections, hematoma, wound healing disturbance, seizures, or hydrocephalus. Evaluation of treatment modality in aneurysmal SAH clip vs. coil showed no significant relation to postoperative complications either. Complications after cranioplastic surgery are a common problem, as prognostic factors could identify a shunt-depending hydrocephalus and epilepsia to develop a major deficit after cranioplastic surgery (GOS 2 or 3). We detected a significant extra risk of people between the age of 51 and 70 years to end up in GOS level 2 or 3.	[Krause-Titz, U. R.; Barth, H.; Mehdorn, H. M.] UKSH, Dept Neurosurg, D-24105 Kiel, Germany; [Warneke, N.] Univ Hosp Munster, Dept Neurosurg, D-48149 Munster, Germany; [Freitag-Wolf, S.] UKSH, Inst Med Informat & Stat, D-24105 Kiel, Germany	Krause-Titz, UR (corresponding author), UKSH, Dept Neurosurg, Campus Kiel,Arnold Heller Str 3,Haus 41, D-24105 Kiel, Germany.	ricklef@web.de					Al-Tamimi YZ, 2012, BRIT J NEUROSURG, V26, P510, DOI 10.3109/02688697.2011.633640; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Butzkueven H, 2000, NEUROLOGY, V55, P1315, DOI 10.1212/WNL.55.9.1315; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chiang HY, 2011, J NEUROSURG, V114, P1746, DOI 10.3171/2011.1.JNS10782; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; ERCULEI F, 1963, J NEUROSURG, V20, P1085, DOI 10.3171/jns.1963.20.12.1085; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; GRANTHAM EG, 1948, J NEUROSURG, V5, P19, DOI 10.3171/jns.1948.5.1.0019; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Hettige S, 2012, ACTA NEUROCHIR, V154, P1725, DOI 10.1007/s00701-012-1429-7; Hill CS, 2012, BRIT J NEUROSURG, V26, P832, DOI 10.3109/02688697.2012.692839; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; JENNETT B, 1975, LANCET, V1, P480; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kim BJ, 2012, J KOREAN NEUROSURG S, V52, P541, DOI 10.3340/jkns.2012.52.6.541; Kolakowsky-Hayner SA, 2013, BRAIN INJURY, V27, P578, DOI 10.3109/02699052.2013.765595; KONIG F, 1890, ZENTRALBL CHIR, V17, P497; Kreider GN, 1920, J AMER MED ASSOC, V74, P1024, DOI 10.1001/jama.1920.26210150001013; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; MARIE P, 1916, SOC CHIR PARIS B MEM, V42, P1608; Nievas MNCY, 2006, NEUROL RES, V28, P139, DOI 10.1179/016164106X98008; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Rahme R, 2012, J NEUROSURG, V117, P749, DOI 10.3171/2012.6.JNS111140; Rahme R, 2010, NEUROSURGERY, V67, P675, DOI 10.1227/01.NEU.0000383142.10103.0B; Rankin J, 1957, SCOTT MED J, V5; Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Thesleff T, 2011, NEUROSURGERY, V68, P1535, DOI 10.1227/NEU.0b013e31820ee24e; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Woolf JI, 1945, INT ABSTR SURG, V81, P1; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547; Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166	45	25	29	0	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JAN	2016	39	1					133	139		10.1007/s10143-015-0678-3			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DA5AL	WOS:000367814400028	26621678				2021-06-18	
J	Nikolakopoulou, AM; Koeppen, J; Garcia, M; Leish, J; Obenaus, A; Ethell, IM				Nikolakopoulou, Angeliki M.; Koeppen, Jordan; Garcia, Michael; Leish, Joshua; Obenaus, Andre; Ethell, Iryna M.			Astrocytic Ephrin-B1 Regulates Synapse Remodeling Following Traumatic Brain Injury	ASN NEURO			English	Article						astrocytes; hippocampus; ephrinB1; STAT3; synapse; traumatic brain injury	DENDRITIC SPINE MORPHOGENESIS; RECEPTOR TYROSINE KINASES; CENTRAL-NERVOUS-SYSTEM; EPHB RECEPTORS; REACTIVE ASTROCYTES; CORD-INJURY; GLUTAMATE TRANSPORT; BINDING-PROTEIN; PLASTICITY; HIPPOCAMPUS	Traumatic brain injury (TBI) can result in tissue alterations distant from the site of the initial injury, which can trigger pathological changes within hippocampal circuits and are thought to contribute to long-term cognitive and neuropsychological impairments. However, our understanding of secondary injury mechanisms is limited. Astrocytes play an important role in brain repair after injury and astrocyte-mediated mechanisms that are implicated in synapse development are likely important in injury-induced synapse remodeling. Our studies suggest a new role of ephrin-B1, which is known to regulate synapse development in neurons, in astrocyte-mediated synapse remodeling following TBI. Indeed, we observed a transient upregulation of ephrin-B1 immunoreactivity in hippocampal astrocytes following moderate controlled cortical impact model of TBI. The upregulation of ephrin-B1 levels in hippocampal astrocytes coincided with a decline in the number of vGlut1-positive glutamatergic input to CA1 neurons at 3 days post injury even in the absence of hippocampal neuron loss. In contrast, tamoxifen-induced ablation of ephrin-B1 from adult astrocytes in ephrin-B1(loxP/y)ERT2-Cre(GFAP) mice accelerated the recovery of vGlut1-positive glutamatergic input to CA1 neurons after TBI. Finally, our studies suggest that astrocytic ephrin-B1 may play an active role in injury-induced synapse remodeling through the activation of STAT3-mediated signaling in astrocytes. TBI-induced upregulation of STAT3 phosphorylation within the hippocampus was suppressed by astrocyte-specific ablation of ephrin-B1 in vivo, whereas the activation of ephrin-B1 in astrocytes triggered an increase in STAT3 phosphorylation in vitro. Thus, regulation of ephrin-B1 signaling in astrocytes may provide new therapeutic opportunities to aid functional recovery after TBI.	[Nikolakopoulou, Angeliki M.; Koeppen, Jordan; Garcia, Michael; Leish, Joshua; Ethell, Iryna M.] Univ Calif Riverside, Sch Med, Div Biomed Sci, 900 Univ Ave, Riverside, CA 92521 USA; [Koeppen, Jordan; Ethell, Iryna M.] Univ Calif Riverside, Cell Mol & Dev Biol Grad Program, Riverside, CA 92521 USA; [Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA	Ethell, IM (corresponding author), Univ Calif Riverside, Sch Med, Div Biomed Sci, 900 Univ Ave, Riverside, CA 92521 USA.	iryna.ethell@ucr.edu		Nikolakopoulou, Angeliki/0000-0002-1621-4965; Koeppen, Jordan/0000-0002-8618-5792	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH67121]; NMSSNational Multiple Sclerosis Society [PP1903]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH067121] Funding Source: NIH RePORTER	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work was supported by MH67121 grant from NIMH (to I. M. E.) and PP1903 grant from NMSS (to A. M. N.).	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Atkins CM, 2011, TRANSL STROKE RES, V2, P546, DOI 10.1007/s12975-011-0123-z; Badaut J, 2011, CEREBROVASC DIS, V31, P521, DOI 10.1159/000324328; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Barker AJ, 2008, J NEUROSCI, V28, P8150, DOI 10.1523/JNEUROSCI.1744-08.2008; Barthet G, 2013, NEUROBIOL AGING, V34, P499, DOI 10.1016/j.neurobiolaging.2012.02.024; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Bong YS, 2007, P NATL ACAD SCI USA, V104, P17305, DOI 10.1073/pnas.0702337104; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Brown CE, 2008, NEUROSCIENTIST, V14, P139, DOI 10.1177/1073858407309854; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Carmona MA, 2009, P NATL ACAD SCI USA, V106, P12524, DOI 10.1073/pnas.0903328106; Catchpole T, 2011, J NEUROSCI, V31, P11472, DOI 10.1523/JNEUROSCI.6349-10.2011; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Cibert-Goton V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053673; Cisse M, 2011, NATURE, V469, P47, DOI 10.1038/nature09635; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; Contractor A, 2002, SCIENCE, V296, P1864, DOI 10.1126/science.1069081; Coulthard MG, 2012, AM J PATHOL, V181, P1493, DOI 10.1016/j.ajpath.2012.06.043; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Du J, 2007, CURR PHARM DESIGN, V13, P2507; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Ethell IM, 2005, PROG NEUROBIOL, V75, P161, DOI 10.1016/j.pneurobio.2005.02.003; Ethell IM, 2001, NEURON, V31, P1001, DOI 10.1016/S0896-6273(01)00440-8; Filosa A, 2009, NAT NEUROSCI, V12, P1285, DOI 10.1038/nn.2394; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Georgakopoulos A, 2011, FASEB J, V25, P3594, DOI 10.1096/fj.11-187856; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goldshmit Y, 2006, BRAIN RES REV, V52, P327, DOI 10.1016/j.brainresrev.2006.04.006; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Grunwald IC, 2004, NAT NEUROSCI, V7, P33, DOI 10.1038/nn1164; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Henderson JT, 2001, NEURON, V32, P1041, DOI 10.1016/S0896-6273(01)00553-0; Henkemeyer M, 2003, J CELL BIOL, V163, P1313, DOI 10.1083/jcb.200306033; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hoogenraad CC, 2005, NAT NEUROSCI, V8, P906, DOI 10.1038/nn1487; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; INNOCENTI GM, 1995, NEUROPSYCHOLOGIA, V33, P961, DOI 10.1016/0028-3932(95)00033-Y; Ito U, 2006, STROKE, V37, P2134, DOI 10.1161/01.STR.0000231875.96714.b1; Kayser MS, 2006, J NEUROSCI, V26, P12152, DOI 10.1523/JNEUROSCI.3072-06.2006; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lauterbach J, 2006, J NEUROSCI, V26, P11575, DOI 10.1523/JNEUROSCI.2697-06.2006; Li SL, 2006, NEUROBIOL DIS, V23, P362, DOI 10.1016/j.nbd.2006.03.011; Lin KT, 2008, J BIOL CHEM, V283, P28969, DOI 10.1074/jbc.M804401200; Liu X, 2006, J NEUROSCI, V26, P3087, DOI 10.1523/JNEUROSCI.4797-05.2006; Luria V, 2008, NEURON, V60, P1039, DOI 10.1016/j.neuron.2008.11.011; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marston DJ, 2003, NAT CELL BIOL, V5, P879, DOI 10.1038/ncb1044; Mendes SW, 2006, J NEUROSCI, V26, P882, DOI 10.1523/JNEUROSCI.3162-05.2006; Moeller ML, 2006, J BIOL CHEM, V281, P1587, DOI 10.1074/jbc.M511756200; Mostany R, 2010, J NEUROSCI, V30, P14116, DOI 10.1523/JNEUROSCI.3908-10.2010; Murai KK, 2011, GLIA, V59, P1567, DOI 10.1002/glia.21226; Murai KK, 2003, NAT NEUROSCI, V6, P153, DOI 10.1038/nn994; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nolt MJ, 2011, J NEUROSCI, V31, P5353, DOI 10.1523/JNEUROSCI.0282-11.2011; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; O'Callaghan JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102003; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Overman JJ, 2012, P NATL ACAD SCI USA, V109, pE2230, DOI 10.1073/pnas.1204386109; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Parker M, 2004, BIOCHEM BIOPH RES CO, V323, P17, DOI 10.1016/j.bbrc.2004.07.209; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Petros TJ, 2009, J NEUROSCI, V29, P3463, DOI 10.1523/JNEUROSCI.5655-08.2009; Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008; Ren Z, 2013, NEUROSCIENCE, V241, P89, DOI 10.1016/j.neuroscience.2013.03.010; Sanders SJ, 2012, NATURE, V485, P237, DOI 10.1038/nature10945; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Segura I, 2007, NAT NEUROSCI, V10, P301, DOI 10.1038/nn1858; Shen XF, 2013, INT J MOL SCI, V14, P21598, DOI 10.3390/ijms141121598; Shields J, 2011, TRANSL STROKE RES, V2, P633, DOI 10.1007/s12975-011-0129-6; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Srivastava N, 2013, MOL CELL NEUROSCI, V52, P106, DOI 10.1016/j.mcn.2012.11.003; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Tyzack GE, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5294; Van Hoecke A, 2012, NAT MED, V18, P1418, DOI 10.1038/nm.2901; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wang Y, 2005, EUR J NEUROSCI, V21, P2336, DOI 10.1111/j.1460-9568.2005.04093.x; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Xu NJ, 2012, SEMIN CELL DEV BIOL, V23, P58, DOI 10.1016/j.semcdb.2011.10.024; Xu NJ, 2009, NAT NEUROSCI, V12, P268, DOI 10.1038/nn.2254; Yu Z, 2010, J NEUROPHYSIOL, V103, P499, DOI 10.1152/jn.00775.2009; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045	92	25	25	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1759-0914			ASN NEURO	ASN Neuro	JAN-FEB	2016	8	1							1759091416630220	10.1177/1759091416630220			18	Neurosciences	Neurosciences & Neurology	DF8VR	WOS:000371639000001	26928051	DOAJ Gold, Green Published			2021-06-18	
J	Park, JH; Park, YS; Lee, JB; Park, KH; Paik, MK; Jeong, M; Koh, HC				Park, Jae Hyeon; Park, Youn Sun; Lee, Je-Bong; Park, Kyung-Hun; Paik, Min-kyoung; Jeong, Mihye; Koh, Hyun Chul			Meloxicam inhibits fipronil-induced apoptosis via modulation of the oxidative stress and inflammatory response in SH-SY5Y cells	JOURNAL OF APPLIED TOXICOLOGY			English	Article						fipronil; cyclooxygenase-2; p53; meloxicam; anti-inflammatory; antioxidant	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; TRAUMATIC BRAIN-INJURY; DOPAMINERGIC-NEURONS; NUCLEAR TRANSLOCATION; PARKINSONS-DISEASE; BAX TRANSLOCATION; INDUCED ARTHRITIS; COX-2 EXPRESSION; KINASE PATHWAYS	Oxidative stress and inflammatory responses have been identified as key elements of neuronal cell apoptosis. In this study, we investigated the mechanisms by which inflammatory responses contribute to apoptosis in human neuroblastoma SH-SY5Y cells treated with fipronil (FPN). Based on the cytotoxic mechanism of FPN, we examined the neuroprotective effects of meloxicam against FPN-induced neuronal cell death. Treatment of SH-SY5Y cells with FPN induced apoptosis via activation of caspase-9 and -3, leading to nuclear condensation. In addition, FPN induced oxidative stress and increased expression of cyclooxygenase-2 (COX-2) and tumor necrosis factor- (TNF-) via inflammatory stimulation. Pretreatment of cells with meloxicam enhanced the viability of FPN-exposed cells through attenuation of oxidative stress and inflammatory response. FPN activated mitogen activated protein kinase (MAPK) and inhibitors of MAPK abolished FPN-induced COX-2 expression. Meloxicam also attenuated FPN-induced cell death by reducing MAPK-mediated pro-inflammatory factors. Furthermore, we observed both nuclear accumulation of p53 and enhanced levels of cytosolic p53 in a concentration-dependent manner after FPN treatment. Pretreatment of cells with meloxicam blocked the translocation of p53 from the cytosol to the nucleus. Together, these data suggest that meloxicam may exert anti-apoptotic effects against FPN-induced cytotoxicity by both attenuating oxidative stress and inhibiting the inflammatory cascade via inactivation of MAPK and p53 signaling. Copyright (c) 2015 John Wiley & Sons, Ltd. Oxidative stress and inflammatory responses have been identified as key elements of neuronal cell apoptosis. In this study, we investigated the mechanisms by which inflammatory responses contribute to apoptosis in human neuroblastoma SH-SY5Y cells treated with fipronil (FPN). Based on the cytotoxic mechanism of FPN, we examined the neuroprotective effects of meloxicam against FPN-induced neuronal cell death.	[Park, Jae Hyeon; Park, Youn Sun; Koh, Hyun Chul] Hanyang Univ, Coll Med, Dept Pharmacol, Seoul 133791, South Korea; [Park, Jae Hyeon; Park, Youn Sun; Koh, Hyun Chul] Hanyang Biomed Res Inst, Seoul, South Korea; [Park, Jae Hyeon; Koh, Hyun Chul] Hanyang Univ, Grad Sch Biomed Sci & Engn, Seoul 133791, South Korea; [Lee, Je-Bong; Park, Kyung-Hun; Paik, Min-kyoung; Jeong, Mihye] Natl Acad Agr Sci, Rural Dev Adm, Dept Agrofood Safety, Suwon, South Korea	Koh, HC (corresponding author), Hanyang Univ, Coll Med, Dept Pharmacol, Heandang Dong 17, Seoul 133791, South Korea.	mhjeong@korea.kr; hckoh@hanyang.ac.kr			Agenda Program, Rural Development Administration, Republic of KoreaRural Development Administration (RDA) [PJ008582]	This work was supported by a grant from the Agenda Program (PJ008582), Rural Development Administration, Republic of Korea.	Agha AM, 1999, PHARMACOL RES, V40, P385, DOI 10.1006/phrs.1999.0522; Arafa HMM, 2007, EUR J PHARMACOL, V564, P181, DOI 10.1016/j.ejphar.2007.02.065; Baek BS, 2001, J GERONTOL A-BIOL, V56, pB426, DOI 10.1093/gerona/56.10.B426; Barbieri SS, 2003, CARDIOVASC RES, V60, P187, DOI 10.1016/S0008-6363(03)00365-1; Bedner E, 2000, CYTOMETRY, V41, P83, DOI 10.1002/1097-0320(20001001)41:2<83::AID-CYTO1>3.0.CO;2-R; Chen C, 2010, NAT CHEM BIOL, V6, P401, DOI 10.1038/nchembio.375; Chen ZX, 2009, J HUAZHONG U SCI-MED, V29, P383, DOI 10.1007/s11596-009-0324-9; Choi EM, 2005, BIOCHEM BIOPH RES CO, V328, P1107, DOI 10.1016/j.bbrc.2005.01.072; Cimen MYB, 2003, DRUG CHEM TOXICOL, V26, P169, DOI 10.1081/DCT-120022645; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; Das PC, 2006, CHEM-BIOL INTERACT, V164, P200, DOI 10.1016/j.cbi.2006.09.013; Edfawy M, 2012, INT J TOXICOL, V31, P276, DOI 10.1177/1091581812442939; Feng ZH, 2002, NEUROSCI LETT, V329, P354, DOI 10.1016/S0304-3940(02)00704-8; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gayle DA, 2002, DEV BRAIN RES, V133, P27, DOI 10.1016/S0165-3806(01)00315-7; Gomez-Santos C, 2002, BRAIN RES, V935, P32, DOI 10.1016/S0006-8993(02)02422-8; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Gurocak S, 2010, UROLOGY, V76, DOI 10.1016/j.urology.2010.03.040; Hakan T, 2010, NEUROL RES, V32, P629, DOI 10.1179/016164109X12464612122731; Hsuan SL, 2006, J NEUROSCI, V26, P4481, DOI 10.1523/JNEUROSCI.4922-05.2006; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Hunter RL, 2007, J NEUROCHEM, V100, P1375, DOI 10.1111/j.1471-4159.2006.04327.x; Jang JH, 2005, FREE RADICAL BIO MED, V38, P1604, DOI 10.1016/j.freeradbiomed.2005.02.023; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Ki YW, 2013, TOXICOL LETT, V218, P235, DOI 10.1016/j.toxlet.2013.02.003; Ki YW, 2012, TOXICOL LETT, V211, P18, DOI 10.1016/j.toxlet.2012.02.022; Kyaw M, 2001, HYPERTENS RES, V24, P251, DOI 10.1291/hypres.24.251; Leavy O, 2011, NAT REV IMMUNOL, V11, P162, DOI 10.1038/nri2943; Lee JE, 2011, TOXICOL LETT, V202, P133, DOI 10.1016/j.toxlet.2011.01.030; Lei XH, 2013, CNS NEUROSCI THER, V19, P109, DOI 10.1111/cns.12045; Leung WK, 2001, BRIT J CANCER, V84, P335, DOI 10.1054/bjoc.2000.1607; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Narita M, 2008, NEUROSCIENCE, V152, P477, DOI 10.1016/j.neuroscience.2007.10.039; Nieminen R, 2005, MEDIAT INFLAMM, P249, DOI 10.1155/MI.2005.249; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Overmyer JP, 2007, J ENVIRON SCI HEAL B, V42, P471, DOI 10.1080/03601230701391823; Park JH, 2013, TOXICOL LETT, V223, P25, DOI 10.1016/j.toxlet.2013.08.015; Ramesh G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/480739; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tasaki Y, 2010, BRAIN RES, V1344, P25, DOI 10.1016/j.brainres.2010.04.085; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Tingle CCD, 2003, REV ENVIRON CONTAM T, V176, P1; Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128; Vidau C, 2011, NEUROTOXICOLOGY, V32, P935, DOI 10.1016/j.neuro.2011.04.006; Vidau C, 2009, TOXICOL IN VITRO, V23, P589, DOI 10.1016/j.tiv.2009.01.017; Wen ZH, 2013, OSTEOARTHR CARTILAGE, V21, P1976, DOI 10.1016/j.joca.2013.09.005; Won JH, 2006, BRIT J PHARMACOL, V148, P216, DOI 10.1038/sj.bjp.0706718; Yamanishi Y, 2002, AM J PATHOL, V160, P123, DOI 10.1016/S0002-9440(10)64356-8; Yang W, 2010, TOXICOL LETT, V199, P239, DOI 10.1016/j.toxlet.2010.09.005; Yu CR, 2004, EXP CELL RES, V295, P555, DOI 10.1016/j.yexcr.2004.02.001	56	25	25	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0260-437X	1099-1263		J APPL TOXICOL	J. Appl. Toxicol.	JAN	2016	36	1					10	23		10.1002/jat.3136			14	Toxicology	Toxicology	CX6FF	WOS:000365795900002	25772694				2021-06-18	
J	Seal, KH; Bertenthal, D; Samuelson, K; Maguen, S; Kumar, S; Vasterling, JJ				Seal, Karen H.; Bertenthal, Daniel; Samuelson, Kristin; Maguen, Shira; Kumar, Sant; Vasterling, Jennifer J.			Association between mild traumatic brain injury and mental health problems and self-reported cognitive dysfunction in Iraq and Afghanistan Veterans	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						cognitive dysfunction; concussion; depression; mental health; mild traumatic brain injury; population-based screening; postdeployment; posttraumatic stress disorder; primary care; recovery expectations; Veterans	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; NEUROPSYCHOLOGICAL OUTCOMES; WAR VETERANS; HEAD-INJURY; COMPLAINTS; PERFORMANCE; DEPLOYMENT; SOLDIERS; CONSEQUENCES	The Department of Veterans Affairs traumatic brain injury (TBI) screening program is intended to detect and expedite treatment for TBI and postconcussive symptoms. Between April 14, 2007, and May 31, 2012, of 66,089 Iraq and Afghanistan Veterans who screened positive on first-level TBI screening and later completed comprehensive TBI evaluation that includes the Neurobehavioral Symptoms Inventory, 72% reported moderate to very severe cognitive impairment (problems with attention, concentration, memory, etc.) that interfered with daily activities. This included 42% who were found not to have sustained combat-related mild TBI (mTBI). In contrast, 70.0% received a posttraumatic stress disorder (PTSD) diagnosis and 45.8% received a depression diagnosis. Compared with Veterans without mTBI, PTSD, or depression diagnoses, the lowest risk for self-reported cognitive impairment was in Veterans with confirmed mTBI only; a greater risk was found in those with PTSD diagnoses, with the greatest risk in Veterans with PTSD, depression, and confirmed mTBI, suggesting only a weakly additive effect of mTBI. These findings suggest that Veterans with multiple mental health comorbidities, not just those with TBI, report moderate to very severe cognitive impahment. Mental health treatment for conditions such as PTSD and depression (with or without TBI) may result in improvements in cognitive functioning and/or include assessment and support for Veterans experiencing cognitive problems.	[Seal, Karen H.; Bertenthal, Daniel; Samuelson, Kristin; Maguen, Shira; Kumar, Sant] San Francisco Dept Vet Affairs VA Hlth Care Syst, San Francisco, CA USA; [Seal, Karen H.; Maguen, Shira] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Samuelson, Kristin] Alliant Int Univ, Calif Sch Profess Psychol, San Francisco, CA USA; [Vasterling, Jennifer J.] VA Boston Healthcare Syst, Boston, MA USA; [Vasterling, Jennifer J.] Boston Univ, Sch Med, Boston, MA 02118 USA	Seal, KH (corresponding author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A-1, San Francisco, CA 94121 USA.	Karen.Seal@va.gov		Kumar, Sant/0000-0001-5294-3682	VA Health Services Research and DevelopmentUS Department of Veterans Affairs [SDR-08-408]	This material was based on work supported by VA Health Services Research and Development (award SDR-08-408).	Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; French LM, 2014, J REHABIL RES DEV, V51, P933, DOI 10.1682/JRRD.2013.10.0226; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Hendricks AM, 2013, BRAIN INJURY, V27, P125, DOI 10.3109/02699052.2012.729284; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kang HK, 2000, J OCCUP ENVIRON MED, V42, P491, DOI 10.1097/00043764-200005000-00006; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maguen S, 2012, J REHABIL RES DEV, V49, P1115, DOI 10.1682/JRRD.2011.02.0015; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrea M, 2008, MILD TRAUMATIC BRAIN; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; OCONNOR DW, 1990, ARCH GEN PSYCHIAT, V47, P224; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Prouteau A, 2004, SCHIZOPHR RES, V69, P85, DOI 10.1016/j.schres.2003.08.011; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Tarrier N, 1999, J CONSULT CLIN PSYCH, V67, P13, DOI 10.1037/0022-006X.67.1.13; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tischler L, 2006, ANN NY ACAD SCI, V1071, P405, DOI 10.1196/annals.1364.031; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2009, J INT NEUROPSYCH SOC, V15, P826, DOI 10.1017/S1355617709990683; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2	41	25	25	0	20	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2016	53	2					185	198		10.1682/JRRD.2014.12.0301			14	Rehabilitation	Rehabilitation	DH4QX	WOS:000372771600002	27148692	Bronze			2021-06-18	
J	Shen, WB; Plachez, C; Tsymbalyuk, O; Tsymbalyuk, N; Xu, S; Smith, AM; Michel, SLJ; Yarnell, D; Mullins, R; Gullapalli, RP; Puche, A; Simard, JM; Fishman, PS; Yarowsky, P				Shen, Wei-Bin; Plachez, Celine; Tsymbalyuk, Orest; Tsymbalyuk, Natalya; Xu, Su; Smith, Aaron M.; Michel, Sarah L. J.; Yarnell, Deborah; Mullins, Roger; Gullapalli, Rao P.; Puche, Adam; Simard, J. Marc; Fishman, Paul S.; Yarowsky, Paul			Cell-Based Therapy in TBI: Magnetic Retention of Neural Stem Cells In Vivo	CELL TRANSPLANTATION			English	Article						Traumatic brain injury rat model; Stem cell transplantation; Magnetic stem cell retention; Human neuroprogenitor cells (hNPCs); Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles	TRAUMATIC BRAIN-INJURY; IRON-OXIDE NANOPARTICLES; FUNCTIONAL BENEFIT; IMAGING TRACKING; PROGENITOR CELLS; VASCULAR INJURY; TRANSPLANTATION; MODEL; DELIVERY; REPAIR	Stem cell therapy is under active investigation for traumatic brain injury (TBI). Noninvasive stem cell delivery is the preferred method, but retention of stem cells at the site of injury in TBI has proven challenging and impacts effectiveness. To investigate the effects of applying a magnetic field on cell homing and retention, we delivered human neuroprogenitor cells (hNPCs) labeled with a superparamagnetic nanoparticle into post-TBI animals in the presence of a static magnetic field. We have previously devised a method of loading hNPCs with ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles Molday ION Rhodamine B (MIRB (TM)). Labeling of hNPCs (MIRB-hNPCs) does not affect hNPC viability, proliferation, or differentiation. The 0.6 tesla (T) permanent magnet was placed similar to 4 mm above the injured parietal cortex prior to intracarotid injection of 4x 10(4) MIRB-hNPCs. Fluorescence imaging, Perls' Prussian blue histochemistry, immunocytochemistry with SC121, a human-specific antibody, and T2-weighted magnetic resonance imaging ex vivo revealed there was increased homing and retention of MIRB-hNPCs in the injured cortex as compared to the control group in which MIRB-hNPCs were injected in the absence of a static magnetic field. Fluoro-Jade C staining and immunolabeling with specific markers confirmed the viability status of MIRB-hNPCs posttransplantation. These results show that increased homing and retention of MIRB-hNPCs post-TBI by applying a static magnetic field is a promising technique to deliver cells into the CNS for treatment of neurological injuries and neurodegenerative diseases.	[Shen, Wei-Bin; Plachez, Celine; Yarowsky, Paul] Univ Maryland, Sch Med, Dept Pharmacol, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Tsymbalyuk, Orest; Tsymbalyuk, Natalya; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Xu, Su; Mullins, Roger; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol Nucl Med, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Smith, Aaron M.; Michel, Sarah L. J.] Univ Maryland, Sch Med, Dept Pharmaceut Sci, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Yarnell, Deborah; Yarowsky, Paul] VA Maryland Healthcare Syst, Res Serv, Baltimore, MD USA; [Puche, Adam] Univ Maryland, Sch Med, Dept Anat & Neurobiol, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Fishman, Paul S.] Univ Maryland, Sch Med, Dept Neurol, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Simard, J. Marc; Fishman, Paul S.] VA Maryland Healthcare Syst, Baltimore, MD USA; [Plachez, Celine] Hussman Inst Autism, Baltimore, MD USA	Yarowsky, P (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA.	pyarowsky@som.umaryland.edu		Mullins, Roger/0000-0002-0561-4402; Smith, Aaron/0000-0001-8864-1934; Plachez, Celine/0000-0002-5550-4316	Maryland Stem Cell Research Fund; US Department of Veterans AffairsUS Department of Veterans Affairs; US National Science FoundationNational Science Foundation (NSF) [1306208]	We acknowledge Dr Ernest Groman, BioPAL, for helpful discussions, and Dr. Stephan Vigues for graphics. This work was supported by grants from the Maryland Stem Cell Research Fund (P.Y.), the US Department of Veterans Affairs (P.S.F, P.Y.), and the US National Science Foundation (1306208, S.L.J.M.). The authors declare no conflicts of interest.	Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Arbab AS, 2004, HUM GENE THER, V15, P351, DOI 10.1089/104303404322959506; Arien-Zakay H, 2014, J NEUROTRAUM, V31, P1405, DOI 10.1089/neu.2013.3270; Auriat AM, 2011, TRANSL STROKE RES, V2, P250, DOI 10.1007/s12975-011-0093-1; Berman SMC, 2011, METHODS MOL BIOL, V711, P435, DOI 10.1007/978-1-61737-992-5_22; Brown GC, 2012, TRENDS BIOCHEM SCI, V37, P325, DOI 10.1016/j.tibs.2012.05.002; Carenza E, 2014, NANOMED-NANOTECHNOL, V10, P225, DOI 10.1016/j.nano.2013.06.005; Chen JL, 2013, ACS APPL MATER INTER, V5, P5976, DOI 10.1021/am400249n; Cheng K, 2012, CELL TRANSPLANT, V21, P1121, DOI 10.3727/096368911X627381; Chua JY, 2011, J CEREBR BLOOD F MET, V31, P1263, DOI 10.1038/jcbfm.2010.213; Cohen ME, 2010, J NEUROSCI RES, V88, P936, DOI 10.1002/jnr.22277; Crabbe A, 2010, CELL TRANSPLANT, V19, P919, DOI 10.3727/096368910X494623; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Gutova M, 2013, STEM CELL TRANSL MED, V2, P766, DOI 10.5966/sctm.2013-0049; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Janowski M, 2013, J CEREBR BLOOD F MET, V33, P921, DOI 10.1038/jcbfm.2013.32; Kamei G, 2013, AM J SPORT MED, V41, P1255, DOI 10.1177/0363546513483270; Khurana A, 2013, RADIOLOGY, V269, P186, DOI 10.1148/radiol.13130858; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kyrtatos PG, 2009, JACC-CARDIOVASC INTE, V2, P794, DOI 10.1016/j.jcin.2009.05.014; Landazuri N, 2013, SMALL, V9, P4017, DOI 10.1002/smll.201300570; Li QY, 2013, BIOMATERIALS, V34, P4982, DOI 10.1016/j.biomaterials.2013.03.030; Luciani A, 2009, EUR RADIOL, V19, P1087, DOI 10.1007/s00330-008-1262-9; Lundberg J, 2012, CELL TRANSPLANT, V21, P333, DOI 10.3727/096368911X576036; Lundberg J, 2009, NEURORADIOLOGY, V51, P661, DOI 10.1007/s00234-009-0551-6; Miyaki LAM, 2012, EINSTEIN-SAO PAULO, V10, P189, DOI 10.1590/S1679-45082012000200012; Matsumoto H, 2008, J CEREBR BLOOD F MET, V28, P149, DOI 10.1038/sj.jcbfm.9600519; Neher JJ, 2014, GLIA, V62, P1463, DOI 10.1002/glia.22693; Nguyen PK, 2014, CELL STEM CELL, V14, P431, DOI 10.1016/j.stem.2014.03.009; Nudi ET, 2015, J NEUROTRAUM, V32, P1117, DOI 10.1089/neu.2014.3618; Oshima S, 2014, J ORTHOP SCI, V19, P478, DOI 10.1007/s00776-014-0548-9; Panizzo RA, 2009, NEUROIMAGE, V44, P1239, DOI 10.1016/j.neuroimage.2008.10.062; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Pendharkar AV, 2010, STROKE, V41, P2064, DOI 10.1161/STROKEAHA.109.575993; Ren ZH, 2011, SCI CHINA LIFE SCI, V54, P981, DOI 10.1007/s11427-011-4239-x; Riegler J, 2013, BIOMATERIALS, V34, P1987, DOI 10.1016/j.biomaterials.2012.11.040; Rosenblum S, 2012, STROKE, V43, P1624, DOI 10.1161/STROKEAHA.111.637884; Sarwar A, 2012, J MAGN MAGN MATER, V324, P742, DOI 10.1016/j.jmmm.2011.09.008; Schafer R, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-22; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Shen WB, 2013, INT J NANOMED, V8, P4593, DOI 10.2147/IJN.S53012; Shen WB, 2010, ANN NEUROL, V68, P70, DOI 10.1002/ana.22018; Shen YL, 2015, CELL TRANSPLANT, V24, P1981, DOI 10.3727/096368914X685302; Shinozuka K, 2013, BRAIN SCI, V3, P239, DOI 10.3390/brainsci3010239; Silvestrini MT, 2013, STEREOT FUNCT NEUROS, V91, P92, DOI 10.1159/000343213; Song M, 2010, HUM GENE THER, V21, P603, DOI 10.1089/hum.2009.144; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074857; Tian CL, 2013, EXP CLIN TRANSPLANT, V11, P176, DOI 10.6002/ect.2012.0053; Vanecek V, 2012, INT J NANOMED, V7, P3719, DOI 10.2147/IJN.S32824; Wang LN, 2015, CONTRAST MEDIA MOL I, V10, P43, DOI 10.1002/cmmi.1601; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Yanai A, 2012, CELL TRANSPLANT, V21, P1137, DOI 10.3727/096368911X627435; Zhu JH, 2006, NEW ENGL J MED, V355, P2376, DOI 10.1056/NEJMc055304	54	25	26	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2016	25	6					1085	1099		10.3727/096368915X689550			15	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	DO5UG	WOS:000377847700007	26395573	Bronze			2021-06-18	
J	Tierney, GJ; Lawler, J; Denvir, K; McQuilkin, K; Simms, CK				Tierney, Gregory J.; Lawler, John; Denvir, Karl; McQuilkin, Kurt; Simms, Ciaran K.			Risks associated with significant head impact events in elite rugby union	BRAIN INJURY			English	Article						Sport; video analysis; statistical analysis	WORLD-CUP; INJURY SURVEILLANCE; TACKLE INJURIES; PLAYERS; EPIDEMIOLOGY; CONCUSSION; FOOTBALL; PROJECT; SEASON; SPORT	Primary objectives: To conduct video and statistical analysis on Rugby Union play, focusing mainly on the tackle, to establish the player to player configurations for significant direct head impacts and non-direct head impacts.Research design: Quantitative, observational cohort study.Methods and procedures: Video analysis of 52 significant direct head impacts (31 Tackle, 10 Ruck, 7 Dive and 4 Ground) and 40 non-direct head impact tackles from 2014/15 International Rugby Union matches. Relative risk, 95% CI and p-values were calculated for a range of tackle variables.Main outcome and results: Upper body tackles and lower body tackles accounted for 37% (19) and 23% (12) of cases, respectively, with the tackler as the head impacted player for 97% (30) of cases. The majority (81%) of tackle-related significant direct head impacts occurred in the second half of the game, with 63% of upper body tackle significant direct head impacts occurring in the final quarter. Tackler head placement and high speed tackles had statistical significance for causing tackle related significant direct head impacts as well as foot planting and difference in tackler and ball carrier mass for upper body tackles and ball carrier change in direction for lower body tackles.Conclusion: Tackle variables that statistically increased the risk of significant direct head impact were identified, which can aid player protection strategies.	[Tierney, Gregory J.; Lawler, John; Simms, Ciaran K.] Trinity Coll Dublin, Trinity Ctr Bioengn, Dublin, Ireland; [Denvir, Karl; McQuilkin, Kurt] Leinster Rugby, Dublin, Ireland	Tierney, GJ (corresponding author), Trinity Coll Dublin, Trinity Ctr Bioengn, Dept Mech & Mfg Engn, Dublin 2, Ireland.	gtierne@tcd.ie	Simms, Ciaran/K-3100-2019	Simms, Ciaran/0000-0001-5564-1620; Tierney, Gregory/0000-0002-4666-4473	Irish Research CouncilIrish Research Council for Science, Engineering and Technology	Acknowledgement should be given to the Irish Research Council for funding this study. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Alexander DG, 2015, BRAIN INJURY, V29, P1113, DOI 10.3109/02699052.2015.1031699; Altman D. G., 1990, PRACTICAL STAT MED R; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Cross M, 2015, BRIT J SPORT MED; Fraas MR, 2014, PHYS THER SPORT, V15, P136, DOI 10.1016/j.ptsp.2013.08.002; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Gauvreau, 2000, PRINCIPLES BIOSTATIS; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Hendricks S, 2014, BRIT J SPORT MED, V48, P606; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hutchison MG, 2013, BRIT J SPORT MED, V49, P552; Jakoet I, 1998, INJURY, V29, P27; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; MacQueen AE, 2010, CURR SPORT MED REP, V9, P139, DOI 10.1249/JSR.0b013e3181df124c; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2005, BRIT J SPORT MED, V39, P2, DOI 10.1136/bjsm.2004.016188; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Shuttleworth-Edwards AB, 2008, CLIN J SPORT MED, V18, P403, DOI 10.1097/JSM.0b013e3181895910; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002	30	25	25	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	11					1350	1361		10.1080/02699052.2016.1193630			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DZ8TP	WOS:000386144900008	27715327	Green Published			2021-06-18	
J	Walker, WC; Carne, W; Franke, LM; Nolen, T; Dikmen, SD; Cifu, DX; Wilson, K; Belanger, HG; Williams, R				Walker, W. C.; Carne, W.; Franke, L. M.; Nolen, T.; Dikmen, S. D.; Cifu, D. X.; Wilson, K.; Belanger, H. G.; Williams, R.			The Chronic Effects of Neurotrauma Consortium (CENC) multi-centre observational study: Description of study and characteristics of early participants	BRAIN INJURY			English	Article						Concussion; traumatic brain injury; military; veterans; post-concussion syndrome; cohort studies	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; COMMON DATA ELEMENTS; IRAQI FREEDOM; DSM-IV; BLAST; SYMPTOMS; VETERANS; CONCUSSION; SOLDIERS	Primary objectives: To establish and comprehensively evaluate a large cohort of US veterans who served in recent military conflicts in order to better understand possible chronic and late-life effects of mild traumatic brain injury (mTBI), including those that may stem from neurodegeneration.Research design: Cross-sectional and prospective longitudinal.Methods and procedures: Inclusion criteria are prior combat exposure and deployment(s) in Operation Enduring Freedom, Operation Iraqi Freedom or one of their follow-on conflicts (collectively OEF/OIF). Effects of mTBI will be assessed by enrolling participants across the entire spectrum of mTBI, from entirely negative to many mTBIs. Longitudinal assessments consist of in-person comprehensive testing at least every 5 years, with interval annual telephonic testing. The primary outcome is the composite score on the NIH Toolbox neuropsychological test battery. Assessments also include structured interviews, questionnaires, traditional neuropsychological testing, motor, sensory and vestibular functions, neuroimaging, electrophysiology, genotypes and biomarkers.Main outcomes and results: The authors fully describe the study methods and measures and report demographic and exposure characteristics from the early portion of the cohort of OEF/OIF veterans.Conclusions: This centrepiece observational study of the Chronic Effects of Neurotrauma Consortium (CENC) is successfully launched and, within several years, should provide fertile data to begin investigating its aims.	[Walker, W. C.; Carne, W.; Franke, L. M.; Cifu, D. X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; [Walker, W. C.; Carne, W.; Franke, L. M.; Cifu, D. X.] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Walker, W. C.; Franke, L. M.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Nolen, T.; Wilson, K.; Williams, R.] RTI Int, Res Triangle Pk, NC USA; [Dikmen, S. D.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Belanger, H. G.] HSR&D Ctr Innovat Disabil & Rehabil Res CINDRR, Tampa, FL USA; [Belanger, H. G.] James A Haley Vet Hosp VH, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Belanger, H. G.] Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL USA	Walker, WC (corresponding author), VCU Dept PM&R, MCV Stn,Box 677, Richmond, VA 23298 USA.	wwalker@mcvh-vcu.edu	; Franke, Lude/P-7036-2016	Cifu, David/0000-0003-1600-9387; Franke, Lude/0000-0002-5159-8802; Nolen, Tracy/0000-0003-2512-343X	Defense and Veterans Brain Injury Center, US Army Medical Research and Material Command (USAMRMC); Hunter Holmes McGuire Veterans Affairs Medical Center (VAMC) in Richmond, VA; James A. Haley Veterans Hospital (VH), Tampa, FL; Michael E. DeBakey VAMC, Houston, TX; Audie L. Murphy Memorial VH, San Antonio, TX	The CENC Observational Study Site PIs or co-PIs also include: Blessen Eapen, MD (SanAntonio), Carlos Jaramillo, MD (SanAntonio), Ajit Pai, MD (Richmond), Maulik Purohit, MD (Fort Belvoir), and Randall Scheibel, PhD (Houston). We also acknowledge the efforts of the entire CENC Observational Study Leadership Working Group and Core Team members who also include: Justin Alicea, Ramon Diaz-Arrastia (Consortium Co-PI), Jessica Berumen, Katrina Burson, Margaret Clarke, Doreen Collins, Shannon Cusack, Cheryl Ford-Smith, George Gitchel, Harvey Levin, Henry Lew, Daryl Matthews, Scott McDonald, Tamara McKenzie-Hartman, Nicholas Pastorek, Judy Pulliam, Risa Richardson, Robert Shin, James K. Sickinger, Chris Siege, Nancy Temkin, Doug Theriaque, Maya Troyanskaya, Rodney Vanderploeg, and Elizabeth Wilde. This material is based upon work supported with resources and the use of facilities at: Hunter Holmes McGuire Veterans Affairs Medical Center (VAMC) in Richmond, VA; James A. Haley Veterans Hospital (VH), Tampa, FL; Michael E. DeBakey VAMC, Houston, TX; Audie L. Murphy Memorial VH, San Antonio, TX; and is based upon work supported in part by the Defense and Veterans Brain Injury Center, US Army Medical Research and Material Command (USAMRMC).	Andrikopoulos J, 2014, JAMA NEUROL, V71, P654, DOI 10.1001/jamaneurol.2013.6408; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Betthauser LM, 2012, NEUROPSYCHOL REV, V22, P35, DOI 10.1007/s11065-012-9191-4; Brown DW, 2003, PREV MED, V37, P520, DOI 10.1016/S0091-7435(03)00179-8; Brueton VC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000032.pub2; Brundage John F, 2015, MSMR, V22, P2; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Chung F, 2016, CHEST, V149, P631, DOI 10.1378/chest.15-0903; Cifu DX, 2015, J HEAD TRAUMA REHAB, V30, P21, DOI 10.1097/HTR.0000000000000036; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Cooper DB, 2011, ARCH CLIN NEUROPSYCH, V26, P718, DOI 10.1093/arclin/acr070; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Dimou S, 2014, J NEUROTRAUM, V31, P413, DOI 10.1089/neu.2013.3050; Dretsch MN, 2015, J NEUROTRAUM, V32, P1217, DOI 10.1089/neu.2014.3637; Duncan CC, 2011, INT J PSYCHOPHYSIOL, V82, P24, DOI 10.1016/j.ijpsycho.2011.02.013; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Haneef Z, 2013, J NEUROTRAUM, V30, P653, DOI 10.1089/neu.2012.2585; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2014, LANCET PSYCHIAT, V1, P269, DOI 10.1016/S2215-0366(14)70235-4; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Jaffee M, 2010, MIL MED, V175, P37, DOI 10.7205/MILMED-D-10-00170; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meyer KS, 2010, PSYCHIAT CLIN N AM, V33, P783, DOI 10.1016/j.psc.2010.08.007; Nelson NW, 2015, BRIT J PSYCHIAT, V206, P237, DOI 10.1192/bjp.bp.114.149096; NEWMAN CW, 1990, EAR HEARING, V11, P430, DOI 10.1097/00003446-199012000-00004; Newman CW, 1996, ARCH OTOLARYNGOL, V122, P143; Olichney JM, 2006, CLIN NEUROPHYSIOL, V117, P1319, DOI 10.1016/j.clinph.2006.02.022; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Schwarzer R, 2000, HEALTH PSYCHOL, V19, P487, DOI 10.1037/0278-6133.19.5.487; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Silver JM, 2014, PSYCHIAT CLIN N AM, V37, P91, DOI 10.1016/j.psc.2013.11.001; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thompson HJ, 2015, ANNU REV NURS RES-SE, V33, P1, DOI 10.1891/0739-6686.33.1; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Waldron-Perrine B, 2014, MIL MED, V179, P856, DOI 10.7205/MILMED-D-13-00282; Walker WC, 2015, J NEUROTRAUM, V32, P464, DOI 10.1089/neu.2014.3433; Walker WC, 2013, J HEAD TRAUMA REHAB, V28, P68, DOI 10.1097/HTR.0b013e318255dfd0; Wares JR, 2015, J REHABIL RES DEV, V52, P591, DOI 10.1682/JRRD.2014.08.0197; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wortzel HS, 2013, BEHAV SCI LAW, V31, P721, DOI 10.1002/bsl.2079; Yudko E, 2007, J SUBST ABUSE TREAT, V32, P189, DOI 10.1016/j.jsat.2006.08.002	50	25	25	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	12					1469	1480		10.1080/02699052.2016.1219061			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ED1IO	WOS:000388599100009	27834538				2021-06-18	
J	Unsal, C; Kanter, M; Aktas, C; Erboga, M				Unsal, Cuneyt; Kanter, Mehmet; Aktas, Cevat; Erboga, Mustafa			Role of quercetin in cadmium-induced oxidative stress, neuronal damage, and apoptosis in rats	TOXICOLOGY AND INDUSTRIAL HEALTH			English	Article						Cadmium; quercetin; oxidative stress; neuronal damage; neuronal apoptosis; rats	TRAUMATIC BRAIN-INJURY; SUPEROXIDE-DISMUTASE; CORTICAL-NEURONS; IN-VIVO; GLUTATHIONE; NEUROTOXICITY; EXPRESSION; METALLOTHIONEIN; NEPHROTOXICITY; CYTOTOXICITY	The present study was carried out to evaluate the neuroprotective effect of quercetin (QE) in protecting the cadmium (Cd)-induced neuronal injury in frontal cortex of rats. A total of 30 adult male Sprague-Dawley rats were randomly divided into three groups of 10 animals each: control, Cd treated and Cd treated with QE. The Cd-treated group was injected subcutaneously with cadmium chloride (CdCl2) dissolved in saline at a dose of 2 ml/kg/day for 30 days, resulting in a dosage of 1 mg/kg Cd. The rats in QE-treated groups were given QE (15 mg/kg body weight) once a day intraperitoneally starting 2 days prior to Cd injection, during the study period. Rats were sacrificed at the end of the study and the frontal cortex tissues were removed for biochemical and histopathological investigation. To date, there is no available information on the effect of QE on neuronal injury after Cd exposure. Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and catalase in the frontal cortex tissue. Administration of QE with Cd significantly diminished the levels of MDA and significantly elevated the levels of enzymatic antioxidants in the frontal cortex tissue. The histopathological studies in the brain of rats also supported that QE markedly reduced the Cd-induced histopathological changes and well preserved the normal histological architecture of the frontal cortex tissue. The caspase-3 immunopositivity was increased in degenerating neurons of the Cd group. Treatment with QE markedly reduced the immunoreactivity of degenerating neurons. In conclusion, the results of the current study suggest that QE may be beneficial in combating the Cd-induced neurotoxicity in the brain of rats. We believe that further preclinical research into the utility of QE may indicate its usefulness as a potential treatment for neurodegeneration after Cd exposure in rats.	[Unsal, Cuneyt] Namik Kemal Univ, Dept Psychiat, Tekirdag, Turkey; [Kanter, Mehmet] Istanbul Medeniyet Univ, Dept Histol & Embryol, Istanbul, Turkey; [Aktas, Cevat; Erboga, Mustafa] Namik Kemal Univ, Dept Histol & Embryol, Tekirdag, Turkey	Kanter, M (corresponding author), Univ Istanbul Medeniyet, Dept Histol & Embryol, TR-34710 Istanbul, Turkey.	mkanter65@yahoo.com	Aktas, Cevat/D-8468-2011				AEBI H, 1984, METHOD ENZYMOL, V105, P121; AFANASEV IB, 1989, BIOCHEM PHARMACOL, V38, P1763, DOI 10.1016/0006-2952(89)90410-3; Aktoz T, 2012, BALK MED J, V29, P56, DOI 10.5152/balkanmedj.2011.014; Bar-Sela S, 2001, Int J Occup Environ Health, V7, P109; Bertin G, 2006, BIOCHIMIE, V88, P1549, DOI 10.1016/j.biochi.2006.10.001; Bondy SC, 1997, FREE RADICAL TOXICOL, P221; Bressler JP, 2007, HUM EXP TOXICOL, V26, P221, DOI 10.1177/0960327107070573; Cho JY, 2006, NEUROSCI LETT, V404, P330, DOI 10.1016/j.neulet.2006.06.010; Choi YJ, 2003, J NUTR, V133, P985; Choudhuri S, 1996, TOXICOL LETT, V84, P127, DOI 10.1016/0378-4274(95)03444-7; Chuang SM, 2000, CARCINOGENESIS, V21, P1423, DOI 10.1093/carcin/21.7.1423; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Dean RT, 1997, BIOCHEM J, V324, P1; El-Missiry MA, 2000, J BIOCHEM MOL TOXIC, V14, P238, DOI 10.1002/1099-0461(2000)14:5<238::AID-JBT2>3.0.CO;2-X; Farombi EO, 2012, ANDROLOGIA, V44, P273, DOI 10.1111/j.1439-0272.2012.01279.x; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Inal ME, 2002, METHOD FIND EXP CLIN, V24, P209, DOI 10.1358/mf.2002.24.4.678452; Kanter M, 2012, TOXICOLOGY IND HLTH; Kanter M, 2012, FOOD CHEM TOXICOL, V50, P719, DOI 10.1016/j.fct.2011.11.051; Kerman M, 2012, J MOL HISTOL, V43, P49, DOI 10.1007/s10735-011-9376-9; Kim SD, 2005, BIOCHEM BIOPH RES CO, V328, P326, DOI 10.1016/j.bbrc.2004.11.173; Koizumi T, 1996, TOXICOLOGY, V114, P125, DOI 10.1016/S0300-483X(96)03477-4; Kondoh M, 2002, TOXICOLOGY, V170, P111, DOI 10.1016/S0300-483X(01)00536-4; Kumar R, 1996, TOXICOL LETT, V89, P65, DOI 10.1016/S0378-4274(96)03780-0; LAUGHTON MJ, 1991, BIOCHEM PHARMACOL, V42, P1673, DOI 10.1016/0006-2952(91)90501-U; Li XL, 2012, EXP THER MED, V4, P125, DOI 10.3892/etm.2012.562; Lopez E, 2006, FREE RADICAL BIO MED, V40, P940, DOI 10.1016/j.freeradbiomed.2005.10.062; Lopez E, 2003, BRIT J PHARMACOL, V138, P901, DOI 10.1038/sj.bjp.0705111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Morales AI, 2006, FOOD CHEM TOXICOL, V44, P2092, DOI 10.1016/j.fct.2006.07.012; Morales AI, 2006, TOXICOL APPL PHARM, V210, P128, DOI 10.1016/j.taap.2005.09.006; Nishimura Y, 2006, TOXICOL IN VITRO, V20, P211, DOI 10.1016/j.tiv.2005.06.006; NORDBERG M, 1984, ENVIRON HEALTH PERSP, V54, P13, DOI 10.2307/3429785; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Okuda B, 1997, CLIN NEUROL NEUROSUR, V99, P263, DOI 10.1016/S0303-8467(97)00090-5; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pandey AK, 2011, BRAIN RES, V1383, P289, DOI 10.1016/j.brainres.2011.01.085; Prabu SM, 2010, EUR REV MED PHARMACO, V14, P903; Prabu SM, 2010, J FOOD SCI, V75, pT132, DOI 10.1111/j.1750-3841.2010.01757.x; Renugadevi J, 2010, EXP TOXICOL PATHOL, V62, P471, DOI 10.1016/j.etp.2009.06.006; Risso-de Faverney C, 2001, AQUAT TOXICOL, V53, P65, DOI 10.1016/S0166-445X(00)00154-5; Schultke E, 2005, J NEUROTRAUM, V22, P1475, DOI 10.1089/neu.2005.22.1475; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Seok SM, 2006, TOXICOL LETT, V165, P212, DOI 10.1016/j.toxlet.2006.04.007; Shagirtha K, 2011, EUR REV MED PHARMACO, V15, P1039; Shimada H, 1998, J TOXICOL ENV HEAL A, V54, P159; SHUKLA GS, 1987, LIFE SCI, V41, P2215, DOI 10.1016/0024-3205(87)90518-2; SHUKLA GS, 1989, IND HEALTH, V27, P59, DOI 10.2486/indhealth.27.59; SUN Y, 1988, CLIN CHEM, V34, P497; Viaene MK, 2000, OCCUP ENVIRON MED, V57, P19, DOI 10.1136/oem.57.1.19; Vicente-Sanchez C, 2008, FOOD CHEM TOXICOL, V46, P2279, DOI 10.1016/j.fct.2008.03.009; Wu XW, 2001, J OCCUP ENVIRON MED, V43, P898, DOI 10.1097/00043764-200110000-00009; Xu CY, 1996, TOXICOLOGY, V107, P1, DOI 10.1016/0300-483X(95)03195-L; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhu YG, 2006, BRAIN RES, V1090, P35, DOI 10.1016/j.brainres.2006.03.063	59	25	28	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0748-2337	1477-0393		TOXICOL IND HEALTH	Toxicol. Ind. Health	DEC	2015	31	12					1106	1115		10.1177/0748233713486960			10	Public, Environmental & Occupational Health; Toxicology	Public, Environmental & Occupational Health; Toxicology	CX5MK	WOS:000365745600006	23645211				2021-06-18	
J	Lee, DJ; Gurkoff, GG; Izadi, A; Seidl, SE; Echeverri, A; Melnik, M; Berman, RF; Ekstrom, AD; Muizelaar, JP; Lyeth, BG; Shahlaie, K				Lee, Darrin J.; Gurkoff, Gene G.; Izadi, Ali; Seidl, Stacey E.; Echeverri, Angela; Melnik, Mikhail; Berman, Robert F.; Ekstrom, Arne D.; Muizelaar, J. Paul; Lyeth, Bruce G.; Shahlaie, Kiarash			Septohippocampal Neuromodulation Improves Cognition after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognition; deep brain stimulation; hippocampal theta oscillation; medial septal nucleus; traumatic brain injury	LATERAL FLUID-PERCUSSION; CHOLINERGIC RECEPTOR-BINDING; HIPPOCAMPAL THETA RHYTHM; SPATIAL WORKING-MEMORY; FREELY MOVING RATS; SHORT-TERM-MEMORY; EPISODIC MEMORY; EVOKED RELEASE; OSCILLATIONS; ACETYLCHOLINE	Traumatic brain injury (TBI) often results in persistent attention and memory deficits that are associated with hippocampal dysfunction. Although deep brain stimulation (DBS) is used to treat neurological disorders related to motor dysfunction, the effectiveness of stimulation to treat cognition remains largely unknown. In this study, adult male Harlan Sprague-Dawley rats underwent a lateral fluid percussion or sham injury followed by implantation of bipolar electrodes in the medial septal nucleus (MSN) and ipsilateral hippocampus. In the first week after injury, there was a significant decrease in hippocampal theta oscillations that correlated with decreased object exploration and impaired performance in the Barnes maze spatial learning task. Continuous 7.7 Hz theta stimulation of the medial septum significantly increased hippocampal theta oscillations, restored normal object exploration, and improved spatial learning in injured animals. There were no benefits with 100 Hz gamma stimulation, and stimulation of sham animals at either frequency did not enhance performance. We conclude, therefore, that there was a theta frequency-specific benefit of DBS that restored cognitive function in brain-injured rats. These data suggest that septal theta stimulation may be an effective and novel neuromodulatory therapy for treatment of persistent cognitive deficits following TBI.	[Lee, Darrin J.; Gurkoff, Gene G.; Izadi, Ali; Seidl, Stacey E.; Echeverri, Angela; Melnik, Mikhail; Berman, Robert F.; Muizelaar, J. Paul; Lyeth, Bruce G.; Shahlaie, Kiarash] Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA; [Berman, Robert F.; Ekstrom, Arne D.; Lyeth, Bruce G.; Shahlaie, Kiarash] Univ Calif Davis, Ctr Neurosci, Sacramento, CA 95817 USA	Shahlaie, K (corresponding author), UC Davis Sch Med, Dept Neurol Surg, 4860 Y St,Suite 3740, Sacramento, CA 95817 USA.	kiarash.shahlaie@ucdmc.ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS084026] Funding Source: NIH RePORTER		Addante RJ, 2011, P NATL ACAD SCI USA, V108, P10702, DOI 10.1073/pnas.1014528108; Aggleton JP, 2010, EUR J NEUROSCI, V31, P2292, DOI 10.1111/j.1460-9568.2010.07251.x; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Buzsaki G, 2005, HIPPOCAMPUS, V15, P827, DOI 10.1002/hipo.20113; BUZSAKI G, 1986, BRAIN RES, V365, P125, DOI 10.1016/0006-8993(86)90729-8; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Caplan JB, 2001, J NEUROPHYSIOL, V86, P368; Caplan JB, 2007, NEUROIMAGE, V38, P604, DOI 10.1016/j.neuroimage.2007.07.054; Cashdollar N, 2009, P NATL ACAD SCI USA, V106, P20493, DOI 10.1073/pnas.0904823106; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eacott MJ, 2005, LEARN MEMORY, V12, P221, DOI 10.1101/lm.92505; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; Ekstrom AD, 2005, HIPPOCAMPUS, V15, P881, DOI 10.1002/hipo.20109; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; Fell J, 2011, J NEUROSCI, V31, P5392, DOI 10.1523/JNEUROSCI.3668-10.2011; Geisler C, 2007, P NATL ACAD SCI USA, V104, P8149, DOI 10.1073/pnas.0610121104; Gibson CJ, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-38; Giovannini MG, 2001, NEUROSCIENCE, V106, P43, DOI 10.1016/S0306-4522(01)00266-4; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GORMAN LK, 1994, NEUROSCI LETT, V166, P199, DOI 10.1016/0304-3940(94)90485-5; Gupta AS, 2012, NAT NEUROSCI, V15, P1032, DOI 10.1038/nn.3138; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Jacobs J, 2009, J NEUROSCI, V29, P10203, DOI 10.1523/JNEUROSCI.2187-09.2009; Jeewajee A, 2008, HIPPOCAMPUS, V18, P1175, DOI 10.1002/hipo.20510; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; Kleen JK, 2011, J NEUROSCI, V31, P15397, DOI 10.1523/JNEUROSCI.2196-11.2011; Laxton AW, 2010, ANN NEUROL, V68, P521, DOI 10.1002/ana.22089; Lee DJ, 2013, J NEUROTRAUM, V30, P131, DOI 10.1089/neu.2012.2646; Leutgeb S, 2005, SCIENCE, V309, P619, DOI 10.1126/science.1114037; Lipponen A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048506; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lundqvist M, 2011, J COGNITIVE NEUROSCI, V23, P3008, DOI 10.1162/jocn_a_00029; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; Mattis J, 2014, J NEUROSCI, V34, P11769, DOI 10.1523/JNEUROSCI.5188-13.2014; MCFARLAND WL, 1975, J COMP PHYSIOL PSYCH, V88, P324, DOI 10.1037/h0076177; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; MIZUMORI SJY, 1990, EXP BRAIN RES, V80, P365; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Nerad L, 2006, EUR J NEUROSCI, V24, P155, DOI 10.1111/j.1460-9568.2006.04902.x; Nyhus E, 2010, NEUROSCI BIOBEHAV R, V34, P1023, DOI 10.1016/j.neubiorev.2009.12.014; O'Neill PK, 2013, J NEUROSCI, V33, P14211, DOI 10.1523/JNEUROSCI.2378-13.2013; Osaka M, 1999, COGNITIVE BRAIN RES, V8, P365, DOI 10.1016/S0926-6410(99)00022-1; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Paz R, 2008, LEARN MEMORY, V15, P524, DOI 10.1101/lm.932408; Raghavachari S, 2001, J NEUROSCI, V21, P3175, DOI 10.1523/JNEUROSCI.21-09-03175.2001; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Rutishauser U, 2010, NATURE, V464, P903, DOI 10.1038/nature08860; Sederberg PB, 2003, J NEUROSCI, V23, P10809; Slovarp L, 2012, BRAIN INJURY, V26, P48, DOI 10.3109/02699052.2011.635355; Suthana N, 2012, NEW ENGL J MED, V366, P502, DOI 10.1056/NEJMoa1107212; Toth Z, 1997, J NEUROSCI, V17, P8106; VANDERWOLF CH, 1988, INT REV NEUROBIOL, V30, P225; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Vertes RP, 2005, HIPPOCAMPUS, V15, P923, DOI 10.1002/hipo.20118; Vertes RP, 2001, NEUROSCIENCE, V104, P619, DOI 10.1016/S0306-4522(01)00131-2; Vinck M, 2010, NEUROIMAGE, V51, P112, DOI 10.1016/j.neuroimage.2010.01.073; Watrous AJ, 2013, NAT NEUROSCI, V16, P349, DOI 10.1038/nn.3315; Watrous AJ, 2011, J NEUROPHYSIOL, V105, P1747, DOI 10.1152/jn.00921.2010; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646; WINSON J, 1974, ELECTROEN CLIN NEURO, V36, P291, DOI 10.1016/0013-4694(74)90171-0	71	25	25	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1822	1832		10.1089/neu.2014.3744			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500013	26096267	Green Published			2021-06-18	
J	Alali, AS; Gomez, D; Sathya, C; Burd, RS; Mainprize, TG; Moulton, R; Falcone, RA; de Mestral, C; Nathens, A				Alali, Aziz S.; Gomez, David; Sathya, Chethan; Burd, Randall S.; Mainprize, Todd G.; Moulton, Richard; Falcone, Richard A., Jr.; de Mestral, Charles; Nathens, Avery			Intracranial pressure monitoring among children with severe traumatic brain injury	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						head injury; intracranial pressure; multilevel analysis; propensity score; traumatic brain injury; trauma	BRIEF CONCEPTUAL TUTORIAL; SOCIAL EPIDEMIOLOGY; MULTILEVEL ANALYSIS; OUTCOMES; IMPACT; RISK	OBJECT Well-designed studies linking intracranial pressure (ICP) monitoring with improved outcomes among children with severe traumatic brain injury (TBI) are lacking. The main objective of this study was to examine the relationship between ICP monitoring in children and in-hospital mortality following severe TBI. METHODS An observational study was conducted using data derived from 153 adult or mixed (adult and pediatric) trauma centers participating in the American College of Surgeons (ACS) Trauma Quality Improvement Program (TQIP) and 29 pediatric trauma centers participating in the pediatric pilot TQIP between 2010 and 2012. Random-intercept multilevel modeling was used to examine the association between ICP monitoring and in-hospital mortality among children with severe TBI <= 16 years of age after adjusting for important confounders. This association was evaluated at the patient level and at the hospital level. In a sensitivity analysis, this association was reexamined in a propensity-matched cohort. RESULTS A total of 1705 children with severe TBI were included in the study cohort. The overall in-hospital mortality was 14.3% of patients (n = 243), whereas the mortality of the 273 patients (16%) who underwent invasive ICP monitoring was 11% (n = 30). After adjusting for patient-and hospital-level characteristics, ICP monitoring was associated with lower in-hospital mortality (adjusted OR 0.50; 95% CI 0.30-0.85; p = 0.01). It is possible that patients who were managed with ICP monitoring were selected because of an anticipated favorable or unfavorable outcome. To further address this potential selection bias, the analysis was repeated with the hospital-specific rate of ICP monitoring use as the exposure. The adjusted OR for death of children treated at high ICP use hospitals was 0.49 compared with those treated at low ICP use hospitals (95% CI 0.31-0.78; p = 0.003). Variations in ICP monitoring use accounted for 15.9% of the interhospital variation in mortality among children with severe TBI. Similar results were obtained after analyzing the data using propensity score matching methods. CONCLUSIONS In this observational study, ICP monitoring use was associated with lower hospital mortality at both the patient and hospital levels. However, the contribution of variable ICP monitoring rates to interhospital variation in pediatric TBI mortality was modest.	[Alali, Aziz S.; Gomez, David; Sathya, Chethan; de Mestral, Charles; Nathens, Avery] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada; [Alali, Aziz S.; Moulton, Richard] Univ Ottawa, Div Neurosurg, Ottawa, ON K1N 6N5, Canada; [Alali, Aziz S.; Gomez, David; Sathya, Chethan; de Mestral, Charles; Nathens, Avery] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada; [Sathya, Chethan; Nathens, Avery] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON M5S 1A1, Canada; [Burd, Randall S.] Childrens Natl Med Ctr, Div Trauma & Burn Surg, Washington, DC 20010 USA; [Mainprize, Todd G.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Neurosurg, Toronto, ON M5S 1A1, Canada; [Falcone, Richard A., Jr.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Surg, Cincinnati, OH 45229 USA; [Nathens, Avery] Sunnybrook Hlth Sci Ctr, Dept Surg, Toronto, ON M4N 3M5, Canada	Alali, AS (corresponding author), Sunnybrook Res Inst, 2075 Bayview Ave,Rm D-574, Toronto, ON M4N 3M5, Canada.	aziz.alali@mail.utoronto.ca		Gomez, David/0000-0002-0926-2547	Canada Research Chair Program in Systems of Trauma Care	This work was supported in part by funds from a Canada Research Chair Program in Systems of Trauma Care (to Dr. Nathens). No competing financial interests exist.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Austin PC, 2007, J THORAC CARDIOV SUR, V134, P1128, DOI 10.1016/j.jtcvs.2007.07.021; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; BARZILAY Z, 1988, INTENS CARE MED, V14, P417, DOI 10.1007/BF00262899; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Chesnut RM, 2008, J TRAUMA, V65, P500, DOI 10.1097/TA.0b013e31818020b3; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Citerio G, 2008, INTENS CARE MED, V34, P1173, DOI 10.1007/s00134-008-1080-1; *COMM INJ SCAL, 1998, ABBR INJ SCAL 1998 R; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Hemmila MR, 2010, J TRAUMA, V68, P253, DOI 10.1097/TA.0b013e3181cfc8e6; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Kleinman ME, 2010, CIRCULATION, V122, pS876, DOI 10.1161/CIRCULATIONAHA.110.971101; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kozar RA, 2014, J TRAUMA ACUTE CARE, V76, P634, DOI 10.1097/TA.0000000000000130; Langlois JA, 2000, TRAUMATIC BRAIN INJU; Larsen K, 2005, AM J EPIDEMIOL, V161, P81, DOI 10.1093/aje/kwi017; Maas AI, 2008, J TRAUMA, V65, P966, DOI 10.1097/TA.0b013e318184ee7b; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P729, DOI 10.1136/jech.2004.023929; Merlo J, 2006, J EPIDEMIOL COMMUN H, V60, P290, DOI 10.1136/jech.2004.029454; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; O'Brien RM, 2007, QUAL QUANT, V41, P673, DOI 10.1007/s11135-006-9018-6; Oyetunji TA, 2011, J SURG RES, V165, pE37, DOI 10.1016/j.jss.2010.09.025; Parsons LS, 2001, SAS US GROUP INT 26; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shafi S, 2009, J AM COLL SURGEONS, V209, P521, DOI 10.1016/j.jamcollsurg.2009.07.001; Shahlaie K, 2011, YOUMANS NEUROL SURG, V4, P3362; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Wijeysundera DN, 2012, ANESTHESIOLOGY, V116, P25, DOI 10.1097/ALN.0b013e31823cfc03	40	25	25	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	NOV	2015	16	5					523	532		10.3171/2015.3.PEDS14507			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CU3QK	WOS:000363439700010	26273741	Bronze			2021-06-18	
J	Bock, S; Grim, R; Barron, TF; Wagenheim, A; Hu, YE; Hendell, M; Deitch, J; Deibert, E				Bock, Suzanne; Grim, Rod; Barron, Todd F.; Wagenheim, Andrew; Hu, Yaowen Eliot; Hendell, Matthew; Deitch, John; Deibert, Ellen			Factors associated with delayed recovery in athletes with concussion treated at a pediatric neurology concussion clinic	CHILDS NERVOUS SYSTEM			English	Article						Pediatric; Concussion; Recovery; Factors	SPORTS CONCUSSION; MANAGEMENT; EPIDEMIOLOGY	With the increase in knowledge and management of sport-related concussion over the last 15 years, there has been a shift from a grading scale approach to an individualized management approach. As a result, there is an increased need to better understand the factors involved in delayed recovery of concussion. The purpose of this retrospective study was to examine factors that may be associated with recovery from sport-related concussion in student athletes aged 11 to 18 years old. Of the 366 patients who met the inclusion criteria, 361 were included in our analysis. The primary dependent variable included days until athlete was able to return to play (RTP). Independent variables of interest included age, gender, academic performance, comorbid factors, sports, on-field markers, days until initial neurological evaluation, Immediate Post-Concussion Assessment and Cognitive Testing (ImPACTA (R)) scores, acute headache rescue medications, chronic headache medication, sleep medication, and referral to concussion rehabilitation program. Variables associated with longer median RTP were being female (35 days), having a referral to concussion rehabilitation program (53 days), being prescribed acute headache rescue therapy (34 days), and having chronic headache treatment (53 days) (all p < 0.05). Variables associated with shorter RTP were on-field marker of headache (23 days) and evaluation within 1 week of concussion by a concussion specialist (16 days) (Both p < 0.05). This study supports the need for a concussed athlete to have access to a provider trained in concussion management in a timely fashion in order to prevent delayed recovery and return to play.	[Bock, Suzanne; Grim, Rod] WellSpan Hlth, Emig Res Ctr, York Hosp, York, PA 17405 USA; [Barron, Todd F.; Hendell, Matthew; Deibert, Ellen] WellSpan Neurosci, York, PA 17402 USA; [Wagenheim, Andrew] Pinnacle Hlth Spine & Sports Med, Mechanicsburg, PA 17050 USA; [Hu, Yaowen Eliot] VCU Fairfax Family Practice Sports Med Fellowship, Richmond, VA USA; [Hu, Yaowen Eliot] George Mason Univ, Team Phys, Fairfax, VA 22030 USA; [Hu, Yaowen Eliot] Herndon High Sch, Team Phys, Herndon, VA 20170 USA; [Deitch, John] Sports Med WellSpan Hlth, York, PA 17403 USA; [Deibert, Ellen] Drexel Univ, Dept Neurol, Coll Med, Philadelphia, PA 19102 USA; [Barron, Todd F.] Penn Coll Med, Hershey, PA 17033 USA	Bock, S (corresponding author), WellSpan Hlth, Emig Res Ctr, York Hosp, 1001 S George St, York, PA 17405 USA.	markbock@comcast.net					Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Carl RL, 2014, CLIN PEDIATR, V53, P689, DOI 10.1177/0009922814526979; CDC, 2007, CDC ANN UPD INF HELP; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Francisco GE, 2007, BRAIN INJURY, V21, P1007, DOI 10.1080/02699050701559558; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Kelly JP, 1997, NEUROLOGY, V48, P581; Kinnaman KA, 2013, ACTA PAEDIATR, V102, pE424, DOI 10.1111/apa.12315; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCarthy Mark, 2010, Conn Med, V74, P485; McCrea M, 2012, CLIN NEUROPSYCHOL, V26, P1, DOI 10.1080/13854046.2012.658678; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	21	25	25	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	NOV	2015	31	11					2111	2116		10.1007/s00381-015-2846-8			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CU4FT	WOS:000363483300019	26243160				2021-06-18	
J	Kerrey, BT; Mittiga, MR; Rinderknecht, AS; Varadarajan, KR; Dyas, JR; Geis, GL; Luria, JW; Frey, ME; Jablonski, TE; Iyer, SB				Kerrey, Benjamin T.; Mittiga, Matthew R.; Rinderknecht, Andrea S.; Varadarajan, Kartik R.; Dyas, Jenna R.; Geis, Gary Lee; Luria, Joseph W.; Frey, Mary E.; Jablonski, Tamara E.; Iyer, Srikant B.			Reducing the incidence of oxyhaemoglobin desaturation during rapid sequence intubation in a paediatric emergency department	BMJ QUALITY & SAFETY			English	Article							TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; TRACHEAL INTUBATION; HYPOXIA; CHECKLIST; RATS; NEUROINFLAMMATION; INTERVENTION; SIMULATION; ANESTHESIA	Objectives Rapid sequence intubation (RSI) is the standard for definitive airway management in emergency medicine. In a video-based study of RSI in a paediatric emergency department (ED), we reported a high degree of process variation and frequent adverse effects, including oxyhaemoglobin desaturation (SpO(2)<90%). This report describes a multidisciplinary initiative to improve the performance and safety of RSI in a paediatric ED. Methods We conducted a local improvement initiative in a high-volume academic paediatric ED. We simultaneously tested: (1) an RSI checklist, (2) a pilot/copilot model for checklist execution, (3) the use of a video laryngoscope and (4) the restriction of laryngoscopy to specific providers. Data were collected primarily by video review during the testing period and the historical period (2009-2010, baseline). We generated statistical process control charts (G-charts) to measure change in the performance of six key processes, attempt failure and the occurrence of oxyhaemoglobin desaturation during RSI. We iteratively revised the four interventions through multiple plan-do-study-act cycles within the Model for Improvement. Results There were 75 cases of RSI during the testing period (July 2012-September 2013). Special cause variation occurred on the G-charts for three of six key processes, attempt failure and desaturation, indicating significant improvement. The frequency of desaturation was 50% lower in the testing period than the historical (16% vs 33%). When all six key processes were performed, only 6% of patients experienced desaturation. Conclusions Following the simultaneous introduction of four interventions in a paediatric ED, RSI was performed more reliably, successfully and safely.	[Kerrey, Benjamin T.; Mittiga, Matthew R.; Rinderknecht, Andrea S.; Varadarajan, Kartik R.; Dyas, Jenna R.; Geis, Gary Lee; Luria, Joseph W.; Frey, Mary E.; Iyer, Srikant B.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Kerrey, Benjamin T.; Geis, Gary Lee] Cincinnati Childrens Hosp Med Ctr, Ctr Simulat & Res, Cincinnati, OH 45229 USA; [Jablonski, Tamara E.] Cincinnati Childrens Hosp Med Ctr, Dept Emergency Serv, Cincinnati, OH 45229 USA; [Iyer, Srikant B.] Cincinnati Childrens Hosp Med Ctr, James M Anderson Ctr Hlth Syst Excellence, Cincinnati, OH 45229 USA	Kerrey, BT (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, 3333 Burnet Ave,ML 12000, Cincinnati, OH 45229 USA.	benjamin.kerrey@cchmc.org	Rinderknecht, Andrea/AAD-8184-2020		Division of Emergency Medicine and Emergency Services at Cincinnati Children's Hospital; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER	We gratefully acknowledge the support of the following individuals and groups, without whom our project would have been impossible to complete: Karen Ahaus and Tina Eubanks, Rachel Talley, Michelle Caruso, Richard Ruddy and the entire Division of Emergency Medicine and Emergency Services at Cincinnati Children's Hospital.	Bosk CL, 2009, LANCET, V374, P444, DOI 10.1016/S0140-6736(09)61440-9; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Feng JF, 2012, J NEUROTRAUM, V29, P1167, DOI 10.1089/neu.2011.1867; Gawande A., 2010, CHECKLIST MANIFESTO; Green SM, 2009, J EMERG MED, V37, P359, DOI 10.1016/j.jemermed.2007.05.048; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Jaber S, 2010, INTENS CARE MED, V36, P248, DOI 10.1007/s00134-009-1717-8; Kerrey BT, 2012, ANN EMERG MED, V60, P251, DOI 10.1016/j.annemergmed.2012.02.013; Leape LL, 2014, NEW ENGL J MED, V370, P1063, DOI 10.1056/NEJMe1315851; Martinon C, 2011, PEDIATR CRIT CARE ME, V12, P65, DOI 10.1097/PCC.0b013e3181e2a244; Mayo Paul H, 2011, J Intensive Care Med, V26, P50, DOI 10.1177/0885066610384070; Mittiga MR, 2013, ANN EMERG MED, V61, P263, DOI 10.1016/j.annemergmed.2012.06.021; Nishisaki A, 2012, RESP CARE, V57, P1121, DOI 10.4187/respcare.01472; Nishisaki A, 2010, ANESTHESIOLOGY, V113, P214, DOI 10.1097/ALN.0b013e3181e19bf2; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Provost LP., 2011, HLTH CARE DATA GUIDE, V1st ed; SCHOENFELD PS, 1993, PEDIATRICS, V91, P726; Thomassen O, 2010, ACTA ANAESTH SCAND, V54, P1179, DOI 10.1111/j.1399-6576.2010.02302.x; Tobin JM, 2013, ANESTH ANALG, V117, P1178, DOI 10.1213/ANE.0b013e3182a44d3e; Walls RM., 2012, MANUAL EMERGENCY AIR, V4th; Wittenberg MD, 2013, INT J OBSTET ANESTH, V22, P264, DOI 10.1016/j.ijoa.2013.03.001; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037	28	25	25	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-5415	2044-5423		BMJ QUAL SAF	BMJ Qual. Saf.	NOV	2015	24	11					709	+		10.1136/bmjqs-2014-003713			9	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	CU4BV	WOS:000363472000008	26183713				2021-06-18	
J	Severini, C; Lattanzi, R; Maftei, D; Marconi, V; Ciotti, MT; Passeri, PP; Florenzano, F; Del Duca, E; Caioli, S; Zona, C; Balboni, G; Salvadori, S; Nistico, R; Negri, L				Severini, Cinzia; Lattanzi, Roberta; Maftei, Daniela; Marconi, Veronica; Ciotti, Maria Teresa; Passeri, Pamela Petrocchi; Florenzano, Fulvio; Del Duca, Ester; Caioli, Silvia; Zona, Cristina; Balboni, Gianfranco; Salvadori, Severo; Nistico, Robert; Negri, Lucia			Bv8/prokineticin 2 is involved in A beta-induced neurotoxicity	SCIENTIFIC REPORTS			English	Article							ALZHEIMERS-DISEASE; PROTEIN; CHEMOKINE; BV8; INFLAMMATION; CYTOKINES; RECEPTORS; OLIGOMERS; NEUROINFLAMMATION; NEURODEGENERATION	Bv8/Prokineticin 2 (PROK2) is a bioactive peptide initially discovered as a regulator of gastrointestinal motility. Among multiple biological roles demonstrated for PROK2, it was recently established that PROK2 is an insult-inducible endangering mediator for cerebral damage. Aim of the present study was to evaluate the PROK2 and its receptors' potential involvement in amyloid beta (A beta) neurotoxicity, a hallmark of Alzheimer's disease (AD) and various forms of traumatic brain injury (TBI). Analyzing primary cortical cultures (CNs) and cortex and hippocampus from A beta treated rats, we found that PROK2 and its receptors PKR1 and PKR2 mRNA are up-regulated by A beta, suggesting their potential involvement in AD. Hence we evaluated if impairing the prokineticin system activation might have protective effect against neuronal death induced by A beta. We found that a PKR antagonist concentration-dependently protects CNs against A beta 1-42-induced neurotoxicity, by reducing the A beta-induced PROK2 neuronal up-regulation. Moreover, the antagonist completely rescued LTP impairment in hippocampal slices from 6 month-old Tg2576 AD mice without affecting basal synaptic transmission and paired pulse-facilitation paradigms. These results indicate that PROK2 plays a role in cerebral amyloidosis and that PROK2 antagonists may represent a new approach for ameliorating the defining pathology of AD.	[Severini, Cinzia; Ciotti, Maria Teresa; Passeri, Pamela Petrocchi] CNR, Inst Cell Biol & Neurobiol, I-00143 Rome, Italy; [Severini, Cinzia; Florenzano, Fulvio; Del Duca, Ester; Nistico, Robert] European Brain Res Inst, I-00143 Rome, Italy; [Lattanzi, Roberta; Maftei, Daniela; Marconi, Veronica; Negri, Lucia] Univ Roma La Sapienza, Dept Human Physiol & Pharmacol Vittorio Erspamer, I-00185 Rome, Italy; [Caioli, Silvia; Zona, Cristina; Nistico, Robert] Univ Roma Tor Vergata, I-00133 Rome, Italy; [Caioli, Silvia; Zona, Cristina] IRCCS Fdn Santa Lucia, I-00142 Rome, Italy; [Balboni, Gianfranco] Univ Cagliari, Dept Life & Environm Sci, I-09124 Cagliari, Italy; [Salvadori, Severo] Univ Ferrara, Dept Pharmaceut Sci, I-44100 Ferrara, Italy	Severini, C (corresponding author), CNR, Inst Cell Biol & Neurobiol, Via Fosso Fiorano 64, I-00143 Rome, Italy.	cinzia.severini@cnr.it	Zona, Cristina/K-5079-2014; Gianfranco, Balboni/K-1503-2019; Caioli, Silvia/I-9106-2014; Severini, Cinzia/AAX-3569-2020	Caioli, Silvia/0000-0002-7888-0664; LATTANZI, Roberta/0000-0002-6377-9256; SEVERINI, CINZIA/0000-0002-6932-704X	Italian Ministry of University and Scientific ResearchMinistry of Education, Universities and Research (MIUR) [20099F3XPM-003]; PNR-CNR Aging Program	This work was supported by a grant from the Italian Ministry of University and Scientific Research (20099F3XPM-003 to LR) and by PNR-CNR Aging Program 2012-2014.	Abou-Hamdan M, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000095; Achour SB, 2010, NEUROCHEM INT, V57, P440, DOI 10.1016/j.neuint.2010.02.013; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Balboni G, 2008, J MED CHEM, V51, P7635, DOI 10.1021/jm800854e; Balducci C, 2011, J ALZHEIMERS DIS, V24, P799, DOI 10.3233/JAD-2011-101839; Cacquevel M, 2004, CURR DRUG TARGETS, V5, P529, DOI 10.2174/1389450043345308; Campolongo P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078036; Cheng MY, 2006, J COMP NEUROL, V498, P796, DOI 10.1002/cne.21087; Cheng MY, 2012, P NATL ACAD SCI USA, V109, P5475, DOI 10.1073/pnas.1113363109; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Congiu C, 2014, EUR J MED CHEM, V81, P334, DOI 10.1016/j.ejmech.2014.05.030; Cooper NR, 2000, IMMUNOL RES, V21, P159, DOI 10.1385/IR:21:2-3:159; Crews L, 2010, HUM MOL GENET, V19, pR12, DOI 10.1093/hmg/ddq160; Dorsch M, 2005, J LEUKOCYTE BIOL, V78, P426, DOI 10.1189/jlb.0205061; Farfara D, 2008, J CELL MOL MED, V12, P762, DOI 10.1111/j.1582-4934.2008.00314.x; Finch CE, 2007, CURR ALZHEIMER RES, V4, P185, DOI 10.2174/156720507780362254; Frozza RL, 2013, MOL NEUROBIOL, V47, P1066, DOI 10.1007/s12035-013-8401-2; Giannini E, 2009, P NATL ACAD SCI USA, V106, P14646, DOI 10.1073/pnas.0903720106; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heneka MT, 2007, J NEUROIMMUNOL, V184, P69, DOI 10.1016/j.jneuroim.2006.11.017; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040; Ingves MV, 2010, AM J PHYSIOL-REG I, V298, pR617, DOI 10.1152/ajpregu.00620.2009; Jacobsen JS, 2006, P NATL ACAD SCI USA, V103, P5161, DOI 10.1073/pnas.0600948103; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; Kaser A, 2003, EMBO REP, V4, P469, DOI 10.1038/sj.embor.embor830; Klein WL, 2013, ADV ALZH DIS, V3, P49, DOI 10.3233/978-1-61499-154-0-49; Lattanzi R, 2014, INT J PHARM SCI RES, V5, P5066, DOI 10.13040/IJPSR.0975-8232.5(11).5066-74; Lattanzi R., 2014, BIOMED RES IN PRESS, DOI [10.1155/2014/301292, DOI 10.1155/2014/301292]; LeCouter J, 2004, P NATL ACAD SCI USA, V101, P16813, DOI 10.1073/pnas.0407697101; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Maftei D, 2014, BRIT J PHARMACOL, V171, P4850, DOI 10.1111/bph.12793; Meda L, 2001, NEUROBIOL AGING, V22, P885, DOI 10.1016/S0197-4580(01)00307-4; Melchiorri D, 2001, EUR J NEUROSCI, V13, P1694, DOI 10.1046/j.1460-9568.2001.01549.x; Rubio-Perez JM, 2012, SCI WORLD J, DOI 10.1100/2012/756357; Mines M, 2007, CURR MED CHEM, V14, P2456, DOI 10.2174/092986707782023686; Mollay C, 1999, EUR J PHARMACOL, V374, P189, DOI 10.1016/S0014-2999(99)00229-0; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Negri L, 2005, BRIT J PHARMACOL, V146, P625, DOI 10.1038/sj.bjp.0706376; Negri L, 2002, BRIT J PHARMACOL, V137, P1147, DOI 10.1038/sj.bjp.0704995; Negri L, 2007, LIFE SCI, V81, P1103, DOI 10.1016/j.lfs.2007.08.011; Negri L, 2006, CURR NEUROPHARMACOL, V4, P207, DOI 10.2174/157015906778019518; Negri L, 2011, CURR PHARM BIOTECHNO, V12, P1720, DOI 10.2174/138920111798357410; Nistico R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054666; Nistico R, 2012, MOL NEUROBIOL, V46, P572, DOI 10.1007/s12035-012-8324-3; Pieri M, 2010, NEUROPHARMACOLOGY, V58, P268, DOI 10.1016/j.neuropharm.2009.06.029; Ren P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020263; Selkoe Dennis J., 1994, Current Opinion in Neurobiology, V4, P708, DOI 10.1016/0959-4388(94)90014-0; Severini C, 2014, J ALZHEIMERS DIS, V38, P281, DOI 10.3233/JAD-131070; Smits HA, 2002, J NEUROIMMUNOL, V127, P160, DOI 10.1016/S0165-5728(02)00112-1; Soga T, 2002, BBA-GENE STRUCT EXPR, V1579, P173, DOI 10.1016/S0167-4781(02)00546-8; Sudduth TL, 2013, NEUROBIOL AGING, V34, P1051, DOI 10.1016/j.neurobiolaging.2012.09.012; Urayama K, 2008, ARTERIOSCL THROM VAS, V28, P841, DOI 10.1161/ATVBAHA.108.162404; Wu J, 2013, NEUROBIOL AGING, V34, P2843, DOI 10.1016/j.neurobiolaging.2013.06.003; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Xiong YC, 2010, NEUROPHARMACOLOGY, V59, P589, DOI 10.1016/j.neuropharm.2010.08.014	58	25	25	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	OCT 19	2015	5								15301	10.1038/srep15301			13	Multidisciplinary Sciences	Science & Technology - Other Topics	CT7GC	WOS:000362981700001	26477583	DOAJ Gold, Green Published			2021-06-18	
J	Chaudhary, N; Pandey, AS; Gemmete, JJ; Hua, Y; Huang, YN; Gu, YX; Xi, GH				Chaudhary, Neeraj; Pandey, Aditya S.; Gemmete, Joseph J.; Hua, Ya; Huang, Yining; Gu, Yuxiang; Xi, Guohua			Diffusion tensor imaging in hemorrhagic stroke	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	3rd Pangu Stroke Conference	OCT 10-12, 2014	Beijing, PEOPLES R CHINA			Cerebral hemorrhage; Diffusion tensor imaging; Subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; WHITE-MATTER INJURY; INTRACEREBRAL HEMORRHAGE; CORTICOSPINAL TRACT; WALLERIAN DEGENERATION; INTRAVENTRICULAR HEMORRHAGE; FRACTIONAL ANISOTROPY; SUBARACHNOID HEMORRHAGE; DECREASED DIFFUSION; AXONAL-TRANSPORT	Diffusion tensor imaging (DTI) has evolved considerably over the last decade to now be knocking on the doors of wider clinical applications. There have been several efforts over the last decade to seek valuable and reliable application of DTI in different neurological disorders. The role of DTI in predicting outcomes in patients with brain tumors has been extensively studied and has become a fairly established clinical tool in this scenario. More recently DTI has been applied in mild traumatic brain injury to predict clinical outcomes based on DTI of the white matter tracts. The resolution of white matter fiber tractography based on DTI has improved over the years with increased magnet strength and better tractography post-processing. The role of DTI in hemorrhagic stroke has been studied preliminarily in the scientific literature. There is some evidence that DTI may be efficacious in predicting outcomes of motor function in animal models of intracranial hemorrhage. Only a handful of studies of DTI have been performed in subarachnoid hemorrhage or intraventricular hemorrhage scenarios. In this manuscript we will review the evolution of DTI, the existing evidence for its role in hemorrhagic stroke and discuss possible application of this non-invasive evaluation technique of human cerebral white matter tracts in the future. (C) 2015 Elsevier Inc. All rights reserved.	[Chaudhary, Neeraj; Pandey, Aditya S.; Gemmete, Joseph J.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; [Chaudhary, Neeraj; Pandey, Aditya S.; Gemmete, Joseph J.; Hua, Ya; Xi, Guohua] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; [Huang, Yining] Peking Univ, Dept Neurol, Affiliated Hosp 1, Beijing 100871, Peoples R China; [Gu, Yuxiang] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China	Chaudhary, N (corresponding author), Univ Michigan Hlth Syst, Dept Radiol, B1D330A,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	guohuaxi@umich.edu	Gemmete, Joseph J./H-5508-2019; Gemmete, JJ/N-1604-2019	Gemmete, Joseph J./0000-0003-2760-3613; 	UMHS-PUHSC Joint Institute; 973 ProgramNational Basic Research Program of China [2014CB541600];  [NS-073595];  [NS-079157];  [NS-084049];  [NS-091545];  [NS-090925]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079157, R01NS090925, R01NS073595, R21NS084049, R21NS091545] Funding Source: NIH RePORTER	Supported by grants NS-073595, NS-079157, NS-084049, NS-091545, NS-090925, 973 Program-2014CB541600 and an UMHS-PUHSC Joint Institute grant.	Arboix A, 2002, ACTA NEUROL SCAND, V105, P282, DOI 10.1034/j.1600-0404.2002.1o170.x; Arboix A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-32; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Binkofski F, 1996, ANN NEUROL, V39, P460, DOI 10.1002/ana.410390408; Bucci M, 2013, NEUROIMAGE-CLIN, V3, P361, DOI 10.1016/j.nicl.2013.08.008; Buffon F, 2005, J CEREBR BLOOD F MET, V25, P641, DOI 10.1038/sj.jcbfm.9600054; Chen S, 2014, PROG NEUROBIOL, V115, P64, DOI 10.1016/j.pneurobio.2013.09.002; Cho SH, 2007, NEUROSCI LETT, V421, P142, DOI 10.1016/j.neulet.2007.04.052; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Chua CO, 2009, STROKE, V40, P3369, DOI 10.1161/STROKEAHA.109.549212; Chua TC, 2008, CURR OPIN NEUROL, V21, P83, DOI 10.1097/WCO.0b013e3282f4594b; Condette-Auliac S, 2001, STROKE, V32, P1818, DOI 10.1161/01.STR.32.8.1818; DELAMONTE SM, 1990, J CHILD NEUROL, V5, P101, DOI 10.1177/088307389000500206; Delsing BJP, 2001, PEDIATR NEUROL, V24, P283, DOI 10.1016/S0887-8994(01)00245-4; DeVetten G, 2010, STROKE, V41, P751, DOI 10.1161/STROKEAHA.109.573287; Diehl B, 2008, EPILEPSIA, V49, P1409, DOI 10.1111/j.1528-1167.2008.01596.x; Domi T, 2009, STROKE, V40, P780, DOI 10.1161/STROKEAHA.108.529958; Egashira Y, 2014, STROKE, V45, P2141, DOI 10.1161/STROKEAHA.114.005307; Fan SJ, 2013, NMR BIOMED, V26, P1089, DOI 10.1002/nbm.2922; FERRANTE L, 1992, SURG NEUROL, V38, P43, DOI 10.1016/0090-3019(92)90210-E; Feys H, 2000, ACTA NEUROL SCAND, V102, P371, DOI 10.1034/j.1600-0404.2000.102006371.x; Filler A, 2009, NEUROSURGERY, V65, pA29, DOI 10.1227/01.NEU.0000351279.78110.00; Filler AG, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-8; FILLER AG, 1994, J MAGN RESON IMAGING, V4, P259, DOI 10.1002/jmri.1880040308; Fujiwara S, 2014, NEUROIMAGE, V102, P789, DOI 10.1016/j.neuroimage.2014.08.049; Garg RK, 2012, STROKE, V43, P67, DOI 10.1161/STROKEAHA.111.629493; GREENE KA, 1995, NEUROLOGY, V45, P45, DOI 10.1212/WNL.45.1.45; Gu YX, 2009, STROKE, V40, P2241, DOI 10.1161/STROKEAHA.108.539536; Hatakeyama T, 2013, TRANSL STROKE RES, V4, P546, DOI 10.1007/s12975-013-0270-5; Hsieh CT, 2008, SURG NEUROL, V70, P75, DOI 10.1016/j.surneu.2007.04.004; Hsieh CT, 2008, SURG NEUROL, V69, P633, DOI 10.1016/j.surneu.2007.03.045; INOUE Y, 1990, AM J NEURORADIOL, V11, P897; Jones DK, 2005, MAGNET RESON MED, V53, P1143, DOI 10.1002/mrm.20466; Kakuda W, 2008, J CEREBR BLOOD F MET, V28, P887, DOI 10.1038/sj.jcbfm.9600604; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Kiphuth IC, 2011, CEREBROVASC DIS, V32, P420, DOI 10.1159/000330652; Koyama T, 2013, NEUROREHABILITATION, V32, P87, DOI 10.3233/NRE-130825; Koyama T, 2012, J STROKE CEREBROVASC, V21, P704, DOI 10.1016/j.jstrokecerebrovasdis.2011.03.004; Kusano Y, 2009, AM J NEURORADIOL, V30, P1561, DOI 10.3174/ajnr.A1639; Kuzu Y, 2012, CEREBROVASC DIS, V33, P566, DOI 10.1159/000338904; Kwak SY, 2010, EUR NEUROL, V63, P149, DOI 10.1159/000281108; Lansberg MG, 2001, AM J NEURORADIOL, V22, P637; Larroque B, 2003, J PEDIATR-US, V143, P477, DOI 10.1067/S0022-3476(03)00417-7; Lazar M, 2003, NEUROIMAGE, V20, P1140, DOI 10.1016/S1053-8119(03)00277-5; Le Bihan D, 1991, Magn Reson Q, V7, P1; Leak RK, 2014, PROG NEUROBIOL, V115, P1, DOI 10.1016/j.pneurobio.2013.12.003; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Liu X, 2012, EUR J RADIOL, V81, P292, DOI 10.1016/j.ejrad.2010.12.053; Ma CC, 2014, J CLIN NEUROSCI, V21, P1388, DOI 10.1016/j.jocn.2013.11.032; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mukherjee P, 2005, NEUROIMAG CLIN N AM, V15, P655, DOI 10.1016/j.nic.2005.08.010; Pandey AS, 2014, TRANSL STROKE RES, V5, P313, DOI 10.1007/s12975-014-0344-z; PANG D, 1986, NEUROSURGERY, V19, P547, DOI 10.1227/00006123-198610000-00009; Parker GJM, 2003, J MAGN RESON IMAGING, V18, P242, DOI 10.1002/jmri.10350; Pendlebury ST, 2007, INT J STROKE, V2, P80, DOI 10.1111/j.1747-4949.2007.00126.x; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Presseau C, 2015, NEUROIMAGE, V109, P73, DOI 10.1016/j.neuroimage.2014.12.058; Puig J, 2011, AM J NEURORADIOL, V32, P857, DOI 10.3174/ajnr.A2400; Qiu TM, 2008, ACTA NEUROCHIR SUPPL, V105, P165; Qureshi AI, 2012, STROKE, V43, P6, DOI 10.1161/STROKEAHA.111.639278; Sawlani V, 1997, J NEUROL SCI, V146, P103, DOI 10.1016/S0022-510X(96)00299-7; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; TAKASHIMA S, 1989, BRAIN DEV-JPN, V11, P121, DOI 10.1016/S0387-7604(89)80080-4; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; TSO MK, 2014, STROKE RES, V5, DOI DOI 10.1007/S12975-014-0323-4; VANGIJN J, 1985, NEUROLOGY, V35, P493, DOI 10.1212/WNL.35.4.493; Wagner KR, 2007, STROKE, V38, P753, DOI 10.1161/01.STR.0000255033.02904.db; Wang DM, 2012, CEREBROVASC DIS, V34, P199, DOI 10.1159/000341857; Wasserman JK, 2008, EXP NEUROL, V214, P266, DOI 10.1016/j.expneurol.2008.08.010; Werring DJ, 2000, J NEUROL NEUROSUR PS, V69, P269, DOI 10.1136/jnnp.69.2.269; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wu GF, 2013, J STROKE CEREBROVASC, V22, P232, DOI 10.1016/j.jstrokecerebrovasdis.2011.08.005; Wu GF, 2011, NEUROL RES, V33, P300, DOI 10.1179/016164110X12759951866993; Wu JS, 2007, NEUROSURGERY, V61, P935, DOI 10.1227/01.neu.0000303189.80049.ab; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 2014, PROG NEUROBIOL, V115, P45, DOI 10.1016/j.pneurobio.2013.09.007; Yeo SS, 2012, STROKE, V43, P2239, DOI 10.1161/STROKEAHA.112.661116; Yeo SS, 2011, EUR NEUROL, V66, P235, DOI 10.1159/000330942; Yokoyama K, 2008, AM J NEURORADIOL, V29, P1159, DOI 10.3174/ajnr.A1001; Yoshioka H, 2008, NEUROSURGERY, V62, P97, DOI 10.1227/01.NEU.0000311066.03121.B8; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhang JH, 2014, TRANSL STROKE RES, V5, P423, DOI 10.1007/s12975-014-0355-9; Zhao XR, 2014, TRANSL STROKE RES, V5, P554, DOI 10.1007/s12975-014-0341-2; Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003	89	25	27	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2015	272				SI		88	96		10.1016/j.expneurol.2015.05.011			9	Neurosciences	Neurosciences & Neurology	CV6AS	WOS:000364353700011	26015333	Green Accepted			2021-06-18	
J	Lewis, PM; Czosnyka, M; Carter, BG; Rosenfeld, JV; Paul, E; Singhal, N; Butt, W				Lewis, Philip M.; Czosnyka, Marek; Carter, Bradley G.; Rosenfeld, Jeffrey V.; Paul, Eldho; Singhal, Nitesh; Butt, Warwick			Cerebrovascular Pressure Reactivity in Children With Traumatic Brain Injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						arterial pressure; cerebrovascular circulation; children; Glasgow Outcome Scale; intracranial pressure; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; BLOOD-FLOW AUTOREGULATION; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; VASOMOTOR REACTIVITY; CRITICAL THRESHOLDS; MYOGENIC RESPONSES; HYPERTENSION; MORTALITY; CARE	Objective: Traumatic brain injury is a significant cause of morbidity and mortality in children. Cerebral autoregulation disturbance after traumatic brain injury is associated with worse outcome. Pressure reactivity is a fundamental component of cerebral autoregulation that can be estimated using the pressure-reactivity index, a correlation between slow arterial blood pressure, and intracranial pressure fluctuations. Pressure-reactivity index has shown prognostic value in adult traumatic brain injury, with one study confirming this in children. Pressure-reactivity index can identify a cerebral perfusion pressure range within which pressure reactivity is optimal. An increasing difference between optimal cerebral perfusion pressure and cerebral perfusion pressure is associated with worse outcome in adult traumatic brain injury; however, this has not been investigated in children. Our objective was to study pressure-reactivity index and optimal cerebral perfusion pressure in pediatric traumatic brain injury, including associations with outcome, age, and cerebral perfusion pressure. Design: Prospective observational study. Setting: ICU, Royal Children's Hospital, Melbourne, Australia. Patients: Patients with traumatic brain injury who are 6 months to 16 years old, are admitted to the ICU, and require arterial blood pressure and intracranial pressure monitoring. Interventions: None. Measurements and Main Results: Arterial blood pressure, intracranial pressure, and end-tidal Co-2 were recorded electronically until ICU discharge or monitoring cessation. Pressure-reactivity index and optimal cerebral perfusion pressure were computed according to previously published methods. Clinical data were collected from electronic medical records. Outcome was assessed 6 months post discharge using the modified Glasgow Outcome Score. Thirty-six patients were monitored, with 30 available for follow-up. Pressure-reactivity index correlated with modified Glasgow Outcome Score (Spearman rho = 0.42; p = 0.023) and was higher in patients with unfavorable outcome (0.23 vs -0.09; p = 0.0009). A plot of pressure-reactivity index averaged within 5 mm Hg cerebral perfusion pressure bins showed a U-shape, reaffirming the concept of cerebral perfusion pressure optimization in children. Optimal cerebral perfusion pressure increased with age (rho = 0.40; p = 0.02). Both the duration and magnitude of negative deviations in the difference between cerebral perfusion pressure and optimal cerebral perfusion pressure were associated with unfavorable outcome. Conclusions: In pediatric patients with traumatic brain injury, pressure-reactivity index has prognostic value and can identify cerebral perfusion pressure targets that may differ from treatment protocols. Our results suggest but do not confirm that cerebral perfusion pressure targeting using pressure-reactivity index as a guide may positively impact on outcome. This question should be addressed by a prospective clinical study.	[Lewis, Philip M.; Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Lewis, Philip M.; Rosenfeld, Jeffrey V.] Monash Univ, Cent Clin Sch, Dept Surg, Melbourne, Vic 3004, Australia; [Czosnyka, Marek] Univ Cambridge, Dept Clin Neurosci, Neurosurg Unit, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Carter, Bradley G.] Royal Childrens Hosp, Paediat Intens Care Unit, Clin Technol Serv, Parkville, Vic 3052, Australia; [Rosenfeld, Jeffrey V.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Surg, Bethesda, MD 20814 USA; [Paul, Eldho] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic, Australia; [Paul, Eldho] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Singhal, Nitesh; Butt, Warwick] Royal Childrens Hosp, Paediat Intens Care Unit, Parkville, Vic 3052, Australia; [Butt, Warwick] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia	Lewis, PM (corresponding author), Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia.	p.lewis@alfred.org.au		Paul, Eldho/0000-0003-1263-7255; czosnyka, marek/0000-0003-2446-8006	Transport Accident Commission; National Institute of Health Research, UK, Biomedical Research Center; National Institute of Health Research, UKNational Institute for Health Research (NIHR); TAC; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390] Funding Source: researchfish	Supported, in part, by the Transport Accident Commission.; Dr. Lewis has a financial interest in a fraction of the licensing fee of ICM+ Tools. Dr. Czosnyka was supported by the National Institute of Health Research, UK, Biomedical Research Center (Neuroscience Theme) and has a financial interest in a fraction of the licensing fee of ICM+. ICM+ (http://www.neurosurg.cam.ac.uk/icmplus) is licensed by Cambridge Enterprise (Cambridge, United Kingdom). ICM+ Tools (http://www.med.monash.edu.au/surgery/alfred/services/icm.html) is licensed by Monash University. Dr. Lewis disclosed royalties (Software only recently licensed, royalties to Dr. Lewis and his institution not received yet. ICM+ Tools is licensed by Monash University. As its developer, Dr. Lewis has a financial interest in a small part of the licensing fee). Dr. Czosnyka received grant support from the National Institute of Health Research, UK; consulted for J&J Codman; is employed by the University of Cambridge; lectured for Integra LifeScience; and received royalties from Cambridge Enterprise Ltd. Dr. Carter's institution received grant support from TAC. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; Bayreuther J, 2009, ARCH DIS CHILDHOOD-E, V94, P37, DOI 10.1136/adc.2007.132787; Bowles AP, 2012, BRAIN INJURY, V26, P1415, DOI 10.3109/02699052.2012.694558; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Brady KM, 2012, J APPL PHYSIOL, V113, P1362, DOI 10.1152/japplphysiol.00853.2012; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Brady KM, 2009, ANESTH ANALG, V108, P1278, DOI 10.1213/ane.0b013e3181964848; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Cremer OL, 2004, ANESTH ANALG, V99, P1211, DOI 10.1213/01.ANE.0000133917.67728.2A; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; DAVIS MJ, 1990, AM J PHYSIOL, V259, pH1890; Deasy C, 2012, INJURY, V43, P2006, DOI 10.1016/j.injury.2011.08.032; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Dias C., 2015, NEUROCRIT CARE; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Howells T, 2015, J CLIN MONIT COMPUT, V29, P97, DOI 10.1007/s10877-014-9573-7; Jaeger M, 2013, NEUROCRIT CARE, V19, P69, DOI 10.1007/s12028-013-9857-7; Johnson U, 2014, NEUROCRIT CARE, V21, P259, DOI 10.1007/s12028-014-9954-2; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Liesemer K, 2014, PEDIATR CRIT CARE ME, V15, P554, DOI 10.1097/PCC.0000000000000150; Miller J D, 1972, Prog Brain Res, V35, P411; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; Paulson O. B., 1990, BRAIN METAB REV, V2, P161; Sanchez-Porras R, 2012, ACTA NEUROCHIR, V154, P1575, DOI 10.1007/s00701-012-1423-0; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Steiner LA, 2005, ACTA NEUROCHIR SUPPL, V95, P17; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2002, ANESTH ANALG, V95, P1463, DOI 10.1097/00000539-200211000-00078; Tang SC, 2013, J FORMOS MED ASS; Taylor A, 2003, INTENS CARE MED, V29, P795, DOI 10.1007/s00134-003-1690-6; Thorat JD, 2008, J CLIN NEUROSCI, V15, P143, DOI 10.1016/j.jocn.2006.08.014; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Wallis SJ, 1996, STROKE, V27, P2287, DOI 10.1161/01.STR.27.12.2287; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Wolff HG, 1928, ARCH NEURO PSYCHIATR, V20, P1035, DOI 10.1001/archneurpsyc.1928.02210170142002; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	45	25	26	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	OCT	2015	16	8					739	749		10.1097/PCC.0000000000000471			11	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	DD1UP	WOS:000369708000015	26132743				2021-06-18	
J	Delano-Wood, L; Bangen, KJ; Sorg, SF; Clark, AL; Schiehser, DM; Luc, N; Bondi, MW; Werhane, M; Kim, RT; Bigler, ED				Delano-Wood, L.; Bangen, K. J.; Sorg, S. F.; Clark, A. L.; Schiehser, D. M.; Luc, N.; Bondi, M. W.; Werhane, M.; Kim, R. T.; Bigler, E. D.			Brainstem white matter integrity is related to loss of consciousness and postconcussive symptomatology in veterans with chronic mild to moderate traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Diffusion tensor imaging; DTI; White matter; Brainstem; Postconcussive syndrome; PCS; Traumatic brain injury; TBI	DIFFUSE AXONAL INJURY; SF-36 HEALTH SURVEY; HEAD-INJURY; PSYCHOMETRIC PROPERTIES; CORPUS-CALLOSUM; IQOLA PROJECT; WEIGHTED MRI; TENSOR; CONCUSSION; NEUROPATHOLOGY	We investigated associations between DTI indices of three brainstem white matter tracts, traumatic brain injury (TBI) injury characteristics, and postconcussive symptomatology (PCS) in a well-characterized sample of veterans with history of mild to moderate TBI (mTBI). 58 military veterans (mTBI: n = 38, mean age = 33.2, mean time since injury = 90.9 months; military controls [MC]; n = 20; mean age = 29.4) were administered 3T DTI scans as well as a comprehensive neuropsychiatric evaluation including evaluation of TBI injury characteristics and PCS symptoms (e.g., negative mood, dizziness, balance and coordination difficulties). Tractography was employed by seeding ROIs along 3 brainstem white matter tracts (i.e., medial lemniscus-central tegmentum tract [ML-CTT]; corticospinal tracts [CST], and pontine tegmentum [PT]), and mean DTI values were derived from fractional anisotropic (FA) maps. Results showed that there were no significant difference in FA between the MC and TBI groups across the 3 regions of interest; however, among the TBI group, CST FA was significantly negatively associated with LOC duration. Additionally, lower FA of certain tracts-most especially the PT-was significantly associated with increased PCS symptoms (i.e., more severe vestibular symptoms, poorer physical functioning, and greater levels of fatigue), even after adjusting for PTSD symptoms. Our findings show that, in our sample of veterans with mTBI, tractography-based DTI indices of brainstem white matter tracts of interest are related to the presence and severity of PCS symptoms. Findings are promising as they show linkages between brainstem white matter integrity and injury severity (LOC), and they raise the possibility that the pontine tegmentum in particular may be a useful marker of PCS symptoms. Collectively, these data point to important neurobiological substrates of the chronic and complex constellation of symptoms following the 'signature injury' of our combat-exposed veterans.	[Delano-Wood, L.; Bangen, K. J.; Sorg, S. F.; Schiehser, D. M.; Luc, N.; Bondi, M. W.; Kim, R. T.] Vet Affairs San Diego Healthcare Syst 116B, San Diego, CA 92161 USA; [Delano-Wood, L.; Sorg, S. F.; Schiehser, D. M.; Luc, N.; Kim, R. T.] Ctr Excellence Stress & Mental Hlth CESAMH, San Diego, CA 92161 USA; [Delano-Wood, L.; Bangen, K. J.; Sorg, S. F.; Schiehser, D. M.; Bondi, M. W.] Univ Calif La Jolla, Dept Psychiat, San Diego, CA 92093 USA; [Clark, A. L.; Werhane, M.] San Diego State Univ, Univ Calif San Diego, San Diego SDSU UCSD Joint Doctoral Program Clin P, San Diego, CA USA; [Bigler, E. D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, E. D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, E. D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, E. D.] Univ Utah, Brain Inst Utah, Salt Lake City, UT USA	Delano-Wood, L (corresponding author), Vet Affairs San Diego Healthcare Syst 116B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	ldelano@ucsd.edu			VA Clinical Science Research Development; Department of Defense Investigator-Initiated Research GrantUnited States Department of Defense; VA Merit ReviewUS Department of Veterans Affairs; Veterans AffairsUS Department of Veterans Affairs [I01CX000842] Funding Source: NIH RePORTER	The current study was supported by a VA Clinical Science Research & Development (Career Development Award-2 to L.D-W, D.S.); Department of Defense Investigator-Initiated Research Grant (L.D-W); and VA Merit Review (L.D-W.)	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Andreasen NC, 1996, P NATL ACAD SCI USA, V93, P9985, DOI 10.1073/pnas.93.18.9985; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Bammer R, 2002, MAGNET RESON MED, V48, P128, DOI 10.1002/mrm.10184; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT., 1996, BECK DEPRESSION INVE, V2; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Dixon C. E., 1995, CENTRAL NERVOUS SYST, P255; FOLTZ EL, 1953, J NEUROSURG, V10, P342, DOI 10.3171/jns.1953.10.4.0342; FOLTZ EL, 1956, J NEUROSURG, V13, P145, DOI 10.3171/jns.1956.13.2.0145; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gean A, 1994, IMAGING HEAD TRAUMA; Habas C, 2007, NEURORADIOLOGY, V49, P849, DOI 10.1007/s00234-007-0267-4; Haber AH, 2006, CLIN NEUROPSYCHOL, V20, P524, DOI 10.1080/13854040590967595; Haberg AK, 2015, J NEUROSCI RES, V93, P1109, DOI 10.1002/jnr.23534; Haines D. H., 2000, NEUROANATOMY ATLAS S; Heitger M.H., 2009, BRAIN; Helton KJ, 2006, AM J NEURORADIOL, V27, P786; Inoue T, 2005, CLIN NEUROL NEUROSUR, V107, P174, DOI 10.1016/j.clineuro.2004.06.011; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Levin H, 2013, LANCET NEUROL, V12, P15, DOI 10.1016/S1474-4422(12)70300-9; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lin W. M., 2014, BIOMED RES INT, V2014, P340; Lui YW, 2007, NEUROSURGERY, V61, P1199, DOI 10.1227/01.neu.0000306098.38141.81; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; McIntosh TK, 1996, LAB INVEST, V74, P315; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Nagae-Poetscher LM, 2004, AM J NEURORADIOL, V25, P1325; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ommaya A. K., 1966, ARCS, V38, P317; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Plum R., 1980, DIAGNOSIS STUPOR COM; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Price JL, 2003, ANN NY ACAD SCI, V985, P50; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Reep RL, 2009, NEUROBIOL LEARN MEM, V91, P104, DOI 10.1016/j.nlm.2008.08.010; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Salamon N, 2005, NEURORADIOLOGY, V47, P895, DOI 10.1007/s00234-005-1439-8; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Shetter A G, 1979, Adv Neurol, V22, P5; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; STRICH SJ, 1961, LANCET, V2, P443; Sugahara T, 1999, JMRI-J MAGN RESON IM, V9, P53, DOI 10.1002/(SICI)1522-2586(199901)9:1<53::AID-JMRI7>3.0.CO;2-2; Sullivan EV, 2003, ALCOHOL CLIN EXP RES, V27, P1409, DOI 10.1097/01.ALC.0000085586.91726.46; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Traumatic Brain Injury Task Force, 2009, REP SURG GEN TBI TAS; Uh J, 2013, INT J RADIAT ONCOL, V86, P292, DOI 10.1016/j.ijrobp.2013.01.028; Vanderploeg RD, 2015, J HEAD TRAUMA REHAB, V30, P1, DOI 10.1097/HTR.0000000000000009; Vanderploeg RD, 2012, J REHABIL RES DEV, V49, P545, DOI 10.1682/JRRD.2011.04.0069; Verhaal A., 1975, HDB CLIN NEUROLOGY, P417; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wang R, 2007, P INT SOC MAG RESON, V15, P3720; WARD AA, 1958, J NEUROSURG, V15, P129, DOI 10.3171/jns.1958.15.2.0129; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P903, DOI 10.1016/S0895-4356(98)00081-X; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P1159, DOI 10.1016/S0895-4356(98)00107-3; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Weathers FW, 1991, PCL C FOR DSM 4; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Zhang WH, 2009, NEUROIMAGE, V44, P906, DOI 10.1016/j.neuroimage.2008.09.013	98	25	26	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2015	9	3					500	512		10.1007/s11682-015-9432-2			13	Neuroimaging	Neurosciences & Neurology	CR8LQ	WOS:000361604300011	26248618				2021-06-18	
J	Sharma, D; Holowaychuk, MK				Sharma, Diya; Holowaychuk, Marie K.			Retrospective evaluation of prognostic indicators in dogs with head trauma: 72 cases (January-March 2011)	JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE			English	Article						canine; perfusion; prognosis; severity score; traumatic brain injury	GLASGOW COMA SCALE; SEVERE BRAIN-INJURY; HYPERGLYCEMIA; PATIENT; SEVERITY; MANAGEMENT; ILLNESS; PATHOPHYSIOLOGY; SYSTEM; SCORE	Objective To investigate the prognostic value of clinical and laboratory variables and scoring systems in dogs with head trauma. Design Retrospective study (January-March, 2011). Setting University teaching hospital. Animals Seventy-two client-owned dogs with a history of head trauma occurring 5 days prior to hospital admission. Dogs were excluded if they had an unconfirmed history of trauma, preexisting neurologic disease, or insufficient data available in the medical record. Interventions None. Measurements and Main Results Data from hospital admission were collected, including vital signs; blood pressure; pulse oximetry; venous blood gases and electrolyte concentrations; plasma lactate and blood glucose concentrations; PCV; total plasma protein concentration; activated clotting time; WBC count; and serum albumin, creatinine, total bilirubin, and BUN concentrations. Modified Glasgow Coma Scale (MGCS), mentation, and animal trauma triage (ATT) scores were also calculated. Treatment with mannitol, hypertonic saline (HS), corticosteroids, benzodiazepines, or phenobarbital, and requirement for endotracheal intubation were also recorded. Outcome was classified as survival or nonsurvival to hospital discharge. Decreased pulse oximetry, pH, bicarbonate concentration, or base excess, and increased potassium concentration, lactate concentration, BUN concentration, ATT score, or mentation score were risk factors for nonsurvival. Decreased MGCS score was the strongest predictor of nonsurvival; a score 11 was 84% sensitive and 73% specific for predicting nonsurvival. Dogs were more likely to die before discharge if they required HS or endotracheal intubation. Conclusions Dogs that did not survive following head trauma were more likely to have poor perfusion, severe concurrent injuries reflected by increased ATT scores, severe traumatic brain injury as evidenced by decreased MGCS or increased mentation scores, or requirement for HS administration or endotracheal intubation.	[Sharma, Diya; Holowaychuk, Marie K.] Univ Guelph, Ontario Vet Coll, Hlth Sci Ctr, Guelph, ON N1G 2W1, Canada	Holowaychuk, MK (corresponding author), Crit Care Vet Consulting, Calgary, AB, Canada.	criticalcarevet@outlook.com					Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; Armitage-Chan EA, 2007, J VET EMERG CRIT CAR, V17, P5, DOI 10.1111/j.1476-4431.2006.00194.x; Buck BD, 2002, J PHARM PRACTICE, V15, P167; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 1998, CHILD NERV SYST, V14, P455, DOI 10.1007/s003810050259; Dewey CW, 2000, VET CLIN N AM-SMALL, V30, P207, DOI 10.1016/S0195-5616(00)50010-2; Green SM, 2011, ANN EMERG MED, V58, P427, DOI 10.1016/j.annemergmed.2011.06.009; Hall KE, 2014, JAVMA-J AM VET MED A, V244, P300, DOI 10.2460/javma.244.3.300; Hayes G, 2010, J VET INTERN MED, V24, P1034, DOI 10.1111/j.1939-1676.2010.0552.x; Hayes G, 2010, J VET INTERN MED, V24, P457, DOI 10.1111/j.1939-1676.2010.0483.x; Hayes GM, 2009, J VET EMERG CRIT CAR, V19, P629, DOI 10.1111/j.1476-4431.2009.00478.x; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Knieriem M, 2007, COMP CONT EDUC PRACT, V29, P360; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; MARGULIES DR, 1994, AM SURGEON, V60, P387; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Pinto FCG, 2006, J TRAUMA, V60, P758, DOI 10.1097/01.ta.0000214581.89316.73; Platt S, 2005, IN PRACTICE, V27, P31; Platt SR, 2001, J VET INTERN MED, V15, P581, DOI 10.1892/0891-6640(2001)015&lt;0581:TPVOTM&gt;2.3.CO;2; Proulx J, 1998, COMP CONT EDUC PRACT, V20, P897; RaeGrant AD, 1996, J TRAUMA, V40, P401, DOI 10.1097/00005373-199603000-00013; Rockar R. A., 1994, Journal of Veterinary Emergency & Critical Care, V4, P77, DOI 10.1111/j.1476-4431.1994.tb00118.x; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; SHORES A, 1983, CURRENT VET THERAPY, P847; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Simpson SA, 2009, J VET EMERG CRIT CAR, V19, P588, DOI 10.1111/j.1476-4431.2009.00468.x; STARMARK JE, 1991, LANCET, V337, P1042, DOI 10.1016/0140-6736(91)92705-7; Streeter EM, 2009, JAVMA-J AM VET MED A, V235, P405, DOI 10.2460/javma.235.4.405; Syring RS, 2001, J AM VET MED ASSOC, V218, P1124, DOI 10.2460/javma.2001.218.1124; Syring RS, 2005, VET CLIN N AM-SMALL, V35, P343, DOI 10.1016/j.cvsm.2004.10.007; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]	33	25	25	1	30	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1479-3261	1476-4431		J VET EMERG CRIT CAR	J. Vet. Emerg. Crit. Care	SEP-OCT	2015	25	5					631	639		10.1111/vec.12328			9	Veterinary Sciences	Veterinary Sciences	CT6ZE	WOS:000362961600008	26112259				2021-06-18	
J	Slowik, A; Beyer, C				Slowik, Alexander; Beyer, Cordian			Inflammasomes are neuroprotective targets for sex steroids	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						Microglia; Astroglia; Estrogen; Progesterone; Neuroinflammation; Inflammasome	ESTROGEN-REGULATED MICRORNAS; TRAUMATIC BRAIN-INJURY; INNATE IMMUNE-RESPONSE; NLRP3 INFLAMMASOME; MOLECULAR PLATFORM; CEREBRAL-CORTEX; ACUTE STROKE; CELL-DEATH; PROGESTERONE; ACTIVATION	Neuroinflammation in the central nervous system is triggered by toxic stimuli or degenerative events, orchestrates the interplay of brain-intrinsic immune cells and neighboring neural cells, and sequentially allows leukocyte extravasation from the periphery into the brain parenchyma. During the inflammatory cascade, immune-competent cells become activated and secrete a plethora of cytokines and chemokines which form a local inflammatory signaling network important for warding off harmful stimuli to the host but are likewise necessary to preserve damaged brain tissue. Inflammatory responses are initiated by extra-and intra-cellular pathogen and danger-associated receptors. These signals are processed by multiprotein complexes termed inflammasomes which trigger the production of biologically active interleukins-1 and 18 after the cleavage of caspase-1. Estrogens and progesterone are neuroprotective and anti-inflammatory in diverse disease models of the brain in particular under acute inflammatory conditions such as stroke and traumatic brain injury. Both steroids are able to attenuate proinflammatory cytokine activity. Recent literature and our own studies provide convincing evidence that the anti-inflammatory potency of these steroids result from a complex interaction with the inflammasome activation and their up-stream regulatory network of miRNAs in brain-intrinsic innate immune cells. This article examines steroid-inflammasome interactions in the brain during brain injury and illuminates the importance of regulation initial upstream events during neuroinflammation. This article is part of a Special Issue entitled 'Steroid Perspectives'. (C) 2015 Elsevier Ltd. All rights reserved.	[Slowik, Alexander; Beyer, Cordian] Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, D-52074 Aachen, Germany	Beyer, C (corresponding author), Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, D-52074 Aachen, Germany.	cbeyer@ukaachen.de		Dr. Slowik, Alexander/0000-0001-9907-2263	Medical Faculty of the RWTH Aachen	We would like to acknowledge Leoni Lammerding and Adib Zendedel for their scientific contributions to this topic in our lab. This work was supported by a START grant (AS) from the Medical Faculty of the RWTH Aachen.	Abais J.M., 2014, ANTIOXID REDOX SIGNA; Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Alcocer-Gomez E, 2014, BRAIN BEHAV IMMUN, V36, P111, DOI 10.1016/j.bbi.2013.10.017; Arevalo MA, 2013, HORM BEHAV, V63, P216, DOI 10.1016/j.yhbeh.2012.02.021; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bauernfeind F, 2012, J IMMUNOL, V189, P4175, DOI 10.4049/jimmunol.1201516; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Bordet R, 2000, J CEREBR BLOOD F MET, V20, P1190, DOI 10.1097/00004647-200008000-00004; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Busillo JM, 2011, J BIOL CHEM, V286, P38703, DOI 10.1074/jbc.M111.275370; Chakraborty S, 2010, J NEUROSCI RES, V88, P1615, DOI 10.1002/jnr.22343; Cochrane DR, 2012, MOL CELL ENDOCRINOL, V357, P50, DOI 10.1016/j.mce.2011.09.022; Codolo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055375; Cunningham M, 2011, CLIN REV ALLERG IMMU, V40, P66, DOI 10.1007/s12016-010-8203-5; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Dai R, 2011, TRANSL RES, V157, P163, DOI 10.1016/j.trsl.2011.01.007; Dai RJ, 2008, BLOOD, V112, P4591, DOI 10.1182/blood-2008-04-152488; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; De Bosscher K, 2010, BRAIN BEHAV IMMUN, V24, P1035, DOI 10.1016/j.bbi.2010.06.010; De Nicola AF, 2013, J NEUROENDOCRINOL, V25, P1095, DOI 10.1111/jne.12043; Duffy BA, 2014, NEUROBIOL DIS, V63, P229, DOI 10.1016/j.nbd.2013.12.001; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Fann DYW, 2014, EXP NEUROL, V257, P114, DOI 10.1016/j.expneurol.2014.04.017; Fann DYW, 2013, AGEING RES REV, V12, P941, DOI 10.1016/j.arr.2013.09.004; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Finger JN, 2012, J BIOL CHEM, V287, P25030, DOI 10.1074/jbc.M112.378323; Finlay-Schultz J., 2014, ONCOGENE; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Frohman EM, 2006, NEW ENGL J MED, V354, P942, DOI 10.1056/NEJMra052130; Giannoni E, 2011, INFECT IMMUN, V79, P2690, DOI 10.1128/IAI.00076-11; Gotte M, 2010, Minerva Ginecol, V62, P559; Grimm A, 2014, BBA-MOL BASIS DIS, V1842, P2427, DOI 10.1016/j.bbadis.2014.09.013; Habib P, 2015, J STEROID BIOCHEM, V146, P3, DOI 10.1016/j.jsbmb.2014.02.018; Habib P, 2014, NEUROENDOCRINOLOGY, V99, P156, DOI 10.1159/000362279; Habib P, 2013, J STEROID BIOCHEM, V138, P195, DOI 10.1016/j.jsbmb.2013.06.003; Han SJ, 2014, HUM REPROD UPDATE, V20, P467, DOI 10.1093/humupd/dmu002; Hanamsagar R, 2011, J NEUROCHEM, V119, P736, DOI 10.1111/j.1471-4159.2011.07481.x; Haneklaus M, 2013, CURR OPIN IMMUNOL, V25, P40, DOI 10.1016/j.coi.2012.12.004; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Hirsch Etienne C, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS210, DOI 10.1016/S1353-8020(11)70065-7; Hoffmann S., 2014, J MOL NEUROSCI; Horvath GL, 2011, IMMUNOL REV, V243, P119, DOI 10.1111/j.1600-065X.2011.01050.x; Hsu LC, 2008, P NATL ACAD SCI USA, V105, P7803, DOI 10.1073/pnas.0802726105; Hughes GC, 2012, AUTOIMMUN REV, V11, pA502, DOI 10.1016/j.autrev.2011.12.003; Iliopoulos D, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005053; Jamilloux Y, 2013, GLIA, V61, P539, DOI 10.1002/glia.22454; Jia SJ, 2014, DISCOV MED, V18, P237; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Kangas R, 2014, MECH AGEING DEV, V143, P1, DOI 10.1016/j.mad.2014.11.001; Kipp M, 2012, J NEUROENDOCRINOL, V24, P62, DOI 10.1111/j.1365-2826.2011.02163.x; Kodahl AR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101950; KOEHLER PJ, 1995, ANTI-CANCER DRUG, V6, P19, DOI 10.1097/00001813-199502000-00002; Kofoed EM, 2011, NATURE, V477, P592, DOI 10.1038/nature10394; Kovats S, 2012, HORM BEHAV, V62, P254, DOI 10.1016/j.yhbeh.2012.04.011; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Lippai D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070945; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Martin BN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5977; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Rubio-Perez JM, 2012, SCI WORLD J, DOI 10.1100/2012/756357; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Moller T, 2010, J NEURAL TRANSM, V117, P1001, DOI 10.1007/s00702-010-0430-7; Momeni M, 2013, IRAN J IMMUNOL, V10, P103, DOI IJIv10i2A5; Munding C, 2006, CELL DEATH DIFFER, V13, P1938, DOI 10.1038/sj.cdd.4401896; Munoz-Cruz S, 2011, CURR TOP MED CHEM, V11, P1714; Nalbandian G, 2005, IMMUNOL RES, V31, P91, DOI 10.1385/IR:31:2:091; Nallamshetty S, 2013, FREE RADICAL BIO MED, V64, P20, DOI 10.1016/j.freeradbiomed.2013.05.022; Nishi Y, 2013, KIDNEY INT, V83, P662, DOI 10.1038/ki.2012.475; Ownby RL, 2010, CURR PSYCHIAT REP, V12, P39, DOI 10.1007/s11920-009-0082-1; Panchanathan R, 2011, MOL IMMUNOL, V49, P273, DOI 10.1016/j.molimm.2011.08.022; Peng H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030344; Pimplikar SW, 2014, J CLIN IMMUNOL, V34, pS64, DOI 10.1007/s10875-014-0032-5; Rao P, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00039; Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864; Rege Shraddha D, 2013, ISRN Neurol, V2013, P375852, DOI 10.1155/2013/375852; Ritzel RM, 2013, HORM BEHAV, V63, P238, DOI 10.1016/j.yhbeh.2012.04.007; Savage CD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00288; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schroder K, 2012, IMMUNOBIOLOGY, V217, P1325, DOI 10.1016/j.imbio.2012.07.020; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; Shi L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-93; Shichita T, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00319; Siegel C, 2011, P NATL ACAD SCI USA, V108, P11662, DOI 10.1073/pnas.1102635108; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Skaper SD, 2014, CNS NEUROL DISORD-DR, V13, P1654; Spence RD, 2013, J NEUROSCI, V33, P10924, DOI 10.1523/JNEUROSCI.0886-13.2013; Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599; Su L, 2009, IMMUNOL LETT, V125, P151, DOI 10.1016/j.imlet.2009.07.003; Sun YX, 2012, IMMUNOL LETT, V146, P25, DOI 10.1016/j.imlet.2012.04.007; Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x; Toms D, 2015, MOL CELL ENDOCRINOL, V399, P95, DOI 10.1016/j.mce.2014.07.022; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Trendelenburg G, 2014, J CEREBR BLOOD F MET, V34, P1857, DOI 10.1038/jcbfm.2014.159; Ulbrich C, 2012, J STEROID BIOCHEM, V131, P10, DOI 10.1016/j.jsbmb.2012.01.007; Unlu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038899; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Verway M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003407; Walker AK, 2014, PHARMACOL REV, V66, P80, DOI 10.1124/pr.113.008144; Williams KC, 2012, MOL ENDOCRINOL, V26, P1857, DOI 10.1210/me.2012-1199; Xie YL, 2014, CLIN TRANSL ONCOL, V16, P898, DOI 10.1007/s12094-014-1166-x; Yao X, 2014, AM J PHYSIOL-HEART C, V306, pH882, DOI 10.1152/ajpheart.00475.2013; Yin Y, 2009, INT J IMMUNOPATH PH, V22, P311, DOI 10.1177/039463200902200208; Yuan DZ, 2015, REPROD SCI, V22, P223, DOI 10.1177/1933719114537714; Zendedel A, 2015, J NEUROIMMUNOL, V278, P200, DOI 10.1016/j.jneuroim.2014.11.007; Zhang N, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/370530; Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072985; Zhao Y, 2011, NATURE, V477, P596, DOI 10.1038/nature10510; Zhu Y, 2013, J HUAZHONG U SCI-MED, V33, P730, DOI [10.3724/SP.J.1087.2013.00730, 10.1007/s11596-013-1188-6]	115	25	25	1	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	SEP	2015	153				SI		135	143		10.1016/j.jsbmb.2015.02.013			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	CS9AY	WOS:000362382700016	25747343				2021-06-18	
J	Kawa, L; Arborelius, UP; Yoshitake, T; Kehr, J; Hokfelt, T; Risling, M; Agoston, D				Kawa, Lizan; Arborelius, Ulf P.; Yoshitake, Takashi; Kehr, Jan; Hokfelt, Tomas; Risling, Marten; Agoston, Denes			Neurotransmitter Systems in a Mild Blast Traumatic Brain Injury Model: Catecholamines and Serotonin	JOURNAL OF NEUROTRAUMA			English	Article						anxiety; mood disorder; noradrenaline; PTSD; stress	POSTTRAUMATIC-STRESS-DISORDER; COERULEUS-NOREPINEPHRINE FUNCTION; CORTICOTROPIN-RELEASING-FACTOR; FORCED SWIMMING TEST; ELEVATED PLUS-MAZE; LOCUS-COERULEUS; TYROSINE-HYDROXYLASE; PREFRONTAL CORTEX; MESSENGER-RNA; RAT	Exposure to improvised explosive devices can result in a unique form of traumatic brain injuryblast-induced traumatic brain injury (bTBI). At the mild end of the spectrum (mild bTBI [mbTBI]), there are cognitive and mood disturbances. Similar symptoms have been observed in post-traumatic stress disorder caused by exposure to extreme psychological stress without physical injury. A role of the monoaminergic system in mood regulation and stress is well established but its involvement in mbTBI is not well understood. To address this gap, we used a rodent model of mbTBI and detected a decrease in immobility behavior in the forced swim test at 1d post-exposure, coupled with an increase in climbing behavior, but not after 14d or later, possibly indicating a transient increase in anxiety-like behavior. Using in situ hybridization, we found elevated messenger ribonucleic acid levels of both tyrosine hydroxylase and tryptophan hydroxylase 2 in the locus coeruleus and the dorsal raphe nucleus, respectively, as early as 2h post-exposure. High-performance liquid chromatography analysis 1d post-exposure primarily showed elevated noradrenaline levels in several forebrain regions. Taken together, we report that exposure to mild blast results in transient changes in both anxiety-like behavior and brain region-specific molecular changes, implicating the monoaminergic system in the pathobiology of mbTBI.	[Kawa, Lizan; Arborelius, Ulf P.; Hokfelt, Tomas; Risling, Marten] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden; [Yoshitake, Takashi; Kehr, Jan] Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden; [Agoston, Denes] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Kawa, L (corresponding author), Karolinska Inst, Dept Neurosci, Retzius Vag 8, SE-17177 Stockholm, Sweden.	lizan.kawa@ki.se		Kehr, Jan/0000-0002-2410-124X	Swedish Armed Forces RD; Swedish Research CouncilSwedish Research CouncilEuropean Commission [04X-2887]; Karolinska Institutet Funds	This study was supported by the Swedish Armed Forces R&D (MR), the Swedish Research Council (04X-2887) (TH) and Karolinska Institutet Funds (TH). The valuable contribution of Maria Angeria is gratefully acknowledged. We thank Ms. Alaa Kamnaksh for her advice on the statistical analysis and for read proofing the paper.	ABERCROMBIE ED, 1988, NEUROSCIENCE, V27, P897, DOI 10.1016/0306-4522(88)90192-3; Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Arnsten AFT, 2009, NAT REV NEUROSCI, V10, P410, DOI 10.1038/nrn2648; ASBERG M, 1976, ARCH GEN PSYCHIAT, V33, P1193; Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; Berridge CW, 2008, BRAIN RES REV, V58, P1, DOI 10.1016/j.brainresrev.2007.10.013; Bjorklund A., 1986, HDB PHYSL; BLANCHARD EB, 1991, J NERV MENT DIS, V179, P371, DOI 10.1097/00005053-199106000-00012; Blier P, 2001, J PSYCHIATR NEUROSCI, V26, pS3; Bogdanova OV, 2013, PHYSIOL BEHAV, V118, P227, DOI 10.1016/j.physbeh.2013.05.012; Bremner JD, 1997, ARCH GEN PSYCHIAT, V54, P246; Bremner JD, 1996, SYNAPSE, V23, P28, DOI 10.1002/(SICI)1098-2396(199605)23:1<28::AID-SYN4>3.0.CO;2-J; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Canli T, 2007, NAT NEUROSCI, V10, P1103, DOI 10.1038/nn1964; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chamas FM, 2004, BIOL PSYCHIAT, V55, P278, DOI 10.1016/S0006-3223(03)00788-1; Chang MS, 2000, NEUROSCIENCE, V101, P131, DOI 10.1016/S0306-4522(00)00352-3; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; CLEMEDSON CARL-JOHAN, 1955, JOUR AVIATION MED, V26, P373; CLEMEDSON CJ, 1956, ACTA PHYSIOL SCAND, V37, P202; CLEMEDSON CJ, 1956, NATURE, V177, P380, DOI 10.1038/177380a0; Cryan JF, 2002, TRENDS PHARMACOL SCI, V23, P238, DOI 10.1016/S0165-6147(02)02017-5; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Dahlstroem A, 1964, ACTA PHYSIOL SCAND S, V232, P1; Davis LL, 1997, J PSYCHIATR NEUROSCI, V22, P318; DEAKIN JFW, 1990, PSYCHOPHARMACOLOGY, V101, P85, DOI 10.1007/BF02253723; Detke MJ, 1996, BEHAV BRAIN RES, V73, P43; DETKE MJ, 1995, PSYCHOPHARMACOLOGY, V121, P66, DOI 10.1007/BF02245592; Drake AI, 2010, NEUROREHABILITATION, V26, P183, DOI 10.3233/NRE-2010-0554; Estanislau C, 2011, BEHAV PROCESS, V86, P46, DOI 10.1016/j.beproc.2010.08.008; Evans AK, 2009, NEUROSCI LETT, V455, P36, DOI 10.1016/j.neulet.2009.03.025; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FINKLESTEIN S, 1983, BRAIN RES, V271, P279, DOI 10.1016/0006-8993(83)90290-1; Flierl MA, 2008, MOL MED, V14, P195, DOI 10.2119/2007-00105.Flierl; Foote S., 1995, PHARM PHYSL CENTRAL; George SA, 2013, EUR J NEUROSCI, V37, P901, DOI 10.1111/ejn.12095; Goddard AW, 2010, DEPRESS ANXIETY, V27, P339, DOI 10.1002/da.20642; Goenjian AK, 2012, J AFFECT DISORDERS, V140, P244, DOI 10.1016/j.jad.2012.02.015; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graeff FG, 1996, PHARMACOL BIOCHEM BE, V54, P129, DOI 10.1016/0091-3057(95)02135-3; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; Harro J, 2001, BRAIN RES REV, V38, P79, DOI 10.1016/S0165-0173(01)00082-0; Harvey BH, 2006, PHYSIOL BEHAV, V87, P881, DOI 10.1016/j.physbeh.2006.01.033; Heim C, 2009, CNS SPECTRUMS, V14, P13; JACOBS BL, 1992, PHYSIOL REV, V72, P165; Kehr J., 2006, ENCY SENSORS, V6; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; KORF J, 1973, NEUROPHARMACOLOGY, V12, P933, DOI 10.1016/0028-3908(73)90024-5; Kuo JR, 2013, J NEUROTRAUM, V30, P1223, DOI 10.1089/neu.2012.2689; Lucassen PJ, 2014, ACTA NEUROPATHOL, V127, P109, DOI 10.1007/s00401-013-1223-5; Maes M, 1995, PSYCHOPHARMACOLOGY 4; Mann JJ, 1999, NEUROPSYCHOPHARMACOL, V21, pS99, DOI 10.1016/S0893-133X(99)00040-8; Mathew SJ, 2008, NEUROPSYCHOPHARMACOL, V33, P2080, DOI 10.1038/sj.npp.1301652; McDevitt RA, 2009, BRAIN RES, V1285, P109, DOI 10.1016/j.brainres.2009.06.017; McEwen BS, 2013, NEURON, V79, P16, DOI 10.1016/j.neuron.2013.06.028; Millan MJ, 2006, PHARMACOL THERAPEUT, V110, P135, DOI 10.1016/j.pharmthera.2005.11.006; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; Ong LK, 2014, J NEUROCHEM, V128, P547, DOI 10.1111/jnc.12482; PAPPIUS HM, 1987, J NEUROCHEM, V49, P321, DOI 10.1111/j.1471-4159.1987.tb03433.x; Pardon MC, 2002, NEUROSCIENCE, V115, P229, DOI 10.1016/S0306-4522(02)00364-0; Paxinos G, 2007, RAT BRAIN STREOTAXIC, V6th; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Robbins T, 1995, CENTRAL NOREPINEPHRI; Robbins TW, 2009, ANNU REV NEUROSCI, V32, P267, DOI 10.1146/annurev.neuro.051508.135535; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Schatzberg AF, 1995, PSYCHOPHARMACOLOGY 4; Sherin Jonathan E, 2011, Dialogues Clin Neurosci, V13, P263; Shinba T, 2010, NEUROCHEM RES, V35, P412, DOI 10.1007/s11064-009-0070-1; Solovieff N, 2014, NEUROPSYCHOPHARMACOL, V39, P1872, DOI 10.1038/npp.2014.34; STEINBUSCH HWM, 1981, NEUROSCIENCE, V6, P557, DOI 10.1016/0306-4522(81)90146-9; Tanaka K, 1997, REGUL PEPTIDES, V70, P173, DOI 10.1016/S0167-0115(97)01013-6; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; TSUIKI K, 1995, J NEUROCHEM, V64, P1319; Tumer N, 2013, NEUROSCI LETT, V544, P62, DOI 10.1016/j.neulet.2013.03.042; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P1; VALENTINO RJ, 1993, ANN NY ACAD SCI, V697, P173, DOI 10.1111/j.1749-6632.1993.tb49931.x; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; Wilson CB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089104; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yehuda R, 1998, BIOL PSYCHIAT, V44, P1305, DOI 10.1016/S0006-3223(98)00276-5	94	25	27	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2015	32	16					1190	1199		10.1089/neu.2014.3669			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CU9RU	WOS:000363883400002	25525686	Green Published			2021-06-18	
J	Abend, NS; Wagenman, KL; Blake, TP; Schultheis, MT; Radcliffe, J; Berg, RA; Topjian, AA; Dlugos, DJ				Abend, Nicholas S.; Wagenman, Katherine L.; Blake, Taylor P.; Schultheis, Maria T.; Radcliffe, Jerilynn; Berg, Robert A.; Topjian, Alexis A.; Dlugos, Dennis J.			Electrographic status epilepticus and neurobehavioral outcomes in critically ill children	EPILEPSY & BEHAVIOR			English	Article						EEG monitoring; Seizure; Status epilepticus; Pediatric; Outcome; Nonconvulsive seizure	NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; CONTINUOUS VIDEO-EEG; INTENSIVE-CARE-UNIT; COMATOSE CHILDREN; SEIZURES; PREDICTORS	Purpose: Electrographic seizures (ESs) and electrographic status epilepticus (ESE) are common in children with acute neurologic conditions in pediatric intensive care units (PICUs), and ESE is associated with worse functional and quality-of-life outcomes. As an exploratory study, we aimed to determine if ESE was associated with worse outcomes using more detailed neurobehavioral measures. Methods: Three hundred children with an acute neurologic condition and altered mental status underwent clinically indicated EEG monitoring and were enrolled in a prospective observational study. We obtained follow-up data from subjects who were neurodevelopmentally normal prior to PICU admission. We evaluated for associations between ESE and adaptive behavior (Adaptive Behavior Assessment System-II, ABAS-II), behavioral and emotional problems (Child Behavior Checklist, CBCL), and executive function (Behavior Rating Inventory of Executive Function, BRIEF) using linear regression analyses. A p-value of <0.05 was considered significant. Results: One hundred thirty-seven of 300 subjects were neurodevelopmentally normal prior to PICU admission. We obtained follow-up data from 36 subjects for the CBCL, 32 subjects for the ABAS-II, and 20 subjects for the BRIEF. The median duration from admission to follow-up was 2.6 years (IQR: 12-3.8). There were no differences in the acute care variables (age, sex, mental status category, intubation status, paralysis status, acute neurologic diagnosis category, seizure category, EEG background category, or short-term outcome) between subjects with and without follow-up data for any of the outcome measures. On univariate analysis, significant differences were not identified for CBCL total problem (ES coefficient: 4.1, p = 0.48; ESE coefficient: 8.9, p = 0.13) or BRIEF global executive function (ES coefficient: 2.1, p = 078; ESE coefficient: 14.1, p = 0.06) scores, although there were trends toward worse scores in subjects with ESE. On univariate analysis, ESs were not associated with worse scores (coefficient: -21.5, p = 0.051), while ESE (coefficient: -29.7, p = 0.013) was associated with worse ABAS-II adaptive behavioral global composite scores. On multivariate analysis, when compared to subjects with no seizures, both ESs (coefficient: 28, p = 0.014) and ESE (coefficient: -36, p = 0.003) were associated with worse adaptive behavioral global composite scores. Discussion: Among previously neuroclevelopmentally normal children with acute neurologic disorders, ESs and ESE were associated with worse adaptive behavior and trends toward worse behavioral emotional and executive function problems. This was a small exploratory study, and the impact of ESs and ESE on these neurobehavioral measures may be clarified by subsequent larger studies. (C) 2015 Elsevier Inc. All rights reserved.	[Berg, Robert A.; Topjian, Alexis A.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Anesthesia & Crit Care Med, Philadelphia, PA 19104 USA; [Abend, Nicholas S.; Wagenman, Katherine L.; Dlugos, Dennis J.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; [Abend, Nicholas S.; Dlugos, Dennis J.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Abend, Nicholas S.; Dlugos, Dennis J.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Blake, Taylor P.; Schultheis, Maria T.] Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA; [Radcliffe, Jerilynn] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	Abend, NS (corresponding author), Childrens Hosp Philadelphia, Div Neurol, 3501 Civ Ctr Blvd,CTRC 10016, Philadelphia, PA 19104 USA.	abend@email.chop.edu		Schultheis, Maria/0000-0002-6558-548X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS076550]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD047349] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024134] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS076550, U01NS077276, U01NS045911, K23NS075363] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01LM011124] Funding Source: NIH RePORTER	The study was supported by NIH (K23NS076550) to Dr. Abend.	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Abend NS, 2007, PEDIATR NEUROL, V37, P165, DOI 10.1016/j.pediatrneurol.2007.05.012; Abend NS, 2013, LANCET NEUROL, V12, P1170, DOI 10.1016/S1474-4422(13)70246-1; Abend NS, 2013, NEUROLOGY, V81, P383, DOI 10.1212/WNL.0b013e31829c5cfe; Abend NS, 2013, SEIZURE-EUR J EPILEP, V22, P467, DOI 10.1016/j.seizure.2013.03.008; Abend NS, 2011, NEUROCRIT CARE, V15, P70, DOI 10.1007/s12028-010-9380-z; Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Abend NS, 2015, J CLIN NEUROPHYSIOL; Achenbach T. M., 2000, MANUAL ASEBA PRESCHO; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Arango JI, 2012, CHILD NERV SYST, V28, P1925, DOI 10.1007/s00381-012-1863-0; Arndt DH, 2013, EPILEPSIA, V54, P1780, DOI 10.1111/epi.12369; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Gioia G.A., 2000, BEHAV RATING INVENTO; Gold JJ, 2014, PEDIATR NEUROL, V50, P318, DOI 10.1016/j.pediatrneurol.2013.12.014; Greiner HM, 2012, PEDIATRICS, V129, pE748, DOI 10.1542/peds.2011-2067; Gutierrez-Colina AM, 2012, PEDIATR NEUROL, V46, P158, DOI 10.1016/j.pediatrneurol.2011.12.009; Gwer S, 2012, ARCH DIS CHILD, V97, P343, DOI 10.1136/archdischild-2011-300935; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hauf M, 2009, AM J NEURORADIOL, V30, P693, DOI 10.3174/ajnr.A1456; Herman ST, 2015, J CLIN NEUROPHYSIOL; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Kirkham FJ, 2012, INTENS CARE MED, V38, P853, DOI 10.1007/s00134-012-2529-9; Lambrechtsen FACP, 2008, EPILEPSIA, V49, P615, DOI 10.1111/j.1528-1167.2007.01465.x; McCoy B, 2011, EPILEPSIA, V52, P1973, DOI 10.1111/j.1528-1167.2011.03291.x; Payne ET, 2014, BRAIN, V137, P1429, DOI 10.1093/brain/awu042; Piantino JA, 2013, PEDIATR CRIT CARE ME, V14, P601, DOI 10.1097/PCC.0b013e318291755a; Sanchez SM, 2013, J CLIN NEUROPHYSIOL, V30, P156, DOI 10.1097/WNP.0b013e31827eda27; Schreiber JM, 2012, NEUROCRIT CARE, V17, P31, DOI 10.1007/s12028-012-9715-z; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; Tay SKH, 2006, EPILEPSIA, V47, P1504, DOI 10.1111/j.1528-1167.2006.00623.x; Topjian AA, 2013, CRIT CARE MED, V41, P215, DOI 10.1097/CCM.0b013e3182668035; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wagenman KL, 2014, NEUROLOGY, V82, P396, DOI 10.1212/WNL.0000000000000082; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x	39	25	25	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	AUG	2015	49						238	244		10.1016/j.yebeh.2015.03.013			7	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	CO7CK	WOS:000359314900044	25908325	Green Accepted			2021-06-18	
J	Thibaut, A; Chatelle, C; Wannez, S; Deltombe, T; Stender, J; Schnakers, C; Laureys, S; Gosseries, O				Thibaut, A.; Chatelle, C.; Wannez, S.; Deltombe, T.; Stender, J.; Schnakers, C.; Laureys, S.; Gosseries, O.			Spasticity in disorders of consciousness: a behavioral study	EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE			English	Article; Proceedings Paper	Siz Kine Congress	JUN 14, 2013	Brussels, BELGIUM	Siz		Muscle spasticity; Pain; Therapeutics; Persistent vegetative state; Brain injuries; Nociception	PERSISTENT VEGETATIVE STATE; QUALITY-OF-LIFE; BRAIN-INJURY; STROKE; RECOVERY; SCALE; PATHOPHYSIOLOGY; CONTRACTURE; PAIN; PHYSIOTHERAPY	Background. Spasticity is a frequent complication after severe brain injury, which may impede the rehabilitation process and diminish the patients' quality of life. Aim. We here investigate the presence of spasticity in a population of non-communicative patients with disorders of consciousness. We also evaluate the correlation between spasticity and potential factors of comorbidity, frequency of physical therapy, time since insult, presence of pain, presence of tendon retraction, etiology and diagnosis. Design. Cross-sectional study. Setting. University Hospital of Liege, Belgium. Population. Sixty-five patients with chronic (>3 months post insult) disorders of consciousness were included (22 women; mean age: 44 14 y; 40 with traumatic etiology; 40 in a minimally conscious state; time since insult: 39 37 months). Methods. Spasticity was measured with the Modified Ashworth Scale (MAS) and pain was assessed using the Nociception Coma Scale-Revised (NCS-R). Results. Out of 65 patients, 58 demonstrated signs of spasticity (89%; MAS >= 1), including 40 who showed severe spasticity (61.5%; MAS >= 3). Patients with spasticity receiving anti-spastic medication were more spastic than unmedicated patients. A negative correlation was observed between the severity of spasticity and the frequency of physical therapy. MAS scores correlated positively with time since injury and NCS-R scores. We did not observe a difference of spasticity between the diagnoses. Conclusion. A large proportion of patients with disorders of consciousness develop severe spasticity, possibly affecting their functional recovery and their quality of life. The observed correlation between degrees of spasticity and pain scores highlights the importance of pain management in these patients with altered states of consciousness. Finally, the relationship between spasticity and treatment (i.e., pharmacological and physical therapy) should be further investigated in order to improve clinical care. Clinical Rehabilitation Impact. Managing spasticity at first signs could improve rehabilitation of patients with disorders of consciousness and maximize their chances of recovery. In addition, decreasing this trouble could allow a better quality of life for these non communicative patients.	[Thibaut, A.; Chatelle, C.; Wannez, S.; Laureys, S.; Gosseries, O.] Univ Liege, GIGA Res Cyclotron Res Ctr, Coma Sci Grp, Liege, Belgium; [Thibaut, A.; Chatelle, C.; Wannez, S.; Laureys, S.; Gosseries, O.] Univ Liege, Dept Neurol, Liege, Belgium; [Thibaut, A.; Chatelle, C.; Wannez, S.; Laureys, S.; Gosseries, O.] Univ Hosp Liege, Liege, Belgium; [Chatelle, C.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Deltombe, T.] Catholic Univ Louvain, CHU Dinant Godinne UCL Namur, Phys Med & Rehabil Dept, Yvoir, Belgium; [Stender, J.] Univ Copenhagen, Inst Neurosci & Pharmacol, Copenhagen, Denmark; [Schnakers, C.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA; [Schnakers, C.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA; [Gosseries, O.] Univ Wisconsin, Ctr Sleep & Consciousness, Madison, WI USA; [Gosseries, O.] Univ Wisconsin, Dept Psychiat & Psychol, Postle Lab, Madison, WI USA	Thibaut, A (corresponding author), Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, Allee Six Aout 8, B-4000 Liege, Sart Tilman, Belgium.	athibaut@ulg.ac.be	Laureys, Steven/AAN-2097-2021; Thibaut, Aurore/U-8101-2019; Gosseries, Olivia/AAB-6469-2020; Laureys, Steven/A-3349-2011	Laureys, Steven/0000-0002-3096-3807; Gosseries, Olivia/0000-0001-9011-7496; Chatelle, Camille/0000-0002-7526-2107	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH064498, MH095984] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH064498, R01MH095984] Funding Source: NIH RePORTER		Ada L, 2006, DISABIL REHABIL, V28, P891, DOI 10.1080/09638280500535165; Ada L, 2005, ARCH PHYS MED REHAB, V86, P230, DOI 10.1016/j.apmr.2004.02.031; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bovend'Eerdt TJ, 2008, ARCH PHYS MED REHAB, V89, P1395, DOI 10.1016/j.apmr.2008.02.015; Brainin M, 2013, NEUROLOGY, V80, pS1, DOI 10.1212/WNL.0b013e3182762379; BROWN GW, 1985, CLIN PEDIATR, V24, P490, DOI 10.1177/000992288502400905; BROWN P, 1994, J NEUROL NEUROSUR PS, V57, P773, DOI 10.1136/jnnp.57.7.773; Chatelle C, 2014, BRAIN INJURY, V28, P1202, DOI 10.3109/02699052.2014.920518; Chatelle C, 2012, J NEUROL NEUROSUR PS, V83, P1233, DOI 10.1136/jnnp-2012-302987; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Dietz V, 2007, LANCET NEUROL, V6, P725, DOI 10.1016/S1474-4422(07)70193-X; Doan QV, 2012, PM&R, V4, P4, DOI 10.1016/j.pmrj.2011.10.001; Elovic EP, 2004, J HEAD TRAUMA REHAB, V19, P155, DOI 10.1097/00001199-200403000-00007; Formisano R, 2014, J HEAD TRAUMA REHAB, V29, P387, DOI 10.1097/HTR.0000000000000027; Formisano R, 2011, FUNCT NEUROL, V26, P15; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gracies JM, 2010, EUR J PHYS REHAB MED, V46, P411; Gracies JM, 2005, MUSCLE NERVE, V31, P535, DOI 10.1002/mus.20284; Gracies JM, 2005, MUSCLE NERVE, V31, P552, DOI 10.1002/mus.20285; Habbal D, 2014, BRAIN INJURY, V28, P1171, DOI 10.3109/02699052.2014.920519; Hart A, 2001, BRIT MED J, V323, P391, DOI 10.1136/bmj.323.7309.391; Hesse S, 2012, CLIN REHABIL, V26, P237, DOI 10.1177/0269215511421355; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P1082; JENNETT B, 1972, LANCET, V1, P734; Kendall MG, 1938, BIOMETRIKA, V30, P81, DOI 10.1093/biomet/30.1-2.81; Kheder Ammar, 2012, Pract Neurol, V12, P289, DOI 10.1136/practneurol-2011-000155; Lance J. W., 1980, SPASTICITY DISORDERS; Lapitskaya N, 2013, BRAIN STIMUL, V6, P590, DOI 10.1016/j.brs.2013.01.002; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Leong B, 2002, BRAIN INJURY, V16, P217, DOI 10.1080/02699050110103283; Malhotra S, 2011, CLIN REHABIL, V25, P184, DOI 10.1177/0269215510381620; MCCOMAS AJ, 1994, MED SCI SPORT EXER, V26, P1498; Mehrholz J, 2005, CLIN REHABIL, V19, P751, DOI 10.1191/0269215505cr889oa; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Pilon M, 1996, BRAIN INJURY, V10, P421, DOI 10.1080/026990596124287; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2007, CURR OPIN NEUROL, V20, P620, DOI 10.1097/WCO.0b013e3282f169d9; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Sommerfeld DK, 2004, STROKE, V35, P134, DOI 10.1161/01.STR.0000105386.05173.5E; Stender J, 2014, LANCET IN PRESS; Svensson J, 2014, ACTA NEUROL SCAND, V129, P13, DOI 10.1111/ane.12139; Thibaut A, 2015, BRAIN INJ; Thibaut A, 2013, BRAIN INJURY, V27, P1093, DOI 10.3109/02699052.2013.804202; Urban PP, 2010, STROKE, V41, P2016, DOI 10.1161/STROKEAHA.110.581991; Ward AB, 2012, EUR J NEUROL, V19, P21, DOI 10.1111/j.1468-1331.2011.03448.x; Wheatley-Smith L, 2013, DISABIL REHABIL, V35, P1006, DOI 10.3109/09638288.2012.720355; Wissel J, 2010, J NEUROL, V257, P1067, DOI 10.1007/s00415-010-5463-1; Yeh CY, 2005, ARCH PHYS MED REHAB, V86, P235, DOI 10.1016/j.apmr.2004.03.032; Zorowitz RD, 2013, NEUROLOGY, V80, pS45, DOI 10.1212/WNL.0b013e3182764c86	50	25	27	0	4	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	1973-9087	1973-9095		EUR J PHYS REHAB MED	Eur. J. Phys. Rehabil. Med.	AUG	2015	51	4					389	397					9	Rehabilitation	Rehabilitation	DB6TW	WOS:000368649500005	25375186				2021-06-18	
J	Wee, HY; Lim, SW; Chio, CC; Niu, KC; Wang, CC; Kuo, JR				Wee, Hsiao-Yue; Lim, Sher-Wei; Chio, Chung-Ching; Niu, Ko-Chi; Wang, Che-Chuan; Kuo, Jinn-Rung			Hyperbaric oxygen effects on neuronal apoptosis associations in a traumatic brain injury rat model	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; Hyperbaric oxygen therapy; Apoptosis; Tumor necrosis factor-alpha; Transforming growth-interacting factor; Transforming growth factor-beta1	TUMOR-NECROSIS-FACTOR; SEVERE HEAD-INJURY; IMPACT INJURY; TNF-ALPHA; THERAPY; MECHANISMS; CONTUSION; PROTEIN; NEURODEGENERATION; INFLAMMATION	Background: The neuroprotective mechanisms of hyperbaric oxygen (HBO) therapy on traumatic brain injury (TBI) remain unclear, especially neuronal apoptosis associations such as the expression of tumor necrosis factor alpha (TNF-alpha), transforming growthinteracting factor (TGIF), and TGF-beta 1 after TBI. The aim of this study was to investigate the neuroprotective effects of HBO therapy in a rat model of TBI. Materials and methods: The experimental rats were randomly divided into three groups as follows: TBI + normobaric air (21% O-2 at one absolute atmosphere), TBI + HBO, and shamoperated normobaric air. The TBI + HBO rats received 100% O-2 at 2.0 absolute atmosphere for 1 h immediately after TBI. Local and systemic TNF-alpha expression, neuropathology, levels of the neuronal apoptosis-associated proteins TGIF and TGF-beta 1, and functional outcome were evaluated 72 h after the onset of TBI. Results: Compared to the TBI control groups, the running speed of rats on the TreadScan after TBI was significantly attenuated by HBO therapy. The TBI-induced local and systemic TNF-alpha expression, neuronal damage score, and neuronal apoptosis were also significantly reduced by HBO therapy. Moreover, HBO treatment attenuated the expression of TGIF but increased TGF-beta 1 expression in neurons. Conclusions: We concluded that treatment of TBI with HBO during the acute phase of injury can decrease local and systemic proinflammatory cytokine TNF-alpha production, resulting in neuroprotective effects. We also suggest that decreased levels of TGIF and increased levels of TGF-beta in the injured cortex leading to decreased neuronal apoptosis is one mechanism by which functional recovery may occur. (C) 2015 Elsevier Inc. All rights reserved.	[Wee, Hsiao-Yue] Dept Neurosurg, Tainan, Taiwan; [Lim, Sher-Wei] Chiali Chi Mei Hosp, Dept Neurosurg, Tainan, Taiwan; [Lim, Sher-Wei] Min Hwei Coll Hlth Care Management, Dept Nursing, Tainan, Taiwan; [Chio, Chung-Ching; Wang, Che-Chuan; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Neurosurg, Tainan 710, Yung Kang, Taiwan; [Niu, Ko-Chi] Chi Mei Med Ctr, Dept Hyperbar Oxygen, Tainan 710, Yung Kang, Taiwan; [Wang, Che-Chuan] Southern Taiwan Univ Sci & Technol, Dept Child Care, Tainan, Taiwan; [Kuo, Jinn-Rung] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan	Kuo, JR (corresponding author), Chi Mei Med Ctr, Dept Neurosurg, 901 Chung Hwa Roado, Tainan 710, Yung Kang, Taiwan.	kuojinnrung@gmail.com					Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Beare JE, 2009, J NEUROTRAUM, V26, P2045, DOI 10.1089/neu.2009.0914; Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Chen X, 2014, NEUROSCIENCE, V266, P235, DOI 10.1016/j.neuroscience.2013.11.036; Chuang CH, 2013, ACUPUNCT MED, V31, P395, DOI 10.1136/acupmed-2013-010406; Demange C, 2009, MOL CELL, V36, P1073, DOI 10.1016/j.molcel.2009.12.009; Hickey RW, 2000, CRIT CARE MED, V28, P3511, DOI 10.1097/00003246-200010000-00027; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Kuo JR, 2011, J TRAUMA, V71, pE87, DOI 10.1097/TA.0b013e31820932e2; Lee YS, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/512978; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Lin HC, 2005, EUR J PHARMACOL, V508, P249, DOI 10.1016/j.ejphar.2004.12.021; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Mascia L, 2009, NEUROCRIT CARE, V11, P417, DOI 10.1007/s12028-009-9242-8; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Niu KC, 2007, EUR J PHARMACOL, V570, P229, DOI 10.1016/j.ejphar.2007.05.056; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Villapol S, 2013, EXP NEUROL, V250, P353, DOI 10.1016/j.expneurol.2013.10.008; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yu CH, 2011, J VET SCI, V12, P299, DOI 10.4142/jvs.2011.12.3.299; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	45	25	31	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	AUG	2015	197	2					382	389		10.1016/j.jss.2015.04.052			8	Surgery	Surgery	CK3CZ	WOS:000356095100024	25982374				2021-06-18	
J	Wood, JN; French, B; Song, LH; Feudtner, C				Wood, Joanne N.; French, Benjamin; Song, Lihai; Feudtner, Chris			Evaluation for Occult Fractures in Injured Children	PEDIATRICS			English	Article							ABUSIVE HEAD TRAUMA; SKELETAL SURVEYS; SUSPECTED ABUSE; INFANTS; DIAGNOSIS; IDENTIFICATION; OUTCOMES; YOUNGER; YIELD; AGE	OBJECTIVES: To examine variation across US hospitals in evaluation for occult fractures in (1) children <2 years old diagnosed with physical abuse and (2) infants,1 year old with injuries associated with a high likelihood of abuse and to identify factors associated with such variation. METHODS: We performed a retrospective study in children,2 years old with a diagnosis of physical abuse and in infants,1 year old with non-motor vehicle crash-related traumatic brain injury or femur fractures discharged from 366 hospitals in the Premier database from 2009 to 2013. We examined across-hospital variation and identified child-and hospital-level factors associated with evaluation for occult fractures. RESULTS: Evaluations for occult fractures were performed in 48% of the 2502 children with an abuse diagnosis, in 51% of the 1574 infants with traumatic brain injury, and in 53% of the 859 infants with femur fractures. Hospitals varied substantially with regard to their rates of evaluation for occult fractures in all 3 groups. Occult fracture evaluations were more likely to be performed at teaching hospitals than at nonteaching hospitals (all P < .001). The hospital-level annual volume of young, injured children was associated with the probability of occult fracture evaluation, such that hospitals treating more young, injured patients were more likely to evaluate for occult fractures (all P < .001). CONCLUSIONS: Substantial variation in evaluation for occult fractures among young children with a diagnosis of abuse or injuries associated with a high likelihood of abuse highlights opportunities for quality improvement in this vulnerable population.	[Wood, Joanne N.; Feudtner, Chris] Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Song, Lihai] Childrens Hosp Philadelphia, PolicyLab, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Feudtner, Chris] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [French, Benjamin] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA	Wood, JN (corresponding author), Childrens Hosp Philadelphia, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA.	woodjo@email.chop.edu	Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD071967-01]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD071967] Funding Source: NIH RePORTER	Dr Wood received salary funding from the National Institute of Child Health and Human Development grant (1K23HD071967-01). Funded by the National Institutes of Health (NIH).	American College of Radiology, 2011, ACR SPR PRACT GUID S; Belfer RA, 2001, AM J EMERG MED, V19, P122, DOI 10.1053/ajem.2001.21345; Berger RP, 2015, INJURY PREV, V21, pE133, DOI 10.1136/injuryprev-2013-040924; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Brehaut JC, 2010, MED DECIS MAKING, V30, P398, DOI 10.1177/0272989X09344747; Centers for Disease Control and Prevention; National Center for Injury Prevention and Control; Division of Unintentional Injury Prevention, 2014, PERC DISTR TBI REL H; Coffey C, 2005, J PEDIATR SURG, V40, P120, DOI 10.1016/j.jpedsurg.2004.09.003; DALTON HJ, 1990, AM J DIS CHILD, V144, P875, DOI 10.1001/archpedi.1990.02150320039022; Damiani G, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-2; Day Fiona, 2006, J Clin Forensic Med, V13, P55, DOI 10.1016/j.jcfm.2005.08.001; Deye KP, 2013, J TRAUMA ACUTE CARE, V74, P1553, DOI 10.1097/TA.0b013e31828b7fc4; Di Pietro MA, 2009, PEDIATRICS, V123, P1430, DOI 10.1542/peds.2009-0558; Duffy SO, 2011, PEDIATRICS, V127, pE47, DOI 10.1542/peds.2010-0298; Feudtner C, 2013, PHARMACOEPIDEM DR S, V22, P890, DOI 10.1002/pds.3456; Fisher BT, 2012, PHARMACOEPIDEM DR S, P246; French B, 2012, STAT MED, V31, P366, DOI 10.1002/sim.4410; Hicks RA, 2007, PEDIATR EMERG CARE, V23, P308, DOI 10.1097/01.pec.0000270174.39228.30; Hooft A, 2013, J PEDIATR-US, V162, P80, DOI 10.1016/j.jpeds.2012.06.037; Hui C, 2008, J PEDIATR ORTHOPED, V28, P297, DOI 10.1097/BPO.0b013e3181653bf9; Hulson OS, 2014, PEDIATR RADIOL, V44, P1557, DOI 10.1007/s00247-014-3063-4; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jenny C, 2007, PEDIATRICS, V119, P1232, DOI 10.1542/peds.2007-0883; Karmazyn B, 2011, AM J ROENTGENOL, V197, pW159, DOI 10.2214/AJR.10.5733; Kemp AM, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1518; Lane WG, 2007, CLIN ORTHOP RELAT R, P219, DOI 10.1097/BLO.0b013e31805c0849; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Laskey AL, 2013, J PEDIATR-US, V162, P86, DOI 10.1016/j.jpeds.2012.06.038; Laskey AL, 2012, J PEDIATR-US, V160, P1003, DOI 10.1016/j.jpeds.2011.11.042; Leventhal JM, 2008, PEDIATRICS, V122, P599, DOI 10.1542/peds.2007-1959; Leventhal JM, 2010, PEDIATRICS, V126, pE104, DOI 10.1542/peds.2009-1076; Lindberg DM, 2014, J PEDIATR-US, V164, P1268, DOI 10.1016/j.jpeds.2014.01.068; Loder RT, 2006, J PEDIATR ORTHOPED, V26, P561, DOI 10.1097/01.bpo.0000230335.19029.ab; Maguire S., 2013, EVID BASED CHILD HLT, V5, P2044, DOI [10.1002/ebch.1941, DOI 10.1002/EBCH.1941]; MERTEN DF, 1983, RADIOLOGY, V146, P377, DOI 10.1148/radiology.146.2.6849085; Myhre MC, 2007, ACTA PAEDIATR, V96, P1159, DOI 10.1111/j.1651-2227.2007.00356.x; Normand SLT, 2007, STAT SCI, V22, P206, DOI 10.1214/088342307000000096; Oderda Gary M, 2013, J Pain Palliat Care Pharmacother, V27, P62, DOI 10.3109/15360288.2012.751956; Oral R, 2003, PEDIATR EMERG CARE, V19, P148, DOI 10.1097/01.pec.0000081234.20228.33; Oral R, 2008, PEDIATR EMERG CARE, V24, P816, DOI 10.1097/PEC.0b013e31818e9f5d; Petska HW, 2013, CLIN PEDIATR, V52, P86, DOI 10.1177/0009922812441675; Prior M, 2008, J EVAL CLIN PRACT, V14, P888, DOI 10.1111/j.1365-2753.2008.01014.x; Rangel EL, 2009, J PEDIATR SURG, V44, P1229, DOI 10.1016/j.jpedsurg.2009.02.044; Ravichandiran N, 2010, PEDIATRICS, V125, P60, DOI 10.1542/peds.2008-3794; Robinson Scott B, 2014, Infect Dis Clin Pract (Baltim Md), V22, P320; Sheets LK, 2013, PEDIATRICS, V131, P701, DOI 10.1542/peds.2012-2780; Thackeray JD, 2007, PEDIATR EMERG CARE, V23, P735, DOI 10.1097/PEC.0b013e3181568039; Thorpe EL, 2014, PEDIATR EMERG CARE, V30, P771, DOI 10.1097/PEC.0000000000000257; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277; Wood JN, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-169; Wood JN, 2012, PEDIATRICS, V130, P853, DOI 10.1542/peds.2012-0244; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031; Wood JN, 2009, PEDIATRICS, V123, pE247, DOI 10.1542/peds.2008-2467; Ziegler DS, 2005, J PAEDIATR CHILD H, V41, P251, DOI 10.1111/j.1440-1754.2005.00605.x	54	25	25	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	AUG	2015	136	2					232	240		10.1542/peds.2014-3977			9	Pediatrics	Pediatrics	CN9SA	WOS:000358788100042	26169425	Green Published, Bronze			2021-06-18	
J	Dams-O'Connor, K; Pretz, C; Billah, T; Hammond, FM; Harrison-Felix, C				Dams-O'Connor, Kristen; Pretz, Christopher; Billah, Tausif; Hammond, Flora M.; Harrison-Felix, Cynthia			Global Outcome Trajectories After TBI Among Survivors and Nonsurvivors: A National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							LONGITUDINAL DESCRIPTION; LIFE EXPECTANCY; SCALE; MORTALITY; INDIVIDUALS; AGE; POPULATION; PREDICTORS; PATTERNS; DATABASE	Objective: To compare long-term functional outcome trajectories of individuals with traumatic brain injury (TBI) who survive with those who expire more than 5 years postinjury, using individual growth curve analysis. Design: Secondary analysis of data from a multicenter longitudinal cohort study. Setting: Acute inpatient rehabilitation facilities that are current or former TBI Model Systems. Participants: Individuals 16 years and older with a primary diagnosis of TBI. Main Outcome Measures: Glasgow Outcome Scale-Extended; Disability Rating Scale. Results: Individuals in the TBI Model Systems who expire several years after injury demonstrate worse functional status at baseline and a steeper rate of decline over time as measured by both the Glasgow Outcome Scale-Extended and the Disability Rating Scale. There was significant variability in each growth parameter (P < .05) for both instruments. A reduced model was built for each outcome, including all covariates that related significantly to the growth parameters. An interactive tool was created for each outcome to generate individual-level trajectories based on various combinations of covariate values. Conclusion: Individuals with TBI who die several years after injury demonstrate functional trajectories that differ markedly from those of survivors. Opportunities should be sought for health management interventions to improve health and longevity after TBI.	[Dams-O'Connor, Kristen; Billah, Tausif] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Pretz, Christopher; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA	Dams-O'Connor, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, One Gustave Levy Pl,Box 1240B, New York, NY 10029 USA.	kristen.dams-o'connor@mountsinai.org			Traumatic Brain Injury Model Systems (TBIMS) National Data and Statistical Center (National Institute on Disability and Rehabilitation Research [NIDRR]) [H133A110006]; New York TBIMS (NIDRR) [H133A070033]; Indiana University TBIMS (NIDRR) [H133A120035]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER	This work was funded by the Traumatic Brain Injury Model Systems (TBIMS) National Data and Statistical Center (National Institute on Disability and Rehabilitation Research [NIDRR] grant no. H133A110006), the New York TBIMS (NIDRR grant no. H133A070033), and Indiana University TBIMS (NIDRR grant no. H133A120035).	Adler M., 1990, DISABLED THEIR HLTH; Arango-Lasprilla JC, 2010, ARCH PHYS MED REHAB, V91, P1495, DOI 10.1016/j.apmr.2010.07.010; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Chan L, 2002, ARCH PHYS MED REHAB, V83, P1196, DOI 10.1053/apmr.2002.34811; Connelly J, 2006, DISABIL REHABIL, V28, P629, DOI 10.1080/09638280500276513; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Graham JE, 2010, ARCH PHYS MED REHAB, V91, P43, DOI 10.1016/j.apmr.2009.09.017; Granger CV, 2007, AM J PHYS MED REHAB, V86, P883, DOI 10.1097/PHM.0b013e318152058a; Hall A, 2007, INTELLECT DEV DISAB, V45, P310, DOI 10.1352/0047-6765(2007)45[310:PIPHCU]2.0.CO;2; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Institute of Medicine Committee on Gulf War Health, 2009, GULF WAR HLTH; JENNETT B, 1975, LANCET, V1, P480; Kolakowsky-Hayner SA, 2012, BRAIN INJURY, V26, P1328, DOI 10.3109/02699052.2012.706353; Kozlowski AJ, 2013, ARCH PHYS MED REHAB, V94, P589, DOI 10.1016/j.apmr.2012.08.199; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Norman G, 2010, ADV HEALTH SCI EDUC, V15, P625, DOI 10.1007/s10459-010-9222-y; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P2486, DOI 10.1016/j.apmr.2013.06.021; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P2478, DOI 10.1016/j.apmr.2013.06.019; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P579, DOI 10.1016/j.apmr.2012.08.197; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Strauss D, 2004, NEUROREHABILITATION, V19, P257; Swaine JG, 2014, J INTELL DISABIL RES, V58, P651, DOI 10.1111/jir.12062; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	38	25	26	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2015	30	4					E1	E10		10.1097/HTR.0000000000000073			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CM8JB	WOS:000357944800001	24922043	Green Accepted			2021-06-18	
J	Lu, XY; Wang, HD; Xu, JG; Ding, K; Li, T				Lu, Xin-Yu; Wang, Han-Dong; Xu, Jian-Guo; Ding, Ke; Li, Tao			Deletion of Nrf2 Exacerbates Oxidative Stress After Traumatic Brain Injury in Mice	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Nrf2; NOX2; Oxidative stress	TRANSCRIPTION FACTOR NRF2; NADPH OXIDASE; TERT-BUTYLHYDROQUINONE; INHIBITION; INFLAMMATION; EXPRESSION; PATHWAY; DAMAGE; MODEL; ANTIOXIDANTS	Traumatic brain injury (TBI) is a worldwide public health and medical problem. Oxidative stress is recognized as an important contributing factor in the pathogenesis of TBI. The present study was designed to explore the anti-oxidative effect of Nuclear factor erythroid 2-related factor 2 (Nrf2) on brain damage induced by traumatic injury in a mouse model. Moderate weight-drop impact head injury was induced in adult male mice. The mice were randomly divided into four groups: Nrf2(+/+) sham-operation, Nrf2(-/-) sham-operation, Nrf2(+/+) TBI, and Nrf2(-/-) TBI group. Neurological scores were evaluated 24 h after TBI, followed by collection of the brain specimens. Brain edema was detected by the wet-dry ratio method. The expression of NOX2 protein in the brain specimen was investigated using Western Blot analysis and immunohistochemical staining. In addition, malondialdehyde (MDA) level and superoxide dismutase (SOD) activity were evaluated in the brain tissues. Twenty-four hours after TBI, our results showed Nrf2(+/+) TBI mice have more severe neurological deficits and brain edema than Nrf2(+/+) sham group. On the other hand, the Nrf2(-/-) TBI mice were found to have significantly increased neurological deficits and brain edema, compared to Nrf2(+/+) TBI mice (P < 0.05). At the same time, we found that the expression of NOX2 protein, MDA level were significantly increased in Nrf2(-/-) mice, while SOD activity was considerably decreased after TBI compared to Nrf2(+/+) mice (P < 0.05). We demonstrated that deletion of Nrf2 exacerbates brain injury after TBI in mice, suggesting that Nrf2 may play an important role in protecting brain injury after TBI, possibly by modulating oxidative stress.	[Lu, Xin-Yu; Wang, Han-Dong; Xu, Jian-Guo; Ding, Ke; Li, Tao] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com					Anrather J, 2006, J BIOL CHEM, V281, P5657, DOI 10.1074/jbc.M506172200; Beziaud T, 2011, CRIT CARE MED, V39, P2300, DOI 10.1097/CCM.0b013e3182227e4a; Cairns B, 2012, CURR DRUG TARGETS, V13, P199, DOI 10.2174/138945012799201676; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Cheng ZG, 2013, ASIAN PAC J TROP MED, V6, P305, DOI 10.1016/S1995-7645(13)60061-9; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Ferrer-Sueta G, 2009, ACS CHEM BIOL, V4, P161, DOI 10.1021/cb800279q; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Kahles T, 2012, CELL MOL LIFE SCI, V69, P2345, DOI 10.1007/s00018-012-1011-8; Kalayci M, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-75; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; Kerman M, 2012, J MOL HISTOL, V43, P49, DOI 10.1007/s10735-011-9376-9; Kim HJ, 2010, AM J PHYSIOL-RENAL, V298, pF662, DOI 10.1152/ajprenal.00421.2009; Kong XN, 2010, J IMMUNOL, V185, P569, DOI 10.4049/jimmunol.0902315; Li HD, 2013, EUR J APPL PHYSIOL, V113, P1555, DOI 10.1007/s00421-012-2584-5; Lo W, 2007, NEUROSCI LETT, V414, P228, DOI 10.1016/j.neulet.2006.12.055; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Lu XY, 2014, J SURG RES, V188, P206, DOI 10.1016/j.jss.2013.11.1106; Mao L, 2011, J SURG RES, V170, pE105, DOI 10.1016/j.jss.2011.05.049; Mao L, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/238321; Marnett LJ, 2001, TRENDS GENET, V17, P214, DOI 10.1016/S0168-9525(01)02239-9; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Pendyala S, 2010, RESP PHYSIOL NEUROBI, V174, P265, DOI 10.1016/j.resp.2010.09.016; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Reddy PVB, 2012, NEUROCHEM RES, V37, P1697, DOI 10.1007/s11064-012-0779-0; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Titova E, 2007, CLIN EXP PHARMACOL P, V34, P845, DOI 10.1111/j.1440-1681.2007.04664.x; Tumer N, 2013, NEUROSCI LETT, V544, P62, DOI 10.1016/j.neulet.2013.03.042; Wang JW, 2013, BIOCHEM BIOPH RES CO, V430, P1016, DOI 10.1016/j.bbrc.2012.12.046; WOOLLIAMS JA, 1983, RES VET SCI, V34, P253, DOI 10.1016/S0034-5288(18)32219-7; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Ye QY, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-156; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	46	25	27	0	12	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JUL	2015	35	5					713	721		10.1007/s10571-015-0167-9			9	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	CL2JJ	WOS:000356769400012	25732597				2021-06-18	
J	Midura, EF; Jernigan, PL; Kuethe, JW; Friend, LA; Veile, R; Makley, AT; Caldwell, CC; Goodman, MD				Midura, Emily F.; Jernigan, Peter L.; Kuethe, Joshua W.; Friend, Lou Ann; Veile, Rosalie; Makley, Amy T.; Caldwell, Charles C.; Goodman, Michael D.			Microparticles impact coagulation after traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						Platelet function; Microparticles; TBI; Hypercoagulability; Thromboelastometry	PLATELET DYSFUNCTION; HYPERCOAGULABLE STATE; CEREBROSPINAL-FLUID; VENOUS THROMBOSIS; PROCOAGULANT; COAGULOPATHY; RESUSCITATION; PREDICTORS; GENERATION; MODEL	Background: The pathophysiology that drives the subacute hypercoagulable state commonly seen after traumatic brain injury (TBI) is not well understood. Alterations caused by TBI in platelet and microparticle (MP) numbers and function have been suggested as possible causes; however, the contributions of platelets and MPs are currently unknown. Materials and methods: A weight-drop technique of TBI using a murine model of moderate head injury was used. Blood was collected at intervals after injury. MP enumeration and characterization were performed using Nanoparticle Tracking Analysis, and platelet counts and coagulation parameters were determined using thromboelastometry. A MP procoagulant assay was used to compare activity between injured and sham mice. Results: At 24 h after injury, there were no changes in circulating platelet numbers. However, there was a decrease in platelet contribution to clot formation. In contrast, there was a decline in circulating total MP numbers. When MPs from sham mice were added to the blood from head-injured animals, there was a normalization of platelet contribution to clot formation. Conversely, when MPs from TBI mice were added to sham blood, there was a significant decrease in platelet contribution to clot formation. Notably, there was an increase in MP procoagulant activity in head-injured mice. Conclusions: MPs generated after TBI likely contribute to altered coagulation after head injury and may play a key role in the development of a posttraumatic hypercoagulable state in TBI patients. (C) 2015 Elsevier Inc. All rights reserved.	[Goodman, Michael D.] Univ Cincinnati, Dept Surg, Div Res, Cincinnati, OH 45267 USA; Univ Cincinnati, Inst Mil Med, Cincinnati, OH 45267 USA	Goodman, MD (corresponding author), Univ Cincinnati, Dept Surg, Div Res, 231 Albert Sabin Way,ML 0558, Cincinnati, OH 45267 USA.	goodmamd@ucmail.uc.edu		Midura, Emily/0000-0002-7659-316X; Goodman, Michael/0000-0001-7218-4855; Veile, Rosalie/0000-0002-0139-7498; Caldwell, Charles/0000-0003-1692-4550	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM100913] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM100913] Funding Source: NIH RePORTER		Brakenridge SC, 2013, J TRAUMA ACUTE CARE, V74, P1231, DOI 10.1097/TA.0b013e31828cc9a0; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Choudhry MA, 2007, INJURY, V38, P1382, DOI 10.1016/j.injury.2007.09.027; Cotton BA, 2012, J TRAUMA ACUTE CARE, V72, P1470, DOI 10.1097/TA.0b013e31824d56ad; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Epstein DS, 2015, BRIT J NEUROSURG, V29, P118, DOI 10.3109/02688697.2014.950632; Geddings JE, 2013, BLOOD, V122, P1873, DOI 10.1182/blood-2013-04-460139; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Gyorgy B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018-011-0689-3; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Haut ER, 2009, J TRAUMA, V66, P994, DOI 10.1097/TA.0b013e3181991adc; Huang M, 2009, SURG NEUROL, V72, P481, DOI 10.1016/j.surneu.2008.12.016; Injury Prevention and Control, INJ PREV CONTR TRAUM; Kaptan K, 2008, INT J GYNECOL OBSTET, V102, P271, DOI 10.1016/j.ijgo.2008.04.007; Kashuk JL, 2010, ANN SURG, V251, P604, DOI 10.1097/SLA.0b013e3181d3599c; Kornblith LZ, 2014, J TRAUMA ACUTE CARE, V76, P255, DOI 10.1097/TA.0000000000000108; Kumar MA, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0391-y; Kushimoto S, 2001, NEUROSURGERY, V49, P1084, DOI 10.1097/00006123-200111000-00011; Lacroix R, 2012, THROMB RES, V129, pS27, DOI 10.1016/j.thromres.2012.02.025; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Matijevic N, 2014, THROMB RES, V134, P652, DOI 10.1016/j.thromres.2014.07.023; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Nekludov M, 2014, J NEUROTRAUM, V31, P1927, DOI 10.1089/neu.2013.3168; Paffrath T, 2010, INJURY, V41, P97, DOI 10.1016/j.injury.2009.06.010; Park MS, 2012, SURGERY, V151, P831, DOI 10.1016/j.surg.2011.12.022; Park MS, 2009, J TRAUMA, V67, P266, DOI 10.1097/TA.0b013e3181ae6f1c; Patz S, 2013, J NEUROTRAUM, V30, P1232, DOI 10.1089/neu.2012.2596; Piccin A, 2007, BLOOD REV, V21, P157, DOI 10.1016/j.blre.2006.09.001; Ploplis VA, 2014, J NEUROTRAUM, V31, P1672, DOI 10.1089/neu.2013.3302; Prakash PS, 2012, J TRAUMA ACUTE CARE, V73, P401, DOI 10.1097/TA.0b013e31825a776d; Schiro A, 2014, ATHEROSCLEROSIS, V234, P295, DOI 10.1016/j.atherosclerosis.2014.03.019; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Schreiber M, 2009, J TRAUMA, V67, P275; Sinauridze EI, 2007, THROMB HAEMOSTASIS, V97, P425, DOI 10.1160/TH06-06-0313; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; VECHT CJ, 1975, J NEUROL NEUROSUR PS, V38, P567, DOI 10.1136/jnnp.38.6.567; Windelov NA, 2014, J TRAUMA ACUTE CARE, V77, P692, DOI 10.1097/TA.0000000000000437; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Zhou L, 2014, ACTA PHARMACOL SIN, V35, P1103, DOI 10.1038/aps.2014.73	41	25	27	1	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUL	2015	197	1					25	31		10.1016/j.jss.2015.02.064			7	Surgery	Surgery	CJ5UA	WOS:000355554900005	25846728	Green Accepted			2021-06-18	
J	Moore, IS; Ranson, C; Mathema, P				Moore, Isabel S.; Ranson, Craig; Mathema, Prabhat			Injury Risk in International Rugby Union Three-Year Injury Surveillance of the Welsh National Team	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						injury epidemiology; rugby; concussion; hematoma	DATA-COLLECTION PROCEDURES; WORLD ATHLETICS CHAMPIONSHIPS; CONSENSUS STATEMENT; SPORTS INJURIES; CUP 2011; EPIDEMIOLOGY; CONCUSSION; FOOTBALL; DEFINITIONS; PLAYERS	Background: Within international Rugby Union, only injury rates during the Rugby World Cup have been reported. Therefore, injury rates and types during other international tournaments are unknown. Purpose: To assess the 3-year incidence, severity, nature, and causes of match and training injuries sustained during different international tournaments played by the Welsh national Rugby Union team. Study Design: Descriptive epidemiology study. Methods: Injury data for all players (n = 78) selected for 1 national Rugby Union team over a 3-year period were analyzed using the international consensus statement methods. Player height (cm) and mass (kg) were recorded. Tournaments were grouped for comparisons as: autumn tournaments (2012 and 2013), Rugby World Cup (RWC; 2011), Six Nations (2012, 2013, and 2014), and summer tournaments (2012, 2013, and 2014). Injury incidence (injuries/1000 hours), prevalence (% of players unavailable), and severity (days lost) were calculated for each tournament. Injury location, type, and cause of match and training injuries were analyzed. Results: Match injury incidence was highest during autumn tournaments (262.5/1000 match-hours) and lowest during the RWC (178.6/1000 match-hours). Summer tournaments had the highest training incidence (5.5 injuries/1000 training-hours). Mild injuries were most likely during the RWC (risk ratio [RR], 2.02; 95% CI, 1.26-3.24), while severe injuries were most likely during autumn tournaments (RR, 3.27; 95% CI, 1.70-6.29). Quadriceps hematomas (18.8/1000 match-hours; 95% CI, 11.3-31.1) and concussions (13.8/1000 match-hours; 95% CI, 7.6-24.8) were the most common match injuries, with shoulder dislocations being the most severe (111 mean days lost per injury). Conclusion: Injury rates were considerably higher than those previously reported for multiple teams during RWC tournaments. Further investigation of injury rates and risk factors is recommended to accurately gauge their impact within international Rugby Union, particularly with regard to lower limb hematoma, concussion, and shoulder injuries.	[Moore, Isabel S.; Ranson, Craig; Mathema, Prabhat] Cardiff Metropolitan Univ, Cardiff Sch Sport, Cardiff CF23 6XD, S Glam, Wales	Moore, IS (corresponding author), Cardiff Metropolitan Univ, Cardiff Sch Sport, Sports Injury Res Grp, Cyncoed Campus, Cardiff CF23 6XD, S Glam, Wales.	imoore@cardiffmet.ac.uk	Ranson, Craig/AAQ-5452-2020	Moore, Isabel/0000-0002-4746-3390			Alonso JM, 2010, BRIT J SPORT MED, V44, P1100, DOI 10.1136/bjsm.2010.078030; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bohu Y, 2015, BRIT J SPORT MED, V49, P1535, DOI 10.1136/bjsports-2014-093718; Brooks JHM, 2011, BRIT J SPORT MED, V45, P765, DOI 10.1136/bjsm.2009.066985; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P288, DOI 10.1136/bjsm.2004.013391; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Brooks JHM, 2006, SPORTS MED, V36, P459, DOI 10.2165/00007256-200636060-00001; Engebretsen L, 2013, BRIT J SPORT MED, V47, P407, DOI 10.1136/bjsports-2013-092380; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Finch CF, 2014, BRIT J SPORT MED, V48, P1276, DOI 10.1136/bjsports-2012-091729; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Hagglund M, 2006, BRIT J SPORT MED, V40, P767, DOI 10.1136/bjsm.2006.026609; Hagglund M, 2013, BRIT J SPORT MED, V47, P738, DOI 10.1136/bjsports-2013-092215; Harris DA, 2010, BRIT J SPORT MED, V44, P200, DOI 10.1136/bjsm.2008.047449; Haseler CM, 2010, BRIT J SPORT MED, V44, P1093, DOI 10.1136/bjsm.2010.074021; Headey J, 2007, AM J SPORT MED, V35, P1537, DOI 10.1177/0363546507300691; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Lynch E, 2013, PAK J MED SCI, V29, P1400; Alonso JM, 2009, CLIN J SPORT MED, V19, P26, DOI 10.1097/JSM.0b013e318191c8e7; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moore I, 2014, BRIT J SPORT MED, V48, P642; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Orchard JW, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.012732; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Ranson C, 2013, BRIT J SPORT MED, V47, P637, DOI 10.1136/bjsports-2012-091783; Roberts SP, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003998; Rugby Football Union, 2014, ENGL PROF RUGB INJ S; Timpka T, 2014, BRIT J SPORT MED, V48, P483, DOI 10.1136/bjsports-2013-093241; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; Usman J, J SCI MED SPORT, DOI [10.1016/jsams.2014.07.020, DOI 10.1016/JSAMS.2014.07.020]; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1; World Rugby, WORLD RUGB RANK	38	25	25	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	JUL	2015	3	7							2325967115596194	10.1177/2325967115596194			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DE1KB	WOS:000370384700008	26674339	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Newell, E; Shellington, DK; Simon, DW; Bell, MJ; Kochanek, PM; Feldman, K; Bayir, H; Aneja, RK; Carcillo, JA; Clark, RSB				Newell, Elizabeth; Shellington, David K.; Simon, Dennis W.; Bell, Michael J.; Kochanek, Patrick M.; Feldman, Keri; Bayir, Huelya; Aneja, Rajesh K.; Carcillo, Joseph A.; Clark, Robert S. B.			Cerebrospinal Fluid Markers of Macrophage and Lymphocyte Activation After Traumatic Brain Injury in Children	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cluster of differentiation 163; ferritin; head injury; interleukin-2 receptor; macrophage activation syndrome; microglia	CONTROLLED CORTICAL IMPACT; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; CD163(+) MACROPHAGES/MICROGLIA; MULTIPLE-SCLEROSIS; IMMATURE RAT; FERRITIN; EXPRESSION; RESPONSES; ACCUMULATION; INTERLEUKIN-10	Objectives: The magnitude and role of the cellular immune response following pediatric traumatic brain injury remains unknown. We tested the hypothesis that macrophage/microglia and T-cell activation occurs following pediatric traumatic brain injury by measuring cerebrospinal fluid levels of soluble cluster of differentiation 163 and ferritin and soluble interleukin-2 receptor , respectively, and determined whether these biomarkers were associated with relevant clinical variables and outcome. Design: Retrospective analysis of samples from an established, single-center cerebrospinal fluid bank. Setting: PICU in a tertiary children's hospital. Patients: Sixty-six pediatric patients after severe traumatic brain injury (Glasgow Coma Scale score < 8) who were 1 month to 16 years old and 17 control patients who were 1 month to 14 years old. Interventions: None. Measurements and Main Results: Cerebrospinal fluid levels of soluble cluster of differentiation 163, ferritin, and soluble interleukin-2 receptor were determined by enzyme-linked immunosorbent assay at two time points (t(1) = 17 10 hr; t(2) = 72 +/- 15 hr) for each traumatic brain injury patient. Cerebrospinal fluid levels of soluble cluster of differentiation 163, ferritin, and soluble interleukin-2 receptor after traumatic brain injury were compared with controls and analyzed for associations with age, patient sex, initial Glasgow Coma Scale score, diagnosis of abusive head trauma, the presence of hemorrhage on CT scan, and Glasgow Outcome Scale score. Cerebrospinal fluid level of soluble cluster of differentiation 163 was increased in traumatic brain injury patients at t(2) versus t(1) and controls (median, 95.4 ng/mL [interquartile range, 21.8-134.0 ng/mL] vs 31.0 ng/mL [5.7-77.7 ng/mL] and 27.8 ng/mL [19.1-43.1 ng/mL], respectively; p < 0.05). Cerebrospinal fluid level of ferritin was increased in traumatic brain injury patients at t(2) and t(1) versus controls (8.3 ng/mL [<7.5-19.8 ng/mL] and 8.9 ng/mL [<7.5-26.7 ng/mL] vs <7.5 ng/mL below lower limit of detection, respectively; p < 0.05). Cerebrospinal fluid levels of soluble interleukin-2 receptor in traumatic brain injury patients at t(2) and t(1) were not different versus controls. Multivariate regression revealed associations between high ferritin and age 4 years or younger, lower Glasgow Coma Scale score, abusive head trauma, and unfavorable Glasgow Outcome Scale score. Conclusions: Children with traumatic brain injury demonstrate evidence for macrophage activation after traumatic brain injury, and in terms of cerebrospinal fluid ferritin, this appears more prominent with young age, initial injury severity, abusive head trauma, and unfavorable outcome. Further study is needed to determine whether biomarkers of macrophage activation may be used to discriminate between aberrant and adaptive immune responses and whether inflammation represents a therapeutic target after traumatic brain injury.	[Newell, Elizabeth] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Shellington, David K.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Simon, Dennis W.; Bell, Michael J.; Kochanek, Patrick M.; Feldman, Keri; Bayir, Huelya; Aneja, Rajesh K.; Carcillo, Joseph A.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Bell, Michael J.; Bayir, Huelya; Aneja, Rajesh K.; Carcillo, Joseph A.; Clark, Robert S. B.] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Bell, Michael J.; Kochanek, Patrick M.; Bayir, Huelya; Aneja, Rajesh K.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Kochanek, Patrick M.; Carcillo, Joseph A.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; [Bayir, Huelya] Univ Pittsburgh, Sch Med, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA	Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu		Newell, Elizabeth/0000-0002-1476-033X	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD40686]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 GM098474, U01 NS081041, R01 GM108618, R01 NS38620]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM108618, R01GM098474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS081041, R01NS038620] Funding Source: NIH RePORTER	Dr. Simon was supported by grants from the National Institutes of Health (NIH; T32 HD40686). Dr. Bell was supported by grants from the NIH (R01 GM098474 and U01 NS081041). Dr. Carcillo was supported by grants from the NIH (R01 GM108618). Dr. Clark was supported by grants from the NIH (R01 NS38620). Dr. Clark is employed by the University of Pittsburgh, received royalties from Elsevier (textbook), and received support for article research from the NIH. His institution received grant support from the NIH (R01 NS38620). Dr. Bell's institution received grant support from the NIH. Dr. Kochanek is a co-provisional patent holder: Emergency preservation and resuscitation, A multiplex panel diagnostic aid for abusive head trauma, and RNA binding motif targeting agents as neuroprotectants. Dr. Bayir received support for article research from the NIH. Dr. Aneja received support for article research from the NIH and received royalties from Uptodate. His institution received grant support from the NIH. Dr. Carcillo disclosed other support (NICHD and NIHMS funding not related to this manuscript). His institution received grant support. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson PD, 2013, CHILD NERV SYST, V29, P43, DOI 10.1007/s00381-012-1932-4; Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Bell MJ, 1997, ACT NEUR S, V70, P96; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Chandrakasan S, 2013, J PEDIATR-US, V163, P1253, DOI 10.1016/j.jpeds.2013.06.053; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cohen LA, 2010, BLOOD, V116, P1574, DOI 10.1182/blood-2009-11-253815; CONNOR JR, 1994, J NEUROSCI RES, V37, P461, DOI 10.1002/jnr.490370405; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Feng L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038400; Fitzgerald NE, 2003, PEDIATR RADIOL, V33, P392, DOI 10.1007/s00247-003-0894-9; Glanzer JG, 2007, J NEUROCHEM, V102, P627, DOI 10.1111/j.1471-4159.2007.04568.x; Hohnholt MC, 2013, BIOCHEM SOC T, V41, P1588, DOI 10.1042/BST20130114; Holfelder K, 2011, HISTOL HISTOPATHOL, V26, P1007, DOI 10.14670/HH-26.1007; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; KANEKO Y, 1989, ACTA NEUROPATHOL, V79, P129, DOI 10.1007/BF00294369; KEIR G, 1993, CLIN CHIM ACTA, V216, P153, DOI 10.1016/0009-8981(93)90148-W; Kim YO, 2003, PEDIATR NEUROL, V28, P271, DOI 10.1016/S0887-8994(02)00625-2; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu HD, 2013, NEUROL SCI, V34, P1173, DOI 10.1007/s10072-012-1214-7; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Meyron-Holtz EG, 2011, J NEURAL TRANSM, V118, P337, DOI 10.1007/s00702-011-0582-0; Moller HJ, 2012, SCAND J CLIN LAB INV, V72, P1, DOI 10.3109/00365513.2011.626868; Petzold A, 2002, BRAIN, V125, P1462, DOI 10.1093/brain/awf165; Potts Mathew B, 2006, NeuroRx, V3, P143; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Robertson CL, 2013, J NEUROTRAUM, V30, P2066, DOI 10.1089/neu.2013.3007; Rooms L, 2003, PEDIATRICS, V111, pE636, DOI 10.1542/peds.111.5.e636; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shein SL, 2012, J PEDIAT, V161; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Su LX, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/969875; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Todorich B, 2011, GLIA, V59, P927, DOI 10.1002/glia.21164; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038; Zhang Z, 2011, J NEUROIMMUNOL, V237, P73, DOI 10.1016/j.jneuroim.2011.06.006	51	25	25	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUL	2015	16	6					549	557		10.1097/PCC.0000000000000400			9	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	CN2YQ	WOS:000358289700008	25850867	Green Accepted			2021-06-18	
J	Wang, Z; Wang, Y; Wang, ZY; Zhao, J; Gutkind, JS; Srivatsan, A; Zhang, GF; Liao, HS; Fu, X; Jin, A; Tong, X; Niu, G; Chen, XY				Wang, Zhe; Wang, Yu; Wang, Zhiyong; Zhao, Jun; Gutkind, J. Silvio; Srivatsan, Avinash; Zhang, Guofeng; Liao, Hsien-Shun; Fu, Xiao; Jin, Albert; Tong, Xiao; Niu, Gang; Chen, Xiaoyuan			Polymeric Nanovehicle Regulated Spatiotemporal Real-Time Imaging of the Differentiation Dynamics of Transplanted Neural Stem Cells after Traumatic Brain Injury	ACS NANO			English	Article						stem cells; imaging; traumatic brain injury; differentiation; nanoparticles	DRUG-DELIVERY SYSTEM; ADULT BRAIN; NEUROGENESIS; ANTICANCER; NEURONS; NANOPARTICLES; MODEL; ANTIANGIOGENESIS; NEUROPROTECTION; PRECURSORS	Recent advances in neural stem cell (NSC) transplantation have led to an inspiring progress in alleviating central nervous system (CNS) damages and restoring brain functions from diseases or injuries. One challenge of NSC transplantation is directed differentiation of transplanted NSCs into desired neuronal subtypes, such as neurons, to compensate the adverse impact of brain injury; another challenge lies in the lack of tools to noninvasively monitor the dynamics of NSC differentiation after transplantation in vivo. In this study, we developed a polymer nanovehicle for morphogen sustained release to overcome the drawbacks of conventional methods to realize the long-term directed NSC differentiation in vivo. Moreover, we constructed a bicistronic vector with a unique neuron specific gene tubb3 promoter to drive reporter gene expression for real-time imaging of NSC differentiation and migration. The developed uniform nanovehicle showed efficient NSC uptake and achieved a controlled release of morphogen in cytosol to consistently stimulate NSC differentiation into neurons at a sustainably effective concentration. The spatiotemporal imaging results showed a multiplexed migration, proliferation, differentiation, and apoptosis orchestra of transplanted NSCs regulated by nanovehicles in TBI mice. The imaging results also uncovered the peak time of NSC differentiation in vivo. Although we observed only a handful of NSCs ultimately migrated to the TBI area and differentiated into neurons, those neurons were functional, ameliorating the detrimental impact of TBI. The imaging findings enabled by the nanovehicle and the neuron specific bicistronic vector provide additional understanding of the in vivo behaviors of transplanted NSCs in neuronal regenerative medicine.	[Wang, Zhe; Wang, Yu; Srivatsan, Avinash; Liao, Hsien-Shun; Fu, Xiao; Tong, Xiao; Niu, Gang; Chen, Xiaoyuan] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA; [Wang, Zhiyong; Gutkind, J. Silvio] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; [Zhao, Jun] NIMH, Unit Synapse Dev & Plast, NIH, Bethesda, MD 20892 USA; [Zhang, Guofeng; Liao, Hsien-Shun; Fu, Xiao; Jin, Albert] Natl Inst Biomed Imaging & Bioengn, Lab Cellular Imaging & Macromol Biophys, NIH, Bethesda, MD 20892 USA	Chen, XY (corresponding author), Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.	shawn.chen@nih.gov	Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Jin, Albert/0000-0003-3826-1081	Center for Neuroscience and Regenerative Medicine (CNRM) program at the Henry M. Jackson Foundation; Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIAEB000015, ZICEB000080, ZIAEB000073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [ZIADE000558, ZIADE000551] Funding Source: NIH RePORTER	This study was supported, in part, by the Center for Neuroscience and Regenerative Medicine (CNRM) program at the Henry M. Jackson Foundation and the Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH).	Abematsu M, 2010, J CLIN INVEST, V120, P3255, DOI 10.1172/JCI42957; Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Attardo A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002388; Beal MF, 2001, P NATL ACAD SCI USA, V98, P3, DOI 10.1073/pnas.98.1.3; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Brito C, 2012, METHODS, V56, P452, DOI 10.1016/j.ymeth.2012.03.005; Carbajal KS, 2010, P NATL ACAD SCI USA, V107, P11068, DOI 10.1073/pnas.1006375107; Chanda B, 2013, CELL, V155, P215, DOI 10.1016/j.cell.2013.08.055; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043; Gaudin A, 2014, NAT NANOTECHNOL, V9, P1054, DOI [10.1038/nnano.2014.274, 10.1038/NNANO.2014.274]; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Gupta N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004373; Hsu YC, 2014, CELL, V157, P935, DOI 10.1016/j.cell.2014.02.057; Hu BY, 2010, METHODS MOL BIOL, V636, P123, DOI 10.1007/978-1-60761-691-7_8; Kokovay E, 2008, NEURON, V60, P420, DOI 10.1016/j.neuron.2008.10.025; Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Louis Sharon A, 2013, Methods Mol Biol, V946, P479, DOI 10.1007/978-1-62703-128-8_30; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Muller FJ, 2006, NAT REV NEUROSCI, V7, P75, DOI 10.1038/nrn1829; Okada Y, 2004, DEV BIOL, V275, P124, DOI 10.1016/j.ydbio.2004.07.038; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pollard SM, 2006, CEREB CORTEX, V16, pI112, DOI 10.1093/cercor/bhj167; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Sanberg PR, 2007, P NATL ACAD SCI USA, V104, P11869, DOI 10.1073/pnas.0704704104; Santos T, 2012, ACS NANO, V6, P10463, DOI 10.1021/nn304541h; Stavridis MP, 2010, DEVELOPMENT, V137, P881, DOI 10.1242/dev.043117; Teng YD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004579; Tonge PD, 2010, DIFFERENTIATION, V80, P20, DOI 10.1016/j.diff.2010.04.001; Uchida N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004371; Varga BV, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-89; Wang Z, 2015, STEM CELLS, V33, P456, DOI 10.1002/stem.1878; Wang Z, 2014, ACS NANO, V8, P12386, DOI 10.1021/nn505047n; Wang Z, 2014, PHARM RES-DORDR, V31, P1358, DOI 10.1007/s11095-013-1103-7; Wang Z, 2013, BIOMATERIALS, V34, P6194, DOI 10.1016/j.biomaterials.2013.05.004; Wang Z, 2011, PHARM RES-DORDR, V28, P585, DOI 10.1007/s11095-010-0308-2; Wang Z, 2010, SMALL, V6, P2576, DOI 10.1002/smll.201001122; Wang Z, 2010, BIOMATERIALS, V31, P7115, DOI 10.1016/j.biomaterials.2010.05.075; Wang Z, 2009, PHARM RES-DORDR, V26, P1162, DOI 10.1007/s11095-009-9837-y; Yang F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6627; Ziller MJ, 2015, NATURE, V518, P355, DOI 10.1038/nature13990	44	25	25	1	64	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	JUL	2015	9	7					6683	6695		10.1021/acsnano.5b00690			13	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Chemistry; Science & Technology - Other Topics; Materials Science	CO0EP	WOS:000358823200005	26020550	Green Accepted			2021-06-18	
J	Liang, FY; Luo, CM; Xu, GQ; Su, FJ; He, XF; Long, SM; Ren, HX; Liu, YN; Feng, YQ; Pei, Z				Liang, Fengyin; Luo, Chuanming; Xu, Guangqing; Su, Fengjuan; He, Xiaofei; Long, Simei; Ren, Huixia; Liu, Yaning; Feng, Yanqing; Pei, Zhong			Deletion of aquaporin-4 is neuroprotective during the acute stage of micro traumatic brain injury in mice	NEUROSCIENCE LETTERS			English	Article						Aquaporin-4 (AQP4); Micro traumatic brain injury; Acute stage; Cerebral edema	FOCAL CEREBRAL-ISCHEMIA; KNOCKOUT MICE; MOUSE MODEL; EDEMA; BARRIER; EPIDEMIOLOGY; EXPRESSION; PATTERNS; FLUID	Micro traumatic brain injury (TBI) is the most common type of brain injury, but the mechanisms underlying it are poorly understood. Aquaporin-4 (AQP4) is a water channel expressed in astrocyte end-feet, which plays an important role in brain edema. However, little is known about the role of AQP4 in micro TBI. Here, we examined the role of AQP4 in the pathogenesis of micro TBI in a closed-skull brain injury model, using two-photon microscopy. Our results indicate that AQP4 deletion reduced cell death, water content, astrocyte swelling and lesion volume during the acute stage of micro TBI. Our data revealed that astrocyte swelling is a decisive pathophysiological factor in the acute phase of this form of micro brain injury. Thus, treatments that inhibit AQP4 could be used as a neuroprotective strategy for micro TBI. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Liang, Fengyin; Su, Fengjuan; Long, Simei; Liu, Yaning; Feng, Yanqing; Pei, Zhong] Sun Yat Sen Univ, Affiliated Hosp 1,Dept Neurol, Guangdong Key Lab Diag & Treatment Major Neurol D, Natl Key Clin Dept & Key Discipline Neurol, Guangzhou 510080, Guangdong, Peoples R China; [Luo, Chuanming; Ren, Huixia] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau 999078, Peoples R China; [Xu, Guangqing; He, Xiaofei] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rehabil Med, Guangzhou 510080, Guangdong, Peoples R China	Pei, Z (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1,Dept Neurol, Guangdong Key Lab Diag & Treatment Major Neurol D, Natl Key Clin Dept & Key Discipline Neurol, Guangzhou 510080, Guangdong, Peoples R China.	fyqgz@vip.sina.com; peizhong@mail.sysu.edu.cn			National Key Clinical Department, National Key Discipline, Guangdong Key Laboratory For Diagnosis and Treatment of Major Neurological Diseases [2010A060801005]; Guangdong Science and technology project [2013B051000018]	This study was supported by grants from the National Key Clinical Department, National Key Discipline, Guangdong Key Laboratory For Diagnosis and Treatment of Major Neurological Diseases (No. 2010A060801005), Guangdong Science and technology project (No. 2013B051000018).	Akdemir G, 2014, NEUROSCI LETT, V574, P70, DOI 10.1016/j.neulet.2014.03.073; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Benedek A, 2006, BRAIN RES, V1116, P159, DOI 10.1016/j.brainres.2006.07.123; Cho EE, 2011, J CEREBR BLOOD F MET, V31, P1852, DOI 10.1038/jcbfm.2011.59; Eilert-Olsen M, 2012, GLIA, V60, P432, DOI 10.1002/glia.22277; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Steiner E, 2012, GLIA, V60, P1646, DOI 10.1002/glia.22383; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Wolff RA, 2000, J MOL CELL CARDIOL, V32, P225, DOI 10.1006/jmcc.1999.1074; Yao XM, 2015, NEUROSCI LETT, V584, P368, DOI 10.1016/j.neulet.2014.10.040; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhou JP, 2008, NEUROREPORT, V19, P1, DOI 10.1097/WNR.0b013e3282f2b4eb	23	25	27	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 26	2015	598						29	35		10.1016/j.neulet.2015.05.006			7	Neurosciences	Neurosciences & Neurology	CK9GY	WOS:000356549800006	25957560				2021-06-18	
J	Kilbaugh, TJ; Lvova, M; Karlsson, M; Zhang, Z; Leipzig, J; Wallace, DC; Margulies, SS				Kilbaugh, Todd J.; Lvova, Maria; Karlsson, Michael; Zhang, Zhe; Leipzig, Jeremy; Wallace, Douglas C.; Margulies, Susan S.			Peripheral Blood Mitochondrial DNA as a Biomarker of Cerebral Mitochondrial Dysfunction following Traumatic Brain Injury in a Porcine Model	PLOS ONE			English	Article							RESPONSES	Background Traumatic brain injury (TBI) has been shown to activate the peripheral innate immune system and systemic inflammatory response, possibly through the central release of damage associated molecular patterns (DAMPs). Our main purpose was to gain an initial understanding of the peripheral mitochondrial response following TBI, and how this response could be utilized to determine cerebral mitochondrial bioenergetics. We hypothesized that TBI would increase peripheral whole blood relative mtDNA copy number, and that these alterations would be associated with cerebral mitochondrial bioenergetics triggered by TBI. Methodology Blood samples were obtained before, 6 h after, and 25 h after focal (controlled cortical impact injury: CCI) and diffuse (rapid non-impact rotational injury: RNR) TBI. PCR primers, unique to mtDNA, were identified by aligning segments of nuclear DNA (nDNA) to mtDNA, normalizing values to nuclear 16S rRNA, for a relative mtDNA copy number. Three unique mtDNA regions were selected, and PCR primers were designed within those regions, limited to 25-30 base pairs to further ensure sequence specificity, and measured utilizing qRT-PCR. Results Mean relative mtDNA copy numbers increased significantly at 6 and 25 hrs after following both focal and diffuse traumatic brain injury. Specifically, the mean relative mtDNA copy number from three mitochondrial-specific regions pre-injury was 0.84 +/- 0.05. At 6 and 25 h after diffuse non-impact TBI, mean mtDNA copy number was significantly higher: 2.07 +/- 0.19 (P < 0.0001) and 2.37 +/- 0.42 (P < 0.001), respectively. Following focal impact TBI, relative mtDNA copy number was also significantly higher, 1.35 +/- 0.12 (P < 0.0001) at 25 hours. Alterations in mitochondrial respiration in the hippocampus and cortex post-TBI correlated with changes in the relative mtDNA copy number measured in peripheral blood. Conclusions Alterations in peripheral blood relative mtDNA copy numbers may be a novel biosignature of cerebral mitochondrial bioenergetics with exciting translational potential for non-invasive diagnostic and interventional studies.	[Kilbaugh, Todd J.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Lvova, Maria; Zhang, Zhe; Leipzig, Jeremy; Wallace, Douglas C.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Ctr Mitochondrial & Epigen Med,Dept Pathol & Lab, Philadelphia, PA 19104 USA; [Karlsson, Michael] Lund Univ, Mitochondrial Med, Dept Clin Sci, Lund, Sweden; [Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Kilbaugh, TJ (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA.	kilbaugh@chop.edu	Karlsson, Michael/AAL-8743-2020	Karlsson, Michael/0000-0002-7247-2133; Kilbaugh, Todd/0000-0002-4959-3092; Leipzig, Jeremy/0000-0001-7224-9620	NIH/NINDS grant [U01NS069545]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS069545, R01NS021328] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS grant: U01NS069545.	Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Chan JK, 2012, J CLIN INVEST, V122, P2711, DOI 10.1172/JCI62423; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Di Filippo M, 2010, J ALZHEIMERS DIS, V20, pS369, DOI 10.3233/JAD-2010-100543; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Durham SR, 2007, J NEUROTRAUM, V24, P5, DOI 10.1089/neu.2006.0054; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Gnaiger E, 2009, INT J BIOCH CELL BIO; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Jaber SM, 2015, DEV NEUROPSYCHOL, V40, P34, DOI 10.1080/87565641.2014.969733; Karlsson M, 2012, INT J BIOCHEM CELL B, DOI [10.1016/j.biocel.2012.08.008, DOI 10.1016/J.BI0CEL.2012.08.008]; Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282; Lartigue L, 2013, INT J BIOCHEM CELL B, V45, P2052, DOI 10.1016/j.biocel.2013.06.014; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Malik AN, 2013, MITOCHONDRION, V13, P481, DOI 10.1016/j.mito.2012.10.011; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Margulies SS, 2015, BRAIN PATHOL, V25, P289, DOI 10.1111/bpa.12247; Miller AC, 2012, COMMON DATA ELEMENTS; Missios S, 2009, J NEUROTRAUM, V26, P1943, DOI [10.1089/neu.2009.0956, 10.1089/neu.2009-0956]; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Walko TD, 2014, SHOCK, V41, P499, DOI 10.1097/SHK.0000000000000160; Weeks D, 2014, J NEUROTRAUM, V31, P206, DOI 10.1089/neu.2013.3113; West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975; Zhang Q, 2010, SHOCK, V34, P55, DOI 10.1097/SHK.0b013e3181cd8c08; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	36	25	25	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0130927	10.1371/journal.pone.0130927			16	Multidisciplinary Sciences	Science & Technology - Other Topics	CL3FM	WOS:000356835800123	26098565	DOAJ Gold, Green Published			2021-06-18	
J	Glenn, TC; Martin, NA; McArthur, DL; Hovda, DA; Vespa, P; Johnson, ML; Horning, MA; Brooks, GA				Glenn, Thomas C.; Martin, Neil A.; McArthur, David L.; Hovda, David A.; Vespa, Paul; Johnson, Matthew L.; Horning, Michael A.; Brooks, George A.			Endogenous Nutritive Support after Traumatic Brain Injury: Peripheral Lactate Production for Glucose Supply via Gluconeogenesis	JOURNAL OF NEUROTRAUMA			English	Article						brain; gluconeogenesis; glucose; glucose homeostasis; glycemia; lactate; mass spectrometry; TBI	SKELETAL-MUSCLE MITOCHONDRIA; TRAINING-INDUCED ALTERATIONS; MODERATE-INTENSITY EXERCISE; MONOCARBOXYLATE TRANSPORTERS; SARCOLEMMAL VESICLES; OXIDATION COMPLEX; HUMANS; MCT1; MEN; METABOLISM	We evaluated the hypothesis that nutritive needs of injured brains are supported by large and coordinated increases in lactate shuttling throughout the body. To that end, we used dual isotope tracer ([6,6-(2)H2]glucose, i.e., D-2-glucose, and [3-C-13]lactate) techniques involving central venous tracer infusion along with cerebral (arterial [art] and jugular bulb [JB]) blood sampling. Patients with traumatic brain injury (TBI) who had nonpenetrating head injuries (n=12, all male) were entered into the study after consent of patients' legal representatives. Written and informed consent was obtained from healthy controls (n=6, including one female). As in previous investigations, the cerebral metabolic rate (CMR) for glucose was suppressed after TBI. Near normal arterial glucose and lactate levels in patients studied 5.7 +/- 2.2 days (range of days 2-10) post-injury, however, belied a 71% increase in systemic lactate production, compared with control, that was largely cleared by greater (hepatic+renal) glucose production. After TBI, gluconeogenesis from lactate clearance accounted for 67.1% of glucose rate of appearance (Ra), which was compared with 15.2% in healthy controls. We conclude that elevations in blood glucose concentration after TBI result from a massive mobilization of lactate from corporeal glycogen reserves. This previously unrecognized mobilization of lactate subserves hepatic and renal gluconeogenesis. As such, a lactate shuttle mechanism indirectly makes substrate available for the body and its essential organs, including the brain, after trauma. In addition, when elevations in arterial lactate concentration occur after TBI, lactate shuttling may provide substrate directly to vital organs of the body, including the injured brain.	[Glenn, Thomas C.; Martin, Neil A.; McArthur, David L.; Hovda, David A.; Vespa, Paul] Univ Calif Los Angeles, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; [Glenn, Thomas C.; Martin, Neil A.] Univ Calif Los Angeles, UCLA Ctr Hlth Sci, Div Neurosurg, Los Angeles, CA 90095 USA; [Johnson, Matthew L.; Horning, Michael A.; Brooks, George A.] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA	Glenn, TC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	tglenn@mednet.ucla.edu		Glenn, Thomas/0000-0003-4273-3408; Brooks, George A./0000-0002-1389-1629; Martin, Neil/0000-0002-6565-4131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS058489] Funding Source: Medline		Abu Fanne R, 2011, AM J PHYSIOL-REG I, V301, pR668, DOI 10.1152/ajpregu.00058.2011; AHLBORG G, 1982, J CLIN INVEST, V69, P45, DOI 10.1172/JCI110440; Armstead WM, 2011, J NEUROTRAUM, V28, P451, DOI 10.1089/neu.2010.1659; Bergman BC, 2000, AM J PHYSIOL-ENDOC M, V278, pE244; Bergman BC, 1999, J APPL PHYSIOL, V87, P1684; Bergman BC, 1999, AM J PHYSIOL-ENDOC M, V277, pE81; Bergman BC, 2009, J PHYSIOL-LONDON, V587, P2087, DOI 10.1113/jphysiol.2008.168286; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Bratton S, 2007, J NEUROTRAUM, V24, P7; Brooks GA, 1998, AM J PHYSIOL-REG I, V275, pR1192; BROOKS GA, 1992, J APPL PHYSIOL, V72, P2435; Brooks GA, 2002, BIOCHEM SOC T, V30, P258, DOI 10.1042/bst0300258; BROOKS GA, 1991, J APPL PHYSIOL, V71, P333; Brooks GA, 1999, J APPL PHYSIOL, V87, P1713; BROOKS GA, 1983, AM J PHYSIOL, V244, pE505; Brooks GA., 1984, COM PHYSL BIOCH, P208, DOI [10.1007/978-3-642-70610-3_15, DOI 10.1007/978-3-642-70610-3_15]; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; Butz CE, 2004, J APPL PHYSIOL, V97, P1059, DOI 10.1152/japplphysiol.00009.2004; Casaer MP, 2014, NEW ENGL J MED, V370, P1227, DOI 10.1056/NEJMra1304623; DONOVAN CM, 1983, AM J PHYSIOL, V244, pE83; Dubouchaud H, 2000, AM J PHYSIOL-ENDOC M, V278, pE571; Elustondo PA, 2013, J BIOL CHEM, V288, P25309, DOI 10.1074/jbc.M113.476648; Emhoff CAW, 2013, J APPL PHYSIOL, V114, P297, DOI 10.1152/japplphysiol.01202.2012; Fattor JA, 2005, AM J PHYSIOL-ENDOC M, V288, pE143, DOI 10.1152/ajpendo.00117.2004; Friedlander AL, 1998, J APPL PHYSIOL, V85, P1175; Friedlander AL, 1997, J APPL PHYSIOL, V82, P1360; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; GERTZ EW, 1981, CIRCULATION, V63, P1273, DOI 10.1161/01.CIR.63.6.1273; GERTZ EW, 1988, J CLIN INVEST, V82, P2017, DOI 10.1172/JCI113822; Glenn T. C., 2014, J NEUROTRAU IN PRESS; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Hashimoto T, 2005, J PHYSIOL-LONDON, V567, P121, DOI 10.1113/jphysiol.2005.087411; Hashimoto T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002915; Hashimoto T, 2007, FASEB J, V21, P2602, DOI 10.1096/fj.07-8174com; Hashimoto T, 2006, AM J PHYSIOL-ENDOC M, V290, pE1237, DOI 10.1152/ajpendo.00594.2005; Henderson GC, 2008, AM J CLIN NUTR, V87, P1686; Henderson GC, 2007, AM J PHYSIOL-ENDOC M, V292, pE366, DOI 10.1152/ajpendo.00363.2006; Herzog RI, 2013, J CLIN INVEST, V123, P1988, DOI 10.1172/JCI65105; Hill AV, 1923, Q J MED, V16, P135, DOI 10.1093/qjmed/os-16.62.135; Hintze JL, 1998, AM STAT, V52, P181, DOI 10.2307/2685478; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Jacobs RA, 2013, AM J PHYSIOL-ENDOC M, V304, pE686, DOI 10.1152/ajpendo.00476.2012; Johnson J A, 1972, Adv Metab Disord, V60, P1; Johnson ML, 2012, AM J PHYSIOL-REG I, V302, pR143, DOI 10.1152/ajpregu.00402.2011; Johnson ML, 2011, AM J PHYSIOL-REG I, V301, pR769, DOI 10.1152/ajpregu.00206.2011; MAZZEO RS, 1995, AM J PHYSIOL-REG I, V269, pR201; MAZZEO RS, 1986, J APPL PHYSIOL, V60, P232; McClelland GB, 2003, BIOCHEM BIOPH RES CO, V304, P130, DOI 10.1016/S0006-291X(03)00550-3; Messonnier LA, 2013, J APPL PHYSIOL, V114, P1593, DOI 10.1152/japplphysiol.00043.2013; Meyer C, 2002, AM J PHYSIOL-ENDOC M, V282, pE419, DOI 10.1152/ajpendo.00032.2001; Meyerhof O, 1920, PFLUG ARCH GES PHYS, V182, P232, DOI 10.1007/BF01723747; Miller BF, 2002, J PHYSIOL-LONDON, V544, P963, DOI 10.1113/jphysiol.2002.027128; Miller BF, 2002, AM J PHYSIOL-ENDOC M, V283, pE889, DOI 10.1152/ajpendo.00266.2002; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Pellerin L, 2005, J NEUROSCI RES, V79, P55, DOI 10.1002/jnr.20307; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Price NT, 1998, BIOCHEM J, V329, P321; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Richardson RS, 1998, J APPL PHYSIOL, V85, P627; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P386, DOI 10.1016/0003-9861(90)90506-T; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P377, DOI 10.1016/0003-9861(90)90505-S; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Schruth D. M., 2012, CAROLINE COLLECTION; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174; Schurr A, 2008, J PHYSIOL-LONDON, V586, P2665, DOI 10.1113/jphysiol.2008.155416; Schurr A, 2012, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00096; STANLEY WC, 1986, J APPL PHYSIOL, V60, P1116; STANLEY WC, 1988, METABOLISM, V37, P850, DOI 10.1016/0026-0495(88)90119-9; STANLEY WC, 1985, AM J PHYSIOL, V249, pE595; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; TSERNG KY, 1984, ANAL CHEM, V56, P517, DOI 10.1021/ac00267a049; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Wilcox R., 2012, INTRO ROBUST ESTIMAT, V1st; Wolfe R. R., 1982, RADIOACTIVE STABLE I, P81; Yuen K.F., 1985, J ROYAL STAT SOC D, V34, P175; Zhang ZH, 2014, CRIT CARE MED, V42, P2118, DOI 10.1097/CCM.0000000000000405; Zilversmit DB, 1943, J GEN PHYSIOL, V26, P333, DOI 10.1085/jgp.26.3.333	80	25	26	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2015	32	11					811	819		10.1089/neu.2014.3482			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0YU	WOS:000363980700006	25279664	Green Published			2021-06-18	
J	Mayhew, J; Beart, PM; Walker, FR				Mayhew, J.; Beart, P. M.; Walker, F. R.			Astrocyte and Microglial Control of Glutamatergic Signalling: A Primer on Understanding the Disruptive Role of Chronic Stress	JOURNAL OF NEUROENDOCRINOLOGY			English	Article; Proceedings Paper	8th International Congress of Neuroendocrinology integrated with the 18th Annual Meeting of the Society for Behavioural Neuroendocrinology	AUG, 2014	Sydney, AUSTRALIA			stress; microglia; astrocyte; glutamate; Chronic stress; depression	FIBRILLARY ACIDIC PROTEIN; LONG-TERM POTENTIATION; MAJOR DEPRESSIVE DISORDER; CHRONIC PSYCHOSOCIAL STRESS; TRAUMATIC BRAIN-INJURY; PREFRONTAL CORTEX; AMINO-ACID; RAT HIPPOCAMPUS; IN-VITRO; EXTRACELLULAR GLUTAMATE	It is now well established that chronic stress can induce significant structural remodelling of astrocytes and microglia. Until recently, however, the full significance of these morphological disturbances has remained unclear. Clues to the significance of astroglial re-organisation following stress are beginning to emerge from a compelling literature describing how astrocytes contribute to glutamatergic neurotransmission. The present review briefly summarises these two fields of research, identifies points of overlap and, in doing so, pin-points future research directions for stress neurobiology. Ultimately, understanding how chronic stress can disrupt the interactions of astrocytes and microglia with neurones has the potential in the future to improve the development of therapeutics designed to treat stress-related illnesses such as depression.	[Mayhew, J.; Walker, F. R.] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia; [Mayhew, J.; Walker, F. R.] Univ Newcastle, Ctr Translat Neurosci, Callaghan, NSW 2308, Australia; [Mayhew, J.; Walker, F. R.] Univ Newcastle, Mental Hlth Res, Callaghan, NSW 2308, Australia; [Mayhew, J.; Walker, F. R.] Hunter Med Res Inst, New Lambton Hts, NSW, Australia; [Beart, P. M.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia	Walker, FR (corresponding author), Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia.	rohan.walker@newcastle.edu.au			NHMRCNational Health and Medical Research Council of Australia [APP1019833]	FRW acknowledges support from the NHMRC. PMB was supported by NHMRC Research Fellowships APP1019833. The Florey Institute of Neuroscience and Mental Health receives infrastructure support from the Victorian State Government (Australia).	Abraham I, 1996, BRAIN RES, V733, P56; Alfarez DN, 2003, EUR J NEUROSCI, V17, P1928, DOI 10.1046/j.1460-9568.2003.02622.x; Ando RD, 2013, BRAIN RES BULL, V93, P80, DOI 10.1016/j.brainresbull.2012.09.016; Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Bagley J, 1997, NEUROSCIENCE, V77, P65, DOI 10.1016/S0306-4522(96)00435-6; Banasr M, 2010, MOL PSYCHIATR, V15, P501, DOI 10.1038/mp.2008.106; Banasr M, 2008, BIOL PSYCHIAT, V64, P863, DOI 10.1016/j.biopsych.2008.06.008; BARTANUSZ V, 1995, NEUROSCIENCE, V66, P247, DOI 10.1016/0306-4522(95)00084-V; Bechtholt-Gompf AJ, 2010, NEUROPSYCHOPHARMACOL, V35, P2049, DOI 10.1038/npp.2010.74; Beschorner R, 2007, HISTOPATHOLOGY, V50, P897, DOI 10.1111/j.1365-2559.2007.02703.x; Beschorner R, 2007, HISTOL HISTOPATHOL, V22, P515, DOI 10.14670/HH-22.515; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bowley MP, 2002, BIOL PSYCHIAT, V52, P404, DOI 10.1016/S0006-3223(02)01404-X; Bowser DN, 2007, J GEN PHYSIOL, V129, P485, DOI 10.1085/jgp.200709780; Brown DR, 1999, GLIA, V25, P282, DOI 10.1002/(SICI)1098-1136(19990201)25:3<282::AID-GLIA8>3.0.CO;2-N; Cao X, 2013, NAT MED, V19, P773, DOI 10.1038/nm.3162; Cervetto C, 2013, J NEUROCHEM, V124, P821, DOI 10.1111/jnc.12143; Chaouloff F, 2007, J NEUROSCI, V27, P7130, DOI 10.1523/JNEUROSCI.1150-07.2007; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Chretien F, 2002, NEUROPATH APPL NEURO, V28, P410, DOI 10.1046/j.1365-2990.2002.00426.x; Chretien F, 2004, J NEUROPATH EXP NEUR, V63, P1058, DOI 10.1093/jnen/63.10.1058; Cotter D, 2001, ARCH GEN PSYCHIAT, V58, P545, DOI 10.1001/archpsyc.58.6.545; Cotter DR, 2001, BRAIN RES BULL, V55, P585, DOI 10.1016/S0361-9230(01)00527-5; Czeh B, 2006, NEUROPSYCHOPHARMACOL, V31, P1616, DOI 10.1038/sj.npp.1300982; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Davis S, 2002, J NEUROL NEUROSUR PS, V73, P556, DOI 10.1136/jnnp.73.5.556; Domin H, 2014, BEHAV BRAIN RES, V273, P23, DOI 10.1016/j.bbr.2014.07.019; Eyo UB, 2014, J NEUROSCI, V34, P10528, DOI 10.1523/JNEUROSCI.0416-14.2014; Fatemi SH, 2004, SCHIZOPHR RES, V69, P317, DOI 10.1016/j.schres.2003.08.014; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fiacco TA, 2004, J NEUROSCI, V24, P722, DOI 10.1523/JNEUROSCI.2859-03.2004; Fontainhas AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015973; Fontella FU, 2004, NEUROCHEM RES, V29, P1703, DOI 10.1023/B:NERE.0000035805.46592.6c; FOY MR, 1987, BEHAV NEURAL BIOL, V48, P138, DOI 10.1016/S0163-1047(87)90664-9; GILAD GM, 1990, BRAIN RES, V525, P335, DOI 10.1016/0006-8993(90)90886-G; Gosselin RD, 2009, NEUROSCIENCE, V159, P915, DOI 10.1016/j.neuroscience.2008.10.018; Gourley SL, 2012, PSYCHOPHARMACOLOGY, V219, P805, DOI 10.1007/s00213-011-2403-4; Hascup ER, 2010, J NEUROCHEM, V115, P1608, DOI 10.1111/j.1471-4159.2010.07066.x; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Hughes EG, 2004, MOL BRAIN RES, V124, P114, DOI 10.1016/j.molbrainres.2004.02.021; Jacobsson J, 2006, NEUROSCIENCE, V139, P475, DOI 10.1016/j.neuroscience.2005.12.046; Joels M, 2007, FRONT NEUROENDOCRIN, V28, P72, DOI 10.1016/j.yfrne.2007.04.001; John CS, 2012, NEUROPSYCHOPHARMACOL, V37, P2467, DOI 10.1038/npp.2012.105; Jourdain P, 2007, NAT NEUROSCI, V10, P331, DOI 10.1038/nn1849; Karst H, 2005, P NATL ACAD SCI USA, V102, P19204, DOI 10.1073/pnas.0507572102; Karst H, 2005, J NEUROPHYSIOL, V94, P3479, DOI 10.1152/jn.00143.2005; Kong H, 2014, CNS NEUROSCI THER, V20, P391, DOI 10.1111/cns.12222; Lau CL, 2010, NEUROCHEM RES, V35, P735, DOI 10.1007/s11064-010-0130-6; Liu RJ, 2008, P NATL ACAD SCI USA, V105, P359, DOI 10.1073/pnas.0706679105; Marcoli M, 2008, J NEUROCHEM, V105, P2330, DOI 10.1111/j.1471-4159.2008.05322.x; Marin-Garcia P, 2008, NEUROSCIENCE, V151, P361, DOI 10.1016/j.neuroscience.2007.10.038; McEwen BS, 2012, NEUROPHARMACOLOGY, V62, P3, DOI 10.1016/j.neuropharm.2011.07.014; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; McNally L, 2008, CNS SPECTRUMS, V13, P501, DOI 10.1017/S1092852900016734; Miguel-Hidalgo JJ, 2000, BIOL PSYCHIAT, V48, P861, DOI 10.1016/S0006-3223(00)00999-9; MOGHADDAM B, 1994, BRAIN RES, V655, P251, DOI 10.1016/0006-8993(94)91622-5; MOGHADDAM B, 1993, J NEUROCHEM, V60, P1650, DOI 10.1111/j.1471-4159.1993.tb13387.x; Montana V, 2004, J NEUROSCI, V24, P2633, DOI 10.1523/JNEUROSCI.3770-03.2004; Murugan M, 2013, CNS NEUROL DISORD-DR, V12, P773, DOI 10.2174/18715273113126660174; Nakajima K, 2001, NEUROSCI LETT, V307, P171, DOI 10.1016/S0304-3940(01)01943-7; Navarrete M, 2008, NEURON, V57, P883, DOI 10.1016/j.neuron.2008.01.029; Ohsawa K, 2007, GLIA, V55, P604, DOI 10.1002/glia.20489; Ohsawa K, 2010, GLIA, V58, P790, DOI 10.1002/glia.20963; Olivenza R, 2000, J NEUROCHEM, V74, P785, DOI 10.1046/j.1471-4159.2000.740785.x; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pascual O, 2012, P NATL ACAD SCI USA, V109, pE197, DOI 10.1073/pnas.1111098109; Pavlides C, 2002, HIPPOCAMPUS, V12, P245, DOI 10.1002/hipo.1116; Perea G, 2005, J NEUROSCI, V25, P2192, DOI 10.1523/JNEUROSCI.3965-04.2005; Perea G, 2007, SCIENCE, V317, P1083, DOI 10.1126/science.1144640; Persson M, 2005, GLIA, V51, P111, DOI 10.1002/glia.20191; Popoli M, 2012, NAT REV NEUROSCI, V13, P22, DOI 10.1038/nrn3138; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; Reagan LP, 2004, P NATL ACAD SCI USA, V101, P2179, DOI 10.1073/pnas.0307294101; Rodrigues RJ, 2005, J NEUROSCI, V25, P6286, DOI 10.1523/JNEUROSCI.0628-05.2005; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Roumier A, 2004, J NEUROSCI, V24, P11421, DOI 10.1523/JNEUROSCI.2251-04.2004; Roumier A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002595; Sanacora G, 2008, NAT REV DRUG DISCOV, V7, P426, DOI 10.1038/nrd2462; Sanacora G, 2012, NEUROPHARMACOLOGY, V62, P63, DOI 10.1016/j.neuropharm.2011.07.036; Schipke CG, 2001, FASEB J, V15, P255, DOI 10.1096/fj.01-0514fje; Shigeri Y, 2004, BRAIN RES REV, V45, P250, DOI 10.1016/j.brainresrev.2004.04.004; SHORS TJ, 1989, SCIENCE, V244, P224, DOI 10.1126/science.2704997; Si XH, 2004, NEUROPSYCHOPHARMACOL, V29, P2088, DOI 10.1038/sj.npp.1300525; Sieger D, 2012, DEV CELL, V22, P1138, DOI 10.1016/j.devcel.2012.04.012; Siegrist J, 2008, EUR ARCH PSY CLIN N, V258, P115, DOI 10.1007/s00406-008-5024-0; Sperlagh B, 2002, J NEUROCHEM, V81, P1196, DOI 10.1046/j.1471-4159.2002.00920.x; Sullivan SM, 2007, J BIOL CHEM, V282, P29414, DOI 10.1074/jbc.M704152200; Tomasello E, 2000, IMMUNITY, V13, P355, DOI 10.1016/S1074-7613(00)00035-2; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Tynan RJ, 2013, ACTA NEUROPATHOL, V126, P75, DOI 10.1007/s00401-013-1102-0; Vallat-Decouvelaere AV, 2003, J NEUROPATH EXP NEUR, V62, P475, DOI 10.1093/jnen/62.5.475; Venero C, 1999, EUR J NEUROSCI, V11, P2465, DOI 10.1046/j.1460-9568.1999.00668.x; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Vesce S, 1997, FEBS LETT, V411, P107, DOI 10.1016/S0014-5793(97)00674-1; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wang CC, 2009, SYNAPSE, V63, P745, DOI 10.1002/syn.20654; Wang ZY, 2003, VIROLOGY, V312, P60, DOI 10.1016/S0042-6822(03)00181-8; Webster MJ, 2001, BRAIN BEHAV IMMUN, V15, P388, DOI 10.1006/brbi.2001.0646; Whitehead G, 2013, BRAIN, V136, P3753, DOI 10.1093/brain/awt293; Wollmer MA, 2001, J NEUROIMMUNOL, V115, P19, DOI 10.1016/S0165-5728(01)00257-0; Wong TP, 2007, P NATL ACAD SCI USA, V104, P11471, DOI 10.1073/pnas.0702308104; Xu L, 1997, NATURE, V387, P497, DOI 10.1038/387497a0; Yang CH, 2005, J NEUROSCI, V25, P4288, DOI 10.1523/JNEUROSCI.0406-05.2005; Ye YY, 2011, NEUROSCI LETT, V503, P15, DOI 10.1016/j.neulet.2011.07.055; Yuen EY, 2012, NEURON, V73, P962, DOI 10.1016/j.neuron.2011.12.033; Zhang Q, 2004, J BIOL CHEM, V279, P12724, DOI 10.1074/jbc.M312845200; Zink M, 2010, NEUROPHARMACOLOGY, V58, P465, DOI 10.1016/j.neuropharm.2009.09.005; Zschocke J, 2005, J BIOL CHEM, V280, P34924, DOI 10.1074/jbc.M502581200	113	25	25	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	JUN	2015	27	6			SI		498	506		10.1111/jne.12273			9	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	CJ1HA	WOS:000355233400014	25737228				2021-06-18	
J	Roguski, M; Morel, B; Sweeney, M; Talan, J; Rideout, L; Riesenburger, RI; Madan, N; Hwang, S				Roguski, Marie; Morel, Brent; Sweeney, Megan; Talan, Jordan; Rideout, Leslie; Riesenburger, Ron I.; Madan, Neel; Hwang, Steven			Magnetic resonance imaging as an alternative to computed tomography in select patients with traumatic brain injury: a retrospective comparison	Journal of Neurosurgery-Pediatrics			English	Article						pediatric; head injury; MRI; CT; trauma	HEAD-INJURY; EMERGENCY-DEPARTMENT; RADIATION-EXPOSURE; UNITED-STATES; CT; CANCER; RISK; PREDICTION; CHILDREN; RULE	OBJECT Traumatic head injury (THI) is a highly prevalent condition in the United States, and concern regarding excess radiation-related cancer mortality has placed focus on limiting the use of CT in the evaluation of pediatric patients with THI. Given the success of rapid-acquisition MRI in the evaluation of ventriculoperitoneal shunt malfunction in pediatric patient populations, this study sought to evaluate the sensitivity of MRI in the setting of acute THI. METHODS Medical records of 574 pediatric admissions for THI to a Level 1 trauma center over a 10-year period were retrospectively reviewed to identify patients who underwent both CT and MRI examinations of the head within a 5-day period. Thirty-five patients were found, and diagnostic images were available for 30 patients. De-identified images were reviewed by a neuroradiologist for presence of any injury, intracranial hemorrhage, diffuse axonal injury (DAD, and skull fracture. Radiology reports were used to calculate interrater reliability scores. Baseline demographics and concordance analysis was performed with Stata version 13. RESULTS The mean age of the 30-patient cohort was 8.5 +/- 6.7 years, and 63.3% were male. The mean Injury Severity Score was 13.7 +/- 9.2, and the mean Glasgow Coma Scale score was 9 +/- 5.7. Radiology reports noted 150 abnormal findings. CT scanning missed findings in 12 patients; the missed findings included DAI (n = 5), subarachnoid hemorrhage (n = 6), small subdural hematomas (n = 6), cerebral contusions (n = 3), and an encephalocele. The CT scan was negative in 3 patients whose subsequent MRI revealed findings. MRI missed findings in 13 patients; missed findings included skull fracture (n = 5), small subdural hematomas (n = 4), cerebral contusions (n = 3), subarachnoid hemorrhage (n = 3), and DAI (n = 1). MRI was negative in 1 patient whose preceding CT scan was read as positive for injury. Although MRI more frequently reported intracranial findings than CT scanning, there was no statistically significant difference between CT and MRI in the detection of any intracranial injury (p = 0.63), DAI (p = 0.22), or intracranial hemorrhage (p = 0.25). CT scanning tended to more frequently identify skull fractures than MRI (p = 0.06). CONCLUSIONS MRI may be as sensitive as CT scanning in the detection of THI, DAI, and intracranial hemorrhage, but missed skull fractures in 5 of 13 patients. MRI may be a useful alternative to CT scanning in select stable patients with mild THI who warrant neuroimaging by clinical decision rules.	[Roguski, Marie; Morel, Brent; Talan, Jordan; Riesenburger, Ron I.; Hwang, Steven] Tufts Med Ctr, Dept Neurosurg, Boston, MA 02111 USA; [Sweeney, Megan; Rideout, Leslie] Tufts Med Ctr, Dept Gen Surg, Boston, MA 02111 USA; [Madan, Neel] Tufts Med Ctr, Dept Radiol, Boston, MA 02111 USA; [Morel, Brent; Talan, Jordan] Tufts Univ, Sch Med, Boston, MA 02111 USA	Hwang, S (corresponding author), Tufts Med Ctr, Dept Neurosurg, Proger 7,800 Washington St, Boston, MA 02111 USA.	shwang@tuftsmedicalcenter.org					Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Berdahl CT, 2013, ANN EMERG MED, V62, P486, DOI 10.1016/j.annemergmed.2013.02.018; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Chelly H, 2011, J TRAUMA, V71, P838, DOI 10.1097/TA.0b013e3182127baa; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Hennelly KE, 2013, J PEDIATR-US, V162, P392, DOI 10.1016/j.jpeds.2012.07.018; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Larson DB, 2011, RADIOLOGY, V259, P793, DOI 10.1148/radiol.11101939; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; O'Neill BR, 2013, WORLD NEUROSURG, V80, pE307, DOI 10.1016/j.wneu.2012.10.066; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Schachar JL, 2011, PEDIATR RADIOL, V41, P971, DOI 10.1007/s00247-011-2032-4; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	19	25	25	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	MAY	2015	15	5					529	534		10.3171/2014.10.PEDS14128			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CG5XM	WOS:000353369200016	25700122	Bronze			2021-06-18	
J	Kuo, CY; Liou, TH; Chang, KH; Chi, WC; Escorpizo, R; Yen, CF; Liao, HF; Chiou, HY; Chiu, WT; Tsai, JT				Kuo, Chia-Ying; Liou, Tsan-Hon; Chang, Kwang-Hwa; Chi, Wen-Chou; Escorpizo, Reuben; Yen, Chia-Feng; Liao, Hua-Fang; Chiou, Hung-Yi; Chiu, Wen-Ta; Tsai, Jo-Ting			Functioning and Disability Analysis of Patients with Traumatic Brain Injury and Spinal Cord Injury by Using the World Health Organization Disability Assessment Schedule 2.0	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH			English	Article							QUALITY-OF-LIFE; INTERNATIONAL CLASSIFICATION; PARTICIPATION; REHABILITATION; TAIWAN; SYSTEM; SCALE	The purpose of this study is to compare traumatic brain injuries (TBI) and spinal cord injuries (SCI) patients' function and disability by using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0); and to clarify the factors that contribute to disability. We analyzed data available between September 2012 and August 2013 from Taiwan's national disability registry which is based on the International Classification of Functioning, Disability, and Health (ICF) framework. Of the 2664 cases selected for the study, 1316 pertained to TBI and 1348 to SCI. A larger percentage of patients with TBI compared with those with SCI exhibited poor cognition, self-care, relationships, life activities, and participation in society (all p < 0.001). Age, sex, injury type, socioeconomic status, place of residence, and severity of impairment were determined as factors that independently contribute to disability (all p < 0.05). The WHODAS 2.0 is a generic assessment instrument which is appropriate for assessing the complex and multifaceted disability associated with TBI and SCI. Further studies are needed to validate the WHODAS 2.0 for TBI and SCI from a multidisciplinary perspective.	[Kuo, Chia-Ying; Chiou, Hung-Yi; Chiu, Wen-Ta] Taipei Med Univ, Sch Publ Hlth, Coll Publ Hlth & Nutr, Taipei 11031, Taiwan; [Kuo, Chia-Ying] Taipei Med Univ, Shuang Ho Hosp, Off Med Affairs, New Taipei City 23561, Taiwan; [Liou, Tsan-Hon; Chang, Kwang-Hwa] Taipei Med Univ, Grad Inst Injury Prevent & Control, Coll Publ Hlth & Nutr, Taipei 11031, Taiwan; [Liou, Tsan-Hon] Taipei Med Univ, Shuang Ho Hosp, Dept Phys Med & Rehabil, New Taipei City 23561, Taiwan; [Liou, Tsan-Hon] Taipei Med Univ, Sch Med, Dept Phys Med & Rehabil, Coll Med, Taipei 11031, Taiwan; [Chang, Kwang-Hwa] Taipei Med Univ, Wan Fang Hosp, Dept Phys Med & Rehabil, Taipei 11696, Taiwan; [Chi, Wen-Chou] Chung Shan Med Univ, Sch Occupat Therapy, Taichung 40201, Taiwan; [Escorpizo, Reuben] Univ Vermont, Dept Rehabil & Movement Sci, Coll Nursing & Hlth Sci, Burlington, VT 05401 USA; [Escorpizo, Reuben] Swiss Parapleg Res, CH-6207 Nottwil, Switzerland; [Yen, Chia-Feng] Tzu Chi Univ, Dept Publ Hlth, Hualien 97004, Taiwan; [Liao, Hua-Fang] Chinese Assoc Early Intervent Profess Children De, Hualien 97064, Taiwan; [Liao, Hua-Fang] Natl Taiwan Univ, Sch & Grad Inst Phys Therapy, Coll Med, Taipei 10055, Taiwan; [Tsai, Jo-Ting] Taipei Med Univ, Shuang Ho Hosp, Dept Radiat Oncol, New Taipei City 23561, Taiwan	Chiu, WT (corresponding author), Taipei Med Univ, Sch Publ Hlth, Coll Publ Hlth & Nutr, Taipei 11031, Taiwan.	kuo@s.tmu.edu.tw; peter_liou@s.tmu.edu.tw; chang2773@gmail.com; y6312002@gmail.com; escorpizo.reuben@gmail.com; mapleyeng@gmail.com; hfliao@ntu.edu.tw; hychiou@tmu.edu.tw; wtchiu@tmu.edu.tw; 10576@s.tmu.edu.tw	Escorpizo, Reuben/AAH-4934-2019; chi, danny/AAK-1579-2020; Liou, Tsan-Hon/I-8808-2019	Chiou, Hung Yi/0000-0002-4545-9697; Liou, Tsan-Hon/0000-0002-0959-4023			Adriaansen JJE, 2013, DISABIL REHABIL, V35, P1104, DOI 10.3109/09638288.2012.712196; Chi WC, 2014, INT J ENV RES PUB HE, V11, P12148, DOI 10.3390/ijerph111212148; Chi WC, 2013, J FORMOS MED ASSOC, V112, P473, DOI 10.1016/j.jfma.2013.06.005; Chiu WT, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-416; Chung P, 2014, J REHABIL MED, V46, P108, DOI 10.2340/16501977-1257; De Wolf AC, 2012, J REHABIL MED, V44, P747, DOI 10.2340/16501977-1016; Derrett S, 2012, INJURY PREV, V18, P343, DOI 10.1136/injuryprev-2011-040266; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dryden DM, 2004, SPINAL CORD, V42, P513, DOI 10.1038/sj.sc.3101629; Gupta A, 2012, ANN INDIAN ACAD NEUR, V15, P120, DOI 10.4103/0972-2327.94995; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lin JW, 2008, ACT NEUR S, V101, P113; Magasi SR, 2008, J SPINAL CORD MED, V31, P145, DOI 10.1080/10790268.2008.11760705; Ministry of Health and Welfare, 2010, VIT STAT TAIW; Noonan V. K., 2010, TOP SPINAL CORD INJU, V4, P49, DOI [10.1310/sci1504-49, DOI 10.1310/SCI1504-49]; Stiers W, 2012, J REHABIL RES DEV, V49, P139, DOI 10.1682/JRRD.2010.07.0131; Teng SW, 2013, J FORMOS MED ASSOC, V112, P691, DOI 10.1016/j.jfma.2013.09.007; Toft AMH, 2010, J TRAUMA, V69, P26, DOI 10.1097/TA.0b013e3181d3cbf2; Ustun TB, 2010, B WORLD HEALTH ORGAN, V88, P815, DOI 10.2471/BLT.09.067231; Ustun TB, 2010, MEASURING HLTH DISAB; van der Zee CH, 2014, ARCH PHYS MED REHAB, V95, P87, DOI 10.1016/j.apmr.2013.08.236; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; WHO, 2011, HLTH STAT HLTH INF S; Yen CF, 2014, J FORMOS MED ASSOC, V113, P839, DOI 10.1016/j.jfma.2014.08.008	26	25	27	0	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1660-4601			INT J ENV RES PUB HE	Int. J. Environ. Res. Public Health	APR	2015	12	4					4116	4127		10.3390/ijerph120404116			12	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	CG7MT	WOS:000353488500045	25874682	DOAJ Gold, Green Published			2021-06-18	
J	Pham, H; Duy, AP; Pansiot, J; Bollen, B; Gallego, J; Charriaut-Marlangueu, C; Baud, O				Pham, Hoa; Duy, An Phan; Pansiot, Julien; Bollen, Bieke; Gallego, Jorge; Charriaut-Marlangueu, Christiane; Baud, Olivier			Impact of inhaled nitric oxide on white matter damage in growth-restricted neonatal rats	PEDIATRIC RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; FOR-GESTATIONAL-AGE; LOW-BIRTH-WEIGHT; INTRAUTERINE GROWTH; PERIVENTRICULAR LEUKOMALACIA; PREMATURE-INFANTS; STROKE MODEL; FETAL-GROWTH; NEUROPROTECTION; INFLAMMATION	BACKGROUND: Fetal growth restriction is the second leading cause of perinatal morbidity and mortality, and neonates with intrauterine growth retardation (IUGR) have increased neurocognitive and neuropsychiatric morbidity. These neurocognitive impairments are mainly related to injury of the developing brain associated with IUGR. Growing evidence from preclinical models of brain injury in both adult and neonatal rodents supports the view that nitric oxide can promote neuroprotection. METHODS: In a model of IUGR induced by protracted gestational hypoxia leading to diffuse white matter injury, we subjected neonatal rats to low dose (5 ppm) but long-lasting (7 d) exposure to inhaled NO (iNO). We used a combination of techniques, including immunohistochemistry, quantitative PCR, and cognitive assessment, to assess neuroprotection. RESULTS: Antenatal hypoxia-induced IUGR was associated with severe neuroinflammation and delayed myelination. iNO exposure during the first postnatal week significantly attenuated cell death and microglial activation, enhanced oligodendroglial proliferation and finally improved myelination. Remarkably, iNO was associated with the specific upregulation of P27kip1, which initiates oligodendrocytic differentiation. Finally, iNO counteracted the deleterious effects of hypoxia on learning abilities. CONCLUSION: This study provides new evidence that iNO could be effective in preventing brain damage and/or enhancing repair of the developing brain.	[Pham, Hoa; Duy, An Phan; Pansiot, Julien; Bollen, Bieke; Gallego, Jorge; Charriaut-Marlangueu, Christiane; Baud, Olivier] Univ Paris Diderot, INSERM, UMR1141, Paris, France; [Pham, Hoa; Duy, An Phan; Pansiot, Julien; Bollen, Bieke; Gallego, Jorge; Charriaut-Marlangueu, Christiane; Baud, Olivier] PremUP Fdn, Paris, France; [Baud, Olivier] Robert Debre Childrens Hosp, AP HP, Neonatal Intens Care Unit, Paris, France	Baud, O (corresponding author), Univ Paris Diderot, INSERM, UMR1141, Paris, France.	olivier.baud@rdb.aphp.fr		Bollen, Bieke/0000-0002-8457-9317	INSERM (Institut National de la Sante et de la Recherche Medicale)Institut National de la Sante et de la Recherche Medicale (Inserm); Premup Foundation	This study was funded by INSERM (Institut National de la Sante et de la Recherche Medicale), and Premup Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or Preparation of the manuscript. We have nothing to disclose.	Amarenco P, 2006, NEW ENGL J MED, V355, P549; Batalle D, 2012, NEUROIMAGE, V60, P1352, DOI 10.1016/j.neuroimage.2012.01.059; Baud O, 2004, BRAIN PATHOL, V14, P1; Bouslama M, 2005, BEHAV BRAIN RES, V161, P102, DOI 10.1016/j.bbr.2005.01.010; Buser JR, 2012, ANN NEUROL, V71, P93, DOI 10.1002/ana.22627; Cannon M, 2002, AM J PSYCHIAT, V159, P1080, DOI 10.1176/appi.ajp.159.7.1080; Charriaut-Marlangue C, 2014, STROKE, V45, P850, DOI 10.1161/STROKEAHA.113.003606; Charriaut-Marlangue C, 2013, ANN NEUROL, V73, P442, DOI 10.1002/ana.23842; Charriaut-Marlangue C, 2012, STROKE, V43, P3078, DOI 10.1161/STROKEAHA.112.664243; Chen W, 2014, NEUROCHEM INT, V68, P28, DOI 10.1016/j.neuint.2014.01.015; Chhor V, 2012, ARCH PEDIATRIE, V19, P946, DOI 10.1016/j.arcped.2012.06.013; Ferriero DM, 2004, NEW ENGL J MED, V351, P1985, DOI 10.1056/NEJMra041996; Fontaine RH, 2008, P NATL ACAD SCI USA, V105, P16779, DOI 10.1073/pnas.0803004105; Gabbe SG, 1996, OBESTETRICS NORMAL P, P863; Geva R, 2006, BRAIN RES, V1117, P186, DOI 10.1016/j.brainres.2006.08.004; Hack M, 2002, NEW ENGL J MED, V346, P149, DOI 10.1056/NEJMoa010856; Hagberg H, 2012, ANN NEUROL, V71, P444, DOI 10.1002/ana.22620; Haynes RL, 2008, PEDIATR RES, V63, P656, DOI 10.1203/PDR.0b013e31816c825c; Pham H, 2014, EXP NEUROL, V252, P114, DOI 10.1016/j.expneurol.2013.11.025; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Isaacs EB, 2000, PEDIATR RES, V47, P713, DOI 10.1203/00006450-200006000-00006; Jarvis S, 2003, LANCET, V362, P1106, DOI 10.1016/S0140-6736(03)14466-2; Johnston MV, 2004, BRAIN DEV-JPN, V26, P73, DOI 10.1016/S0387-7604(03)00102-5; Leviton A, 2013, PEDIATR RES, V73, P362, DOI 10.1038/pr.2012.188; Li YS, 2013, BRAIN RES, V1507, P134, DOI 10.1016/j.brainres.2013.02.031; McElrath TF, 2013, ACTA PAEDIATR, V102, pE439, DOI 10.1111/apa.12339; NEERHOF MG, 1995, CLIN PERINATOL, V22, P375; O'Keeffe MJ, 2003, PEDIATRICS, V112, P301, DOI 10.1542/peds.112.2.301; Olivier P, 2010, J NEUROPATH EXP NEUR, V69, P828, DOI 10.1097/NEN.0b013e3181ea5203; Ozanne SE, 2004, SEMIN PERINATOL, V28, P81, DOI 10.1053/j.semperi.2003.10.015; Pansiot J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010916; Rees S, 2011, INT J DEV NEUROSCI, V29, P551, DOI 10.1016/j.ijdevneu.2011.04.004; Segovia KN, 2008, ANN NEUROL, V63, P520, DOI 10.1002/ana.21359; Terpolilli NA, 2013, J CEREBR BLOOD F MET, V33, P311, DOI 10.1038/jcbfm.2012.176; Terpolilli NA, 2012, J CEREBR BLOOD F MET, V32, P1332, DOI 10.1038/jcbfm.2012.12; Terpolilli NA, 2012, CIRC RES, V110, P727, DOI 10.1161/CIRCRESAHA.111.253419; Volpe JJ, 2009, LANCET NEUROL, V8, P110, DOI 10.1016/S1474-4422(08)70294-1; Wiles NJ, 2006, AM J EPIDEMIOL, V163, P829, DOI 10.1093/aje/kwj108; Yuen TJ, 2014, CELL, V158, P383, DOI 10.1016/j.cell.2014.04.052	39	25	25	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	APR	2015	77	4					563	569		10.1038/pr.2015.4			7	Pediatrics	Pediatrics	CD8HK	WOS:000351335600010	25580736	Bronze			2021-06-18	
J	Ziebell, JM; Adelson, PD; Lifshitz, J				Ziebell, Jenna M.; Adelson, P. David; Lifshitz, Jonathan			Microglia: dismantling and rebuilding circuits after acute neurological injury	METABOLIC BRAIN DISEASE			English	Article						Microglia; Synaptic stripping; Neurological disease; Traumatic brain injury; Epilepsy	TRAUMATIC BRAIN-INJURY; ACTIVATED MICROGLIA; ALZHEIMERS-DISEASE; MULTIPLE ROLES; CELLS; COMPLEMENT; ASTROCYTES; NEUROTOXICITY; FRACTALKINE; SYSTEM	The brain is comprised of neurons and its support system including astrocytes, glial cells and microglia, thereby forming neurovascular units. Neurons require support from glial cells to establish and maintain functional circuits, but microglia are often overlooked. Microglia function as the immune cell of the central nervous system, acting to monitor the microenvironment for changes in signaling, pathogens and injury. More recently, other functional roles for microglia within the healthy brain have been identified, including regulating synapse formation, elimination and function. This review aims to highlight and discuss these alternate microglial roles in the healthy and in contrast, diseased brain with a focus on two acute neurological diseases, traumatic brain injury and epilepsy. In these conditions, microglial roles in synaptic stripping and stabilization as part of neuronal:glial interactions may position them as mediators of the transition between injury-induced circuit dismantling and subsequent reorganization. Increased understanding of microglia roles could identify therapeutic targets to mitigate the consequences of neurological disease.	[Ziebell, Jenna M.; Adelson, P. David; Lifshitz, Jonathan] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ USA; [Ziebell, Jenna M.; Adelson, P. David; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Adelson, P. David; Lifshitz, Jonathan] Arizona State Univ, Neurosci Program, Tempe, AZ USA; [Lifshitz, Jonathan] Phoenix VA Healthcare Syst, Phoenix, AZ USA	Ziebell, JM (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, 1919 E Thomas Rd, Phoenix, AZ 85016 USA.	jmziebell@email.arizona.edu	Ziebell, Jenna/Y-4496-2019; Adelson, David/W-2083-2019	Ziebell, Jenna/0000-0003-2497-4347	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065052] Funding Source: Medline		Adalbert R, 2007, TRENDS MOL MED, V13, P135, DOI 10.1016/j.molmed.2007.02.004; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Annunziato L, 2013, J CEREBR BLOOD F MET, V33, P969, DOI 10.1038/jcbfm.2013.44; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Barclay AN, 2002, TRENDS IMMUNOL, V23, P285, DOI 10.1016/S1471-4906(02)02223-8; Benarroch EE, 2013, NEUROLOGY, V81, P1079, DOI 10.1212/WNL.0b013e3182a4a577; Beumer W, 2012, J LEUKOCYTE BIOL, V92, P959, DOI 10.1189/jlb.0212100; Biber K, 2006, CURR DRUG TARGETS, V7, P29, DOI 10.2174/138945006775270196; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Blank T, 2013, GLIA, V61, P62, DOI 10.1002/glia.22372; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boer K, 2006, J NEUROIMMUNOL, V173, P188, DOI 10.1016/j.jneuroim.2006.01.002; Brockhaus J, 1996, GLIA, V16, P81, DOI 10.1002/(SICI)1098-1136(199601)16:1<81::AID-GLIA9>3.0.CO;2-E; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Carthew HL, 2012, NEUROSCIENCE, V214, P78, DOI 10.1016/j.neuroscience.2012.04.028; Chen SK, 2010, CELL, V141, P775, DOI 10.1016/j.cell.2010.03.055; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Derecki NC, 2012, NATURE, V484, P105, DOI 10.1038/nature10907; Dityatev A, 2011, CURR OPIN NEUROBIOL, V21, P353, DOI 10.1016/j.conb.2010.12.006; Drexel M, 2012, NEUROPHARMACOLOGY, V63, P806, DOI 10.1016/j.neuropharm.2012.06.009; Frick LR, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/608654; Goldberg EM, 2013, NAT REV NEUROSCI, V14, P337, DOI 10.1038/nrn3482; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Greer JM, 2002, NEURON, V33, P23, DOI 10.1016/S0896-6273(01)00564-5; Hailer NP, 1997, EUR J NEUROSCI, V9, P863, DOI 10.1111/j.1460-9568.1997.tb01436.x; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Kalla R, 2001, J COMP NEUROL, V436, P182; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Lazar G, 1996, GLIA, V16, P101; Learoyd AE, 2012, BEHAV BRAIN RES, V226, P197, DOI 10.1016/j.bbr.2011.09.016; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morris GP, 2013, NEUROBIOL LEARN MEM, V105, P40, DOI 10.1016/j.nlm.2013.07.002; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Pardo CA, 2004, EPILEPSIA, V45, P516, DOI 10.1111/j.0013-9580.2004.33103.x; Perry VH, 2010, ASN NEURO, V2, P281, DOI 10.1042/AN20100024; Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Schafer DP, 2013, GLIA, V61, P24, DOI 10.1002/glia.22389; Schafer DP, 2010, BIOCHEM SOC T, V38, P476, DOI 10.1042/BST0380476; Schlegelmilch T, 2011, CURR OPIN NEUROBIOL, V21, P5, DOI 10.1016/j.conb.2010.08.004; Scott DA, 2010, J NEUROSCI, V30, P8083, DOI 10.1523/JNEUROSCI.1091-10.2010; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Siskova Z, 2009, AM J PATHOL, V175, P1610, DOI 10.2353/ajpath.2009.090372; Sofroniew MV, 2014, NEUROSCIENTIST, V20, P160, DOI 10.1177/1073858413504466; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; SVENSSON M, 1993, EXP NEUROL, V120, P123, DOI 10.1006/exnr.1993.1046; Tambuyzer BR, 2009, J LEUKOCYTE BIOL, V85, P352, DOI 10.1189/jlb.0608385; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Veerhuis R, 1999, EXP NEUROL, V160, P289, DOI 10.1006/exnr.1999.7199; Veerhuis R, 2011, MOL IMMUNOL, V48, P1592, DOI 10.1016/j.molimm.2011.04.003; Vezzani Annamaria, 2012, Handb Clin Neurol, V107, P163, DOI 10.1016/B978-0-444-52898-8.00010-0; Wake H, 2013, TRENDS NEUROSCI, V36, P209, DOI 10.1016/j.tins.2012.11.007; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wang CC, 1996, J ANAT, V189, P567; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Wirenfeldt M, 2009, NEUROBIOL DIS, V34, P432, DOI 10.1016/j.nbd.2009.02.015; Woodruff TM, 2010, NEUROMOL MED, V12, P179, DOI 10.1007/s12017-009-8085-y; Wright GJ, 2001, IMMUNOLOGY, V102, P173, DOI 10.1046/j.1365-2567.2001.01163.x; Yamada J, 2011, NEUROSCIENCE, V182, P1, DOI 10.1016/j.neuroscience.2011.03.030; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Zujovic V, 2000, GLIA, V29, P305, DOI 10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V	81	25	25	1	11	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	APR	2015	30	2					393	400		10.1007/s11011-014-9539-y			8	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	CD2HA	WOS:000350894800005	24733573	Green Accepted			2021-06-18	
J	Mychasiuk, R; Hehar, H; Ma, I; Kolb, B; Esser, MJ				Mychasiuk, R.; Hehar, H.; Ma, I.; Kolb, B.; Esser, M. J.			THE DEVELOPMENT OF LASTING IMPAIRMENTS: A MILD PEDIATRIC BRAIN INJURY ALTERS GENE EXPRESSION, DENDRITIC MORPHOLOGY, AND SYNAPTIC CONNECTIVITY IN THE PREFRONTAL CORTEX OF RATS	NEUROSCIENCE			English	Article						Golgi-Cox; qRT-PCR; telomere; neurodegeneration; pruning; epigenetics	NOGO-A; CORTICAL DEVELOPMENT; ALZHEIMERS-DISEASE; SOCIAL-BEHAVIOR; SEX-DIFFERENCES; ANIMAL-MODEL; CONCUSSION; OXYTOCIN; PLAY; SINGLE	Apart from therapeutic discovery, the study of mild traumatic brain injury (mTBI) has been focused on two challenges: why do a majority of individuals recover with little concern, while a considerable proportion suffer with persistent and often debilitating symptomology; and, how do mild injuries significantly increase risk for an early-onset neurodegeneration? Owing to a lack of observable damage following mTBI, this study was designed to determine if there were changes in neuronal morphology, synaptic connectivity, and epigenetic patterning that could contribute to the manifestation of persistent neurological dysfunction. Prefrontal cortex tissue from male and female rats was used for Golgi-Cox analysis along with the profiling of changes in gene expression (BDNF, DNMT1, FGF2, IGF1, Nogo-A, OXYR, and TERT) and telomere length (TL), following a single mTBI or sham injury in the juvenile period. Golgi-Cox analysis of dendritic branch order, dendritic length, and spine density demonstrate that an early mTBI increases complexity of pyramidal neurons in the mPFC. Furthermore, there are also substantial changes in the expression levels of the seven genes of interest and TL following a single mild injury in this brain region. The results from the neuroanatomical measures and changes in gene expression indicate that the mTBI disrupts normal pruning processes that are typically underway at this point in development. In addition, there are significant interactions between the social environment and epigenetic processes that work in concert to perpetuate neurological dysfunction. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Mychasiuk, R.; Hehar, H.; Ma, I.; Esser, M. J.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Fac Med, Calgary, AB T2N 1N4, Canada; [Kolb, B.] Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada	Mychasiuk, R (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, Fac Med, Heritage Med Res Bldg Room 274,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.	rmmychas@ucalgary.ca			Alberta Children's Hospital Research Institute, Alberta Children's Hospital Foundation; Markin USRP for Health and Wellness; NSERC of Canada grant	The authors would like to acknowledge Yilin Li and Kehe Xe for their technical assistance with the Golgi-Cox analysis, Dr. Jong Rho and Rose Tobias for organizational support, and the Alberta Children's Hospital Research Institute, Alberta Children's Hospital Foundation, and the Markin USRP for Health and Wellness, and an NSERC of Canada grant to B.K. for their financial contribution.	Andersen SL, 2003, NEUROSCI BIOBEHAV R, V27, P3, DOI 10.1016/S0149-7634(03)00005-8; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bell HC, 2010, BEHAV BRAIN RES, V207, P7, DOI 10.1016/j.bbr.2009.09.029; Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Bock J, 2005, CEREB CORTEX, V15, P802, DOI 10.1093/cercor/bhh181; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; Bongiorno D, 2010, INT J BIOCHEM CELL B, V42, P1072, DOI 10.1016/j.biocel.2010.02.007; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Ceanga M, 2010, NEUROSCI LETT, V477, P15, DOI 10.1016/j.neulet.2010.04.024; Cheatwood JL, 2008, STROKE, V39, P2091, DOI 10.1161/STROKEAHA.107.507426; Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003; Crews F, 2007, PHARMACOL BIOCHEM BE, V86, P189, DOI 10.1016/j.pbb.2006.12.001; Cruz EMV, 2007, HORM BEHAV, V51, P611, DOI 10.1016/j.yhbeh.2007.02.010; D'Ercole AJ, 2008, ENDOCRINOLOGY, V149, P5958, DOI 10.1210/en.2008-0920; Entringer S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003580; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frith C. D., 2003, AUTISM NEURAL BASIS; Gibb R, 1998, J NEUROSCI METH, V79, P1, DOI 10.1016/S0165-0270(97)00163-5; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Golmirzaei J, 2013, INT J PEDIAT, V2013, DOI 10.1155/2013/953103; Golshani Peyman, 2005, Thalamus & Related Systems, V3, P227, DOI 10.1017/S1472928807000222; Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110; Gordon NS, 2003, NEUROSCI LETT, V341, P17, DOI 10.1016/S0304-3940(03)00158-7; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Heinrichs M, 2008, PROG BRAIN RES, V170, P337, DOI 10.1016/S0079-6123(08)00428-7; Horch HW, 2002, NAT NEUROSCI, V5, P1177, DOI 10.1038/nn927; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Irwin SA, 2001, AM J MED GENET, V98, P161, DOI 10.1002/1096-8628(20010115)98:2<161::AID-AJMG1025>3.0.CO;2-B; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kaufmann WE, 2000, CEREB CORTEX, V10, P981, DOI 10.1093/cercor/10.10.981; KESHAVAN MS, 1994, J PSYCHIATR RES, V28, P239, DOI 10.1016/0022-3956(94)90009-4; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mattson MP, 2000, EXP GERONTOL, V35, P489, DOI 10.1016/S0531-5565(00)00115-7; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2015, NEUROBIOL DIS, V73, P1, DOI 10.1016/j.nbd.2014.09.003; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Mychasiuk R, 2012, SYNAPSE, V66, P308, DOI 10.1002/syn.21512; Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x; Niblock MM, 2000, J NEUROSCI, V20, P4165; Panossian LA, 2003, NEUROBIOL AGING, V24, P77, DOI 10.1016/S0197-4580(02)00043-X; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Pellis SM, 2007, CURR DIR PSYCHOL SCI, V16, P95, DOI 10.1111/j.1467-8721.2007.00483.x; Pellis SM, 2010, AM J PLAY, V2, P278; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0; Viano DC, 2012, ANN BIOMED ENG, V40, P213, DOI 10.1007/s10439-011-0386-2; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zagrebelsky M, 2010, J NEUROSCI, V30, P13220, DOI 10.1523/JNEUROSCI.1044-10.2010; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x; Zilles K., 1985, CORTEX RAT STEREOTAX	64	25	25	0	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 12	2015	288						145	155		10.1016/j.neuroscience.2014.12.034			11	Neurosciences	Neurosciences & Neurology	CA2TD	WOS:000348759600014	25555930				2021-06-18	
J	Almolda, B; de Labra, C; Barrera, I; Gruart, A; Delgado-Garcia, JM; Villacampa, N; Vilella, A; Hofer, MJ; Hidalgo, J; Campbell, IL; Gonzalez, B; Castellano, B				Almolda, Beatriz; de Labra, Carmen; Barrera, Iliana; Gruart, Agnes; Delgado-Garcia, Jose M.; Villacampa, Nadia; Vilella, Antonietta; Hofer, Markus J.; Hidalgo, Juan; Campbell, Iain L.; Gonzalez, Berta; Castellano, Bernardo			Alterations in microglial phenotype and hippocampal neuronal function in transgenic mice with astrocyte-targeted production of interleukin-10	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Transgenic mice; Cytokine; Neuroinflammation; Gliosis; Microglial plasticity; LTP; Iba1; CD16/32; CD11b; F4/80; CD150; GFAP; IL-10R	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PRO-INFLAMMATORY CYTOKINES; TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; DEVELOPING RAT-BRAIN; TRANSCRIPTION FACTOR; TGF-BETA; EXPRESSION PATTERNS; MULTIPLE-SCLEROSIS	Interleukin-10 (IL-10) is a cytokine classically linked with anti-inflammatory and protective functions in the central nervous system (CNS) in different neurodegenerative and neuroinflammatory conditions. In order to study the specific role of local CNS produced IL-10, we have created a new transgenic mouse line with astrocyte-targeted production of IL-10 (GFAP-IL10Tg). In the present study, the effects of local CNS IL-10 production on microglia, astrocytes and neuronal connectivity under basal conditions were investigated using immunohistochemistry, molecular biology techniques, electrophysiology and behavioural studies. Our results showed that, in GFAP-IL10Tg animals, microglia displayed an increase in density and a specific activated phenotype characterised by morphological changes in specific areas of the brain including the hippocampus, cortex and cerebellum that correlated with the level of transgene expressed IL-10 mRNA. Distinctively, in the hippocampus, microglial cells adopted an elongated morphology following the same direction as the dendrites of pyramidal neurons. Moreover, this IL-10-induced microglial phenotype showed increased expression of certain molecules including Iba1, CD11b, CD16/32 and F4/80 markers, "de novo" expression of CD150 and no detectable levels of either CD206 or MHCII. To evaluate whether this specific activated microglial phenotype was associated with changes in neuronal activity, the electrophysiological properties of pyramidal neurons of the hippocampus (CA3-CA1) were analysed in vivo. We found a lower excitability of the CA3-CA1 synapses and absence of long-term potentiation (LTP) in GFAP-IL10Tg mice. This study is the first description of a transgenic mouse with astrocyte-targeted production of the cytokine IL-10. The findings indicate that IL-10 induces a specific activated microglial phenotype concomitant with changes in hippocampal LTP responses. This transgenic animal will be a very useful tool to study IL-10 functions in the CNS, not only under basal conditions, but also after different experimental lesions or induced diseases. (C) 2014 Elsevier Inc. All rights reserved.	[Almolda, Beatriz; de Labra, Carmen; Barrera, Iliana; Villacampa, Nadia; Hidalgo, Juan; Gonzalez, Berta; Castellano, Bernardo] Univ Autonoma Barcelona, Inst Neurosci, Dept Cell Biol Physiol & Immunol, Bellaterra 08193, Spain; [Gruart, Agnes; Delgado-Garcia, Jose M.] Pablo de Olavide Univ, Div Neurosci, Seville 41013, Spain; [Vilella, Antonietta] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, I-41125 Modena, Italy; [Hofer, Markus J.; Campbell, Iain L.] Univ Sydney, Sch Mol Biosci, Sydney, NSW 2006, Australia	Almolda, B (corresponding author), Univ Autonoma Barcelona, Fac Med, Unitat Histol, Torre M5, Bellaterra 08193, Spain.	beatriz.almolda@uab.cat	Hofer, Markus J/C-3688-2013; de Labra, Carmen/C-9992-2017; Castellano, Bernardo/G-1428-2010; Villacampa, Dr Nadia/K-5304-2014; Vilella, Antonietta/AAF-2084-2019; Barrera, Iliana/AAM-1992-2021; Almolda, Beatriz/L-6920-2014; Hidalgo, Juan/C-9082-2011; Delgado-Garcia, Jose M./V-1567-2019; Gonzalez, Berta/G-1428-2010	Hofer, Markus J/0000-0001-5111-3978; de Labra, Carmen/0000-0002-5306-0475; Castellano, Bernardo/0000-0003-1976-971X; Villacampa, Dr Nadia/0000-0001-6513-0250; Almolda, Beatriz/0000-0001-6631-4385; Hidalgo, Juan/0000-0003-0921-1122; , Gerontology Research Group/0000-0001-7207-9481; Gonzalez, Berta/0000-0002-1860-3980; Vilella, Antonietta/0000-0003-3820-0115	Spanish Ministry of Science and InnovationSpanish Government [BFU2011-27400]; Spanish MINECO [BFU2011-29089, BFU2011-29286]; Junta de AndaluciaJunta de Andalucia [BIO122, CVI 2487, P07-CVI-02686, SAF2008-00435, SAF2011-23272]; NHMRC projectNational Health and Medical Research Council of Australia [632754]	The authors would like to thank Miguel A. Martil, Isabella Appiah, B. Ferrer, J. Carrasco, Sue Ling Lim and Maria Sanchez-Enciso for their outstanding technical help. This work was supported by the Spanish Ministry of Science and Innovation (BFU2011-27400), the Spanish MINECO (BFU2011-29089 and BFU2011-29286) and Junta de Andalucia (BIO122, CVI 2487, and P07-CVI-02686), SAF2008-00435, SAF2011-23272 and an NHMRC project grant 632754. The authors declare no competing financial interests.	Abutbul S, 2012, GLIA, V60, P1160, DOI 10.1002/glia.22343; Almolda B, 2014, GLIA, V62, P1142, DOI 10.1002/glia.22668; Apelt J, 2001, BRAIN RES, V894, P21, DOI 10.1016/S0006-8993(00)03176-0; Appel SH, 2010, TRENDS IMMUNOL, V31, P7, DOI 10.1016/j.it.2009.09.003; Arimoto T, 2007, NEUROBIOL AGING, V28, P894, DOI 10.1016/j.neurobiolaging.2006.04.011; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Balasingam V, 1996, J NEUROSCI, V16, P2945; Beers DR, 2006, P NATL ACAD SCI USA, V103, P16021, DOI 10.1073/pnas.0607423103; Biber K, 2014, GLIA, V62, P841, DOI 10.1002/glia.22654; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; CAMPBELL IL, 1994, J IMMUNOL, V152, P716; Cannella B, 1996, J NEUROSCI RES, V45, P735, DOI 10.1002/(SICI)1097-4547(19960915)45:6<735::AID-JNR10>3.0.CO;2-V; Cannella B, 2004, ANN NEUROL, V55, P46, DOI 10.1002/ana.10764; Carson MJ, 2007, NEUROTHERAPEUTICS, V4, P571, DOI 10.1016/j.nurt.2007.07.002; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Crain JM, 2013, J NEUROSCI RES, V91, P1143, DOI 10.1002/jnr.23242; Cua DJ, 2001, J IMMUNOL, V166, P602, DOI 10.4049/jimmunol.166.1.602; Dalmau I, 1998, HIPPOCAMPUS, V8, P458, DOI 10.1002/(SICI)1098-1063(1998)8:5<458::AID-HIPO6>3.3.CO;2-E; Dalmau I, 2003, J COMP NEUROL, V458, P144, DOI 10.1002/cne.10572; Dalmau I, 1998, J COMP NEUROL, V398, P333, DOI 10.1002/(SICI)1096-9861(19980831)398:3<333::AID-CNE3>3.0.CO;2-0; Eleore L, 2007, BEHAV NEUROSCI, V121, P1203, DOI 10.1037/0735-7044.121.6.1203; Ellis SL, 2010, J IMMUNOL, V185, P1864, DOI 10.4049/jimmunol.1000900; Gonzalez P, 2009, J NEUROPATH EXP NEUR, V68, P391, DOI 10.1097/NEN.0b013e31819dca30; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Gruart A, 2006, J NEUROSCI, V26, P1077, DOI 10.1523/JNEUROSCI.2834-05.2006; Gureviciene I, 2004, NEUROBIOL DIS, V15, P188, DOI 10.1016/j.nbd.2003.11.011; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Howie D, 2002, BLOOD, V100, P2899, DOI 10.1182/blood-2002-02-0445; Hulshof S, 2002, GLIA, V38, P24, DOI 10.1002/glia.10050; ISSAZADEH S, 1995, J NEUROIMMUNOL, V61, P205, DOI 10.1016/0165-5728(95)00100-G; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Ledeboer A, 2000, GLIA, V30, P134, DOI 10.1002/(SICI)1098-1136(200004)30:2<134::AID-GLIA3>3.0.CO;2-3; Ledeboer A, 2003, J NEUROIMMUNOL, V136, P94, DOI 10.1016/S0165-5728(03)00031-6; Ledeboer A, 2002, EUR J NEUROSCI, V16, P1175, DOI 10.1046/j.1460-9568.2002.02200.x; Li Ying, 2013, Commun Integr Biol, V6, pe24493, DOI 10.4161/cib.24493; Li Y, 2012, DEV CELL, V23, P1189, DOI 10.1016/j.devcel.2012.10.027; Lim SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081218; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lodge PA, 1996, J LEUKOCYTE BIOL, V60, P502; Madronal N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011130; Madronal N, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.007.2009; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Molina-Holgado E, 2001, EUR J NEUROSCI, V13, P493, DOI 10.1046/j.0953-816x.2000.01412.x; Molina-Holgado F, 2001, GLIA, V33, P97, DOI 10.1002/1098-1136(200102)33:2<97::AID-GLIA1009>3.0.CO;2-N; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; Navascues J, 2000, AN ACAD BRAS CIENC, V72, P91, DOI 10.1590/S0001-37652000000100013; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Norden DM, 2014, GLIA, V62, P881, DOI 10.1002/glia.22647; Olah M, 2012, GLIA, V60, P306, DOI 10.1002/glia.21266; Ooboshi H, 2005, CIRCULATION, V111, P913, DOI 10.1161/01.CIR.0000155622.68580.DC; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Pang Y, 2005, DEV BRAIN RES, V157, P141, DOI 10.1016/j.devbrainres.2005.03.015; Park KW, 2007, EXP MOL MED, V39, P812, DOI 10.1038/emm.2007.88; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; Prinz M, 2014, ACTA NEUROPATHOL, V128, P319, DOI 10.1007/s00401-014-1267-1; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; Schilling T, 2001, EUR J NEUROSCI, V14, P463, DOI 10.1046/j.0953-816x.2001.01661.x; Shechter R, 2013, J PATHOL, V229, P332, DOI 10.1002/path.4106; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; Stalder AK, 1998, AM J PATHOL, V153, P767, DOI 10.1016/S0002-9440(10)65620-9; Strle K, 2002, J NEUROIMMUNOL, V122, P9, DOI 10.1016/S0165-5728(01)00444-1; Taylor M E, 2001, Results Probl Cell Differ, V33, P105; Jurado-Parras MT, 2012, LEARN MEMORY, V19, P99, DOI 10.1101/lm.024760.111; Walker FR, 2014, BRAIN BEHAV IMMUN, V37, P1, DOI 10.1016/j.bbi.2013.12.010; Walton MR, 2000, J NEUROIMMUNOL, V104, P109, DOI 10.1016/S0165-5728(99)00262-3; Xin JP, 2011, BRAIN BEHAV IMMUN, V25, P820, DOI 10.1016/j.bbi.2010.08.004; Zhai QH, 1997, J NEUROL SCI, V152, P119, DOI 10.1016/S0022-510X(97)00154-8	80	25	27	1	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAR	2015	45						80	97		10.1016/j.bbi.2014.10.015			18	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	CC7BX	WOS:000350523800010	25449577				2021-06-18	
J	Polak, P; Leddy, JJ; Dwyer, MG; Willer, B; Zivadinov, R				Polak, Paul; Leddy, John J.; Dwyer, Michael G.; Willer, Barry; Zivadinov, Robert			Diffusion Tensor Imaging Alterations in Patients With Postconcussion Syndrome Undergoing Exercise Treatment: A Pilot Longitudinal Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						diffusion tensor imaging; exercise; mild traumatic brain injury; postconcussion syndrome; potholes analysis; tract-based spatial statistics	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; HEAD-INJURY; RELIABILITY; INTEGRITY; VETERANS; RECOVERY; MODERATE; DAMAGE; TIME	Purpose: To investigate diffusion tensor imaging characteristics in patients with postconcussion syndrome (PCS) who received exercise (n = 4) and placebo stretching (n = 4) treatments compared with a group of healthy controls (n = 15). Methods: Subjects diagnosed with PCS obtained a diffusion tensor imaging magnetic resonance image at pretreatment (baseline) and approximately 8 weeks later (follow-up). Analyses included a groupwise comparison using tract-based spatial statistics and a z-score map that investigated localized regional anomalies compared with the healthy control group projected onto the tract-based spatial statistics skeleton. Results: The tract-based spatial statistics analysis detected groupwise differences in the genu of the corpus callosum at both time points with decreased fractional anisotropy and increased radial diffusivity and mean diffusivity values. In contrast, the z-score analysis was more sensitive to heterogeneous changes in fractional anisotropy, with both low-and high-localized areas across various white matter regions, the most prevalent being the corpus callosum, anterior and superior corona radiata, and internal and external capsules. The mean number of voxels different in patients with PCS versus healthy controls was greater in all cases (baseline lower: P < .03 and higher: P < .0001; follow-up lower: P < .0001 and higher: P < .0001). The volume and location of these abnormal regions changed between the 2 diffusion tensor imaging scans, but these did not correlate with the mitigation of symptoms in the patients with PCS. Conclusions: Diffusion tensor imaging revealed spatially varying and heterogeneous localized irregularities in patients with PCS that persisted even as patient symptoms decreased and prognosis improved.	[Polak, Paul; Dwyer, Michael G.; Zivadinov, Robert] SUNY Buffalo, Buffalo Neuroimaging Anal Ctr, Dept Neurol, Buffalo, NY 14203 USA; [Leddy, John J.] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14203 USA; [Leddy, John J.] SUNY Buffalo, Univ Sports Med, Buffalo, NY 14203 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14203 USA	Zivadinov, R (corresponding author), SUNY Buffalo, Buffalo Neuroimaging Anal Ctr, Dept Neurol, 100 High St, Buffalo, NY 14203 USA.	rzivadinov@bnac.net	Zivadinov, Robert/Q-2054-2019	Zivadinov, Robert/0000-0002-7799-1485; Polak, Paul/0000-0002-7719-7572; Dwyer, Michael/0000-0003-4684-4658			Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; DiFiori JP, 2010, CURR SPORT MED REP, V9, P35, DOI 10.1249/JSR.0b013e3181caba67; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Koso M, 2006, EUR PSYCHIAT, V21, P167, DOI 10.1016/j.eurpsy.2005.06.004; Kozlowski KF, 2007, NEUROREHABILITATION, V22, P191; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Ma R, 2012, J BONE JOINT SURG AM, V94A, P1618, DOI 10.2106/JBJS.K.01127; Mathias C., 2013, AUTONOMIC FAILURE TX; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Oishi K, JHU MNI SS ATLAS; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Schmidt OI., 2004, EUR J TRAUMA, V30, P135, DOI [10.1007/s00068-004-1394-9, DOI 10.1007/S00068-004-1394-9]; Schulte T, 2005, CEREB CORTEX, V15, P1384, DOI 10.1093/cercor/bhi020; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014	35	25	26	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2015	30	2					E32	E42		10.1097/HTR.0000000000000037			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CF1MG	WOS:000352309300004	24721808				2021-06-18	
J	Wintermark, M; Coombs, L; Druzgal, TJ; Field, AS; Filippi, CG; Hicks, R; Horton, R; Lui, YW; Law, M; Mukherjee, P; Norbash, A; Riedy, G; Sanelli, PC; Stone, JR; Sze, G; Tilkin, M; Whitlow, CT; Wilde, EA; York, G; Provenzale, JM				Wintermark, M.; Coombs, L.; Druzgal, T. J.; Field, A. S.; Filippi, C. G.; Hicks, R.; Horton, R.; Lui, Y. W.; Law, M.; Mukherjee, P.; Norbash, A.; Riedy, G.; Sanelli, P. C.; Stone, J. R.; Sze, G.; Tilkin, M.; Whitlow, C. T.; Wilde, E. A.; York, G.; Provenzale, J. M.		Amer Coll Radiology	Traumatic Brain Injury Imaging Research Roadmap	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							COMMON DATA ELEMENTS; WHITE-MATTER ABNORMALITIES; MILD HEAD TRAUMA; FUNCTIONAL CONNECTIVITY; COGNITIVE DEFICITS; OUTCOME MEASURES; RECOMMENDATIONS; MEG; MODERATE; SPECT	The past decade has seen impressive advances in the types of neuroimaging information that can be acquired in patients with traumatic brain injury. However, despite this increase in information, understanding of the contribution of this information to prognostic accuracy and treatment pathways for patients is limited. Available techniques often allow us to infer the presence of microscopic changes indicative of alterations in physiology and function in brain tissue. However, because histologic confirmation is typically lacking, conclusions reached by using these techniques remain solely inferential in almost all cases. Hence, a need exists for validation of these techniques by using data from large population samples that are obtained in a uniform manner, analyzed according to well-accepted procedures, and correlated with closely monitored clinical outcomes. At present, many of these approaches remain confined to population-based research rather than diagnosis at an individual level, particularly with regard to traumatic brain injury that is mild or moderate in degree. A need and a priority exist for patient-centered tools that will allow advanced neuroimaging tools to be brought into clinical settings. One barrier to developing these tools is a lack of an age-, sex-, and comorbidities-stratified, sequence-specific, reference imaging data base that could provide a clear understanding of normal variations across populations. Such a data base would provide researchers and clinicians with the information necessary to develop computational tools for the patient-based interpretation of advanced neuroimaging studies in the clinical setting. The recent "Joint ASNR-ACR HII-ASFNR TBI Workshop: Bringing Advanced Neuroimaging for Traumatic Brain Injury into the Clinic" on May 23, 2014, in Montreal, Quebec, Canada, brought together neuroradiologists, neurologists, psychiatrists, neuropsychologists, neuroimaging scientists, members of the National Institute of Neurologic Disorders and Stroke, industry representatives, and other traumatic brain injury stakeholders to attempt to reach consensus on issues related to and develop consensus recommendations in terms of creating both a well-characterized normative data base of comprehensive imaging and ancillary data to serve as a reference for tools that will allow interpretation of advanced neuroimaging tests at an individual level of a patient with traumatic brain injury. The workshop involved discussions concerning the following: 1) designation of the policies and infrastructure needed for a normative data base, 2) principles for characterizing normal control subjects, and 3) standardizing research neuroimaging protocols for traumatic brain injury. The present article summarizes these recommendations and examines practical steps to achieve them.	[Wintermark, M.] Stanford Univ, Dept Radiol, Neuroradiol Div, Stanford, CA 94305 USA; [Coombs, L.; Horton, R.; Tilkin, M.] Amer Coll Radiol, Reston, VA USA; [Druzgal, T. J.; Stone, J. R.] Univ Virginia, Dept Radiol, Charlottesville, VA USA; [Stone, J. R.] Univ Virginia, Dept Med Imaging & Neurol Surg, Charlottesville, VA USA; [Field, A. S.] Univ Wisconsin, Dept Radiol, Neuroradiol Sect, Madison, WI 53706 USA; [Filippi, C. G.] Columbia Univ, Dept Radiol, New York, NY USA; [Filippi, C. G.; Sanelli, P. C.] North Shore Long Isl Jewish Hlth Syst, Dept Radiol, Manhasset, NY USA; [Hicks, R.] One Mind, Seattle, WA USA; [Lui, Y. W.] NYU, Dept Radiol, Neuroradiol Div, Sch Med, New York, NY 10016 USA; [Law, M.] Univ So Calif, Dept Radiol, Neuroradiol Sect, Los Angeles, CA USA; [Mukherjee, P.] Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, San Francisco, CA 94143 USA; [Norbash, A.] Boston Univ, Sch Med, Dept Radiol, Boston, MA 02118 USA; [Riedy, G.] Natl Intrepid Ctr Excellence, Washington, DC USA; [Sze, G.] Yale Univ, Dept Radiol, Neuroradiol Sect, New Haven, CT USA; [Whitlow, C. T.] Wake Forest Sch Med, Dept Radiol, Neuroradiol & Translat Sci Inst, Winston Salem, NC USA; [Wilde, E. A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, E. A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, E. A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [York, G.] San Antonio Mil Med Ctr, San Antonio, TX USA; [Provenzale, J. M.] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA	Wintermark, M (corresponding author), Stanford Univ, Dept Radiol, Neuroradiol Div, 300 Pasteur Dr,Room SO47, Stanford, CA 94305 USA.	Max.Wintermark@gmail.com	Filippi, Christopher/AAA-5493-2021; Rettmann, Dan/G-5265-2015	Andrews, Trevor/0000-0003-0331-1798; Mukherjee, Pratik/0000-0001-7473-7409; Wintermark, Max/0000-0002-6726-3951; Druzgal, Jason/0000-0001-7240-9487	American Society of Neuroradiology; Head Injury Institute of the American College of Radiology; American Society of Functional Neuroradiology; GE HealthcareGE Healthcare; Philips Healthcare	We wish to acknowledge the generous support of the American Society of Neuroradiology, the Head Injury Institute of the American College of Radiology, the American Society of Functional Neuroradiology, GE Healthcare and Philips Healthcare, whose contributions made possible the "Joint ASNR-ACR HII-ASFNR TBI Workshop: Bringing Advanced Neuroimaging for TBI into the Clinic," held on Friday May 23, 2014, in Montreal, Quebec, Canada, as a parallel session during the 52nd Annual Meeting of the ASNR and The Foundation of the ASNR Symposium 2014,	Adamson C, 2013, BRAIN INJURY, V27, P454, DOI 10.3109/02699052.2012.750756; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baek SO, 2013, NEUROREHABILITATION, V33, P465, DOI 10.3233/NRE-130979; Batoulis H, 2014, CLIN EXP IMMUNOL, V175, P41, DOI 10.1111/cei.12209; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Chokshi FH, 2011, AM J ROENTGENOL, V196, pW309, DOI 10.2214/AJR.10.4548; Das S, 2012, FRONT NEUROINFORM, V5, DOI 10.3389/fninf.2011.00037; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maller JJ, 2014, HUM BRAIN MAPP, V35, P227, DOI 10.1002/hbm.22171; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2008, ACTA NEUROCHIR SUPPL, V102, P247, DOI 10.1007/978-3-211-85578-2_47; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Patel R, 2012, NEUROSCI BIOBEHAV R, V36, P2130, DOI 10.1016/j.neubiorev.2012.06.003; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pitkanen A, 2014, EPILEPSY BEHAV, V38, P19, DOI 10.1016/j.yebeh.2014.01.013; Schonberger M, 2011, BRAIN INJURY, V25, P543, DOI 10.3109/02699052.2011.565013; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Stamatakis EA, 2002, J NUCL MED, V43, P476; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Venkatesan UM, 2015, J NEUROTRAUM, V32, P252, DOI 10.1089/neu.2013.3318; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	51	25	25	0	19	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	2015	36	3					E12	E23		10.3174/ajnr.A4254			12	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CD3PL	WOS:000350990900001	25655872	Green Published, Other Gold			2021-06-18	
J	Maki-Marttunen, V; Kuusinen, V; Brause, M; Perakyla, J; Polvivaara, M; Ribeiro, RD; Ohman, J; Hartikainen, KM				Maki-Marttunen, Veronica; Kuusinen, Venla; Brause, Maarja; Perakyla, Jari; Polvivaara, Markus; Ribeiro, Rodolfo dos Santos; Ohman, Juha; Hartikainen, Kaisa M.			Enhanced Attention Capture by Emotional Stimuli in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						attention; response inhibition; mTBI; emotion; EEG	FUNCTIONAL CONNECTIVITY; NEURAL MECHANISMS; COGNITIVE CONTROL; HEAD-INJURY; DEPRESSION; SYMPTOMS; MODERATE; COMPETE; ERP	Mild traumatic brain injury (mTBI) may be associated with compromised executive functioning and altered emotional reactivity. Despite frequent affective and cognitive symptoms in mTBI, objective evidence for brain dysfunction is often lacking. Previously we have reported compromised performance in symptomatic mTBI patients in an executive reaction time (RT) test, a computer-based RT test engaging several executive functions simultaneously. Here, we investigated the cognitive control processes in mTBI in context of threat-related stimuli. We used behavioral measures and event-related potentials (ERP) to investigate attentional capture by task-relevant and task-irrelevant emotional stimuli during a Go-NoGo task requiring cognitive control. We also assessed subjective cognitive, somatic, and emotional symptoms with questionnaires. Twenty-seven subjects with previous mTBI and 17 controls with previous ankle injury participated in the study over 9 months post-injury. Electroencephalogram (EEG) was recorded while patients performed a modified executive RT-test. N2-P3 ERP component was used as a general measure of allocated attentional and executive processing resources. Although at the time of the testing, the mTBI and the control groups did not differ in symptom endorsement, mTBI patients reported having had more emotional symptoms overall since the injury than controls. The overall RT-test performance levels did not differ between groups. However, when threat-related emotional stimuli were used as Go-signals, the mTBI group was faster than the control group. In comparison to neutral stimuli, threat-related stimuli were associated with increased N2-P3 amplitude in all conditions. This threat-related enhancement of the N2-P3 complex was greater in mTBI patients than in controls in response to Go signals and NoGo signals, independent of relevance. We conclude that mTBI may be associated with enhanced attentional and executive resource allocation to threat-related stimuli. Along with behavioral evidence for enhanced attention allocation to threat stimuli, increased brain responses to threat were observed in mTBI. Enhanced attention capture by threat-related emotional stimuli may reflect inefficient top-down control of bottom-up influences of emotion, and might contribute to affective symptoms in mTBI.	[Maki-Marttunen, Veronica; Kuusinen, Venla; Brause, Maarja; Perakyla, Jari; Polvivaara, Markus; Ribeiro, Rodolfo dos Santos; Hartikainen, Kaisa M.] Tampere Univ Hosp, Behav Neurol Res Unit, Tampere 33520, Finland; [Ohman, Juha; Hartikainen, Kaisa M.] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere 33520, Finland	Hartikainen, KM (corresponding author), Tampere Univ Hosp, Behav Neurol Res Unit, POB 2000, Tampere 33520, Finland.	kaisa.hartikainen@uta.fi		Ohman, Juha/0000-0002-6592-1367; Hartikainen, Kaisa/0000-0001-7278-9635	Academy of FinlandAcademy of FinlandEuropean Commission; Competitive Research Fund of Pirkanmaa Hospital District	This research was supported by the Academy of Finland and the Competitive Research Fund of Pirkanmaa Hospital District.	Albert J, 2012, HUM BRAIN MAPP, V33, P2147, DOI 10.1002/hbm.21347; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bishop SJ, 2008, ANN NY ACAD SCI, V1129, P141, DOI 10.1196/annals.1417.016; Bombardier CH, 2010, PHYS MED REH CLIN N, V21, P281, DOI 10.1016/j.pmr.2009.12.005; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Daffner KR, 2000, J COGNITIVE NEUROSCI, V12, P393, DOI 10.1162/089892900562219; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; Fisher R, 2010, EPILEPSIA, V51, P899, DOI 10.1111/j.1528-1167.2010.02536.x; Folstein JR, 2008, PSYCHOPHYSIOLOGY, V45, P152, DOI 10.1111/j.1469-8986.2007.00602.x; Funahashi S, 2001, NEUROSCI RES, V39, P147, DOI 10.1016/S0168-0102(00)00224-8; Hartikainen KM, 2007, NEUROREPORT, V18, P1929, DOI 10.1097/WNR.0b013e3282f1ca18; Hartikainen KM, 2014, J CLIN EXP NEUROPSYC, V36, P540, DOI 10.1080/13803395.2014.913554; Hartikainen KM, 2012, J CLIN EXP NEUROPSYC, V34, P588, DOI 10.1080/13803395.2012.666231; Hartikainen KM, 2012, NEUROREPORT, V23, P447, DOI 10.1097/WNR.0b013e3283531e74; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hartikainen KM, 2010, NEUROREPORT, V21, P344, DOI 10.1097/WNR.0b013e328336eeb3; Hartikainen KM, 2000, NEUROPSYCHOLOGIA, V38, P1576, DOI 10.1016/S0028-3932(00)00072-5; Ito TA, 1998, J PERS SOC PSYCHOL, V75, P887, DOI 10.1037/0022-3514.75.4.887; Kaiser S, 2006, INT J PSYCHOPHYSIOL, V61, P279, DOI 10.1016/j.ijpsycho.2005.09.006; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Maki-Marttunen V, 2014, NEUROREPORT, V25, P1038, DOI 10.1097/WNR.0000000000000223; Matthews G, 2000, BEHAV MODIF, V24, P69, DOI 10.1177/0145445500241004; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Newsome MR, 2013, J INT NEUROPSYCH SOC, V19, P911, DOI 10.1017/S1355617713000817; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; Ohman A, 2001, J EXP PSYCHOL GEN, V130, P466, DOI 10.1037/0096-3445.130.3.466; Pessoa Luiz, 2010, Dialogues Clin Neurosci, V12, P433; Pessoa L, 2009, TRENDS COGN SCI, V13, P160, DOI 10.1016/j.tics.2009.01.006; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Schupp HT, 2007, J NEUROSCI, V27, P1082, DOI 10.1523/JNEUROSCI.3223-06.2007; Shimamura AP, 2000, CONSCIOUS COGN, V9, P313, DOI 10.1006/ccog.2000.0450; Solbakk AK, 2005, J CLIN EXP NEUROPSYC, V27, P205, DOI 10.1080/13803390490515739; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Spinella M, 2007, J GEN PSYCHOL, V134, P101, DOI 10.3200/GENP.134.1.101-111; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; Vuilleumier P, 2003, NAT NEUROSCI, V6, P624, DOI 10.1038/nn1057; Vuilleumier P, 2001, NEUROREPORT, V12, P1119, DOI 10.1097/00001756-200105080-00014; Zhang WH, 2012, BIOL PSYCHOL, V89, P444, DOI 10.1016/j.biopsycho.2011.12.011	46	25	26	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2015	32	4					272	279		10.1089/neu.2014.3557			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CB0KN	WOS:000349314900008	25274125	Green Published, Bronze			2021-06-18	
J	Tan, L; Ge, HF; Tang, J; Fu, CH; Duanmu, WS; Chen, YJ; Hu, R; Sui, JF; Liu, X; Feng, H				Tan, Liang; Ge, Hongfei; Tang, Jun; Fu, Chuhua; Duanmu, Wangsheng; Chen, Yujie; Hu, Rong; Sui, Jianfeng; Liu, Xin; Feng, Hua			Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Depression; Dopamine; Amantadine; Nigrostriatal pathway	SUBSTANTIA-NIGRA VULNERABILITY; ANTIDEPRESSANT; RECEPTOR; TRANSPORTER; EXPRESSION; NEURONS; FLUID; PATHOPHYSIOLOGY; PARKINSONISM; RESTORATION	Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (C) 2014 Published by Elsevier B.V.	[Tan, Liang; Ge, Hongfei; Tang, Jun; Fu, Chuhua; Duanmu, Wangsheng; Chen, Yujie; Hu, Rong; Liu, Xin; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China; [Tan, Liang; Ge, Hongfei; Tang, Jun; Fu, Chuhua; Duanmu, Wangsheng; Chen, Yujie; Hu, Rong; Liu, Xin; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Key Lab Neurotrauma, Chongqing 400038, Peoples R China; [Sui, Jianfeng] Third Mil Med Univ, Coll Basic Med Sci, Expt Ctr Basic Med, Chongqing 400038, Peoples R China	Feng, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China.	tracy200712@hotmail.com; mudan13868@126.com; juntang881025@sina.com; 87848946@qq.com; 510149003@qq.com; yujiechen6886@foxmail.com; huchrong@aliyun.com; jfsui2003@163.com; shenwai@tmmu.edu.cn; fenghua8888@aliyun.com.cn	Tan, Liang/AAS-3997-2020	Chen, Yujie/0000-0002-9905-9138	Natural Basic Research Program of China (973 program)National Basic Research Program of China [SQ2013CB051394]	This study was supported by the Natural Basic Research Program of China (973 program SQ2013CB051394).	Alimoradian A, 2013, IRAN J BASIC MED SCI, V16, P743; [Anonymous], 2006, MMWR, V55, P201; Autry AE, 2011, NATURE, V475, P91, DOI 10.1038/nature10130; BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; Balasubramani PP, 2014, FRONT COMPUT NEUROSC, V8, DOI 10.3389/fncom.2014.00047; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; BRAESTRUP C, 1975, EUR J PHARMACOL, V34, P181, DOI 10.1016/0014-2999(75)90238-1; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cryan JF, 2002, TRENDS PHARMACOL SCI, V23, P238, DOI 10.1016/S0165-6147(02)02017-5; Dunlop BW, 2007, ARCH GEN PSYCHIAT, V64, P327, DOI 10.1001/archpsyc.64.3.327; Eakin K, 2013, EXP NEUROL, V240, P103, DOI 10.1016/j.expneurol.2012.11.005; Ehara A, 2009, ACTA HISTOCHEM CYTOC, V42, P171, DOI 10.1267/ahc.09018; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FRITSCHY JM, 1992, J COMP NEUROL, V321, P421, DOI 10.1002/cne.903210309; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Harsing L. G, 2008, HDB NEUROCHEMISTRY M, P149, DOI [10.1007/978-0-387-30382-6_7, DOI 10.1007/978-0-387-30382-6_7]; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hu JH, 2013, J NEUROTRAUM, V30, P1755, DOI 10.1089/neu.2013.2857; Hu ZL, 2004, J COMP NEUROL, V476, P301, DOI 10.1002/cne.20230; Huang EYK, 2014, BEHAV BRAIN RES, V267, P156, DOI 10.1016/j.bbr.2014.03.033; Huang EYK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086354; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Kulkarni SK, 2009, EXPERT OPIN INV DRUG, V18, P767, DOI [10.1517/13543780902880850 , 10.1517/13543780902880850]; Lambert G, 2000, ARCH GEN PSYCHIAT, V57, P787, DOI 10.1001/archpsyc.57.8.787; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Leggio GM, 2013, EUR J PHARMACOL, V719, P25, DOI 10.1016/j.ejphar.2013.07.022; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Ossola B, 2011, NEUROPHARMACOLOGY, V61, P574, DOI 10.1016/j.neuropharm.2011.04.030; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Park SK, 2005, CELL, V122, P275, DOI 10.1016/j.cell.2005.05.031; Parsons CG, 1996, EUR J NEUROSCI, V8, P446, DOI 10.1111/j.1460-9568.1996.tb01228.x; Patel J, 2003, J NEUROCHEM, V85, P898, DOI 10.1046/j.1471-4159.2003.01732.x; Peeters M, 2002, BRAIN RES, V949, P32, DOI 10.1016/S0006-8993(02)02961-X; Penmatsa A, 2013, NATURE, V503, P85, DOI 10.1038/nature12533; Piotrowska A, 2013, J PHYSIOL PHARMACOL, V64, P493; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.0.CO;2-K; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rogoz Z, 2007, PHARMACOL REP, V59, P778; Roman A, 2009, PHARMACOL REP, V61, P1069, DOI 10.1016/S1734-1140(09)70169-0; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Shimada R, 2014, NEUROL RES, V36, P239, DOI 10.1179/1743132813Y.0000000289; Shin SS, 2013, J NEUROTRAUM, V30, P259, DOI 10.1089/neu.2012.2462; Stein DJ, 2007, LANCET, V369, P139, DOI 10.1016/S0140-6736(07)60075-0; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tye KM, 2013, NATURE, V493, P537, DOI 10.1038/nature11740; van Bregt DR, 2012, EXP NEUROL, V234, P8, DOI 10.1016/j.expneurol.2011.12.003; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Wen XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063691; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1080/09602010244000444, 10.1016/S0960-9822(02)01374-X]; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Wong JC, 2013, CRIT REV CL LAB SCI, V50, P103, DOI 10.3109/10408363.2013.844678; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang QJ, 2010, BRAIN RES, V1312, P127, DOI 10.1016/j.brainres.2009.11.052	60	25	27	0	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 15	2015	279						274	282		10.1016/j.bbr.2014.10.037			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	AZ5IO	WOS:000348255200033	25447294				2021-06-18	
J	Whiteside, DM; Kogan, J; Wardin, L; Phillips, D; Franzwa, MG; Rice, L; Basso, M; Roper, B				Whiteside, Douglas M.; Kogan, Julia; Wardin, Lydia; Phillips, Derek; Franzwa, M. Graciela; Rice, Linda; Basso, Michael; Roper, Brad			Language-based embedded performance validity measures in traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Boston Naming Test; Performance validity testing; Verbal fluency; Traumatic brain injury	CARD SORTING TEST; CLASSIFICATION ACCURACY; TEST-II; SPECIFICITY; SENSITIVITY; INDICATORS; FLUENCY; SCORES; BIAS	No studies to date have investigated the Boston Naming Test (BNT) as an embedded performance validity test (PVT). This study investigated the classification accuracy of the Boston Naming Test (BNT) and the Verbal Fluency Test (FAS and Animal Fluency), as embedded PVTs in a compensation-seeking mild traumatic brain injury (MTBI) sample (N = 57) compared to a non-compensation-seeking moderate-to-severe TBI (STBI) sample (N = 61). Participants in the MTBI sample who failed two or more PVTs were included, as were STBI participants who passed all PVTs. The classification accuracy of the individual tests and a logistically derived combined (LANGPVT) measure were studied. Results showed significant group differences (p < .05) on BNT, Animal Fluency, and LANGPVT between the MTBI and STBI groups. However, receiver operating characteristic (ROC) analyses indicated that only LANGPVT had acceptable classification accuracy (area under the curve > .70). Setting specificity at approximately .90, the recommended LANGPVT cutoff scores had sensitivity of .26. Results indicated that, similar to other embedded PVTs, these measures had low sensitivity when adequate specificity levels were maintained. However, extremely low scores on these measures are unlikely to occur in non-compensation-seeking, non-language-impaired, STBI cases.	[Whiteside, Douglas M.] Univ Iowa, Dept Psychiat, Iowa City, IA 52245 USA; [Kogan, Julia] Vanderbilt Univ, Nashville, TN 37235 USA; [Kogan, Julia; Wardin, Lydia; Phillips, Derek] Adler Univ, Chicago, IL USA; [Wardin, Lydia] PA Vet Affairs Med Ctr, Coatesville, PA USA; [Franzwa, M. Graciela] Thomson Memory Ctr, Hoffman Estates, IL USA; [Rice, Linda] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Basso, Michael] Univ Tulsa, Dept Psychol, Tulsa, OK 74104 USA; [Roper, Brad] Memphis Vet Affairs Med Ctr, Memphis, TN USA	Whiteside, DM (corresponding author), Univ Iowa, Dept Psychiat, 200 Hawkins Dr, Iowa City, IA 52245 USA.	douglas-whiteside@uiowa.edu	Basso, Michael/S-9587-2019; Whiteside, Douglas/AAK-6396-2020	Basso, Michael/0000-0002-0217-662X; Whiteside, Douglas/0000-0002-8454-4413			Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Benton A., 1994, MULTILINGUAL APHASIA; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Bodin D., 2012, PEDIAT ADOLESCENT CO; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Carone D. A., 2012, MILD TRAUMATIC BRAIN; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Heaton RK, 2004, REVISED COMPREHENSIV; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Johnson SC, 2012, CLIN NEUROPSYCHOL, V26, P1230, DOI 10.1080/13854046.2012.709886; Kaplan E., 1983, BOSTON NAMING TEST; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/S15324826AN0804_6; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; Schroeder RW, 2010, CLIN NEUROPSYCHOL, V24, P326, DOI 10.1080/13854040903369441; Silverberg ND, 2008, CLIN NEUROPSYCHOL, V22, P140, DOI 10.1080/13854040601160597; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh TN, 1996, TEST MEMORY MALINGER; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Whiteside D, 2011, CLIN NEUROPSYCHOL, V25, P287, DOI 10.1080/13854046.2010.538436; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	30	25	25	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB 7	2015	37	2					220	227		10.1080/13803395.2014.1002758			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CC9IP	WOS:000350682700009	25655924				2021-06-18	
J	Albaugh, MD; Orr, C; Nickerson, JP; Zweber, C; Slauterbeck, JR; Hipko, S; Gonyea, J; Andrews, T; Brackenbury, JC; Watts, R; Hudziak, JJ				Albaugh, Matthew D.; Orr, Catherine; Nickerson, Joshua P.; Zweber, Cole; Slauterbeck, James R.; Hipko, Scott; Gonyea, Jay; Andrews, Trevor; Brackenbury, J. Curtis; Watts, Richard; Hudziak, James J.			Postconcussion Symptoms Are Associated with Cerebral Cortical Thickness in Healthy Collegiate and Preparatory School Ice Hockey Players	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE IMAGES; SURFACE-BASED ANALYSIS; GEOMETRICALLY ACCURATE; CONCUSSION; SEGMENTATION; PATTERNS; CHILDREN; SPORTS; CORTEX	Objective To investigate the degree to which concussion history and postconcussive symptoms are associated with cortical morphology among male hockey players. Study design Male subjects (n = 29), ranging in age from 14 to 23 years (mean 17.8 years), were recruited from preparatory school and collegiate ice hockey teams and underwent neuroimaging and baseline Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) testing. Cerebral cortical thickness was regressed against ImPACT Total Symptom Score (TSS), concussion history, as well as baseline measures of psychopathology. Reconstruction of surfaces and cortical thickness analysis were conducted with FreeSurfer (version 5.3.0). Results ImPACT TSS was inversely associated with local cortical thickness in widespread brain areas. Associations were revealed in a host of frontal as well as bilateral temporoparietal cortices. Conversely, concussion history was not associated with cortical thickness. An "Age by Concussion History" interaction was associated with thickness in the right ventrolateral and right parietal cortices. Post-hoc analysis revealed that concussed participants did not exhibit age-related cortical thinning in these regions. Conclusion We have identified an association between brain structure and postconcussive symptoms among young, otherwise-healthy male athletes. Postconcussive symptoms and related reductions in cortical thickness may be tied to participation in a full-contact sport that involves frequent blows to the head.	[Albaugh, Matthew D.; Orr, Catherine; Zweber, Cole; Hudziak, James J.] Univ Vermont, Coll Med, Vermont Ctr Children Youth & Families, Div Child Psychiat, Burlington, VT 05401 USA; [Nickerson, Joshua P.; Hipko, Scott; Gonyea, Jay; Andrews, Trevor; Watts, Richard] Univ Vermont, Coll Med, Dept Radiol, Burlington, VT 05401 USA; [Slauterbeck, James R.] Univ Vermont, Coll Med, Dept Orthopaed & Rehabil, Burlington, VT 05401 USA; [Hipko, Scott; Gonyea, Jay; Andrews, Trevor; Watts, Richard] Univ Vermont MRI Ctr Biomed Imaging, Burlington, VT USA; [Andrews, Trevor] Philips Healthcare, Cleveland, OH USA; [Brackenbury, J. Curtis] DC Hybrid Skating, Milwaukee, WI USA	Hudziak, JJ (corresponding author), Univ Vermont, Coll Med, Vermont Ctr Children Youth & Families, Univ Hlth Ctr Campus,1 South Prospect St, Burlington, VT 05401 USA.	james.hudziak@uvm.edu	Meijer, Anna/K-5118-2016; Albaugh, Matthew D/R-4349-2016; Albaugh, Matthew/ABB-5839-2020	Albaugh, Matthew/0000-0002-5971-6658; Andrews, Trevor/0000-0003-0331-1798	Child and Adolescent Psychology Training and Research Foundation	M.A. is funded by the Child and Adolescent Psychology Training and Research Foundation. The authors declare no conflicts of interest.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Achenbach TM., 2003, MANUAL ASEBA SCH AGE; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; Ducharme S, 2014, CEREB CORTEX, V24, P2941, DOI 10.1093/cercor/bht151; Ducharme S, 2012, J AM ACAD CHILD PSY, V51, P18, DOI 10.1016/j.jaac.2011.09.022; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kuperberg GR, 2003, J COGNITIVE NEUROSCI, V15, P272, DOI 10.1162/089892903321208204; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P69; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Petrides M, 2002, PRINCIPLES FRONTAL L, V1, P31, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0003; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Rumsey JM, 2009, NEUROIMAGING IN DEVELOPMENTAL CLINICAL NEUROSCIENCE, P387, DOI 10.1017/CBO9780511757402.030; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schmahmann JD, 2006, FIBER PATHWAYS BRAIN; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Shaw P, 2007, P NATL ACAD SCI USA, V104, P19649, DOI 10.1073/pnas.0707741104; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith AM, 2011, CLIN J SPORT MED, V21, P281, DOI 10.1097/JSM.0b013e318225bc15; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Wilde EA, 2012, NEUROREHABILITATION, V31, P245, DOI 10.3233/NRE-2012-0794	40	25	25	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	FEB	2015	166	2					394	+		10.1016/j.jpeds.2014.10.016			8	Pediatrics	Pediatrics	AZ8XY	WOS:000348496200040	25454943				2021-06-18	
J	Franke, LM; Czarnota, JN; Ketchum, JM; Walker, WC				Franke, Laura M.; Czarnota, Jenna N.; Ketchum, Jessica M.; Walker, William C.			Factor Analysis of Persistent Postconcussive Symptoms Within a Military Sample With Blast Exposure	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast; factor analysis; postconcussive syndrome; Rivermead Postconcussion Questionnaire; traumatic brain injury	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYNDROME; HEAD-INJURY; QUESTIONNAIRE; ASSOCIATION; PREVALENCE; COMPLAINTS; MECHANISM; CRITERIA; FIT	Objective: To determine the factor structure of persistent postconcussive syndrome symptoms in a blast-exposed military sample and validate factors against objective and symptom measures. Setting: Veterans Affairs medical center and military bases. Participants: One hundred eighty-one service members and veterans with at least 1 significant exposure to blast during deployment within the 2 years prior to study enrollment. Design: Confirmatory and exploratory factor analyses of the Rivermead Postconcussion Questionnaire. Main Measures: Rivermead Postconcussion Questionnaire, PTSD (posttraumatic stress disorder) Symptom Checklist-Civilian, Center for Epidemiological Studies Depression scale, Sensory Organization Test, Paced Auditory Serial Addition Test, California Verbal Learning Test, and Delis-Kaplan Executive Function System subtests. Results: The 3-factor structure of persistent postconcussive syndrome was not confirmed. A 4-factor structure was extracted, and factors were interpreted as reflecting emotional, cognitive, visual, and vestibular functions. All factors were associated with scores on psychological symptom inventories; visual and vestibular factors were also associated with balance performance. There was no significant association between the cognitive factor and neuropsychological performance or between a history of mild traumatic brain injury and factor scores. Conclusion: Persistent postconcussive symptoms observed months after blast exposure seem to be related to 4 distinct forms of distress, but not to mild traumatic brain injury per se, with vestibular and visual factors possibly related to injury of sensory organs by blast.	[Franke, Laura M.; Walker, William C.] Def & Vet Brain Injury Ctr, Richmond, VA 23249 USA; [Franke, Laura M.; Walker, William C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA USA; [Czarnota, Jenna N.; Ketchum, Jessica M.] Virginia Commonwealth Univ, Dept Biostat, Sch Med, Richmond, VA USA; [Franke, Laura M.; Walker, William C.] Adv Mil Med Inc, Henry M Jackson Fdn, Bethesda, MD USA	Franke, LM (corresponding author), Def & Vet Brain Injury Ctr, 1201 Broad Rock Blvd 151, Richmond, VA 23249 USA.	Laura.Manning3@va.gov	Ketchum, Jessica/AAE-8200-2020	Ketchum, Jessica/0000-0002-5566-3691	Congressionally Directed Medical Research Projects (CDMRP) [W91ZSQ8118N620]; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs [W91YTZ-12-C-0132]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32ES007334]; NIEHS, T32 Training Grant: Integration of Mixtures, Toxicology, Toxicogenomics and Statistics [T32ES007334]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32ES007334] Funding Source: NIH RePORTER	This work was funded by the Congressionally Directed Medical Research Projects (CDMRP) Award # W91ZSQ8118N620 and in part by the Defense and Veterans Brain Injury Center (DVBIC) through contract # W91YTZ-12-C-0132 to the Henry M. Jackson Foundation.; The project was supported by National Institutes of Health T32ES007334. Jenna Czarnota is supported by NIEHS, T32 Training Grant: Integration of Mixtures, Toxicology, Toxicogenomics and Statistics (T32ES007334).	[Anonymous], 2008, DOD VA COMM DEF TBI; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Browne M. W., 1992, SOCIOL METHOD RES, V21, P136; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Cernich AN, 2012, J HEAD TRAUMA REHAB, V27, P253, DOI 10.1097/HTR.0b013e3182585cd5; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Ehrlinger J, 2003, J PERS SOC PSYCHOL, V84, P5, DOI 10.1037/0022-3514.84.1.5; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Gorsuch R. L., 1983, FACTOR ANAL; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Husaini B. A., 1980, J COMMUNITY PSYCHOL, V8, P20, DOI [10 .1002/1520-6629( 198001) 8:1 20:: AID-JCOP2290080105 3.0.CO; ~ ~ 2-Y, DOI 10.1002/1520-6629(198001]; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; LIPOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; TANELIAN T, 2008, INVISIBLE WOUNDS MEN; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 1996, TEST MEMORY MALINGER; Walker WC, 2013, J HEAD TRAUMA REHAB, V28, P68, DOI 10.1097/HTR.0b013e318255dfd0; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; ZANE RS, 1991, OTOLARYNG HEAD NECK, V104, P137, DOI 10.1177/019459989110400129	48	25	25	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					E34	E46		10.1097/HTR.0000000000000042			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400005	24695267	Green Accepted			2021-06-18	
J	Godbolt, AK; Stenberg, M; Jakobsson, J; Sorjonen, K; Krakau, K; Stalnacke, BM; DeBoussard, CN				Godbolt, Alison K.; Stenberg, Maud; Jakobsson, Jan; Sorjonen, Kimmo; Krakau, Karolina; Stalnacke, Britt-Marie; DeBoussard, Catharina Nygren			Subacute complications during recovery from severe traumatic brain injury: frequency and associations with outcome	BMJ OPEN			English	Article							PAROXYSMAL SYMPATHETIC HYPERACTIVITY; DEEP-VEIN THROMBOSIS; INPATIENT REHABILITATION; DIAGNOSTIC-CRITERIA; CONTINUOUS CHAIN; CONSCIOUSNESS; GUIDELINES; SCALE; DISORDERS; NUTRITION	Background: Medical complications after severe traumatic brain injury (S-TBI) may delay or prevent transfer to rehabilitation units and impact on long-term outcome. Objective: Mapping of medical complications in the subacute period after S-TBI and the impact of these complications on 1-year outcome to inform healthcare planning and discussion of prognosis with relatives. Setting: Prospective multicentre observational study. Recruitment from 6 neurosurgical centres in Sweden and Iceland. Participants and assessments: Patients aged 18-65 years with S-TBI and acute Glasgow Coma Scale 3-8, who were admitted to neurointensive care. Assessment of medical complications 3 weeks and 3 months after injury. Follow-up to 1 year. 114 patients recruited with follow-up at 1 year as follows: 100 assessed, 7 dead and 7 dropped out. Outcome measure: Glasgow Outcome Scale Extended. Results: 68 patients had >= 1 complication 3 weeks after injury. 3 weeks after injury, factors associated with unfavourable outcome at 1 year were: tracheostomy, assisted ventilation, on-going infection, epilepsy and nutrition via nasogastric tube or percutaneous endoscopic gastroscopy (PEG) tube (univariate logistic regression analyses). Multivariate analysis demonstrated that tracheostomy and epilepsy retained significance even after incorporating acute injury severity into the model. 3 months after injury, factors associated with unfavourable outcome were tracheostomy and heterotopic ossification (Fisher's test), infection, hydrocephalus, autonomic instability, PEG feeding and weight loss (univariate logistic regression). PEG feeding and weight loss at 3 months were retained in a multivariate model. Conclusions: Subacute complications occurred in two-thirds of patients. Presence of a tracheostomy or epilepsy at 3 weeks, and of PEG feeding and weight loss at 3 months, had robust associations with unfavourable outcome that were incompletely explained by acute injury severity.	[Godbolt, Alison K.; Krakau, Karolina; DeBoussard, Catharina Nygren] Karolinska Inst, Dept Clin Sci, Stockholm, Sweden; [Godbolt, Alison K.; Krakau, Karolina; DeBoussard, Catharina Nygren] Danderyd Hosp, Univ Dept Rehabil Med Stockholm, Stockholm, Sweden; [Godbolt, Alison K.] Univ Uppsala Hosp, Dept Rehabil Med, Uppsala, Sweden; [Godbolt, Alison K.] Uppsala Univ, Uppsala, Sweden; [Stenberg, Maud; Stalnacke, Britt-Marie] Umea Univ, Dept Community Med & Rehabil, Rehabil Med, Umea, Sweden; [Jakobsson, Jan] Karolinska Inst, Danderyd Hosp, Inst Clin Sci, Natl Resp Ctr,Dept Anaesthesia & Intens Care, Stockholm, Sweden; [Sorjonen, Kimmo] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden	Godbolt, AK (corresponding author), Karolinska Inst, Dept Clin Sci, Stockholm, Sweden.	alison.godbolt@ki.se		Godbolt, Alison/0000-0003-4511-6181	AFA insurance [060833]; Uppsala University Hospital; Danderyd Hospital; Umea University Hospital	This study was supported by grant 060833 from AFA insurance (to Professor Jorgen Borg). AKG has received support from ALF-grants from Uppsala University Hospital and Danderyd Hospital. MS and B-MS have received ALF-grants from Umea University Hospital.	Andelic N, 2014, J NEUROTRAUM, V31, P1313, DOI 10.1089/neu.2013.3292; Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; British Society of Rehabilitation Medicine, 2013, SPEC REH TRAUM PATHW; Dizdar D, 2013, BRAIN INJURY, V27, P807, DOI 10.3109/02699052.2013.775490; Godbolt AK, 2014, J HEAD TRAUMA REHABI; Kammersgaard LP, 2013, NEUROREHABILITATION, V33, P473, DOI 10.3233/NRE-130980; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Loser C, 2005, CLIN NUTR, V24, P848, DOI 10.1016/j.clnu.2005.06.013; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Perkes IE, 2011, BRAIN INJURY, V25, P925, DOI 10.3109/02699052.2011.589797; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Praeger AJ, 2012, CRIT CARE RESUSC, V14, P10; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Scrimgeour AG, 2014, J NEUROTRAUM, V31, P989, DOI 10.1089/neu.2013.3234; Socialstyrelsen, 2012, REH PERS MED TRAUM H; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1877, DOI 10.1016/j.apmr.2012.12.027; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	26	25	27	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2015	5	4							e007208	10.1136/bmjopen-2014-007208			9	Medicine, General & Internal	General & Internal Medicine	CI4GB	WOS:000354705000065	25941181	DOAJ Gold, Green Published			2021-06-18	
J	Hyde, GA; Savage, SA; Zarzaur, BL; Hart-Hyde, JE; Schaefer, CB; Croce, MA; Fabian, TC				Hyde, Glendon A.; Savage, Stephanie A.; Zarzaur, Ben L.; Hart-Hyde, Jensen E.; Schaefer, Candace B.; Croce, Martin A.; Fabian, Timothy C.			Early tracheostomy in trauma patients saves time and money	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Tracheostomy; Thoracic trauma; Traumatic brain injury; Ventilator associated pneumonia; Medical costs	MECHANICAL VENTILATION; TRACHEOTOMY; METAANALYSIS; COMPLICATIONS; INTUBATION; OUTCOMES; WORK	Introduction: Patients suffering traumatic brain and chest wall injuries are often difficult to liberate from the ventilator yet best timing of tracheostomy remains ill-defined. While prior studies have addressed early versus late tracheostomy, they generally suffer from the use of historical controls, which cannot account for variations in management over time. Propensity scoring can be utilized to identify controls from the same patient population, minimizing impact of confounding variables. The purpose of this study was to determine outcomes associated with early versus late tracheostomy by application of propensity scoring. Methods: Patients requiring intubation within 48 h and receiving tracheostomy from January 2010 to June 2012 were identified. Early tracheostomy (ET) was a tracheostomy performed by the fifth hospital day. ET patients were matched to late tracheostomy patients (LT, tracheostomy after day 5) using propensity scoring and compared for multiple outcomes. Cost for services was calculated using average daily billing rates at our institution. Results: One hundred and six patients were included, 53 each in the ET (mean day tracheostomy = 4) and the LT (mean day tracheostomy = 10) cohorts. The average age was 47 years and 94% suffered blunt injury, with an average NISS of 23.7. Patients in the ET group had significantly shorter TICU LOS (21.4 days vs. 28.6 days, p < 0.0001) and significantly fewer ventilator days (16.7 days vs. 21.9, p < 0.0001) compared to the LT group. ET patients also had significantly less VAP (34% vs. 64.2%, p = 0.0019). Conclusion: In the current era of increased health-care costs, early tracheostomy significantly decreased both pulmonary morbidity and critical care resource utilization. This translates to an appreciable cost savings, at minimum $52,173 per patient and a potential total savings of $2.8 million/year for the entire LT cohort. For trauma patients requiring prolonged ventilator support, early tracheostomy should be performed. (C) 2014 Elsevier Ltd. All rights reserved.	[Savage, Stephanie A.; Hart-Hyde, Jensen E.; Schaefer, Candace B.; Croce, Martin A.; Fabian, Timothy C.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38163 USA; [Hyde, Glendon A.] Univ Tennessee, Chattanooga, TN USA; [Zarzaur, Ben L.] Indiana Univ Purdue Univ, Indianapolis, IN 46202 USA	Savage, SA (corresponding author), Univ Tennessee, Hlth Sci Ctr, 910 Madison Ave,Suite 220, Memphis, TN 38163 USA.	ghyde@uthsc.edu; ssavage1@uthsc.edu; bzarzaur@iupui.edu; jhart27@uthsc.edu; cschaefe@uthsc.edu; mcroce@uthsc.edu; tfabian@uthsc.edu	Zarzaur, Ben/S-6572-2019				ASTRACHAN DI, 1988, LARYNGOSCOPE, V98, P1165; Bacchetta MD, 2005, ANN THORAC SURG, V79, P1879, DOI 10.1016/j.athoracsur.2004.10.042; Brotfain E, 2014, CRIT CARE RES PRACT, V2014, DOI 10.1155/2014/156814; Chadha NK, 2011, ARCH OTOLARYNGOL, V137, P30, DOI 10.1001/archoto.2010.228; COLICE GL, 1989, CHEST, V96, P877, DOI 10.1378/chest.96.4.877; Combes A, 2007, CRIT CARE MED, V35, P802, DOI 10.1097/01.CCM.0000256721.60517.B1; Diehl JL, 1999, AM J RESP CRIT CARE, V159, P383, DOI 10.1164/ajrccm.159.2.9707046; Griffiths J, 2005, BMJ-BRIT MED J, V330, P1243, DOI 10.1136/bmj.38467.485671.E0; Higgins KM, 2007, LARYNGOSCOPE, V117, P447, DOI 10.1097/01.mlg.0000251585.31778.c9; Holevar M, 2009, J TRAUMA, V67, P870, DOI 10.1097/TA.0b013e3181b5a960; Moller MG, 2005, AM J SURG, V189, P293, DOI 10.1016/j.amjsurg.2005.01.002; Nieszkowska A, 2005, CRIT CARE MED, V33, P2527, DOI 10.1097/01.CCM.0000186898.58709.AA; Rodriguez JL, 1990, BRIT J SURG, V77, P1406; Rumbak MJ, 2004, CRIT CARE MED, V32, P1689, DOI 10.1097/01.CCM.0000134835.05161.B6; Shirawi N, 2006, CRIT CARE, V10, DOI 10.1186/cc3828; Terragni PP, 2010, JAMA-J AM MED ASSOC, V303, P1483, DOI 10.1001/jama.2010.447; Wang F, 2011, CHEST, V140, P1456, DOI 10.1378/chest.11-2024; Wu YK, 2010, CRIT CARE, V14, DOI 10.1186/cc8890	18	25	28	1	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2015	46	1					110	114		10.1016/j.injury.2014.08.049			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AX1YJ	WOS:000346739600021	25441577				2021-06-18	
J	Nishijima, DK; Yang, Z; Urbich, M; Holmes, JF; Zwienenberg-Lee, M; Melnikow, J; Kuppermann, N				Nishijima, Daniel K.; Yang, Zhuo; Urbich, Michael; Holmes, James F.; Zwienenberg-Lee, Marike; Melnikow, Joy; Kuppermann, Nathan			Cost-effectiveness of the PECARN Rules in Children With Minor Head Trauma	ANNALS OF EMERGENCY MEDICINE			English	Article							CLINICAL DECISION RULES; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; EMERGENCY-DEPARTMENTS; UNITED-STATES; BRAIN-TUMORS; CT SCANS; INJURY; STRATEGIES; PREDICTION	Study objective: To improve the efficiency and appropriateness of computed tomography (CT) use in children with minor head trauma, clinical prediction rules were derived and validated by the Pediatric Emergency Care Applied Research Network (PECARN). The objective of this study was to conduct a cost-effectiveness analysis comparing the PECARN traumatic brain injury prediction rules to usual care for selective CT use. Methods: We used decision analytic modeling to project the outcomes, costs, and cost-effectiveness of applying the PECARN rules compared with usual care in a hypothetical cohort of 1,000 children with minor blunt head trauma. Clinical management was directed by level of risk as specified by the presence or absence of variables in the PECARN traumatic brain injury prediction rules. Immediate costs of care (diagnostic testing, treatment [not including clinician time], and hospital stay) were derived on single-center data. Quality-adjusted life-year losses related to the sequelae of clinically important traumatic brain injuries and to radiation-induced cancers, number of CT scans, number of radiation-induced cancers, number of missed clinically important traumatic brain injury, and total costs were evaluated. Results: Compared with the usual care strategy, the PECARN strategy was projected to miss slightly more children with clinically important traumatic brain injuries (0.26 versus 0.02 per 1,000 children) but used fewer cranial CT scans (274 versus 353), resulted in fewer radiation-induced cancers (0.34 versus 0.45), cost less ($904,940 versus $954,420), and had lower net quality-adjusted life-year loss (-4.64 versus -5.79). Because the PECARN strategy was more effective (less quality-adjusted life-year loss) and less costly, it dominated the usual care strategy. Results were robust under sensitivity analyses. Conclusion: Application of the PECARN traumatic brain injury prediction rules for children with minor head trauma would lead to beneficial outcomes and more cost-effective care.	[Nishijima, Daniel K.; Holmes, James F.; Kuppermann, Nathan] UC Davis Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Yang, Zhuo; Melnikow, Joy] UC Davis Sch Med, Ctr Healthcare Policy & Res, Sacramento, CA USA; [Zwienenberg-Lee, Marike] UC Davis Sch Med, Dept Neurol Surg, Sacramento, CA USA; [Urbich, Michael] Univ York, Dept Econ & Related Studies, York YO10 5DD, N Yorkshire, England	Nishijima, DK (corresponding author), UC Davis Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA.	daniel.nishijima@ucdmc.ucdavis.edu	yang, zhuo/D-7378-2018	yang, zhuo/0000-0003-1998-1104; Yang, Zhuo/0000-0002-8158-3003	Mentored Clinical Research Training Program [KL2]; National Center for Advancing Translational Sciences [NCATS], a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 RR024146]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Health Resources Services Administration (HRSA)/Maternal Child Health Bureau (MCHB)/Emergency Medical Services for Children (EMSC); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024146] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist and provided the following details: Dr. Nishijima was supported through a Mentored Clinical Research Training Program Award (KL2), grant UL1 RR024146 from the National Center for Research Resources (now National Center for Advancing Translational Sciences [NCATS]), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The PECARN was funded by the Health Resources Services Administration (HRSA)/Maternal Child Health Bureau (MCHB)/Emergency Medical Services for Children (EMSC).	American Academy of Pediatrics, 2013, 5 THINGS PHYS PAT SH; Arias E., 2007, NATL VITAL STAT REPO; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Bobinac A, 2013, HEALTH ECON, V22, P1272, DOI 10.1002/hec.2879; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Garber AM, 1997, J HEALTH ECON, V16, P1, DOI 10.1016/S0167-6296(96)00506-1; Gausche-Hill M, 2007, PEDIATRICS, V120, P1229, DOI 10.1542/peds.2006-3780; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Holmes JF, 2011, ANN EMERG MED, V58, P315, DOI 10.1016/j.annemergmed.2011.03.060; Holmes MW, 2012, INJURY, V43, P1423, DOI 10.1016/j.injury.2011.07.017; Kirkdale R, 2010, QJM-INT J MED, V103, P715, DOI 10.1093/qjmed/hcq081; Kosty J, 2012, J NEUROTRAUM, V29, P1322, DOI 10.1089/neu.2011.2222; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kutikova L, 2007, J NEURO-ONCOL, V81, P61, DOI 10.1007/s11060-006-9197-y; Lyttle MD, 2012, EMERG MED J, V29, P785, DOI 10.1136/emermed-2011-200225; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Prieto Luis, 2003, Health Qual Life Outcomes, V1, P80, DOI 10.1186/1477-7525-1-80; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stein SC, 2008, PEDIATR NEUROSURG, V44, P448, DOI 10.1159/000172967; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Weinstein MC, 2003, VALUE HEALTH, V6, P9, DOI 10.1046/j.1524-4733.2003.00234.x	29	25	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JAN	2015	65	1					72	80		10.1016/j.annemergmed.2014.08.019			9	Emergency Medicine	Emergency Medicine	AY6GC	WOS:000347664200017	25443992	Green Accepted			2021-06-18	
J	Yang, LPH; Deeks, ED				Yang, Lily P. H.; Deeks, Emma D.			Dextromethorphan/Quinidine: A Review of Its Use in Adults with Pseudobulbar Affect	DRUGS			English	Article							AFFECT PBA; QUINIDINE; MANAGEMENT	Fixed-dose dextromethorphan/quinidine capsules (Nuedexta (R)) utilize quinidine to inhibit the metabolism of dextromethorphan, enabling high plasma dextromethorphan concentrations to be reached without using a larger dose of the drug. The drug combination is the first treatment to be approved for pseudobulbar affect (PBA), a condition of contextually inappropriate/exaggerated emotional expression that often occurs in adults with neurological damage conditions, such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, traumatic brain injury, Alzheimer's disease or Parkinson's disease. Dextromethorphan/quinidine at the recommended dosages of 20/10 or 30/10 mg twice daily reduced the rate of PBA episodes and improved PBA severity in a 12-week, double-blind, placebo-controlled trial in adults with ALS or MS (STAR), with further improvements in the severity of the condition observed in a 12-week open-label extension phase. Dextromethorphan/quinidine 20/10 mg twice daily also improved PBA secondary to dementia in a cohort of a 12-week noncomparative trial (PRISM II). The drug combination was generally well tolerated in these studies, with no particular safety or tolerability concerns. Although longer-term efficacy and tolerability data for dextromethorphan/quinidine 20/10 or 30/10 mg twice daily would be beneficial, current evidence indicates that it is a useful option in the treatment of adults with PBA.	[Yang, Lily P. H.; Deeks, Emma D.] Springer, Auckland 0754, New Zealand	Deeks, ED (corresponding author), Springer, Private Bag 65901, Auckland 0754, New Zealand.	demail@springer.com		Yang, Li (Francoise)/0000-0002-3756-8789			Andersen PM, 2012, EUR J NEUROL, V19, P360, DOI 10.1111/j.1468-1331.2011.03501.x; Avanir Pharmaceuticals, 2013, SAF EFF AVP 923 PBA; Avanir Pharmaceuticals Inc, 2010, NUED DEXTR HYDR QUIN; Brooks BR, 2012, ANN NEUROL, V72, pS65; Capon DA, 1996, CLIN PHARMACOL THER, V60, P295, DOI 10.1016/S0009-9236(96)90056-9; CODD EE, 1995, J PHARMACOL EXP THER, V274, P1263; Cruz MP, 2013, DRUG FORCAST, V38, P325; Cummings J., 2009, NEUROPSYCHIATRIC INV; Doody RS, 2014, 139 ANN M AM NEUR AS; European Medicines Agency, NUED DEXTR QUIN OR C; European Medicines Agency, 2013, NEUD DEXTR QUIN ASS; Haiman G, 2009, J CLIN PSYCHOPHARM, V29, P444, DOI 10.1097/JCP.0b013e3181b5ae5c; Jillapalli D., 2010, US FDA CTR DRUG EVAL; Marier JF, 2005, LIFE SCI, V77, P2911, DOI 10.1016/j.lfs.2005.04.025; Miller A, 2011, EXPERT REV NEUROTHER, V11, P1077, DOI [10.1586/ERN.11.68, 10.1586/ern.11.68]; Miller RG, 2009, NEUROLOGY, V73, P1227, DOI 10.1212/WNL.0b013e3181bc01a4; Nguyen L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089985; Parvizi J, 2006, MAYO CLIN PROC, V81, P1482, DOI 10.4065/81.11.1482; Parvizi J, 2009, J NEUROPSYCH CLIN N, V21, P75, DOI 10.1176/appi.neuropsych.21.1.75; Pattee GL, 2014, CURR MED RES OPIN, V30, P2255, DOI 10.1185/03007995.2014.940040; Pioro E, 2010, 62 ANN M AM AC NEUR; Pioro E, 2010, NEUROLOGY, V75, P380; Pioro EP, 2011, DRUGS, V71, P1193, DOI 10.2165/11591450-000000000-00000; Pioro EP, 2010, ANN NEUROL, V68, P693, DOI 10.1002/ana.22093; Pope LE, 2004, J CLIN PHARMACOL, V44, P1132, DOI 10.1177/0091270004269521; Schoedel KA, 2012, CLIN DRUG INVEST, V32, P157, DOI 10.2165/11633850-000000000-00000; Siffert J, 2013, CONSULT PHARM, V28; Werling LL, 2007, EXP NEUROL, V207, P248, DOI 10.1016/j.expneurol.2007.06.013; Zawertailo LA, 2010, HUM PSYCHOPHARM CLIN, V25, P71, DOI 10.1002/hup.1086	29	25	27	0	10	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0012-6667	1179-1950		DRUGS	Drugs	JAN	2015	75	1					83	90		10.1007/s40265-014-0328-z			8	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	AX8GR	WOS:000347148600006	25420446				2021-06-18	
J	Brands, I; Kohler, S; Stapert, S; Wade, D; van Heugten, C				Brands, Ingrid; Kohler, Sebastian; Stapert, Sven; Wade, Derick; van Heugten, Caroline			Influence of Self-Efficacy and Coping on Quality of Life and Social Participation After Acquired Brain Injury: A 1-Year Follow-Up Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Coping; Quality of life; Rehabilitation; Self-efficacy; Social participation	FRENCHAY ACTIVITIES INDEX; STROKE PATIENTS; HEALTH-STATUS; SATISFACTION; STRATEGIES; REHABILITATION; INTERVENTION; PREDICTORS; DISABILITY; ADJUSTMENT	Objectives: To investigate the relations linking self-efficacy and coping to quality of life (QOL) and social participation and what effect self-efficacy, changes in self-efficacy, and coping style have on long-term QOL and social participation. Design: Prospective clinical cohort study. Setting: General hospitals, rehabilitation centers. Participants: Patients with newly acquired brain injury (ABI) (N = 148) were assessed at baseline (start outpatient rehabilitation or discharge hospital/inpatient rehabilitation; mean time since injury, 15wk) and 1 year later (mean time since injury, 67wk). Interventions: Not applicable. Main Outcome Measures: QOL was measured with the EuroQuol 5D (the EQ-5D index and the EQ-5D visual analog scale [EQ VAS]) and the 9-item Life Satisfaction Questionnaire (LiSat-9), social participation with the modified Frenchay Activities Index, coping with the Coping Inventory for Stressful Situations, and self-efficacy with the Traumatic Brain Injury Self-efficacy Questionnaire. Results: At baseline, self-efficacy moderated the effect of emotion-oriented coping on the EQ-5D index and of avoidance coping on the EQ VAS. Self-efficacy mediated the relation between emotion-oriented coping and LiSat-9. An increase in self-efficacy over time predicted better scores on the EQ-5D index (beta = .30), the EQ VAS (beta = .49), and LiSat-9 (beta = .44) at follow-up. In addition, higher initial self-efficacy (beta = .40) predicted higher LiSat-9 scores at follow-up; higher initial emotion-oriented coping (beta = -.23) predicted lower EQ VAS scores at follow-up. Higher modified Frenchay Activities Index scores at follow-up were predicted by higher self-efficacy (beta =.19) and higher task-oriented coping (beta = .14) at baseline (combined R-2 = 5.1%). Conclusions: Self-efficacy and coping predict long-term QOL but seem less important in long-term social participation. High self-efficacy protects against the negative effect of emotion-oriented coping. Enhancing self-efficacy in the early stage after ABI may have beneficial long-term effects. (C) 2014 by the American Congress of Rehabilitation Medicine	[Brands, Ingrid] Dept Neurorehabil Libra Rehabil Med & Audiol, Eindhoven, Netherlands; [Kohler, Sebastian; van Heugten, Caroline] Maastricht Univ, Fac Hlth Med & Life Sci, Alzheimer Ctr Limburg, Sch Mental Hlth & Neurosci, Maastricht, Netherlands; [Stapert, Sven; van Heugten, Caroline] Maastricht Univ, Fac Psychol & Neurosci, Dept Neuropsychol & Psychopharmacol, Maastricht, Netherlands; [Wade, Derick] Maastricht Univ, Sch Publ Hlth & Primary Care, Dept Rehabil Med, Maastricht, Netherlands; [Wade, Derick] Oxford Ctr Enablement, Oxford, England	Brands, I (corresponding author), POB 1355, NL-5602 BJ Eindhoven, Netherlands.	i.brands@libranet.nl		Wade, Derick/0000-0002-1188-8442	CZ Fund [AFVV11-045]	Supported by CZ Fund (grant no AFVV11-045).	Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Azulay J, 2013, J HEAD TRAUMA REHAB, V28, P323, DOI 10.1097/HTR.0b013e318250ebda; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Bandura A., 1997, SELF EFFICACY EXERCI; Belgen B, 2006, ARCH PHYS MED REHAB, V87, P554, DOI 10.1016/j.apmr.2005.12.027; Bonetti D, 2008, BRIT J HEALTH PSYCH, V13, P463, DOI 10.1348/135910707X216648; Brands I, 2014, J REHABIL MED; Brands IM, 2014, PSYCHOL ASSESS; Brands IMH, 2012, CLIN REHABIL, V26, P840, DOI 10.1177/0269215511432018; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; De Ridder DT, 2004, CISS HANDLEIDING; DEBIE SE, 1987, STANDAARDVRAGEN 1987; Deno M, 2012, PSYCHO-ONCOLOGY, V21, P144, DOI 10.1002/pon.1877; Devonport TJ, 2006, SOC BEHAV PERSONAL, V34, P127, DOI 10.2224/sbp.2006.34.2.127; Dumont C, 2004, J HEAD TRAUMA REHAB, V19, P431, DOI 10.1097/00001199-200411000-00002; Endler NS, 1990, Coping Inventory for Stressful Situations (CISS): Manual; EuroQol Group, MEAS SELF REP POP HL; Finset A, 2000, BRAIN INJURY, V14, P887; Fugl-Meyer A. R., 1991, CLIN REHABIL, V5, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105, 10.1177/026921559100500105.]; Gregorio GW, 2014, J HEAD TRAUMA REHAB, V29, pE43, DOI 10.1097/HTR.0b013e318292fb00; Gregorio GW, 2014, J HEAD TRAUMA REHAB, V29, pE30, DOI 10.1097/HTR.0b013e31828f93db; Hellstrom K, 2003, J REHABIL MED, V35, P202, DOI 10.1080/16501970310000836; Herrmann M, 2000, DISABIL REHABIL, V22, P539, DOI 10.1080/096382800416788; Hesselink AE, 2004, QUAL LIFE RES, V13, P509, DOI 10.1023/B:QURE.0000018474.14094.2f; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Jones F, 2009, CLIN REHABIL, V23, P522, DOI 10.1177/0269215508101749; Kristofferzon ML, 2011, SCAND J CARING SCI, V25, P476, DOI 10.1111/j.1471-6712.2010.00851.x; Levin C, 2007, PSYCHOL ADDICT BEHAV, V21, P108, DOI 10.1037/0893-164X.21.1.108; Lowe R, 2008, PSYCHOL HEALTH, V23, P155, DOI 10.1080/14768320601139160; Miller C, 1998, ANXIETY STRESS COPIN, V11, P311, DOI 10.1080/10615809808248317; Moore AD, 1994, CAN J REHABIL, V4, P122; Post MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3; Post MWM, 2003, CLIN REHABIL, V17, P548, DOI 10.1191/0269215503cr648oa; Prati G, 2010, ANXIETY STRESS COPIN, V23, P463, DOI 10.1080/10615800903431699; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; Szende A, 2007, EQ 5D VALUE SETS INV; Trouillet R, 2009, AGING MENT HEALTH, V13, P357, DOI 10.1080/13607860802626223; Visser-Meily A, 2005, CEREBROVASC DIS, V20, P443, DOI 10.1159/000088983; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wolters G, 2011, J HEAD TRAUMA REHAB, V26, P150, DOI 10.1097/HTR.0b013e3181e421dc; Wolters G, 2010, NEUROPSYCHOL REHABIL, V20, P587, DOI 10.1080/09602011003683836; Wolters Gregorio G, 2012, BRAIN IMPAIR, V13, P167; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	47	25	25	3	40	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2014	95	12					2327	2334		10.1016/j.apmr.2014.06.006			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AW0AY	WOS:000345954000013	24973499				2021-06-18	
J	Bryczkowski, SB; Lopreiato, MC; Yonclas, PP; Sacca, JJ; Mosenthal, AC				Bryczkowski, Sarah B.; Lopreiato, Maeve C.; Yonclas, Peter P.; Sacca, James J.; Mosenthal, Anne C.			Risk factors for delirium in older trauma patients admitted to the surgical intensive care unit	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Delirium; trauma; SICU; benzodiazepines; mechanical ventilation	POSTOPERATIVE DELIRIUM; PREDICTOR	BACKGROUND: Adults (age > 50 years) admitted to the surgical intensive care unit (SICU) are at high risk for delirium. Little is known about the role traumatic injury plays in the development of delirium because these patients have often been excluded from studies. Identification of specific risk factors for delirium among older adults following injury would be useful to guide prevention strategies. We attempted to identify modifiable factors that would predict delirium in an older trauma population admitted to the SICU. METHODS: Data were collected prospectively from July 2012 to August 2013 at a Level I trauma center on consecutive trauma patients, older than 50 years, admitted to the SICU. Patients who died in the SICU were excluded. Delirium was assessed every 12 hours using the Confusion Assessment Method for the ICU scale. Demographic, injury, social, and clinical variables were reviewed. Bivariate analysis determined significant factors associated with delirium. A multivariate logistic regression model was used to predict delirium risk. After preliminary results, additional analysis compared patients with chest injury (defined as chest Abbreviated Injury Scale [AIS] score >= 3) with those without. RESULTS: A total of 115 patients met criteria, with a mean age of 67 years, Injury Severity Score (ISS) of 19, and Glasgow Coma Scale (GCS) score of 14. The incidence of delirium was 61%. Variables present on admission, which were positive predictors of delirium, were as follows: age, ISS greater than 17, GCS score less than 15, substance abuse, and traumatic brain injury (defined as head AIS score >= 3). Chest injury (defined as chest AIS score >= 3) was a negative predictor of delirium. Significant risk factors influenced by clinical treatment included doses of opioids and propofol, restraint use, and hours deeply sedated (Richmond Agitation Sedation Scale [RASS] score <= -3). Clinical treatments with negative predictability were ventilator-free days/30 (vent-free), benzodiazepine-free days/30 (benzo-free), and restraint-free days/30. In a regression model considering age, vent-free days, chest injury, traumatic brain injury, GCS score, benzo-free days, and hours sedated, only age (odds ratio [OR], 1.1; 95% confidence interval [CI], 1.01-1.1; p = 0.03) was a predictor of delirium, while vent-free days (OR, 0.79; 95% CI, 0.65-0.96; p = 0.02) and chest injury (OR, 0.3; 95% CI, 0.09-0.83; p = 0.02) were significant negative predictors of delirium. Patients with chest injury had lower delirium incidence (44%) versus those without (75%) (p = 0.002) despite similar GCS score, ISS, and clinical variables. CONCLUSION: Delirium is common in older trauma patients admitted to the SICU, and for every year for those older than 50 years, the chance of delirium increases by 10%. While higher ISS increases delirium risk, we identified several modifiable treatment variables including days patients were deeply sedated, mechanically ventilated, and physically restrained. Interestingly, patients with chest injury experienced less delirium, despite similar injury severity and clinical variables, perhaps owing to frequent health care provider interactions. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Bryczkowski, Sarah B.; Lopreiato, Maeve C.; Yonclas, Peter P.; Sacca, James J.; Mosenthal, Anne C.] Rutgers New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA	Bryczkowski, SB (corresponding author), Rutgers New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA.	Sarahb459@gmail.com					Adams SD, 2012, J TRAUMA ACUTE CARE, V72, P112, DOI 10.1097/TA.0b013e318241f073; Aldemir M, 2001, CRIT CARE, V5, P265, DOI 10.1186/cc1044; Angles EM, 2008, AM J SURG, V196, P864, DOI 10.1016/j.amjsurg.2008.07.037; [Anonymous], 2010, OP CONV RAT GUID PRA; Brummel NE, 2013, CRIT CARE MED, V42, P1; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Fineberg SJ, 2013, SPINE, V38, P1790, DOI 10.1097/BRS.0b013e3182a0d507; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Khan BA, 2012, CHEST, V142, P48, DOI 10.1378/chest.11-2100; Lat I, 2009, CRIT CARE MED, V37, P1898, DOI 10.1097/CCM.0b013e31819ffe38; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; Marcantonio ER, 1998, AM J MED, V105, P380, DOI 10.1016/S0002-9343(98)00292-7; National Center for Injury Prevention and Control, WISQARS LEAD CAUS DE; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Pisani MA, 2009, CRIT CARE MED, V37, P177, DOI 10.1097/CCM.0b013e318192fcf9; Soja SL, 2008, INTENS CARE MED, V34, P1263, DOI 10.1007/s00134-008-1031-x; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.0.CO;2-0; van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X	21	25	29	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2014	77	6					944	951		10.1097/TA.0000000000000427			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AU8EE	WOS:000345828500035	25248058				2021-06-18	
J	Kontos, AP; Huppert, TJ; Beluk, NH; Elbin, RJ; Henry, LC; French, J; Dakan, SM; Collins, MW				Kontos, A. P.; Huppert, T. J.; Beluk, N. H.; Elbin, R. J.; Henry, L. C.; French, J.; Dakan, S. M.; Collins, M. W.			Brain activation during neurocognitive testing using functional near-infrared spectroscopy in patients following concussion compared to healthy controls	BRAIN IMAGING AND BEHAVIOR			English	Article						Concussion; Mild Traumatic Brain Injury; Neurocognitive Testing; Near Infrared Spectroscopy	SPORTS-RELATED CONCUSSION; RETURN-TO-PLAY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; SEX-DIFFERENCES; STROOP TASK; INJURY; MILD; ABNORMALITIES; FMRI	There is no accepted clinical imaging modality for concussion, and current imaging modalities including fMRI, DTI, and PET are expensive and inaccessible to most clinics/patients. Functional near-infrared spectroscopy (fNIRS) is a non-invasive, portable, and low-cost imaging modality that can measure brain activity. The purpose of this study was to compare brain activity as measured by fNIRS in concussed and age-matched controls during the performance of cognitive tasks from a computerized neurocognitive test battery. Participants included nine currently symptomatic patients aged 18-45 years with a recent (15-45 days) sport-related concussion and five age-matched healthy controls. The participants completed a computerized neurocognitive test battery while wearing the fNIRS unit. Our results demonstrated reduced brain activation in the concussed subject group during word memory, (spatial) design memory, digit-symbol substitution (symbol match), and working memory (X's and O's) tasks. Behavioral performance (percent-correct and reaction time respectively) was lower for concussed participants on the word memory, design memory, and symbol match tasks than controls. The results of this preliminary study suggest that fNIRS could be a useful, portable assessment tool to assess reduced brain activation and augment current approaches to assessment and management of patients following concussion.	[Kontos, A. P.; Elbin, R. J.; Henry, L. C.; French, J.; Dakan, S. M.; Collins, M. W.] Univ Pittsburgh, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA 15203 USA; [Huppert, T. J.; Beluk, N. H.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15203 USA; [Huppert, T. J.] Univ Pittsburgh, Dept Biomed Engn, Pittsburgh, PA 15203 USA; [Kontos, A. P.] Univ Pittsburgh, UPMC Ctr Sports Med, UPMC Sports Med Concuss Program, Dept Orthopaed Surg,Sch Med, Pittsburgh, PA 15203 USA	Kontos, AP (corresponding author), Univ Pittsburgh, UPMC Ctr Sports Med, UPMC Sports Med Concuss Program, Dept Orthopaed Surg,Sch Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	University of Pittsburgh Department of Radiology; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024827] Funding Source: NIH RePORTER	Funding for this study was provided by the University of Pittsburgh Department of Radiology.	Abdelnour AF, 2009, NEUROIMAGE, V46, P133, DOI 10.1016/j.neuroimage.2009.01.033; Abdelnour F, 2010, BIOMED OPT EXPRESS, V1, P1084, DOI 10.1364/BOE.1.001084; Abdelnour F, 2011, BIOMED OPT EXPRESS, V2, P1, DOI 10.1364/BOE.2.000001; Adelson PD, 1998, ACT NEUR S, V71, P250; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chul J, 2009, NEUROIMAGE, V44, P428, DOI 10.1016/j.neuroimage.2008.08.036; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Cope M, 1988, Adv Exp Med Biol, V222, P183; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Custo A, 2006, APPL OPTICS, V45, P4747, DOI 10.1364/AO.45.004747; Dehghani H, 2009, COMMUN NUMER METH EN, V25, P711, DOI 10.1002/cnm.1162; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Giza CC, 2001, J ATHL TRAINING, V36, P228; Haitsma IK, 2007, PROG BRAIN RES, V161, P207, DOI 10.1016/S0079-6123(06)61014-5; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Huppert TJ, 2009, APPL OPTICS, V48, pD280, DOI 10.1364/AO.48.00D280; Huppert TJ, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2976432; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Leon-Carrion J, 2008, BEHAV BRAIN RES, V193, P248, DOI 10.1016/j.bbr.2008.06.013; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mattout J, 2006, NEUROIMAGE, V30, P753, DOI 10.1016/j.neuroimage.2005.10.037; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Obrig H, 2003, J CEREBR BLOOD F MET, V23, P1, DOI 10.1097/01.WCB.0000043472.45775.29; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Sicard KM, 2005, NEUROIMAGE, V25, P850, DOI 10.1016/j.neuroimage.2004.12.010; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Stulemeijer M, 2010, J NEUROTRAUM, V27, P1585, DOI 10.1089/neu.2010.1298; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Weatherall A, 2012, ACTA ANAESTH SCAND, V56, P172, DOI 10.1111/j.1399-6576.2011.02591.x	50	25	26	2	31	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	DEC	2014	8	4					621	634		10.1007/s11682-014-9289-9			14	Neuroimaging	Neurosciences & Neurology	AX4SA	WOS:000346920400015	24477579	Green Accepted			2021-06-18	
J	Mannix, R; Berglass, J; Berkner, J; Moleus, P; Qiu, JH; Jantzie, LL; Meehan, WP; Stanley, RM; Robinson, S				Mannix, Rebekah; Berglass, Jacqueline; Berkner, Justin; Moleus, Philippe; Qiu, Jianhua; Jantzie, Lauren L.; Meehan, William P., III; Stanley, Rachel M.; Robinson, Shenandoah			Sex differences in the effect of progesterone after controlled cortical impact in adolescent mice: a preliminary study	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; progesterone; adolescent; sex differences; neuroprotection	TRAUMATIC BRAIN-INJURY; INFLAMMATORY RESPONSE; IMMATURE; EDEMA; EXPRESSION; RAT	Object. While progesterone has been well studied in experimental models of adult traumatic brain injury (TBI), it has not been evaluated in pediatric models. The study of promising interventions in pediatric TBI is important because children have the highest public health burden of such injuries. Therapies that are beneficial in adults may not necessarily be effective in the pediatric population. The purpose of this study was to evaluate whether progesterone treatment improves outcomes in an experimental model of pediatric TBI. Methods. The authors determined whether progesterone administered after controlled cortical impact (CCI) improves functional and histopathological outcomes in 4-week-old mice. Both male and female mice (58 mice total) were included in this study, as the majority of prior studies have used only male and/or reproductively senescent females. Mice were randomized to treatment with progesterone or vehicle and to CCI injury or sham injury. Motor (wire grip test) and memory (Morris water maze) testing were performed to determine the effect of progesterone on TBI. Lesion volume was also assessed. Results. Compared with their vehicle-treated counterparts, the progesterone-treated CCI-injured male mice had improved motor performance (p < 0.001). In contrast, progesterone-treated CCI-injured female mice had a worse performance than their vehicle-treated counterparts (p = 0.001). Progesterone treatment had no effect on spatial memory performance or lesion volume in injured male or female mice. Conclusions. These data suggest a sex-specific effect of progesterone treatment after CCI in adolescent mice and could inform clinical trials in children.	[Mannix, Rebekah; Berglass, Jacqueline; Berkner, Justin; Moleus, Philippe; Qiu, Jianhua; Meehan, William P., III] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Sports Concuss Clin, Boston, MA 02115 USA; [Jantzie, Lauren L.; Robinson, Shenandoah] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Mannix, Rebekah; Qiu, Jianhua; Jantzie, Lauren L.; Meehan, William P., III; Robinson, Shenandoah] Harvard Univ, Sch Med, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Stanley, Rachel M.] Univ Michigan Hlth Syst, Dept Emergency Med, Ann Arbor, MI USA	Mannix, R (corresponding author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	rebekah.mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020		HRSAUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [U03 MC 00003]; Baby Alex Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103400] Funding Source: NIH RePORTER	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. Drs. Mannix and Stanley were supported by Grant HRSA U03 MC 00003, and Drs. Mannix and Robinson were supported by The Baby Alex Foundation.	Adelson PD, 1998, ACT NEUR S, V71, P104; Behl C, 1997, EUR J NEUROSCI, V9, P912, DOI 10.1111/j.1460-9568.1997.tb01442.x; Bergeron R, 1996, J NEUROSCI, V16, P1193; CAMPAGNE MV, 1994, J CEREBR BLOOD F MET, V14, P1011, DOI 10.1038/jcbfm.1994.133; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Concas A, 1999, EUR J PHARMACOL, V375, P225, DOI 10.1016/S0014-2999(99)00232-0; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Ma JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub3; Mannix RC, 2011, J NEUROTRAUM, V28, P1855, DOI 10.1089/neu.2011.1759; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Tsuji M, 2012, EXP NEUROL, V233, P214, DOI 10.1016/j.expneurol.2011.10.004; Uysal N, 2013, TURK NEUROSURG, V23, P129, DOI 10.5137/1019-5149.JTN.5582-11.1; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	25	25	25	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2014	121	6					1337	1341		10.3171/2014.8.JNS14715			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AU3CP	WOS:000345490700006	25280093	Green Accepted			2021-06-18	
J	Wang, X; Ding, XB; Tong, Y; Zong, JY; Zhao, X; Ren, H; Li, Q				Wang, Xin; Ding, Xibing; Tong, Yao; Zong, Jiaying; Zhao, Xiang; Ren, Hao; Li, Quan			Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials	JOURNAL OF ANESTHESIA			English	Article						Ketamine; Opioids; Intracranial pressure; Hemodynamic instability; Brain injuries	CEREBROSPINAL-FLUID PRESSURE; CEREBRAL-BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; HYDROCEPHALIC CHILDREN; INTRAVENOUS KETAMINE; UNITED-KINGDOM; INTENSIVE-CARE; ANESTHESIA; SEDATION	Ketamine is traditionally avoided in sedation management of patients with risk of intracranial hypertension. However, results from many clinical trials contradict this concern. We critically analyzed the published data of the effects of ketamine on intracranial pressure (ICP) and other cerebral hemodynamics to determine whether ketamine was safe for patients with hemodynamic instability and brain injuries. We systematically searched the online databases of PubMed, Medline, Embase, Current Controlled Trials, and Cochrane Central (last search performed on January 15, 2014). Trial characteristics and outcomes were independently extracted by two assessors (Xin Wang, Xibing Ding). For continuous data, mean differences (MD) were formulated. If the P value of the chi-square test was > 0.10 or I (2) < 50 %, a fixed-effects model was used; otherwise, the random effects model was adopted. Five trials (n = 198) met the inclusion criteria. Using ICP levels within the first 24 h of ketamine administration as the main outcome, the use of ketamine leads to the same ICP levels as opioids [MD = 1.94; 95 % confidence interval (95 % CI), -2.35, 6.23; P = 0.38]. There were no significant differences in mean arterial pressure values between the two groups (MD = 0.99; 95 % CI, -2.24, 4.22; P = 0.55). Ketamine administration was also comparable with opioids in the maintenance of cerebral perfusion pressure (MD = -1.07; 95 % CI, -7.95, 5.8; P = 0.76). The results of this study suggest that ketamine does not increase ICP compared with opioids. Ketamine provides good maintenance of hemodynamic status. Clinical application of ketamine should not be discouraged on the basis of ICP-related concerns.	[Wang, Xin; Ding, Xibing; Tong, Yao; Zong, Jiaying; Zhao, Xiang; Ren, Hao; Li, Quan] Tongji Univ, Sch Med, Dept Anesthesiol, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China; [Wang, Xin; Zong, Jiaying] Nanjing Med Univ, Clin Med Coll 1, Nanjing, Jiangsu, Peoples R China; [Li, Quan] Tongji Univ, Sch Med, Dept Anesthesiol, East Hosp, Shanghai 200072, Peoples R China	Li, Q (corresponding author), Tongji Univ, Sch Med, Dept Anesthesiol, Shanghai Peoples Hosp 10, 301 Yanchang Zhong Rd, Shanghai 200072, Peoples R China.	liquantongji@163.com			National Natural Science FoundationNational Natural Science Foundation of China (NSFC)	We are grateful for the support from the National Natural Science Foundation. We also thank all authors of the publications included in this study for contributing information as requested.	Albanese J, 1997, ANESTHESIOLOGY, V87, P1328, DOI 10.1097/00000542-199712000-00011; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; BELOPAVLOVIC M, 1982, ACTA ANAESTH SCAND, V26, P458, DOI 10.1111/j.1399-6576.1982.tb01799.x; Bhutta AT, 2012, PEDIATR CRIT CARE ME, V13, P328, DOI 10.1097/PCC.0b013e31822f18f9; Bourgoin A, 2005, CRIT CARE MED, V33, P1109, DOI 10.1097/01.CCM.0000162491.26292.98; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; Bowles Eric D, 2012, AANA J, V80, P445; Caricato A, 2013, CRIT CARE, V17, DOI 10.1186/cc13097; Chang LC, 2013, CNS NEUROSCI THER, V19, P390, DOI 10.1111/cns.12077; CHI OZ, 1994, ANESTH ANALG, V79, P860; Craven R, 2007, ANAESTHESIA, V62, P48, DOI 10.1111/j.1365-2044.2007.05298.x; CRUMRINE RS, 1975, ANESTHESIOLOGY, V42, P758, DOI 10.1097/00000542-197506000-00026; EVANS J, 1971, LANCET, V1, P40; Filanovsky Y, 2010, CAN J EMERG MED, V12, P154; Flower O, 2012, EMERG MED INT, V2012, DOI 10.1155/2012/637171; GARDNER AE, 1972, ANESTH ANAL CURR RES, V51, P741; GIBBS JM, 1972, BRIT J ANAESTH, V44, P1298, DOI 10.1093/bja/44.12.1298; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Himmelseher S, 2005, ANESTH ANALG, V101, P524, DOI 10.1213/01.ANE.0000160585.43587.5B; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; KAUL HL, 1976, ANAESTHESIA, V31, P698, DOI 10.1111/j.1365-2044.1976.tb11853.x; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; Langsjo JW, 2003, ANESTHESIOLOGY, V99, P614, DOI 10.1097/00000542-200309000-00016; LIST WF, 1972, ANESTHESIOLOGY, V36, P98, DOI 10.1097/00000542-197201000-00023; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; MAYBERG TS, 1995, ANESTH ANALG, V81, P84, DOI 10.1097/00000539-199507000-00017; MCDONALD JW, 1989, EXP NEUROL, V106, P289, DOI 10.1016/0014-4886(89)90162-3; Mennella F, 1976, Minerva Anestesiol, V42, P418; Michalczyk K, 2013, PEDIATR CRIT CARE ME, V14, pE149, DOI 10.1097/PCC.0b013e3182720459; MIRSKI MA, 1995, CRIT CARE MED, V23, P2038, DOI 10.1097/00003246-199512000-00013; Miyamoto E, 2004, NEUROSCI LETT, V354, P26, DOI 10.1016/j.neulet.2003.09.058; Nagase K, 2003, J NEUROSURG ANESTH, V15, P98, DOI 10.1097/00008506-200304000-00006; Nimkoff L, 1997, J CRIT CARE, V12, P132, DOI 10.1016/S0883-9441(97)90042-3; Ohata H, 2001, ANESTH ANALG, V93, P697, DOI 10.1097/00000539-200109000-00032; PFENNINGER E, 1990, STATUS OF KETAMINE IN ANESTHESIOLOGY, P109; Polocki B, 1976, Anaesth Resusc Intensive Ther, V4, P121; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Schmittner MD, 2007, J NEUROSURG ANESTH, V19, P257, DOI 10.1097/ANA.0b013e31811f3feb; SCHULTEAMESCH J, 1978, ACTA NEUROCHIR, V45, P15, DOI 10.1007/BF01774380; Sehdev Rajesh S, 2006, Emerg Med Australas, V18, P37; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; STREBEL S, 1995, ANAESTHESIA, V50, P223, DOI 10.1111/j.1365-2044.1995.tb04561.x; TAKESHITA H, 1972, ANESTHESIOLOGY, V36, P69, DOI 10.1097/00000542-197201000-00013; Urwin SC, 2004, DRUG SAFETY, V27, P107, DOI 10.2165/00002018-200427020-00003; Wilson E, 1976, Acta Neurol Latinoam, V22, P10; WYTE SR, 1972, ANESTHESIOLOGY, V36, P174, DOI 10.1097/00000542-197202000-00021	47	25	25	0	5	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2014	28	6					821	827		10.1007/s00540-014-1845-3			7	Anesthesiology	Anesthesiology	AW4GX	WOS:000346240300004	24859931				2021-06-18	
J	Knutsen, AK; Magrath, E; McEntee, JE; Xing, FX; Prince, JL; Bayly, PV; Butman, JA; Pham, DL				Knutsen, Andrew K.; Magrath, Elizabeth; McEntee, Julie E.; Xing, Fangxu; Prince, Jerry L.; Bayly, Philip V.; Butman, John A.; Pham, Dzung L.			Improved measurement of brain deformation during mild head acceleration using a novel tagged MRI sequence	JOURNAL OF BIOMECHANICS			English	Article						Magnetic resonance imaging (MRD); Acceleration; Deformation; Strain; Traumatic brain injury (TBI)	MAGNETIC-RESONANCE ELASTOGRAPHY; SINGLE IMAGE PLANE; MOTION TRACKING; ALZHEIMERS-DISEASE; MYOCARDIAL MOTION; IN-VIVO; INJURY; TISSUE; TRAUMA; IMPACT	In vivo measurements of human brain deformation during mild acceleration are needed to help validate computational models of traumatic brain injury and to understand the factors that govern the mechanical response of the brain. Tagged magnetic resonance imaging is a powerful, noninvasive technique to track tissue motion in vivo which has been used to quantify brain deformation in live human subjects. However, these prior studies required from 72 to 144 head rotations to generate deformation data for a single image slice, precluding its use to investigate the entire brain in a single subject. Here, a novel method is introduced that significantly reduces temporal variability in the acquisition and improves the accuracy of displacement estimates. Optimization of the acquisition parameters in a gelatin phantom and three human subjects leads to a reduction in the number of rotations from 72 to 144 to as few as 8 for a single image slice. The ability to estimate accurate, well-resolved, fields of displacement and strain in far fewer repetitions will enable comprehensive studies of acceleration-induced deformation throughout the human brain in vivo. (C) 2014 Elsevier Ltd. All rights reserved.	[Knutsen, Andrew K.; Magrath, Elizabeth; McEntee, Julie E.; Butman, John A.; Pham, Dzung L.] Henry M Jackson Fdn, Ctr Neurosci & Regenerat Med, Bethesda, MD 20892 USA; [Xing, Fangxu; Prince, Jerry L.] Johns Hopkins Univ, Dept Elect & Comp Engn, Baltimore, MD 21218 USA; [Prince, Jerry L.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA; [Bayly, Philip V.] Dept Mech Engn & Mat Sci, St Louis, MO USA; [Bayly, Philip V.] Washington Univ, Dept Biomed Engn, St Louis, MO USA; [Butman, John A.] NIH, Dept Diagnost Radiol, Ctr Clin, Bethesda, MD 20892 USA	Knutsen, AK (corresponding author), Henry M Jackson Fdn, Ctr Neurosci & Regenerat Med, 9000 Rockville Pike,Bldg 10-B1N264B, Bethesda, MD 20892 USA.	andrew.knutsen@nih.gov	Pham, Dzung/AAR-8263-2020; Butman, John A/A-2694-2008; Butman, John/J-2780-2013	Butman, John/0000-0002-1547-9195; Xing, Fangxu/0000-0002-0517-0952; Bayly, Philip/0000-0003-4303-0704	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS055951]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER	We would like to thank the seven participants for their time and effort. We would also like to acknowledge Bruce Pritchard, Danny Trang, and George Do Id at the NINDS Machine Shop for their assistance. Support for this work included funding from Department of Defense in the Center for Neuroscience and Regenerative Medicine and from the National Institutes of Health (R01-NS055951).	Abd-Elmoniem KZ, 2007, MAGN RESON MED, V58, P92, DOI 10.1002/mrm.21267; Abd-Elmoniem KZ, 2005, LECT NOTES COMPUT SC, V3565, P639; Augenstein KF, 2005, J BIOMECH ENG-T ASME, V127, P148, DOI 10.1115/1.1835360; AXEL L, 1989, RADIOLOGY, V171, P841, DOI 10.1148/radiology.171.3.2717762; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bayly PV, 2008, J MECH PHYS SOLIDS, V56, P2036, DOI 10.1016/j.jmps.2007.10.012; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Clayton EH, 2012, J R SOC INTERFACE, V9, P2899, DOI 10.1098/rsif.2012.0325; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Feng Y, 2013, J MECH BEHAV BIOMED, V23, P117, DOI 10.1016/j.jmbbm.2013.04.007; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu XF, 2012, IEEE T MED IMAGING, V31, P326, DOI 10.1109/TMI.2011.2168825; Liu XF, 2010, IEEE T MED IMAGING, V29, P1560, DOI 10.1109/TMI.2010.2045509; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; MOULTON MJ, 1995, J BIOMECH, V28, P935, DOI 10.1016/0021-9290(94)00144-S; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Osman NF, 1999, MAGN RESON MED, V42, P1048; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sack I, 2008, NMR BIOMED, V21, P265, DOI 10.1002/nbm.1189; Taber L. A., 2004, NONLINEAR THEORY ELA; Van Houten EEW, 1999, MAGNET RESON MED, V42, P779, DOI 10.1002/(SICI)1522-2594(199910)42:4<779::AID-MRM21>3.3.CO;2-Q; Vappou J, 2008, J BIOMECH, V41, P2954, DOI 10.1016/j.jbiomech.2008.07.034; ZERHOUNI EA, 1988, RADIOLOGY, V169, P59, DOI 10.1148/radiology.169.1.3420283; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhong XD, 2010, MAGN RESON MED, V64, P1089, DOI 10.1002/mrm.22503	34	25	25	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	NOV 7	2014	47	14					3475	3481		10.1016/j.jbiomech.2014.09.010			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	AT8KZ	WOS:000345183500007	25287113	Green Accepted			2021-06-18	
J	Andelic, N; Soberg, HL; Berntsen, S; Sigurdardottir, S; Roe, C				Andelic, Nada; Soberg, Helene L.; Berntsen, Svein; Sigurdardottir, Solrun; Roe, Cecilie			Self-Perceived Health Care Needs and Delivery of Health Care Services 5 Years After Moderate-to-Severe Traumatic Brain Injury	PM&R			English	Article							DISABILITY; REHABILITATION; POPULATION; PEOPLE; NORWAY; ADULTS; COMA	Objective: To describe the self-perceived health care needs of patients with moderate-to-severe traumatic brain injury (TBI) and to assess the impact of the functional level at 1 year after injury on patients' unmet needs at the 5-year follow-up. Design: A prospective follow-up study. Setting: Clinical research. Participants: A total of 93 patients participated in the 5-year follow-up. Methods: We registered demographic and injury-related data at the time of admission and the scores for the Disability Rating Scale, Glasgow Outcome Scale-Extended, and Short Form 36 subscales for physical functioning and mental health at 1 and 5 years. The patients' self-perceived health care needs and use of health care services at 5 years were the main outcome measurements. Results: At the 5-year follow-up, 70% of patients reported at least 1 perceived need. The self-perceived health care needs were met for 39% of the patients. The patients with unmet needs (n = 29 [31%]) reported frequent needs in emotional (65%), vocational (62%), and cognitive (58%) domains. These patients were significantly more likely to present a less severe disability on the Disability Rating Scale at the 1-year follow-up (odds ratio [OR] 0.11 [95% confidence interval {CI}, 0.02-0.7]; P = .02). Worse mental health at the 1-year follow-up and a younger age (16-29 years) largely predicted unmet needs at the 5-year follow-up (OR 3.28 [95% CI, 1.1-10.04], P = .04; and OR 4.93 [95% CI, 0.16-15.2], P = .005, respectively). Conclusion: Gaps between self-perceived health care needs and health care services received at the 5-year follow-up were found. An important message to clinicians who provide health care services in the late TBI phase is that they should be aware of patients' long-term needs regarding cognitive and emotional difficulties. Of equal importance is an emphasis on long-term vocational rehabilitation services. To ensure the appropriateness of health care service delivery, health care services after TBI should be better targeted at less-severe TBI population as well.	[Andelic, Nada; Soberg, Helene L.; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Div Surg & Clin Neurosci, Oslo, Norway; [Soberg, Helene L.; Sigurdardottir, Solrun] Univ Oslo, Inst Hlth & Soc, Res Ctr Habilitat & Rehabil Models & Serv, Fac Med, Oslo, Norway; [Berntsen, Svein] Sorlandet Hosp, Dept Phys Med & Rehabil, Kristiansand, Norway; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Dept Res, Nesoddtangen, Norway	Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, Div Surg & Clin Neurosci, Oslo, Norway.	nandelic@online.no		Andelic, Nada/0000-0002-3719-4406	Institute of Health and Society, Research Centre for Habilitation and Rehabilitation Models and Services; Faculty of Medicine, University of Oslo; Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway	This study was funded by the Institute of Health and Society, Research Centre for Habilitation and Rehabilitation Models and Services, the Faculty of Medicine, University of Oslo, and the Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway.	Allen SM, 1997, MED CARE, V35, P1132, DOI 10.1097/00005650-199711000-00005; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; Borg J, 2011, AM J PHYS MED REHAB, V90, P65, DOI 10.1097/PHM.0b013e3181fc80e7; Clemes M D, 2001, Health Mark Q, V19, P3, DOI 10.1300/J026v19n01_02; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Fraas M, 2007, BRAIN INJURY, V21, P1267, DOI 10.1080/02699050701721794; Grasdal AL, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-25; Greenspan AI, 2000, BRAIN INJURY, V14, P417; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Kjeldsberg M, 2013, SCAND J PRIM HEALTH, V31, P36, DOI 10.3109/02813432.2012.751697; Laursen B, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001521; Loge JH, 1998, SCAND J SOC MED, V26, P250; McColl MA, 2010, DISABIL SOC, V25, P205, DOI 10.1080/09687590903537406; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Prang KH, 2012, BRAIN INJURY, V26, P1611, DOI 10.3109/02699052.2012.698790; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Stover M, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-375; TEASDALE G, 1974, LANCET, V2, P81; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; WARE JE, 1994, INT J MENT HEALTH, V23, P49, DOI 10.1080/00207411.1994.11449283; Willemse-van Son AHP, 2009, J REHABIL MED, V41, P59, DOI 10.2340/16501977-0294; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	32	25	25	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	NOV	2014	6	11					1013	1021		10.1016/j.pmrj.2014.05.005			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AU4YJ	WOS:000345614000008	24844444				2021-06-18	
J	Gabriel, WM; Rowe, AS				Gabriel, Wendy M.; Rowe, A. Shaun			Long-Term Comparison of GOS-E Scores in Patients Treated With Phenytoin or Levetiracetam for Posttraumatic Seizure Prophylaxis After Traumatic Brain Injury	ANNALS OF PHARMACOTHERAPY			English	Article						phenytoin; levetiracetam; traumatic brain injury; seizure; post-traumatic seizure prophylaxis; Glasgow Outcome Scale-Extended; GOS-E; Keppra; fosphenytoin	PREVENTION; CARE	Background: Much debate exists on the optimal medication for posttraumatic seizure prophylaxis after traumatic brain injury (TBI). There is some evidence that levetiracetam (LEV) could be neuroprotective and provide long-term benefits in this patient population. Objective: The primary objective was to compare the Glasgow Outcome Scale Extended (GOS-E) 6 months or more after severe TBI. Secondary end points were presence of early seizures (0 to 7 days post-TBI) or late seizures (8 days post-TBI to phone interview), use of anticonvulsant medication when interviewed, medication-related hospital complications, and a summary of phenytoin (PHT) and LEV dosing regimens. Methods: This was an IRB-approved, single-center, prospective cohort analysis. Patients were identified by cross-referencing a list of patients receiving LEV or PHT, with a list of patients with ICD-9 code consistent with TBI. After study inclusion, patients were contacted by telephone, and the GOS-E was administered. Data for secondary end points were gathered by retrospective chart review. Results: In all, 19 patients were included in the final analysis. There was no difference in the GOS-E score assessed >= 6 months after injury (5.07 +/- 1.69 vs 5.60 +/- 2.07, P = 0.58). There was no difference in the secondary end points of early seizures (P = 0.53) or late seizures (P = 0.53). However, the PHT group experienced a higher rate of hospital days with recorded fever (0.20 +/- 0.22 vs 0 0; P = 0.014). Conclusions: Long-term functional outcome in patients who experienced a TBI was not affected by treatment with PHT or LEV; however, patients treated with PHT had a higher incidence of fever during hospitalization.	[Gabriel, Wendy M.] Univ Tennessee, Med Ctr, Knoxville, TN USA; [Gabriel, Wendy M.; Rowe, A. Shaun] Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Knoxville, TN 37996 USA	Rowe, AS (corresponding author), Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Knoxville Campus,1924 Alcoa Highway,Box 117, Knoxville, TN 37996 USA.	arowe@uthsc.edu					Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Cook AM, 2013, NEUROCRIT CARE, V19, P210, DOI 10.1007/s12028-013-9837-y; Fuller KL, 2013, EPILEPSIA, V54, P45, DOI 10.1111/j.1528-1167.2012.03563.x; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Klein P, 2012, EPILEPSY BEHAV, V24, P457, DOI 10.1016/j.yebeh.2012.05.011; Ling GSF, 2008, NEUROL CLIN, V26, P409, DOI 10.1016/j.ncl.2008.02.001; Rowe AS, 2014, PHARMACOTHERAPY, V34, P396, DOI 10.1002/phar.1374; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Scheinfeld Noah, 2003, Dermatol Online J, V9, P6; Schierhout G, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000173; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Taylor S, 2011, NEUROCRIT CARE, V15, P80, DOI 10.1007/s12028-010-9341-6; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Walia Kulbir S, 2004, Pain Pract, V4, P194, DOI 10.1111/j.1533-2500.2004.04304.x; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zafar SN, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-30	21	25	27	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	NOV	2014	48	11					1440	1444		10.1177/1060028014549013			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AR1PE	WOS:000343356300005	25169249				2021-06-18	
J	Yanamadala, V; Walcott, BP; Fecci, PE; Rozman, P; Kumar, JI; Nahed, BV; Swearingen, B				Yanamadala, Vijay; Walcott, Brian P.; Fecci, Peter E.; Rozman, Peter; Kumar, Jay I.; Nahed, Brian V.; Swearingen, Brooke			Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Fresh frozen plasma; Intracranial hemorrhage; Prothrombin complex concentrate; Subdural hematoma; Warfarin	PLASMA	Warfarin-associated intracranial hemorrhage is associated with a high mortality rate. Ongoing coagulopathy increases the likelihood of hematoma expansion and can result in catastrophic hemorrhage if surgery is performed without reversal. The current standard of care for emergency reversal of warfarin is with fresh frozen plasma (FFP). In April 2013, the USA Food and Drug Administration approved a new reversal agent, 4-factor prothrombin complex concentrate (PCC), which has the potential to more rapidly correct coagulopathy. We sought to determine the feasibility and outcomes of using PCC for neurosurgical patients. A prospective, observational study of all patients undergoing coagulopathy reversal for intracranial hemorrhage from April 2013 to December 2013 at a single, tertiary care center was undertaken. Thirty three patients underwent emergent reversal of coagulopathy using either FFP or FCC at the discretion of the treating physician. Intracranial hemorrhage included subdural hematoma, intraparenchymal hematoma, and subarachnoid hemorrhage. FFP was used in 28 patients and FCC was used in five patients. International normalized ratio at presentation was similar between groups (FFP 2.9, PCC 3.1, p = 0.89). The time to reversal was significantly shorter in the PCC group (FFP 256 minutes, PCC 65 minutes, p < 0.05). When operations were performed, the time delay to perform operations was also significantly shorter in the PCC group (FFP 307 minutes, PCC 159 minutes, p <0.05). In this preliminary experience, FCC appears to provide a rapid reversal of coagulopathy. Normalization of coagulation parameters may prevent further intracranial hematoma expansion and facilitate rapid surgical evacuation, thereby improving neurological outcomes. (C) 2014 Elsevier Ltd. All rights reserved.	[Walcott, Brian P.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Walcott, BP (corresponding author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White Bldg Room 502, Boston, MA 02114 USA.	walcott.brian@mgh.harvard.edu	Nahed, Brian/E-4239-2014	Nahed, Brian/0000-0001-8537-106X; Fecci, Peter/0000-0002-2912-8695	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25NS065743] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25 NS065743] Funding Source: Medline		Awad AJ, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS1323; Bershad EM, 2008, J NEUROSURG, V109, P664, DOI 10.3171/JNS/2008/109/10/0664; Hickey M, 2013, CIRCULATION, V128, P360, DOI 10.1161/CIRCULATIONAHA.113.001875; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Pabinger I, 2008, J THROMB HAEMOST, V6, P622, DOI 10.1111/j.1538-7836.2008.02904.x; RADBERG JA, 1991, STROKE, V22, P571, DOI 10.1161/01.STR.22.5.571; Rossi E., 2009, ROSSIS PRINCIPLES TR; Sarode R, 2013, CIRCULATION, V128, P1234, DOI 10.1161/CIRCULATIONAHA.113.002283; Zubkov AY, 2008, ARCH NEUROL-CHICAGO, V65, P1320, DOI 10.1001/archneur.65.10.1320	10	25	25	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	NOV	2014	21	11					1881	1884		10.1016/j.jocn.2014.05.001			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AU4TK	WOS:000345604100007	24953825	Green Accepted			2021-06-18	
J	Lu, XP; Chen-Roetling, J; Regan, RF				Lu, Xiangping; Chen-Roetling, Jing; Regan, Raymond F.			Systemic hemin therapy attenuates blood-brain barrier disruption after intracerebral hemorrhage	NEUROBIOLOGY OF DISEASE			English	Article						Heme; Heme oxygenase; Preconditioning; Stroke	OXYGENASE-1 INDUCTION; TRANSCRIPTION FACTORS; PROTECTS; KIDNEY; INJURY; HEME-OXYGENASE-1; HEMOGLOBIN; EDEMA; RAT; TRANSDUCTION	Injury to the blood-brain barrier (BBB) is a key feature of intracerebral hemorrhage (ICH) and may contribute to perihematomal cell injury. Pretreatment with the heme oxygenase (HO)-1 inducer hemin improves barrier function and neurological outcome in experimental models of traumatic and ischemic CNS injury. Since hemin is already in clinical use to treat acute porphyrias, this translational study was designed to test its effect on BBB function when initiated after ICH in two mouse models. At a dose similar to those used in most preconditioning studies (26 mg/kg i.p.), post-hemorrhage treatment with hemin reduced parenchymal extravasation of Evans blue by about three-quarters in both the blood injection and collagenase ICH models. Similar efficacy was observed when treatment was begun at 1 or 3 h. At the lower dose that is currently in clinical use (4 mg/kg beginning at 3 h), hemin also improved barrier function in both models, as assessed by both Evans blue and FITC-dextran leakage; however, it was somewhat less potent, reducing Evans blue leakage by about half. This dose was nevertheless sufficient to attenuate striatal cell loss and accelerate neurological recovery. Consistent with prior observations, striatal HO-1 expression was increased by hemin, and was localized to perivascular cells. These results suggest that hemin may be an effective therapy for ICH with a clinically relevant time window. Further study of the repurposing of this old drug seems warranted. (C) 2014 Elsevier Inc. All rights reserved.	[Lu, Xiangping; Chen-Roetling, Jing; Regan, Raymond F.] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA	Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1025 Walnut St,Coll Bldg,Room 813, Philadelphia, PA 19107 USA.	Raymond.Regan@jefferson.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS079500]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079500] Funding Source: NIH RePORTER	This study was supported by a grant from the National Institutes of Health (NS079500) to R.F.R.	Abraham NG, 2003, J CELL BIOCHEM, V90, P1098, DOI 10.1002/jcb.10736; Anderson KE, 2005, ANN INTERN MED, V142, P439, DOI 10.7326/0003-4819-142-6-200503150-00010; Attuwaybi BO, 2004, J SURG RES, V118, P53, DOI 10.1016/j.jss.2004.01.010; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Belcher JD, 2006, J CLIN INVEST, V116, P808, DOI 10.1172/JCI26857; BUNN HF, 1968, J BIOL CHEM, V243, P465; Chen LF, 2011, J NEUROSURG, V114, P1159, DOI 10.3171/2010.10.JNS10861; Chen-Roetling J, 2013, J NEUROSCI METH, V216, P128, DOI 10.1016/j.jneumeth.2013.03.025; Chen-Roetling J, 2012, TRANSL STROKE RES, V3, P452, DOI 10.1007/s12975-012-0195-4; Chok Mohammed Koussai, 2009, Inflammation & Allergy Drug Targets, V8, P252; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643; Correa-Costa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049569; Demirogullari B, 2006, NEPHRON EXP NEPHROL, V103, P1, DOI 10.1159/000090113; Desbuards N, 2009, NEPHRON EXP NEPHROL, V113, pE35, DOI 10.1159/000228081; DHAR GJ, 1978, ACTA MED SCAND, V203, P437; Habtezion A, 2011, GUT, V60, P671, DOI 10.1136/gut.2010.217208; Hangaishi M, 2000, BIOCHEM BIOPH RES CO, V279, P582, DOI 10.1006/bbrc.2000.3973; Holzen JP, 2008, J SURG RES, V148, P126, DOI 10.1016/j.jss.2007.10.007; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Jadhav A, 2009, AM J PHYSIOL-RENAL, V296, pF521, DOI 10.1152/ajprenal.00510.2007; Kang K, 2013, SHOCK, V40, P136, DOI 10.1097/SHK.0b013e31829d23f5; Keep RF, 2008, ACT NEUR S, V105, P73; Kim JH, 2006, J AM SOC NEPHROL, V17, P1373, DOI 10.1681/ASN.2005091001; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; LETARTE PB, 1993, J NEUROSURG, V79, P252, DOI 10.3171/jns.1993.79.2.0252; Li RC, 2009, J CEREBR BLOOD F MET, V29, P953, DOI 10.1038/jcbfm.2009.19; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; LINDEN IB, 1987, J PHARM PHARMACOL, V39, P96, DOI 10.1111/j.2042-7158.1987.tb06952.x; Lindenblatt N, 2004, ARTERIOSCL THROM VAS, V24, P601, DOI 10.1161/01.ATV.0000118279.74056.8a; Liu DZ, 2008, NEUROBIOL DIS, V30, P201, DOI 10.1016/j.nbd.2008.01.006; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; MacLellan CL, 2006, J CEREBR BLOOD F MET, V26, P1031, DOI 10.1038/sj.jcbfm.9600255; Mense SM, 2006, CELL RES, V16, P681, DOI 10.1038/sj.cr.7310086; Nakamura T, 2004, J CEREBR BLOOD F MET, V24, P487, DOI 10.1097/00004647-200405000-00002; Ogawa T, 2011, J CEREBR BLOOD F MET, V31, P2231, DOI 10.1038/jcbfm.2011.87; Ono S, 2002, J NEUROSURG, V96, P1094, DOI 10.3171/jns.2002.96.6.1094; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Robinson SR, 2009, REDOX REP, V14, P228, DOI 10.1179/135100009X12525712409931; Suzuki H, 1999, J CLIN INVEST, V104, P59, DOI 10.1172/JCI5357; Takizawa S, 1998, J CEREBR BLOOD F MET, V18, P559, DOI 10.1097/00004647-199805000-00011; TENHUNEN R, 1987, J PHARM PHARMACOL, V39, P780, DOI 10.1111/j.2042-7158.1987.tb05119.x; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xue H, 2007, WORLD J GASTROENTERO, V13, P5384, DOI 10.3748/wjg.v13.i40.5384; Yamauchi T, 2004, J NEUROTRAUM, V21, P1017, DOI 10.1089/0897715041651042; Zhang B, 2008, ANESTHESIOLOGY, V109, P260, DOI 10.1097/ALN.0b013e31817f5c2e; Zhong WW, 2010, J PEDIATR GASTR NUTR, V50, P132, DOI 10.1097/MPG.0b013e3181c61591	49	25	26	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	OCT	2014	70						245	251		10.1016/j.nbd.2014.06.005			7	Neurosciences	Neurosciences & Neurology	AN6FW	WOS:000340691400023	24952361	Green Accepted			2021-06-18	
J	Wang, X; Wei, XE; Li, MH; Li, WB; Zhou, YJ; Zhang, B; Li, YH				Wang, Xuan; Wei, Xiao-Er; Li, Ming-Hua; Li, Wen-Bin; Zhou, Ya-Jun; Zhang, Bin; Li, Yue-Hua			Microbleeds on susceptibility-weighted MRI in depressive and non-depressive patients after mild traumatic brain injury	NEUROLOGICAL SCIENCES			English	Article						Traumatic brain injury; Depression; Magnetic resonance imaging; Susceptibility-weighted imaging; Microbleeds	DIFFUSE AXONAL INJURY; MAJOR DEPRESSION; DISORDERS; LESIONS	The aim of this study was to explore the relationship between abnormality on susceptibility-weighted imaging (SWI) and newly-developed depression after mild traumatic brain injury. The study registered 200 patients with closed TBI and normal finding at CT and conventional MRI. All patients underwent MRI including conventional MR sequences and SWI. The number and volume of microbleed lesions were semi-automatically outlined and manually counted. All patients were followed up with the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-IV) within 1 year after TBI. The difference in microbleed lesions on SWI was compared between the depressive and non-depressive groups. The depressive group had a higher rate of abnormality on SWI than did the non-depressive group (p < 0.001). Among patients that had exhibited microbleed lesions, the number and volume of lesions were greater in the depressive group than the non-depressive group (both p < 0.001). These differences in numbers and volume of lesions were found only at the frontal, parietal and temporal lobes (all p < 0.001). Among patients that had exhibited microbleed lesions, the number and volume of lesions in other areas were not significantly different between the depressive and non-depressive groups (all p > 0.05). In conclusion, SWI was useful to identify the microbleed lesions after mild TBI. The distribution range and location of microbleed lesions were correlated with depression after TBI.	[Wang, Xuan; Wei, Xiao-Er; Li, Ming-Hua; Li, Wen-Bin; Li, Yue-Hua] Shanghai Jiao Tong Univ, Inst Diagnost & Intervent Radiol, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China; [Zhou, Ya-Jun; Zhang, Bin] Shanghai Jiao Tong Univ, Dept Neurol, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China	Li, YH (corresponding author), Shanghai Jiao Tong Univ, Inst Diagnost & Intervent Radiol, Affiliated Peoples Hosp 6, 600 Yi Shan Rd, Shanghai 200233, Peoples R China.	xvanwang@163.com			National Natural Scientific Fund of ChinaNational Natural Science Foundation of China (NSFC) [81000609, 81271540, 81301213]	This study is supported by the National Natural Scientific Fund of China (No. 81000609, No. 81271540 and No. 81301213).	Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; First M.B., 2002, BIOMETRICS RES; Freire MAM, 2012, W INDIAN MED J, V61, P751; Goos JDC, 2011, STROKE, V42, P1894, DOI 10.1161/STROKEAHA.110.599837; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Maller JJ, 2014, HUM BRAIN MAPP, V35, P227, DOI 10.1002/hbm.22171; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Ohara Kazuyuki, 2004, Seishin Shinkeigaku Zasshi, V106, P458; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Rao V, 2012, J NEUROPSYCH CLIN N, V24, P309, DOI 10.1176/appi.neuropsych.11080188; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P231, DOI 10.1176/appi.neuropsych.22.2.231; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050706; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	28	25	25	0	11	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	OCT	2014	35	10					1533	1539		10.1007/s10072-014-1788-3			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AP9YP	WOS:000342438400006	24740482				2021-06-18	
J	Semple, BD; Noble-Haeusslein, LJ; Kwon, YJ; Sam, PN; Gibson, AM; Grissom, S; Brown, S; Adahman, Z; Hollingsworth, CA; Kwakye, A; Gimlin, K; Wilde, EA; Hanten, G; Levin, HS; Schenk, AK				Semple, Bridgette D.; Noble-Haeusslein, Linda J.; Kwon, Yong Jun; Sam, Pingdewinde N.; Gibson, A. Matt; Grissom, Sarah; Brown, Sienna; Adahman, Zahra; Hollingsworth, Christopher A.; Kwakye, Alexander; Gimlin, Kayleen; Wilde, Elisabeth A.; Hanten, Gerri; Levin, Harvey S.; Schenk, A. Katrin			Sociosexual and Communication Deficits after Traumatic Injury to the Developing Murine Brain	PLOS ONE			English	Article							MOUSE ULTRASONIC VOCALIZATIONS; SCENT MARKING BEHAVIOR; MICE MUS-DOMESTICUS; SOCIAL COGNITION; C57BL/6J MICE; HOUSE MICE; VOCAL COMMUNICATION; COPULATORY-BEHAVIOR; CORPUS-CALLOSUM; SEXUAL-BEHAVIOR	Despite the life-long implications of social and communication dysfunction after pediatric traumatic brain injury, there is a poor understanding of these deficits in terms of their developmental trajectory and underlying mechanisms. In a well-characterized murine model of pediatric brain injury, we recently demonstrated that pronounced deficits in social interactions emerge across maturation to adulthood after injury at postnatal day (p) 21, approximating a toddler-aged child. Extending these findings, we here hypothesized that these social deficits are dependent upon brain maturation at the time of injury, and coincide with abnormal sociosexual behaviors and communication. Age-dependent vulnerability of the developing brain to social deficits was addressed by comparing behavioral and neuroanatomical outcomes in mice injured at either a pediatric age (p21) or during adolescence (p35). Sociosexual behaviors including social investigation and mounting were evaluated in a resident-intruder paradigm at adulthood. These outcomes were complemented by assays of urine scent marking and ultrasonic vocalizations as indices of social communication. We provide evidence of sociosexual deficits after brain injury at p21, which manifest as reduced mounting behavior and scent marking towards an unfamiliar female at adulthood. In contrast, with the exception of the loss of social recognition in a three-chamber social approach task, mice that received TBI at adolescence were remarkably resilient to social deficits at adulthood. Increased emission of ultrasonic vocalizations (USVs) as well as preferential emission of high frequency USVs after injury was dependent upon both the stimulus and prior social experience. Contrary to the hypothesis that changes in white matter volume may underlie social dysfunction, injury at both p21 and p35 resulted in a similar degree of atrophy of the corpus callosum by adulthood. However, loss of hippocampal tissue was greater after p21 compared to p35 injury, suggesting that a longer period of lesion progression or differences in the kinetics of secondary pathogenesis after p21 injury may contribute to observed behavioral differences. Together, these findings indicate vulnerability of the developing brain to social dysfunction, and suggest that a younger age-at-insult results in poorer social and sociosexual outcomes.	[Semple, Bridgette D.; Noble-Haeusslein, Linda J.; Sam, Pingdewinde N.; Gimlin, Kayleen] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Semple, Bridgette D.] Univ Melbourne, Dept Med, Melbourne Brain Ctr, Royal Melbourne Hosp, Parkville, Vic 3052, Australia; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil, San Francisco, CA 94143 USA; [Kwon, Yong Jun; Gibson, A. Matt; Grissom, Sarah; Brown, Sienna; Adahman, Zahra; Hollingsworth, Christopher A.; Kwakye, Alexander; Schenk, A. Katrin] Randolph Coll, Dept Phys, Lynchburg, VA USA; [Sam, Pingdewinde N.] San Francisco State Univ, San Francisco, CA 94132 USA; [Wilde, Elisabeth A.; Hanten, Gerri; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hanten, Gerri; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA	Semple, BD (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.	Bridgette.Semple@ucsf.edu	Tercovich, Kayleen/I-8941-2018	Tercovich, Kayleen/0000-0003-0450-8912; Adahman, Zahra/0000-0001-6306-6486	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159, NS077767]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [1052505]; Randolph College start-up funds; Division Of Human Resource DevelopmentNational Science Foundation (NSF)NSF- Directorate for Education & Human Resources (EHR) [1302873] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T34GM008574, R25GM059298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077767, R01NS050159] Funding Source: NIH RePORTER	Funding was provided by National Institutes of Health/National Institute of Neurological Disorders and Stroke (http://www.ninds.nih.gov/), R01 #NS050159 and #NS077767 (awarded to LJNH), a CJ Martin Overseas Biomedical Postdoctoral Fellowship from the National Health and Medical Research Council of Australia (https://www.nhmrc.gov.au/) #1052505(awarded to BDS), and Randolph College start-up funds (AKS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acerini CL, 2007, PITUITARY, V10, P373, DOI 10.1007/s11102-007-0052-8; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Arakawa H, 2008, BEHAV BRAIN RES, V190, P97, DOI 10.1016/j.bbr.2008.02.009; Arakawa H, 2007, BEHAV BRAIN RES, V182, P73, DOI 10.1016/j.bbr.2007.05.007; Arriaga G, 2013, BRAIN LANG, V124, P96, DOI 10.1016/j.bandl.2012.10.002; BEAN NJ, 1982, PHYSIOL BEHAV, V28, P31, DOI 10.1016/0031-9384(82)90097-X; BEAN NJ, 1981, BRAIN RES BULL, V6, P109, DOI 10.1016/S0361-9230(81)80033-0; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Bigler ED, 2013, NEUROREHABILITATION, V32, P707, DOI 10.3233/NRE-130896; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Bruell JH, 2006, ANN NY ACAD SCI, V159, P825; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chabout J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029401; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chen CY, 2013, DEV NEUROSCI-BASEL, V35, P474, DOI 10.1159/000355874; Claus CP, 2010, DEV NEUROSCI-BASEL, V32, P454, DOI 10.1159/000316805; Crawley JN, 2007, BRAIN PATHOL, V17, P448, DOI 10.1111/j.1750-3639.2007.00096.x; Didus E, 1999, Pediatr Rehabil, V3, P177; Downing MG, 2013, J HEAD TRAUMA REHAB, V28, P171, DOI 10.1097/HTR.0b013e31828b4f63; Duvoisin RM, 2011, BEHAV BRAIN RES, V221, P50, DOI 10.1016/j.bbr.2011.02.049; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2012, INT J DEV NEUROSCI, V30, P247, DOI 10.1016/j.ijdevneu.2011.07.004; Fairless AH, 2012, BEHAV BRAIN RES, V228, P299, DOI 10.1016/j.bbr.2011.12.001; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Fischer J, 2011, GENES BRAIN BEHAV, V10, P17, DOI 10.1111/j.1601-183X.2010.00610.x; Frith CD, 2007, PHILOS T R SOC B, V362, P671, DOI 10.1098/rstb.2006.2003; Fyrberg A, 2007, INT J REHABIL RES, V30, P153; GEYER LA, 1978, J COMP PHYSIOL PSYCH, V92, P447, DOI 10.1037/h0077487; Giannantoni A, 2011, ARCH PHYS MED REHAB, V92, P1134, DOI 10.1016/j.apmr.2011.02.013; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; Hall CS, 1934, J COMP PSYCHOL, V18, P385, DOI 10.1037/h0071444; Hammerschmidt K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041133; Hanson JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040782; Heyes S. B., 2012, DEV SOCIAL NEUROSCIE, P325; Hoang TX, 2006, J NEUROSCI, V26, P8672, DOI 10.1523/JNEUROSCI.1259-06.2006; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hurst JL, 2004, BIOESSAYS, V26, P1288, DOI 10.1002/bies.20147; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Keightley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00139; Kennedy BC, 2011, BEHAV PHARMACOL, V22, P147, DOI 10.1097/FBP.0b013e328343d7dd; Kennedy Sidney H, 2008, Dialogues Clin Neurosci, V10, P271; Kim S, 2012, NMR BIOMED, V25, P104, DOI 10.1002/nbm.1722; Kimura A, 2010, ANN NEUROL, V67, P794, DOI 10.1002/ana.22023; Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6; Kumar M, 2012, BRAIN RES, V1455, P56, DOI 10.1016/j.brainres.2012.03.041; Lehmann ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069822; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Leypold BG, 2002, P NATL ACAD SCI USA, V99, P6376, DOI 10.1073/pnas.082127599; MAGGIO JC, 1983, PHYSIOL BEHAV, V31, P269, DOI 10.1016/0031-9384(83)90186-5; Mahrt EJ, 2013, J NEUROSCI, V33, P5573, DOI 10.1523/JNEUROSCI.5054-12.2013; Manzo J, 2002, PHYSIOL BEHAV, V75; Matsumoto YK, 2012, NEUROREPORT, V23, P676, DOI 10.1097/WNR.0b013e3283557eea; McCall C, 2012, NAT NEUROSCI, V15, P681, DOI 10.1038/nn.3084; McDonald S., 2012, DEV SOCIAL NEUROSCIE, P325; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P528, DOI 10.1017/S1355617713000039; McFarlane HG, 2008, GENES BRAIN BEHAV, V7, P152, DOI 10.1111/j.1601-183X.2007.00330.x; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Mckinlay A, 2013, J HEAD TRAUMA REHABI; Moreau OK, 2012, J NEUROTRAUM, V29, P81, DOI 10.1089/neu.2011.2048; Moy SS, 2008, MOL PSYCHIATR, V13, P4, DOI 10.1038/sj.mp.4002082; Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-1848.2004.00076.x; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Musolf K, 2010, ANIM BEHAV, V79, P757, DOI 10.1016/j.anbehav.2009.12.034; NYBY J, 1976, BEHAV BIOL, V18, P285, DOI 10.1016/S0091-6773(76)92198-2; NYBY J, 1983, BEHAV NEURAL BIOL, V38, P32, DOI 10.1016/S0163-1047(83)90354-0; NYBY J, 1992, HORM BEHAV, V26, P24, DOI 10.1016/0018-506X(92)90029-U; NYBY J, 1978, NEUROSCI BIOBEHAV R, V2, P1, DOI 10.1016/0149-7634(78)90003-9; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Paul LK, 2007, NAT REV NEUROSCI, V8, P287, DOI 10.1038/nrn2107; Pobbe RLH, 2012, PHYSIOL BEHAV, V107, P641, DOI 10.1016/j.physbeh.2012.02.024; Pobbe RLH, 2012, HORM BEHAV, V61, P436, DOI 10.1016/j.yhbeh.2011.10.010; POMERANTZ SM, 1983, PHYSIOL BEHAV, V31, P91, DOI 10.1016/0031-9384(83)90101-4; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Ponsford JL, 2013, J HEAD TRAUMA REHAB, V28, P195, DOI 10.1097/HTR.0b013e31828b4f7b; Portfors CV, 2007, J AM ASSOC LAB ANIM, V46, P28; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Richmond E, 2014, ENDOCRINE, V45, P3, DOI 10.1007/s12020-013-0049-1; Rose SR, 2012, PITUITARY, V15, P267, DOI 10.1007/s11102-011-0360-x; Rosema S, 2014, J NEUROTRAUM, V13, P13; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Roullet FI, 2011, BEHAV BRAIN RES, V216; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; SALES GD, 1972, ANIM BEHAV, V20, P88, DOI 10.1016/S0003-3472(72)80177-5; Sander AM, 2012, ARCH PHYS MED REHAB, V93, P1331, DOI 10.1016/j.apmr.2012.03.037; Scattoni ML, 2011, GENES BRAIN BEHAV, V10, P44, DOI 10.1111/j.1601-183X.2010.00623.x; Scattoni ML, 2009, NEUROSCI BIOBEHAV R, V33, P508, DOI 10.1016/j.neubiorev.2008.08.003; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Sigurdardottir S, 2013, J REHABIL MED, V45, P808, DOI 10.2340/16501977-1156; Simpson GK, 2013, J HEAD TRAUMA REHAB, V28, P202, DOI 10.1097/HTR.0b013e31828dc5ae; SIPOS ML, 1992, BEHAV NEURAL BIOL, V58, P138, DOI 10.1016/0163-1047(92)90375-E; Slifer KJ, 2009, DEV DISABIL RES REV, V15, P144, DOI 10.1002/ddrr.60; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Sullivan JR, 2010, APPL NEUROPSYCHOL, V17, P93, DOI 10.1080/09084281003708852; Terranova M.L., 2005, CURR PROT TOXICOL; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; van der Kooij MA, 2012, NEUROSCI BIOBEHAV R, V36, P1763, DOI 10.1016/j.neubiorev.2011.10.006; Veenema AH, 2012, HORM BEHAV, V61, P304, DOI 10.1016/j.yhbeh.2011.12.002; Wei L, 2011, J NEUROSCI, V31, P14335, DOI 10.1523/JNEUROSCI.1333-11.2011; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109; White NR, 1998, PHYSIOL BEHAV, V63, P467, DOI 10.1016/S0031-9384(97)00484-8; WHITNEY G, 1973, J COMP PHYSIOL PSYCH, V84, P445, DOI 10.1037/h0034899; Whitney G, 1979, AM ZOOL, V19; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Willott J. F., 2001, HDB MOUSE AUDITORY R; Wohr M, 2011, GENES BRAIN BEHAV, V10, P35, DOI 10.1111/j.1601-183X.2010.00582.x; Wohr M, 2013, BEHAV BRAIN RES, V251, P5, DOI 10.1016/j.bbr.2013.05.047; Wohr M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020631; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yang M, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00159; Yang M, 2012, J NEUROSCI, V32, P6525, DOI 10.1523/JNEUROSCI.6107-11.2012; Yang Mu, 2011, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0826s56; Yang M, 2009, EUR J NEUROSCI, V29, P1663, DOI 10.1111/j.1460-9568.2009.06714.x; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Ylvisaker Mark, 2007, Phys Med Rehabil Clin N Am, V18, P133, DOI 10.1016/j.pmr.2006.11.007; Young DM, 2010, P NATL ACAD SCI USA, V107, P11074, DOI 10.1073/pnas.1005620107	133	25	25	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2014	9	8							e103386	10.1371/journal.pone.0103386			18	Multidisciplinary Sciences	Science & Technology - Other Topics	AR0CG	WOS:000343231900011	25106033	DOAJ Gold, Green Published			2021-06-18	
J	Gawryluk, JR; Mazerolle, EL; Beyea, SD; D'Arcy, RCN				Gawryluk, Jodie R.; Mazerolle, Erin L.; Beyea, Steven D.; D'Arcy, Ryan C. N.			Functional MRI activation in white matter during the Symbol Digit Modalities Test	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						neuroimaging; functional magnetic resonance imaging; white matter; Symbol Digit Modalities Test; neuropsychology	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; COGNITIVE IMPAIRMENT; CORPUS-CALLOSUM; INTERHEMISPHERIC-TRANSFER; NEUROPSYCHOLOGICAL ASSESSMENT; CEREBROVASCULAR REACTIVITY; VISUOMOTOR INFORMATION; MOTION CORRECTION; AXONAL INJURY	Background: Recent evidence shows that functional magnetic resonance imaging (fMRI) can detect activation in white matter (WM). Such advances have important implications for understanding WM dysfunction. A key step in linking neuroimaging advances to the evaluation of clinical disorders is to examine whether WM activation can be detected at the individual level during clinical tests associated with WM function. We used an adapted Symbol Digit Modalities Test (SDMT) in a 4T fMRI study of healthy adults. Results: Results from 17 healthy individuals revealed WM activation in 88% of participants (15/17). The activation was in either the corpus callosum (anterior and/or posterior) or internal capsule (left and/or right). Conclusions: The findings link advances in fMRI to an established clinical test of WM function. Future work should focus on evaluating patients with WM dysfunction.	[Gawryluk, Jodie R.] Univ Victoria, Dept Psychol Neurosci, Victoria, BC, Canada; [Mazerolle, Erin L.] Univ Calgary, Fac Med, Dept Radiol, Calgary, AB, Canada; [Beyea, Steven D.] IWK Hlth Ctr, Biomed Translat Imaging Ctr, Halifax, NS, Canada; [D'Arcy, Ryan C. N.] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada; [D'Arcy, Ryan C. N.] Surrey Mem Hosp, Fraser Hlth Author, Surrey, BC V3T 0H1, Canada	D'Arcy, RCN (corresponding author), Surrey Mem Hosp, Fraser Hlth Author, Suite 400,Cent City Tower 13450-102nd Ave, Surrey, BC V3T 0H1, Canada.	rdarcy@sfu.ca		Gawryluk, Jodie/0000-0003-4924-7517; Beyea, Steven/0000-0001-7851-0017	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; National Research Council; Nova Scotia Health Research Foundation; Killam Trusts	The authors thank C. Liu, D. McAllindon, and J. Quenneville, who assisted with data collection. This work was funded by the Natural Sciences and Engineering Research Council of Canada, the National Research Council, the Nova Scotia Health Research Foundation, and the Killam Trusts.	Amato MP, 2010, MULT SCLER, V16, P1474, DOI 10.1177/1352458510380089; Andersson J.L.R., 2007, TR07JA1 FMRIB; Andersson J.L.R., 2007, NONLINEAR REGISTRATI; ANZOLA GP, 1990, J NEUROL NEUROSUR PS, V53, P142, DOI 10.1136/jnnp.53.2.142; Barbaresi P, 2014, BRAIN BEHAV, V4, P317, DOI 10.1002/brb3.218; Baudewig J., 2008, P 14 ANN M ORG HUM B, P618; Black SE, 2007, BRAIN COGNITION, V63, P192, DOI 10.1016/j.bandc.2006.08.010; Brewer KD, 2009, NMR BIOMED, V22, P654, DOI 10.1002/nbm.1380; Chakravarty MM, 2009, HUM BRAIN MAPP, V30, P3574, DOI 10.1002/hbm.20780; Charil A, 2003, NEUROIMAGE, V19, P532, DOI 10.1016/S1053-8119(03)00117-4; Chiaravalloti ND, 2008, LANCET NEUROL, V7, P1139, DOI 10.1016/S1474-4422(08)70259-X; Connolly JF, 2000, INT J PSYCHOPHYSIOL, V37, P31, DOI 10.1016/S0167-8760(00)00093-3; D'Arcy RCN, 2006, MAGN RESON MED, V55, P952, DOI 10.1002/mrm.20839; Ding ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082107; Driver I, 2010, NEUROIMAGE, V51, P274, DOI 10.1016/j.neuroimage.2009.12.113; Fabri M, 2011, BRAIN RES, V1370, P99, DOI 10.1016/j.brainres.2010.11.039; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Figley CR, 2011, EUR J NEUROSCI, V33, P577, DOI 10.1111/j.1460-9568.2010.07584.x; Forn C, 2009, NEUROSCI LETT, V456, P11, DOI 10.1016/j.neulet.2009.03.081; Fraser LM, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-91; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Gawryluk JR, 2011, NEUROIMAGE, V54, P10, DOI 10.1016/j.neuroimage.2010.07.028; Gawryluk JR, 2009, NEUROIMAGE, V45, P83, DOI 10.1016/j.neuroimage.2008.11.005; Genova HM, 2009, J INT NEUROPSYCH SOC, V15, P383, DOI 10.1017/S1355617709090535; Helenius J, 2003, ACTA RADIOL, V44, P538, DOI 10.1034/j.1600-0455.2003.00104.x; Hoffmann S, 2007, CURR OPIN NEUROL, V20, P275, DOI 10.1097/WCO.0b013e32810c8e87; Iacoboni M, 2004, NEUROPSYCHOLOGIA, V42, P419, DOI 10.1016/j.neuropsychologia.2003.10.007; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kalsi AS, 2004, J ANAT, V204, P475, DOI 10.1111/j.0021-8782.2004.00288.x; Klein A, 2009, NEUROIMAGE, V46, P786, DOI 10.1016/j.neuroimage.2008.12.037; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Macey PM, 2003, RESP PHYSIOL NEUROBI, V139, P41, DOI 10.1016/j.resp.2003.09.006; Maldjian J. A., 1999, P 7 ANN M INT SOC MA; Mandell DM, 2008, STROKE, V39, P1993, DOI 10.1161/STROKEAHA.107.501692; Mazerolle EL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058130; Mazerolle EL, 2010, NEUROIMAGE, V50, P616, DOI 10.1016/j.neuroimage.2009.12.102; Mazerolle EL, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-84; Miller MB, 2009, NEUROIMAGE, V48, P625, DOI 10.1016/j.neuroimage.2009.06.033; Morrow SA, 2010, CLIN NEUROPSYCHOL, V24, P1131, DOI 10.1080/13854046.2010.511272; Newman AJ, 2010, P NATL ACAD SCI USA, V107, P7539, DOI 10.1073/pnas.1003174107; NOLTE J, 2002, HUMAN BRAIN INTRO IT; Oakes TR, 2005, NEUROIMAGE, V28, P529, DOI 10.1016/j.neuroimage.2005.05.058; Omura K, 2004, NEUROREPORT, V15, P2707; Orthmann-Murphy JL, 2008, J MOL NEUROSCI, V35, P101, DOI 10.1007/s12031-007-9027-5; Pelletier J, 2009, Int MS J, V16, P26; Petzold GC, 2011, NEURON, V71, P782, DOI 10.1016/j.neuron.2011.08.009; Preibisch C, 2001, MAGNET RESON MED, V46, P172, DOI 10.1002/mrm.1173; Ranjeva JP, 2006, J NEUROL SCI, V245, P161, DOI 10.1016/j.jns.2005.09.019; Rogers JM, 2007, J CLIN NEUROSCI, V14, P919, DOI 10.1016/j.jocn.2007.02.006; Rostrup E, 2000, NEUROIMAGE, V11, P87, DOI 10.1006/nimg.1999.0526; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith AM, 2012, J NEUROL SCI, V312, P131, DOI 10.1016/j.jns.2011.08.003; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Sperling RA, 2001, ARCH NEUROL-CHICAGO, V58, P115, DOI 10.1001/archneur.58.1.115; Stancak A, 2000, NEUROREPORT, V11, P329, DOI 10.1097/00001756-200002070-00021; Sun D, 2010, J NEUROSCI, V30, P14008, DOI 10.1523/JNEUROSCI.3605-10.2010; Tettamanti M, 2002, J NEUROPHYSIOL, V88, P1051, DOI 10.1152/jn.2002.88.2.1051; Thomas BP, 2014, J CEREBR BLOOD F MET, V34, P242, DOI 10.1038/jcbfm.2013.194; van der Zande FHR, 2005, NEURORADIOLOGY, V47, P114, DOI 10.1007/s00234-004-1274-3; Weber B, 2005, J COGNITIVE NEUROSCI, V17, P113, DOI 10.1162/0898929052880002; Weis S, 2011, INT J NEUROSCI, V121, P384, DOI 10.3109/00207454.2011.565892; Wise RG, 2004, NEUROIMAGE, V21, P1652, DOI 10.1016/j.neuroimage.2003.11.025; Wishart H A, 2001, Curr Psychiatry Rep, V3, P373, DOI 10.1007/s11920-996-0029-8; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Woolrich MW, 2001, NEUROIMAGE, V14, P1370, DOI 10.1006/nimg.2001.0931; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Yarkoni T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004257; Yu HJ, 2012, NEUROIMAGE, V59, P3713, DOI 10.1016/j.neuroimage.2011.10.053; Zarei M, 2006, J ANAT, V209, P311, DOI 10.1111/j.1469-7580.2006.00615.x; ZEFFIRO T, 2007, P 13 ANN M ORG HUM B	75	25	25	0	11	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	AUG 4	2014	8								589	10.3389/fnhum.2014.00589			8	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AN5HG	WOS:000340620800001	25136311	DOAJ Gold, Green Published			2021-06-18	
J	Umschweif, G; Shabashov, D; Alexandrovich, AG; Trembovler, V; Horowitz, M; Shohami, E				Umschweif, Gali; Shabashov, Dalia; Alexandrovich, Alexander G.; Trembovler, Victoria; Horowitz, Michal; Shohami, Esther			Neuroprotection after traumatic brain injury in heat-acclimated mice involves induced neurogenesis and activation of angiotensin receptor type 2 signaling	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						angiotensin receptor type 2; heat acclimation; neurogenesis; neuroprotection; PD123319; traumatic brain injury	NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; FUNCTIONAL RECOVERY; AT(2) RECEPTOR; STROKE; MECHANISMS; APOPTOSIS; SEVERITY; ISCHEMIA; CELLS	Long-term exposure of mice to mild heat (34 degrees C +/- 1 degrees C) confers neuroprotection against traumatic brain injury (TBI); however, the underling mechanisms are not fully understood. Heat acclimation (HA) increases hypothalamic angiotensin II receptor type 2 (AT(2)) expression and hypothalamic neurogenesis. Accumulating data suggest that activation of the brain AT(2) receptor confers protection against several types of brain pathologies, including ischemia, a hallmark of the secondary injury occurring following TBI. As AT(2) activates the same pro-survival pathways involved in HA-mediated neuroprotection (e.g., Akt phosphorylation, hypoxia-inducible factor 1 alpha (HIF-1 alpha), and brain-derived neurotrophic factor (BDNF)), we examined the role of AT(2) in HA-mediated neuroprotection after TBI. Using an AT(2)-specific antagonist PD123319, we found that the improvements in motor and cognitive recovery as well as reduced lesion volume and neurogenesis seen in HA mice were all diminished by AT(2) inhibition, whereas no significant alternations were observed in control mice. We also found that nerve growth factor/tropomyosin-related kinase receptor A (TrkA), BDNF/TrkB, and HIF-1a pathways are upregulated by HA and inhibited on PD123319 administration, suggesting that these pathways play a role in AT(2) signaling in HA mice. In conclusion, AT(2) is involved in HA-mediated neuroprotection, and AT(2) activation may be protective and should be considered a novel drug target in the treatment of TBI patients.	[Umschweif, Gali; Shabashov, Dalia; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther] Sch Pharm, Inst Drug Res, Dept Pharmacol, Jerusalem, Israel; [Umschweif, Gali; Horowitz, Michal] Hebrew Univ Jerusalem, Lab Environm Physiol, IL-91120 Jerusalem, Israel	Horowitz, M (corresponding author), Hebrew Univ Jerusalem, Lab Environm Physiol, POB 12272, IL-91120 Jerusalem, Israel.	m.horowitz@mail.huji.ac.il; esty.shohami@mail.huji.ac.il			Brettler Foundation at the School of Pharmacy; Dr Miriam and Sheldon G Adelson Medical Research Foundation (AMRF)	This study was partially supported by grants from Brettler Foundation at the School of Pharmacy, and by the Dr Miriam and Sheldon G Adelson Medical Research Foundation (AMRF).	Chao J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063488; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Cunningham LA, 2012, BEHAV BRAIN RES, V227, P410, DOI 10.1016/j.bbr.2011.08.002; Day RT, 2010, CELL SIGNAL, V22, P1849, DOI 10.1016/j.cellsig.2010.07.012; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dumont EC, 1999, NEUROSCIENCE, V93, P877, DOI 10.1016/S0306-4522(99)00206-7; Ferrer I, 2001, ACTA NEUROPATHOL, V101, P229; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Guimond MO, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/351758; Guimond Marie-Odile, 2012, Front Endocrinol (Lausanne), V3, P164, DOI 10.3389/fendo.2012.00164; Hafko R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069234; Hagg T, 2009, NEUROSCIENTIST, V15, P20, DOI 10.1177/1073858408324789; Horowitz M, 2014, COMPR PHYSIOL, V4, P199, DOI 10.1002/cphy.c130025; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Kan I, 2011, STEM CELL REV REP, V7, P404, DOI 10.1007/s12015-010-9190-x; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Laflamme L, 1996, J BIOL CHEM, V271, P22729, DOI 10.1074/jbc.271.37.22729; Lu B, 2013, NAT REV NEUROSCI, V14, P401, DOI 10.1038/nrn3505; Lu J, 2013, P NATL ACAD SCI USA, V110, P10747, DOI 10.1073/pnas.1308950110; Macova M, 2009, BRAIN RES, V1250, P130, DOI 10.1016/j.brainres.2008.11.006; Matsuzaki K, 2009, PFLUG ARCH EUR J PHY, V458, P661, DOI 10.1007/s00424-009-0654-2; McCarthy CA, 2012, HYPERTENSION, V60, P1531, DOI 10.1161/HYPERTENSIONAHA.112.199646; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mogi M, 2013, GERIATR GERONTOL INT, V13, P13, DOI 10.1111/j.1447-0594.2012.00900.x; Muller HD, 2008, STROKE, V39, P1012, DOI 10.1161/STROKEAHA.107.495069; Namsolleck P, 2013, NEUROBIOL DIS, V51, P177, DOI 10.1016/j.nbd.2012.11.008; Naruse M, 2002, HYPERTENSION, V40, P28, DOI 10.1161/01.HYP.0000022606.52221.2F; Reinecke K, 2003, FASEB J, V17, P2094, DOI 10.1096/fj.02-1193fje; Saavedra JM, 2006, CELL MOL NEUROBIOL, V26, P1099, DOI 10.1007/s10571-006-9009-0; Schwimmer H, 2004, MOL BRAIN RES, V130, P95, DOI 10.1016/j.molbrainres.2004.07.011; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tota S, 2012, PSYCHOPHARMACOLOGY, V222, P185, DOI 10.1007/s00213-012-2639-7; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Umschweif G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076129; Umschweif G, 2013, J CEREBR BLOOD F MET, V33, P524, DOI 10.1038/jcbfm.2012.193; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; VARON S, 1994, J NEUROTRAUM, V11, P473, DOI 10.1089/neu.1994.11.473; Wolf G, 2004, AM J NEPHROL, V24, P415, DOI 10.1159/000080086; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang P, 2012, NEUROSCIENCE, V201, P297, DOI 10.1016/j.neuroscience.2011.11.005; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	44	25	26	1	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2014	34	8					1381	1390		10.1038/jcbfm.2014.93			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AM4ZG	WOS:000339864100015	24849663	Bronze, Green Published			2021-06-18	
J	Waldron-Perrine, B; Hennrick, H; Spencer, RJ; Pangilinan, PH; Bieliauskas, LA				Waldron-Perrine, Brigid; Hennrick, Heather; Spencer, Robert J.; Pangilinan, Percival H.; Bieliauskas, Linas A.			Postconcussive Symptom Report in Polytrauma: Influence of Mild Traumatic Brain Injury and Psychiatric Distress	MILITARY MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; NEUROPSYCHOLOGICAL PERFORMANCE; CHRONIC PAIN; BASE RATES; VETERANS; DEPLOYMENT; BLAST; IRAQ; AFGHANISTAN	Many studies have evaluated the influence of mild traumatic brain injury (mTBI) on neuropsychological test performance and on report of postconcussive symptoms. However, most studies that examine postconcussion syndrome (PCS) do not address the issue of "polytrauma," which is common in military mTBI. This study investigated simultaneously demographic, injury-related, and psychiatric symptom predictors of PCS report in a veteran, polytrauma sample. In prediction of overall report of PCS symptoms with demographic, traumatic brain injury, psychiatric and sleep variables, 60% of the variance was explained. Semipartial correlations revealed that post-traumatic stress disorder uniquely explained 7% of the variance, depression 2%, and sleep dissatisfaction 3%; injury and demographic characteristics accounted for no unique variance. In all 5 hierarchical multiple regressions (prediction of total Neurobehavioral Symptom Inventory score and 4 individual factor scores), the total models were significant (p < 0.001). Accurate diagnosis and treatment necessitates an integrative analysis of PCS, psychiatric, behavioral, and health symptom report in addition to neuropsychological functioning in the polytrauma population. This study demonstrated that emotional distress was uniquely predictive of total report of PCS and that no injury-related characteristics were predictive. This is of particular relevance in a Veteran population given the high rates of both mTBI and psychiatric disturbance.	[Waldron-Perrine, Brigid; Hennrick, Heather; Spencer, Robert J.; Pangilinan, Percival H.; Bieliauskas, Linas A.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI 48105 USA; [Pangilinan, Percival H.] Univ Michigan Hlth Syst, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA; [Bieliauskas, Linas A.] Univ Michigan Hlth Syst, Dept Psychiat, Ann Arbor, MI 48109 USA	Waldron-Perrine, B (corresponding author), VA Ann Arbor Healthcare Syst, 2215 Fuller Dr, Ann Arbor, MI 48105 USA.						Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Demery JA, 2010, CLIN NEUROPSYCHOL, V24, P1292, DOI 10.1080/13854046.2010.528452; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Drag LL, 2011, J CLIN PSYCHOL MED S, V18, P91, DOI 10.1007/s10880-011-9222-y; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Reitan R. M., 1992, TRAIL MAKING TEST MA; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Spencer R, 2012, NEUROPSYCHOLOGY PRAC; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Tombaugh TN, 1996, TEST MEMORY MALINGER; Uomoto JM, 2009, REHABIL PSYCHOL, V54, P259, DOI 10.1037/a0016907; Waldron-Perrine B, 2012, MIL MED, V177, P1293, DOI 10.7205/MILMED-D-12-00169; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; ZACHARY RA, 2000, SHIPLEY I LIVING SCA; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	48	25	25	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	AUG	2014	179	8					856	864		10.7205/MILMED-D-13-00282			9	Medicine, General & Internal	General & Internal Medicine	AN7UO	WOS:000340806700007	25102528	Bronze			2021-06-18	
J	Sahuquillo, J; Merino, MA; Sanchez-Guerrero, A; Arikan, F; Vidal-Jorge, M; Martinez-Valverde, T; Rey, A; Riveiro, M; Poca, MA				Sahuquillo, Juan; Merino, Maria-Angels; Sanchez-Guerrero, Angela; Arikan, Fuat; Vidal-Jorge, Marian; Martinez-Valverde, Tamara; Rey, Anna; Riveiro, Marilyn; Poca, Maria-Antonia			Lactate and the Lactate-to-Pyruvate Molar Ratio Cannot Be Used as Independent Biomarkers for Monitoring Brain Energetic Metabolism: A Microdialysis Study in Patients with Traumatic Brain Injuries	PLOS ONE			English	Article							SEVERE HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL PERFUSION-PRESSURE; FLUID-PERCUSSION INJURY; INTRACRANIAL-PRESSURE; MITOCHONDRIAL DYSFUNCTION; NORMOBARIC HYPEROXIA; TISSUE-OXYGENATION; INSPIRED OXYGEN	Background: For decades, lactate has been considered an excellent biomarker for oxygen limitation and therefore of organ ischemia. The aim of the present study was to evaluate the frequency of increased brain lactate levels and the LP ratio (LPR) in a cohort of patients with severe or moderate traumatic brain injury (TBI) subjected to brain microdialysis monitoring to analyze the agreement between these two biomarkers and to indicate brain energy metabolism dysfunction. Methods: Forty-six patients with an admission Glasgow coma scale score of <= 13 after resuscitation admitted to a dedicated 10-bed Neurotraumatology Intensive Care Unit were included, and 5305 verified samples of good microdialysis data were analyzed. Results: Lactate levels were above 2.5 mmol/L in 56.9% of the samples. The relationships between lactate and the LPR could not be adequately modeled by any linear or non-linear model. Neither Cohen's kappa nor Gwet's statistic showed an acceptable agreement between both biomarkers to classify the samples in regard to normal or abnormal metabolism. The dataset was divided into four patterns defined by the lactate concentrations and the LPR. A potential interpretation for these patterns is suggested and discussed. Pattern 4 (low pyruvate levels) was found in 10.7% of the samples and was characterized by a significantly low concentration of brain glucose compared with the other groups. Conclusions: Our study shows that metabolic abnormalities are frequent in the macroscopically normal brain in patients with traumatic brain injuries and a very poor agreement between lactate and the LPR when classifying metabolism. The concentration of lactate in the dialysates must be interpreted while taking into consideration the LPR to distinguish between anaerobic metabolism and aerobic hyperglycolysis.	[Sahuquillo, Juan; Arikan, Fuat; Poca, Maria-Antonia] Univ Autonoma Barcelona, Dept Neurosurg, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain; [Sahuquillo, Juan; Merino, Maria-Angels; Sanchez-Guerrero, Angela; Arikan, Fuat; Vidal-Jorge, Marian; Martinez-Valverde, Tamara; Riveiro, Marilyn; Poca, Maria-Antonia] Univ Autonoma Barcelona, Neurotraumatol & Neurosurg Res Unit UNINN, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain; [Rey, Anna; Riveiro, Marilyn] Univ Autonoma Barcelona, Neurotraumatol Intens Care Unit, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain	Sahuquillo, J (corresponding author), Univ Autonoma Barcelona, Dept Neurosurg, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain.	sahuquillo@neurotrauma.net	Vidal-Jorge, Marian/D-4402-2017; Poca, Maria A./B-8475-2008; Sahuquillo, Juan/B-3577-2008; Arikan, Fuat/F-8900-2016; Riveiro, Marilyn/S-5242-2016; Perez, Anna Rey/AAF-8420-2019	Vidal-Jorge, Marian/0000-0002-3459-9336; Poca, Maria A./0000-0002-3831-0536; Sahuquillo, Juan/0000-0003-0713-5875; Arikan, Fuat/0000-0002-9459-0915; Riveiro, Marilyn/0000-0002-1645-3720; Perez, Anna Rey/0000-0001-6014-3829	Fondo de Investigacion Sanitaria (Instituto de Salud Carlos III)Instituto de Salud Carlos III; European Regional Development FundEuropean Commission [PI10/00302, PI11/00700]; Fundacion Mutua MadrilenaInstituto de Salud Carlos III [FMM-2010-10]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission [FI12/00074, FI11/00195]	This study has been supported by the Fondo de Investigacion Sanitaria (Instituto de Salud Carlos III-http://www.isciii.es/) with grants PI10/00302 and PI11/00700, which were co-financed by the European Regional Development Fund and awarded to MP and JS, respectively. This work has also been partially supported by the Fundacion Mutua Madrilena (http://www.fundacionmutua.es/) with grant FMM-2010-10 given to JS. AS and TM are the recipients of two pre-doctoral grants from the Instituto de Salud Carlos III (grants number FI12/00074 and FI11/00195, respectively). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abi-Saab WM, 2002, J CEREBR BLOOD F MET, V22, P271, DOI 10.1097/00004647-200203000-00004; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Debray FG, 2007, CLIN CHEM, V53, P916, DOI 10.1373/clinchem.2006.081166; Dienel GA, 2012, J CEREBR BLOOD F MET, V32, P1107, DOI 10.1038/jcbfm.2011.175; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Fox J., 2011, R COMPANION APPL REG, V2; Gerdle B, 2010, J REHABIL MED, V42, P679, DOI 10.2340/16501977-0581; Gladden LB, 2001, P NATL ACAD SCI USA, V98, P395, DOI 10.1073/pnas.98.2.395; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Horn T, 2010, NEUROCHEM INT, V57, P940, DOI 10.1016/j.neuint.2010.09.014; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Jones AE, 2010, JAMA-J AM MED ASSOC, V303, P739, DOI 10.1001/jama.2010.158; Leen WG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042745; Lourido J, 2002, SCAND J CLIN LAB INV, V62, P285, DOI 10.1080/003655102760145843; Mader JK, 2012, DIABETES RES CLIN PR, V97, P112, DOI 10.1016/j.diabres.2012.02.010; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marmarou A, 2005, ACT NEUR S, V95, P149; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Massabuau JC, 2001, RESP PHYSIOL, V128, P249, DOI 10.1016/S0034-5687(01)00305-X; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Merino MA, 2010, NEUROCIRUGIA, V21, P289; Nelson DW, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-21; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P793, DOI 10.1111/aas.12092; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P229, DOI 10.1111/j.1399-6576.2012.02783.x; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Poca MA, 2002, J NEUROTRAUM, V19, P439, DOI 10.1089/08977150252932398; Poca MA, 2006, J NEUROTRAUM, V23, P1510, DOI 10.1089/neu.2006.23.1510; R Core Team, 2017, R LANG ENV STAT COMP; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Rieger A, 1997, NEUROSURGERY, V41, P462, DOI 10.1097/00006123-199708000-00027; RStudio, 2013, RSTUDIO INT DEV ENV; Sahuquillo J, 2002, NEUROCIRUGIA, V13, P78; Sahuquillo J, 1994, INTRACRANIAL PRESSUR, P48; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Sanchez Jose J, 2013, Acta Neurochir Suppl, V118, P223, DOI 10.1007/978-3-7091-1434-6_42; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; SIGGAARDANDERSEN O, 1995, CRIT CARE MED, V23, P1284, DOI 10.1097/00003246-199507000-00020; SIGGAARDANDERSEN O, 1995, ACTA ANAESTH SCAND, V39, P137; Suistomaa M, 2000, SHOCK, V14, P8, DOI 10.1097/00024382-200014010-00002; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Viera AJ, 2005, FAM MED, V37, P360; Vilalta A, 2011, J NEUROTRAUM, V28, P1139, DOI 10.1089/neu.2010.1720; Wacharasint P, 2012, SHOCK, V38, P4, DOI 10.1097/SHK.0b013e318254d41a; WASSERMAN K, 1964, AM J CARDIOL, V14, P844, DOI 10.1016/0002-9149(64)90012-8; WEIL MH, 1970, CIRCULATION, V41, P989, DOI 10.1161/01.CIR.41.6.989; Wongpakaran N, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-61; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	59	25	25	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2014	9	7							e102540	10.1371/journal.pone.0102540			11	Multidisciplinary Sciences	Science & Technology - Other Topics	AM6RN	WOS:000339992400085	25025772	DOAJ Gold, Green Published			2021-06-18	
J	Haegerich, TM; Dahlberg, LL; Simon, TR; Baldwin, GT; Sleet, DA; Greenspan, AI; Degutis, LC				Haegerich, Tamara M.; Dahlberg, Linda L.; Simon, Thomas R.; Baldwin, Grant T.; Sleet, David A.; Greenspan, Arlene I.; Degutis, Linda C.			Prevention of injury and violence in the USA	LANCET			English	Article							ADVERSE CHILDHOOD EXPERIENCES; TRAUMATIC BRAIN-INJURY; PEDIATRIC PRIMARY-CARE; UNITED-STATES; PUBLIC-HEALTH; OLDER-ADULTS; EMERGENCY-DEPARTMENT; INTERVENTIONS; RISK; DEATHS	In the first three decades of life, more individuals in the USA die from injuries and violence than from any other cause. Millions more people survive and are left with physical, emotional, and financial problems. Injuries and violence are not accidents; they are preventable. Prevention has a strong scientific foundation, yet efforts are not fully implemented or integrated into clinical and community settings. In this Series paper, we review the burden of injuries and violence in the USA, note effective interventions, and discuss methods to bring interventions into practice. Alliances between the public health community and medical care organisations, health-care providers, states, and communities can reduce injuries and violence. We encourage partnerships between medical and public health communities to consistently frame injuries and violence as preventable, identify evidence-based interventions, provide scientific information to decision makers, and strengthen the capacity of an integrated health system to prevent injuries and violence.	[Haegerich, Tamara M.; Dahlberg, Linda L.; Simon, Thomas R.; Baldwin, Grant T.; Sleet, David A.; Greenspan, Arlene I.; Degutis, Linda C.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; [Haegerich, Tamara M.; Dahlberg, Linda L.; Simon, Thomas R.; Baldwin, Grant T.; Sleet, David A.; Greenspan, Arlene I.; Degutis, Linda C.] US Dept HHS, Atlanta, GA USA	Haegerich, TM (corresponding author), Ctr Dis Control & Prevent, Div Unint Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA.	thaegerich@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline		ACIP, 2012, SOC DET INJ; Adams WG, 2003, PEDIATRICS, V111, P626, DOI 10.1542/peds.111.3.626; Bilukha O, 2005, AM J PREV MED, V28, P11, DOI 10.1016/j.amepre.2004.10.004; Black M.C., 2011, NATL INTIMATE PARTNE; Brownson RC, 2012, DISSEMINATION IMPLEM; Carande-Kulis VG, 2010, INJURY PREV, V16, pA249, DOI 10.1136/ip.2010.029215.886; Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; Chorpita Bruce F, 2005, Ment Health Serv Res, V7, P5, DOI 10.1007/s11020-005-1962-6; Cook PJ, 2011, ECON J, V121, P445, DOI 10.1111/j.1468-0297.2011.02419.x; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Crosby Alex E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cubbin C, 2000, J EPIDEMIOL COMMUN H, V54, P517, DOI 10.1136/jech.54.7.517; Cubbin C, 2002, ANNU REV PUBL HEALTH, V23, P349, DOI 10.1146/annurev.publhealth.23.100901.140548; D'Onofrio G, 2008, ANN EMERG MED, V51, P742, DOI 10.1016/j.annemergmed.2007.11.028; D'Onofrio G, 2010, ACAD EMERG MED, V17, P903, DOI 10.1111/j.1553-2712.2010.00824.x; Dahlberg L. L., 2006, PREVENTING VIOLENCE, P97, DOI DOI 10.1037/11385-004; Danese A, 2009, ARCH PEDIAT ADOL MED, V163, P1135, DOI 10.1001/archpediatrics.2009.214; Dellinger AM, 2009, FAM COMMUNITY HEALTH, V32, P115, DOI 10.1097/FCH.0b013e31819946e7; Dinh-Zarr TB, 2001, AM J PREV MED, V21, P48, DOI 10.1016/S0749-3797(01)00378-6; Doll L.S., 2007, HDB INJURY VIOLENCE; Dubowitz H, 2009, PEDIATRICS, V123, P858, DOI 10.1542/peds.2008-1376; Fang XM, 2012, CHILD ABUSE NEGLECT, V36, P156, DOI 10.1016/j.chiabu.2011.10.006; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Finkelhor D, 2005, CHILD MALTREATMENT, V10, P5, DOI 10.1177/1077559504271287; Finkelhor D, 2009, PEDIATRICS, V124, P1411, DOI 10.1542/peds.2009-0467; Florence C, 2014, INJURY PREV, V20, P108, DOI 10.1136/injuryprev-2012-040622; Florence C, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3313; Frieden TR, 2010, AM J PUBLIC HEALTH, V100, P590, DOI 10.2105/AJPH.2009.185652; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Gielen AC, 2002, ARCH PEDIAT ADOL MED, V156, P33, DOI 10.1001/archpedi.156.1.33; Gilchrist Julie, 2012, Morbidity and Mortality Weekly Report, V61, P270; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Girasek DC, 2001, ACCIDENT ANAL PREV, V33, P455, DOI 10.1016/S0001-4575(00)00059-2; Haegerich TM, 2011, AM J LIFESTYLE MED, V5, P392, DOI 10.1177/1559827611409127; Hahn RA, 2005, AM J PREV MED, V28, P72, DOI 10.1016/j.amepre.2004.10.007; Hahn R, 2007, AM J PREV MED, V33, pS114, DOI 10.1016/j.amepre.2007.04.012; Hall JE, 2012, AM J PREV MED, V43, pS60, DOI 10.1016/j.amepre.2012.04.019; Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893; Health Resources and Services Administration. (ND), MAT INF EARL CHILDH; Ikeda RM, 2010, AM J LIFESTYLE MED, V4, P5, DOI 10.1177/1559827609348459; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Koppaka Ram, 2011, Morbidity and Mortality Weekly Report, V60, P619; Lee S, 2012, 12041201 WASH STAT I; Lyons RA, 2010, INT J INJ CONTROL SA, V17, P145, DOI 10.1080/17457300903453104; MacDonald J, 2010, INJURY PREV, V16, P327, DOI 10.1136/ip.2009.024943; McClure R, 2004, SCI BASIS INJURY PRE; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miller TR, 2006, INJURY PREVENTION CH; *NAT CTR INJ PREV, 2009, CDC INJ RES AG 2009; Neumann T, 2006, J TRAUMA, V61, P805, DOI 10.1097/01.ta.0000196399.29893.52; Owen N., 2012, DISSEMINATION IMPLEM, P114, DOI DOI 10.1093/ACPROF.OSO/9780199751877.003.0006; Owusu-Edusei K, 2013, SEX TRANSM DIS, V40, P197, DOI 10.1097/OLQ.0b013e318285c6d2; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Pollack KM, 2012, EPIDEMIOL REV, V34, P73, DOI 10.1093/epirev/mxr019; Rubenstein LZ, 2002, CLIN GERIATR MED, V18, P141, DOI 10.1016/S0749-0690(02)00002-2; Sachs-Ericsson N, 2009, J TRAUMA DISSOCIATIO, V10, P170, DOI 10.1080/15299730802624585; SCHEIER MF, 1992, COGNITIVE THER RES, V16, P201, DOI 10.1007/BF01173489; Scutchfield FD, 2012, AM J PREV MED, V42, pS1, DOI 10.1016/j.amepre.2012.01.027; Shakur H, 2012, LANCET, V380, P2062, DOI 10.1016/S0140-6736(12)62037-6; Shiffman J, 2007, LANCET, V370, P1370, DOI 10.1016/S0140-6736(07)61579-7; Shonkoff JP, 2012, PEDIATRICS, V129, pE232, DOI 10.1542/peds.2011-2663; Shults RA, 2001, AM J PREV MED, V21, P66, DOI 10.1016/S0749-3797(01)00381-6; Sleet DA, 2012, J SAFETY RES, V43, P233, DOI 10.1016/j.jsr.2012.09.002; Sleet David A, 2011, MMWR Suppl, V60, P78; Sleet DA, 2009, FAM COMMUNITY HEALTH, V32, P88, DOI 10.1097/01.FCH.0000347985.67681.9d; Sleet David A., 2009, P439, DOI 10.1007/978-3-7643-9923-8_27; Sogolow E. D., 2007, Handbook of injury and violence prevention, P493, DOI 10.1007/978-0-387-29457-5_28; Stevens J. A., 2006, Morbidity and Mortality Weekly Report, V55, P1221; Stevens JA, 2013, HEALTH PROMOT PRACT, V14, P706, DOI 10.1177/1524839912463576; TENO J, 1990, J AM GERIATR SOC, V38, P1321, DOI 10.1111/j.1532-5415.1990.tb03455.x; The American Geriatrics Society and British Geriatric Society, 2010, AGS ABS CLIN PRACT G; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; TORELL U, 1995, J SAFETY RES, V26, P63, DOI 10.1016/0022-4375(95)00007-D; US Department of Health and Human Services Administration on Children and Families, 2011, DROP; Wandersman A, 2008, AM J COMMUN PSYCHOL, V41, P171, DOI 10.1007/s10464-008-9174-z; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635; Zaza S, 2001, AM J PREV MED, V21, P31, DOI 10.1016/S0749-3797(01)00377-4; Zaza S, 2005, GUIDE COMMUNITY PREV	81	25	25	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 5	2014	384	9937					64	74		10.1016/S0140-6736(14)60074-X			11	Medicine, General & Internal	General & Internal Medicine	AL1XL	WOS:000338919600027	24996591	Green Accepted			2021-06-18	
J	Bryczkowski, SB; Lopreiato, MC; Yonclas, PP; Sacca, JJ; Mosenthal, AC				Bryczkowski, Sarah B.; Lopreiato, Maeve C.; Yonclas, Peter P.; Sacca, James J.; Mosenthal, Anne C.			Delirium prevention program in the surgical intensive care unit improved the outcomes of older adults	JOURNAL OF SURGICAL RESEARCH			English	Article						Delirium; Outcomes; SICU; Benzodiazepines; Mechanical ventilation; ICU; Elderly; Old; Surgery; Trauma	MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; CRITICALLY-ILL PATIENTS; RISK-FACTORS; DURATION; HALOPERIDOL; INTERVENTION; RELIABILITY; PROPHYLAXIS; PREDICTOR	Background: Hospital-acquired delirium is a known risk factor for negative outcomes in patients admitted to the surgical intensive care unit (SICU). Outcomes worsen as the duration of delirium increases. The purpose of this study was to evaluate the efficacy of a delirium prevention program and determine whether it decreased the incidence and duration of hospital-acquired delirium in older adults (age > 50 y) admitted to the SICU. Methods: A prospective pre-or post-intervention cohort study was done at an academic level I trauma center. Older adults admitted to the SICU were enrolled in a delirium prevention program. Those with traumatic brain injury, dementia, or 0 d of obtainable delirium status were excluded from analysis. The intervention consisted of multidisciplinary education, a pharmacologic protocol to limit medications associated with delirium, and a nonpharmacologic sleep enhancement protocol. Primary outcomes were incidence of delirium and delirium-free days/30. Secondary outcomes were ventilator-free days/30, SICU length of stay (LOS), daily and cumulative doses of opioids (milligram, morphine equivalents) and benzodiazepines (milligram, lorazepam equivalents), and time spent in severe pain (greater than or equal to 6 on a scale of 1 -10). Delirium was measured using the Confusion Assessment Method for the ICU. Data were analyzed using Chi-squared and Wilcoxon rank sum analysis. Results: Of 624 patients admitted to the SICU, 123 met inclusion criteria: 57 preintervention (3/12-6/12) and 66 postintervention (7/12-3/13). Cohorts were similar in age, gender, ratio of trauma patients, and Injury Severity Score. Postintervention, older adults experienced delirium at the same incidence (pre 47% versus 58%, P = 0.26), but for a significantly decreased duration as indicated by an increase in delirium-free days/30 (pre 24 versus 27, P = 0.002). After intervention, older adults with delirium had more vent-free days (pre 21 versus 25, P = 0.03), shorter SICU LOS (pre 13 [median 12] versus 7 [median 6], P 0.01) and were less likely to be treated with benzodiazepines (pre 85% versus 63%, P = 0.05) with a lower daily dose when prescribed (pre 5.7 versus 3.6 mg, P = 0.04). After intervention, all older adults spent less time in pain (pre 4.7 versus 3.1 h, P = 0.02), received less total opioids (pre 401 versus 260 mg, P= 0.01), and had shorter SICU LOS (pre 9 [median 5] versus 6 [median 4], P = 0.04). Conclusions: Although delirium prevention continues to be a challenge, this study successfully decreased the duration of delirium for older adults admitted to the SICU. Our simple, cost-effective program led to improved pain and sedation outcomes. Older adults with delirium spent less time on the ventilator and all patients spent less time in the SICU. (C) 2014 Elsevier Inc. All rights reserved.	[Bryczkowski, Sarah B.; Lopreiato, Maeve C.; Yonclas, Peter P.; Sacca, James J.; Mosenthal, Anne C.] Rutgers New Jersey Med Sch, Dept Surg, Newark, NJ 07101 USA	Mosenthal, AC (corresponding author), Rutgers New Jersey Med Sch, Dept Surg, 185 South Orange Ave,MSB G506, Newark, NJ 07101 USA.	Mosentac@NJMS.Rutgers.edu			Healthcare Foundation of New Jersey; Department of Surgery at Rutgers-New Jersey Medical School	Research made possible by the funding of the Healthcare Foundation of New Jersey and the Department of Surgery at Rutgers-New Jersey Medical School. The authors give a special thanks to Jasmine Garces-King, MSN, RN, ACNP-BC, and Patricia Walling, APN for their vital role in staff education. The authors also thank David Livingston, MD for his guidance during the writing process. Finally, the authors thank Robert Lavery for his statistical guidance.	Angles EM, 2008, AM J SURG, V196, P864, DOI 10.1016/j.amjsurg.2008.07.037; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; Fann J R, 2000, Semin Clin Neuropsychiatry, V5, P64; GANDEVIA B, 1964, Med J Aust, V2, P320; Gilmore ML, 2013, GEN HOSP PSYCHIAT, V35, P370, DOI 10.1016/j.genhosppsych.2012.12.009; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Hopkins RO, 2006, CURR OPIN CRIT CARE, V12, P388, DOI 10.1097/01.ccx.0000244115.24000.f5; Inouye SK, 2006, NEW ENGL J MED, V354, P1157, DOI 10.1056/NEJMra052321; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Jackson N, 2008, POSTGRAD MED J, V84, P121, DOI 10.1136/pgmj.2007.062117; Jones SF, 2012, CURR OPIN CRIT CARE, V18, P146, DOI 10.1097/MCC.0b013e32835132b9; Khan BA, 2012, CHEST, V142, P48, DOI 10.1378/chest.11-2100; Lat I, 2009, CRIT CARE MED, V37, P1898, DOI 10.1097/CCM.0b013e31819ffe38; McAvay GJ, 2006, J AM GERIATR SOC, V54, P1245, DOI 10.1111/j.1532-5415.2006.00815.x; Meagher D, 2008, ADV PSYCH TREAT, V14, P292, DOI DOI 10.1192/APT.BP.107.003723; Mistraletti G, 2008, MINERVA ANESTESIOL, V74, P329; Morandi A, 2011, CURR OPIN CRIT CARE, V17, P43, DOI 10.1097/MCC.0b013e3283427243; Morrison RS, 2003, J GERONTOL A-BIOL, V58, P76; Page VJ, 2013, LANCET RESP MED, V1, P515, DOI 10.1016/S2213-2600(13)70166-8; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC; Pisani MA, 2009, CRIT CARE MED, V37, P177, DOI 10.1097/CCM.0b013e318192fcf9; Rea RS, 2007, PHARMACOTHERAPY, V27, P588, DOI 10.1592/phco.27.4.588; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Soja SL, 2008, INTENS CARE MED, V34, P1263, DOI 10.1007/s00134-008-1031-x; Tabet N, 2005, AGE AGEING, V34, P152, DOI 10.1093/ageing/afi031; van den Boogaard M, 2013, CRIT CARE, V17, DOI 10.1186/cc11933; van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892	32	25	29	1	33	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUL	2014	190	1					280	288		10.1016/j.jss.2014.02.044			9	Surgery	Surgery	AK5DN	WOS:000338444700043	24666988				2021-06-18	
J	Carl, RL; Kinsella, SB				Carl, Rebecca L.; Kinsella, Sarah B.			Pediatricians' Knowledge of Current Sports Concussion Legislation and Guidelines and Comfort With Sports Concussion Management: A Cross-Sectional Study	CLINICAL PEDIATRICS			English	Article						sports medicine; concussion; legislation	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; POSTURAL CONTROL; HIGH-SCHOOL; SOCCER; RECOVERY; PLAYERS; ZURICH	Background. Sports-related concussions disproportionately affect young athletes. The primary objective of our study was to determine Illinois pediatricians' level of familiarity with state concussion legislation and with published consensus guidelines for sports concussion diagnosis and treatment. We also sought to determine pediatricians' knowledge regarding concussion management and comfort treating sports concussion patients. Methods. This was a cross-sectional survey of pediatrician members of the Illinois Chapter of the American Academy of Pediatrics. Results. Few general pediatricians (26.6%, n = 42) were "very familiar" or "somewhat familiar" with the recently passed Illinois state concussion legislation. Only 14.6% (n = 23) of general pediatrician respondents use concussion consensus guidelines in their practice. Pediatricians were generally very knowledgeable about concussions; only 5 out of 19 knowledge-based items were answered incorrectly by more than 25% of the study participants. Conclusions. General pediatricians are knowledgeable about concussions but most are not well aware of state concussion legislation and concussion consensus guidelines.	[Carl, Rebecca L.; Kinsella, Sarah B.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Carl, Rebecca L.; Kinsella, Sarah B.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Carl, RL (corresponding author), Ann & Robert H Lurie Childrens Hosp Chicago, 225 E Chicago Ave,Box 69, Chicago, IL 60611 USA.	rcarl@luriechildrens.org			Ann & Robert H. Lurie Children's Hospital Department of Pediatrics	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Ann & Robert H. Lurie Children's Hospital Department of Pediatrics.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Broshek DK, 2014, J CHILD NEUROL, V29, P17, DOI 10.1177/0883073812464525; Center for Sports Concussion at Idaho State University, 2012, KNOW CONC CONC LEG U; Centers for Disease Control and Prevention, HEADS CLIN ADDR CONC; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Delaney J Scott, 2005, Clin J Sport Med, V15, P216, DOI 10.1097/01.jsm.0000168077.74497.a4; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Illinois Chapter of the American Academy of Pediatrics, ICAAP COMM SPORTS ME; Kellerman SE, 2001, AM J PREV MED, V20, P61, DOI 10.1016/S0749-3797(00)00258-0; Koutures CG, 2010, PEDIATRICS, V125, P410, DOI 10.1542/peds.2009-3009; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Pickett W, 2005, BRIT J SPORT MED, V39, P226, DOI 10.1136/bjsm.2004.013169; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Putukian Margot, 2004, Curr Sports Med Rep, V3, P9; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	25	25	25	1	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	JUN	2014	53	7					689	697		10.1177/0009922814526979			9	Pediatrics	Pediatrics	AJ4GM	WOS:000337631200011	24634428				2021-06-18	
J	Mannix, R; Eisenberg, M; Berry, M; Meehan, WP; Hayes, RL				Mannix, Rebekah; Eisenberg, Matthew; Berry, Mark; Meehan, William P., III; Hayes, Ronald L.			Serum Biomarkers Predict Acute Symptom Burden in Children after Concussion: A Preliminary Study	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; concussion; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; S100B; MILD; KNOWLEDGE; IMPACT; GFAP	Pediatric emergency department (ED) visits for concussion have nearly tripled in the past decade. Despite this, there are limited bedside tools available to objectively diagnose injury and prognosticate recovery. Here, we perform a preliminary evaluation of the utility of glial fibrillary acidic protein (GFAP) in predicting initial and follow-up symptom burden in children and young adults 11-21 years of age, presenting to the ED after concussion. We enrolled 13 children and young adults presenting to the ED within 24 h of concussion, and obtained initial serum samples at that time as well as follow-up samples within 24-72 h of injury. Initial GFAP levels were associated with initial and follow-up symptom burden up to 1 month after injury, whereas follow-up GFAP levels did not correlate with symptom burden. These preliminary data suggest that GFAP may offer an objective measure of injury and recovery after pediatric concussion, potentially offering clinicians a new tool in the management of this common injury.	[Mannix, Rebekah; Eisenberg, Matthew; Berry, Mark; Meehan, William P., III] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Concuss Clin, Boston, MA 02115 USA; [Mannix, Rebekah; Eisenberg, Matthew] Harvard Univ, Sch Med, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA	Mannix, R (corresponding author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	Rebekah.Mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020				Babcock L., 2013, AM ACAD PED C ORL FL; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	17	25	25	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2014	31	11					1072	1075		10.1089/neu.2013.3265			4	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AJ7RS	WOS:000337895300010	24494742				2021-06-18	
J	Sullivan-Singh, SJ; Sawyer, K; Ehde, DM; Bell, KR; Temkin, N; Dikmen, S; Williams, RM; Hoffman, JM				Sullivan-Singh, Sarah J.; Sawyer, Kathryn; Ehde, Dawn M.; Bell, Kathleen R.; Temkin, Nancy; Dikmen, Sureyya; Williams, Rhonda M.; Hoffman, Jeanne M.			Comorbidity of Pain and Depression Among Persons With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Pain; Rehabilitation	CUT-POINTS; SEVERITY; PREVALENCE; DISORDERS; VALIDITY; OUTCOMES	Objective: To assess the prevalence of pain, depression, and comorbid pain and depression among a civilian sample of persons with traumatic brain injury (TBI). Design: Longitudinal survey design with 1-year follow-up. Setting: Inpatient rehabilitation and the community. Participants: Participants (N = 158) admitted to inpatient rehabilitation after moderate to severe TBI. Interventions: Not applicable. Main Outcome Measures: Depression was assessed with the Patient Health Questionnaire-9 (PHQ-9); pain was assessed with a numerical rating scale from 0 (no pain) to 10 (worst pain). Participants who reported average pain >= 4 were classified as having pain, and participants with PHQ-9 scores >= 10 were classified as depressed. Results: Both pain and depression were more prevalent at baseline assessment (pain: 70%; depression: 31%) than at year 1 (pain: 34%; depression: 22%). Comorbid pain and depression declined from 27% at baseline to 18% at year 1. Pain was significantly associated with depression at baseline (relative risk: 2.62, P = .003) and at year 1 (relative risk: 7.98, P<.001). Conclusions: Pain and depression are common and frequently co-occur in persons with TBI. Although their frequency declined over the first year after injury, the strength of their association increased. Assessment and treatment of both conditions simultaneously may lead to improved outcomes, both early after TBI and over time. (C) 2014 by the American Congress of Rehabilitation Medicine	[Sullivan-Singh, Sarah J.; Sawyer, Kathryn; Ehde, Dawn M.; Bell, Kathleen R.; Temkin, Nancy; Dikmen, Sureyya; Williams, Rhonda M.; Hoffman, Jeanne M.] Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98104 USA; [Temkin, Nancy; Dikmen, Sureyya] Univ Washington, Dept Neurol Surg, Sch Med, Seattle, WA 98104 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Sch Med, Seattle, WA 98104 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Biobehav Sci, Sch Med, Seattle, WA 98104 USA; [Williams, Rhonda M.] Vet Affairs Puget Sound Healthcare Syst, Rehabil Care Serv, Seattle, WA USA	Sullivan-Singh, SJ (corresponding author), Univ Washington, Dept Rehabil Med, Harborview Med Ctr, 325 Ninth Ave,Box 359612, Seattle, WA 98104 USA.	sarahsullivansingh@gmail.com	Ehde, Dawn/K-1883-2016	Bell, Kathleen/0000-0002-0928-2046; Ehde, Dawn/0000-0002-9555-2347	National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems [H133A070032]; Department of Defense Congressionally Directed Medical Research ProgramsUnited States Department of Defense [W81XWH-12-2-0109]	Supported by the National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems (grant no. H133A070032) and Department of Defense Congressionally Directed Medical Research Programs (grant no. W81XWH-12-2-0109).	Alschuler KN, 2013, REHABIL PSYCHOL, V58, P217, DOI 10.1037/a0032008; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Ericsson M, 2002, DISABIL REHABIL, V24, P334, DOI 10.1080/09638280110096241; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fejer R, 2005, PAIN, V119, P176, DOI 10.1016/j.pain.2005.09.033; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Health United States, 2010, HLTH US; Jensen M.P., 2001, HDB PAIN ASSESSMENT, P15; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2008, PAIN, V134, P209, DOI 10.1016/j.pain.2007.09.021; Kroenke K, 2011, J PAIN, V12, P964, DOI 10.1016/j.jpain.2011.03.003; LINDSAY PG, 1981, PSYCHOSOMATICS, V22, P571; Mavandadi S, 2007, J AM GERIATR SOC, V55, P202, DOI 10.1111/j.1532-5415.2007.01042.x; Miller LR, 2009, J PAIN, V10, P619, DOI 10.1016/j.jpain.2008.12.007; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Tan G., 2008, PSYCHOL, V5, P239, DOI [10.1037/1541-1559.5.3.239, DOI 10.1037/1541-1559. 5. 3. 239, DOI 10.1037/1541-1559.5.3.239]; Tsang A, 2008, J PAIN, V9, P883, DOI 10.1016/j.jpain.2008.05.005; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zelman DC, 2005, PAIN, V115, P29, DOI 10.1016/j.pain.2005.01.028	27	25	25	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2014	95	6					1100	1105		10.1016/j.apmr.2014.02.001			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AI3OY	WOS:000336773000014	24561058				2021-06-18	
J	Fu, J; Fan, HB; Guo, Z; Wang, Z; Li, XD; Li, J; Pei, GX				Fu, Jun; Fan, Hong-bin; Guo, Zheng; Wang, Zhen; Li, Xiang-dong; Li, Jing; Pei, Guo-xian			Salvianolic acid B attenuates spinal cord ischemia-reperfusion-induced neuronal injury and oxidative stress by activating the extracellular signal-regulated kinase pathway in rats	JOURNAL OF SURGICAL RESEARCH			English	Article						Salvianolic acid B; Ischemia-reperfusion injury; Neuroprotection; Oxidative stress	TRAUMATIC BRAIN-INJURY; ISCHEMIA/REPERFUSION INJURY; CORTICAL-NEURONS; MILTIORRHIZA; MECHANISMS; AKT; ERK; NEUROPROTECTION; EXTRACT; RABBITS	Background: Salvianolic acid B (SalB), the main bioactive compound isolated from the traditional Chinese medicinal herb broad Radix Salviae Miltiorrhizae exerts a spectrum of pharmacologic activities. We investigated the effects of SalB treatment in a rat model of spinal cord ischemia and reperfusion (I/R) injury and the underlying mechanism. Materials and methods: SalB was administered at 1, 10, or 50 mg/kg after spinal cord ischemia. The potential protective effects on spinal cord injury were determined by spinal cord edema, infarct volume, and motor function assessment of the hind limbs. Results: SalB treatment significantly decreased spinal cord edema and infarct volume and preserved motor function of the hind limbs in a dose-dependent manner. SalB administration ameliorated the generation of oxidative products and preserved antioxidant defense activities in the injured spinal cord at both 4 and 24 h after I/R injury. Moreover, SalB prolonged the I/R injury-induced activation of extracellular signal-regulated kinase (ERK), and blocking ERK activation with PD98059 partially prevented the neuroprotective effects of SalB. Conclusions: These findings demonstrate the neuroprotective effects of SalB in a spinal cord I/R injury model and suggest that SalB-induced neuroprotection was mediated by ERK activation. (C) 2014 Elsevier Inc. All rights reserved.	[Fu, Jun; Fan, Hong-bin; Guo, Zheng; Wang, Zhen; Li, Xiang-dong; Li, Jing; Pei, Guo-xian] Fourth Mil Med Univ, Xijing Hosp, Dept Orthopaed Oncol, Xian 710032, Shaanxi, Peoples R China	Guo, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Orthopaed Oncol, Xian 710032, Shaanxi, Peoples R China.	fmmuguozheng@163.com; fmmuwangzhen@163.com					Cao W, 2012, CHIN J INTEGR MED, V18, P316, DOI [10.1007/s11655-011-012-1052-8, 10.1007/s11655-012-1052-8]; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; de Haan P, 2001, J NEUROSURG ANESTH, V13, P3, DOI 10.1097/00008506-200101000-00002; Fan H., 2012, EVID-BASED COMPL ALT, V2012, DOI DOI 10.1155/2012/508938; Ho JHC, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-30; Hung YC, 2009, J ETHNOPHARMACOL, V124, P463, DOI 10.1016/j.jep.2009.05.020; Ji XY, 2000, ACTA PHARMACOL SIN, V21, P1089; Kam A, 2012, CURR MED CHEM, V19, P1830, DOI 10.2174/092986712800099794; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kitagawa H, 1999, NEUROSCI LETT, V274, P45, DOI 10.1016/S0304-3940(99)00676-X; Kleikers PWM, 2012, J MOL MED, V90, P1391, DOI 10.1007/s00109-012-0963-3; LIU GT, 1992, BIOCHEM PHARMACOL, V43, P147, DOI 10.1016/0006-2952(92)90271-J; Liu SP, 2010, APPL BIOCHEM BIOTECH, V162, P1206, DOI 10.1007/s12010-009-8888-1; Lu K, 2010, J NEUROCHEM, V114, P237, DOI 10.1111/j.1471-4159.2010.06747.x; Ma WY, 2005, EXPERT OPIN THER TAR, V9, P699, DOI 10.1517/14728222.9.4.699; Sawe N, 2008, J NEUROSCI RES, V86, P1659, DOI 10.1002/jnr.21604; Saxena P, 2012, J CARDIAC SURG, V27, P45, DOI 10.1111/j.1540-8191.2011.01330.x; Shioda N, 2009, INT REV NEUROBIOL, V85, P375, DOI 10.1016/S0074-7742(09)85026-5; Sun YS, 2009, J CHROMATOGR B, V877, P733, DOI 10.1016/j.jchromb.2009.02.013; SVENSSON LG, 1993, J VASC SURG, V17, P357, DOI 10.1016/0741-5214(93)90421-H; Tan DX, 2005, ENDOCRINE, V27, P149, DOI 10.1385/ENDO:27:2:149; Tang MK, 2006, BEHAV PHARMACOL, V17, P493, DOI 10.1097/00008877-200609000-00015; Wang ZS, 2013, CELL MOL NEUROBIOL, V33, P921, DOI 10.1007/s10571-013-9958-z; Wu YJ, 1998, ARTERIOSCL THROM VAS, V18, P481, DOI 10.1161/01.ATV.18.3.481; Wu YT, 2006, INT J PHARM, V326, P25, DOI 10.1016/j.ijpharm.2006.07.003; Zhang JL, 2005, BIOMED CHROMATOGR, V19, P15, DOI 10.1002/bmc.408; Zhao GR, 2008, FOOD CHEM TOXICOL, V46, P73, DOI 10.1016/j.fct.2007.06.034; Zhu JW, 2012, NEUROCHEM INT, V61, P640, DOI 10.1016/j.neuint.2012.06.021	32	25	28	0	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAY	2014	188	1					222	230		10.1016/j.jss.2013.11.1118			9	Surgery	Surgery	AE4RS	WOS:000333971300028	24387840				2021-06-18	
J	Sohlberg, MM; Griffiths, GG; Fickas, S				Sohlberg, Mckay Moore; Griffiths, Gina G.; Fickas, Stephen			An Evaluation of Reading Comprehension of Expository Text in Adults With Traumatic Brain Injury	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						traumatic brain injury; cognition; reading; adults; education; assessment; dyslexia	CLOSED-HEAD-INJURY; WORKING-MEMORY; DISCOURSE; DEFICITS; ADOLESCENTS; IMPAIRMENT; MODEL; TASK	Purpose: This project was conducted to obtain information about reading problems of adults with traumatic brain injury (TBI) with mild-to-moderate cognitive impairments and to investigate how these readers respond to reading comprehension strategy prompts integrated into digital versions of text. Method: Participants from 2 groups, adults with TBI (n = 15) and matched controls (n = 15), read 4 different 500-word expository science passages linked to either a strategy prompt condition or a no-strategy prompt condition. The participants' reading comprehension was evaluated using sentence verification and free recall tasks. Results: The TBI and control groups exhibited significant differences on 2 of the 5 reading comprehension measures: paraphrase statements on a sentence verification task and communication units on a free recall task. Unexpected group differences were noted on the participants' prerequisite reading skills. For the within-group comparison, participants showed significantly higher reading comprehension scores on 2 free recall measures: words per communication unit and type-token ratio. There were no significant interactions. Conclusion: The results help to elucidate the nature of reading comprehension in adults with TBI with mild-to-moderate cognitive impairments and endorse further evaluation of reading comprehension strategies as a potential intervention option for these individuals. Future research is needed to better understand how individual	[Sohlberg, Mckay Moore; Griffiths, Gina G.; Fickas, Stephen] Univ Oregon, Eugene, OR 97403 USA	Sohlberg, MM (corresponding author), Univ Oregon, Eugene, OR 97403 USA.	mckay@uoregon.edu			Direct For Computer & Info Scie & EnginrNational Science Foundation (NSF)NSF - Directorate for Computer & Information Science & Engineering (CISE) [1013054] Funding Source: National Science Foundation		Ackerman R., 2009, NEW DIRECTIONS STUDE, V2009, P5, DOI [DOI 10.1002/SS.311, 10.1002/ss.311]; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Berkeley S, 2010, REM SPEC EDUC, V31, P423, DOI 10.1177/0741932509355988; Biancarosa C., 2004, READING NEXT VISION; BLOOM L, 1980, J CHILD LANG, V7, P235, DOI 10.1017/S0305000900002610; Brown J., 1993, NELSON DENNY READING; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; CARLISLE JF, 1989, LEARNING DISABILITY, V5, P33; Carretti B, 2005, J EXP CHILD PSYCHOL, V91, P45, DOI 10.1016/j.jecp.2005.01.005; Caspari I, 2000, J NEUROLINGUIST, V13, P15, DOI 10.1016/S0911-6044(99)00009-3; Chambers J. M, 1983, GRAPHICAL METHODS DA; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coelho C, 2013, AM J SPEECH-LANG PAT, V22, pS438, DOI 10.1044/1058-0360(2013/12-0076); Conners C., 2000, CONNERS CONTINUOUS P; Connexions, 2009, CONN CONS; Cook B, 2009, SOLDIER STUDENT EASI; Delis DC, 2000, CALIFORNIA VERBAL LE; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Dunn L., 2007, PEABODY PICTURE VOCA, V4th ed.; ERICSSON KA, 1995, PSYCHOL REV, V102, P211, DOI 10.1037/0033-295X.102.2.211; Fan XT, 2001, EDUC PSYCHOL MEAS, V61, P517, DOI 10.1177/00131640121971365; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferstl EC, 2005, J CLIN EXP NEUROPSYC, V27, P367, DOI 10.1080/13803390490515784; Fuchs LS., 2001, SCI STUDIES READING, V5, P239, DOI [10.1207/S1532799XSSR0503_3, DOI 10.1207/S1532799XSSR0503_3]; Gajria M, 2007, J LEARN DISABIL-US, V40, P210, DOI 10.1177/00222194070400030301; George D., 2003, SPSS WINDOWS STEP ST, V4th; Gernsbacher MA, 1997, DISCOURSE PROCESS, V23, P265, DOI 10.1080/01638539709544994; Griffiths G., 2010, OR SPEECH LANG HEAR; Griffiths G. G., 2012, ANN C INT NEUR SOC M; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Guskiewicz K. M., 2003, J AM MED, V19, P2459; Hall D. E., 1986, COGNITIVE REHABILITA, V4, P6; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; HESS CW, 1984, PSYCHOL REP, V55, P51, DOI 10.2466/pr0.1984.55.1.51; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hughes D., 1997, GUIDE NARRATIVE LANG; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kennedy M. R., 2008, NEUROPSYCHOL REHABIL, V1, P1; Kennedy Mary R. T, 2005, Seminars in Speech and Language, V26, P242, DOI 10.1055/s-2005-922103; Kennedy MRT, 2008, NEUROREHABILITATION, V23, P511; Kincaid J. Peter, 1975, 875 CHIEF NAV TECHN; KINTSCH W, 1988, PSYCHOL REV, V95, P163, DOI 10.1037/0033-295X.95.2.163; Le K, 2012, AM J SPEECH-LANG PAT, V21, pS115, DOI 10.1044/1058-0360(2012/11-0114); Lee CD., 2010, READING DISCIPLINES; Lennon C., 2004, LEXILE FRAMEWORK APP; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; LEZAK M, 1995, NEUROLOGICAL ASSESSM; Loban W. D., 1976, LANGUAGE DEV KINDERG; Mann L., 2006, THESIS U MICHIGAN AN; Manset-Williamson G, 2008, INT J SPEC EDUC, V23, P123; MASTROPIERI MA, 1996, EXCEPTIONALITY, V6, P1, DOI DOI 10.1207/S15327035EX0601_; McNamara DS, 2004, DISCOURSE PROCESS, V38, P1, DOI 10.1207/s15326950dp3801_1; Mitchell AJ, 2010, ACTA NEUROPSYCHIATR, V22, P2, DOI 10.1111/j.1601-5215.2009.00439.x; Moran C, 2005, BRAIN INJURY, V19, P743, DOI 10.1080/02699050500110199; Moran C, 2012, LANG SPEECH HEAR SER, V43, P264, DOI 10.1044/0161-1461(2011/10-0114); Moser R. S., 2011, CLIN NEUROPSYCHOL, V1, P1; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Murnane R, 2012, FUTURE CHILD, V22, P3, DOI 10.1353/foc.2012.0013; National Center for Education Statistics, 2011, 2011455 NCES, V2011-455; Nippold M. A., 1993, LANG SPEECH HEAR SER, V24, P21; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; OGLE DM, 1986, READ TEACH, V39, P564, DOI 10.1598/RT.39.6.11; Palincsar A.S., 1984, COG I, V1, P117, DOI [10.1207/s1532690xci0102_1, DOI 10.1207/S1532690XCI0102_1]; Perfetti C.A., 1985, READING ABILITY; Perfetti CA, 1996, READING COMPREHENSION DIFFICULTIES, P137; Radford A. W., 2009, 2009182 NCES US DEP; RAND Reading Study Group, 2002, READING UNDERSTANDIN; ROYER JM, 1979, J READING BEHAV, V11, P355, DOI 10.1080/10862967909547341; Rumelhart D.E., 2004, THEORETICAL MODELS P; Salmen D. J., 2004, THESIS U UTAH SALT L; Samuelsson S, 2004, J LEARN DISABIL-US, V37, P155, DOI 10.1177/00222194040370020601; Schmitter-Edgecombe M, 2005, BRAIN LANG, V94, P331, DOI 10.1016/j.bandl.2005.01.007; Sohlberg M. M., 2011, ANN C AM SPEECH LANG; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg MM., 2011, OPTIMIZING COGNITIVE; Souvignier E, 2006, LEARN INSTR, V16, P57, DOI 10.1016/j.learninstruc.2005.12.006; Stenner A Jackson, 2006, J Appl Meas, V7, P307; Stine-Morrow EAL, 2008, PSYCHOL AGING, V23, P131, DOI 10.1037/0882-7974.23.1.131; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; TANIELIAN T, 2008, MG720CCF RAND; Todis B, 2011, J HEAD TRAUMA REHAB, V26, P138, DOI 10.1097/HTR.0b013e3181e5a87a; TOMPKINS CA, 1994, J SPEECH HEAR RES, V37, P896, DOI 10.1044/jshr.3704.896; Verhoeven L, 2008, APPL COGNITIVE PSYCH, V22, P293, DOI 10.1002/acp.1417; Zwaan RA, 1998, PSYCHOL BULL, V123, P162, DOI 10.1037/0033-2909.123.2.162	86	25	25	0	21	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY	2014	23	2					160	175		10.1044/2013_AJSLP-12-0005			16	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	AU5ZP	WOS:000345682200006	24687229				2021-06-18	
J	Miguel-Hidalgo, JJ; Whittom, A; Villarreal, A; Soni, M; Meshram, A; Pickett, JC; Rajkowska, G; Stockmeier, CA				Miguel-Hidalgo, Jose J.; Whittom, Angela; Villarreal, Ashley; Soni, Madhav; Meshram, Ashish; Pickett, Jason C.; Rajkowska, Grazyna; Stockmeier, Craig A.			Apoptosis-related proteins and proliferation markers in the orbitofrontal cortex in major depressive disorder	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Depression; Prefrontal cortex; Comorbidity; Vulnerability; Postmortem	FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN-INJURY; CELL-PROLIFERATION; PREFRONTAL CORTEX; MOOD DISORDERS; TNF-ALPHA; ANTIDEPRESSANT DRUGS; COGNITIVE DEFICITS; CASPASE ACTIVATION; POSTMORTEM DELAY	Background: In major depressive disorder (MDD), lowered neural activity and significant reductions of markers of cell resiliency to degeneration occur in the prefrontal cortex (PFC). It is still unclear whether changes in other relevant markers of cell vulnerability to degeneration and markers of cell proliferation are associated with MDD. Methods: Levels of caspase 8 (C8), X-linked inhibitor of apoptosis protein (XIAP), direct IAP binding protein with low pI (DIABLO), proliferating cell nuclear antigen (PCNA) and density of cells immunoreactive (-IR) for proliferation marker Ki-67 were measured in postmortem samples of the left orbitofrontal cortex (OFC) of subjects with MDD, and psychiatrically-normal comparison subjects. Results: There was significant increase in C8, a higher ratio of DIABLO to XIAP, lower packing density of Ki-67-IR cells, and an unexpected age-dependent increase in PCNA in subjects with MDD vs. controls. PCNA levels were significantly higher in MDD subjects unresponsive to antidepressants or untreated with antidepressants. The DIABLO/XIAP ratio was higher in MDD subjects without antidepressants than in comparison subjects. Limitations: Qualitative nature of responsiveness assessments; definition of resistance to antidepressant treatment is still controversial; and unclear role of PCNA. Conclusions: Markers of cell vulnerability to degeneration are increased and density of Ki67-positive cells is low MDD, but accompanied by normal MAP levels. The results suggest increased vulnerability to cell pathology in depression that is insufficient to cause morphologically conspicuous cell death. Persistent but low-grade vulnerability to cell degeneration coexisting with reduced proliferation readiness may explain age-dependent reductions in neuronal densities in the OFC of depressed subjects. (C) 2014 Elsevier B.V. All rights reserved.	[Miguel-Hidalgo, Jose J.; Whittom, Angela; Villarreal, Ashley; Soni, Madhav; Meshram, Ashish; Pickett, Jason C.; Rajkowska, Grazyna; Stockmeier, Craig A.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Stockmeier, Craig A.] Case Western Reserve Univ, Cleveland, OH 44106 USA	Miguel-Hidalgo, JJ (corresponding author), Univ Mississippi, Dept Psychiat & Human Behav, Med Ctr, 2500 N State St,Box 127, Jackson, MS 39216 USA.	jmiguel-bidalgo@umc.edu		Miguel-Hidalgo, Jose/0000-0002-4094-1249	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH82297, P30 GM103328]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH082297] Funding Source: NIH RePORTER	Funding for this study was provided by NIH grants MH82297 and P30 GM103328. The NIH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	Albeck JG, 2008, MOL CELL, V30, P11, DOI 10.1016/j.molcel.2008.02.012; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Austin MP, 2001, BRIT J PSYCHIAT, V178, P200, DOI 10.1192/bjp.178.3.200; Banasr M, 2010, MOL PSYCHIATR, V15, P501, DOI 10.1038/mp.2008.106; Banasr M, 2007, BIOL PSYCHIAT, V62, P496, DOI 10.1016/j.biopsych.2007.02.006; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Berthold-Losleben M, 2008, CURR NEUROPHARMACOL, V6, P193, DOI 10.2174/157015908785777238; Boldrini M, 2009, NEUROPSYCHOPHARMACOL, V34, P2376, DOI 10.1038/npp.2009.75; Brasnjevic I, 2008, DNA REPAIR, V7, P1087, DOI 10.1016/j.dnarep.2008.03.010; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Chiou SH, 2006, BIOCHEM BIOPH RES CO, V343, P391, DOI 10.1016/j.bbrc.2006.02.180; Choi C, 2004, BRAIN RES REV, V44, P65, DOI 10.1016/j.brainresrev.2003.08.007; Choi C, 1999, J IMMUNOL, V162, P1889; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cotter DR, 2001, BRAIN RES BULL, V55, P585, DOI 10.1016/S0361-9230(01)00527-5; Cusack CL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2910; Dejong TM, 2009, SUICIDE LIFE-THREAT, V39, P38, DOI 10.1521/suli.2009.39.1.38; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Drapeau E, 2008, AGING CELL, V7, P569, DOI 10.1111/j.1474-9726.2008.00369.x; Drevets WC, 2008, BRAIN STRUCT FUNCT, V213, P93, DOI 10.1007/s00429-008-0189-x; Drevets WC, 2007, ANN NY ACAD SCI, V1121, P499, DOI 10.1196/annals.1401.029; DUVERNOY HM, 1981, BRAIN RES BULL, V7, P519, DOI 10.1016/0361-9230(81)90007-1; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Epp JR, 2009, HIPPOCAMPUS, V19, P1040, DOI 10.1002/hipo.20546; Essers J, 2005, MOL CELL BIOL, V25, P9350, DOI 10.1128/MCB.25.21.9350-9359.2005; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Honer WG, 1999, NEUROSCIENCE, V91, P1247, DOI 10.1016/S0306-4522(98)00679-4; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Khundakar AA, 2009, INT PSYCHOGERIATR, V21, P844, DOI 10.1017/S104161020999007X; Koski CL, 2004, ENDOCRINOLOGY, V145, P95, DOI 10.1210/en.2003-0803; Kubitz N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076882; Kulmatycki KM, 2006, J PHARM PHARM SCI, V9, P292, DOI 10.18433/J36P47; Kuranaga E, 2007, TRENDS CELL BIOL, V17, P135, DOI 10.1016/j.tcb.2007.01.001; KURKI P, 1986, EXP CELL RES, V166, P209, DOI 10.1016/0014-4827(86)90520-3; Lavrik IN, 2005, J CLIN INVEST, V115, P2665, DOI 10.1172/JCI26252; Lucassen PJ, 2010, NEUROPHARMACOLOGY, V58, P940, DOI 10.1016/j.neuropharm.2010.01.012; LUCASSEN PJ, 1995, J HISTOCHEM CYTOCHEM, V43, P1163, DOI 10.1177/43.11.7560899; Lucassen PJ, 2001, AM J PATHOL, V158, P453, DOI 10.1016/S0002-9440(10)63988-0; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Manev H, 2001, EUR J PHARMACOL, V411, P67, DOI 10.1016/S0014-2999(00)00904-3; Manji HK, 2000, MOL PSYCHIATR, V5, P578, DOI 10.1038/sj.mp.4000811; Manji HK, 2001, NAT MED, V7, P541, DOI 10.1038/87865; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Merkl A, 2011, BIOL PSYCHIAT, V69, P772, DOI 10.1016/j.biopsych.2010.08.009; Miguel-Hidalgo JJ, 2000, BIOL PSYCHIAT, V48, P861, DOI 10.1016/S0006-3223(00)00999-9; Muskhelishvili L, 2003, J HISTOCHEM CYTOCHEM, V51, P1681, DOI 10.1177/002215540305101212; Niizuma K, 2010, BBA-MOL BASIS DIS, V1802, P92, DOI 10.1016/j.bbadis.2009.09.002; Olesen BT, 2008, NEUROTOXICOLOGY, V29, P13, DOI 10.1016/j.neuro.2007.08.010; Rajkowska G, 2000, BIOL PSYCHIAT, V48, P766, DOI 10.1016/S0006-3223(00)00950-1; Rajkowska G., 2007, CNS & Neurological Disorders-Drug Targets, V6, P219, DOI 10.2174/187152707780619326; Rajkowska G, 2005, BIOL PSYCHIAT, V58, P297, DOI 10.1016/j.biopsych.2005.04.013; Riddle D.R., 2007, BRAIN AGING MODELS M; Sairanen M, 2005, J NEUROSCI, V25, P1089, DOI 10.1523/JNEUROSCI.3741-04.2005; Saito A, 2003, J CEREBR BLOOD F MET, V23, P1010, DOI 10.1097/01.WCB.0000080702.47016.FF; Scarabelli TM, 2004, J AM COLL CARDIOL, V43, P865, DOI 10.1016/j.jacc.2003.09.050; Schallock K, 1997, CLIN NEUROPATHOL, V16, P133; Schamberger CJ, 2005, EXP CELL RES, V302, P115, DOI 10.1016/j.yexcr.2004.08.026; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Scott RJ, 1997, NEUROPATH APPL NEURO, V23, P307; Segura MF, 2007, J NEUROSCI, V27, P11228, DOI 10.1523/JNEUROSCI.3462-07.2007; Si XH, 2004, NEUROPSYCHOPHARMACOL, V29, P2088, DOI 10.1038/sj.npp.1300525; Souery D, 1999, EUR NEUROPSYCHOPHARM, V9, P83, DOI 10.1016/S0924-977X(98)00004-2; Suberbielle E, 2013, NAT NEUROSCI, V16, P613, DOI 10.1038/nn.3356; Uranova NA, 2004, SCHIZOPHR RES, V67, P269, DOI 10.1016/S0920-9964(03)00181-6; Uylings HBM, 2010, PSYCHIAT RES-NEUROIM, V183, P1, DOI 10.1016/j.pscychresns.2010.04.012; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vostrikov V, 2011, SCHIZOPHR RES TREAT, V2011, DOI 10.1155/2011/174689; Wang XY, 2004, NEUROBIOL DIS, V16, P179, DOI 10.1016/j.nbd.2004.01.014	70	25	29	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	APR	2014	158						62	70		10.1016/j.jad.2014.02.010			9	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	AD4ZB	WOS:000333259500010	24655767	Green Accepted			2021-06-18	
J	Mitchell, K; Shah, JP; Tsytsikova, LV; Campbell, AM; Affram, K; Symes, AJ				Mitchell, Kendall; Shah, Jill P.; Tsytsikova, Lyubov V.; Campbell, Ashley M.; Affram, Kwame; Symes, Aviva J.			LPS antagonism of TGF-beta signaling results in prolonged survival and activation of rat primary microglia	JOURNAL OF NEUROCHEMISTRY			English	Article						cytokines; inflammation; LPS; TLR4; microglia; smad signaling; TGF-	GROWTH-FACTOR-BETA; ALTERNATIVE ACTIVATION; INHIBITORY SMADS; SPINAL-CORD; IN-VITRO; TGF-BETA-1; BRAIN; CELLS; MACROPHAGES; NEUROTOXICITY	Accumulating evidence indicates that activated microglia contribute to the neuropathology involved in many neurodegenerative diseases and after traumatic injury to the CNS. The cytokine transforming growth factor-beta 1 (TGF-beta 1), a potent deactivator of microglia, should have the potential to reduce microglial-mediated neurodegeneration. It is therefore perplexing that high levels of TGF-beta 1 are found in conditions where microglia are chronically activated. We hypothesized that TGF-beta 1 signaling is suppressed in activated microglia. We therefore activated primary rat microglia with lipopolysaccharide (LPS) and determined the expression of proteins important to TGF-beta 1 signaling. We found that LPS treatment decreased the expression of the TGF-beta receptors, T beta R1 and T beta R2, and reduced protein levels of Smad2, a key mediator of TGF-beta signaling. LPS treatment also antagonized the ability of TGF-beta to suppress expression of pro-inflammatory cytokines and to induce microglial cell death. LPS treatment similarly inhibited the ability of the TGF-beta related cytokine, Activin-A, to down-regulate expression of pro-inflammatory cytokines and to induce microglial cell death. Together, these data suggest that microglial activators may oppose the actions of TGF-beta 1, ensuring continued microglial activation and survival that eventually may contribute to the neurodegeneration prevalent in chronic neuroinflammatory conditions.	[Mitchell, Kendall; Shah, Jill P.; Tsytsikova, Lyubov V.; Campbell, Ashley M.; Affram, Kwame; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Affram, Kwame; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Program Neurosci, Bethesda, MD 20814 USA	Symes, AJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	aviva.symes@usuhs.edu	Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939	Defense Medical Research Development Program	This study was supported by a grant from the Defense Medical Research Development Program (AJS). We are grateful to members of the Symes laboratory for their helpful comments and suggestions. The opinions and assertions contained herein are the private opinions of the authors and are not to be construed as reflecting the views of the Uniformed Services University of the Health Sciences or the US Department of Defense. The authors have no conflict of interest to declare.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Bitzer M, 2000, GENE DEV, V14, P187; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Brodie C, 1998, J NEUROIMMUNOL, V81, P20, DOI 10.1016/S0165-5728(97)00154-9; Choi KC, 2006, NAT IMMUNOL, V7, P1057, DOI 10.1038/ni1383; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Dmitriev AE, 2011, J BONE JOINT SURG AM, V93A, P1488, DOI 10.2106/JBJS.J.00904; Dmitriev AE, 2010, SPINE J, V10, P16, DOI 10.1016/j.spinee.2009.10.003; Echeverry S, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-16; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Gordon S, 2007, EUR J IMMUNOL, V37, pS9, DOI 10.1002/eji.200737638; Heldin CH, 2012, CELL TISSUE RES, V347, P21, DOI 10.1007/s00441-011-1190-x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herrera AJ, 2000, NEUROBIOL DIS, V7, P429, DOI 10.1006/nbdi.2000.0289; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim EY, 2011, FEBS LETT, V585, P779, DOI 10.1016/j.febslet.2011.01.044; Kim WK, 2004, J IMMUNOL, V172, P7015, DOI 10.4049/jimmunol.172.11.7015; Kofler J, 2011, TOXICOL PATHOL, V39, P103, DOI 10.1177/0192623310387619; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Lanz TV, 2010, J CLIN INVEST, V120, P2782, DOI 10.1172/JCI41709; Le YY, 2004, J IMMUNOL, V173, P962, DOI 10.4049/jimmunol.173.2.962; Lodge PA, 1996, J LEUKOCYTE BIOL, V60, P502; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Park SH, 2005, J BIOCHEM MOL BIOL, V38, P9; Quan TH, 2005, J BIOL CHEM, V280, P8079, DOI 10.1074/jbc.M409647200; SALIMUDDIN, 1999, AM J PHYSIOL, V277, pE110; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Smith GM, 1997, J NEUROSCI, V17, P9624; Spittau B, 2013, GLIA, V61, P287, DOI 10.1002/glia.22435; Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272; Sugama S, 2007, J NEUROIMMUNOL, V192, P31, DOI 10.1016/j.jneuroim.2007.08.016; Susarla BTS, 2011, J NEUROCHEM, V119, P868, DOI 10.1111/j.1471-4159.2011.07470.x; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tarkowski E, 2002, NEUROBIOL AGING, V23, P237, DOI 10.1016/S0197-4580(01)00285-8; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Tsunobuchi H, 2004, BIOCHEM BIOPH RES CO, V316, P712, DOI 10.1016/j.bbrc.2004.02.104; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; van Rossum D, 2008, GLIA, V56, P271, DOI 10.1002/glia.20611; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Xiao BG, 1997, NEUROSCI LETT, V226, P71, DOI 10.1016/S0304-3940(97)00234-6; Zhang BX, 2009, CANCER LETT, V277, P114, DOI 10.1016/j.canlet.2008.11.035; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhou XL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-210	53	25	27	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2014	129	1					155	168		10.1111/jnc.12612			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AD3JT	WOS:000333135800014	24251648	Bronze			2021-06-18	
J	Skidmore, ER; Dawson, DR; Whyte, EM; Butters, MA; Dew, MA; Grattan, ES; Becker, JT; Holm, MB				Skidmore, Elizabeth R.; Dawson, Deirdre R.; Whyte, Ellen M.; Butters, Meryl A.; Dew, Mary Amanda; Grattan, Emily S.; Becker, James T.; Holm, Margo B.			Developing complex interventions: lessons learned from a pilot study examining strategy training in acute stroke rehabilitation	CLINICAL REHABILITATION			English	Article						stroke; strategy training; Rehabilitation interventions; cognitive impairment	TRAUMATIC BRAIN-INJURY; EXECUTIVE DYSFUNCTION; COGNITIVE IMPAIRMENT; DEVELOPMENTAL-APPROACH; INTERVIEW; APHASIA; ADULTS; TRIAL; PARTICIPATION; DETERMINANTS	Objective: To examine the feasibility of a strategy training clinical trial in a small group of adults with stroke-related cognitive impairments in inpatient rehabilitation, and to explore the impact of strategy training on disability. Design: Non-randomized two-group intervention pilot study. Setting: Two inpatient rehabilitation units within an academic health centre. Participants: Individuals with a primary diagnosis of acute stroke, who were admitted to inpatient rehabilitation and demonstrated cognitive impairments were included. Individuals with severe aphasia; dementia; major depressive disorder, bipolar, or psychotic disorder; recent drug or alcohol abuse; and anticipated length of stay less than five days were excluded. Intervention: Participants received strategy training or an attention control session in addition to usual rehabilitation care. Sessions in both groups were 30-40 minutes daily, five days per week, for the duration of inpatient rehabilitation. Main outcome measures: We assessed feasibility through participants' recruitment and retention; research intervention session number and duration; participants' comprehension and engagement; intervention fidelity; and participants' satisfaction. We assessed disability at study admission, inpatient rehabilitation discharge, 3 and 6 months using the Functional Independence Measure. Results: Participants in both groups (5 per group) received the assigned intervention (>92% planned sessions; >94% fidelity) and completed follow-up testing. Strategy training participants in this small sample demonstrated significantly less disability at six months (M (SE) = 117 (3)) than attention control participants (M(SE) = 96 (14); t(8) = 7.87, P = 0.02). Conclusions: It is feasible and acceptable to administer both intervention protocols as an adjunct to acute inpatient rehabilitation, and strategy training shows promise for reducing disability.	[Skidmore, Elizabeth R.; Grattan, Emily S.; Holm, Margo B.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Occupat Therapy, Pittsburgh, PA 15260 USA; [Skidmore, Elizabeth R.; Grattan, Emily S.] Univ Pittsburgh, Med Ctr, Inst Rehabil, Pittsburgh, PA 15260 USA; [Skidmore, Elizabeth R.; Whyte, Ellen M.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Dawson, Deirdre R.] Rotman Res Inst Baycrest, Toronto, ON, Canada; [Dawson, Deirdre R.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Dawson, Deirdre R.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Whyte, Ellen M.; Butters, Meryl A.; Dew, Mary Amanda; Becker, James T.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Whyte, Ellen M.; Butters, Meryl A.; Dew, Mary Amanda] Western Psychiat Inst & Clin, Adv Ctr Intervent & Serv Res Late Life Mood Disor, Pittsburgh, PA USA	Skidmore, ER (corresponding author), Univ Pittsburgh, Dept Occupat Therapy, 5012 Forbes Tower, Pittsburgh, PA 15260 USA.	skidmore@pitt.edu	Butters, Meryl/AAR-2863-2021; Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121; Becker, James/0000-0003-4425-4726	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12 HD055931]; University of Pittsburgh Medical Center Rehabilitation Institute; University of Pittsburgh Office of Research Health Sciences; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD055931] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (K12 HD055931), the University of Pittsburgh Medical Center Rehabilitation Institute and the University of Pittsburgh Office of Research Health Sciences.	Attkisson C., 1994, USE PSYCHOL TESTING, P402; Berthier ML, 2005, DRUG AGING, V22, P163, DOI 10.2165/00002512-200522020-00006; Blanton S, 2006, PHYS THER, V86, P1520, DOI 10.2522/ptj.20060091; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Butters MA, 2004, ARCH GEN PSYCHIAT, V61, P587, DOI 10.1001/archpsyc.61.6.587; Craig P., 2008, DEV EVALUATING COMPL; Dawson DR, 2009, CAN J OCCUP THER, V76, P115, DOI 10.1177/000841740907600209; Dickey L, 2010, ARCH PHYS MED REHAB, V91, P196, DOI 10.1016/j.apmr.2009.09.020; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; Goodglass H, 2001, ASSESSMENT APHASIA R; Hart T, 2012, ARCH PHYS MED REHAB, V93, pS117, DOI 10.1016/j.apmr.2011.11.039; Heruti RJ, 2002, ARCH PHYS MED REHAB, V83, P742, DOI 10.1053/apmr.2002.32739; Hildebrand MW, 2012, AM J PHYS MED REHAB, V91, P715, DOI 10.1097/PHM.0b013e31824ad462; Holm MB, 2000, AM J OCCUP THER, V54, P575, DOI 10.5014/ajot.54.6.575; Kwakkel G, 1996, AGE AGEING, V25, P479, DOI 10.1093/ageing/25.6.479; Larson EB, 2010, ARCH PHYS MED REHAB, V91, P389, DOI 10.1016/j.apmr.2009.11.015; Law M, 1998, CANADIAN OCCUPATIONA; Lenze EJ, 2004, ARCH PHYS MED REHAB, V85, P380, DOI 10.1016/j.apmr.2003.06.001; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lubinsky T, 2009, J INT NEUROPSYCH SOC, V15, P704, DOI 10.1017/S1355617709990270; McColl M.A., 2006, RES CANADIAN OCCUPAT; Meichenbaum D., 1977, COGNITIVE BEHAV MODI; Miotto EC, 2009, NEUROPSYCHOL REHABIL, V19, P517, DOI 10.1080/09602010802332108; Patel M, 2003, CLIN REHABIL, V17, P158, DOI 10.1191/0269215503cr596oa; PEDERSEN PM, 1995, ANN NEUROL, V38, P659, DOI 10.1002/ana.410380416; Perepletchikova F, 2005, CLIN PSYCHOL-SCI PR, V12, P365, DOI 10.1093/clipsy/bpi045; Polatajko H. J., 2004, ENABLING OCCUPATION; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; ROYALL DR, 1992, J AM GERIATR SOC, V40, P1221, DOI 10.1111/j.1532-5415.1992.tb03646.x; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Skidmore ER, 2011, NEUROPSYCHOL REHABIL, V21, P208, DOI 10.1080/09602011.2011.552559; Skidmore ER, 2010, ARCH PHYS MED REHAB, V91, P203, DOI 10.1016/j.apmr.2009.10.026; Skidmore ER, PEDIAT BLOO IN PRESS; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Wales C.E., 1986, EDUC LEADERSHIP, V43, P203; Whyte J, 2007, AM J PHYS MED REHAB, V86, P835, DOI 10.1097/PHM.0b013e3181570b74; Whyte J, 2012, ARCH PHYS MED REHAB, V93, pS101, DOI 10.1016/j.apmr.2011.11.040; Whyte J, 2009, ARCH PHYS MED REHAB, V90, pS3, DOI 10.1016/j.apmr.2009.07.008	42	25	26	0	33	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	APR	2014	28	4					378	387		10.1177/0269215513502799			10	Rehabilitation	Rehabilitation	AC0OZ	WOS:000332195900009	24113727	Green Accepted			2021-06-18	
J	Kontos, AP; Braithwaite, R; Dakan, S; Elbin, RJ				Kontos, Anthony P.; Braithwaite, Rock; Dakan, Scott; Elbin, R. J.			Computerized Neurocognitive Testing within 1 Week of Sport-Related Concussion: Meta-analytic Review and Analysis of Moderating Factors	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						ANAM; CogSport; Headminder; ImPACT; Neuropsychology; Mild traumatic brain injury	COUNSELING PSYCHOMETRIC ISSUES; IMPACT ASSESSMENT; CLINICAL UTILITY; HIGH-SCHOOL; PLAY; EPIDEMIOLOGY; PERFORMANCE; COLLEGIATE; SYMPTOMS; BIAS	The purpose of this study is to perform a meta-analysis assessing the effects of sport-related concussion as measured by computerized neurocognitive tests (NCT) 1-week post injury. Thirty-seven studies involving 3960 participants between 2000 and 2011 were included. Hedge's g provides an adjusted effect size for smaller sample sizes and was calculated for overall and cognitive task effects, and subgroup analyses were conducted for age, type of NCT, and sport. Concussions had a low negative effect (g=-0.16; p<.001) across all groups, outcomes, and time points. Code substitution (g=-0.27; p<.05), visual memory (g=-0.25; p<.05), processing speed (g=-0.18; p<.05), and memory (g=-0.21; p<.05) tasks demonstrated negative effects for concussion. Younger adolescents had lower (g=-0.29; p<.05) NCT performance than older adolescents (g=-0.01) and college aged athletes (g=-0.11). ImPACT studies (g=-0.19; p<.05) demonstrated a negative effect for concussion as did those involving contact sports (g=-0.20; p<.05). A low to moderate overall effect size of concussion on neurocognitive performance was supported. Subgroup analyses revealed different effect sizes for specific cognitive tasks, types of NCTs, age, and type of sport.	[Kontos, Anthony P.; Dakan, Scott] Univ Pittsburgh, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA USA; [Braithwaite, Rock] Humboldt State Univ, Dept Kinesiol & Recreat Adm, Arcata, CA 95521 USA; [Elbin, R. J.] Univ Arkansas, Dept Hlth Human Performance & Recreat, Fayetteville, AR 72701 USA	Kontos, AP (corresponding author), Univ Pittsburgh, UPMC Ctr Sports Med, Dept Orthoped Surg, UPMC Sports Med Concuss Program, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu	Meijer, Anna/K-5118-2016	Kontos, Anthony/0000-0002-3749-4310			[Anonymous], 2001, REP TRENDS PART YOUT; Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Borenstein M., 2005, COMPREHENSIVE METAAN; Borenstein M., 2009, INTRO METAANALYSIS; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Dougan B.K., 2013, J INT NEUROPSYCH SOC, P1; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field AP, 2003, PSYCHOLOGIST, V16, P642; Field AP, 2001, PSYCHOL METHODS, V6, P161, DOI 10.1037//1082-989X.6.2.161; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hedges L. V., 1981, J EDUC STAT, V6, P107; Hedges L.V., 1985, STAT METHODS META AN; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hunter JE, 2000, INT J SELECT ASSESS, V8, P275, DOI 10.1111/1468-2389.00156; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Light R. J., 1984, SUMMING SCI REV RES; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P1, DOI 10.1002/0470870168; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; SHADISH WR, 1991, J CONSULT CLIN PSYCH, V59, P883, DOI 10.1037/0022-006X.59.6.883	31	25	25	1	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2014	20	3					324	332		10.1017/S1355617713001471			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	AM0UG	WOS:000339561800008	24521662				2021-06-18	
J	Sajja, VSSS; Perrine, SA; Ghoddoussi, F; Hall, CS; Galloway, MP; VandeVord, PJ				Sajja, Venkata Siva Sai Sujith; Perrine, Shane A.; Ghoddoussi, Farhad; Hall, Christina S.; Galloway, Matthew P.; VandeVord, Pamela J.			Blast neurotrauma impairs working memory and disrupts prefrontal myo-inositol levels in rats	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Working memory; Myo-inositol; Glia; Prefrontal cortex; Blast neurotrauma	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; ALZHEIMERS-DISEASE; NEUROCHEMICAL CHANGES; OXIDATIVE STRESS; CREATINE-KINASE; MR SPECTROSCOPY; ATP REGULATION; CORTEX; MODEL	Working memory, which is dependent on higher-order executive function in the prefrontal cortex, is often disrupted in patients exposed to blast overpressure. In this study, we evaluated working memory and medial prefrontal neurochemical status in a rat model of blast neurotrauma. Adult male Sprague-Dawley rats were anesthetized with 3% isoflurane and exposed to calibrated blast overpressure (17 psi, 117 kPa) while sham animals received only anesthesia. Early neurochemical effects in the prefrontal cortex included a significant decrease in betaine (trimethylglycine) and an increase in GABA at 24 h, and significant increases in glycerophosphorylcholine, phosphorylethanolamine, as well as glutamate/creatine and lactate/creatine ratios at 48 h. Seven days after blast, only myo-inositol levels were altered showing a 15% increase. Compared to controls, short-term memory in the novel object recognition task was significantly impaired in animals exposed to blast overpressure. Working memory in control animals was negatively correlated with myo-inositol levels (r = -.759, p < 0.05), an association that was absent in blast exposed animals. Increased myo-inositol may represent tardive glial scarring in the prefrontal cortex, a notion supported by GFAP changes in this region after blast overexposure as well as clinical reports of increased myo-inositol in disorders of memory. (C) 2014 Elsevier Inc All rights reserved.	[Sajja, Venkata Siva Sai Sujith; Hall, Christina S.; VandeVord, Pamela J.] Virginia Polytech & State Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24060 USA; [Perrine, Shane A.; Ghoddoussi, Farhad; Galloway, Matthew P.] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA; [Ghoddoussi, Farhad; Galloway, Matthew P.] Wayne State Univ, Sch Med, Dept Anesthesiol, Detroit, MI USA; [VandeVord, Pamela J.] Salem VA Med Ctr, Res & Dev Serv, Salem, VA USA	VandeVord, PJ (corresponding author), Virginia Polytech & State Univ, Sch Biomed Engn & Sci, 447 ICTAS Bldg,Stanger St, Blacksburg, VA 24060 USA.	pvord@vt.edu	Sajja, Sujith/I-5289-2019	Sajja, Sujith/0000-0002-1992-9501; Galloway, Matthew/0000-0002-7856-9606	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0207]	We would like to thank Ms. Megan Roberts in assisting with the behavioral experiments, the WSU Bioengineering Center Staff for assisting with the blast testing, especially Dr. Bin Wu and Mr. James Kopaz. This project was partially funded by the Department of Defense (Award no. W81XWH-08-2-0207).	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; An SJ, 2003, J NEUROSCI RES, V71, P534, DOI 10.1002/jnr.10502; Andrade CS, 2011, EPILEPSIA, V52, P2276, DOI 10.1111/j.1528-1167.2011.03281.x; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bolanos JP, 2010, TRENDS BIOCHEM SCI, V35, P145, DOI 10.1016/j.tibs.2009.10.006; Bosco D, 2011, J CELL MOL MED, V15, P1807, DOI 10.1111/j.1582-4934.2011.01318.x; Brown JW, 2011, NEUROIMAGE, V57, P314, DOI 10.1016/j.neuroimage.2011.04.028; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cheng LL, 1997, P NATL ACAD SCI USA, V94, P6408, DOI 10.1073/pnas.94.12.6408; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Ciccarelli O., 2014, ANN NEUROL; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Di Costanzo A, 2007, EUR RADIOL, V17, P1651, DOI 10.1007/s00330-006-0546-1; Eagle AL, 2013, BEHAV BRAIN RES, V256, P591, DOI 10.1016/j.bbr.2013.09.014; Ebrahimi F, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-89; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Fan YQ, 2012, INT J BIOL MACROMOL, V51, P845, DOI 10.1016/j.ijbiomac.2012.07.026; Forster DM, 2012, NMR BIOMED, V25, P52, DOI 10.1002/nbm.1712; Goldstein LE, 1996, J NEUROSCI, V16, P4787; Groenewegen HJ, 1997, J PSYCHOPHARMACOL, V11, P99, DOI 10.1177/026988119701100202; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Holtzman D, 1997, AM J PHYSIOL-CELL PH, V272, pC1567; Hur YS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011973; Jenkins BG, 1999, CURR OPIN NEUROL, V12, P753, DOI 10.1097/00019052-199912000-00016; KASSER TR, 1985, AM J PHYSIOL, V248, pR453; Kekelidze T, 2001, J NEUROSCI RES, V66, P866, DOI 10.1002/jnr.10060; Kelm MK, 2010, NEUROPHARMACOLOGY, V58, P1179, DOI 10.1016/j.neuropharm.2010.02.018; Koenigs M, 2012, REV NEUROSCIENCE, V23, P253, DOI 10.1515/revneuro-2012-0036; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi E., 2012, FRONT NEUROL, V3, P11; Lassmann H, 2011, FEBS LETT, V585, P3715, DOI 10.1016/j.febslet.2011.08.004; Li ZY, 2008, J LIPID RES, V49, P1187, DOI 10.1194/jlr.R700019-JLR200; Mamelak M, 2012, J ALZHEIMERS DIS, V31, P459, DOI 10.3233/JAD-2012-120370; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Moore Gregory J, 2002, Psychopharmacol Bull, V36, P5; Nelson TJ, 2008, EUR J PHARMACOL, V585, P76, DOI 10.1016/j.ejphar.2008.01.051; Nucci-Da-Silva MP, 2009, BRAIN INJURY, V23, P707, DOI 10.1080/02699050903123351; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Paling D, 2011, J NEUROL, V258, P2113, DOI 10.1007/s00415-011-6117-7; PASSE TJ, 1995, PROG NEURO-PSYCHOPH, V19, P541, DOI 10.1016/0278-5846(95)00101-Z; Patel AB, 2005, P NATL ACAD SCI USA, V102, P5588, DOI 10.1073/pnas.0501703102; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Pocernich CB, 2012, BBA-MOL BASIS DIS, V1822, P625, DOI 10.1016/j.bbadis.2011.10.003; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Rushworth MFS, 2011, NEURON, V70, P1054, DOI 10.1016/j.neuron.2011.05.014; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Saljo A., 2009, J NEUROTRAUM, V25, P1397; Schousboe A, 2003, NEUROCHEM INT, V43, P311, DOI 10.1016/S0197-0186(03)00017-2; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Song D, 2008, PSYCHOPHARMACOLOGY, V200, P187, DOI 10.1007/s00213-008-1194-8; STRANGE K, 1994, GLIA, V12, P35, DOI 10.1002/glia.440120105; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Suzuki T, 2012, EUR J NEUROSCI, V36, P3653, DOI 10.1111/j.1460-9568.2012.08280.x; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thierry AM, 2000, HIPPOCAMPUS, V10, P411, DOI 10.1002/1098-1063(2000)10:4<411::AID-HIPO7>3.0.CO;2-A; Tuinstra HM, 2013, BIOTECHNOL BIOENG, V110, P947, DOI 10.1002/bit.24750; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Vertes RP, 2006, NEUROSCIENCE, V142, P1, DOI 10.1016/j.neuroscience.2006.06.027; Wilcox CS, 2010, PHARMACOL THERAPEUT, V126, P119, DOI 10.1016/j.pharmthera.2010.01.003; Wilson M, 2013, EUR J CANCER, V49, P457, DOI 10.1016/j.ejca.2012.09.002; Yang MX, 2012, TALANTA, V88, P136, DOI 10.1016/j.talanta.2011.10.022; Yoon SJ, 2005, CLIN REHABIL, V19, P209, DOI 10.1191/0269215505cr813oa	74	25	25	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAR	2014	59						119	126		10.1016/j.mcn.2014.02.004			8	Neurosciences	Neurosciences & Neurology	AH7TP	WOS:000336338400012	24534010				2021-06-18	
J	Shivaji, T; Lee, A; Dougall, N; McMillan, T; Stark, C				Shivaji, Tara; Lee, Andrew; Dougall, Nadine; McMillan, Thomas; Stark, Cameron			The epidemiology of hospital treated traumatic brain injury in Scotland	BMC NEUROLOGY			English	Article						Traumatic brain injury; Accidental falls; Patient admissions; Epidemiology; Scotland; Trends	HEAD-INJURY; OLDER-ADULTS; TRENDS; ENGLAND; POPULATION; ADMISSION; SUICIDE; PEOPLE; IMPACT; STAY	Background: Traumatic Brain Injury (TBI) is an important global public health problem made all the more important by the increased likelihood of disability following a hospital admission for TBI. Understanding those groups most at risk will help inform interventions designed to prevent causes of TBI, such as falls prevention measures. This study identifies the rate of hospitalisation episodes of TBI in Scotland, explores causes of TBI admissions, and trends in hospitalisation episodes by age and gender over a twelve year period using routinely collected hospital data. Methods: A retrospective analysis of routine hospital episode data identified records relating to TBI for the twelve years between 1998 and 2009. Descriptive and joinpoint regression analysis were used, average annual percentage changes (AAPC) and annual percentage change (APC) in rates were calculated. Results: Between 1998 and 2009 there were 208,195 recorded episodes of continuous hospital care in Scotland as a result of TBI. Almost half (47%) of all TBIs were the result of falls, with marked peaks observed in the very young and the oldest groups. The AAPC of hospitalization episode rates over the study period for boys and girls aged 0-14 were -4.9% (95% CI -3.5 to-6.3) and -4.7% (95% CI -2.6 to -6.8) respectively. This reduction was not observed in older age groups. In women aged 65 and over there was an APC of 3.9% (95% CI 1.2 to 6.6) between 2004 and 2009. Conclusions: Hospitalisation for TBI is relatively common in Scotland. The rise in the age-adjusted rate of hospitalisation episodes observed in older people indicates that reduction of TBI should be a public health priority in countries with an ageing population. Public health interventions such as falls prevention measures are well advised and evaluations of such interventions should consider including TBI hospitalisation as an alternative or supplementary outcome measure to fractured neck of femur. Further research is needed to advance understanding of the associations of risk factors with increased incidence of TBI hospital episodes in the elderly population.	[Shivaji, Tara; Stark, Cameron] NHS Highland, Dept Publ Hlth, Inverness IV2 3BW, Scotland; [Lee, Andrew] NHS Natl Serv Scotland, Informat Serv Div, Edinburgh EH12 9EB, Midlothian, Scotland; [Dougall, Nadine] Univ Stirling, Sch Nursing Midwifery & Hlth, NMAHP Res Unit, Stirling FK9 4NF, Scotland; [McMillan, Thomas] Univ Glasgow, Gartnavel Royal Hosp, Coll Med Vet & Life Sci, Inst Hlth & Wellbeing, Glasgow G12 0XH, Lanark, Scotland; [Stark, Cameron] Univ Aberdeen, Ctr Hlth Sci, Ctr Rural Hlth, Inverness IV2 3JH, Scotland	Dougall, N (corresponding author), Univ Stirling, Sch Nursing Midwifery & Hlth, NMAHP Res Unit, Unit 13 Sc House, Stirling FK9 4NF, Scotland.	nadine.dougall@stir.ac.uk	Stark, Cameron R/D-5874-2017; Dougall, Nadine J/O-8145-2015	Stark, Cameron R/0000-0003-1255-7415; Dougall, Nadine J/0000-0003-3462-6960	Chief Scientist Office [NMAHP1] Funding Source: Medline		Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Bajaj A, 2010, WIEN KLIN WOCHENSCHR, V122, P346, DOI 10.1007/s00508-010-1394-1; Bellner J, 2003, J NEUROL NEUROSUR PS, V74, P351, DOI 10.1136/jnnp.74.3.351; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P272; Dunn L, 2003, J NEUROL NEUROSUR PS, V74, P1060, DOI 10.1136/jnnp.74.8.1060; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kempton A, 2000, HEALTH PROMOT INT, V15, P27, DOI 10.1093/heapro/15.1.27; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Langlios JA, 2006, TRAUMATIC BRAIN INJU; Lopez-Campos JL, 2013, INT J TUBERC LUNG D, V17, P131, DOI 10.5588/ijtld.12.0419; Marr A, 2002, CENTRAL NERVOUS SYST; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; McClure R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004441.pub2; McKee M, 2003, UNDERSTANDING HLTH S; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nichols M, 2013, EUR HEART J, V34, P3017, DOI 10.1093/eurheartj/eht159; OECD / European Union, 2018, HLTH GLANC EUR 2010, DOI [10.1787/health_glance-2010-en, DOI 10.1787/HEALTH_GLANCE-2010-EN]; Ponsky TA, 2005, J TRAUMA, V59, P1292, DOI 10.1097/01.ta.0000197439.19171.25; Saxena S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007484; Scottish Intercollegiate Guidelines Network, 2009, EARL MAN PAT HEAD IN; Shravat BP, 2006, EMERG MED J, V23, P109, DOI 10.1136/emj.2004.022327; Stark C, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-80; Stavrinides V, 2010, ONLINE J CLIN AUDITS, V2; Stephenson S, 2005, ACCIDENT ANAL PREV, V37, P825, DOI 10.1016/j.aap.2005.03.024; Swann IJ, 2001, EMERG MED J, V18, P352, DOI 10.1136/emj.18.5.352; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tennant A, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-21; Thomas K, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-314; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P1631; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	41	25	26	0	18	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	JAN 6	2014	14								2	10.1186/1471-2377-14-2			7	Clinical Neurology	Neurosciences & Neurology	294QV	WOS:000330062800001	24386897	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Beurskens, CJ; Horn, J; de Boer, AMT; Schultz, MJ; van Leeuwen, EMM; Vroom, MB; Juffermans, NP				Beurskens, Charlotte J.; Horn, Janneke; de Boer, Anita M. Tuip; Schultz, Marcus J.; van Leeuwen, Ester M. M.; Vroom, Margreeth B.; Juffermans, Nicole P.			Cardiac arrest patients have an impaired immune response, which is not influenced by induced hypothermia	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; INDUCED LUNG INJURY; THERAPEUTIC HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; MILD HYPOTHERMIA; SEPTIC SHOCK; REDUCES EXPRESSION; RISK-FACTORS; RATS; FEVER	Introduction: Induced hypothermia is increasingly applied as a therapeutic intervention in ICUs. One of the underlying mechanisms of the beneficial effects of hypothermia is proposed to be reduction of the inflammatory response. However, a fear of reducing the inflammatory response is an increased infection risk. Therefore, we studied the effect of induced hypothermia on immune response after cardiac arrest. Methods: A prospective observational cohort study in a mixed surgical-medical ICU. Patients admitted at the ICU after surviving cardiac arrest were included and during 24 hours body temperature was strictly regulated at 33 degrees C or 36 degrees C. Blood was drawn at three time points: after reaching target temperature, at the end of the target temperature protocol and after rewarming to 37 degrees C. Plasma cytokine levels and response of blood leucocytes to stimulation with toll-like receptor (TLR) ligands lipopolysaccharide (LPS) from Gram-negative bacteria and lipoteicoic acid (LTA) from Gram-positive bacteria were measured. Also, monocyte HLA-DR expression was determined. Results: In total, 20 patients were enrolled in the study. Compared to healthy controls, cardiac arrest patients kept at 36 degrees C (n = 9) had increased plasma cytokines levels, which was not apparent in patients kept at 33 degrees C (n = 11). Immune response to TLR ligands in patients after cardiac arrest was generally reduced and associated with lower HLA-DR expression. Patients kept at 33 degrees C had preserved ability of immune cells to respond to LPS and LTA compared to patients kept at 36 degrees C. These differences disappeared over time. HLA-DR expression did not differ between 33 degrees C and 36 degrees C. Conclusions: Patients after cardiac arrest have a modest systemic inflammatory response compared to healthy controls, associated with lower HLA-DR expression and attenuated immune response to Gram-negative and Gram-positive antigens, the latter indicative of an impaired immune response to bacteria. Patients with a body temperature of 33 degrees C did not differ from patients with a body temperature of 36 degrees C, suggesting induced hypothermia does not affect immune response in patients with cardiac arrest.	[Beurskens, Charlotte J.; de Boer, Anita M. Tuip; Schultz, Marcus J.; Juffermans, Nicole P.] Univ Amsterdam, Acad Med Ctr, Lab Expt Intens Care & Anaesthesiol, NL-1105 AZ Amsterdam, Netherlands; [Beurskens, Charlotte J.; Horn, Janneke; Schultz, Marcus J.; Vroom, Margreeth B.; Juffermans, Nicole P.] Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1105 AZ Amsterdam, Netherlands; [van Leeuwen, Ester M. M.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands; [Beurskens, Charlotte J.] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, LEICA, NL-1105 AZ Amsterdam, Netherlands	Beurskens, CJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Expt Intens Care & Anaesthesiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	c.j.beurskens@amc.nl	Schultz, Marcus/AAB-6379-2021	Schultz, Marcus/0000-0003-3969-7792	NWO ZonMW Clinical Fellowship [90700269]	NWO ZonMW Clinical Fellowship to Dr. N. P. Juffermans. (Project number: 90700269). Funding did not influence the design, data collection, analysis, data interpretation, writing or the decision to submit the manuscript for publication.	Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Arts D, 2002, INTENS CARE MED, V28, P656, DOI 10.1007/s00134-002-1272-z; Bekeredjian-Ding I, 2009, IMMUNOLOGY, V128, P311, DOI 10.1111/j.1365-2567.2009.03173.x; BERNHEIM HA, 1976, SCIENCE, V193, P237, DOI 10.1126/science.935867; Beurskens CJ, 2012, CRIT CARE MED, V40, P319; BIGGAR WD, 1986, J APPL PHYSIOL, V60, P1186; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; Bisschops LLA, 2012, CRIT CARE MED, V40, P1136, DOI 10.1097/CCM.0b013e3182377050; Chin JY, 2007, ANESTH ANALG, V104, P1171, DOI 10.1213/01.ane.0000260316.95836.1c; Chu SJ, 2005, CHEST, V128, P327, DOI 10.1016/S0012-3692(15)37965-4; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; Fumeaux T, 2002, AM J RESP CRIT CARE, V166, P1475, DOI 10.1164/rccm.200203-217OC; Geurts M, 2014, CRIT CARE MED, V42, P231, DOI 10.1097/CCM.0b013e3182a276e8; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jiang QQ, 2000, INFECT IMMUN, V68, P1265, DOI 10.1128/IAI.68.3.1265-1270.2000; Kamps M, 2011, CRIT CARE, V15, DOI 10.1186/cc10012; Kimura A, 2002, CRIT CARE MED, V30, P1499, DOI 10.1097/00003246-200207000-00017; Kira S, 2005, ACTA ANAESTH SCAND, V49, P351, DOI 10.1111/j.1399-6576.2005.00593.x; KLASTERS.J, 1970, J INFECT DIS, V121, P81, DOI 10.1093/infdis/121.1.81; Kluger MJ, 1996, INFECT DIS CLIN N AM, V10, P1, DOI 10.1016/S0891-5520(05)70282-8; L'Her E, 2006, CRIT CARE MED, V34, P2621, DOI 10.1097/01.CCM.0000240231.76837.DC; Lim CM, 2003, INTENS CARE MED, V29, P453, DOI 10.1007/s00134-002-1529-6; Lukaszewicz AC, 2009, CRIT CARE MED, V37, P2746, DOI 10.1097/CCM.0b013e3181ab858a; Meybohm P, 2010, CRIT CARE, V14, DOI 10.1186/cc8879; Monneret G, 2002, CLIN CHEM, V48, P1589; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Perbet S, 2011, AM J RESP CRIT CARE, V184, P1048, DOI 10.1164/rccm.201102-0331OC; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Qadan M, 2009, ANN SURG, V250, P134, DOI 10.1097/SLA.0b013e3181ad85f7; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; RAO V, 1995, J CARDIAC SURG, V10, P468, DOI 10.1111/j.1540-8191.1995.tb00679.x; Rees K, 2001, COCHRANE DATABASE SY, V1, pCD002138; RELLO J, 1995, CLIN INFECT DIS, V21, P310, DOI 10.1093/clinids/21.2.310; Sarcia PJ, 2003, SHOCK, V20, P41, DOI 10.1097/01.shk.0000071080.50028.f2; Schortgen F, 2012, AM J RESP CRIT CARE, V185, P1088, DOI 10.1164/rccm.201110-1820OC; Skrzeczynska-Moncznik J, 2008, SCAND J IMMUNOL, V67, P152, DOI 10.1111/j.1365-3083.2007.02051.x; Su FH, 2005, SHOCK, V23, P516, DOI 10.1097/01.shk.000161390.46688.da; Taniguchi T, 2003, CLIN DIAGN LAB IMMUN, V10, P940, DOI 10.1128/CDLI.10.5.940-943.2003; Torossian A, 2004, CRIT CARE MED, V32, P1899, DOI 10.1097/01.CCM.0000139608.34486.FD; Tsai MS, 2005, INTENS CARE MED, V31, P621, DOI 10.1007/s00134-005-2612-6; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	46	25	26	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2014	18	4							R162	10.1186/cc14002			9	Critical Care Medicine	General & Internal Medicine	CA4MJ	WOS:000348878200046	25078879	DOAJ Gold, Green Published			2021-06-18	
J	Chen, SH; Wang, JJ; Chen, CH; Chang, HK; Lin, MT; Chang, FM; Chio, CC				Chen, Sheng-Hsien; Wang, Jhi-Joung; Chen, Chung-Hwan; Chang, Hsiu-Kang; Lin, Mao-Tsun; Chang, Fong-Ming; Chio, Chung-Ching			Umbilical Cord Blood-Derived CD34(+) Cells Improve Outcomes of Traumatic Brain Injury in Rats by Stimulating Angiogenesis and Neurogenesis	CELL TRANSPLANTATION			English	Article						Traumatic brain injury; CD34(+) cells; Apoptosis; Cytokines; Angiogenesis; Neurogenesis; Progenitor cells	MARROW STROMAL CELLS; MESENCHYMAL STEM-CELLS; INTESTINAL ISCHEMIA-REPERFUSION; HYPERBARIC-OXYGEN THERAPY; EXCITATORY AMINO-ACIDS; EXPERIMENTAL HEATSTROKE; NEUROTROPHIC FACTORS; CEREBRAL-ISCHEMIA; PROGENITOR CELLS; HEAD-INJURY	Human umbilical cord blood cells (HUCBCs) have been shown to be beneficial in reducing neurological deficits in rats with brain fluid percussion injury (FPI). This study aimed to assess the basic mechanisms underlying the neuroprotective effects of HUCBC-derived cluster of differentiation 34-positive (CD34(+)) cells. Rats were divided into three major groups: (i) sham-operated controls; (ii) FPI rats treated with phosphate-buffered saline (PBS); (iii) FPI rats treated with 0.2%, 50%, or 95% CD34(+) cells (in 5 x 10(5) cord blood lymphocytes and monocytes). Intravenous (IV) administration of 0.3 ml of PBS, 0.2% CD34(+) cells, 50% CD34(+) cells, or 95% CD34(+) cells was conducted immediately after FPI. It was found that 4 days post-FPI, CD34(+) cells could be detected in the ischemic brain tissues for 50% CD34(+) cell- or 95% CD34(+) cell-treated FPI rats, but not for the PBS-treated FPI rats or the 0.2% CD34(+) cell-treated FPI rats. CD34(+) cell (0.2%)-treated FPI rats or PBS-treated FPI rats displayed neurological and motor deficits, cerebral contusion and apoptosis [e.g., increased numbers of both TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling)-positive cells and caspase-3-positive cells], and activated inflammation (e.g., increased serum levels of tumor necrosis factor-alpha). FPI-induced neurological motor dysfunction, cerebral contusion and apoptosis, and activated inflammation could be attenuated by 50% CD34(+) or 95% CD34(+) cell therapy. In addition 50% or 95% CD34(+) cell therapy but not PBS or 0.2% CD34(+) cell therapy significantly promoted angiogenesis (e.g., increased numbers of both vasculoendothelial growth factor-positive cells and 5-bromodeoxyuridine (BrdU)-endothelial double-positive cells), neurogenesis (e.g., increased numbers of both glial cell line-derived neurotrophic factor-positive cells and BrdU/neuronal nuclei double-positive cells) in the ischemic brain after FPI, and migration of endothelial progenitor cells from the bone marrow. Our data suggest that IV administration of HUCBC-derived CD34(+) cells may improve outcomes of FPI in rats by stimulating both angiogenesis and neurogenesis.	[Chen, Sheng-Hsien] Da An Hosp Women & Children, Tainan, Taiwan; [Chen, Sheng-Hsien] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Wang, Jhi-Joung; Lin, Mao-Tsun] Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan; [Chen, Chung-Hwan] Kaohsiung Med Univ, Dept Orthoped, Kaohsiung, Taiwan; [Chang, Hsiu-Kang] Hlth Banks Biotech Co Ltd, Stem Cell Res Ctr, Taipei, Taiwan; [Chang, Fong-Ming] Natl Cheng Kung Univ, Sch Med, Dept Obstet & Gynecol, Tainan 70101, Taiwan; [Chio, Chung-Ching] Chi Mei Med Ctr, Dept Surg, Tainan 710, Taiwan	Chio, CC (corresponding author), Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan.	891201@mail.chimei.org.tw	Chen, Chung-Hwan/D-4036-2009	Chen, Chung-Hwan/0000-0001-8941-4792	National Science Council of the Republic of ChinaMinistry of Science and Technology, Taiwan [NSC100-2314-B-218-001, NSC 102-2314-B-218-001-MY2, NSC99-2314-B-218-006-MY2]; Department of Health of the Republic of China (Center of Excellence for Clinical Trial and Research in Neuroscience) [DOH99-TD-B-111-003]	This study was funded in part by the National Science Council of the Republic of China (Grant Nos. NSC100-2314-B-218-001, NSC 102-2314-B-218-001-MY2, and NSC99-2314-B-218-006-MY2) and the Department of Health of the Republic of China (DOH99-TD-B-111-003, Center of Excellence for Clinical Trial and Research in Neuroscience). The authors declare no conflict of interest.	BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen SH, 2005, CRIT CARE MED, V33, P1377, DOI 10.1097/01.CCM.0000165966.28936.89; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Cheng BC, 2007, NEUROPHARMACOLOGY, V52, P297, DOI 10.1016/j.neuropharm.2006.07.033; Chio C.C., 2012, SCIENCE S, V338, P1485; Chio C.C., 2012, SCIENCE S, V338, P59; Chou YT, 2003, SHOCK, V19, P388, DOI 10.1097/00024382-200304000-00016; Dennis JE, 2002, STEM CELLS, V20, P205, DOI 10.1634/stemcells.20-3-205; DRAGO J, 1991, P NATL ACAD SCI USA, V88, P2199, DOI 10.1073/pnas.88.6.2199; Elfenbein GJ, 2004, EXP HEMATOL, V32, P327, DOI 10.1016/j.exphem.2004.01.010; Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Galvin-Parton PA, 2003, PEDIATR TRANSPLANT, V7, P83, DOI 10.1034/j.1399-3046.2003.00032.x; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Ha Y, 2001, NEUROREPORT, V12, P3523, DOI 10.1097/00001756-200111160-00030; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kuo JR, 2010, J TRAUMA, V69, P1467, DOI 10.1097/TA.0b013e3181f31b06; Kuzu MA, 2002, AM J SURG, V183, P70, DOI 10.1016/S0002-9610(01)00846-7; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li Y, 2000, J HEMATOTH STEM CELL, V9, P445, DOI 10.1089/152581600419107; Lian QZ, 2010, CIRCULATION, V121, P1113, DOI 10.1161/CIRCULATIONAHA.109.898312; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Liu WS, 2009, PEDIATR NEONATOL, V50, P208, DOI 10.1016/S1875-9572(09)60065-6; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Murasawa S, 2005, PHYSIOLOGY, V20, P36, DOI 10.1152/physiol.00033.2004; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Olanders K, 2002, SHOCK, V18, P86, DOI 10.1097/00024382-200207000-00016; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Quinones-Hinojosa A, 2006, J COMP NEUROL, V494, P415, DOI 10.1002/cne.20798; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Saporta S, 2003, J HEMATOTH STEM CELL, V12, P271, DOI 10.1089/152581603322023007; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shyu WC, 2006, J NEUROSCI, V26, P3444, DOI 10.1523/JNEUROSCI.5165-05.2006; Staimirovic D., 2000, BRAIN PATHOL, V10, P113; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Walczak P, 2004, J NEUROSCI RES, V76, P244, DOI 10.1002/jnr.20042; Wang Y, 1997, J NEUROSCI, V17, P4341; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Wu JY, 2008, J PINEAL RES, V45, P106, DOI 10.1111/j.1600-079X.2008.00567.x; Wyble CW, 1996, J SURG RES, V63, P333, DOI 10.1006/jsre.1996.0271; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yunoki M, 1998, ACT NEUR S, V71, P142; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	75	25	25	0	9	COGNIZANT COMMUNICATION CORP	PUTNAM VALLEY	18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2014	23	8					959	979		10.3727/096368913X667006			21	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	AN7YB	WOS:000340815800004	23582375	Bronze			2021-06-18	
J	Choi, BY; Kim, JH; Kim, HJ; Lee, BE; Kim, IY; Sohn, M; Suh, SW				Choi, Bo Young; Kim, Jin Hee; Kim, Hyun Jung; Lee, Bo Eun; Kim, In Yeol; Sohn, Min; Suh, Sang Won			Zinc chelation reduces traumatic brain injury-induced neurogenesis in the subgranular zone of the hippocampal dentate gyrus	JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY			English	Article; Proceedings Paper	10th Meeting of the International-Society-for-Trace-Element-Research-in-Humans (ISTERH)10th International Society for Trace Element Research in Humans (ISTERH)	NOV 18-22, 2013NOV 18-22, 2013	Tokyo, JAPANTokyo, JAPAN	Int Soc Trace Element Res Humans		Traumatic brain injury; Zinc; Hippocampus; Neurogenesis; Clioquinol	HYPOGLYCEMIC NEURONAL DEATH; GENERATED GRANULE CELLS; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; CORTICAL NEUROGENESIS; CEREBRAL-ISCHEMIA; CHELATABLE ZINC; MEMORY DEFICITS; MICE; PROLIFERATION	Numerous studies have demonstrated that traumatic brain injury (TBI) increases hippocampal neurogenesis in the rodent brain. However, the mechanisms underlying increased neurogenesis after TBI remain unknown. Continuous neurogenesis occurs in the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG) in the adult brain. The mechanism that maintains active neurogenesis in the hippocampal area is not known. A high level of vesicular zinc is localized in the presynaptic terminals of the SGZ (mossy fiber). The mossy fiber of dentate granular cells contains high levels of chelatable zinc in their terminal vesicles, which can be released into the extracellular space during neuronal activity. Previously, our lab presented findings indicating that a possible correlation may exist between synaptic zinc localization and high rates of neurogenesis in this area after hypoglycemia or epilepsy. Using a weight drop animal model to mimic human TBI, we tested our hypothesis that zinc plays a key role in modulating hippocampal neurogenesis after TBI. Thus, we injected a zinc chelator, clioquinol (CQ 30 mg/kg), into the intraperitoneal space to reduce brain zinc availability twice per day for 1 week. Neuronal death was evaluated with Fluoro Jade-B and NeuN staining to determine whether CQ has neuroprotective effects after TBI. The number of degenerating neurons (FJB (+)) and live neurons (NeuN (+)) was similar in vehicle and in CQ-treated rats at 1 week after TBI. Neurogenesis was evaluated using BrdU, Ki67 and doublecortin (DCX) immunostaining 1 week after TBI. The number of BrdU, Ki67 and DCX positive cell was increased after TBI. However, the number of BrdU, Ki67 and DCX positive cells was significantly decreased by CQ treatment. The present study shows that zinc chelation did not prevent neurodegeneration but did reduce TBI-induced progenitor cell proliferation and neurogenesis. Therefore, this study suggests that zinc has an essential role for modulating hippocampal neurogenesis after TBI. (C) 2014 Elsevier GmbH. All rights reserved.	[Choi, Bo Young; Kim, Jin Hee; Kim, Hyun Jung; Lee, Bo Eun; Kim, In Yeol; Suh, Sang Won] Hallym Univ, Dept Physiol, Coll Med, Chunchon, South Korea; [Sohn, Min] Inha Univ, Dept Nursing, Inchon, South Korea	Suh, SW (corresponding author), Hallym Univ, Dept Physiol, Coll Med, Chunchon, South Korea.	swsuh@hallym.ac.kr		SOHN, MIN/0000-0003-4021-2051; Choi, Bo Young/0000-0002-9579-3503	National Research Foundation of Korea (NRF) - Korea government (MEST)Ministry of Education, Science and Technology, Republic of KoreaNational Research Foundation of KoreaKorean Government [2012R1A2A2A01040132]; Hallym University Specialization Fund [HRF-S-51]	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (2012R1A2A2A01040132) and by Hallym University Specialization Fund (HRF-S-51). The authors thank Aaron M. Hamby, University of California, Berkeley, for help with preparing the manuscript.	Aballay A, 1995, BIOCHEM J, V312, P919, DOI 10.1042/bj3120919; Adlard PA, 2010, J NEUROSCI, V30, P1631, DOI 10.1523/JNEUROSCI.5255-09.2010; Adlard Paul Anthony, 2012, Front Psychiatry, V3, P15, DOI 10.3389/fpsyt.2012.00015; APOSHIAN HV, 1995, TOXICOLOGY, V97, P23, DOI 10.1016/0300-483X(95)02965-B; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Colvin RA, 2008, AM J PHYSIOL-CELL PH, V294, pC726, DOI 10.1152/ajpcell.00541.2007; DANSCHER G, 1985, J HISTOCHEM CYTOCHEM, V33, P706, DOI 10.1177/33.7.4008918; DVERGSTEN CL, 1983, BRAIN RES, V271, P217, DOI 10.1016/0006-8993(83)90284-6; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; GOLUB MS, 1994, AM J CLIN NUTR, V60, P238; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; HALAS ES, 1983, PHYSIOL BEHAV, V30, P371, DOI 10.1016/0031-9384(83)90140-3; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jo SM, 2000, BRAIN RES, V870, P163, DOI 10.1016/S0006-8993(00)02418-5; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048543; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Leuner B, 2006, HIPPOCAMPUS, V16, P216, DOI 10.1002/hipo.20153; MacDonald RS, 2000, J NUTR, V130, p1500S, DOI 10.1093/jn/130.5.1500S; Magavi SS, 2000, NATURE, V405, P951; Maret W, 2006, J TRACE ELEM MED BIO, V20, P3, DOI 10.1016/j.jtemb.2006.01.006; Markakis EA, 1999, J COMP NEUROL, V406, P449; Martel G, 2011, BEHAV BRAIN RES, V223, P233, DOI 10.1016/j.bbr.2011.04.020; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Nitzan YB, 2003, J MOL MED-JMM, V81, P637, DOI 10.1007/s00109-003-0462-7; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PRASAD AS, 1963, AM J CLIN NUTR, V12, P437, DOI 10.1093/ajcn/12.6.437; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sandstead HH, 2000, J NUTR, V130, p496S, DOI 10.1093/jn/130.2.496S; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SEKI T, 1993, J NEUROSCI, V13, P2351; Sindreu C, 2011, P NATL ACAD SCI USA, V108, P3366, DOI 10.1073/pnas.1019166108; STEWART GR, 1984, BRAIN RES, V290, P43, DOI 10.1016/0006-8993(84)90734-0; Suh SW, 2007, GLIA, V55, P1280, DOI 10.1002/glia.20440; Suh SW, 2009, J CEREBR BLOOD F MET, V29, P1579, DOI 10.1038/jcbfm.2009.80; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2005, DIABETES, V54, P500, DOI 10.2337/diabetes.54.2.500; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 2003, J NEUROSCI, V23, P10681; Suh SW, 1999, J HISTOCHEM CYTOCHEM, V47, P969, DOI 10.1177/002215549904700715; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	59	25	25	0	6	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0946-672X			J TRACE ELEM MED BIO	J. Trace Elem. Med. Biol.		2014	28	4			SI		474	481		10.1016/j.jtemb.2014.07.007			8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AX8AW	WOS:000347133800024	25200616				2021-06-18	
J	Cook, LG; Chapman, SB; Elliott, AC; Evenson, NN; Vinton, K				Cook, Lori G.; Chapman, Sandra B.; Elliott, Alan C.; Evenson, Nellie N.; Vinton, Kami			Cognitive gains from gist reasoning training adolescents with chronic-stage traumatic brain injury	FRONTIERS IN NEUROLOGY			English	Article						adolescence; brain injury; cognitive plasticity; cognitive training; complex information; executive function; frontal lobe; reasoning		Adolescents with traumatic brain injury (TBI) typically demonstrate good recovery of previously acquired skills. However, higher-order and later emergent cognitive functions are often impaired and linked to poor outcomes in academic and social/behavioral domains. Few control trials exist that test cognitive treatment effectiveness at chronic recovery stages. The current pilot study compared the effects of two forms of cognitive training, gist reasoning (top-down) versus rote memory learning (bottom-up), on ability to abstract meanings, recall facts, and utilize core executive functions (i.e., working memory, inhibition) in 20 adolescents (ages 12-20) who were 6 months or longer post-TBI. Participants completed eight 45-min sessions over 1 month. After training, the gist reasoning group (n = 10) exhibited significant improvement in ability to abstract meanings and increased fact recall. This group also showed significant generalizations to untrained executive functions of working memory and inhibition. The memory training group (n = 10) failed to show significant gains in ability to abstract meaning or on other untrained specialized executive functions, although improved fact recall approached significance. These preliminary results suggest that relatively short-term training (6 h) utilizing a top-down reasoning approach is more effective than a bottom-up rote learning approach in achieving gains in higher-order cognitive abilities in adolescents at chronic stages of TBI. These findings need to be replicated in a larger study; nonetheless, the preliminary data suggest that traditional cognitive intervention schedules need to extend to later-stage training opportunities. Chronic-stage, higher-order cognitive trainings may serve to elevate levels of cognitive performance in adolescents with TBI.	[Cook, Lori G.; Chapman, Sandra B.; Evenson, Nellie N.; Vinton, Kami] Univ Texas Dallas, Ctr Brain Hlth, 2200 West,Mockingbird Lane, Dallas, TX 75235 USA; [Cook, Lori G.; Chapman, Sandra B.] Univ Texas Dallas, Sch Behav & Brain Sci, Dallas, TX 75235 USA; [Elliott, Alan C.] So Methodist Univ, Dept Stat Sci, Dallas, TX 75275 USA	Cook, LG (corresponding author), Univ Texas Dallas, Ctr Brain Hlth, 2200 West,Mockingbird Lane, Dallas, TX 75235 USA.	lori.cook@utdallas.edu			National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21-HD062835]; Crystal Charity Ball Foundation	This work was supported by funding from the National Institute of Child Health and Human Development (R21-HD062835). We would also like to acknowledge the generous support from the Crystal Charity Ball Foundation.	Anand R, 2011, INT J GERIATR PSYCH, V26, P961, DOI 10.1002/gps.2633; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Beller S, 2007, THINK REASONING, V13, P426, DOI 10.1080/13546780701319122; Bjork R. A., 1989, VARIETIES MEMORY CON, P309; Blosser J, 2003, PEDIAT TRAUMATIC BRA; Brainerd CJ, 1996, DEV PSYCHOL, V32, P467, DOI 10.1037/0012-1649.32.3.467; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; BROWN AL, 1983, J VERB LEARN VERB BE, V22, P1, DOI 10.1016/S0022-5371(83)80002-4; Brown AL., 1981, EDUC RESEARCHER, V10, P14, DOI [DOI 10.3102/0013189X010002014, 10.2307/1174401, DOI 10.2307/1174401]; Casey BJ, 2005, TRENDS COGN SCI, V9, P104, DOI 10.1016/j.tics.2005.01.011; Chapman S.B., 2006, BRAIN INJ PROF, V3, P10; Chapman SB, 2015, CEREB CORTEX, V25, P396, DOI 10.1093/cercor/bht234; Chapman SB, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00069; Chapman Sandra B., 2012, ADOLESCENT BRAIN LEA, P123, DOI DOI 10.1037/13493-005; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chapman SB, TEST STRATEGIC LEARN; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cook L. G., 2013, SOCIAL COMMUNICATION, P258; Cook L. G., 2011, SIG 2 PERSPECTIVES N, V21, P33, DOI DOI 10.1044/NNSLD21.1.33; Cook LG, 2007, CHILDRENS COMPREHENS, P218; Cook LG, 2008, NEUROREHABILITATION, V23, P467; COX BD, 1989, DEV PSYCHOL, V25, P619, DOI 10.1037/0012-1649.25.4.619; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gabrieli John D E, 2004, Cerebrum, V6, P39; Gamino JF, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00188; Gamino JF, 2009, TOP LANG DISORD, V29, P224, DOI 10.1097/TLD.0b013e3181b531da; Gamino JF, 2009, INT NEUR SOC ANN M A; Garcia-Madruga JA, 2007, THINK REASONING, V13, P370, DOI [10.1080/13546780701203813, DOI 10.1080/13546780701203813]; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; Kane MJ, 2004, J EXP PSYCHOL GEN, V133, P189, DOI 10.1037/0096-3445.133.2.189; Koehler R, 2011, COGNITIVE REHABILITATION THERAPY FOR TRAUMATIC BRAIN INJURY: EVALUATING THE EVIDENCE, P1; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846; Marschark M., 1989, EUROPEAN J COGNITIVE, V1, P251, DOI DOI 10.1080/09541448908403084; Mayer R.E., 1984, EDUC PSYCHOL, V19, P30, DOI DOI 10.1080/00461528409529279; MAYER RE, 1989, REV EDUC RES, V59, P43, DOI 10.2307/1170446; Motes MA, 2014, BRAIN COGNITION, V84, P44, DOI 10.1016/j.bandc.2013.10.007; PALINCSAR AS, 1988, REM SPEC EDUC, V9, P53, DOI 10.1177/074193258800900110; Reyna VF, 2008, MED DECIS MAKING, V28, P850, DOI 10.1177/0272989X08327066; Reyna VF, 2009, PSYCHOL LEARN MOTIV, V50, P207, DOI 10.1016/S0079-7421(08)00407-6; REYNA VF, 1994, DEV PSYCHOL, V30, P178, DOI 10.1037/0012-1649.30.2.178; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Tenenbaum JB, 2006, TRENDS COGN SCI, V10, P309, DOI 10.1016/j.tics.2006.05.009; Tuthill S, 2013, COGN NEUR SOC C SAN; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; Van Dijk T.A., 1983, STRATEGIES DISCOURSE; VANDIJK TA, 1995, DISCOURSE COMPREHENSION, P383; Vas AK, 2011, J HEAD TRAUMA REHAB, V26, P224, DOI 10.1097/HTR.0b013e318218dd3d; Verhaeghen P, 1996, PSYCHOL AGING, V11, P164, DOI 10.1037/0882-7974.11.1.164; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M	65	25	25	0	10	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								87	10.3389/fneur.2014.00087			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QW	WOS:000209629300086	24966850	DOAJ Gold, Green Published			2021-06-18	
J	Henden, PL; Sondergaard, S; Rydenhag, B; Reinsfelt, B; Ricksten, SE; Aring;neman, A				Henden, Pia Lowhagen; Sondergaard, Soren; Rydenhag, Bertil; Reinsfelt, Bjorn; Ricksten, Sven-Erik; Aneman, Anders			Can Baroreflex Sensitivity and Heart Rate Variability Predict Late Neurological Outcome in Patients With Traumatic Brain Injury?	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						traumatic brain injury; baroreflex sensitivity; heart rate variability; autonomic dysfunction; neurointensive care	INTRACRANIAL HYPERTENSION; PRESSURE VARIABILITY; SPECTRAL-ANALYSIS; BLOOD-PRESSURE; NERVE ACTIVITY; LUND CONCEPT; PROPOFOL; ANESTHESIA; INDUCTION; DEATH	Background:Previous studies have suggested that depressed heart rate variability (HRV) and baroreflex sensitivity (BRS) are associated with early mortality and morbidity in patients with acute brain injuries of various etiologies. The aim of the present study was to assess changes in HRV and BRS in isolated traumatic brain injury (TBI), with the hypothesis that measurement of autonomic nervous system dysfunction can provide prognostic information on late neurological outcome.Materials and Methods:Nineteen patients with TBI, requiring mechanical ventilation, sedation and analgesia, and with arterial and intracranial pressure monitoring for at least 1 week, were included. Physiological and treatment variables were collected and power spectral analyses of HRV and BRS analyses in time domain were performed daily. HRV in the high-frequency (HF) and low-frequency (LF) domains, as well as LF/HF ratio and total power, were investigated. The power of these variables to predict poor (Glasgow Outcome Scale Extended [GOSE] score <5), late (1 y) neurological outcome was assessed.Results:Total power, LF, HF, and BRS were all significantly depressed in patients with GOSE score <5. This difference could not be explained by a more severe brain injury at admission or more extensive use of sedative or analgesic drugs. The autonomic variables predicted the late neurological outcome with areas under the receiver-operating curves between 0.78 and 0.83 (sensitivity: 0.63 to 0.88 and specificity: 0.73 to 0.82).Conclusions:HRV and BRS measures in TBI patients during intensive care treatment, including sedative, analgesic, and vasoactive drugs, may identify patients with poor late neurological outcome.	[Henden, Pia Lowhagen; Sondergaard, Soren; Reinsfelt, Bjorn; Ricksten, Sven-Erik] Univ Gothenburg, Dept Anaesthesiol & Intens Care Med, Sahlgrenska Acad, Gothenburg, Sweden; [Rydenhag, Bertil] Univ Gothenburg, Dept Neurosurg, Sahlgrenska Acad, Gothenburg, Sweden; [Rydenhag, Bertil] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; [Aneman, Anders] Univ New S Wales, Intens Care Unit, Liverpool Hosp, South Western Sydney Local Hlth Dist, Sydney, NSW, Australia	Henden, PL (corresponding author), Sahlgrens Univ Hosp, Dept Anaesthesiol & Intens Care Med, S-41345 Gothenburg, Sweden.	pia.lowhagen@vgregion.se		Aneman, Anders/0000-0003-2096-5304; Lowhagen Henden, Pia/0000-0002-0466-319X	Swedish State Support for Clinical Research [ALFGBG-75870]; Gothenburg Medical Society; Health and Medical Care Executive Board of Vastra Gotaland Region (FoU)	Supported by Swedish State Support for Clinical Research (ALFGBG-75870), The Gothenburg Medical Society, and The Health and Medical Care Executive Board of Vastra Gotaland Region (FoU).	Aono H, 2001, ACTA MED OKAYAMA, V55, P197; Baillard C, 2002, CRIT CARE MED, V30, P306, DOI 10.1097/00003246-200202000-00007; Boudreau P, 2012, CHRONOBIOL INT, V29, P757, DOI 10.3109/07420528.2012.674592; BROWN TE, 1993, J APPL PHYSIOL, V75, P2310; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Camm AJ, 1996, EUR HEART J, V17, P354; Conci F, 2001, J NEUROL NEUROSUR PS, V71, P621, DOI 10.1136/jnnp.71.5.621; GALLETLY DC, 1994, BRIT J ANAESTH, V72, P219, DOI 10.1093/bja/72.2.219; Gang Yi, 2002, Curr Opin Crit Care, V8, P371, DOI 10.1097/00075198-200210000-00002; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Grande PO, 2011, J NEUROSURG ANESTH, V23, P358, DOI 10.1097/01.ana.0000405612.20356.84; Guo Yi-Fang, 2002, Card Electrophysiol Rev, V6, P267, DOI 10.1023/A:1016337210738; Haji-Michael PG, 2000, CRIT CARE MED, V28, P2578, DOI 10.1097/00003246-200007000-00066; HOWELL SJ, 1995, BRIT J ANAESTH, V74, P168, DOI 10.1093/bja/74.2.168; Hsueh C W, 1998, Zhonghua Yi Xue Za Zhi (Taipei), V61, P199; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Kahraman S, 2010, J NEUROSURG ANESTH, V22, P296, DOI 10.1097/ANA.0b013e3181e25fc3; Korach M, 2001, CRIT CARE MED, V29, P1380, DOI 10.1097/00003246-200107000-00013; La Rovere MT, 2008, ANN NONINVAS ELECTRO, V13, P191, DOI 10.1111/j.1542-474X.2008.00219.x; LATSON TW, 1992, J CLIN ANESTH, V4, P265, DOI 10.1016/0952-8180(92)90127-M; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; Marthol H, 2010, CLIN AUTON RES, V20, P363, DOI 10.1007/s10286-010-0072-8; MARTY J, 1986, ANESTH ANALG, V65, P113; Mazzeo AT, 2011, ACTA ANAESTH SCAND, V55, P797, DOI 10.1111/j.1399-6576.2011.02466.x; Mendez GD, 2013, J CLIN MONIT COMPUT, V27, P417, DOI 10.1007/s10877-012-9426-1; Modesti PA, 2004, HEART, V90, P30, DOI 10.1136/heart.90.1.30; Mowery NT, 2008, J TRAUMA, V65, P621, DOI 10.1097/TA.0b013e3181837980; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; Okada Y, 2012, HYPERTENSION, V59, P98, DOI 10.1161/HYPERTENSIONAHA.111.176560; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; Riordan WP, 2009, J SURG RES, V156, P283, DOI 10.1016/j.jss.2009.03.086; Riznyk L, 2005, PHARMACOL REP, V57, P128; Sato M, 2005, BRIT J ANAESTH, V94, P577, DOI 10.1093/bja/aei092; SELLGREN J, 1994, ANESTHESIOLOGY, V80, P534, DOI 10.1097/00000542-199403000-00009; Stein PK, 2008, CRIT CARE MED, V36, P1025, DOI 10.1097/CCM.0B013E318164EC6D; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tsuchiya S, 2006, EUR J ANAESTH, V23, P454, DOI 10.1017/S0265021506000159; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; Zickmann B, 1996, J CARDIOTHOR VASC AN, V10, P609, DOI 10.1016/S1053-0770(96)80138-8; Ziegler D, 2001, CLIN AUTON RES, V11, P369, DOI 10.1007/BF02292769	43	25	25	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2014	26	1					50	59		10.1097/ANA.0b013e3182a47b62			10	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	275CW	WOS:000328654300010	24064714				2021-06-18	
J	Miller, NR; Yasen, AL; Maynard, LF; Chou, LS; Howell, DR; Christie, AD				Miller, Nick R.; Yasen, Alia L.; Maynard, Logan F.; Chou, Li-Shan; Howell, David R.; Christie, Anita D.			Acute and longitudinal changes in motor cortex function following mild traumatic brain injury	BRAIN INJURY			English	Article						Evoked potentials; mild traumatic brain injury; neurobehavioural	TRANSCRANIAL MAGNETIC STIMULATION; COGNITIVE IMPAIRMENT; CEREBRAL CONCUSSION; SPORTS CONCUSSION; HEAD-INJURY; LONG-TERM; INHIBITION; RECOVERY; ATTENTION; DEFICITS	Primary objective: To evaluate excitability and inhibition of the motor cortex acutely and longitudinally following mild traumatic brain injury (mTBI). Research design: A longitudinal paired case-control design was used to examine cortical excitability and inhibition in 15 adults who had sustained an mTBI (mean age = 20.8 +/- 1.2 years) and 15 matched control participants (mean age = 21.1 +/- 1.3 years). Methods and procedures: Participants visited the lab within 72 hours of injury and again at 1, 2, 4 and 8 weeks post-injury. During each visit, transcranial magnetic stimulation was used to examine resting motor threshold (RMT), motor evoked potential peak-to-peak amplitude (MEPamp) and cortical silent period (CSP) duration of the first dorsal interosseous muscle. Main outcomes and results: There were no differences between groups in RMT (p = 0.10) or MEPamp (p = 0.22) at 72 hours post-injury or across the 2-month testing period (p >= 0.68), indicating similar cortical excitability. However, the CSP duration was higher in individuals with mTBI, indicating greater intra-cortical inhibition compared with the control group at 72 hours post-injury (p = 0.03) and throughout the 2 months of recovery (p = 0.009). Conclusions: mTBI appeared to have little effect on cortical excitability, but an acute and long-lasting effect on intra-cortical inhibition.	[Miller, Nick R.; Yasen, Alia L.; Maynard, Logan F.; Chou, Li-Shan; Howell, David R.; Christie, Anita D.] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA	Christie, AD (corresponding author), 1240 Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA.	adc1@uoregon.edu		Howell, David/0000-0002-2955-0191			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; Livingston SC, 2012, J CLIN NEUROPHYSIOL, V29, P23, DOI 10.1097/WNP.0b013e318246ae46; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; Orth M, 2004, CLIN NEUROPHYSIOL, V115, P1076, DOI 10.1016/j.clinph.2003.12.025; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Rossi S, 2011, CLIN NEUROPHYSIOL, V122, P1686, DOI 10.1016/j.clinph.2010.12.037; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; Vink R, 1990, Magnes Res, V3, P163; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006	40	25	25	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	10					1270	1276		10.3109/02699052.2014.915987			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AN2ZZ	WOS:000340455900006	24841536				2021-06-18	
J	Wu, AG; Ying, Z; Gomez-Pinilla, F				Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando			Dietary Strategy to Repair Plasma Membrane After Brain Trauma: Implications for Plasticity and Cognition	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; BDNF; curcumin; DHA	OXIDATIVE STRESS; CORTICAL IMPACT; FATTY-ACIDS; INJURY; CURCUMIN; RATS; OMEGA-3-FATTY-ACIDS; SUPPLEMENTATION; DHA; ADOLESCENTS	Background. Damage to the plasma membrane is a prevalent but often neglected aspect of traumatic brain injury (TBI), which can impair neuronal signaling and hamper neurological recovery. Objective. This study was performed to assess a new noninvasive intervention to counteract peroxidative damage to the phospholipids in the membrane using the powerful action of foods. Although dietary docosahexaenoic acid (C22:6n-3; DHA) provides protection against TBI, the pervasive effects of TBI that cause phospholipid damage, including to DHA, raises concerns about how to preserve DHA in the brain for optimal functional recovery. Methods. Rats were maintained on curcumin and/or DHA-enriched diets for 2 weeks postinjury, and their brains were subjected to analyses. Results. Fluid percussion injury reduced DHA levels as well as levels of enzymes involved in the metabolism of DHA such as FADS2 and 17-HSD4 and elevated levels of markers of lipid peroxidation such as 4-hydroxy-2-nonenal (4-HNE) and 4-hydroxy-2-hexenal (4-HHE). These effects were counteracted by DHA or curcumin, whereas the combination of curcumin and DHA had an enhanced effect on DHA and 4-HNE. The combination of curcumin and DHA was also efficient in counteracting reductions in the plasticity markers, brain-derived neurotrophic factor and its receptor p-trkB, and learning ability, which had been lessened after TBI. Conclusions. Curcumin complements the action of DHA on TBI pathology, and this property appears to be a viable strategy to counteract neuronal dysfunction after TBI and complement the application of rehabilitative interventions to foster functional recovery.	[Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Los Angeles, CA USA; [Gomez-Pinilla, Fernando] UCLA Brain Injury Res Ctr, Los Angeles, CA USA	Gomez-Pinilla, F (corresponding author), Dept Integrat Biol & Physiol, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			NIH awardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS50465]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by NIH award NS50465.	Cartagena CM, 2010, BRAIN RES, V1319, P1, DOI 10.1016/j.brainres.2009.12.080; Chytrova G, 2010, BRAIN RES, V1341, P32, DOI 10.1016/j.brainres.2009.05.018; Farooqui AA, 2004, NEUROCHEM RES, V29, P1961, DOI 10.1007/s11064-004-6871-3; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Kaur G, 2010, BRIT J NUTR, V103, P32, DOI 10.1017/S0007114509991334; Lim GP, 2001, J NEUROSCI, V21, P8370; Long EK, 2008, J NEUROCHEM, V105, P714, DOI 10.1111/j.1471-4159.2007.05175.x; Ma QL, 2009, J NEUROSCI, V29, P9078, DOI 10.1523/JNEUROSCI.1071-09.2009; Mehla J, 2010, LIFE SCI, V87, P596, DOI 10.1016/j.lfs.2010.09.006; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; Poudyal H, 2011, PROG LIPID RES, V50, P372, DOI 10.1016/j.plipres.2011.06.003; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Saw CLL, 2010, BIOCHEM PHARMACOL, V79, P421, DOI 10.1016/j.bcp.2009.08.030; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872	25	25	25	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JAN	2014	28	1					75	84		10.1177/1545968313498650			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	274HW	WOS:000328598400009	23911971				2021-06-18	
J	Grulova, I; Slovinska, L; Nagyova, M; Cizek, M; Cizkova, D				Grulova, Ivana; Slovinska, Lucia; Nagyova, Miriam; Cizek, Milan; Cizkova, Dasa			The effect of hypothermia on sensory-motor function and tissue sparing after spinal cord injury	SPINE JOURNAL			English	Article						Spinal cord injury; Hypothermia; Urinary bladder; Sensory outcome; Functional recovery	TRAUMATIC BRAIN-INJURY; SYSTEMIC HYPOTHERMIA; COMPRESSION INJURY; MODERATE HYPOTHERMIA; ELECTRICAL-STIMULATION; RAT; TEMPERATURE; CONTUSION; RECOVERY; EXPRESSION	BACKGROUND CONTEXT: In recent years, hypothermia has been described as a therapeutic approach that leads to potential protective effects via minimization of secondary damage consequences, reduction of neurologic deficit, and increase of motor performance after spinal cord injury (SCI) in animal models and humans. PURPOSE: The objective of this study was to determine the therapeutic efficacy of hypothermia treatment on sensory-motor function and bladder activity outcome correlated with the white and gray matter sparing and neuronal survival after SCI in adult rats. STUDY DESIGN: A standardized animal model of compression SCI was used to test the hypothesis that hypothermia could have a neuroprotective effect on neural cell death and loss of white and/or gray matter. METHODS: Animals underwent spinal cord compression injury at the Th8-Th9 level followed by systemic hypothermia of 32.0 degrees C with gradual re-warming to 37.0 degrees C. Motor function of hind limbs (BBB score) and mechanical allodynia (von Frey hair filaments) together with function of urinary bladder was monitored in all experimental animals throughout the whole survival period. RESULTS: Present results showed that hypothermia had beneficial effects on urinary bladder activity and on locomotor function recovery at Days 7 and 14 post-injury. Furthermore, significant increase of NeuN-positive neuron survival within dorsal and ventral horns at Days 7, 14, and 21 were documented. CONCLUSIONS: Our conclusions suggest that hypothermia treatment may not only promote survival of neurons, which can have a significant impact on the improvement of motor and vegetative functions, but also induce mechanical allodynia. (C) 2013 Elsevier Inc. All rights reserved.	[Grulova, Ivana; Slovinska, Lucia; Nagyova, Miriam; Cizkova, Dasa] Slovak Acad Sci, Inst Neurobiol, Ctr Excellence Brain Res, Kosice, Slovakia; [Cizek, Milan; Cizkova, Dasa] Univ Vet Med & Pharm, Kosice, Slovakia	Grulova, I (corresponding author), Slovak Acad Sci, Inst Neurobiol, Ctr Excellence Brain Res, Soltesovej 4, Kosice, Slovakia.	novotna@saske.sk	Cizkova, Dasa/AAF-8976-2019	cizkova, dasa/0000-0002-2504-3993; Cizek, Milan/0000-0003-2623-9194			Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Amar AP, 1999, J AM COLL SURGEONS, V188, P550, DOI 10.1016/S1072-7515(99)00013-7; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BERIC A, 1992, J UROLOGY, V148, P1845, DOI 10.1016/S0022-5347(17)37047-7; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BOVOLENTA P, 1993, EUR J NEUROSCI, V5, P454, DOI 10.1111/j.1460-9568.1993.tb00512.x; Casas CE, 2005, J NEUROSURG-SPINE, V2, P308, DOI 10.3171/spi.2005.2.3.0308; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Christensen MD, 1996, PAIN, V68, P97, DOI 10.1016/S0304-3959(96)03224-1; CHUONG CM, 1991, AM J PATHOL, V138, P427; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; DEGROAT WC, 1990, J AUTONOM NERV SYST, V30, pS71, DOI 10.1016/0165-1838(90)90105-R; Detloff MR, 2010, EXP NEUROL, V225, P366, DOI 10.1016/j.expneurol.2010.07.009; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; Dimar JR, 2000, SPINE, V25, P2294, DOI 10.1097/00007632-200009150-00006; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; EBNER A, 1992, J UROLOGY, V148, P920, DOI 10.1016/S0022-5347(17)36778-2; Fukui O, 2006, BRAIN RES, V1121, P35, DOI 10.1016/j.brainres.2006.08.121; Ghosh A, 2009, J NEUROSCI, V29, P12210, DOI 10.1523/JNEUROSCI.1828-09.2009; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Ha KY, 2008, SPINE, V33, P2059, DOI 10.1097/BRS.0b013e31818018f6; HALL ED, 1993, STROKE, V24, P711, DOI 10.1161/01.STR.24.5.711; Hutchinson KJ, 2004, BRAIN, V127, P1403, DOI 10.1093/brain/awh160; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Jou IM, 2000, SPINE, V25, P1878, DOI 10.1097/00007632-200008010-00004; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; Kumar K, 1997, METAB BRAIN DIS, V12, P21, DOI 10.1007/BF02676351; Kwon BK, 2008, SPINE J, V8, P859, DOI 10.1016/j.spinee.2007.12.006; LIESI P, 1984, EMBO J, V3, P683, DOI 10.1002/j.1460-2075.1984.tb01867.x; LIGHT JK, 1992, J UROLOGY, V148, P355, DOI 10.1016/S0022-5347(17)36595-3; Lo TP, 2009, J COMP NEUROL, V514, P433, DOI 10.1002/cne.22014; MAGASI P, 1986, UROL INT, V41, P241, DOI 10.1159/000281209; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; Morino T, 2008, SPINAL CORD, V46, P425, DOI 10.1038/sj.sc.3102163; Morochovic R, 2008, INT J NEUROSCI, V118, P555, DOI 10.1080/00207450601123456; Nagel Simon, 2008, Expert Rev Neurother, V8, P1255, DOI 10.1586/14737175.8.8.1255; Park WB, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-119; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; Sirimanne ES, 1996, PEDIATR RES, V39, P591, DOI 10.1203/00006450-199604000-00005; Steinberg GK, 2004, NEUROSURGERY, V55, P307, DOI 10.1227/01.NEU.0000129683.99430.8C; Stichel CC, 1998, PROG NEUROBIOL, V56, P119, DOI 10.1016/S0301-0082(98)00033-1; Strauch JT, 2004, EUR J CARDIO-THORAC, V25, P708, DOI 10.1016/j.ejcts.2004.01.007; STRONG MJ, 1967, ANESTHESIOLOGY, V28, P920, DOI 10.1097/00000542-196709000-00032; Svensson LG, 2003, ARCH SURG-CHICAGO, V138, P175, DOI 10.1001/archsurg.138.2.175; TABAYASHI K, 1993, ANN THORAC SURG, V56, P494, DOI 10.1016/0003-4975(93)90885-L; Tetik O, 2002, EUR J VASC ENDOVASC, V24, P540, DOI 10.1053/ejvs.2002.1753; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Vanicky I, 2001, J NEUROTRAUM, V18, P1399, DOI 10.1089/08977150152725687; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wakamatsu H, 1999, ANESTH ANALG, V88, P56, DOI 10.1097/00000539-199901000-00011; Westergren H, 2000, ACTA NEUROCHIR, V142, P567, DOI 10.1007/s007010050471; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; Westergren H, 1998, J NEUROTRAUM, V15, P943, DOI 10.1089/neu.1998.15.943; Westergren H, 2001, SPINAL CORD, V39, P74, DOI 10.1038/sj.sc.3101127; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046; Yu WR, 2000, ACTA NEUROPATHOL, V100, P546, DOI 10.1007/s004010000206; ZARZECKI P, 1982, EXP BRAIN RES, V48, P28	68	25	25	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1529-9430	1878-1632		SPINE J	Spine Journal	DEC	2013	13	12					1881	1891		10.1016/j.spinee.2013.06.073			11	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	272XG	WOS:000328495800029	24012427				2021-06-18	
J	Harty, S; O'Connell, RG; Hester, R; Robertson, IH				Harty, Siobhan; O'Connell, Redmond G.; Hester, Robert; Robertson, Ian H.			Older Adults Have Diminished Awareness of Errors in the Laboratory and Daily Life	PSYCHOLOGY AND AGING			English	Article						cognitive aging; self-awareness; error awareness; prefrontal cortex; sustained attention	TRAUMATIC BRAIN-INJURY; SELF-AWARENESS; ALZHEIMERS-DISEASE; SUSTAINED ATTENTION; MEMORY PERFORMANCE; IMPAIRED AWARENESS; EXECUTIVE FUNCTION; CINGULATE CORTEX; OWN INCOMPETENCE; AGE-DIFFERENCES	Poor recognition of the degree or scope of one's own cognitive deficits is a common feature of many neurological conditions, including diseases of aging, but little is known about the impact the natural aging process has on this aspect of self-awareness (SA). Here, a group of 45 healthy older adults and a comparison group of 45 young adults completed a multidomain assessment of SA. Awareness of daily functioning was evaluated based on discrepancies between self-and informant ratings on questionnaire measures of attentional control, memory functioning, and socioemotional functioning. Online error awareness was also assessed using a variant of the Go/No-Go Error Awareness Task (EAT) in which participants are required to signal commission errors via a separate manual response. Whereas younger participants tended to underestimate their attentional control and memory functioning relative to informant reports, older adults significantly overestimated their abilities. The older adults also exhibited substantially poorer online error awareness compared with young adults, despite the fact that the two groups were matched for overall accuracy. Levels of online error awareness were significantly correlated with discrepancy scores for daily attentional and memory functioning, and with performance of a sustained attention task. These novel findings suggest that an important aspect of the neuropsychology of healthy aging has hitherto been overlooked.	[Harty, Siobhan; O'Connell, Redmond G.; Robertson, Ian H.] Univ Dublin Trinity Coll, Trinity Coll, Inst Neurosci, Dublin 2, Ireland; [Harty, Siobhan; O'Connell, Redmond G.; Robertson, Ian H.] Univ Dublin Trinity Coll, Sch Psychol, Dublin 2, Ireland; [Hester, Robert] Univ Melbourne, Dept Psychol Sci, Melbourne, Vic, Australia	Harty, S (corresponding author), Univ Dublin Trinity Coll, Trinity Coll, Inst Neurosci, Lloyd Bldg, Dublin 2, Ireland.	sharty@tcd.ie	Hester, Robert/F-2097-2011	Hester, Robert/0000-0003-0982-8026; Robertson, Ian H/0000-0001-8637-561X; Harty, Siobhan/0000-0001-7560-9185; O'Connell, Redmond/0000-0001-6949-2793			Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; Balota DA, 2000, OXFORD HDB MEMORY, P395; Band GPH, 2000, BIOL PSYCHOL, V51, P201, DOI 10.1016/S0301-0511(99)00038-1; Bramham J, 2009, J NEUROPSYCHOL, V3, P125, DOI 10.1348/174866408X293994; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BRUCE PR, 1982, J GERONTOL, V37, P354, DOI 10.1093/geronj/37.3.354; Burke DM, 2004, CURR DIR PSYCHOL SCI, V13, P21, DOI 10.1111/j.0963-7214.2004.01301006.x; Clare L, 2002, NEUROPSYCHOL REHABIL, V12, P341, DOI 10.1080/09602010244000129; Clare L, 2011, DEMENT GERIATR COGN, V31, P317, DOI 10.1159/000327356; Clare L, 2010, AGING NEUROPSYCHOL C, V17, P462, DOI 10.1080/13825580903581558; David AS, 2012, PHILOS T R SOC B, V367, P1379, DOI 10.1098/rstb.2012.0002; DAVID AS, 1992, BRIT J HOSP MED, V48, P652; Endrass T, 2005, J PSYCHOPHYSIOL, V19, P275, DOI 10.1027/0269-8803.19.4.275; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Falkenstein M., 1990, PSYCHOPHYSIOLOGICAL, P192; Fleming JM, 1996, BRAIN INJURY, V10, P1; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gold BT, 2010, NEUROBIOL AGING, V31, P512, DOI 10.1016/j.neurobiolaging.2008.04.005; Grady C, 2012, NAT REV NEUROSCI, V13, P491, DOI 10.1038/nrn3256; Graham DP, 2005, COGNITIVE BRAIN RES, V25, P144, DOI 10.1016/j.cogbrainres.2005.05.001; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hedden T, 2004, NAT REV NEUROSCI, V5, P87, DOI 10.1038/nrn1323; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hester R, 2009, NEUROPSYCHOPHARMACOL, V34, P2450, DOI 10.1038/npp.2009.67; Hodges B, 2001, ACAD MED, V76, pS87, DOI 10.1097/00001888-200110001-00029; Hoerold D, 2008, EXP BRAIN RES, V186, P509, DOI 10.1007/s00221-008-1341-9; Hoerold D, 2013, NEUROPSYCHOLOGIA, V51, P385, DOI 10.1016/j.neuropsychologia.2012.11.019; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Jenkinson PM, 2009, CONSCIOUS COGN, V18, P458, DOI 10.1016/j.concog.2008.12.005; Krueger J, 2002, J PERS SOC PSYCHOL, V82, P180, DOI 10.1037//0022-3514.82.2.180; Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121; Larson GE, 1997, BRIT J PSYCHOL, V88, P29, DOI 10.1111/j.2044-8295.1997.tb02618.x; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Leuthold H, 1999, CLIN NEUROPHYSIOL, V110, P342, DOI 10.1016/S1388-2457(98)00058-3; LOVELACE EA, 1985, J GERONTOL, V40, P192, DOI 10.1093/geronj/40.2.192; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Mathalon DH, 2003, NEUROBIOL AGING, V24, P675, DOI 10.1016/S0197-4580(02)00154-9; Mathewson KJ, 2005, BIOL PSYCHOL, V70, P88, DOI 10.1016/j.biopsycho.2004.12.005; Mavroveli S, 2009, BRIT J EDUC PSYCHOL, V79, P259, DOI 10.1348/000709908X368848; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; McAvinue LP, 2012, ATTEN PERCEPT PSYCHO, V74, P1570, DOI 10.3758/s13414-012-0352-6; MCEVOY JP, 1989, J NERV MENT DIS, V177, P43, DOI 10.1097/00005053-198901000-00007; MCGLYNN SM, 1991, J COGNITIVE NEUROSCI, V3, P183, DOI 10.1162/jocn.1991.3.2.183; Murphy PR, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00065; Nelson HE, 1982, NATL ADULT READING T; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2009, NEUROPSYCHOLOGIA, V47, P1149, DOI 10.1016/j.neuropsychologia.2009.01.011; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Pia L, 2004, CORTEX, V40, P367, DOI 10.1016/S0010-9452(08)70131-X; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rabbitt P, 2002, Q J EXP PSYCHOL-A, V55, P1081, DOI 10.1080/02724980244000080; RABBITT P, 1990, ERGONOMICS, V33, P1291, DOI 10.1080/00140139008925333; Robertson I., 2010, STUDY ANOSOGNOSIA, P321; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rosen HJ, 2010, NEUROIMAGE, V49, P3358, DOI 10.1016/j.neuroimage.2009.11.041; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Seltzer B, 1997, GERONTOLOGIST, V37, P20, DOI 10.1093/geront/37.1.20; Shalgi S, 2007, EXP BRAIN RES, V182, P119, DOI 10.1007/s00221-007-1054-5; STARKSTEIN SE, 1995, ARCH NEUROL-CHICAGO, V52, P415, DOI 10.1001/archneur.1995.00540280105024; Starratt C., 1997, HDB NEUROPSYCHOLOGY, P15; Suchy Y, 2011, J CLIN EXP NEUROPSYC, V33, P92, DOI 10.1080/13803395.2010.493148; TIPPER SP, 1987, PERS INDIV DIFFER, V8, P667, DOI 10.1016/0191-8869(87)90064-X; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; Wall Sarah E, 2011, Clin Child Psychol Psychiatry, V16, P301, DOI 10.1177/1359104511401187; Wallace JC, 2003, J BUS PSYCHOL, V17, P503, DOI 10.1023/A:1023452218225; Wallace JC, 2002, J GEN PSYCHOL, V129, P238, DOI 10.1080/00221300209602098; Wang HX, 2012, BBA-MOL BASIS DIS, V1822, P482, DOI 10.1016/j.bbadis.2011.09.002; Wechsler D., 1997, WAIS 3 ADM SCORING M; Young Mark S, 2011, J Aging Res, V2011, P918782, DOI 10.4061/2011/918782; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	78	25	25	2	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0882-7974	1939-1498		PSYCHOL AGING	Psychol. Aging	DEC	2013	28	4					1032	1041		10.1037/a0033567			10	Gerontology; Psychology, Developmental	Geriatrics & Gerontology; Psychology	280QT	WOS:000329046600015	24364407				2021-06-18	
J	Honeybul, S; Janzen, C; Kruger, K; Ho, KM				Honeybul, Stephen; Janzen, Courtney; Kruger, Kate; Ho, Kwok M.			Decompressive craniectomy for severe traumatic brain injury: is life worth living? Clinical article	JOURNAL OF NEUROSURGERY			English	Article						decompressive craniectomy; traumatic brain injury; outcome; retrospective consent	MIDDLE CEREBRAL-ARTERY; MINIMALLY CONSCIOUS STATE; SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; SUBARACHNOID HEMORRHAGE; FOLLOW-UP; HEMICRANIECTOMY; INFARCTION; RECOVERY; SURGERY	Object. The object of this study was to assess the long-term outcome and quality of life of patients who have survived with severe disability following decompressive craniectomy for severe traumatic brain injury (TBI). Methods. The authors assessed outcome beyond 3 years among a cohort of 39 patients who had been adjudged either severely disabled or in vegetative state 18 months after decompressive craniectomy for TBI. Assessments performed included the Extended Glasgow Outcome Scale, modified Barthel Index (mBI), Zarit Burden Interview, and 36-Item Short-Form Health Survey (SF-36). The issue of retrospective consent for surgery was also assessed. Results. Of the 39 eligible patients, 7 died, 12 were lost to follow-up, and 20 patients or their next of kin consented to participate in the study. Among those 20 patients, 5 in a vegetative state at 18 months remained so beyond 3 years, and the other 15 patients remained severely disabled after a median follow-up of 5 years. The patients' average daily activity per the mBI (Pearson correlation coefficient [r] = -0.661, p = 0.01) and SF-36 physical score (r = -0.543, p = 0.037) were inversely correlated with the severity of TBI. However, the SF-36 mental scores of the patients were reasonably high (median 46, interquartile range 37-52). The majority of patients and their next of kin believed that they would have provided consent for surgical decompression even if they had known the eventual outcome. Conclusions. Substantial physical recovery beyond 18 months after decompressive craniectomy for severe TBI was not observed; however, many patients appeared to have recalibrated their expectations regarding what they believed to be an acceptable quality of life.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6009, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA 6001, Australia; [Janzen, Courtney; Kruger, Kate] Sir Charles Gairdner Hosp, Dept Occupat Therapy, Perth, WA 6009, Australia; [Ho, Kwok M.] Royal Perth Hosp, Dept Intens Care Med, Perth, WA 6001, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA 6009, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Agrawal D, 2005, EUR J CLIN MICROBIOL, V24, P772, DOI 10.1007/s10096-005-0017-7; Ahmed AI, 2010, NEUROCRIT CARE, V13, P393, DOI 10.1007/s12028-010-9420-8; Baussart B, 2006, ACTA ANAESTH SCAND, V50, P762, DOI 10.1111/j.1399-6576.2006.01038.x; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper P R, 1976, Surg Neurol, V5, P25; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; Di Rienzo A, 2008, ACTA NEUROCHIR, V150, P1057, DOI 10.1007/s00701-008-0019-1; Ferro JM, 2011, STROKE, V42, P2825, DOI 10.1161/STROKEAHA.111.615393; Fins JJ, 2009, ANN NY ACAD SCI, V1157, P131, DOI 10.1111/j.1749-6632.2009.04473.x; Foerch C, 2004, J NEUROSURG, V101, P248, DOI 10.3171/jns.2004.101.2.0248; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; Honeybul S, 2012, J MED ETHICS, V38, P657, DOI 10.1136/medethics-2012-100672; Honeybul S, 2012, MED J AUSTRALIA, V196, P531, DOI 10.5694/mja11.11485; Honeybul S, 2011, J NEUROTRAUM, V28, P2199, DOI 10.1089/neu.2011.1907; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2011, J NEUROTRAUM, V28, P13, DOI 10.1089/neu.2010.1584; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Kiphuth IC, 2010, NEUROCRIT CARE, V13, P380, DOI 10.1007/s12028-010-9449-8; Kobylarz E, 2004, ARCH NEUROL-CHICAGO, V61, P1357, DOI 10.1001/archneur.61.9.1357; Lanterna LA, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0910; Leonhardt G, 2002, J NEUROL, V249, P1433, DOI 10.1007/s00415-002-0875-1; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Puetz V, 2007, LANCET NEUROL, V6, P580, DOI 10.1016/S1474-4422(07)70160-6; Rahme R, 2012, J NEUROSURG, V117, P749, DOI 10.3171/2012.6.JNS111140; Romero CM, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schneider GH, 2002, ACT NEUR S, V81, P77; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; ZARIT SH, 1986, GERONTOLOGIST, V26, P260, DOI 10.1093/geront/26.3.260	53	25	25	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2013	119	6					1566	1575		10.3171/2013.8.JNS13857			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	257EU	WOS:000327367200030	24116729				2021-06-18	
J	Stewart, TC; Alharfi, IM; Fraser, DD				Stewart, Tanya Charyk; Alharfi, Ibrahim M.; Fraser, Douglas D.			The role of serious concomitant injuries in the treatment and outcome of pediatric severe traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; concomitant injury; children and adolescents; outcome; mortality	SYSTEMIC CYTOKINE EXPRESSION; HEAD-INJURY; MORTALITY; CHILDREN; VOLUME	BACKGROUND: The study objective was to describe the epidemiology of serious concomitant injuries and their effects on outcome in pediatric severe traumatic brain injury (sTBI). METHODS: A retrospective cohort of all severely injured (Injury Severity Score [ISS] >= 12) pediatric patients (<18 years) admitted to our pediatric intensive care unit, between 2000 and 2011, after experiencing an sTBI (Glasgow Coma Scale [GCS] score <= 8 and head Abbreviated Injury Scale [AIS] >= 4) were included. Two groups were compared based on the presence of serious concomitant injuries (maximum AIS score >= 3). Multivariate logistic regression was undertaken to determine variable associations with mortality. RESULTS: Of the 180 patients with sTBI, 113 (63%) sustained serious concomitant injuries. Chest was the most commonly injured extracranial body region (84%), with lung being the most often injured. Patients with serious concomitant injuries had increased age, weight, and injury severity (p < 0.001) and were more likely injured in a motor vehicle collision (91% vs. 48%, p < 0.001). Those with serious concomitant injuries had worse sTBI, based on lower presedation GCS (p = 0.031), higher frequency of fixed pupils (p = 0.006), and increased imaging abnormalities (SAH and DAI, p <= 0.01). Non-neurosurgical operations and blood transfusions were more frequent in the serious concomitant injury group (p < 0.01). The differences in mortality for the two groups failed to reach statistical significant (p = 0.053), but patients with serious concomitant injuries had higher rates of infection and acute central diabetes insipidus, fewer ventilator-free days, and greater length of stays (p < 0.05). Multivariate analyses revealed fixed pupillary response (odd ratio [OR], 63.58; p < 0.001), presedation motor GCS (OR, 0.23; p = 0.001), blood transfusion (OR, 5.80; p = 0.008), and hypotension (OR, 4.82; p = 0.025) were associated with mortality, but serious concomitant injuries was not (p = 0.283). CONCLUSION: Head injury is the most important prognostic factor in mortality for sTBI pediatric patients, but the presence of serious concomitant injuries does contribute to greater morbidity, including longer stays, more infections, fewer ventilator-free days, and a higher level of care required on discharge from hospital. (J Trauma Acute Care Surg. 2013;75:836-842. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Stewart, Tanya Charyk] Univ Western Ontario, Dept Surg, London, ON N6A 3K7, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Pediat, London, ON N6A 3K7, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada; [Stewart, Tanya Charyk] London Hlth Sci Ctr, Trauma Program, London, ON, Canada; [Fraser, Douglas D.] Translat Res Ctr, London, ON, Canada; [Fraser, Douglas D.] Childrens Hlth Res Inst, London, ON, Canada; [Fraser, Douglas D.] Ctr Crit Illness Res, London, ON, Canada; [Alharfi, Ibrahim M.] King Fahad Med City, Dept Pediat Crit Care, Riyadh, Saudi Arabia	Stewart, TC (corresponding author), Childrens Hosp, LHSC, Trauma Program, Room E1-129,800 Commissioners Rd E, London, ON N6A 5W9, Canada.	Tanya.CharykStewart@lhsc.on.ca					Al-Sharif A, 2012, INJURY, V43, P2078, DOI 10.1016/j.injury.2012.01.012; Alharfi IM, 2013, J NEUROTRAUM, V30, P361, DOI 10.1089/neu.2012.2410; Alharfi IM, 2013, PEDIATR CRIT CARE ME, V14, P203, DOI 10.1097/PCC.0b013e31827127b5; [Anonymous], 2012, INJ PREV CONTR TRAUM; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Association for the Advancement of Automotive Medicine European Vehicle Passive Safety Network. International Research Council on the Biomechanics of Impact, 1999, CHILD OCC PROT MOT V; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Ballesteros MF, 2003, INJURY PREV, V9, P173, DOI 10.1136/ip.9.2.173; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Croce MA, 2012, J AM COLL SURGEONS, V214, P486; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Hosmer D, 1989, APPL LOGISTIC REGRES; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LaPar DJ, 2012, J AM COLL SURGEONS, V214, P478, DOI 10.1016/j.jamcollsurg.2011.12.015; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Leong BK, 2013, DISABIL REHABIL, V35, P1546, DOI 10.3109/09638288.2012.748832; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Yuan F, 2012, J TRAUMA ACUTE CARE, V73, P137, DOI 10.1097/TA.0b013e31824b00ac	24	25	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2013	75	5					836	842		10.1097/TA.0b013e3182a685b0			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	300IP	WOS:000330457900013	24158203				2021-06-18	
J	Yu, DT; Li, MF; Ni, B; Kong, JM; Zhang, ZF				Yu, Datang; Li, Mingfang; Ni, Bing; Kong, Jiming; Zhang, Zhengfeng			Induction of Neuronal Mitophagy in Acute Spinal Cord Injury in Rats	NEUROTOXICITY RESEARCH			English	Article						Spinal cord injury; Mitophagy; BNIP3; NIX; p53	TRAUMATIC BRAIN-INJURY; CELL-DEATH; UP-REGULATION; MITOCHONDRIAL AUTOPHAGY; BNIP3 EXPRESSION; MAMMALIAN-CELLS; HYPOXIA; P53; RAPAMYCIN; ACTIVATION	Autophagy and up-regulation of autophagy-associated proteins microtubule-associated protein 1 light chain 3 (LC3) and Beclin-1 have been shown to occur in spinal cord injury (SCI). Bcl-2/E1B-19 K-interacting protein 3 (BNIP3) and Nip-like protein X (NIX, also known as BNIP3L) are mitochondrial BH3-only proteins that are implicated in mitophagy. In this study, we show that mitophagy is activated in the injured neurons, and hypoxia-inducible proteins BNIP3, NIX, and p53 are upregulated after SCI. Numerous autophagosomes containing damaged mitochondria (mitophagosomes) were found in the injured neurons 24 h after SCI in rats by transmission electron microscopy; mitophagy, therefore, had occurred. Hypoxia-inducible proteins BNIP3, NIX, and p53 were upregulated in spinal cord neurons in both a rat model of SCI and cultured primary spinal neurons exposed to hypoxia. BNIP3 and NIX were transcriptionally regulated mainly by hypoxia-inducible factor-1 alpha as well as p53 in cultured spinal cord neurons. This study provides direct morphological and biochemical evidence for mitophagy in the damaged neural tissue after SCI.	[Yu, Datang; Zhang, Zhengfeng] Third Mil Med Univ, Xinqiao Hosp, Dept Orthoped, Chongqing 400037, Peoples R China; [Li, Mingfang] Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Chongqing 400038, Peoples R China; [Ni, Bing] Third Mil Med Univ, Inst Immunol, Chongqing 400038, Peoples R China; [Kong, Jiming] Univ Manitoba, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada	Zhang, ZF (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Dept Orthoped, Chongqing 400037, Peoples R China.	kongj@cc.umanitoba.ca; zhangz3@126.com		Kong, Jiming/0000-0002-2859-9831; Ni, Bing/0000-0002-4297-5346	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070980]; CIHRCanadian Institutes of Health Research (CIHR); Canadian Stroke Network	This study was supported by Grants from the National Natural Science Foundation of China (81070980 to Z. Z.), CIHR and Canadian Stroke Network. We would like to thank Zhongfen Tao for technical assistance of electron microscope.	Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Burton TR, 2009, CELL DEATH DIFFER, V16, P515, DOI 10.1038/cdd.2008.185; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Chen HC, 2012, SPINE, V37, P470, DOI 10.1097/BRS.0b013e318221e859; Chen HC, 2012, INTEGR SER INFORM SY, V30, P203, DOI 10.1007/978-1-4614-1557-2_11; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Feng X, 2011, EMBO J, V30, P3397, DOI 10.1038/emboj.2011.248; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Grossman SD, 1999, J NEUROSCI, V19, P5711, DOI 10.1523/JNEUROSCI.19-14-05711.1999; Jian BX, 2011, MOL MED, V17, P542, DOI 10.2119/molmed.2010.00195; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034; Kitada T, 1998, NATURE, V392, P605; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Novak I, 2011, AUTOPHAGY, V7, P301, DOI 10.4161/auto.7.3.14509; Pan TH, 2008, NEUROBIOL DIS, V32, P16, DOI 10.1016/j.nbd.2008.06.003; Quinsay MN, 2010, AUTOPHAGY, V6, P855, DOI 10.4161/auto.6.7.13005; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Rikka S, 2011, CELL DEATH DIFFER, V18, P721, DOI 10.1038/cdd.2010.146; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Walker CL, 2012, PLOS ONE, V7, P315, DOI 10.1371/journal.pone.0030012; Webster KA, 2005, J MOL CELL CARDIOL, V38, P35, DOI 10.1016/j.yjmcc.2004.11.007; Yan J, 2006, BIOCHEM BIOPH RES CO, V346, P501, DOI 10.1016/j.bbrc.2006.05.160; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang SR, 2007, BRAIN RES, V1138, P221, DOI 10.1016/j.brainres.2006.12.086; Zhang XD, 2009, AUTOPHAGY, V5, P339, DOI 10.4161/auto.5.3.8174; Zhang ZF, 2007, STROKE, V38, P1606, DOI 10.1161/STROKEAHA.106.475129; Zhang ZF, 2011, FEBS J, V278, P134, DOI 10.1111/j.1742-4658.2010.07939.x	47	25	33	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428	1476-3524		NEUROTOX RES	Neurotox. Res.	NOV	2013	24	4					512	522		10.1007/s12640-013-9397-0			11	Neurosciences	Neurosciences & Neurology	268CJ	WOS:000328145300006	23637053				2021-06-18	
J	Brogaard, B				Brogaard, Berit			Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						acquired synesthesia; autism spectrum disorder; drug-induced synaesthesia; left-hemisphere injuries; multisensory perception; savant syndrome; serotonin hypothesis; traumatic brain injury	AUDITORY-VISUAL SYNESTHESIA; STRUCTURAL CONNECTIVITY; SAVANT MEMORY; BRAIN INJURY; SYNAESTHESIA; COLOR; AUTISM; RELEASE; PREVALENCE; PERCEPTION	Though synesthesia research has seen a huge grow thin recent decades, and tremendous progress has been made in terms of understanding the mechanism and cause of synesthesia, we are still left mostly in the dark when it comes to the mechanistic commonalities (if any) among developmental, acquired and drug-induced synesthesia. We know that many forms of synesthesia involve aberrant structural or functional brain connectivity. Proposed mechanisms include direct projection and disinhibited feedback mechanisms, in which information from two otherwise structurally or functionally separate brain regions mix. We also know that synesthesia sometimes runs in families. However, it is unclear what causes its on set. Studies of psychedelic drugs, such as psilocybin, LSD and mescaline, reveal that exposure to these drugs can induce synesthesia. One neurotransmitter suspected to be central to the perceptual changes is serotonin. Excessive serotonin in the brain may cause many of the characteristics of psychedelic in toxication. Excessive serotonin levels may also play a role in synesthesia acquired after brain injury. In brain injury sudden cell death floods local brain regions with serotonin and glutamate. This neurotransmitter flooding could perhaps result in unusual feature binding. Finally, developmental synesthesia that occurs in individuals with autism may be a result of alterations in the serotonergic system, leading to a blockage of regular gating mechanisms. I conclude on these grounds that one commonality among at least some cases of acquired, developmental and drug-induced synesthesia may be the presence of excessive levels of serotonin, which increases the excitability and connectedness of sensory brain regions.	[Brogaard, Berit] Univ Missouri, Dept Philosophy, St Louis, MO 63121 USA; [Brogaard, Berit] Univ Missouri, Ctr Neurodynam, St Louis, MO 63121 USA	Brogaard, B (corresponding author), Univ Missouri, Dept Philosophy, St Louis, MO 63121 USA.	brogaardb@gmail.com					ABRAHAM HD, 1983, ARCH GEN PSYCHIAT, V40, P884; Afra P, 2009, PSYCHOL RES BEHAV MA, V2, P31; Aghajanian GK, 1997, NEUROPHARMACOLOGY, V36, P589, DOI 10.1016/S0028-3908(97)00051-8; Alstadhaug KB, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-121; Armel KC, 1999, NEUROCASE, V5, P293, DOI 10.1093/neucas/5.4.293; Asher JE, 2009, AM J HUM GENET, V84, P279, DOI 10.1016/j.ajhg.2009.01.012; Banissy MJ, 2009, EXP BRAIN RES, V196, P565, DOI 10.1007/s00221-009-1888-0; BARKAI E, 1994, J NEUROPHYSIOL, V72, P72; Baron-Cohen S, 2007, J CONSCIOUSNESS STUD, V14, P237; Baron-Cohen S, 2009, PHILOS T R SOC B, V364, P1377, DOI 10.1098/rstb.2008.0337; BARONCOHEN S, 1987, PERCEPTION, V16, P761, DOI 10.1068/p160761; BaronCohen S, 1996, PERCEPTION, V25, P1073, DOI 10.1068/p251073; Beauchamp MS, 2008, J NEUROSCI, V28, P13696, DOI 10.1523/JNEUROSCI.3872-08.2008; Behrendt RP, 2004, BEHAV BRAIN SCI, V27, P771, DOI 10.1017/S0140525X04000184; Bor D, 2007, NEUROCASE, V13, P311, DOI 10.1080/13554790701844945; Brang D, 2008, MED HYPOTHESES, V70, P903, DOI 10.1016/j.mehy.2007.09.007; Brang D, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001205; Brogaard B., 2013, GURU MAG, V11, P10; Brogaard B., 2012, COGNITION LANGUAGE E; Brogaard B., 2013, SENSORY INTEGRATION; Brogaard B., 2013, SENSORY BLENDINGS NE; Brogaard B, 2013, NEUROCASE, V19, P566, DOI 10.1080/13554794.2012.701646; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; Carhart-Harris RL, 2012, P NATL ACAD SCI USA, V109, P2138, DOI 10.1073/pnas.1119598109; Ceglia I, 2004, J NEUROCHEM, V91, P189, DOI 10.1111/j.1471-4159.2004.02704.x; Chandana SR, 2005, INT J DEV NEUROSCI, V23, P171, DOI 10.1016/j.ijdevneu.2004.08.002; Chugani DC, 1999, ANN NEUROL, V45, P287, DOI 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9; Chugani DC, 1997, ANN NEUROL, V42, P666, DOI 10.1002/ana.410420420; Ciranna L, 2006, CURR NEUROPHARMACOL, V4, P101, DOI 10.2174/157015906776359540; Cott C, 2008, J SCI EXPLORATION, V22, P359; Cytowic R. E., 1989, SYNESTHESIA UNION SE, DOI [10.1007/978-1-4612-3542-2, DOI 10.1007/978-1-4612-3542-2]; Cytowic Richard E., 1997, SYNAESTHESIA CLASSIC, P17; DeLong GR, 1999, NEUROLOGY, V52, P911, DOI 10.1212/WNL.52.5.911; DEVINSKY O, 1991, SEMIN NEUROL, V11, P100, DOI 10.1055/s-2008-1041211; Dixon MJ, 2004, COGN AFFECT BEHAV NE, V4, P335, DOI 10.3758/CABN.4.3.335; Dixon MJ, 2006, CORTEX, V42, P243, DOI 10.1016/S0010-9452(08)70349-6; Domino G., 1989, CREAT RES J, V2, P17, DOI [10.1080/10400418909534297, DOI 10.1080/10400418909534297]; DORMAN C, 1991, BRAIN COGNITION, V15, P26, DOI 10.1016/0278-2626(91)90013-X; Dovern A, 2012, J NEUROSCI, V32, P7614, DOI 10.1523/JNEUROSCI.5401-11.2012; Eagleman DM, 2007, J NEUROSCI METH, V159, P139, DOI 10.1016/j.jneumeth.2006.07.012; Esterman M, 2006, J COGNITIVE NEUROSCI, V18, P1570, DOI 10.1162/jocn.2006.18.9.1570; Eysel UT, 1999, RESTOR NEUROL NEUROS, V15, P153; Ffytche Dominic H, 2007, Dialogues Clin Neurosci, V9, P173; Friedrichs H, 1940, PSYCHOL MESKALINRAUS; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; GLENNON RA, 1990, NEUROPSYCHOPHARMACOL, V3, P509; Gonzalez-Maeso J, 2008, NATURE, V452, P93, DOI 10.1038/nature06612; Gonzalez-Maeso J, 2007, NEURON, V53, P439, DOI 10.1016/j.neuron.2007.01.008; Grandin T., 1995, THINKING PICTURES MY; Grossenbacher PG, 2001, TRENDS COGN SCI, V5, P36, DOI 10.1016/S1364-6613(00)01571-0; Guillery RW, 2003, J COMP NEUROL, V463, P360, DOI 10.1002/cne.10738; Hanggi J, 2011, J NEUROSCI, V31, P5816, DOI 10.1523/JNEUROSCI.0964-10.2011; Harrison J, 2004, J AUTISM DEV DISORD, V34, P727, DOI 10.1007/s10803-004-5293-z; HIER DB, 1979, J AUTISM DEV DISORD, V9, P153, DOI 10.1007/BF01531531; Hintzen A., 2010, PHARM LSD; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Hubbard Edward M, 2007, Curr Psychiatry Rep, V9, P193, DOI 10.1007/s11920-007-0018-6; Hubbard EM, 2006, CORTEX, V42, P184, DOI 10.1016/S0010-9452(08)70343-5; JACOBS L, 1981, ARCH NEUROL-CHICAGO, V38, P211, DOI 10.1001/archneur.1981.00510040037005; JACOME DE, 1979, NEUROLOGY, V29, P1050, DOI 10.1212/WNL.29.7.1050; Jancke L, 2009, EUR J NEUROSCI, V29, P1287, DOI 10.1111/j.1460-9568.2009.06673.x; Kadosh RC, 2009, PSYCHOL SCI, V20, P258, DOI 10.1111/j.1467-9280.2009.02286.x; Kamal Sahar Mohamed, 2010, J Exp Pharmacol, V2, P65; KEMNER C, 1995, BIOL PSYCHIAT, V38, P150, DOI 10.1016/0006-3223(94)00247-Z; Kim U, 1998, J NEUROSCI, V18, P9500; Klimesch W, 2011, BRAIN RES, V1408, P52, DOI 10.1016/j.brainres.2011.06.003; Kometer M, 2013, J NEUROSCI, V33, P10544, DOI 10.1523/JNEUROSCI.3007-12.2013; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; KRAMER K, 1994, DEV BRAIN RES, V78, P142, DOI 10.1016/0165-3806(94)90019-1; LaFay L., 1987, VIRGINIA PILOT, P31; Leboyer M, 1999, BIOL PSYCHIAT, V45, P158, DOI 10.1016/S0006-3223(97)00532-5; Lee HM, 2012, P NATL ACAD SCI USA, V109, P1820, DOI 10.1073/pnas.1121358109; LESSELL S, 1979, NEUROLOGY, V29, P1524, DOI 10.1212/WNL.29.11.1524; Loui P, 2011, J COGNITIVE NEUROSCI, V23, P1015, DOI 10.1162/jocn.2010.21500; Lythgoe MFX, 2005, NEUROLOGY, V64, P397, DOI 10.1212/01.WNL.0000150526.09499.3E; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; Mattingley JB, 2001, NATURE, V410, P580, DOI 10.1038/35069062; McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P993; Miller BL, 2000, BRIT J PSYCHIAT, V176, P458, DOI 10.1192/bjp.176.5.458; Miller BL, 1998, NEUROLOGY, V51, P978, DOI 10.1212/WNL.51.4.978; Milner B., 1973, NEUROSCIENCES 3RD ST, P75; Mueller S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067329; Mulvenna C, 2005, CURR BIOL, V15, pR399, DOI 10.1016/j.cub.2005.05.039; Neufeld J, 2012, NEUROPSYCHOLOGIA, V50, P1471, DOI 10.1016/j.neuropsychologia.2012.02.032; Newbury DF, 2009, AM J MED GENET A, V149A, P588, DOI 10.1002/ajmg.a.32704; Nichols DE, 2004, PHARMACOL THERAPEUT, V101, P131, DOI 10.1016/j.pharmthera.2003.11.002; ORNITZ EM, 1978, COGNITIVE DEFECTS DE, P24; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Pesenti M, 2001, NAT NEUROSCI, V4, P103; Pralong E, 2002, PROG NEUROBIOL, V67, P173, DOI 10.1016/S0301-0082(02)00017-5; Presti D. E., 2004, TEONANACATL, P89; Previc F., 2011, ALTERING CONSCIOUSNE, V2, P43; Ramachandran V, 2001, J CONSCIOUSNESS STUD, V8, P3; Ramachandran VS, 2001, P ROY SOC B-BIOL SCI, V268, P979, DOI 10.1098/rspb.2000.1576; Rich AN, 2002, NAT REV NEUROSCI, V3, P43, DOI 10.1038/nrn702; Ro T, 2007, ANN NEUROL, V62, P433, DOI 10.1002/ana.21219; Ro T, 2013, CEREB CORTEX, V23, P1724, DOI 10.1093/cercor/bhs166; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; Rogowska A, 2011, REV GEN PSYCHOL, V15, P213, DOI 10.1037/a0024078; Rothen N, 2012, NEUROSCI BIOBEHAV R, V36, P1952, DOI 10.1016/j.neubiorev.2012.05.004; Rothen N, 2010, PERCEPTION, V39, P718, DOI 10.1068/p6680; Rouw R, 2007, NAT NEUROSCI, V10, P792, DOI 10.1038/nn1906; Sacks OW, 2012, HALLUCINATIONS: RESEARCH AND PRACTICE, P133, DOI 10.1007/978-1-4614-0959-5_11; Sagiv N., 2011, INTELLECTICA, V55, P81; Sagiv N, 2006, PROG BRAIN RES, V155, P259, DOI 10.1016/S0079-6123(06)55015-0; SCHAIN RJ, 1961, J PEDIATR-US, V58, P315, DOI 10.1016/S0022-3476(61)80261-8; Schott GD, 2012, BRAIN, V135, P1947, DOI 10.1093/brain/awr314; Schroeder CE, 2005, CURR OPIN NEUROBIOL, V15, P454, DOI 10.1016/j.conb.2005.06.008; Scruggs JL, 2003, NEUROSCI LETT, V346, P137, DOI 10.1016/S0304-3940(03)00547-0; Shanon B, 2003, J CONSCIOUSNESS STUD, V10, P69; Shanon B., 2002, ANTIPODES MIND; Simner J, 2006, PERCEPTION, V35, P1024, DOI 10.1068/p5469; Sinke C, 2012, CONSCIOUS COGN, V21, P1419, DOI 10.1016/j.concog.2012.03.009; Snyder A, 2009, PHILOS T R SOC B, V364, P1399, DOI 10.1098/rstb.2008.0290; Snyder Allan W, 2003, J Integr Neurosci, V2, P149, DOI 10.1142/S0219635203000287; Takeuchi N, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/823285; Tammet D., 2006, BORN BLUE DAY INSIDE; Terhune DB, 2012, HALLUCINATIONS: RESEARCH AND PRACTICE, P91, DOI 10.1007/978-1-4614-0959-5_7; Terhune DB, 2011, CURR BIOL, V21, P2006, DOI 10.1016/j.cub.2011.10.032; Thomas-Anterion C, 2010, PAIN, V150, P121, DOI 10.1016/j.pain.2010.04.010; Tomson SN, 2011, BEHAV BRAIN RES, V223, P48, DOI 10.1016/j.bbr.2011.03.071; Torres-Escalante JL, 2004, J NEUROSCI RES, V78, P268, DOI 10.1002/jnr.20247; TREFFERT DA, 2006, EXTRAORDINARY PEOPLE; Treffert DA, 2009, PHILOS T R SOC B, V364, P1351, DOI 10.1098/rstb.2008.0326; Trudeau LE, 2004, J PSYCHIATR NEUROSCI, V29, P296; Veenstra-VanderWeele J, 2012, P NATL ACAD SCI USA, V109, P5469, DOI 10.1073/pnas.1112345109; Vollenweider FX, 1997, NEUROPSYCHOPHARMACOL, V16, P357, DOI 10.1016/S0893-133X(96)00246-1; Vollenweider FX, 1998, NEUROREPORT, V9, P3897, DOI 10.1097/00001756-199812010-00024; Walsh R, 2005, J CONSCIOUSNESS STUD, V12, P5; Ward J., 2012, NEUROSCI BIOBEHAV R, DOI [10.1016/j.neubiorev.2012.07.007, DOI 10.1016/J.NEUBI0REV.2012.07.007]; Ward J, 2008, BRIT J PSYCHOL, V99, P127, DOI 10.1348/000712607X204164; Ward J, 2013, ANNU REV PSYCHOL, V64, P49, DOI 10.1146/annurev-psych-113011-143840; Weiss PH, 2009, BRAIN, V132, P65, DOI 10.1093/brain/awn304; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whitaker-Azmitia PM, 2005, INT J DEV NEUROSCI, V23, P75, DOI 10.1016/j.ijdevneu.2004.07.022; WHITAKERAZMITIA PM, 1994, NEUROPSYCHOPHARMACOL, V11, P125, DOI 10.1038/npp.1994.42; Yaro C, 2007, Q J EXP PSYCHOL, V60, P681, DOI 10.1080/17470210600785208; Young RL, 2004, NEUROCASE, V10, P215, DOI 10.1080/13554790490495140; Yuan JY, 2009, APOPTOSIS, V14, P469, DOI 10.1007/s10495-008-0304-8; Zamm A, 2013, NEUROIMAGE, V74, P359, DOI 10.1016/j.neuroimage.2013.02.024	141	25	25	0	80	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	OCT 21	2013	7								657	10.3389/fnhum.2013.00657			13	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	238BV	WOS:000325916500001	24155703	DOAJ Gold, Green Published			2021-06-18	
J	Volman, V; Ng, LJ				Volman, Vladislav; Ng, Laurel J.			Computer Modeling of Mild Axonal Injury: Implications for Axonal Signal Transmission	NEURAL COMPUTATION			English	Article							TRAUMATIC BRAIN-INJURY; POTASSIUM-ION ACCUMULATION; SPINAL-CORD AXONS; MYELINATED NERVE; WHITE-MATTER; HEAD-INJURY; CONDUCTION DEFICITS; CORPUS-CALLOSUM; SODIUM-CHANNELS; IN-VIVO	Diffusion imaging and postmortem studies of patients with mild traumatic brain injury (mTBI) of the concussive type are consistent with the observations of diffuse axonal injury to the white matter axons. Mechanical trauma to axons affects the properties of tetrodotoxin-sensitive sodium channels at the nodes of Ranvier, leading to axonal degeneration through intra-axonal accumulation of calcium ions and activation of calcium proteases; however, the immediate implications of axonal trauma regarding axonal functionality and their relevance to transient impairment of function as observed in concussion remain elusive. A biophysically realistic computational model of a myelinated axon was developed to investigate how mTBI could immediately affect axonal function. Traumatized axons showed alterations in signal propagation properties that nonlinearly depended on the level of trauma; subthreshold traumatized axons had decreased spike propagation time, whereas suprathreshold traumatized axons exhibited a slowdown of spike propagation and spike propagation failure. Trauma had consistently reduced axonal spike amplitude. The susceptibility of an axon to trauma could be modulated by the function of an ATP-dependent sodium-potassium pump. The results suggest a mechanism by which concussive mTBI could lead to the immediate impairment of signal propagation through the axon and the emerging dysfunctional neuronal information exchange.	[Volman, Vladislav; Ng, Laurel J.] L3 Appl Technol Simulat Engn & Testing, San Diego, CA 92121 USA; [Volman, Vladislav] Salk Inst Biol Studies, Computat Neurobiol Lab, La Jolla, CA 92037 USA; [Volman, Vladislav] Univ Calif San Diego, Ctr Theoret Biol Phys, La Jolla, CA 92093 USA	Volman, V (corresponding author), L3 Appl Technol Simulat Engn & Testing, San Diego, CA 92121 USA.	Vladislav.Volman@l-3com.com; Laurel.Ng@l-3com.com					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADELMAN WJ, 1973, J MEMBRANE BIOL, V13, P387, DOI 10.1007/BF01868237; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bazhenov M, 2004, J NEUROPHYSIOL, V92, P1116, DOI 10.1152/jn.00529.2003; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Boucher PA, 2012, J COMPUT NEUROSCI, V33, P301, DOI 10.1007/s10827-012-0387-7; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CHIU SY, 1979, J PHYSIOL-LONDON, V292, P149, DOI 10.1113/jphysiol.1979.sp012843; Choo A. M., 2011, SOC NEUR M, V159, pAA32; Coggan JS, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/065002; Coggan JS, 2010, P NATL ACAD SCI USA, V107, P20602, DOI 10.1073/pnas.1013798107; Destexhe A, 1994, J Comput Neurosci, V1, P195, DOI 10.1007/BF00961734; FRANKENHAEUSER B, 1964, J PHYSIOL-LONDON, V171, P302, DOI 10.1113/jphysiol.1964.sp007378; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; HEINEMANN U, 1977, EXP BRAIN RES, V27, P237; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hille B., 2001, IONS CHANNELS EXCITA; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; Huff TB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017176; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jensen MS, 1997, J NEUROPHYSIOL, V77, P1224; JONAS P, 1989, P NATL ACAD SCI USA, V86, P7238, DOI 10.1073/pnas.86.18.7238; Kager H, 2000, J NEUROPHYSIOL, V84, P495; Krishnan GP, 2011, J NEUROSCI, V31, P8870, DOI 10.1523/JNEUROSCI.6200-10.2011; Leao RM, 2005, J NEUROSCI, V25, P3724, DOI 10.1523/JNEUROSCI.3983-04.2005; Li JM, 2007, J BIOMECH, V40, P569, DOI 10.1016/j.jbiomech.2006.02.009; Lopreore CL, 2008, BIOPHYS J, V95, P2624, DOI 10.1529/biophysj.108.132167; Lundborg G, 1973, J Bone Joint Surg Br, V55, P390; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MORAN N, 1980, BIOPHYS J, V32, P939, DOI 10.1016/S0006-3495(80)85028-4; OGATA K, 1986, J HAND SURG-BRIT EUR, V11B, P10, DOI 10.1016/0266-7681(86)90003-3; Patel TP, 2012, ANN BIOMED ENG, V40, P23, DOI 10.1007/s10439-011-0390-6; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rickett T, 2011, J MED SYST, V35, P787, DOI 10.1007/s10916-010-9468-1; RINGO JL, 1994, CEREB CORTEX, V4, P331, DOI 10.1093/cercor/4.4.331; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Singh A, 2009, J NEUROTRAUM, V26, P627, DOI 10.1089/neu.2008.0621; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sun WJ, 2012, J NEUROTRAUM, V29, P611, DOI 10.1089/neu.2011.2086; Sun WJ, 2010, J NEUROPHYSIOL, V103, P469, DOI 10.1152/jn.00154.2009; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Wang JA, 2009, AM J PHYSIOL-CELL PH, V297, pC823, DOI 10.1152/ajpcell.00505.2008; WAXMAN SG, 1985, SCIENCE, V228, P1502, DOI 10.1126/science.2409596; WAXMAN SG, 1977, PROG NEUROBIOL, V8, P297, DOI 10.1016/0301-0082(77)90009-0; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yu N., 2012, PLOS COMPUT BIOL, V8; Yu Z, 2010, J NEUROPHYSIOL, V103, P499, DOI 10.1152/jn.00775.2009	61	25	25	1	20	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	0899-7667	1530-888X		NEURAL COMPUT	Neural Comput.	OCT	2013	25	10					2646	2681		10.1162/NECO_a_00491			36	Computer Science, Artificial Intelligence; Neurosciences	Computer Science; Neurosciences & Neurology	210HW	WOS:000323822800004	23777525				2021-06-18	
J	Boulet, T; Kelso, ML; Othman, SF				Boulet, Thomas; Kelso, Matthew L.; Othman, Shadi F.			Long-Term In Vivo Imaging of Viscoelastic Properties of the Mouse Brain after Controlled Cortical Impact	JOURNAL OF NEUROTRAUMA			English	Article						inverse problem; MRE; MRI; TBI; viscoelasticity	MAGNETIC-RESONANCE ELASTOGRAPHY; MR ELASTOGRAPHY; TISSUE ELASTICITY; INJURY; MICE; CONTUSION; BARRIER; EDEMA; RAT; INDENTATION	Traumatic brain injury (TBI) presents a variety of causes and symptoms, thus making the development of reliable diagnostic methods and therapeutic treatments challenging. Magnetic resonance elastography (MRE) is a technique that allows for a noninvasive assessment of the mechanical properties of soft biological tissue, such as tissue stiffness, storage modulus, and loss modulus. Importantly, by quantifying the changes in the stiffness of tissue that is often associated with disease, MRE is able to detect tissue pathologies at early stages. Recent improvements in instrumentation have allowed for the investigation of small samples with microscopic resolution (mu MRE). We hypothesize that mu MRE can sensitively detect variations in micromechanical properties in the brain caused by the compressive and shearing forces sustained during TBI. To test this hypothesis, we randomized 13 C57BL mice to receive a controlled cortical impact at a 0.5 mm or 0.75 mm depth, with both sham and naive mice as controls. Our objective was to propagate mechanical shear waves throughout the brain for in vivo TBI mu MRE imaging. The mechanical properties of the injured brain tissue were determined at days 0, 1, 7, and 28 post-injury. For both groups, we observed a significant drop in the stiffness of the impacted region immediately following the injury; the 0.75 mm animals experienced increased tissue softness that lasted longer than that for the 0.5 mm group. Although the shear stiffness, storage modulus, and loss modulus parameters all followed the same trend, the tissue stiffness yielded the most statistically significant results. Overall, this article introduces a transformative technique for mechanically mapping the brain and detecting brain diseases and injury.	[Boulet, Thomas] Univ Nebraska, Dept Engn Mech, Lincoln, NE 68583 USA; [Othman, Shadi F.] Univ Nebraska, Dept Biol Syst Engn, Lincoln, NE 68583 USA; [Kelso, Matthew L.] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharm Practice, Omaha, NE USA	Othman, SF (corresponding author), Univ Nebraska, Translat & Regenerat Med TREM Imaging Lab, 249 LW Chase Hall, Lincoln, NE 68583 USA.	sothman2@unl.edu			University of Nebraska-Lincoln (UNL)/University of Nebraska Medical Center (UNMC) Engineering for Medicine Research Collaboration Seed Grant; National Institutes of Health (NIH) COBRE grant [RR021937]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR021937] Funding Source: NIH RePORTER	The authors thank Vahid Khalilzad-Sharghi for his technical assistance with the MRE pulse sequence, as well as the publishers and authors mentioned in Table 2 for providing their permission to replicate a figure. The authors also thank Melody Montgomery for help in editing this manuscript. This research was supported in part by University of Nebraska-Lincoln (UNL)/University of Nebraska Medical Center (UNMC) Engineering for Medicine Research Collaboration Seed Grant and National Institutes of Health (NIH) COBRE grant RR021937 (Nebraska Center for Nanomedicine).	Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bitner BR, 2010, J CEREBR BLOOD F MET, V30, P1105, DOI 10.1038/jcbfm.2010.47; Boulet T, 2011, J NEUROSCI METH, V201, P296, DOI 10.1016/j.jneumeth.2011.08.019; Christ AF, 2010, J BIOMECH, V43, P2986, DOI 10.1016/j.jbiomech.2010.07.002; Clayton EH, 2011, PHYS MED BIOL, V56, P2391, DOI 10.1088/0031-9155/56/8/005; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000164; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Foley LM, 2009, J NEUROTRAUM, V26, P1509, DOI 10.1089/neu.2008.0747; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Fung Y., 1993, BIOMECHANICS MECH PR; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hamhaber U, 2010, J MAGN RESON IMAGING, V32, P577, DOI 10.1002/jmri.22294; Johnson C.L., 2012, MAGN RESON MED; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kelso ML, 2006, BRAIN RES, V1083, P204, DOI 10.1016/j.brainres.2006.01.127; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kuroiwa T, 1997, ACT NEUR S, V70, P87; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Manduca A, 2003, MED IMAGE ANAL, V7, P465, DOI 10.1016/S1361-8415(03)00038-0; Mariappan YK, 2010, CLIN ANAT, V23, P497, DOI 10.1002/ca.21006; Murphy MC, 2012, MAGN RESON IMAGING, V30, P535, DOI 10.1016/j.mri.2011.12.019; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Oliphant TE, 2001, MAGNET RESON MED, V45, P299, DOI 10.1002/1522-2594(200102)45:2<299::AID-MRM1039>3.0.CO;2-O; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Othman SF, 2005, MAGN RESON MED, V54, P605, DOI 10.1002/mrm.20584; Othman SF, 2012, NMR BIOMED, V25, P452, DOI 10.1002/nbm.1663; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Rnjak J, 2011, TISSUE ENG PART B-RE, V17, P81, DOI [10.1089/ten.teb.2010.0452, 10.1089/ten.TEB.2010.0452]; Romano AJ, 1998, IEEE T ULTRASON FERR, V45, P751, DOI 10.1109/58.677725; Schuhmann MU, 2002, ACTA NEUROCHIR SUPPL, V81, P213; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Shire NJ, 2011, J MAGN RESON IMAGING, V34, P947, DOI 10.1002/jmri.22716; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Warner L, 2011, INVEST RADIOL, V46, P509, DOI 10.1097/RLI.0b013e3182183a95	41	25	26	3	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2013	30	17					1512	1520		10.1089/neu.2012.2788			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202HX	WOS:000323205800007	23534701	Green Published			2021-06-18	
J	Larsson, J; Bjorkdahl, A; Esbjornsson, E; Sunnerhagen, KS				Larsson, Jerry; Bjorkdahl, Ann; Esbjornsson, Eva; Sunnerhagen, Katharina. S.			FACTORS AFFECTING PARTICIPATION AFTER TRAUMATIC BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						social participation; brain injury; depression; self-centring; cognitive	MINOR DEPRESSION; IMPACT; SCALE; MODEL; LIFE	Objective: The aim of this work was to explore the extent to which social, cognitive, emotional and physical aspects influence participation after a traumatic brain injury. Design/subjects: An explorative study of the patient perspective of participation 4 years after traumatic brain injury. The cohort consisted of all patients (age range 18-65 years), presenting in 1999-2000, admitted to the hospital (n=129). Sixty-three patients responded; 46 males and 17 females, mean age 41 (range 19-60) years. Methods: Four years after the injury, the European Brain Injury Questionnaire (EBIQ), EuroQoI-5D, Swedish Stroke Register Questionnaire and Impact on Participation and Autonomy (IPA) questionnaire were sent to the sample. Data were analysed with logistic regression. Results: On the EBIQ, 40% of the sample reported problems in most questions. According to IPA, between 20% and 40% did not perceive that they had a good participation. The analyses gave 5 predictors reflecting emotional and social aspects, which could explain up to 70% of the variation in participation. Conclusion: It is not easy to find single predictors, as there seems to be a close interaction between several aspects. Motor deficits appear to have smaller significance for participation in this late state, while emotional and social factors play a major role.	[Larsson, Jerry; Bjorkdahl, Ann; Esbjornsson, Eva; Sunnerhagen, Katharina. S.] Univ Gothenburg, Inst Neurosci & Physiol, Gothenburg, Sweden; [Bjorkdahl, Ann] Ersta Skondal Univ Coll, Gothenburg, Sweden; [Sunnerhagen, Katharina. S.] Univ Oslo, Fac Med, Sunaas Rehabil Hosp, Oslo, Norway	Larsson, J (corresponding author), Univ Gothenburg, Inst Neurosci & Physiol, Gothenburg, Sweden.	jerry.larsson@vgregion.se	Sunnerhagen, Katharina Stibrant/AAE-2405-2020	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400			Arango-Lasprilla JC, 2012, BRAIN INJURY, V26, P825, DOI 10.3109/02699052.2012.655364; Bedard M, 2012, ADV MIND BODY MED, V26, P6; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cicerone KD, 2004, J HEAD TRAUMA REHAB, V19, P494, DOI 10.1097/00001199-200411000-00006; COX DR, 1981, APPL STAT PRINCIPLES; Dykeman B, 2003, J INSTRUCTIONAL PSYC, P225; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Guillamondegui OD, 2011, 11EHC017EF AG HEALTH; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Hoyle M, 2012, BRAIN IMPAIR, V13, P4, DOI 10.1017/BrImp.2012.9; Huang SJ, 2010, BRAIN INJURY, V24, P1606, DOI 10.3109/02699052.2010.523056; Larsson J, 2010, SCAND J PUBLIC HEALT, V38, P541, DOI 10.1177/1403494810371143; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Nagelkerke NJD, 1992, MAXIMUM LIKELIHOOD E; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Sveen U, 2013, DISABIL REHABIL, V35, P749, DOI 10.3109/09638288.2012.707741; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Truelle JL, 2010, CURR OPIN NEUROL, V23, P688, DOI 10.1097/WCO.0b013e3283404258; Wise EK, 2010, ARCH PHYS MED REHAB, V91, P1357, DOI 10.1016/j.apmr.2010.06.009; World Health Organization, 2001, INT CLASS FUNCT DIS	28	25	27	0	13	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					765	770		10.2340/16501977-1184			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500011	24002312	DOAJ Gold, Green Published			2021-06-18	
J	Parra, MW; Zucker, L; Johnson, ES; Gullett, D; Avila, C; Wichner, ZA; Kokaram, CR				Parra, Michael W.; Zucker, Lloyd; Johnson, Eric S.; Gullett, Diane; Avila, Cristina; Wichner, Zachary A.; Kokaram, Candace R.			Dabigatran bleed risk with closed head injuries: are we prepared? Clinical article	JOURNAL OF NEUROSURGERY			English	Article						dabigatran; warfarin; closed head injury; anticoagulation reversal protocol; traumatic brain injury	TRAUMATIC INTRACRANIAL HEMORRHAGE; ATRIAL-FIBRILLATION; STROKE PREVENTION; WARFARIN REVERSAL; SINGLE-CENTER; ETEXILATE; MORTALITY; PHARMACODYNAMICS; PHARMACOKINETICS; ANTICOAGULATION	Object. The direct thrombin inhibitor dabigatran has recently been approved in the US as an alternative to warfarin. The lack of guidelines, protocols, and an established specific antidote to reverse the anticoagulation effect of dabigatran potentially increases the rates of morbidity and mortality in patients with closed head injury (CHI). Confronted with this new problem, the authors reviewed their initial clinical experience. Methods. The authors retrospectively reviewed all cases of adult patients (age >= 18 years) who sustained CHI secondary to ground-level falls and who presented to the authors' provisional regional Level I trauma center between February 2011 and May 2011. The authors divided these patients into 3 groups based on anticoagulant therapy: dabigatran, warfarin, and no anticoagulants. Results. Between February 2011 and May 2011, CHIs from ground-level falls were sustained by 5 patients while on dabigatran, by 15 patients on warfarin, and by 25 patients who were not on anticoagulants. The treatment of the patients on dabigatran at the authors' institution had great diversity. Repeat CT scans obtained during reversal showed 4 of 5 patients with new or expanded hemorrhages in the dabigatran group, whereas the warfarin group had 3 of 15 (p = 0.03). The overall mortality rate for patients sustaining CHI on dabigatran was 2(40%) of 5, whereas that of the warfarin group was 0 (0%) of 15 (p = 0.05). Conclusions. It is critical for physicians involved in the care of patients with CHI on dabigatran to be aware of an elevated mortality rate if no treatment protocol or guideline is in place. The authors will soon implement a reversal management protocol for patients with CHI on dabigatran at their institution in an attempt to improve efficacy and safety in their treatment approach.	[Parra, Michael W.; Zucker, Lloyd; Johnson, Eric S.; Gullett, Diane; Avila, Cristina; Wichner, Zachary A.; Kokaram, Candace R.] Delray Med Ctr, Provis Level Trauma Ctr 1, Delray Beach, FL USA; [Parra, Michael W.; Johnson, Eric S.; Avila, Cristina; Wichner, Zachary A.] Nova SE Univ, Coll Osteopath Med, Ft Lauderdale, FL 33314 USA	Parra, MW (corresponding author), Nova SE Univ, Sch Med, Dept Surg, Delray Med Ctr,Provis Level Trauma Ctr 1, 5352 Linton Blvd, Delray Beach, FL 33484 USA.	michaelwparra@yahoo.com					American College of Surgeons, NAT TRAUMA DAT REP 2; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Hanley JP, 2004, J CLIN PATHOL, V57, P1132, DOI 10.1136/jcp.2003.008904; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Kalina M, 2008, AM SURGEON, V74, P858; Makris M, 2001, BRIT J HAEMATOL, V114, P271, DOI 10.1046/j.1365-2141.2001.02908.x; OSLER T, 1988, AM J SURG, V156, P537, DOI 10.1016/S0002-9610(88)80548-8; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Safaoui MN, 2009, AM J SURG, V197, P785, DOI 10.1016/j.amjsurg.2008.04.003; Sartori MT, 2009, CLIN APPL THROMB-HEM, V15, P628, DOI 10.1177/1076029609335909; Sorensen B, 2006, THROMB HAEMOSTASIS, V96, P446, DOI 10.1160/TH06-04-0205; Stangier J, 2008, CLIN PHARMACOKINET, V47, P285, DOI 10.2165/00003088-200847050-00001; Stangier J, 2010, CLIN PHARMACOKINET, V49, P259, DOI 10.2165/11318170-000000000-00000; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Testerman George M, 2009, Tenn Med, V102, P37; Tran A, 2011, CARDIOL REV, V19, P154, DOI 10.1097/CRD.0b013e3182137758; van Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758; VANRYN J, 2008, HAEMATOL HEMATOL S1, V93, P148; Wallentin L, 2010, LANCET, V376, P975, DOI 10.1016/S0140-6736(10)61194-4	21	25	25	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2013	119	3					760	765		10.3171/2013.3.JNS12503			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	204IJ	WOS:000323358700028	23634730	Bronze			2021-06-18	
J	Hein, M; Zoremba, N; Bleilevens, C; Bruells, C; Rossaint, R; Roehl, AB				Hein, Marc; Zoremba, Norbert; Bleilevens, Chistian; Bruells, Christian; Rossaint, Rolf; Roehl, Anna B.			Levosimendan limits reperfusion injury in a rat middle cerebral artery occlusion (MCAO) model	BMC NEUROLOGY			English	Article						Experimental stroke; Postconditioning; Levosimendan; Cerebral reperfusion injury	ACUTE ISCHEMIC-STROKE; POTASSIUM CHANNEL; BRAIN-DAMAGE; SPINAL-CORD; EXPRESSION; RECOVERY; NEUROPROTECTION; HEMORRHAGE; INFARCTION; INHIBITION	Background: Neuroprotective strategies in ischemic stroke are an important challenge in clinical and experimental research as an adjunct to reperfusion therapy that may reduce neurologic injury and improve outcome. The neuroprotective properties of levosimendan in traumatic brain injury in vitro, transient global brain ischemia and focal spinal cord ischemia suggest the potential for similar effects in transient brain ischemia. Methods: Transient brain ischemia was induced for 60 min by intraluminal occlusion of the middle cerebral artery in 40 male Wistar rats under general anesthesia with s-ketamine and xylazine and with continuous monitoring of their blood pressure and cerebral perfusion. Five minutes before inducing reperfusion, a levosimendan bolus (24 mu g kg (-1)) was administered over a 20 minute period. Infarct size, brain swelling, neurological function and the expression of inflammatory markers were quantified 24 hours after reperfusion. Results: Although levosimendan limited the infarct size and brain swelling by 40% and 53%, respectively, no effect on neurological outcome or mortality could be demonstrated. Upregulation of tumor necrosis factor a and intercellular adhesion molecule 1 was significantly impeded. Cerebral blood flow during reperfusion was significantly reduced as a consequence of sustained autoregulation. Conclusions: Levosimendan demonstrated significant neuroprotective properties in a rat model of transient brain ischemia by reducing reperfusion injury.	[Hein, Marc; Zoremba, Norbert; Bleilevens, Chistian; Bruells, Christian; Rossaint, Rolf; Roehl, Anna B.] RWTH Aachen Univ Hosp, Dept Anesthesiol, D-52074 Aachen, Germany	Hein, M (corresponding author), RWTH Aachen Univ Hosp, Dept Anesthesiol, Pauwelstr 30, D-52074 Aachen, Germany.	mhein@ukaachen.de	Bleilevens, Christian/AAG-8034-2020	Bleilevens, Christian/0000-0002-2104-1843	Medical Faculty RWTH Aachen [10/2010]	This work was supported by the Medical Faculty RWTH Aachen (START grant number 10/2010). We would like to specifically thank Renate Nadenau and Christian Beckers (Department of Anaesthesiology) for their help in our laboratory.	Armstead WM, 2011, J NEUROTRAUM, V28, P105, DOI 10.1089/neu.2010.1581; Bleilevens C, 2013, EXP BRAIN RES, V224, P155, DOI 10.1007/s00221-012-3296-0; Cengiz SL, 2010, BRAIN INJURY, V24, P877, DOI 10.3109/02699051003789260; Choi SK, 2011, J KOREAN NEUROSURG S, V49, P1, DOI 10.3340/jkns.2011.49.1.1; Das B, 2007, VASC PHARMACOL, V47, P248, DOI 10.1016/j.vph.2007.06.008; David HN, 2003, J CEREBR BLOOD F MET, V23, P1168, DOI 10.1097/01.WCB.0000087342.31689.18; Bravo MD, 2011, NEONATOLOGY, V99, P217, DOI 10.1159/000314955; Denes A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-164; Dittmar M, 2003, STROKE, V34, P2252, DOI 10.1161/01.STR.0000083625.54851.9A; Domoki F, 1999, STROKE, V30, P2713, DOI 10.1161/01.STR.30.12.2713; Durukan A, 2007, PHARMACOL BIOCHEM BE, V87, P179, DOI 10.1016/j.pbb.2007.04.015; Encarnacion A, 2011, J NEUROSCI METH, V196, P247, DOI 10.1016/j.jneumeth.2011.01.010; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Haelewyn B, 2008, EXP NEUROL, V213, P238, DOI 10.1016/j.expneurol.2008.05.012; Hein M, 2009, ACTA ANAESTH SCAND, V53, P941, DOI 10.1111/j.1399-6576.2009.01994.x; Institute of Laboratory Animal Research, 1996, GUIDE CARE USE LAB A, V7th; Kang SW, 2011, BRAIN RES, V1371, P121, DOI 10.1016/j.brainres.2010.11.057; Katircioglu SF, 2008, J CARDIAC SURG, V23, P44, DOI 10.1111/j.1540-8191.2007.00486.x; Kramer M, 2010, J NEUROSCI METH, V187, P84, DOI 10.1016/j.jneumeth.2009.12.020; Lafci B, 2008, EUR SURG RES, V41, P1, DOI 10.1159/000121394; Mayanagi K, 2007, BRAIN RES, V1168, P106, DOI 10.1016/j.brainres.2007.06.071; Munakata H, 2010, PERFUSION-UK, V25, P159, DOI 10.1177/0267659110370068; Nogueira RG, 2009, AM J NEURORADIOL, V30, P859, DOI 10.3174/ajnr.A1604; Robin E, 2011, BRAIN RES, V1375, P137, DOI 10.1016/j.brainres.2010.12.054; Roehl AB, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-81; Roehl AB, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-97; Ryang YM, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-113; Segreti JA, 2008, J PHARMACOL EXP THER, V325, P331, DOI 10.1124/jpet.107.132530; Sheng SP, 2012, ANESTHESIOLOGY, V117, P1262, DOI 10.1097/ALN.0b013e3182746b81; Shuaib A, 2011, LANCET NEUROL, V10, P909, DOI 10.1016/S1474-4422(11)70195-8; Strom JO, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-41; Sutherland BA, 2012, INT J STROKE, V7, P407, DOI 10.1111/j.1747-4949.2012.00770.x; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; Ulbrich C, 2012, J STEROID BIOCHEM, V131, P10, DOI 10.1016/j.jsbmb.2012.01.007; Vemuganti R, 2004, STROKE, V35, P179, DOI 10.1161/01.STR.0000106479.53235.3E; Xu XH, 2006, LIFE SCI, V78, P704, DOI 10.1016/j.lfs.2005.05.080; Yoshimura S, 2008, ANN NEUROL, V64, P547, DOI 10.1002/ana.21459; Zhu HL, 2008, NEUROSCIENCE, V157, P884, DOI 10.1016/j.neuroscience.2008.09.033	39	25	30	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	AUG 12	2013	13								106	10.1186/1471-2377-13-106			8	Clinical Neurology	Neurosciences & Neurology	200NI	WOS:000323075400001	23937651	DOAJ Gold, Green Published			2021-06-18	
J	Kvandal, P; Sheppard, L; Landsverk, SA; Stefanovska, A; Kirkeboen, KA				Kvandal, Per; Sheppard, Lawrence; Landsverk, Svein A.; Stefanovska, Aneta; Kirkeboen, Knut A.			Impaired cerebrovascular reactivity after acute traumatic brain injury can be detected by wavelet phase coherence analysis of the intracranial and arterial blood pressure signals	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article; Proceedings Paper	SCAI 10th International Conference on Complexity in Acute Illness (ICCAI)	SEP, 2011	Bonn, GERMANY	Soc Complex Acute Illness (SCAI)		Brain injury; Autoregulation; Cerebrovascular reactivity; Cerebral perfusion pressure; Wavelet transform; Spectral energy; Wavelet phase coherence; Phase shift	CEREBRAL VASOMOTOR REACTIVITY; HEAD-INJURY; FLOW VELOCITY; TIME-SERIES; AUTOREGULATION; OSCILLATIONS; SKIN	The objective of the study was to evaluate the wavelet spectral energy of oscillations in the intracranial pressure (ICP) signal in patients with acute traumatic brain injury (TBI). The wavelet phase coherence and phase shift in the 0.006-2 Hz interval between the ICP and the arterial blood pressure (ABP) signals were also investigated. Patients were separated into normal or impaired cerebrovascular reactivity, based on the pressure reactivity index (PRx). Spectral energy, phase coherence and phase shift in the low frequency and cardiorespiratory intervals were compared for the two groups. Data were prospectively collected and analyzed retrospectively in 22 patients, within the first week after acute TBI. The ICP and ABP signals were continuously recorded for 40 min and the wavelet transform was used to calculate the spectral energy and phase of the signals. The average ICP wavelet energy spectrum showed distinct peaks around 1.0 (cardiac), 0.25 (respiratory) and 0.03 Hz. Patients with normal cerebrovascular reactivity (negative PRx) had 38.6 % (+/- SD 16.7 %) of the mean wavelet energy below the lower limit of the respiratory frequency band (0.14 Hz) compared to only 18.1 % (+/- SD 17.8 %) in patients with altered cerebrovascular reactivity (positive PRx) (difference: p = 0.0057). Wavelet phase coherence between the ABP and ICP signals was statistically significant (p < 0.05) in the 0.006-2 Hz interval. The phase shift between the ABP and ICP signals was around zero in the 0.14-1.0 Hz interval. Seven patients with PRx between -0.4943 and -0.1653 had a phase shift in the interval 0.07-0.14 Hz, whereas 15 patients with PRx between -0.1019 and 0.3881 had a phase shift in the interval 0.006-0.07 Hz. We conclude that the wavelet transform of the ICP signal shows spectral peaks at the cardiac, respiratory and 0.03 Hz frequencies. Normal cerebrovascular reactivity seems to be manifested as increased spectral energy in the frequency interval < 0.14 Hz. A phase shift between the ICP and ABP signals in the interval 0.07-0.14 Hz indicates normal cerebrovascular reactivity, while a phase shift in the interval 0.006-0.07 Hz indicates altered cerebrovascular reactivity.	[Kvandal, Per] Oslo Univ Hosp, Intens Care Unit, N-0407 Oslo, Norway; [Sheppard, Lawrence; Stefanovska, Aneta] Univ Lancaster, Dept Phys, Nonlinear Biomed Phys Grp, Lancaster, England; [Landsverk, Svein A.; Kirkeboen, Knut A.] Dept Anesthesiol, Ulleval, Norway; [Landsverk, Svein A.; Kirkeboen, Knut A.] Univ Oslo, Fac Med, Oslo Univ Hosp, Oslo, Norway	Kvandal, P (corresponding author), Oslo Univ Hosp, Intens Care Unit, N-0407 Oslo, Norway.	uxpekv@ous-hf.no; aneta@lancaster.ac.uk	Stefanovska, Aneta/AAH-3651-2020; Sheppard, Lawrence/P-3653-2016	Stefanovska, Aneta/0000-0001-6952-8370; 			Addison P, 2002, ILLUSTRATED WAVELET; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Bandrivskyy A., 2004, CARDIOVASC ENG, V4, P89, DOI [DOI 10.1023/B:CARE.0000025126.63253.43, 10.1023/B:CARE.0000025126.63253.43]; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Kvandal P, 2006, MICROVASC RES, V72, P120, DOI 10.1016/j.mvr.2006.05.006; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; Lang EW, 1999, NEUROL RES, V21, P665, DOI 10.1080/01616412.1999.11740995; Latka M, 2007, PHYSIOL MEAS, V28, P465, DOI 10.1088/0967-3334/28/5/002; Lemaire JJ, 2002, ACTA NEUROCHIR, V144, P243, DOI 10.1007/s007010200032; Lewis PM, 2008, ACTA NEUROCHIR, V150, P139, DOI 10.1007/s00701-007-1447-z; Morlet J., 1983, NATO ASI SER, VI, P233, DOI DOI 10.1007/978-3-642-82002-1_12; Schreiber T, 2000, PHYSICA D, V142, P346, DOI 10.1016/S0167-2789(00)00043-9; Sheppard LW, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.046205; Soderstrom T, 2003, AM J PHYSIOL-HEART C, V284, pH1638, DOI 10.1152/ajpheart.00826.2000; Stefanovska A, 1999, IEEE T BIO-MED ENG, V46, P1230, DOI 10.1109/10.790500; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Zunker P, 1986, NEW TRENDS CEREBRAL, P718	23	25	29	0	21	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307			J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	AUG	2013	27	4			SI		375	383		10.1007/s10877-013-9484-z			9	Anesthesiology	Anesthesiology	175VJ	WOS:000321261400002	23748602	Other Gold, Green Accepted, Green Published			2021-06-18	
J	Silverberg, ND; Lange, RT; Millis, SR; Rose, A; Hopp, G; Leach, S; Iverson, GL				Silverberg, Noah D.; Lange, Rael T.; Millis, Scott R.; Rose, Alice; Hopp, Grace; Leach, Suzanne; Iverson, Grant L.			Post-Concussion Symptom Reporting after Multiple Mild Traumatic Brain Injuries	JOURNAL OF NEUROTRAUMA			English	Article						concussion; cumulative effects; head trauma; mild traumatic brain injury; post-concussion syndrome	SPORT-RELATED CONCUSSION; POSTCONCUSSION-LIKE SYMPTOMS; COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; NEUROCOGNITIVE PERFORMANCE; TEMPORAL WINDOW; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; HISTORY; VULNERABILITY	The relationship between previous mild traumatic brain injury/ injuries (MTBI) and recovery from a subsequent MTBI may be complex. The present study investigated three factors hypothesized to influence this relation: (1) the number of prior MTBIs, (2) the interval between MTBIs, and (3) the certainty level of previous MTBIs. The study design was retrospective cross-sectional. Participants (N = 105) were evaluated at a concussion clinic on average 1 month after sustaining an MTBI, defined by World Health Organization diagnostic criteria. Approximately half the sample had at least one previous MTBI. Subgroups with 0, 1, or 2 + previous MTBIs did not differ in levels of current post-concussion symptom reporting on the British Columbia Post-Concussion Symptom Inventory. Time since the most recent previous MTBI was significantly associated with current post-concussion symptom reporting. This relation was best characterized as logarithmic; i.e., the impact of previous MTBI(s) lessens exponentially as time elapses to a subsequent MTBI. Defining previous MTBIs with a higher certainty level (i.e., probable versus possible) was not consistently associated with greater post-concussion symptom reporting. In conclusion, participants with multiple MTBIs did not report more post-concussion symptoms than those with no history of MTBI. Previous MTBI(s), however, were associated with increased symptom reporting from a subsequent MTBI to the extent they occurred closer in time. Having one or two previous remote MTBIs was not associated with worse outcome from subsequent MTBI in this sample.	[Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Dept Med, GF Strong Rehab Ctr, Vancouver, BC V5Z 2G9, Canada; [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, North Bethesda, MD USA; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 2G9, Canada; [Millis, Scott R.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Rose, Alice] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Hopp, Grace] Independent Practice, Port Coquitlam, BC, Canada; [Leach, Suzanne] Simon Fraser Univ, Ctr Students Disabil, Burnaby, BC V5A 1S6, Canada; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA	Silverberg, ND (corresponding author), Univ British Columbia, Div Phys Med & Rehabil, Dept Med, GF Strong Rehab Ctr, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Iverson, Grant/0000-0001-7348-9570			Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Edmed S, 2012, PSYCHIAT RES, V200, P41, DOI 10.1016/j.psychres.2012.05.022; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Gardner A, 2010, EVOLUTION, V64, P25, DOI 10.1111/j.1558-5646.2009.00842.x; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harris AW, 2012, CLIN J SPORT MED, V22, P91, DOI 10.1097/JSM.0b013e31823776cb; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/316575; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kirsch NL, 2010, ARCH PHYS MED REHAB, V91, P35, DOI 10.1016/j.apmr.2009.09.019; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; MacGregor AJ, 2011, J REHABIL RES DEV, V48, P1269, DOI 10.1682/JRRD.2011.01.0013; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Sullivan K, 2011, J HEAD TRAUMA REHAB, V26, P170, DOI 10.1097/HTR.0b013e3181e47f95; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	57	25	25	0	29	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2013	30	16					1398	1404		10.1089/neu.2012.2827			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	199JB	WOS:000322989500003	23458451				2021-06-18	
J	Deans, KJ; Minneci, PC; Lowell, W; Groner, JI				Deans, Katherine J.; Minneci, Peter C.; Lowell, Wendi; Groner, Jonathan I.			Increased morbidity and mortality of traumatic brain injury in victims of nonaccidental trauma	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Child abuse; nonaccidental trauma (NAT); traumatic brain injury (TBI); intentional injury; intentional trauma	ABUSIVE HEAD TRAUMA; DECOMPRESSIVE CRANIECTOMY; PHYSICAL ABUSE; OUTCOMES; MODEL	BACKGROUND: The purpose of this study was to determine if the morbidity and mortality associated with traumatic brain injury (TBI) are worse in children who experienced nonaccidental trauma (NAT) compared with TBI from other traumatic mechanisms. METHODS: We identified all pediatric patients admitted with the diagnosis of TBI between 2001 and 2010 in our institutional trauma registry with an Abbreviated Injury Scale (AIS) score greater than 1. Patients were divided into groups based on a nonaccidental (NAT) or accidental mechanism of injury. Need for gastrostomy tube insertion was used as a marker of more severe neurologic morbidity in survivors of TBI. Group comparisons were made using Fisher's exact tests. RESULTS: A total of 2,782 patients with TBI were included; 315 (11.3%) patients had TBI secondary to NAT. Overall mortality and AIS-specific mortality were higher in patients with TBI secondary to NAT. In comparison with patients with TBI secondary to accidental mechanisms, patients with TBI secondary to NAT were younger (mean, 1 year vs. 8 years), had longer intensive care unit stays (mean, 3 days vs. 1 day), and required gastrostomy tubes more often (6% vs. 1%, p < 0.0001). Even among the subgroup of patients with severe TBI, (AIS score 4 and 5), patients with NAT required gastrostomy tubes more often (5% vs. 2%, p = 0.014). CONCLUSION: Patients with TBI from NAT have increased morbidity and mortality compared with patients with TBI from accidental mechanisms; these differences are present at all levels of severity of injury. Patients with TBI from NAT represent a vulnerable group of pediatric trauma patients who are at increased risk for death and worse outcome and who will require greater short-and long-term medical resources. (J Trauma Acute Care Surg. 2013; 75: 157-160. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Deans, Katherine J.; Minneci, Peter C.] Nationwide Childrens Hosp, Ctr Surg Outcomes Res, Columbus, OH 43205 USA; [Lowell, Wendi; Groner, Jonathan I.] Nationwide Childrens Hosp, Trauma Program, Columbus, OH 43205 USA; [Deans, Katherine J.; Minneci, Peter C.; Groner, Jonathan I.] Ohio State Univ, Coll Med, Dept Surg, Columbus, OH 43210 USA	Groner, JI (corresponding author), Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA.	Jonathan.groner@nationwidechildrens.org	Groner, Jonathan/E-3156-2011	Groner, Jonathan/0000-0002-0998-593X			Ashwal S, 2010, DEV NEUROSCI-BASEL, V32, P343, DOI 10.1159/000316801; Barr RG, 2012, P NATL ACAD SCI USA, V109, P17294, DOI 10.1073/pnas.1121267109; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Berger RP, 2011, PEDIATRICS, V128, P637, DOI 10.1542/peds.2010-2185; Carroll Christopher P, 2010, Ann Adv Automot Med, V54, P233; Cuff S, 2007, J TRAUMA, V63, P172, DOI 10.1097/TA.0b013e31805c14b1; Finnie JW, 2012, J CLIN NEUROSCI, V19, P1159, DOI 10.1016/j.jocn.2011.12.019; Finnie JW, 2010, J CLIN NEUROSCI, V17, P237, DOI 10.1016/j.jocn.2009.07.001; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Leventhal JM, 2012, PEDIATRICS, V130, P847, DOI 10.1542/peds.2012-0922; Leventhal JM, 2012, PEDIATRICS, V129, P458, DOI 10.1542/peds.2011-1277; Oluigbo CO, 2012, J NEUROSURG-PEDIATR, V9, P125, DOI 10.3171/2011.11.PEDS09449	13	25	27	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2013	75	1					157	160		10.1097/TA.0b013e3182984acb			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	300EV	WOS:000330448100039	23940862				2021-06-18	
J	Dizdar, D; Tiftik, T; Kara, M; Tunc, H; Ersoz, M; Akkus, S				Dizdar, Dilek; Tiftik, Tulay; Kara, Murat; Tunc, Hakan; Ersoz, Murat; Akkus, Selami			Risk factors for developing heterotopic ossification in patients with traumatic brain injury	BRAIN INJURY			English	Article						Heterotopic ossification; traumatic brain injury; functional ambulation category; severity of injury	SPINAL-CORD INJURY; URINARY-INCONTINENCE; BONE-FORMATION; REHABILITATION; TONE	Objective: To evaluate the possible risk factors of heterotopic ossification (HO) in traumatic brain injury (TBI) patients. Methods: A total of 151 patients with TBI were included. Demographical variables, laboratory investigations and risk factors for HO including spasticity, walking ability (using Functional Ambulation Category (FAC)), pressure ulcer, neurogenic bladder and systemic infection were recorded. Results: Fifty-six patients (37.1%) had HO. Time since injury and serum ALP and ESR levels were significantly higher in HO patients than in non-HO patients. Hip (73.2%) and knee (44.6%) were the most commonly involved joints. This study has detected significant associations between FAC scores (FAC 0-1-2 vs. FAC 3-4-5, p<0.001), degree of spasticity (p=0.01), pressure ulcer (Absent/Grade 1 vs. Grade 2, 3 and 4, p=0.001), presence of neurogenic bladder (p<0.001) and systemic infection (p=0.002) with the development of HO. According to the final logistical regression analysis, only lower FAC score was independently associated with HO development (p=0.006). Conclusion: As lower scores of FAC is an independent risk factor for HO formation and is related to the severity and consequences of injury, ambulation and regular/cautious mobilization of the joints are of paramount importance in the early period of the rehabilitation in TBI patients.	[Dizdar, Dilek; Tiftik, Tulay; Kara, Murat; Tunc, Hakan; Ersoz, Murat; Akkus, Selami] Ankara Phys Med & Rehabil Educ & Res Hosp, Ankara, Turkey	Tiftik, T (corresponding author), Ankara Fizik Tedavi Egitim & Arastirma Hastanesi, Ankara, Turkey.	drttiftik@gmail.com					BRAVOPAYNO P, 1992, PARAPLEGIA, V30, P740, DOI 10.1038/sc.1992.142; BUSCHBACHER R, 1992, CRIT REV PHYS MED RE, V4, P199; Chua K, 2003, BRAIN INJURY, V17, P469, DOI 10.1080/02699050210154268; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; da Paz AC, 2007, MED HYPOTHESES, V68, P67, DOI 10.1016/j.mehy.2006.06.035; Daud O, 1993, Disabil Rehabil, V15, P114; Ersoz M, 2011, TURK FIZ TIP REHAB D, V57, P80, DOI 10.4274/tftr.57.16; Flin C., 2002, Annales de Readaptation et de Medecine Physique, V45, P517, DOI 10.1016/S0168-6054(02)00305-7; GARLAND DE, 1988, CLIN ORTHOP RELAT R, P86; Garland DE., 1995, TRAUMATIC BRAIN INJU, P119; Gebuhr P, 1996, ACTA ORTHOP SCAND, V67, P29, DOI 10.3109/17453679608995604; Greenwood R, 1993, NEUROLOGICAL REHABIL, P206; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Jacobsen S, 1995, Ugeskr Laeger, V157, P5385; Krimchansky BZ, 1999, BRAIN INJURY, V13, P899; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; MIELANTS H, 1975, ACTA ORTHOP SCAND, V46, P190, DOI 10.3109/17453677508989207; Moiyadi AV, 2007, NEUROREHABILITATION, V22, P93; Oostra K, 1996, BRAIN INJURY, V10, P459, DOI 10.1080/026990596124313; ORZEL JA, 1985, J NUCL MED, V26, P125; Rosenthal M, 1999, CONTEMP PSYCHOL, V44, P63; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; SPIELMAN G, 1983, ARCH PHYS MED REHAB, V64, P539; Stohrer M, 2009, EUR UROL, V56, P81, DOI 10.1016/j.eururo.2009.04.028; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; van Kampen PJ, 2011, J HEAD TRAUMA REHAB, V26, P384, DOI 10.1097/HTR.0b013e3181f78a59; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; WADE DT, 1985, Q J MED, V56, P601; YOUNGSON HA, 1994, BRAIN INJURY, V8, P23, DOI 10.3109/02699059409150956	32	25	30	0	11	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					807	811		10.3109/02699052.2013.775490			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200006	23730889				2021-06-18	
J	Gonda, DD; Meltzer, HS; Crawford, JR; Hilfiker, ML; Shellington, DK; Peterson, BM; Levy, ML				Gonda, David D.; Meltzer, Hal S.; Crawford, John R.; Hilfiker, Mary L.; Shellington, David K.; Peterson, Bradley M.; Levy, Michael L.			Complications Associated With Prolonged Hypertonic Saline Therapy in Children With Elevated Intracranial Pressure	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						acute kidney injury; acute respiratory distress syndrome; anemia; hypertonic saline solution; intracranial hypertension; neutropenia; thrombocytopenia	TRAUMATIC BRAIN-INJURY; ACUTE KIDNEY INJURY; SEVERE HEAD-INJURY; CONSENSUS CONFERENCE; BARBITURATE COMA; CEREBRAL EDEMA; RENAL-FAILURE; RESUSCITATION; MANNITOL; FLUID	Objectives: Safe upper limits for therapeutic hypernatremia in the treatment of intracranial hypertension have not been well established. We investigated complications associated with hypernatremia in children who were treated with prolonged infusions of hypertonic saline. Design: Retrospective chart analysis. Setting: PICU in university-affiliated children's hospital. Patients: All children from 2004 to 2009 requiring intracranial pressure monitoring (external ventricular drain or fiberoptic intraparenchymal monitor) for at least 4 days who were treated with hypertonic saline infusion for elevated intracranial pressure and did not meet exclusion criteria. Intervention: Continuous hypertonic saline infusion on a sliding scale was used to achieve target sodium levels that would keep intracranial pressure less than 20 mm Hg once the conventional therapies failed. Measurements and Main Results: Eighty-eight children met inclusion criteria. Etiologies of elevated intracranial pressure included trauma (n = 48), ischemic or hemorrhagic stroke (n = 20), infection (n = 8), acute disseminated encephalomyelitis (n = 5), neoplasm (n = 2), and others (n = 5). The mean peak serum sodium was 171.3 mEq/L (range, 150-202). The mean Glasgow Outcome Score was 2.8 (+/- 1.1) at time of discharge from the hospital. Overall mortality was 15.9%. Children with sustained (> 72 hr) serum sodium levels above 170 mEq/L had a significantly higher occurrence of thrombocytopenia (p < 0.001), renal failure (p < 0.001), neutropenia (p = 0.006), and acute respiratory distress syndrome (p = 0.029) after controlling for variables of age, gender, Pediatric Risk of Mortality score, duration of barbiturate-induced coma, duration of intracranial pressure monitoring, vasopressor requirements, and underlying pathology. Children with sustained serum sodium levels greater than 165 mEq/L had a significantly higher prevalence of anemia (p < 0.001). Conclusions: Children treated by continuous hypertonic saline infusion for intracranial hypertension whose serum sodium levels exceeded certain thresholds experienced significantly more events of acute renal failure, thrombocytopenia, neutropenia, anemia, and acute respiratory distress syndrome than those whose sodium level was maintained below these thresholds.	[Gonda, David D.; Meltzer, Hal S.; Levy, Michael L.] Univ Calif San Diego, San Diego Med Ctr, Div Neurosurg, San Diego, CA 92103 USA; [Meltzer, Hal S.; Levy, Michael L.] Rady Childrens Hosp, Div Neurosurg, San Diego, CA USA; [Crawford, John R.] Rady Childrens Hosp, Dept Neurol, San Diego, CA USA; [Hilfiker, Mary L.] Rady Childrens Hosp, Div Pediat Surg, San Diego, CA USA; [Shellington, David K.; Peterson, Bradley M.] Rady Childrens Hosp, Dept Crit Care Med, San Diego, CA USA	Gonda, DD (corresponding author), Univ Calif San Diego, San Diego Med Ctr, Div Neurosurg, San Diego, CA 92103 USA.	dgonda@ucsd.edu	Levy, Michael/AAL-4647-2020	Shellington, David/0000-0001-6708-6978			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS40; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; Akcan-Arikan A, 2007, KIDNEY INT, V71, P1028, DOI 10.1038/sj.ki.5002231; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Bennett TD, 2012, CRIT CARE MED, V40, P208, DOI 10.1097/CCM.0b013e31822e9d31; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BINGHAM WF, 1986, SURG NEUROL, V25, P340, DOI 10.1016/0090-3019(86)90207-7; Ciesla DJ, 2000, J TRAUMA, V48, P388, DOI 10.1097/00005373-200003000-00004; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; DuBose JJ, 2010, J TRAUMA, V68, P1172, DOI 10.1097/TA.0b013e3181d76d40; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; GERBER JG, 1979, AM J PHYSIOL, V237, pF441; Greinacher A, 2010, HEMATOL-AM SOC HEMAT, P135, DOI 10.1182/asheducation-2010.1.135; Hanke AA, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-12; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; HUANG PP, 1995, ANN SURG, V221, P543, DOI 10.1097/00000658-199505000-00012; Huang SJ, 2006, SURG NEUROL, V65, P539, DOI 10.1016/j.surneu.2005.11.019; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Liumbruno G, 2009, BLOOD TRANSFUS-ITALY, V7, P132, DOI 10.2450/2009.0005-09; Liumbruno G, 2009, BLOOD TRANSFUS-ITALY, V7, P49, DOI 10.2450/2008.0020-08; Llompart-Pou JA, 2007, J ENDOCRINOL INVEST, V30, P393, DOI 10.1007/BF03346316; Lozance K, 1998, J CLIN NEUROSCI, V5, P394, DOI 10.1016/S0967-5868(98)90269-7; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Murao Y, 2000, SHOCK, V14, P18, DOI 10.1097/00024382-200014010-00004; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; R Development Core Team, 2011, R LANG ENV STAT COMP; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Therneau T., PACKAGE SURVIVAL ANA PACKAGE SURVIVAL ANA PACKAGE SURVIVAL ANA; TODD MM, 1985, ANESTH ANALG, V64, P681; Yildizdas D, 2006, INDIAN PEDIATR, V43, P771	42	25	27	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUL	2013	14	6					610	620		10.1097/PCC.0b013e318291772b			11	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	AL4IF	WOS:000339095600012	23823197				2021-06-18	
J	Kuo, JR; Cheng, YH; Chen, YS; Chio, CC; Gean, PW				Kuo, Jinn-Rung; Cheng, Yi-Hsuan; Chen, Yi-Shion; Chio, Chung-Ching; Gean, Po-Wu			Involvement of Extracellular Signal Regulated Kinases in Traumatic Brain Injury-Induced Depression in Rodents	JOURNAL OF NEUROTRAUMA			English	Article						antidepressant; depression; extracellular signal regulated kinases (ERK); hippocampus; traumatic brain injury	MAP KINASE; FLUOXETINE; DISORDER; BEHAVIOR; MODEL; RATES	Traumatic brain injury (TBI) is the most common cause of death and acquired disability among children and young adults in the developed countries. In clinical studies, the incidence of depression is high after TBI, and the mechanisms behind TBI-induced depression remain unclear. In the present study, we subjected rats to a moderate fluid percussion into the closed cranial cavity to induce TBI. After 3 days of recovery, injured rats were given a forced swim test (FST) and novelty-suppressed feeding tests. We found that TBI rats exhibited increased duration of immobility and longer latency to begin chewing food in a new environment compared with sham-operated rats. Western blot analysis showed that TBI led to a decrease in the phosphorylated levels of extracellular signal regulated kinases (ERK1/2) and p38 mitogen-activated protein kinase (p38 MAPK). Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), significantly reduced the duration of immobility when administered once per day for 14 days. Consistent with behavioral tests, fluoxetine treatment reversed TBI-induced decrease in p-ERK1/2 and p-p38 MAPK levels. Pre-treatment with a selective tryptophan hydroxylase inhibitor para-chlorophenylalanine (PCPA) blocked the antidepressant effect of fluoxetine. PCPA also prevented the effect of fluoxetine on ERK1/2 phosphorylation without affecting p38 MAPK phosphorylation. Pre-treatment with ERK inhibitor SL327 but not p38 MAPK inhibitor SB203580 prevented the antidepressant effect of fluoxetine. These results suggest that ERK1/2 plays a critical role in TBI-induced depression.	[Kuo, Jinn-Rung; Chio, Chung-Ching] Taiwan Univ Sci & Technol, Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan; [Kuo, Jinn-Rung] Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Cheng, Yi-Hsuan; Chen, Yi-Shion; Gean, Po-Wu] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan	Gean, PW (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.	Chiocc@ms28.hinet.net; powu@mail.ncku.edu.tw			National Health Research InstituteNational Health Research Institutes - Taiwan [NHRI-EX101-10117NI]; National Science CouncilMinistry of Science and Technology, Taiwan [NSC101-2321-B-006-025]; Aim for the Top University Project of the National Cheng-Kung University	This study was supported by grants NHRI-EX101-10117NI from the National Health Research Institute, NSC101-2321-B-006-025 from the National Science Council and Aim for the Top University Project of the National Cheng-Kung University. We thank Dr Min-Der Lai for critical comments on thearticle.	Adachi M, 2008, BIOL PSYCHIAT, V63, P642, DOI 10.1016/j.biopsych.2007.09.019; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; CLIFTON PG, 1989, PSYCHOPHARMACOLOGY, V97, P89, DOI 10.1007/BF00443419; Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8; Duman CH, 2007, BIOL PSYCHIAT, V61, P661, DOI 10.1016/j.biopsych.2006.05.047; Duric V, 2010, NAT MED, V16, P1328, DOI 10.1038/nm.2219; Dwivedi Y, 2001, J NEUROCHEM, V77, P916, DOI 10.1046/j.1471-4159.2001.00300.x; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Feng PF, 2003, BRAIN RES, V991, P195, DOI 10.1016/j.brainres.2003.08.018; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Fumagalli F, 2005, J NEUROCHEM, V93, P1551, DOI 10.1111/j.1471-4159.2005.03149.x; Harrison PJ, 2002, BRAIN, V125, P1428, DOI 10.1093/brain/awf149; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huber D, 2008, NATURE, V451, P61, DOI 10.1038/nature06445; Iversen L, 2003, BRAIN, V126, P1252, DOI 10.1093/brain/awg143; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; KOE BK, 1966, J PHARMACOL EXP THER, V154, P499; MacQueen GM, 2008, BIOL PSYCHIAT, V64, P880, DOI 10.1016/j.biopsych.2008.06.027; Manji HK, 2001, NAT MED, V7, P541, DOI 10.1038/87865; Nielsen CK, 2000, BEHAV BRAIN RES, V107, P21; Page ME, 1999, PSYCHOPHARMACOLOGY, V147, P162, DOI 10.1007/s002130051156; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Rajkowska G, 2003, NEUROSCIENTIST, V9, P273, DOI 10.1177/1073858403252773; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Savitz J, 2009, NEUROSCI BIOBEHAV R, V33, P699, DOI 10.1016/j.neubiorev.2009.01.004; Sheline YI, 2003, BIOL PSYCHIAT, V54, P338, DOI 10.1016/S0006-3223(03)00347-0; Stedenfeld KA, 2011, PHYSIOL BEHAV, V103, P210, DOI 10.1016/j.physbeh.2011.02.001; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Yin HQ, 2008, INFLAMMATION, V31, P65, DOI 10.1007/s10753-007-9050-2; Zheng SQ, 2004, MOL PHARMACOL, V65, P1172, DOI 10.1124/mol.65.5.1172	37	25	25	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1223	1231		10.1089/neu.2012.2689			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100002	23360216	Green Published			2021-06-18	
J	Solaiman, O; Singh, JM				Solaiman, Othman; Singh, Jeffrey M.			Hypocapnia in Aneurysmal Subarachnoid Hemorrhage: Incidence and Association With Poor Clinical Outcomes	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						subarachnoid hemorrhage; mechanical ventilation; hypocapnia; hyperventilation; Glasgow Outcome Scale	TRAUMATIC BRAIN-INJURY; CEREBRAL BLOOD-FLOW; HEAD-INJURY; HYPERVENTILATION; MANAGEMENT; VASOSPASM; HYPOXIA; METABOLISM; GUIDELINES; ISCHEMIA	Background: The impact of hypocapnia on outcome in aneurysmal subarachnoid hemorrhage (SAH) is unclear, although hypocapnia is associated with poor outcome in other brain injuries. We sought to determine the incidence and impact of hypocapnia in mechanically ventilated patients with aneurysmal SAH.Methods: We assembled a retrospective cohort of 102 consecutive mechanically ventilated patients with aneurysmal SAH admitted to an academic neurosurgical intensive care unit (ICU). Ventilation records, arterial blood gas data, and clinical outcomes were reviewed. The primary outcome was 3-month Glasgow Outcome Scale, with secondary outcomes of ICU and hospital mortality and symptomatic vasospasm.Results: Hypocapnia was common (92% of patients had 1 or more PaCO2 measurements <35 mm Hg), with 68% of these measurements occurring while breathing spontaneously with minimal ventilator support. Median duration of hypocapnia was 4 days (interquartile range, 2 to 12). Forty-eight percent of all PaCO2 measurements on a given day were below 30 mm Hg. Unfavorable outcome (Glasgow Outcome Scale <4) occurred in 52 of 89 patients (58.4%). ICU and hospital mortality was 26.5% and 32.4%, respectively, and 34% developed symptomatic vasospasm. Duration of hypocapnia was associated with unfavorable outcome (adjusted odds ratio 1.33 for each additional day of hypocapnia) and symptomatic vasospasm (adjusted odds ratio 1.25 for each additional day of hypocapnia), but not ICU or hospital mortality. These associations appeared robust in sensitivity analyses to address potential misclassification and ascertainment bias.Conclusions: Hypocapnia is common in ventilated patients with aneurysmal SAH, and a significant proportion of this developed spontaneously despite minimal ventilator support. The duration of hypocapnia is independently associated with poor functional outcomes and symptomatic vasospasm. Further study is warranted to confirm a causal link between hypocapnia and poor outcomes, and to confirm whether tight control of PaCO2 might improve outcomes in aneurysmal SAH.	[Solaiman, Othman] Univ Toronto, Toronto Western Hosp, Neurovasc Therapeut Program, Toronto, ON M5T 2S8, Canada; [Singh, Jeffrey M.] Univ Toronto, Dept Med, Interdept Div Crit Care Med, Toronto, ON, Canada	Singh, JM (corresponding author), Univ Hlth Network, 2nd Floor McLaughlin Wing Room 411K, Toronto, ON M5T 2S8, Canada.	jeff.singh@uhn.ca		Singh, Jeffrey/0000-0003-3499-574X			Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS87; Carrera E, 2010, J NEUROL NEUROSUR PS, V81, P793, DOI 10.1136/jnnp.2009.174425; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Graham EM, 1996, NEUROSCI LETT, V218, P29, DOI 10.1016/0304-3940(96)13114-1; Heran NS, 2004, CAN J NEUROL SCI, V31, P80, DOI 10.1017/S0317167100002870; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Jennett B, 1975, J R Coll Physicians Lond, V9, P231; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Knuth T., 2005, GUIDELINES FIELD MAN; LEITCH AG, 1980, J APPL PHYSIOL, V49, P52; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Marshall SA, 2010, NEUROSURG CLIN N AM, V21, P291, DOI 10.1016/j.nec.2009.10.010; MATSUDA M, 1990, ACTA NEUROCHIR, V105, P98, DOI 10.1007/BF01669990; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Neumann JO, 2008, INTENS CARE MED, V34, P1676, DOI 10.1007/s00134-008-1123-7; NORTH JB, 1974, ARCH NEUROL-CHICAGO, V31, P338, DOI 10.1001/archneur.1974.00490410086010; PLUM F, 1972, ANN INTERN MED, V76, P328, DOI 10.7326/0003-4819-76-2-328; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; ROUT MW, 1971, BRIT MED J, V3, P7, DOI 10.1136/bmj.3.5765.7; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593; Vannucci RC, 1997, PEDIATR RES, V42, P24, DOI 10.1203/00006450-199707000-00005	32	25	26	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2013	25	3					254	261		10.1097/ANA.0b013e3182806465			8	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	202LJ	WOS:000323217100005	23295268				2021-06-18	
J	Wilson, AG; Pizzo, MJ; Crystal, JD				Wilson, A. George; Pizzo, Matthew J.; Crystal, Jonathon D.			Event-Based Prospective Memory in the Rat	CURRENT BIOLOGY			English	Article							MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; COMPUTERIZED TASK; TIME; PERFORMANCE; COMPLEXITY; DEFICITS; REMEMBER; DEMANDS	People plan to act in the future when an appropriate event occurs, a capacity known as event-based prospective memory [1]. Prospective memory involves forming a representation of a planned future action, subsequently inactivating the representation, and ultimately reactivating it at an appropriate point in the future. Recent studies suggest that monkeys, chimpanzees, and rats display elements of prospective memory [2-5], but it is uncertain if the full sequence (activation-inactivation-reactivation) that occurs in humans also occurs in nonhumans [6-8]. Here, we asked if rats exhibit event-based prospective memory. Rats completed an ongoing temporal-discrimination task while waiting for a large meal. To promote the use of event-based prospective memory, we created an event (tone pulses) that provided information that the meal could be obtained soon. Event-based prospective memory was suggested by the dramatic decline in ongoing-task performance after the event, with excellent performance at other times. To document that the event initiated memory activation, we arranged for the event to occur at novel times. Finally, multiple, repeated presentations of the event on the same day demonstrate that rats inactivate and reactivate the memory representation in an on-demand, event-based fashion. Development of an animal model of prospective memory may be valuable to probe the biological underpinnings of memory disorders [7, 9].	[Wilson, A. George; Pizzo, Matthew J.; Crystal, Jonathon D.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA; [Wilson, A. George] Virginia Tech Caril Res Inst, Roanoke, VA 24016 USA	Crystal, JD (corresponding author), Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA.	jcrystal@indiana.edu			National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080052]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080052] Funding Source: NIH RePORTER	All procedures were approved by the Institutional Animal Care and Use Committee at Indiana University, Bloomington, and followed the guidelines of the National Research Council Guide for the Care and Use of Laboratory Animals. This work was supported by National Institute of Mental Health grant R01MH080052 to J.D.C.	Aberle I, 2010, DEV PSYCHOL, V46, P1444, DOI 10.1037/a0020718; Beran MJ, 2012, LEARN MOTIV, V43, P192, DOI 10.1016/j.lmot.2012.05.002; Beran MJ, 2012, J EXP PSYCHOL ANIM B, V38, P233, DOI 10.1037/a0027796; Blanco-Campal A, 2009, J INT NEUROPSYCH SOC, V15, P154, DOI 10.1017/S1355617708090127; Blough DS, 1996, J EXP PSYCHOL ANIM B, V22, P118, DOI 10.1037/0097-7403.22.1.118; Carey CL, 2006, J CLIN EXP NEUROPSYC, V28, P536, DOI 10.1080/13803390590949494; CHURCH RM, 1977, J EXP PSYCHOL ANIM B, V3, P216, DOI 10.1037/0097-7403.3.3.216; Craik F.I.M., 1986, HUMAN MEMORY COGNITI, P409; Crystal JD, 2013, BEHAV PROCESS, V93, P39, DOI 10.1016/j.beproc.2012.11.014; Crystal JD, 2012, LEARN MOTIV, V43, P181, DOI 10.1016/j.lmot.2012.05.006; d'Ydewalle G, 2001, AM J PSYCHOL, V114, P411, DOI 10.2307/1423688; Driscoll I, 2005, NEUROPSYCHOLOGY, V19, P28, DOI 10.1037/0894-4105.19.1.28; Einstein GO, 1997, PSYCHOL AGING, V12, P479, DOI 10.1037/0882-7974.12.3.479; Evans TA, 2012, COGNITION, V125, P131, DOI 10.1016/j.cognition.2012.07.012; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Jones S, 2006, NEUROPSYCHOLOGY, V20, P144, DOI 10.1037/0894-4105.20.2.144; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; McDaniel M. A., 2007, PROSPECTIVE MEMORY O; Nader K, 2003, TRENDS NEUROSCI, V26, P65, DOI 10.1016/S0166-2236(02)00042-5; Raskin SA, 2011, NEUROPSYCHOLOGY, V25, P201, DOI 10.1037/a0020999; Roberts WA, 2002, PSYCHOL BULL, V128, P473, DOI 10.1037//0033-2909.128.3.473; Schmitter-Edgecombe M, 2009, NEUROPSYCHOLOGY, V23, P168, DOI 10.1037/a0014186; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Troyer AK, 2007, J INT NEUROPSYCH SOC, V13, P365, DOI 10.1017/S1355617707070452; Wilson AG, 2012, ANIM COGN, V15, P349, DOI 10.1007/s10071-011-0459-5; Woods SP, 2009, J INT NEUROPSYCH SOC, V15, P42, DOI 10.1017/S1355617708090012	28	25	25	1	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0960-9822			CURR BIOL	Curr. Biol.	JUN 17	2013	23	12					1089	1093		10.1016/j.cub.2013.04.067			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	168CH	WOS:000320682800023	23727093	Green Accepted, Bronze			2021-06-18	
J	Peach, RK				Peach, Richard K.			The Cognitive Basis for Sentence Planning Difficulties in Discourse After Traumatic Brain Injury	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						cognition; language disorders; traumatic brain injury; executive functions; attention	CLOSED-HEAD INJURY; COLORED PROGRESSIVE MATRICES; WORKING-MEMORY; NARRATIVE DISCOURSE; LANGUAGE; INTELLIGENCE; SPEECH; PERFORMANCE; IMPAIRMENT; RETENTION	Purpose: Analyses of language production of individuals with traumatic brain injury (TBI) place increasing emphasis on microlinguistic (i.e., within-sentence) patterns. It is unknown whether the observed problems involve implementation of well-formed sentence frames or represent a fundamental linguistic disturbance in computing sentence structure. This study investigated the cognitive basis for microlinguistic deficits in individuals with TBI. Method: Fifteen nonaphasic individuals with severe TBI and 6 age- and education-matched non brain-injured adults participated in this study. Monologic discourse samples were analyzed for pausing patterns, mazes, errors, and abandoned utterances. Measures of cognitive abilities were correlated with the sentence measures. Results: The speakers with TBI produced more pauses between clauses (but not within clauses) as well as more mazes than did the non brain-injured speakers. Significant regression models were built. Raven's Coloured Progressive Matrices (Raven, 1965), a measure associated with working memory, predicted pause behavior, and Likenesses-Differences (Baker & Leland, 1967), a measure of executive function, predicted maze behavior. Conclusions: Sentence planning impairments following TBI are associated with deficient organization and monitoring of language representations in working memory. These findings suggest that the deficits are due to problems in the recruitment and control of attention for sentence planning. These findings bear on sentence processing models that emphasize the activation, organization, and maintenance of language representations for accurate sentence production.	Rush Univ, Chicago, IL 60612 USA	Peach, RK (corresponding author), Rush Univ, Chicago, IL 60612 USA.	richard_k_peach@rush.edu					Baker H.J, 1967, DETROIT TESTS LEARNI; Boersma P., 2010, PRAAT DOING PHONETIC; BUTTERWORTH B, 1979, BRAIN LANG, V8, P133, DOI 10.1016/0093-934X(79)90046-4; CARPENTER PA, 1990, PSYCHOL REV, V97, P404, DOI 10.1037/0033-295X.97.3.404; Coelho CA, 2005, BRAIN INJURY, V19, P1139, DOI 10.1080/02699050500110678; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Colom R, 2004, INTELLIGENCE, V32, P277, DOI 10.1016/j.intell.2003.12.002; Conway ARA, 2002, INTELLIGENCE, V30, P163, DOI 10.1016/S0160-2896(01)00096-4; COOPER WE, 1984, LANG SPEECH, V27, P17, DOI 10.1177/002383098402700102; Copland DA, 2000, J MED SPEECH-LANG PA, V8, P1; COPPENS P, 1995, BRAIN INJURY, V9, P195, DOI 10.3109/02699059509008192; Crosson B., 2012, COGNITION ACQUIRED L, P167; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; DeShon RP, 1995, INTELLIGENCE, V21, P135, DOI 10.1016/0160-2896(95)90023-3; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Ellis C, 2009, NEUROREHABILITATION, V24, P255, DOI 10.3233/NRE-2009-0476; FERREIRA F, 1991, J MEM LANG, V30, P210, DOI 10.1016/0749-596X(91)90004-4; Ferreira F., 2006, HDB PSYCHOLINGUISTIC, V2nd, P61, DOI DOI 10.1016/B978-012369374-7/50004-3; GAINOTTI G, 1986, J CLIN EXP NEUROPSYC, V8, P37, DOI 10.1080/01688638608401295; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Goldman-Eisler F., 1968, PSYCHOLINGUISTICS EX; Goodglass H., 1972, BOSTON DIAGNOSTIC AP; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Heaton R., 1993, WISCONSIN CARD SORTI; Heitz R. P., 2005, HDB UNDERSTANDING ME, DOI [10.4135/9781452233529.n5, DOI 10.4135/9781452233529.N5]; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P369, DOI 10.1080/026990598122502; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; Holland A, 1980, COMMUNICATIVE ABILIT; Holmes V. M., 1988, LANG COGNITIVE PROC, V3, P323; Hough MS, 2003, APHASIOLOGY, V17, P183, DOI 10.1080/02687030244000608; Jennett B, 1981, MANAGEMENT HEAD INJU; Kaplan E., 1983, BOSTON NAMING TEST; KERTESZ A, 1975, BRAIN LANG, V2, P387, DOI 10.1016/S0093-934X(75)80079-4; Kertesz A, 1982, W APHASIA BATTERY TE; Kircher TTJ, 2004, NEUROIMAGE, V21, P84, DOI 10.1016/j.neuroimage.2003.09.041; Kirsner K., 2002, P 9 AUSTR INT C SPEE, P52; Levelt W. J. M., 1989, SPEAKING INTENTION A; LEVELT WJM, 1983, COGNITION, V14, P41, DOI 10.1016/0010-0277(83)90026-4; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lynn R, 2004, INTELLIGENCE, V32, P411, DOI 10.1016/j.intell.2004.06.007; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; Martin RC, 2004, COGN NEUROPSYCHOL, V21, P625, DOI 10.1080/02643290342000302; Martin RC, 2001, MEMORY, V9, P261, DOI 10.1080/09658210143000173; McNeil MR, 2000, SCI PRACT NEUROPSYCH, P221; Miller J. F., 2008, SYSTEMATIC ANAL LANG; Navarro-Ruiz MI, 2001, CLIN LINGUIST PHONET, V15, P63, DOI 10.3109/02699200109167632; Peach R., 2012, COGNITION ACQUIRED L, P241; Peach R. K., 1990, ANN CONV AM SPEECH L; Peach R. K., 1986, ANN CONV AM SPEECH L; Peach R.K, 2012, **DROPPED REF**; Raven J, 2000, COGNITIVE PSYCHOL, V41, P1, DOI 10.1006/cogp.1999.0735; Raven J.C, 1965, RAVENS COLOURED PROG; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rispoli M, 2008, J SPEECH LANG HEAR R, V51, P953, DOI 10.1044/1092-4388(2008/070); SHALLICE T, 1977, NEUROPSYCHOLOGIA, V15, P729, DOI 10.1016/0028-3932(77)90002-1; Shapiro L. P., 2012, COGNITION ACQUIRED L, P61; Smits CHM, 1997, J CLIN PSYCHOL, V53, P687, DOI 10.1002/(SICI)1097-4679(199711)53:7<687::AID-JCLP6>3.0.CO;2-F; Spreen O., 1998, COMPENDIUM NEUROPSYC; Spreen O., 1977, NEUROSENSORY CTR COM; SPSS-Inc, 2007, SPSS WIND VERS 16 0; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thordardottir ET, 2002, BRAIN COGNITION, V48, P587, DOI 10.1006/brcg.2001.1422; WECHSLER D, 1973, INSTRUCTION MANUAL W; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	67	25	26	0	19	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY 1	2013	22	2					S285	S297		10.1044/1058-0360(2013/12-0081)			13	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	156LD	WOS:000319822600007	23695905				2021-06-18	
J	Bodart, O; Laureys, S; Gosseries, O				Bodart, Olivier; Laureys, Steven; Gosseries, Olivia			Coma and Disorders of Consciousness: Scientific Advances and Practical Considerations for Clinicians	SEMINARS IN NEUROLOGY			English	Article						unresponsive wakefulness syndrome-vegetative state; minimally conscious state; consciousness; functional magnetic resonance imaging (fMRI); neuroimaging	PERSISTENT VEGETATIVE STATE; CORTICAL EFFECTIVE CONNECTIVITY; REGIONAL CEREBRAL METABOLISM; EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; RESTING-STATE; UNRESPONSIVE WAKEFULNESS; FUNCTIONAL CONNECTIVITY; COGNITIVE FUNCTION; DEFAULT NETWORK	Recently, neuroscientists and clinicians have seen the rapid evolution of diagnoses in disorders of consciousness. The unresponsive wakefulness syndrome-vegetative state, the minimally conscious state plus and minus, and the functional locked-in syndrome have been defined using new neuroimaging techniques. Diffusion tensor imaging, positron emission tomography, functional magnetic resonance imaging, electroencephalography, and transcranial magnetic stimulation techniques have all promoted important discoveries in the field of disorders of consciousness. This has led to a better understanding of these patients' condition and to the development of new prognosis, therapeutic, and communication tools. However, low sensitivity and artifacts problems need to be solved to bring these new technologies to the single-patient level; they also need to be studied in larger scale and randomized control trials. In addition, new ethics questions have arisen and need to be investigated.	[Bodart, Olivier; Laureys, Steven; Gosseries, Olivia] Univ Liege, Univ Hosp Liege, Cyclotron Res Ctr, Dept Neurol,Coma Sci Grp, B-4031 Liege, Belgium	Laureys, S (corresponding author), Univ Liege, Cyclotron Res Ctr, Sart Tilman B30,Allee 6 Aout 8, B-4031 Liege, Belgium.	steven.laureys@ulg.ac.be	Gosseries, Olivia/AAB-6469-2020; Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011	Laureys, Steven/0000-0002-3096-3807; Gosseries, Olivia/0000-0001-9011-7496	Belgian National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; Fonds Leon Fredericq; Belgian interuniversity attraction poleBelgian Federal Science Policy Office; James S. McDonnell Foundation; Mind Science Foundation; European CommissionEuropean CommissionEuropean Commission Joint Research Centre; Concerted Research Action [ARC 06/11-340]; Public Utility Foundation "Universite Europeenne du Travail"; Fondazione Europea di Ricerca Biomedica; University of LiegeUniversity of Liege	This work was supported by the Belgian National Funds for Scientific Research (FNRS), Fonds Leon Fredericq, Belgian interuniversity attraction pole, James S. McDonnell Foundation, Mind Science Foundation, European Commission (Mindbridge, DISCOS, DECODER & COST), Concerted Research Action (ARC 06/11-340), Public Utility Foundation "Universite Europeenne du Travail," "Fondazione Europea di Ricerca Biomedica," and the University of Liege. We also thank Erik Ziegler and Francisco Gomez for their help with the illustrations.	Bekinschtein TA, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00005; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Babiloni C, 2009, CLIN NEUROPHYSIOL, V120, P719, DOI 10.1016/j.clinph.2009.02.157; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Bekinschtein TA, 2009, P NATL ACAD SCI USA, V106, P1672, DOI 10.1073/pnas.0809667106; Beuthien-Baumann B, 2003, NUCL MED COMMUN, V24, P643, DOI 10.1097/00006231-200306000-00005; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Bruno MA, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-35; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Clauss RP, 2000, S AFR MED J, V90, P68; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Cruse D, 2010, CURR OPIN NEUROL, V23, P656, DOI 10.1097/WCO.0b013e32833fd4e7; Daltrozzo J, 2007, CLIN NEUROPHYSIOL, V118, P606, DOI 10.1016/j.clinph.2006.11.019; Demertzi A, 2011, J NEUROL, V258, P1058, DOI 10.1007/s00415-010-5882-z; Demertzi A, 2009, PROG BRAIN RES, V177, P329, DOI 10.1016/S0079-6123(09)17722-1; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fischer C, 2006, CRIT CARE MED, V34, P1520, DOI 10.1097/01.CCM.0000215823.36344.99; Friston KJ, 2011, BRAIN CONNECT, V1, P13, DOI 10.1089/brain.2011.0008; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill-Thwaites H, 2006, BRAIN INJURY, V20, P1321, DOI 10.1080/02699050601081802; Godbolt AK, 2012, BRAIN INJURY, V26, P188, DOI 10.3109/02699052.2011.648708; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Gosseries O, 2012, COMA DISORDERS CONSC, P121; Gosseries O, 2011, FUNCT NEUROL, V26, P25; Gosseries O, 2009, NEUROLOGY OF CONSCIOUSNESS: COGNITIVE NEUROSCIENCE AND NEUROPATHOLOGY, P191, DOI 10.1016/B978-0-12-374168-4.00015-0; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Karantanas A, 2000, J NEUROSURG, V92, P896; Larriviere D, 2006, NEUROLOGY, V66, P1624, DOI 10.1212/01.wnl.0000217133.21665.55; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Luaute J, 2005, ARCH PHYS MED REHAB, V86, P917, DOI 10.1016/j.apmr.2004.08.011; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Lule D, 2013, CLIN NEUROPHYSIOL, V124, P101, DOI 10.1016/j.clinph.2012.04.030; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; Massimini M, 2010, COGN NEUROSCI-UK, V1, P176, DOI 10.1080/17588921003731578; Monti MM, 2013, HUM BRAIN MAPP, V34, P1245, DOI 10.1002/hbm.21507; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Moreno DR, 2010, NEUROLOGY, V75, P1871, DOI 10.1212/WNL.0b013e3181feb259; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Noe E, 2012, ARCH PHYS MED REHAB, V93, P428, DOI 10.1016/j.apmr.2011.08.048; Norton L, 2012, NEUROLOGY, V78, P175, DOI 10.1212/WNL.0b013e31823fcd61; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Owen AM, 2002, NEUROCASE, V8, P394, DOI 10.1076/neur.8.4.394.16184; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Qin PM, 2010, HUM BRAIN MAPP, V31, P1993, DOI 10.1002/hbm.20989; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Rudolf J, 1999, J NEUROSURG ANESTH, V11, P17, DOI 10.1097/00008506-199901000-00004; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schnakers C, 2010, PAIN, V148, P215, DOI 10.1016/j.pain.2009.09.028; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Silva S, 2010, NEUROLOGY, V74, P313, DOI 10.1212/WNL.0b013e3181cbcd96; Soddu A, 2011, FUNCT NEUROL, V26, P37; Sorger B, 2012, CURR BIOL, V22, P1333, DOI 10.1016/j.cub.2012.05.022; TEASDALE G, 1974, LANCET, V2, P81; Thibaut A, 2012, J REHABIL MED, V44, P487, DOI 10.2340/16501977-0940; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; Tshibanda L, 2009, PROG BRAIN RES, V177, P215, DOI 10.1016/S0079-6123(09)17715-4; Vanhaudenhuyse A, 2008, NEUROLOGY, V71, P1374, DOI 10.1212/01.wnl.0000320110.70134.60; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Vanhaudenhuyse A, 2008, NEUROCRIT CARE, V8, P262, DOI 10.1007/s12028-007-9016-0; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4; Whyte J, 2009, PROG BRAIN RES, V177, P63, DOI 10.1016/S0079-6123(09)17706-3; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	94	25	28	1	39	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	APR	2013	33	2					83	90		10.1055/s-0033-1348965			8	Clinical Neurology	Neurosciences & Neurology	188VS	WOS:000322225300003	23888393				2021-06-18	
J	Ferguson, M; Bianchi, MT; Sutter, R; Rosenthal, ES; Cash, SS; Kaplan, PW; Westover, MB				Ferguson, Matthew; Bianchi, Matt T.; Sutter, Raoul; Rosenthal, Eric S.; Cash, Sydney S.; Kaplan, Peter W.; Westover, M. Brandon			Calculating the Risk Benefit Equation for Aggressive Treatment of Non-convulsive Status Epilepticus	NEUROCRITICAL CARE			English	Article						Non-convulsive status epilepticus; Risk benefit analysis; NCSE; Decision analysis	REFRACTORY STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; CONVULSIVE STATUS EPILEPTICUS; QUALITY-OF-LIFE; INTRACEREBRAL HEMORRHAGE; ABSENCE STATUS; ELECTROGRAPHIC SEIZURES; HOSPITAL MORTALITY; CRITICALLY-ILL	To address the question: does non-convulsive status epilepticus warrant the same aggressive treatment as convulsive status epilepticus? We used a decision model to evaluate the risks and benefits of treating non-convulsive status epilepticus with intravenous anesthetics and ICU-level aggressive care. We investigated how the decision to use aggressive versus non-aggressive management for non-convulsive status epilepticus impacts expected patient outcome for four etiologies: absence epilepsy, discontinued antiepileptic drugs, intraparenchymal hemorrhage, and hypoxic ischemic encephalopathy. Each etiology was defined by distinct values for five key parameters: baseline mortality rate of the inciting etiology; efficacy of non-aggressive treatment in gaining control of seizures; the relative contribution of seizures to overall mortality; the degree of excess disability expected in the case of delayed seizure control; and the mortality risk of aggressive treatment. Non-aggressive treatment was favored for etiologies with low morbidity and mortality such as absence epilepsy and discontinued antiepileptic drugs. The risk of aggressive treatment was only warranted in etiologies where there was significant risk of seizure-induced neurologic damage. In the case of post-anoxic status epilepticus, expected outcomes were poor regardless of the treatment chosen. The favored strategy in each case was determined by strong interactions of all five model parameters. Determination of the optimal management approach to non-convulsive status epilepticus is complex and is ultimately determined by the inciting etiology.	[Ferguson, Matthew; Bianchi, Matt T.; Rosenthal, Eric S.; Cash, Sydney S.; Westover, M. Brandon] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Sutter, Raoul] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Div Neurosci Crit Care, Baltimore, MD 21205 USA; [Sutter, Raoul; Kaplan, Peter W.] Johns Hopkins Bayview Med Ctr, Dept Neurol, Baltimore, MD USA; [Westover, M. Brandon] Massachusetts Gen Hosp, Boston, MA 02114 USA	Westover, MB (corresponding author), Massachusetts Gen Hosp, Wang 7 Neurol,55 Fruit St, Boston, MA 02114 USA.	gferguson1212@gmail.com; mtbianchi@partners.org; rsutter3@jhmi.edu; erosenthal@partners.org; pkaplan@jhmi.edu; mb.westover@gmail.com	Raoul Christian Sutter/J-7747-2019; Rosenthal, Eric Scott/A-2085-2017	Raoul Christian Sutter/0000-0002-6575-356X; Rosenthal, Eric Scott/0000-0003-3900-356X	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS062092]; American Brain Foundation; National Center for Research Resources: Harvard Clinical and Translational Science CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); Center for Integration of Medicine and Innovative Technology (CIMIT); NIH/NIBIBUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [5U54EB007954-04]; Department of DefenseUnited States Department of Defense [W81XWH-08-2-0154]; Andrew David Heitman Neuroendovascular Research Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB007954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062092] Funding Source: NIH RePORTER	MBW receives research support from the NIH/NINDS (NS062092) and American Brain Foundation. MTB receives research support from the National Center for Research Resources: Harvard Clinical and Translational Science Center and the Center for Integration of Medicine and Innovative Technology (CIMIT). ESR receives research support from the Center for Integration of Medicine and Innovative Technology (CIMIT), the NIH/NIBIB (5U54EB007954-04), the Department of Defense (W81XWH-08-2-0154), and the Andrew David Heitman Neuroendovascular Research Foundation.	Agathonikou A, 1998, EPILEPSIA, V39, P1265, DOI 10.1111/j.1528-1157.1998.tb01324.x; Ali NA, 2008, AM J RESP CRIT CARE, V178, P261, DOI 10.1164/rccm.200712-1829OC; Alvarez V, 2012, EPILEPSIA, V53, pe89, DOI 10.1111/j.1528-1167.2012.03451.x; Aminoff MJ, 1998, ARCH NEUROL-CHICAGO, V55, P119, DOI 10.1001/archneur.55.1.119; ANDERMANN F, 1972, EPILEPSIA, V13, P177, DOI 10.1111/j.1528-1157.1972.tb04565.x; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; Anon JM, 2012, MED INTENSIVA; BAYLIFF CD, 1985, CLIN PHARMACOL THER, V38, P457, DOI 10.1038/clpt.1985.204; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Cheung AM, 2006, AM J RESP CRIT CARE, V174, P538, DOI 10.1164/rccm.200505-693OC; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x; Claassen J, 2002, NEUROLOGY, V58, P139, DOI 10.1212/WNL.58.1.139; Cooper AD, 2009, ARCH NEUROL-CHICAGO, V66, P1505, DOI 10.1001/archneurol.2009.273; Cordato DJ, 1999, ANESTHESIOLOGY, V91, P1693, DOI 10.1097/00000542-199912000-00022; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; Delanty N, 2001, SEIZURE-EUR J EPILEP, V10, P116, DOI 10.1053/seiz.2000.0482; DeLorenzo RJ, 1999, EPILEPSIA, V40, P164, DOI 10.1111/j.1528-1157.1999.tb02070.x; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Dennis LJ, 2002, NEUROSURGERY, V51, P1136, DOI 10.1097/00006123-200211000-00006; Drislane FW, 2008, J CLIN NEUROPHYSIOL, V25, P181, DOI 10.1097/WNP.0b013e31817be70e; Drislane FW, 2009, EPILEPSIA, V50, P1566, DOI 10.1111/j.1528-1167.2008.01993.x; Eckman MH, 2003, STROKE, V34, P1710, DOI 10.1161/01.STR.0000078311.18928.16; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Foreman B, 2012, NEUROL CLIN, V30, P11, DOI 10.1016/j.ncl.2011.09.005; Forster AJ, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-259; Fuchs L, 2012, INTENSIVE CARE MED; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Garrouste-Orgeas M, 2010, AM J RESP CRIT CARE, V181, P134, DOI 10.1164/rccm.200812-1820OC; GOKYIGIT A, 1995, EPILEPSIA, V36, P210, DOI 10.1111/j.1528-1157.1995.tb00982.x; Grundmann H, 2005, CRIT CARE MED, V33, P946, DOI 10.1097/01.CCM.0000163223.26234.56; Guerrini R, 2004, AICARDIS EPILEPSY CH; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; Jordan KG, 2006, EPILEPSIA, V47, P41, DOI 10.1111/j.1528-1167.2006.00659.x; Kaplan PW, 1999, J CLIN NEUROPHYSIOL, V16, P341, DOI 10.1097/00004691-199907000-00006; Kaplan PW, 2000, NEUROPHYSIOL CLIN, V30, P377, DOI 10.1016/S0987-7053(00)00238-0; Kosty J, 2012, J NEUROTRAUM, V29, P1322, DOI 10.1089/neu.2011.2222; Koubeissi M, 2007, NEUROLOGY, V69, P886, DOI 10.1212/01.wnl.0000269791.96189.70; KRESS HG, 1987, ANAESTHESIST, V36, P356; Logroscino G, 1997, EPILEPSIA, V38, P1344, DOI 10.1111/j.1528-1157.1997.tb00073.x; Mayer SA, 2002, ARCH NEUROL-CHICAGO, V59, P205, DOI 10.1001/archneur.59.2.205; Meierkord H, 2006, EUR J NEUROL, V13, P445, DOI 10.1111/j.1468-1331.2006.01397.x; Meldrum BS, 2002, PROG BRAIN RES, V135, P3; Naidech AM, 2009, NEUROCRIT CARE, V10, P11, DOI 10.1007/s12028-008-9148-x; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Novy J, 2010, EPILEPSIA, V51, P251, DOI 10.1111/j.1528-1167.2009.02323.x; Oddo M, 2011, CURR OPIN CRIT CARE, V17, P254, DOI 10.1097/MCC.0b013e328344f2ae; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Panayiotopoulos C., 2005, EPILEPSIES SEIZURES; Rossetti AO, 2007, NEUROLOGY, V69, P255, DOI 10.1212/01.wnl.0000265819.36639.e0; Rossetti AO, 2007, EPILEPSIA, V48, P52, DOI 10.1111/j.1528-1167.2007.01350.x; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Rossetti AO, 2008, J NEUROL, V255, P1561, DOI 10.1007/s00415-008-0989-1; Rossetti AO, 2005, ARCH NEUROL-CHICAGO, V62, P1698, DOI 10.1001/archneur.62.11.1698; Rost NS, 2008, STROKE, V39, P2304, DOI 10.1161/STROKEAHA.107.512202; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Shirasaka Y, 2002, EPILEPSIA, V43, P1498, DOI 10.1046/j.1528-1157.2002.10502.x; Shneker BF, 2003, NEUROLOGY, V61, P1066, DOI 10.1212/01.WNL.0000082653.40257.0B; Shorvon S, 2005, EPILEPSIA, V46, P73, DOI 10.1111/j.1528-1167.2005.00316.x; TOWNE AR, 1994, EPILEPSIA, V35, P27, DOI 10.1111/j.1528-1157.1994.tb02908.x; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Vignatelli L, 2008, J NEUROL, V255, P197, DOI 10.1007/s00415-008-0635-y; Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5; Waterhouse EJ, 1999, EPILEPSIA, V40, P752, DOI 10.1111/j.1528-1157.1999.tb00774.x; Westover MB, 2011, ARCH NEUROL-CHICAGO, V68, P573, DOI 10.1001/archneurol.2010.356; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Wunsch H, 2012, CHEST, V141, P1393, DOI 10.1378/chest.11-2819; Young GB, 2010, NEUROLOGY, V75, P760, DOI 10.1212/WNL.0b013e3181f32141; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117; Young GB, 1996, NEUROLOGY, V47, P83	78	25	26	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2013	18	2					216	227		10.1007/s12028-012-9785-y			12	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	105PR	WOS:000316084700009	23065689	Green Accepted			2021-06-18	
J	Park, E; Eisen, R; Kinio, A; Baker, AJ				Park, Eugene; Eisen, Rebecca; Kinio, Anna; Baker, Andrew J.			Electrophysiological white matter dysfunction and association with neurobehavioral deficits following low-level primary blast trauma	NEUROBIOLOGY OF DISEASE			English	Article						Primary blast; Mild traumatic brain injury; White matter injury; AlphaII-spectrin; Blast injury; Electrophysiology	DEPENDENT SODIUM-CHANNELS; FLUID PERCUSSION INJURY; AXONAL INITIAL SEGMENT; DIFFUSE BRAIN-INJURY; ANKYRIN-G; MILITARY PERSONNEL; CORPUS-CALLOSUM; SERVICE MEMBERS; MOUSE MODEL; ADULT-RAT	There is strong evidence that primary blast injuries can cause neuropathological alterations in the brain. Clinical findings from war veterans indicating evidence of diffuse axonal injury have been corroborated by numerous primary blast models in animals. However, the effect of a subclinical blast (blast with no obvious sign of external trauma or lung injury) as a contributing factor to the neurological symptoms and neuropathology is less clear. Our group recently developed a model of low-level primary blast and characterized aberrant expression of white matter cytoskeletal proteins in the cortex and hippocampus following a subclinical wave shock exposure. Here we examined the susceptibility of the corpus callosum following subclinical blast. We also demonstrate that white matter dysfunction is associated with neurobehavioral deficits associated with anxiety and stress in rats. Anesthetized male Sprague-Dawley rats (similar to 300 g) were exposed to a primary blast (approx. 28 kPa), below the threshold required to induce pulmonary trauma. Rats were evaluated on three behavioral outcome measures; the rotarod, the light/dark box and open field anxiety test. We used Western blotting to examine expression and degradation of axonally expressed cell-spectrin, NF200 and voltage-gated sodium channels (VGSC) in the corpus callosum. Acute slice preparations were used for electrophysiological analysis of evoked compound action potentials (CAPs) in the corpus callosum. There was evidence of alpha II-spectrin degradation in the corpus callosum at 48 h post-injury detectable up to 14 days post-injury, as well as increased heavy neurofilament expression. A reduction in VGSC expression was observed at 48 h post-blast as well as a reduction in the interaction between ankyrin G and intact all-spectrin. Blast exposed rats had significantly lower rotarod latency times relative to sham rats (p = 0.002). Increased anxiety-related and stress-related behavior were observed in blast rats relative to sham animals as indicated by the increased frequency of fecal droppings (p = 0.029) and reduced exploratory activity (p = 0.036) in the open-field test. Blast rats had fewer transitions and time spent in lit sections of the light/dark box. Electrophysiological recordings from the corpus callosum indicated greater deficits in unmyelinated fibers of the corpus callosum relative to myelinated fibers characterized by reduced CAP amplitude response at 14 days post-injury. Analysis of the relationship between stimulation distance to evoked response indicated an underlying abnormality in N1 myelinated fibers at close stimulation distances. Collectively, our results indicate that subclinical blast exposure can result in persistent neurological changes in cerebral white matter occurring in parallel with detectable neurobehavioral deficits. (C) 2012 Elsevier Inc. All rights reserved.	[Park, Eugene; Eisen, Rebecca; Kinio, Anna; Baker, Andrew J.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Baker, Andrew J.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Baker, Andrew J.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, Dept Surg, Toronto, ON, Canada	Park, E (corresponding author), St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.	parke@smh.ca; bakera@smh.ca					Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Brachet A, 2010, J CELL BIOL, V191, P383, DOI 10.1083/jcb.201003042; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Crawford DK, 2009, NEUROSCIENCE, V164, P1407, DOI 10.1016/j.neuroscience.2009.09.069; Cullen DK, 2011, J NEUROTRAUM, V28, P2307, DOI [10.1089/neu.2010.1718, 10.1089/neu.2011.1718]; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; GENTSCH C, 1981, PHYSIOL BEHAV, V27, P183, DOI 10.1016/0031-9384(81)90320-6; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hu H, 2010, NEUROSCIENCE, V169, P171, DOI 10.1016/j.neuroscience.2010.04.057; IBRAHIM M, 1995, J NEUROL SCI, V133, P119, DOI 10.1016/0022-510X(95)00174-Z; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Perrot R, 2008, MOL NEUROBIOL, V38, P27, DOI 10.1007/s12035-008-8033-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rubtsov AM, 2000, FEBS LETT, V482, P1, DOI 10.1016/S0014-5793(00)01924-4; Ruff RL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000312; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Shea TB, 2008, EUR J NEUROSCI, V27, P1893, DOI 10.1111/j.1460-9568.2008.06165.x; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	48	25	25	0	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	APR	2013	52				SI		150	159		10.1016/j.nbd.2012.12.002			10	Neurosciences	Neurosciences & Neurology	096UL	WOS:000315430000015	23238347				2021-06-18	
J	Clement, RC; Carr, BG; Kallan, MJ; Wolff, C; Reilly, PM; Malhotra, NR				Clement, R. Carter; Carr, Brendan G.; Kallan, Michael J.; Wolff, Catherine; Reilly, Patrick M.; Malhotra, Neil R.			Volume-outcome relationship in neurotrauma care	JOURNAL OF NEUROSURGERY			English	Article						neurotrauma; volume-outcome relationship; cost; center size; traumatic brain injury	TRAUMA CENTER DESIGNATION; HOSPITAL VOLUME; UNITED-STATES; SURGEON VOLUME; POTENTIAL BENEFITS; MORTALITY; CANCER; ASSOCIATION; CENTERS; IMPACT	Object. A positive correlation between outcomes and the volume of patients seen by a provider has been supported by numerous studies. Volume-outcome relationships (VORs) have been well documented in the setting of both neurosurgery and trauma care and have shaped regionalization policies to optimize patient outcomes. Several authors have also investigated the correlation between patient volume and cost of care, known as the volume-cost relationship (VCR), with mixed results. The purpose of the present study was to investigate VORs and VCRs in the treatment of common intracranial injuries by testing the hypotheses that outcomes suffer at small-volume centers and costs rise at large-volume centers. Methods. The authors performed a cross-sectional cohort study of patients with neurological trauma using the 2006 Nationwide Inpatient Sample, the largest nationally representative all-payer data set. Patients were identified using ICD-9 codes for subdural, subarachnoid, and extradural hemorrhage following injury. Transfers were excluded from the study. In the primary analysis the association between a facility's neurotrauma patient volume and patient survival was tested. Secondary analyses focused on the relationships between patient volume and discharge status as well as between patient volume and cost. Analyses were performed using logistic regression. Results. In-hospital mortality in the overall cohort was 9.9%. In-hospital mortality was 14.9% in the group with the smallest volume of patients, that is, fewer than 6 cases annually. At facilities treating 6-11, 12-23, 24-59, and 60+ patients annually, mortality was 8.0%, 8.3%, 9.5%, and 10.0%, respectively. For these groups there was a significantly reduced risk of in-hospital mortality as compared with the group with fewer than 6 annual patients; the adjusted ORs (and corresponding 95% CIs) were 0.45 (0.29-0.68), 0.56 (0.38-0.81), 0.63 (0.44-0.90), and 059 (0.41-0.87), respectively. For these same groups (once again using < 6 cases/year as the reference), there were no statistically significant differences in either estimated actual cost or duration of hospital stay. Conclusions. A VOR exists in the treatment of neurotrauma, and a meaningful threshold for significantly improved mortality is 6 cases per year. Emergency and interfacility transport policies based on this threshold might improve national outcomes. Cost of care does not differ significantly with patient volume. (http://thejns.org/doi/abs/10.3171/2012.10.JNS12682)	[Clement, R. Carter] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Clement, R. Carter] Univ Penn, Wharton Sch Business, Philadelphia, PA 19104 USA; [Carr, Brendan G.] Leonard Davis Inst Healthcare Econ, Philadelphia, PA USA; [Carr, Brendan G.; Kallan, Michael J.; Wolff, Catherine] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Carr, Brendan G.] Hosp Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Reilly, Patrick M.] Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Malhotra, Neil R.] Hosp Univ Penn, Dept Neurol Surg, Philadelphia, PA 19104 USA	Malhotra, NR (corresponding author), Univ Penn, Dept Neurol Surg, 3 Silverstein Pavil,3400 Spruce St, Philadelphia, PA 19104 USA.	NRM@UPHS.UPenn.edu		Clement, Rutledge/0000-0002-9959-9644	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5K08HS017960-04]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS017960] Funding Source: NIH RePORTER	Study funding was provided by NIH KO8 Grant No. 5K08HS017960-04 (B.G.C.).	Bardach NS, 2002, STROKE, V33, P1851, DOI 10.1161/01.STR.0000019126.43079.7B; Barker FG, 2003, J CLIN ENDOCR METAB, V88, P4709, DOI 10.1210/jc.2003-030461; Barker FG, 2005, NEURO-ONCOLOGY, V7, P49, DOI 10.1215/S1152851704000146; Bennett KM, 2011, J SURG RES, V167, P19, DOI 10.1016/j.jss.2010.05.020; Birkmeyer JD, 2004, SURGERY, V135, P569, DOI 10.1016/j.surg.2004.03.004; Birkmeyer JD, 2002, HEALTH AFFAIR, V21, P234, DOI 10.1377/hlthaff.21.5.234; Birkmeyer JD, 2001, SURGERY, V130, P415, DOI 10.1067/msy.2001.117139; Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Demetriades D, 2006, J AM COLL SURGEONS, V202, P212, DOI 10.1016/j.jamcollsurg.2005.09.027; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Frontera JA, 2011, CRIT CARE MED, V39, P1619, DOI 10.1097/CCM.0b013e3182186ed6; Gooiker GA, 2011, BRIT J SURG, V98, P485, DOI 10.1002/bjs.7413; Gooiker G A, 2010, Eur J Surg Oncol, V36 Suppl 1, pS27, DOI 10.1016/j.ejso.2010.06.024; Goossens-Laan CA, 2011, EUR UROL, V59, P775, DOI 10.1016/j.eururo.2011.01.037; Gourin CG, 2011, LARYNGOSCOPE, V121, P85, DOI 10.1002/lary.21348; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V274, P1282, DOI 10.1001/jama.274.16.1282; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; Harmon JW, 1999, ANN SURG, V230, P404, DOI 10.1097/00000658-199909000-00013; Hastan D, 2009, OTOL NEUROTOL, V30, P975, DOI 10.1097/MAO.0b013e3181b0d04a; Ho V, 2008, MED CARE, V46, P718, DOI 10.1097/MLR.0b013e3181653d6b; Ho Vivian, 2007, Cost Eff Resour Alloc, V5, P7, DOI 10.1186/1478-7547-5-7; Holt PJE, 2007, BRIT J SURG, V94, P441, DOI 10.1002/bjs.5725; Joynt KE, 2011, ANN INTERN MED, V154, P94, DOI 10.7326/0003-4819-154-2-201101180-00008; Kates SL, 2011, J ORTHOP TRAUMA, V25, P233, DOI 10.1097/BOT.0b013e3181e5e901; Koelemay MJ, 2007, BRIT J SURG, V94, P1041, DOI 10.1002/bjs.5969; Konety BR, 2004, J UROLOGY, V172, P1056, DOI 10.1097/01.ju.0000136382.51688.21; Kuo EY, 2001, ANN THORAC SURG, V72, P1118, DOI 10.1016/S0003-4975(01)02962-9; Markar SR, 2012, J GASTROINTEST SURG, V16, P2055; Nathens A B, 2001, Adv Surg, V35, P61; Oyetunji TA, 2011, AM J SURG, V201, P445, DOI 10.1016/j.amjsurg.2010.10.006; Smith ER, 2004, J NEUROSURG, V100, P90, DOI 10.3171/ped.2004.100.2.0090; Solheim O, 2011, ACTA NEUROCHIR, V153, P1219, DOI 10.1007/s00701-011-0967-8; Sosa JA, 1998, ANN SURG, V228, P429, DOI 10.1097/00000658-199809000-00016; Swisher SG, 2000, J THORAC CARDIOV SUR, V119, P1126, DOI 10.1067/mtc.2000.105644; van Gijn W, 2010, Eur J Surg Oncol, V36 Suppl 1, pS55, DOI 10.1016/j.ejso.2010.06.027; Vespa P, 2011, NEUROCRIT CARE, V15, P369, DOI 10.1007/s12028-011-9602-z; Wilson A, 2010, ANZ J SURG, V80, P24, DOI 10.1111/j.1445-2197.2009.05172.x	39	25	25	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2013	118	3					687	693		10.3171/2012.10.JNS12682			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	094DW	WOS:000315244200033	23240697				2021-06-18	
J	Liegeois, F; Tournier, JD; Pigdon, L; Connelly, A; Morgan, AT				Liegeois, Frederique; Tournier, Jacques-Donald; Pigdon, Lauren; Connelly, Alan; Morgan, Angela T.			Corticobulbar tract changes as predictors of dysarthria in childhood brain injury	NEUROLOGY			English	Article							WHITE-MATTER INTEGRITY; SPHERICAL DECONVOLUTION; DIFFUSION TRACTOGRAPHY; CHILDREN; SPEECH; PLASTICITY; EPIDEMIOLOGY; PERFORMANCE; OUTCOMES; STROKE	Objectives: To identify corticobulbar tract changes that may predict chronic dysarthria in young people who have sustained a traumatic brain injury (TBI) in childhood using diffusion MRI tractography. Methods: We collected diffusion-weighted MRI data from 49 participants. We compared 17 young people (mean age 17 years, 10 months; on average 8 years postinjury) with chronic dysarthria who sustained a TBI in childhood (range 3-16 years) with 2 control groups matched for age and sex: 1 group of young people who sustained a traumatic injury but had no subsequent dysarthria (n = 15), and 1 group of typically developing individuals (n = 17). We performed tractography from spherical seed regions within the precentral gyrus white matter to track: 1) the hand-related corticospinal tract; 2) the dorsal corticobulbar tract, thought to correspond to the lips/larynx motor representation; and 3) the ventral corticobulbar tract, corresponding to the tongue representation. Results: Despite widespread white matter damage, radial (perpendicular) diffusivity within the left dorsal corticobulbar tract was the best predictor of the presence of dysarthria after TBI. Diffusion metrics in this tract also predicted speech and oromotor performance across the whole group of TBI participants, with additional significant contributions from ventral speech tract volume in the right hemisphere. Conclusion: An intact left dorsal corticobulbar tract seems crucial to the normal execution of speech long term after acquired injury. Examining the speech-related motor pathways using diffusion-weighted MRI tractography offers a promising prognostic tool for people with acquired, developmental, or degenerative neurologic conditions likely to affect speech. Neurology (R) 2013;80:926-932	[Liegeois, Frederique] UCL Inst Child Hlth, Dev Cognit Neurosci Unit, London, England; [Tournier, Jacques-Donald; Connelly, Alan; Morgan, Angela T.] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Pigdon, Lauren; Morgan, Angela T.] Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Morgan, Angela T.] Univ Melbourne, Royal Childrens Hosp, Melbourne, Vic, Australia; [Morgan, Angela T.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	Liegeois, F (corresponding author), UCL Inst Child Hlth, Dev Cognit Neurosci Unit, London, England.	F.Liegeois@ucl.ac.uk	Liegeois, Frederique/A-6351-2009; Connelly, Alan/A-9065-2013; Morgan, Angela/J-5235-2017	Connelly, Alan/0000-0001-7159-8079; Liegeois, Frederique/0000-0002-8640-6217; Morgan, Angela/0000-0003-1147-7405	Transport Accident Commission, TAC [D131]; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [607315]; Operational Infrastructure Support Program of the State Government of Victoria	This study was supported by grant D131 from Victorian Neurotrauma Initiative, Australia (now Transport Accident Commission, TAC), awarded to A. T. M., F. L., A. C., and J.-D.T.; and National Health and Medical Research Council grant 607315 awarded to A.T.M.; The authors thank all participants and their families for their time and support. The authors also thank Shawna Farquharson and her team of radiographers for scanning participants. J.-D.T. and A. C. are grateful to the Operational Infrastructure Support Program of the State Government of Victoria for their support.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Hayden D.A., 1999, VERBAL MOTOR PRODUCT; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kim JS, 2003, NEUROLOGY, V60, P1178, DOI 10.1212/01.WNL.0000055930.28954.E9; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lawes INC, 2008, NEUROIMAGE, V39, P62, DOI 10.1016/j.neuroimage.2007.06.041; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Liegeois F, 2004, BRAIN, V127, P1229, DOI 10.1093/brain/awh159; Liegeois F, 2010, BRAIN LANG, V114, P126, DOI 10.1016/j.bandl.2009.12.004; Liegeois FJ, 2012, NEUROSCI BIOBEHAV R, V36, P439, DOI 10.1016/j.neubiorev.2011.07.011; McCauley RJ, 2008, AM J SPEECH-LANG PAT, V17, P81, DOI 10.1044/1058-0360(2008/007); Morgan AT, 2011, BRAIN LANG, V117, P69, DOI 10.1016/j.bandl.2011.01.002; Morgan AT, 2010, CHILD CARE HLTH DEV, V36, P44, DOI 10.1111/j.1365-2214.2009.00961.x; Northam GB, 2012, J PEDIATR-US, V160, P402, DOI 10.1016/j.jpeds.2011.08.055; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Pan C, 2012, AM J NEURORADIOL, V33, P1274, DOI 10.3174/ajnr.A2952; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Shin SS, 2012, J NEUROSURG, V116, P1062, DOI 10.3171/2012.1.JNS111282; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Terao Y, 2007, J NEUROL, V254, P442, DOI 10.1007/s00415-006-0385-7; Tournier JD, 2008, NEUROIMAGE, V42, P617, DOI 10.1016/j.neuroimage.2008.05.002; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Urban PP, 1997, BRAIN, V120, P1077, DOI 10.1093/brain/120.6.1077; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Yallampalli R, J NEUROIMAGING	34	25	25	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR	2013	80	10					926	932		10.1212/WNL.0b013e3182840c6d			7	Clinical Neurology	Neurosciences & Neurology	101KI	WOS:000315773500015	23390172	Green Published, Other Gold			2021-06-18	
J	Kuhlmei, A; Walther, B; Becker, T; Muller, U; Nikolaus, T				Kuhlmei, A.; Walther, B.; Becker, T.; Mueller, U.; Nikolaus, T.			Actigraphic daytime activity is reduced in patients with cognitive impairment and apathy	EUROPEAN PSYCHIATRY			English	Article						Alzheimer's disease; Actigraphy; Apathy; Dementia; Mild cognitive impairment/MCI	TRAUMATIC BRAIN-INJURY; NURSING-HOME RESIDENTS; EVALUATION SCALE; ALZHEIMERS-DISEASE; CIRCADIAN-RHYTHMS; DISORDERS; SCHIZOPHRENIA; SLEEP/WAKE; DEMENTIA	Objectives: Apathy is a neuropsychiatric symptom in mild cognitive impairment (MCI) and dementia. This study examines correlations between Apathy Evaluation Scale (AES) ratings and actigraphic measures of daytime activity. The aim of this study is to determine the value of ambulatory actigraphy in the assessment of locomotor deficits as a correlate of apathy in geriatric patients with cognitive impairment. Patients and methods: In this cross-sectional study a total of 82 participants were recruited, 32 patients with dementia, 21 patients with MCI and 23 elderly controls. Rating scales for apathy (AES) and depression (Beck Depression Inventory, BDI) were completed. To measure daytime activity a wrist-worn actigraph and an established protocol were used. A single measure of mean daytime activity per participant was calculated for further statistical analysis. Results: In the two groups of patients with MCI and dementia, apathy is associated with reduced daytime activity, independent of diagnosis (no group by apathy interaction). AES scores correlate significantly with daytime activity. Cognitive impairment reduces daytime activity (effect greater in dementia than in MCI). Daytime activity is negatively correlated with memory deficits. Conclusion: Ambulatory actigraphy is a promising method to evaluate self-initiated action as a correlate of apathy in patients with cognitive impairment. (C) 2011 Elsevier Masson SAS. All rights reserved.	[Kuhlmei, A.] Bethesda Geriatr Klin Ulm, D-89073 Ulm, Germany; [Kuhlmei, A.; Walther, B.; Becker, T.; Nikolaus, T.] Univ Ulm, Bezirkskrankenhaus Gunzburg, Dept Psychiat 2, D-89312 Gunzburg, Germany; [Mueller, U.] Cambridge Behav & Clin Neurosci Inst BCNI, Dept Expt Psychol, Cambridge CB2 3EB, England; [Mueller, U.] Cambridge Behav & Clin Neurosci Inst BCNI, Dept Psychiat, Cambridge CB2 3EB, England	Kuhlmei, A (corresponding author), Bethesda Geriatr Klin Ulm, Zollernring 26, D-89073 Ulm, Germany.	a.kuhlmei@gmx.de	Becker, Thomas/O-9769-2014	Becker, Thomas/0000-0001-8179-1219	Forschungskolleg Geriatrie, Robert Bosch Foundation, Stuttgart, Germany	Funded by a grant of the Forschungskolleg Geriatrie, Robert Bosch Foundation, Stuttgart, Germany. We thank all patients and healthy volunteers for their participation.	Alessi CA, 2005, J AM GERIATR SOC, V53, P803, DOI 10.1111/j.1532-5415.2005.53251.x; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Borod JC, 2000, NEUROPSYCHOLOGY EMOT, P340; Bruck D, 2005, HUM PSYCHOPHARM CLIN, V20, P105, DOI 10.1002/hup.666; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dane AV, 2000, J AM ACAD CHILD PSY, V39, P752, DOI 10.1097/00004583-200006000-00014; Deb S, 2004, BRAIN INJURY, V18, P1, DOI 10.1080/0269905031000110463; Glenn MB, 2002, BRAIN INJURY, V16, P509, DOI 10.1080/02699050110119132; Harper DG, 2001, ARCH GEN PSYCHIAT, V58, P353, DOI 10.1001/archpsyc.58.4.353; Hatfield CF, 2004, BRAIN, V127, P1061, DOI 10.1093/brain/awh129; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kiang M, 2003, SCHIZOPHR RES, V63, P79, DOI 10.1016/S0920-9964(02)00433-4; Lemke MR, 1999, J PSYCHIAT RES, V33, P215, DOI 10.1016/S0022-3956(98)00067-3; Lueken U, 2006, FORTSCHR NEUROL PSYC, V74, P714, DOI 10.1055/s-2006-932164; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; Marit RS, 2005, J HEAD TRAUMA REHAB, V20, P377, DOI 10.1097/00001199-200507000-00009; Martin J, 2001, SCHIZOPHR RES, V47, P77, DOI 10.1016/S0920-9964(00)00029-3; McAllister T W, 2000, Semin Clin Neuropsychiatry, V5, P275, DOI 10.1053/scnp.2000.9557; Muller U, 2006, BRAIN INJURY, V20, P157, DOI 10.1080/02699050500443467; Paavilainen P, 2005, J SLEEP RES, V14, P61, DOI 10.1111/j.1365-2869.2004.00433.x; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Robert P, 2009, EUR PSYCHIAT, V24, P98, DOI 10.1016/j.eurpsy.2008.09.001; Sadeh A, 2002, SLEEP MED REV, V6, P113, DOI 10.1053/smrv.2001.0182; Volicer L, 2001, AM J PSYCHIAT, V158, P704, DOI 10.1176/appi.ajp.158.5.704; Winkler D, 2005, BIOL PSYCHIAT, V58, P331, DOI 10.1016/j.biopsych.2005.01.031	25	25	25	0	17	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0924-9338			EUR PSYCHIAT	Eur. Psychiat.	FEB	2013	28	2					94	97		10.1016/j.eurpsy.2011.04.006			4	Psychiatry	Psychiatry	088XK	WOS:000314871000005	21696925				2021-06-18	
J	Mahmood, A; Wu, HT; Qu, CS; Xiong, Y; Chopp, M				Mahmood, Asim; Wu, Hongtao; Qu, Changsheng; Xiong, Ye; Chopp, Michael			Effects of treating traumatic brain injury with collagen scaffolds and human bone marrow stromal cells on sprouting of corticospinal tract axons into the denervated side of the spinal cord	JOURNAL OF NEUROSURGERY			English	Article						human bone marrow stromal cell; collagen scaffolds; traumatic brain injury; axonal sprouting; basic science; rat	MESENCHYMAL STEM-CELLS; ADULT-RATS; HEAD-INJURY; TRANSPLANTATION; STROKE; TISSUE; REGENERATION; RECOVERY; MOTOR; INCREASES	Object. This study was designed to investigate how transplantation into injured brain of human bone marrow stromal cells (hMSCs) impregnated in collagen scaffolds affects axonal sprouting in the spinal cord after traumatic brain injury (TBI) in rats. Also investigated was the relationship of axonal sprouting to sensorimotor functional recovery after treatment. Methods. Adult male Wistar rats (n = 24) underwent a controlled cortical impact injury and were divided into three equal groups (8 rats/group). The two treatment groups received either hMSCs (3 x 106) alone or hMSC (3 x 106) impregnated collagen scaffolds transplanted into the lesion cavity. In the control group, saline was injected into the lesion cavity. All treatments were performed 7 days after TBI. On Day 21 after TBI, a 10% solution of biotinylated dextran amine (10,000 MW) was stereotactically injected into the contralateral motor cortex to label the corticospinal tract (CST) originating from this area. Sensorimotor function was tested using the modified neurological severity score (mNSS) and foot-fault tests performed on Days 1, 7, 14, 21, 28, and 35 after TBI. Spatial learning was tested with Morris water maze test on Days 31-35 after TBI. All rats were sacrificed on Day 35 after TBI, and brain and spinal cord (cervical and lumbar) sections were stained inununohistochemically for histological analysis. Results. Few biotinylated dextran amine labeled CST fibers crossing over the midline were found in the contralateral spinal cord transverse sections at both cervical and lumbar levels in saline-treated (control) rats. However, hMSC-alone treatment significantly increased axonal sprouting from the intact CST into the denervated side of the gray matter of both cervical and lumbar levels of the spinal cord (p < 0.05). Also, this axonal sprouting was significantly more in the scaffold+hMSC group compared with the hMSC-alone group (p < 0.05). Sensorimotor functional analysis showed significant improvement of mNSS (p < 0.05) and foot-fault tests (p < 0.05) in hMSC-alone and scaffold+hMSC-treated rats compared with controls (p < 0.05). Functiohal improvement, however, was Significantly greater in the scaffold+hMSC group compared with the hMSC-alone group (p < 0.05). Morris water maze testing also showed significant improvement in spatial learning in scaffold+hMSC and hMSC-alone groups compared with the control group (p < 0.05), with rats in the scaffold+hMSC group performing significantly better than those in the hMSC-alone group (p < 0.05). Pearson correlation data showed significant correlation between the number of crossing CST fibers detected and sensorimotor recovery (p < 0.05). Conclusions. Axonal plasticity plays an important role in neurorestoration after TBI. Transplanting hMSCs with scaffolds enhances the effect of hMSCs on axonal sprouting of CST fibers from the contralateral intact cortex into the denervated side of spinal cord after TBI. This enhanced axonal regeneration may at least partially contribute to the therapeutic benefits of treating TBI with hMSCs. (http://thejns.org/doi/abs/10.3171/2012.11.JNS12753)	[Mahmood, Asim; Wu, Hongtao; Qu, Changsheng; Xiong, Ye] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neurou.hfh.edu		Xiong, Ye/0000-0001-9770-6031			Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322; Bancroft GN, 2002, P NATL ACAD SCI USA, V99, P12600, DOI 10.1073/pnas.202296599; BENFEY M, 1982, NATURE, V296, P150, DOI 10.1038/296150a0; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; COLTON CK, 1995, CELL TRANSPLANT, V4, P415, DOI 10.1016/0963-6897(95)00025-S; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Di Giovanni S, 2009, EXPERT OPIN THER TAR, V13, P1387, DOI 10.1517/14728220903307517; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Huebner EA, 2009, RESULTS PROBL CELL D, V48, P339, DOI 10.1007/400_2009_19; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Li CM, 2006, BIOMATERIALS, V27, P3115, DOI 10.1016/j.biomaterials.2006.01.022; Liu ZW, 2008, STROKE, V39, P2571, DOI 10.1161/STROKEAHA.107.511659; Liu ZW, 2010, J CEREBR BLOOD F MET, V30, P1288, DOI 10.1038/jcbfm.2010.8; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Martin I, 2001, J BIOMED MATER RES, V55, P229, DOI 10.1002/1097-4636(200105)55:2<229::AID-JBM1009>3.3.CO;2-H; Mathias SD, 1997, STROKE, V28, P1888, DOI 10.1161/01.STR.28.10.1888; Meinel L, 2005, BONE, V37, P688, DOI 10.1016/j.bone.2005.06.010; Meinel L, 2004, ANN BIOMED ENG, V32, P112, DOI 10.1023/B:ABME.0000007796.48329.b4; Meinel L, 2004, BIOTECHNOL BIOENG, V88, P379, DOI 10.1002/bit.20252; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Navarro X, 2009, INT REV NEUROBIOL, V87, P483, DOI 10.1016/S0074-7742(09)87027-X; Netz J, 1997, BRAIN, V120, P1579, DOI 10.1093/brain/120.9.1579; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Qu CS, 2011, BRAIN RES, V1371, P129, DOI 10.1016/j.brainres.2010.10.088; Reddi AH, 2000, BIOCHEM SOC T, V28, P345, DOI 10.1042/0300-5127:0280345; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Shen LH, 2008, GLIA, V56, P1747, DOI 10.1002/glia.20722; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Sun F, 2010, CURR OPIN NEUROBIOL, V20, P510, DOI 10.1016/j.conb.2010.03.013; Teng FYH, 2006, J NEUROCHEM, V96, P1501, DOI 10.1111/j.1471-4159.2006.03663.x; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	54	25	30	0	16	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2013	118	2					381	389		10.3171/2012.11.JNS12753			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	076DY	WOS:000313937900023	23198801				2021-06-18	
J	Wang, ZT; Yao, WF; Deng, QJ; Zhang, XH; Zhang, JN				Wang, Zhitao; Yao, Weifeng; Deng, Quanjun; Zhang, Xiaohui; Zhang, Jianning			Protective Effects of BDNF Overexpression Bone Marrow Stromal Cell Transplantation in Rat Models of Traumatic Brain Injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Marrow stromal cells; Brain-derived neurotrophic factor; Traumatic brain injury	MESENCHYMAL STEM-CELLS; NEUROTROPHIC FACTOR; INTRACEREBRAL TRANSPLANTATION; FUNCTIONAL RECOVERY; EXPRESSION; ENHANCEMENT; PHENOTYPE; INFUSION; CHILDREN; DEFICITS	Bone marrow stromal cells (MSCs) were used as cell therapy for various diseases in recent years. Some reports showed that transplanted MSCs promote functional recovery in animal models of brain trauma. But other studies indicate that tissue replacement by this method may not be the main source of therapeutic benefit. Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) therapeutic potential may contribute to the recovery of function after trauma. Our previous study showed that BDNF-MSCs could promote the survival of neurons in neuronal injured models in vitro. The present study was undertaken to explore the therapeutic effects of MSCs transfected with BDNF in vivo. After intraventricular injection of MSCs-BDNF, BDNF levels were increased significantly in cerebrospinal fluid by ELISA. Further studies showed that treatment of traumatic brain injury with MSCs-BDNF could attenuate neuronal injury as measurement of biological behavior assessment. These studies demonstrate that by increasing the brain concentration of BDNF, intraventricularly transplanted MSCs-BDNF might play an important role in the treatment of traumatic brain injury and might be an optional therapeutic strategy.	[Wang, Zhitao; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Wang, Zhitao; Zhang, Jianning] Tianjin Neurol Inst, Tianjin 300052, Peoples R China; [Wang, Zhitao; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Wang, Zhitao; Zhang, Jianning] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin 300052, Peoples R China; [Yao, Weifeng] Tianjin Acad Tradit Chinese Med, Affiliated Hosp, Tianjin 300052, Peoples R China; [Deng, Quanjun] Tianjin Huanghe Rd Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Zhang, Xiaohui] Tianjin Med Univ, Canc Inst & Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China	Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com					Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bocker W, 2008, J CELL MOL MED, V12, P1347, DOI [10.1111/j.1582-4934.2008.0299.x, 10.1111/j.1582-4934.2008.00299.x]; Bolton MM, 2000, J NEUROSCI, V20, P3221, DOI 10.1523/JNEUROSCI.20-09-03221.2000; Borlongan CV, 1996, NEUROL RES, V18, P297; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; Desai NS, 1999, NAT NEUROSCI, V2, P515; Diogenes MJ, 2011, NEUROPSYCHOPHARMACOL, V36, P1823, DOI 10.1038/npp.2011.64; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; FLEMING JO, 1983, J NEUROIMMUNOL, V4, P129, DOI 10.1016/0165-5728(83)90017-6; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Jendelova P, 2003, MAGNET RESON MED, V50, P767, DOI 10.1002/mrm.10585; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lipsky RH, 2007, ANN NY ACAD SCI, V1122, P130, DOI 10.1196/annals.1403.009; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; McIntosh TK, 1996, LAB INVEST, V74, P315; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mori T, 2005, MOL CELL BIOL, V25, P5183, DOI 10.1128/MCB.25.12.5183-5195.2005; Mu JS, 1999, BRAIN RES, V835, P259, DOI 10.1016/S0006-8993(99)01592-9; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Wang ZT, 2009, J MOL NEUROSCI, V38, P265, DOI 10.1007/s12031-009-9208-5; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C	42	25	28	0	15	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	FEB	2013	49	2					409	416		10.1007/s12031-012-9908-0			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	070OW	WOS:000313519900019	23143881				2021-06-18	
J	Dolle, JP; Morrison, B; Schloss, RS; Yarmush, ML				Dolle, Jean-Pierre; Morrison, Barclay, III; Schloss, Rene S.; Yarmush, Martin L.			An organotypic uniaxial strain model using microfluidics	LAB ON A CHIP			English	Article							TRAUMATIC BRAIN-INJURY; HIPPOCAMPAL SLICE CULTURES; DIFFUSE AXONAL INJURY; IN-VITRO MODEL; DYNAMIC STRETCH INJURY; HEAD-INJURY; MECHANICAL STRETCH; SODIUM-CHANNELS; NEURAL TRAUMA; OPTIC-NERVE	Traumatic brain injuries are the leading cause of disability each year in the US. The most common and devastating consequence is the stretching of axons caused by shear deformation that occurs during rotational acceleration of the brain during injury. The injury effects on axonal molecular and functional events are not fully characterized. We have developed a strain injury model that maintains the three dimensional cell architecture and neuronal networks found in vivo with the ability to visualize individual axons and their response to a mechanical injury. The advantage of this model is that it can apply uniaxial strains to axons that make functional connections between two organotypic slices and injury responses can be observed in real-time and over long term. This uniaxial strain model was designed to be capable of applying an array of mechanical strains at various rates of strain, thus replicating a range of modes of axonal injury. Long term culture, preservation of slice and cell orientation, and slice-slice connection on the device was demonstrated. The device has the ability to strain either individual axons or bundles of axons through the control of microchannel dimensions. The fidelity of the model was verified by observing characteristic responses to various strain injuries which included axonal beading, delayed elastic effects and breakdown in microtubules. Microtubule breakdown was shown to be dependent on the degree of the applied strain field, where maximal breakdown was observed at peak strain and minimal breakdown is observed at low strain. This strain injury model could be a powerful tool in assessing strain injury effects on functional axonal connections.	[Dolle, Jean-Pierre; Schloss, Rene S.; Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA; [Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Yarmush, Martin L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA	Yarmush, ML (corresponding author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.	jpdolle@rutgers.edu; bm2119@columbia.edu; schloss@soemail.rutgers.edu; yarmush@rci.rutgers.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864	New Jersey Commission for Brain Injury Research [BIR-1.08.016]; National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [NIH P41 EB002503]; National Institute of General Medical Sciences (Rutgers-UMDNJ Biotechnology Training Program) [T32 GM 008339]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008339] Funding Source: NIH RePORTER	This work was supported by grants from the New Jersey Commission for Brain Injury Research (BIR-1.08.016), the National Institute of Biomedical Imaging and Bioengineering (NIH P41 EB002503), and the National Institute of General Medical Sciences (Rutgers-UMDNJ Biotechnology Training Program: T32 GM 008339).	Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Berdichevsky Y, 2010, LAB CHIP, V10, P999, DOI 10.1039/b922365g; Berdichevsky Y, 2009, J NEUROSCI METH, V178, P59, DOI 10.1016/j.jneumeth.2008.11.016; Bottlang M, 2007, J NEUROTRAUM, V24, P1068, DOI 10.1089/neu.2006.3772; BUCHS PA, 1993, DEV BRAIN RES, V71, P81, DOI 10.1016/0165-3806(93)90108-M; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Choi KM, 2003, J AM CHEM SOC, V125, P4060, DOI 10.1021/ja029973k; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Del Turco Domenico, 2007, V399, P55, DOI 10.1007/978-1-59745-504-6_5; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fischer Y, 1999, J PHYSIOL-LONDON, V519, P405, DOI 10.1111/j.1469-7793.1999.0405m.x; GAHWILER BH, 1984, EXPERIENTIA, V40, P235, DOI 10.1007/BF01947561; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Kawalec M, 2011, NEUROCHEM RES, V36, P2091, DOI 10.1007/s11064-011-0568-1; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Mata A, 2005, BIOMED MICRODEVICES, V7, P281, DOI 10.1007/s10544-005-6070-2; Meaney D.F., 1990, INT C BIOM IMP LYON, P215; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Molnar Z, 1999, EXP NEUROL, V156, P363, DOI 10.1006/exnr.1999.7032; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Sia SK, 2003, ELECTROPHORESIS, V24, P3563, DOI 10.1002/elps.200305584; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STRICH SJ, 1961, LANCET, V2, P443; Sundstrom L, 2005, DRUG DISCOV TODAY, V10, P993, DOI 10.1016/S1359-6446(05)03502-6; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; WYSS JM, 1980, ANAT EMBRYOL, V158, P303, DOI 10.1007/BF00301819; Yu Z, 2009, J NEUROTRAUM, V26, P1135, DOI 10.1089/neu.2008.0810	49	25	26	1	41	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1473-0197	1473-0189		LAB CHIP	Lab Chip		2013	13	3					432	442		10.1039/c2lc41063j			11	Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry, Analytical; Nanoscience & Nanotechnology; Instruments & Instrumentation	Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics; Instruments & Instrumentation	062UE	WOS:000312947300015	23233120	Green Accepted			2021-06-18	
J	Meng, X; Browne, KD; Huang, SM; Mietus, C; Cullen, DK; Tofighi, MR; Rosen, A				Meng, Xu; Browne, Kevin D.; Huang, Shi-Min; Mietus, Constance; Cullen, D. Kacy; Tofighi, Mohammad-Reza; Rosen, Arye			Dynamic Evaluation of a Digital Wireless Intracranial Pressure Sensor for the Assessment of Traumatic Brain Injury in a Swine Model	IEEE TRANSACTIONS ON MICROWAVE THEORY AND TECHNIQUES			English	Article						Digital wireless implants; intracranial pressure (ICP); rotational head injury; slot antenna; traumatic brain injury (TBI)	CLINICAL-PRACTICE; HEAD-INJURY; DEVICE; TRANSMISSION; IMPLANT; PIG	The monitoring and control of increased intracranial pressure (ICP) are the major requirements for the diagnosis and treatment of patients suffering from traumatic brain injury (TBI) or hydrocephalus. Widely used commercially available ICP measuring devices require the use of a tethered fiber optic probe, which can cause complications, such as infection and hemorrhage. The use of a probe also prohibits immediate (at the time of induced injury) and long-term measurements of ICP. Therefore, we have developed and tested a small fully embedded wireless ICP sensor, incorporating a novel antenna and packaging arrangement. Evaluations were performed in-vitro and in-vivo to demonstrate the robustness of this microwave pressure-monitoring system. This is the first report of in-vivo tests in a dynamic study of continuous (every 6 s) wireless ICP measurements in a swine model of closed-head rotational-acceleration induced TBI using a digital device. In particular, our device measured extreme changes in ICP immediately upon rapid head rotation that persisted for hours after the injury. The readings matched well those obtained from a commercially available tethered monitor. Our device can be utilized in the future as a tool to diagnose and track long-term ICP changes.	[Meng, Xu; Rosen, Arye] Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19104 USA; [Browne, Kevin D.; Mietus, Constance; Cullen, D. Kacy] Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Huang, Shi-Min] Drexel Univ, Dept Elect Engn, Philadelphia, PA 19104 USA; [Tofighi, Mohammad-Reza] Penn State Univ, Capital Coll, Middletown, PA 17057 USA	Meng, X (corresponding author), Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19104 USA.	xm26@drexel.edu; kbrowne@mail.med.upenn.edu; sh592@drexel.edu; mi-etus@mail.med.upenn.edu; dkacy@mail.med.upenn.edu; mtofighi@psu.edu; ar86@drexel.edu	Huang, Shimin/X-6369-2019		Department of Neurosurgery, University of Pennsylvania; University Research Foundation, University of Pennsylvania; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS050598]	This work was supported in part by the Department of Neurosurgery and University Research Foundation, University of Pennsylvania, and the National Institutes of Health (NIH) under Grant NS050598.	[Anonymous], 2009, HYDR STAT; Bashirullah R, 2010, IEEE MICROW MAG, V11, pS14, DOI 10.1109/MMM.2010.938579; CHAMBERS IR, 1990, NEUROSURGERY, V26, P421, DOI 10.1227/00006123-199003000-00007; CHAMBERS IR, 1993, NEUROSURGERY, V33, P866; Chen PJ, 2010, J MICROELECTROMECH S, V19, P721, DOI 10.1109/JMEMS.2010.2049825; Chow EY, 2010, IEEE T BIO-MED ENG, V57, P1487, DOI 10.1109/TBME.2010.2041058; Chow EY, 2008, IEEE T MICROW THEORY, V56, P3200, DOI 10.1109/TMTT.2008.2007338; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Gelabert-Gonzalez M, 2006, ACTA NEUROCHIR, V148, P435, DOI 10.1007/s00701-005-0683-3; Kawoos U., 2009, THESIS DREXEL U PHIL; Kawoos U, 2008, IEEE T MICROW THEORY, V56, P2356, DOI 10.1109/TMTT.2008.2004253; Mahfouz MR, 2009, IEEE T MICROW THEORY, V57, P2550, DOI 10.1109/TMTT.2009.2029721; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Majerus SJA, 2011, IEEE T BIO-MED ENG, V58, P763, DOI 10.1109/TBME.2010.2085002; March K, 2005, AACN ADV CRIT CARE, V16, P456, DOI 10.1097/00044067-200510000-00004; Meng X, 2012, ELECTRON LETT, V48, P363, DOI 10.1049/el.2012.0281; Meng X., 2011, IEEE MTT S INT MICR, P1; Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Schepps J, 2002, IEEE T MICROW THEORY, V50, P1044, DOI 10.1109/22.989992; SCHICKNER DJ, 1992, SURG NEUROL, V37, P251, DOI 10.1016/0090-3019(92)90147-F; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Sodagar AM, 2009, IEEE J SOLID-ST CIRC, V44, P2591, DOI 10.1109/JSSC.2009.2023159; Tofighi M. R, 2011, 12 ANN IEEE WIR MICR, P1; Vorst A.V., 2006, RF MICROWAVE INTERAC; Warty R, 2008, IEEE T MICROW THEORY, V56, P2366, DOI 10.1109/TMTT.2008.2004254; Yakovlev A, 2012, IEEE COMMUN MAG, V50, P152, DOI 10.1109/MCOM.2012.6178849	29	25	25	0	18	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9480	1557-9670		IEEE T MICROW THEORY	IEEE Trans. Microw. Theory Tech.	JAN	2013	61	1	1				316	325		10.1109/TMTT.2012.2224361			10	Engineering, Electrical & Electronic	Engineering	076EW	WOS:000313940300034					2021-06-18	
J	Miller, KJ; Ivins, BJ; Schwab, KA				Miller, Kelly J.; Ivins, Brian J.; Schwab, Karen A.			Self-Reported Mild TBI and Postconcussive Symptoms in a Peacetime Active Duty Military Population: Effect of Multiple TBI History Versus Single Mild TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; military; multiple TBI; postconcussive symptoms; soldier	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; BASE-RATE; CONCUSSION; FOOTBALL; PREVALENCE; EXPECTATION; VETERANS; SEQUELAE	Objective: To investigate the potential cumulative impact of mild traumatic brain injury (MTBI) on postconcussive symptoms. Participants: A total of 224 active duty soldiers reporting MTBI within 1 year of testing. For 101, this MTBI was their only reported traumatic brain injury (TBI); 123 had sustained at least 1 additional MTBI during their lifetime. A No TBI control group (n = 224) was included for comparison. Main Measure: Self-report symptoms data via questionnaire. Within time since injury subgroups (<= 3 months; Post-3 months), symptom endorsement (no symptoms, 1 or 2 symptoms, 3+ symptoms) among soldiers with 1 MTBI was compared with that of soldiers with 2 or more MTBIs. Injured soldiers' symptom endorsement was compared with that of soldiers who had not sustained a TBI. Results: Among the recently injured (<= 3 months), those with 2 or more MTBIs endorsed significantly more symptoms than those with 1 MTBI: 67% of soldiers with 2 or more MTBIs reported 3+ symptoms, versus 29% of One MTBI soldiers. Among Post-3 month soldiers, there were no significant differences between MTBI groups. Overall, soldiers with MTBI endorsed significantly more symptoms than those without TBI. Conclusion: Past experience of MTBI may be a risk factor for increased symptom difficulty for several months postinjury. Clinicians should ascertain lifetime history of brain injury when evaluating patients for MTBI.	[Miller, Kelly J.; Ivins, Brian J.; Schwab, Karen A.] Def & Vet Brain Injury Ctr, Rockville, MD 20852 USA; [Schwab, Karen A.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Miller, KJ (corresponding author), Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, Rockville, MD 20852 USA.	kelly.j.miller2.ctr@us.army.mil					Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANDRASIK F, 1994, SEMIN NEUROL, V14, P60, DOI 10.1055/s-2008-1041060; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; EVANS RW, 1992, NEUROL CLIN, V10, P815; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Makdissi M, 2009, BRIT J SPORT MED, V43, pI23, DOI 10.1136/bjsm.2009.058206; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1993, ICD 10 CLASS MENT BE, P63	41	25	25	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2013	28	1					31	38		10.1097/HTR.0b013e318255ceae			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	070ZW	WOS:000313555400004	22647963				2021-06-18	
J	Sandel, NK; Lovell, MR; Kegel, NE; Collins, MW; Kontos, AP				Sandel, Natalie K.; Lovell, Mark R.; Kegel, Nathan E.; Collins, Michael W.; Kontos, Anthony P.			The Relationship of Symptoms and Neurocognitive Performance to Perceived Recovery From Sports-Related Concussion Among Adolescent Athletes	APPLIED NEUROPSYCHOLOGY-CHILD			English	Article						adolescent; athletes; concussion; neurocognitive; perceptions; recovery	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; IMPACT	Sports medicine practitioners often consider athletes' self-reports of recovery for the management of concussion, and it is not clear which factors (i.e., neurocognitive performance and symptoms) athletes consider when forming perceptions of recovery from concussion. The current study assessed the relationship of perceptions of recovery to neurocognitive performance on the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) battery and to symptoms using the Post-Concussion Symptom Scale (PCSS). A total of 101 concussed athletes (62 males, 39 females) aged 12 to 18 years old were included in the study (M-age = 14.75, SD = 1.76). Athletes were asked to rate their "percent back to normal" (i.e., perception of recovery) at the time of evaluation. A multiple regression for neurocognitive performance and symptoms revealed a significant model that accounted for 58% of the variance in perceptions of recovery. Adolescent athletes base their perceptions primarily on somatic symptoms (e. g., headache, nausea, vomiting, etc.), and these perceptions may be incongruent with objective neurocognitive measures. Athletes' tendency to overlook several factors when forming their perceptions of recovery should caution the sports medicine practitioner from relying on self-reported symptoms as their primary criterion for return-to-play decisions. These data further support the need for valid and reliable measures for concussion management.	[Sandel, Natalie K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15203 USA; [Sandel, Natalie K.] Univ Pittsburgh, Sch Med Sports Med, Ctr Sports Med, Concuss Program, Pittsburgh, PA 15203 USA; [Lovell, Mark R.] Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA 15203 USA; [Kegel, Nathan E.; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, Sch Med, Ctr Sports Med, Dept Orthoped Surg, Pittsburgh, PA 15203 USA	Kontos, AP (corresponding author), Univ Pittsburgh, Sch Med Sports Med, Ctr Sports Med, Concuss Program, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu	Meijer, Anna/K-5118-2016	Kontos, Anthony/0000-0002-3749-4310			CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	16	25	25	0	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2162-2965	2162-2973		APPL NEUROPSYCH-CHIL	Appl. Neuropsychol.-Child		2013	2	1					64	69		10.1080/21622965.2012.670580			6	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	AD0SV	WOS:000332945300009	23427778				2021-06-18	
J	Zheng, B; Wang, CY; He, LH; Xu, XJ; Qu, J; Hu, J; Zhang, HX				Zheng, Bing; Wang, Chunyan; He, Lihong; Xu, Xiaojing; Qu, Jing; Hu, Jun; Zhang, Huanxiang			Neural differentiation of mesenchymal stem cells influences chemotactic responses to HGF	JOURNAL OF CELLULAR PHYSIOLOGY			English	Article							MARROW STROMAL CELLS; GROWTH FACTOR/SCATTER FACTOR; UMBILICAL-CORD BLOOD; MAGNETIC-RESONANCE TRACKING; FACTOR-INDUCED MIGRATION; TRAUMATIC BRAIN-INJURY; BONE-MARROW; IN-VITRO; FUNCTIONAL RECOVERY; PROGENITOR CELLS	Recently, mesenchymal stem cells (MSCs) have been extensively used for cell-based therapies in neuronal degenerative disease. Although much effort has been devoted to the delineation of factors involved in the migration of MSCs, the relationship between the chemotactic responses and the differentiation status of these cells remains elusive. Here, we report that MSCs in varying neural differentiation states display different chemotactic responses to hepatocyte growth factor (HGF): first, the number of chemotaxing MSCs and the optimal concentrations of HGF that induced the peak migration varied greatly; second, time-lapse video analysis showed that MSCs in certain differentiation state migrated more efficiently toward HGF; third, the phosphorylation levels of Akt, ERK1/2, SAPK/JNK, and p38MAPK were closely related to the differentiation levels of MSCs subjected to HGF; and finally, although inhibition of ERK1/2 signaling significantly attenuated HGF-stimulated transfilter migration of both undifferentiated and differentiating MSCs, abolishment of PI3K/Akt, p38MAPK, or SAPK/JNK signaling only decreased the number of migrated cells in certain differentiation state(s). Blocking of PI3K/Akt or MAPK signaling impaired the migration efficiency and/or speed, the extent of which depends on the cell differentiation states. Meanwhile, F-actin rearrangement, which is essential for MSCs chemotaxis, was induced by HGF, and the time points of cytoskeletal reorganization were different among these cells. Collectively, these results demonstrate that neural differentiation of MSCs influences their chemotactic responses to HGF: MSCs in varying differentiation states possess different migratory capacities, thereby shedding light on optimization of the therapeutic potential of MSCs to be employed for neural regeneration after injury. J. Cell. Physiol. 228: 149162, 2013. (c) 2012 Wiley Periodicals, Inc.	[Zheng, Bing; Wang, Chunyan; He, Lihong; Xu, Xiaojing; Qu, Jing; Hu, Jun; Zhang, Huanxiang] Soochow Univ, Coll Med, Dept Cell Biol, Jiangsu Key Lab Stem Cell Res, Suzhou 215123, Peoples R China	Zhang, HX (corresponding author), Soochow Univ, Coll Med, Dept Cell Biol, Jiangsu Key Lab Stem Cell Res, Ren Ai Rd 199,Suzhou Ind Pk, Suzhou 215123, Peoples R China.	hzhang@suda.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31071220, 30870642]; China Project 211 (Reconstruction of Spinal Functions and Bone Tissue Engineering After Minimal Invasive Surgery)	Contract grant sponsor: National Natural Science Foundation of China;; Contract grant numbers: 31071220, 30870642.; Contract grant sponsor: China Project 211 (Reconstruction of Spinal Functions and Bone Tissue Engineering After Minimal Invasive Surgery).	Alexanian AR, 2008, STEM CELLS DEV, V17, P1123, DOI 10.1089/scd.2007.0212; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI15392; Corti S, 2004, J CELL MOL MED, V8, P329, DOI 10.1111/j.1582-4934.2004.tb00322.x; Cova L, 2010, BRAIN RES, V1311, P12, DOI 10.1016/j.brainres.2009.11.041; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Delcroix GJR, 2009, BRAIN RES, V1255, P18, DOI 10.1016/j.brainres.2008.12.013; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Doucette T, 2011, NEOPLASIA, V13, P716, DOI 10.1593/neo.101680; Duan HF, 2004, EXP CELL RES, V298, P593, DOI 10.1016/j.yexcr.2004.04.049; Fiedler J, 2005, BIOCHEM BIOPH RES CO, V334, P561, DOI 10.1016/j.bbrc.2005.06.116; Fiedler J, 2002, J CELL BIOCHEM, V87, P305, DOI 10.1002/jcb.10309; Forte G, 2006, STEM CELLS, V24, P23, DOI 10.1634/stemcells.2004-0176; Gagari E, 2006, EUR J ORAL SCI, V114, P409, DOI 10.1111/j.1600-0722.2006.00388.x; Garzotto D, 2008, J NEUROSCI, V28, P5901, DOI 10.1523/JNEUROSCI.1083-08.2008; Giacobini P, 2002, ENDOCRINOLOGY, V143, P3306, DOI 10.1210/en.2002-220146; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Hu SL, 2010, CRIT CARE MED, V38, P2181, DOI 10.1097/CCM.0b013e3181f17c0e; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huttenlocher A, 2005, NAT CELL BIOL, V7, P336, DOI 10.1038/ncb0405-336; Isakova IA, 2007, STEM CELLS, V25, P3261, DOI 10.1634/stemcells.2007-0543; Jendelova P, 2004, J NEUROSCI RES, V76, P232, DOI 10.1002/jnr.20041; Jin HK, 2002, J CLIN INVEST, V109, P1183, DOI 10.1072/JCI200214862; Kao AP, 2011, FERTIL STERIL, V95, P1308, DOI 10.1016/j.fertnstert.2010.09.064; Kim SM, 2008, CANCER RES, V68, P9614, DOI 10.1158/0008-5472.CAN-08-0451; Kitada Masaaki, 2008, Nihon Rinsho, V66, P921; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Lee WJ, 2006, CHEM-BIOL INTERACT, V160, P123, DOI 10.1016/j.cbi.2006.01.002; Lepski G, 2010, TISSUE ENG PT A, V16, P2769, DOI [10.1089/ten.tea.2009.0686, 10.1089/ten.TEA.2009.0686]; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Magavi SS, 2000, NATURE, V405, P951; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mishima Y, 2008, J ORTHOP RES, V26, P1407, DOI 10.1002/jor.20668; Mortimer D, 2008, TRENDS NEUROSCI, V31, P90, DOI 10.1016/j.tins.2007.11.008; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Neuss S, 2004, STEM CELLS, V22, P405, DOI 10.1634/stemcells.22-3-405; Pisati F, 2007, CELL TRANSPLANT, V16, P41, DOI 10.3727/000000007783464443; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; Rosova I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007-1104; Ryu CH, 2010, BIOCHEM BIOPH RES CO, V398, P105, DOI 10.1016/j.bbrc.2010.06.043; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Segarra J, 2006, J BIOL CHEM, V281, P4771, DOI 10.1074/jbc.M508298200; Serrador JM, 1999, TRENDS CELL BIOL, V9, P228, DOI 10.1016/S0962-8924(99)01553-6; Shyu WC, 2007, STROKE, V38, P367, DOI 10.1161/01.STR.0000254463.24655.14; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood-2004-09-3507; Stephens P, 2001, WOUND REPAIR REGEN, V9, P34, DOI 10.1046/j.1524-475x.2001.00034.x; Sykova E, 2006, NEURODEGENER DIS, V3, P62, DOI 10.1159/000092095; Tang JM, 2009, EXP CELL RES, V315, P3521, DOI 10.1016/j.yexcr.2009.09.026; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Tfilin M, 2010, MOL PSYCHIATR, V15, P1164, DOI 10.1038/mp.2009.110; van Haaften T, 2009, AM J RESP CRIT CARE, V180, P1131, DOI 10.1164/rccm.200902-0179OC; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; VANDEWOUDE GF, 1997, CIBA F SYMP, V212, P130; VANDEWOUDE GF, 1997, CIBA FOUND S, V212, P148; Veit C, 2004, CANCER RES, V64, P5291, DOI 10.1158/0008-5472.CAN-04-1112; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Wang Lei, 2002, Hematology, V7, P113; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wu GD, 2003, TRANSPLANTATION, V75, P679, DOI 10.1097/01.TP.0000048488.35010.95; Xu F, 2010, ONCOL REP, V23, P1561, DOI 10.3892/or_00000796; Yang M, 2010, CELL TRANSPLANT, V19, P1073, DOI 10.3727/096368910X503415; Zhao Zhiqiang, 2011, Eur Cell Mater, V22, P344; ZICHA D, 1991, J CELL SCI, V99, P769; Zou CY, 2011, IN VITRO CELL DEV-AN, V47, P241, DOI 10.1007/s11626-010-9377-0	68	25	28	1	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9541	1097-4652		J CELL PHYSIOL	J. Cell. Physiol.	JAN	2013	228	1					149	162		10.1002/jcp.24114			14	Cell Biology; Physiology	Cell Biology; Physiology	018QW	WOS:000309678000019	22570218				2021-06-18	
J	Luukkainen, S; Riala, K; Laukkanen, M; Hakko, H; Rasanen, P				Luukkainen, Saku; Riala, Kaisa; Laukkanen, Matti; Hakko, Helina; Rasanen, Pirkko			Association of traumatic brain injury with criminality in adolescent psychiatric inpatients from Northern Finland	PSYCHIATRY RESEARCH			English	Article						Adolescent; Criminality; Substance-related disorders; Conduct disorder	JUVENILE-DELINQUENCY; SUBSTANCE USE; BIRTH COHORT; DISORDERS; CHILDHOOD; SYMPTOMS; LIFETIME; BEHAVIOR; CHILDREN; SMOKING	The association of traumatic brain injuries (TBI) with criminality, substance-related disorders and conduct disorders has mainly been studied in adult populations. In our study we examine the association in an adolescent population. We used a population-based clinical sample of 508 psychiatric inpatient adolescents from Northern Finland. The prevalences of TBI and criminality were 26 (5.1%) and 85 (16.7%), respectively. The information on TBI was acquired from the Finnish Hospital Discharge Register and on criminality from the Legal Register Center. DSM-IV diagnoses were obtained by interviewing the subjects using the semi-structured Schedule for Affective Disorder and Schizophrenia for School-Age Children, Present and Lifetime (K-SADS-PL). Adolescents with TBI had significantly more often committed crimes compared to adolescents without TBI (53.8% vs. 14.7%, respectively). Prevalences of both violent crimes (42.9% vs. 9.1%) and non-violent crimes (29.4% vs. 6.8%) were also higher in the TBI group. TBI during childhood and adolescence increased the risk of any criminality 6.8-fold (95% 3.0-15.2), conduct disorder 5.7-fold (95% 2.1-15.4) and concomitant criminality and conduct disorder 18.7-fold (95% 4.3-80.1). Our results suggest that clinicians working with mentally ill adolescents who have experienced head injuries should be aware of the increased risk for delinquency and violent tendencies occurring later in the adolescents' lives. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Luukkainen, Saku; Rasanen, Pirkko] Univ Oulu, Dept Psychiat, Oulu 90014, Finland; [Riala, Kaisa; Laukkanen, Matti; Hakko, Helina] Oulu Univ Hosp, Dept Psychiat, Oys 90029, Finland; [Riala, Kaisa] Univ Helsinki, Cent Hosp, Dept Adolescent Psychiat, Huch Helsinki 00029, Finland	Hakko, H (corresponding author), Oulu Univ Hosp, Dept Psychiat, POB 26, Oys 90029, Finland.	helina.hakko@oulu.fi					Bauer SM, 2011, PSYCHIAT RES, V185, P193, DOI 10.1016/j.psychres.2010.04.052; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI 10.1089/neu.2008-0849; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Hux D, 1998, BRAIN INJURY, V12, P667; Ilomaki R, 2008, EUR PSYCHIAT, V23, P85, DOI 10.1016/j.eurpsy.2007.10.009; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Keskimaki I, 1991, INT J HLTH SCI, V2, P15; Kokkevi A., 1995, EUR ADDICT RES, V1, P208, DOI 10.1159/000259089.; Laukkanen M, 2008, J ADDICT DIS, V27, P69, DOI 10.1080/10550880802324853; Luukkonen AH, 2011, FORENSIC SCI INT, V207, P106, DOI 10.1016/j.forsciint.2010.09.012; Maniadaki Katerina, 2008, Crim Behav Ment Health, V18, P207, DOI 10.1002/cbm.698; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Najman JM, 2010, J ADOLESCENT HEALTH, V46, P538, DOI 10.1016/j.jadohealth.2009.12.001; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; RANTAKALLIO P, 1992, ARCH DIS CHILD, V67, P1459, DOI 10.1136/adc.67.12.1459; Schroeder RD, 2010, SOCIOL INQ, V80, P579, DOI 10.1111/j.1475-682X.2010.00351.x; Stoddard SA, 2011, PEDIATRICS, V127, P1074, DOI 10.1542/peds.2010-2453; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613	22	25	25	0	17	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	DEC 30	2012	200	2-3					767	772		10.1016/j.psychres.2012.04.018			6	Psychiatry	Psychiatry	073TF	WOS:000313764700109	22560660				2021-06-18	
J	Guingab-Cagmat, JD; Newsom, K; Vakulenko, A; Cagmat, EB; Kobeissy, FH; Zoltewicz, S; Wang, KK; Anagli, J				Guingab-Cagmat, Joy D.; Newsom, Kimberly; Vakulenko, Anatoliy; Cagmat, Emilio B.; Kobeissy, Firas H.; Zoltewicz, Susie; Wang, Kevin K.; Anagli, John			In vitro MS-based proteomic analysis and absolute quantification of neuronal-glial injury biomarkers in cell culture system	ELECTROPHORESIS			English	Article						Absolute mass pectrometric quantitation; Cell culture; GFAP; Proteomics; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; PEPTIDE IMMUNOAFFINITY ENRICHMENT; MAITOTOXIN INDUCES CALPAIN; MASS-SPECTROMETRY; BREAKDOWN PRODUCTS; STATISTICAL-MODEL; ACTIVATION; SERUM; NEUROPROTEOMICS	MS-based proteomics has been the method of choice for biomarker discovery in the field of traumatic brain injury (TBI). Due to its high sensitivity and specificity, MS is now being explored for biomarker quantitative validation in tissue and biofluids. In this study, we demonstrate the use of MS in both qualitative protein identification and targeted detection of acute TBI biomarkers released from degenerating cultured rat cortical mixed neuronal cells, mimicking intracellular fluid in the central nervous system after TBI. Calpain activation was induced by cell treatment with maitotoxin (MTX), a known calcium channel opener. Separate plates of mixed neuronal-glial culture were subjected to excitotoxin N-methyl-D-aspartate (NMDA) and apoptotic inducer staurosporine. Acute TBI biomarkers, GFAP and UCH-L1, were first detected and assessed in the culture media by Western blot. The cell-conditioned media were then trypsinized and subjected to bottom up proteomic analysis. GFAP was readily detected by data-dependent scanning but not UCH-L1. As a proof-of-principle study, rat glia-enriched cell cultures treated with MTX were used to investigate the time-dependent release of GFAP breakdown product by Western blot and for isotope dilution MS absolute quantitation method development. Absolute quantitation of the GFAP release was conducted using the three cortical mixed neuronal cell cultures treated with different agents. Other differentially expressed proteins identified in the glial-enriched and cortical mixed neuronal cell culture models were further analyzed by bioinformatic tools. In summary, this study demonstrates the use of MS in both protein identification and targeted quantitation of acute TBI biomarkers and is the preliminary step toward development of TBI biomarker validation by targeted MS.	[Guingab-Cagmat, Joy D.; Newsom, Kimberly; Vakulenko, Anatoliy; Cagmat, Emilio B.; Kobeissy, Firas H.; Zoltewicz, Susie; Anagli, John] Banyan Biomarkers Inc, Alachua, FL 32615 USA; [Wang, Kevin K.] Univ Florida, Dept Psychiat, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32611 USA	Guingab-Cagmat, JD (corresponding author), Banyan Biomarkers Inc, 2076 Technol Ave, Alachua, FL 32615 USA.	jguingab@banyanbio.com	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473			Addona TA, 2009, NAT BIOTECHNOL, V27, P633, DOI 10.1038/nbt.1546; Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Ahn YH, 2009, J PROTEOME RES, V8, P4216, DOI 10.1021/pr900269s; DEARMOND SJ, 1983, BRAIN RES, V262, P275, DOI 10.1016/0006-8993(83)91018-1; Dongre AR, 1997, TRENDS BIOTECHNOL, V15, P418, DOI 10.1016/S0167-7799(97)01110-4; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Ottens AK, 2008, J NEUROCHEM, V104, P1404, DOI 10.1111/j.1471-4159.2007.05086.x; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Rauh M, 2012, J CHROMATOGR B, V883, P59, DOI 10.1016/j.jchromb.2011.09.030; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Whiteaker JR, 2011, CLIN LAB MED, V31, P385, DOI 10.1016/j.cll.2011.07.004; Whiteaker JR, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005645; Whiteaker JR, 2011, NAT BIOTECHNOL, V29, P625, DOI 10.1038/nbt.1900; Whiteaker JR, 2010, CLIN CHEM, V56, P1373, DOI 10.1373/clinchem.2010.150383; Whiteaker JR, 2010, MOL CELL PROTEOMICS, V9, P184, DOI 10.1074/mcp.M900254-MCP200; Zhang Z., 2010, ANN ADV TECHNOLOGY A; Zhang Z., 2010, J NEUROTRAUM, pA1; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078; Zhao L, 2011, JOVE-J VIS EXP, DOI 10.3791/2812; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351	35	25	25	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	DEC	2012	33	24			SI		3786	3797		10.1002/elps.201200326			12	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	057FT	WOS:000312548900022	23161537				2021-06-18	
J	Van Houtven, CH; Friedemann-Sanchez, G; Clothier, B; Levison, D; Taylor, BC; Jensen, AC; Phelan, SM; Griffin, JM				Van Houtven, Courtney Harold; Friedemann-Sanchez, Greta; Clothier, Barbara; Levison, Deborah; Taylor, Brent C.; Jensen, Agnes C.; Phelan, Sean M.; Griffin, Joan M.			Is Policy Well-Targeted to Remedy Financial Strain among Caregivers of Severely Injured US Service Members?	INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING			English	Article							TRAUMATIC BRAIN-INJURY; INFORMAL CARE; REHABILITATION; WORK; WAR; PARTICIPATION; EMPLOYMENT; VETERANS; BURDEN; IMPACT	US. military service members have sustained severe injuries since the start of the wars in Iraq and Afghanistan. This paper aims to determine the factors associated with financial strain of their caregivers and establish whether recent federal legislation targets caregivers experiencing financial strain. In our national survey, 62.3% of caregivers depleted assets and/or accumulated debt, and 41% of working caregivers left the labor force. If a severely injured veteran needed intensive help, the primary caregiver faced odds 4.63 times higher of leaving the labor force, and used $27,576 more in assets and/or accumulated debt compared to caregivers of veterans needing little or no assistance.	[Van Houtven, Courtney Harold] Vet Adm Med Ctr, Ctr Hlth Serv Res Primary Care, Dept Vet Affairs VA Med Ctr, Durham, NC 27705 USA; [Van Houtven, Courtney Harold] Duke Univ, Med Ctr, Durham, NC 27706 USA; [Friedemann-Sanchez, Greta; Levison, Deborah] Univ Minnesota, Hubert H Humphrey Sch Publ Affairs, Minneapolis, MN 55455 USA; [Clothier, Barbara; Taylor, Brent C.; Jensen, Agnes C.; Griffin, Joan M.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Taylor, Brent C.; Griffin, Joan M.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Taylor, Brent C.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA; [Phelan, Sean M.] Univ Minnesota, Med Sch, Dept Family Med & Community Hlth, Minneapolis, MN 55455 USA	Van Houtven, CH (corresponding author), 508 Fulton St 558-152, Durham, NC 27705 USA.	courtney.vanhoutven@duke.edu	Taylor, Brent C/A-8069-2009	Taylor, Brent C/0000-0002-2140-8377; Van Houtven, Courtney/0000-0002-0783-1611; Friedemann-Sanchez, Greta/0000-0002-0493-7218	Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health Administration Office of Research and Development; Health Services Research and Development Service, VA [SDR 07-044]; VA HSR&D Career Development Award [MRP 05-311]	Courtney Harold Van Houtven, Ph.D., is a research scientist at the Center for Health Services Research in Primary Care, Department of Veterans Affairs (VA) Medical Center, Durham, N. C., and an associate professor in general internal medicine at the Duke University Medical Center. Greta Friedemann-Sanchez, Ph.D., is an assistant professor at the Hubert H Humphrey School of Public Affairs, University of Minnesota. Barbara Clothier, M.S., M.A., is a statistician at the Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System. Deborah Levison, Ph.D., is a professor at the Hubert H. Humphrey School of Public Affairs, University of Minnesota. Brent C. Taylor, Ph.D., is a core investigator at the Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System, an assistant professor at the University of Minnesota Medical School, and an adjunct assistant professor at the University of Minnesota School of Public Health. Joan M. Griffin, Ph.D., is a core investigator at the Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System, and an associate professor at the University of Minnesota Medical School. Agnes C Jensen, is a research coordinator at the Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System. Sean M. Phelan, Ph.D., M.P.H., is an assistant professor in the Department of Family Medicine and Community Health, University of Minnesota Medical School. This research was supported by the Department of Veterans Affairs, Veterans Health Administration Office of Research and Development, and a grant from the Health Services Research and Development Service, VA (SDR 07-044: Griffin, PI). Dr. Van Houtven was funded by a VA HSR&D Career Development Award (MRP 05-311). Address correspondence to Dr. Van Houtven at 508 Fulton Street (558/152), Durham, NC 27705. Email: courtney.vanhoutven@duke.edu	Arno PS, 1999, HEALTH AFFAIR, V18, P182, DOI 10.1377/hlthaff.18.2.182; Bolin K, 2008, J HEALTH ECON, V27, P718, DOI 10.1016/j.jhealeco.2007.10.004; Carlson KF, 2012, J HEAD TRAUMA REHAB, V27, P14, DOI 10.1097/HTR.0b013e318236bd86; Carmichael F, 2003, J HEALTH ECON, V22, P781, DOI 10.1016/S0167-6296(03)00044-4; Deb P., 2012, AM SOC HLTH EC C MIN; Deere CD, 2006, FEM ECON, V12, P1, DOI 10.1080/13545700500508056; Dillman D.A., 2011, MAIL INTERNET SURVEY; Duan N., 1984, J BUS ECON STAT, V2, P283, DOI DOI 10.1080/07350015.1984.10509396; Einhorn C., 2011, NY TIMES, pA12; ETTNER SL, 1995, DEMOGRAPHY, V32, P63, DOI 10.2307/2061897; Fast JE., 1999, J FAM ECON ISS, V20, P301; Feinberg LF, 2004, GERONTOLOGIST, V44, P760, DOI 10.1093/geront/44.6.760; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Griffin JM, 2012, J HEAD TRAUMA REHAB, V27, P3, DOI 10.1097/HTR.0b013e3182274260; Grunfeld E, 2004, CAN MED ASSOC J, V170, P1795, DOI 10.1503/cmaj.1031205; Hayman JA, 2001, J CLIN ONCOL, V19, P3219, DOI 10.1200/JCO.2001.19.13.3219; Heitmueller A, 2007, J HEALTH ECON, V26, P536, DOI 10.1016/j.jhealeco.2006.10.005; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Johnson RW, 2006, INQUIRY-J HEALTH CAR, V43, P195, DOI 10.5034/inquiryjrnl_43.3.195; Jones A., 2000, HDB HLTH EC A, V1A; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lilly MB, 2007, MILBANK Q, V85, P641, DOI 10.1111/j.1468-0009.2007.00504.x; Longo CJ, 2006, SUPPORT CARE CANCER, V14, P1077, DOI 10.1007/s00520-006-0088-8; McGarry K., 2003, HLTH CARE ISSUES US; Mincer J., 1974, MARRIAGE FAMILY HUMA; Moore MJ, 2001, J GERONTOL B-PSYCHOL, V56, pS219, DOI 10.1093/geronb/56.4.S219; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SCHARLACH AE, 1989, GERONTOLOGIST, V29, P382, DOI 10.1093/geront/29.3.382; Timmermans S, 2007, SOC SCI MED, V65, P1351, DOI 10.1016/j.socscimed.2007.05.027; Van Houtven CH, 2013, J HEALTH ECON, V32, P240, DOI 10.1016/j.jhealeco.2012.10.006; WOLF DA, 1994, J HUM RESOUR, V29, P1259, DOI 10.2307/146140; Wright J, 2000, FIM TM	33	25	25	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0046-9580	1945-7243		INQUIRY-J HEALTH CAR	Inquiry-J. Health Care Organ. Provis. Financ.	WIN	2012	49	4					339	351		10.5034/inquiryjrnl_49.04.01			13	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	092MZ	WOS:000315128000008	23469677				2021-06-18	
J	Englot, DJ; Rolston, JD; Wang, DD; Hassnain, KH; Gordon, CM; Chang, EF				Englot, Dario J.; Rolston, John D.; Wang, Doris D.; Hassnain, Kevin H.; Gordon, Charles M.; Chang, Edward F.			Efficacy of vagus nerve stimulation in posttraumatic versus nontraumatic epilepsy Clinical article	JOURNAL OF NEUROSURGERY			English	Article						posttraumatic epilepsy; seizure; epilepsy; traumatic brain injury; vagus nerve stimulation	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; TREATMENT-RESISTANT DEPRESSION; PATIENT OUTCOME REGISTRY; TEMPORAL-LOBE EPILEPSY; FAILED CRANIAL SURGERY; INTRACTABLE EPILEPSY; MULTICENTER; THERAPY; VNS	Object. In the US, approximately 500,000 individuals are hospitalized yearly for traumatic brain injury (TBI), and posttraumatic epilepsy (PTE) is a common sequela of TBI. Improved treatment strategies for PTE are critically needed, as patients with the disorder are often resistant to antiepileptic medications and are poor candidates for definitive resection. Vagus nerve stimulation (VNS) is an adjunctive treatment for medically refractory epilepsy that results in a >= 50% reduction in seizure frequency in approximately 50% of patients after 1 year of therapy. The role of VNS in PTE has been poorly studied. The aim of this study was to determine whether patients with PTE attain more favorable seizure outcomes than individuals with nontraumatic epilepsy etiologies. Methods. Using a case-control study design, the authors retrospectively compared seizure outcomes after VNS therapy in patients with PTE versus those with nontraumatic epilepsy (non-PTE) who were part of a large prospectively collected patient registry. Results. After VNS therapy, patients with PTE demonstrated a greater reduction in seizure frequency (50% fewer seizures at the 3-month follow-up; 73% fewer seizures at 24 months) than patients with non-PTE (46% fewer seizures at 3 months; 57% fewer seizures at 24 months). Overall, patients with PTE had a 78% rate of clinical response to VNS therapy at 24 months (that is, >= 50% reduction in seizure frequency) as compared with a 61% response rate among patients with non-PTE (OR 1.32, 95% CI 1.07-1.61), leading to improved outcomes according to the Engel classification (p < 0.0001, Cochran-Mantel-Haenszel statistic). Conclusions. Vagus nerve stimulation should be considered in patients with medically refractory PTE who are not good candidates for resection. A controlled prospective trial is necessary to further examine seizure outcomes as well as neuropsychological outcomes after VNS therapy in patients with intractable PTE. (http://thejns.org/doi/abs/10.3171/2012.8.JN122)	[Englot, Dario J.; Rolston, John D.; Wang, Doris D.; Chang, Edward F.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Englot, Dario J.; Rolston, John D.; Wang, Doris D.; Chang, Edward F.] Univ Calif San Francisco, Comprehens Epilepsy Ctr, San Francisco, CA 94143 USA; [Hassnain, Kevin H.; Gordon, Charles M.] Cyberonics Inc, Houston, TX USA	Englot, DJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Box 0112, San Francisco, CA 94143 USA.	EnglotDJ@neurosurg.ucsf.edu	Rolston, John/AAG-3436-2019; Englot, Dario J./C-3656-2013	Rolston, John/0000-0002-8843-5468; Englot, Dario J./0000-0001-8373-690X	Cyberonics, Inc.	Two authors (K.H.H. and C.M.G.) are employees of Cyberonics, Inc., the manufacturer of the VNS Therapy System and sponsor of the VNS Therapy Patient Outcome Registry. They assisted in the statistical analyses.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Amar AP, 2004, NEUROSURGERY, V55, P1086, DOI 10.1227/01.NEU.0000141073.08427.76; Amar AP, 2008, NEUROSURGERY, V62, P506, DOI [10.1227/01.neu.0000316253.54651.5e, 10.1227/01.NEU,0000141073.08427.76]; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Ansari S, 2007, ACTA NEUROCHIR SUPPL, V97, P281; Ben-Menachem E, 2002, LANCET NEUROL, V1, P477, DOI 10.1016/S1474-4422(02)00220-X; Birbeck GL, 2002, EPILEPSIA, V43, P535, DOI 10.1046/j.1528-1157.2002.32201.x; Cecchini AP, 2009, NEUROL SCI, V30, pS101, DOI 10.1007/s10072-009-0073-3; Chang EF, 2010, EPILEPSIA, V51, P87, DOI 10.1111/j.1528-1167.2009.02457.x; CHASE MICHAEL H., 1967, BRAIN RES, V5, P236, DOI 10.1016/0006-8993(67)90089-3; Elliott RE, 2011, EPILEPSY BEHAV, V20, P57, DOI 10.1016/j.yebeh.2010.10.017; Engel Jr J, 1987, SURG TREATMENT EPILE, P553; Englot DJ, 2011, J NEUROSURG, V115, P1248, DOI 10.3171/2011.7.JNS11977; Englot DJ, 2011, NEUROSURG CLIN N AM, V22, P443, DOI 10.1016/j.nec.2011.07.002; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; George MS, 2008, BRAIN STIMUL, V1, P112, DOI 10.1016/j.brs.2008.02.001; George MS, 2005, BIOL PSYCHIAT, V58, P364, DOI 10.1016/j.biopsych.2005.07.028; Henry TR, 2002, NEUROLOGY, V59, pS3, DOI 10.1212/WNL.59.6_suppl_4.S3; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hord ED, 2003, J PAIN, V4, P530, DOI 10.1016/j.jpain.2003.08.001; Jabbari B, 2002, BRAIN INJURY, V16, P463, DOI 10.1080/02699050110102086; Klinkenberg S, 2012, CLIN NEUROL NEUROSUR, V114, P336, DOI 10.1016/j.clineuro.2011.11.016; Koo B, 2001, J CLIN NEUROPHYSIOL, V18, P434, DOI 10.1097/00004691-200109000-00008; Lee HO, 2008, J KOREAN NEUROSURG S, V44, P196, DOI 10.3340/jkns.2008.44.4.196; Luoni C, 2011, EPILEPSIA, V52, P2181, DOI 10.1111/j.1528-1167.2011.03325.x; McLachlan RS, 1997, ANN NEUROL, V41, P482, DOI 10.1002/ana.410410411; Neese SL, 2007, BRAIN RES, V1128, P157, DOI 10.1016/j.brainres.2006.09.073; Riggio S, 2010, PSYCHIAT CLIN N AM, V33, P807, DOI 10.1016/j.psc.2010.08.004; Rush AJ, 2000, BIOL PSYCHIAT, V47, P276, DOI 10.1016/S0006-3223(99)00304-2; Rush AJ, 2005, BIOL PSYCHIAT, V58, P355, DOI 10.1016/j.biopsych.2005.05.024; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; von Lehe M, 2006, EPILEPSY BEHAV, V9, P73, DOI 10.1016/j.yebeh.2006.03.014	34	25	26	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	2012	117	5					970	977		10.3171/2012.8.JNS122			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	027UW	WOS:000310380300033	22978542	Bronze			2021-06-18	
J	Harrison-Felix, C; Kreider, SED; Arango-Lasprilla, JC; Brown, AW; Dijkers, MP; Hammond, FM; Kolakowsky-Hayner, SA; Hirshson, C; Whiteneck, G; Zasler, ND				Harrison-Felix, Cynthia; Kreider, Scott E. D.; Arango-Lasprilla, Juan C.; Brown, Allen W.; Dijkers, Marcel P.; Hammond, Flora M.; Kolakowsky-Hayner, Stephanie A.; Hirshson, Chari; Whiteneck, Gale; Zasler, Nathan D.			Life Expectancy Following Rehabilitation: A NIDRR Traumatic Brain Injury Model Systems Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; chronic; epidemiology; life expectancy; mortality; rehabilitation; vital statistics	TERM MORTALITY TRENDS; HEAD-INJURY; SURVIVAL; DEATH; RISK; COMA	Objective: To characterize overall and cause-specific mortality and life expectancy among persons who have completed inpatient traumatic brain injury rehabilitation and to assess risk factors for mortality. Design: Prospective cohort study. Setting: The Traumatic Brain Injury Model Systems. Participants: A total of 8573 individuals injured between 1988 and 2009, with survival status per December 31, 2009, determined. Interventions: Not applicable. Main Outcome Measures: Standardized mortality ratio (SMR), life expectancy, cause of death. Results: SMR was 2.25 overall and was significantly elevated for all age groups, both sexes, all race/ethnic groups (except Native Americans), and all injury severity groups. SMR decreased as survival time increased but remained elevated even after 10 years postinjury. SMR was elevated for all cause-of-death categories but especially so for seizures, aspiration pneumonia, sepsis, accidental poisonings, and falls. Life expectancy was shortened an average of 6.7 years. Multivariate Cox regression showed age at injury, sex, race/ethnic group, marital status and employment status at the time of injury year of injury, preinjury drug use, days unconscious, functional independence and disability on rehabilitation discharge, and comorbid spinal cord injury to be independent risk factors for death. Conclusion: There is an increased risk of death after moderate or severe traumatic brain injury. Risk factors and causes of death have been identified that may be amenable to intervention.	[Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO 80113 USA; [Arango-Lasprilla, Juan C.] Univ Deusto Ikerbasque, Basque Fdn Sci, Bilbao, Spain; [Brown, Allen W.] Mayo Clin, Rochester, MN USA; [Dijkers, Marcel P.; Hirshson, Chari] Mt Sinai Sch Med, New York, NY USA; [Hammond, Flora M.] Carolinas HealthCare Syst, Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN USA; [Kolakowsky-Hayner, Stephanie A.] Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; [Zasler, Nathan D.] Concuss Care Ctr Virginia Ltd, Richmond, VA USA; [Zasler, Nathan D.] Tree Life Serv Inc, Richmond, VA 23233 USA; [Zasler, Nathan D.] Virginia Commonwealth Univ, Richmond, VA 23284 USA	Harrison-Felix, C (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	charrison-felix@craighospital.org	Kolakowsky-Hayner, Stephanie A./I-9858-2019; Heinemann, Allen W/K-6283-2012	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Heinemann, Allen W/0000-0003-2782-7326; Brown, Allen W./0000-0001-7228-3351; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research; Office of Special Education Services; Department of EducationUS Department of Education [H133A110006, H133A070022]; Mount Sinai School of Medicine [H133A070033]; Virginia Commonwealth University [H133A070036]; Mayo Clinic [H133A070013]; Santa Clara Valley Medical Center [H133A070038]; Carolinas HealthCare System [H133A070042]	This work was supported, in part, by grants from the National Institute on Disability and Rehabilitation Research, Office of Special Education Services, Department of Education to Craig Hospital (H133A110006, H133A070022), Mount Sinai School of Medicine (H133A070033), Virginia Commonwealth University (H133A070036), Mayo Clinic (H133A070013), Santa Clara Valley Medical Center (H133A070038), and Carolinas HealthCare System (H133A070042). However, the contents of this manuscript do not necessarily represent the policy of the Department of Education and endorsement by the Federal Government should not be assumed.	Baguley I, 2000, BRAIN INJURY, V14, P505; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Baguley IJ, 2008, BRAIN INJURY, V22, P919, DOI 10.1080/02699050802448578; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; DeVivo M. J, 2002, TOP SPINAL CORD INJ, V7, P49; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Egede LE, 2012, AM J PUBLIC HEALTH, V102, pS266, DOI 10.2105/AJPH.2011.300176; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Kobeissy FH, 2011, PM&R, V3, pS139, DOI 10.1016/j.pmrj.2011.02.012; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Roberts A.V., 1979, SEVERE ACCIDENTAL HE, P140; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shavelle RM, 2007, BRAIN INJURY MED PRI, P247; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151	38	25	25	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2012	27	6					E69	E80		10.1097/HTR.0b013e3182738010			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	039CU	WOS:000311221200007	23131972				2021-06-18	
J	Nishijima, DK; Shahlaie, K; Echeverri, A; Holmes, JF				Nishijima, Daniel K.; Shahlaie, Kiarash; Echeverri, Angela; Holmes, James F.			A clinical decision rule to predict adult patients with traumatic intracranial haemorrhage who do not require intensive care unit admission	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic brain injury; Intensive care; Clinical decision rule	COMPUTED AXIAL-TOMOGRAPHY; INJURY SEVERITY SCORE; BRAIN-INJURY; HEAD-INJURY; LOGISTIC-REGRESSION; EMERGENCY-MEDICINE; TREE ANALYSIS; GUIDELINES; STATES; CLASSIFICATION	Objective: To derive a clinical decision rule to identify adult emergency department (ED) patients with traumatic intracranial haemorrhage (tICH) who are at low risk for requiring critical care resources during hospitalization. Methods: This is a retrospective cohort study of patients (>= 18 years) with tICH presenting to the ED. The need for intensive care unit (ICU) admission was defined as the presence of a critical care intervention including: intubation, neurosurgical intervention, blood product transfusion, vasopressor or inotrope administration, invasive monitoring for haemodynamic instability, emergent treatment for arrhythmia, therapeutic angiography, and cardiopulmonary resuscitation. The decision rule was derived using binary recursive partitioning. Results: A total of 432 patients were identified (median age 48 years) of which 174 patients (40%) had a critical care intervention. We performed binary recursive partitioning with Classification and Regression Trees (CART) software to develop the clinical decision rule. Patients with a normal mental status (Glasgow Coma Score = 15), isolated head injury, and age < 65 were considered low risk for a critical care intervention. The derived rule had a sensitivity of 98% (95% confidence interval [CI] 94-99), a specificity of 50% (95% CI 44-56), a positive predictive value of 57% (95% CI 51-62), and a negative predictive value of 97% (95% CI 93-99). The area under the curve for the decision rule was 0.74 (95% CI 0.70-0.77). Conclusions: This clinical decision rule identifies low risk adult ED patients with tICH who do not need ICU admission. Further validation and refinement of these findings would allow for more appropriate ICU resource utilisation. (C) 2011 Elsevier Ltd. All rights reserved.	[Nishijima, Daniel K.; Echeverri, Angela; Holmes, James F.] Univ Calif Davis, Sch Med, Dept Emergency Med, Davis, CA USA; [Shahlaie, Kiarash] Univ Calif Davis, Sch Med, Dept Neurosurg, Davis, CA USA	Nishijima, DK (corresponding author), Univ Calif Davis, Med Ctr, Dept Emergency Med, 2315 Stockton Blvd,PSSB 2100, Sacramento, CA 95817 USA.	daniel.nishijima@ucdmc.ucdavis.edu		Nishijima, Daniel/0000-0003-4952-8212	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000002] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000002] Funding Source: Medline		Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; [Anonymous], 1999, CRIT CARE MED, V27, P633; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Bullock MR, 2006, NEUROSURGERY, V58, pS1; Bullock MR, 2006, NEUROSURGERY, V58, pS25; Bullock MR, 2006, NEUROSURGERY, V58, pS16; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; ESCARCE JJ, 1990, JAMA-J AM MED ASSOC, V264, P2389, DOI 10.1001/jama.264.18.2389; Escher M, 2004, BRIT MED J, V329, P425, DOI 10.1136/bmj.329.7463.425; Frost SA, 2009, RESUSCITATION, V80, P224, DOI 10.1016/j.resuscitation.2008.10.030; Goldhill DR, 1998, CRIT CARE MED, V26, P1337, DOI 10.1097/00003246-199808000-00017; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; HECKERLING PS, 1990, ANN INTERN MED, V113, P664, DOI 10.7326/0003-4819-113-9-664; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Hesdorffer DC, 2007, J TRAUMA, V63, P7; Hillman KM, 2002, INTENS CARE MED, V28, P1629, DOI 10.1007/s00134-002-1496-y; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2005, INTENS CARE MED, V31, P799, DOI 10.1007/s00134-005-2628-y; Huynh T, 2006, AM SURGEON, V72, P6; Huynh T, 2006, AM SURGEON, V72, P1162; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Olshen RA, 1984, CLASSIFICATION REGRE; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; SAX FL, 1987, CRIT CARE MED, V15, P510, DOI 10.1097/00003246-198705000-00012; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Vergouwe Y, 2005, J CLIN EPIDEMIOL, V58, P475, DOI 10.1016/j.jclinepi.2004.06.017; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Worster A, 2005, ANN EMERG MED, V45, P448, DOI 10.1016/j.annemergmed.2004.11.021	41	25	26	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	NOV	2012	43	11					1827	1832		10.1016/j.injury.2011.07.020			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	014VR	WOS:000309404300009	21839444	Green Accepted			2021-06-18	
J	Schnieders, J; Willemsen, D; de Boer, H				Schnieders, Jessica; Willemsen, Dennis; de Boer, Hans			Factors Contributing to Chronic Fatigue After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						pituitary hormone deficiency; sleep disorders; traumatic brain injury; vitamin D deficiency	QUALITY-OF-LIFE; POSTTRAUMATIC HYPOPITUITARISM; SLEEP DISORDERS; PREVALENCE; MILD; DYSFUNCTION; INSTRUMENT; RECOVERY; INSOMNIA; INDEX	Background: The annual incidence of traumatic brain injury in Europe amounts to 235 per 100 000 persons. About two-thirds will develop posttraumatic brain injury chronic fatigue (pTBI-CF). Aim: To identify the reversible hormonal and nonhormonal causes of pTBI-CF. Patients and Methods: Ninety patients with varying degrees of pTBI-CF underwent endocrine testing and an evaluation of sleep, attention, coping style, daily activity and dependency, physical performance, emotional well-being, and quality of life. Results: Vitamin D deficiency was found in 65%, poor sleep quality in 54%, anxiety disorders in 36%, growth hormone deficiency in 16%, and gonadal hormone deficiencies in 9%. Fatigue severity was correlated with poor sleep (R = +0.65, P < .0001), serum 25-hydroxy vitamin D levels (R = -0.50, P < .0001), and anxiety (R = +0.50, P < .0001) but not with growth hormone deficiency or gonadal hormone deficiencies. The first 3 factors together explained 59% of the fatigue score variance. Conclusions: Poor sleep, vitamin D deficiency, and anxiety were the most important factors associated with pTBI-CF. Appropriate treatment of these disorders may help to reduce fatigue in these patients.	[Schnieders, Jessica] Waterland Hosp, Dept Rehabil, NL-1441 RN Purmerend, Netherlands; [Willemsen, Dennis; de Boer, Hans] Rijnstate Hosp, Dept Internal Med, Arnhem, Netherlands	Schnieders, J (corresponding author), Waterland Hosp, Dept Rehabil Med, Waterlandlaan 250, NL-1441 RN Purmerend, Netherlands.	j_schnieders@hotmail.com					Aaronson L S, 1999, Image J Nurs Sch, V31, P45; ASTRAND PO, 1986, TXB WORK PHYSL PHYSL, P354; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Blair JC, 2010, BRIT J NEUROSURG, V24, P10, DOI 10.3109/02688690903536637; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; Eskes SA, 2009, NETH J MED, V67, P127; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Hayes SC, 2004, PSYCHOL REC, V54, P553, DOI 10.1007/BF03395492; Hintzpeter B, 2008, EUR J CLIN NUTR, V62, P1079, DOI 10.1038/sj.ejcn.1602825; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Larson EB, 2010, J HEAD TRAUMA REHAB, V25, P61, DOI 10.1097/HTR.0b013e3181c1d1e1; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Molitch ME, 2006, J CLIN ENDOCR METAB, V91, P1621, DOI 10.1210/jc.2005-2227; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Valsamis HA, 2006, NUTR METABOLISM, V3, DOI 10.1186/1743-7075-3-36; Van Cauter E, 1998, SLEEP, V21, P553; Van den Berghe G, 2003, ENDOCRIN METAB CLIN, V32, P385, DOI 10.1016/S0889-8529(03)00005-7; van der Eerden AW, 2010, EUR J ENDOCRINOL, V162, P19, DOI 10.1530/EJE-09-0436; van Groningen L, 2010, EUR J ENDOCRINOL, V162, P805, DOI 10.1530/EJE-09-0932; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; Vermeulen A, 1999, J CLIN ENDOCR METAB, V84, P3666, DOI 10.1210/jc.84.10.3666; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	48	25	25	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2012	27	6					404	412		10.1097/HTR.0b013e3182306341			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	039CU	WOS:000311221200011	22190008				2021-06-18	
J	Siddiq, I; Park, E; Liu, E; Spratt, SK; Surosky, R; Lee, G; Ando, D; Giedlin, M; Hare, GMT; Fehlings, MG; Baker, AJ				Siddiq, Ishita; Park, Eugene; Liu, Elaine; Spratt, S. Kaye; Surosky, Richard; Lee, Gary; Ando, Dale; Giedlin, Marty; Hare, Gregory M. T.; Fehlings, Michael G.; Baker, Andrew J.			Treatment of Traumatic Brain Injury Using Zinc-Finger Protein Gene Therapy Targeting VEGF-A	JOURNAL OF NEUROTRAUMA			English	Article						Adeno-associated virus; adenovirus; electrophysiology; gene therapy; microvasculature; traumatic brain injury	ENDOTHELIAL GROWTH-FACTOR; ENGINEERED TRANSCRIPTION FACTOR; CLINICAL-TRIALS; ANGIOGENESIS; ACTIVATION; INHIBITION; EXPRESSION; RECOVERY; NEURONS; HIPPOCAMPUS	Vascular endothelial growth factor (VEGF) plays a role in angiogenesis and has been shown to be neuroprotective following central nervous system trauma. In the present study we evaluated the pro-angiogenic and neuroprotective effects of an engineered zinc-finger protein transcription factor transactivator targeting the vascular endothelial growth factor A (VEGF-ZFP). We used two virus delivery systems, adeno-virus and adeno-associated virus, to examine the effects of early and delayed VEGF-A upregulation after brain trauma, respectively. Male Sprague-Dawley rats were subject to a unilateral fluid percussion injury (FPI) of moderate severity (2.2-2.5 atm) followed by intracerebral microinjection of either adenovirus vector (Adv) or an adeno-associated vector (AAV) carrying the VEGF-ZFP construct. Adv-VEGF-ZFP-treated animals had significantly fewer TUNEL positive cells in the injured penumbra of the cortex (p < 0.001) and hippocampus (p = 0.001) relative to untreated rats at 72 h post-injury. Adv-VEGF-ZFP treatment significantly improved fEPSP values (p = 0.007) in the CA1 region relative to injury alone. Treatment with AAV2-VEGF-ZFP resulted in improved post-injury microvascular diameter and improved functional recovery on the balance beam and rotarod task at 30 days post-injury. Collectively, the results provide supportive evidence for the concept of acute and delayed treatment following TBI using VEGF-ZFP to induce angiogenesis, reduce cell death, and enhance functional recovery.	[Park, Eugene] St Michaels Hosp, Dept Trauma Res, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Hare, Gregory M. T.; Baker, Andrew J.] St Michaels Hosp, Dept Anesthesia, Toronto, ON M5B 1W8, Canada; [Siddiq, Ishita; Hare, Gregory M. T.; Fehlings, Michael G.; Baker, Andrew J.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Hare, Gregory M. T.] Univ Toronto, Dept Physiol, Toronto, ON, Canada; [Spratt, S. Kaye; Surosky, Richard; Lee, Gary; Ando, Dale; Giedlin, Marty] Sangamo BioSci Inc, Richmond, CA USA; [Fehlings, Michael G.] Univ Toronto, Div Neurosurg, Krembil Neurosci Ctr, Toronto, ON, Canada; [Fehlings, Michael G.] Univ Toronto, McEwen Ctr Regenerat Med, Toronto, ON, Canada	Park, E (corresponding author), St Michaels Hosp, Dept Trauma Res, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St,7-080 Bond Wing, Toronto, ON M5B 1W8, Canada.	parke@smh.ca	Hare, Greg/AAM-5599-2021	Fehlings, Michael/0000-0002-5722-6364			Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Baumgartner I, 2000, ANN INTERN MED, V132, P880, DOI 10.7326/0003-4819-132-11-200006060-00005; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Burger C, 2004, MOL THER, V10, P302, DOI 10.1016/j.ymthe.2004.05.024; Cammalleri M, 2011, EUR J NEUROSCI, V33, P482, DOI 10.1111/j.1460-9568.2010.07529.x; D'Onofrio PM, 2011, J NEUROTRAUM, V28, P1863, DOI 10.1089/neu.2011.1896; Dai QS, 2004, CIRCULATION, V110, P2467, DOI 10.1161/01.CIR.0000145139.53840.49; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Enomoto T, 2005, J NEUROTRAUM, V22, P783, DOI 10.1089/neu.2005.22.783; Farin A, 2004, ACT NEUR S, V89, P101; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Hermens WTJMC, 1997, J NEUROSCI METH, V71, P85, DOI 10.1016/S0165-0270(96)00129-X; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Liu Y, 2010, NEUROBIOL DIS, V37, P384, DOI 10.1016/j.nbd.2009.10.018; Lock M, 2010, HUM GENE THER, V21, P1273, DOI 10.1089/hum.2009.223; Maas AIR, 2004, ACT NEUR S, V89, P113; McCloskey DP, 2008, BRAIN RES BULL, V76, P36, DOI 10.1016/j.brainresbull.2007.11.018; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Price SA, 2006, DIABETES, V55, P1847, DOI 10.2337/db05-1060; Rajagopalan S, 2003, CIRCULATION, V108, P1933, DOI 10.1161/01.CIR.0000093398.16124.29; Rebar EJ, 2002, NAT MED, V8, P1427, DOI 10.1038/nm795; Sakowski SA, 2009, GENE THER, V16, P1292, DOI 10.1038/gt.2009.111; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tolias C.M., 2004, J NEUROTRAUM, V17, P471; Xie DH, 2006, J VASC SURG, V44, P166, DOI 10.1016/j.jvs.2006.03.024; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	40	25	26	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	17					2647	2659		10.1089/neu.2012.2444			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	047QU	WOS:000311856400006	23016562				2021-06-18	
J	Stippler, M; Ortiz, V; Adelson, PD; Chang, YF; Tyler-Kabara, EC; Wisniewski, SR; Fink, EL; Kochanek, PM; Brown, SD; Bell, MJ				Stippler, Martina; Ortiz, Veronica; Adelson, P. David; Chang, Yue-Fang; Tyler-Kabara, Elizabeth C.; Wisniewski, Stephen R.; Fink, Ericka L.; Kochanek, Patrick M.; Brown, S. Danielle; Bell, Michael J.			Brain tissue oxygen monitoring after severe traumatic brain injury in children: relationship to outcome and association with other clinical parameters Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						intracranial pressure; cerebral perfusion pressure; Glasgow Outcome Scale; temperature; trauma; partial pressure oxygen	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; LENGTH-OF-STAY; INTRACRANIAL-PRESSURE; MODERATE HYPOTHERMIA; TENSION; METABOLISM; HYPERTHERMIA; TEMPERATURE; EXPERIENCE	Object. Minimizing secondary brain injuries after traumatic brain injury (TBI) in children is critical to maximizing neurological outcome. Brain tissue oxygenation monitoring (as measured by interstitial partial pressure of O-2 [PbO2]) is a new tool that may aid in guiding therapies, yet experience in children is limited. This study aims to describe the authors' experience of PbO2 monitoring after TBI. It was hypothesized that PbO2 thresholds could be established that were associated with favorable neurological outcome, and it was determined whether any relationships between PbO2 and other important clinical variables existed. Methods. Forty-six children with severe TBI (Glasgow Coma Scale score <= 8 after resuscitation) who underwent PbO2 and brain temperature monitoring between September 2004 and June 2008 were studied. All patients received standard neurocritical care, and 24 were concurrently enrolled in a trial of therapeutic early hypothermia (n = 12/group). The PbO2 was measured in the uninjured frontal cortex. Hourly recordings and calculated daily means of various variables including PbO2, intracranial pressure (ICP), cerebral perfusion pressure (CPP), mean arterial blood pressure, partial pressure of arterial O-2, and fraction of inspired O-2 were compared using several statistical approaches. Glasgow Outcome Scale scores were determined at 6 months after injury. Results. The mean patient age was 9.4 years (range 0.1-16.5 years; 13 girls) and 8554 hours of monitoring were analyzed (PbO2 range 0.0-97.2 mm Hg). A PbO2 of 30 mm Hg was associated with the highest sensitivity/specificity for favorable neurological outcome at 6 months after TBI, yet CPP was the only factor that was independently associated with favorable outcome. Surprisingly, instances of preserved PbO2 with altered ICP and CPP were observed in some children with unfavorable outcomes. Conclusions. Monitoring of PbO2 demonstrated complex interactions with clinical variables reflecting intracranial dynamics using this protocol. A higher threshold than reported in studies in adults was suggested as a potential therapeutic target, but this threshold was not associated with improved outcomes. Additional studies to assess the utility of PbO2 monitoring after TBI in children are needed. (http://thejns.org/doi/abs/10.3171/2012.8.PEDS12165)	[Fink, Ericka L.; Kochanek, Patrick M.; Bell, Michael J.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Stippler, Martina; Ortiz, Veronica; Adelson, P. David; Chang, Yue-Fang; Tyler-Kabara, Elizabeth C.; Brown, S. Danielle; Bell, Michael J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Fink, Ericka L.; Kochanek, Patrick M.; Bell, Michael J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Adelson, P. David; Brown, S. Danielle] Phoenix Childrens Hosp, Dept Neurosurg, Phoenix, AZ USA; [Stippler, Martina] Univ New Mexico, Dept Neurol Surg, Albuquerque, NM 87131 USA	Bell, MJ (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	bellmj4@upmc.edu	Tyler-Kabara, Elizabeth/H-4930-2013; Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Kochanek, Patrick M/0000-0002-2627-913X; Fink, Ericka/0000-0002-3683-4571; Wisniewski, Stephen/0000-0002-3877-9860	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS38448, NS052478, NS30318, HD040686]; Office of the Dean of the University of Pittsburgh School of Medicine; Integra Life Sciences	This work was supported in part by NIH grants NS38448, NS052478, NS30318, and HD040686, and a grant from the Office of the Dean of the University of Pittsburgh School of Medicine. Dr. Adelson received clinical or research support for this study from Integra Life Sciences, and serves as a consultant to Traumatec.	Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Badiatia N, 2009, CURR OPIN CRIT CARE, V15, P79, DOI 10.1097/MCC.0b013e32832922e9; Bratton SL, 2008, J NEUROTRAUM, V25, P276; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Exo J, 2011, PEDIATR CRIT CARE ME, V12, P560, DOI 10.1097/PCC.0b013e3181e8b3ee; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Figaji AA, 2009, CHILD NERV SYST, V25, P1335, DOI 10.1007/s00381-009-0821-y; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Hardman J M, 1979, Adv Neurol, V22, P15; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Jia Jun, 2005, Chin J Traumatol, V8, P138; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Spiotta AM, 2008, NEUROSURGERY, V62, P864, DOI 10.1227/01.neu.0000316900.63124.ce; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; Stocchetti N, 2005, J NEUROL NEUROSUR PS, V76, P1135, DOI 10.1136/jnnp.2004.041269; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Zhang Sai, 2002, Chin J Traumatol, V5, P43	40	25	25	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	NOV	2012	10	5					383	391		10.3171/2012.8.PEDS12165			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	027UZ	WOS:000310380600005	22978637				2021-06-18	
J	Tian, Z; Yu, W; Liu, HB; Zhang, N; Li, XB; Zhao, MG; Liu, SB				Tian, Zhen; Yu, Wei; Liu, Hong-bao; Zhang, Nan; Li, Xu-bo; Zhao, Ming-gao; Liu, Shui-bing			Neuroprotective effects of curculigoside against NMDA-induced neuronal excitoxicity in vitro	FOOD AND CHEMICAL TOXICOLOGY			English	Article						Excitotoxicity; NMDA; Curculigoside; Neuroprotection	CELL-LINE; GLUTAMATE; EXCITOTOXICITY; DEATH; CONTRIBUTES; ORCHIOIDES; ANTAGONIST; RECEPTORS; TOXICITY; DISEASE	Glutamate is an important excitatory neurotransmitter in the central nervous system. Excessive accumulation of glutamate can cause excitotoxicity, which plays a key role in spinal cord injury, traumatic brain injury, stroke, and neurodegenerative diseases. Curculigoside (CCGS) is a major bioactive compound isolated from the rhizome of Curculigo orchioides Gaertn. CCGS has an extensive biological effect and has been used in Traditional Chinese Medicine. However, little is known about the neuroprotective effects of CCGS on glutamate-induced excitotoxicity. This study aims to evaluate the neuroprotective effects of CCGS in cultured cortical neurons. The results indicated that treatment with 1 and 10 mu M CCGS evidently prevented N-methyl-D-aspartate (NMDA)-induced neuronal cell loss and reduced the number of apoptotic and necrotic cells in a time- and concentration-dependent manner. The neuroprotective effects of CCGS are related to down regulating the apoptotic protein levels and reducing the production of intracellular reactive oxygen species in cultured cortical neurons. These findings give a new insight into the development of natural anti-excitotoxicity agents. (C) 2012 Elsevier Ltd. All rights reserved.	[Tian, Zhen; Zhang, Nan; Li, Xu-bo; Zhao, Ming-gao; Liu, Shui-bing] Sch Pharm, Dept Pharmacol, Xian 710032, Shaanxi, Peoples R China; [Liu, Hong-bao] Fourth Mil Med Univ, Xijing Hosp, Dept Nephrol, Xian 710032, Shaanxi, Peoples R China; [Yu, Wei] 208th Hosp Peoples Liberat Army, Dept Clin Lab, Changchun 130062, Jilin, Peoples R China	Liu, SB (corresponding author), Sch Pharm, Dept Pharmacol, Xian 710032, Shaanxi, Peoples R China.	liushb1974@yahoo.com.cn			NSF of ChinaNational Natural Science Foundation of China (NSFC) [31070923, 30900277, 2008ZXJ09004-023, 2009ZX09103-111, 2011ZXJ091 06-01C]; Program for New Century Excellent Talents in UniversityProgram for New Century Excellent Talents in University (NCET)	This research was supported by NSF of China, Nos. 31070923, 30900277, 2008ZXJ09004-023, 2009ZX09103-111, 2011ZXJ091 06-01C, and Program for New Century Excellent Talents in University.	Behbahani H, 2005, J NEUROSCI RES, V82, P432, DOI 10.1002/jnr.20634; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BRORSON JR, 1994, J NEUROSCI, V14, P187; Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000; Chen J, 2011, NEUROSCI LETT, V499, P181, DOI 10.1016/j.neulet.2011.05.054; Chen L, 2008, NEUROPHARMACOLOGY, V54, P1175, DOI 10.1016/j.neuropharm.2008.03.007; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Gonzalez-Juanatey JR, 2004, J ENDOCRINOL, V180, P325; Hirata Y, 2011, J NEUROCHEM, V119, P839, DOI 10.1111/j.1471-4159.2011.07464.x; Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017; Jiang W, 2011, NEUROSCIENCE, V192, P572, DOI 10.1016/j.neuroscience.2011.06.079; Jiao L, 2009, PHYTOMEDICINE, V16, P874, DOI 10.1016/j.phymed.2009.01.005; Leaver KR, 2008, CLIN EXP PHARMACOL P, V35, P1388, DOI 10.1111/j.1440-1681.2008.05046.x; Li ST, 2012, CURR DRUG TARGETS, V13, P207, DOI 10.2174/138945012799201630; Ma CJ, 2011, PHYTOTHER RES, V25, P922, DOI 10.1002/ptr.3449; MANEV H, 1989, MOL PHARMACOL, V36, P106; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Shen H., 2008, BRAIN RES B; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tahar AH, 2004, NEUROBIOL DIS, V15, P171, DOI 10.1016/j.nbd.2003.10.007; Tao LZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026055; Wang H, 2008, NEURON, V59, P634, DOI 10.1016/j.neuron.2008.06.027; Wang Y, 2012, ACTA BIOCH BIOPH SIN, V44, P431, DOI 10.1093/abbs/gms014; Wang YK, 2010, J ETHNOPHARMACOL, V132, P233, DOI 10.1016/j.jep.2010.08.008; Wu Q, 2005, CHEM PHARM BULL, V53, P1065, DOI 10.1248/cpb.53.1065; Zhang Y., 2012, CHEM-BIOL INTERACT, V53, P1065	30	25	27	1	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-6915			FOOD CHEM TOXICOL	Food Chem. Toxicol.	NOV	2012	50	11					4010	4015		10.1016/j.fct.2012.08.006			6	Food Science & Technology; Toxicology	Food Science & Technology; Toxicology	031PL	WOS:000310654300019	22902827				2021-06-18	
J	Kreuzer, PM; Landgrebe, M; Schecklmann, M; Staudinger, S; Langguth, B				Kreuzer, Peter M.; Landgrebe, Michael; Schecklmann, Martin; Staudinger, Susanne; Langguth, Berthold		TRI Database Study Grp	Trauma-Associated Tinnitus: Audiological, Demographic and Clinical Characteristics	PLOS ONE			English	Article							OPERATION IRAQI FREEDOM; BRAIN-INJURY; DEPRESSION; ANXIETY; SEVERITY; SENSITIVITY; DYSFUNCTION; INVENTORY; ANNOYANCE; ATTENTION	Background: Tinnitus can result from different etiologies. Frequently, patients report the development of tinnitus after traumatic injuries. However, to which extent this specific etiologic factor plays a role for the phenomenology of tinnitus is still incompletely understood. Additionally, it remains a matter of debate whether the etiology of tinnitus constitutes a relevant criterion for defining tinnitus subtypes. Objective: By investigating a worldwide sample of tinnitus patients derived from the Tinnitus Research Initiative (TRI) Database, we aimed to identify differences in demographic, clinical and audiological characteristics between tinnitus patients with and without preceding trauma. Materials: A total of 1,604 patients were investigated. Assessment included demographic data, tinnitus related clinical data, audiological data, the Tinnitus Handicap Inventory, the Tinnitus Questionnaire, the Beck Depression Inventory, various numeric tinnitus rating scales, and the World Health Organisation Quality of Life Scale (WHOQoL). Results: Our data clearly indicate differences between tinnitus patients with and without trauma at tinnitus onset. Patients suffering from trauma-associated tinnitus suffer from a higher mental burden than tinnitus patients presenting with phantom perceptions based on other or unknown etiologic factors. This is especially the case for patients with whiplash and head trauma. Patients with posttraumatic noise-related tinnitus experience more frequently hyperacousis, were younger, had longer tinnitus duration, and were more frequently of male gender. Conclusions: Trauma before tinnitus onset seems to represent a relevant criterion for subtypization of tinnitus. Patients with posttraumatic tinnitus may require specific diagnostic and therapeutic management. A more systematic and - at best standardized assessment for hearing related sequelae of trauma is needed for a better understanding of the underlying pathophysiology and for developing more tailored treatment approaches as well.	[Kreuzer, Peter M.; Landgrebe, Michael; Schecklmann, Martin; Staudinger, Susanne; Langguth, Berthold] Univ Regensburg, Dept Psychiat & Psychotherapy, Regensburg, Germany; [Landgrebe, Michael] Sozialstiftung Bamberg, Dept Psychiat Psychosomat Med & Psychotherapy, Bamberg, Germany	Kreuzer, PM (corresponding author), Univ Regensburg, Dept Psychiat & Psychotherapy, Regensburg, Germany.	peter.kreuzer@medbo.de	Coelho, Claudia/J-6250-2016; Langguth, Berthold/AAP-2638-2021; Kleinjung, Tobias/AAJ-3141-2020	Coelho, Claudia/0000-0002-2441-0739; Kleinjung, Tobias/0000-0003-3867-234X; Vanneste, Sven/0000-0003-1513-5752	Tinnitus Research Initiative/TRI	The study was supported by the Tinnitus Research Initiative/TRI (www.tinnitusresearch.org). All authors confirm no conflicts of interest in regard to the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamchic L, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00018; Andersson G, 2009, J AM ACAD AUDIOL, V20, P315, DOI 10.3766/jaaa.20.5.5; AXELSSON A, 1985, British Journal of Audiology, V19, P271, DOI 10.3109/03005368509078983; Bauer CA, 2001, JARO-J ASSOC RES OTO, V2, P54, DOI 10.1007/s101620010030; Belli S, 2008, EUR ARCH OTO-RHINO-L, V265, P279, DOI 10.1007/s00405-007-0440-8; Boniver Raymond, 2002, Int Tinnitus J, V8, P129; Budd RJ, 1996, J PSYCHOSOM RES, V41, P327, DOI 10.1016/S0022-3999(96)00171-7; Crocetti A, 2009, OTOLARYNG HEAD NECK, V140, P403, DOI 10.1016/j.otohns.2008.11.036; Cronlein T, 2007, PROG BRAIN RES, V166, P227, DOI 10.1016/S0079-6123(07)66021-X; De Ridder D, 2011, P NATL ACAD SCI USA, V108, P8075, DOI 10.1073/pnas.1018466108; Dobie RA, 2003, OTOLARYNG CLIN N AM, V36, P383, DOI 10.1016/S0030-6665(02)00168-8; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Folmer RL, 2003, LARYNGOSCOPE, V113, P821, DOI 10.1097/00005537-200305000-00010; Folmer RL, 1999, OTOLARYNG HEAD NECK, V121, P48, DOI 10.1016/S0194-5998(99)70123-3; Geckle L, 2004, SOLDIER PERCEPTIONS; Gu JW, 2010, J NEUROPHYSIOL, V104, P3361, DOI 10.1152/jn.00226.2010; HALFORD JBS, 1991, J PSYCHOSOM RES, V35, P383, DOI 10.1016/0022-3999(91)90033-K; HALLAM RS, 1988, BRIT J CLIN PSYCHOL, V27, P213, DOI 10.1111/j.2044-8260.1988.tb00778.x; Hesser H, 2009, INT J AUDIOL, V48, P295, DOI 10.1080/14992020802635325; Hiller W, 2006, ARCH OTOLARYNGOL, V132, P1323, DOI 10.1001/archotol.132.12.1323; Hinton DE, 2006, J TRAUMA STRESS, V19, P541, DOI 10.1002/jts.20138; Jacobson G P, 2001, J Am Acad Audiol, V12, P493; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Landgrebe M, 2010, BMC MED INFORM DECIS, V10, DOI 10.1186/1472-6947-10-42; Langguth B, 2007, PROG BRAIN RES, V166, P221, DOI 10.1016/S0079-6123(07)66020-8; Langguth B, 2011, WORLD J BIOL PSYCHIA, V12, P489, DOI 10.3109/15622975.2011.575178; Leske M C, 1981, ASHA, V23, P229; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lewis J E, 2002, J Am Acad Audiol, V13, P339; LEWIS JE, 1994, CLIN OTOLARYNGOL, V19, P50, DOI 10.1111/j.1365-2273.1994.tb01147.x; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Malouff JM, 2011, CURR PSYCHIAT REP, V13, P31, DOI 10.1007/s11920-010-0163-1; Mao J. C., 2011, J NEUROTRAUMA; Marciano E, 2003, INT J AUDIOL, V42, P4, DOI 10.3109/14992020309056079; Moller AR, 2011, TEXTBOOK OF TINNITUS, P1; Nageris Ben I., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P185; Newman CW, 1996, ARCH OTOLARYNGOL, V122, P143; Nicolas-Puel Cecile, 2006, Int Tinnitus J, V12, P64; Nolle C, 2004, J NEUROTRAUM, V21, P251, DOI 10.1089/089771504322972040; Potier M, 2009, EAR HEARING, V30, P291, DOI 10.1097/AUD.0b013e31819769fc; Quintanilla-Dieck MD, 2009, J PEDIATR-US, V155, P550, DOI 10.1016/j.jpeds.2009.04.053; Rossiter S, 2006, J SPEECH LANG HEAR R, V49, P150, DOI 10.1044/1092-4388(2006/012); Schlee W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027379; Shida S, 1990, Nihon Jibiinkoka Gakkai Kaiho, V93, P1823; Sindhusake Doungkamol, 2004, J Am Acad Audiol, V15, P269; STEER RA, 1986, J CLIN PSYCHOL, V42, P475, DOI 10.1002/1097-4679(198605)42:3<475::AID-JCLP2270420311>3.0.CO;2-D; Stevens C, 2007, INT J AUDIOL, V46, P208, DOI 10.1080/14992020601102329; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner Oliver, 2007, Ann Gen Psychiatry, V6, P26, DOI 10.1186/1744-859X-6-26; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; World Health Organization, 1996, WHOQOL BREF INTR ADM; Yankaskas K, 2012, HEAR RES	55	25	26	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2012	7	9							e45599	10.1371/journal.pone.0045599			9	Multidisciplinary Sciences	Science & Technology - Other Topics	016KP	WOS:000309517300037	23049821	DOAJ Gold, Green Published			2021-06-18	
J	Resnick, EM; Mallampalli, M; Carter, CL				Resnick, Eileen M.; Mallampalli, Monica; Carter, Christine L.			Current Challenges in Female Veterans' Health	JOURNAL OF WOMENS HEALTH			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; OPERATION IRAQI FREEDOM; PELVIC ORGAN PROLAPSE; MENTAL-HEALTH; URINARY-INCONTINENCE; GENDER-DIFFERENCES; UNITED-STATES; WOMEN; RISK	Women in the U.S. military are technically barred from serving in combat specialties, positions, or units; however, since Operation Desert Storm, women have served in forward positions in greater numbers. This increased involvement in combat zones has resulted in exposures to trauma, injury, and a myriad of environmental hazards associated with modern war. Some of these hazards present new health risks specifically relevant to women who have been deployed to or recently returned from Iraq or Afghanistan or both. To address this evolving public health concern, the Society for Women's Health Research (SWHR) convened a 1-day interdisciplinary scientific conference, with speakers and attendees from civilian, military, and veteran settings. The purpose of the conference was to reveal the state-of-the-science on the health of the female veteran and to focus attention on recent advances in biomedical research related to female veterans' health. The following topics were discussed: mental health (posttraumatic stress disorder [PTSD] and depression), urogenital health, musculoskeletal health, and traumatic brain injury (TBI).	[Resnick, Eileen M.; Mallampalli, Monica; Carter, Christine L.] Soc Womens Hlth Res, Washington, DC 20036 USA	Carter, CL (corresponding author), Soc Womens Hlth Res, 1025 Connecticut Ave NW,Suite 601, Washington, DC 20036 USA.	chris@swhr.org					Anger JT, 2008, UROLOGY, V72, P37, DOI 10.1016/j.urology.2007.11.163; Arellano-Orden V, 2011, NEUROCRIT CARE, V14, P18, DOI 10.1007/s12028-010-9441-3; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Cross JD, 2011, CLIN ORTHOP RELAT R, V469, P1956, DOI 10.1007/s11999-011-1840-z; Cross JD, 2011, J AM ACAD ORTHOP SUR, V19, pS1, DOI 10.5435/00124635-201102001-00002; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Fritel X, 2009, OBSTET GYNECOL, V113, P609, DOI 10.1097/AOG.0b013e3181985312; Graham JE, 2010, ARCH PHYS MED REHAB, V91, P43, DOI 10.1016/j.apmr.2009.09.017; Haskell SG, 2011, WOMEN HEALTH ISS, V21, P92, DOI 10.1016/j.whi.2010.08.001; Kang H, 2005, ANN EPIDEMIOL, V15, P191, DOI 10.1016/j.annepidem.2004.05.009; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kimerling R, 2007, AM J PUBLIC HEALTH, V97, P2160, DOI 10.2105/AJPH.2006.092999; Larsen WI, 2007, INT UROGYNECOL J, V18, P769, DOI 10.1007/s00192-006-0226-3; Larsen WI, 2006, INT UROGYNECOL J, V17, P208, DOI 10.1007/s00192-005-1366-6; Lowe NK, 2003, MIL MED, V168, P569; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Masini BD, 2009, J ORTHOP TRAUMA, V23, P261, DOI 10.1097/BOT.0b013e31819dfa04; Mattocks KM, 2010, J WOMENS HEALTH, V19, P2159, DOI 10.1089/jwh.2009.1892; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Morgan CA, 2000, BIOL PSYCHIAT, V47, P891, DOI 10.1016/S0006-3223(99)00307-8; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Rasmusson AM, 2006, BIOL PSYCHIAT, V60, P704, DOI 10.1016/j.biopsych.2006.03.026; Schmidt PJ, 2009, ANN NY ACAD SCI, V1179, P70, DOI 10.1111/j.1749-6632.2009.04982.x; Schmidt PJ, 1998, NEW ENGL J MED, V338, P209, DOI 10.1056/NEJM199801223380401; Schmidt PJ, 2000, AM J OBSTET GYNECOL, V183, P414, DOI 10.1067/mob.2000.106004; Slewa-Younan S, 2008, BRAIN INJURY, V22, P183, DOI 10.1080/02699050801888808; Sohn Min-Woong, 2006, BMC Urol, V6, P30, DOI 10.1186/1471-2490-6-30; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; U.S. Department of Health and Human Services Health Resources and Services Administration, WOM HLTH US 2010; U. S. Department of Veterans Affairs, 2011, WOM VET HLTH CAR CHA; U.S. Department of Veterans Affairs, 2010, CTR WOM VET FACT SHE; Vogt D, 2011, J ABNORM PSYCHOL, V120, P797, DOI 10.1037/a0023452; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yeung JHH, 2011, ARCH SURG-CHICAGO, V146, P436, DOI 10.1001/archsurg.2011.46; Young EA, 2004, BIOL PSYCHIAT, V56, P205, DOI 10.1016/j.biopsych.2004.05.011; Young EA, 2004, ARCH GEN PSYCHIAT, V61, P394, DOI 10.1001/archpsyc.61.4.394	38	25	25	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1540-9996	1931-843X		J WOMENS HEALTH	J. Womens Health	SEP	2012	21	9					895	900		10.1089/jwh.2012.3644			6	Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies	Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies	000SR	WOS:000308409200002	22876756	Green Published			2021-06-18	
J	Rohacek, M; Albrecht, M; Kleim, B; Zimmermann, H; Exadaktylos, A				Rohacek, Martin; Albrecht, Marcel; Kleim, Birgit; Zimmermann, Heinz; Exadaktylos, Aristomenis			Reasons for ordering computed tomography scans of the head in patients with minor brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Computed tomography; Minor brain injury; Fear	RULE; PHYSICIANS; TRAUMA	Background: Minor brain injury is a frequent condition. Validated clinical decision rules can help in deciding whether a computed tomogram (CT) of the head is required. We hypothesized that institutional guidelines are not frequently used, and that psychological factors are a common reason for ordering an unnecessary CT. Methods: Physicians at the emergency department of a tertiary care hospital completed an anonymous questionnaire before ordering a CT of the head for a patient presenting with a GCS of 13-15 after a head trauma. Results: Over a period of 10 months, 1018 CTs of the head were performed in patients presenting with a GCS of 13-15 after a head trauma; 168 (16.5%) questionnaires were completed. The most four common reasons for ordering a CT were "to confirm/rule out traumatic intracranial lesion'' (in 94% of all questionnaires), "to expedite diagnosis" (63%) "guidelines" (58%) and "fear of missing a traumatic intracranial lesion" (50%). A positive answer for "fear of being sued" was declared in 21%, and "pressure from the patient or his relatives" in 8% of all questionnaires. Of 71 questionnaires without "guidelines" as a positive answer, there were 40 (56%) positive answers of "fear of missing a traumatic cerebral lesion". Conclusion: Besides guidelines, fear of missing a traumatic intracranial lesion played a role in ordering head CTs. Although the physicians had been instructed in the use of guidelines, including validated clinical decision rules, this did not prevent them from ordering unnecessary CTs. (C) 2012 Elsevier Ltd. All rights reserved.	[Rohacek, Martin; Albrecht, Marcel; Zimmermann, Heinz; Exadaktylos, Aristomenis] Univ Hosp Bern, Dept Emergency Med, Inselspital, CH-3010 Bern, Switzerland; [Kleim, Birgit] Univ Zurich, Dept Clin Psychol, CH-8006 Zurich, Switzerland	Rohacek, M (corresponding author), Univ Hosp Bern, Dept Emergency Med, Inselspital, Freiburgstr, CH-3010 Bern, Switzerland.	martin.rohacek@gmail.com	Kleim, Birgit/AAM-5309-2021				American College of Surgeons Committee on Trauma, 2008, ATLS STUD COURS MAN, P137; Boehnert MU, 2009, J EVAL CLIN PRACT, V15, P1177, DOI 10.1111/j.1365-2753.2009.01348.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Eagles D, 2008, ACAD EMERG MED, V15, P1256, DOI 10.1111/j.1553-2712.2008.00265.x; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Jeret JS, 1993, NEUROSURGERY, V32, P15; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mello MM, 2010, HEALTH AFFAIR, V29, P1569, DOI 10.1377/hlthaff.2009.0807; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Studdert DM, 2005, JAMA-J AM MED ASSOC, V293, P2609, DOI 10.1001/jama.293.21.2609	14	25	26	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	SEP	2012	43	9					1415	1418		10.1016/j.injury.2012.01.001			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	977MK	WOS:000306666100014	22277106				2021-06-18	
J	Toien, K; Skogstad, L; Ekeberg, O; Myhren, H; Bredal, IS				Toien, Kirsti; Skogstad, Laila; Ekeberg, Oivind; Myhren, Hilde; Bredal, Inger Schou			Prevalence and predictors of return to work in hospitalised trauma patients during the first year after discharge: A prospective cohort study	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Return to work; Injury; Injury severity scale; Life orientation test	ACQUIRED BRAIN-INJURY; QUALITY-OF-LIFE; MAJOR TRAUMA; FOLLOW-UP; FUNCTIONAL RECOVERY; DEPRESSION SCALE; HEALTH SURVEY; OUTCOMES; DETERMINANTS; DISABILITIES	Objective: The aim of the study was to investigate the proportion of patients who return to work and predictors of return to pre-injury level of work participation the first year after trauma. Methods: A prospective single-centre study of 188 patients aged 18-65 years with different degrees of injury severity was carried out in a trauma referral centre. All patients were working or studying full or part time before the injury. The first assessments were performed a median time of 27 days after discharge. Participation in work/education was measured 3 and 12 months after the first assessment with self-report questionnaires. The Hospital Anxiety and Depression Scale (HADS) and Impact of Event Scale (IES) were independent measures of anxiety, depression and post-traumatic stress symptoms (PTS) at baseline and 3 months. The Life Orientation Test Revised (LOT-R) measured optimism and pessimism at baseline. Predictors of return to work were identified by multiple logistic regression analysis. Results: After one year, 131 patients (70%) had returned to the same level of participation in work or education; 95 (50%) had returned at 3 months. Independent predictors of return to work after 3 months were low age, low Injury Severity Score (ISS) score, not needing ventilator treatment and low score for depression symptoms, adjusted for gender (Nagelkerke R square 0.38). Low ISS, absence of serious head injury, low HADS depression score and an optimistic life orientation remained significant predictors of return to work at the same level after 12 months (Nagelkerke R square 0.38). In addition, good physical function (SF-36 PF score > 65) at 3 months was an independent predictor of return to work at 12 months in the 93 patients who had not returned to work at 3 months. Conclusion: Independent predictors of return to work at 3 months were low age, low ISS and absence of depression symptoms. At 12 months, independent predictors of return to work were low ISS, low depression score and an optimistic life orientation. To promote early return to work, trauma patients might be screened for depression symptoms and pessimism, and intervention or treatment provided for those in need. (C) 2011 Elsevier Ltd. All rights reserved.	[Toien, Kirsti; Skogstad, Laila] Oslo Univ Hosp, Div Crit Care, Ulleval, Norway; [Ekeberg, Oivind] Oslo Univ Hosp, Dept Acute Med, Ulleval, Norway; [Ekeberg, Oivind] Univ Oslo, Fac Med, Dept Behav Sci Med, N-0316 Oslo, Norway; [Myhren, Hilde] Oslo Univ Hosp, Intens Care Unit, Ulleval, Norway; [Bredal, Inger Schou] Oslo Univ Hosp, Unit Breast & Endocrine Surg, Ulleval, Norway; [Bredal, Inger Schou] Univ Oslo, Fac Med, Inst Hlth & Soc, N-0316 Oslo, Norway	Toien, K (corresponding author), Oslo Univ Hosp, Div Crit Care, Ulleval, Norway.	kirsti.toien@uus.no					Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; *ASS ADV AUT MED, 1998, ABBR INJ SCAL 1990 R; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; Clay FJ, 2010, J REHABIL MED, V42, P162, DOI 10.2340/16501977-0495; Clay FJ, 2010, INJURY; Davydow DS, 2009, GEN HOSP PSYCHIAT, V31, P428, DOI 10.1016/j.genhosppsych.2009.05.007; Fern KT, 1998, J TRAUMA, V45, P489, DOI 10.1097/00005373-199809000-00010; Gabbe BJ, 2006, J TRAUMA, V61, P1393, DOI 10.1097/01.ta.0000225926.34180.47; Holtslag HR, 2007, CLIN REHABIL, V21, P373, DOI 10.1177/0269215507072084; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Jaquet JB, 2005, PLAST RECONSTR SURG, V115, P1609, DOI 10.1097/01.PRS.0000160697.41738.EA; KIVIOJA AH, 1990, J TRAUMA, V30, P480, DOI 10.1097/00005373-199030040-00020; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Lidal IB, 2007, DISABIL REHABIL, V29, P1341, DOI 10.1080/09638280701320839; Loge JH, 1998, SCAND J SOC MED, V26, P250; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MacKenzie EJ, 2006, J TRAUMA, V61, P688, DOI 10.1097/01.ta.0000195985.56153.68; Mason S, 2002, J TRAUMA, V53, P98, DOI 10.1097/00005373-200207000-00019; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Myhren H, 2010, CRIT CARE MED, V38, P1554, DOI 10.1097/CCM.0b013e3181e2c8b1; Nes LS, 2006, PERS SOC PSYCHOL REV, V10, P235, DOI 10.1207/s15327957pspr1003_3; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; Read KM, 2004, J TRAUMA, V57, P815, DOI 10.1097/01.TA.0000136289.15303.44; Richmond TS, 2009, PSYCHOL MED, V39, P1709, DOI 10.1017/S0033291709005376; ROSS CE, 1995, J HEALTH SOC BEHAV, V36, P230, DOI 10.2307/2137340; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; Schou I, 2004, PSYCHO-ONCOLOGY, V13, P309, DOI 10.1002/pon.747; Soberg HL, 2007, J TRAUMA, V62, P471, DOI 10.1097/TA.0b013e31802e95f4; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Ware J.E., 1997, SF 36 HLTH SURVEY MA, V2nd ed; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 2000, SF 36 HLTH SURVEY MA; Wohlfarth TD, 2003, PSYCHOL ASSESSMENT, V15, P101, DOI 10.1037/1040-3590.15.1.101; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	43	25	25	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	SEP	2012	43	9					1606	1613		10.1016/j.injury.2011.03.038			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	977MK	WOS:000306666100049	21489524				2021-06-18	
J	Van Calster, B; Van Belle, V; Vergouwe, Y; Steyerberg, EW				Van Calster, Ben; Van Belle, Vanya; Vergouwe, Yvonne; Steyerberg, Ewout W.			Discrimination ability of prediction models for ordinal outcomes: Relationships between existing measures and a new measure	BIOMETRICAL JOURNAL			English	Article						c-Index; Discrimination; Model performance; Ordinal outcomes; Prediction models	TRAUMATIC BRAIN-INJURY; CONFIDENCE-INTERVALS; EXTERNAL VALIDATION; ROC ANALYSIS; RISK; AREA; ACCURACY; CURVE; ASSOCIATION; PERFORMANCE	In this paper, we focus on measures to evaluate discrimination of prediction models for ordinal outcomes. We review existing extensions of the dichotomous c-indexwhich is equivalent to the area under the receiver operating characteristic (ROC) curvesuggest a new measure, and study their relationships. The volume under the ROC surface (VUS) scores sets of cases including one case from each outcome category. VUS considers sets as either correctly or incorrectly ordered by the model. All other existing measures assess pairs of cases. We propose an ordinal c-index (ORC) that is set-based but, contrary to VUS, scores sets more gradually by indicating the closeness of the model-based ordering to the perfect ordering. As a result, the ORC does not decrease rapidly as the number of outcome categories increases. It turns out that the ORC can be rewritten as the average of pairwise c-indexes. Hence, the ORC has both a set- and pair-based interpretation. There are several relationships between the existing measures, leading to only two types of existing measures: a prevalence-weighted average of pairwise c-indexes and the VUS. Our suggested measure ORC positions itself in between as it is set-based but turns out to equal an unweighted average of pairwise c-indexes. The measures are demonstrated through a case study on the prediction of six-month outcome after traumatic brain injury. In conclusion, the set-based nature and graded scoring system make the ORC an attractive measure with a simple interpretation, together with its prevalence-independence that is a natural property of a discrimination measure.	[Van Calster, Ben] Univ Louvain, KU Leuven, Dept Dev, B-3000 Louvain, Belgium; [Van Belle, Vanya] Univ Louvain, KU Leuven, Dept Elect Engn ESAT SCD, B-3001 Louvain, Belgium; [Van Belle, Vanya] Univ Louvain, KU Leuven, IBBT Future Hlth Dept, B-3001 Louvain, Belgium; [Vergouwe, Yvonne; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands	Van Calster, B (corresponding author), Univ Louvain, KU Leuven, Dept Dev, Herestr 49,Box 7003, B-3000 Louvain, Belgium.	ben.vancalster@med.kuleuven.be	Steyerberg, Ewout W/C-1509-2018; Van Calster, Ben/F-9150-2010	Steyerberg, Ewout W/0000-0002-7787-0122; Van Calster, Ben/0000-0003-1613-7450	Research Foundation - Flanders (FWO)FWO [1.2516.09 N, 1.2516.12 N, G.0493.12 N]; Katholieke Universiteit LeuvenKU Leuven; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-042691]; Netherlands Organization for Scientific ResearchNetherlands Organization for Scientific Research (NWO) [9120.8004]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	Ben Van Calster was supported by the Research Foundation - Flanders (FWO) (grants 1.2516.09 N, 1.2516.12 N, G.0493.12 N). Vanya Van Belle was supported by a BOF-PDM postdoctoral fellowship from the Katholieke Universiteit Leuven. Ewout Steyerberg was supported by NIH (NS-042691). Yvonne Vergouwe was supported by the Netherlands Organization for Scientific Research (grant 9120.8004).	Adams NM, 2000, COMPUT BIOL MED, V30, P89, DOI 10.1016/S0010-4825(99)00025-6; Alonzo TA, 2009, STAT MED, V28, P1144, DOI 10.1002/sim.3536; Baker SG, 2009, J R STAT SOC A STAT, V172, P729, DOI 10.1111/j.1467-985X.2009.00592.x; BAMBER D, 1975, J MATH PSYCHOL, V12, P387, DOI 10.1016/0022-2496(75)90001-2; Cook NR, 2007, CIRCULATION, V115, P928, DOI 10.1161/CIRCULATIONAHA.106.672402; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P109, DOI 10.1016/0895-4356(90)90064-V; Flandre P, 2007, STAT MED, V26, P4441, DOI 10.1002/sim.2871; Gerds TA, 2008, BIOMETRICAL J, V50, P457, DOI 10.1002/bimj.200810443; Gerds TA, 2011, BIOMETRICAL J, V53, P259, DOI 10.1002/bimj.201000157; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrell FE, 1998, STAT MED, V17, P909, DOI 10.1002/(SICI)1097-0258(19980430)17:8<909::AID-SIM753>3.0.CO;2-O; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harrell Frank E., 2001, REGRESSION MODELING; Herbrich R, 2000, ADV NEUR IN, P115; HILDEN J, 1991, MED DECIS MAKING, V11, P95, DOI 10.1177/0272989X9101100204; Hlatky Mark A, 2009, Circulation, V119, P2408, DOI 10.1161/CIRCULATIONAHA.109.192278; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Janes H, 2008, ANN INTERN MED, V149, P751, DOI 10.7326/0003-4819-149-10-200811180-00009; JENNETT B, 1975, LANCET, V1, P480; JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.2307/2333011; KIM JO, 1971, AM J SOCIOL, V76, P891, DOI 10.1086/225004; Mossman D, 1999, MED DECIS MAKING, V19, P78, DOI 10.1177/0272989X9901900110; Nakas CT, 2004, STAT MED, V23, P3437, DOI 10.1002/sim.1917; Newcombe RG, 2006, STAT MED, V25, P559, DOI 10.1002/sim.2324; Newcombe RG, 2006, STAT MED, V25, P543, DOI 10.1002/sim.2323; Obuchowski NA, 2005, ACAD RADIOL, V12, P1198, DOI 10.1016/j.acra.2005.05.013; Pencina MJ, 2011, STAT MED, V30, P11, DOI 10.1002/sim.4085; Scurfield BK, 1996, J MATH PSYCHOL, V40, P253, DOI 10.1006/jmps.1996.0024; Smith WD, 1996, STAT MED, V15, P1199, DOI 10.1002/(SICI)1097-0258(19960615)15:11<1199::AID-SIM218>3.0.CO;2-Y; SOMERS RH, 1962, AM SOCIOL REV, V27, P799, DOI 10.2307/2090408; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Terpstra JT, 2003, J NONPARAMETR STAT, V15, P289, DOI 10.1080/1048525031000078349; Timmerman D, 2010, ULTRASOUND OBST GYN, V36, P226, DOI 10.1002/uog.7636; Van Calster B, 2010, STAT MED, V29, P318, DOI 10.1002/sim.3761; Van Holsbeke C, 2012, CLIN CANCER RES, V18, P815, DOI 10.1158/1078-0432.CCR-11-0879; Vergouwe Yvonne, 2002, Semin Urol Oncol, V20, P96, DOI 10.1053/suro.2002.32521; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Waegeman W, 2008, PATTERN RECOGN LETT, V29, P1, DOI 10.1016/j.patrec.2007.07.019; Xiong CJ, 2006, STAT MED, V25, P1251, DOI 10.1002/sim.2433	41	25	25	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0323-3847	1521-4036		BIOMETRICAL J	Biom. J.	SEP	2012	54	5					674	685		10.1002/bimj.201200026			12	Mathematical & Computational Biology; Statistics & Probability	Mathematical & Computational Biology; Mathematics	995TQ	WOS:000308036200006	22711459				2021-06-18	
J	Tsai, J; Whealin, JM; Scott, JC; Harpaz-Rotem, I; Pietrzak, RH				Tsai, Jack; Whealin, Julia M.; Scott, J. Cobb; Harpaz-Rotem, Ilan; Pietrzak, Robert H.			Examining the Relation Between Combat-Related Concussion, a Novel 5-Factor Model of Posttraumatic Stress Symptoms, and Health-Related Quality of Life in Iraq and Afghanistan Veterans	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; OPERATIONS ENDURING FREEDOM; DYSPHORIC AROUSAL; DISORDER; PTSD; DIMENSIONALITY; CHALLENGES; CHECKLIST; HOSTILITY; SLEEP	Objective: This study examined demographic, military, and clinical characteristics associated with combat-related concussion and persistent postconcussive symptoms; and how combat-related concussion and persistent postconcussive symptoms and a novel 5-factor model of posttraumatic stress disorder (PTSD) symptoms are related to physical and mental health-related quality of life in veterans who served in Iraq and Afghanistan. Method: 233 veterans recruited from the Veterans Affairs Hawaii Program Registry who served in Iraq and Afghanistan completed a survey in 2010 that assessed combat-related concussion and persistent postconcussive symptoms, PTSD (DSM-IV criteria), alcohol use problems, and physical and mental health-related quality of life. The primary measure was physical and mental health-related quality of life as assessed by the 12-item Short-Form Health Survey, version 2. Results: Veterans who screened positive for combat-related concussion and persistent postconcussive symptoms were more likely than those who did not to report direct combat exposure (x(2) = 15.46, P < .001), living in a rural area (x(2) = 6.86, P < .01), and screening positive for PTSD (x(2) = 37.67, P < .001) and alcohol use problems (x(2) = 11.62, P < .01); 57.3% of veterans who screened positive for combat-related concussion and persistent postconcussive symptoms screened positive for PTSD. In bivariate analyses, combat-related concussion and persistent postconcussive symptoms were associated with lower scores on measures of physical and mental health-related quality of life (r=-0.27 to -0.45, P < .001). In multivariate analyses, combat-related concussion and persistent postconcussive symptoms were no longer related to these outcomes, with PTSD-related dysphoric arousal symptoms as the strongest predictor of physical health-related quality of life (beta=-0.55, P < .001) and PTSD-related emotional numbing symptoms (beta=-0.56, P < .001) as the strongest predictor of mental health-related quality of life. Conclusions: Results of this study suggest that a 5-factor model of PTSD symptoms may provide greater specificity in understanding the relation between combat-related concussion and persistent postconcussive symptoms, PTSD symptoms, and health-related physical and mental quality of life in Iraq/Afghanistan veterans. Psychiatric clinicians should consider this heterogeneity of PTSD symptoms when assessing and treating symptomatic veterans. J Clin Psychiatry 2012;73(8):1110-1118 (c) Copyright 2012 Physicians Postgraduate Press, Inc.	[Tsai, Jack; Harpaz-Rotem, Ilan] VA New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA; [Scott, J. Cobb; Harpaz-Rotem, Ilan; Pietrzak, Robert H.] VA Connecticut Healthcare Syst, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA; [Tsai, Jack; Scott, J. Cobb; Harpaz-Rotem, Ilan; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Whealin, Julia M.] VA Pacific Isl Hlth Care Syst, Honolulu, HI USA	Tsai, J (corresponding author), Yale Univ, Dept Psychiat, 950 Campbell Ave,151D, West Haven, CT 06516 USA.	Jack.Tsai@yale.edu	Tsai, Jack/D-3889-2013; Whealin, Julia/J-8819-2015	Tsai, Jack/0000-0002-0329-648X; harpaz-rotem, ilan/0000-0002-6066-9406; Whealin, Julia/0000-0002-2876-6783; Scott, J. Cobb/0000-0001-6538-9043	Health Services Research and Development; US Department of Veterans AffairsUS Department of Veterans Affairs; Clinical Neurosciences Division of the National Center for Posttraumatic Stress Disorder; Veterans Affairs Pacific Islands Health Care System	This work was funded by a Health Services Research and Development grant from the US Department of Veterans Affairs and was supported by the Clinical Neurosciences Division of the National Center for Posttraumatic Stress Disorder, the Veterans Affairs Pacific Islands Health Care System, and a private donation.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2008, MILD TRAUM BRAIN INJ; Armed Forces Health Surveillance Center (AFHSC), 2011, MSMR, V18, P2; Armour C, 2012, J ANXIETY DISORD, V26, P368, DOI 10.1016/j.janxdis.2011.12.002; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Asmundson GJG, 2004, J TRAUMA STRESS, V17, P467, DOI 10.1007/s10960-004-5795-7; Beckham JC, 2009, BIOL PSYCHIAT, V65, P268, DOI 10.1016/j.biopsych.2008.06.024; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Bentler P.M., 2001, EQS 6 STRUCTURAL EQU; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Clum GA, 2001, J NERV MENT DIS, V189, P618, DOI 10.1097/00005053-200109000-00008; Cohen BE, 2010, J GEN INTERN MED, V25, P18, DOI 10.1007/s11606-009-1117-3; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Dhalla S, 2007, CLIN INVEST MED, V30, P33, DOI 10.25011/cim.v30i1.447; DSM-5 Development, DSM 5 DEV G 05 POSTT; Elhai JD, 2011, J ANXIETY DISORD, V25, P340, DOI 10.1016/j.janxdis.2010.10.007; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Feeny NC, 2000, J TRAUMA STRESS, V13, P489, DOI 10.1023/A:1007789409330; Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530; Han SD, 2009, J HEAD TRAUMA REHAB, V24, P57, DOI 10.1097/HTR.0b013e3181957055; Harder LH, 2011, J NERV MENT DIS, V199, P940, DOI 10.1097/NMD.0b013e3182392bfb; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Keane, 1991, PCL C DSM 4; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; KUBANY ES, 1994, J TRAUMA STRESS, V7, P21, DOI 10.1007/BF02111909; LITZ BT, 1992, CLIN PSYCHOL REV, V12, P417, DOI 10.1016/0272-7358(92)90125-R; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mohr D, 2003, PSYCHOSOM MED, V65, P485, DOI 10.1097/01.PSY.0000041404.96597.38; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pietrzak RH, 2012, J PSYCHIATR RES, V46, P317, DOI 10.1016/j.jpsychires.2011.11.013; Pietrzak RH, 2010, PSYCHIAT RES, V178, P323, DOI 10.1016/j.psychres.2010.04.039; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Riviere LA, 2011, J NERV MENT DIS, V199, P199, DOI 10.1097/NMD.0b013e31820caee4; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Statistical Package for the Social Sciences, 2008, STAT PACK SOC SCI SP; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tabachnick B.G., 2001, USING MULTIVARIATE A; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Tsai J, 2011, J AFFECT DISORDERS, V135, P310, DOI 10.1016/j.jad.2011.06.057; Wang L, 2011, DEPRESS ANXIETY, V28, P1097, DOI 10.1002/da.20823; Wang L, 2011, J ANXIETY DISORD, V25, P771, DOI 10.1016/j.janxdis.2011.03.011; Wang L, 2011, J ABNORM CHILD PSYCH, V39, P749, DOI 10.1007/s10802-011-9508-4; Ware J.E., 2002, VERSION 2 SF 12 HLTH; Weathers F. W., 1993, 9 ANN M INT SOC TRAU	56	25	25	0	13	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689	1555-2101		J CLIN PSYCHIAT	J. Clin. Psychiatry	AUG	2012	73	8					1110	1118		10.4088/JCP.11m07587			9	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	090SM	WOS:000315000300006	22781019				2021-06-18	
J	de Kloet, AJ; Berger, MAM; Verhoeven, IMAJ; Callenfels, KV; Vlieland, TPMV				de Kloet, A. J.; Berger, M. A. M.; Verhoeven, I. M. A. J.; Callenfels, K. van Stein; Vlieland, T. P. M. Vliet			Gaming supports youth with acquired brain injury? A pilot study	BRAIN INJURY			English	Article						Acquired brain injury; traumatic brain injury; children; youth; rehabilitation; participation; information processing; gaming	RANDOMIZED CLINICAL-TRIAL; VIRTUAL-REALITY; STROKE REHABILITATION; CHILDREN; WII; OUTCOMES	Aim: To explore the effects of usage of the Nintendo Wii on physical, cognitive and social functioning in patients with acquired brain injury (ABI). Methods: This multi-centre, observational proof-of-concept study included children, adolescents and young adults with ABI aged 6-29 years. A standardized, yet individually tailored 12-week intervention with the Nintendo Wii was delivered by trained instructors. The treatment goals were set on an individual basis and included targets regarding physical, mental and/or social functioning. Outcome assessments were done at baseline and after 12 weeks and included: the average number of minutes per week of recreational physical activity; the CAPE (Children's Assessment of Participation and Enjoyment); the ANT (Amsterdam Neuropsychological Tasks); the achievement of individual treatment goals (Goal Attainment Scaling); and quality-of-life (PedsQL; Pediatric Quality of Life Inventory). Statistical analyses included paired t-tests or Wilcoxon-Signed-Rank tests. Results: Fifty patients were included (31 boys and 19 girls; mean age 17.1 years (SD = 4.4)), of whom 45 (90%) completed the study. Significant changes of the amount of physical activity, speed of information processing, attention, response inhibition and visual-motor coordination (p < 0.05) were seen after 12 weeks, whereas there were no differences in CAPE or PedsQL scores. Two-thirds of the patients reported an improvement of the main treatment goal. Conclusion: This study supports the potential benefits of gaming in children and youth with ABI.	[de Kloet, A. J.; Vlieland, T. P. M. Vliet] Sophia Rehabil, The Hague, Netherlands; [de Kloet, A. J.; Berger, M. A. M.; Callenfels, K. van Stein] Hague Univ Appl Sci, The Hague, Netherlands; [Verhoeven, I. M. A. J.] Delft Univ Technol, Delft, Netherlands; [Vlieland, T. P. M. Vliet] Leiden Univ, Med Ctr, Dept Orthopaed, Leiden, Netherlands	de Kloet, AJ (corresponding author), Sophia Revalidatie, Vrederustlaan 180,2543 SW, The Hague, Netherlands.	a.dekloet@sophiarevalidatie.nl	Vlieland, Thea Vliet/AAJ-8119-2020	Vlieland, Thea Vliet/0000-0001-6322-3859	Sponsor Bingo Lottery [HsN090609]; Achmea (Injury Assurances; Apeldoorn); Fonds (The Hague); City of The Hague (Department of Education and Health)	This study was financially supported by the Sponsor Bingo Lottery (HsN090609), Achmea (Injury Assurances; Apeldoorn), Fonds 1818 (The Hague) and City of The Hague (Department of Education and Health) facilitated the purchase of 30 extra Wii sets. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Bedell GM, 2008, BRAIN INJURY, V22, P313, DOI 10.1080/02699050801978948; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Buizer A, 2005, PEDIAT BLOOD CANC, V45, P291; Bult MK, 2010, CLIN REHABIL, V24, P412; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; de Sonneville LMJ, 1999, COMP PSYCH, V6, P187; DeMatteo CA, 2008, ARCH PHYS MED REHAB, V89, P1803, DOI 10.1016/j.apmr.2008.02.025; Deutsch JE, 2008, PHYS THER, V88, P1196, DOI 10.2522/ptj.20080062; Galvin J, 2011, DEV NEUROREHABIL, V14, P112, DOI 10.3109/17518423.2010.535805; Gil-Gomez JA, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-30; Hanisch C, 2004, J NEURAL TRANSM, V111, P865, DOI 10.1007/s00702-003-0056-0; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hendriks CM, 1996, ATAG K AMSTERDAMSE T; Joo LY, 2010, J REHABIL MED, V42, P437, DOI 10.2340/16501977-0528; Kalff AC, 2003, J CHILD PSYCHOL PSYC, V44, P1049, DOI 10.1111/1469-7610.00189; King G., 2004, CAPE PAC CHILDRENS A; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Laver KE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008349.pub2; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Meerhoff S R, 2000, Ned Tijdschr Geneeskd, V144, P1915; Missiuna Cheryl, 2008, Can J Occup Ther, V75, P157; Saposnik G, 2011, STROKE, V42, P1380, DOI 10.1161/STROKEAHA.110.605451; Saposnik G, 2010, STROKE, V41, P1477, DOI 10.1161/STROKEAHA.110.584979; Slaats-Willemse D, 2005, J AM ACAD CHILD PSY, V44, P385, DOI 10.1097/01.chi.0000153227.34473.c7; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Wilken JP, 1994, NIET AANGEBOREN HERS	28	25	25	0	45	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2012	26	7-8					1021	1029		10.3109/02699052.2012.654592			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	957CB	WOS:000305135100014	22632604				2021-06-18	
J	Ley, EJ; Clond, MA; Bukur, M; Park, R; Chervonski, M; Dagliyan, G; Margulies, DR; Lyden, PD; Conti, PS; Salim, A				Ley, Eric J.; Clond, Morgan A.; Bukur, Marko; Park, Ryan; Chervonski, Michael; Dagliyan, Grant; Margulies, Dan R.; Lyden, Patrick D.; Conti, Peter S.; Salim, Ali			beta-Adrenergic receptor inhibition affects cerebral glucose metabolism, motor performance, and inflammatory response after traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; beta-adrenergic receptor; cerebral glucose metabolism; propranolol; knockout	HEAD-INJURY; BETA(2)-ADRENERGIC RECEPTOR; CELL-CULTURE; PROPRANOLOL; IMPACT; RATS; PERFUSION; ISCHEMIA; SURVIVAL; STATE	BACKGROUND: The purpose of this study was to evaluate how beta-adrenergic receptor inhibition after traumatic brain injury (TBI) alters changes in early cerebral glucose metabolism and motor performance, as well as cerebral cytokine and heat shock protein (HSP) expression. METHODS: Mouse cerebral glucose metabolism was measured by microPET fluorodeoxyglucose uptake and converted into standardized uptake values (SUV). Four groups of C57/Bl6 mice (wild type [WT]) were initially evaluated: sham or TBI, followed by tail vein injection of either saline or a nonselective beta-adrenergic receptor inhibitor (propranolol, 4 mg/kg). Then motor performance, cerebral cytokine, and HSP70 expression were studied at 12 hours and 24 hours after sham injury or TBI in WT mice treated with saline or propranolol and in beta 1-adrenergic/beta 2-adrenergic receptor knockout (BARKO) mice treated with saline. RESULTS: Cerebral glucose metabolism was significantly reduced after TBI (mean SUV TBI, 1.63 vs. sham 1.97, p < 0.01) and propranolol attenuated this reduction (mean SUV propranolol, 1.89 vs. saline 1.63, p < 0.01). Both propranolol and BARKO reduced motor deficits at 24 hours after injury, but only BARKO had an effect at 12 hours after injury. TBI WT mice treated with saline performed worse than propranolol mice at 24 hours after injury on rotarod (23 vs. 44 seconds, p < 0.01) and rearing (130 vs. 338 events, p = 0.01) results. At 24 hours after injury, sham BARKO and TBI BARKO mice were similar on rotarod (21 vs. 19 seconds, p = 0.53), ambulatory testing (2,891 vs. 2,274 events, p = 0.14), and rearing (129 vs. 64 events, p = 0.09) results. Interleukin 1 beta expression was affected by BARKO and propranolol after TBI; attenuation of interleukin 6 and increased HSP70 expression were noted only with BARKO. CONCLUSION: beta-adrenergic receptor inhibition affects cerebral glucose metabolism, motor performance, as well as cerebral cytokine and HSP expression after TBI. (J Trauma Acute Care Surg. 2012; 73: 33-40. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Ley, Eric J.; Clond, Morgan A.; Bukur, Marko; Margulies, Dan R.; Lyden, Patrick D.; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Park, Ryan; Chervonski, Michael; Dagliyan, Grant; Conti, Peter S.] Univ So Calif, Dept Radiol, Los Angeles, CA USA	Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	eric.ley@cshs.org		Clond, Morgan/0000-0002-3036-4193; Bukur, Marko/0000-0002-1850-7147	American Association for the Surgery of Trauma Research and Education Foundation	This study was supported in part by a grant from the American Association for the Surgery of Trauma Research and Education Foundation.	AKAIKE N, 1981, BRIT J PHARMACOL, V73, P431, DOI 10.1111/j.1476-5381.1981.tb10439.x; Beere HM, 2000, NAT CELL BIOL, V2, P469; Beiermeister KA, 2010, J TRAUMA, V69, P338, DOI 10.1097/TA.0b013e3181e5d35e; Bracken MB, 2005, NEUROSURGERY, V57, P1300, DOI 10.1227/01.NEU.0000187320.71967.59; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fonseca RB, 2005, J TRAUMA, V59, P884, DOI 10.1097/01.ta.0000187653.64300.f5; Friese RS, 2008, J TRAUMA, V64, P1061, DOI 10.1097/TA.0b013e3181684cf0; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Han RQ, 2009, ANESTH ANALG, V108, P280, DOI 10.1213/ane.0b013e318187ba6b; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Laureys G, 2010, PROG NEUROBIOL, V91, P189, DOI 10.1016/j.pneurobio.2010.01.011; Lee SH, 2004, STROKE, V35, P2195, DOI 10.1161/01.STR.0000136150.73891.14; Ley EJ, 2011, J SURG RES, V170, P253, DOI 10.1016/j.jss.2011.03.006; Ley EJ, 2010, J TRAUMA, V68, P353, DOI 10.1097/TA.0b013e3181c8269a; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mannick JA, 2002, J AM COLL SURGEONS, V194, P104, DOI 10.1016/S1072-7515(01)01123-1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Oberbeck R, 2009, CURR MED CHEM, V16, P1082, DOI 10.2174/092986709787581770; Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001; RAINBOW TC, 1984, P NATL ACAD SCI-BIOL, V81, P1585, DOI 10.1073/pnas.81.5.1585; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang J, 2010, J NEUROIMMUNOL, V223, P77, DOI 10.1016/j.jneuroim.2010.04.006; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Ye CI, 2000, BIOPHYS J, V79, P2547, DOI 10.1016/S0006-3495(00)76495-2; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200	40	25	25	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2012	73	1					33	40		10.1097/TA.0b013e31825a769b			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	979JU	WOS:000306814100006	22743370				2021-06-18	
J	Ma, YY; Prince, DA				Ma, Yunyong; Prince, David A.			Functional alterations in GABAergic fast-spiking interneurons in chronically injured epileptogenic neocortex	NEUROBIOLOGY OF DISEASE			English	Article						Inhibition; Paired recordings; Barrel; Fast-spiking; Epilepsy	INHIBITORY SYNAPTIC-TRANSMISSION; HILAR SOMATOSTATIN INTERNEURONS; ACTION-POTENTIAL PROPAGATION; PAIRED-PULSE DEPRESSION; TRAUMATIC BRAIN-INJURY; DENTATE GRANULE CELLS; AXON INITIAL SEGMENT; V PYRAMIDAL NEURONS; GABA(A) RECEPTOR; RELEASE PROBABILITY	Progress toward developing effective prophylaxis and treatment of posttraumatic epilepsy depends on a detailed understanding of the basic underlying mechanisms. One important factor contributing to epileptogenesis is decreased efficacy of GABAergic inhibition. Here we tested the hypothesis that the output of neocortical fast-spiking (FS) interneurons onto postsynaptic targets would be decreased in the undercut (UC) model of chronic posttraumatic epileptogenesis. Using dual whole-cell recordings in layer IV barrel cortex, we found a marked increase in the failure rate and a very large reduction in the amplitude of unitary inhibitory postsynaptic currents (uIPSCs) from FS cells to excitatory regular spiking (RS) neurons and neighboring FS cells. Assessment of the paired pulse ratio and presumed quantal release showed that there was a significant, but relatively modest, decrease in synaptic release probability and a non-significant reduction in quantal size. A reduced density of boutons on axons of biocytin-filled UC FS cells, together with a higher coefficient of variation of uIPSC amplitude in RS cells, suggested that the number of functional synapses presynaptically formed by FS cells may be reduced. Given the marked reduction in synaptic strength, other defects in the presynaptic vesicle release machinery likely occur, as well. (C) 2012 Elsevier Inc. All rights reserved.	[Ma, Yunyong; Prince, David A.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Prince, DA (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Room M016,Alway Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	daprince@stanford.edu			National Institutes of Health from National Institute of Neurological Disorders and Stroke [NS012151, NS039579]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039579, P01NS012151, P50NS012151, R56NS039579, R01NS006477] Funding Source: NIH RePORTER	We thank Ms. Isabel Parada for assistance in immunocytochemical experiments and Professor Michael Gutnick for helpful suggestions. This work was supported by the National Institutes of Health grants NS012151 and NS039579 from National Institute of Neurological Disorders and Stroke.	ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; Andre V, 2001, HIPPOCAMPUS, V11, P452, DOI 10.1002/hipo.1060.abs; Andrioli A, 2007, NEUROSCIENCE, V149, P131, DOI 10.1016/j.neuroscience.2007.07.029; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Arellano JI, 2004, BRAIN, V127, P45, DOI 10.1093/brain/awh004; Ascoli GA, 2008, NAT REV NEUROSCI, V9, P557, DOI 10.1038/nrn2402; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Bacci A, 2004, NATURE, V431, P312, DOI 10.1038/nature02913; Bacci A, 2006, NEURON, V49, P119, DOI 10.1016/j.neuron.2005.12.014; Bacci A, 2003, J NEUROSCI, V23, P9664; Bacci A, 2003, J NEUROSCI, V23, P859; Bacci A, 2002, P NATL ACAD SCI USA, V99, P17125, DOI 10.1073/pnas.012481899; Bausch SB, 2005, EPILEPSY BEHAV, V7, P390, DOI 10.1016/j.yebeh.2005.07.019; Beierlein M, 2003, J NEUROPHYSIOL, V90, P2987, DOI 10.1152/jn.00283.2003; Bernard C, 2000, EPILEPSIA, V41, pS90, DOI 10.1111/j.1528-1157.2000.tb01564.x; Bianchi MT, 2001, J NEUROSCI, V21, P9083, DOI 10.1523/JNEUROSCI.21-23-09083.2001; Biro AA, 2006, J NEUROSCI, V26, P12487, DOI 10.1523/JNEUROSCI.3106-06.2006; Bodor AL, 2005, J NEUROSCI, V25, P6845, DOI 10.1523/JNEUROSCI.0442-05.2005; BOWERY NG, 1980, NATURE, V283, P92, DOI 10.1038/283092a0; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brooks-Kayal AR, 1999, J NEUROSCI, V19, P8312; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Caillard O, 2000, P NATL ACAD SCI USA, V97, P13372, DOI 10.1073/pnas.230362997; CELIO MR, 1986, SCIENCE, V231, P995, DOI 10.1126/science.3945815; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747; Collin T, 2005, CURR OPIN NEUROBIOL, V15, P275, DOI 10.1016/j.conb.2005.05.003; Cossart R, 2005, TRENDS NEUROSCI, V28, P108, DOI 10.1016/j.tins.2004.11.011; Cossart R, 2001, NAT NEUROSCI, V4, P52; Cowan AI, 2004, J NEUROPHYSIOL, V92, P2137, DOI 10.1152/jn.01262.2003; Cox CL, 2000, P NATL ACAD SCI USA, V97, P9724, DOI 10.1073/pnas.170278697; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; Daw MI, 2009, J NEUROSCI, V29, P11112, DOI 10.1523/JNEUROSCI.5760-08.2009; Debanne D, 1997, NATURE, V389, P286, DOI 10.1038/38502; Dinocourt C, 2003, J COMP NEUROL, V459, P407, DOI 10.1002/cne.10622; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Dobrunz LE, 2002, INT J DEV NEUROSCI, V20, P225, DOI 10.1016/S0736-5748(02)00015-1; Dougherty KJ, 2008, J NEUROPHYSIOL, V100, P212, DOI 10.1152/jn.01104.2007; ECHLIN FA, 1959, ELECTROEN CLIN NEURO, V11, P697, DOI 10.1016/0013-4694(59)90110-5; Elfant D, 2008, EUR J NEUROSCI, V27, P104, DOI 10.1111/j.1460-9568.2007.06001.x; FABER DS, 1991, BIOPHYS J, V60, P1288, DOI 10.1016/S0006-3495(91)82162-2; Faria LC, 2010, J NEUROPHYSIOL, V104, P280, DOI 10.1152/jn.00351.2010; Feldmeyer D, 1999, J PHYSIOL-LONDON, V521, P169, DOI 10.1111/j.1469-7793.1999.00169.x; Feldmeyer D, 2005, J NEUROSCI, V25, P3423, DOI 10.1523/JNEUROSCI.5227-04.2005; FLEIDERVISH IA, 1995, J NEUROPHYSIOL, V73, P2591; FRERKING M, 1995, NEURON, V15, P885, DOI 10.1016/0896-6273(95)90179-5; Galante M, 2003, J NEUROSCI, V23, P11229; Galarreta M, 2002, P NATL ACAD SCI USA, V99, P12438, DOI 10.1073/pnas.192159599; Galarreta M, 2008, CEREB CORTEX, V18, P2296, DOI 10.1093/cercor/bhm253; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P1924; Gibson JR, 2009, J NEUROSCI, V29, P13883, DOI 10.1523/JNEUROSCI.2457-09.2009; Gibson JR, 1999, NATURE, V402, P75; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 2006, MODELS OF SEIZURES AND EPILEPSY, P477, DOI 10.1016/B978-012088554-1/50040-2; Grubb MS, 2010, NATURE, V465, P1070, DOI 10.1038/nature09160; Halabisky B, 2010, J NEUROPHYSIOL, V104, P2214, DOI 10.1152/jn.00147.2010; Hanse E, 2002, J NEUROSCI, V22, P4381, DOI 10.1523/JNEUROSCI.22-11-04381.2002; HATT H, 1976, J PHYSIOL-LONDON, V259, P367, DOI 10.1113/jphysiol.1976.sp011471; Hirsch JC, 1999, NAT NEUROSCI, V2, P499; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; Houser CR, 2003, HIPPOCAMPUS, V13, P633, DOI 10.1002/hipo.10108; Huguenard JR, 2000, P NATL ACAD SCI USA, V97, P9349, DOI 10.1073/pnas.97.17.9349; Jensen K, 1999, J NEUROPHYSIOL, V82, P42; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Kawaguchi Y, 2002, J NEUROCYTOL, V31, P277, DOI 10.1023/A:1024126110356; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Kravchenko MO, 2006, NEUROSCI LETT, V395, P133, DOI 10.1016/j.neulet.2005.10.070; Kumar SS, 2006, J NEUROSCI, V26, P4613, DOI 10.1523/JNEUROSCI.0064-06.2006; LAMBERT NA, 1993, NEURON, V11, P1057, DOI 10.1016/0896-6273(93)90219-H; LAMBERT NA, 1994, J NEUROPHYSIOL, V72, P121; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Li HF, 2011, NEUROSCI LETT, V497, P172, DOI 10.1016/j.neulet.2011.02.042; Lisman JE, 2007, NAT REV NEUROSCI, V8, P597, DOI 10.1038/nrn2191; Loup F, 2000, J NEUROSCI, V20, P5401, DOI 10.1523/JNEUROSCI.20-14-05401.2000; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUHMANN HJ, 1995, EPILEPSY RES, V22, P43, DOI 10.1016/0920-1211(95)00032-6; LUSCHER HR, 1990, BIOPHYS J, V58, P1389; Maccaferri G, 2000, J PHYSIOL-LONDON, V524, P91, DOI 10.1111/j.1469-7793.2000.t01-3-00091.x; Magloczky Z, 2005, TRENDS NEUROSCI, V28, P334, DOI 10.1016/j.tins.2005.04.002; Manita S, 2007, BRAIN RES, V1154, P71, DOI 10.1016/j.brainres.2007.03.089; Manseau F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000492; Marco P, 1997, BRAIN RES BULL, V44, P47, DOI 10.1016/S0361-9230(97)00090-7; Marco P, 1996, BRAIN, V119, P1327, DOI 10.1093/brain/119.4.1327; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; Markram H, 1998, NEUROPHARMACOLOGY, V37, P489, DOI 10.1016/S0028-3908(98)00049-5; Marsicano G, 1999, EUR J NEUROSCI, V11, P4213, DOI 10.1046/j.1460-9568.1999.00847.x; Marty S, 2000, J NEUROSCI, V20, P8087; McBain CJ, 2001, NAT REV NEUROSCI, V2, P11, DOI 10.1038/35049047; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Mitchell SJ, 2003, NEURON, V38, P433, DOI 10.1016/S0896-6273(03)00200-9; Morin F, 1998, J NEUROPHYSIOL, V80, P2836; Morishita W, 1997, J PHYSIOL-LONDON, V505, P307, DOI 10.1111/j.1469-7793.1997.307bb.x; Oleskevich S, 2000, J PHYSIOL-LONDON, V524, P513, DOI 10.1111/j.1469-7793.2000.00513.x; Oleskevich S, 2002, J PHYSIOL-LONDON, V540, P447, DOI 10.1113/jphysiol.2001.013821; Perrais D, 1999, J NEUROSCI, V19, P578; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Rempe DA, 1997, J NEUROPHYSIOL, V78, P1504; RIBAK CE, 1982, J NEUROSCI, V2, P1725; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; RIBAK CE, 1979, SCIENCE, V205, P211, DOI 10.1126/science.109922; Roper SN, 1999, EPILEPSY RES, V37, P63, DOI 10.1016/S0920-1211(99)00035-2; Rosen GD, 1998, CEREB CORTEX, V8, P753, DOI 10.1093/cercor/8.8.753; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Sakaba T, 2008, NEURON, V57, P406, DOI 10.1016/j.neuron.2007.11.029; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Scanziani M, 1998, P NATL ACAD SCI USA, V95, P12004, DOI 10.1073/pnas.95.20.12004; Schwaller B, 2004, MOL CELL NEUROSCI, V25, P650, DOI 10.1016/j.mcn.2003.12.006; Schwarzer C, 1997, NEUROSCIENCE, V80, P1001, DOI 10.1016/S0306-4522(97)00145-0; Scotti AL, 1997, HIPPOCAMPUS, V7, P524; Shah MM, 2004, NEURON, V44, P495, DOI 10.1016/j.neuron.2004.10.011; Silva AV, 2002, BRAIN RES BULL, V58, P417, DOI 10.1016/S0361-9230(02)00811-0; Stewart BA, 2000, P NATL ACAD SCI USA, V97, P13955, DOI 10.1073/pnas.250491397; Sun Qian-Quan, 2005, Thalamus & Related Systems, V3, P261, DOI 10.1017/S1472928807000283; Sun QQ, 2003, J NEUROSCI, V23, P9639; Tamas G, 2000, NAT NEUROSCI, V3, P366, DOI 10.1038/73936; TAUCK DL, 1985, J NEUROSCI, V5, P1016; TRAUB RD, 1982, SCIENCE, V216, P745, DOI 10.1126/science.7079735; Trotter SA, 2006, J NEUROSCI, V26, P10756, DOI 10.1523/JNEUROSCI.2323-06.2006; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248; Uematsu M, 2008, CEREB CORTEX, V18, P315, DOI 10.1093/cercor/bhm056; Ulrich D, 1996, J PHYSIOL-LONDON, V493, P845, DOI 10.1113/jphysiol.1996.sp021427; vandenPol AN, 1996, J NEUROSCI, V16, P4283; Vreugdenhil M, 2003, J NEUROPHYSIOL, V89, P1414, DOI 10.1152/jn.00576.2002; Wang Y, 2002, CEREB CORTEX, V12, P395, DOI 10.1093/cercor/12.4.395; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; WILCOX KS, 1994, J NEUROSCI, V14, P1775; Williamson A, 1999, ANN NEUROL, V45, P92, DOI 10.1002/1531-8249(199901)45:1<92::AID-ART15>3.0.CO;2-N; Wittner L, 2005, BRAIN, V128, P138, DOI 10.1093/brain/awh339; Wittner L, 2001, NEUROSCIENCE, V108, P587, DOI 10.1016/S0306-4522(01)00446-8; Wyeth MS, 2010, J NEUROSCI, V30, P8993, DOI 10.1523/JNEUROSCI.1183-10.2010; Xiang ZX, 2002, J NEUROPHYSIOL, V88, P740, DOI 10.1152/jn.2002.88.2.740; Yamamoto K, 2010, J NEUROPHYSIOL, V104, P1933, DOI 10.1152/jn.00438.2010; Zamecnik J, 2006, BRAIN RES BULL, V68, P474, DOI 10.1016/j.brainresbull.2005.10.008; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009; Zhang W, 2009, J NEUROSCI, V29, P7846, DOI 10.1523/JNEUROSCI.6199-08.2009; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	143	25	27	1	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUL	2012	47	1					102	113		10.1016/j.nbd.2012.03.027			12	Neurosciences	Neurosciences & Neurology	952KP	WOS:000304791700010	22484482	Green Accepted			2021-06-18	
J	Arango-Lasprilla, JC; Krch, D; Drew, A; Aragon, CJD; Stevens, LF				Arango-Lasprilla, Juan Carlos; Krch, Denise; Drew, Allison; De los Reyes Aragon, Carlos Jose; Stevens, Lillian Flores			Health-related quality of life of individuals with traumatic brain injury in Barranquilla, Colombia	BRAIN INJURY			English	Article						Quality-of-life; traumatic brain injury; depression; cognition	COPING STRATEGIES; SOCIAL SUPPORT; HEAD-INJURY; VALIDITY; SPANISH; SF-36; COMMUNITY; MODERATE; OUTCOMES; ADULTS	Objective: To assess health-related quality of life (HRQoL) of individuals with traumatic brain injury (TBI) in Barranquilla, Colombia. Participants/methods: Thirty-one individuals with TBI and 61 healthy controls completed the SF-36, a self-report HRQoL measure composed of eight component areas: physical health problems, pain, role limitations due to physical problems or due to emotional problems, emotional well-being, social functioning, energy/fatigue and general health perceptions. Results: The samples were statistically similar with respect to age, gender and education and statistically different with respect to depression, SES, social support and cognition. Compared to healthy controls, individuals with TBI had significantly lower means on all SF-36 sub-scales. However, after adjusting for depression, SES, social support and cognitive performance, significant differences remained on three of the SF-36 sub-scales. Specifically, individuals with TBI had lower adjusted means on Role-Physical (p-value <0.005), Role-Emotional (p-value <0.005) and Bodily Pain (p-value <0.05). Conclusion: Even after controlling for depression, SES, social support and cognitive performance, individuals with TBI living in Barranquilla Colombia report having poorer quality of life across various domains, including Role-Physical, Role-Emotional and Bodily Pain. These findings suggest the need for rehabilitation health professionals to develop and implement culturally-appropriate interventions to improve quality of life in Colombian individuals with TBI.	[Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA 23219 USA; [Krch, Denise] Kessler Fdn Res Ctr, W Orange, NJ USA; [Krch, Denise] UMDNJ New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [De los Reyes Aragon, Carlos Jose] Univ Norte, Dept Psychol, Barranquilla, Colombia	Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Theater Row Bldg,4th Floor,Room 4230A,POB 843038,, Richmond, VA 23219 USA.	jcarangolasp@vcu.edu	De los Reyes Aragon, Carlos Jose/P-3516-2019; De los Reyes Aragon, Carlos Jose CDA/E-2585-2015	De los Reyes Aragon, Carlos Jose/0000-0003-4472-0635; De los Reyes Aragon, Carlos Jose CDA/0000-0003-4472-0635	Department of Education, NIDRR [H133P090009]	The contents of this article were developed partially under a grant from the Department of Education, NIDRR grant number H133P090009. However, those contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Arango-Lasprilla JC, 2010, BRAIN INJURY, V24, P1017, DOI 10.3109/02699052.2010.490516; Augustovski FA, 2008, J CLIN EPIDEMIOL, V61, P1279, DOI 10.1016/j.jclinepi.2008.05.004; Ayuso-Mateos JL, 1999, ACTA PSYCHIAT SCAND, V99, P26, DOI 10.1111/j.1600-0447.1999.tb05381.x; Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Blair H, 2010, BRAIN INJURY, V24, P833, DOI 10.3109/02699051003789203; BROOKS DN, 1984, CLOSED HEAD INJURY P, P148; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carnegie Mellon University, LAB STUD STRESS IMM; CELLA DF, 1995, SEMIN ONCOL, V22, P73; COHEN S, 1983, J APPL SOC PSYCHOL, V13, P99, DOI 10.1111/j.1559-1816.1983.tb02325.x; Cunningham JM, 1999, HLTH CARE DISABILITY, P475; Diez-Quevedo C, 2001, PSYCHOSOM MED, V63, P679, DOI 10.1097/00006842-200107000-00021; Donlan W, 2010, PSYCHOL REP, V106, P419, DOI 10.2466/PR0.106.2.419-432; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; International Brain Injury Association (IBIA), BRAIN INJ FACTS WORL; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Johnstone B, 2009, BRAIN INJURY, V23, P411, DOI 10.1080/02699050902788501; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Lynch R. T., 1986, APPL REHABILITATION, P262; Machnicki G, 2009, DEMENT GERIATR COGN, V28, P206, DOI 10.1159/000236912; Man DWK, 2004, BRAIN INJURY, V18, P577, DOI 10.1080/02699050310001646143; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Molloy M., 1983, AUSTR REHABILITATION, V7, P34; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; Ostrosky-Solis F, 1999, J INT NEUROPSYCH SOC, V5, P413, DOI 10.1017/S1355617799555045; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Smith L.M., 1995, FAMILY SUPPORT PROGR; Souza Ligia Maria Do N, 2007, Dev Neurorehabil, V10, P35, DOI 10.1080/13638490600822239; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Ware JE., 2000, SF 36 HLTH SURVEY MA; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wolters G, 2010, NEUROPSYCHOL REHABIL, V20, P587, DOI 10.1080/09602011003683836; WULSIN L, 2002, PRIM CARE COMPANION, V4, P191, DOI DOI 10.4088/PCC.V04N0504; Zitnay GA, 2005, ACT NEUR S, V93, P131	55	25	28	0	16	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2012	26	6					825	833		10.3109/02699052.2012.655364			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	943EO	WOS:000304103500004	22583173				2021-06-18	
J	Gupta, A; Taly, AB				Gupta, Anupam; Taly, Arun B.			Functional outcome following rehabilitation in chronic severe traumatic brain injury patients: A prospective study	ANNALS OF INDIAN ACADEMY OF NEUROLOGY			English	Article						Functional outcome; inpatient rehabilitation; severe traumatic brain injury	COGNITIVE REHABILITATION; EPIDEMIOLOGY; POPULATION; RECOVERY; TBI	Objective: The objective was to assess functional outcome of rehabilitation in chronic severe traumatic brain injury (TBI) in-patients. Setting: The study was performed at university tertiary research hospital. Study Design: A prospective cross-sectional study Materials and Methods: Forty patients (34 men) with mean age of 30.1 years (range 6--60, SD 10.8), severe TBI (Glasgow coma scale 3--8, duration of coma > 6 hours, post-traumatic amnesia > 1 day postinjury) were admitted in rehabilitation unit minimum 3 months (mean 7.74.6 months, range 3--22 months) following injury falling in Glasgow outcome scale (GOS) of 3. Functional recovery was assessed using the Barthel Index (BI) score and disability rating scores (DRS). Data Analysis: Paired Students t-test was used for the assessment of functional recovery using mean BI scores at admission and discharge. The Wilcoxon nonparametric test was used for the assessment of functional recovery by comparing admission and discharge DRS scores. Results: Mean duration of stay was 30.8 days (range 18--91, SD15.6). Significant functional recovery observed in patients comparing BI and DRS scores at admission and discharge (mean BI admission 50.525.4, range 0--85 vs. mean discharge BI score 61.125.3, range 0--95, P < 0.001, mean DRS admission score 7.574.1, range 2.5--21.0 vs. mean discharge DRS score 6.364.3, range 1.0-21.0, P < 0.001). Conclusion: Patients with severe TBI continue to show functional recovery even in chronic phase with rehabilitation. They are left with significant residual physical and cognitive deficits and would require long-term care and assistance from care givers for the daily activities, as suggested by the mean DRS score at discharge.	[Gupta, Anupam; Taly, Arun B.] Natl Inst Mental Hlth & Neurosci, Dept Psychiat & Neurol Rehabil, Neurol Rehabil Div, Bangalore 560029, Karnataka, India	Gupta, A (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Psychiat & Neurol Rehabil, Neurol Rehabil Div, Bangalore 560029, Karnataka, India.	drgupta159@yahoo.co.in					Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Avesani R, 2011, EUR J PHYS REHAB MED, V47, P203; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cullen NK, 2011, BRAIN INJURY, V25, P35, DOI 10.3109/02699052.2010.531691; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gururaj G, 2008, NATL MED J INDIA, V21, P14; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Hoffmann B, 2002, ACT NEUR S, V79, P33; Huang SJ, 2010, BRAIN INJURY, V24, P1606, DOI 10.3109/02699052.2010.523056; Krug E., 1999, INJURY LEADING CAUSE; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Rao S.L., 2004, NIMHANS NEUROPSYCHOL; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Singh RB, 2005, ACTA CARDIOL, V60, P611, DOI 10.2143/AC.60.6.2004933; Stalp M, 2002, J TRAUMA, V52, P1160, DOI 10.1097/00005373-200206000-00023; Svestkova O, 2010, DISABIL REHABIL, V32, pS68, DOI 10.3109/09638288.2010.511690; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Turner-Stokes L, 2005, COCHRANE DB SYST REV, V20; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265; von Wild KRH, 2008, ACT NEUR S, V101, P55; Weninger P, 2008, J TRAUMA, V65, P799, DOI 10.1097/TA.0b013e3181820dae; Wertheimer JC, 2008, ARCH PHYS MED REHAB, V89, P1983, DOI 10.1016/j.apmr.2008.04.010; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	30	25	25	0	6	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0972-2327	1998-3549		ANN INDIAN ACAD NEUR	Ann. Indian Acad. Neurol.	APR-JUN	2012	15	2					120	124		10.4103/0972-2327.94995			5	Clinical Neurology	Neurosciences & Neurology	932YV	WOS:000303327300010	22566725	DOAJ Gold, Green Published			2021-06-18	
J	Iwamura, A; Taoka, T; Fukusumi, A; Sakamoto, M; Miyasaka, T; Ochi, T; Akashi, T; Okuchi, K; Kichikawa, K				Iwamura, Asami; Taoka, Toshiaki; Fukusumi, Akio; Sakamoto, Masahiko; Miyasaka, Toshiteru; Ochi, Tomoko; Akashi, Toshiaki; Okuchi, Kazuo; Kichikawa, Kimihiko			Diffuse vascular injury: convergent-type hemorrhage in the supratentorial white matter on susceptibility-weighted image in cases of severe traumatic brain damage	NEURORADIOLOGY			English	Article						Susceptibility-weighted image; Apparent diffusion coefficient; Diffuse axonal injury; Diffuse vascular injury; Glasgow Coma Scale	HEAD-INJURY; AXONAL INJURY; LESIONS	Susceptibility-weighted image (SWI) is one of the most sensitive methods for detect microbleeding and useful for evaluation of traumatic brain damage. The purpose of this study is to delineate the characteristics and importance of supratentorial deep white matter hemorrhages detected by SWI in cases of traumatic brain damage. Twenty-one consecutive cases with severe traumatic head injury were included in the current study. MRI examinations were made within 1 month after injury. We evaluated the degree and distribution of the supratentorial hemorrhages on SWI retrospectively. We classified the degree of bleeding into four grades: "small hemorrhage," "single bead-like hemorrhage," "convergent-type hemorrhage," and "massive hemorrhage." We then correlated the degree and distribution of the hemorrhage to clinical outcomes. We also evaluated the apparent diffusion coefficient (ADC) image of lobes with "convergent-type hemorrhage." Existence of "massive hemorrhage" correlated with a poor outcome, that is, worse than "severely disabled" on the Glasgow Outcome Scale. The number of lobes affected by "convergent-type hemorrhage" also correlated with poor outcome. There were 45 lobes with "convergent-type hemorrhage" and 27 of them showed increased diffusivity on ADC images. Supratentorial massive hemorrhages and supratentorial convergent-type multiple hemorrhages were associated with poor prognosis after traumatic brain injury. The increased diffusivity in lobes with convergent-type hemorrhages may indicate that congestion of the proximal medullary vein may play some role for these hemorrhages.	[Iwamura, Asami; Taoka, Toshiaki; Fukusumi, Akio; Sakamoto, Masahiko; Miyasaka, Toshiteru; Ochi, Tomoko; Akashi, Toshiaki; Kichikawa, Kimihiko] Nara Med Univ, Dept Radiol, Kashihara, Nara 6348522, Japan; [Iwamura, Asami; Okuchi, Kazuo] Nara Med Univ, Dept Emergency & Crit Care Med, Kashihara, Nara 6348522, Japan	Iwamura, A (corresponding author), Nara Med Univ, Dept Radiol, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	asami20050512@yahoo.co.jp	Taoka, Toshiaki/A-1637-2016	Taoka, Toshiaki/0000-0001-9227-0240			ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Akiyama Y, 2009, NEUROL MED-CHIR, V49, P97, DOI 10.2176/nmc.49.97; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Blumbergs P.C., 2008, GREENFIELDS NEUROPAT, P733; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Okudera T, 1999, NEUROPATHOLOGY, V19, P93, DOI 10.1046/j.1440-1789.1999.00215.x; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Pearl GS, 1998, CLIN LAB MED, V18, P39; Pittella JEH, 2003, J FORENSIC SCI, V48, P626; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Yuan Mei-Kang, 2005, J Chin Med Assoc, V68, P131	16	25	25	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	APR	2012	54	4					335	343		10.1007/s00234-011-0892-9			9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	912IQ	WOS:000301791000007	21611726				2021-06-18	
J	Laskowitz, DT; Lei, BL; Dawson, HN; Wang, HC; Bellows, ST; Christensen, DJ; Vitek, MP; James, ML				Laskowitz, Daniel T.; Lei, Beilei; Dawson, Hana N.; Wang, Haichen; Bellows, Steven T.; Christensen, Dale J.; Vitek, Michael P.; James, Michael L.			The apoE-mimetic Peptide, COG1410, Improves Functional Recovery in a Murine Model of Intracerebral Hemorrhage	NEUROCRITICAL CARE			English	Article						Intracerebral hemorrhage; Murine model; Apolipoprotein E; Therapeutic; Outcome	PROTEIN PHOSPHATASE 2A; SYSTEM INFLAMMATORY RESPONSE; TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E; SERINE/THREONINE PHOSPHATASE; KINASE PATHWAYS; MOUSE MODEL; ACTIVATION; RAT; EXCITOTOXICITY	Background Apolipoprotein E has previously been demonstrated to modulate acute brain injury responses, and administration of COG1410, an apoE-mimetic peptide derived from the receptor-binding region of apoE, improves outcome in preclinical models of acute neurological injury. In the current study, we sought to establish the optimal dose and timing of peptide administration associated with improved functional outcome in a murine model of intracerebral hemorrhage (ICH). Methods Ten to twelve-week-old C57/BL6 male mice were injured by collagenase-induced ICH and randomly selected to receive either vehicle or one of four doses of COG1410 (0.5, 1, 2, or 4 mg/kg) via tail vein injection at 30 min after injury and then daily for 5 days. The injured mice were euthanized at various time points to assess inflammatory mediators, cerebral edema, and hematoma volume. Over the first 5 days following injury, vestibulomotor function was tested via Rotorod (RR) latency. After an optimal dose was demonstrated, a final cohort of animals was injured with ICH and randomly assigned to receive the first dose of COG1410 or vehicle at increasingly longer treatment initiation times after injury. The mice were then assessed for functional deficit via RR testing over the first 5 days following injury. Results The mice receiving 2 mg/kg of COG1410 after injury demonstrated reduced functional deficit, decreased brain concentrations of inflammatory proteins, and less cerebral edema, although hematoma volume did not vary. The improved RR performance was maintained when peptide administration was delayed for up to 2 h after ICH. Conclusions COG1410 administered at a dose of 2 mg/kg within 2 h after injury improves functional recovery in a murine model of ICH.	[Laskowitz, Daniel T.; Lei, Beilei; James, Michael L.] Duke Univ, Multidisciplinary Neuroprotect Labs, Dept Anesthesiol, Durham, NC 27710 USA; [Laskowitz, Daniel T.; Dawson, Hana N.; Wang, Haichen; James, Michael L.] Duke Univ, Multidisciplinary Neuroprotect Labs, Dept Med Neurol, Durham, NC 27710 USA; [Laskowitz, Daniel T.] Duke Univ, Multidisciplinary Neuroprotect Labs, Dept Neurobiol, Durham, NC 27710 USA; [Christensen, Dale J.] Duke Univ, Dept Med Hematol, Durham, NC 27710 USA; [Christensen, Dale J.; Vitek, Michael P.] Cognosci Inc, Res Triangle Pk, NC USA	James, ML (corresponding author), Duke Univ, Multidisciplinary Neuroprotect Labs, Dept Anesthesiol, DUMC 3094, Durham, NC 27710 USA.	Daniel.laskowitz@duke.edu; beilei.lei@duke.edu; hana.dawson@duke.edu; haichen.wang@duke.edu; steven.bellows@gmail.com; dchristensen@cognosci.com; mvitek@cognosci.com; Michael.james@duke.edu	James, Michael L./AAJ-5592-2020; tao, li/G-7956-2011	James, Michael L./0000-0002-8715-5210; Vitek, Michael/0000-0001-8140-8048	American Heart AssociationAmerican Heart Association; Foundation of Anesthesia Education and Research;  [R43NS064651-01A1]	The authors would like to thank Jessica Oddo for technical assistance. This research was made possible through grants from R43NS064651-01A1 (DJC), the American Heart Association Scientist Development Grant (MLJ), and Foundation of Anesthesia Education and Research Mentored Research Training Grant (MLJ). COG1410 was provided by Cognosci, Inc. (Research Triangle Park, NC, USA).	Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Christensen DJ, 2011, J IMMUNOL, V186, P2535, DOI 10.4049/jimmunol.1002847; Colton CA, 2002, ANN NY ACAD SCI, V962, P212, DOI 10.1111/j.1749-6632.2002.tb04070.x; Dawson HN, 2010, NEUROSCIENCE, V169, P516, DOI 10.1016/j.neuroscience.2010.04.037; Dawson HN, 2007, J NEUROSCI, V27, P9155, DOI 10.1523/JNEUROSCI.5492-06.2007; Fujimoto S, 2007, NEUROSCIENCE, V144, P694, DOI 10.1016/j.neuroscience.2006.09.049; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; GARCIA JH, 1995, STROKE, V26, P636, DOI 10.1161/01.STR.26.4.636; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hoe HS, 2006, J BIOL CHEM, V281, P3425, DOI 10.1074/jbc.M509380200; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; James ML, 2010, J NEUROTRAUM, V27, P217, DOI 10.1089/neu.2009.1022; James ML, 2009, J STROKE CEREBROVASC, V18, P144, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.012; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; James ML, 2008, NEUROCRIT CARE, V9, P139, DOI 10.1007/s12028-007-9030-2; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Liu QH, 2004, AM J PHYSIOL-HEART C, V286, pH2204, DOI 10.1152/ajpheart.01050.2003; Lomnitski L, 1999, J NEUROSCI RES, V58, P586; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; MacLellan CL, 2010, STROKE, V41, pS95, DOI 10.1161/STROKEAHA.110.594457; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; Mendelow AD, 2005, LANCET, V365, P387; Mesis Rachel G, 2006, Neurosurg Focus, V21, pE4; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Ohnishi M, 2007, EXP NEUROL, V206, P43, DOI 10.1016/j.expneurol.2007.03.030; ROSENBERG GA, 1990, ACT NEUR S, V51, P280; Shanley TP, 2001, J IMMUNOL, V166, P966, DOI 10.4049/jimmunol.166.2.966; Singh K, 2008, J BIOL CHEM, V283, P16752, DOI 10.1074/jbc.M710530200; Singh K, 2011, J BIOL CHEM, V286, P3839, DOI 10.1074/jbc.M110.176719; Song EC, 2003, STROKE, V34, P2215, DOI 10.1161/01.STR.0000088060.83709.2C; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Tukhovskaya EA, 2009, J NEUROSCI RES, V87, P677, DOI 10.1002/jnr.21874; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wasserman JK, 2007, BRAIN RES, V1180, P140, DOI 10.1016/j.brainres.2007.08.058; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	52	25	31	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2012	16	2					316	326		10.1007/s12028-011-9641-5			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	949ZS	WOS:000304618500018	21989844				2021-06-18	
J	Tomaiuolo, F; Bivona, U; Lerch, JP; Di Paola, M; Carlesimo, GA; Ciurli, P; Matteis, M; Cecchetti, L; Forcina, A; Silvestro, D; Azicnuda, E; Sabatini, U; Di Giacomo, D; Caltagirone, C; Petrides, M; Formisano, R				Tomaiuolo, Francesco; Bivona, Umberto; Lerch, Jason P.; Di Paola, Margherita; Carlesimo, Giovanni A.; Ciurli, Paola; Matteis, Mariella; Cecchetti, Luca; Forcina, Antonio; Silvestro, Daniela; Azicnuda, Eva; Sabatini, Umberto; Di Giacomo, Dina; Caltagirone, Carlo; Petrides, Michael; Formisano, Rita			Memory and anatomical change in severe non missile traumatic brain injury: similar to 1 vs. similar to 8 years follow-up	BRAIN RESEARCH BULLETIN			English	Article						Craniocerebral trauma; nmTBI; CHI; Coma; Neuroanatomy; Memory	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; HIPPOCAMPAL ATROPHY; LESIONS; FORNIX; MRI; CONSEQUENCES; MORPHOLOGY; SURVIVORS; MATTER	In previous studies, we investigated a group of subjects who had suffered from a severe non missile traumatic brain injury (nmTBI) without macroscopic focal lesions and we found brain atrophy involving the hippocampus, fornix, corpus callosum, optic chiasm, and optic radiations. Memory test scores correlated mainly with fornix volumes [37,38]. In the present study, we re-examined 11 of these nmTBI subjects approximately 8 yr later. High-spatial resolution T1 weighted magnetic resonance images of the brain (1 mm(3)) and standardised memory tests were performed once more in order to compare brain morphology and memory performance originally assessed 3-13 months after head injury (first study) and after 8-10 yr (present study). An overall improvement of memory test performance was demonstrated in the latest assessment, indicating that cognitive recovery in severe nmTBI subjects had not been completed within 3-13 months post-injury. It is notable that the volumes of the fornix and the hippocampus were reduced significantly from normal controls, but these volumes do not differ appreciatively between nmTBI subjects at first (after 1 yr) and at second (after similar to 8yr) scans. On the contrary, a clear reduction in the volume of the corpus callosus can be observed after similar to 1 yr and a further significant reduction is evident after similar to 8yr, indicating that the neural degeneration in severe nmTBI continues long after the head trauma and relates to specific structures and not to the overall brain. (C) 2012 Elsevier Inc. All rights reserved.	[Tomaiuolo, Francesco] Auxilium Vitae Volterra, Unita Cerebroles Acquisite, I-56048 Volterra, PI, Italy; [Tomaiuolo, Francesco; Bivona, Umberto; Di Paola, Margherita; Carlesimo, Giovanni A.; Ciurli, Paola; Matteis, Mariella; Silvestro, Daniela; Azicnuda, Eva; Sabatini, Umberto; Caltagirone, Carlo; Formisano, Rita] IRCCS Fdn Santa Lucia, Rome, Italy; [Tomaiuolo, Francesco; Di Paola, Margherita; Di Giacomo, Dina] Univ Aquila, Dept Internal Med & Publ Hlth, I-67100 Laquila, Italy; [Lerch, Jason P.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Forcina, Antonio] Univ Cassino, Dept Ind Engn, Cassino, Italy; [Carlesimo, Giovanni A.; Caltagirone, Carlo] Univ Rome, Clin Neurol, Tor Vergata, Italy; [Petrides, Michael] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada	Tomaiuolo, F (corresponding author), Auxilium Vitae Volterra, Unita Cerebroles Acquisite, Borgo San Lazzero 5, I-56048 Volterra, PI, Italy.	f.tomaiuolo@riabilitazione-volterra.it	Tomaiuolo, Francesco/AAC-1534-2019; Di Paola, Margherita/A-8480-2010; Cecchetti, Luca/K-7060-2016; Azicnuda, Eva/K-9010-2016; Sabatini, Umberto/K-4659-2016; Di Giacomo, Dina/K-1983-2016; Caltagirone, Carlo/B-4930-2013	Cecchetti, Luca/0000-0001-5184-6477; Sabatini, Umberto/0000-0001-5321-8626; Di Giacomo, Dina/0000-0001-8189-2052; Tomaiuolo, Fancesco/0000-0003-1230-2770			Adams J.H., 1990, HDB CLIN NEUROLOGY, V13, P43; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Adams JH, 1994, INTRO NEUROPATHOLOGY; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Azouvi P., 1993, ANN READAPTATION MED, V36, P1; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Capitani E., 1987, J NEUROL SCI S8, P14; Carlesimo G.A., 2002, NUOVA RIV NEUROLOGIA, V12, P1, DOI DOI 10.1080/17408989.2016.1268591; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; Rey A., 1968, REATTIVO FIGURA COMP; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wilson JTL, 1990, NEUROPSYCHOLOGY, V4, P261, DOI 10.1037/0894-4105.4.4.261; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328	36	25	25	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	MAR 10	2012	87	4-5					373	382		10.1016/j.brainresbull.2012.01.008			10	Neurosciences	Neurosciences & Neurology	922YS	WOS:000302585500002	22289841				2021-06-18	
J	Duhaime, AC; Holshouser, B; Hunter, JV; Tong, K				Duhaime, Ann-Christine; Holshouser, Barbara; Hunter, Jill V.; Tong, Karen			Common Data Elements for Neuroimaging of Traumatic Brain Injury: Pediatric Considerations	JOURNAL OF NEUROTRAUMA			English	Article						CT; common data elements; MRI; pediatrics; traumatic brain injury	CLOSED HEAD-INJURY; THERAPEUTIC PROCEDURES; WHITE-MATTER; MATURATION; CHILDREN; CT; ADOLESCENCE; GUIDELINES; MANAGEMENT; CHILDHOOD	As part of the Traumatic Brain Injury Common Data Elements project, a large-scale effort to define common data elements across a variety of domains, including neuroimaging, special considerations for pediatric patients were introduced. This article is an extension of that initial work, in which pediatric-specific pathoanatomical entities, technical considerations, interpretation paradigms, and safety considerations were reviewed. The goal of this review was to outline differences and specific information relevant to optimal performance and proper interpretation of neuroimaging in pediatric patients with traumatic brain injury. The long-range goal of this project is to facilitate data sharing as well as to provide critical infrastructure for potential clinical trials in this major public health area.	[Duhaime, Ann-Christine] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Holshouser, Barbara] Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA USA; [Hunter, Jill V.] Texas Childrens Hosp, Baylor Coll Med, Dept Neuroradiol, Houston, TX 77030 USA; [Tong, Karen] Loma Linda Univ, Med Ctr, Loma Linda, CA USA	Duhaime, AC (corresponding author), Massachusetts Gen Hosp, 15 Parkman St,Wang 331, Boston, MA 02114 USA.	aduhaime@partners.org			National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR)	We gratefully acknowledge the valuable contributions of Ramona Hicks for providing the impetus as well as the organization and format for this project and for assistance with manuscript preparation. This project was jointly supported by the National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS) and the United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR).	ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Amis E Stephen Jr, 2007, J Am Coll Radiol, V4, P272, DOI 10.1016/j.jacr.2007.03.002; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bryan YF, 2006, ANESTH ANALG, V102, P1674, DOI 10.1213/01.ane.0000216292.82271.bc; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Girard N, 2007, J NEURORADIOLOGY, V34, P290, DOI 10.1016/j.neurad.2007.07.007; Glenn OA, 2006, AM J NEURORADIOL, V27, P1604; Gorman R, 2002, PEDIATRICS, V110, P836; Goske MJ, 2010, SEMIN ULTRASOUND CT, V31, P57, DOI 10.1053/j.sult.2009.09.007; Hicks R., 2011, J NEUROTRAU IN PRESS; Kanal E, 2007, AM J ROENTGENOL, V188, P1447, DOI 10.2214/AJR.06.1616; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; Miller JH, 2003, AM J ROENTGENOL, V180, P851, DOI 10.2214/ajr.180.3.1800851; Mukherjee P, 2006, NEUROIMAG CLIN N AM, V16, P19, DOI 10.1016/j.nic.2005.11.004; Mukherjee P, 2001, RADIOLOGY, V221, P349, DOI 10.1148/radiol.2212001702; Mukherjee P, 2002, AM J NEURORADIOL, V23, P1445; Nievelstein RAJ, 2010, PEDIATR RADIOL, V40, P1324, DOI 10.1007/s00247-010-1714-7; Penzkofer AK, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.2.1790509; Radiologic Society of North America, 2010, SPIK MR IM ACC UND N; Schneider JFL, 2004, NEURORADIOLOGY, V46, P258, DOI 10.1007/s00234-003-1154-2; Strauss KJ, 2010, AM J ROENTGENOL, V194, P868, DOI 10.2214/AJR.09.4091; Strauss KJ, 2009, AM J ROENTGENOL, V192, P1169, DOI 10.2214/AJR.08.2172; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034	27	25	25	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	4					629	633		10.1089/neu.2011.1927			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	901SQ	WOS:000300987500002	21671798	Green Published			2021-06-18	
J	Gerring, JP; Wade, S				Gerring, Joan P.; Wade, Shari			The Essential Role of Psychosocial Risk and Protective Factors in Pediatric Traumatic Brain Injury Research	JOURNAL OF NEUROTRAUMA			English	Article						additive model; moderation model; psychosocial protective factors; psychosocial risk factors; TBI research	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; BEHAVIOR PROBLEMS; SHORT-TERM; PSYCHIATRIC-DISORDER; YOUNG-CHILDREN; HEAD-INJURIES; OUTCOMES; ADOLESCENTS; PREDICTORS; COMPETENCE	This article builds upon Traumatic Brain Injury Common Data Elements (TBI CDE) version 1.0 and the pediatric CDE Initiative by emphasizing the essential role of psychosocial risk and protective factors in pediatric TBI research. The goals are to provide a compelling rationale for including psychosocial risk and protective factors in addition to socioeconomic status (SES), age, and sex in the study design and analyses of pediatric TBI research and to describe recommendations for core common data elements in this domain. Risk and protective factor research is based on the ecological theory of child development in which children develop through a series of interactions with their immediate and more distant environments. Home, school, religious, and social influences are conceptualized as risk and/or protective factors. Child development and TBI researchers have interpreted risk and protective variables as main effects or as interactions and have used cumulative risk indices and moderation models to describe the relationship among these variables and outcomes that have to do with development and with recovery from TBI. It is likely that the number, type, and interaction among risk and protective factors each contribute unique variance to study outcomes. Longitudinal designs in TBI research will be essential to understanding the reciprocal relationships between risk/protective factors and the recovery/outcome made by the child. The search for effective interventions to hasten TBI recovery mandates the need to target modifiable risks and to promote protective factors in the child's environment.	[Gerring, Joan P.] Johns Hopkins Univ, Sch Med, Kennedy Krieger Res Inst, Dept Psychiat & Pediat, Baltimore, MD USA; [Wade, Shari] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Wade, Shari] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA	Gerring, JP (corresponding author), Johns Hopkins Bayview Med Ctr, Dept Psychiat, 4840 Eastern Ave D2 E, Baltimore, MD 21224 USA.	jgerring@jhmi.edu			National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR) including NIDRR Rehabilitation Research and Training Center [H133B090010]	This project was jointly supported by the National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS) and the United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR) including NIDRR Rehabilitation Research and Training Center grant H133B090010.	Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; BOYLE MH, 1987, ARCH GEN PSYCHIAT, V44, P826; Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Byrne B. M, 2001, STRUCTURAL EQUATION; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Copeland-Linder N, 2010, J CLIN CHILD ADOLESC, V39, P176, DOI 10.1080/15374410903532601; GARMEZY N, 1984, CHILD DEV, V55, P97, DOI 10.1111/j.1467-8624.1984.tb00276.x; Gerrard-Morris A., 2009, J INT NEUROPSYCH SOC, V16, P1; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Grados MA, 2008, DEPRESS ANXIETY, V25, P398, DOI 10.1002/da.20398; Green JG, 2010, ARCH GEN PSYCHIAT, V67, P113, DOI 10.1001/archgenpsychiatry.2009.186; Halle T., 2009, DISPARITIES EARLY LE; Kessler RC, 1997, PSYCHOL MED, V27, P1101, DOI 10.1017/S0033291797005588; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037/0003-066X.56.3.227; MASTEN AS, 1988, J CHILD PSYCHOL PSYC, V29, P745, DOI 10.1111/j.1469-7610.1988.tb00751.x; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; McCauley S.R., 2011, J NEUROTRAUMA; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; PRINZ RJ, 1979, J APPL BEHAV ANAL, V12, P691, DOI 10.1901/jaba.1979.12-691; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; RUTTER M, 1987, AM J ORTHOPSYCHIAT, V57, P316, DOI 10.1111/j.1939-0025.1987.tb03541.x; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stouthamer-Loeber M, 2002, J CONSULT CLIN PSYCH, V70, P111, DOI 10.1037//0022-006X.70.1.111; SZATMARI P, 1994, INT J METHOD PSYCH, V4, P231; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2009, J HEAD TRAUMA REHAB, V24, P239, DOI 10.1097/HTR.0b013e3181ad6680; Wallander JL, 1998, J CHILD PSYCHOL PSYC, V39, P29, DOI 10.1111/1469-7610.00302; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	49	25	25	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	4					621	628		10.1089/neu.2011.2234			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	901SQ	WOS:000300987500001	22091875	Green Published			2021-06-18	
J	Lusardi, TA; Lytle, NK; Szybala, C; Boison, D				Lusardi, Theresa A.; Lytle, Nikki K.; Szybala, Cory; Boison, Detlev			Caffeine prevents acute mortality after TBI in rats without increased morbidity	EXPERIMENTAL NEUROLOGY			English	Article						FPI; Caffeine; Traumatic brain injury; Apnea; EEG; Neuroprotection	TRAUMATIC BRAIN-INJURY; SUDDEN UNEXPECTED DEATH; FLUID PERCUSSION INJURY; ADENOSINE KINASE; POSTTRAUMATIC EPILEPSY; HEAD-INJURY; RECEPTORS; EPILEPTOGENESIS; OVEREXPRESSION; MODEL	Severe traumatic brain injury (TBI) is associated with a high incidence of acute mortality followed by chronic alteration of homeostatic network activity that includes the emergence of posttraumatic seizures. We hypothesized that acute and chronic outcome after severe TBI critically depends on disrupted bioenergetic network homeostasis, which is governed by the availability of the brain's endogenous neuroprotectant adenosine. We used a rat lateral fluid percussion injury (FPI) model of severe TBI with an acute mortality rate of 46.7%. A subset of rats was treated with 25 mg/kg caffeine intraperitoneally within 1 min of the injury. We assessed neuromotor function at 24 h and 4 weeks, and video-EEG activity and histology at 4 weeks following injury. We first demonstrate that acute mortality is related to prolonged apnea and that a single acute injection of the adenosine receptor antagonist caffeine can completely prevent TBI-induced mortality when given immediately following the TBI. Second, we demonstrate that neuromotor function is not affected by caffeine treatment at either 24 h or 4 weeks following injury. Third, we demonstrate development of epileptiform EEG bursts as early as 4 weeks post-injury that are significantly reduced in duration in the rats that received caffeine. Our data demonstrate that acute treatment with caffeine can prevent lethal apnea following fluid percussion injury, with no negative influence on motor function or histological outcome. Further, we show epileptiform bursting is reduced after caffeine treatment, suggesting a potential role in the modulation of epilepsy development after severe injury. (C) 2011 Elsevier Inc. All rights reserved.	[Lusardi, Theresa A.; Lytle, Nikki K.; Szybala, Cory; Boison, Detlev] Legacy Res Inst, Robert Stone Dow Neurobiol Labs, Portland, OR 97232 USA	Boison, D (corresponding author), 1225 NE 2nd Ave, Portland, OR 97232 USA.	DBoison@DowNeurobiology.org	Boison, Detlev/ABE-6302-2020	Lusardi, Theresa/0000-0003-0699-5662; Boison, Detlev/0000-0002-7740-5781	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS057475, NS061844]; CURE Foundation; USAMRMCU.S. Army Medical Research & Materiel Command (USAMRMC) [05154001]; Telemedicine & Advanced Technology Research Center (TATRC) [W81XWH-10-1-0757]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS057475, R01NS061844] Funding Source: NIH RePORTER	We thank Dr. Asia Pitkanen and her laboratory for their generous assistance in establishing the FPI model in our lab. This research and development project/program was conducted by the RS Dow Neurobiology Labs, and is made possible by grants from the National Institute of Neurological Disorders and Stroke (NS057475 and NS061844), the CURE Foundation in collaboration with the USAMRMC (05154001), and a cooperative agreement that was awarded and administered by the U.S. Army Medical Research & Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC), under Contract Number: W81XWH-10-1-0757. The TATRC Contracting Officer's Representative (COR) is Dr. Brenda Bart-Knauer (Brenda.Bart-Knauer@TATRC.ORG) and the TATRC Project Officer is Cheryll Quinn (Cheryll.Quirin@TATRC.ORG). The views, opinions and findings contained in this research are those of the company and do not necessarily reflect the views of the Department of Defense and should not be construed as an official DOD/Army policy unless so designated by other documentation. No official endorsement should be made. We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. None of the authors has any conflicts of interest to disclose.	Al Moutaery K, 2003, NEUROSURGERY, V53, P704, DOI 10.1227/01.NEU.0000079487.66013.6F; Barone JJ, 1996, FOOD CHEM TOXICOL, V34, P119, DOI 10.1016/0278-6915(95)00093-3; BARRACO RA, 1990, BRAIN RES, V507, P234, DOI 10.1016/0006-8993(90)90277-I; Basheer R, 2004, PROG NEUROBIOL, V73, P379, DOI 10.1016/j.pneurobio.2004.06.004; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Boison D, 2002, P NATL ACAD SCI USA, V99, P6985, DOI 10.1073/pnas.092642899; Boison D, 2010, HDB EXP PHARM, V200, P251; Boison D, 2008, PROG NEUROBIOL, V84, P249, DOI 10.1016/j.pneurobio.2007.12.002; Boison D, 2008, CURR OPIN PHARMACOL, V8, P2, DOI 10.1016/j.coph.2007.09.002; Boison D, 2011, EXPERT OPIN DRUG DIS, V6, P713, DOI 10.1517/17460441.2011.575777; BONATI M, 1985, DRUG METAB REV, V15, P1355, DOI 10.3109/03602538409029964; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; Cotter G, 2008, J CARD FAIL, V14, P631, DOI 10.1016/j.cardfail.2008.08.010; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; DRAGUNOW M, 1986, NEUROSCI BIOBEHAV R, V10, P229, DOI 10.1016/0149-7634(86)90010-2; DRAGUNOW M, 1988, TRENDS PHARMACOL SCI, V9, P193, DOI 10.1016/0165-6147(88)90079-X; DUNWIDDIE TV, 1980, EPILEPSIA, V21, P541, DOI 10.1111/j.1528-1157.1980.tb04305.x; DURING MJ, 1992, ANN NEUROL, V32, P618, DOI 10.1002/ana.410320504; Elmenhorst D, 2009, BRAIN RES, V1258, P53, DOI 10.1016/j.brainres.2008.12.056; Fedele DE, 2006, EXP NEUROL, V200, P184, DOI 10.1016/j.expneurol.2006.02.133; Fredholm BB, 2005, INT REV NEUROBIOL, V63, P191, DOI 10.1016/S0074-7742(05)63007-3; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; Fredholm BB, 1999, PHARMACOL REV, V51, P83; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Golarai G, 2001, J NEUROSCI, V21, P8523; Gouder N, 2004, J NEUROSCI, V24, P692, DOI 10.1523/JNEUROSCI.4781-03.2004; Hasko G, 2005, TRENDS PHARMACOL SCI, V26, P511, DOI 10.1016/j.tips.2005.08.004; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Hirsch LJ, 2010, ANN NEUROL, V68, P773, DOI 10.1002/ana.22242; Jacobson KA, 1996, TRENDS PHARMACOL SCI, V17, P108, DOI 10.1016/0165-6147(96)10002-X; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; McCarley RW, 2007, SLEEP MED, V8, P302, DOI 10.1016/j.sleep.2007.03.005; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nantwi KD, 2009, RESP PHYSIOL NEUROBI, V169, P102, DOI 10.1016/j.resp.2009.07.014; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Pignataro G, 2008, J CEREBR BLOOD F MET, V28, P17, DOI 10.1038/sj.jcbfm.9600499; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Ribeiro JA, 2005, CNS NEUROL DISORD-DR, V4, P325, DOI 10.2174/1568007054546090; Ribeiro JA, 2003, DRUG NEWS PERSPECT, V16, P80, DOI 10.1358/dnp.2003.16.2.740246; ROTH T., 2000, PRINCIPLES NEURAL SC, P948; RUNOLD M, 1989, J APPL PHYSIOL, V67, P541; Sachse KT, 2008, J CEREBR BLOOD F MET, V28, P395, DOI 10.1038/sj.jcbfm.9600539; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schmidt B, 2007, NEW ENGL J MED, V357, P1893, DOI 10.1056/NEJMoa073679; Shen HY, 2010, EPILEPSIA, V51, P465, DOI 10.1111/j.1528-1167.2009.02248.x; Stewart TH, 2010, J NEUROPHYSIOL, V104, P3345, DOI 10.1152/jn.00398.2010; Svenningsson P, 1999, J NEUROSCI, V19, P4011; TSENG CJ, 1988, HYPERTENSION, V11, P191, DOI 10.1161/01.HYP.11.2.191; Weber JT, 2002, J NEUROTRAUM, V19, P1433, DOI 10.1089/089771502320914660; Yee BK, 2007, EUR J NEUROSCI, V26, P3237, DOI 10.1111/j.1460-9568.2007.05897.x	57	25	29	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2012	234	1					161	168		10.1016/j.expneurol.2011.12.026			8	Neurosciences	Neurosciences & Neurology	910DN	WOS:000301617500018	22226594	Green Accepted			2021-06-18	
J	Foreman, B; Hirsch, LJ				Foreman, Brandon; Hirsch, Lawrence J.			Epilepsy Emergencies: Diagnosis and Management	NEUROLOGIC CLINICS			English	Article						Epilepsy; Seizures; Status epilepticus; Coma; Intensive care unit; Nonconvulsive seizures; Critical care	REFRACTORY STATUS EPILEPTICUS; NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; CONVULSIVE STATUS EPILEPTICUS; ADD-ON TREATMENT; ACUTE SYMPTOMATIC SEIZURE; INTENSIVE-CARE-UNIT; CRITICALLY-ILL; CONTINUOUS EEG; INTRAVENOUS LEVETIRACETAM	Seizures and status epilepticus are epilepsy emergencies with high morbidity and mortality. Early treatment is crucial, and the identification of an underlying etiology informs both continued treatment and prognosis. Many patients have underdiagnosed nonconvulsive seizures or nonconvulsive status epilepticus, particularly the comatose or critically ill. Timely EEG can be useful for diagnosis, management, optimizing treatment response, and determining prognosis in these patients. Refractory conditions can be quite complicated with limited evidence-based guidance, but treatment should not be restricted by nihilism even in the most prolonged cases, especially if there is not widespread irreversible brain injury.	[Hirsch, Lawrence J.] Yale Univ, Sch Med, Div Epilepsy & EEG, New Haven, CT 06520 USA; [Foreman, Brandon] Columbia Univ, Med Ctr, Neurol Inst New York, Comprehens Epilepsy Ctr, New York, NY 10032 USA	Hirsch, LJ (corresponding author), Yale Univ, Sch Med, Div Epilepsy & EEG, POB 208018, New Haven, CT 06520 USA.	Lawrence.Hirsch@yale.edu		Foreman, Brandon/0000-0002-5418-674X; Hirsch, Lawrence/0000-0002-6333-832X	UCB-PharmaUCB Pharma SA; LundbeckLundbeck Corporation; GlaxoSmithKlineGlaxoSmithKline; Upsher-Smith; PfizerPfizer; EisaiEisai Co Ltd	Dr Hirsch has received lecture fees from UCB-Pharma, Lundbeck, and GlaxoSmithKline; consulting fees from Lundbeck and Upsher-Smith; research funding from Lundbeck, Pfizer, Upsher-Smith, Eisai, and UCB-Pharma; and receives royalties from authoring chapters in UpToDate: Neurology as well as from coauthoring Atlas of EEG in Critical Care (Wiley, 2010). There are no disclosures related to stock ownership or options, or expert testimony. Dr Foreman has nothing to disclose.	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abou Khaled KJ, 2008, NEUROL CLIN, V26, P385, DOI 10.1016/j.ncl.2008.03.017; Agarwal P, 2007, SEIZURE-EUR J EPILEP, V16, P527, DOI 10.1016/j.seizure.2007.04.012; Aiguabella M, 2011, SEIZURE-EUR J EPILEP, V20, P60, DOI 10.1016/j.seizure.2010.10.009; Alldredge BK, 2001, NEW ENGL J MED, V345, P631, DOI 10.1056/NEJMoa002141; AMINOFF MJ, 1980, AM J MED, V69, P657, DOI 10.1016/0002-9343(80)90415-5; ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; Arif H, 2008, SEMIN NEUROL, V28, P342, DOI 10.1055/s-2008-1079339; BAUER LA, 1982, NEUROLOGY, V32, P570, DOI 10.1212/WNL.32.5.570; Beach RL, 2008, INT REV NEUROBIOL, V83, P259, DOI 10.1016/S0074-7742(08)00015-9; Berning S, 2009, J NEUROL, V256, P1634, DOI 10.1007/s00415-009-5166-7; Bleck TP, 2010, EPILEPSY CURR, V10, P31, DOI 10.1111/j.1535-7511.2009.01345.x; BOGGS JG, 1993, EPILEPSY RES, V14, P87, DOI 10.1016/0920-1211(93)90077-K; Borris DJ, 2000, EPILEPSY RES, V42, P117, DOI 10.1016/S0920-1211(00)00175-3; Brenner RP, 2002, EPILEPSIA, V43, P103, DOI 10.1046/j.1528-1157.43.s.3.9.x; Burneo JG, 2001, EPILEPSIA, V42, P1156, DOI 10.1046/j.1528-1157.2001.12901.x; Camilo O, 2004, STROKE, V35, P1769, DOI 10.1161/01.STR.0000130989.17100.96; Chen JWY, 2006, LANCET NEUROL, V5, P246, DOI 10.1016/S1474-4422(06)70374-X; Chin RFM, 2004, EUR J NEUROL, V11, P800, DOI 10.1111/j.1468-1331.2004.00943.x; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Chu K, 2008, EPILEPSIA, V49, P1723, DOI 10.1111/j.1528-1167.2008.01644.x; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2003, J NEUROL SCI, V211, P37, DOI 10.1016/S0022-510X(03)00036-4; Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x; Claassen J, 2001, NEUROLOGY, V57, P1036, DOI 10.1212/WNL.57.6.1036; Claassen J, 2002, NEUROLOGY, V58, P139, DOI 10.1212/WNL.58.1.139; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen J, 2011, ATLAS VIDEO EEG MONI, P473; Cooper AD, 2009, ARCH NEUROL-CHICAGO, V66, P1505, DOI 10.1001/archneurol.2009.273; Corry JJ, 2008, NEUROCRIT CARE, V9, P189, DOI 10.1007/s12028-008-9092-9; Costello Daniel J, 2007, J Intensive Care Med, V22, P319, DOI 10.1177/0885066607307506; Costello DJ, 2006, ARCH NEUROL-CHICAGO, V63, P895, DOI 10.1001/archneur.63.6.895; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; Delanty N, 2001, SEIZURE-EUR J EPILEP, V10, P116, DOI 10.1053/seiz.2000.0482; DeLorenzo RJ, 1999, EPILEPSIA, V40, P164, DOI 10.1111/j.1528-1157.1999.tb02070.x; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; DeLorenzo RJ, 1996, NEUROLOGY, V46, P1029, DOI 10.1212/WNL.46.4.1029; Dennis LJ, 2002, NEUROSURGERY, V51, P1136, DOI 10.1097/00006123-200211000-00006; DeToledo JC, 2000, DRUG SAFETY, V22, P459, DOI 10.2165/00002018-200022060-00004; DODSON WE, 1993, JAMA-J AM MED ASSOC, V270, P854; Drislane FW, 2008, J CLIN NEUROPHYSIOL, V25, P181, DOI 10.1097/WNP.0b013e31817be70e; Drislane FW, 2009, EPILEPSIA, V50, P1566, DOI 10.1111/j.1528-1167.2008.01993.x; Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x; Eue S, 2009, EPILEPSY BEHAV, V15, P467, DOI 10.1016/j.yebeh.2009.05.020; Fattouch J, 2010, ACTA NEUROL SCAND, V121, P418, DOI 10.1111/j.1600-0404.2010.01351.x; Fisher A, 2004, EPILEPSIA, V45, P1300, DOI 10.1111/j.0013-9580.2004.26404.x; Fisher R, 2010, EPILEPSIA, V51, P899, DOI 10.1111/j.1528-1167.2010.02536.x; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Foreman B, 2011, CONTROLLED STUDY 202; Fountain NB, 2001, J CLIN NEUROPHYSIOL, V18, P345, DOI 10.1097/00004691-200107000-00006; FOUNTAIN NB, 1995, J CLIN NEUROPHYSIOL, V12, P326; Fountain NB, 2000, EPILEPSIA, V41, pS23, DOI 10.1111/j.1528-1157.2000.tb01521.x; Fugate JE, 2010, ANESTH ANALG, V111, P1520, DOI 10.1213/ANE.0b013e3181f6da34; Gouveia TLF, 2011, EPILEPSY BEHAV, V20, P1, DOI 10.1016/j.yebeh.2010.10.001; Gastaut H, 1983, Adv Neurol, V34, P15; Greenaway C, 2011, EPILEPSIA, V52, P258, DOI 10.1111/j.1528-1167.2010.02751.x; Hamani C, 2008, EPILEPSY RES, V78, P117, DOI 10.1016/j.eplepsyres.2007.09.010; Hamer HM, 2000, NEUROLOGY, V54, P230, DOI 10.1212/WNL.54.1.230; Hauser WA, 2008, EPILEPSIA, V49, P8, DOI 10.1111/j.1528-1167.2008.01443.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Hesdorffer DC, 2009, EPILEPSIA, V50, P1102, DOI 10.1111/j.1528-1167.2008.01945.x; Hesdorffer DC, 1998, ANN NEUROL, V44, P908, DOI 10.1002/ana.410440609; Hesdorffer DC, 1998, NEUROLOGY, V50, P735, DOI 10.1212/WNL.50.3.735; Hirsch Lawrence J, 2002, Curr Neurol Neurosci Rep, V2, P345, DOI 10.1007/s11910-002-0010-9; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Holtkamp M, 2005, ARCH NEUROL-CHICAGO, V62, P1428, DOI 10.1001/archneur.62.9.1428; Holtkamp M, 2005, J NEUROL NEUROSUR PS, V76, P534, DOI 10.1136/jnnp.2004.041947; Jaitly R, 1997, J CLIN NEUROPHYSIOL, V14, P326, DOI 10.1097/00004691-199707000-00005; Jambroszyk M, 2011, EPILEPSIA, V52, P284, DOI 10.1111/j.1528-1167.2010.02886.x; Jenssen S, 2006, EPILEPSIA, V47, P1499, DOI 10.1111/j.1528-1167.2006.00622.x; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jordan KG, 2006, EPILEPSIA, V47, P41, DOI 10.1111/j.1528-1167.2006.00659.x; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Kamel H, 2010, NEUROCRIT CARE, V12, P204, DOI 10.1007/s12028-009-9288-7; Kapur J, 2000, EPILEPSIA, V41, pS86, DOI 10.1111/j.1528-1157.2000.tb01563.x; Kellinghaus C, 2011, ACTA NEUROL SCAND, V123, P137, DOI 10.1111/j.1600-0404.2010.01423.x; Kilbride RD, 2009, ARCH NEUROL-CHICAGO, V66, P723, DOI 10.1001/archneurol.2009.100; Knake S, 2008, J NEUROL NEUROSUR PS, V79, P588, DOI 10.1136/jnnp.2007.130260; Koubeissi MZ, 2011, ACTA NEUROL SCAND, V123, P142, DOI 10.1111/j.1600-0404.2010.01430.x; Koubeissi M, 2007, NEUROLOGY, V69, P886, DOI 10.1212/01.wnl.0000269791.96189.70; Krishnamurthy KB, 1996, EPILEPSIA, V37, P863, DOI 10.1111/j.1528-1157.1996.tb00039.x; Krsek P, 2004, EPILEPSY BEHAV, V5, P180, DOI 10.1016/j.yebeh.2003.11.032; Legriel S, 2008, NEUROCRIT CARE, V9, P118, DOI 10.1007/s12028-008-9107-6; LEPPIK IE, 1983, JAMA-J AM MED ASSOC, V249, P1452, DOI 10.1001/jama.249.11.1452; Lhatoo SD, 2007, EPILEPSIA, V48, P61, DOI 10.1111/j.1528-1167.2007.01353.x; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; Loescher W, 2007, EPILEPSIA, V48, P74, DOI 10.1111/j.1528-1167.2007.01357.x; Logroscino G, 1997, EPILEPSIA, V38, P1344, DOI 10.1111/j.1528-1157.1997.tb00073.x; Lowenstein DH, 1999, EPILEPSIA, V40, P120, DOI 10.1111/j.1528-1157.1999.tb02000.x; LOWENSTEIN DH, 1993, NEUROLOGY, V43, P483, DOI 10.1212/WNL.43.3_Part_1.483; Ma XP, 2001, EPILEPSY RES, V46, P33, DOI 10.1016/S0920-1211(01)00252-2; Manno EM, 2005, ANN NEUROL, V58, P954, DOI 10.1002/ana.20677; Martin BS, 2008, EPILEPSIA, V49, P248, DOI 10.1111/j.1528-1167.2007.01384.x; Martindale JL, 2011, EMERG MED CLIN N AM, V29, P15, DOI 10.1016/j.emc.2010.08.002; Mayer SA, 2002, ARCH NEUROL-CHICAGO, V59, P205, DOI 10.1001/archneur.59.2.205; Mazarati AM, 1998, BRAIN RES, V814, P179, DOI 10.1016/S0006-8993(98)01080-4; McIntyre J, 2005, LANCET, V366, P205, DOI 10.1016/S0140-6736(05)66909-7; Meador K, 2008, EPILEPSY RES, V81, P1, DOI 10.1016/j.eplepsyres.2008.04.022; Meierkord H, 2010, EUR J NEUROL, V17, P348, DOI 10.1111/j.1468-1331.2009.02917.x; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V29, P82, DOI 10.1001/archneur.1973.00490260026003; Miranda M, 2010, EPILEPSY BEHAV, V19, P539, DOI 10.1016/j.yebeh.2010.07.025; Mirsattari SM, 2004, ARCH NEUROL-CHICAGO, V61, P1254, DOI 10.1001/archneur.61.8.1254; Misra UK, 2006, NEUROLOGY, V67, P340, DOI 10.1212/01.wnl.0000224880.35053.26; Muayqil T, 2007, EPILEPTIC DISORD, V9, P43; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Nei M, 1999, EPILEPSIA, V40, P157, DOI 10.1111/j.1528-1157.1999.tb02069.x; Nocero M, 2011, NEUROLOGY S, V76, pA1; Novy J, 2010, EPILEPSIA, V51, P2207, DOI 10.1111/j.1528-1167.2010.02646.x; Novy J, 2010, EPILEPSIA, V51, P251, DOI 10.1111/j.1528-1167.2009.02323.x; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Ono S, 1997, INTERNAL MED, V36, P59, DOI 10.2169/internalmedicine.36.59; Orta DS, 2009, ARCH NEUROL-CHICAGO, V66, P985, DOI 10.1001/archneurol.2009.137; Pallin DJ, 2008, INT J EMERG MED, V1, P97, DOI 10.1007/s12245-008-0024-4; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; PASCUAL J, 1992, J NEUROL NEUROSUR PS, V55, P49, DOI 10.1136/jnnp.55.1.49; Pellock JM, 2004, EPILEPSY BEHAV, V5, P192, DOI 10.1016/j.yebeh.2003.12.012; Penberthy LT, 2005, SEIZURE-EUR J EPILEP, V14, P46, DOI 10.1016/j.seizure.2004.06.001; Prasad K, 2005, COCHRANE DB SYST REV, V4; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Robakis TK, 2006, NEUROCRIT CARE, V4, P35, DOI 10.1385/NCC:4:1:035; Rossetti AO, 2011, NEUROCRIT CARE, V14, P4, DOI 10.1007/s12028-010-9445-z; Rossetti AO, 2005, ARCH NEUROL-CHICAGO, V62, P1698, DOI 10.1001/archneur.62.11.1698; Rossetti AO, 2004, EPILEPSIA, V45, P757, DOI 10.1111/j.0013-9580.2004.01904.x; Sander JW, 2003, ACTA NEUROL SCAND, V108, P16, DOI 10.1034/j.1600-0404.108.s180.3.x; Schmitt FC, 2006, NEUROBIOL DIS, V23, P689, DOI 10.1016/j.nbd.2006.05.008; Schmitt FC, 2010, EPILEPSY BEHAV, V17, P565, DOI 10.1016/j.yebeh.2010.01.166; Seow SC, 2008, EUR J NEUROL, V15, pE46, DOI 10.1111/j.1468-1331.2008.02125.x; Shneker BF, 2003, NEUROLOGY, V61, P1066, DOI 10.1212/01.WNL.0000082653.40257.0B; Silbergleit R, 2000, DOUBLE BLIND RANDOMI; Sinha S, 2000, NEUROLOGY, V55, P722, DOI 10.1212/WNL.55.5.722; Sisodiya SM, 2003, EPILEPSIA, V44, P261, DOI 10.1046/j.1528-1157.2003.42802.x; THEODORE WH, 1994, NEUROLOGY, V44, P1403, DOI 10.1212/WNL.44.8.1403; Tomson T, 2006, NEUROLOGY, V66, P354; Towne AR, 2003, NEUROLOGY, V60, P332, DOI 10.1212/01.WNL.0000042783.86439.27; TOWNE AR, 1994, EPILEPSIA, V35, P27, DOI 10.1111/j.1528-1157.1994.tb02908.x; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Ubogu EE, 2003, EPILEPSY BEHAV, V4, P70, DOI 10.1016/S1525-5050(02)00643-1; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Vignatelli L, 2008, J NEUROL, V255, P197, DOI 10.1007/s00415-008-0635-y; Visser NA, 2011, J NEUROL, V258, P218, DOI 10.1007/s00415-010-5721-2; Walker LA, 1997, ACAD EMERG MED, V4, P918; Walker M, 2005, EPILEPTIC DISORD, V7, P253; Wasterlain CG, 2002, EPILEPSIA, V43, P20, DOI 10.1046/j.1528-1157.43.s.5.1.x; Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5; Waterhouse EJ, 1999, EPILEPSIA, V40, P752, DOI 10.1111/j.1528-1157.1999.tb00774.x; Wijdicks EFM, 1996, NEUROLOGY, V47, P1523, DOI 10.1212/WNL.47.6.1523; Williams AJ, 2004, J PHARMACOL EXP THER, V311, P220, DOI 10.1124/jpet.104.069146; Willmore LJ, 1998, NEUROLOGY, V51, pS34, DOI 10.1212/WNL.51.5_Suppl_4.S34; Wusthoff CJ, 2010, EPILEPSIA, V51, P1083, DOI 10.1111/j.1528-1167.2009.02388.x; Young GB, 1996, NEUROLOGY, V47, P83; Zeller JA, 1999, EPILEPSIA, V40, P186, DOI 10.1111/j.1528-1157.1999.tb02073.x	160	25	27	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	FEB	2012	30	1					11	+		10.1016/j.ncl.2011.09.005			32	Clinical Neurology; Neurosciences	Neurosciences & Neurology	894ZC	WOS:000300465000003	22284053				2021-06-18	
J	Osanai, T; Kuroda, S; Sugiyama, T; Kawabori, M; Ito, M; Shichinohe, H; Kuge, Y; Houkin, K; Tamaki, N; Iwasaki, Y				Osanai, Toshiya; Kuroda, Satoshi; Sugiyama, Taku; Kawabori, Masahito; Ito, Masaki; Shichinohe, Hideo; Kuge, Yuji; Houkin, Kiyohiro; Tamaki, Nagara; Iwasaki, Yoshinobu			Therapeutic Effects of Intra-Arterial Delivery of Bone Marrow Stromal Cells in Traumatic Brain Injury of Rats-In Vivo Cell Tracking Study by Near-Infrared Fluorescence Imaging	NEUROSURGERY			English	Article						Bone marrow stromal cell; Clinical application; Intra-arterial transplantation; In vivo optical imaging; Traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; MICE CEREBRAL INFARCT; SECONDARY MITOCHONDRIAL DYSFUNCTION; MESENCHYMAL STEM-CELLS; GROWTH-FACTOR; SPINAL-CORD; NEUROTROPHIC FACTORS; FUNCTIONAL RECOVERY; ACID RECEPTOR; AXON GROWTH	BACKGROUND: A noninvasive and effective route of cell delivery should be established to yield maximal therapeutic effects for central nervous system (CNS) disorders. OBJECTIVE: To elucidate whether intra-arterial delivery of bone marrow stromal cells (BMSCs) significantly promotes functional recovery in traumatic brain injury (TBI) in rats. METHODS: Rat BMSCs were transplanted through the ipsilateral internal carotid artery 7 days after the onset of cortical freezing injury. The BMSCs were labeled with fluorescent dye, and in vivo optical imaging was employed to monitor the behaviors of cells for 4 weeks after transplantation. Motor function was assessed for 4 weeks, and the transplanted BMSCs were examined using immunohistochemistry. RESULTS: In vivo optical imaging and histologic analysis clearly demonstrated that the intra-arterially injected BMSCs were engrafted during the first pass without systemic circulation, and the transplanted BMSCs started to migrate from the cerebral capillary bed to the injured CNS tissue within 3 hours. Intra-arterial BMSC transplantation significantly promoted functional recovery after cortical freezing injury. A subgroup of BMSCs expressed the phenotypes of neurons, astrocytes, and endothelial cells around the injured neocortex 4 weeks after transplantation. CONCLUSION: Intra-arterial transplantation may be a valuable option for prompt, noninvasive delivery of BMSCs to the injured CNS tissue, enhancing functional recovery after TBI. In vivo optical imaging may provide important information on the intracerebral behaviors of donor cells by noninvasive, serial visualization.	[Osanai, Toshiya; Kuroda, Satoshi; Sugiyama, Taku; Kawabori, Masahito; Ito, Masaki; Shichinohe, Hideo; Houkin, Kiyohiro; Iwasaki, Yoshinobu] Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Sapporo, Hokkaido 0608638, Japan; [Kuge, Yuji; Tamaki, Nagara] Hokkaido Univ, Grad Sch Med, Dept Nucl Med, Sapporo, Hokkaido 0608638, Japan	Kuroda, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Neurosurg, North 15,West 7, Sapporo, Hokkaido 0608638, Japan.	skuroda@med.hokudai.ac.jp	Yasuda, Kazunori/D-4156-2012; Houkin, Kiyohiro/G-5364-2012; Shichinohe, Hideo/G-5367-2012; Osanai, Toshiya/AAF-3011-2020; Kuge, Yuji/E-1290-2012; Sugiyama, Taku/U-9482-2018; Kawabori, Masahito/AAH-7117-2020	Sugiyama, Taku/0000-0003-0398-225X; Kawabori, Masahito/0000-0002-3574-8380	Ministry of Education, Science and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [19390371, 20591701, 20390377, 21390400]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21390400, 23390342] Funding Source: KAKEN	This study was supported by Grant-in-aid from the Ministry of Education, Science and Culture of Japan (No. 19390371, No. 20591701, No. 20390377 and No. 21390400). The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bliss T, 2007, STROKE, V38, P817, DOI 10.1161/01.STR.0000247888.25985.62; Boddington Sophie, 2008, J Vis Exp, DOI 10.3791/686; Borlongan CV, 2008, REGEN MED, V3, P249, DOI 10.2217/17460751.3.3.249; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chiba Y, 2009, NEUROSURGERY, V64, P991, DOI 10.1227/01.NEU.0000341905.57162.1D; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; Gu Y, 2010, J MOL NEUROSCI, V40, P332, DOI 10.1007/s12031-009-9304-6; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Hokari M, 2009, CYTOKINE, V46, P260, DOI 10.1016/j.cyto.2009.02.008; Kamei N, 2007, J NEUROSURG-SPINE, V6, P412, DOI 10.3171/spi.2007.6.5.412; Kuroda S, 2011, J STEM CELLS REGEN, V7, P2; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lacza Z, 2003, BRAIN RES PROTOC, V11, P145, DOI 10.1016/S1385-299X(03)00039-4; Lee JB, 2004, BRAIN RES PROTOC, V14, P37, DOI 10.1016/j.brainresprot.2004.09.004; Lee PH, 2008, CLIN PHARMACOL THER, V83, P723, DOI 10.1038/sj.clpt.6100386; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Lundberg J, 2009, NEURORADIOLOGY, V51, P661, DOI 10.1007/s00234-009-0551-6; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2003, NEUROSURGERY, V53, P702; Maruichi K, 2009, NEUROPATHOLOGY, V29, P422, DOI 10.1111/j.1440-1789.2008.00995.x; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Mori K, 2005, J CEREBR BLOOD F MET, V25, P887, DOI 10.1038/sj.jcbfm.9600083; Nakai A, 1997, NEUROBIOL DIS, V4, P288, DOI 10.1006/nbdi.1997.0146; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Orlacchio A, 2010, CURR MED CHEM, V17, P595, DOI 10.2174/092986710790416272; Osanai T, 2010, NEUROSURGERY, V66, P1140, DOI 10.1227/01.NEU.0000369610.76181.CF; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Shichinohe H, 2007, BRAIN RES, V1183, P138, DOI 10.1016/j.brainres.2007.08.091; Shichinohe H, 2006, J NUCL MED, V47, P486; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Sugiyama T, 2011, NEUROSURGERY, V68, P1036, DOI 10.1227/NEU.0b013e318208f891; Vaquero J, 2006, NEUROSCI LETT, V398, P129, DOI 10.1016/j.neulet.2005.12.072; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Wang Lei, 2002, Hematology, V7, P113; Wechsler L, 2009, STROKE, V40, P510, DOI 10.1161/STROKEAHA.108.526863; Yamaguchi S, 2006, BRAIN RES, V1087, P15, DOI 10.1016/j.brainres.2006.02.127; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Yano S, 2006, J NEUROTRAUM, V23, P1682, DOI 10.1089/neu.2006.23.1682; Yasuda H, 2010, J NEUROSURG, V112, P336, DOI 10.3171/2009.2.JNS08495; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061	48	25	27	1	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2012	70	2					435	444		10.1227/NEU.0b013e318230a795			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	879IK	WOS:000299322700052	21822154				2021-06-18	
J	Zhang, X; Lu, XM; Huang, LF; Ye, H				Zhang, Xin; Lu, Xiao-Min; Huang, Li-Fa; Ye, Hui			Copeptin is associated with one-year mortality and functional outcome in patients with acute spontaneous basal ganglia hemorrhage	PEPTIDES			English	Article						Copeptin; Intracerebral hemorrhage; Early neurological deterioration; 1-Year outcome	TRAUMATIC BRAIN-INJURY; SPONTANEOUS INTRACEREBRAL HEMORRHAGE; VASOPRESSIN PRECURSOR; STABLE PEPTIDE; ANTIDIURETIC-HORMONE; PROGNOSTIC MARKER; CEREBRAL-ISCHEMIA; HEART-FAILURE; V-2 RECEPTORS; STROKE	High plasma copeptin levels have been found to be associated with short-term poor outcome after intracerebral hemorrhage (ICH). We furthermore evaluate the relation of plasma copeptin levels to long-term outcome and early neurological deterioration after ICH. Fifty healthy controls and 89 patients with acute spontaneous basal ganglia hemorrhage were recruited in this study. Plasma copeptin concentrations on admission measured by enzyme-linked immunosorbent assay were considerably high in patients than healthy controls. A multivariate analysis identified plasma copeptin level as an independent predictor for 1-year mortality, 1-year unfavorable outcome (modified Rankin Scale score > 2) and early neurological deterioration. A receiver operating characteristic curve showed that the predictive value of plasma copeptin concentration was similar to that of National Institutes of Health Stroke Scale scores for long-term poor outcome and early neurological deterioration. However, copeptin did not obviously improve the predictive values of National Institutes of Health Stroke Scale scores. Thus, increased plasma copeptin level is an independent prognostic marker of 1-year mortality, 1-year unfavorable outcome and early neurological deterioration after ICH. (C) 2012 Elsevier Inc. All rights reserved.	[Zhang, Xin; Huang, Li-Fa; Ye, Hui] Tradit Chinese Med Hosp Zhejiang Prov, Dept Neurosurg, Hangzhou 310006, Zhejiang, Peoples R China; [Lu, Xiao-Min] First Hangzhou Municipal Peoples Hosp, Wushan Branch, Dept Surg, Hangzhou 310002, Zhejiang, Peoples R China	Zhang, X (corresponding author), Tradit Chinese Med Hosp Zhejiang Prov, Dept Neurosurg, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.	changzhouzhangxin@163.com					Barat C, 2004, BIOCHEMISTRY-US, V43, P8191, DOI 10.1021/bi0400094; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Darzy KH, 2010, CLIN CHEM, V56, P1190, DOI 10.1373/clinchem.2009.141689; de Bree FM, 1998, CELL MOL NEUROBIOL, V18, P173, DOI 10.1023/A:1022564803093; Delgado P, 2007, NEUROLOGIA, V22, P448; Dong XQ, 2011, J TRAUMA, V71, P1194, DOI 10.1097/TA.0b013e31821283f2; Dong XQ, 2011, PEPTIDES, V32, P253, DOI 10.1016/j.peptides.2010.11.021; HOLWERDA DA, 1972, EUR J BIOCHEM, V28, P334, DOI 10.1111/j.1432-1033.1972.tb01918.x; Katan M, 2011, NEUROLOGY, V76, P563, DOI 10.1212/WNL.0b013e31820b75e6; Katan M, 2008, NEUROENDOCRINOL LETT, V29, P341; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Molnar AH, 2008, ACTA NEUROCHIR, V150, P265, DOI 10.1007/s00701-007-1400-1; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Morgenthaler NG, 2007, SHOCK, V28, P219, DOI 10.1097/SHK.0b013e318033e5da; North WC, 1987, VASOPRESSIN PRINCIPL, P175; Ranger GS, 2002, INT J CLIN PRACT, V56, P777; Robertson GL, 2001, ENDOCRIN METAB CLIN, V30, P671, DOI 10.1016/S0889-8529(05)70207-3; Robertson GL, 2001, ENDOCRIN METAB CLIN, V30, pvii; Sacco RL, 2006, NAT CLIN PRACT NEURO, V2, P577, DOI 10.1038/ncpneuro0345; SMYTH DG, 1979, BIOCHEM BIOPH RES CO, V87, P1006, DOI 10.1016/S0006-291X(79)80007-8; Stoiser B, 2006, EUR J CLIN INVEST, V36, P771, DOI 10.1111/j.1365-2362.2006.01724.x; Struck J, 2005, PEPTIDES, V26, P2500, DOI 10.1016/j.peptides.2005.04.019; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Urwyler SA, 2010, STROKE, V41, P1564, DOI 10.1161/STROKEAHA.110.584649; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Voors AA, 2009, EUR HEART J, V30, P1187, DOI 10.1093/eurheartj/ehp098; Xu Miao, 2007, Chin J Traumatol, V10, P90; Yu GF, 2012, PEPTIDES, V33, P164, DOI 10.1016/j.peptides.2011.11.017; Zhu XD, 2011, CRIT CARE, V15, DOI 10.1186/cc10575; Zweifel C, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-34	32	25	25	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0196-9781	1873-5169		PEPTIDES	Peptides	FEB	2012	33	2					336	341		10.1016/j.peptides.2012.01.011			6	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	913IP	WOS:000301871200020	22286033				2021-06-18	
J	Heled, E; Hoofien, D; Margalit, D; Natovich, R; Agranov, E				Heled, Eyal; Hoofien, Dan; Margalit, Dana; Natovich, Rachel; Agranov, Eugenia			The Delis-Kaplan Executive Function System Sorting Test as an evaluative tool for executive functions after severe traumatic brain injury: A comparative study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Executive functions; Delis-Kaplan Executive Function System Sorting Test; Traumatic brain injury; Neuropsychological evaluation	TEST-PERFORMANCE; DEVELOPMENTAL-CHANGES; WISCONSIN; TRAIL; VALIDATION; ATTENTION; VALIDITY; LESION; NORMS	Neuropsychological tests are often used to evaluate executive function (EF) deficits in patients suffering traumatic brain injuries (TBIs). This study compared the sensitivity of three such tests-namely, the Delis-Kaplan Executive Function System Sorting Test (D-KEFS ST), the Wisconsin Card Sorting Test (WCST), and the Trail Making Test (TMT)-in differentiating between severe TBI patients and healthy controls. The differences between the two groups were significant for 5/5 variables evaluated through the D-KEFS ST, for 4/6 variables evaluated through the WCST, and for 2/2 variables evaluated through the TMT. Receiver operating characteristic analysis revealed that the variables "attempted sorts" in the D-KEFS ST and completion time in Part B of the TMT were the most powerful predictors of group assignment, with cutoff points of 9.5 sorts and 84.5 seconds, respectively. Our results highlight the possible value of the D-KEFS ST in the evaluation of postinjury EF deficits in TBI patients.	[Heled, Eyal; Margalit, Dana; Natovich, Rachel] Sheba Med Ctr, Day Treatment Rehabil Unit, Ramat Gan, Israel; [Heled, Eyal; Hoofien, Dan] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; [Hoofien, Dan] Natl Inst Rehabil Brain Injured, Tel Aviv, Israel; [Agranov, Eugenia] Tel Aviv Univ, Fac Med, Dept Phys Med & Rehabil, IL-69978 Tel Aviv, Israel	Heled, E (corresponding author), Sheba Med Ctr, Day Treatment Rehabil Unit, Ramat Gan, Israel.	eyalheled@walla.com					ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Anderson V, 2002, PRINCIPLES FRONTAL L, P504; Arffa S, 1998, ARCH CLIN NEUROPSYCH, V13, P713; Beatty W W, 1990, J Geriatr Psychiatry Neurol, V3, P163, DOI 10.1177/089198879000300308; Beatty W W, 1996, J Int Neuropsychol Soc, V2, P134; Beatty WW, 1994, NEUROPSYCHOLOGY, V8, P49, DOI 10.1037/0894-4105.8.1.49; BEATTY WW, 1993, J STUD ALCOHOL, V54, P687, DOI 10.15288/jsa.1993.54.687; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bergquist T, 2009, BRAIN INJURY, V23, P790, DOI 10.1080/02699050903196688; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Davidson PSR, 2008, J CLIN EXP NEUROPSYC, V30, P18, DOI 10.1080/13803390601161166; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Demakis GJ, 2003, NEUROPSYCHOLOGY, V17, P255, DOI 10.1037/0894-4105.17.2.255; Dimitrov M, 1999, NEUROPSYCHOLOGY, V13, P135, DOI 10.1037/0894-4105.13.1.135; Elliott R, 2003, BRIT MED BULL, V65, P49, DOI 10.1093/bmb/65.1.49; Fernandez AL, 2008, SCAND J PSYCHOL, V49, P239, DOI 10.1111/j.1467-9450.2008.00637.x; Fossati P, 2001, PSYCHIAT RES, V104, P145, DOI 10.1016/S0165-1781(01)00307-9; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GREVE KW, 1995, ARCH CLIN NEUROPSYCH, V10, P265, DOI 10.1016/0887-6177(94)00046-S; Greve KW, 2000, ARCH CLIN NEUROPSYCH, V15, P243, DOI 10.1016/S0887-6177(99)00015-3; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R. K, 1981, WISCONSIN CARD SORTI; Herman L. E., 2008, CAN J CLIN PHARM, V15, P411; Homack S, 2005, J CLIN EXP NEUROPSYC, V27, P599, DOI 10.1080/13803390490918444; Kaleita TA, 2004, J NEURO-ONCOL, V67, P245, DOI 10.1023/B:NEON.0000021900.29176.58; Kramer JH, 2002, J NEUROL NEUROSUR PS, V72, P217, DOI 10.1136/jnnp.72.2.217; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Lewine RRJ, 1996, AM J PSYCHIAT, V153, P1178; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; McCulloch KL, 2010, J HEAD TRAUMA REHAB, V25, P155, DOI 10.1097/HTR.0b013e3181dc82e7; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Nilson L, 1999, CLIN NEUROPSYCHOL, V13, P314, DOI 10.1076/clin.13.3.314.1737; Nyhus E, 2009, BRAIN COGNITION, V71, P437, DOI 10.1016/j.bandc.2009.03.005; Parmenter BA, 2007, J CLIN EXP NEUROPSYC, V29, P215, DOI 10.1080/13803390600672163; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; PENDLETON MG, 1982, J CLIN PSYCHOL, V38, P392, DOI 10.1002/1097-4679(198204)38:2<392::AID-JCLP2270380232>3.0.CO;2-W; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schisterman EF, 2005, EPIDEMIOLOGY, V16, P73, DOI 10.1097/01.ede.0000147512.81966.ba; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss DT, 2005, NEUROPSYCHOLOGIA, V43, P396, DOI 10.1016/j.neuropsychologia.2004.06.010; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Vakil E, 2009, CHILD NEUROPSYCHOL, V15, P21, DOI 10.1080/09297040801947069; WALDMANN BW, 1992, J CLIN PSYCHOL, V48, P360, DOI 10.1002/1097-4679(199205)48:3<360::AID-JCLP2270480314>3.0.CO;2-P; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; Winblad Stefan, 2006, Behav Brain Funct, V2, P16, DOI 10.1186/1744-9081-2-16	57	25	25	0	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2012	34	2					151	159		10.1080/13803395.2011.625351			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	916EC	WOS:000302079900004	22114911				2021-06-18	
J	Lebowitz, MS; Dams-O'Connor, K; Cantor, JB				Lebowitz, Matthew S.; Dams-O'Connor, Kristen; Cantor, Joshua B.			Feasibility of computerized brain plasticity-based cognitive training after traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						attention; brain injury; cognitive symptoms; computer-assisted therapy; feasibility; human information processing; neuronal plasticity; neuropsychology; rehabilitation; self-report	OLDER-ADULTS; REHABILITATION; RECOVERY; MEMORY; NEUROPLASTICITY; REMEDIATION; EXERCISE; FAILURES; PROGRAM; SPEED	The present study investigates the feasibility and utility of using a computerized brain plasticity-based cognitive training (BPCT) program as an intervention for community-dwelling individuals with traumatic brain injury (TBI). In a pre-post pilot study, 10 individuals with mild to severe TBI who were 6 mo to 22 yr postinjury were asked to use a computerized BPCT intervention designed to improve cognitive functioning through a graduated series of structured exercises at their homes in an urban community. Outcome measures included objective neuropsychological and self-report measures of cognitive functioning. All participants were able to use the software in their homes. Some mild fatigue was reported, which tended to dissipate over time. Few technical difficulties were reported. Remote support was sufficient for what technical assistance was needed. Participants reported subjective improvement in cognitive functioning, and small to large effect sizes on self-report and neuropsychological measures are reported. We conclude that BPCT may be a viable intervention for TBI outpatients as an adjunct to comprehensive neurorehabilitation. The intervention can be delivered in patients' homes with support provided remotely. Results of this study demonstrate the potential for treatment-related improvements many years after injury. Further study in controlled trials is warranted.	[Lebowitz, Matthew S.; Dams-O'Connor, Kristen; Cantor, Joshua B.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA	Lebowitz, MS (corresponding author), Yale Univ, Dept Psychol, 2 Hillhouse Ave, New Haven, CT 06520 USA.	Matthew.Lebowitz@yale.edu			National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133P050004]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1R49CE001171-01]	This material was based on work supported by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant H133P050004), and the Centers for Disease Control and Prevention (grant 1R49CE001171-01). Computer software was provided by Posit Science Corporation, San Francisco, California.	Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Barnes DE, 2009, ALZ DIS ASSOC DIS, V23, P205, DOI 10.1097/WAD.0b013e31819c6137; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Bergquist T, 2008, BRAIN INJURY, V22, P891, DOI 10.1080/02699050802405487; Berry AS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011537; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Diamond MC, 2001, AN ACAD BRAS CIENC, V73, P211, DOI 10.1590/S0001-37652001000200006; Edwards JD, 2005, AGING MENT HEALTH, V9, P262, DOI 10.1080/13607860412331336788; Edwards JD, 2002, GERONTOLOGY, V48, P329, DOI 10.1159/000065259; Etchells E, 1996, CAN MED ASSOC J, V155, P657; Fisher M, 2010, SCHIZOPHRENIA BULL, V36, P869, DOI 10.1093/schbul/sbn170; Fisher M, 2009, AM J PSYCHIAT, V166, P805, DOI 10.1176/appi.ajp.2009.08050757; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Jones WP, 2008, CLIN NEUROPSYCHOL, V22, P305, DOI 10.1080/13854040701281483; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keefe R, 2010, SCHIZOPHR RES, V117, P394, DOI 10.1016/j.schres.2010.02.712; Levin HS, 2006, ARCH PHYS MED REHAB, V87, pS1, DOI 10.1016/j.apmr.2006.09.010; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; Malloy P, 2005, COGN BEHAV NEUROL, V18, P18, DOI 10.1097/01.wnn.0000152232.47901.88; REASON J, 1984, BRIT J CLIN PSYCHOL, V23, P121, DOI 10.1111/j.2044-8260.1984.tb00635.x; Schallert T, 2000, J CEREBR BLOOD F MET, V20, P1513, DOI 10.1097/00004647-200011000-00001; Smith GE, 2009, J AM GERIATR SOC, V57, P594, DOI 10.1111/j.1532-5415.2008.02167.x; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; Vom Hofe A, 1998, EUR REV APPL PSYCHOL, V48, P49; Wexler BE, 2005, SCHIZOPHRENIA BULL, V31, P931, DOI 10.1093/schbul/sbi038; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; YATES GCR, 1985, BRIT J EDUC PSYCHOL, V55, P28, DOI 10.1111/j.2044-8279.1985.tb02603.x	35	25	26	0	36	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	10					1547	1556		10.1682/JRRD.2011.07.0133			10	Rehabilitation	Rehabilitation	149FD	WOS:000319303500012	23516058	Bronze			2021-06-18	
J	Maguen, S; Lau, KM; Madden, E; Seal, K				Maguen, Shira; Lau, Karen M.; Madden, Erin; Seal, Karen			Relationship of screen-based symptoms for mild traumatic brain injury and mental health problems in Iraq and Afghanistan veterans: Distinct or overlapping symptoms?	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						depression; factor analysis; hypervigilance; insomnia; mental health; OIF/OEF; posttraumatic stress disorder; screen; traumatic brain injury; veteran	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; PRIMARY-CARE; PTSD SCREEN; VALIDITY	This study used factor analytic techniques to differentiate distinct from overlapping screen-based symptoms of traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), and depression in Iraq and Afghanistan veterans. These symptoms were derived from screen results of 1,549 veterans undergoing Department of Veterans Affairs postdeployment screening between April 2007 and January 2010. Veterans with positive TBI screens were approximately twice as likely to also screen positive for depression and PTSD (adjusted relative risks = 1.9 and 2.1, respectively). Irritability was a shared symptom between TBI and PTSD, and emotional numbing was a shared symptom between PTSD and depression. Symptoms unique to TBI included dizziness, headaches, memory problems, and light sensitivity. Four separate constructs emerged: TBI, PTSD, depression, and a fourth construct consisting of hypervigilance and sleep problems. These findings illuminate areas of overlap between TBI and common postdeployment mental health problems. Discriminating symptoms of TBI from mental health problems may facilitate diagnosis, triage to specialty care, and targeted symptom management. The emergence of a fourth factor consisting of sleep problems and hypervigilance highlights the need to attend to specific symptoms in the postdeployment screening process.	[Maguen, Shira; Lau, Karen M.; Madden, Erin; Seal, Karen] San Francisco Dept Vet Affairs VA Med Ctr, San Francisco, CA USA; [Maguen, Shira; Seal, Karen] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Maguen, Shira; Seal, Karen] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA USA	Maguen, S (corresponding author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA.	Shira.Maguen@va.gov			Department of Defense Psychological Health and Traumatic Brain Injury Research Program; VA Health Sciences Research and Development Service Career Development Award	This material was based on work supported by the Department of Defense Psychological Health and Traumatic Brain Injury Research Program and a VA Health Sciences Research and Development Service Career Development Award to Dr. Maguen.	Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Browne M.W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002005; Calhoun PS, 2010, PSYCHIAT RES, V178, P330, DOI 10.1016/j.psychres.2009.11.009; Elbogen EB, 2010, AM J PSYCHIAT, V167, P1051, DOI 10.1176/appi.ajp.2010.09050739; FISCHER H, 2010, RS22452 C RES SERV; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; *MANP DAT CTR CON, 2009, OEF IF ROST; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Prins A, 2004, PRIMARY CARE PSYCHIA, V9, P151, DOI 10.1185/135525703125002360; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schell T.L., 2008, INVISIBLE WOUNDS WAR, DOI [10.7249/mg720-1ccf.12, DOI 10.7249/MG720-1CCF.12]; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; TUCKER LR, 1973, PSYCHOMETRIKA, V38, P1, DOI 10.1007/bf02291170; *US GOV ACC OFF, 2008, GAO08276; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004	27	25	25	1	3	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	7					1115	1125		10.1682/JRRD.2011.02.0015			11	Rehabilitation	Rehabilitation	149EZ	WOS:000319303100013	23341283	Bronze			2021-06-18	
J	Voelbel, GT; Genova, HM; Chiaravalotti, ND; Hoptman, MJ				Voelbel, Gerald T.; Genova, Helen M.; Chiaravalotti, Nancy D.; Hoptman, Matthew J.			Diffusion tensor imaging of traumatic brain injury review: Implications for neurorehabilitation	NEUROREHABILITATION			English	Article						Traumatic brain injury; diffusion tensor imaging; neurorehabilitation	WHITE-MATTER ABNORMALITIES; AXONAL INJURY; CORPUS-CALLOSUM; MILD; INTEGRITY; MODERATE; PLASTICITY; DYSFUNCTION	Diffusion tensor imaging (DTI) has widely been used to investigate the microstructural damage of white matter tracts that occur in individuals with traumatic brain injury (TBI). In the current review, we discuss the white matter regions which are commonly affected in adults with TBI. We also describe the current literature that has utilized DTI to investigate the relationship between microstructural integrity with neuropsychological performance and clinical outcome measures. Finally, a model is presented of the potential utilization of DTI as a biomarker of efficacy in neurorehabilitation for individuals with TBI.	[Voelbel, Gerald T.] NYU, Steinhardt Sch Educ Culture & Human Dev, Dept Occupat Therapy, New York, NY 10012 USA; [Voelbel, Gerald T.] NYU, Langone Med Ctr, Rusk Inst Rehabil Med, New York, NY 10012 USA; [Genova, Helen M.; Chiaravalotti, Nancy D.] Kessler Fdn Res Ctr, Neuropsychol & Neurosci Lab, W Orange, NJ USA; [Genova, Helen M.; Chiaravalotti, Nancy D.] UMDNJ New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [Hoptman, Matthew J.] Nathan S Kline Inst Psychiat Res, Schizophrenia Res Ctr, Orangeburg, NY 10962 USA; [Hoptman, Matthew J.] NYU, Sch Med, Dept Psychiat, New York, NY 10012 USA; [Hoptman, Matthew J.] CUNY City Coll, Dept Psychol, New York, NY 10031 USA	Voelbel, GT (corresponding author), NYU, Steinhardt Sch Educ Culture & Human Dev, Dept Occupat Therapy, 35 W 4th St,11th Floor, New York, NY 10012 USA.	gv23@nyu.edu	Hoptman, Matthew J./N-1035-2014	Hoptman, Matthew J./0000-0003-4485-6102; Chiaravalloti, Nancy/0000-0003-2943-7567			Alexopoulos GS, 2008, AM J PSYCHIAT, V165, P238, DOI 10.1176/appi.ajp.2007.07050744; Ardekani BA, 2003, NEUROREPORT, V14, P2025, DOI 10.1097/00001756-200311140-00004; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bennett IJ, 2010, HUM BRAIN MAPP, V31, P378, DOI 10.1002/hbm.20872; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CDC, 1999, TRAUM BRAIN INJ US R; Christidi F, 2011, J NEUROTRAUM, V28, P711, DOI 10.1089/neu.2010.1644; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Driemeyer J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002669; Engvig A, 2012, HUM BRAIN MAPP, V33, P2390, DOI 10.1002/hbm.21370; Faul M., 2010, TRAUM BRAIN INJURY U; Fu M, 2012, NATURE, V483, P92, DOI 10.1038/nature10844; Ge YL, 2005, ANN NY ACAD SCI, V1064, P202, DOI 10.1196/annals.1340.039; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kay T., J HEAD TRAUMA REHABI, V8, P86; Keller TA, 2009, NEURON, V64, P624, DOI 10.1016/j.neuron.2009.10.018; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lee B, 2010, NEUROIMAGE, V52, P9, DOI 10.1016/j.neuroimage.2010.04.014; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Lovden M, 2010, NEUROPSYCHOLOGIA, V48, P3878, DOI 10.1016/j.neuropsychologia.2010.08.026; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mateer CA, 2000, NEUROPSYCHOLOGICAL M, P3; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Matthews PM, 2013, J ALZHEIMERS DIS, V33, pS163, DOI 10.3233/JAD-2012-129012; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oechslin MS, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/neuro.09.076.2009; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Penner IK, 2006, J PHYSIOL-PARIS, V99, P455, DOI 10.1016/j.jphysparis.2006.03.008; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pfefferbaum A, 2005, NEUROIMAGE, V26, P891, DOI 10.1016/j.neuroimage.2005.02.034; Rogalski E, 2012, NEUROPSYCHOLOGIA, V50, P1759, DOI 10.1016/j.neuropsychologia.2012.03.033; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schlaug G, 2009, ANN NY ACAD SCI, V1169, P385, DOI 10.1111/j.1749-6632.2009.04587.x; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tana M G, 2010, Comput Intell Neurosci, P329213, DOI 10.1155/2010/329213; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	67	25	25	0	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2012	31	3					281	293		10.3233/NRE-2012-0796			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	028QC	WOS:000310436200005	23093455				2021-06-18	
J	Hearst, SM; Walker, LR; Shao, Q; Lopez, M; Raucher, D; Vig, PJS				Hearst, S. M.; Walker, L. R.; Shao, Q.; Lopez, M.; Raucher, D.; Vig, P. J. S.			THE DESIGN AND DELIVERY OF A THERMALLY RESPONSIVE PEPTIDE TO INHIBIT S100B-MEDIATED NEURODEGENERATION	NEUROSCIENCE			English	Article						S100B; spinocerebellar ataxia type 1; cerebellum; neurodegeneration; elastin-like polypeptide; thermal targeting	ELASTIN-LIKE POLYPEPTIDE; INTENSITY FOCUSED ULTRASOUND; BLOOD-BRAIN-BARRIER; TRYPTOPHAN FLUORESCENCE; OXIDATIVE STRESS; TRANSGENIC MICE; S100 PROTEINS; CELL-SURVIVAL; BINDING; TARGET	S100B, a glial-secreted protein, is believed to play a major role in neurodegeneration in Alzheimer's disease, Down syndrome, traumatic brain injury, and spinocerebellar ataxia type 1 (SCA1). SCA1 is a trinucleotide repeat disorder in which the expanded polyglutamine mutation in the protein ataxin-1 primarily targets Purkinje cells of the cerebellum. Currently, the exact mechanism of S100B-mediated Purkinje cell damage in SCA1 is not clear. However, here we show that S100B may act via the activation of the receptor for advanced glycation end product (RAGE) signaling pathway, resulting in oxidative stress-mediated injury to mutant ataxin-1-expressing neurons. To combat S100B-mediated neurodegeneration, we have designed a selective thermally responsive S100B inhibitory peptide, Synb1-ELP-TRTK. Our therapeutic polypeptide was developed using three key elements: (1) the elastin-like polypeptide (ELP), a thermally responsive polypeptide, (2) the TRTK12 peptide, a known S100B inhibitory peptide, and (3) a cell-penetrating peptide, Synb1, to enhance intracellular delivery. Binding studies revealed that our peptide, Synb1-ELP-TRTK, interacts with its molecular target S100B and maintains a high S100B binding affinity as comparable with the TRTK12 peptide alone. In addition, in vitro studies revealed that Synb1-ELP-TRTK treatment reduces S100B uptake in SHSY5Y cells. Furthermore, the Synb1-ELP-TRTK peptide decreased S100B-induced oxidative damage to mutant ataxin-1-expressing neurons. To test the delivery capabilities of ELP-based therapeutic peptides to the cerebellum, we treated mice with fluorescently labeled Synb1-ELP and observed that thermal targeting enhanced peptide delivery to the cerebellum. Here, we have laid the framework for thermal-based therapeutic targeting to regions of the brain, particularly the cerebellum. Overall, our data suggest that thermal targeting of ELP-based therapeutic peptides to the cerebellum is a novel treatment strategy for cerebellar neurodegenerative disorders. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.	[Hearst, S. M.; Shao, Q.; Lopez, M.; Vig, P. J. S.] Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; [Hearst, S. M.; Walker, L. R.; Raucher, D.; Vig, P. J. S.] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	Vig, PJS (corresponding author), Univ Mississippi, Med Ctr, Dept Neurol, 2500 N State St, Jackson, MS 39216 USA.	pvig@umc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R03 NS070065-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS070065] Funding Source: NIH RePORTER	This work was supported by R03 NS070065-01 grant from the NIH. We would like to thank Dr. Gene Bidwell III, for his help with ELP protein labeling and animal studies; and Henry Murphy II, for his help with binding studies, cell culture and protein purification experiments.	Adami C, 2004, BBA-MOL CELL RES, V1742, P169, DOI 10.1016/j.bbamcr.2004.09.008; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Bianchi R, 1996, BBA-MOL CELL RES, V1313, P258, DOI 10.1016/0167-4889(96)00098-5; Bidwell GL, 2007, BIOCHEM PHARMACOL, V73, P620, DOI 10.1016/j.bcp.2006.10.028; Bidwell GL, 2010, ADV DRUG DELIVER REV, V62, P1486, DOI 10.1016/j.addr.2010.05.003; Bidwell GL, 2010, PEPTIDES, V31, P834, DOI 10.1016/j.peptides.2010.02.007; Bidwell GL, 2009, EXPERT OPIN DRUG DEL, V6, P1033, DOI 10.1517/17425240903143745; Bidwell GL, 2009, J CONTROL RELEASE, V135, P2, DOI 10.1016/j.jconrel.2008.11.015; Bidwell GL, 2005, MOL CANCER THER, V4, P1076, DOI 10.1158/1535-7163.MCT-04-0253; Bocedi A, 2004, IUBMB LIFE, V56, P609, DOI 10.1080/15216540400016286; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Charpentier TH, 2010, J MOL BIOL, V396, P1227, DOI 10.1016/j.jmb.2009.12.057; Chen THH, 2008, PHARM RES, V25, P683, DOI 10.1007/s11095-007-9382-5; Cheung YT, 2009, NEUROTOXICOLOGY, V30, P127, DOI 10.1016/j.neuro.2008.11.001; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Dreher MR, 2007, CANCER RES, V67, P4418, DOI 10.1158/0008-5472.CAN-06-4444; Esposito G, 2008, J CELL MOL MED, V12, P914, DOI 10.1111/j.1582-4934.2008.00159.x; Frizzo JK, 2004, NEUROCHEM RES, V29, P735, DOI 10.1023/B:NERE.0000018844.51009.40; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hearst SM, 2010, J NEUROCHEM, V114, P706, DOI 10.1111/j.1471-4159.2010.06791.x; Hertzberg Y, 2010, MED PHYS, V37, P2934, DOI 10.1118/1.3395553; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Inman KG, 2002, J MOL BIOL, V324, P1003, DOI 10.1016/S0022-2836(02)01152-X; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; Jiang HB, 2004, HUM MOL GENET, V13, P1745, DOI 10.1093/hmg/ddh180; KATO K, 1990, J MOL NEUROSCI, V2, P109, DOI 10.1007/BF02876918; Kim SJ, 2003, NEUROSCI LETT, V348, P21, DOI 10.1016/S0304-3940(03)00657-8; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V307, P660, DOI 10.1016/S0006-291X(03)01241-5; Koeppen AH, 2005, CEREBELLUM, V4, P62, DOI 10.1080/14734220510007950; Leclerc E, 2007, J BIOL CHEM, V282, P31317, DOI 10.1074/jbc.M703951200; Li B, 2001, J AM CHEM SOC, V123, P11991, DOI 10.1021/ja010363e; Liu WE, 2006, J CONTROL RELEASE, V116, P170, DOI 10.1016/j.jconrel.2006.06.026; MacKay JA, 2009, NAT MATER, V8, P993, DOI [10.1038/NMAT2569, 10.1038/nmat2569]; Martin E, 2009, ANN NEUROL, V66, P858, DOI 10.1002/ana.21801; Massodi I, 2009, MOLECULES, V14, P1999, DOI 10.3390/molecules14061999; Matilla-Duenas A, 2008, CEREBELLUM, V7, P106, DOI 10.1007/s12311-008-0009-0; McClintock KA, 2000, PROTEIN SCI, V9, P2043, DOI 10.1110/ps.9.10.2043; Meyer DE, 1999, NAT BIOTECHNOL, V17, P1112, DOI 10.1038/15100; Meyer DE, 2001, CANCER RES, V61, P1548; Moktan S, INVEST NEW IN PRESS; Mori T, 2010, GLIA, V58, P300, DOI 10.1002/glia.20924; Orr HT, 2007, ANNU REV NEUROSCI, V30, P575, DOI 10.1146/annurev.neuro.29.051605.113042; Perrone L, 2008, J CELL PHYSIOL, V217, P60, DOI 10.1002/jcp.21474; Presgraves SP, 2004, NEUROTOX RES, V5, P579, DOI 10.1007/bf03033178; Ram Z, 2006, NEUROSURGERY, V59, P949; Raucher D, 2009, EXPERT OPIN DRUG DEL, V6, P1049, DOI 10.1517/17425240903158909; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; Roltsch E, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-78; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rousselle C, 2000, MOL PHARMACOL, V57, P679; Ryu J, 2010, BIOCHEM BIOPH RES CO, V393, P280, DOI 10.1016/j.bbrc.2010.01.122; Sarantseva S. V., 2009, Biomeditsinskaya Khimiya, V55, P41; Shcherbo D, 2010, NAT METHODS, V7, P827, DOI [10.1038/NMETH.1501, 10.1038/nmeth.1501]; Skinner PJ, 2001, AM J PATHOL, V159, P905, DOI 10.1016/S0002-9440(10)61766-X; Sorci G, CARDIOVASC IN PRESS; Takano K, 2007, AM J PHYSIOL-CELL PH, V293, pC1884, DOI 10.1152/ajpcell.00305.2007; Vig PJS, 2011, CEREBELLUM, V10, P254, DOI 10.1007/s12311-011-0262-5; Vig Parminder J S, 2006, J Neurol Sci Turk, V23, P166; Vig PJS, 2009, CEREBELLUM, V8, P231, DOI 10.1007/s12311-009-0125-5; Vivian JT, 2001, BIOPHYS J, V80, P2093, DOI 10.1016/S0006-3495(01)76183-8; Weljie AM, 2000, PROTEIN ENG, V13, P59, DOI 10.1093/protein/13.1.59; Whitaker-Azmitia PM, 1997, BRAIN RES, V776, P51, DOI 10.1016/S0006-8993(97)01002-0; Wilder PT, 2006, BBA-MOL CELL RES, V1763, P1284, DOI 10.1016/j.bbamcr.2006.08.024; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Wright Nathan T, 2009, Curr Chem Biol, V3, P138; Zimmer DB, 2005, CELL MOL BIOL, V51, P201, DOI 10.1170/T620; Zimmer DB, CARDIOVASC IN PRESS	70	25	25	2	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 1	2011	197						369	380		10.1016/j.neuroscience.2011.09.025			12	Neurosciences	Neurosciences & Neurology	849QR	WOS:000297140700035	21958864	Green Accepted			2021-06-18	
J	Helton, WS; Head, J; Kemp, S				Helton, William S.; Head, James; Kemp, Simon			Natural disaster induced cognitive disruption: Impacts on action slips	CONSCIOUSNESS AND COGNITION			English	Article						Attention; Cognitive disruption; Consciousness; Earthquake; Natural disaster	TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; TASK; MIND; EARTHQUAKE; FAILURES; PERFORMANCE; DEPRESSION; VIGILANCE; DISORDER	Previous research has indicated an increase in stress levels and cognitive intrusions after natural disasters. These previous studies have not, however, assessed the impact disaster induced cognitive disruption has on human performance. In the present report, we investigated the impact of the 7.1 magnitude 2010 Christchurch, New Zealand earthquake on self-reported earthquake-induced cognitive disruption and its relationship to performance on the Sustained Attention to Response Task (SART). Participants who self-reported greater cognitive disruption induced by the earthquake also had higher levels of errors of commission during SART (r = .80, p < .001). This was even the case when controlling for earthquake-induced anxiety, depression, participant sex, and self-reported sleep amount. Post-disaster assessments need to include the impact of the events directly on cognitive self-regulation and conscious thoughts, in addition to more clinical constructs, such as anxiety and depression. (C) 2011 Elsevier Inc. All rights reserved.	[Helton, William S.; Head, James; Kemp, Simon] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand	Helton, WS (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	deak.helton@canterbury.ac.nz		Kemp, Simon/0000-0002-8880-2416			AIKEN EG, 1967, PSYCHOL BULL, V68, P330, DOI 10.1037/h0025123; Annett K., 1967, ACTA PSYCHOL, V27, P420; Bergiannaki JD, 2003, ACTA PSYCHIAT SCAND, V107, P18, DOI 10.1034/j.1600-0447.2003.01467.x; CARDENA E, 1993, AM J PSYCHIAT, V150, P474; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Helton WS, 2011, CONSCIOUS COGN, V20, P696, DOI 10.1016/j.concog.2010.09.019; Helton WS, 2010, CONSCIOUS COGN, V19, P77, DOI 10.1016/j.concog.2010.01.006; Helton WS, 2009, CONSCIOUS COGN, V18, P600, DOI 10.1016/j.concog.2009.06.002; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Kemp S., 2011, PSYCHOL EFFECT UNPUB; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Mcvay JC, 2010, PSYCHOL BULL, V136, P188, DOI 10.1037/a0018298; Neria Y, 2008, PSYCHOL MED, V38, P467, DOI 10.1017/S0033291707001353; NOLENHOEKSEMA S, 1991, J PERS SOC PSYCHOL, V61, P115, DOI 10.1037/0022-3514.61.1.115; Peebles D, 2004, PROCEEDINGS OF THE SIXTH INTERNATIONAL CONFERENCE ON COGNITIVE MODELING, P231; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Smallwood J, 2004, CONSCIOUS COGN, V13, P657, DOI 10.1016/j.concog.2004.06.003; Smallwood JM, 2003, CONSCIOUS COGN, V12, P452, DOI 10.1016/S1053-8100(03)00018-7; Smallwood J, 2010, PSYCHOL BULL, V136, P202, DOI 10.1037/a0018673; Smallwood J, 2009, EMOTION, V9, P271, DOI 10.1037/a0014855; Smilek D, 2010, NEUROPSYCHOLOGIA, V48, P2564, DOI 10.1016/j.neuropsychologia.2010.05.002	30	25	25	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8100			CONSCIOUS COGN	Conscious. Cogn.	DEC	2011	20	4			SI		1732	1737		10.1016/j.concog.2011.02.011			6	Psychology, Experimental	Psychology	851NP	WOS:000297278100070	21397520				2021-06-18	
J	Honeybul, S; Gillett, GR; Ho, KM; Lind, CRP				Honeybul, S.; Gillett, G. R.; Ho, K. M.; Lind, C. R. P.			Neurotrauma and the rule of rescue	JOURNAL OF MEDICAL ETHICS			English	Article							DECOMPRESSIVE CRANIECTOMY	The rule of rescue describes the powerful human proclivity to rescue identified endangered lives, regardless of cost or risk. Deciding whether or not to perform a decompressive craniectomy as a life-saving or 'rescue' procedure for a young person with a severe traumatic brain injury provides a good example of the ethical tensions that occur in these situations. Unfortunately, there comes a point when the primary brain injury is so severe that if the patient survives they are likely to remain severely disabled and fully dependent. The health resource implications of this outcome are significant. By using a web-based outcome prediction model this study compares the long-term outcome and designation of two groups of patients. One group had a very severe injury as adjudged by the model and the other group a less severe injury. At 18 month follow-up there were significant differences in outcome and healthcare requirements. This raises important ethical issues when considering life-saving but non-restorative surgical intervention. The discussion about realistic outcome cannot be dichotomised into simply life or death so that the outcome for the patient must enter the equation. As in other 'rescue situations', the utility of the procedure cannot be rationalised on a mere cost-benefit analysis. A compromise has to be reached to determine at what point either the likely outcome would be unacceptable to the person on whom the procedure is being performed or the social utility gained from the rule of rescue intervention fails to justify the utilitarian value and justice of equitable resource allocation.	[Honeybul, S.; Lind, C. R. P.] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6009, Australia; [Honeybul, S.; Lind, C. R. P.] Royal Perth Hosp, Perth, WA, Australia; [Gillett, G. R.] Univ Otago, Dunedin Hosp, Dunedin, New Zealand; [Gillett, G. R.] Univ Otago, Otago Bioeth Ctr, Dunedin, New Zealand; [Ho, K. M.] Univ Western Australia, Dept Intens Care Med, Perth, WA 6009, Australia; [Ho, K. M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia; [Lind, C. R. P.] Univ Western Australia, Sch Surg, Perth, WA 6009, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6009, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010; Lind, Christopher/K-3629-2012	Ho, Kwok M./0000-0002-6705-6004; Lind, Christopher/0000-0001-9991-1725			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; BOCHNER F, 1994, BRIT MED J, V308, P901, DOI 10.1136/bmj.308.6933.901; Cookson R, 2000, J MED ETHICS, V26, P323, DOI 10.1136/jme.26.5.323; Cookson R, 2008, J MED ETHICS, V34, DOI 10.1136/jme.2007.021790; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; DANIELS N, 1986, NEW ENGL J MED, V314, P1380, DOI 10.1056/NEJM198605223142109; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; GILLETT G, 2004, BIOETHICS CLIN; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; GILLETT GR, 2001, NZ MED J, V27, P188; Gillett G, 2006, QUT LAW REV, V6, P243; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; Harris J., 1985, VALUE LIFE; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hope T, 2001, J MED ETHICS, V27, P179, DOI 10.1136/jme.27.3.179; Jonsen A R, 1986, Law Med Health Care, V14, P172; Kaplan RM, 1993, HIPPOCRATIC PREDICAM; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RELMAN AS, 1990, NEW ENGL J MED, V322, P1809, DOI 10.1056/NEJM199006213222510; Sheehan M., 2007, J APPL PHILOS, V24, P352, DOI DOI 10.1111/J.1468-5930.2007.00383.X	25	25	25	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-6800	1473-4257		J MED ETHICS	J. Med. Ethics	DEC	2011	37	12					707	710		10.1136/medethics-2011-100081			4	Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical	Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences	852AB	WOS:000297313100002	21947803	Bronze			2021-06-18	
J	Levy, AS; Orlando, A; Hawkes, AP; Salottolo, K; Mains, CW; Bar-Or, D				Levy, A. Stewart; Orlando, Alessandro; Hawkes, Allison P.; Salottolo, Kristin; Mains, Charles W.; Bar-Or, David			Should the Management of Isolated Traumatic Subarachnoid Hemorrhage Differ From Concussion in the Setting of Mild Traumatic Brain Injury?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Subarachnoid hemorrhage; Intensive care unit; Concussion; Mild traumatic brain injury	MINOR HEAD-INJURY; NEW-ORLEANS CRITERIA; CARE-UNIT ADMISSION; INTENSIVE-CARE; MORTALITY; PATIENT; RULE	Background: In the setting of mild traumatic brain injury (TBI), the clinical significance of a traumatic subarachnoid hemorrhage (tSAH) has not been sufficiently studied. We examined the impact of an isolated tSAH on patient outcomes in the mild TBI population. Methods: We retrospectively identified all mild TBI patients (Glasgow Coma Scale score >= 13) who presented to a Level I trauma center over a 10-year period. We compared isolated tSAH patients with isolated concussion patients. chi(2) and logistic regression analyses were used to compare intensive care unit (ICU) admission, ICU length of stay (LOS), hospital LOS, progression of tSAH, in-hospital mortality, and disposition to rehabilitation. Results: There were 1,144 concussion and 117 tSAH patients included in our study. After adjustment, tSAH patients had increased odds of admission to the ICU (odds ratio, [OR] = 8.87; p < 0.0001), yet their ICU LOS was significantly shorter (OR = 0.29; p = 0.01). The overall hospital LOS and mortality rate were not significantly different between the TBI groups. When stratified by age, only the 40-year to 69-year-old tSAH patients had significantly increased adjusted odds of disposition to rehabilitation compared with concussion patients, independent of ICU admission (OR = 7.96; p = 0.004). None of the patients required any neurosurgical interventions. Conclusions: We encourage healthcare facilities to consider revising or creating ICU admission criteria for the mild TBI population to help optimize the utilization of their ICUs. We believe clinicians should place more emphasis on variables such as age, comorbidities, and neurologic condition rather than the presence of a small volume of blood in the subarachnoid space when admitting mild isolated TBI patients to the ICU.	[Orlando, Alessandro; Salottolo, Kristin; Bar-Or, David] Swedish Med Ctr, Trauma Res Dept, Englewood, CO 80113 USA; [Orlando, Alessandro; Hawkes, Allison P.; Salottolo, Kristin; Mains, Charles W.; Bar-Or, David] St Anthony Cent Hosp, Trauma Res Dept, Denver, CO USA; [Mains, Charles W.] St Anthony Cent Hosp, Trauma Serv Dept, Denver, CO USA; [Mains, Charles W.; Bar-Or, David] Rocky Vista Univ, Aurora, CO USA	Bar-Or, D (corresponding author), Swedish Med Ctr, Trauma Res Dept, 501 E Hampden Ave,Room 4-454, Englewood, CO 80113 USA.	dbaror@dmibio.com	Bar-Or, David/AAE-9328-2020		St. Anthony Central Hospital, Denver, Colorado	Supported by St. Anthony Central Hospital, Denver, Colorado.	Boesiger BM, 2005, J EMERG MED, V29, P23, DOI 10.1016/j.jemermed.2005.02.002; BONE RC, 1993, CHEST, V104, P1806, DOI 10.1378/chest.104.6.1806; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Clement CM, 2006, ANN EMERG MED, V48, P245, DOI 10.1016/j.annemergmed.2006.04.008; Egol A, 1999, CRIT CARE MED, V27, P633; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Holmes JF, 2006, AM J EMERG MED, V24, P167, DOI 10.1016/j.ajem.2005.08.009; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Klein Y, 2010, J TRAUMA, V69, P544, DOI 10.1097/TA.0b013e3181c99936; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; NISHIJIMA DK, 2010, J TRAUMA        0827; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511	21	25	25	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1199	1204		10.1097/TA.0b013e31822067fc			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	849IG	WOS:000297118600025	21841515				2021-06-18	
J	Moulaert, VRMP; Verbunt, JA; Bakx, WGM; Gorgels, APM; de Krom, MCFTM; Heuts, PHTG; Wade, DT; van Heugten, CM				Moulaert, Veronique R. M. P.; Verbunt, Jeanine A.; Bakx, Wilbert G. M.; Gorgels, Anton P. M.; de Krom, Marc C. F. T. M.; Heuts, Peter H. T. G.; Wade, Derick T.; van Heugten, Caroline M.			'Stand still ..., and move on', a new early intervention service for cardiac arrest survivors and their caregivers: rationale and description of the intervention	CLINICAL REHABILITATION			English	Article						Heart arrest; hypoxic brain injury; cognitive impairment; rehabilitation interventions; nursing care	TRAUMATIC BRAIN-INJURY; CORONARY-ARTERY-DISEASE; TELEPHONE INTERVENTION; HEAD-INJURY; NURSING INTERVENTIONS; RANDOMIZED-TRIAL; SELF-MANAGEMENT; MILD; REHABILITATION; QUALITY	Objective: To describe a new early intervention service for survivors of cardiac arrest and their caregivers, and to explain the evidence and rationale behind it. Rationale: A cardiac arrest may cause hypoxic-ischaemic brain injury, which often results in cognitive impairments. Survivors of cardiac arrest can also encounter emotional problems, limitations in daily life, reduced participation in society and a decreased quality of life. A new early intervention service was designed based on literature study, expert opinion and patient experiences. Description of the intervention: The early intervention service is an individualized programme, consisting of one to six consultations by a specialized nurse for the patient and their caregiver. The intervention starts soon after discharge from the hospital and can last up to three months. The intervention consists of screening for cognitive and emotional problems, provision of information and support, promotion of self-management strategies and can include referral to further specialized care if indicated. Discussion: This intervention is assumed to reduce future problems related to hypoxic-ischaemic brain injury in the patient and caregiver, and its effectiveness is currently being investigated in a randomized controlled multicentre trial.	[Moulaert, Veronique R. M. P.; Verbunt, Jeanine A.; Bakx, Wilbert G. M.; Wade, Derick T.] Ctr Expertise Rehabil & Audiol, NL-6432 CC Adelante, Hoensbroek, Netherlands; [Moulaert, Veronique R. M. P.; Verbunt, Jeanine A.] Maastricht Univ, Dept Rehabil Med, CAPHRI Sch Publ Hlth & Primary Care, Med Ctr, Maastricht, Netherlands; [Gorgels, Anton P. M.] Maastricht Univ, Dept Cardiol, Med Ctr, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands; [de Krom, Marc C. F. T. M.] Maastricht Univ, Dept Neurol, Med Ctr, Maastricht, Netherlands; [Heuts, Peter H. T. G.] Vrije Univ Amsterdam, Dept Rehabil Med, Med Ctr, Amsterdam, Netherlands; [Heuts, Peter H. T. G.] Ctr Rehabil & Rheumatol, Amsterdam, Netherlands; [Wade, Derick T.] Nuffield Orthopaed Ctr, Oxford Ctr Enablement, Oxford OX3 7LD, England; [van Heugten, Caroline M.] Maastricht Univ, Sch Mental Hlth & Neurosci, Maastricht, Netherlands; [van Heugten, Caroline M.] Maastricht Univ, Dept Neuropsychol & Psychopharmacol, Maastricht, Netherlands	Moulaert, VRMP (corresponding author), Ctr Expertise Rehabil & Audiol, Zandbergsweg 111, NL-6432 CC Adelante, Hoensbroek, Netherlands.	v.moulaert@adelante-zorggroep.nl		Wade, Derick/0000-0002-1188-8442	Netherlands Organization for Health Research and Development (ZON/MW)Netherlands Organization for Health Research and Development; Fonds Nuts Ohra	This study is funded by the Netherlands Organization for Health Research and Development (ZON/MW); and Fonds Nuts Ohra.	Alderson AL, 2003, ARCH PHYS MED REHAB, V84, P668, DOI 10.1016/S0003-9993(03)04842-6; Allen JK, 2010, J CARDIOVASC NURS, V25, P207, DOI 10.1097/JCN.0b013e3181cc79be; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Cowan MJ, 2001, NURS RES, V50, P68, DOI 10.1097/00006199-200103000-00002; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; Dougherty CM, 2005, PACE, V28, P1157, DOI 10.1111/j.1540-8159.2005.09500.x; Dougherty CM, 2004, PACE, V27, P1594, DOI 10.1111/j.1540-8159.2004.00691.x; Dougherty CM, 2004, HEART LUNG, V33, P183, DOI 10.1016/j.hrtlng.2004.01.003; Dougherty CM, 2000, HEART LUNG, V29, P79; Dougherty CM, 2001, ADV NURS SCI, V24, P78, DOI 10.1097/00012272-200109000-00009; Dougherty Cynthia M, 2004, J Cardiovasc Nurs, V19, P21; Dusseldorp E, 1999, HEALTH PSYCHOL, V18, P506, DOI 10.1037/0278-6133.18.5.506; Edwards DF, 2006, NEUROREHAB NEURAL RE, V20, P42, DOI 10.1177/1545968305283038; Gorgels APM, 2003, EUR HEART J, V24, P1204, DOI 10.1016/S0195-668X(03)00191-X; Jovicic Aleksandra, 2006, BMC Cardiovasc Disord, V6, P43, DOI 10.1186/1471-2261-6-43; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KOSTER RW, 2009, HART VAATZIEKTEN NED, P49; Linden W, 1996, ARCH INTERN MED, V156, P745, DOI 10.1001/archinte.156.7.745; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Lundgren-Nilsson A, 2005, RESUSCITATION, V66, P285, DOI 10.1016/j.resuscitation.2005.04.001; Moulaert Veronique R M P, 2007, BMC Cardiovasc Disord, V7, P26, DOI 10.1186/1471-2261-7-26; Moulaert VRMP, 2009, RESUSCITATION, V80, P297, DOI 10.1016/j.resuscitation.2008.10.034; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nys GMS, 2005, ARCH CLIN NEUROPSYCH, V20, P623, DOI 10.1016/j.acn.2005.04.001; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Pendlebury ST, 2010, STROKE, V41, P1290, DOI 10.1161/STROKEAHA.110.579888; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Pusswald G, 2000, RESUSCITATION, V47, P241, DOI 10.1016/S0300-9572(00)00240-9; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Straus SMJM, 2004, J CLIN EPIDEMIOL, V57, P98, DOI 10.1016/S0895-4356(03)00210-5; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Thornton M, 2003, J GERONTOL B-PSYCHOL, V58, pS127, DOI 10.1093/geronb/58.2.S127; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; van Heugten C, 2007, CLIN NEUROL NEUROSUR, V109, P257, DOI 10.1016/j.clineuro.2006.10.002; Wachelder EM, 2009, RESUSCITATION, V80, P517, DOI 10.1016/j.resuscitation.2009.01.020; Wade DT, 2004, BMJ-BRIT MED J, V329, P1398, DOI 10.1136/bmj.329.7479.1398; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; World Health Organization, 2001, INT CLASS FUNCT DIS	42	25	26	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	OCT	2011	25	10					867	879		10.1177/0269215511399937			13	Rehabilitation	Rehabilitation	834AH	WOS:000295928500001	21565869	Green Published, Other Gold			2021-06-18	
J	Armstead, WM; Kiessling, JW; Riley, J; Cines, DB; Higazi, A				Armstead, William M.; Kiessling, J. Willis; Riley, John; Cines, Douglas B.; Higazi, Abd Al-Roof			tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK	NEUROLOGICAL RESEARCH			English	Article						Newborn; Cerebral circulation; TBI; Plasminogen activators; Signal transduction	N-TERMINAL KINASE; TISSUE-PLASMINOGEN ACTIVATOR; CEREBRAL-BLOOD-FLOW; CHILDREN; ERK; LRP; HEMODYNAMICS; METABOLISM; POTASSIUM; NOC/OFQ	Objective: N-methyl-D-aspartate (NMDA)-induced pial artery dilation (PAD) is reversed to vasoconstriction after fluid percussion brain injury (FPI). Tissue type plasminogen activator (tPA) is up-regulated and the tPA antagonist, EEIIMD, prevents impaired NMDA PAD after FPI. Mitogen-activated protein kinase (MAPK), a family of at least three kinases, ERK, p38, and JNK, is also up-regulated after traumatic brain injury (TBI). We hypothesize that tPA impairs NMDA-induced cerebrovasodilation after FPI in a MAPK isoform-dependent mechanism. Methods: Lateral FPI was induced in newborn pigs. The closed cranial window technique was used to measure pial artery diameter and to collect cerebrospinal fluid (CSF). ERK, p38, and JNK MAPK concentrations in CSF were quantified by ELISA. Results: CSF JNK MAPK was increased by FPI, increased further by tPA, but blocked by JNK antagonists SP600125 and D-JNKI1. FPI modestly increased p38 and ERK isoforms of MAPK. NMDA-induced PAD was reversed to vasoconstriction after FPI, whereas dilator responses to papaverine were unchanged. tPA, in post-FPI CSF concentration, potentiated NMDA-induced vasoconstriction while papaverine dilation was unchanged. SP 600125 and D-JNKI1, blocked NMDA-induced vasoconstriction and fully restored PAD. The ERK antagonist U 0126 partially restored NMDA-induced PAD, while the p38 inhibitor SB203580 aggravated NMDA-induced vasoconstriction observed in the presence of tPA after FPI. Discussion: These data indicate that tPA contributes to impairment of NMDA-mediated cerebrovasodilation after FPI through JNK, while p38 may be protective. These data suggest that inhibition of the endogenous plasminogen activator system and JNK may improve cerebral hemodynamic outcome post-TBI.	[Armstead, William M.; Kiessling, J. Willis; Riley, John] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Armstead, William M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Higazi, Abd Al-Roof] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Clin Biochem, IL-91010 Jerusalem, Israel	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu		Riley, John/0000-0002-7932-8935	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS53410, HD57355, HL76406, CA83121, HL76206, HL07971, HL81864, HL77760, HL82545]; University of Pennsylvania Research Foundation; University of Pennsylvania Institute for Translational Medicine and Therapeutics; Israeli Science FoundationIsrael Science Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD057355] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA083121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL077760, T32HL007971, R21HL081864, R01HL076206, P01HL076406] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053410] Funding Source: NIH RePORTER	This research was supported by grants from the National Institutes of Health, NS53410 and HD57355 (WMA), HL76406, CA83121, HL76206, HL07971, and HL81864 (DBC), and HL77760 and HL82545 (AARH), the University of Pennsylvania Research Foundation (WMA), the University of Pennsylvania Institute for Translational Medicine and Therapeutics (DBC), and the Israeli Science Foundation (AARH).	Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Akkawi S, 2006, AM J PHYSIOL-HEART C, V291, pH1351, DOI 10.1152/ajpheart.01042.2005; Armstead WM, 2008, BRAIN RES, V1231, P121, DOI 10.1016/j.brainres.2008.06.115; Armstead WM, 2009, J CEREBR BLOOD F MET, V29, P524, DOI 10.1038/jcbfm.2008.142; Armstead WM, 2005, DEV BRAIN RES, V156, P139, DOI 10.1016/j.devbraines.2005.02.012; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 2003, EUR J PHARMACOL, V474, P249, DOI 10.1016/S0014-2999(03)02012-0; Armstead WM, 2002, DEV BRAIN RES, V139, P19, DOI 10.1016/S0165-3806(02)00511-4; Armstead WM, 2001, PEPTIDES, V22, P39, DOI 10.1016/S0196-9781(00)00354-5; Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; COLLEN D, 1991, BLOOD, V78, P3114; Faraci FM, 1998, PHYSIOL REV, V78, P53; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kulkarni M, 2002, J NEUROTRAUM, V19, P965, DOI 10.1089/089771502320317113; Laher I, 2001, J CEREBR BLOOD F MET, V21, P887, DOI 10.1097/00004647-200108000-00001; MERCHANT RE, 1999, ANN NY ACAD SCI, V890, P41; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Muniyappa H, 2008, CELL SIGNAL, V20, P675, DOI 10.1016/j.cellsig.2007.12.003; Nassar T, 2004, BLOOD, V103, P897, DOI 10.1182/blood-2003-05-1685; Nicole O, 2001, NAT MED, V7, P59; Parathath SR, 2006, J CELL SCI, V119, P339, DOI 10.1242/jcs.02734; Park L, 2008, P NATL ACAD SCI USA, V105, P1073, DOI 10.1073/pnas.0708823105; Pawlak R, 2005, P NATL ACAD SCI USA, V102, P443, DOI 10.1073/pnas.0406454102; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P625, DOI 10.1001/archpedi.1990.02150300019014; Thomas S, 2000, ACT NEUR S, V76, P397; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Vavilala Monica S, 2002, Anesthesiol Clin North Am, V20, P247, DOI 10.1016/S0889-8537(01)00012-8; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Yatsushige H, 2007, J NEUROSCI RES, V85, P1436, DOI 10.1002/jnr.21281	36	25	28	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	SEP	2011	33	7					726	733		10.1179/016164110X12807570509853			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	790MI	WOS:000292591700008	21756552	Green Accepted			2021-06-18	
J	Bouzat, P; Francony, G; Thomas, S; Valable, S; Mauconduit, F; Fevre, MC; Barbier, EL; Bernaudin, M; Lahrech, H; Payen, JF				Bouzat, Pierre; Francony, Gilles; Thomas, Sebastien; Valable, Samuel; Mauconduit, Franck; Fevre, Marie-Cecile; Barbier, Emmanuel L.; Bernaudin, Myriam; Lahrech, Hana; Payen, Jean-Francois			Reduced brain edema and functional deficits after treatment of diffuse traumatic brain injury by carbamylated erythropoietin derivative	CRITICAL CARE MEDICINE			English	Article						brain edema; carbamylated erythropoietin; erythropoietin; magnetic resonance diffusion-weighted imaging; magnetic resonance imaging; neurological outcome; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; CULTURED ASTROCYTES; HEAD-INJURY; MODEL; RAT; BARRIER; PROTECTS; RECOVERY; MOTOR; CEPO	Objective: To investigate the effects of carbamylated erythropoietin, a modified erythropoietin lacking erythropoietic activity, on brain edema and functional recovery in a model of diffuse traumatic brain injury. Design: Adult male Wistar rats. Setting: Neurosciences and physiology laboratories. Interventions: Thirty minutes after diffuse traumatic brain injury (impact-acceleration model), rats were intravenously administered with either a saline solution (traumatic brain injury-saline) or carbamylated erythropoietin (50 mu g/kg; traumatic brain injury-carbamylated erythropoietin). A third group received no traumatic brain injury insult (sham-operated). Measurements and Main Results: Three series of experiments were conducted to investigate: 1) the effect of carbamylated erythropoietin on brain edema before and 1 hr after traumatic brain injury using diffusion-weighted magnetic resonance imaging and measurements of apparent diffusion coefficient (n = 10 rats per group), and the phosphorylation level of brain extracellular-regulated kinase-1/-2 was also determined to indicate the presence of an activated cell signaling pathway; 2) the time course of brain edema using magnetic resonance imaging between 4 and 6 hrs postinjury and the gravimetric technique at 6 hrs (n = 10 rats per group); and 3) motor and cognitive function over 10 days post traumatic brain injury, testing acute somato-motor reflexes, adhesive paper removal, and two-way active avoidance (n = 8 rats per group). Compared to traumatic brain injury-saline rats, rats receiving traumatic brain injury-carbamylated erythropoietin showed a significant reduction in brain edema formation at 1 hr that was sustained until 6 hrs when results were comparable with sham-operated rats. This anti-edematous effect of carbamylated erythropoietin was possibly mediated through an early inhibition of extracellular-regulated kinase-1/-2 phosphorylation. Compared to traumatic brain injury-saline rats, traumatic brain injury-carbamylated erythropoietin rats showed improved functional recovery of the acute somato-motor reflexes post traumatic brain injury, took less time to remove adhesive from the forelimbs, and showed higher percentages of correct avoidance responses. Conclusion: Our findings indicate that early posttraumatic administration of carbamylated erythropoietin reduces brain edema development until at least 6 hrs postinjury and improves neurologic recovery. Carbamylated erythropoietin can thus be considered as a potential agent in the treatment of traumatic brain injury-induced diffuse edema. (Crit Care Med 2011; 39: 2099-2105)	[Bouzat, Pierre; Francony, Gilles; Thomas, Sebastien; Mauconduit, Franck; Fevre, Marie-Cecile; Barbier, Emmanuel L.; Lahrech, Hana; Payen, Jean-Francois] INSERM, U836, F-38042 Grenoble, France; [Bouzat, Pierre; Francony, Gilles; Thomas, Sebastien; Mauconduit, Franck; Fevre, Marie-Cecile; Barbier, Emmanuel L.; Lahrech, Hana; Payen, Jean-Francois] Univ Grenoble 1, Grenoble Inst Neurosci, F-38042 Grenoble, France; [Bouzat, Pierre; Francony, Gilles; Thomas, Sebastien; Fevre, Marie-Cecile; Payen, Jean-Francois] Hop Michallon, Dept Anesthesie Reanimat, F-38043 Grenoble, France; [Valable, Samuel; Bernaudin, Myriam] Univ Paris 05, Univ Caen Basse Normandie, CEA, CI NAPS,UMR 6232,CNRS,Equipe CERVOxy, Caen, France	Payen, JF (corresponding author), INSERM, U836, F-38042 Grenoble, France.	jfpayen@ujf-grenoble.fr	Payen, Jean-Francois/L-6667-2014; Bernaudin, Myriam/B-7663-2008; Bouzat, Pierre/AAC-4105-2019; valable, samuel/B-7578-2008; Lahrech, Hana/M-5229-2018; Bouzat, Pierre/L-6881-2014; Barbier, Emmanuel/E-6302-2011	Bernaudin, Myriam/0000-0003-0778-3397; Bouzat, Pierre/0000-0003-4667-6738; valable, samuel/0000-0003-0355-0270; Barbier, Emmanuel/0000-0002-4952-1240; Mauconduit, Franck/0000-0002-0128-061X; Lahrech, Hana/0000-0003-3843-3410	Institut National de la Sante et de la Recherche Medicale (INSERM)Institut National de la Sante et de la Recherche Medicale (Inserm); Institut pour la Recherche sur la Moelle Epiniere et l'Encephale (IRME); Association Francaise contre les Myopathies (AFM)Association Francaise contre les Myopathies; Centre National de la Recherche Scientifique (CNRS)Centre National de la Recherche Scientifique (CNRS); Ministere de l'Education, de la Recherche et de la Technologie, France	Supported, in part, by grants from Institut National de la Sante et de la Recherche Medicale (INSERM), Institut pour la Recherche sur la Moelle Epiniere et l'Encephale (IRME), Association Francaise contre les Myopathies (AFM), Centre National de la Recherche Scientifique (CNRS), and Ministere de l'Education, de la Recherche et de la Technologie, France.	Adembri C, 2008, CRIT CARE MED, V36, P975, DOI 10.1097/CCM.0B013E3181644343; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; FREI HJ, 1973, ACTA NEUROCHIR, V29, P15, DOI 10.1007/BF01414613; Freret T, 2006, EUR J NEUROSCI, V23, P1757, DOI 10.1111/j.1460-9568.2006.04699.x; Gassmann M, 2003, ADV EXP MED BIOL, V543, P323; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Huang H, 2009, J INT MED RES, V37, P511, DOI 10.1177/147323000903700227; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; King VR, 2007, EUR J NEUROSCI, V26, P90, DOI 10.1111/j.1460-9568.2007.05635.x; Kirkeby A, 2008, THROMB HAEMOSTASIS, V99, P720, DOI 10.1160/TH07-03-0208; Lapchak PA, 2008, BRAIN RES, V1238, P208, DOI 10.1016/j.brainres.2008.08.017; Lapchak PA, 2008, EXPERT OPIN INV DRUG, V17, P1175, DOI [10.1517/13543784.17.8.1175, 10.1517/13543784.17.8.1175 ]; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lukoyanov NV, 2006, BEHAV BRAIN RES, V173, P229, DOI 10.1016/j.bbr.2006.06.026; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Montero M, 2007, EXP NEUROL, V204, P106, DOI 10.1016/j.expneurol.2006.09.026; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Otani N, 2007, J CLIN NEUROSCI, V14, P42, DOI 10.1016/j.jocn.2005.11.044; Rao KVR, 2010, GLIA, V58, P1490, DOI 10.1002/glia.21023; Shein NA, 2008, J NEUROTRAUM, V25, P112, DOI 10.1089/neu.2007.0358; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Velly L, 2010, PHARMACOL THERAPEUT, V128, P445, DOI 10.1016/j.pharmthera.2010.08.002; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925	40	25	28	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	SEP	2011	39	9					2099	2105		10.1097/CCM.0b013e31821cb7b2			7	Critical Care Medicine	General & Internal Medicine	808TH	WOS:000294000800011	21552121				2021-06-18	
J	Kuceyeski, A; Maruta, J; Niogi, SN; Ghajar, J; Raj, A				Kuceyeski, Amy; Maruta, Jun; Niogi, Sumit N.; Ghajar, Jamshid; Raj, Ashish			The generation and validation of white matter connectivity importance maps	NEUROIMAGE			English	Article						white matter importance map; brain connectivity networks; graph theory; tractography; prediction of impairment; traumatic brain injury	DIFFUSION-WEIGHTED MRI; MULTIPLE-SCLEROSIS; BRAIN; TENSOR; ORGANIZATION; TRACTOGRAPHY; DISABILITY; NETWORKS; TRACKING; FEATURES	Both the size and location of injury in the brain influences the type and severity of cognitive or sensorimotor dysfunction. However, even with advances in MR imaging and analysis, the correspondence between lesion location and clinical deficit remains poorly understood. Here, structural and diffusion images from 14 healthy subjects are used to create spatially unbiased white matter connectivity importance maps that quantify the amount of disruption to the overall brain network that would be incurred if that region were compromised. Some regions in the white matter that were identified as highly important by such maps have been implicated in strategic infarct dementia and linked to various attention tasks in previous studies. Validation of the maps is performed by investigating the correlations of the importance maps' predicted cognitive deficits in a group of 15 traumatic brain injury patients with their cognitive test scores measuring attention and memory. While no correlation was found between amount of white matter injury and cognitive test scores, significant correlations (r>0.68, p <0.006) were found when including location information contained in the importance maps. These tools could be used by physicians to improve surgical planning, diagnosis, and assessment of disease severity in a variety of pathologies like multiple sclerosis, trauma, and stroke. (C) 2011 Elsevier Inc. All Fights reserved.	[Kuceyeski, Amy; Raj, Ashish] Weill Cornell Med Coll, IDEAL, Dept Radiol, New York, NY 10065 USA; [Maruta, Jun; Ghajar, Jamshid] Brain Trauma Fdn, World Trade Ctr 7, New York, NY 10007 USA; [Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10065 USA	Kuceyeski, A (corresponding author), Weill Cornell Med Coll, IDEAL, Dept Radiol, 515 E 71st St,S-125, New York, NY 10065 USA.	amk2012@med.cornell.edu; jmartuta@braintrauma.org; sun2003@nyp.org; ghajar@braintrauma.org; asi2004@med.cornell.edu	Maruta, Jun/I-3790-2019	Maruta, Jun/0000-0002-5054-6605	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32 EB012404-01, P41 RR023953-02, P41 RR023953-02S1, R21 EB008138-02]; Department of DefenseUnited States Department of Defense [W81XWH-08-1-0646, W81XWH-08-2-0177]; James S. McDonnell Foundation; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR023953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB008138, F32EB012404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS075425] Funding Source: NIH RePORTER	The data processing, analysis, importance map creation and validation were supported by the following National Institutes of Health grants: F32 EB012404-01, P41 RR023953-02, P41 RR023953-02S1 and R21 EB008138-02. The data were collected and maintained with support from the Department of Defense grants W81XWH-08-1-0646 and W81XWH-08-2-0177, and a James S. McDonnell Foundation grant for the Cognitive Neurobiological Research Consortium in Traumatic Brain Injury. Rachel Roister and Ranjeeta Sarkar provided assistance with subject enrollment and cognitive testing.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Alernan-Gomez Y., 2005, 12 ANN M ORG HUM BRA; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; BOWMAN FD, 2009, NEUROIMAGE, V47, pS147; Charil A, 2003, NEUROIMAGE, V19, P532, DOI 10.1016/S1053-8119(03)00117-4; Collins DL, 1998, IEEE T MED IMAGING, V17, P463, DOI 10.1109/42.712135; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Friman O, 2006, IEEE T MED IMAGING, V25, P965, DOI 10.1109/TMI.2006.877093; FRISTON KJ, 2006, STAT PARAMETRIC MAPP, P656; GONDRAN M, 1984, DISCREET MATH SERIES, V1484; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; Iturria-Medina Y, 2007, NEUROIMAGE, V36, P645, DOI 10.1016/j.neuroimage.2007.02.012; Iturria-Medina Y, 2008, NEUROIMAGE, V40, P1064, DOI 10.1016/j.neuroimage.2007.10.060; ITURRIAMEDINA Y, 2005, NEUROIMAGE, V26; IVKOVICH M, PLOS ONE IN PRESS; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; KUCEYESKI A, 2010, JOINT ANN M ISMRM ES, P1676; Lo CY, 2010, J NEUROSCI, V30, P16876, DOI 10.1523/JNEUROSCI.4136-10.2010; Lu YG, 2006, NEUROIMAGE, V31, P1061, DOI 10.1016/j.neuroimage.2006.01.043; Mainero C, 2001, NEUROLOGY, V56, P1331, DOI 10.1212/WNL.56.10.1331; Mammi S, 1996, ACTA NEUROL SCAND, V94, P93, DOI 10.1111/j.1600-0404.1996.tb07036.x; Menezes NM, 2007, STROKE, V38, P194, DOI 10.1161/01.STR.0000251792.76080.45; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nazzal ME, 2009, DISABIL REHABIL, V31, P1501, DOI 10.1080/09638280802627702; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi S, 2010, FRONT NEUROANAT, V4, DOI [10.3389/neuro.05.002.2010, 10.3389/fneur.2010.00149]; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720; Pereira JMS, 2010, NEUROIMAGE, V49, P2205, DOI 10.1016/j.neuroimage.2009.10.068; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schmahmann JD, 2006, FIBER PATHWAYS BRAIN; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Sotero RC, 2007, NEURAL COMPUT, V19, P478, DOI 10.1162/neco.2007.19.2.478; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; TATEMICHI TK, 1995, ARZNEIMITTEL-FORSCH, V45-1, P371; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vaessen MJ, 2010, NEUROIMAGE, V51, P1106, DOI 10.1016/j.neuroimage.2010.03.011; Vellinga MM, 2009, J MAGN RESON IMAGING, V29, P768, DOI 10.1002/jmri.21679; Wen W, 2011, J NEUROSCI, V31, P1204, DOI 10.1523/JNEUROSCI.4085-10.2011; Wilson M, 2003, J NEUROL NEUROSUR PS, V74, P203, DOI 10.1136/jnnp.74.2.203; Zalesky A, 2011, BIOL PSYCHIAT, V69, P80, DOI 10.1016/j.biopsych.2010.08.022; Zhang F, 2009, MED IMAGE ANAL, V13, P5, DOI 10.1016/j.media.2008.05.001	50	25	26	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	SEP 1	2011	58	1					109	121		10.1016/j.neuroimage.2011.05.087			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	802ZC	WOS:000293548500014	21722739	Green Accepted			2021-06-18	
J	Zhang, XY; Yang, ZJ; Wang, QX; Fan, HR				Zhang, Xiang-yu; Yang, Zi-jian; Wang, Qi-xing; Fan, Hai-rong			Impact of positive end-expiratory pressure on cerebral injury patients with hypoxemia	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							LUNG-PROTECTIVE VENTILATION; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; NEUROSURGICAL PATIENTS; BRAIN; RECRUITMENT; MANEUVER; PEEP	Background: Traumatic brain injury or intracranial hemorrhage patients with acute lung injury/acute respiratory distress syndrome need mechanical ventilation. The use of positive end-expiratory pressure (PEEP) in this situation remains controversial. This study explored the impact of PEEP on intracranial pressure (ICP), cerebral perfusion pressure (CPP), central venous pressure (CVP), and mean arterial pressure (MAP) in cerebral injury patients. Methods: Nine cerebral injury patients with lung injury who needed mechanical ventilation and met the criteria for ICP monitoring were included in this study. Intraventricular catheters were positioned in 1 of the bilateral ventricles and connected to pressure transducers. Invasive arterial pressure and CVP were monitored continuously. Pressure control ventilation was applied during this clinical trial in a stepwise recruitment maneuver (RM) with 3 cm H2O intermittent increments and decrements of PEEP. Results: A total of 28 RMs were completed in 9 patients. Mean values of MAP, CVP, ICP, and CPP 5 minutes after RMs showed no significant differences compared with baseline (P > 0.05). Correlation analysis of all the mean values of MAP, CVP, ICP, and CPP showed significant correlation between MAP and CPP, PEEP and CVP, PEEP and ICP, and PEEP and CPP with all P values less than 0.05. Conclusion: The impact of PEEP on blood pressure, ICP, and CPP varies greatly in cerebral injury patients. Mean arterial pressure and ICP monitoring is of benefit when using PEEP in cerebral injury patients with hypoxemia. (C) 2011 Elsevier Inc. All rights reserved.	[Zhang, Xiang-yu; Yang, Zi-jian; Wang, Qi-xing; Fan, Hai-rong] Tongji Univ, Dept Emergency & Crit Care Med, Shanghai Peoples Hosp 10, Sch Med, Shanghai 200072, Peoples R China	Zhang, XY (corresponding author), Tongji Univ, Dept Emergency & Crit Care Med, Shanghai Peoples Hosp 10, Sch Med, Shanghai 200072, Peoples R China.	xiangyu62@126.com					Bein T, 2002, INTENS CARE MED, V28, P554, DOI 10.1007/s00134-002-1273-y; Caricato A, 2005, J TRAUMA, V58, P571, DOI 10.1097/01.TA.0000152806.19198.DB; David M, 2006, BRIT J ANAESTH, V97, P525, DOI 10.1093/bja/ael215; Fan E, 2008, AM J RESP CRIT CARE, V178, P1156, DOI 10.1164/rccm.200802-335OC; FARGE D, 1995, CHEST, V107, P1095, DOI 10.1378/chest.107.4.1095; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Georgiadis D, 2001, STROKE, V32, P2088, DOI 10.1161/hs0901.095406; Haitsma JJ, 2006, MINERVA ANESTESIOL, V72, P117; Huynh T, 2002, J TRAUMA, V53, P488, DOI 10.1097/00005373-200209000-00016; Lowe GJ, 2006, CURR OPIN CRIT CARE, V12, P3, DOI 10.1097/01.ccx.0000198055.29600.4b; Mascia L, 2005, INTENS CARE MED, V31, P373, DOI 10.1007/s00134-004-2491-2; McGuire G, 1997, CRIT CARE MED, V25, P1059, DOI 10.1097/00003246-199706000-00025; Muench E, 2005, CRIT CARE MED, V33, P2367, DOI 10.1097/01.CCM.0000181732.37319.DF; Qiu Hai-Bo, 2004, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V16, P399; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Stocchetti N, 2008, MINERVA ANESTESIOL, V74, P199; Stonestreet BS, 2000, J APPL PHYSIOL, V88, P1672; The Brain Trauma Foundation; The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P479; Wolf S, 2002, ACT NEUR S, V81, P99; Yang Zi-jian, 2008, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V20, P588	20	25	25	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	SEP	2011	29	7					699	703		10.1016/j.ajem.2010.01.042			5	Emergency Medicine	Emergency Medicine	818MV	WOS:000294756700001	20825872				2021-06-18	
J	Vender, J; Waller, J; Dhandapani, K; McDonnell, D				Vender, John; Waller, Jennifer; Dhandapani, Krishnan; McDonnell, Dennis			AN EVALUATION AND COMPARISON OF INTRAVENTRICULAR, INTRAPARENCHYMAL, AND FLUID-COUPLED TECHNIQUES FOR INTRACRANIAL PRESSURE MONITORING IN PATIENTS WITH SEVERE TRAUMATIC BRAIN INJURY	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						traumatic brain injury; intracranial pressure monitoring; intraparenchymal; intraventricular; fluid-coupled	CEREBRAL PERFUSION-PRESSURE; CLINICAL-EVALUATION; CODMAN MICROSENSOR; ICP SIGNALS; OXYGEN	Objective. Intracranial pressure measurements have become one of the mainstays of traumatic brain injury management. Various technologies exist to monitor intracranial pressure from a variety of locations. Transducers are usually placed to assess pressure in the brain parenchyma and the intraventricular fluid, which are the two most widely accepted compartmental monitoring sites. The individual reliability and inter-reliability of these devices with and without cerebrospinal fluid diversion is not clear. The predictive capability of monitors in both of these sites to local, regional, and global changes also needs further clarification. The technique of monitoring intraventricular pressure with a fluid-coupled transducer system is also reviewed. There has been little investigation into the relationship among pressure measurements obtained from these two sources using these three techniques. Methods. Eleven consecutive patients with severe, closed traumatic brain injury not requiring intracranial mass lesion evacuation were admitted into this prospective study. Each patient underwent placement of a parenchymal and intraventricular pressure monitor. The ventricular catheter tubing was also connected to a sensor for fluid-coupled measurement. Pressure from all three sources was measured hourly with and without ventricular drainage. Results. Statistically significant correlation within each monitoring site was seen. No monitoring location was more predictive of global pressure changes or more responsive to pressure changes related to patient stimulation. However, the intraventricular pressure measurements were not reliable in the presence of cerebrospinal fluid drainage whereas the parenchymal measurements remained unaffected. Conclusion. Intraparenchymal pressure monitoring provides equivalent, statistically similar pressure measurements when compared to intraventricular monitors in all care and clinical settings. This is particularly valuable when uninterrupted cerebrospinal fluid drainage is desirable.	[Vender, John; Dhandapani, Krishnan; McDonnell, Dennis] Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA; [Waller, Jennifer] Med Coll Georgia, Dept Biostat, Augusta, GA 30912 USA	Vender, J (corresponding author), Med Coll Georgia, Dept Neurosurg, BI 3088,1120 15th St, Augusta, GA 30912 USA.	jvender@mail.mcg.edu		Dhandapani, Krishnan/0000-0001-7044-1117	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065172] Funding Source: Medline		Brain Trauma Foundation, 2000, MAN PROGN SEV TRAU 1; Brean A, 2006, J Clin Monit Comput, V20, P411, DOI 10.1007/s10877-006-9047-7; BRUDER N, 1995, INTENS CARE MED, V21, P850, DOI 10.1007/BF01700971; Chambers IR, 2001, J NEUROL NEUROSUR PS, V71, P383, DOI 10.1136/jnnp.71.3.383; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Eide PK, 2008, MED ENG PHYS, V30, P34, DOI 10.1016/j.medengphy.2007.01.005; Eide PK, 2006, MED ENG PHYS, V28, P542, DOI 10.1016/j.medengphy.2005.09.003; Fernandes HM, 1998, ACT NEUR S, V71, P44; Huschak G, 2009, J NEUROSURG ANESTH, V21, P155, DOI 10.1097/ANA.0b013e31818f2eac; Isa Ruwaida, 2003, Neurosurg Focus, V15, pE1; Khan SH, 1998, ACT NEUR S, V71, P50; Maas AI, 2008, J TRAUMA, V65, P966, DOI 10.1097/TA.0b013e318184ee7b; Munch EC, 2001, CRIT CARE MED, V29, P976; Murad A, 2008, ACT NEUR S, V102, P89, DOI 10.1007/978-3-211-85578-2_18; Poca MA, 2002, J NEUROTRAUM, V19, P439, DOI 10.1089/08977150252932398; Schneider GH, 1998, ACT NEUR S, V71, P62; Signorini DF, 1998, BRIT J NEUROSURG, V12, P223; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7	21	25	27	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	AUG	2011	25	4					231	236		10.1007/s10877-011-9300-6			6	Anesthesiology	Anesthesiology	872NJ	WOS:000298816100003	21938526				2021-06-18	
J	Berrigan, L; Marshall, S; Mccullagh, S; Velikonja, D; Bayley, M				Berrigan, Lindsay; Marshall, Shawn; Mccullagh, Scott; Velikonja, Diana; Bayley, Mark			Quality of clinical practice guidelines for persons who have sustained mild traumatic brain injury	BRAIN INJURY			English	Article						Mild traumatic brain injury; clinical practice guidelines; evidence-based practice; AGREE instrument; post-concussion syndrome	POST-CONCUSSION SYMPTOMS; POSTCONCUSSION SYNDROME; CHRONIC PAIN; HEAD-INJURY; VALIDATION; INSTRUMENT; PREDICTION; APPRAISAL	Background: Mild TBI is one of the most common neurological disorders occurring today. For individuals who experience persistent symptoms following mild TBI, consequences can include functional disability, stress and time away from one's occupation. The objective of the study was to evaluate the quality of clinical practice guidelines (CPGs) that include recommendations on the care of persons who have sustained mild TBI and associated persistent symptoms. Methods: A minimum of four appraisers used the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument to evaluate seven CPGs found via a systematic search of bibliographic databases and internet resources. Results: High AGREE scores were obtained for the domains Scope and Purpose and Clarity and Presentation. The CPGs fared less well on Rigour of Development, Stakeholder Involvement, Editorial Independence and Applicability. The number of recommendations addressing the care of persistent symptoms following mild TBI was meager, with the exception of military guidelines. Conclusions: There is considerable variability in the quality of guidelines addressing mild TBI and, overall, the CPGs reviewed score lower on Rigour of Development than CPGs for other medical conditions. There is a clear need for clinical guidance on the management of individuals who experience persistent symptoms following mild TBI.	[Berrigan, Lindsay; Marshall, Shawn] Ottawa Gen Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada; [Marshall, Shawn] Univ Ottawa, Ottawa, ON, Canada; [Mccullagh, Scott; Bayley, Mark] Univ Toronto, Toronto, ON, Canada; [Velikonja, Diana] McMaster Univ, Hamilton, ON, Canada	Berrigan, L (corresponding author), Ottawa Gen Hosp, Res Inst, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	lberrigan@Ottawahospital.on.ca		Bayley, Mark/0000-0001-7860-9463	Ontario Neurotrauma Foundation	This work was conducted with funding support from the Ontario Neurotrauma Foundation. The authors report no conflicts of interest.	American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Burgers JS, 2004, J CLIN ONCOL, V22, P2000, DOI 10.1200/JCO.2004.06.157; Cluzeau F, 2003, QUAL SAF HEALTH CARE, V12, P18; *DEP LAB EMPL STAT, 2005, TRAUM BRAIN INJ MED; *DVBIC, 2008, UPD MTBI CLIN GUID; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Hurdowar A, 2007, J EVAL CLIN PRACT, V13, P657, DOI 10.1111/j.1365-2753.2007.00708.x; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; KRAUS JF, 1996, NEUROTRAUMA, P13; Lohr KN, 1992, GUIDELINES CLIN PRAC; *MAANSW, 2008, GUID MILD TRAUM BRAI; Martelli MF, 2007, BRAIN INJURY MED PRI, P1183; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; National Institute for Health and Clinical Excellence (NICE), 2007, HEAD INJ TRIAG ASS I; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Rusnak M, 2008, BRATISL MED J, V109, P374; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spinos P, 2010, J TRAUMA, V69, P789, DOI 10.1097/TA.0b013e3181edea67; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stone MA, 2010, DIABETES RES CLIN PR, V87, P252, DOI 10.1016/j.diabres.2009.10.020; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; *WORKPL SAF INS BO, 2006, MILD TRAUM BRAIN INJ; World Health Organization, 1992, ICD 10 INT STAT CLAS	46	25	25	0	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2011	25	7-8					742	751		10.3109/02699052.2011.580317			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	769RJ	WOS:000291035600010	21604931				2021-06-18	
J	Heuer, JF; Pelosi, P; Hermann, P; Perske, C; Crozier, TA; Bruck, W; Quintel, M				Heuer, Jan Florian; Pelosi, Paolo; Hermann, Peter; Perske, Christina; Crozier, Thomas A.; Brueck, Wolfgang; Quintel, Michael			Acute effects of intracranial hypertension and ARDS on pulmonary and neuronal damage: a randomized experimental study in pigs	INTENSIVE CARE MEDICINE			English	Article						ABI; ARDS; ELWI; CT scan; Organ dysfunction	RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; ACUTE LUNG INJURY; SEVERE HEAD-INJURY; HIGH TIDAL VOLUME; CRITICALLY-ILL PATIENTS; NSE SERUM MEASUREMENTS; S-100 PROTEIN; S100B PROTEIN; SERIAL S-100	To determine reciprocal and synergistic effects of acute intracranial hypertension and ARDS on neuronal and pulmonary damage and to define possible mechanisms. Twenty-eight mechanically ventilated pigs were randomized to four groups of seven each: control; acute intracranial hypertension (AICH); acute respiratory distress syndrome (ARDS); acute respiratory distress syndrome in combination with acute intracranial hypertension (ARDS + AICH). AICH was induced with an intracranial balloon catheter and the inflation volume was adjusted to keep intracranial pressure (ICP) at 30-40 cmH(2)O. ARDS was induced by oleic acid infusion. Respiratory function, hemodynamics, extravascular lung water index (ELWI), lung and brain computed tomography (CT) scans, as well as inflammatory mediators, S100B, and neuronal serum enolase (NSE) were measured over a 4-h period. Lung and brain tissue were collected and examined at the end of the experiment. In both healthy and injured lungs, AICH caused increases in NSE and TNF-alpha plasma concentrations, extravascular lung water, and lung density in CT, the extent of poorly aerated (dystelectatic) and atelectatic lung regions, and an increase in the brain tissue water content. ARDS and AICH in combination induced damage in the hippocampus and decreased density in brain CT. AICH induces lung injury and also exacerbates pre-existing damage. Increased extravascular lung water is an early marker. ARDS has a detrimental effect on the brain and acts synergistically with intracranial hypertension to cause histological hippocampal damage.	[Heuer, Jan Florian; Hermann, Peter; Crozier, Thomas A.; Quintel, Michael] Univ Gottingen, Med Ctr, Dept Anaesthesiol Emergency & Intens Care Med, Gottingen, Germany; [Pelosi, Paolo] Univ Genoa, Dipartimento Sci Chirurg & Diagnost Integrate, Genoa, Italy; [Perske, Christina] Univ Gottingen, Dept Pathol, Med Ctr, D-3400 Gottingen, Germany; [Brueck, Wolfgang] Univ Gottingen, Med Ctr, Dept Neuropathol, Gottingen, Germany	Heuer, JF (corresponding author), Univ Gottingen, Med Ctr, Dept Anaesthesiol Emergency & Intens Care Med, Gottingen, Germany.	jheuer@med.uni-goettingen.de; ppelosi@hotmail.com; phermann@med.uni-goettingen.de; tinaperske@med.uni-goettingen.de; tcrozier@med.uni-goettingen.de; wbrueck@med.uni-goettingen.de; mquintel@med.uni-goettingen.de		Pelosi, Paolo/0000-0001-5055-3023			Appelberg J, 2010, CLIN PHYSIOL FUNCT I, V30, P301, DOI 10.1111/j.1475-097X.2010.00941.x; Avlonitis VS, 2005, AM J TRANSPLANT, V5, P684, DOI 10.1111/j.1600-6143.2005.00755.x; Beaudeux JL, 2000, CLIN CHEM, V46, P989; Beilin B, 2007, BRIT J ANAESTH, V99, P522, DOI 10.1093/bja/aem218; Bickenbach J, 2009, ANESTH ANALG, V109, P847, DOI 10.1213/ane.0b013e3181ad5769; BIGGER JT, 1992, CIRCULATION, V85, P164, DOI 10.1161/01.CIR.85.1.164; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Broccard AF, 1997, CRIT CARE MED, V25, P16, DOI 10.1097/00003246-199701000-00007; DAUBER IM, 1983, J CLIN INVEST, V72, P1977, DOI 10.1172/JCI111162; de Oliveira RP, 2010, CRIT CARE, V14, DOI 10.1186/cc8919; Florio P, 2006, PEDIATRICS, V118, pE747, DOI 10.1542/peds.2005-2875; Fries M, 2005, ANESTHESIOLOGY, V102, P761, DOI 10.1097/00000542-200504000-00011; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Gazzolo D, 2005, PEDIATR RES, V58, P1170, DOI 10.1203/01.pdr.0000185131.22985.30; GOLDMAN G, 1992, J APPL PHYSIOL, V73, P571; Gonzalvo R, 2007, CRIT CARE, V11, DOI 10.1186/cc5930; Haitsma JJ, 2009, ACTA ANAESTH SCAND, V53, P176, DOI 10.1111/j.1399-6576.2008.01844.x; HALPERIN BD, 1985, CHEST, V88, P649, DOI 10.1378/chest.88.5.649; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 2006, BRAIN INJURY, V20, P263, DOI 10.1080/02699050500488199; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; HORN M, 1995, STROKE, V26, P296; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; KOWALSKI ML, 1989, AM REV RESPIR DIS, V140, P101, DOI 10.1164/ajrccm/140.1.101; Lopez-Aguilar J, 2005, CRIT CARE MED, V33, P1077, DOI 10.1097/01.CCM.0000162913.72479.F7; Lopez-Aguilar J, 2010, INTENS CARE MED, V36, P347, DOI 10.1007/s00134-009-1695-x; Lou JN, 1997, AM J PATHOL, V151, P1397; Lowe GJ, 2006, CURR OPIN CRIT CARE, V12, P3, DOI 10.1097/01.ccx.0000198055.29600.4b; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; Mascia L, 2009, NEUROCRIT CARE, V11, P417, DOI 10.1007/s12028-009-9242-8; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; PELOSI P, 1994, AM J RESP CRIT CARE, V149, P8, DOI 10.1164/ajrccm.149.1.8111603; Rassler B, 2003, RESP PHYSIOL NEUROBI, V135, P25, DOI 10.1016/S1569-9048(03)00062-4; Rohde V, 2002, J NEUROSURG, V97, P954, DOI 10.3171/jns.2002.97.4.0954; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; ROZSA L, 1989, NEUROSURG REV, V12, P133, DOI 10.1007/BF01741486; Rylander C, 2005, CRIT CARE, V9, pR165, DOI 10.1186/cc3058; Sakka SG, 2002, CHEST, V122, P2080, DOI 10.1378/chest.122.6.2080; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SIBILLE Y, 1993, EUR RESPIR J, V6, P1529; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; STRIETER RM, 1994, J INVEST MED, V42, P640; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; Takada M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001; Takahashi N, 2010, JPN J RADIOL, V28, P349, DOI 10.1007/s11604-010-0430-4; TOUHO H, 1989, NEUROSURGERY, V25, P762, DOI 10.1227/00006123-198911000-00011; Unden J, 2007, NEUROCRIT CARE, V6, P94, DOI 10.1007/s12028-007-0005-0; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valenza F, 2005, CRIT CARE MED, V33, P361, DOI 10.1097/01.CCM.0000150660.45376.7C; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Vlahakis NE, 1999, AM J PHYSIOL-LUNG C, V277, pL167; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1165; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	66	25	26	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUL	2011	37	7					1182	1191		10.1007/s00134-011-2232-2			10	Critical Care Medicine	General & Internal Medicine	786ET	WOS:000292286800020	21544692	Green Published, Other Gold			2021-06-18	
J	van Veldhoven, LM; Sander, AM; Struchen, MA; Sherer, M; Clark, AN; Hudnall, GE; Hannay, HJ				van Veldhoven, L. M.; Sander, A. M.; Struchen, M. A.; Sherer, M.; Clark, A. N.; Hudnall, Gina Evans; Hannay, H. J.			Predictive ability of preinjury stressful life events and post-traumatic stress symptoms for outcomes following mild traumatic brain injury: analysis in a prospective emergency room sample	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HEAD-INJURY; POSTCONCUSSIONAL-SYNDROME; PSYCHOMETRIC PROPERTIES; PTSD CHECKLIST; DISORDER; CRITERIA; DEPRESSION	Background A subset of persons with mild traumatic brain injury (mTBI) experience long-term difficulties. Preinjury stress has been hypothesised to play a role in long-term maintenance of symptoms. Objective To investigate the predictive ability of preinjury stressful life events and post-traumatic stress symptoms to health-related quality of life and emotional distress after mTBI. Methods Within 2 weeks of injury, 186 participants with mTBI who were admitted to an emergency centre completed an interview and questionnaires regarding preinjury functioning, including the Stressful Life Events Questionnaire and the Post-Traumatic Stress Disorder Checklist. Outcomes were assessed at 3 months after injury and included the depression and anxiety subscales of the Brief Symptom Inventory, and the physical and mental component scores of the 36-item Short-Form Health Survey (SF-36). The incidence and type of stressful life events were reported. Hierarchical regression analyses were used to determine the predictive utility of Stressful Life Events Questionnaire and Post-Traumatic Stress Disorder Checklist after controlling for age, injury severity (complicated versus uncomplicated mild) and preinjury depression. Results Several potentially life-altering stressful events were endorsed by at least 25% of participants as having been experienced prior to injury. The incidence of stressful life events was a significant predictor of all four outcome variables. History of post-traumatic stress symptoms was predictive of scores on the SF-36 mental health component. Conclusions A history of stressful events may predispose persons with mTBI to have poor outcomes. History of stress should be assessed during the early stages after mTBI to help identify those who could benefit from therapies to assist with adjustment and maximise recovery.	[van Veldhoven, L. M.; Sander, A. M.; Sherer, M.; Clark, A. N.] Brain Injury Res Ctr, TIRR Mem Hermann, Houston, TX 77019 USA; [van Veldhoven, L. M.; Sander, A. M.; Struchen, M. A.; Sherer, M.; Clark, A. N.; Hudnall, Gina Evans; Hannay, H. J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, A. M.; Hannay, H. J.] Harris Cty Hosp Dist, Houston, TX USA; [Hudnall, Gina Evans] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Hannay, H. J.] Univ Houston, Dept Psychol, Houston, TX USA	Sander, AM (corresponding author), Brain Injury Res Ctr, TIRR Mem Hermann, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	asander@bcm.edu		Hannay, H. Julia/0000-0001-7023-912X	National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133B990014, H133B090023, H133A070043]	This work was supported by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grant nos H133B990014, H133B090023 and H133A070043).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P427; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cutrona CE, 2005, J ABNORM PSYCHOL, V114, P3, DOI 10.1037/0021-843X.114.1.3; Derogatis L, 1993, BRIEF SYMPTOM INVENT; Derogatis LR, 1975, BRIEF SYMPTOM INVENT; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Goodman LA, 1998, J TRAUMA STRESS, V11, P521, DOI 10.1023/A:1024456713321; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Keane T., 1994, PTSD CHECKLIST CIVIL; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lynch JW, 1997, NEW ENGL J MED, V337, P1889, DOI 10.1056/NEJM199712253372606; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; ORSILLO SM, 2001, PRACTITIONERS GUIDE, P287; Ponniah K, 2009, DEPRESS ANXIETY, V26, P1086, DOI 10.1002/da.20635; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Symonds C. P, 1937, P ROY SOC MED, V30, P33; United States Department of Health and Human Services, 2001, MENT HLTH REP SURG G; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Weathers F.W., 1993, PTSD CHECKLIST RELIA; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	40	25	25	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2011	82	7					782	787		10.1136/jnnp.2010.228254			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	775AR	WOS:000291429200018	21242288				2021-06-18	
J	Duffy, AM; Schaner, MJ; Wu, SH; Staniszewski, A; Kumar, A; Arevalo, JC; Arancio, O; Chao, MV; Scharfman, HE				Duffy, Aine M.; Schaner, Michael J.; Wu, Synphen H.; Staniszewski, Agnieszka; Kumar, Asok; Carlos Arevalo, Juan; Arancio, Ottavio; Chao, Moses V.; Scharfman, Helen E.			A selective role for ARMS/Kidins220 scaffold protein in spatial memory and trophic support of entorhinal and frontal cortical neurons	EXPERIMENTAL NEUROLOGY			English	Article						BDNF; Neurotrophin; Sex differences; Spatial memory; Myelin; Oxidative stress	AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; MORRIS WATER TASK; RADIAL-ARM MAZE; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; OXIDATIVE STRESS; SEX-DIFFERENCES; MOUSE MODEL	Progressive cortical pathology is common to several neurodegenerative and psychiatric disorders. The entorhinal cortex (EC) and frontal cortex (FC) are particularly vulnerable, and neurotrophins have been implicated because they appear to be protective. A downstream signal transducer of neurotrophins, the ankyrin repeat-rich membrane spanning scaffold protein/Kidins 220 (ARMS) is expressed in the cortex, where it could play an important role in trophic support. To test this hypothesis, we evaluated mice with a heterozygous deletion of ARMS (ARMS' mice). Remarkably, the EC and FC were the regions that demonstrated the greatest defects. Many EC and FC neurons became pyknotic in ARMS(+/-) mice, so that large areas of the EC and FC were affected by 12 months of age. Areas with pyknosis in the EC and FC of ARMS(+/-) mice were also characterized by a loss of immunoreactivity to a neuronal antigen. NeuN, which has been reported after insult or injury to cortical neurons. Electron microscopy showed that there were defects in mitochondria, myelination, and multilamellar bodies in the EC and FC of ARMS(+/-) mice. Although primarily restricted to the EC and FC, pathology appeared to be sufficient to cause functional impairments, because ARMS(+/-) mice performed worse than wild-type on the Morris water maze. Comparisons of males and females showed that female mice were the affected sex in all comparisons. Taken together, the results suggest that the expression of a prominent neurotrophin receptor substrate normally protects the EC and FC, and that ARMS may be particularly important in females. Published by Elsevier Inc.	[Duffy, Aine M.; Schaner, Michael J.; Kumar, Asok; Scharfman, Helen E.] Nathan S Kline Inst Psychiat Res, Ctr Dementia Res, Orangeburg, NY 10962 USA; [Wu, Synphen H.; Chao, Moses V.] NYU, Skirball Inst Biomol Med, Mol Neurobiol Program, Dept Cell Biol,Langone Med Ctr, New York, NY 10016 USA; [Wu, Synphen H.; Chao, Moses V.] NYU, Skirball Inst Biomol Med, Mol Neurobiol Program, Dept Physiol & Neurosci,Langone Med Ctr, New York, NY 10016 USA; [Wu, Synphen H.; Chao, Moses V.] NYU, Skirball Inst Biomol Med, Mol Neurobiol Program, Dept Psychiat,Langone Med Ctr, New York, NY 10016 USA; [Scharfman, Helen E.] NYU, Langone Med Ctr, Dept Child & Adolescent Psychiat, New York, NY 10016 USA; [Staniszewski, Agnieszka; Arancio, Ottavio] Columbia Univ, Med Ctr New York, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Staniszewski, Agnieszka; Arancio, Ottavio] Columbia Univ, Med Ctr New York, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; [Carlos Arevalo, Juan] Univ Salamanca, Dept Cell Biol & Pathol, INCyL, Salamanca 37007, Spain	Duffy, AM (corresponding author), Nathan S Kline Inst Psychiat Res, Ctr Dementia Res, 140 Old Orangeburg Rd,Bldg 35, Orangeburg, NY 10962 USA.	aduffy@nki.rfmh.org; hscharfman@nki.rfmh.org	Arevalo, Juan Carlos/J-8154-2014; arancio, ottavio/AAB-7959-2019	Arevalo, Juan Carlos/0000-0003-1994-3095; Chao, Moses/0000-0002-6969-3744; arancio, ottavio/0000-0001-6335-164X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-37562, MH-084215, NS-21072, HD-23315, AG-034248]; New York University Langone Medical Center; New York State Office of Mental Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD023315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH084215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS037562, R56NS021072, R01NS021072, R01NS037562] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034248] Funding Source: NIH RePORTER	This study was supported by NIH NS-37562 and MH-084215 to H.E.S., NIH NS-21072 and HD-23315 to M.V.C., NIH AG-034248 to O.A., the New York University Langone Medical Center CoE Seed Grant Program, and the New York State Office of Mental Health. We thank Dr. Ralph Nixon, Dr. Neil Maclusky, Dr. Daniel Wesson, and Patrice Pearce for their suggestions.	Andreazza AC, 2010, ARCH GEN PSYCHIAT, V67, P360, DOI 10.1001/archgenpsychiatry.2010.22; Arevalo JC, 2004, EMBO J, V23, P2358, DOI 10.1038/sj.emboj.7600253; Arevolo JC, 2006, J BIOL CHEM, V281, P1001, DOI 10.1074/jbc.M504163200; ARNOLD SE, 1995, AM J PSYCHIAT, V152, P738; Arnold SE, 2000, ANN NY ACAD SCI, V911, P275; Astur RS, 2004, BEHAV BRAIN RES, V151, P103, DOI 10.1016/j.bbr.2003.08.024; Astur RS, 1998, BEHAV BRAIN RES, V93, P185, DOI 10.1016/S0166-4328(98)00019-9; Barnes CA, 2000, NEUROBIOL AGING, V21, P613, DOI 10.1016/S0197-4580(00)00163-9; Bimonte-Nelson HA, 2004, NEUROREPORT, V15, P2659, DOI 10.1097/00001756-200412030-00021; Binder DK, 2004, ADV EXP MED BIOL, V548, P34; Bogolepov N N, 1971, Zh Nevropatol Psikhiatr Im S S Korsakova, V71, P1337; Boland B, 2008, J NEUROSCI, V28, P6926, DOI 10.1523/JNEUROSCI.0800-08.2008; Boland Barry, 2006, Molecular Aspects of Medicine, V27, P503, DOI 10.1016/j.mam.2006.08.009; BRAAK H, 1990, ACTA NEUROPATHOL, V80, P479, DOI 10.1007/BF00294607; Brinton RD, 2008, TRENDS NEUROSCI, V31, P529, DOI 10.1016/j.tins.2008.07.003; BUCCI DJ, 1995, BEHAV NEUROSCI, V109, P180, DOI 10.1037/0735-7044.109.1.180; Buckingham BP, 2008, J NEUROSCI, V28, P2735, DOI 10.1523/JNEUROSCI.4443-07.2008; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Cellerino A, 1997, MOL CELL NEUROSCI, V9, P397, DOI 10.1006/mcne.1997.0641; Chao MV, 2006, CLIN SCI, V110, P167, DOI 10.1042/CS20050163; Davoli MA, 2002, NEUROSCIENCE, V115, P125, DOI 10.1016/S0306-4522(02)00376-7; de Leon MJ, 2007, ANN NY ACAD SCI, V1097, P114, DOI 10.1196/annals.1379.012; De Toledo-Morrell L, 2000, ANN NY ACAD SCI, V911, P240, DOI 10.1111/j.1749-6632.2000.tb06730.x; DeToledo-Morrell L, 2007, PROG BRAIN RES, V163, P741, DOI 10.1016/S0079-6123(07)63040-4; Dolorfo CL, 1998, J COMP NEUROL, V398, P49, DOI 10.1002/(SICI)1096-9861(19980817)398:1<49::AID-CNE4>3.0.CO;2-9; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Drevets WC, 2000, PROG BRAIN RES, V126, P413; DU F, 1993, EPILEPSY RES, V16, P223, DOI 10.1016/0920-1211(93)90083-J; Duffy AM, 2009, NEUROSCIENCE, V161, P1091, DOI 10.1016/j.neuroscience.2009.04.024; Durany N, 2001, SCHIZOPHR RES, V52, P79, DOI 10.1016/S0920-9964(00)00084-0; Finn PF, 2006, NUTRITION, V22, P830, DOI 10.1016/j.nut.2006.04.008; Gawryluk JW, 2010, INT J NEUROPSYCHOPH, V16, P1; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Gresack JE, 2003, BRAIN RES, V982, P98, DOI 10.1016/S0006-8993(03)03000-2; Hayakawa N, 2008, EXP MOL PATHOL, V85, P135, DOI 10.1016/j.yexmp.2008.05.001; Hebert AE, 2002, LEARN MEMORY, V9, P156, DOI 10.1101/lm.48502; Henderson VW, 2010, PROG BRAIN RES, V182, P77, DOI 10.1016/S0079-6123(10)82003-5; HEVNER RF, 1992, J COMP NEUROL, V326, P451, DOI 10.1002/cne.903260310; Hirata-Fukae C, 2008, BRAIN RES, V1216, P92, DOI 10.1016/j.brainres.2008.03.079; Holland D, 2009, P NATL ACAD SCI USA, V106, P20954, DOI 10.1073/pnas.0906053106; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Irwin RW, 2008, ENDOCRINOLOGY, V149, P3167, DOI 10.1210/en.2007-1227; Jo YS, 2007, J NEUROSCI, V27, P13567, DOI 10.1523/JNEUROSCI.3589-07.2007; Kadriu B, 2009, TOXICOLOGY, V256, P164, DOI 10.1016/j.tox.2008.11.021; Knusel B, 1996, LIFE SCI, V58, P2019, DOI 10.1016/0024-3205(96)00193-2; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; Kong HY, 2001, J NEUROSCI, V21, P176, DOI 10.1523/JNEUROSCI.21-01-00176.2001; Kong JM, 1998, J NEUROSCI, V18, P3241; Kordower JH, 2001, ANN NEUROL, V49, P202, DOI 10.1002/1531-8249(20010201)49:2<202::AID-ANA40>3.3.CO;2-V; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Koyama R, 2005, NEUROSCIENTIST, V11, P282, DOI 10.1177/1073858405278266; Krimer LS, 1997, CEREB CORTEX, V7, P732, DOI 10.1093/cercor/7.8.732; LaBuda CJ, 2002, PHYSIOL BEHAV, V76, P213, DOI 10.1016/S0031-9384(02)00713-8; Lai KO, 2009, CURR OPIN NEUROBIOL, V19, P275, DOI 10.1016/j.conb.2009.04.009; Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032; Leon WC, 2010, LEARN MEMORY, V17, P297, DOI 10.1101/lm.1804410; Lewis DA, 2003, ANN NY ACAD SCI, V1003, P102, DOI 10.1196/annals.1300.007; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lind D, 2005, J NEUROSCI RES, V79, P295, DOI 10.1002/jnr.20354; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Lopez-Menendez C, 2009, J CELL SCI, V122, P3554, DOI 10.1242/jcs.056473; MAREN S, 1994, BRAIN RES, V661, P25, DOI 10.1016/0006-8993(94)91176-2; Martin LJ, 2007, J COMP NEUROL, V500, P20, DOI 10.1002/cne.21160; Matsuda S, 2009, J NEURAL TRANSM, V116, P395, DOI 10.1007/s00702-009-0194-0; Mayeaux DJ, 2004, PHYSIOL BEHAV, V82, P653, DOI 10.1016/j.physbeh.2004.06.002; McDonald CR, 2009, NEUROLOGY, V73, P457, DOI 10.1212/WNL.0b013e3181b16431; MCNAMARA JO, 2011, TEMPORAL LOBE EPILEP; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; McTigue DM, 1998, J NEUROSCI, V18, P5354; Michel TM, 2007, PSYCHIAT RES, V151, P145, DOI 10.1016/j.psychres.2006.04.013; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Murai KK, 2004, NEUROSCIENTIST, V10, P304, DOI 10.1177/1073858403262221; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Nakazawa K, 2006, NEURON, V50, P183, DOI 10.1016/j.neuron.2006.04.007; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Peng S, 2009, J NEUROSCI, V29, P9321, DOI 10.1523/JNEUROSCI.4736-08.2009; PerrotSinal TS, 1996, BEHAV NEUROSCI, V110, P1309, DOI 10.1037/0735-7044.110.6.1309; Peters A, 1991, FINE STRUCTURE NERVO; Petrulis A, 2003, NEUROSCIENCE, V122, P599, DOI 10.1016/j.neuroscience.2003.08.009; Portiansky EL, 2006, EXP NEUROL, V202, P519, DOI 10.1016/j.expneurol.2006.07.014; Postma A, 1999, PSYCHONEUROENDOCRINO, V24, P175, DOI 10.1016/S0306-4530(98)00073-0; POSTMA A, 2004, BRAIN COGN, V54; Puzzo D, 2009, J NEUROSCI, V29, P8075, DOI 10.1523/JNEUROSCI.0864-09.2009; Rajeswari A, 2008, TOXICOL IND HEALTH, V24, P189, DOI 10.1177/0748233708093726; Rajkowska G, 2002, BIPOLAR DISORD, V4, P105, DOI 10.1034/j.1399-5618.2002.01149.x; Rideout HJ, 2004, INT J BIOCHEM CELL B, V36, P2551, DOI 10.1016/j.biocel.2004.05.008; Schafer S, 2007, J NEURAL TRANSM, V114, P387, DOI 10.1007/s00702-006-0580-9; Scharfman HE, 2003, J NEUROSCI, V23, P11641; Scharfman HE, 2005, TRENDS NEUROSCI, V28, P79, DOI 10.1016/j.tins.2004.12.005; Scharfman HE, 2002, J COMP NEUROL, V454, P424, DOI 10.1002/cne.10449; Scharfman HE, 2000, ANN NY ACAD SCI, V911, P305; Scharfman HE, 2006, FRONT NEUROENDOCRIN, V27, P415, DOI 10.1016/j.yfrne.2006.09.004; Scharfman HE, 2006, EPILEPSIA, V47, P1423, DOI 10.1111/j.1528-1167.2006.00672.x; Scharfman Helen E, 2005, Epilepsy Curr, V5, P83, DOI 10.1111/j.1535-7511.2005.05312.x; Scharfman HE, 2009, ENDOCRINOLOGY, V150, P4437, DOI 10.1210/en.2009-0135; SCHENK F, 1985, EXP BRAIN RES, V58, P11; Schroeter ML, 2009, NEUROIMAGE, V47, P1196, DOI 10.1016/j.neuroimage.2009.05.037; Schuessel K, 2005, NEUROBIOL DIS, V18, P89, DOI 10.1016/j.nbd.2004.09.003; Selvamani A, 2010, J NEUROSCI, V30, P6852, DOI 10.1523/JNEUROSCI.0761-10.2010; Selvamani A, 2010, NEUROBIOL AGING, V31, P1618, DOI 10.1016/j.neurobiolaging.2008.08.014; Shah PJ, 2002, BRIT J PSYCHIAT, V180, P434, DOI 10.1192/bjp.180.5.434; Shoval G, 2005, EUR NEUROPSYCHOPHARM, V15, P319, DOI 10.1016/j.euroneuro.2004.12.005; Silachev D N, 2009, Neurosci Behav Physiol, V39, P749, DOI 10.1007/s11055-009-9197-4; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; SKUCAS V, 2009, 2009 NEUR M PLANN SO; Snedecor G.W., 1989, STAT METHODS, V8th; Sniderhan LF, 2008, MOL CELL NEUROSCI, V38, P404, DOI 10.1016/j.mcn.2008.04.001; Sohrabji F, 2006, ENDOCRINE, V29, P191, DOI 10.1385/ENDO:29:2:191; Spowart-Manning L, 2005, BEHAV BRAIN RES, V156, P269, DOI 10.1016/j.bbr.2004.05.031; Steffenach HA, 2005, NEURON, V45, P301, DOI 10.1016/j.neuron.2004.12.044; STEWARD O, 1976, J COMP NEUROL, V169, P347, DOI 10.1002/cne.901690306; Sutcliffe JS, 2007, BEHAV BRAIN RES, V177, P117, DOI 10.1016/j.bbr.2006.10.029; Tapia-Arancibia L, 2008, BRAIN RES REV, V59, P201, DOI 10.1016/j.brainresrev.2008.07.007; Terni B, 2010, BRAIN PATHOL, V20, P222, DOI 10.1111/j.1750-3639.2009.00266.x; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; Tongiorgi E, 2006, MOL NEUROBIOL, V33, P17, DOI 10.1385/MN:33:1:017; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; Van't Veer A, 2009, J NEUROSCI RES, V87, P69, DOI 10.1002/jnr.21841; Wang J, 2003, NEUROBIOL DIS, V14, P318, DOI 10.1016/j.nbd.2003.08.009; Wang JF, 2009, BIPOLAR DISORD, V11, P523, DOI 10.1111/j.1399-5618.2009.00717.x; Weickert CS, 2003, MOL PSYCHIATR, V8, P592, DOI 10.1038/sj.mp.4001308; Weickert CS, 2005, MOL PSYCHIATR, V10, P637, DOI 10.1038/sj.mp.4001678; WHITTEN WK, 1968, SCIENCE, V161, P584, DOI 10.1126/science.161.3841.584; Winawer MR, 2007, NEUROSCIENCE, V149, P465, DOI 10.1016/j.neuroscience.2007.06.009; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; Wizemann T.M., 2001, EXPLORING BIOL CONTR; Won SY, 2009, J NEUROIMMUNOL, V214, P83, DOI 10.1016/j.jneuroim.2009.07.005; Wu KL, 2010, J NEUROPATH EXP NEUR, V69, P272, DOI 10.1097/NEN.0b013e3181d1afe4; Wu SH, 2009, DEV NEUROBIOL, V69, P547, DOI 10.1002/dneu.20723; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yazdani U, 2006, EXP NEUROL, V200, P172, DOI 10.1016/j.expneurol.2006.02.002; Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524	138	25	25	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2011	229	2					409	420		10.1016/j.expneurol.2011.03.008			12	Neurosciences	Neurosciences & Neurology	774XF	WOS:000291419400026	21419124	Green Accepted			2021-06-18	
J	Nicol, A; Pollock, A; Kirkwood, G; Parekh, N; Robson, J				Nicol, Alastair; Pollock, Allyson; Kirkwood, Graham; Parekh, Nikesh; Robson, James			Rugby union injuries in Scottish schools	JOURNAL OF PUBLIC HEALTH			English	Article						injuries; rugby union; schools	SPORTS INJURIES; CONCUSSION; HEAD	Background Rugby union is the most popular worldwide collision sport, yet concerns have been raised regarding the safety of the sport due to the physical, high impact nature and an increasing number of injuries. Methods A prospective, cohort study of the incidence, pattern and severity of injuries in rugby players in six Scottish schools during the second half of the 2008-09 season. Definition of injury and severity of injury were taken from International Rugby Board (IRB) consensus guidelines. Injury report forms and exposure data for match play were completed by a nominated staff member. Results Four hundred and seventy consent forms with survey information were returned. Of 37 rugby injuries in the study, 11 occurred during training. Head and face were the most injured body part and sprain/ligament injury the most common injury. Twenty injuries required attendance at Accident & Emergency with one admission. The tackle was the commonest phase of play causing injury. In the 193 matches played, the injury incidence during the match play was 10.8 injuries per 1000 player hours. Conclusions This study confirms the feasibility of collecting relevant injury data in schools rugby in Scotland. The findings are consistent with other studies with respect to incidence and profile of injuries sustained.	[Nicol, Alastair] Univ Edinburgh, Fitness Assessment & Sports Injury Ctr FASIC, Edinburgh EH8 9TJ, Midlothian, Scotland; [Pollock, Allyson; Kirkwood, Graham; Parekh, Nikesh] Univ Edinburgh, Ctr Int Publ Hlth Policy, Edinburgh EH8 9EG, Midlothian, Scotland; [Robson, James] Scottish Rugby Union, Edinburgh EH12 5PJ, Midlothian, Scotland	Nicol, A (corresponding author), Univ Edinburgh, Fitness Assessment & Sports Injury Ctr FASIC, 46 Pleasance, Edinburgh EH8 9TJ, Midlothian, Scotland.	anicnicol@doctors.org.uk		pollock, allyson/0000-0002-7388-3110	Chief Medical Officer Directorate at the Scottish Government; Scottish Rugby Union; University of Edinburgh	This work was supported by the Chief Medical Officer Directorate at the Scottish Government; the Scottish Rugby Union and the University of Edinburgh.	Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; Brooks JHM, 2006, SPORTS MED, V36, P459, DOI 10.2165/00007256-200636060-00001; Caine D, 2006, CLIN J SPORT MED, V16, P500, DOI 10.1097/01.jsm.0000251181.36582.a0; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; FINCH CF, 2001, BRIT J SPORT MED, V35, P85; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; McIntosh Andrew S, 2005, Med Sport Sci, V49, P120, DOI 10.1159/000085394; McManus A, 2004, J SCI MED SPORT, V7, P438, DOI 10.1016/S1440-2440(04)80261-5; MICHELI LJ, 2003, ENHANCING SAFETY YOU, P1; NATHAN M, 1983, S AFR MED J, V64, P132; Quarrie KL, 2005, BRIT J SPORT MED, V39, P650, DOI 10.1136/bjsm.2004.016022; ROUX CE, 1987, S AFR MED J, V71, P307; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002	22	25	27	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1741-3842			J PUBLIC HEALTH-UK	J. Public Health	JUN	2011	33	2					256	261		10.1093/pubmed/fdq047			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	770CO	WOS:000291064800015	20581127	Bronze, Green Published			2021-06-18	
J	Koike, MA; Garcia, FG; Kitazawa, M; Green, KN; LaFerla, FM				Koike, M. A.; Garcia, F. G.; Kitazawa, M.; Green, K. N.; LaFerla, F. M.			Long term changes in phospho-APP and tau aggregation in the 3xTg-AD mice following cerebral ischemia	NEUROSCIENCE LETTERS			English	Article						Alzheimer's disease; Ischemia; Stroke; Phospho-APP	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; A-BETA; VASCULAR-LESIONS; EXPRESSION; PLAQUES; BACE1; PHOSPHORYLATION; PREVALENCE	The risk of Alzheimer's disease increases following cerebral hypoperfusion. We studied the long-term interaction between low blood flow to the brain and Alzheimer's disease by inducing a transient global ischemic insult in aged 3xTg-AD mice and determining the effects on AD pathology 3-months post injury. We found that global ischemia does not increase the levels of amyloid-beta in these mice. However, the injury did lead to enhanced phosphorylation of the amyloid precursor protein (APP) at the Thr668 site in both the 3xTg-AD mice and wild-type controls. Furthermore, we found an increase in insoluble total tau 3-months post-injury. Together these findings further elucidate the long-term impact of cerebral hypoperfusion on Alzheimer's disease. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Koike, M. A.; Garcia, F. G.; Kitazawa, M.; Green, K. N.; LaFerla, F. M.] Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA	Green, KN (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, 3222 Biol Sci 3, Irvine, CA 92697 USA.	kngreen@uci.edu; laferla@uci.edu	Kitazawa, Masashi/AAI-1721-2021	Kitazawa, Masashi/0000-0003-2165-8197	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG-021982, 1F31NS063650-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS063650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021982] Funding Source: NIH RePORTER	This work was supported by grants from the NIH AG-021982 to FML and NIH 1F31NS063650-01A1 to MAK. We thank Mr. David Cheng for assistance with the mice.	Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Cai ZY, 2009, NEUROCHEM RES, V34, P1226, DOI 10.1007/s11064-008-9899-y; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Doraiswamy PM, 2002, J GERONTOL A-BIOL, V57, pM173, DOI 10.1093/gerona/57.3.M173; Gentile MT, 2009, NEUROBIOL AGING, V30, P222, DOI 10.1016/j.neurobiolaging.2007.06.005; Goulding JMR, 1999, J NEUROL NEUROSUR PS, V67, P654, DOI 10.1136/jnnp.67.5.654; Hiltunen M, 2009, NEUROBIOL DIS, V35, P103, DOI 10.1016/j.nbd.2009.04.009; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Koike MA, 2010, AM J PATHOL, V177, P300, DOI 10.2353/ajpath.2010.090750; Lee JH, 2000, ARCH NEUROL-CHICAGO, V57, P1474, DOI 10.1001/archneur.57.10.1474; Li ZG, 2007, DIABETES, V56, P1817, DOI 10.2337/db07-0171; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; McLin JP, 2006, EUR J NEUROSCI, V24, P2191, DOI 10.1111/j.1460-9568.2006.05111.x; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Pluta R, 2007, CURR NEUROVASC RES, V4, P121, DOI 10.2174/156720207780637207; Purandare N, 2009, J NEUROL SCI, V283, P17, DOI 10.1016/j.jns.2009.02.306; Riekse RG, 2004, J AM GERIATR SOC, V52, P1442, DOI 10.1111/j.1532-5415.2004.52405.x; Sadowski M, 2004, NEUROCHEM RES, V29, P1257, DOI 10.1023/B:NERE.0000023612.66691.e6; Sheng B, 2007, J AM GERIATR SOC, V55, P918, DOI 10.1111/j.1532-5415.2007.01171.x; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Suzuki T, 2008, J BIOL CHEM, V283, P29633, DOI 10.1074/jbc.R800003200; van Groen T, 2005, STROKE, V36, P1551, DOI 10.1161/01.STR.0000169933.88903.cf; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Webster CM, 2009, NEUROBIOL DIS, V33, P301, DOI 10.1016/j.nbd.2008.11.001; Ye JT, 2009, NEUROREPORT, V20, P1456, DOI 10.1097/WNR.0b013e328332024a; Zhang X, 2007, J BIOL CHEM, V282, P10873, DOI 10.1074/jbc.M608856200	31	25	25	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAY 9	2011	495	1					55	59		10.1016/j.neulet.2011.03.034			5	Neurosciences	Neurosciences & Neurology	766YA	WOS:000290821300012	21419194	Green Accepted			2021-06-18	
J	Verlhac, S				Verlhac, Suzanne			Transcranial Doppler in children	PEDIATRIC RADIOLOGY			English	Article						Transcranial Doppler; Mean velocity; Circle of Willis; Sickle cell anaemia; Children	SICKLE-CELL-DISEASE; CEREBRAL-BLOOD-FLOW; BRAIN-DEATH; SONOGRAPHY; STROKE; ULTRASONOGRAPHY; AUTOREGULATION; HEMODYNAMICS; ULTRASOUND; VELOCITIES	Transcranial Doppler US, a non-invasive tool for evaluating the cerebral arteries, has evolved significantly during the last two decades. This review describes the practical procedure, and summarises and illustrates its established and "work-in-progress" indications in children. Indications for a transcranial Doppler US examination include, but are not limited to: (1) evaluation of cerebral blood flow velocities in the circle of Willis in patients with sickle cell anaemia to guide transfusion therapy; (2) diagnosis and follow-up of vasculopathy, such as moyamoya disease; (3) diagnosis and monitoring of acute cerebrovascular disorders in intensive care patients, in particular following traumatic brain injury, and during cardiovascular surgery; and (4) confirmation of a clinical diagnosis of brain death by documentation of cerebral circulatory arrest.	[Verlhac, Suzanne] Hop Robert Debre, Paediat Imaging Dept Sebag G, F-75935 Paris 19, France; [Verlhac, Suzanne] Intercommunal Hosp, Reference Ctr Sickle Cell Dis, Creteil, France	Verlhac, S (corresponding author), Hop Robert Debre, Paediat Imaging Dept Sebag G, 48 Blvd Serurier, F-75935 Paris 19, France.	suzanne.verlhac@rdb.aphp.fr					AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Abboud MR, 2004, BLOOD, V103, P2822, DOI 10.1182/blood-2003-06-1972; ADAMS R, 1992, NEW ENGL J MED, V326, P605, DOI 10.1056/NEJM199202273260905; Adams RJ, 1997, ANN NEUROL, V42, P699, DOI 10.1002/ana.410420505; Adams RJ, 2004, BLOOD, V103, P3689, DOI 10.1182/blood-2003-08-2733; ADAMS RJ, 1989, J CARDIOVASC TECHNOL, V8, P97; ADAMS RJ, 1992, STROKE, V23, P1073, DOI 10.1161/01.STR.23.8.1073; Bernaudin F, 2000, J CHILD NEUROL, V15, P333, DOI 10.1177/088307380001500510; Bernaudin F, 2011, BLOOD, V117, P1130, DOI 10.1182/blood-2010-06-293514; BODE H, 1988, ARCH DIS CHILD, V63, P1474, DOI 10.1136/adc.63.12.1474; BODE H, 1988, ARCH DIS CHILD, V63, P606, DOI 10.1136/adc.63.6.606; BODE H, 1989, ULTRASCHALL MED, V10, P54, DOI 10.1055/s-2007-1005962; Brouh Y, 2002, ANN FR ANESTH, V21, P676, DOI 10.1016/S0750-7658(02)00698-6; Bulas D, 2005, PEDIATR RADIOL, V35, P235, DOI 10.1007/s00247-005-1417-7; BULAS DI, 2009, ULTRASOUND CLIN, V4, P533; Chabrier S, 1998, J CHILD NEUROL, V13, P27, DOI 10.1177/088307389801300105; CHADDUCK WM, 1989, J CHILD NEUROL, V4, pS77, DOI 10.1177/0883073889004001S12; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; Enninful-Eghan H, 2010, J PEDIATR-US, V157, P479, DOI 10.1016/j.jpeds.2010.03.007; FERI M, 1994, CRIT CARE MED, V22, P1120, DOI 10.1097/00003246-199407000-00012; Figaji AA, 2010, CHILD NERV SYST, V26, P431, DOI 10.1007/s00381-009-1036-y; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Fullerton HJ, 2004, BLOOD, V104, P336, DOI 10.1182/blood-2004-02-0636; Galarza M, 2004, NEUROL RES, V26, P409, DOI 10.1179/016164104225016010; Goutorbe Ph, 2001, SFAR R, V451, p266s; Hankins JS, 2008, BRIT J HAEMATOL, V142, P94, DOI 10.1111/j.1365-2141.2008.07167.x; HAS, 2010, SYNDR DREP MAJ ENF A; Hirsch W, 2002, CLIN RADIOL, V57, P492, DOI 10.1053/crad.2002.0949; HOFFMAN WH, 1995, J CLIN ULTRASOUND, V23, P517, DOI 10.1002/jcu.1870230903; Le Moigno S, 2001, SFAR R, V452, p266s; Lee YS, 2004, J NEUROIMAGING, V14, P319, DOI 10.1177/1051228404264958; Lowe LH, 2005, AM J NEURORADIOL, V26, P1698; Lowe LH, 1989, PEDIATR RADIOL, V35, P54; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; McCarville MB, 2008, PEDIATR BLOOD CANCER, V50, P818, DOI 10.1002/pbc.21430; Monteiro LM, 2006, INTENS CARE MED, V32, P1937, DOI 10.1007/s00134-006-0353-9; MUTTAQIN Z, 1993, ACTA NEUROCHIR, V123, P76, DOI 10.1007/BF01476289; O'Brien NF, 2010, INTENS CARE MED, V36, P680, DOI 10.1007/s00134-009-1747-2; Ohene-Frempong K, 1998, BLOOD, V91, P288; Orliaguet GA, 2004, PEDIATR ANESTH, V14, P407, DOI 10.1111/j.1460-9592.2004.01340.x; Polito Angelo, 2006, Cardiovasc Ultrasound, V4, P47, DOI 10.1186/1476-7120-4-47; Qian S. Y., 1998, SMJ, V39, P247; Rafay MF, 2006, J CHILD NEUROL, V21, P8, DOI 10.1177/08830738060210010101; RAJU TNK, 1992, CRIT CARE CLIN, V8, P93; Roberts JS, 2006, CRIT CARE MED, V34, P2217, DOI 10.1097/01.CCM.0000227182.51591.21; Rodriguez Rosendo A., 2002, Pediatr Crit Care Med, V3, P153, DOI 10.1097/00130478-200204000-00012; Rougeot C, 2006, EUR J PAEDIATR NEURO, V10, P152, DOI 10.1016/j.ejpn.2006.04.001; Sadik JC, 2001, J RADIOL, V82; Schatlo B, 2007, REV RECENT CLIN TRIA, V2, P49, DOI 10.2174/157488707779318125; Soetaert AM, 2009, CURR PROBL DIAGN RAD, V38, P218, DOI 10.1067/j.cpradiol.2008.05.004; SOPER R, 1995, J PEDIATR-US, V126, P945, DOI 10.1016/S0022-3476(95)70217-2; Takase K, 1997, CLIN NEUROL NEUROSUR, V99, pS101; The American College of Radiology, 2007, ACR AIUM PRACT GUID; Tontisirin N, 2007, CHILD NERV SYST, V23, P1163, DOI 10.1007/s00381-007-0339-0; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; U.S. Department of Health and Human Services, 2007, GUID SUMM; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vavilala MS, 2008, NEUROCRIT CARE, V9, P45, DOI 10.1007/s12028-007-9036-9; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F; Vavilala MS, 2004, PED AN M PHOEN AZ US; Verlhac S, 2008, ARCH PEDIATRIE, V15, P636, DOI 10.1016/S0929-693X(08)71858-X; Verlhac S, 2003, J RADIOL, V84, P131; Verlhac S, 1995, PEDIATR RADIOL, V25, pS14; Visocchi M, 2007, ACTA NEUROCHIR, V149, P347, DOI 10.1007/s00701-006-1102-0	64	25	25	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	MAY	2011	41			1			S153	S165		10.1007/s00247-011-2038-y			13	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	V32CS	WOS:000208929900026	21523592	Bronze			2021-06-18	
J	Wood, RL; Alderman, N				Wood, Rodger Ll; Alderman, Nick			Applications of Operant Learning Theory to the Management of Challenging Behavior After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavior management; challenging behavior; cognitive impairment; operant learning theory; traumatic brain injury	AGGRESSIVE-BEHAVIOR; ENVIRONMENTAL DETERMINANTS; REHABILITATION; ESCAPE; REDUCTION; COST; INTERVENTIONS; EXTINCTION; DISORDERS; PROGRAM	For more than 3 decades, interventions derived from learning theory have been delivered within a neurobehavioral framework to manage challenging behavior after traumatic brain injury with the aim of promoting engagement in the rehabilitation process and ameliorating social handicap. Learning theory provides a conceptual structure that facilitates our ability to understand the relationship between challenging behavior and environmental contingencies, while accommodating the constraints upon learning imposed by impaired cognition. Interventions derived from operant learning theory have most frequently been described in the literature because this method of associational learning provides good evidence for the effectiveness of differential reinforcement methods. This article therefore examines the efficacy of applying operant learning theory to manage challenging behavior after TBI as well as some of the limitations of this approach. Future developments in the application of learning theory are also considered.	[Wood, Rodger Ll] Swansea Univ, Dept Psychol, Swansea SA2 8PP, W Glam, Wales; [Alderman, Nick] St Andrews Healthcare, Natl Brain Injury Ctr, Northampton, England; [Alderman, Nick] Kings Coll London, St Andrews Acad Ctr, Northampton, England	Wood, RL (corresponding author), Swansea Univ, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk		Alderman, Nick/0000-0002-8523-4142			ALDERMAN N, 1995, NEUROPSYCHOL REHABIL, V5, P193, DOI 10.1080/09602019508401467; Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Alderman N, 2003, STUD NEUROPSYCHOL DE, P171; Alderman N, 2001, BRAIN DAM B, P175; ALDERMAN N, 1991, Brain Injury, V5, P77, DOI 10.3109/02699059108998516; ALDERMAN N, 1994, NEUROPSYCHOL REHABIL, V4, P31, DOI 10.1080/09602019408401454; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Alderman N, 1997, BRAIN INJURY, V11, P79, DOI 10.1080/026990597123683; ALDERMAN N, 1992, PHYSIOTHERAPY, V78, P335; ALDERMAN N, 1991, NEUROPSYCHOL REHABIL, V1, P65, DOI DOI 10.1080/09602019108401380; Alderman N, 2007, BRAIN INJURY, V21, P891, DOI 10.1080/02699050701543560; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BAUMESITER AA, 1978, QUALITY LIFE SEVEREL; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BURKE WH, 1988, INT J REHABIL RES, V11, P235, DOI 10.1097/00004356-198809000-00003; CARR EG, 1977, PSYCHOL BULL, V84, P800, DOI 10.1037/0033-2909.84.4.800; CARR EG, 1980, J APPL BEHAV ANAL, V13, P101, DOI 10.1901/jaba.1980.13-101; Crane A. A., 1991, BEHAV RESIDENTIAL TR, V6, P65; DAY RM, 1988, BEHAV MODIF, V12, P565, DOI 10.1177/01454455880124005; Dayus B, 2000, NEUROPSYCHOL REHABIL, V10, P415, DOI 10.1080/096020100411998; Donaghey CL, 2010, CLIN REHABIL, V24, P195, DOI 10.1177/0269215509353270; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Emerson Eric, 2001, CHALLENGING BEHAV AN; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Giles GM, 2006, J HEAD TRAUMA REHAB, V21, P168, DOI 10.1097/00001199-200603000-00009; GUESS D, 1991, AM J MENT RETARD, V96, P299; Hegel MT, 2000, BEHAV MODIF, V24, P94, DOI 10.1177/0145445500241005; Howells K, 2009, CRIM BEHAV MENT HEAL, V19, P308, DOI 10.1002/cbm.745; IWATA BA, 1990, J APPL BEHAV ANAL, V23, P11, DOI 10.1901/jaba.1990.23-11; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Knight C, 2008, NEUROPSYCHOL REHABIL, V18, P129, DOI 10.1080/09602010701822381; Kodak T, 2007, J APPL BEHAV ANAL, V40, P167, DOI 10.1901/jaba.2007.43-06; LOVAAS I, 1987, J APPL BEHAV ANAL, V20, P45, DOI 10.1901/jaba.1987.20-45; MACE FC, 1986, APPL RES MENT RETARD, V7, P203; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Manchester D, 1997, BRAIN INJURY, V11, P271; MATEER CA, 1990, NEUROBEHAVIOURAL SEQ; MCGLYNN SM, 1990, PSYCHOL BULL, V108, P420, DOI 10.1037/0033-2909.108.3.420; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER E, 1981, BRIT J CLIN PSYCHOL, V20, P69, DOI 10.1111/j.2044-8260.1981.tb00498.x; Mozzoni MP, 2000, BEHAV INTERVENT, V15, P153, DOI 10.1002/1099-078X(200007/09)15:3<153::AID-BIN52>3.0.CO;2-K; Oliver C, 1999, RES DEV DISABIL, V20, P197, DOI 10.1016/S0891-4222(99)00003-7; PETERS M D, 1992, Brain Injury, V6, P299, DOI 10.3109/02699059209034944; POWELL GE, 1981, BRAIN FUNCTION THERA; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Rahman B, 2010, NEUROPSYCHOL REHABIL, V20, P212, DOI 10.1080/09602010903021097; RAPOFF MA, 1980, J MENT DEFIC RES, V24, P37; REPP AC, 1988, J APPL BEHAV ANAL, V21, P281, DOI 10.1901/jaba.1988.21-281; Rothwell NA, 1999, BRAIN INJURY, V13, P521; Sandman C.A., 1995, MENTAL RETARDATION D, V1, P130, DOI DOI 10.1002/mrdd.1410010209; STEWART I, BRAIN INJ IN PRESS; TANNER BA, 1975, J APPL BEHAV ANAL, V8, P53, DOI 10.1901/jaba.1975.8-53; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Treadwell K, 1996, J HEAD TRAUMA REHAB, V11, P62, DOI 10.1097/00001199-199602000-00008; TURNER JM, 1990, BEHAV RESID TREAT, V90, P15; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; Wilson B., 1989, PRACTICE BEHAV MED; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood R. L. L., 1981, APPL CONDITIONING TH; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; Wood RL, 2001, NEUROBEHAVIOURAL DIS; WOOD RL, 1984, OUTCOME SEVERE BLUNT; Woodhead E. L., 2008, CLIN CASE STUD, V7, P301; Worthington AD, 2006, BRAIN INJURY, V20, P947, DOI 10.1080/02699050600888314; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Yody BB, 2000, J HEAD TRAUMA REHAB, V15, P1041, DOI 10.1097/00001199-200008000-00006; YOUNGSON HA, 1994, BRAIN INJURY, V8, P23, DOI 10.3109/02699059409150956; ZARCONE JR, 1993, J APPL BEHAV ANAL, V26, P135, DOI 10.1901/jaba.1993.26-135	74	25	26	2	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2011	26	3					202	211		10.1097/HTR.0b013e318217b46d			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	760CY	WOS:000290301800004	21552069				2021-06-18	
J	Kasner, SE; Baren, JM; Le Roux, PD; Nathanson, PG; Lamond, K; Rosenberg, SL; Karlawish, J				Kasner, Scott E.; Baren, Jill M.; Le Roux, Peter D.; Nathanson, Pamela G.; Lamond, Katherine; Rosenberg, Stacy L.; Karlawish, Jason			Community Views on Neurologic Emergency Treatment Trials	ANNALS OF EMERGENCY MEDICINE			English	Article							ACUTE STROKE TRIALS; INFORMED-CONSENT; RESUSCITATION RESEARCH; CLINICAL-TRIALS; CONSULTATION; EXCEPTION; QUALITY; VOICES	Study objective: We improve our understanding of the community consultation process for acute neurologic emergency trials conducted under the federal regulations for Exception From Informed Consent (EFIC) for emergency research. Methods: We performed a qualitative study using focus groups to collect data from patients with a previous stroke or brain injury and their families and from young men at risk for traumatic brain injury. Discussions were transcribed, coded, and analyzed for major themes and subthemes. Results: Five focus groups, involving 40 participants, were convened. Major themes included the awareness and understanding of key clinical trial concepts, including prominent concerns about placebo and therapeutic misconception; inability to obtain informed consent and acceptable surrogate decisionmaking; EFIC in emergency research and whether existing regulations are acceptable; specific trial design problems, including comparison to standard of care versus 2 competing active therapies; and community consultation and representation. Conclusion: In this study sample, EFIC trials were deemed appropriate and acceptable for acute neurologic emergency research. Education, along with open discussion about basic clinical research concepts, disease- and trial-specific information, and potential surrogate decisionmaking, was essential to determine the acceptability of an EFIC trial. Approval by institutional review boards was highly regarded as a means of human protection and effective community consultation for such trials. A data repository of information gained from similar qualitative research may help investigators and regulators who wish to plan, conduct, review, and provide oversight for acute neurologic emergency trials under EFIC regulations. [Ann Emerg Med. 2011;57:346-354.]	[Kasner, Scott E.; Rosenberg, Stacy L.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Baren, Jill M.; Nathanson, Pamela G.; Lamond, Katherine] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Le Roux, Peter D.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Karlawish, Jason] Univ Penn, Dept Med, Div Geriatr Med, Philadelphia, PA 19104 USA	Kasner, SE (corresponding author), Univ Penn, Dept Neurol, 3400 Spruce St, Philadelphia, PA 19104 USA.	kasner@mail.med.upenn.edu	Kasner, Scott/C-6109-2011	Nathanson, Pamela/0000-0002-1471-6670	University of Pennsylvania Comprehensive Neuroscience Center	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article that might create any potential conflict of interest. The authors have stated that no such relationships exist. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. Funded by a grant from the University of Pennsylvania Comprehensive Neuroscience Center.	Alexandrov AV, 2006, INT J STROKE, V1, P160, DOI 10.1111/j.1747-4949.2006.00046.x; [Anonymous], 1996, Fed Regist, V61, P51498; Baren JM, 2007, ACAD EMERG MED, V14, P346, DOI 10.1197/j.aem.2007.01.002; Baren JM, 1999, ACAD EMERG MED, V6, P1210, DOI 10.1111/j.1553-2712.1999.tb00135.x; BIROS MH, 2009, RESUSCITATION, V7, P7; Blixen CE, 2005, J MED ETHICS, V31, P608, DOI 10.1136/jme.2004.010488; Chamberlain JM, 2009, ACAD EMERG MED, V16, P763, DOI 10.1111/j.1553-2712.2009.00455.x; Elkins JS, 2006, STROKE, V37, P123, DOI 10.1161/01.STR.0000195149.44390.aa; Flaherty ML, 2008, NEUROLOGY, V71, P1566, DOI 10.1212/01.wnl.0000316196.63704.f5; Halpern SD, 2002, CONTROL CLIN TRIALS, V23, P274, DOI 10.1016/S0197-2456(02)00191-5; Halpern SD, 2001, J ACQ IMMUN DEF SYND, V27, P281, DOI 10.1097/00126334-200107010-00011; Kalviainen R, 2007, EPILEPSIA, V48, P99, DOI 10.1111/j.1528-1167.2007.01364.x; Kasner SE, 2009, NEUROLOGY, V72, P1682, DOI 10.1212/WNL.0b013e3181a55fbe; Kimmelman J, 2007, HASTINGS CENT REP, V37, P36, DOI 10.1353/hcr.2007.0092; Lavori PW, 2007, CLIN TRIALS, V4, P638, DOI 10.1177/1740774507085144; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; McClure KB, 2007, J MED ETHICS, V33, P289, DOI 10.1136/jme.2005.014878; McClure KB, 2003, ACAD EMERG MED, V10, P352, DOI 10.1197/aemj.10.4.352; Merchant RM, 2008, ACAD EMERG MED, V15, P581, DOI 10.1111/j.1553-2712.2008.00134.x; Merton R.K., 1990, FOCUSED INTERVIEW MA; Morris MC, 2004, PEDIATRICS, V114, P776, DOI 10.1542/peds.2004-0482; Patton M. Q, 2002, QUALITATIVE RES METH; Ragin DF, 2008, SOC SCI MED, V66, P1379, DOI 10.1016/j.socscimed.2007.10.022; Richardson LD, 2005, ACAD EMERG MED, V12, P1082, DOI 10.1197/j.aem.2005.06.008; Sen Biswas M, 2007, CLIN TRIALS, V4, P258, DOI 10.1177/1740774507079434; Sugarman J, 2005, CLIN TRIALS, V2, P34, DOI 10.1191/1740774505cn066oa; 1996, FED REG, V61, P51531; 2006, FED REG, V167, P51198	28	25	25	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	APR	2011	57	4					346	354		10.1016/j.annemergmed.2010.07.009			9	Emergency Medicine	Emergency Medicine	747JN	WOS:000289316200010	20875693				2021-06-18	
J	Preece, MHW; Horswill, MS; Geffen, GM				Preece, Megan H. W.; Horswill, Mark S.; Geffen, Gina M.			Assessment of drivers' ability to anticipate traffic hazards after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							ACCIDENT RATE; RETURN; CONCUSSION; IDENTIFY; REDUCE; COMA	Objectives The aim of this study was to examine the effect of traumatic brain injury (TBI) on drivers' ability to anticipate traffic hazards. Slower anticipation of hazards has been associated with higher crash rates, but this driving skill has never been assessed after TBI. Methods The anticipatory ability of 31 drivers with TBI and 24 age-matched uninjured controls was assessed with a validated drivers' Hazard Perception Test. The Hazard Perception Test displayed videos of genuine traffic scenes filmed from the driver's perspective, and participants had to respond as soon as they anticipated a traffic hazard in a scene. The primary dependent measure was mean response latency. Results Participants with TBI were significantly slower to anticipate traffic hazards than controls (p<0.001). Within the TBI group, while hazard perception response times were significantly related to duration of post-traumatic amnesia (Spearman rho=0.63; p<0.001), they were not significantly related to Glasgow Coma Scale scores (r=-0.19; p=0.33). Also, participants with a complicated mild TBI were significantly faster in anticipating traffic conflicts than participants with moderate to severe TBI (p=0.04). Conclusions Individuals with TBI were slower to anticipate traffic hazards than age-matched uninjured controls. This finding signifies the need for hazard perception testing and training as part of driving rehabilitation after TBI.	[Preece, Megan H. W.; Horswill, Mark S.; Geffen, Gina M.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia	Preece, MHW (corresponding author), Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.	m.preece@psy.uq.edu.au	Preece, Megan/A-7186-2013; Horswill, Mark/J-9029-2019	Preece, Megan/0000-0003-4852-8712; Horswill, Mark/0000-0002-0286-6292			Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Darby P, 2009, SAFETY SCI, V47, P436, DOI 10.1016/j.ssci.2008.05.004; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Fisk GD, 1998, BRAIN INJURY, V12, P683; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Horswill MS, 2010, PSYCHOL AGING, V25, P464, DOI 10.1037/a0017306; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Lundqvist A, 2007, BRAIN INJURY, V21, P1109, DOI 10.1080/02699050701651660; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; Milleville-Pennel I, 2010, BRAIN INJURY, V24, P678, DOI 10.3109/02699051003692159; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; Novack TA, 2010, BRAIN INJURY, V24, P464, DOI 10.3109/02699051003601713; PARKER D, 1995, ERGONOMICS, V38, P1036, DOI 10.1080/00140139508925170; Peltz D.C., 1974, ACCIDENT ANAL PREV, V6, P45, DOI [10.1016/0001-4575(74)90015-3, DOI 10.1016/0001-4575(74)90015-3]; Pietrapiana P, 2005, BRAIN INJURY, V19, P197, DOI 10.1080/02699050400017197; Poulsen AA, 2010, AUST NZ J PSYCHIAT, V44, P528, DOI 10.3109/00048671003596048; Pradhan AK, 2009, ERGONOMICS, V52, P657, DOI 10.1080/00140130802550232; Preece MHW, 2010, NEUROPSYCHOLOGY, V24, P493, DOI 10.1037/a0018903; Rapport LJ, 2008, ARCH PHYS MED REHAB, V89, P922, DOI 10.1016/j.apmr.2008.01.009; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schanke AK, 2008, J REHABIL MED, V40, P733, DOI 10.2340/16501977-0256; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith SS, 2009, ACCIDENT ANAL PREV, V41, P729, DOI 10.1016/j.aap.2009.03.016; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Wechsler D, 1981, WESCHLER ADULT INTEL; Wells P., 2008, 81 DEP TRANSP; Wilson, 1991, NATL ADULT READING T; Wilson B., 1987, BEHAV INATTENTION TE	40	25	26	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2011	82	4					447	451		10.1136/jnnp.2010.215228			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	734ZY	WOS:000288384100022	20884679				2021-06-18	
J	Wang, W; Li, MH; Li, YD; Gu, BX; Wang, J; Zhang, PL; Li, M				Wang, Wu; Li, Ming-Hua; Li, Yong-Dong; Gu, Bin-Xian; Wang, Ju; Zhang, Pei-Lei; Li, Min			Treatment of Traumatic Internal Carotid Artery Pseudoaneurysms With the Willis Covered Stent: A Prospective Study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Pseudoaneurysm; Covered stent; Internal carotid artery (ICA)	ANGIOGRAPHIC FOLLOW-UP; INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT; GRAFT TREATMENT; ARTERIOVENOUS-FISTULAS; PLACEMENT; INJURY; REPAIR; COILS	Purpose: To evaluate the efficacy of the Willis covered stent in the treatment of traumatic pseudoaneurysms of the internal carotid artery (ICA). Materials: Thirty-eight patients with traumatic head and neck injury underwent angiography. We evaluated 14 delayed pseudoaneurysms in 13 patients who underwent angiography after treatment with the Willis covered stent. Prospective data on the technical success, initial and final angiographic results, mortality, morbidity, and final clinical outcome were analyzed immediately after the procedure, at the time of discharge from the hospital, at 3 months, 6 months, and 12 months after the procedures, and yearly thereafter. Results: The Willis covered stent placement was successful in all 14 pseudoaneurysms. The initial angiographic results showed complete exclusion in 9 patients with 10 aneurysms (71.4% [95% confidence interval {CI}: 44-98%]) and incomplete exclusion in 4 patients. The angiographic follow-up (mean, 15 months [95% CI: 9-20 months]; range, 3-36 months) findings exhibited a complete exclusion in 12 patients with 13 aneurysms (92.9% [95% CI: 77-108%]) and an incomplete exclusion in 1 patient and maintained patency of the ICA in all patients. The clinical follow-up (mean, 20 months [95% CI: 14-27 months]) findings demonstrated full recovery (11 patients), symptom improvement (1 patient), or no change in the symptoms (1 patient). No procedure-related complications or deaths occurred during follow-up. Conclusion: Treatment with the Willis covered stent provides a viable approach for patients with traumatic pseudoaneurysms of the ICA, maintaining patency of the ICA and thus leading to excellent clinical results. An expanded clinical experiences and a larger sample are needed.	[Wang, Wu; Li, Ming-Hua; Li, Yong-Dong; Gu, Bin-Xian; Wang, Ju; Zhang, Pei-Lei; Li, Min] Shanghai Jiao Tong Univ, Dept Diagnost & Intervent Radiol, Affiliated Peoples Hosp 6, Shanghai 200030, Peoples R China	Li, YD (corresponding author), 600 Yi Shan Rd, Shanghai 200233, Peoples R China.	liyongdong2009@tom.com			National Natural Scientific Fund of ChinaNational Natural Science Foundation of China (NSFC) [30570540]; Shanghai Important Subject Fund of Medicine [05 III 023]; Program for Shanghai Outstanding Medical Academic Leader [LJ 06016]	Supported by the National Natural Scientific Fund of China (contract number: 30570540), the Shanghai Important Subject Fund of Medicine (contract number: 05 III 023), and the Program for Shanghai Outstanding Medical Academic Leader (contract number: LJ 06016).	Akiyama Y, 2005, J TRAUMA, V58, P624, DOI 10.1097/01.TA.0000096662.79685.EA; Archondakis E, 2007, AM J NEURORADIOL, V28, P342; Bouthillier A, 1996, NEUROSURGERY, V38, P425, DOI 10.1097/00006123-199603000-00001; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; Cohen JE, 2008, NEUROSURGERY, V63, P476, DOI 10.1227/01.NEU.0000324995.57376.79; Coldwell DM, 2000, J TRAUMA, V48, P470, DOI 10.1097/00005373-200003000-00016; Felber S, 2004, NEUROSURGERY, V55, P631, DOI 10.1227/01.NEU.0000134455.02947.1F; Gomez F, 2007, AM J NEURORADIOL, V28, P1762, DOI 10.3174/ajnr.A0636; Hoit DA, 2008, NEUROSURGERY, V62, P380, DOI [10.1227/01.NEU.0000297138.40345.25, 10.1227/01.NEU.0000335088.85470.FC]; Hori Y, 2007, J VASC INTERV RADIOL, V18, P1300, DOI 10.1016/j.jvir.2007.06.032; Kadyrov NA, 2002, J NEUROSURG, V96, P624, DOI 10.3171/jns.2002.96.3.0624; Klein GE, 1997, AM J NEURORADIOL, V18, P1261; Kubaska SM, 2003, J ENDOVASC THER, V10, P182, DOI 10.1583/1545-1550(2003)010<0182:ICAPTW>2.0.CO;2; LARSON JJ, 1995, NEUROSURGERY, V36, P26; Layton KF, 2004, AM J NEURORADIOL, V25, P1760; Li MH, 2008, AM J NEURORADIOL, V29, P1395, DOI 10.3174/ajnr.A1096; Li MH, 2007, AM J NEURORADIOL, V28, P1579, DOI 10.3174/ajnr.A0668; Li MH, 2006, AM J NEURORADIOL, V27, P1107; Li MH, 2009, RADIOLOGY, V253, P470, DOI 10.1148/radiol.2532090037; Li YD, 2010, J NEUROL NEUROSUR PS, V81, P74, DOI 10.1136/jnnp.2009.171967; Maras D, 2006, CARDIOVASC INTER RAD, V29, P958, DOI 10.1007/s00270-005-0367-7; Marotta TR, 1998, NEUROSURGERY, V42, P408, DOI 10.1097/00006123-199802000-00138; Parodi JC, 1999, ANN VASC SURG, V13, P121, DOI 10.1007/s100169900230; Redekop G, 2001, J NEUROSURG, V95, P412, DOI 10.3171/jns.2001.95.3.0412; Reiter BP, 1998, J VASC INTERV RADIOL, V9, P245, DOI 10.1016/S1051-0443(98)70264-7; Saatci I, 2004, AM J NEURORADIOL, V25, P1742; Scavee V, 2001, CARDIOVASC INTER RAD, V24, P283, DOI 10.1007/s00270-001-0012-z; ul Haq Tanveer, 2004, Australas Radiol, V48, P220; Wang Jian B, 2008, Neurosurgery, V62, pE1176, DOI 10.1227/01.neu.0000325886.00033.18	29	25	33	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2011	70	4					816	822		10.1097/TA.0b013e3181f892af			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	750OV	WOS:000289558700016	21610389				2021-06-18	
J	Li, J; Li, GB; Hu, JL; Fu, XH; Zeng, YJ; Zhou, YG; Xiong, G; Yang, N; Dai, SS; He, FT				Li, Jun; Li, Gongbo; Hu, Jian-Lin; Fu, Xiao-Hong; Zeng, Yi-Jun; Zhou, Yuan-Guo; Xiong, Gang; Yang, Nan; Dai, Shuang-Shuang; He, Feng-Tian			Chronic or high dose acute caffeine treatment protects mice against oleic acid-induced acute lung injury via an adenosine A(2A) receptor-independent mechanism	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Adenosine A(2A) receptor; Caffeine; Acute lung injury; Inflammation	TRAUMATIC BRAIN-INJURY; A(2A)-RECEPTOR ACTIVATION; EXTRACELLULAR ADENOSINE; LIVER-INJURY; INFLAMMATION; HYPOXIA; MOUSE; THERAPY; INACTIVATION; REPERFUSION	The antagonism or genetic deletion of adenosine A(2A) receptors has been shown to exacerbate tissue damage in acute lung injury. Caffeine, a widely consumed behavioral drug, acts as a non-selective antagonist of A(2A) receptor and also has additional pharmacological effects. Thus, the protective vs. deleterious effects of caffeine in acute lung injury should be evaluated. In a murine oleic acid-induced model of acute lung injury, we found that chronic caffeine treatment by drinking water (0.1 g/l or 0.25 g/l for 2 weeks before acute lung injury) or acute caffeine treatment at high dose (i.p. 50 mg/kg, injection, 30 min before acute lung injury) significantly attenuated the lung edema, hemorrhage, neutrophil recruitment as well as the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) expressions in both of the wild type (WT) and A(2A) receptor knockout (KO) mice. This profile was accompanied by increased cAMP levels and up-regulation of A2B receptor mRNAs in the lungs. In contrast, acute caffeine treatment at low dose (i.p. 5 mg/kg or 15 mg/kg, injection, 30 min before acute lung injury) enhanced the inflammation and lung damage in WT mice with decreasing cAMP but not in A(2A) receptor KO mice. These results indicate that caffeine either enhances lung damage by antagonizing A(2A) receptor or exerts protection against lung damage via A(2A) receptor-independent mechanisms, depending on the timing of exposure (chronic vs. acute) and dose of administration (low vs. high). These findings provide new insight of caffeine in acute lung injury and highlight the potential benefit and strategy of caffeine intake or administration for preventing acute lung injury. (C) 2011 Elsevier B.V. All rights reserved.	[Li, Gongbo; Fu, Xiao-Hong; Zeng, Yi-Jun; Dai, Shuang-Shuang; He, Feng-Tian] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China; [Li, Jun; Xiong, Gang] Third Mil Med Univ, SE Hosp, Dept Cardiothorac Surg, Chongqing 400038, Peoples R China; [Zhou, Yuan-Guo; Yang, Nan] Third Mil Med Univ, Inst Surg Res, State Key Lab Trauma Burn & Combined Injury, Ctr Mol Biol, Chongqing 400042, Peoples R China; [Zhou, Yuan-Guo; Yang, Nan] Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China; [Hu, Jian-Lin] Third Mil Med Univ, SE Hospital, Dept Resp Dis, Chongqing 400038, Peoples R China	Dai, SS (corresponding author), Third Mil Med Univ, Dept Biochem & Mol Biol, 30 Gaotanyan, Chongqing 400038, Peoples R China.	tmmubiodss@yahoo.com.cn; hefengtian06@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30900587]; Natural Science Foundation of Chongqing, ChinaNatural Science Foundation of Chongqing [CSTC2009BB5317]; Science Foundation of Third Military Medical University	This work was supported by National Natural Science Foundation of China (No. 30900587) and Natural Science Foundation of Chongqing, China (NO. CSTC2009BB5317) and Science Foundation of Third Military Medical University (to Dai SS).	Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; Day YJ, 2004, AM J PHYSIOL-GASTR L, V286, pG285, DOI 10.1152/ajpgi.00348.2003; Donadieu E, 2007, ACTA HISTOCHEM, V109, P177, DOI 10.1016/j.acthis.2007.01.004; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Eckle T, 2008, BLOOD, V111, P2024, DOI 10.1182/blood-2007-10-117044; Eckle T, 2009, PHYSIOLOGY, V24, P298, DOI 10.1152/physiol.00022.2009; Ellman PI, 2008, J SURG RES, V149, P3, DOI 10.1016/j.jss.2007.08.008; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Fozard JR, 2002, EUR J PHARMACOL, V438, P183, DOI 10.1016/S0014-2999(02)01305-5; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Gantner F, 1997, J PHARMACOL EXP THER, V280, P53; Graham TE, 2001, SPORTS MED, V31, P785, DOI 10.2165/00007256-200131110-00002; Hasko G, 2006, CRIT CARE MED, V34, P1119, DOI 10.1097/01.CCM.0000206467.19509.C6; Hasko G, 2008, J LEUKOCYTE BIOL, V83, P447, DOI 10.1189/jlb.0607359; Johansson B, 1997, BRAIN RES, V762, P153, DOI 10.1016/S0006-8993(97)00378-8; Koshiba M, 1997, J BIOL CHEM, V272, P25881, DOI 10.1074/jbc.272.41.25881; Lappas CM, 2005, J IMMUNOL, V174, P1073, DOI 10.4049/jimmunol.174.2.1073; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li W, 2009, EXP NEUROL, V215, P69, DOI 10.1016/j.expneurol.2008.09.012; Linden J, 2005, MOL PHARMACOL, V67, P1385, DOI 10.1124/mol.105.011783; Link AA, 2000, J IMMUNOL, V164, P436, DOI 10.4049/jimmunol.164.1.436; Morote-Garcia JC, 2009, GASTROENTEROLOGY, V136, P607, DOI 10.1053/j.gastro.2008.10.037; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Ohta A, 2007, J IMMUNOL, V179, P7431, DOI 10.4049/jimmunol.179.11.7431; Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254; Riksen NP, 2006, J AM COLL CARDIOL, V48, P700, DOI 10.1016/j.jacc.2006.04.083; Rosenberger P, 2009, NAT IMMUNOL, V10, P195, DOI 10.1038/ni.1683; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Schmidt B, 2007, NEW ENGL J MED, V357, P1893, DOI 10.1056/NEJMoa073679; Spicuzza L, 2006, EUR J PHARMACOL, V533, P77, DOI 10.1016/j.ejphar.2005.12.056; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Thong FSL, 2002, CAN J APPL PHYSIOL, V27, P152, DOI 10.1139/h02-011; Ulrich K, 2005, AM J PHYSIOL-LUNG C, V288, pL1179, DOI 10.1152/ajplung.00450.2004; Varani K, 2005, CELL MOL LIFE SCI, V62, P2350, DOI 10.1007/s00018-005-5312-z; Varani K, 2000, CIRCULATION, V102, P285; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wu RQ, 2006, CRIT CARE MED, V34, P1273, DOI 10.1097/01.CCM.0000208437.93725.18; Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933; Yu LQ, 2004, BRAIN RES, V1000, P156, DOI 10.1016/j.brainres.2003.11.072	43	25	28	1	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	MAR 11	2011	654	3					295	303		10.1016/j.ejphar.2010.12.040			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	731YS	WOS:000288147300015	21238452				2021-06-18	
J	Eastman, CL; Verley, DR; Fender, JS; Stewart, TH; Nov, E; Curia, G; D'Ambrosio, R				Eastman, Clifford L.; Verley, Derek R.; Fender, Jason S.; Stewart, Tessandra H.; Nov, Eytan; Curia, Giulia; D'Ambrosio, Raimondo			Antiepileptic and Antiepileptogenic Performance of Carisbamate after Head Injury in the Rat: Blind and Randomized Studies	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							SPONTANEOUS MOTOR SEIZURES; KAINATE-INDUCED EPILEPSY; FLUID PERCUSSION INJURY; TEMPORAL-LOBE EPILEPSY; PARTIAL-ONSET SEIZURES; INTERNATIONAL-BUREAU; REFRACTORY EPILEPSY; PILOCARPINE MODEL; ANIMAL-MODELS; DRUGS	Carisbamate (CRS) exhibits broad acute anticonvulsant activity in conventional anticonvulsant screens, genetic models of absence epilepsy and audiogenic seizures, and chronic spontaneous motor seizures arising after chemoconvulsant-induced status epilepticus. In add-on phase III trials with pharmacoresistant patients CRS induced <30% average decreases in partial-onset seizure frequency. We assessed the antiepileptogenic and antiepileptic performance of subchronic CRS administration on posttraumatic epilepsy (PTE) induced by rostral parasaggital fluid percussion injury (rpFPI), which closely replicates human contusive closed head injury. Studies were blind and randomized, and treatment effects were assessed on the basis of sensitive electrocorticography (ECoG) recordings. Antiepileptogenic effects were assessed in independent groups of control and CRS-treated rats, at 1 and 3 months postinjury, after completion of a 2-week prophylactic treatment initiated 15 min after injury. The antiepileptic effects of 1-week CRS treatments were assessed in repeated measures experiments at 1 and 4 months postinjury. The studies were powered to detect similar to 50 and similar to 40% decreases in epilepsy incidence and frequency of seizures, respectively. Drug/vehicle treatment, ECoG analysis, and [CRS](plasma) determination all were performed blind. We detected no antiepileptogenic and an equivocal transient antiepileptic effects of CRS despite [CRS](plasma) comparable with or higher than levels attained in previous preclinical and clinical studies. These findings contrast with previous preclinical data demonstrating large efficacy of CRS, but agree with the average effect of CRS seen in clinical trials. The data support the use of rpFPI-induced PTE in the adolescent rat as a model of pharmacoresistant epilepsy for preclinical development.	[Eastman, Clifford L.; Verley, Derek R.; Fender, Jason S.; Nov, Eytan; Curia, Giulia; D'Ambrosio, Raimondo] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo] Univ Washington, Sch Med, Reg Epilepsy Ctr, Seattle, WA 98104 USA; [Stewart, Tessandra H.] Univ Washington, Sch Med, Grad Program Neurobiol & Behav, Seattle, WA 98104 USA	D'Ambrosio, R (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurosurg, Box 359915,325 9th Ave, Seattle, WA 98104 USA.	raid@u.washington.edu	Curia, Giulia/A-8863-2008; Verley, Derek/J-4550-2015	Curia, Giulia/0000-0002-8472-350X; Verley, Derek/0000-0002-2670-6568	Johnson and Johnson Pharmaceutical Research and Development, LLCJohnson & JohnsonJohnson & Johnson USA; National Institutes of Health National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS053928]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053928] Funding Source: NIH RePORTER	This work was supported by Johnson and Johnson Pharmaceutical Research and Development, LLC, and the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant NS053928] (to R. D.).	Andre V, 2007, EPILEPSIA, V48, P41, DOI 10.1111/j.1528-1167.2007.01288.x; Beghi E, 2005, EPILEPSIA, V46, P1698, DOI 10.1111/j.1528-1167.2005.00273_1.x; Callaghan BC, 2007, ANN NEUROL, V62, P382, DOI 10.1002/ana.21166; Crossley NA, 2008, STROKE, V39, P929, DOI 10.1161/STROKEAHA.107.498725; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P90, DOI 10.1111/j.1535-7511.2010.01367.x; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Duncan JS, 2006, LANCET, V367, P1087, DOI 10.1016/S0140-6736(06)68477-8; Eastman CL, 2010, EXP NEUROL, V224, P369, DOI 10.1016/j.expneurol.2010.04.013; Faught E, 2008, NEUROLOGY, V71, P1586, DOI 10.1212/01.wnl.0000334751.89859.7f; Fisher RS, 2008, EPILEPSIA, V49, P7, DOI 10.1111/j.1528-1167.2008.01921.x; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Francois J, 2008, EPILEPSIA, V49, P393, DOI 10.1111/j.1528-1167.2007.01278.x; French JA, 2007, EPILEPSIA, V48, P3, DOI 10.1111/j.1528-1167.2007.00992.x; Glien M, 2002, EPILEPSIA, V43, P350, DOI 10.1046/j.1528-1157.2002.18101.x; Grabenstatter HL, 2008, EPILEPSIA, V49, P1787, DOI 10.1111/j.1528-1167.2008.01657.x; Grabenstatter HL, 2005, EPILEPSIA, V46, P8, DOI 10.1111/j.0013-9580.2005.13404.x; Hitiris N, 2007, EPILEPSY RES, V75, P192, DOI 10.1016/j.eplepsyres.2007.06.003; JUULJENSEN P, 1986, INTRACTABLE EPILEPSY, P5; Klein BD, 2007, EPILEPSIA, V48, P367; Kwan P, 2003, NEUROLOGY, V60, pS2, DOI 10.1212/WNL.60.11_suppl_4.S2; Loscher W, 2007, EPILEPSIA, V48, P1245, DOI 10.1111/j.1528-1167.2007.01093.x; Loscher W, 2004, EPILEPSY RES, V60, P77, DOI 10.1016/j.eplepsyres.2004.06.004; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; LOSCHER W, 1995, EPILEPSIA, V36, P929, DOI 10.1111/j.1528-1157.1995.tb01637.x; Lu Y, 2009, CNS DRUGS, V23, P351, DOI 10.2165/00023210-200923040-00006; Mamidi RNVS, 2007, DRUG METAB DISPOS, V35, P566, DOI 10.1124/dmd.106.012336; Mattson RH, 1996, NEUROLOGY, V47, P68, DOI 10.1212/WNL.47.1.68; Meldrum B, 2002, EPILEPSY RES, V50, P33, DOI 10.1016/S0920-1211(02)00066-9; Novak GP, 2007, NEUROTHERAPEUTICS, V4, P106, DOI 10.1016/j.nurt.2006.11.016; Philip M, 2009, STROKE, V40, P577, DOI 10.1161/STROKEAHA.108.524330; Rogawski MA, 2006, EPILEPSY RES, V69, P273, DOI 10.1016/j.eplepsyres.2006.02.004; Schmidt D, 2002, EPILEPSY RES, V50, P71, DOI 10.1016/S0920-1211(02)00070-0; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Sperling MR, 2010, EPILEPSIA, V51, P333, DOI 10.1111/j.1528-1167.2009.02318.x; Stables James P., 2002, Epilepsia, V43, P1410, DOI 10.1046/j.1528-1157.2002.06702.x; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; White HS, 2006, EPILEPSIA, V47, P200; White HS, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s7.10.x; White HS, 2002, NEUROLOGY, V59, pS7, DOI 10.1212/WNL.59.9_suppl_5.S7	43	25	25	0	7	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	MAR	2011	336	3					779	790		10.1124/jpet.110.175133			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	723AI	WOS:000287477200021	21123672	Green Published			2021-06-18	
J	Eckner, JT; Lipps, DB; Kim, H; Richardson, JK; Ashton-Miller, JA				Eckner, James T.; Lipps, David B.; Kim, Hogene; Richardson, James K.; Ashton-Miller, James A.			Can a Clinical Test of Reaction Time Predict a Functional Head-Protective Response?	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CLINICAL ASSESSMENT; GENDER; INJURY AVOIDANCE; SPORT CONCUSSION	STABILITY FOLLOWING CONCUSSION; SPORT-RELATED CONCUSSION; BRAIN-INJURY; INTERNATIONAL-CONFERENCE; GAIT; VULNERABILITY; STATEMENT; ATTENTION; PLAYERS; IMPACT	ECKNER, J. T., D. B. LIPPS, H. KIM, J. K. RICHARDSON, and J. A. ASHTON-MILLER. Can a Clinical Test of Reaction Time Predict a Functional Head-Protective Response? Med. Sci. Sports Exerc., Vol. 43, No. 3, pp. 382-387, 2011. Purpose: Reaction time is commonly prolonged after a sport-related concussion. Besides being a marker for injury, a rapid reaction time is necessary for protective maneuvers that can reduce the frequency and severity of additional head impacts. The purpose of this study was to determine whether a clinical test of simple visuomotor reaction time predicted the time taken to raise the hands to protect the head from a rapidly approaching ball. Methods: Twenty-six healthy adult participants recruited from campus and community recreation and exercise facilities completed two experimental protocols during a single session: a manual visuomotor simple reaction time test (RT(clin)) and a sport-related head-protective response (RT(sprt)). RT(clin) measured the time required to catch a thin vertically oriented device on its release by the tester and was calculated from the distance the device fell before being arrested. RT(sprt) measured the time required to raise the hands from waist level to block a foam tennis ball fired toward the subject's face from an air cannon and was determined using an optoelectronic camera system. A correlation coefficient was calculated between RT(clin) and RT(sprt), with linear regression used to assess for effect modification by other covariates. Results: A strong positive correlation was found between RT(clin) and RT(sprt) (r = 0.725, P < 0.001) independent of age, gender, height, or weight. Conclusions: RT(clin) is predictive of a functional sport-related head-protective response. To our knowledge, this is the first demonstration of a clinical test predicting the ability to protect the head in a simulated sport environment. This correlation with a functional head-protective response is a relevant consideration for the potential use of RT(clin) as part of a multifaceted concussion assessment program.	[Eckner, James T.; Richardson, James K.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA; [Lipps, David B.; Kim, Hogene; Ashton-Miller, James A.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48108 USA; [Ashton-Miller, James A.] Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48108 USA	Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower Pkwy, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu	Lipps, David/C-3964-2014; Lipps, David/A-7080-2013; Ashton-Miller, James A/C-2949-2011	Lipps, David/0000-0003-1140-9891; 	Foundation for PMR; U-M Bone and Joint Injury Prevention and Rehabilitation Center; National Defense Science and Engineering; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD078502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024824, R01AG026569] Funding Source: NIH RePORTER	The authors thank the assistance of Trina DeMott, P. T., for her help in screening the subjects and with the experiment, and Nick LeCursi, C. P. O., for making the custom sabot. The authors thank the financial support of a new investigator research grant from the Foundation for PM&R (J. T. E.), a pilot grant from the U-M Bone and Joint Injury Prevention and Rehabilitation Center (J. K. R. and J. T. E.), and a National Defense Science and Engineering Graduate fellowship (D. B. L.).	Brown AM, 2008, MED SCI SPORT EXER, V40, P1142, DOI 10.1249/MSS.0b013e31816770e1; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dane S, 2003, INT J NEUROSCI, V113, P923, DOI 10.1080/00207450390220367; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Eckner JT, 2010, J ATHL TRAINING, V45, P327, DOI 10.4085/1062-6050-45.4.327; Eckner JT, 2010, NEUROLOGY, V74, pA202; Eckner JT, 2009, PERCEPT MOTOR SKILL, V108, P717, DOI 10.2466/PMS.108.3.717-720; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Goodman D, 2001, BRIT J SPORT MED, V35, P371; Grindel Scott H, 2006, Curr Sports Med Rep, V5, P9; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell M., 2001, BRIT J SPORT MED, V35, P373; Lovell M, 2008, NEUROL CLIN, V26, P45, DOI 10.1016/j.ncl.2007.12.001; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	32	25	25	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	MAR	2011	43	3					382	387		10.1249/MSS.0b013e3181f1cc51			6	Sport Sciences	Sport Sciences	722OL	WOS:000287443200002	20689458	Green Accepted			2021-06-18	
J	Gehring, K; Aaronson, NK; Gundy, CM; Taphoorn, MJB; Sitskoorn, MM				Gehring, Karin; Aaronson, Neil K.; Gundy, Chad M.; Taphoorn, Martin J. B.; Sitskoorn, Margriet M.			Predictors of Neuropsychological Improvement Following Cognitive Rehabilitation in Patients with Gliomas	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Neuropsychological rehabilitation; Brain tumor; Prediction; Individual change; Reliable change; Cognitive impairment	TRAUMATIC BRAIN-INJURY; LOW-GRADE GLIOMA; RECOVERY; TUMORS; AGE; RESERVE; DAMAGE	This study investigated the specific patient factors that predict responsiveness to a cognitive rehabilitation program. The program has previously been demonstrated to be successful at the group level in patients with gliomas, but it is unclear which patient characteristics optimized the effect of the intervention at the individual level. Four categories of possible predictors of improvement were selected for evaluation: sociodemographic and clinical variables, self-reported cognitive symptoms, and objective neuropsychological test performance. Hierarchical logistic regression analyses were conducted, beginning with the most accessible (sociodemographic) variables and ending with the most difficult (baseline neuropsychological) to identify in clinical practice. Nearly 60% of the participants of the intervention were classified as reliably improved. Reliable improvement was predicted by age (p = .003) and education (p = .011). Additional results suggested that younger patients were more likely to benefit specifically from the cognitive rehabilitation program (p = .001), and that higher education was also associated with improvement in the control group (p = .024). The findings are discussed in light of brain reserve theory. A practical implication is that cognitive rehabilitation programs should take the patients' age into account and, if possible, adapt programs to increase the likelihood of improvement among older participants. (JINS, 2011, 17, 256-266)	[Gehring, Karin; Sitskoorn, Margriet M.] Tilburg Univ, Fac Social & Behav Sci, CoRPS, NL-5000 LE Tilburg, Netherlands; [Aaronson, Neil K.] Univ Amsterdam, Dept Clin Psychol, NL-1012 WX Amsterdam, Netherlands; [Taphoorn, Martin J. B.] Med Ctr Haaglanden, Dept Neurol, The Hague, Netherlands; [Taphoorn, Martin J. B.] VU Univ Med Ctr Amsterdam, Dept Neurol, Amsterdam, Netherlands	Gehring, K (corresponding author), Tilburg Univ, Fac Social & Behav Sci, CoRPS, Prisma Bldg,Room P 512,POB 90153, NL-5000 LE Tilburg, Netherlands.	k.gehring@uvt.nl	Gehring, Karin/N-6341-2014	Gehring, Karin/0000-0002-6989-1855	Dutch Cancer SocietyKWF Kankerbestrijding [UU2003-2783]; Health Insurers Innovation Foundation [504]	We thank Gerard Maassen for his advice on the use of the Reliable Change Index, Wobbe P. Zijlstra for his statistical advice, and Ruth E. Nieuwenhuis-Mark for editing an earlier version of this draft of this manuscript. This study was supported by the Dutch Cancer Society (UU2003-2783) and Health Insurers Innovation Foundation (file 504). There are no conflicts of interest.	ANDERSON SW, 1990, ARCH NEUROL-CHICAGO, V47, P397, DOI 10.1001/archneur.1990.00530040039017; BRAND N, 1987, PSYCHOL MED, V17, P145, DOI 10.1017/S0033291700013040; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks J O 3rd, 1999, Int Psychogeriatr, V11, P75; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Charlton RA, 2006, NEUROLOGY, V66, P217, DOI 10.1212/01.wnl.0000194256.15247.83; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Correa DD, 2008, J NEURO-ONCOL, V86, P321, DOI 10.1007/s11060-007-9474-4; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Evans C., 1998, EVID-BASED MENT HEAL, V1, P70, DOI DOI 10.1136/EBMH.1.3.70; Field A.P., 2005, DISCOVERING STAT USI; Fiszdon JM, 2005, J NERV MENT DIS, V193, P602, DOI 10.1097/01.nmd.0000177790.23311.ba; Fratiglioni L, 2007, J ALZHEIMERS DIS, V12, P11; GEHRING K, DESCRIPTION IN PRESS; Gehring K., 2004, HANDLEIDING C CAR MA; Gehring K, 2009, J CLIN ONCOL, V27, P3712, DOI 10.1200/JCO.2008.20.5765; Gordon BA, 2008, PSYCHOPHYSIOLOGY, V45, P825, DOI 10.1111/j.1469-8986.2008.00676.x; GRAFMAN J, 1986, J NEUROSCI, V6, P301; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Hammes JGW, 1971, STROOP KLEUR WOORD T; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jolles J, 1995, MAASTRICHT AGING STU; Klein M, 2001, J CLIN ONCOL, V19, P4037, DOI 10.1200/JCO.2001.19.20.4037; Laack NN, 2005, INT J RADIAT ONCOL, V63, P1175, DOI 10.1016/j.ijrobp.2005.04.016; Langbaum JBS, 2009, J GERONTOL B-PSYCHOL, V64, P14, DOI 10.1093/geronb/gbn026; Lidstone V, 2003, PALLIATIVE MED, V17, P588, DOI 10.1191/0269216303pm814oa; Luteijn F., 1983, Handleiding Groninger Intelligentie Test [Manual Groningen Intelligence Test]; Maassen GH, 2009, J CLIN EXP NEUROPSYC, V31, P339, DOI 10.1080/13803390802169059; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; McSweeny A., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; Medalia A, 2005, SCHIZOPHRENIA BULL, V31, P942, DOI 10.1093/schbul/sbi045; Meyers CA, 2006, J CLIN ONCOL, V24, P1305, DOI 10.1200/JCO.2005.04.6086; MEYERS CA, 2005, TXB NEUROONCOLOGY, P101; Mukand JA, 2001, AM J PHYS MED REHAB, V80, P346, DOI 10.1097/00002060-200105000-00005; NEELY AS, 1995, J GERONTOL B-PSYCHOL, V50, pP134, DOI 10.1093/geronb/50B.3.P134; Ponds RWHM, 1999, COGNITIVE FAILURE QU; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Schiff D, 2007, NEUROLOGY, V69, P1366, DOI 10.1212/01.wnl.0000277271.47601.a1; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Stewart AL, 1992, MEASURING FUNCTIONIN, P102, DOI [10.7249/cb361, DOI 10.7249/CB361]; Strangman GE, 2008, ARCH PHYS MED REHAB, V89, P974, DOI 10.1016/j.apmr.2008.02.011; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; van Boxtel MPJ, 1998, J GERONTOL A-BIOL, V53, pM147; VERHAEGHEN P, 1992, HDB HULPVERLENERS CU; YESAVAGE JA, 1990, PSYCHOL AGING, V5, P133, DOI 10.1037/0882-7974.5.1.133; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	49	25	25	0	16	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2011	17	2					256	266		10.1017/S1355617710001530			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	738DY	WOS:000288620900006	21205412				2021-06-18	
J	Pascual, JL; Georgoff, P; Maloney-Wilensky, E; Sims, C; Sarani, B; Stiefel, MF; LeRoux, PD; Schwab, CW				Pascual, Jose L.; Georgoff, Patrick; Maloney-Wilensky, Eileen; Sims, Carrie; Sarani, Babak; Stiefel, Michael F.; LeRoux, Peter D.; Schwab, C. William			Reduced Brain Tissue Oxygen in Traumatic Brain Injury: Are Most Commonly Used Interventions Successful?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Brain tissue oxygenation; Traumatic brain injury; Treatment interventions; PbtO(2)-guided management; Clinical practice guidelines	SEVERE HEAD-INJURIES; CEREBRAL-BLOOD-FLOW; INTRACRANIAL-PRESSURE; AGGRESSIVE TREATMENT; HYPEROXIA; METABOLISM; MANAGEMENT; THERAPY; TENSION; HYPERTENSION	Background: Brain tissue oxygenation (PbtO(2))-guided management facilitates treatment of reduced PbtO(2) episodes potentially conferring survival and outcome advantages in severe traumatic brain injury (TBI). To date, the nature and effectiveness of commonly used interventions in correcting compromised PbtO(2) in TBI remains unclear. We sought to identify the most common interventions used in episodes of compromised PbtO(2) and to analyze which were effective. Methods: A retrospective 7-year review of consecutive severe TBI patients with a PbtO(2) monitor was conducted in a Level I trauma center's intensive care unit or neurosurgical registry. Episodes of compromised PbtO(2) (defined as < 20 mm Hg for 0.25-4 hours) were identified, and clinical interventions conducted during these episodes were analyzed. Response to treatment was gauged on how rapidly (Delta T) PbtO(2) normalized (> 20 mm Hg) and how great the PbtO(2) increase was (Delta PbtO(2)). Intracranial pressure (Delta ICP) and cerebral perfusion pressure (Delta CPP) also were examined for these episodes. Results: Six hundred twenty-five episodes of reduced PbtO(2) were identified in 92 patients. Patient characteristics were: age 41.2 years, 77.2% men, and Injury Severity Score and head or neck Abbreviated Injury Scale score of 34.0 +/- 9.2 and 4.9 +/- 0.4, respectively. Five interventions: narcotics or sedation, pressors, repositioning, FIO2/PEEP increases, and combined sedation or narcotics + pressors were the most commonly used strategies. Increasing the number of interventions resulted in worsening the time to PbtO(2) correction. Triple combinations resulted in the lowest Delta ICP and dual combinations in the highest Delta CPP (p < 0.05). Conclusion: Clinicians use a limited number of interventions when correcting compromised PbtO(2). Using strategies employing many interventions administered closely together may be less effective in correcting PbO2, ICP, and CPP deficits. Some PbtO(2) deficits may be self-limited.	[Pascual, Jose L.] Univ Penn, Sch Med, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, Philadelphia, PA 19104 USA; [Maloney-Wilensky, Eileen; Stiefel, Michael F.; LeRoux, Peter D.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Pascual, JL (corresponding author), Univ Penn, Sch Med, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.	jose.pascual@uphs.upenn.edu		Sarani, Babak/0000-0001-6247-3004			Adamides AA, 2009, ACTA NEUROCHIR, V151, P1399, DOI 10.1007/s00701-009-0398-y; Bardt TF, 1998, ACT NEUR S, V71, P153; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, pS65; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; Fletcher JJ, 2010, NEUROCRIT CARE, V13, P47, DOI 10.1007/s12028-010-9345-2; Fluckiger C, 2010, ACTA NEUROCHIR, V152, P627, DOI 10.1007/s00701-009-0579-8; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gremmelt A, 1995, ANAESTHESIST, V44, pS559; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Longhi L, 2002, ACT NEUR S, V81, P315; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Myburgh J A, 2005, Crit Care Resusc, V7, P200; NANGUNOORI RMW, 2010, LAS VEG NEV NAT NEUR; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Pascual JL, 2008, AM SURGEON, V74, P253; Pfister D, 2008, EUR J ANAESTH, V25, P98, DOI 10.1017/S0265021507003407; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Sabsovich I, 2007, AM J CRIT CARE, V16, P82, DOI 10.4037/ajcc2007.16.1.82; Schmittner MD, 2007, J NEUROSURG ANESTH, V19, P257, DOI 10.1097/ANA.0b013e31811f3feb; SCHMOKER JD, 1992, J TRAUMA, V33, P476, DOI 10.1097/00005373-199209000-00024; Senft C, 2009, NEUROL RES, V31, P1012, DOI 10.1179/174313209X409034; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2007, J TRAUMA, V63, P1155, DOI 10.1097/TA.0b013e31815965e3; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; Wilensky Eileen Maloney, 2005, J Neurosci Nurs, V37, P278; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	59	25	28	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2011	70	3					535	545		10.1097/TA.0b013e31820b59de			11	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	732PU	WOS:000288201200009	21610340				2021-06-18	
J	Pielmaier, L; Walder, B; Rebetez, MML; Maercker, A				Pielmaier, Laura; Walder, Bernhard; Rebetez, Marie My Lien; Maercker, Andreas			Post-traumatic stress symptoms in relatives in the first weeks after severe traumatic brain injury	BRAIN INJURY			English	Article						Head injury; trauma; distress; family	INTENSIVE-CARE-UNIT; FAMILY-MEMBERS; EVENT SCALE; DISORDER; RISK; IMPACT; CAREGIVERS; ADULTS; EPIDEMIOLOGY; SATISFACTION	Introduction: Severe traumatic brain injury (STBI) can cause psychological stress in proxies in the long-term. This study assessed post-traumatic stress (PTS) symptoms in proxies of survivors of STBI in the short-term and investigated stress-associated factors. Methods: Prospective cross-sectional study, conducted at three Swiss trauma centres over 1 year. Patient and proxy demographics, trauma data including Glasgow Coma Scale (GCS) and management data were collected. The proxies' PTS symptoms were assessed by applying the Impact of Event Scale Revised (IES-R), once in the first month after the accident (median: 11 days). Results: Sixty-nine proxies were included; 52 proxies were female (77.8%). Mean IES-R sum score for intrusions was 13.38 (SD = 7.26), for avoidance 8.91 (SD = 5.94), and for hyperarousal 9.07 (SD = 6.75). Clinically significant PTS symptoms were observed in 36 proxies (52.2%); mean IES-R sum scores were significantly higher in women. IES-R sub-scale values were inversely related with GCS at the scene of the accident and on hospital admission. Conclusions: More than half of proxies had clinically significant PTS symptoms shortly after their relative's accident. More severe PTS symptoms were found in women and in proxies of patients with poorer initial GCS scores. Further research into risk groups in the short- and long-term and the long-term impact on patients of PTS syndrome in proxies is warranted.	[Pielmaier, Laura; Maercker, Andreas] Univ Zurich, Inst Psychol, Dept Psychopathol & Clin Intervent, CH-8050 Zurich, Switzerland; [Walder, Bernhard; Rebetez, Marie My Lien] Univ Hosp Geneva, Div Anaesthesiol, Geneva, Switzerland	Pielmaier, L (corresponding author), Univ Zurich, Inst Psychol, Dept Psychopathol & Clin Intervent, Binzmuhlestr 14,Box 17, CH-8050 Zurich, Switzerland.	l.pielmaier@psychologie.uzh.ch	Maercker, Andreas/D-2814-2017	Maercker, Andreas/0000-0001-6925-3266			American Association for the Advancement for Automotive Medicine, 2001, ABBR INJ SCAL 1990 R; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson WG, 2008, J GEN INTERN MED, V23, P1871, DOI 10.1007/s11606-008-0770-2; Auerbach SM, 2005, AM J CRIT CARE, V14, P202, DOI 10.4037/ajcc2005.14.3.202; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brewin CR, 2005, J TRAUMA STRESS, V18, P53, DOI 10.1002/jts.20007; Brunet A, 2003, CAN J PSYCHIAT, V48, P56; Bunzel B, 2007, J HEART LUNG TRANSPL, V26, P384, DOI 10.1016/j.healun.2007.01.025; Chui WYY, 2007, J CLIN NURS, V16, P372, DOI 10.1111/j.1365-2702.2005.01461.x; Creamer M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/j.brat.2003.07.010; Dew MA, 2004, PSYCHOL MED, V34, P1065, DOI 10.1017/S0033291703001387; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jones C, 2004, INTENS CARE MED, V30, P456, DOI 10.1007/s00134-003-2149-5; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Maercker A, 1998, DIAGNOSTICA, V44, P130; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McAdam JL, 2010, CRIT CARE MED, V38, P1078, DOI 10.1097/CCM.0b013e3181cf6d94; McAdam JL, 2009, AM J CRIT CARE, V18, P200, DOI 10.4037/ajcc2009252; Noble AJ, 2008, J NEUROSURG, V109, P1027, DOI 10.3171/JNS.2008.109.12.1027; Olff M, 2007, PSYCHOL BULL, V133, P183, DOI 10.1037/0033-2909.133.2.183; OLSON CL, 1976, PSYCHOL BULL, V83, P579, DOI 10.1037/0033-2909.83.4.579; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Paparrigopoulos T, 2006, J PSYCHOSOM RES, V61, P719, DOI 10.1016/j.jpsychores.2006.05.013; Schlechtriemen T, 2005, NOTFALL RETTUNGSMED, V8, P96, DOI DOI 10.1007/S10049-005-0718-6; TEASDALE G, 1974, LANCET, V2, P81; Tolin DF, 2006, PSYCHOL BULL, V132, P959, DOI 10.1037/0033-2909.132.6.959; *U HOSP GEN, 2010, PAT REL ENDP BRAIN I; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; von Elm E, 2008, SWISS MED WKLY, V138, P327, DOI 2008/23/smw-12025; Weiss DS, 1996, IMPACT EVENTS SCALE, P399; Weiss M, 2001, ANAESTHESIST, V50, P150, DOI 10.1007/s001010170030; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062	37	25	25	1	10	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2011	25	3					259	265		10.3109/02699052.2010.542429			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	734UP	WOS:000288365400001	21280978				2021-06-18	
J	Brakenridge, SC; Toomay, SM; Sheng, JL; Gentilello, LM; Shafi, S				Brakenridge, Scott C.; Toomay, Seth M.; Sheng, Jean L.; Gentilello, Larry M.; Shafi, Shahid			Predictors of early versus late timing of pulmonary embolus after traumatic injury	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	National Meeting of the American-College-of-Surgeons-Committee-on-Trauma	MAR 20, 2009	Chicago, IL	Amer Coll Surg Comm Trauma		Pulmonary embolus; Trauma; Injury	VENA-CAVA FILTERS; RESOLUTION CT FINDINGS; VENOUS THROMBOEMBOLISM; BRAIN-INJURY; MAJOR TRAUMA; HYPERCOAGULABILITY; PROPHYLAXIS; COAGULATION; PREVENTION; HEPARIN	OBJECTIVE: To identify risk factors predictive of pulmonary embolus (PE) timing after a traumatic injury. METHODS: One hundred eight traumatic injury patients with a confirmed diagnosis of PE were classified as early PE (<= 4 days, n = 54) or late PE (>4 days, n = 54). Independent predictors of early versus late PE were identified using multivariate logistic regression. RESULTS: Half the PEs were diagnosed <= 4 days of injury. Only long bone fractures independently predicted early PE (odds ratio 2.8; 95% confidence interval, 1.1-7.1). Severe head injuries were associated with late PE (odds ratio 11.1; 95% confidence interval, 3.9-31). Established risk factors such as age did not affect timing. CONCLUSIONS: Half the PEs were diagnosed 4 days after injury. The risk of early PE appeared highest in patients with long bone fractures, and the benefits of immediate prophylaxis may outweigh risks. Patients with severe head injuries appear to have later PE events. Prospective interventional trials in these injury populations are needed. (C) 2011 Published by Elsevier Inc.	[Brakenridge, Scott C.; Gentilello, Larry M.; Shafi, Shahid] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Toomay, Seth M.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [Sheng, Jean L.] Univ Texas SW Med Sch, Dallas, TX USA; [Shafi, Shahid] Baylor Hlth Care Syst, Inst Hlth Care Res & Improvement, Dallas, TX USA	Shafi, S (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA.	rhcmd@uab.edu	; Brakenridge, Scott/AAD-6691-2019	Toomay, Seth/0000-0002-3962-9653; Brakenridge, Scott/0000-0002-7327-3718	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024982, UL1RR024982] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024982] Funding Source: NIH RePORTER		Adair JD, 2008, J TRAUMA, V64, P509, DOI 10.1097/TA.0b013e318058251c; Antevil JL, 2006, J TRAUMA, V60, P35, DOI 10.1097/01.ta.0000197607.23019.ab; Arakawa H, 2003, CHEST, V123, P1096, DOI 10.1378/chest.123.4.1096; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; FERRARO FJ, 1992, AM SURGEON, V58, P355; Friis E, 2004, WORLD J SURG, V28, P540, DOI 10.1007/s00268-004-723-9; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Ginzburg E, 2003, BRIT J SURG, V90, P1338, DOI 10.1002/bjs.4309; GREEN D, 1988, JAMA-J AM MED ASSOC, V260, P1255, DOI 10.1001/jama.260.9.1255; Hermsen JL, 2008, WORLD J SURG, V32, P1444, DOI 10.1007/s00268-007-9462-z; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Karmy-Jones R, 2007, J TRAUMA, V62, P17, DOI 10.1097/TA.0b013e31802dd72a; Kim KI, 1999, RADIOLOGY, V210, P693, DOI 10.1148/radiology.210.3.r99mr01693; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Kovac M, 2010, CLIN APPL THROMB-HEM, V16, P66, DOI 10.1177/1076029608320721; Mahrer A, 2008, CARDIOVASC INTER RAD, V31, P785, DOI 10.1007/s00270-008-9294-8; Malagari K, 2003, CHEST, V123, P1196, DOI 10.1378/chest.123.4.1196; Meissner MH, 2003, J TRAUMA, V54, P224, DOI 10.1097/01.TA.0000046253.33495.70; Menaker J, 2007, J TRAUMA, V63, P620, DOI 10.1097/TA.0b013e31812f60aa; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Owings JT, 1997, ARCH SURG-CHICAGO, V132, P862; Pasquier E, 2001, THROMB HAEMOSTASIS, V86, P538; Rodeghiero F, 1999, ANN INTERN MED, V130, P643, DOI 10.7326/0003-4819-130-8-199904200-00004; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schreiber MA, 2005, J TRAUMA, V58, P475, DOI 10.1097/01.TA.0000153938.77777.26; Schultz DJ, 2004, J TRAUMA, V56, P727, DOI 10.1097/01.TA.0000119687.23542.EC; Sing RF, 2006, J TRAUMA, V60, P732, DOI 10.1097/01.ta.0000210285.22571.66; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Velmahos GC, 2009, ARCH SURG-CHICAGO, V144, P928, DOI 10.1001/archsurg.2009.97; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	33	25	25	0	3	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	FEB	2011	201	2					209	215		10.1016/j.amjsurg.2009.12.005			7	Surgery	Surgery	722KE	WOS:000287430300012	20385370	Green Accepted			2021-06-18	
J	Brown, CVR; Hejl, K; Mandaville, AD; Chaney, PE; Stevenson, G; Smith, C				Brown, Carlos V. R.; Hejl, Kelli; Mandaville, Amy D.; Chaney, Paul E.; Stevenson, Guy; Smith, Charlotte			Swallowing dysfunction after mechanical ventilation in trauma patients	JOURNAL OF CRITICAL CARE			English	Article						Mechanical ventilation; Dysphagia; Swallowing; Aspiration		Background: Swallowing dysfunction can occur after mechanical ventilation, leading to complications such as aspiration and pneumonia. After mechanical ventilation, authors have recommended evaluating patients with contrast studies or endoscopy to identify patients at risk for swallowing dysfunction and aspiration. The purpose of the study was to determine if a bedside swallowing evaluation (BSE) can identify patients with swallowing dysfunction after mechanical ventilation. Methods: This is a 1-year (2008) prospective study of all adult trauma patients admitted to the intensive care unit requiring mechanical ventilation. Upon separation from mechanical, all patients received a BSE. The BSE used mental status, facial symmetry, swallow reflex, and oral ice chips and water to identify swallowing dysfunction. Patients who passed the BSE were advanced to oral intake per physician orders, whereas patients who failed the BSE were allowed nothing by mouth. Results: A total of 345 patients were included; 54 died before separation from mechanical ventilation and were excluded. The remaining 291 patients underwent BSE after separation from mechanical ventilation, with 143 (49%) passing and 148 (51%) failing. Patients who failed the BSE required mechanical ventilation longer than those who passed (14 +/- 13 vs 5 +/- 20 days, P = .001). In addition, only 23% of patients extubated within 72 hours failed the BSE, whereas 78% of those intubated more than 72 hours failed the BSE (P < .001). All patients who passed the BSE were discharged from the hospital without a clinical aspiration event. Independent risk factors for failure of BSE included tracheostomy, older age, prolonged mechanical ventilation, delirium tremens, traumatic brain injury, and spine fracture. Three (2%) patients who failed the BSE had a clinical aspiration event despite taking nothing by mouth. Conclusions: A simple BSE can be used to identify patients at risk for swallowing dysfunction after mechanical ventilation. More importantly, BSE can safely clear patients without swallowing dysfunction, avoiding costly and time-consuming contrast studies or endoscopic evaluation. (C) 2011 Elsevier Inc. All rights reserved.	[Brown, Carlos V. R.] Univ Med Ctr Brackenridge, Trauma Serv, Austin, TX 78701 USA	Brown, CVR (corresponding author), Univ Med Ctr Brackenridge, Trauma Serv, Austin, TX 78701 USA.	cvrbrown@seton.org					Morgan AS, 1999, J HEAD TRAUMA REHAB, V14, P454, DOI 10.1097/00001199-199910000-00006	1	25	26	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441			J CRIT CARE	J. Crit. Care	FEB	2011	26	1							108.e9	10.1016/j.jcrc.2010.05.036			4	Critical Care Medicine	General & Internal Medicine	722WL	WOS:000287465900027	20869841				2021-06-18	
J	Tucha, L; Tucha, O; Sontag, TA; Stasik, D; Laufkotter, R; Lange, KW				Tucha, Lara; Tucha, Oliver; Sontag, Thomas A.; Stasik, Dorota; Laufkoetter, Rainer; Lange, Klaus W.			Differential Effects of Methylphenidate on Problem Solving in Adults With ADHD	JOURNAL OF ATTENTION DISORDERS			English	Article						ADHD; adulthood; problem solving; Tower of London; verbal fluency; methylphenidate	DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; STRIATAL COGNITIVE DEFICITS; CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL PERFORMANCE; VERBAL FLUENCY; RESPONSE-INHIBITION; PARKINSONS-DISEASE; TESTS; DYSFUNCTION	Objective: Two studies were performed to assess both divergent and convergent thinking in adults with ADHD. Method: The first study compared the problem-solving abilities of healthy participants (N = 144) and unmedicated adults with ADHD (N = 144). In the second study, problem-solving abilities of adults with diagnosed ADHD (N = 22) were examined twice, that is, on and off methylphenidate (MPH), and compared with the performance of a healthy control group (N = 22). Convergent thinking was measured using a Tower of London task, whereas divergent thinking was assessed using verbal fluency tasks. Results: Adults with ADHD off MPH displayed marked deficits of both divergent and convergent thinking. MPH treatment resulted in a marked improvement of convergent thinking, while no effect of medication was found regarding divergent thinking. Conclusion: Pharmacological treatment of adults with ADHD revealed a differential effect of MPH on problem solving abilities. (I. of Att. Dis. 2011; 15(2) 161-173)	[Tucha, Lara] Univ Groningen, Fac Behav & Social Sci, Dept Psychol, NL-9712 TS Groningen, Netherlands; [Sontag, Thomas A.; Stasik, Dorota; Lange, Klaus W.] Univ Regensburg, Dept Expt Psychol, D-8400 Regensburg, Germany; [Laufkoetter, Rainer] Univ Regensburg, Dept Psychiat, D-8400 Regensburg, Germany	Tucha, L (corresponding author), Univ Groningen, Fac Behav & Social Sci, Dept Psychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.	L.I.Tucha@rug.nl	Tucha, Oliver/AAD-1403-2019				AMABILE TM, 1983, J PERS SOC PSYCHOL, V45, P357, DOI 10.1037/0022-3514.45.2.357; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Aron AR, 2003, BIOL PSYCHIAT, V54, P1465, DOI 10.1016/S0006-3223(03)00609-7; Aschenbrenner S, 2000, REGENSBURGER WORTFLU; Barkley R.A, 2006, ATTENTION DEFICIT HY; Barkley R. A., 2006, ATTENTION DEFICIT HY, P248; BARKLEY RA, 1991, J ABNORM CHILD PSYCH, V19, P149, DOI 10.1007/BF00909976; BARKLEY RA, 1998, ATTENTION DEFICIT HY, P164; Ben-Yishay Y, 1983, REHABILITATION HEAD, P367; BENSON DF, 1991, J CHILD NEUROL, V6, pS9, DOI 10.1177/0883073891006001S02; Benton A, 1989, MULTILINGUAL APHASIA; Berg D, 1999, NEUROLOGY, V53, P1026, DOI 10.1212/WNL.53.5.1026; Bezeau S, 2001, J CLIN EXP NEUROPSYC, V23, P399, DOI 10.1076/jcen.23.3.399.1181; Biederman J, 2006, AM J PSYCHIAT, V163, P1730, DOI 10.1176/appi.ajp.163.10.1730; BOLLA KI, 1990, J CLIN PSYCHOL, V46, P623, DOI 10.1002/1097-4679(199009)46:5<623::AID-JCLP2270460513>3.0.CO;2-C; Boonstra AM, 2005, PSYCHOL MED, V35, P1097, DOI 10.1017/S003329170500499X; BOUCUGNANI LL, 1989, ARCH CLIN NEUROPSYCH, V4, P161; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; COOK EH, 1995, AM J HUM GENET, V56, P993; Corbett B, 1999, ARCH CLIN NEUROPSYCH, V14, P373, DOI 10.1016/S0887-6177(98)00037-7; CRAMON DYV, 1993, NEUROPSYCHOLOGISCHE, P123; Culbertson WC, 1998, ASSESSMENT, V5, P215, DOI 10.1177/107319119800500302; DESROSIERS G, 1987, INT J CLIN NEUROPSYC, V9, P162; Dinn WM, 2001, BRAIN COGNITION, V46, P114, DOI 10.1016/S0278-2626(01)80046-4; DUPAUL GJ, 1998, ATTENTION DEFICIT HY, P510; Epstein JN, 2001, J CLIN EXP NEUROPSYC, V23, P362, DOI 10.1076/jcen.23.3.362.1186; Faraone SV, 2000, BIOL PSYCHIAT, V48, P9, DOI 10.1016/S0006-3223(00)00889-1; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GRAFMAN J, 1999, SCI PRACT NEUROPSYCH, P321; GURD JM, 1989, NEUROPSYCHOLOGIA, V27, P743, DOI 10.1016/0028-3932(89)90120-6; Hanes KR, 1996, ARCH CLIN NEUROPSYCH, V11, P185, DOI 10.1016/0887-6177(95)00034-8; Hodgson TL, 2002, NEUROPSYCHOLOGIA, V40, P411, DOI 10.1016/S0028-3932(01)00099-9; HOLDNACK JA, 1995, NEUROPSY NEUROPSY BE, V8, P282; Hollingsworth DE, 2001, J COGNITIVE NEUROSCI, V13, P298, DOI 10.1162/08989290151137359; HOPKINS J, 1979, J CHILD PSYCHOL PSYC, V20, P209, DOI 10.1111/j.1469-7610.1979.tb00504.x; Horton A M Jr, 1996, Appl Neuropsychol, V3, P181, DOI 10.1207/s15324826an0303&4_12; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; HYND GW, 1993, J CHILD NEUROL, V8, P339, DOI 10.1177/088307389300800409; Jenkins M, 1998, CLIN NEUROPSYCHOL, V12, P74, DOI 10.1076/clin.12.1.74.1725; Johnson DE, 2001, ARCH CLIN NEUROPSYCH, V16, P587; KLEE SH, 1986, PSYCHIAT ANN, V16, P52, DOI 10.3928/0048-5713-19860101-12; Kline P, 2000, HDB PSYCHOL TESTING, V2; KONIG F, 1986, DIAGNOSTICA, V4, P345; Kovner R, 1998, INT J NEUROSCI, V96, P225, DOI 10.3109/00207459808986470; Krampen G., 1993, TESTS TRENDS, V10, P11; Kuperman S, 2001, Ann Clin Psychiatry, V13, P129, DOI 10.1023/A:1012239823148; LaHoste GJ, 1996, MOL PSYCHIATR, V1, P121; LANGE KW, 1992, PSYCHOPHARMACOLOGY, V107, P394, DOI 10.1007/BF02245167; Lange KW, 2003, J NEURAL TRANSM, V110, P983, DOI 10.1007/s00702-003-0011-0; Lange KW, 1995, J NEURAL TRANSM-SUPP, P423; LEHRL S, 1995, ACTA NEUROL SCAND, V91, P335, DOI 10.1111/j.1600-0404.1995.tb07018.x; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; LINDENBERGER U, 1993, PSYCHOL AGING, V8, P207, DOI 10.1037/0882-7974.8.2.207; LOU HC, 1984, ARCH NEUROL-CHICAGO, V41, P825, DOI 10.1001/archneur.1984.04050190031010; Lovejoy DW, 1999, J INT NEUROPSYCH SOC, V5, P222, DOI 10.1017/S1355617799533055; LUER G, 1992, ALLGEMEINE PSYCHOL, P189; Luria A. R, 1973, WORKING BRAIN; MARTIN A, 1994, NEUROPSYCHOLOGIA, V32, P1487, DOI 10.1016/0028-3932(94)90120-1; McCann B S, 2000, Semin Clin Neuropsychiatry, V5, P191, DOI 10.1053/scnp.2000.6730; Mehta MA, 2000, J PSYCHOPHARMACOL, V14, P299, DOI 10.1177/026988110001400314; MERCUGLIANO M, 1995, MRDD RES REV, V1, P220; MORRIS RG, 1988, J NEUROL NEUROSUR PS, V51, P757, DOI 10.1136/jnnp.51.6.757; OWEN AM, 1995, NEUROPSYCHOLOGY, V9, P126, DOI 10.1037/0894-4105.9.1.126; OWEN AM, 1992, BRAIN, V115, P1727, DOI 10.1093/brain/115.6.1727; Pantelis C, 1997, BRAIN, V120, P1823, DOI 10.1093/brain/120.10.1823; PARKIN AJ, 1994, NEUROPSYCHOLOGIA, V32, P1523, DOI 10.1016/0028-3932(94)90124-4; PASQUIER F, 1995, J NEUROL NEUROSUR PS, V58, P81, DOI 10.1136/jnnp.58.1.81; Pedhazur E.J., 1991, MEASUREMENT DESIGN A; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Riccio CA, 2004, ARCH CLIN NEUROPSYCH, V19, P661, DOI 10.1016/j.acn.2003.09.001; Riordan HJ, 1999, ARCH CLIN NEUROPSYCH, V14, P217, DOI 10.1016/S0887-6177(98)00015-8; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; ROBBINS TW, 1994, J NEUROL NEUROSUR PS, V57, P79, DOI 10.1136/jnnp.57.1.79; Rowe H.A.H., 1985, PROBLEM SOLVING INTE; Ruprecht-Dorfler P, 2003, NEUROIMAGE, V18, P416, DOI 10.1016/S1053-8119(02)00035-6; SALTHOUSE TA, 1993, J GERONTOL, V48, pP245, DOI 10.1093/geronj/48.5.P245; Schweitzer JB, 2004, BIOL PSYCHIAT, V56, P597, DOI 10.1016/j.biopsych.2004.07.011; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SILVERSTEIN SM, 1995, NEUROPSYCHOLOGY, V9, P157, DOI 10.1037/0894-4105.9.2.157; SIMON HA, 1975, COGNITIVE PSYCHOL, V7, P268, DOI 10.1016/0010-0285(75)90012-2; SINGER HS, 1993, NEUROLOGY, V43, pA409; Smith E.E., 2007, COGNITIVE PSYCHOL MI; Sohlberg MM, 2001, ANN NY ACAD SCI, V931, P359; Spreen O., 1991, COMPENDIUM NEUROPSYC; Sternberg R. J, 1985, IQ TRIARCHIC THEORY; STERNBERG RJ, 1981, J PERS SOC PSYCHOL, V41, P37, DOI 10.1037/0022-3514.41.1.37; Stuss D.T., 1986, FRONTAL LOBES; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Tucha O, 2006, J NEURAL TRANSM, V113, P1575, DOI 10.1007/s00702-005-0437-7; Tucha O, 2004, TOWER LONDON; Tucha Oliver, 2005, Cogn Neuropsychiatry, V10, P231, DOI 10.1080/13546800444000047; Turner DC, 2005, PSYCHOPHARMACOLOGY, V178, P286, DOI 10.1007/s00213-004-1993-5; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; Walker AJ, 2000, J CLIN EXP NEUROPSYC, V22, P115, DOI 10.1076/1380-3395(200002)22:1;1-8;FT115; Wasserstein J, 2001, ANN NY ACAD SCI, V931, P376; Wender PH, 1995, ATTENTION DEFICIT HY; Weyandt LL, 1998, DEV NEUROPSYCHOL, V14, P643, DOI 10.1080/87565649809540734; WIEDERHOLT WC, 1993, J AM GERIATR SOC, V41, P639, DOI 10.1111/j.1532-5415.1993.tb06738.x; Wilens TE, 2004, J CLIN PSYCHIAT, V65, P1301, DOI 10.4088/JCP.v65n1003; Willams C, 1999, BRIT J GEN PRACT, V49, P563; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7; ZAMETKIN AJ, 1993, ARCH GEN PSYCHIAT, V50, P333; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001; Zimmermann P, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P110; Zimmermann P, 1993, COMPUTERIZED NEUROPS	109	25	25	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1087-0547	1557-1246		J ATTEN DISORD	J. Atten. Disord.	FEB	2011	15	2					161	173		10.1177/1087054709356391			13	Psychology, Developmental; Psychiatry	Psychology; Psychiatry	714XZ	WOS:000286846300008	20484710	Green Published			2021-06-18	
J	Bohman, K; Arbogast, KB; Bostrom, O				Bohman, Katarina; Arbogast, Kristy B.; Bostrom, Ola			Head Injury Causation Scenarios for Belted, Rear-Seated Children in Frontal Impacts	TRAFFIC INJURY PREVENTION			English	Article						Head injury; Rear seat; Frontal impact; Child	TRAUMATIC BRAIN-INJURY; SHORT-TERM; PREDICTORS; OUTCOMES	Objectives: Head injuries are the most common serious injuries sustained by children in motor vehicle crashes and are of critical importance with regard to long-term disability. There is a lack of understanding of how seat belt-restrained children sustain head injuries in frontal impacts. The aim of the study was to identify the AIS2+ head injury causation scenarios for rear-seated, belt-restrained children in frontal impacts, including the set of parameters contributing to the injury. Method: In-depth crash investigations from two National Highway Traffic Safety Administration (NHTSA) databases, the National Automotive Sampling System-Crashworthiness Data System (NASS-CDS; 1997-2008) and the Crash Injury Research and Engineering Network (CIREN; 1996-2009), were collected and analyzed in detail. Selection criteria were all frontal impacts with principal direction of force (PDOF) of 11, 12, and 1 o'clock involving rear-seated, three-point belt-restrained, with or without booster cushion, children from 3 to 13 years with an AIS2+ head injury. Cases were analyzed using the BioTab method of injury causation assessment in order to systematically analyze the injury causation scenario for each case. Results: There were 27 cases meeting the inclusion criteria, 19 cases with MAIS2 head injuries and 8 cases with MAIS3+ head injuries, including 2 fatalities. Three major injury causation scenarios were identified, including head contact with seatback (10 cases), head contact with side interior (7 cases,) and no evidence of head contact (9 cases). Conclusions: Head injuries with seatback or side interior contact typically included a PDOF greater than 10 degree (similar to the Insurance Institute for Highway Safety [IIHS] and EuroNCAP offset frontal testing) and vehicle maneuvers. For seatback contact, the vehicle's movements contributed to occupant kinematics inboard the vehicle, causing a less than optimal restraint of the torso and/or torso roll out of the shoulder belt. For side interior contact, the PDOF and/or maneuvers forced the occupant toward the side interior. The cases without evidence of head/face contact were characterized by high crash severity and accompanied by severe injuries to the thorax and spine. These data lead to increased understanding of the injury patterns and causation in this crash restraint scenario so that interventions to mitigate the burden of injury can be advanced.	[Bohman, Katarina] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Arbogast, Kristy B.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Bohman, Katarina; Bostrom, Ola] Autoliv Res, Vargarda, Sweden	Bohman, K (corresponding author), Autoliv Dev AB, Wallentinsvagen 22, S-44783 Vargarda, Sweden.	katarina.bohman@autoliv.com		Arbogast, Kristy/0000-0002-1694-4562	National Science Foundation (NSF) Center for Child Injury Prevention Studies at the Children's Hospital of Philadelphia (CCHIPS)National Science Foundation (NSF); institute FFI	The authors acknowledge the National Science Foundation (NSF) Center for Child Injury Prevention Studies at the Children's Hospital of Philadelphia (CCHIPS) for partially sponsoring this study and its Industry Advisory Board (IAB) members for their support, valuable input, and advice. The views presented are those of the authors and not necessarily the views of CHOP, the NSF, or the IAB members.; The authors also acknowledge the institute FFI for partially funding the project. Ulrich Sander, Autoliv Research, is acknowledged for his contribution in analyzing the PDOF of the cases.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Andersson M., 2010, P 54 ANN AAAM LAS VE; ARBOGAST KB, 2005, P INT RES C BIOM INJ; Arbogast KB, 2010, J TRAUMA, V69, P913, DOI 10.1097/TA.0b013e3181e883f9; BIDEZ MW, 2005, SAE 2005 WORLD C EXH; BOHMAN K, 2007, 20 INT TECHN C ENH S; Bose Dipan, 2008, Ann Adv Automot Med, V52, P61; BOSTROM O, 2008, P 52 ANN AAAM SAN DI, P289; GLASS W, 2002, NAWCADPAXTR2001184 N; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Howard A, 2004, J TRAUMA, V56, P1276, DOI 10.1097/01.TA.0000078883.74947.EB; Huang S, 2006, 2006011142 SAE; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KENT R, 2007, 20 INT TECHN C ENH S; Klinich KD, 2008, UMTRI2008492, VII; Lindquist MO, 2006, J TRAUMA, V61, P1506, DOI 10.1097/01.ta.0000210496.52412.02; LOPEZVALDEZ FJ, 2009, P INT RES C BIOM INJ; Maltese MR, 2007, STAPP CAR CRASH JO, V51, P299; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; *NAT HIGHW TRAFF S, 2008, 810654 DOT HS NAT HI; *NAT HIGHW TRAFF S, 2010, 4 STEPS KIDS BOOST S; PHEASANT ST, 1996, BODYSPACE; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Scheidler MG, 2000, J TRAUMA, V49, P864, DOI 10.1097/00005373-200011000-00012; SHERWOOD CP, 2006, P 50 ANN AAAM CHIC I; Swanson J, 2003, 18 INT TECHN C ENH S; Talmor D, 2010, ACCIDENT ANAL PREV, V42, P672, DOI 10.1016/j.aap.2009.10.015; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; THIELMAN CY, 1998, PUBLICATION FEDERAL; TORNVALL F, 2008, THESIS CHALMERS U TE; TYLKO S, 2005, 19 INT TECHN C ENH S; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	36	25	25	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.		2011	12	1					62	70	PII 932649413	10.1080/15389588.2010.526159			9	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	717LD	WOS:000287044500009	21259175				2021-06-18	
J	Jia, YL; Grafe, MR; Gruber, A; Alkayed, NJ; Wang, RKK				Jia, Yali; Grafe, Marjorie R.; Gruber, Andras; Alkayed, Nabil J.; Wang, Ruikang K.			In vivo optical imaging of revascularization after brain trauma in mice	MICROVASCULAR RESEARCH			English	Article						Traumatic brain injury; Cerebral blood flow; Revascularization; EETs; Soluble epoxide hydrolase; Optical imaging	VESSEL FORMATION; BLOOD PERFUSION; ANGIOGENESIS; MECHANISMS; INJURY; MORPHOGENESIS; EXPRESSION; GENE	Revascularization following brain trauma is crucial to the repair process. We used optical micro-angiography (OMAG) to study endogenous revascularization in living mice following brain injury. OMAG is a volumetric optical imaging method capable of in vivo mapping of localized blood perfusion within the scanned tissue beds down to capillary level imaging resolution. We demonstrated that OMAG can differentiate revascularization progression between traumatized mice with and without soluble epoxide hydrolase (sEH) gene deletion. The time course of revascularization was determined from serial imaging of the traumatic region in the same mice over a one-month period of rehabilitation. Restoration of blood volume at the lesion site was more pronounced in sEH knockout mice than in wild-type mice as determined by OMAG. These OMAG measurements were confirmed by histology and showed that the sEH knockout effect may be involved in enhancing revascularization. The correlation of OMAG with histology also suggests that OMAG is a useful imaging tool for real-time in vivo monitoring of post-traumatic revascularization and for evaluating agents that inhibit or promote endogenous revascularization during the recovery process in small rodents. Published by Elsevier Inc.	[Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Jia, Yali; Gruber, Andras; Wang, Ruikang K.] Oregon Hlth & Sci Univ, Sch Med, Dept Biomed Engn, Portland, OR 97239 USA; [Grafe, Marjorie R.] Oregon Hlth & Sci Univ, Sch Med, Dept Pathol, Portland, OR 97239 USA; [Alkayed, Nabil J.; Wang, Ruikang K.] Oregon Hlth & Sci Univ, Sch Med, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA	Wang, RKK (corresponding author), Univ Washington, Dept Bioengn, 3720 15th Ave NE, Seattle, WA 98195 USA.	wangrk@uw.edu	Wang, Ruikang K./L-3889-2019	Wang, Ruikang K./0000-0001-5169-8822; Jia, Yali/0000-0002-2784-1905; Gruber, Andras/0000-0001-6212-2247	National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL093140]; National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB009682]; National Institute of Deafness and other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01 DC010201]; American Heart AssociationAmerican Heart Association [0855733G]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL093140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044313, R01NS070837, P30NS061800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC010201] Funding Source: NIH RePORTER	This work was supported in part by research grants from the National Heart, Lung, and Blood Institute (R01 HL093140), the National Institute of Biomedical Imaging and Bioengineering (R01 EB009682), the National Institute of Deafness and other Communication Disorders (R01 DC010201), and the American Heart Association (0855733G).	ARNOLD F, 1991, PHARMACOL THERAPEUT, V52, P407, DOI 10.1016/0163-7258(91)90034-J; Briers JD, 2001, PHYSIOL MEAS, V22, pR35, DOI 10.1088/0967-3334/22/4/201; Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158; Carmeliet Peter, 2002, P1; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; ELLIS EF, 1990, AM J PHYSIOL, V259, pH1171, DOI 10.1152/ajpheart.1990.259.4.H1171; Fercher AF, 2003, REP PROG PHYS, V66, P239, DOI 10.1088/0034-4885/66/2/204; FINA L, 1990, BLOOD, V75, P2417; Folkman J, 1998, CIRCULATION, V97, P1108, DOI 10.1161/01.CIR.97.12.1108; Frontczak-Baniewicz M, 2003, ACTA NEUROBIOL EXP, V63, P65; Iliff JJ, 2009, FUTUR NEUROL, V4, P179, DOI 10.2217/14796708.4.2.179; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Lipowsky HH, 2005, MICROCIRCULATION, V12, P5, DOI 10.1080/10739680590894966; Mazur G, 2004, FOLIA HISTOCHEM CYTO, V42, P241; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Morisseau C, 2005, ANNU REV PHARMACOL, V45, P311, DOI 10.1146/annurev.pharmtox.45.120403.095920; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Patan S, 2001, CIRC RES, V89, P723, DOI 10.1161/hh2001.097870; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schaerer L, 2000, AM J DERMATOPATH, V22, P140, DOI 10.1097/00000372-200004000-00009; Tomlins PH, 2005, J PHYS D APPL PHYS, V38, P2519, DOI 10.1088/0022-3727/38/15/002; Wang RKK, 2007, OPT EXPRESS, V15, P11402, DOI 10.1364/OE.15.011402; Wang RK, 2007, OPT EXPRESS, V15, P4083, DOI 10.1364/OE.15.004083; Zhang CY, 2002, STROKE, V33, P2957, DOI 10.1161/01.STR.0000037787.07479.9A; Zhang WR, 2008, STROKE, V39, P2073, DOI 10.1161/STROKEAHA.107.508325	27	25	25	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0026-2862	1095-9319		MICROVASC RES	Microvasc. Res.	JAN	2011	81	1					73	80		10.1016/j.mvr.2010.11.003			8	Peripheral Vascular Disease	Cardiovascular System & Cardiology	710HK	WOS:000286501600009	21075124	Green Accepted			2021-06-18	
J	Jones, A; Ingram, MV				Jones, Alvin; Ingram, M. Victoria			A Comparison of Selected MMPI-2 and MMPI-2-RF Validity Scales in Assessing Effort on Cognitive Tests in a Military Sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						MMPI-2; Optimal Data analysis; MMPI-2-RF; Symptom validity tests	FAKE-BAD-SCALE; HENRY-HEILBRONNER INDEX; TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TESTS; FORENSIC SETTINGS; LEES-HALEY; METAANALYSIS; VALIDATION; DISABILITY; DISORDERS	Using a relatively new statistical paradigm, Optimal Data Analysis (ODA; Yarnold & Soltysik, 2005), this research demonstrated that newly developed scales for the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) and MMPI-2 Restructured Form (MMPI-2-RF) specifically designed to assess over-reporting of cognitive and/or somatic symptoms were more effective than the MMPI-2 F-family of scales in predicting effort status on tests of cognitive functioning in a sample of 288 military members. ODA demonstrated that when all scales were performing at their theoretical maximum possible level of classification accuracy, the Henry Heilbronner Index (HHI), Response Bias Scale (RBS), Fake Bad Scale (FBS), and the Symptom Validity Scale (FBS-r) outperformed the F-family of scales on a variety of ODA indexes of classification accuracy, including an omnibus measure (effect strength total, EST) of the descriptive and prognostic utility of ODA models developed for each scale. Based on the guidelines suggested by Yarnold and Soltysik for evaluating effect strengths for ODA models, the newly developed scales had effects sizes that were moderate in size (37.66 to 45.68), whereas the F-family scales had effects strengths that ranged from weak to moderate (15.42 to 32.80). In addition, traditional analysis demonstrated that HHI, RBS, FBS, and FBS-R had large effect sizes (0.98 to 1.16) based on Cohen's (1988) suggested categorization of effect size when comparing mean scores for adequate versus inadequate effort groups, whereas F-family of scales had small to medium effect sizes (0.25 to 0.76). The MMPI-2-RF Infrequent Somatic Responses Scale (F-S) tended to perform in a fashion similar to F, the best performing F-family scale.	[Ingram, M. Victoria] Womack Army Med Ctr, Dept Behav Hlth, Ft Bragg, NC 28310 USA; [Jones, Alvin] Landstuhl Reg Med Ctr, Dept Behav Hlth, Landstuhl, Germany	Ingram, MV (corresponding author), Womack Army Med Ctr, Dept Behav Hlth, 2817 Riley Rd,Bldg 4-2817, Ft Bragg, NC 28310 USA.	victoria.ingram@amedd.army.mil					Arbisi P. A., 1995, PSYCHOL ASSESSMENT, V7, P425; Arbisi PA, 2004, ARCH CLIN NEUROPSYCH, V19, P341, DOI 10.1016/j.acn.2003.12.003; Bagby RM, 2000, ASSESSMENT, V7, P55, DOI 10.1177/107319110000700104; Ben-Porath Y. S., 2008, MINNESOTA MULTIPHASI; Butcher, 1989, MINNESOTA MULTIPHASI; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; GERVAIS R, 2005, ANN MMPI 2 S WORKSH; Gervais R. O., 2008, CLIN NEUROPSYCHOL, V3, P1; Gervais R. O., J PERSONALI IN PRESS; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; GREEN P, 1997, MEMORY COMPLAINTS IN; Henry GK, 2008, CLIN NEUROPSYCHOL, V22, P919, DOI 10.1080/13854040701625853; Henry GK, 2006, CLIN NEUROPSYCHOL, V20, P786, DOI 10.1080/13854040500287749; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 2002, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2007, J CLIN EXP NEUROPSYC, V29, P67, DOI 10.1080/13803390500488546; Nelson NW, 2010, CLIN NEUROPSYCHOL, V24, P701, DOI 10.1080/13854040903482863; Nelson NW, 2006, CLIN NEUROPSYCHOL, V20, P39, DOI 10.1080/13854040500459322; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ostrander R, 1998, J CONSULT CLIN PSYCH, V66, P660, DOI 10.1037/0022-006X.66.4.660; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Smart CM, 2008, J INT NEUROPSYCH SOC, V14, P842, DOI 10.1017/S1355617708081034; Stump N., 2007, NEUROLOGY TODAY, V7, P15; Tellegen A, 2008, **DROPPED REF**; Tombaugh TN, 1996, TEST MEMORY MALINGER; Whitney K. A., 2008, ARCH CLIN NEUROPSYCH, V2, P8; Wygant DB, 2011, PSYCHOL INJ LAW, V4, P13, DOI 10.1007/s12207-011-9098-z; Wygant DB, 2010, PSYCHOL ASSESSMENT, V22, P745, DOI 10.1037/a0020042; Wygant DB, 2009, ARCH CLIN NEUROPSYCH, V24, P671, DOI 10.1093/arclin/acp073; Yarnold P. R., 2005, OPTIMAL DATA ANAL GU; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]; Youngjohn JR, 2011, CLIN NEUROPSYCHOL, V25, P463, DOI [10.1080/13854046.2011.554444, 10.1080/13854046.2010.550635]	38	25	26	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	7					1207	1227		10.1080/13854046.2011.600726			21	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	882JJ	WOS:000299559600008	21902565				2021-06-18	
J	Lew, HL; Kraft, M; Pogoda, TK; Amick, MM; Woods, P; Cifu, DX				Lew, Henry L.; Kraft, Malissa; Pogoda, Terri K.; Amick, Melissa M.; Woods, Patricia; Cifu, David X.			Prevalence and characteristics of driving difficulties in Operation Iraqi Freedom/Operation Enduring Freedom combat returnees	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						automobiles; combat; concussion; deployment; driving; OIF/OEF; posttraumatic stress disorder; road rage; traumatic brain injury; veterans	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE ACCIDENT; MENTAL-HEALTH PROBLEMS; WAR VETERANS; POSTCONCUSSIVE SYMPTOMS; SLEEP DISTURBANCE; FOLLOW-UP; GULF-WAR; AFGHANISTAN	We studied the prevalence and characteristics of self-reported driving difficulties and examined their association with traumatic brain injury (TBI) and/or posttraumatic stress disorder (PTSD) in Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) veterans who were seen at a Department of Veterans Affairs outpatient polytrauma clinic. In this study, we used a brief driving questionnaire and chart reviews to assess the prevalence and characteristics of driving difficulties in the following four groups of patients: TBI only, PTSD only, TBI + PTSD, and Neither (neither TBI nor PTSD). Compared with before deployment, 93% of OIF/OEF veterans seen in the polytrauma clinic reported more difficulties with driving in at least one domain, with the most common areas of difficulty being (1) problems with anger or impatience (82%), (2) general driving difficulties (65%), and (3) experiences with near misses (57%). Patients with PTSD (with or without TBI) reported the most significant driving impairments, whereas respondents with a history of only TBI endorsed driving difficulties similar to veterans without either diagnosis. Qualitative analysis of veterans' comments also revealed similar patterns. Self-reported driving problems were common among OIF/OEF returnees. Respondents who had a diagnosis of PTSD (with or without TBI) reported the most severe driving difficulties since returning from deployment. The association between PTSD and driving problems warrants further investigation.	[Lew, Henry L.] DVBIC, Richmond, VA USA; [Lew, Henry L.] Univ Manoa, Honolulu, HI USA; [Kraft, Malissa; Pogoda, Terri K.; Amick, Melissa M.; Woods, Patricia] VA Boston Healthcare Syst, Polytrauma & Traumat Brain Injury Res Ctr, Dept Vet Affairs, Boston, MA USA; [Pogoda, Terri K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA; [Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Amick, Melissa M.] DVBIC, Boston, MA USA; [Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Phys Med & Rehabil Serv, Richmond, VA USA	Lew, HL (corresponding author), Univ Hawaii Manoa, 1410 Lower Campus Rd, Honolulu, HI 96822 USA.	hlew@dvbic.org	Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780; Cifu, David/0000-0003-1600-9387	VA Merit Review GrantUS Department of Veterans Affairs [B5009R]	This material was based on work supported by VA Merit Review Grant B5009R.	Amin MM, 2010, MIL MED, V175, P155; Atkinson MP, 2009, MANAGE SCI, V55, P1454, DOI 10.1287/mnsc.1090.1042; Boehmer TKC, 2004, ARCH INTERN MED, V164, P1908, DOI 10.1001/archinte.164.17.1908; Calhoun PS, 2007, J TRAUMA STRESS, V20, P1009, DOI 10.1002/jts.20255; CARDEN MJ, DEP LAUNCH SAFE DRIV; CASTRO CA, 2005, P NATO RES TECHN ORG; Contardi S, 2004, BRAIN RES BULL, V63, P427, DOI 10.1016/j.brainresbull.2003.12.016; *DEP DEF INJ SURV, 1999, MIL MED S, V164; *DEP VET AFF, 2010, VET SAF DRIV IN; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Fear NT, 2008, AM J PREV MED, V35, P230, DOI 10.1016/j.amepre.2008.05.027; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hooper TI, 2005, AM J IND MED, V48, P118, DOI 10.1002/ajim.20190; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kang HK, 2002, OCCUP ENVIRON MED, V59, P794, DOI 10.1136/oem.59.12.794; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Knapik JJ, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-231; KORB LJ, 2007, CALL DUTY COMPREHENS; Kuch K, 1996, CAN J PSYCHIAT, V41, P429, DOI 10.1177/070674379604100707; Kupchik M, 2007, DEPRESS ANXIETY, V24, P244, DOI 10.1002/da.20189; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2011, J REHABIL RES DEV, V48, P913, DOI 10.1682/JRRD.2010.08.0140; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2010, NEUROREHABILITATION, V26, P271, DOI 10.3233/NRE-2010-0562; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lewis V, 2009, MIL MED, V174, P948, DOI 10.7205/MILMED-D-04-0208; Lincoln Andrew E, 2006, Traffic Inj Prev, V7, P31, DOI 10.1080/15389580500412028; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Maher MJ, 2006, CNS DRUGS, V20, P567, DOI 10.2165/00023210-200620070-00003; Mann RE, 2010, ACCIDENT ANAL PREV, V42, P1538, DOI 10.1016/j.aap.2010.03.010; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Matsuoka Y, 2008, CRIT CARE MED, V36, P74, DOI 10.1097/01.CCM.0000291650.70816.D6; Mayou RA, 2002, BEHAV RES THER, V40, P665, DOI 10.1016/S0005-7967(01)00069-9; Miyata S, 2010, NEUROSCI LETT, V469, P229, DOI 10.1016/j.neulet.2009.12.001; Philip P, 2005, SLEEP, V28, P1511, DOI 10.1093/sleep/28.12.1511; Pietrzak Robert H, 2009, J Spec Oper Med, V9, P74; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Reger MA, 2009, J CLIN PSYCHIAT, V70, P1266, DOI 10.4088/JCP.08m04361; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Schwab KA, 2007, J REHABIL RES DEV, V44, pXIII; Sivak M, 1996, J SAFETY RES, V27, P225, DOI 10.1016/S0022-4375(96)00027-8; Tanielian T, 2008, INVISIBLE WOUNDS WAR; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; *W REED ARM I RES, 2007, P COMB STRESS REL DI; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Ware J Catesby, 2006, Behav Sleep Med, V4, P1, DOI 10.1207/s15402010bsm0401_1; Wickens CM, 2008, ACCIDENT ANAL PREV, V40, P1223, DOI 10.1016/j.aap.2008.01.006	59	25	25	0	5	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2011	48	8					913	925		10.1682/JRRD.2010.08.0140			13	Rehabilitation	Rehabilitation	847DM	WOS:000296952100004	22068370	Bronze			2021-06-18	
J	Lu, XCM; Hartings, JA; Si, YZ; Balbir, A; Cao, Y; Tortella, FC				Lu, Xi-Chun May; Hartings, Jed A.; Si, Yuanzheng; Balbir, Alexander; Cao, Ying; Tortella, Frank C.			Electrocortical Pathology in a Rat Model of Penetrating Ballistic-Like Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						electrophysiology; penetrating ballistic-like brain injury; rat	LATERALIZED EPILEPTIFORM DISCHARGES; NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN; CONTINUOUS EEG; ELECTROGRAPHIC SEIZURES; POSTTRAUMATIC EPILEPSY; QUANTITATIVE ELECTROENCEPHALOGRAPHY; INTRACEREBRAL HEMORRHAGE; CLINICAL-FEATURES; SPECTRAL-ANALYSIS	Traumatic brain injury (TBI) causes severe disruption of cerebral electrical activity and electroencephalography (EEG) is emerging as a standard tool to monitor TBI patients in the acute period of risk for secondary injuries. However, animal studies of EEG pathology in the context of TBI are surprisingly sparse, largely because of the lack of real-time continuous EEG (cEEG) monitoring in animal TBI models. Here, we performed long-term EEG monitoring to study nonconvulsive seizures (NCS), periodic epileptiform discharges (FED), and EEG power spectra following three injury severity levels in a rat model of penetrating ballistic-like brain injury (PBBI). EEG signals were recorded continuously from bilateral hemispheres of freely behaving rats for 72 h and for 2 h on days 7 and 14 after the injury. We report that the incidence of NCS and FED positively correlated with the injury severity, where 13%, 39%, and 59% of the animals exhibited NCS, and 0%, 30%, and 65% of the animals exhibited PED following 5%, 10% and 12.5% PBBI, respectively. Similar correlations existed for the number of NCS and FED events and their duration. NCS and FED occurred either independently or in tandem. Longer NCS durations were associated with larger lesion volumes. Significant EEG slowing evidenced by the EEG power shift toward the frequency band (0.5-4 Hz) occurred within 2 h after PBBI, which resolved over time but persisted longer after greater injury severity. In contrast, decreases in higher frequency power (i.e., 30-35 Hz) remained depressed throughout 14 days. This is the first long-term cEEG study of the acute injury phase in a rat model of severe TBI, demonstrating common occurrences of clinically observed electrocortical pathology, such as NCS, FED, and cortical slowing. These EEG pathologies may serve as critical care biomarkers of brain injury, and offer clinically relevant metrics for studying acute therapeutic interventions.	[Lu, Xi-Chun May; Hartings, Jed A.; Si, Yuanzheng; Balbir, Alexander; Cao, Ying; Tortella, Frank C.] Walter Reed Army Inst Res, Div Psychiat & Neurosci, Dept Appl Neurobiol, Silver Spring, MD 20910 USA	Lu, XCM (corresponding author), Walter Reed Army Inst Res, Div Psychiat & Neurosci, Dept Appl Neurobiol, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	may.lu@us.army.mil		Hartings, Jed/0000-0001-8583-3471			Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Alster Jason, 1993, Brain Injury, V7, P191, DOI 10.3109/02699059309029672; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Baayen JC, 2003, BRAIN TOPOGR, V16, P85, DOI 10.1023/B:BRAT.0000006332.71345.b7; BALL GJ, 1977, ELECTROEN CLIN NEURO, V43, P346, DOI 10.1016/0013-4694(77)90258-9; Baykan B, 2000, SEIZURE-EUR J EPILEP, V9, P402, DOI 10.1053/seiz.2000.0435; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; CHATRIAN GE, 1964, ELECTROEN CLIN NEURO, V17, P177, DOI 10.1016/0013-4694(64)90149-X; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; COBB W, 1950, BRAIN, V73, P392, DOI 10.1093/brain/73.3.392; de Jongh A, 2003, NEUROIMAGE, V20, P2291, DOI 10.1016/j.neuroimage.2003.07.030; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; DECKER DA, 1972, ELECTROEN CLIN NEURO, V33, P303, DOI 10.1016/0013-4694(72)90157-5; DELAPAZ D, 1981, ARCH NEUROL-CHICAGO, V38, P713, DOI 10.1001/archneur.1981.00510110073012; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Fabene PF, 2008, NAT MED, V14, P1377, DOI 10.1038/nm.1878; Fishman O, 2010, CLIN EEG NEUROSCI, V41, P11, DOI 10.1177/155005941004100104; Fitzpatrick W, 2007, CAN J NEUROL SCI, V34, P443, DOI 10.1017/S0317167100007332; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Garcia-Morales I, 2002, J CLIN NEUROPHYSIOL, V19, P172, DOI 10.1097/00004691-200203000-00009; Garzon E, 2001, NEUROLOGY, V57, P1175, DOI 10.1212/WNL.57.7.1175; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hirsch Lawrence J, 2008, Epilepsy Curr, V8, P97, DOI 10.1111/j.1535-7511.2008.00254.x; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Husain AM, 1999, J CLIN NEUROPHYSIOL, V16, P51, DOI 10.1097/00004691-199901000-00005; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; JORDAN KG, 1995, NEUROL CLIN, V13, pR9, DOI 10.1016/S0733-8619(18)30029-X; KARNAZE DS, 1982, NEUROLOGY, V32, P289, DOI 10.1212/WNL.32.3.289; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; KUROIWA Y, 1980, ARCH NEUROL-CHICAGO, V37, P15, DOI 10.1001/archneur.1980.00500500045005; Lawn ND, 2000, CLIN NEUROPHYSIOL, V111, P2125, DOI 10.1016/S1388-2457(00)00466-1; Lowenstein D H, 1996, Epilepsy Res Suppl, V11, P45; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; Lu XCM, 2009, J CEREBR BLOOD F MET, V29, P1924, DOI 10.1038/jcbfm.2009.109; MARKAND ON, 1971, NEUROLOGY, V21, P975, DOI 10.1212/WNL.21.10.975; MEYER K, 2008, J TRAUMA NURS, V15, P190; Meyer Kimberly, 2008, J Trauma Nurs, V15, P185, DOI 10.1097/01.JTN.0000343324.55087.de; MOULTON RJ, 1988, CAN J NEUROL SCI, V15, P82, DOI 10.1017/S0317167100027244; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Olson S, 2004, J CLIN NEUROSCI, V11, P1, DOI 10.1016/j.jocn.2003.03.002; Orta DS, 2009, ARCH NEUROL-CHICAGO, V66, P985, DOI 10.1001/archneurol.2009.137; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; Paul Danie B, 2006, J Clin Monit Comput, V20, P399, DOI 10.1007/s10877-006-9045-9; Privitera Michael D., 1994, Emergency Medicine Clinics of North America, V12, P1089; RAROQUE HG, 1995, EPILEPSIA, V36, P58, DOI 10.1111/j.1528-1157.1995.tb01666.x; Reid WM, 2010, J NEUROTRAUM, V27, P1243, DOI 10.1089/neu.2010.1270; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1995, NEUROSURG CLIN N AM, V6, P715; SCHEAR HE, 1984, CLIN ELECTROENCEPHAL, V15, P32, DOI 10.1177/155005948401500105; SCHRAEDER PL, 1980, EPILEPSIA, V21, P647, DOI 10.1111/j.1528-1157.1980.tb04318.x; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; SHEAR DA, 2010, NAT NEUR S; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Thapa A, 2010, SEIZURE-EUR J EPILEP, V19, P211, DOI 10.1016/j.seizure.2010.02.004; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Verma A, 2006, J CLIN NEUROPHYSIOL, V23, P333, DOI 10.1097/01.wnp.0000228497.89734.7a; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Vieth JB, 1996, BRAIN TOPOGR, V8, P215, DOI 10.1007/BF01184772; Wallace BE, 2001, J HEAD TRAUMA REHAB, V16, P165, DOI 10.1097/00001199-200104000-00006; Wetherington J, 2008, NEURON, V58, P168, DOI 10.1016/j.neuron.2008.04.002; Williams AJ, 2001, J PHARMACOL EXP THER, V299, P48; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2004, J PHARMACOL EXP THER, V311, P220, DOI 10.1124/jpet.104.069146; Williams AJ, 2008, NEUROSCI LETT, V430, P7, DOI 10.1016/j.neulet.2007.09.052; Williams AJ, 2006, J PHARMACOL EXP THER, V318, P947, DOI 10.1124/jpet.106.105999; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Yemisci M, 2003, SEIZURE-EUR J EPILEP, V12, P465, DOI 10.1016/S1059-1311(02)00351-5; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117	86	25	25	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					71	83		10.1089/neu.2010.1471			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800007	20964535				2021-06-18	
J	Schultz, BA; Cifu, DX; McNamee, S; Nichols, M; Carne, W				Schultz, Billie A.; Cifu, David X.; McNamee, Shane; Nichols, Michelle; Carne, William			Assessment and treatment of common persistent sequelae following blast induced mild traumatic brain injury	NEUROREHABILITATION			English	Article						Blast injury; polytrauma; rehabilitation	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; COGNITIVE REHABILITATION; POSTCONCUSSIVE SYMPTOMS; BEHAVIORAL TREATMENT; CLINICAL MANAGEMENT; SERVICE MEMBERS; EYE INJURIES; SLEEP; IRAQ	The ongoing wars in Iraq and Afghanistan and terrorist activity worldwide have been associated with an increased incidence of blast injuries. While blast injuries share similarities with blunt or penetrating traumatic injuries, there are unique mechanistic elements of blast injury that create increased vulnerability to damage of specific organs. This review highlights the mechanism of blast-related injury, describes the common sequelae of blast exposure that may impact rehabilitation care, and summarizes the intervention strategies for these blast-related sequelae.	[Schultz, Billie A.; McNamee, Shane] Hunter Holmes McGuire Vet Med Ctr, Dept Phys Med & Rehabil, Richmond, VA USA; [Schultz, Billie A.; Cifu, David X.; McNamee, Shane; Nichols, Michelle; Carne, William] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Nichols, Michelle; Carne, William] Henry M Jackson Fdn, Hunter Holmes McGuire Vet Med Ctr, Def & Vet Brain Injury Ctr, Richmond, VA USA; [Cifu, David X.] US Dept Vet Affairs, Phys Med & Rehabil Program Off, Washington, DC USA	Schultz, BA (corresponding author), Hunter Holmes McGuire Vet Med Ctr, Dept Phys Med & Rehabil, Richmond, VA USA.	schultz.billie@mayo.edu	Nichols, Michelle/AAV-2740-2020	Nichols, Michelle/0000-0002-2078-9649; Cifu, David/0000-0003-1600-9387			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; [Anonymous], 2005, NIH Consens State Sci Statements, V22, P1; [Anonymous], 2007, SCREENING EVALUATION; [Anonymous], 2010, ACT DUT MIL PERS STR; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Becker WJ, 2010, HEADACHE, V50, P698, DOI 10.1111/j.1526-4610.2010.01648.x; Belanger HG, 2011, CLIN NEUROPSYCHOL, V1, P1; Bergemalm PO, 2001, ACTA OTO-LARYNGOL, V121, P724, DOI 10.1080/00016480152583674; Binder WJ, 2000, OTOLARYNG HEAD NECK, V123, P669, DOI 10.1067/mhn.2000.110960; Bogduk N, 2009, LANCET NEUROL, V8, P959, DOI 10.1016/S1474-4422(09)70209-1; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cifu D.X., 2009, CRIT REV PHYS REHABI, V21, P197, DOI DOI 10.1615/CRITREVPHYSREHABI1MED.V2113-4.10; Cifu DX, 2010, AM J PHYS MED REHAB, V89, P688, DOI 10.1097/PHM.0b013e3181e722ad; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Cullen DK, 2011, NEUROIMAGE, V54, pS37, DOI 10.1016/j.neuroimage.2010.10.076; Daniel J.H., 2010, IEEE SENS 2010 C WAI; Darley DS, 2010, DISASTER MED PUBLIC, V4, P145, DOI 10.1001/dmphp.D-08-00057R2; Defense Manpower Data Center, 2010, CTS DEPL FIL BAS REP; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Veterans Affairs/ Department of Defense ( VA/ DoD), 2009, VA DOD CLIN PRACT GU; Difede J, 2002, CYBERPSYCHOL BEHAV, V5, P529, DOI 10.1089/109493102321018169; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Ferrari MD, 2001, LANCET, V358, P1668, DOI 10.1016/S0140-6736(01)06711-3; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; Garman R.H., 2011, J NEUROTRAUMAM; GARTH RJN, 1995, INJURY, V26, P363, DOI 10.1016/0020-1383(95)00042-8; Germain A, 2007, BEHAV RES THER, V45, P627, DOI 10.1016/j.brat.2006.04.009; Gervil M, 1998, CEPHALALGIA, V18, P342, DOI 10.1046/j.1468-2982.1998.1806342.x; Goadsby PJ, 2010, LANCET NEUROL, V9, P285, DOI 10.1016/S1474-4422(10)70005-3; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Headache Classification Committee of the International Headache Society, 2004, CEPHALALGIA S1, V24, P115; Henry JA, 2005, J REHABIL RES DEV, V42, P95, DOI 10.1682/JRRD.2005.01.0005; Henry James A, 2008, Trends Amplif, V12, P188, DOI 10.1177/1084713808321184; Henry James A, 2008, Trends Amplif, V12, P170, DOI 10.1177/1084713808319941; HERDMAN SJ, 1993, ARCH OTOLARYNGOL, V119, P450; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kaufman Y., 2001, PEDIATR NEUROL, V41, P469; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lanius R.A., 2010, EUROPEAN J PSYCHOTRA, V1, P54; LARSON EB, 1980, JAMA-J AM MED ASSOC, V243, P359, DOI 10.1001/jama.243.4.359; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Martin BC, 2000, HEADACHE, V40, P204, DOI 10.1046/j.1526-4610.2000.00030.x; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Morin CM, 2006, SLEEP, V29, P1398, DOI 10.1093/sleep/29.11.1398; Morin CM., 1993, INSOMNIA PSYCHOL ASS; Morin CM, 2003, INSOMNIA CLIN GUIDE; Morley MG, 2010, DISASTER MED PUBLIC, V4, P154, DOI 10.1001/dmp.v4n2.hra10003; NEWMAN CW, 1990, EAR HEARING, V11, P430, DOI 10.1097/00003446-199012000-00004; Ohayon M M, 2000, Semin Clin Neuropsychiatry, V5, P56; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; PAHOR AL, 1981, J LARYNGOL OTOL, V95, P399, DOI 10.1017/S0022215100090873; PELI E, 2000, VISION REHABILITATIO, P104; Pizzamiglio L, 2006, RESTOR NEUROL NEUROS, V24, P337; Plurad DS, 2011, MIL MED, V176, P276, DOI 10.7205/MILMED-D-10-00147; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Ruff Robert L, 2010, F1000 Med Rep, V2, P64, DOI 10.3410/M2-64; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Spoormaker VI, 2008, SLEEP MED REV, V12, P169, DOI 10.1016/j.smrv.2007.08.008; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thach AB, 2000, OPHTHALMOLOGY, V107, P844, DOI 10.1016/S0161-6420(00)00029-4; VA/DoD, 2010, VA DOD CLIN PRACT GU; VA Office of Public Health and Environmental Hazards, 2010, AN VA HLTH CAR UT OP; van Liempt S, 2006, INT CLIN PSYCHOPHARM, V21, P193, DOI 10.1097/00004850-200607000-00001; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vincent MB, 2010, HEADACHE, V50, P705, DOI 10.1111/j.1526-4610.2010.01643.x; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Weber M, 2010, BRAIN INJURY, V24, P1364, DOI 10.3109/02699052.2010.507110; Writer BW, 2009, J NEUROPSYCH CLIN N, V21, P362, DOI 10.1176/appi.neuropsych.21.4.362; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Yetkin S, 2010, PSYCHIAT CLIN NEUROS, V64, P309, DOI 10.1111/j.1440-1819.2010.02084.x; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	101	25	25	0	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2011	28	4					309	320		10.3233/NRE-2011-0659			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	795VL	WOS:000293004900001	21725164				2021-06-18	
J	Huang, HK; Su, YP; Chen, CM; Chiu, FY; Liu, CL				Huang, Hui-Kuang; Su, Yu-Ping; Chen, Chuan-Mu; Chiu, Fang-Yao; Liu, Chien-Lin			Displaced Femoral Neck Fractures in Young Adults Treated With Closed Reduction and Internal Fixation	ORTHOPEDICS			English	Article								This article describes the effect of closed reduction and internal fixation with 3 different screw configurations for acute completely displaced femoral neck fractures in young adults. From 2001 to 2006, 136 patients (age range, 20-50 years) who had acute unilaterally completely displaced femoral neck fractures were evaluated retrospectively. All fractures were managed with closed reduction and internal fixation with 3 cannulated screws. The follow-up period was 55 months on average (range, 36-90 months). One hundred twenty-two patients were available for final evaluation of union condition and late complication. Twenty-three patients (18.9%) had nonunion, 15 (12.3%) had fixation failure, and 21 (17.2%) had avascular necrosis of the femoral head. The average duration from injury to surgery was 18.4 hours in the union group and 23.3 hours in the nonunion group, with no statistical significance (P=.196). The average duration from injury to surgery was 17.3 hours in the avascular necrosis of the femoral head group and 22.3 hours in the non-avascular necrosis of the femoral head group, with no statistical significance (P=.155). Vertical-and separated-type screw configurations resulted in a significantly higher nonunion rate (P=.001 and P=.0017, respectively) than parallel configuration. The complication rate in treating completely displaced femoral neck fractures with internal fixation in young adults is high, and screw configuration may further affect results.	[Huang, Hui-Kuang; Su, Yu-Ping; Chen, Chuan-Mu; Chiu, Fang-Yao; Liu, Chien-Lin] Taipei Vet Gen Hosp, Dept Orthoped & Traumatol, Taipei 112, Taiwan; [Chen, Chuan-Mu; Chiu, Fang-Yao; Liu, Chien-Lin] Natl Yang Ming Univ, Taipei 112, Taiwan	Chiu, FY (corresponding author), Taipei Vet Gen Hosp, Dept Orthoped & Traumatol, 201,Sec 2,Shih Pai Rd, Taipei 112, Taiwan.	fychiu@vghtpe.gov.tw					ALBERTS KA, 1990, CLIN ORTHOP RELAT R, P129; Alho A, 1999, ACTA ORTHOP SCAND, V70, P141, DOI 10.3109/17453679909011252; American Society of Anesthesiologists, 2009, ANESTHESIOLOGY, V24, P111; Aminian A, 2007, J ORTHOP TRAUMA, V21, P544, DOI 10.1097/BOT.0b013e31814b822e; ASNIS SE, 1994, J BONE JOINT SURG AM, V76A, P1793, DOI 10.2106/00004623-199412000-00005; Baitner AC, 1999, CLIN ORTHOP RELAT R, P300; Bartonicek J, 2001, J ORTHOP TRAUMA, V15, P358, DOI 10.1097/00005131-200106000-00009; Bjorgul K, 2007, ACTA ORTHOP, V78, P498, DOI 10.1080/17453670710014149; Bjorgul K, 2006, ACTA ORTHOP, V77, P368, DOI 10.1080/17453670610046271; Bonnaire F, 1998, CLIN ORTHOP RELAT R, P148; Butt MF, 2008, INJURY, V39, P238, DOI 10.1016/j.injury.2007.09.002; Castillo RC, 2005, J ORTHOP TRAUMA, V19, P151, DOI 10.1097/00005131-200503000-00001; Caviglia HA, 2002, CLIN ORTHOP RELAT R, P17; Chen F, 2001, Am J Orthop (Belle Mead NJ), V30, P486; CLARK DI, 1990, J BONE JOINT SURG BR, V72, P797; CRAWFURD EJP, 1988, J BONE JOINT SURG BR, V70, P195; Damany DS, 2005, INJURY, V36, P131, DOI 10.1016/j.injury.2004.05.023; DEDRICK DK, 1986, J TRAUMA, V26, P932, DOI 10.1097/00005373-198610000-00013; ELMERSON S, 1987, ACTA ORTHOP SCAND, V58, P109, DOI 10.3109/17453678709146451; Gurusamy K, 2005, J BONE JOINT SURG BR, V87B, P632, DOI 10.1302/0301-620X.87B5.15237; Haidukewych GJ, 2004, J BONE JOINT SURG AM, V86A, P1711, DOI 10.2106/00004623-200408000-00015; HARPER WM, 1991, J BONE JOINT SURG BR, V73, P73; HEDLUND R, 1987, CLIN ORTHOP RELAT R, P132; HODGES DL, 1986, AM FAM PHYSICIAN, V34, P149; Kauffman JI, 1999, J ORTHOP TRAUMA, V13, P155, DOI 10.1097/00005131-199903000-00001; KOFOED H, 1982, INJURY, V14, P146, DOI 10.1016/0020-1383(82)90049-3; KYRO A, 1993, ANN CHIR GYNAECOL FE, V82, P254; Lagerby M, 1998, ACTA ORTHOP SCAND, V69, P387, DOI 10.3109/17453679808999052; Lee CH, 2003, ARCH ORTHOP TRAUM SU, V123, P527, DOI 10.1007/s00402-003-0579-8; LINDEQUIST S, 1993, ACTA ORTHOP SCAND, V64, P289, DOI 10.3109/17453679308993627; Liporace F, 2008, J BONE JOINT SURG AM, V90A, P1654, DOI 10.2106/JBJS.G.01353; Ly TV, 2008, J BONE JOINT SURG AM, V90A, P2254; Ly Thuan V, 2009, Instr Course Lect, V58, P69; Lykke N, 2003, J BONE JOINT SURG BR, V85B, P426, DOI 10.1302/0301-620X.85B3.13788; MADSEN F, 1987, ACTA ORTHOP SCAND, V58, P212, DOI 10.3109/17453678709146468; MARTENS M, 1979, CLIN ORTHOP RELAT R, P199; Maruenda JI, 1997, CLIN ORTHOP RELAT R, P172; MATSUO K, 1988, CLIN ORTHOP RELAT R, P115; Oakey JW, 2006, CLIN ORTHOP RELAT R, P302, DOI 10.1097/01.blo.0000188557.65387.fc; Pape HC, 1999, J TRAUMA, V46, P58, DOI 10.1097/00005373-199901000-00010; PARKER MJ, 1991, J BONE JOINT SURG BR, V73, P826; Paus A, 1986, J Oslo City Hosp, V36, P55; PROTZMAN RR, 1976, J BONE JOINT SURG AM, V58, P689, DOI 10.2106/00004623-197658050-00020; Raaymakers Ernst L F B, 2006, Acta Chir Orthop Traumatol Cech, V73, P45; REHNBERG L, 1989, ACTA ORTHOP SCAND, V60, P579, DOI 10.3109/17453678909150126; RUBIN R, 1981, J TRAUMA, V21, P1036, DOI 10.1097/00005373-198112000-00006; SCHECK M, 1980, CLIN ORTHOP RELAT R, P138; Schmitz MA, 1999, CLIN ORTHOP RELAT R, P184, DOI 10.1097/00003086-199908000-00024; Selvan VT, 2004, INJURY, V35, P136, DOI 10.1016/S0020-1383(03)00059-7; SHIH CH, 1991, CLIN ORTHOP RELAT R, P195; Stankewich CJ, 1996, J ORTHOP TRAUMA, V10, P248, DOI 10.1097/00005131-199605000-00005; Stiasny Jerzy, 2008, Ortop Traumatol Rehabil, V10, P350; STROMQVIST B, 1988, J BONE JOINT SURG BR, V70, P192; SWIONTKOWSKI MF, 1984, J BONE JOINT SURG AM, V66A, P837, DOI 10.2106/00004623-198466060-00003; Tian Wei, 2009, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V23, P440; Upadhyay A, 2004, J BONE JOINT SURG BR, V86B, P1035, DOI 10.1302/0301-620X.86B7.15047; Wosje KS, 2007, OSTEOPOROSIS INT, V18, P391, DOI 10.1007/s00198-006-0249-0; ZETTERBERG CH, 1982, ACTA ORTHOP SCAND, V53, P427, DOI 10.3109/17453678208992237; Zlowodzki M, 2005, J TRAUMA, V59, P969, DOI 10.1097/01.ta.0000188130.99626.8c	59	25	25	1	7	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0147-7447	1938-2367		ORTHOPEDICS	Orthopedics	DEC	2010	33	12								10.3928/01477447-20101021-15			13	Orthopedics	Orthopedics	V24SP	WOS:000208430400009					2021-06-18	
J	Wills, KE; Nelson, SC; Hennessy, J; Nwaneri, MO; Miskowiec, J; McDonough, E; Moquist, K				Wills, Karen E.; Nelson, Stephen C.; Hennessy, Jane; Nwaneri, M. Osita; Miskowiec, Joyce; McDonough, Elizabeth; Moquist, Kristin			Transition Planning for Youth With Sickle Cell Disease: Embedding Neuropsychological Assessment Into Comprehensive Care	PEDIATRICS			English	Article						adolescent transition; sickle cell disease; neuropsychological assessment; executive function; behavioral adjustment	TRAUMATIC BRAIN-INJURY; CHILDREN; TERM	OBJECTIVE: Sickle cell disease (SCD) conveys a high risk of neuropsychological impairment due to chronic anemia, hypoxemia, cerebrovascular ischemia and stroke, in addition to causing pain and other biomedical complications. Few families accessed neuropsychological testing via the traditional referral system. In this paper, we describe a successful alternative strategy for addressing cognitive and behavioral needs of youth with SCD. METHOD: The Sickle Cell Disease Program for Learning and Neuropsychological Evaluation (SCD-PLANE) was embedded in 2007 into the SCD Comprehensive Clinic of Children's Hospitals and Clinics of Minnesota. SCD-PLANE includes brief neuropsychological testing, individualized recommendations, patient education and advocacy, interdisciplinary collaboration, and follow-through to assure patients' access to recommended resources. The purpose of SCD-PLANE is to identify and recommend interventions for cognitive, academic, emotional, behavioral, or social problems affecting child development and transition to adulthood. RESULTS: Access to neuropsychological testing improved dramatically and is well accepted by SCD patients and families. Test results reveal increased risk of problems with executive function, speed of processing, graphomotor function, academic achievement, and parent-reported anxious/depressed symptoms, despite normal intelligence and language abilities. Patients' needs had not been previously identified or served by schools or other community agencies. CONCLUSIONS: The SCD-PLANE, providing brief neuropsychological testing embedded within routine annual visits to SCD Comprehensive Clinic, is an effective approach to detect unmet developmental, educational, and behavioral needs within an underserved high-risk population. As youth move towards adulthood, considering cognitive, academic, and mental health status facilitates successful health care transitions. Pediatrics 2010; 126: S151-S159	[Wills, Karen E.; Nelson, Stephen C.; Hennessy, Jane; Miskowiec, Joyce; McDonough, Elizabeth; Moquist, Kristin] Childrens Hosp & Clin Minnesota, Psychol Serv Dept, Minneapolis, MN 55404 USA; [Nwaneri, M. Osita] Univ Minnesota, Dept Pediat, Dept Hematol Oncol, Minneapolis, MN 55455 USA	Wills, KE (corresponding author), Childrens Hosp & Clin Minnesota, Psychol Serv Dept, 2525 Chicago Ave S, Minneapolis, MN 55404 USA.	karen.wills@childrensmn.org	Nwaneri, Michael/AAB-2594-2020	Nwaneri, Michael/0000-0002-8282-4673			BEERY KE, 2006, BEERYBUKTENICA DEV T; Benton Tami D, 2007, Curr Psychiatry Rep, V9, P114; Berkelhammer LD, 2007, CHILD NEUROPSYCHOL, V13, P120, DOI 10.1080/09297040600800956; Burlew K, 2000, J PEDIATR PSYCHOL, V25, P287, DOI 10.1093/jpepsy/25.5.287; Curtin RB, 2008, ADV CHRONIC KIDNEY D, V15, P191, DOI 10.1053/j.ackd.2008.01.006; Dawson P., 2009, SMART SCATTERED; DeBaun MR, 1998, NEUROLOGY, V50, P1678, DOI 10.1212/WNL.50.6.1678; Gioia G.A., 2000, BEHAV RATING INVENTO; Heffelfinger AK, 2008, J INT NEUROPSYCH SOC, V14, P793, DOI 10.1017/S1355617708081022; Herron S, 2003, ARCH PEDIAT ADOL MED, V157, P104, DOI 10.1001/archpedi.157.1.104; HILL S, 2003, MANAGING SICKLE CELL; Johson BJ, 2007, ANN FAM MED, V5, P534, DOI 10.1370/afm.752; Korkman M., 2007, NEPSY; Logan DE, 2002, J PEDIATR PSYCHOL, V27, P475, DOI 10.1093/jpepsy/27.5.475; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Ohene-Frempong K, 1998, BLOOD, V91, P288; Pegelow CH, 2002, BLOOD, V99, P3014, DOI 10.1182/blood.V99.8.3014; Reynolds C.R., 2003, BEHAV ASSESSMENT SYS; Schatz J, 2002, J PEDIATR PSYCHOL, V27, P739, DOI 10.1093/jpepsy/27.8.739; Sheslow D., 2003, WIDE RANGE ASSESSMEN, V2nd; Thompson RJ, 2003, J PEDIATR PSYCHOL, V28, P59, DOI 10.1093/jpepsy/28.1.59; Torgesen J.K., 1999, TOWRE TEST WORD READ; Wagner RK., 1999, COMPREHENSIVE TEST P; Wang WC, 2007, CHILD NEUROPSYCHOL, V13, P103, DOI 10.1080/09297040600788136; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHLSER ABBREVIATED; Woodcock R.W., 2001, WOODCOCKJOHNSON 3 TE; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	28	25	25	0	12	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2010	126			S			S151	S159		10.1542/peds.2010-1466J			9	Pediatrics	Pediatrics	734IV	WOS:000288328700008	21123479	Bronze			2021-06-18	
J	Altman, IM; Swick, S; Parrot, D; Malec, JF				Altman, Irwin M.; Swick, Shannon; Parrot, Devan; Malec, James F.			Effectiveness of Community-Based Rehabilitation After Traumatic Brain Injury for 489 Program Completers Compared With Those Precipitously Discharged	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Rehabilitation	PORTLAND ADAPTABILITY INVENTORY; RANDOMIZED CONTROLLED-TRIAL; POSTACUTE REHABILITATION; COGNITIVE REHABILITATION; PARTICIPATION; OUTCOMES; IMPACT	Objective: To evaluate outcomes of home- and community-based postacute brain injury rehabilitation (PABIR). Design: Retrospective analysis of program evaluation data for treatment completers and noncompleters. Setting: Home- and community-based PABIR conducted in 7 geographically distinct U.S. cities. Participants: Patients (N=489) with traumatic brain injury who completed the prescribed course of rehabilitation (completed-course-of-treatment [CCT] group) compared with 114 who were discharged precipitously before program completion (precipitous-discharge [PD] group). Intervention: PABIR delivered in home and community settings by certified professional staff on an individualized basis. Main Outcome Measures: Mayo-Portland Adaptability Inventory (MPAI-4) completed by means of professional consensus on admission and at discharge; MPAI-4 Participation Index at 3- and 12-month follow-up through telephone contact. Results: Analysis of covariance (CCT vs PD group as between-subjects variable, admission MPAI-4 score as covariate) showed significant differences between groups at discharge on the full MPAI-4 (F=82.25; P<.001), Ability Index (F=50.24; P<.001), Adjustment Index (F=81.20; P<.001), and Participation Index (F=59.48; P<.001). A large portion of the sample was lost to follow-up; however, available data showed that group differences remained statistically significant at follow-up. Conclusions: Results provided evidence of the effectiveness of home- and community-based PABIR and that treatment effects were maintained at follow-up.	[Parrot, Devan; Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN 46254 USA; [Malec, James F.] Indiana Univ Sch Med, Indianapolis, IN USA; [Altman, Irwin M.] Gentiva Rehab Walls, Phoenix, AZ USA; [Swick, Shannon] Gentiva Rehab Walls, Marshall, MI USA	Malec, JF (corresponding author), Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46254 USA.	jmalec@rhin.com					Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Constantinidou F, 2005, J HEAD TRAUMA REHAB, V20, P143, DOI 10.1097/00001199-200503000-00003; Field A. P, 2009, DISCOVERING STAT USI; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; Malec J., 2003, J INT NEUROPSYCH SOC, V9, P533; Malec J., 2008, MANUAL MAYO PORTLAND; Malec JF, 2009, NEUROPSYCHOL REHABIL, V19, P790, DOI 10.1080/09602010903031203; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Pace GM, 1999, BRAIN INJURY, V13, P535; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624	25	25	25	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2010	91	11					1697	1704		10.1016/j.apmr.2010.08.001			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	681UQ	WOS:000284346400010	21044714				2021-06-18	
J	Fabbri, A; Servadei, F; Marchesini, G; Stein, SC; Vandelli, A				Fabbri, Andrea; Servadei, Franco; Marchesini, Giulio; Stein, Sherman C.; Vandelli, Alberto			Predicting intracranial lesions by antiplatelet agents in subjects with mild head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE; EMERGENCY-DEPARTMENT; COMPUTED-TOMOGRAPHY; ELDERLY-PATIENTS; NICE GUIDELINES; RULE; HEMORRHAGE; MANAGEMENT; PROPOSAL	Background The effect of pre-injury antiplatelet treatment in the risk of intracranial lesions in subjects after mild head injury (Glasgow Coma Scale (GCS) 14-15) is uncertain. Methods The potential risk was determined, considering its increasing use in guidelines on cardiovascular disease prevention, and ageing of the trauma population in Europe. Patients The interaction of antiplatelet therapy with the prediction variables of main decision aids was analysed in 14 288 consecutive adolescent and adult subjects with mild head injury. Measurements Any intracranial lesion at CT scan was selected as an outcome measure in a multivariable logistic regression analysis. Results Intracranial lesions were demonstrated in 880 cases (6.2%), with an unfavourable outcome at 6 months in 86 (0.6%). Antiplatelet drugs were recorded in 10% of the entire cohort (24.7% in the group over 65 years). They increased the risk of intracranial lesions in the univariate analysis (OR 2.6; 95% CI 2.2 to 3.1), interacting with age in the multivariate analysis (antiplatelet OR 2.7 (1.9 to 3.7); age >= 75 years 1.4 (1.0 to 1.9)). The inclusion of these two variables with those included in previous decision aids for CT scanning (GCS, neurodeficit, post-traumatic seizures, suspected skull fracture, vomiting, loss of consciousness, coagulopathy) predicted intracranial lesions with a sensitivity of 99.7% (95% CI 98.9 to 99.8) and a specificity of 54.0% (95% CI 53.1 to 54.8), with a CT ordering rate of 49.3% (undetermined events 0.2:1000). Interpretation Antiplatelet drugs need to be considered in future prediction models on mild head injury, considering their increasing use and progressive ageing of the trauma population.	[Fabbri, Andrea; Vandelli, Alberto] Presidio Osped Morgagni Pierantoni, Azienda USL Forli, Dipartimento Emergenza, I-47100 Forli, Italy; [Servadei, Franco] Univ Parma, Azienda Osped, Unita Operativa Neurochirurg, I-43100 Parma, Italy; [Marchesini, Giulio] Univ Bologna, I-40126 Bologna, Italy; [Stein, Sherman C.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Fabbri, A (corresponding author), Presidio Osped Morgagni Pierantoni, Azienda USL Forli, Dipartimento Emergenza, Via Forlanini 34, I-47100 Forli, Italy.	dr.andrea.fabbri@gmail.com	Fabbri, Andrea/K-9994-2016	Marchesini, Giulio/0000-0003-2407-9860; Fabbri, Andrea/0000-0002-9837-4638; Servadei, Franco/0000-0002-3595-3464			Bramley R, 2002, CLIN RADIOL, V57, P151, DOI 10.1053/crad.2001.0868; DEROSA M, 2007, COLLANA RAPPORTI ARN, P47; Dunning J, 2004, EMERG MED J, V21, P404, DOI 10.1136/emj.2004.014944; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; GIANNOUDIS PV, 2009, J TRAUMA, V40, P362, DOI DOI 10.1016/J.INJURY.2008.10.016; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; *ISS AIFA, 2008, OSS NAZ SULL MED US; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jagoda A, 2008, ANN EMERG MED, V52, pS3, DOI 10.1016/j.annemergmed.2008.04.030; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; National Institute for Clinical Excellence, 2007, CLIN GUID; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Patrono C, 2004, EUR HEART J, V25, P166, DOI 10.1016/j.ehj.2003.10.013; REYMOND MA, 1992, NEUROSURG REV, V15, P21, DOI 10.1007/BF02352062; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shravat BP, 2006, EMERG MED J, V23, P109, DOI 10.1136/emj.2004.022327; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; STROOBANDT G, 1995, ACTA NEUROCHIR, V137, P6, DOI 10.1007/BF02188772; Sultan HY, 2004, EMERG MED J, V21, P420, DOI 10.1136/emj.2003.011353; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631	32	25	25	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2010	81	11					1275	1279		10.1136/jnnp.2009.197467			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	669ML	WOS:000283354800238	20643657				2021-06-18	
J	Filippidis, AS; Papadopoulos, DC; Kapsalaki, EZ; Fountas, KN				Filippidis, Aristotelis S.; Papadopoulos, Dimitrios C.; Kapsalaki, Eftychia Z.; Fountas, Kostas N.			Role of the S100B serum biomarker in the treatment of children suffering from mild traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						biomarker; children; mild traumatic brain injury; S100B biomarker	NEURON-SPECIFIC ENOLASE; PROTEIN; HEAD; EMPHASIS; RELEASE; MARKERS; DAMAGE	Object. The aim of this study was to provide a systematic update of the current literature regarding the clinical role of the S100B serum biomarker in the initial evaluation of children who have sustained a mild traumatic brain injury (TBI). Methods. Searches in MEDLINE were defined with the keywords "mild TBI children S100," "mild TBI pediatric S100," and " children S100 brain injury." From the pool of obtained studies, those that had the inclusion criteria of mild TBI only or mixed types of TBI but including detailed information about groups of children with mild TBI were used. Results. Few studies were identified and fewer included more than 100 cases. The prospective studies showed that the S100B biomarker levels could be influenced by patient age and the time frame between head injury and blood sampling. Moreover, extracranial sources of S100B or additional injuries could influence the measured levels of this biomarker. A normal value of S100B in children with mild TBI could rule out injury-associated abnormalities on CT scans in the majority of reported cases. Conclusions. The vulnerability of S100B serum levels to the influences of patient age, blood sampling time, and extracranial S100B release limits the biomarker's role in the initial evaluation of children with mild TBI. The application of S100B in pediatric mild TBI cases has an elusive role, although it could help in selected cases to avoid unnecessary head CT scans. (DOI: 10.3171/2010.8.FOCUS10185)	[Filippidis, Aristotelis S.; Fountas, Kostas N.] Univ Thessaly, Sch Med, Univ Hosp Larissa, Dept Neurosurg, Biopolis, Larissa, Greece; [Papadopoulos, Dimitrios C.] Gen Hosp Larissa, Dept Crit Care Med, Larisa, Greece; [Kapsalaki, Eftychia Z.] Univ Thessaly, Sch Med, Univ Hosp Larissa, Dept Diagnost Radiol, Biopolis, Larissa, Greece	Fountas, KN (corresponding author), Univ Thessaly, Sch Med, Univ Hosp Larissa, Dept Neurosurg, Build A,3rd Floor,Suite 56, Biopolis, Larissa, Greece.	fountas@med.uth.gr					Akhtar Javed I, 2003, Pediatr Crit Care Med, V4, P322; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Castellani C, 2009, ACTA PAEDIATR, V98, P1607, DOI 10.1111/j.1651-2227.2009.01423.x; Castellani C, 2008, CLIN CHEM LAB MED, V46, P1296, DOI 10.1515/CCLM.2008.262; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Hatpio R, 2004, CLIN BIOCHEM, V37, P512, DOI 10.1016/j.clinbiochem.2004.05.012; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Morochovic R, 2009, EUR J NEUROL, V16, P1112, DOI 10.1111/j.1468-1331.2009.02653.x; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Unden J, 2007, NEUROCRIT CARE, V6, P94, DOI 10.1007/s12028-007-0005-0; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Whitaker-Azmitia PM, 1997, BRAIN RES, V776, P51, DOI 10.1016/S0006-8993(97)01002-0; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	27	25	26	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E2	10.3171/2010.8.FOCUS10185			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900003	21039136				2021-06-18	
J	Olson-Madden, JH; Brenner, L; Harwood, JEF; Emrick, CD; Corrigan, JD; Thompson, C				Olson-Madden, Jennifer H.; Brenner, Lisa; Harwood, Jeri E. F.; Emrick, Chad D.; Corrigan, John D.; Thompson, Caitlin			Traumatic Brain Injury and Psychiatric Diagnoses in Veterans Seeking Outpatient Substance Abuse Treatment	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alcohol; drug; psychiatric diagnosis; substance abuse; traumatic brain injury; veteran	RISK-FACTORS; ALCOHOL-USE; PREVALENCE; IDENTIFICATION; RELIABILITY; VALIDITY; OUTCOMES; TBI; 1ST	Objectives: Explore the incidence of traumatic brain injury (TBI) in veterans seeking outpatient substance abuse treatment and the association between TBI and psychiatric diagnoses. MainMeasure: The Ohio State University TBI identification method (OSU TBI-ID) was administered to veterans with positive TBI-4 screens; substance-related and psychiatric diagnoses were extracted from the medical record. Participants: Over an 18-month period, 247 veterans completed the TBI-4. Of the 136 who screened positive, 70 were administered the OSU TBI-ID. Results: On the basis of the TBI-4, 55% (95% CI: 49%-61%) of veterans screened positive for a history of TBI. The OSU TBI-ID was used to confirm screening results. Those who completed the OSU TBI-ID sustained an average of 3.4 lifetime TBIs. For each additional TBI sustained, after initial injury, there was an estimated 9% increase in the number of psychiatric diagnoses documented (99% CI: 1%-17%). For each additional documented psychiatric diagnosis, there was an estimated increase of 11% in the number of injuries sustained (99% CI: 1%-22%). Also, 54% (38/70) had a positive history of TBI prior to adulthood. Conclusion: These results emphasize the need for TBI screening in this vulnerable population, as well as the importance of increasing brain injury awareness among those abusing substances and their care providers. These findings also highlight the need for specialized services for those with TBI and co-occurring substance misuse aimed at decreased future TBIs or negative psychiatric outcomes or both. Further study is needed to clarify best practices.	[Olson-Madden, Jennifer H.; Brenner, Lisa] Mental Illness Res Educ & Clin Ctr, VA VISN 19, Denver, CO 80220 USA; [Olson-Madden, Jennifer H.] Univ Colorado, Denver Sch Med, Dept Psychiat, Aurora, CO USA; [Brenner, Lisa] Univ Colorado, Denver Sch Med, Dept Psychiat Neurol Phys Med & Rehabil, Aurora, CO USA; [Harwood, Jeri E. F.] Univ Colorado, Denver Sch Med, Dept Pediat, Aurora, CO USA; [Emrick, Chad D.] Affairs Med Ctr, Eastern Colorado Healthcare Syst Outpatient Subst, Denver, CO USA; [Thompson, Caitlin] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14627 USA; [Thompson, Caitlin] Canandaigua VA Med Ctr, Canandaigua, NY USA; [Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA	Olson-Madden, JH (corresponding author), Mental Illness Res Educ & Clin Ctr, VA VISN 19, 1055 Clermont St, Denver, CO 80220 USA.	jennifer.olson-madden@va.gov	Corrigan, John D./E-2921-2011; Brenner, Lisa A./AAG-2442-2019		VA VISN 19 MIRECC	This project was supported by the VA VISN 19 MIRECC.	Basco MR, 2000, AM J PSYCHIAT, V157, P1599, DOI 10.1176/appi.ajp.157.10.1599; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Brenner LA, 2008, J HEAD TRAUMA REHAB, V23, P401, DOI 10.1097/01.HTR.0000341436.59627.a5; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CORRIGAN JD, 2005, REHABILITATION TRAUM, P133; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Felde AB, 2006, BRAIN INJURY, V20, P41, DOI 10.1080/02699050500309718; Institute of Medicine, 2009, GULF WAR HLTH, V7; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Karon SL, 2007, J HEAD TRAUMA REHAB, V22, P350, DOI 10.1097/01.HTR.0000300230.13490.11; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Miller N. S., 2005, TXB TRAUMATIC BRAIN, P509; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *US DEP HHS, HEAD FACTS PHYS MILD; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; Wiedemayer H, 2002, BRAIN INJURY, V16, P323, DOI 10.1080/02699050110102077	45	25	25	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2010	25	6					470	479		10.1097/HTR.0b013e3181d717a7			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	679HA	WOS:000284151300009	20414130				2021-06-18	
J	Schwartzkroin, PA; Wenzel, HJ; Lyeth, BG; Poon, CC; DeLance, A; Van, KC; Campos, L; Nguyen, DV				Schwartzkroin, Philip A.; Wenzel, H. Juergen; Lyeth, Bruce G.; Poon, Carrie C.; DeLance, Arthur; Van, Ken C.; Campos, Luis; Nguyen, Danh V.			Does ketogenic diet alter seizure sensitivity and cell loss following fluid percussion injury?	EPILEPSY RESEARCH			English	Article						Animal model; Diet; Posttraumatic; epilepsy; Histology; Seizure threshold; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; EKER RAT MODEL; EPILEPTOGENESIS; MECHANISMS; SCLEROSIS; EPILEPSY; BEHAVIOR; DEATH; MICE	Traumatic brain injury (TBI) frequently leads to epilepsy. The process of epileptogenesis the development of that seizure state is still poorly understood, and effective antiepileptogenic treatments have yet to be identified. The ketogenic diet (KD) has been shown to be effective as an antiepileptic therapy, but has not been extensively tested for its efficacy in preventing the development of the seizure state, and certainly not within the context of TBI-induced epileptogenesis. We have used a rat model of TBI - fluid percussion injury (FPI) to test the hypothesis that KD treatment is antiepileptogenic and protects the brain from neuronal cell loss following TBI. Rats fed a KD had a higher seizure threshold (longer latency to fiurothyl-induced seizure activity) than rats fed a standard diet (SD); this effect was seen when KD was in place at the time of seizure testing (3 and 6 weeks following FPI), but was absent when KD had been replaced by SD at time of testing. FPI caused significant hippocampal cell loss in both KD-fed and SD-fed rats; the degree of cell loss appeared to be reduced by KD treatment before FPI but not after FPI. These results are consistent with prior demonstrations that KD raises seizure threshold, but do not provide support for the hypothesis that KD administered for a limited time directly before or after FPI alters later seizure sensitivity; that is, within the limits of this model and protocol, there is no evidence for KD-induced antiepileptogenesis. (C) 2010 Elsevier B.V. All rights reserved.	[Schwartzkroin, Philip A.; Wenzel, H. Juergen; Lyeth, Bruce G.; Poon, Carrie C.; DeLance, Arthur; Van, Ken C.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95618 USA; [Campos, Luis; Nguyen, Danh V.] Univ Calif Davis, Div Biostat, Davis, CA 95616 USA	Schwartzkroin, PA (corresponding author), Univ Calif Davis, Dept Neurol Surg, Med Neurosci Bldg,1515 Newton Court,Rm 612G, Davis, CA 95618 USA.	paschwartzkroin@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024146]; Citizens United for Research in Epilepsy in conjunction with the Department of Defense; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024146] Funding Source: NIH RePORTER	This study was supported by a grant from Citizens United for Research in Epilepsy in conjunction with the Department of Defense (PAS) and grant UL1 RR024146 from the National Center for Research Resources (DVN).	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Bough KJ, 2003, EPILEPSIA, V44, P752, DOI 10.1046/j.1528-1157.2003.55502.x; Bough KJ, 2007, EPILEPSIA, V48, P43, DOI 10.1111/j.1528-1167.2007.00915.x; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Freeman J, 2006, EPILEPSY RES, V68, P145, DOI 10.1016/j.eplepsyres.2005.10.003; Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P129; Hansen SL, 2009, NEUROCHEM INT, V54, P199, DOI 10.1016/j.neuint.2008.10.012; Hori A, 1997, EPILEPSIA, V38, P750, DOI 10.1111/j.1528-1157.1997.tb01461.x; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Kossoff EH, 2008, EPILEPSIA, V49, P316, DOI 10.1111/j.1528-1167.2007.01256.x; Kossoff EH, 2009, NEUROTHERAPEUTICS, V6, P406, DOI 10.1016/j.nurt.2009.01.005; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKhann GM, 2003, NEUROSCIENCE, V122, P551, DOI 10.1016/S0306-4522(03)00562-1; Muller-Schwarze AB, 1999, NEUROREPORT, V10, P1517, DOI 10.1097/00001756-199905140-00023; Noh HS, 2003, EPILEPSY RES, V53, P119, DOI 10.1016/S0920-1211(02)00262-0; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Puchowicz MA, 2008, J CEREBR BLOOD F MET, V28, P1907, DOI 10.1038/jcbfm.2008.79; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; SALAZAR AM, 1999, MISSILE WOUNDS HEAD, V2, P281; Samoilova M, 2010, J NEUROCHEM, V113, P826, DOI 10.1111/j.1471-4159.2010.06645.x; Sankar Raman, 2004, Epilepsy Curr, V4, P91, DOI 10.1111/j.1535-7597.2004.43002.x; Schwartzkroin PA, 1999, EPILEPSY RES, V37, P171, DOI 10.1016/S0920-1211(99)00069-8; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sutula TP, 2001, NEUROLOGY, V57, P169, DOI 10.1212/WNL.57.2.169; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Todorova MT, 2000, EPILEPSIA, V41, P933, DOI 10.1111/j.1528-1157.2000.tb00275.x; Tschuluun N, 2007, EPILEPSY RES, V73, P53, DOI 10.1016/j.eplepsyres.2006.08.003; Wenzel HJ, 2007, EPILEPSIA, V48, P2023, DOI 10.1111/j.1528-1167.2007.01189.x; Wenzel HJ, 2004, ACTA NEUROPATHOL, V108, P97, DOI 10.1007/s00401-004-0865-8; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Zhao XR, 2008, J NEUROTRAUM, V25, P1195, DOI 10.1089/neu.2008.0635; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29	44	25	25	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	NOV	2010	92	1					74	84		10.1016/j.eplepsyres.2010.08.009			11	Clinical Neurology	Neurosciences & Neurology	684CB	WOS:000284523500007	20863664				2021-06-18	
J	Randazzo, C; Nelson, NG; McKenzie, LB				Randazzo, Charles; Nelson, Nicolas G.; McKenzie, Lara B.			Basketball-Related Injuries in School-Aged Children and Adolescents in 1997-2007	PEDIATRICS			English	Article						basketball; injuries; child; adolescent; emergency department; National Electronic Injury Surveillance System; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PATTERNS; SPORTS; RISK; EPIDEMIOLOGY; ASSOCIATION; PLAYERS; SOCCER; MEN	OBJECTIVE: The objective was to determine national patterns of basketball-related injuries treated in emergency departments in the United States among children and adolescents <20 years of age. METHODS: A retrospective analysis was conducted with data from the National Electronic Injury Surveillance System of the US Consumer Product Safety Commission, from 1997 to 2007. Sample weights provided by the Consumer Product Safety Commission were used to calculate national estimates of basketball-related injuries. Trend significance of the numbers and rates of basketball-related injuries over time was analyzed by using linear regression. RESULTS: An estimated 4 128 852 pediatric basketball-related injuries were treated in emergency departments. Although the total number of injuries decreased during the study period, the number of traumatic brain injuries (TBIs) increased by 70%. The most common injury was a strain or sprain to the lower extremities (30.3%), especially the ankle (23.8%). Boys were more likely to sustain lacerations and fractures or dislocations. Girls were more likely to sustain TBIs and to injure the knee. Older children (15-19 years of age) were 3 times more likely to injure the lower extremities. Younger children (5-10 years of age) were more likely to injure the upper extremities and to sustain TBIs and fractures or dislocations. CONCLUSIONS: Although the total number of basketball-related injuries decreased during the 11-year study period, the large number of injuries in this popular sport is cause for concern. Pediatrics 2010;126:727-733	[Randazzo, Charles; Nelson, Nicolas G.; McKenzie, Lara B.] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH 43205 USA; [McKenzie, Lara B.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA	McKenzie, LB (corresponding author), Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	lara.mckenzie@nationwidechildrens.org	McKenzie, Lara/C-5122-2012	McKenzie, Lara/0000-0003-2889-0001	Dorothy M. Bennett and Clark L. Bennett Medical Research Scholarship	We gratefully acknowledge the Dorothy M. Bennett and Clark L. Bennett Medical Research Scholarship for financial stipend support for Mr Randazzo during this study.	Adirim TA, 2003, SPORTS MED, V33, P75, DOI 10.2165/00007256-200333010-00006; Agel J, 2005, AM J SPORT MED, V33, P524, DOI 10.1177/0363546504269937; ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Borowski LA, 2008, AM J SPORT MED, V36, P2328, DOI 10.1177/0363546508322893; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; CHANDY T A, 1985, Physician and Sportsmedicine, V13, P106; Damore DT, 2003, PEDIATR EMERG CARE, V19, P65, DOI 10.1097/00006565-200304000-00001; Deitch JR, 2006, AM J SPORT MED, V34, P1077, DOI 10.1177/0363546505285383; Emery CA, 2007, CLIN J SPORT MED, V17, P17, DOI 10.1097/JSM.0b013e31802e9c05; Finch C, 1998, BRIT J SPORT MED, V32, P220, DOI 10.1136/bjsm.32.3.220; Gomez E, 1996, AM J SPORT MED, V24, P684, DOI 10.1177/036354659602400521; Hamming BJ, 2007, CLIN J SPORT MED, V17, P446, DOI 10.1097/JSM.0b013e31815aed13; Harmer Peter A, 2005, Med Sport Sci, V49, P31, DOI 10.1159/000085341; Hickey GJ, 1997, CLIN J SPORT MED, V7, P252, DOI 10.1097/00042752-199710000-00002; LANESE RR, 1990, AM J PUBLIC HEALTH, V80, P1459, DOI 10.2105/AJPH.80.12.1459; McGuine TA, 2006, AM J SPORT MED, V34, P1103, DOI 10.1177/0363546505284191; McQuillan R, 2006, PUBLIC HEALTH, V120, P732, DOI 10.1016/j.puhe.2006.02.011; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Meeuwisse WH, 2003, AM J SPORT MED, V31, P379, DOI 10.1177/03635465030310030901; Messina DF, 1999, AM J SPORT MED, V27, P294, DOI 10.1177/03635465990270030401; *NAT FED STAT HIGH, 2004, PART SETS REC 6 STRA; *NAT FED STAT HIGH, 2007, 2004 06 HIGH SCH ATH; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Prebble T B, 1999, WMJ, V98, P22; Sallis RE, 2001, INT J SPORTS MED, V22, P420, DOI 10.1055/s-2001-16246; Schroeder T., 2001, NEISS SAMPLE DESIGN; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Taylor BL, 2000, ACAD EMERG MED, V7, P1376, DOI 10.1111/j.1553-2712.2000.tb00495.x; United States Consumer Product Safety Commission, 2000, NEISS NAT EL INJ SUR; *US BUR CENS, 2008, PUBL US CENS BUR; *US BUR CENS, 2008, INT EST US POP AG SE; Xiang HY, 2007, BRAIN INJURY, V21, P293, DOI 10.1080/02699050701311034; Yde J, 1990, Br J Sports Med, V24, P51	35	25	27	0	14	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2010	126	4					727	733		10.1542/peds.2009-2497			7	Pediatrics	Pediatrics	658WW	WOS:000282526100044	20837592	Bronze			2021-06-18	
J	Clauss, RP				Clauss, R. P.			Neurotransmitters in Coma, Vegetative and Minimally Conscious States, pharmacological interventions	MEDICAL HYPOTHESES			English	Article							TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; AMINO-ACIDS; CIRCADIAN-RHYTHMS; AWAKE RAT; GLUTAMATE; ZOLPIDEM; ASPARTATE; ISCHEMIA; RELEASE	Articles on pharmacological interventions in disorders of consciousness after brain damage are increasingly appearing in the medical literature. This hypothesis links disorders of consciousness to the depletion of oxygen reliant neurotransmitters based in two biochemical axes, the amino acid axis (glutamate/ GABA) and the monoamine axis (dopamine/noradrenalin and serotonin). After a brain injury, an immediate response inside the brain constitutes a surge of amino acids such as glutamate, GABA and others. Glutamate is excitatory and GABA inhibitory. The inhibitory response dominates and the brain becomes suppressed, leading to a loss in consciousness which reduces oxygen requirements. In time, GABA depletes after increased usage and leakage from the brain into the blood. If it cannot be restored sufficiently in some parts of the brain, a secondary response in these regions occurs which makes GABA receptors oversensitive to GABA, so that decreased GABA levels can maintain their suppressive effect. This occurs in prolonged disorders of consciousness as in the Vegetative State, which can be broken by agents such as zolpidem in some patients. In addition to amino acids, monoamine systems such as dopamine are essential to cognition and motor function. Their depletion or the suppression of brain regions in which they function, are proposed as contributors to disorders of consciousness. Reports of successful arousals after amino acid and monoamine based therapies supports the hypothesis that depletion of these brain chemicals may play a fundamental role in disorders of consciousness. (C) 2010 Elsevier Ltd. All rights reserved.	Royal Surrey Cty Hosp, Dept Nucl Med, Guildford GU2 7XX, Surrey, England	Clauss, RP (corresponding author), Royal Surrey Cty Hosp, Dept Nucl Med, Guildford GU2 7XX, Surrey, England.	rclauss@royalsurrey.nhs.uk					ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Cardinali DP, 1998, NEUROCHEM RES, V23, P607, DOI 10.1023/A:1022426519297; Castaneda TR, 2004, J PINEAL RES, V36, P177, DOI 10.1046/j.1600-079X.2003.00114.x; Clark JF, 2006, MED HYPOTHESES, V67, P506, DOI 10.1016/j.mehy.2006.02.047; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss RP, 2004, ARZNEIMITTELFORSCH, V54, P641; Clauss RP, 2000, S AFR MED J, V90, P68; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; COOPER AJL, 1979, J BIOL CHEM, V254, P4982; Dawson LA, 2000, BRAIN RES BULL, V53, P767, DOI 10.1016/S0361-9230(00)00363-4; de Prado BM, 2000, J PINEAL RES, V29, P209; Du B, 2008, NEUROL REGENERAT RES, V3, P1673; ERECINSKA M, 1993, J NEUROCHEM, V60, P1696, DOI 10.1111/j.1471-4159.1993.tb13393.x; Fernstrom JD, 2005, J NUTR, V135, p1539S, DOI 10.1093/jn/135.6.1539S; Fridman EA, 2009, BRAIN INJURY, V23, P172, DOI 10.1080/02699050802649662; Goddard AW, 2010, DEPRESS ANXIETY, V27, P339, DOI 10.1002/da.20642; Grimes MA, 2009, METABOLISM, V58, P129, DOI 10.1016/j.metabol.2008.08.015; Hall SD, 2010, CLIN NEUROPHYSIOL, V121, P549, DOI 10.1016/j.clinph.2009.11.084; HARDEBO JE, 1980, ANN NEUROL, V8, P1, DOI 10.1002/ana.410080102; Hawkins RA, 2009, AM J CLIN NUTR, V90, p867S, DOI 10.3945/ajcn.2009.27462BB; Higuchi T, 1996, NEUROSURGERY, V38, P121, DOI 10.1097/00006123-199601000-00030; JENNETT B, 1977, LANCET, V1, P878; Lee DH, 2005, KOREAN J RADIOL, V6, P64, DOI 10.3348/kjr.2005.6.2.64; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; Matsuda W, 2005, NEUROPSYCHOL REHABIL, V15, P414, DOI 10.1080/09602010443000588; Newsholme P, 2003, BRAZ J MED BIOL RES, V36, P153, DOI 10.1590/S0100-879X2003000200002; Niimura K, 1999, NEUROLOGY, V52, P792, DOI 10.1212/WNL.52.4.792; NILSSON GE, 1991, AM J PHYSIOL, V261, pR32; Nilsson GE, 2004, J CEREBR BLOOD F MET, V24, P475, DOI 10.1097/00004647-200405000-00001; NILSSON GE, 1990, AM J PHYSIOL, V259, pR376; Nyakala NE, 2010, ARZNEIMITTEL-FORSCH, V60, P681; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; REINHARD DL, 1997, ARCH PHYS MED REHAB, V78, P109; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; Sanger DJ, 1999, PHARMACOL BIOCHEM BE, V64, P269, DOI 10.1016/S0091-3057(99)00081-7; Sara M, 2007, BRAIN INJURY, V21, P101, DOI 10.1080/02699050601151761; Sara M, 2009, ARCH PHYS MED REHAB, V90, P1245, DOI 10.1016/j.apmr.2009.01.012; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; Shadan FF, 2004, SOUTH MED J, V97, P791, DOI 10.1097/00007611-200408000-00025; Siegel JM, 2003, SCI AM, V289, P92, DOI 10.1038/scientificamerican1103-92; Smith Y, 2008, MOVEMENT DISORD, V23, pS534, DOI 10.1002/mds.22027; Suzuki M, 2002, J NEUROTRAUM, V19, P285, DOI 10.1089/08977150252807027; Taira T, 2009, PROG BRAIN RES, V177, P317, DOI 10.1016/S0079-6123(09)17721-X; Tapiero H, 2002, BIOMED PHARMACOTHER, V56, P446, DOI 10.1016/S0753-3322(02)00285-8; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Waagepetersen HS, 2005, NEUROCHEM INT, V47, P92, DOI 10.1016/j.neuint.2005.04.012; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Witte OW, 1997, ADV NEUROL, V73, P207; Wroblewski Bruno, 1993, Brain Injury, V7, P353, DOI 10.3109/02699059309034962; Aviles-Reyes RX, 2010, J NEUROCHEM, V112, P854, DOI 10.1111/j.1471-4159.2009.06535.x; Yogeeswari P, 2005, CURR DRUG METAB, V6, P127, DOI 10.2174/1389200053586073; Young GB, 2009, ANN NY ACAD SCI, V1157, P32, DOI 10.1111/j.1749-6632.2009.04471.x; Zafonte RD, 1998, BRAIN INJURY, V12, P617	59	25	29	0	6	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	SEP	2010	75	3					287	290		10.1016/j.mehy.2010.03.005			4	Medicine, Research & Experimental	Research & Experimental Medicine	647IF	WOS:000281611100005	20347531				2021-06-18	
J	Rapoport, MJ; Mitchell, RA; McCullagh, S; Herrmann, N; Chan, F; Kiss, A; Feinstein, A; Lanctot, KL				Rapoport, Mark J.; Mitchell, Robert A.; McCullagh, Scott; Herrmann, Nathan; Chan, Florance; Kiss, Alex; Feinstein, Anthony; Lanctot, Krista L.			A Randomized Controlled Trial of Antidepressant Continuation for Major Depression Following Traumatic Brain Injury	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							PLACEBO-CONTROLLED TRIAL; ILLNESS RATING-SCALE; STAR-ASTERISK-D; MAINTENANCE TREATMENT; HEAD-INJURY; SERTRALINE; DISORDERS; OUTCOMES; RECURRENCE; CITALOPRAM	Objective: This study examines whether continuation therapy with citalopram can prevent a relapse following remission of major depression due to traumatic brain injury. Method: After 65 subjects with DSM-IV- diagnosed major depression following traumatic brain injury were treated with open-label citalopram (20 mg to 50 mg/d), 25 subjects (38.5%) met criteria for remission. Of those, 21 (84.0%) were randomly assigned to either same-dose citalopram or placebo and followed monthly over 40 weeks. Remission was defined as a Hamilton Depression Rating Scale (HDRS) score of <= 7 or a Clinical Global Impressions-Improvement rating of "much improved" or better. The main outcome variable was the presence of relapse, as defined by meeting criteria for major depressive episode according to the DSM-IV and an HDRS score >= 16. Data were collected from February 16, 2005, to May 5, 2008. Results: Ten subjects were randomly assigned to citalopram and 11 to placebo. There were 3 dropouts, including 1 for adverse drug effects (diarrhea). Relapse occurred in 11 subjects (52.4%), with a mean +/- SD time to relapse of 23.52 +/- 16.6 weeks. The groups did not differ in relapse rates (drug: 50.0% [5/10] vs placebo: 54.5% [6/11], Fisher exact test, P = .835) or time to relapse (log rank test chi(2) = 0.148, P = .700). Conclusions: The present study suggests important limitations of continuation pharmacotherapy in the prevention of relapse of major depression following traumatic brain injury. Trial Registration: clinicaltrials.gov Identifier: NCT00162916 J Clin Psychiatry 2010;71(9):1125-1130 (C) Copyright 2010 Physicians Postgraduate Press, Inc.	[Rapoport, Mark J.; Mitchell, Robert A.; McCullagh, Scott; Herrmann, Nathan; Chan, Florance; Kiss, Alex; Feinstein, Anthony; Lanctot, Krista L.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON M5S 1A1, Canada	Rapoport, MJ (corresponding author), 2075 Bayview Ave,Rm FG37, Toronto, ON M4N 3M5, Canada.	mark.rapoport@sunnybrook.ca	Lanctot, Krista L./AAY-4820-2020; Rapoport, Mark/AAD-8581-2020	Lanctot, Krista L./0000-0001-7024-6637; 	AbbottAbbott Laboratories; Lundbeck CanadaLundbeck Corporation; Neurochem; Pfizer CanadaPfizer; Janssen-Ortho; Eli LillyEli Lilly; WyethWyeth; Ontario Neurotrauma Foundation (ONF) [2004-ABI-DEP-03]; Ontario Mental Health Foundation (OMHF); AstraZenecaAstraZeneca; Eli Lilly CanadaEli Lilly; BrainCells Inc; ServierServier	Dr Rapoport has received honoraria from Janssen-Ortho. Dr Lanctot is a consultant for the Worker's Safety Insurance Board (WSIB) of Ontario and the Royal Bank of Canada Insurance and has received grant research support from Abbott, Lundbeck Canada, Neurochem, Pfizer Canada, Janssen-Ortho, Eli Lilly, and Wyeth. Ms Chan is a former employee of Sunnybrook Health Sciences Center and is currently an employee of Wyeth. Drs McCullagh, Herrmann, Kiss, and Feinstein and Mr Mitchell have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.; Funding provided by the Ontario Neurotrauma Foundation (ONF-grant # 2004-ABI-DEP-03) and the Ontario Mental Health Foundation (OMHF).; The authors thank John Iazzetta, PharmD, for assistance with randomization and blinding of the capsules; Anthony Levitt, MD, FRCPC, for scholarly advice; Ayal Schaffer, MD, FRCPC, for scholarly advice; Andrea Phillips, BA, for assistance with ethics review, coordinating subjects, data management, and writing; and Carla Zucchero-Sarracini, BA, for assistance with ethics review, coordinating subjects, data management, and writing, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada. Dr Levitt has received grant/research support from AstraZeneca and Eli Lilly Canada and has received honoraria from Pfizer. Dr Schaffer has received grant/research support from AstraZeneca, BrainCells Inc, and Servier; has received honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Lundbeck, and Pfizer; and is a member of the speakers/advisory boards for AstraZeneca, Bristol-Myers Squibb, and Eli Lilly. Dr lazzetta and Mss Phillips and Zucchero-Sarracini have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.	Alamo C, 2007, ACTA NEUROPSYCHIATR, V19, P291, DOI 10.1111/j.1601-5215.2007.00187.x; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Carrasco JL, 2005, INT J CLIN PRACT, V59, P1428, DOI 10.1111/j.1368-5031.2005.00681.x; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Dombrovski AY, 2007, J AFFECT DISORDERS, V103, P77, DOI 10.1016/j.jad.2007.01.020; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Fava M, 2008, AM J PSYCHIAT, V165, P342, DOI 10.1176/appi.ajp.2007.06111868; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FIRST MB, 1996, CLIN RES VERSIONS; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; Geddes JR, 2003, LANCET, V361, P653, DOI 10.1016/S0140-6736(03)12599-8; Gelenberg AJ, 2003, BIOL PSYCHIAT, V54, P806, DOI 10.1016/S0006-3223(02)01971-6; Guy, 1976, ECDEU ASSESSMENT MAN; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Judd LL, 1997, ARCH GEN PSYCHIAT, V54, P989; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keller MB, 1998, JAMA-J AM MED ASSOC, V280, P1665, DOI 10.1001/jama.280.19.1665; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kocsis JH, 2002, ARCH GEN PSYCHIAT, V59, P723, DOI 10.1001/archpsyc.59.8.723; Koran LM, 2001, J AFFECT DISORDERS, V65, P27, DOI 10.1016/S0165-0327(00)00272-X; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lepine JP, 2004, AM J PSYCHIAT, V161, P836, DOI 10.1176/appi.ajp.161.5.836; LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Robinson RG, 2002, ARCH GEN PSYCHIAT, V59, P23, DOI 10.1001/archpsyc.59.1.23; SILVER JM, 1994, SYNOPSIS NEUROPSYCHI, P279; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; TURNERSTOKES L, 2003, REHABILITATION FOLLO	45	25	25	0	4	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 240008, MEMPHIS, TN 38124 USA	0160-6689			J CLIN PSYCHIAT	J. Clin. Psychiatry	SEP	2010	71	9					1125	1130		10.4088/JCP.09m05086blu			6	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	661EF	WOS:000282705700003	20441723				2021-06-18	
J	Senathi-Raja, D; Ponsford, J; Schonberger, M				Senathi-Raja, Dawn; Ponsford, Jennie; Schoenberger, Michael			The Association of Age and Time Postinjury With Long-Term Emotional Outcome Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aging; anxiety; brain injuries; depression; emotional stress; neuropsychology; traumatic brain injury	CLOSED-HEAD INJURY; ADULT LIFE-SPAN; DEPRESSION SCALE; HOSPITAL ANXIETY; AXIS-I; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; RISK; OLD; REHABILITATION	Objective: To examine the effect of age and time postinjury on emotional distress, 5 to 22 years following traumatic brain injury (TBI). Participants: One hundred twelve participants with mild to very severe TBI, aged 16 to 81 years at the time of injury, and 112 healthy controls matched for current age, gender, education, and estimated IQ. Main outcome measure: The Hospital Anxiety and Depression Scale (HADS). Results: The difference in HADS scores between participants with TBI and controls did not vary according to the separate variables of age at injury or time postinjury. There was an interaction between age at injury and time postinjury whereby the youngest group demonstrated higher HADS scores with longer time postinjury, whereas the older groups displayed lower HADS scores with longer time postinjury, relative to controls. Conclusions: Long-term emotional outcome following TBI is related to the combined influence of age and time postinjury. Higher levels of emotional distress, evident at longer time postinjury in younger individuals, are particularly concerning and warrant attention from clinicians.	[Senathi-Raja, Dawn; Ponsford, Jennie; Schoenberger, Michael] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Ponsford, Jennie; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au					Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; *AUSTR BUR STAT, 1997, 43260 AUSTR BUR STAT; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Blazer DG, 2000, AM J PSYCHIAT, V157, P1915, DOI 10.1176/appi.ajp.157.12.1915; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Carstensen LL, 2000, J PERS SOC PSYCHOL, V79, P644, DOI 10.1037//0022-3514.79.4.644; Christensen H, 1999, PSYCHOL MED, V29, P325, DOI 10.1017/S0033291798008150; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorm AF, 2005, PSYCHOL MED, V35, P1253, DOI 10.1017/S0033291705004976; Jorm AF, 2000, PSYCHOL MED, V30, P11, DOI 10.1017/S0033291799001452; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraaij V, 2001, AGING MENT HEALTH, V5, P84, DOI 10.1080/13607860020020681; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rapoport MJ, 2001, BRAIN INJURY, V15, P857, DOI 10.1080/02699050110065303; Roberts RE, 1997, AM J PSYCHIAT, V154, P1384; Rothermund K, 2003, PSYCHOL AGING, V18, P80, DOI 10.1037/0882-7974.18.1.80; SCHONBERGER M, PSYCHIAT RE IN PRESS; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SENATHIRAJA DR, NEUROPSYCHO IN PRESS; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Wechsler D., 2001, WECHSLER TEST ADULT; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; WHELANGOODINSON R, J HEAD TRAU IN PRESS; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	46	25	25	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2010	25	5					330	338		10.1097/HTR.0b013e3181ccc893			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	649JR	WOS:000281765400005	20118790				2021-06-18	
J	Souter, M; Van Norman, G				Souter, Michael; Van Norman, Gail			Ethical controversies at end of life after traumatic brain injury: Defining death and organ donation	CRITICAL CARE MEDICINE			English	Article						ethics; end of life; brain death; controlled donation after cardiac death; donation after cardiac death; double effect; cardiac arrest; organ transplantation; death; declaring death	VEGETATIVE STATE	Death is more than a mere biological occurrence. It has important legal, medical, and social ramifications that make it imperative that those who are responsible for determination of death be accurate and above suspicion. The medical and legal definitions of death have evolved to include consideration of such concepts as loss of integration of the whole organism, loss of autonomy, and loss of personhood. Development of the concept of brain death coincided with advances in medical technology that facilitated artificial ventilation and organ transplantation. More recently, the process of "timed" death with subsequent organ donation (controlled donation after cardiac death transplantation) has raised controversial questions having to do with the limits of treatments that facilitate organ transplant but might hasten death, and the duration of cardiac arrest necessary for declaration of death and the commencement of organ procurement. In this review, we discuss the background and ethical ramifications of the concepts of brain death, and of controversies involved in controlled donation after cardiac death organ transplantation. (Crit Care Med 2010; 38[Suppl.]:S502-S509)	[Souter, Michael] Univ Washington, Harborview Med Ctr, Dept Anesthesiol & Pain Med & Neurosurg, Seattle, WA 98104 USA; [Van Norman, Gail] Univ Washington, Dept Anesthesiol & Pain Management, Seattle, WA 98104 USA	Souter, M (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol & Pain Med & Neurosurg, 325 9Th Ave, Seattle, WA 98104 USA.		Souter, Michael/ABE-1890-2020				Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; [Anonymous], 1995, Neurology, V45, P1012; BARTLETT E, 1988, HUMAN DEATH DESTRUCT, P199; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Bernat J. L., 2008, ETHICAL ISSUES NEURO; Cushing H, 1902, AM J MED SCI, V124, P375, DOI 10.1097/00000441-190209000-00001; Doig CJ, 2003, CAN J ANAESTH, V50, P1069, DOI 10.1007/BF03018376; GILDER SSB, 1968, BRIT MED J, V3, P493, DOI 10.1136/bmj.3.5616.493; Goldenberg F, 2009, CRIT CARE MED, V37, pA395; Greer DM, 2008, NEUROLOGY, V70, P284, DOI 10.1212/01.wnl.0000296278.59487.c2; Hawryluck LA, 2000, J PALLIATIVE CARE, V16, pS24, DOI 10.1177/082585970001601S06; Institute of Medicine, 1997, NON HEART BEAT ORG T; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Joffe Ari R, 2007, Philos Ethics Humanit Med, V2, P28, DOI 10.1186/1747-5341-2-28; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Kootstra G, 1997, TRANSPLANTATION, V63, P917, DOI 10.1097/00007890-199704150-00001; KOOTSTRA G, 1995, TRANSPLANT P, V27, P2893; Korein J, 1978, Ann N Y Acad Sci, V315, P1, DOI 10.1111/j.1749-6632.1978.tb50324.x; Kothari S, 2008, ARCH PHYS MED REHAB, V89, pS27, DOI 10.1016/j.apmr.2007.12.014; Lock M., 2002, TWICE DEAD ORGAN TRA; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; Machado C, 2005, NEUROLOGY, V64, P1938, DOI 10.1212/01.WNL.0000163515.09793.CB; Machado C, 1994, J Neurosurg Sci, V38, P209; Machado C, 2007, J MED ETHICS, V33, P197, DOI 10.1136/jme.2006.016931; Mandell MS, 2006, CRIT CARE MED, V34, P2952, DOI 10.1097/01.CCM.0000247718.27324.65; Marini AM, 2001, ANN NY ACAD SCI, V939, P238; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Menikoff J, 2002, ISSUES LAW MED, V18, P3; MOLLARET P., 1959, REV NEUROL [PARIS], V101, P3; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; PALLIS C, 1998, MED LEG J, V51, P1538; Plum F, 1982, DIAGNOSIS STUPOR COM; PUCCETTI R, 1976, MONIST, V59, P249, DOI 10.5840/monist197659227; SADLER AM, 1968, J AMER MED ASSOC, V206, P2501, DOI 10.1001/jama.1968.03150110049007; SANZ ABR, 2005, ORGANS TISSUES, V3, P151; Siminoff Laura A, 2003, Prog Transplant, V13, P218; SPELLMAN B, 1995, I ETHICS J, V5, P323; Truog RD, 2007, J LAW MED ETHICS, V35, P273, DOI 10.1111/j.1748-720X.2007.00136.x; Turgeon A, 2009, CRIT CARE MED, V37, pA314; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143; Van Norman GA, 1999, ANESTHESIOLOGY, V91, P275, DOI 10.1097/00000542-199907000-00036; VEATCH RM, 1989, DYING BIOLOGICAL REV; Viruses and renal disease, 1968, JAMA, V204, P539; WERTHEIMER P, 1959, PRESSE MED, V67, P87; Whetstine LM, 2007, CRIT CARE, V11, DOI 10.1186/cc5690; Wijdicks EFM, 2006, NEUROLOGY, V66, P1300, DOI 10.1212/01.wnl.0000210497.62202.e9; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; WUDICKS EFM, 2003, NEUROLOGY, V61, P970; Yamamoto T, 2005, ACTA NEUROCHIR SUPPL, V93, P101; Youngner SJ, 1999, HASTINGS CENT REP, V29, P14, DOI 10.2307/3527866; 1968, BRAIN DEATH, V205, P337; 2007, 134 ANN SESS TAC WA; 1977, JAMA, V237, P982	53	25	26	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2010	38	9		S			S502	S509		10.1097/CCM.0b013e3181ec5354			8	Critical Care Medicine	General & Internal Medicine	647FB	WOS:000281602100012	20724884				2021-06-18	
J	Walz, NC; Yeates, KO; Taylor, HG; Stancin, T; Wade, SL				Walz, Nicolay Chertkoff; Yeates, Keith Owen; Taylor, H. Gerry; Stancin, Terry; Wade, Shari L.			Theory of mind skills I year after traumatic brain injury in 6-to 8-year-old children	JOURNAL OF NEUROPSYCHOLOGY			English	Article							APPEARANCE-REALITY DISTINCTION; CHILDHOOD HEAD-INJURY; FALSE BELIEF; 2ND-ORDER BELIEFS; SOCIAL COMPETENCE; ATTRIBUTION; OUTCOMES; ADULTS; 5-YEAR-OLD; DISORDER	This study examined the longer-term effects of traumatic brain injury (TBI) on theory of mind (ToM) skills of children who were between the ages of 5 and 7 years at the time of injury. Fifty-two children with orthopaedic injury, 30 children with moderate TBI, and 12 children with severe TBI were evaluated approximately I year post-injury (mean age = 6.98 years, SD = 0.59, range = 6.02-8.26). Children with severe TBI did not engage in representation of first- and second-order mental states at a developmental level comparable to their peers, suggesting stagnation or lack of development, as well as regression of putatively existing ToM skills. Age, task-specific cognitive demands, and verbal abilities were strong predictors of ToM performance. However, even after taking those factors into account, children with severe TBI had poorer ToM performance than children with orthopaedic injuries.	[Walz, Nicolay Chertkoff] Cincinnati Childrens Hosp Med Ctr, Div Behav Med & Clin Psychol, Dept Pediat, Cincinnati, OH 45229 USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Res Inst, Nationwide Childrens Hosp, Columbus, OH 43210 USA; [Yeates, Keith Owen] Ctr Biobehav Hlth, Columbus, OH USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Pediat Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Rehabil, Cincinnati, OH USA; [Walz, Nicolay Chertkoff; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Walz, NC (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Behav Med & Clin Psychol, Dept Pediat, MLC 10006,2800 Winslow Ave, Cincinnati, OH 45229 USA.	nicolay.walz@cchmc.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	CCHMC [K23 HD046690, R01 HD42729]; State of Ohio Emergency Medical Services; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD046690] Funding Source: NIH RePORTER	Supported by a CCHMC GCRC CReFF award and grant K23 HD046690 to Dr Walz, grant R01 HD42729 to Dr Wade, and Trauma Research grants from the State of Ohio Emergency Medical Services to Dr Taylor. The authors wish to acknowledge the contributions of Christine Abraham, Andrea Beebe, Lori Bernard, Anne Birnbaum, Beth Bishop, Tammy Matecun, Karen Oberjohn, Elizabeth Roth, Elizabeth Shaver, and Maegan Swartwout in data collection and coding. The Cincinnati Children's Medical Center Trauma Registry, Rainbow Pediatric Trauma Center, Rainbow Babies & Children's Hospital, Columbus Children's Hospital Trauma Program, and MetroHealth Center Department of Pediatrics and Trauma Registry provided assistance with recruitment.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Blair C, 2002, AM PSYCHOL, V57, P111, DOI 10.1037//0003-066X.57.2.111; Bloom P, 2000, COGNITION, V77, pB25, DOI 10.1016/S0010-0277(00)00096-2; Caldarella, 2002, HOME COMMUNITY SOCIA; Carlson SM, 2001, CHILD DEV, V72, P1032, DOI 10.1111/1467-8624.00333; *CDCP NAT CTR INJ, 2000, TRAUM BRAIN INJ US A; Coull GJ, 2006, SOC DEV, V15, P548; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Elliott C.D., 1990, DIFFERENTIAL ABILITY; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FLAVELL JH, 1983, COGNITIVE PSYCHOL, V15, P95, DOI 10.1016/0010-0285(83)90005-1; FLAVELL JH, 1986, MONOGR SOC RES CHILD, V51, pR1, DOI 10.2307/1165866; GOPNIK A, 1988, CHILD DEV, V59, P26, DOI 10.2307/1130386; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; HOGREFE GJ, 1986, CHILD DEV, V57, P567, DOI 10.2307/1130337; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Ladd GW, 1999, ANNU REV PSYCHOL, V50, P333, DOI 10.1146/annurev.psych.50.1.333; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; Merrell KW, 2001, PSYCHOL SCHOOLS, V38, P313, DOI 10.1002/pits.1021; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Roeyers H, 2001, J CHILD PSYCHOL PSYC, V42, P271, DOI 10.1111/1469-7610.00718; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; SULLIVAN K, 1994, DEV PSYCHOL, V30, P395, DOI 10.1037/0012-1649.30.3.395; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; Taylor M, 2008, RETHINK GLOB, V14, P1; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wiig E.H., 1985, TEST LANGUAGE COMPET; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	42	25	25	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-6645	1748-6653		J NEUROPSYCHOL	J. Neuropsychol.	SEP	2010	4		2				181	195		10.1348/174866410X488788			15	Psychology; Psychology, Experimental	Psychology	670DO	WOS:000283401600004	20307379	Green Accepted			2021-06-18	
J	Walker, CT; Marky, AH; Petraglia, AL; Ali, T; Chow, N; Zlokovic, BV				Walker, Corey T.; Marky, Andrew H.; Petraglia, Anthony L.; Ali, Tracy; Chow, Nienwen; Zlokovic, Berislav V.			Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact	BRAIN RESEARCH			English	Article						Activated protein C analog; Traumatic brain injury; Neuroprotection; Hemorrhage	TISSUE-PLASMINOGEN ACTIVATOR; HUMAN BRAIN ENDOTHELIUM; SPINAL-CORD-INJURY; RECEPTOR; APOPTOSIS; STROKE; RATS; MICE; NEUROGENESIS; HEMORRHAGE	The anticoagulant activated protein C (APC) protects neurons and vascular cells from injury through its direct cytoprotective effects that are independent of its anticoagulant action. Wild-type recombinant murine APC (wt-APC) exerts significant neuroprotection in mice if administered early after traumatic brain injury (TBI). Here, we compared efficacy and safety of a late therapy for TBI with wt-APC and 3K3A-APC, an APC analog with similar to 80% reduced anticoagulant activity but normal cytoprotective activity, using a controlled cortical impact model of TBI. Mice received 0.8 mg/kg intraperitoneally of recombinant murine 3K3A-APC, wt-APC or saline at 6, 12, 24 and 48 h after injury. 3K3A-APC (n=15) relative to wt-APC (n=15) improved motor and sensorimotor recovery within the first three days post-trauma as demonstrated by rotarod (p<0.05) and beam balance test (p<0.05), respectively. Both, wt-APC and 3K3A-APC reduced the lesion volume seven days after injury by 36% (n=8; p<0.01) and 56% (n=8; p<0.01), respectively, compared to saline (n=8). Three days post-TBI, the hemoglobin levels in the injured brain were increased by similar to 3-fold after wt-APC treatment compared to saline indicating an increased risk for intracerebral bleeding. In contrast, comparable levels of brain hemoglobin in 3K3A-APC-treated and saline-treated mice suggested that 3K3A-APC treatment did not increase risk for bleeding after TBI. Thus, compared to wt-APC, 3K3A-APC is more efficacious and safer therapy for TBI with no risk for intracerebral hemorrhage. (C) 2010 Elsevier B.V. All rights reserved.	[Walker, Corey T.; Marky, Andrew H.; Zlokovic, Berislav V.] Univ Rochester, Ctr Neurodegenerat & Vasc Brain Disorders, Med Ctr, Rochester, NY 14642 USA; [Petraglia, Anthony L.] Univ Rochester, Dept Neurosurg, Med Ctr, Rochester, NY 14642 USA; [Ali, Tracy; Chow, Nienwen] ZZ Biotech LLC, Rochester, NY USA	Zlokovic, BV (corresponding author), Univ Rochester, Ctr Neurodegenerat & Vasc Brain Disorders, Med Ctr, Arthur Kornberg Med Res Bldg,601 Elmwood Ave,Box, Rochester, NY 14642 USA.	Berislav_Zlokovic@URMC.Rochester.edu			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL63290, HL81528]; ZZ Biotech; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL081528, R01HL063290] Funding Source: NIH RePORTER	This work is supported by the National Institute of Health grants HL63290 and HL81528 and ZZ Biotech.	Bernard GR, 2001, CRIT CARE MED, V29, P2051, DOI 10.1097/00003246-200111000-00003; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Cheng T, 2006, NAT MED, V12, P1278, DOI 10.1038/nm1498; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Domotor E, 2003, BLOOD, V101, P4797, DOI 10.1182/blood-2002-12-3680; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; Gorbacheva L, 2010, NEUROSCIENCE, V165, P1138, DOI 10.1016/j.neuroscience.2009.11.027; Gorbacheva L, 2009, J NEUROCHEM, V111, P967, DOI 10.1111/j.1471-4159.2009.06380.x; Griffin JH, 2002, SEMIN HEMATOL, V39, P197, DOI 10.1053/shem.2002.34093; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Guo H, 2009, J NEUROCHEM, V109, P116, DOI 10.1111/j.1471-4159.2009.05921.x; Guo H, 2009, EUR J NEUROSCI, V29, P1119, DOI 10.1111/j.1460-9568.2009.06664.x; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Han MH, 2008, NATURE, V451, P1076, DOI 10.1038/nature06559; Hirose K, 2000, ANN SURG, V232, P272, DOI 10.1097/00000658-200008000-00018; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Liu D, 2004, NAT MED, V10, P1379, DOI 10.1038/nm1122; Mosnier LO, 2007, BLOOD, V109, P3161, DOI 10.1182/blood-2006-09-003004; Mosnier LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Petraglia AL, 2010, NEUROSURGERY, V66, P165, DOI 10.1227/01.NEU.0000363148.49779.68; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Shibata M, 2001, CIRCULATION, V103, P1799, DOI 10.1161/01.CIR.103.13.1799; Taoka Y, 1998, J NEUROSCI, V18, P1393; Thiyagarajan M, 2008, J NEUROSCI, V28, P12788, DOI 10.1523/JNEUROSCI.3485-08.2008; Wang L, 1997, J CEREBR BLOOD F MET, V17, P136, DOI 10.1097/00004647-199702000-00002; Wang YM, 2009, STROKE, V40, P1864, DOI 10.1161/STROKEAHA.108.536680; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Yamauchi T, 2006, STROKE, V37, P1081, DOI 10.1161/01.STR.0000206280.30972.21; Yesilirmak DC, 2008, BRAIN RES, V1210, P56, DOI 10.1016/j.brainres.2008.02.088; Zhong ZH, 2009, J CLIN INVEST, V119, P3437, DOI 10.1172/JCI38476; Zlokovic BV, 2005, ANN NEUROL, V58, P474, DOI 10.1002/ana.20602	35	25	25	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 6	2010	1347						125	131		10.1016/j.brainres.2010.05.075			7	Neurosciences	Neurosciences & Neurology	639LC	WOS:000280975300014	20513369	Green Accepted			2021-06-18	
J	Radyushkin, K; El-Kordi, A; Boretius, S; Castaneda, S; Ronnenberg, A; Reim, K; Bickeboller, H; Frahm, J; Brose, N; Ehrenreich, H				Radyushkin, K.; El-Kordi, A.; Boretius, S.; Castaneda, S.; Ronnenberg, A.; Reim, K.; Bickeboeller, H.; Frahm, J.; Brose, N.; Ehrenreich, H.			Complexin2 null mutation requires a 'second hit' for induction of phenotypic changes relevant to schizophrenia	GENES BRAIN AND BEHAVIOR			English	Article						Animal model; cryolesion; etiology; MK-801; mouse model; neurotrauma; parietal cortex; PPI; schizophrenia	TRAUMATIC BRAIN INJURY; PREPULSE INHIBITION; ANIMAL-MODELS; TRANSGENIC MICE; MOUSE MODEL; KETAMINE; VULNERABILITY; DISORDER; SIGNS; RATS	Schizophrenia is a devastating disease that affects approximately 1% of the population across cultures. Its neurobiological underpinnings are still unknown. Accordingly, animal models of schizophrenia often lack construct validity. As concordance rate in monozygotic twins amounts to only 50%, environmental risk factors (e.g. neurotrauma, drug abuse, psychotrauma) likely act as necessary 'second hit' to trigger/drive the disease process in a genetically predisposed individual. Valid animal models would have to consider this genetic-environmental interaction. Based on this concept, we designed an experimental approach for modeling a schizophrenia-like phenotype in mice. As dysfunction in synaptic transmission plays a key role in schizophrenia, and complexin2 (CPLX2) gene expression is reduced in hippocampus of schizophrenic patients, we developed a mouse model with Cplx2 null mutation as genetic risk factor and a mild parietal neurotrauma, applied during puberty, as environmental 'second hit'. Several months after lesion, Cplx2 null mutants showed reduced pre-pulse inhibition, deficit of spatial learning and loss of inhibition after MK-801 challenge. These abnormalities were largely absent in lesioned wild-type mice and non-lesioned Cplx2 null mutants. Forced alternation in T-maze, object recognition, social interaction and elevated plus maze tests were unaltered in all groups. The previously reported mild motor phenotype of Cplx2 null mutants was accentuated upon lesion. MRI volumetrical analysis showed a decrease of hippocampal volume exclusively in lesioned Cplx2 null mutants. These findings provide suggestive evidence for the 'second hit' hypothesis of schizophrenia and may offer new tools for the development of advanced treatment strategies.	[Reim, K.; Brose, N.] Georg August Univ, Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany; [Radyushkin, K.; El-Kordi, A.; Castaneda, S.; Ronnenberg, A.; Ehrenreich, H.] Georg August Univ, Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany; [Boretius, S.; Frahm, J.] Georg August Univ, Max Planck Inst Biophys Chem, Biomed NMR Forsch GmbH, D-37075 Gottingen, Germany; [Bickeboeller, H.] Georg August Univ, Dept Genet Epidemiol, D-37075 Gottingen, Germany; [Radyushkin, K.; El-Kordi, A.; Boretius, S.; Frahm, J.; Brose, N.; Ehrenreich, H.] DFG Ctr Mol Physiol Brain, Gottingen, Germany	Brose, N (corresponding author), Georg August Univ, Max Planck Inst Expt Med, Dept Mol Neurobiol, Hermann Rein Str 3, D-37075 Gottingen, Germany.	brose@em.mpg.de; ehrenreich@em.mpg.de	Bickeboller, Heike/V-2318-2018	Bickeboller, Heike/0000-0002-3361-5488; Ehrenreich, Hannelore/0000-0001-8371-5711; Boretius, Susann/0000-0003-2792-7423	Max Planck SocietyMax Planck SocietyFoundation CELLEX; DFG Center for Molecular Physiology of the Brain (CMPB)German Research Foundation (DFG)	This study was supported by the Max Planck Society and the DFG Center for Molecular Physiology of the Brain (CMPB). The staff of the Transgenic Animal Facility at the Max Planck Institute for Experimental Medicine is gratefully acknowledged for excellent technical assistance.	Adler CM, 1999, AM J PSYCHIAT, V156, P1646, DOI 10.1176/ajp.156.10.1646; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson JE, 1998, RESTOR NEUROL NEUROS, V12, P175; Ayhan Y, 2009, BEHAV BRAIN RES, V204, P274, DOI 10.1016/j.bbr.2009.04.010; Bayer TA, 1999, J PSYCHIATR RES, V33, P543, DOI 10.1016/S0022-3956(99)00039-4; BEGEMANN M, 2010, ARCH GEN PS IN PRESS; Blumenthal TD, 2004, PSYCHOPHYSIOLOGY, V41, P326, DOI 10.1111/j.1469-8986.2003.00144.x; BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181; Brose N, 2008, TRAFFIC, V9, P1403, DOI 10.1111/j.1600-0854.2008.00758.x; Carlsson A, 1999, BRIT J PSYCHIAT, V174, P2, DOI 10.1192/S0007125000293574; Chan RCK, 2008, NEUROSCI BIOBEHAV R, V32, P957, DOI 10.1016/j.neubiorev.2008.01.005; Coyle JT, 2004, BIOCHEM PHARMACOL, V68, P1507, DOI 10.1016/j.bcp.2004.07.034; Csomor PA, 2008, BEHAV NEUROSCI, V122, P885, DOI 10.1037/0735-7044.122.4.885; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; GEYER MA, 1984, NEUROBEH TOXICOL TER, V6, P161; GEYER MA, 2002, PSYCHOPHARMACOLOGY 4, pR42; Glynn D, 2003, HUM MOL GENET, V12, P2431, DOI 10.1093/hmg/ddg249; Glynn D, 2007, BRAIN RES BULL, V72, P108, DOI 10.1016/j.brainresbull.2006.10.017; GOTTESMAN II, 1976, SCHIZOPHRENIA BULL, V2, P360, DOI 10.1093/schbul/2.3.360; Gunduz-Bruce H, 2009, BRAIN RES REV, V60, P279, DOI 10.1016/j.brainresrev.2008.07.006; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Harrison PJ, 1998, LANCET, V352, P1669, DOI 10.1016/S0140-6736(98)03341-8; HEINRICHS DW, 1988, AM J PSYCHIAT, V145, P11; HYDE TM, 1990, SEMIN NEUROL, V10, P276, DOI 10.1055/s-2008-1041279; Ison JR, 1997, PSYCHOBIOLOGY, V25, P266; Jamain S, 2008, P NATL ACAD SCI USA, V105, P1710, DOI 10.1073/pnas.0711555105; Janus C, 2004, LEARN MEMORY, V11, P337, DOI 10.1101/lm.70104; Karl T, 2010, BEHAV BRAIN RES, V207, P434, DOI 10.1016/j.bbr.2009.10.029; Lahti AC, 2001, NEUROPSYCHOPHARMACOL, V25, P455, DOI 10.1016/S0893-133X(01)00243-3; Lee HJ, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-15; Lipska BK, 2004, J PSYCHIATR NEUROSCI, V29, P282; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Malhotra AK, 1997, NEUROPSYCHOPHARMACOL, V17, P141; Malhotra AK, 1996, NEUROPSYCHOPHARMACOL, V14, P301, DOI 10.1016/0893-133X(95)00137-3; McAllister TW, 1998, SEMIN CLIN NEUROPSYC, V3, P211; MCIIWAIN KL, 2001, PHYSIOL BEHAV, V73, P705; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Natt O, 2002, J NEUROSCI METH, V120, P203, DOI 10.1016/S0165-0270(02)00211-X; Olney JW, 1999, J PSYCHIAT RES, V33, P523, DOI 10.1016/S0022-3956(99)00029-1; ONEILL SK, 1989, BRAIN RES BULL, V22, P611, DOI 10.1016/0361-9230(89)90078-6; Radyushkin K, 2009, GENES BRAIN BEHAV, V8, P416, DOI 10.1111/j.1601-183X.2009.00487.x; Reim K, 2005, J CELL BIOL, V169, P669, DOI 10.1083/jcb.200502115; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Sargin D, 2009, GLIA, V57, P693, DOI 10.1002/glia.20797; Sawa A, 2002, SCIENCE, V296, P692, DOI 10.1126/science.1070532; Sawada K, 2002, MOL PSYCHIATR, V7, P484, DOI 10.1038/sj.mp.4000978; Shenton ME, 2001, SCHIZOPHR RES, V49, P1, DOI 10.1016/S0920-9964(01)00163-3; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; Swerdlow NR, 1998, SCHIZOPHRENIA BULL, V24, P285, DOI 10.1093/oxfordjournals.schbul.a033326; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; van Os J, 2009, LANCET, V374, P635, DOI 10.1016/S0140-6736(09)60995-8; WILLNER P, 1986, PROG NEURO-PSYCHOPH, V10, P677, DOI 10.1016/0278-5846(86)90051-5; Wolfer DP, 1998, NEWS PHYSIOL SCI, V13, P118; Wong AHC, 2003, NEUROSCI BIOBEHAV R, V27, P269, DOI 10.1016/S0149-7634(03)00035-6; Yamauchi Y, 2005, BRAIN RES, V1056, P59, DOI 10.1016/j.brainres.2005.07.015; Yee BK, 2005, BEHAV BRAIN RES, V163, P265, DOI 10.1016/j.bbr.2005.05.013; Yee BK, 2004, NEUROPSYCHOPHARMACOL, V29, P240, DOI 10.1038/sj.npp.1300323; Zhang Qingchen, 2003, Curr Psychiatry Rep, V5, P197, DOI 10.1007/s11920-003-0042-0	60	25	25	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1601-1848	1601-183X		GENES BRAIN BEHAV	Genes Brain Behav.	AUG	2010	9	6					592	602		10.1111/j.1601-183X.2010.00590.x			11	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	640FA	WOS:000281032700005	20412316	Bronze			2021-06-18	
J	Kallakuri, S; Kreipke, CW; Schafer, PC; Schafer, SM; Rafols, JA				Kallakuri, S.; Kreipke, C. W.; Schafer, P. C.; Schafer, S. M.; Rafols, J. A.			BRAIN CELLULAR LOCALIZATION OF ENDOTHELIN RECEPTORS A AND B IN A RODENT MODEL OF DIFFUSE TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						endothelin (ET)-1; vasoreactivity; immunoreactivity; immunofluorescence; sensorimotor cortex; hippocampus	CEREBRAL-ARTERY OCCLUSION; PULMONARY-HYPERTENSION; AXONAL INJURY; RAT-BRAIN; EXPRESSION; ASTROCYTES; MICROCIRCULATION; ANTAGONIST; SUBTYPE; CORTEX	Endothelin-1 exerts potent vasoconstrictor and vasodilatory effects through its actions on its receptors A (ETrA) and B (ETrB), respectively. While ETrA and B have classically been thought to be expressed on vascular cell types, more recent evidcence suggests that, particularly following brain injury, their expression may be seen in other, non-vascular cell types. To date no studies have comprehensively studied the cellular location of endothlelin receptors following traumatic brain injury (TBI). Therefore, this study investigates the cellular localization of ETrA and B in normal and traumatized brains using an impact acceleration device. Adult male Sprague Dawley rats were subjected to TBI by weight drop (450 g) from either 1.5, a distance known to elicit mild TBI in the absence of changed in cerebral blood flow (CBF) or 2 m, a distance shown to cause a significant reduction in CBF. One set of impacted brains were processed for Western determination of ETrA and B expression. Another set were processed for immunofluorescence (IF). For IF, ETrA and ETrB antibodies were combined with cell markers for neurons, astrocytes, microglia, oligodendrocytes, smooth muscle cells and endothelial cells of blood vessels. While ETrA and B was upregulated after more moderate to severe injury (2 m) overall receptor expression was unchanged in response to mild trauma (1.5 m). Double labeling IF confirmed prominent ETrA and ETrB labeling in NeuN labeled pyramidal neurons and interneurons in sensorymotor cortex (smCx) and hippocampus (hipp) post TBI. ETrA rather than ETrB was preferentially co-localized in vascular smooth muscle cells. After injury, a subpopulation of astrocytes in white matter co-localized ETrA but not ETrB. Localization of either receptor in endothelial cells was sparse. No prominent IF was detected in microglia and oligodendrocytes. Taken together with previous findings in other pathological states that show an apparent shift in the localization of ETrA and B, the observed receptor shifts in this work may underlie the ET-1- mediated pathotrajectory of TBI including hypoperfusion. Published by Elsevier Ltd on behalf of IBRO.	[Kallakuri, S.; Kreipke, C. W.; Schafer, P. C.; Schafer, S. M.; Rafols, J. A.] Wayne State Univ, Dept Anat & Cell Biol, Sch Med, Detroit, MI 48201 USA	Rafols, JA (corresponding author), Wayne State Univ, Dept Anat & Cell Biol, Sch Med, 9312 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.	jrafols@med.wayne.edu					ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; Armstead WM, 2001, J NEUROTRAUM, V18, P1039, DOI 10.1089/08977150152693737; BARONE FC, 1994, J CEREBR BLOOD F MET, V14, P337, DOI 10.1038/jcbfm.1994.41; Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cacoub P, 1997, CARDIOVASC RES, V33, P196, DOI 10.1016/S0008-6363(96)00189-7; Cazaubon S, 1997, J NEUROSCI, V17, P6203; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; CLOZEL M, 1992, BIOCHEM BIOPH RES CO, V186, P867, DOI 10.1016/0006-291X(92)90826-7; Dawson DA, 1999, NEUROCHEM RES, V24, P1499, DOI 10.1023/A:1021139713026; EHRENREICH H, 2005, SCIENCE, V309, P392; FEUERSTEIN G, 1994, PEPTIDES, V15, P467, DOI 10.1016/0196-9781(94)90207-0; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FUKURODA T, 1994, BRIT J PHARMACOL, V113, P336, DOI 10.1111/j.1476-5381.1994.tb16901.x; Galley HF, 2004, BRIT J ANAESTH, V93, P105, DOI 10.1093/bja/aeh163; Gresle MM, 2006, BRAIN RES, V1110, P13, DOI 10.1016/j.brainres.2006.06.111; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; HAYNES WG, 1994, LANCET, V344, P852, DOI 10.1016/S0140-6736(94)92827-4; Hill BJF, 2000, J PHARMACOL EXP THER, V295, P484; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; Ihling C, 2001, CIRCULATION, V104, P864, DOI 10.1161/hc3301.094742; IVY DD, 1994, J CLIN INVEST, V93, P2141, DOI 10.1172/JCI117210; Just A, 2004, AM J PHYSIOL-RENAL, V286, pF660, DOI 10.1152/ajprenal.00368.2003; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; Kallakuri S, 2007, NEUROL RES, V29, P362, DOI 10.1179/016164107X204675; Kasemsri T, 1997, AM J PHYSIOL-HEART C, V273, pH2639; Koyama Y, 1996, GLIA, V16, P342, DOI 10.1002/(SICI)1098-1136(199604)16:4<342::AID-GLIA6>3.0.CO;2-1; Kreipke CW, 2007, NEUROL RES, V29, P604, DOI 10.1179/016164107X166317; Kreipke CW, 2006, MICROVASC RES, V71, P197, DOI 10.1016/j.mvr.2006.02.002; Kreipke CW, 2010, NEUROL RES, V32, P209, DOI 10.1179/174313209X414515; Kurokawa K, 1997, J COMP NEUROL, V389, P348, DOI 10.1002/(SICI)1096-9861(19971215)389:2<348::AID-CNE11>3.0.CO;2-H; Lazarini F, 1996, J NEUROCHEM, V66, P459; Legos JJ, 2008, EXP NEUROL, V212, P53, DOI 10.1016/j.expneurol.2008.03.011; LI JS, 1994, HYPERTENSION, V24, P183, DOI 10.1161/01.HYP.24.2.183; Lo ACY, 2005, J CEREBR BLOOD F MET, V25, P998, DOI 10.1038/sj.jcbfm.9600108; Loo LS, 2002, NEUROSCIENCE, V112, P993, DOI 10.1016/S0306-4522(02)00043-X; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSAULT R, 1990, BIOCHEM BIOPH RES CO, V171, P301, DOI 10.1016/0006-291X(90)91392-6; MCMURRAY JJ, 1992, CIRCULATION, V85, P1374, DOI 10.1161/01.CIR.85.4.1374; Naidoo V, 2004, J CHEM NEUROANAT, V27, P87, DOI 10.1016/j.jchemneu.2003.12.002; Nakagomi S, 2000, NEUROSCIENCE, V101, P441, DOI 10.1016/S0306-4522(00)00345-6; NOOTENS M, 1995, J AM COLL CARDIOL, V26, P1581, DOI 10.1016/0735-1097(95)00399-1; ORLEANSJUSTE PD, 1990, BIOCHEM PHARMACOL, V39, pR21, DOI 10.1016/0006-2952(90)90419-L; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Peters C. M., 2001, Society for Neuroscience Abstracts, V27, P2046; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; POVLISHOCK JT, 1983, AM J PATHOL, V110, P148; Prasanna G, 2002, INVEST OPHTH VIS SCI, V43, P2704; Rafols JA, 2007, NEUROL RES, V29, P339, DOI 10.1179/016164107X204648; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; RANDALL MD, 1989, BRIT J PHARMACOL, V98, P685, DOI 10.1111/j.1476-5381.1989.tb12644.x; Rogers SD, 2003, GLIA, V41, P180, DOI 10.1002/glia.10173; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; Siren AL, 2000, NEUROCHEM RES, V25, P957, DOI 10.1023/A:1007552408463; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; TEERLINK JR, 1994, CIRCULATION, V90, P2510, DOI 10.1161/01.CIR.90.5.2510; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zimmermann M, 1998, NEUROSURGERY, V43, P863, DOI 10.1097/00006123-199810000-00083	62	25	26	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUL 14	2010	168	3					820	830		10.1016/j.neuroscience.2010.01.018			11	Neurosciences	Neurosciences & Neurology	608UM	WOS:000278611500023	20144696				2021-06-18	
J	Kuypers, NJ; Hoane, MR				Kuypers, Nicholas J.; Hoane, Michael R.			Pyridoxine Administration Improves Behavioral and Anatomical Outcome after Unilateral Contusion Injury in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						B-vitamin; controlled cortical impact; recovery of function; treatment; traumatic brain injury; vita-nutrient; vitamin B-6	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; NICOTINAMIDE TREATMENT; OXIDATIVE STRESS; SENSORIMOTOR FUNCTION; FUNCTIONAL RECOVERY; SENSORY NEUROPATHY; REDUCES EDEMA; HEAD-INJURY; VITAMIN-B-6	The purpose of this project was to evaluate the preclinical efficacy of pyridoxine, or vitamin B-6. Rats received a 3.0mm unilateral controlled cortical impact (CCI) injury of the sensorimotor cortex or sham surgery. Treatment with vitamin B-6 (600 or 300mg/kg IP) or vehicle was administered at 30min and 24 h post-CCI. Somatosensory dysfunction was evaluated with the vibrissae-forelimb placing and bilateral tactile adhesive removal tests. Sensorimotor dysfunction was evaluated with the locomotor placing and the forelimb asymmetry tests. On the forelimb asymmetry test both treatment groups displayed no asymmetry bias on any of the testing days post-CCI and were statistically no different than the shams. Both vitamin B-6 groups displayed a significant improvement in behavioral performance on the locomotor placing test compared to the vehicle-treated group. Administration of 600mg/kg also significantly reduced tactile adhesive removal latencies on days 2, 4, 6, and 12 post-CCI. Both treatment groups were improved in their rate of recovery post-CCI on the vibrissae-forelimb placing test, but only the recovery seen in the 600-mg/kg group was significantly improved compared to vehicle. Finally, the 600-mg/kg dose resulted in significant cortical sparing compared to the vehicle-treated group. In general, the effects of vitamin B-6 on recovery of function were dose-dependent, with the 600-mg/kg dose consistently showing greater recovery than the 300-mg/kg dose. More experimental analyses are warranted to evaluate the potential preclinical efficacy and mechanistic action of vitamin B-6.	[Kuypers, Nicholas J.; Hoane, Michael R.] So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045647]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	Funding was provided by National Institutes of Health grant NS045647.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; BARTH TM, 1990, STROKE, V21, P153; Becerra GD, 2007, BEHAV BRAIN RES, V179, P118, DOI 10.1016/j.bbr.2007.01.024; Bender DA, 1999, BRIT J NUTR, V81, P7, DOI 10.1017/S0007114599000082; BETZ AL, 1994, ACTA NEUROCHIR, P314; Cabrini L, 1998, BIOCHEM MOL BIOL INT, V46, P689; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chong ZZ, 2008, CURR NEUROVASC RES, V5, P159, DOI 10.2174/156720208785425666; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Cuskelly GJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1182; Friso S, 2004, AM J CLIN NUTR, V79, P992; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane Michael R, 2004, Clin Calcium, V14, P65; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Hwang IK, 2007, EXP NEUROL, V206, P114, DOI 10.1016/j.expneurol.2007.04.005; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Kelly PJ, 2003, STROKE, V34, pE51, DOI 10.1161/01.STR.0000071109.23410.AB; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; KRINKE G, 1981, NEUROTOXICOLOGY, V2, P13; KRINKE G, 1985, J NEUROPATH EXP NEUR, V44, P117, DOI 10.1097/00005072-198503000-00001; Kruman I, 1997, J NEUROSCI, V17, P5089; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Oka T, 2001, NUTR RES REV, V14, P257, DOI [10.1079/095442201108729231, 10.1079/NRR200125]; OKADA M, 1991, J NUTR SCI VITAMINOL, V37, P349, DOI 10.3177/jnsv.37.349; PARRY GJ, 1985, NEUROLOGY, V35, P1466, DOI 10.1212/WNL.35.10.1466; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Perry TA, 2004, EXP NEUROL, V190, P133, DOI 10.1016/j.expneurol.2004.07.013; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; ROBERTS E, 1964, VITAM HORM, V22, P503, DOI 10.1016/S0083-6729(08)60351-9; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SCHALLERT T, 2005, ORIENTING PLACING BE, P129; Shen J, 2010, AM J CLIN NUTR, V91, P337, DOI 10.3945/ajcn.2009.28571; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van den Heuvel Corinna, 2004, Clin Calcium, V14, P9; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; XU Y, 1989, NEUROLOGY, V39, P1077, DOI 10.1212/WNL.39.8.1077	50	25	27	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1275	1282		10.1089/neu.2010.1327			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100012	20486803	Green Published			2021-06-18	
J	Schmitt, KRL; Boato, F; Diestel, A; Hechler, D; Kruglov, A; Berger, F; Hendrix, S				Schmitt, Katharina R. L.; Boato, Francesco; Diestel, Antje; Hechler, Daniel; Kruglov, Andrei; Berger, Felix; Hendrix, Sven			Hypothermia-Induced Neurite Outgrowth is Mediated by Tumor Necrosis Factor-Alpha	BRAIN PATHOLOGY			English	Article						brain slices; hypothermia; TNF-alpha; neurite outgrowth; traumatic brain injury; regeneration	MICE LACKING; TNF-ALPHA; CEREBRAL-ISCHEMIA; IL-6 RELEASE; BRAIN-INJURY; CELLS; ACTIVATION; GROWTH; INFLAMMATION; CYTOTOXICITY	Systemic or brain-selective hypothermia is a well-established method for neuroprotection after brain trauma. There is increasing evidence that hypothermia exerts beneficial effects on the brain and may also support regenerative responses after brain damage. Here, we have investigated whether hypothermia influences neurite outgrowth in vitro via modulation of the post-injury cytokine milieu. Organotypic brain slices were incubated: deep hypothermia (2 h at 17 degrees C), rewarming (2 h up to 37 degrees C), normothermia (20 h at 37 degrees C). Neurite density and cytokine release (IL 1beta, IL-6, IL-10, and TNF-alpha) were investigated after 24 h. For functional analysis mice deficient in NT-3/NT-4 and TNF-alpha as well as the TNF-alpha inhibitor etanercept were used. Hypothermia led to a significant increase of neurite outgrowth, which was independent of neurotrophin signaling. In contrast to other cytokines investigated, TNF-alpha secretion by organotypic brain slices was significantly increased after deep hypothermia. Moreover, hypothermia-induced neurite extension was abolished after administration of the TNF-alpha inhibitor and in TNF-alpha knockout mice. We demonstrate that TNF-alpha is responsible for inducing neurite outgrowth in the context of deep hypothermia and rewarming. These data suggest that hypothermia not only exerts protective effects in the CNS but may also support neurite outgrowth as a potential mechanism of regeneration.	[Schmitt, Katharina R. L.] Deutsch Herzzentrum Berlin, Dept Pediat Cardiol, Clin Congenital Heart Dis & Pediat Cardiol, D-13353 Berlin, Germany; [Boato, Francesco; Hechler, Daniel; Hendrix, Sven] Charite, Ctr Anat, Inst Cell Biol & Neurobiol, Berlin, Germany; [Diestel, Antje; Berger, Felix] Charite, Dept Pediat Cardiol, Berlin, Germany; [Kruglov, Andrei] German Rheumatism Res Ctr DRFZ, AG Inflammat Biol, Berlin, Germany; [Hendrix, Sven] Univ Hasselt, Dept Funct Morphol, Hasselt, Belgium; [Hendrix, Sven] Univ Hasselt, Inst Biomed, Hasselt, Belgium	Schmitt, KRL (corresponding author), Deutsch Herzzentrum Berlin, Dept Pediat Cardiol, Clin Congenital Heart Dis & Pediat Cardiol, Augustenburger Pl 1, D-13353 Berlin, Germany.	kschmitt@dhzb.de	Kruglov, Andrey A/F-7543-2017; Kruglov, Andrey/AAP-2023-2021; Hendrix, Sven/F-4059-2010	Kruglov, Andrey A/0000-0002-4597-2087; Hendrix, Sven/0000-0003-2344-7369; Boato, Francesco/0000-0001-9741-8021; Berger, Felix/0000-0001-7881-1557	European union (EFRE)European Commission; Hasselt University [BOF09NI07]	The authors wish to thank Doreen Ludecke for excellent technical assistance and Anne Gale for editing the manuscript. NT-3 and NT-4 knockout mice [NT-3<SUP>+/+</SUP>/NT-4<SUP>-/-</SUP> and NT-3 +/-/NT-4<SUP>-/-</SUP>] were a kind gift from G. Lewin, Max-Delbruck Center for Molecular Medicine, Berlin-Buch, Germany, respectively. This study was supported in part by grants from the European union (EFRE) to KS and SH and by Hasselt University to SH (BOF09NI07). FB is a member of the Marie-Curie network CORTEX, DH was a member of GRK1258.	Abe K, 2003, BLOOD, V101, P1477, DOI 10.1182/blood.V101.4.1477; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Christian E, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E9; Clarke P, 2001, ONCOGENE, V20, P6910, DOI 10.1038/sj.onc.1204842; Diestel A, 2009, VASC PHARMACOL, V51, P246, DOI 10.1016/j.vph.2009.06.006; Diestel A, 2008, CRYOBIOLOGY, V57, P216, DOI 10.1016/j.cryobiol.2008.08.005; Ehrlich MP, 2002, ANN THORAC SURG, V73, P191, DOI 10.1016/S0003-4975(01)03273-8; Eyupoglu IY, 2003, BRAIN RES PROTOC, V11, P1, DOI 10.1016/S1385-299X(02)00186-1; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Ginis I, 2002, J CEREBR BLOOD F MET, V22, P142, DOI 10.1097/00004647-200202000-00002; Golz G, 2006, EUR J NEUROSCI, V24, P2721, DOI 10.1111/j.1460-9568.2006.05155.x; Goldberg DJ, 1996, PERSPECT DEV NEUROBI, V4, P183; Hechler D, 2006, BRAIN RES REV, V52, P160, DOI 10.1016/j.brainresrev.2006.01.005; Hendrix S, 2007, J NEUROIMMUNOL, V184, P113, DOI 10.1016/j.jneuroim.2006.11.020; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Holtje M, 2009, FASEB J, V23, P1115, DOI 10.1096/fj.08-116855; Jiang JY, 2006, J NEUROTRAUM, V23, P1847, DOI 10.1089/neu.2006.23.1847; Kirov SA, 2004, NEUROSCIENCE, V127, P69, DOI 10.1016/j.neuroscience.2004.04.053; Koizumi H, 1998, PATHOL INT, V48, P93, DOI 10.1111/j.1440-1827.1998.tb03877.x; Larsson K, 2005, SPINE, V30, P621, DOI 10.1097/01.brs.0000155410.48700.9e; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Marschinke F, 2008, BRAIN RES, V1215, P30, DOI 10.1016/j.brainres.2008.03.070; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; McGuire TR, 2001, BONE MARROW TRANSPL, V28, P889, DOI 10.1038/sj.bmt.1703238; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; POPOV VI, 1992, NEUROSCIENCE, V48, P45, DOI 10.1016/0306-4522(92)90336-Z; Schmitt FC, 2006, NEUROBIOL DIS, V23, P689, DOI 10.1016/j.nbd.2006.05.008; Schmitt KRL, 2007, NEUROSCI RES, V59, P68, DOI 10.1016/j.neures.2007.05.011; Schmitt KRL, 2006, NEUROSCI LETT, V404, P309, DOI 10.1016/j.neulet.2006.05.064; Schmitt KRL, 2007, J NEUROIMMUNOL, V189, P7, DOI 10.1016/j.jneuroim.2007.06.010; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Wang Y, 2002, BRAIN RES, V934, P7, DOI 10.1016/S0006-8993(02)02278-3	42	25	25	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	JUL	2010	20	4					771	779		10.1111/j.1750-3639.2009.00358.x			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	606BX	WOS:000278396800008	20070303				2021-06-18	
J	Yoganandan, N; Baisden, JL; Maiman, DJ; Gennarelli, TA; Guan, YB; Pintar, FA; Laud, P; Ridella, SA				Yoganandan, Narayan; Baisden, Jamie L.; Maiman, Dennis J.; Gennarelli, Thomas A.; Guan, Yabo; Pintar, Frank A.; Laud, Prakash; Ridella, Stephen A.			Severe-to-fatal head injuries in motor vehicle impacts	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Angular acceleration; Brain injuries; Contact loading; Impact biomechanics; Head trauma	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; UNITED-STATES; CRASHES; ASSOCIATION; COLLISIONS; ASSAULT; FALL; RISK	Severe-to-fatal head injuries in motor vehicle environments were analyzed using the United States Crash Injury Research and Engineering Network database for the years 1997-2006. Medical evaluations included details and photographs of injury, and on-scene, trauma bay, emergency room, intensive care unit, radiological, operating room, in-patient, and rehabilitation records. Data were synthesized on a case-by-case basis. X-rays, computed tomography scans, and magnetic resonance images were reviewed along with field evaluations of scene and photographs for the analyses of brain injuries and skull fractures. Injuries to the parenchyma, arteries, brainstem, cerebellum, cerebrum, and loss of consciousness were included. In addition to the analyses of severe-to-fatal (AIS4+) injuries, cervical spine, face, and scalp trauma were used to determine the potential for head contact. Fatalities and survivors were compared using nonparametric tests and confidence intervals for medians. Results were categorized based on the mode of impact with a focus on head contact. Out of the 3178 medical cases and 169 occupants sustaining head injuries, 132 adults were in frontal (54), side (75), and rear (3) crashes. Head contact locations are presented for each mode. A majority of cases clustered around the mid-size anthropometry and normal body mass index (BMI). Injuries occurred at change in velocities (Delta V) representative of US regulations. Statistically significant differences in Delta V between fatalities and survivors were found for side but not for frontal impacts. Independent of the impact mode and survivorship, contact locations were found to be superior to the center of gravity of the head, suggesting a greater role for angular than translational head kinematics. However, contact locations were biased to the impact mode: anterior aspects of the frontal bone and face were involved in frontal impacts while temporal-parietal regions were involved in side impacts. Because head injuries occur at regulatory Delta V in modern vehicles and angular accelerations are not directly incorporated in crashworthiness standards, these findings from the largest dataset in literature, offer a field-based rationale for including rotational kinematics in injury assessments. In addition. it may be necessary to develop injury criteria and evaluate dummy biofidelity based on contact locations as this parameter depended on the impact mode. The current field-based analysis has identified the importance of both angular acceleration and contact location in head injury assessment and mitigation. Published by Elsevier Ltd.	[Yoganandan, Narayan; Baisden, Jamie L.; Maiman, Dennis J.; Gennarelli, Thomas A.; Guan, Yabo; Pintar, Frank A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Laud, Prakash] Med Coll Wisconsin, Dept Biostat, Milwaukee, WI 53226 USA; [Ridella, Stephen A.] US Dept Transportat, NHTSA, Washington, DC USA	Yoganandan, N (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	yoga@mcw.edu					ADAMS JH, 1984, LANCET, V2, P1420; American Association for Automotive Medicine, 1990, ABBR INJ SCAL; Augenstein Jeffrey, 2003, Annu Proc Assoc Adv Automot Med, V47, P561; Bazarian JJ, 2004, ANN EMERG MED, V44, P142, DOI 10.1016/j.annemergmed.2004.03.029; Gennarelli T, 2002, P IRCOBI MUN GERM, P223; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENNARELLI TA, 1987, P 31 STAPP CAR CRASH, P49; Hodgson VR, 1983, P 27 STAPP CAR CRASH, P225; IMAJO T, 1992, AM J FOREN MED PATH, V13, P169; Imajo T, 1996, AM J FOREN MED PATH, V17, P324, DOI 10.1097/00000433-199612000-00010; IMAJO T, 1984, AM J FOREN MED PATH, V5, P217, DOI 10.1097/00000433-198409000-00005; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; McGwin G, 2003, J TRAUMA, V54, P1182, DOI 10.1097/01.TA.0000056165.49112.F4; MCLEAN AJ, 1995, J NEUROTRAUM, V12, P621, DOI 10.1089/neu.1995.12.621; MEANEY D, 1994, P IRCOBI LYON FRANC; Morris A, 1995, ACCIDENT ANAL PREV, V27, P749, DOI 10.1016/0001-4575(95)00020-8; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Siegel JH, 2001, J TRAUMA, V51, P975, DOI 10.1097/00005373-200111000-00024; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stitzel Joel D, 2007, Annu Proc Assoc Adv Automot Med, V51, P395; STRICH SJ, 1961, LANCET, V2, P443; Tagliaferri F, 2009, J TRAUMA, V66, P727, DOI 10.1097/TA.0b013e31815edefd; Wang Stewart C, 2003, Annu Proc Assoc Adv Automot Med, V47, P545; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yoganandan N, 2005, ACCIDENT ANAL PREV, V37, P505, DOI 10.1016/j.aap.2005.01.002; Yoganandan N, 2007, ACCIDENT ANAL PREV, V39, P22, DOI 10.1016/j.aap.2006.05.014; Yoganandan N, 2009, J TRAUMA, V66, P309, DOI 10.1097/TA.0b013e3181692104; Zhang Jiangyue, 2006, Annu Proc Assoc Adv Automot Med, V50, P1	29	25	25	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	JUL	2010	42	4					1370	1378		10.1016/j.aap.2010.02.017			9	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	607LD	WOS:000278504700051	20441854				2021-06-18	
J	Lescot, T; Fulla-Oller, L; Palmier, B; Po, C; Beziaud, T; Puybasset, L; Plotkine, M; Gillet, B; Meric, P; Marchand-Leroux, C				Lescot, Thomas; Fulla-Oller, Laurence; Palmier, Bruno; Po, Christelle; Beziaud, Tiphaine; Puybasset, Louis; Plotkine, Michel; Gillet, Brigitte; Meric, Philippe; Marchand-Leroux, Catherine			Effect of Acute Poly(ADP-Ribose) Polymerase Inhibition by 3-AB on Blood-Brain Barrier Permeability and Edema Formation after Focal Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; matrix metalloproteinase; nuclear magnetic resonance; poly(ADP-ribose) polymerase; traumatic brain injury		Recent evidence supports a crucial role for matrix metalloproteinase-9 (MMP-9) in blood-brain barrier (BBB) disruption and vasogenic edema formation after traumatic brain injury (TBI). Although the exact causes of MMP-9 upregulation after TBI are not fully understood, several arguments suggest a contribution of the enzyme poly(ADP-ribose) polymerase (PARP) in the neuroinflammatory response leading to MMP-9 activation. The objectives of this study were to evaluate the effect of PARP inhibition by 3-aminobenzamide (3-AB) (1) on MMP-9 upregulation and BBB integrity, (2) on edema formation as assessed by magnetic resonance imaging (MRI), (3) on neuron survival as assessed by H-1 magnetic resonance spectroscopy (H-1-MRS), and (4) on neurological deficits at the acute phase of TBI. Western blots and zymograms showed blunting of MMP-9 upregulation 6 h after TBI. BBB permeability was decreased at the same time point in 3-AB-treated rats compared to vehicle-treated rats. Cerebral MRI showed less "free" water in 3-AB-treated than in vehicle-treated rats 6 h after TBI. MRI findings 24 h after TBI indicated predominant cytotoxic edema, and at this time point no significant differences were found between 3-AB-and vehicle-treated rats with regard to MMP-9 upregulation, BBB permeability, or MRI changes. At both 6 and 24 h, neurological function was better in the 3-AB-treated than in the vehicle-treated rats. These data suggest that PARP inhibition by 3-AB protected the BBB against hyperpermeability induced by MMP-9 upregulation, thereby decreasing vasogenic edema formation 6 h after TBI. Furthermore, our data confirm the neuroprotective effect of 3-AB at the very acute phase of TBI.	[Lescot, Thomas; Palmier, Bruno; Beziaud, Tiphaine; Plotkine, Michel; Marchand-Leroux, Catherine] Univ Paris 05, Equipe Rech Pharmacol Circulat Cerebrale EA 2510, Fac Sci Pharmaceut & Biol, F-75006 Paris, France; [Lescot, Thomas; Fulla-Oller, Laurence; Puybasset, Louis] Grp Hosp Pitie Salpetriere, AP HP, Dept Anesthesie Reanimat, F-75634 Paris, France; [Lescot, Thomas; Fulla-Oller, Laurence; Puybasset, Louis] Univ Paris 06, Paris, France; [Fulla-Oller, Laurence; Po, Christelle; Gillet, Brigitte; Meric, Philippe] CNRS, Inst Chim Subst Nat, Lab Resonance Magnet Nucl Biol, Gif Sur Yvette, France	Lescot, T (corresponding author), Univ Paris 05, Equipe Rech Pharmacol Circulat Cerebrale EA 2510, Fac Sci Pharmaceut & Biol, 4 Ave Observ, F-75006 Paris, France.	thomas.lescot@psl.aphp.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Po, Chrystelle/0000-0001-9785-9572	nonprofit organization Fondation des Gueules Cassees	The authors are very grateful to Dr. Antoinette Wolfe for helping to prepare the manuscript. This work was supported by the nonprofit organization Fondation des Gueules Cassees (grants to T.L. and L.F.O.).	Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BEDERSON JB, 1986, J NEUROSURG, V64, P795, DOI 10.3171/jns.1986.64.5.0795; Besson VC, 2005, BRAIN RES, V1041, P149, DOI 10.1016/j.brainres.2005.01.096; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Couturier JY, 2003, EXP NEUROL, V184, P973, DOI 10.1016/S0014-4886(03)00367-4; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GUIMARAES AR, 1995, NEUROSCIENCE, V69, P1095, DOI 10.1016/0306-4522(95)00300-8; Haddad M, 2008, EUR J PHARMACOL, V588, P52, DOI 10.1016/j.ejphar.2008.04.013; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kawai N, 2003, J NEUROTRAUM, V20, P649, DOI 10.1089/089771503322144563; Koh SH, 2005, TOXICOLOGY, V214, P131, DOI 10.1016/j.tox.2005.06.023; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; LEBIHAN D, 1988, MAGNET RESON MED, V7, P346, DOI 10.1002/mrm.1910070312; Lenzser G, 2007, J CEREBR BLOOD F MET, V27, P1318, DOI 10.1038/sj.jcbfm.9600437; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; Naressi A, 2001, COMPUT BIOL MED, V31, P269, DOI 10.1016/S0010-4825(01)00006-3; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SKAPER SD, 2003, ANN NY ACAD SCI, P217; SKAPER SD, 2003, ANN NY ACAD SCI, P287; Thompson WRE, 2005, ORAL ONCOL, V1, P75, DOI 10.1016/S1744-7895(05)80156-7; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; WANG J, 2005, BRAIN PT, V7, P1622; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008	38	25	29	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1069	1079		10.1089/neu.2009.1188			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300010	20380552				2021-06-18	
J	Di Russo, F; Spinelli, D				Di Russo, Francesco; Spinelli, Donatella			Sport is not always healthy: Executive brain dysfunction in professional boxers	PSYCHOPHYSIOLOGY			English	Article						Brain trauma; ERPs; Executive control; Sport; Boxing	RESPONSE SELECTION; AMATEUR BOXERS; INJURY; P300; TASK; DISCRIMINATION; CONCUSSION; DEFICITS; CORTEX; DAMAGE	We measured ERPs of professional boxers in a Go/No-Go task, comparing them to fencers and non-athletes. Results showed that fencing improved attention and motor response control, but boxing did not. More strikingly, in boxers, as in brain trauma patients, the P3 component was delayed and reduced. The P3 delay of boxers was correlated with the amount of performed sport exercise. Furthermore, in terms of behavior, boxers showed increased intra-individual variability and switch cost. Results were consistent with the hypothesis of specific impairment at the level of response inhibition processing. We suggest that this impairment is derived from the cumulative effect of blows to the head. The changes found in boxers suggest that ERPs and reaction times may be a tool for early detection of specific brain dysfunction.	[Di Russo, Francesco] Univ Rome Foro Italico, Dept Educ Sci Motor Act & Sport, I-00194 Rome, Italy; IRCCS, Santa Lucia Fdn, Neuropsychol Lab, Rome, Italy	Di Russo, F (corresponding author), Univ Rome Foro Italico, Dept Educ Sci Motor Act & Sport, Largo Lauro De Bosis 15, I-00194 Rome, Italy.	francesco.dirusso@iusm.it	Di Russo, Francesco/N-6686-2015	Di Russo, Francesco/0000-0002-3127-9433; SPINELLI, Donatella/0000-0002-4890-6931	MIURMinistry of Education, Universities and Research (MIUR) [PRIN 2007]	Support was provided by PRIN 2007 MIUR grant. Thanks to M. Di Sera. no for his contributions to subject recruitment.	Aron AR, 2004, BRAIN, V127, P1561, DOI 10.1093/brain/awh169; Bekker EM, 2005, COGNITIVE BRAIN RES, V22, P221, DOI 10.1016/j.cogbrainres.2004.08.011; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BRETON F, 1991, BIOL PSYCHOL, V3, P57; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Di Russo F, 2005, MED SCI SPORT EXER, V37, P1586, DOI 10.1249/01.mss.0000177458.71676.0d; Di Russo F, 2006, NEUROSCI LETT, V408, P113, DOI 10.1016/j.neulet.2006.08.085; Dias EC, 2003, CEREB CORTEX, V13, P701, DOI 10.1093/cercor/13.7.701; Dien J, 2004, PSYCHOPHYSIOLOGY, V41, P665, DOI 10.1111/j.1469-8986.2004.00193.x; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Fallgatter AJ, 1999, INT J PSYCHOPHYSIOL, V32, P233, DOI 10.1016/S0167-8760(99)00018-5; Gajewski PD, 2008, BRAIN RES, V1189, P127, DOI 10.1016/j.brainres.2007.10.076; Giugni E, 2005, AM J NEURORADIOL, V26, P1140; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; HAENEL S, 2008, IMAGING AM SOC NEURO, V29, P88; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Loosemore M, 2007, BMJ-BRIT MED J, V335, P809, DOI 10.1136/bmj.39342.690220.55; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P334, DOI 10.1111/j.1469-8986.1996.tb01058.x; RAYLE C, 2006, J NEUROSCI, V4, P186; RITTER W, 1982, SCIENCE, V218, P909, DOI 10.1126/science.7134983; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Rossini PM, 2007, PROG NEUROBIOL, V83, P375, DOI 10.1016/j.pneurobio.2007.07.010; Rushworth MFS, 2001, J NEUROSCI, V21, P5262, DOI 10.1523/JNEUROSCI.21-14-05262.2001; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Verleger R, 2005, J PSYCHOPHYSIOL, V19, P165, DOI 10.1027/0269-8803.19.3.165; Vogel EK, 2000, PSYCHOPHYSIOLOGY, V37, P190, DOI 10.1111/1469-8986.3720190; Zimmermann P, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P110	33	25	26	0	15	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0048-5772			PSYCHOPHYSIOLOGY	Psychophysiology	MAY	2010	47	3					425	434		10.1111/j.1469-8986.2009.00950.x			10	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	579VY	WOS:000276406100004	20030763	Green Published			2021-06-18	
J	Mealings, M; Douglas, J				Mealings, Margaret; Douglas, Jacinta			'School's a big part of your life ... ': Adolescent Perspectives of Their School Participation Following Traumatic Brain Injury	BRAIN IMPAIRMENT			English	Article						traumatic brain injury; adolescent; student	STUDENTS; CHILDREN; REHABILITATION; EDUCATION; PREDICTORS; CHILDHOOD; SERVICES; OUTCOMES; TBI	Sustaining a traumatic brain injury (TBI) as an adolescent has a significant impact on life roles and most notably on that of school participation. In the literature there is a wide range of studies that provide clinicians with information regarding recommendations for assisting students in their return to school. However this information has predominantly been provided from the perspectives of educators and rehabilitation staff. The aim of this preliminary project was to hear the stories of three male adolescent students as they reflected on their own experiences of what it was like to go back to school after sustaining a severe TBI. Using a qualitative research design and in-depth interviews, the students' stories were transcribed and coded using grounded theory principles. Despite persisting communication difficulties, the students were able to provide rich stories indicative of their personal experiences. Three key themes emerged from the interviews: the adolescent student's sense of self, changes the students noted; and supports the students identified. A tentative model illustrating the relationship between these areas was developed. It is anticipated that this model will assist clinicians and educators to develop a holistic picture of a student's school participation from transition to ongoing school life.	[Mealings, Margaret] Epworth Healthcare, Melbourne, Vic, Australia; [Mealings, Margaret; Douglas, Jacinta] La Trobe Univ, Bundoora, Vic 3086, Australia	Mealings, M (corresponding author), Epworth Rehabil, Community Integrat Team, 89 Bridge Rd, Richmond, Vic 3121, Australia.	margaret.mealings@epworth.org.au		Douglas, Jacinta/0000-0003-0940-6624			Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; [Anonymous], 2009, EC COST SPINAL CORD, P1; Backhouse M, 1999, AUST OCCUP THER J, V46, P99, DOI DOI 10.1046/J.1440-1630.1999.00183.X; Beaulieu CL, 2002, SURG CLIN N AM, V82, P393, DOI 10.1016/S0039-6109(02)00009-9; Bedell G, 2008, J HEAD TRAUMA REHAB, V23, P220, DOI 10.1097/01.HTR.0000327254.61751.e7; Blosser J, 1997, J HEAD TRAUMA REHAB, V12, P21, DOI 10.1097/00001199-199704000-00004; Blosser J, 2003, PEDIAT TRAUMATIC BRA; Blosser JL, 1991, J HEAD TRAUMA REHAB, V6, P73; BROWNE J, 2004, HDB RES METHODS NURS; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Clark E, 1996, J LEARN DISABIL, V29, P549, DOI 10.1177/002221949602900509; Corbin J, 1998, BASICS QUALITATIVE R; DAmato RC, 1996, J LEARN DISABIL, V29, P670, DOI 10.1177/002221949602900611; Farmer J., 1996, 5 C INT ASS STUD BRA; Farmer JE, 1996, J LEARN DISABIL-US, V29, P532, DOI 10.1177/002221949602900508; Feeney T., 1997, STUDENTS ACQUIRED BR; Gfroerer SD, 2008, BRAIN INJURY, V22, P649, DOI 10.1080/02699050802227162; Glang A, 2004, NEUROREHABILITATION, V19, P219; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Heiman T, 2003, J LEARN DISABIL-US, V36, P248, DOI 10.1177/002221940303600304; Helps Y., 2008, INJURY RES STAT SERI, V45; Johnson P, 2006, BRAIN COGNITION, V60, P205; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; Kao Hsueh-Fen S, 2004, J Neurosci Nurs, V36, P73; Kennedy M, 2008, NEUROREHABILITATION, V23, P219; King Gillian, 2002, Physical and Occupational Therapy in Pediatrics, V22, P53, DOI 10.1300/J006v22n02_04; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Lloyd V, 2006, QUAL HEALTH RES, V16, P1386, DOI 10.1177/1049732306293846; Maddren E.K., 1996, 5 C INT ASS STUD TRA; McGavin Heather, 1998, Physical and Occupational Therapy in Pediatrics, V18, P69, DOI 10.1300/J006v18n01_05; McMahon MA, 2001, J HEAD TRAUMA REHAB, V16, P587, DOI 10.1097/00001199-200112000-00006; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Minichiello V., 2004, HDB RES METHODS NURS, P59; Morse J., 2002, READ ME 1 USERS GUID; Parkin AE., 1996, AUSTR OCCUPATIONAL T, V43, P133; Patton M.Q., 2002, QUALITATIVE RES EVAL; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; Savage RC, 1997, J HEAD TRAUMA REHAB, V12, P11, DOI 10.1097/00001199-199704000-00003; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Stewart-Scott AM, 1998, BRAIN INJURY, V12, P317, DOI 10.1080/026990598122629; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Todis B., 1997, STUDENTS ACQUIRED BR; Todis B, 2008, J HEAD TRAUMA REHAB, V23, P252, DOI 10.1097/01.HTR.0000327257.84622.bc; Vaidya A., 2002, COGNITIVE TECHNOLOGY, V7, P38; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; *WHO, INT CLASS FUNCT; Yates L., 2008, KEEP CONN YOUNG PEOP; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; Ylvisaker Mark, 2007, Phys Med Rehabil Clin N Am, V18, P133, DOI 10.1016/j.pmr.2006.11.007	52	25	25	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	MAY	2010	11	1					1	16		10.1375/brim.11.1.1			16	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	V24IR	WOS:000208404600001					2021-06-18	
J	Pavlovic, D; Pekic, S; Stojanovic, M; Zivkovic, V; Djurovic, B; Jovanovic, V; Miljic, N; Medic-Stojanoska, M; Doknic, M; Miljic, D; Djurovic, M; Casanueva, F; Popovic, V				Pavlovic, D.; Pekic, S.; Stojanovic, M.; Zivkovic, V.; Djurovic, B.; Jovanovic, V.; Miljic, N.; Medic-Stojanoska, M.; Doknic, M.; Miljic, D.; Djurovic, M.; Casanueva, F.; Popovic, V.			Chronic cognitive sequelae after traumatic brain injury are not related to growth hormone deficiency in adults	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						brain injury; cognition; growth hormone deficiency; hypopituitarism; neuroendocrine dysfunction	ANEURYSMAL SUBARACHNOID HEMORRHAGE; GH-RELEASING HORMONE; FUNCTIONAL CONNECTIVITY; FACTOR-I; HYPOPITUITARISM; PERFORMANCE; DYSFUNCTION; RECEPTORS; REPLACEMENT; HIPPOCAMPUS	Objective: The objective of the study was to asses the possible influence of hypothalamo-pituitary deficiencies, and growth hormone (GH) deficiency in particular, on cognition in adult patients with traumatic brain injury (TBI). TBI is a recently identified risk factor for cognitive deficits and hypopituitarism. Even the patients with favorable outcome after TBI may present with persistent bodily, psychosocial, and cognitive impairments, resembling patients with untreated partial or complete pituitary insufficiency. Design: We performed retrospective and cross-sectional study of endocrine and cognitive function in TBI in 61 patients (aged 37.7 +/- 1.7 years) of both sexes (44 m,17 f), at least 1 year after TBI (3.9 +/- 0.6 years). Serum insulin-like growth factor 1 (IGF-I), thyroxin, thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone (in men), prolactin, and cortisol were measured, and GH secretion was assessed by growth hormone releasing hormone (GHRH) + growth hormone releasing peptide-6 (GHRP-6) test. Cognitive function was assessed by using a standard neuropsychological battery. Results: GH deficiency (GHD) and GH insufficiency (GHI) were found in 20 patients (32.8%). After adjustment for confounders [age, body mass index (BMI), education level, time elapsed from TBI], there were no significant differences in results of neuropsychological tests between patients with TBI with GHD, GHI, and normal GH secretion. There were no correlations of neuropsychological variables with stimulated peak GH secretion or IGF-I level. Conclusions: GHD persists long after the TBI, independently of trauma severity and age at traumatic event. GH secretion is more sensitive to TBI than other pituitary hormones. No evidence is found for an association of cognitive function impairment and somatotropic axis impairment in adult patients tested more than 1 year after the TBI.	[Pavlovic, D.] Univ Clin Ctr, Inst Neurol, Belgrade 11000, Serbia; [Pekic, S.; Stojanovic, M.; Zivkovic, V.; Doknic, M.; Miljic, D.; Djurovic, M.; Popovic, V.] Univ Clin Ctr, Inst Endocrinol, Belgrade 11000, Serbia; [Djurovic, B.; Jovanovic, V.] Univ Clin Ctr, Inst Neurosurg, Belgrade 11000, Serbia; [Miljic, N.] Fac Med, Inst Med Stat & Hlth Res, Belgrade, Serbia; [Medic-Stojanoska, M.] Univ Novi Sad, Inst Endocrinol, Novi Sad 21000, Serbia; [Casanueva, F.] Univ Santiago de Compostela, Endocrine Sect, Complejo Hosp, Santiago De Compostela, Spain	Pavlovic, D (corresponding author), Univ Clin Ctr, Inst Neurol, Dr Subotica 6, Belgrade 11000, Serbia.	dpavlovic53@hotmail.com	Pekic, Sandra/S-7175-2016		Ministry of Science of Republic of SerbiaMinistry of Science, Serbia [145019]	This study was supported by a grant from the Ministry of Science of Republic of Serbia (Project 145019).	ADEM A, 1989, BRAIN RES, V503, P299, DOI 10.1016/0006-8993(89)91678-8; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Bulow B, 2002, CLIN ENDOCRINOL, V56, P183, DOI 10.1046/j.0300-0664.2001.01461.x; Clayton P, 2007, GROWTH HORM IGF RES, V17, P369, DOI 10.1016/j.ghir.2007.04.010; DANIEL PM, 1959, LANCET, V2, P927; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Fernandez S, 2007, GROWTH HORM IGF RES, V17, P89, DOI 10.1016/j.ghir.2007.01.006; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gentry LR., 1996, MAGNETIC RESONANCE I, P611; Heaton R., 1981, MANUAL WISCONSIN CAR; Kaplan E, 1978, BOSTON NAMING TEST; Kelestimur F, 2006, CLIN ENDOCRINOL, V64, P667, DOI 10.1111/j.1365-2265.2006.02525.x; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; LAI ZN, 1991, BRAIN RES, V546, P222, DOI 10.1016/0006-8993(91)91485-J; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Link K, 2006, CLIN ENDOCRINOL, V65, P617, DOI 10.1111/j.1365-2265.2006.02637.x; Micic D, 1998, J CLIN ENDOCR METAB, V83, P2569, DOI 10.1210/jc.83.7.2569; Nyberg F, 2000, FRONT NEUROENDOCRIN, V21, P330, DOI 10.1006/frne.2000.0200; Nyberg F, 1996, HORM RES, V45, P18, DOI 10.1159/000184753; Oertel H, 2004, PSYCHONEUROENDOCRINO, V29, P839, DOI 10.1016/S0306-4530(03)00151-3; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Ranganath C, 2005, HIPPOCAMPUS, V15, P997, DOI 10.1002/hipo.20141; Reitan R.M., 1993, HALSTEADREITAN NEURO; Rey A, 1964, EXAMEN CLIN PSYCHOL; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; SmithSeemiller L, 1997, BRAIN INJURY, V11, P191; Soares CDN, 1999, ARQ NEURO-PSIQUIAT, V57, P182; Stein T, 2000, AM J NEURORADIOL, V21, P1397; Svensson AL, 2008, P NATL ACAD SCI USA, V105, P7304, DOI 10.1073/pnas.0802531105; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; VANCE ML, 1994, NEW ENGL J MED, V330, P1651, DOI 10.1056/NEJM199406093302306; Vogenthaler D R, 1987, Brain Inj, V1, P113	35	25	27	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	MAY	2010	17	5					696	702		10.1111/j.1468-1331.2009.02910.x			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	582NE	WOS:000276603700012	20050894				2021-06-18	
J	Dimoska, A; McDonald, S; Pell, MC; Tate, RL; James, CM				Dimoska, A.; McDonald, S.; Pell, M. C.; Tate, R. L.; James, C. M.			Recognizing vocal expressions of emotion in patients with social skills deficits following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Emotion perception; Prosody; Semantic; Inhibitory control; Filtered; Nonsense	BLUNT HEAD-INJURY; AFFECTIVE PROSODY; FACIAL EXPRESSION; NEURAL RESPONSE; RECOGNITION; PERCEPTION; SPEECH; LATERALIZATION; LANGUAGE; FMRI	Perception of emotion in voice is impaired following traumatic brain injury (TBI). This Study examined whether an inability to concurrently process semantic information (the "what") and emotional prosody (the "how") of spoken speech contributes to impaired recognition of emotional prosody and whether impairment is ameliorated when little or no semantic information is provided. Eighteen individuals with mod crate-to-severe TBI showing social skills deficits during inpatient rehabilitation were compared with 18 demographically matched controls. Participants completed two discrimination tasks using spoken sentences that varied in the amount of semantic information: that is, (I) well-formed English, (2) a nonsense language, and (3) low-pass filtered speech producing "muffled" voices. Reducing semantic processing demands did not improve perception of emotional prosody. The TBI group were significantly less accurate than controls. Impairment was greater within the TB I group when accessing semantic memory to label the emotion of sentences, compared with simply making "same/different" judgments. Findings suggest an impairment of processing emotional prosody itself rather than semantic processing demands which leads to an over-reliance oil the "what" rather than the "how," in conversational remarks. Emotional recognition accuracy was significantly related to the ability to inhibit prepotent responses, consistent with neuroanatomical research suggesting similar ventrofrontal systems subserve both functions. (JINS, 2010, 16, 369-382.)	[Dimoska, A.; McDonald, S.; James, C. M.] Univ New S Wales, Sch Psychol, Kensington, NSW 2052, Australia; [Pell, M. C.] McGill Univ, Sch Commun Sci & Disorders, Montreal, PQ H3G 1A8, Canada; [Tate, R. L.] Univ Sydney, Rehabil Studies Unit, No Cent Clin Sch, Sydney, NSW 2006, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Kensington, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014; Pell, Marc D./AAL-3121-2021	McDonald, Skye/0000-0003-0723-6094; Pell, Marc D./0000-0002-9947-1552	National Health & Medical Research Council of AustraliaNational Health and Medical Research Council of Australia	This research was supported by a project grant from the National Health & Medical Research Council of Australia. We express our gratitude to people with traumatic brain injuries who participated in the Studies reported here as well as to our community control participants who gave willingly of' their time. The authors have no competing or conflicts of interest to report.	Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs Ralph, 2002, Behav Cogn Neurosci Rev, V1, P21, DOI 10.1177/1534582302001001003; Baum SR, 1999, APHASIOLOGY, V13, P581, DOI 10.1080/026870399401957; Beaucousin V, 2007, CEREB CORTEX, V17, P339, DOI 10.1093/cercor/bhj151; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BEHRENS SJ, 1985, BRAIN LANG, V26, P332, DOI 10.1016/0093-934X(85)90047-1; Besle J, 2004, EUR J NEUROSCI, V20, P2225, DOI 10.1111/j.1460-9568.2004.03670.x; Besson M, 2002, TRENDS COGN SCI, V6, P405, DOI 10.1016/S1364-6613(02)01975-7; Boersma P, 2007, PRAAT MANUAL VERSION; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; BOWERS D, 1987, NEUROPSYCHOLOGIA, V25, P317, DOI 10.1016/0028-3932(87)90021-2; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Buchanan TW, 2000, COGNITIVE BRAIN RES, V9, P227, DOI 10.1016/S0926-6410(99)00060-9; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Creusere M, 2004, J COMMUN DISORD, V37, P5, DOI 10.1016/S0021-9924(03)00036-4; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; DAMASIO AR, 1994, SCI AM, V271, P144, DOI 10.1038/scientificamerican1094-144; de Gelder B, 2000, COGNITION EMOTION, V14, P289, DOI 10.1080/026999300378824; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Dujardin K, 2004, NEUROPSYCHOLOGIA, V42, P239, DOI 10.1016/S0028-3932(03)00154-4; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; EKMAN P, 1976, PICTURES FACIAL EFFE; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Freedman M, 1998, CEREB CORTEX, V8, P18, DOI 10.1093/cercor/8.1.18; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Grandjean D, 2005, NAT NEUROSCI, V8, P145, DOI 10.1038/nn1392; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Grimshaw GM, 1998, BRAIN COGNITION, V36, P108, DOI 10.1006/brcg.1997.0949; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hariri AR, 2000, NEUROREPORT, V11, P43, DOI 10.1097/00001756-200001170-00009; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HEILMAN KM, 1984, NEUROLOGY, V34, P917, DOI 10.1212/WNL.34.7.917; Hess U., 1988, FACETS EMOTION RECEN, P161; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; JERGER S, 1993, PERCEPT PSYCHOPHYS, V54, P310, DOI 10.3758/BF03205266; Johnstone T, 2006, SOC COGN AFFECT NEUR, V1, P242, DOI 10.1093/scan/nsl027; Kaganovich N, 2006, BRAIN RES, V1114, P161, DOI 10.1016/j.brainres.2006.07.049; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Koff E, 1999, J INT NEUROPSYCH SOC, V5, P32, DOI 10.1017/S1355617799511053; Kotz SA, 2003, BRAIN LANG, V86, P366, DOI 10.1016/S0093-934X(02)00532-1; LALANDE S, 1992, BRAIN LANG, V42, P165, DOI 10.1016/0093-934X(92)90123-V; Langenecker SA, 2005, J CLIN EXP NEUROPSYC, V27, P320, DOI 10.1080/13803390490490515720; Leinonen L, 1997, J ACOUST SOC AM, V102, P1853, DOI 10.1121/1.420109; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lew H, 1997, J Am Acad Audiol, V8, P104; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; Martin I, 2004, J AUTISM DEV DISORD, V34, P311, DOI 10.1023/B:JADD.0000029553.52889.15; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; McHugh L, 2008, BRAIN INJURY, V22, P715, DOI 10.1080/02699050802263027; Meyer M, 2002, HUM BRAIN MAPP, V17, P73, DOI 10.1002/hbm.10042; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Mitchell RLC, 2008, NEUROPSYCHOLOGIA, V46, P2880, DOI 10.1016/j.neuropsychologia.2008.05.024; Mitchell RLC, 2003, NEUROPSYCHOLOGIA, V41, P1410, DOI 10.1016/S0028-3932(03)00017-4; MORGAN ALR, 1989, BRAIN LANG, V36, P592, DOI 10.1016/0093-934X(89)90088-6; OSCHNER KN, 2001, EMOTIONS CURRENT ISS, P38; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Pell MD, 2003, COGN AFFECT BEHAV NE, V3, P275, DOI 10.3758/CABN.3.4.275; Pell MD, 2009, J PHONETICS, V37, P417, DOI 10.1016/j.wocn.2009.07.005; Pell MD, 1997, BRAIN LANG, V57, P80, DOI 10.1006/brln.1997.1638; Pell MD, 2006, BRAIN LANG, V96, P221, DOI 10.1016/j.bandl.2005.04.007; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; Ross ED, 1997, BRAIN LANG, V56, P27, DOI 10.1006/brln.1997.1731; Ross ED, 2008, BRAIN LANG, V104, P51, DOI 10.1016/j.bandl.2007.04.007; Roth PL, 1999, ORGAN RES METHODS, V2, P211, DOI 10.1177/109442819923001; Scherer KR, 2003, SPEECH COMMUN, V40, P227, DOI 10.1016/S0167-6393(02)00084-5; SCHLANGER BB, 1976, BRAIN LANG, V3, P396, DOI 10.1016/0093-934X(76)90035-3; Scott SK, 1997, NATURE, V385, P254, DOI 10.1038/385254a0; Shallice, 1997, HAYLING BRIXTON TEST; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; Steinhauer K, 1999, NAT NEUROSCI, V2, P191, DOI 10.1038/5757; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TOMPKING CA, 1985, J SPEECH HEAR RES, V28, P527, DOI 10.1044/jshr.2804.527; Uekermann J, 2005, CORTEX, V41, P189, DOI 10.1016/S0010-9452(08)70893-1; VOGT BA, 1986, CEREB CORTEX, V4, P89; Votruba KL, 2008, J HEAD TRAUMA REHAB, V23, P65, DOI 10.1097/01.HTR.0000314525.93381.69; Wambacq IJA, 2004, COGNITIVE BRAIN RES, V20, P427, DOI 10.1016/j.cogbrainres.2004.03.015; Zupan B, 2009, J COMMUN DISORD, V42, P1, DOI 10.1016/j.jcomdis.2008.06.001	93	25	27	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2010	16	2					369	382		10.1017/S1355617709991445			14	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	562DZ	WOS:000275030900018	20128951				2021-06-18	
J	Kosch, Y; Browne, S; King, C; Fitzgerald, J; Cameron, I				Kosch, Y.; Browne, S.; King, C.; Fitzgerald, J.; Cameron, I.			Post-traumatic amnesia and its relationship to the functional outcome of people with severe traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; post-traumatic amnesia; outcome; length of stay	CLOSED-HEAD INJURY; INDEPENDENCE MEASURE; MEDICAL REHABILITATION; RELIABILITY; VALIDATION; SYSTEM	Objective: To investigate the relationship between Post-Traumatic Amnesia (PTA) duration, length of stay and functional outcomes in Australian in-patients with severe traumatic brain injury (TBI). Design: Retrospective, descriptive study using prospectively collected data from the Uniform Data Set for Medical Rehabilitation (UDSMR). Methods: Prospective collection of Westmead PTA scores and analysis of database for admissions for primary TBI rehabilitation from 1993-2003. Functional Independence Measure (FIM) was used to measure functional outcome. Statistical analysis using SPSS Version 13. Results: Six hundred and thirty-eight consecutive admissions; 611 patients had PTA classified by ranges, 436 of whom had an exact number of PTA days. Mean age 37.6 years; more than 90% had a PTA duration greater than 1 week. Significant predictors of discharge FIM scores and total length of hospitalization were PTA duration, admission FIM scores and acute length of hospitalization. Conclusions: PTA duration correlates with length of hospitalization and discharge function. PTA duration affects recovery rate. Implications include use of PTA duration for prognosticating, discharge planning and funding systems.	[Kosch, Y.; Browne, S.; King, C.; Fitzgerald, J.; Cameron, I.] Royal Rehabil Ctr Sydney, Brain Injury Unit, Ryde, NSW, Australia	Kosch, Y (corresponding author), Liverpool Hosp, Brain Injury Unit, Locked Bag 7103, Bc, NSW 1871, Australia.	yvette.kosch@sswahs.nsw.gov.au					Ahmed S, 2000, BRAIN INJURY, V14, P765; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Frey KL, 2007, BRAIN INJURY, V21, P513, DOI 10.1080/02699050701311026; GRANGER CV, 1992, AM J PHYS MED REHAB, V71, P108, DOI 10.1097/00002060-199204000-00009; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; GRANGER CV, 1997, GUIDE UNIFORM DATA M; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Marosszeky NEV, 1998, PTA PROTOCOL GUIDELI; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; RUSSEL WR, 1935, LANCET           OCT, P762; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Shores E A, 1995, Appl Neuropsychol, V2, P167; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; STINEMAN MG, 1994, MED CARE, V32, P366, DOI 10.1097/00005650-199404000-00005; STINEMAN MG, 1994, ARCH PHYS MED REHAB, V75, P1277; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; TATE R, BRAIN INJURY OUTCOME; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; Tate RL., 2000, BRAIN IMPAIR, V1, P116; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	31	25	26	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2010	24	3					479	485		10.3109/02699051003610417			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	574JR	WOS:000275985800004	20184405				2021-06-18	
J	Newsome, MR; Scheibel, RS; Hanten, G; Chu, Z; Steinberg, JL; Hunter, JV; Lu, HZ; Vasquez, AC; Li, XQ; Lin, XD; Cook, L; Levin, HS				Newsome, Mary R.; Scheibel, Randall S.; Hanten, Gerri; Chu, Z.; Steinberg, Joel L.; Hunter, Jill V.; Lu, Hanzhang; Vasquez, Ana C.; Li, Xiaoqi; Lin, Xiaodi; Cook, Lori; Levin, Harvey S.			Brain Activation While Thinking About the Self From Another Person's Perspective After Traumatic Brain Injury in Adolescents	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; fMRI; social cognition; adolescents	CLOSED-HEAD-INJURY; EMOTION RECOGNITION; EXECUTIVE FUNCTION; CHILDREN; MIND; CHILDHOOD; MEMORY; TERM; IMPAIRMENTS; AWARENESS	Deficits in self awareness and taking the perspective of others are often observed following traumatic brain injury (TBI). Nine adolescents (ages 12-19 years) who had sustained moderate to severe TBI after an average interval of 2.6 years and nine typically developing (TD) adolescents underwent functional MRI (fMRI) while performing a perspective taking task (D'Argembeau et al., 2007). Participants made trait attributions either from their own perspective or from that of the significant other. The groups did not differ in reaction time or on a consistency criterion. When thinking of the self from a third-person perspective, adolescents with TBI demonstrated greater activation in posterior brain regions implicated in social cognition, the left lingual gyrus (BA 18) and posterior cingulate (BA 31), extending into neighboring regions not generally associated with social cognition, that is, cuneus (BA 31) and parahippocampal gyros, relative to TD adolescents. We postulate that adolescents with moderate to severe TBI recruited alternative neural pathways during perspective-taking because traumatic axonal injury disrupted their fronto-parietal networks mediating social cognition.	[Newsome, Mary R.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Chu, Z.; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Chu, Z.; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Steinberg, Joel L.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX USA; [Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX USA; [Cook, Lori] Univ Texas Dallas, Ctr BrainHlth, Richardson, TX 75083 USA	Newsome, MR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	mnewsome@bcm.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS021889, R01 NS021889-26A1, R01 NS021889-18, R01 NS021889-23, R01 NS021889-17S2, R01 NS021889-27, R01 NS021889-21A1S1, R01 NS021889-24S1, R01 NS021889-21A1, R01 NS021889-22, R01 NS021889-19, R01 NS021889-28, R01 NS021889-20, R01 NS021889-18S1, R01 NS021889-17, R01 NS021889-25, R01 NS021889-23S1A1, R01 NS021889-17S1, R01 NS021889-24, NS021889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Allen P, 2008, J COGNITIVE NEUROSCI, V20, P1656, DOI 10.1162/jocn.2008.20107; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Bohnert AM, 2007, J ABNORM CHILD PSYCH, V35, P1021, DOI 10.1007/s10802-007-9152-1; BRETT M, 1999, MNI BRAIN TALAIRACH; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; D'Argembeau A, 2005, NEUROIMAGE, V25, P616, DOI 10.1016/j.neuroimage.2004.11.048; D'Argembeau A, 2007, J COGNITIVE NEUROSCI, V19, P935, DOI 10.1162/jocn.2007.19.6.935; DAMON W, 1982, CHILD DEV, V53, P841, DOI 10.2307/1129122; Damon W., 1988, SELF UNDERSTANDING C; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Eliassen JC, 2008, EPILEPSY BEHAV, V13, P463, DOI 10.1016/j.yebeh.2008.06.011; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V2, P823; Grizenko N, 2000, AM J ORTHOPSYCHIAT, V70, P501, DOI 10.1037/h0087662; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Haldane M, 2008, J PSYCHOPHARMACOL, V22, P138, DOI 10.1177/0269881107082955; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Leonard B, 2009, NEUROIMAGE, V45, P572, DOI 10.1016/j.neuroimage.2008.11.017; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Macdonald S, 2005, BRAIN INJURY, V19, P895, DOI 10.1080/02699050400004294; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; MUSCARA F, 2008, NEUROPSYCHOLOGICAL R, V1; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Parker J. G., 2006, DEV PSYCHOPATHOLOGY, P419, DOI DOI 10.1002/9780470939383.CH12; Perfetti B, 2009, HUM BRAIN MAPP, V30, P497, DOI 10.1002/hbm.20519; Pfeifer JH, 2007, J COGNITIVE NEUROSCI, V19, P1323, DOI 10.1162/jocn.2007.19.8.1323; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Ruby P, 2004, J COGNITIVE NEUROSCI, V16, P988, DOI 10.1162/0898929041502661; Ruby P, 2001, NAT NEUROSCI, V4, P546; Scarmeas N, 2003, NEUROIMAGE, V19, P1215, DOI 10.1016/S1053-8119(03)00074-0; Schmitz TW, 2007, NEUROSCI BIOBEHAV R, V31, P585, DOI 10.1016/j.neubiorev.2006.12.003; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Wechsler D., 2011, WECHLSER ABBREVIATED; Weiderholt JL., 2001, GRAY ORAL READING TE, V4th; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WILSON M, 1988, BEHAV RES METH INSTR, V20, P6, DOI 10.3758/BF03202594; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; YEATES KO, 1990, CLIN PSYCHOL REV, V10, P567, DOI 10.1016/0272-7358(90)90097-T	63	25	25	0	11	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2010	24	2					139	147		10.1037/a0017432			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	567XV	WOS:000275483100001	20230107	Green Accepted			2021-06-18	
J	Crowe, LM; Anderson, V; Catroppa, C; Babl, FE				Crowe, Louise M.; Anderson, Vicki; Catroppa, Cathy; Babl, Franz E.			Head injuries related to sports and recreation activities in school-age children and adolescents: Data from a referral centre in Victoria, Australia	EMERGENCY MEDICINE AUSTRALASIA			English	Article						Australian Rules football; head injury; sport	TRAUMATIC BRAIN-INJURY; CONCUSSION; EMERGENCY; IMPACT	Objectives: Head injuries (HI) in children are common and even mild HI can lead to ongoing cognitive and behavioural changes. We set out to determine the causes of sport-related HI in school-age children presenting to a large urban ED as a basis for future interventions. Method: Identification and medical record review of all sport-related HI in children aged 6-16 years at a tertiary children's hospital ED in Victoria, Australia, over a 1 year period. Information was collected on demographics, injury variables and radiology findings. HI were classified as mild, moderate and severe based on GCS and radiography reports. Results: Over 12 months there were 406 HI in school-age children. Seventy per cent were male. A large number of HI (129; 33%) were related to sports. Of these, most were classified as mild and 13% were classified as moderate or severe. Among a range of sports, Australian Rules football was associated with more than 30% of all HI attributable to a sport and recreation cause. Equestrian activities were the main cause of moderate HI. Conclusion: The present study identified sports as a major cause of HI in the Victorian paediatric emergency setting with Australian Rules football the most commonly involved sport. Further prevention initiatives should consider targeting Australian Rules football and equestrian activities.	[Crowe, Louise M.; Anderson, Vicki; Catroppa, Cathy; Babl, Franz E.] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Crowe, Louise M.; Anderson, Vicki; Catroppa, Cathy] Univ Melbourne, Dept Behav Sci, Melbourne, Vic 3010, Australia; [Anderson, Vicki; Babl, Franz E.] Royal Childrens Hosp, Melbourne, Vic, Australia	Crowe, LM (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	louise.crowe@mcri.edu.au		Crowe, Louise/0000-0003-4619-9708	Murdoch Childrens Research Institute	The present study was supported by a small grant from the Murdoch Childrens Research Institute.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; *AUSTR BUR STAT, 2008, SPORT RECR STAT OV A; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BOND GR, 1995, PEDIATRICS, V95, P487; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Cameron PA, 2004, ANZ J SURG, V74, P424, DOI 10.1111/j.1445-1433.2004.03029.x; Cassell E, 2007, HAZARD VISU, V65, P1; Finch C, 1998, BRIT J SPORT MED, V32, P220, DOI 10.1136/bjsm.32.3.220; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Hillier SL, 1997, BRAIN INJURY, V11, P649; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McManus Alexandra, 2006, Health Promot J Austr, V17, P67; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; World Health Organization, 1992, INT CLASS DIS	23	25	25	0	10	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1742-6731			EMERG MED AUSTRALAS	Emerg. Med. Australas.	FEB	2010	22	1					56	61		10.1111/j.1742-6723.2009.01249.x			6	Emergency Medicine	Emergency Medicine	554BA	WOS:000274409300008	20015247				2021-06-18	
J	Saval, A; Chiodo, AE				Saval, April; Chiodo, Anthony E.			Intrathecal Baclofen for Spasticity Management: A Comparative Analysis of Spasticity of Spinal vs Cortical Origin	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Spinal cord injuries; Multiple sclerosis; Cerebral palsy; Stroke; Brain injury, traumatic; Baclofen, intrathecal; Botulinum toxin type A; Phenol; Spasticity, cortical, spinal; Intrathecal pump	HYPERTONIA; THERAPY; IMPROVEMENT; TOLERANCE; INFUSION; PUMP	Background/Objective: To examine the differences in intrathecal baclofen management of individuals with spasticity of cortical vs spinal etiologies. Design: Retrospective chart review of 57 individuals with the diagnoses of severe cortical and spinal spasticity requiring an intrathecal baclofen pump. Methods: Parameters evaluated included daily dosage of medication required, flex vs simple continuous delivery modes, dosing changes, need for other local spasticity treatment, and catheter complications. Results: There were no statistically significant differences between individuals with cortical spasticity and spinal spasticity when comparing daily dosage, number of contacts, and mode of delivery. At 6 months, there was a statistically significant difference in dosing between individuals with multiple sclerosis and those without. Within groups, there was a significant difference in average daily dosing over 3 years. A significant difference was found comparing the use of botulinum toxin type A for upper extremity spasticity within the cortical group. Nine individuals had catheter complications. Conclusions: Cortical and spinal spasticity appear to parallel each other with no significant differences in daily dosing, dosing changes, and mode of delivery of intrathecal baclofen. This did not hold true at all time points for the multiple sclerosis subgroup. The significant difference noted within groups for daily dosing over the first 3 years challenges the notion of stable dosing over time. Focal injections of Botox/phenol in the upper extremities are an important adjunct therapy for patients with cortical spasticity, even after the placement of an intrathecal baclofen pump. Our complication rate was slightly lower than that reported in the literature.	[Saval, April; Chiodo, Anthony E.] Univ Michigan, Med Ctr, Dept Phys Med & Rehabil, SCI Program, Ann Arbor, MI 48108 USA	Chiodo, AE (corresponding author), Univ Michigan, Med Ctr, Dept Phys Med & Rehabil, SCI Program, 325 E Eisenhower Pkwy, Ann Arbor, MI 48108 USA.	tchiodo@med.umich.edu					AKMAN MN, 1993, PARAPLEGIA, V31, P516, DOI 10.1038/sc.1993.84; Albright AL, 2003, J NEUROSURG, V98, P291, DOI 10.3171/jns.2003.98.2.0291; Azouvi P, 1996, ARCH PHYS MED REHAB, V77, P35, DOI 10.1016/S0003-9993(96)90217-8; Ben Smail D, 2006, MULT SCLER, V12, P101, DOI 10.1191/1352458506ms1232sr; Boviatsis EJ, 2005, CLIN NEUROL NEUROSUR, V107, P289, DOI 10.1016/j.clineuro.2004.09.007; BROWN P, 1994, J NEUROL NEUROSUR PS, V57, P773, DOI 10.1136/jnnp.57.7.773; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Francisco G E, 2001, Top Stroke Rehabil, V8, P36; Francisco GE, 2005, BRAIN INJURY, V19, P359, DOI 10.1080/02699050400003999; Francisco GE, 2006, TOP STROKE REHABIL, V13, P74, DOI 10.1310/tsr1304-74; Hsieh Joseph C, 2006, Neurosurg Focus, V21, pe5; Ivanhoe CB, 2006, ARCH PHYS MED REHAB, V87, P1509, DOI 10.1016/j.apmr.2006.08.323; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; KNUTSSON E, 1974, J NEUROL SCI, V23, P473, DOI 10.1016/0022-510X(74)90163-4; Korenkov AI, 2002, NEUROSURG REV, V25, P228, DOI 10.1007/s10143-002-0221-1; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1999, AM J PHYS MED REHAB, V78, P247, DOI 10.1097/00002060-199905000-00012; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; Nielsen JF, 2002, CLIN NEUROL NEUROSUR, V104, P142, DOI 10.1016/S0303-8467(02)00009-4; Ordia JI, 2002, NEUROMODULATION, V5, P16, DOI 10.1046/j.1525-1403.2002._2004.x; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Rawlins Patrice Korth, 2004, J Neurosci Nurs, V36, P322; Ridley B, 2006, REHABIL NURS, V31, P158, DOI 10.1002/j.2048-7940.2006.tb00381.x; Schiess M, 2006, NEUROLOGY, V66, pA324; Vender John R, 2006, Neurosurg Focus, V21, pe6; Wahlquist G I, 1987, Nurse Pract, V12, P27; Zahavi A, 2004, J NEUROL NEUROSUR PS, V75, P1553, DOI 10.1136/jnnp.2003.014282	28	25	27	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	FEB	2010	33	1					16	21		10.1080/10790268.2010.11689670			6	Clinical Neurology	Neurosciences & Neurology	586IP	WOS:000276900700004	20397440	Green Published			2021-06-18	
J	Seyfried, DM; Han, YX; Yang, DM; Ding, J; Shen, LH; Savant-Bhonsale, S; Chopp, M				Seyfried, Donald M.; Han, Yuxia; Yang, Dongmei; Ding, Jennifer; Shen, Li Hong; Savant-Bhonsale, Smita; Chopp, Michael			Localization of bone marrow stromal cells to the injury site after intracerebral hemorrhage in rats Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						bone marrow stromal cell; intracerebral hemorrhage; rat	TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; THERAPEUTIC BENEFIT; FUNCTIONAL RECOVERY; STEM-CELLS; STROKE; TRANSPLANTATION	Object. Previous studies demonstrated that intravascular injection of bone marrow stromal cells (BMSCs) significantly improved neurological functional recovery in a rat model of intracerebral hemorrhage (ICH). To further investigate the fate of transplanted cells, we examined the effect of male rat BMSCs administered to female rats after ICH. Methods. Twenty-seven female Wistar rats were subjected to ICH surgery. At 24 hours after ICH, these rats were randomly divided into 3 groups and injected intravenously with I ml phosphate-buffered saline or 0.5 million or I million male rat BMSCs in phosphate-buffered saline. To evaluate the neurological functional Outcome, each rat was subjected to a series of behavioral tests (modified neurological severity score and corner turn test) at 1, 7, and 14 days after ICH. The rats were anesthetized intraperitoneally and killed, and the brain tissues were processed at Day 14 after ICH. Immunohistochemistry and in situ hybridization were used to identify cell-specific markers. Results. The male rat BMSCs significantly improved the neurological functional outcome and also significantly diminished tissue loss when intravenously transplanted into the rats after ICH. Immunoassay for bromodeoxyuridine (BrdU) and neuronal markers demonstrated a significant increase in the number of BrdU-positive cells, which indicated endogenous neurogenesis, and a significant increase in the number of cells positive for immature neuronal markers. In situ hybridization showed that more BMSCs resided around the hematoma of the rats treated with the I-million-cell dose compared with the 0.5-million-cell-dose group. In addition, a subfraction of Y chromosome-positive cells were co-immunostained with the neuronal marker microtubule-associated protein-2 or the astrocytic marker glial fibrillary acidic protein. Conclusions. Male rat BMSCs improve neurological outcome and increase histochemical parameters of neurogenesis when administered to female rats after ICH. This study has shown that the intravenously administered male rat BMSCs enter the brain, migrate to the perihematomal area, and express parenchymal markers. (DOI: 10.3171/2009.2.JNS08907)	[Seyfried, Donald M.; Han, Yuxia; Yang, Dongmei; Ding, Jennifer] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Shen, Li Hong; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Savant-Bhonsale, Smita] Theradigm Inc, Dept Neurobiol, Baltimore, MD USA	Seyfried, DM (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsdos@neuro.hfh.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NSO58581]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058581] Funding Source: NIH RePORTER	This work was supported by internal (departmental) funds and NIH Grant NSO58581. The authors report no conflict of interest concerning the materials or methods used ill this Study or the findings specified ill this paper.	Broderick J, 2007, CIRCULATION, V116, pE391, DOI 10.1161/CIRCULATIONAHA.107.183689; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Cheung RTF, 2007, REV RECENT CLIN TRIA, V2, P174, DOI 10.2174/157488707781662751; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Harvey Richard L, 2003, Phys Med Rehabil Clin N Am, V14, pS143, DOI 10.1016/S1047-9651(02)00058-X; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lindvall O, 2004, STROKE, V35, P2691, DOI 10.1161/01.STR.0000143323.84008.f4; Liu H, 2006, BRAIN, V129, P2734, DOI 10.1093/brain/awl207; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Seyfried D, 2006, J NEUROSURG, V104, P313, DOI 10.3171/jns.2006.104.2.313; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Seyfried DM, 2008, BRAIN RES, V1224, P12, DOI 10.1016/j.brainres.2008.05.080; Shen LH, 2007, STROKE, V38, P2150, DOI 10.1161/STROKEAHA.106.481218; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Shintani A, 2007, BRAIN RES, V1186, P48, DOI 10.1016/j.brainres.2007.09.086; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	25	25	27	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2010	112	2					329	335		10.3171/2009.2.JNS08907			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	550CX	WOS:000274107000019	19284233	Green Accepted			2021-06-18	
J	Sivan, M; Neumann, V; Kent, R; Stroud, A; Bhakta, BB				Sivan, Manoj; Neumann, Vera; Kent, Ruth; Stroud, Amanda; Bhakta, Bipinchandra B.			Pharmacotherapy for treatment of attention deficits after non-progressive acquired brain injury. A systematic review	CLINICAL REHABILITATION			English	Article							DOUBLE-BLIND; SUSTAINED ATTENTION; METHYLPHENIDATE TREATMENT; CONTROLLED-TRIAL; PLACEBO; AMANTADINE; NEGLECT; RECOVERY; DONEPEZIL; SYMPTOMS	Objective: To systematically review the effectiveness of medications used to improve attention in people with non-progressive acquired brain injury. Design: A systematic review. Methods: MEDLINE, EMBASE, CINALH, PUBMED and PsychINFO databases were used to identify studies published between 1987 and 2008 meeting the following criteria: studies with subjects older than 18 years; diagnosis of new onset or previous acquired brain injury; medication given to improve attention and use of outcome to measure attention. Studies involving subjects in low arousal states or with neurogenerative conditions were excluded. The studies were categorized into three evidence levels: I - Randomized controlled trials; II - Prospective studies, controlled trials with methodological limitations; and III - Retrospective studies, clinical case series. Results: Forty-seven articles were identified on initial search. Twenty-six met the pre-specified criteria. Five articles were assessed as meeting the level I evidence criteria, 12 were level II studies and 9 were level III studies. Methylphenidate can improve information processing speed but not all attention aspects in some people after traumatic brain injury. There is weak evidence for use of dopamine agonists to improve neglect/inattention after stroke. There is little evidence on the frequency of adverse effects and long-term functional benefits. Conclusion: Although there is lack of robust evidence to recommend the routine use of medication to improve attention after traumatic brain injury and stroke, the existing evidence indicates potential for benefit in some patents and therefore further research is warranted.	[Sivan, Manoj] Univ Leeds, Acad Dept Rehabil Med, Leeds Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; [Sivan, Manoj; Neumann, Vera; Bhakta, Bipinchandra B.] Leeds Teaching Hosp NHS Trust, Dept Rehabil Med, Leeds, W Yorkshire, England; [Kent, Ruth] Mid Yorkshire NHS Trust, Dept Neurol Rehabil, Leeds, W Yorkshire, England; [Stroud, Amanda] Leeds Teaching Hosp NHS Trust, Dept Neuropsychol, Leeds, W Yorkshire, England	Sivan, M (corresponding author), Univ Leeds, Acad Dept Rehabil Med, Leeds Gen Infirm, Level D,Martin Wing, Leeds LS1 3EX, W Yorkshire, England.	M.Sivan@leeds.ac.uk		Sivan, Manoj/0000-0002-0334-2968			Bellgrove MA, 2004, NEUROREPORT, V15, P1065, DOI 10.1097/00001756-200404290-00027; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Buxbaum LJ, 2007, AM J PHYS MED REHAB, V86, P527, DOI 10.1097/PHM.0b013e31806e3392; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; Cohen J. D., 2004, COGNITIVE NEUROSCIEN, P71; Flanagan SR, 2003, J NEUROL PHYS THER, V3, P129; FLEET WS, 1987, NEUROLOGY, V37, P1765, DOI 10.1212/WNL.37.11.1765; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Hjaltason H, 1996, NEUROPSYCHOLOGIA, V34, P1229, DOI 10.1016/0028-3932(96)00044-9; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Khateb A, 2005, EUR NEUROL, V54, P39, DOI 10.1159/000087718; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Michel J A, 2006, Eura Medicophys, V42, P59; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; Mukand JA, 2001, ARCH PHYS MED REHAB, V82, P1279, DOI 10.1053/apmr.2001.25149; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Pierce SR, 2002, ARCH PHYS MED REHAB, V83, P256, DOI 10.1053/apmr.2002.27333; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Raz Amir, 2004, Anatomical Record Part B:The New Anatomist, V281, P21, DOI 10.1002/ar.b.20035; Schneider WN, 1999, BRAIN INJURY, V13, P863; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2008, AM J PHYS MED REHAB, V87, P85, DOI 10.1097/PHM.0b013e3181619609; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	36	25	26	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	FEB	2010	24	2					110	121		10.1177/0269215509343234			12	Rehabilitation	Rehabilitation	548MY	WOS:000273968700002	20103574				2021-06-18	
J	Cernak, I; Chang, T; Ahmed, FA; Cruz, MI; Vink, R; Stoica, B; Faden, AI				Cernak, Ibolja; Chang, Taeun; Ahmed, Farid A.; Cruz, Maria I.; Vink, Robert; Stoica, Bogdan; Faden, Alan I.			Pathophysiological Response to Experimental Diffuse Brain Trauma Differs as a Function of Developmental Age	DEVELOPMENTAL NEUROSCIENCE			English	Article						Diffuse traumatic brain injury; Brain, immature; Motor deficit; Brain edema	GLUTATHIONE-PEROXIDASE ACTIVITY; FREE MAGNESIUM CONCENTRATION; IMMATURE BRAIN; HEAD-INJURY; MAGNETIC-RESONANCE; ENERGY-METABOLISM; HYPOXIA-ISCHEMIA; AXONAL INJURY; RAT PUPS; MODEL	The purpose of experimental models of traumatic brain injury (TBI) is to reproduce selected aspects of human head injury such as brain edema, contusion or concussion, and functional deficits, among others. As the immature brain may be particularly vulnerable to injury during critical periods of development, and pediatric TBI may cause neurobehavioral deficits, our aim was to develop and characterize as a function of developmental age a model of diffuse TBI (DTBI) with quantifiable functional deficits. We modified a DTBI rat model initially developed by us in adult animals to study the graded response to injury as a function of developmental age - 7-, 14- and 21-day-old rats compared to young adult (3-month-old) animals. Our model caused motor deficits that persisted even after the pups reached adulthood, as well as reduced cognitive performance 2 weeks after injury. Moreover, our model induced prominent edema often seen in pediatric TBI, particularly evident in 7- and 14-day-old animals, as measured by both the wet weight/dry weight method and diffusion-weighted MRI. Blood-brain barrier permeability, as measured by the Evans blue dye technique, peaked at 20 min after trauma in all age groups, with a second peak found only in adult animals at 24 h after injury. Phosphorus MR spectroscopy showed no significant changes in the brain energy metabolism of immature rats with moderate DTBI, in contrast to significant decreases previously identified in adult animals. Copyright (C) 2010 S. Karger AG, Basel	[Cernak, Ibolja; Chang, Taeun; Ahmed, Farid A.; Cruz, Maria I.; Stoica, Bogdan; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Chang, Taeun] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Cernak, Ibolja; Ahmed, Farid A.] Johns Hopkins Univ, Appl Phys Lab, Biomed Business Area, Natl Secur Technol Dept, Laurel, MD USA; [Stoica, Bogdan; Faden, Alan I.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA; [Vink, Robert] Univ Adelaide, Dept Pathol, Adelaide, SA, Australia	Faden, AI (corresponding author), Univ Maryland, Sch Med, STAR Organized Res Ctr, HSF 2,247,20 S Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019; STOICA, BOGDAN/H-9782-2013	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667; STOICA, BOGDAN/0000-0002-2501-6434; Chang, Taeun/0000-0002-1797-8449; Ibolja, Cernak/0000-0003-3214-698X			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Ahmed F, 2009, BRAIN BEHAV IMMUN, V23, P355, DOI 10.1016/j.bbi.2008.11.007; Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Dennis M, 2000, J COMMUN DISORD, V33, P321, DOI 10.1016/S0021-9924(00)00028-9; Derugin N, 1998, NEUROSCI RES, V32, P349, DOI 10.1016/S0168-0102(98)00096-0; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; DUFFY TE, 1975, J NEUROCHEM, V24, P271, DOI 10.1111/j.1471-4159.1975.tb11875.x; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1999, MAGNESIUM RES, V12, P269; HIDA K, 1991, MAGNET RESON MED, V22, P128, DOI 10.1002/mrm.1910220113; Li FH, 1996, DRUG TODAY, V32, P615; Liu CL, 2004, NEUROSCIENCE, V127, P113, DOI 10.1016/j.neuroscience.2004.03.062; LUSTYIK G, 1985, SCAN ELECTRON MICROS, P323; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCPHERSON GK, 1980, J BIOMECH, V13, P9, DOI 10.1016/0021-9290(80)90003-2; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Potts Mathew B, 2006, NeuroRx, V3, P143; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Robertson CL, 2004, DEV BRAIN RES, V151, P141, DOI 10.1016/j.devbrainres.2004.04.007; SCHMUED L, 1990, BRAIN RES, V526, P127, DOI 10.1016/0006-8993(90)90258-D; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schuchmann S, 2005, EUR J NEUROSCI, V21, P2721, DOI 10.1111/j.1460-9568.2005.04109.x; SUZUKI N, 1992, MAGNET RESON MED, V24, P205, DOI 10.1002/mrm.1910240202; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Towfighi J, 1998, DEV BRAIN RES, V109, P169, DOI 10.1016/S0165-3806(98)00077-7; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Vink R, 1996, J NEUROCHEM, V66, P2477; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Waters KA, 2004, NEUROSIGNALS, V13, P162, DOI 10.1159/000077523; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1007/BF03206563	49	25	25	0	8	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					442	453		10.1159/000320085			12	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900012	20948187				2021-06-18	
J	Lajiness-O'Neill, R; Erdodi, L; Bigler, ED				Lajiness-O'Neill, Renee; Erdodi, Laszlo; Bigler, Erin D.			Memory and Learning in Pediatric Traumatic Brain Injury: A Review and Examination of Moderators of Outcome	APPLIED NEUROPSYCHOLOGY			English	Article						learning; memory; outcome; pediatric; traumatic brain injury	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; TEST-CHILDRENS VERSION; WORKING-MEMORY; COGNITIVE REHABILITATION; HEAD-INJURY; 1ST YEAR; PERFORMANCE; RECOVERY; PREDICTORS; MANAGEMENT	This article reviews empirically supported assessment methods to examine impairments in memory and learning following pediatric traumatic brain injury (TBI). Critical factors affecting outcome are explored with an emphasis on an examination of age at injury. The article closes with discussion of current evidence-based interventions for deficits in memory and learning following pediatric TBI.	[Lajiness-O'Neill, Renee; Erdodi, Laszlo] Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA; [Lajiness-O'Neill, Renee] Henry Ford Hlth Syst, Dept Behav Serv, Div Neuropsychol, Detroit, MI USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA	Lajiness-O'Neill, R (corresponding author), Eastern Michigan Univ, Dept Psychol, 537 F Mark Jefferson, Ypsilanti, MI 48197 USA.	rlajines@emich.edu					Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Alexander AI, 2005, ARCH CLIN NEUROPSYCH, V20, P587, DOI 10.1016/j.acn.2004.12.005; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; Bigler ED, 1996, J LEARN DISABIL, V29, P512, DOI 10.1177/002221949602900506; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Chambless DL, 1998, J CONSULT CLIN PSYCH, V66, P7, DOI 10.1037/0022-006X.66.1.7; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coffey C. E., 1998, TXB PEDIAT NEUROPSYC, P1093; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Delis D, 1994, CALIFORNIA VERBAL LE; Donders J, 2004, J INT NEUROPSYCH SOC, V10, P482, DOI 10.1017/S1355617704104025; Donders J, 2007, PEDIATRIC NEUROPSYCHOLOGICAL INTERVENTION: A CRITICAL REVIEW OF SCIENCE AND PRACTICE, P91; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FLETCHER JM, 1985, J EXP CHILD PSYCHOL, V40, P244, DOI 10.1016/0022-0965(85)90088-8; Glang A, 2008, J HEAD TRAUMA REHAB, V23, P243, DOI 10.1097/01.HTR.0000327256.46504.9f; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; Gonzalez-Rothi L. J., 2006, J INT NEUROPSYCH SOC, V21, P812; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; Graham DI, 2001, BRAIN, V124, P1261, DOI 10.1093/brain/124.7.1261; Guthrie E, 1999, CHILD ADOL PSYCH CL, V8, P807; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; Jin C, 2004, CNS SPECTRUMS, V9, P217, DOI 10.1017/S1092852900009019; Kibby M, 2008, CHILD NEUROPSYCHOL, V14, P525, DOI 10.1080/09297040701821752; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Limond J, 2005, J CHILD PSYCHOL PSYC, V46, P339, DOI 10.1111/j.1469-7610.2004.00397.x; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; Melton AK, 2005, APHASIOLOGY, V19, P353, DOI 10.1080/02687030444000804; Mottram L, 2006, DEV NEUROPSYCHOL, V30, P865, DOI 10.1207/s15326942dn3003_6; Nelson J E, 2002, Pediatr Rehabil, V5, P37, DOI 10.1080/1363849021000007088; Paniak C, 1997, CLIN NEUROPSYCHOL, V11, P198, DOI 10.1080/13854049708407051; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Rey A, 1964, EXAMEN CLIN PSYCHOL; Reynolds C. R., 2007, TEST MEMORY LEARNING; Reynolds C.R., 1994, TEST MEMORY LEARNING; Riccio CA, 2007, APPL NEUROPSYCHOL, V14, P255, DOI 10.1080/09084280701719203; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; SCHACTER DL, 2000, J CLIN EXPT NEUROPSY, V8, P727; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sheslow D., 2003, WIDE RANGE ASSESSMEN, V2nd; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Verger K, 2000, BRAIN INJURY, V14, P495; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; WILSON BA, 1993, J CLIN EXP NEUROPSYC, V15, P474, DOI 10.1080/01688639308402572; Woodward H, 1998, APPL NEUROPSYCHOL, V5, P113, DOI 10.1207/s15324826an0503_1; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	74	25	25	0	8	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2010	17	2					83	92	PII 922182556	10.1080/09084281003708837			10	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	596CX	WOS:000277662800002	20467947				2021-06-18	
J	Morgan, AT; Mageandran, SD; Mei, C				Morgan, A. T.; Mageandran, S-D.; Mei, C.			Incidence and clinical presentation of dysarthria and dysphagia in the acute setting following paediatric traumatic brain injury	CHILD CARE HEALTH AND DEVELOPMENT			English	Article						dysarthria; dysphagia; paediatric; speech language pathology; traumatic brain injury	EMERGENCY-MEDICINE RESEARCH; INSTRUMENTAL ANALYSIS; CHILDHOOD; CHILDREN; SPEECH; ELECTROPALATOGRAPHY; DYNAMICS; RECORDS; MOTOR	Background A lack of data on dysarthria and dysphagia outcomes for children following traumatic brain injury (TBI) limits our clinical evidence base, and poses daily challenges for the speech language pathologist (SLP) managing this group. The present study aimed to examine dysarthria and dysphagia incidence and the clinical presentation of children with these disorders in the acute phase following TBI. Methods Incidence and characteristics were determined via a comprehensive retrospective medical chart review of children consecutively referred to a tertiary paediatric hospital over an 8-year period. Cases (n = 22 dysarthria, n = 72 dysphagia) and matched controls were compared across ancillary variables (e.g. age, severity of TBI, motor impairment). Results Incidence across the entire cohort was low [i.e. dysarthria (1.2%, 22/1895), dysphagia (3.8%, 72/1895)], but was markedly higher for the sub-category of children with severe TBI [e.g. dysphagia (76%, 63/83)]. Speech deficits were reported across respiration, phonation, resonance, articulation and prosody. Swallowing deficits included reduced lip closure, delayed swallow initiation, wet voice and coughing. Language and swallowing deficits were often co-morbid with dysarthria. Motor impairment was frequently co-morbid with both dysarthria and dysphagia. Cases had longer periods of hospitalization, ventilation and supplementary feeding compared with controls. Conclusion Despite the low incidence of dysarthria and dysphagia across the entire TBI cohort, this sub-group may place longer-term burden on SLP services, having prolonged periods of ventilation, extended periods of hospitalization and a complex co-morbid clinical presentation compared with controls. The prevalence of co-morbid communication and swallowing impairments suggests a need for integrated rather than single discipline (i.e. dysphagia stream only) SLP services.	[Morgan, A. T.; Mageandran, S-D.; Mei, C.] Murdoch Childrens Res Inst, Language & Literacy Grp, Melbourne, Vic, Australia; [Morgan, A. T.; Mei, C.] Royal Childrens Hosp, Speech Pathol Dept, Parkville, Vic, Australia; [Morgan, A. T.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Morgan, A. T.; Mageandran, S-D.] La Trobe Univ, Melbourne, Vic, Australia	Morgan, AT (corresponding author), 50 Flemington Rd, Parkville, Vic 3052, Australia.	angela.morgan@mcri.edu.au	Morgan, Angela/J-5235-2017	Morgan, Angela/0000-0003-1147-7405; Mei, Cristina/0000-0002-6765-8064			Allison J J, 2000, Jt Comm J Qual Improv, V26, P115; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Burd R S, 2001, Respir Care Clin N Am, V7, P79, DOI 10.1016/S1078-5337(05)70024-1; Cahill LM, 2005, BRAIN INJURY, V19, P41, DOI 10.1080/02699050410001719961; Cahill LM, 2002, BRAIN INJURY, V16, P415, DOI 10.1080/02699050110119871; Cahill LM, 2003, J HEAD TRAUMA REHAB, V18, P268, DOI 10.1097/00001199-200305000-00005; Cahill LM, 2000, J MED SPEECH-LANG PA, V8, P347; CAHILL LM, 2001, ASIA PAC J SPEECH LA, V6, P33; CAHILL LM, 2001, TRAUMATIC BRAIN INJU, P121; Cheng HY, 2005, J MED SPEECH-LANG PA, V13, P15; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DANIELWHITNEY B, 1989, RECENT ADVANCES IN CLINICAL DYSARTHRIA, P129; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Humbert IA, 2007, DYSPHAGIA, V22, P266, DOI 10.1007/s00455-007-9080-9; Jansen ACM, 2005, J CLIN EPIDEMIOL, V58, P269, DOI 10.1016/j.jclinepi.2004.07.006; Kendall KA, 2004, DYSPHAGIA, V19, P65, DOI 10.1007/s00455-003-0500-1; LANDIS JR, 1977, BIOMETRICS, V33, P174; Morgan A, 2005, J MED SPEECH-LANG PA, V13, P109; Morgan A, 2004, J HEAD TRAUMA REHAB, V19, P226, DOI 10.1097/00001199-200405000-00004; Morgan A, 2004, J CLIN NEUROSCI, V11, P182, DOI 10.1016/S0967-5868(03)00195-4; Morgan A, 2004, BRAIN INJURY, V18, P359, DOI 10.1080/02699050310001617424; Morgan A, 2003, J HEAD TRAUMA REHAB, V18, P239, DOI 10.1097/00001199-200305000-00002; Morgan A, 2002, J HEAD TRAUMA REHAB, V17, P220, DOI 10.1097/00001199-200206000-00004; Morgan AT, 2007, BRAIN INJURY, V21, P1183, DOI 10.1080/02699050701649573; Morgan AT, 2001, ASIA PACIFIC J SPEEC, V6, P9; Murdoch BE, 2003, BRAIN INJURY, V17, P79, DOI 10.1080/0269905021000010203; Murdoch BE, 1997, INT CONGR SER, V1146, P621; Saarinen T, 2006, CEREB CORTEX, V16, P212, DOI 10.1093/cercor/bhi099; SHOUMITRO D, 1999, BRAIN INJURY, V13, P369; Stierwalt JAG, 1996, DISORDERS MOTOR SPEE, P241; Theodoros D G, 1998, Pediatr Rehabil, V2, P107; To T, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-29; WARD EC, 2001, TRAUMATIC BRAIN INJU, P331; Worster A, 2005, ANN EMERG MED, V45, P448, DOI 10.1016/j.annemergmed.2004.11.021; Yawn BP, 2005, AM J EPIDEMIOL, V161, P974, DOI 10.1093/aje/kwi122	37	25	26	0	22	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0305-1862			CHILD CARE HLTH DEV	Child Care Health Dev.	JAN	2010	36	1					44	53		10.1111/j.1365-2214.2009.00961.x			10	Psychology, Developmental; Pediatrics	Psychology; Pediatrics	536BF	WOS:000273016400005	19320903				2021-06-18	
J	Ptyushkin, P; Vidmar, G; Burger, H; Marincek, C				Ptyushkin, Pavel; Vidmar, Gaj; Burger, Helena; Marincek, Crt			Use of the International Classification of Functioning, Disability and Health (ICF) in patients with traumatic brain injury	BRAIN INJURY			English	Article						ICF; traumatic brain injury; rehabilitation; linking rules	CORE SETS; REHABILITATION; LINKING; QUESTIONNAIRE; PARTICIPATION; LIMITATIONS; VALIDATION; DISORDERS; PROFILES	Introduction: Many tools exist for assessing the functioning of a patient with traumatic brain injury. Possible benefits of the ICF in TBI rehabilitation are currently under discussion. Goal: The study explored to what extend the ICF is useful to organize existing clinical information and to retrospectively evaluate the effect of interventions in patients with TBI. Method: A retrospective patient record study was conducted. Medical records of 100 patients admitted to the Slovenian University Rehabilitation Institute from 2007-2009 were linked to the ICF. Results: The majority of the functional problems at the level of body functions corresponded to mental and movement-related functions. Within the list of activities and participation, the patients experienced more difficulties in tasks that require intellectual effort, communicational ability, mobility and self-care. The ICF detected substantial improvement after rehabilitation regarding body functions and activities related to mobility and self-care and little improvement regarding mental functions and related activities. Some important environmental factors were also identified. Conclusions: The translation of the information about functioning into the ICF format provided a well-structured functional profile of the selected group of patients in a language-independent format. ICF also clearly outlined the environmental factors important for the recovery and functioning.	[Ptyushkin, Pavel; Vidmar, Gaj; Burger, Helena; Marincek, Crt] Univ Rehabil Inst, European Project MURINET, Ljubljana, Slovenia; [Ptyushkin, Pavel] Univ Lucerne, Dept Hlth Sci & Hlth Policy, Nottwil, Switzerland; [Ptyushkin, Pavel] Swiss Parapleg Res SPF, Nottwil, Switzerland	Ptyushkin, P (corresponding author), Univ Rehabil Inst, European Project MURINET, Ljubljana, Slovenia.	pavel.ptyushkin@yandex.ru	Vidmar, Gaj/H-5950-2011	Vidmar, Gaj/0000-0002-5682-3124			Alachini B, 2010, EUR J PHYS REHAB MED, V46, P27; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Bernabeu M, 2009, NEUROREHAB NEURAL RE, V23, P464, DOI 10.1177/1545968308328725; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; CAMERON ID, 2009, APPL ICF ASSESSMENT; Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263; Cieza A, 2002, J REHABIL MED, V34, P205, DOI 10.1080/165019702760279189; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Ehrenfors R, 2009, DISABIL REHABIL, V31, P1392, DOI 10.1080/09638280802621366; Fries W, 2008, REHABILITATION, V47, P265, DOI 10.1055/s-2008-1081473; Grill E, 2006, AM J PHYS MED REHAB, V85, P640, DOI 10.1097/01.phm.0000228537.17239.7f; *I PUBL HLTH REP S, BOLN OBR ZAR POSK ZA; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Koskinen S, 2007, J REHABIL MED, V39, P467, DOI 10.2340/16501977-0077; Larkins Brigette, 2007, Seminars in Speech and Language, V28, P334, DOI 10.1055/s-2007-986530; Leonardi M, 2009, INT J REHABIL RES, V32, P167, DOI 10.1097/MRR.0b013e32831e4587; Post MWM, 2008, J REHABIL MED, V40, P620, DOI 10.2340/16501977-0223; PTYUSHKIN P, 2009, REHABILITACIJA, V8, P49; RAGGI A, 2010, INT J REHABILITATION; Raggi A, 2010, INT J REHABIL RES, V33, P225, DOI 10.1097/MRR.0b013e3283375e53; Raggi A, 2009, INT J REHABIL RES, V32, P148, DOI 10.1097/MRR.0b013e32831e4573; Scarponi F, 2009, DISABIL REHABIL, V31, pS134, DOI 10.3109/09638280903317906; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265; 2007, ZDRAVSTVENI STAT LET	25	25	29	0	24	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	13-14					1519	1527		10.3109/02699052.2010.523054			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691QV	WOS:000285096800001	20973629				2021-06-18	
J	Rohling, ML; Demakis, GJ				Rohling, Martin L.; Demakis, George J.			Bowden, shores, mathias (2006): failure to replicate or just failure to notice. Does effort still account for more variance in neuropsychological test scores than tbi severity?	CLINICAL NEUROPSYCHOLOGIST			English	Article						Word Memory test; Symptom validity tests; Neuropsychological assessment; Traumatic brain injury; Suboptimal effort	TRAUMATIC BRAIN-INJURY; WORD MEMORY TEST; HEAD-INJURY; PERFORMANCE; CLAIMANTS	Several studies have reported that traumatic brain injury (TBI) has a smaller effect on neuropsychological test scores, in contrast to the large effect of poor effort on test performance. Consequently, many authors have concluded that effort needs to be measured routinely and that it is necessary to control for poor effort when measuring the effects of brain disease or injury on performance. Recently, however, Bowden, Shores, and Mathias (2006) have challenged these notions. They argued that the Immediate Recognition subtest of the Word Memory Test (Green Flaro, 2003), an effort measure, is another verbal memory test rather than a measure of cognitive effort. In this study we re-examine the data from Bowden et al. (2006) and Green, Rohling, Lees-Haley, and Allen (2001) to identify differences between the two studies that might account for their contradictory conclusions. In both sets of data, reanalysis showed that effort explains approximately five times more of the variance in composite neuropsychological test scores than TBI severity. Importantly, scores on the Word Memory Test-Immediate Recognition (WMT-IR) were not correlated with measures of TBI severity, and were not found to correlate with major variables known to be measuring ability (e.g., years of education). These findings challenge the conclusions offered by Bowden and colleagues (2006).	[Rohling, Martin L.] Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA; [Demakis, George J.] Univ N Carolina, Charlotte, NC 28223 USA	Rohling, ML (corresponding author), Univ S Alabama, Dept Psychol, 331 Life Sci Bldg, Mobile, AL 36688 USA.	mrohling@usouthal.edu					Allen L.M., 1997, CARB 97 MANUAL COMPU; Bianchini KJ, 2003, CLIN NEUROPSYCHOL, V17, P574, DOI 10.1076/clin.17.4.574.27946; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Carless SA, 2000, EDUC PSYCHOL MEAS, V60, P592, DOI 10.1177/00131640021970745; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; GREEN P, 2003, STORY RECALL TEST; Green P., 2003, WORD MEMORY TEST MAN; Heaton RK, 2004, REVISED COMPREHENSIV; Jackson DN., 1998, MULTIDIMENSIONAL APT; Meyers J., 1995, REY COMPLEX FIGURE T; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MILLIS SR, 1999, WORKSH S MILL UNPUB; PANIAK C, 2008, NEUROPSYCHOLOGY MALI, P101; Rohling Martin L, 2002, CNS Spectr, V7, P387; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Shores EA, 2000, AUST PSYCHOL, V35, P41, DOI 10.1080/00050060008257467; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M	29	25	25	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	1					119	136	PII 918004709	10.1080/13854040903307243			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535MK	WOS:000272972300010	20029718				2021-06-18	
J	Salisbury, E; Sonnet, C; Heggeness, M; Davis, AR; Olmsted-Davis, E				Salisbury, Elizabeth; Sonnet, Corinne; Heggeness, Michael; Davis, Alan R.; Olmsted-Davis, Elizabeth			Heterotopic Ossification Has Some Nerve	CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION			English	Article						heterotopic ossification; peripheral nervous system; BMP2; neurogenic inflammation; sensory; sympathetic	GENE-RELATED PEPTIDE; BONE MORPHOGENETIC PROTEINS; MATRIX GLA PROTEIN; VANILLOID RECEPTOR TRPV1; SMOOTH-MUSCLE-CELLS; SUBSTANCE-P; STEM-CELLS; IN-VITRO; VASCULAR CALCIFICATION; OSTEOBLAST PRECURSORS	Heterotopic ossification, defined as the formation of bone in abnormal anatomic locations, can be clinically insignificant or devastating and debilitating, depending on the site and duration of new bone formation. There are many causes of heterotopic ossification (HO), including soft tissue trauma, central nervous system injury, vasculopathies, arthropathies, and inheritance. One of the least understood components of HO is the interaction of the peripheral nervous system with the induction of this process. Recent work has shown that, upon traumatic injury, a cascade of events termed neurogenic inflammation is initiated, which involves the release of neuropeptides, such as substance P and calcitonin gene related peptide. Release of these peptides ultimately leads to the recruitment of activated platelets, mast cells, and neutrophils to the injury site. These cells appear to be involved with both remodeling of the nerve, as well as potentially recruiting additional cells from the bone marrow to the injury site. Further, sensory neurons stimulated at the injury site relay local information to the brain, which can then redirect neuroendocrine signaling in the hypothalamus towards repair of the injured site. While numerous studies have highlighted the important role of nerve-derived signals, both central and peripheral, in the regulation of normal bone remodeling of the skeleton,(1) this review focuses on the role of the local, peripheral nerves in the formation of heterotopic bone. We concentrate on the manner in which local changes in bone morphogenetic protein (BMP) expression contribute to a cascade of events within the peripheral nerves, both sensory and sympathetic, in the immediate area of HO formation.	[Salisbury, Elizabeth; Sonnet, Corinne; Davis, Alan R.; Olmsted-Davis, Elizabeth] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; [Heggeness, Michael; Davis, Alan R.; Olmsted-Davis, Elizabeth] Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA; [Davis, Alan R.; Olmsted-Davis, Elizabeth] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Olmsted-Davis, E (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 1 Baylor Plaza,BCM505, Houston, TX 77030 USA.	edavis@bcm.edu		Salisbury, Elizabeth/0000-0003-3607-2367; Olmsted-Davis, Elizabeth/0000-0001-9457-1848	Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [W911NF-09-1-0040)]; Department of DefenseUnited States Department of Defense [W81XWH-07-0281, W81XWH-07-1-0214, W81XWH-08-1-0489, W81XWH-07-1-025]; National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [NIH RO1EB005173-01]; Kirschtein-National Research Service Award [T-32 HL092332-08]; American Heart AssociationAmerican Heart Association [AHA 10815339F]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL096360, T32HL092332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB005173] Funding Source: NIH RePORTER	We thank the following agencies for their support: Defense Advanced Research Projects Agency (W911NF-09-1-0040), Department of Defense (W81XWH-07-0281, W81XWH-07-1-0214, W81XWH-08-1-0489, W81XWH-07-1-025), the National Institute of Biomedical Imaging and Bioengineering (NIH RO1EB005173-01), the Kirschtein-National Research Service Award (T-32 HL092332-08), and the American Heart Association (AHA 10815339F).	ADARNEYKO I, 2009, CELL, V139, P366; AOKI M, 1994, INT ORTHOP, V18, P317; Apel PJ, 2009, J BONE JOINT SURG AM, V91A, P2886, DOI 10.2106/JBJS.H.01878; ARO H, 1985, CLIN ORTHOP RELAT R, P292; ARO H, 1985, ACTA ORTHOP SCAND, V56, P233, DOI 10.3109/17453678508993002; Azzolina A, 2003, BBA-MOL CELL RES, V1643, P75, DOI 10.1016/j.bbamcr.2003.09.003; Beiner JM, 2002, CLIN ORTHOP RELAT R, pS110, DOI 10.1097/01.blo.0000037969.69509.2c; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blasius AL, 2009, P NATL ACAD SCI USA, V106, P2706, DOI 10.1073/pnas.0813208106; Bobryshev YV, 2005, J PATHOL, V205, P641, DOI 10.1002/path.1743; Bournat Juan C, 2010, Curr Opin Endocrinol Diabetes Obes, V17, P446, DOI 10.1097/MED.0b013e32833c3026; Bucelli RC, 2008, J PHARMACOL EXP THER, V324, P1172, DOI 10.1124/jpet.107.132795; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Clever JL, 2010, AM J PHYSIOL-CELL PH, V298, pC1087, DOI 10.1152/ajpcell.00388.2009; Dilling CF, 2010, J BONE MINER RES, V25, P1147, DOI 10.1359/jbmr.091031; Dominici M, 2004, P NATL ACAD SCI USA, V101, P11761, DOI 10.1073/pnas.0404626101; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 2010, J CELL BIOL, V191, P7, DOI 10.1083/jcb.201006123; El-Maadawy S, 2003, CONNECT TISSUE RES, V44, P272, DOI 10.1080/03008200390181762; Elefteriou F, 2005, CELL MOL LIFE SCI, V62, P2339, DOI 10.1007/s00018-005-5175-3; FANN MJ, 1994, J NEUROCHEM, V63, P2074; Flanagan Thomas C., 2003, European Cells & Materials, V6, P28; Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792; Fouletier-Dilling CM, 2007, HUM GENE THER, V18, P733, DOI 10.1089/hum.2006.190; Gannon FH, 2001, HUM PATHOL, V32, P842, DOI 10.1053/hupa.2001.26464; Geppetti P., 1996, NEUROGENIC INFLAMMAT; Goolsby J, 2003, P NATL ACAD SCI USA, V100, P14926, DOI 10.1073/pnas.2434383100; Graham GJ, 2004, BLOOD, V104, P1058, DOI 10.1182/blood-2003-11-3979; Hruska KA, 2005, CIRC RES, V97, P105, DOI 10.1161/01.RES.00000175571.53833.6c; Hwang SJ, 2005, BRAIN RES, V1047, P261, DOI 10.1016/j.brainres.2005.04.036; JOHNSON D, 1988, BRAIN RES, V444, P195, DOI 10.1016/0006-8993(88)90929-8; Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041; Khairatkar-Joshi N, 2009, TRENDS MOL MED, V15, P14, DOI 10.1016/j.molmed.2008.11.004; Kitterman JA, 2005, PEDIATRICS, V116, pE654, DOI 10.1542/peds.2005-0469; Kleij Hanneke Pm van der, 2005, Allergy Asthma Clin Immunol, V1, P65, DOI 10.1186/1710-1492-1-2-65; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; Li L, 2007, J ORTHOP RES, V25, P1204, DOI 10.1002/jor.20406; Li JA, 2010, J ORTHOP RES, V28, P1643, DOI 10.1002/jor.21169; Lowell BB, 2000, NATURE, V404, P652; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010; Mendez-Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685; Mendez-Ferrer S, 2010, ANN NY ACAD SCI, V1192, P139, DOI 10.1111/j.1749-6632.2010.05390.x; Morikawa Y, 2009, DEVELOPMENT, V136, P3575, DOI 10.1242/dev.038133; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; NORDSLETTEN L, 1994, ACTA ORTHOP SCAND, V65, P299, DOI 10.3109/17453679408995457; Offley SC, 2005, J BONE MINER RES, V20, P257, DOI 10.1359/JBMR.041108; Olmsted-Davis EA, 2003, P NATL ACAD SCI USA, V100, P15877, DOI 10.1073/pnas.2632959100; Olmsted-Davis EA, 2002, HUM GENE THER, V13, P1337, DOI 10.1089/104303402760128568; Olmsted-Davis E, 2007, AM J PATHOL, V170, P620, DOI 10.2353/ajpath.2007.060692; Onuoha GN, 2001, PEPTIDES, V22, P1107, DOI 10.1016/S0196-9781(01)00434-X; Parrinello S, 2010, CELL, V143, P145, DOI 10.1016/j.cell.2010.08.039; Richardson JD, 2002, J PHARMACOL EXP THER, V302, P839, DOI 10.1124/jpet.102.032797; Ringvall M, 2008, J ALLERGY CLIN IMMUN, V121, P1020, DOI 10.1016/j.jaci.2007.11.031; Salari Sharif P., 2010, INFLAMM ALLERGY 0603; Schaible HG, 2005, RHEUM DIS CLIN N AM, V31, P77, DOI 10.1016/j.rdc.2004.09.004; Schneider C, 1999, NEURON, V24, P861, DOI 10.1016/S0896-6273(00)81033-8; Shafer J, 2007, TISSUE ENG, V13, P2011, DOI 10.1089/ten.2006.0063; Shah AJ, 1996, BLOOD, V87, P3563, DOI 10.1182/blood.V87.9.3563.bloodjournal8793563; Shih C, 1997, CLIN ORTHOP RELAT R, P335; Shih C, 1997, PEPTIDES, V18, P323, DOI 10.1016/S0196-9781(96)00280-X; Shih CC, 2001, BLOOD, V98, P2412, DOI 10.1182/blood.V98.8.2412; Shore EM, 2010, NAT REV RHEUMATOL, V6, P518, DOI 10.1038/nrrheum.2010.122; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; Speer MY, 2009, CIRC RES, V104, P733, DOI 10.1161/CIRCRESAHA.108.183053; Starinsky-Elbaz S, 2009, MOL CELL NEUROSCI, V42, P278, DOI 10.1016/j.mcn.2009.07.014; Sucosky P, 2009, ARTERIOSCL THROM VAS, V29, P254, DOI 10.1161/ATVBAHA.108.176347; Sviderskaya EV, 1998, GENETICS, V148, P381; Szallasi A, 2007, NAT REV DRUG DISCOV, V6, P357, DOI 10.1038/nrd2280; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Takeda S, 2008, BONE, V42, P837, DOI 10.1016/j.bone.2008.01.005; Tsujii M, 2009, CLIN ORTHOP RELAT R, V467, P3183, DOI 10.1007/s11999-009-1009-1; Turner CH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.268pt3; WALLENGREN J, 1987, EUR J PHARMACOL, V143, P267, DOI 10.1016/0014-2999(87)90542-5; Yao Y, 2007, J BIOL CHEM, V282, P30131, DOI 10.1074/jbc.M704297200; Yao YC, 2010, CIRC RES, V107, P485, DOI 10.1161/CIRCRESAHA.110.219071	76	25	27	0	5	BEGELL HOUSE INC	DANBURY	50 NORTH ST, DANBURY, CT 06810 USA	1045-4403	2162-6502		CRIT REV EUKAR GENE	Crit. Rev. Eukaryot. Gene Expr.		2010	20	4					313	324		10.1615/CritRevEukarGeneExpr.v20.i4.30			12	Biotechnology & Applied Microbiology; Genetics & Heredity	Biotechnology & Applied Microbiology; Genetics & Heredity	737OJ	WOS:000288577800003	21395504	Green Accepted			2021-06-18	
J	Mogensen, J; Mala, H				Mogensen, Jesper; Mala, Hana			Post-traumatic functional recovery and reorganization in animal models: A theoretical and methodological challenge	SCANDINAVIAN JOURNAL OF PSYCHOLOGY			English	Article						Functional recovery; functional localization; brain injury; post-traumatic reorganization; animal models; neural plasticity; cognitive plasticity; experimental methodology; challenges	FORNIX AND/OR ABLATION; SPATIAL DELAYED ALTERNATION; HUMAN CEREBRAL-CORTEX; PREFRONTAL CORTEX; BRAIN-DAMAGE; WATER MAZE; CONCEPT-IDENTIFICATION; TRANSECTED RATS; LESIONS; REHABILITATION	Studies addressing cerebral functional localization face methodological and theoretical problems. Lesion experiments expect that when a functionally specialized structure is missing, its function can be deduced from the resulting impairments. Mostly, however, initial impairments are partially or fully eliminated through functional recovery. Apparently, such a recovery contradicts the notion of functional localization. In order to understand the mechanisms of recovery, improved methodology and a new theoretical framework are required. Insights into the mechanisms of recovery can be achieved by using "challenge" techniques, where functionally recovered individuals are exposed to organic and behavioral challenges, e.g. pharmacological manipulations or additional lesions, as well as modified test situations. Using such methods, a number of principles of functional recovery have emerged. We evaluate some of the available theories of post-traumatic recovery against these principles and find that none of them can account for the principles. Finally, we present a new conceptual framework - the Reorganization of Elementary Functions (REF) model. This model reconceptualizes the term "function", suggests mechanisms of post-traumatic reorganizations, and resolves the contradiction between localization and functional recovery.	[Mogensen, Jesper; Mala, Hana] Univ Copenhagen, Dept Psychol, Unit Cognit Neurosci, DK-1353 Copenhagen K, Denmark	Mogensen, J (corresponding author), Univ Copenhagen, Dept Psychol, Unit Cognit Neurosci, Oester Farimagsgade 2 A, DK-1353 Copenhagen K, Denmark.	jesper.mogensen@psy.ku.dk		Rytter, Hana Mala/0000-0002-2910-372X; Mogensen, Jesper/0000-0003-1959-581X			BOURNE LE, 1959, PSYCHOL REV, V66, P278, DOI 10.1037/h0041365; BOWER G, 1963, J EXP PSYCHOL, V66, P409, DOI 10.1037/h0044972; Bressler SL, 2006, INT J PSYCHOPHYSIOL, V60, P139, DOI 10.1016/j.ijpsycho.2005.12.008; Buller D. J., 2000, BRAIN MIND, V1, P307, DOI [10.1023/A:1011573226794, DOI 10.1023/A:1011573226794]; Butefisch CM, 2004, NEUROSCIENTIST, V10, P163, DOI 10.1177/1073858403262152; Coltheart M., 2001, HDB COGNITIVE NEUROP, P3; deBruin JPC, 1997, BEHAV BRAIN RES, V85, P47, DOI 10.1016/S0166-4328(96)00163-5; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510; DIVAC I, 1985, BRAIN PLASTICITY LEA, P205; DUNNETT SB, 1982, SCAND J PSYCHOL, P104; Elbert T, 2004, NEUROSCIENTIST, V10, P129, DOI 10.1177/1073858403262111; Fodor J. A., 1983, MODULARITY MIND; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Krechevsky I, 1933, J COMP PSYCHOL, V16, P99, DOI 10.1037/h0072223; Krechevsky I, 1932, PSYCHOL REV, V39, P516, DOI 10.1037/h0073500; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; LEVERE ND, 1982, PHYSIOL PSYCHOL, V10, P165; LEVERE TE, 1975, PSYCHOL REV, V82, P344; LEVINE M, 1963, PSYCHOL REV, V70, P254, DOI 10.1037/h0045543; LEVINE M, 1970, PSYCHOL BULL, V74, P397, DOI 10.1037/h0032951; Marr D., 1982, VISION COMPUTATIONAL; Mogensen J, 2005, BRAIN RES BULL, V65, P41, DOI 10.1016/j.brainresbull.2004.11.010; Mogensen J, 2004, PHARMACOL BIOCHEM BE, V77, P381, DOI 10.1016/j.pbb.2003.11.017; Mogensen J, 2004, BRAIN RES BULL, V63, P217, DOI 10.1016/j.brainresbull.2004.02.008; Mogensen J, 2003, PHARMACOL BIOCHEM BE, V75, P381, DOI 10.1016/S0091-3057(03)00107-2; MOGENSEN J, 1987, ACTA NEUROBIOL EXP, V47, P45; Mogensen J, 2002, NEUROBIOL LEARN MEM, V78, P139, DOI 10.1006/nlme.2001.4055; MOGENSEN J, 2003, HOMEOSTASIS HLTH DIS, V42, P97; Mogensen J., 2003, HDB LAB ANIMAL SCI, VII, P95; Mogensen J, 2007, BRAIN RES BULL, V73, P86, DOI 10.1016/j.brainresbull.2007.02.006; Monakow C., 1914, LOKALISATION GROSSHI; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nieto-Escamez FA, 2002, BEHAV BRAIN RES, V134, P93, DOI 10.1016/S0166-4328(01)00458-2; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Olton D. S., 1978, CIBA F S, V58, P327; Panksepp J., 2000, EVOLUTION COGNITION, V6, P108, DOI DOI 10.1146/ANNUREV.AN.18.100189.0; Racine RJ, 1965, PSYCHON SCI, V3, P285; Ramachandran VS, 1998, PHANTOMS BRAIN PROBI; RESTLE F, 1962, PSYCHOL REV, V69, P329, DOI 10.1037/h0044672; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; ROSNER BS, 1970, ANNU REV PSYCHOL, V21, P555, DOI 10.1146/annurev.ps.21.020170.003011; Rumelhart D. E., 1986, PARALLEL DISTRIBUTED; Selnes OA., 2001, HDB COGNITIVE NEUROP, P23; STEIN DG, 1997, BRAIN REPAIR; Teasell R, 2006, CAN J NEUROL SCI, V33, P357, DOI 10.1017/S0317167100005308; Trabasso T., 1968, ATTENTION LEARNING T; Werbos P.J., 1994, ROOTS BACKPROPAGATIO, VVolume 1; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; WORTWEIN G, 1994, BEHAV BRAIN RES, V63, P127, DOI 10.1016/0166-4328(94)90083-3; WORTWEIN G, 1995, INT J NEUROSCI, V82, P71, DOI 10.3109/00207459508994291	50	25	25	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0036-5564	1467-9450		SCAND J PSYCHOL	Scand. J. Psychol.	DEC	2009	50	6					561	573		10.1111/j.1467-9450.2009.00781.x			13	Psychology, Multidisciplinary	Psychology	522CR	WOS:000271975800006	19930255	Bronze			2021-06-18	
J	van 't Ent, D; van Beijsterveldt, CEM; Derks, EM; Hudziak, JJ; Veltman, DJ; Todd, RD; Boomsma, DI; De Geus, EJC				van 't Ent, D.; van Beijsterveldt, C. E. M.; Derks, E. M.; Hudziak, J. J.; Veltman, D. J.; Todd, R. D.; Boomsma, D. I.; De Geus, E. J. C.			NEUROIMAGING OF RESPONSE INTERFERENCE IN TWINS CONCORDANT OR DISCORDANT FOR INATTENTION AND HYPERACTIVITY SYMPTOMS	NEUROSCIENCE			English	Article						functional MRI; Stroop task; flanker task; ADHD; genetic risk; environmental risk	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; OPERATING CHARACTERISTIC ANALYSIS; DOPAMINE TRANSPORTER GENOTYPE; CHILD-BEHAVIOR CHECKLIST; PURE CONDUCT DISORDER; CLOSED-HEAD INJURY; BRAIN ABNORMALITIES; SUSTAINED ATTENTION; UNAFFECTED SIBLINGS; STRIATAL ACTIVATION	Attention deficit hyperactivity disorder (ADHD) is to a large extent influenced by genetic factors, but environmental influences are considered important as well. To distinguish between functional brain changes underlying primarily genetically and environmentally mediated ADHD, we used functional magnetic resonance imaging (fMRI) to compare response interference in monozygotic twins highly concordant or discordant for attention problems (AP). AP scores were assessed longitudinally with the Child Behavior Check List attention problem scale (CBCL-AP). Response interference was measured during two executive function paradigms; a color-word Stroop and a flanker task. The neuroimaging results indicated that, across the entire sample, children with high CBCL-AP scores, relative to children with low CBCL-AP scores, showed decreased activation to response interference in dorsolateral prefrontal, parietal and temporal brain regions. Increased activation was noted in the premotor cortex and regions associated with visual selective attention processing, possibly reflecting compensatory mechanisms to maintain task performance. Specific comparisons of high and low scoring concordant twin pairs suggest that AP of genetic origin was characterized by decreased activation of the left dorsolateral prefrontal cortex during the Stroop task and right parietal lobe during the flanker task. In contrast, comparison of twins from discordant monozygotic pairs, suggests that AP of environmental origin was characterized by decreased activation in left and right temporal lobe areas, but only during Stroop interference. The finding of distinct brain activation changes to response interference in inattention/hyperactivity of "genetic" versus "environmental" origin, indicates that genetic and environmental risk factors for attention/hyperactivity problems affect the brain in different ways. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.	[van 't Ent, D.; van Beijsterveldt, C. E. M.; Hudziak, J. J.; Boomsma, D. I.; De Geus, E. J. C.] Vrije Univ Amsterdam, Dept Biol Psychol, NL-1081 BT Amsterdam, Netherlands; [Derks, E. M.] Univ Med Ctr Utrecht, Dept Psychiat, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands; [Hudziak, J. J.] Univ Vermont, Dept Psychiat, Burlington, VT USA; [Veltman, D. J.] Vrije Univ Amsterdam Med Ctr, Dept Psychiat, Amsterdam, Netherlands; [Veltman, D. J.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Todd, R. D.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA	van 't Ent, D (corresponding author), Vrije Univ Amsterdam, Dept Biol Psychol, Boechorststr 1, NL-1081 BT Amsterdam, Netherlands.	d.vant.ent@psy.vu.nl	de Geus, Eco J.C./M-9318-2015; Boomsma, Dorret I/AAX-4470-2020; Derks, Eske M/A-1652-2017	de Geus, Eco J.C./0000-0001-6022-2666; Derks, Eske M/0000-0002-6292-6883; van 't Ent, Dennis/0000-0003-2001-1375; van Beijsterveldt, Toos/0000-0002-6617-4201	NWO/SPINetherlands Organization for Scientific Research (NWO) [56-464-14192]; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RO1 MH58799-03]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 MH66148-01]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH066148, R01MH058799] Funding Source: NIH RePORTER	We thank Hanne Lehn, Niels van Strien, Hester van den Akker and Marit de Haas for help with MRI data collection. Funded by NWO/SPI 56-464-14192; NIMH, RO1 MH58799-03; NIH R21 MH66148-01.	ACHENBACH TM, 1991, MONOGR SOC RES CHILD, V56, pR5; Achenbach TM, 2003, J CLIN CHILD ADOLESC, V32, P328, DOI 10.1207/S15374424JCCP3203_02; American Psychiatric Association, 1994, DIAGN STAT MAN DIS D; Arend I, 2008, BRAIN, V131, P2140, DOI 10.1093/brain/awn135; Auerbach JG, 2001, PSYCHIATR GENET, V11, P31, DOI 10.1097/00041444-200103000-00006; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Bhutta AT, 2001, TRENDS NEUROSCI, V24, P129, DOI 10.1016/S0166-2236(00)01747-1; Boomsma D, 2002, NAT REV GENET, V3, P872, DOI 10.1038/nrg932; Boomsma DI, 2002, TWIN RES, V5, P401, DOI 10.1375/twin.5.5.401; Booth JR, 2005, J CHILD PSYCHOL PSYC, V46, P94, DOI 10.1111/j.1469-7610.2004.00337.x; Brieber S, 2007, J CHILD PSYCHOL PSYC, V48, P1251, DOI 10.1111/j.1469-7610.2007.01799.x; Brookes K, 2006, MOL PSYCHIATR, V11, P934, DOI 10.1038/sj.mp.4001869; Brookes KJ, 2006, ARCH GEN PSYCHIAT, V63, P74, DOI 10.1001/archpsyc.63.1.74; Buitelaar J K, 2000, Ned Tijdschr Geneeskd, V144, P1716; Bush G, 2005, BIOL PSYCHIAT, V57, P1273, DOI 10.1016/j.biopsych.2005.01.034; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; Cao QJ, 2008, BRAIN RES, V1219, P159, DOI 10.1016/j.brainres.2008.04.028; Carmona S, 2005, NEUROSCI LETT, V389, P88, DOI 10.1016/j.neulet.2005.07.020; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Castellanos FX, 2003, AM J PSYCHIAT, V160, P1693, DOI 10.1176/appi.ajp.160.9.1693; CHEN WJ, 1994, J CONSULT CLIN PSYCH, V62, P1017, DOI 10.1037/0022-006X.62.5.1017; Constable RT, 2004, NEUROIMAGE, V22, P11, DOI 10.1016/j.neuroimage.2004.01.001; Derks EM, 2006, COMPR PSYCHIAT, V47, P116, DOI 10.1016/j.comppsych.2005.05.006; Derks EM, 2008, BEHAV GENET, V38, P11, DOI 10.1007/s10519-007-9178-8; Dickstein SG, 2006, J CHILD PSYCHOL PSYC, V47, P1051, DOI 10.1111/j.1469-7610.2006.01671.x; Doyle AE, 2006, J CLIN PSYCHIAT, V67, P21; Durston S, 2005, MOL PSYCHIATR, V10, P678, DOI 10.1038/sj.mp.4001649; Durston S, 2004, J AM ACAD CHILD PSY, V43, P332, DOI 10.1097/00004583-200403000-00016; Durston S, 2003, MENT RETARD DEV D R, V9, P184, DOI 10.1002/mrdd.10079; Durston S, 2003, BIOL PSYCHIAT, V53, P871, DOI 10.1016/S0006-3223(02)01904-2; Durston S, 2008, J AM ACAD CHILD PSY, V47, P61, DOI 10.1097/chi.0b013e31815a5f17; Durston S, 2006, BIOL PSYCHIAT, V60, P1062, DOI 10.1016/j.biopsych.2005.12.020; Ellison-Wright I, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-51; Ent DV, 2007, NEUROIMAGE, V35, P1004, DOI 10.1016/j.neuroimage.2007.01.037; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Fassbender C, 2006, CLIN PSYCHOL REV, V26, P445, DOI 10.1016/j.cpr.2006.01.003; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Gerring J, 2000, BRAIN INJURY, V14, P205; Giedd JN, 2001, ANN NY ACAD SCI, V931, P33; Goldman LS, 1998, JAMA-J AM MED ASSOC, V279, P1100, DOI 10.1001/jama.279.14.1100; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hill DE, 2003, NEUROPSYCHOLOGY, V17, P496, DOI 10.1037/0894-4105.17.3.496; Homack S, 2004, ARCH CLIN NEUROPSYCH, V19, P725, DOI 10.1016/j.acn.2003.09.003; Hudziak JJ, 2004, J CHILD PSYCHOL PSYC, V45, P1299, DOI 10.1111/j.1469-7610.2004.00314.x; Hudziak JJ, 2000, J AM ACAD CHILD PSY, V39, P469, DOI 10.1097/00004583-200004000-00016; Hudziak JJ, 2005, AM J PSYCHIAT, V162, P1614, DOI 10.1176/appi.ajp.162.9.1614; Huizink AC, 2006, NEUROSCI BIOBEHAV R, V30, P24, DOI 10.1016/j.neubiorev.2005.04.005; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; Kahn RS, 2003, J PEDIATR-US, V143, P104, DOI 10.1016/S0022-3476(03)00208-7; Kates WR, 2002, PSYCHIAT RES-NEUROIM, V116, P63, DOI 10.1016/S0925-4927(02)00066-5; Konrad K, 2006, BIOL PSYCHIAT, V59, P643, DOI 10.1016/j.biopsych.2005.08.013; Krain AL, 2006, CLIN PSYCHOL REV, V26, P433, DOI 10.1016/j.cpr.2006.01.005; Lansbergen MM, 2007, NEUROPSYCHOLOGY, V21, P251, DOI 10.1037/0894-4105.21.2.251; Lasky-Su J, 2008, AM J MED GENET B, V147B, P1345, DOI 10.1002/ajmg.b.30867; Leh SE, 2008, INT J BIOMED IMAGING, V2008, DOI 10.1155/2008/789539; Lehn H, 2007, J AM ACAD CHILD PSY, V46, P83, DOI 10.1097/01.chi.0000242244.00174.d9; Linnet KM, 2003, AM J PSYCHIAT, V160, P1028, DOI 10.1176/appi.ajp.160.6.1028; Lou HC, 2004, DEV MED CHILD NEUROL, V46, P179; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2002, J AM ACAD CHILD PSY, V41, P563, DOI 10.1097/00004583-200205000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P443, DOI 10.1097/01.chi.0000156661.38576.0f; Mulder MJ, 2008, J AM ACAD CHILD PSY, V47, P68, DOI 10.1097/chi.0b013e31815a56dc; Mullane JC, 2009, CHILD NEUROPSYCHOL, V15, P321, DOI 10.1080/09297040802348028; Neuman RJ, 1999, J AM ACAD CHILD PSY, V38, P25, DOI 10.1097/00004583-199901000-00016; Overmeyer S, 2001, PSYCHOL MED, V31, P1425, DOI 10.1017/S0033291701004706; Peterson BS, 2000, ARCH GEN PSYCHIAT, V57, P364, DOI 10.1001/archpsyc.57.4.364; Powell AL, 1997, NEUROPSY NEUROPSY BE, V10, P151; Qiu AQ, 2009, AM J PSYCHIAT, V166, P74, DOI 10.1176/appi.ajp.2008.08030426; Rietveld MJH, 2004, J CHILD PSYCHOL PSYC, V45, P577, DOI 10.1111/j.1469-7610.2004.00247.x; Rietveld MJH, 2003, AM J MED GENET B, V117B, P102, DOI 10.1002/ajmg.b.10024; Rubia K, 1999, AM J PSYCHIAT, V156, P891, DOI 10.1176/ajp.156.6.891; Rubia K, 2008, AM J PSYCHIAT, V165, P889, DOI 10.1176/appi.ajp.2008.07071084; Rubia K, 2009, AM J PSYCHIAT, V166, P83, DOI 10.1176/appi.ajp.2008.08020212; Schubert R, 2005, PEDIATR NEUROL, V32, P1, DOI 10.1016/j.pediatrneurol.2004.06.007; Seidman LJ, 2005, BIOL PSYCHIAT, V57, P1263, DOI 10.1016/j.biopsych.2004.11.019; Semrud-Clikeman M, 2000, J AM ACAD CHILD PSY, V39, P477, DOI 10.1097/00004583-200004000-00017; Sergeant JA, 2002, BEHAV BRAIN RES, V130, P3, DOI 10.1016/S0166-4328(01)00430-2; SHAFFER D, 1993, J AM ACAD CHILD PSY, V32, P643, DOI 10.1097/00004583-199305000-00023; Shaw P, 2007, P NATL ACAD SCI USA, V104, P19649, DOI 10.1073/pnas.0707741104; Shaw P, 2007, ARCH GEN PSYCHIAT, V64, P921, DOI 10.1001/archpsyc.64.8.921; Smith AB, 2008, J CHILD PSYCHOL PSYC, V49, P977, DOI 10.1111/j.1469-7610.2008.01870.x; Smith AB, 2006, AM J PSYCHIAT, V163, P1044, DOI 10.1176/appi.ajp.163.6.1044; Sowell ER, 2003, LANCET, V362, P1699, DOI 10.1016/S0140-6736(03)14842-8; Stins JF, 2005, CHILD NEUROPSYCHOL, V11, P191, DOI 10.1080/092970490911351; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tamm L, 2004, J AM ACAD CHILD PSY, V43, P1430, DOI 10.1097/01.chi.0000140452.51205.8d; Thapar A, 1999, BRIT J PSYCHIAT, V174, P105, DOI 10.1192/bjp.174.2.105; Vaidya CJ, 2005, AM J PSYCHIAT, V162, P1605, DOI 10.1176/appi.ajp.162.9.1605; Valera EM, 2007, BIOL PSYCHIAT, V61, P1361, DOI 10.1016/j.biopsych.2006.06.011; van Mourik R, 2005, J CHILD PSYCHOL PSYC, V46, P150, DOI 10.1111/j.1469-7610.2004.00345.x; Vance A, 2007, MOL PSYCHIATR, V12, P826, DOI 10.1038/sj.mp.4001999; Verhulst F. C., 1996, HANDLEIDING CBCL 4 1; Wait JWV, 2002, J TROP PEDIATRICS, V48, P294, DOI 10.1093/tropej/48.5.294; Wang HX, 2007, PEPTIDES, V28, P547, DOI 10.1016/j.peptides.2006.10.006; Wascher E, 1999, J COGNITIVE NEUROSCI, V11, P214, DOI 10.1162/089892999563346; Willemssen R, 2004, PSYCHOPHYSIOLOGY, V41, P762, DOI 10.1111/j.1469-8986.2004.00201.x; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001; Zang YF, 2005, BRAIN DEV-JPN, V27, P544, DOI 10.1016/j.braindev.2004.11.009; Zhu CZ, 2008, NEUROIMAGE, V40, P110, DOI 10.1016/j.neuroimage.2007.11.029	100	25	25	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	NOV 24	2009	164	1			SI		16	29		10.1016/j.neuroscience.2009.01.056			14	Neurosciences	Neurosciences & Neurology	517JI	WOS:000271609000003	19409224	Green Accepted			2021-06-18	
J	MacNevin, CJ; Atif, F; Sayeed, I; Stein, DG; Liotta, DC				MacNevin, Christopher J.; Atif, Fahim; Sayeed, Iqbal; Stein, Donald G.; Liotta, Dennis C.			Development and Screening of Water-Soluble Analogues of Progesterone and Allopregnanolone in Models of Brain Injury	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MALE-RATS; CORTICAL CONTUSION; CONTROLLED-TRIAL; HEAD-INJURY; FEMALE RATS; CELL-DEATH; EDEMA; EXPRESSION; INDUCTION	Preclinical and clinical research findings have revealed that the hormone progesterone, when acutely administered, can dramatically reduce cerebral edema, inflammation, tissue necrosis, and programmed cell death following traumatic brain injury (TBI). The poor aqueous solubility of progesterone, however, limits its potential use as a therapeutic. Several chemically novel analogues of progesterone and its natural metabolite allopregnanolone have been synthesized and screened using both in vitro and whole animal models of TBI. The new derivatives demonstrated greatly improved solubility and select compounds have shown equivalent effectiveness to progesterone in reducing cerebral edema after TBI.	[MacNevin, Christopher J.; Liotta, Dennis C.] Emory Univ, Dept Chem, Atlanta, GA 30322 USA; [Atif, Fahim; Sayeed, Iqbal; Stein, Donald G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA	Liotta, DC (corresponding author), Emory Univ, Dept Chem, 1515 Dickey Dr,Emerson Bldg Room 403, Atlanta, GA 30322 USA.	dliotta@emory.edu	Stein, Donald/AAJ-5139-2020		Department of DefenseUnited States Department of Defense	We thank the Department of Defense for funding support.	ADEOTI SB, 1989, TETRAHEDRON, V45, P3717, DOI 10.1016/S0040-4020(01)89233-4; Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Alderson P, 2004, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001048.PUB2, 10.1002/14651858.CD001048.pub2]; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; BACH G, 1968, CAN J CHEMISTRY, V46, P733, DOI 10.1139/v68-123; Brann DW, 2005, NEUROENDOCRINOLOGY, V81, P120, DOI 10.1159/000086405; Chan JR, 1998, P NATL ACAD SCI USA, V95, P10459, DOI 10.1073/pnas.95.18.10459; CHAO TC, 1994, AM J REPROD IMMUNOL, V32, P43, DOI 10.1111/j.1600-0897.1994.tb00877.x; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Comin MJ, 2004, TETRAHEDRON, V60, P11851, DOI 10.1016/j.tet.2004.09.097; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Davies A R, 2005, Crit Care Resusc, V7, P238; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; KHOURI N, 1991, J PHARM SCI-US, V80, P661, DOI 10.1002/jps.2600800710; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; LUCHE JL, 1978, J CHEM SOC CHEM COMM, P601, DOI 10.1039/c39780000601; LUCHE JL, 1978, J AM CHEM SOC, V100, P2226, DOI 10.1021/ja00475a040; MANCERA O, 1953, J AM CHEM SOC, V75, P1286, DOI 10.1021/ja01102a006; Mani SK, 2006, NEUROSCIENCE, V138, P773, DOI 10.1016/j.neuroscience.2005.07.034; Marin-Husstege M, 2004, DEV NEUROSCI-BASEL, V26, P245, DOI 10.1159/000082141; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Pierson RC, 2005, MOL BRAIN RES, V138, P105, DOI 10.1016/j.molbrainres.2004.10.047; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shen H, 2005, NEUROPHARMACOLOGY, V49, P573, DOI 10.1016/j.neuropharm.2005.04.026; Shimamura K, 1995, J REPROD FERTIL, V105, P253, DOI 10.1530/jrf.0.1050253; Sim FJ, 2002, J NEUROSCI, V22, P2451, DOI 10.1523/JNEUROSCI.22-07-02451.2002; SOLOWAY AH, 1953, J AM CHEM SOC, V75, P2356, DOI 10.1021/ja01106a020; SUBRAMANIAN M, 1993, NEUROSCI LETT, V155, P151, DOI 10.1016/0304-3940(93)90695-H; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; VARASI M, 1987, J ORG CHEM, V52, P4235, DOI 10.1021/jo00228a016; Verkman AS, 2000, EXP PHYSIOL, V85, p233S, DOI 10.1111/j.1469-445X.2000.tb00028.x; WIELAND P, 1950, HELV CHIM ACTA, V33, P2215, DOI 10.1002/hlca.19500330730; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	62	25	35	0	19	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	OCT 8	2009	52	19					6012	6023		10.1021/jm900712n			12	Chemistry, Medicinal	Pharmacology & Pharmacy	501EF	WOS:000270361600023	19791804				2021-06-18	
J	Sherer, M; Yablon, SA; Nakase-Richardson, R				Sherer, Mark; Yablon, Stuart A.; Nakase-Richardson, Risa			Patterns of Recovery of Posttraumatic Confusional State in Neurorehabilitation Admissions After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Confusion; Rehabilitation	HEAD-INJURY; AMNESIA; SCALE; ORIENTATION; SEVERITY	Objective: To provide preliminary descriptions of patterns of resolution of symptoms of acute confusion after traumatic brain injury (TBI). Design: Prospective, descriptive, cohort Study. Setting: Inpatient neurorehabilitation unit. Participants: Patients (N=107) meeting criteria for posttraumatic confusional state at admission to inpatient rehabilitation. Interventions: Not applicable. Main Outcome Measure: Patterns of resolution of posttraumatic confusional state symptoms over the first 3 confusion assessment protocol evaluations for patients with mild, moderate, and severe confusion. Results: Posttraumatic confusional state symptoms resolving earliest were psychotic-type symptoms, decreased daytime arousal, and nighttime sleep disturbance. Fluctuation and cognitive impairment were the 2 most persistent symptoms. Seventy-three percent of patients showed improvement of I or more symptoms from the first to third evaluation. Confusion severity groups did not significantly differ on indices of injury severity (Glasgow Coma Scale score, time to follow commands) but did differ on functional status at discharge from inpatient rehabilitation. Conclusions: While posttraumatic confusional state is a heterogeneous disorder, there is a predictable pattern of symptom resolution. Differences in patients' confusion severity and patterns of symptoms may relate to differing underlying neural injury.	[Sherer, Mark] TIRR Mem Hermann, Dept Res, Houston, TX 77030 USA; [Sherer, Mark] Baylor Coll Med, Houston, TX 77030 USA; [Yablon, Stuart A.] Methodist Rehabil Ctr, Jackson, MS USA; [Nakase-Richardson, Risa] James A Haley Vet Affairs Med Ctr, Tampa, FL USA	Sherer, M (corresponding author), TIRR Mem Hermann, Dept Res, 1333 Moursund, Houston, TX 77030 USA.	Mark.Sherer@memorialhermann.org			U.S. Department of Education National Institute on Disability and Rehabilitation ResearchUS Department of Education [H133A020514, H133A070043]	Supported by the U.S. Department of Education National Institute on Disability and Rehabilitation Research (grant nos. H133A020514 and H133A070043).	CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; ELLENBERG JH, 1996, ARCH NEUROL-CHICAGO, V53, P792; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; NAKASERICHARDSO.R, 2006, J INT NEUROPSYCHO S1, V12, P215; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sherer M, 2008, ARCH PHYS MED REHAB, V89, P42, DOI 10.1016/j.apmr.2007.08.128; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Weir N, 2006, BRAIN INJURY, V20, P927, DOI 10.1080/02699050600832684	13	25	25	1	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2009	90	10					1749	1754		10.1016/j.apmr.2009.05.011			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	507UA	WOS:000270879400016	19801066				2021-06-18	
J	Shafieian, M; Darvish, KK; Stone, JR				Shafieian, Mehdi; Darvish, Kurosh K.; Stone, James R.			Changes to the viscoelastic properties of brain tissue after traumatic axonal injury	JOURNAL OF BIOMECHANICS			English	Article						Traumatic brain injury; Traumatic axonal injury; Brain biomechanics; Viscoelastic; Properties of brain tissue; Indentation test; Finite element analysis; Damage function	BIOMECHANICS; DEFORMATION; MODEL; TESTS; RAT	While it has been shown that repetitive mild brain injuries can cause cumulative damage to the brain, changes to the mechanical properties of brain tissue at large deformations were also noted in the literature. The goal of this study was to show that the viscoelastic properties of brain tissue significantly change after traumatic axonal injury (TAI). An impact acceleration model was used to create TAI in the rat brainstem which was quantified with an immunohistochemistry technique at the ponto-medullary junction (PmJ) and pyramidal decussation (PDx). The viscoelastic properties at these two points with and without preconditioning were characterized using an indentation technique combined with finite element analysis and a comparison was made between injured and uninjured specimens, which revealed statistically significant reduction in the instantaneous elastic force at PDx where the brain tissue sustained a significantly higher level of injury. The result of this study can be used to characterize a damage function for the brain tissue undergoing large deformation. (C) 2009 Elsevier Ltd. All rights reserved	[Shafieian, Mehdi; Darvish, Kurosh K.] Temple Univ, Dept Mech Engn, Philadelphia, PA 19122 USA; [Stone, James R.] Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22908 USA	Darvish, KK (corresponding author), Temple Univ, Dept Mech Engn, 1947 N 12th St, Philadelphia, PA 19122 USA.	kdarvish@temple.edu	; Shafieian, Mehdi/S-9091-2017	Darvish, Kurosh/0000-0002-6674-266X; Shafieian, Mehdi/0000-0001-8533-0241	Southern Consortium for Injury Biomechanics [DTNH22-01-H-07551]	The authors wish to acknowledge the help of Dr. Jeff Crandall and Dr. David Okonkwo, and also David McDaniel, Jamie Wagner and Prachi Sanghavi for their assistance in conducting the experiments at the Center for Applied Biomechanics and the Department of Neurosurgery at the University of Virginia. The support for this study was provided by the Southern Consortium for Injury Biomechanics under Grant no. DTNH22-01-H-07551.	Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Darvish K., 2003, STAPP CAR CRASH J, V47, P79; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; FALLENSTEIN GT, 1969, 69BHF6 ASME; Fung Y., 1993, BIOMECHANICS MECH PR; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; HAYES WC, 1972, J BIOMECH, V5, P541, DOI 10.1016/0021-9290(72)90010-3; LJUNG C, 1975, J BIOMECH, V8, P263, DOI 10.1016/0021-9290(75)90078-0; Macosko C. W., 1994, RHEOLOGY PRINCIPLES; Maikos JT, 2008, J NEUROTRAUM, V25, P795, DOI 10.1089/neu.2007.0423; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MELVIN, 2002, ACCIDENTAL INJURIES, P277; MERTZ, 2002, ACCIDENTAL INJURIES, P72; MONTGOMERY, 2004, DESIGN ANAL EXPT; Motulsky H. J., 2007, PRISM 5 STAT GUIDE; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Simo J.C., 1998, COMPUTATIONAL INELAS; Sneddon I.N., 1965, INT J ENG SCI, V3, P47, DOI [DOI 10.1016/0020-7225(65)90019-4, 10.1016/0020-7225(65)90019-4]; STAINAKER, 1969, THESIS W VIRGINIA U; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Yang KH, 2003, INT J VEHICLE DES, V32, P116, DOI 10.1504/IJVD.2003.003240	29	25	26	0	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	SEP 18	2009	42	13					2136	2142		10.1016/j.jbiomech.2009.05.041			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	502RO	WOS:000270478000019	19698945				2021-06-18	
J	Frederick, RI; Bowden, SC				Frederick, Richard I.; Bowden, Stephen C.			The Test Validation Summary	ASSESSMENT			English	Article						psychological testing; malingering; predictive power; test utilities	MEMORY MALINGERING TOMM; TRAUMATIC BRAIN-INJURY; MIXED GROUP VALIDATION; BASE-RATE PROBLEM; STRUCTURED INVENTORY; HEAD-INJURY; NEUROCOGNITIVE DYSFUNCTION; CLASSIFICATION ACCURACY; COGNITIVELY INTACT; DIAGNOSTIC SIGNS	Common rates employed in classificatory testing are the true positive rate (TPR), false positive rate (FPR), positive predictive power (PPP), and negative predictive power (NPP). FPR and TPR are estimated from research samples representing populations to be distinguished by classificatory testing. PPP and NPP are used by clinicians to classify test takers into populations. PPP and NPP depend on the base rate (BR) of population members in the clinician's sample. The authors introduce the test validation summary (TVS) as a means to report within a single graph the FPR and TPR and the ranges of PPP and NPP across all potential sample BRs for any chosen cut score. The authors investigate how the TVS has other applications, including the estimation of local BR for the condition of interest and the estimation of standard errors for FPR and TPR when estimated across multiple independent validation studies of the classificatory test.	[Frederick, Richard I.] US Med Ctr Fed Prisoners, Dept Psychol, Springfield, MO 65807 USA; [Bowden, Stephen C.] Univ Melbourne, Melbourne, Vic 3010, Australia	Frederick, RI (corresponding author), US Med Ctr Fed Prisoners, Dept Psychol, 1900 W Sunshine St, Springfield, MO 65807 USA.	rickfrederick@gmail.com					Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; Bolan B, 2002, J CLIN EXP NEUROPSYC, V24, P154, DOI 10.1076/jcen.24.2.154.1000; Bowden SC, 1998, NEUROPSYCHOL REHABIL, V8, P243, DOI 10.1080/713755573; BROWN GW, 1976, AM J DIS CHILD, V130, P56, DOI 10.1001/archpedi.1976.02120020058009; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Cragar DE, 2006, CLIN NEUROPSYCHOL, V20, P552, DOI 10.1080/13854040590947380; DAWES RM, 1967, J CLIN PSYCHOL, V23, P403, DOI 10.1002/1097-4679(196710)23:4<403::AID-JCLP2270230402>3.0.CO;2-N; DAWES RM, 1966, PSYCHOL BULL, V66, P63, DOI 10.1037/h0023584; Delain SL, 2003, ASSESSMENT, V10, P370, DOI 10.1177/1073191103259156; Dickens S. E., 1992, STRUCTURED INTERVIEW; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Duncan A, 2005, ASSESSMENT, V12, P123, DOI 10.1177/1073191105275512; Edens JF, 1999, J AM ACAD PSYCHIATRY, V27, P387; ELWOOD RW, 1993, CLIN PSYCHOL REV, V13, P409, DOI 10.1016/0272-7358(93)90012-B; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; Frederick RI, 2000, BEHAV SCI LAW, V18, P693, DOI 10.1002/bsl.432; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gierok SD, 2005, ARCH CLIN NEUROPSYCH, V20, P755, DOI 10.1016/j.acn.2005.04.008; GREEN P, 2007, DETECTION NONCREDIBL, P50; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Griner P F, 1981, Ann Intern Med, V94, P557; Haber AH, 2006, CLIN NEUROPSYCHOL, V20, P524, DOI 10.1080/13854040590967595; Hill SK, 2003, J FORENSIC NEUROPSYC, V3, P1; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; Lewis JL, 2002, PSYCHOL ASSESSMENT, V14, P170, DOI 10.1037//1040-3590.14.2.170; McCaffrey R. J., 2003, J FORENSIC NEUROPSYC, V3, P45, DOI [10.1300/J151v03n03_03, DOI 10.1300/J151V03N03_03]; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; Merckelbach H, 2003, ARCH CLIN NEUROPSYCH, V18, P145, DOI 10.1016/S0887-6177(01)00191-3; Miller, 2001, MILLER FORENSIC ASSE; Mitrushina M., 2005, HDB NORMATIVE DATA N; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Moss A, 2003, BRAIN INJURY, V17, P377, DOI 10.1080/0269905031000070125; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; O'Bryant SE, 2006, CLIN NEUROPSYCHOL, V20, P533, DOI 10.1080/13854040590967568; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rogers R, 2004, PSYCHOL ASSESSMENT, V16, P139, DOI 10.1037/1040-3590.16.2.139; Rogers R., 2004, EVALUATION COMPETENC; ROHLING ML, 2007, DETECTION NONCREDIBL, P453; RORER LG, 1982, J CONSULT CLIN PSYCH, V50, P419, DOI 10.1037/0022-006X.50.3.419; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; SOPER HV, 1988, J CLIN EXP NEUROPSYC, V10, P255, DOI 10.1080/01688638808408240; Straus SE., 2005, EVIDENCE BASED MED P, V3rd; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481; Widows M. R., 2005, STRUCTURED INVENTORY; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594; Woods SP, 2003, J CLIN EXP NEUROPSYC, V25, P431, DOI 10.1076/jcen.25.3.431.13800; Zakzanis KK, 1998, J CLIN EXP NEUROPSYC, V20, P419, DOI 10.1076/jcen.20.3.419.821; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	64	25	26	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911			ASSESSMENT	Assessment	SEP	2009	16	3					215	236		10.1177/1073191108325005			22	Psychology, Clinical	Psychology	482YS	WOS:000268927400001	18838580				2021-06-18	
J	Adams, EN; Marks, A; Lizer, MH				Adams, Erin N.; Marks, Alla; Lizer, Mitsi H.			Carbamazepine-induced hyperammonemia	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article						Anticonvulsants; Carbamazepine; Desmopressin acetate; Guanfacine; Hyperammonemia; Olanzapine; Quetiapine; Topiramate; Toxicity	VALPROIC ACID; ENCEPHALOPATHY; ASTERIXIS; CARNITINE	Purpose. A case of carbamazepine-induced hyperammonemia is presented. Summary. A 26-year-old man with bipolar disorder, seizures, and mild mental retardation secondary to a traumatic brain injury began treatment with carbamazepine for aggression and seizure control. After three weeks of carbamazepine therapy, the patient arrived at the emergency department (ED) with severe agitation and aggressive behavior. His oral medications included topiramate, carbamazepine, olanzapine, quetiapine, guanfacine, and desmopressin acetate. The patient's medications had been stable for at least six months except for the addition of carbamazepine one month before his arrival at the ED. Upon admission, the patient's vital signs were found to be within normal limits, as were his liver profile results, complete blood count, thyroid-stimulating-hormone level, and serum chemistry panel. His serum carbamazepine concentration was 3.9 mu g/mL (reference range, 4-12 mu g/mL), and his serum ammonia concentration was 127 mu g/dL (reference range, 19-60 mu g/dL). Carbamazepine was discontinued upon admission, and the patient was treated with oral lactulose. Since carbamazepine was discontinued and had been prescribed for bipolar disorder, his olanzapine dosage was increased, and trazodone was added at bedtime for insomnia. Of note, the patient had been on carbamazepine therapy one year earlier and had experienced the same adverse event. He had also developed elevated serum ammonia levels while on valproic acid. The patient's serum ammonia level returned to normal by hospital day 4, and he was discharged to his group home. Conclusion. A 26-year-old man with bipolar disorder developed hyperammonemia three weeks after initiating carbamazepine therapy.	[Adams, Erin N.; Marks, Alla] Shenandoah Univ, Bernard J Dunn Sch Pharm, Div Technol Educ, Winchester, VA 22601 USA	Adams, EN (corresponding author), Shenandoah Univ, Bernard J Dunn Sch Pharm, Div Technol Educ, Hlth Profess Bldg,Room 145,1775 N Sector Court, Winchester, VA 22601 USA.	eadams@su.edu					Alqahtani S, 2007, CAN MED ASSOC J, V177, P568, DOI 10.1503/cmaj.061272; AMBROSETTO G, 1984, ACTA NEUROL SCAND, V69, P186, DOI 10.1111/j.1600-0404.1984.tb07799.x; Bjornsson E, 2008, ACTA NEUROL SCAND, V118, P281, DOI 10.1111/j.1600-0404.2008.01009.x; BROWN JR, 2006, TXB THERAPEUTICS DRU, P1358; Carr RB, 2007, AM J PSYCHIAT, V164, P1020, DOI 10.1176/appi.ajp.164.7.1020; Clay AS, 2007, CHEST, V132, P1368, DOI 10.1378/chest.06-2940; Endo F, 2004, J NUTR, V134, p1605S, DOI 10.1093/jn/134.6.1605S; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Hamer HM, 2000, NEUROLOGY, V54, P230, DOI 10.1212/WNL.54.1.230; KLASCO RK, DRUGDEX SYSTEM; LAUB MC, 1986, EPILEPSIA, V27, P559, DOI 10.1111/j.1528-1157.1986.tb03584.x; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; *NAT UR CYCL DIS F, WHAT IS UR CYCL DIS; *NOV, 2008, TEGR CARB PACK INS; OHTANI Y, 1982, J PEDIATR-US, V101, P782, DOI 10.1016/S0022-3476(82)80320-X; Raja M, 2002, J CLIN PSYCHOPHARM, V22, P631, DOI 10.1097/00004714-200212000-00019; RIVELLI M, 1988, AM J PSYCHIAT, V145, P269; SEASE JM, 2008, PHARMACOTHERAPY PATH, P645; Verrotti A, 2002, METAB BRAIN DIS, V17, P367, DOI 10.1023/A:1021918104127; Wadzinski J, 2007, J AM BOARD FAM MED, V20, P499, DOI 10.3122/jabfm.2007.05.070062; WEINER DL, PEDIAT INBORN ERRORS; WILLIAMS CA, 1984, NEUROLOGY, V34, P550, DOI 10.1212/WNL.34.4.550; Yee Jennie L., 2005, Journal of Pharmacy Technology, V21, P348	23	25	25	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	AUG 15	2009	66	16					1468	1470		10.2146/ajhp080454			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	482UO	WOS:000268914500012	19667003				2021-06-18	
J	Sher, L				Sher, Leo			A model of suicidal behavior in war veterans with posttraumatic mood disorder	MEDICAL HYPOTHESES			English	Article							TRAUMATIC BRAIN-INJURY; STRESS-DISORDER; DEPRESSED-PATIENTS; MAJOR DEPRESSION; RISK-FACTORS; COMORBIDITY; ANXIETY; HEALTH; PREDICTORS; MILITARY	Many wars have been fought during the history of civilization. About 30 armed conflicts are occurring now around the globe involving more than 25 countries. Many war veterans have symptoms of posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) including suicidal ideation and behavior. PTSD is frequently comorbid with MDD. I have previously proposed that some or all individuals diagnosed with comorbid PTSD and MDD have a separate psychobiological condition that can be termed "posttraumatic mood disorder" (PTMD). This idea was based on the fact that a significant number of studies suggested that patients suffering from comorbid PTSD and MDD differed clinically and biologically from individuals with PTSD alone or MDD alone. Individuals with comorbid PTSD and MDD are characterized by greater severity of symptoms, increased suicidality and the higher level of impairment in social and occupational functioning compared to individuals with PTSD alone or MDD alone. Neurobiological evidence supporting the concept of PTMD includes the findings from neuroendocrine challenge, cerebrospinal fluid, neuroimaging, sleep and other studies. In this paper, I propose a model of suicidal behavior in war veterans with PTMD. The model consists of the following components: (1) genetic factors; (2) prenatal development; (3) biological and psychosocial influences from birth to mobilization/deployment; (4) mobilization/pre-deployment stress; (5) combat stress, traumatic brain injury, and physical injury: (6) post-deployment stress; (7) biological and psychosocial influences after the deployment; (8) trigger (precipitant) of a suicidal act; and (9) suicidal act. The first four components determine vulnerability to combat stress. The first seven components determine predisposition to suicidal behavior, a key element that differentiates PTMD patients who are at high risk from those at lower risk. Suicidal behavior in PTMD can be attributed to the coincidence of a trigger with a predisposition for suicidal behavior. Suicide prevention in war veterans with PTMD should focus on (1) improvement in recognition of PTMD; (2) treating symptoms of PTMD; (3) preventing a relapse when the patient is in remission; (4) treating suicidal ideation; (5) treating comorbid psychiatric conditions including alcohol and drug abuse; (6) treating medical and neurological disorders including traumatic brain injury; and (7) social support. It is extremely important to understand PTMD, to optimize assessment and treatment for people with PTMD, and to identify processes that facilitate recovery from exposure to traumatic events. Every nation, every generation, faces traumas that cause suicide. The world needs to deal with this and it is one thing that the world can come together on. (C) 2009 Elsevier Ltd. All rights reserved.	Columbia Univ, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA	Sher, L (corresponding author), Columbia Univ, New York State Psychiat Inst, Dept Psychiat, 1051 Riverside Dr,Suite 2917,Box 42, New York, NY 10032 USA.	LS2003@columbia.edu					Bowman M., 2004, POSTTRAUMATIC STRESS, P15, DOI [10.1002/9780470713570.ch2, DOI 10.1002/9780470713570.CH2, DOI 10.1002/9780470713570]; Breslau N, 1998, ADVERSITY, STRESS AND PSYCHOPATHOLOGY, P319; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brown AS, 2000, AM J PSYCHIAT, V157, P190, DOI 10.1176/appi.ajp.157.2.190; Brown TA, 2001, J ABNORM PSYCHOL, V110, P585, DOI 10.1037//0021-843X.110.4.585; Bryant RA, 2005, PSYCHOL SCI, V16, P749, DOI 10.1111/j.1467-9280.2005.01608.x; Engel SM, 2005, PAEDIATR PERINAT EP, V19, P334, DOI 10.1111/j.1365-3016.2005.00676.x; Flint Jonathan, 2008, Novartis Found Symp, V289, P23; Ghafoori B, 2008, J TRAUMA DISSOCIATIO, V9, P85, DOI 10.1080/15299730802073726; Glover V, 2002, BRIT J PSYCHIAT, V180, P389, DOI 10.1192/bjp.180.5.389; Godleski L, 2008, BEHAV SCI LAW, V26, P271, DOI 10.1002/bsl.811; Hampton T, 2007, JAMA-J AM MED ASSOC, V298, P2732, DOI 10.1001/jama.298.23.2732; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Koenen KC, 2008, J AFFECT DISORDERS, V105, P109, DOI 10.1016/j.jad.2007.04.021; Koren D, 2006, CNS SPECTRUMS, V11, P616, DOI 10.1017/S1092852900013675; KRAMER TL, 1994, SUICIDE LIFE-THREAT, V24, P58; Landrigan PJ, 2008, MT SINAI J MED, V75, P129, DOI 10.1002/msj.20032; Mills PD, 2008, JT COMM J QUAL PATIE, V34, P482, DOI 10.1016/S1553-7250(08)34061-6; Mittendorfer-Rutz E, 2004, LANCET, V364, P1135, DOI 10.1016/S0140-6736(04)17099-2; Nad S, 2008, J NERV MENT DIS, V196, P79, DOI [10.1097/NMD.0b013e1815faa5f, 10.1097/NMD.0b013e31815faa5f]; Nugent NR, 2008, AM J MED GENET C, V148C, P127, DOI 10.1002/ajmg.c.30169; Oquendo M, 2005, AM J PSYCHIAT, V162, P560, DOI 10.1176/appi.ajp.162.3.560; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Reyes Gilbert., 2008, ENCY PSYCHOL TRAUMA; Rihmer Z, 2007, CURR OPIN PSYCHIATR, V20, P17, DOI 10.1097/YCO.0b013e3280106868; Riordan DV, 2006, BRIT J PSYCHIAT, V189, P502, DOI 10.1192/bjp.bp.105.015974; Rona RJ, 2009, J PSYCHIATR RES, V43, P649, DOI 10.1016/j.jpsychires.2008.09.006; Rosenman S, 2002, AUST NZ J PSYCHIAT, V36, P515, DOI 10.1046/j.1440-1614.2002.01039.x; Sareen J, 2005, J NERV MENT DIS, V193, P450, DOI 10.1097/01.nmd.0000168263.89652.6b; Sher L, 2008, Minerva Pediatr, V60, P1393; Sher L, 2005, CAN J PSYCHIAT, V50, P127; Sher L, 2005, MED HYPOTHESES, V65, P205, DOI 10.1016/j.mehy.2005.03.014; Sher L, 2004, Forsch Komplementarmed Klass Naturheilkd, V11, P354, DOI 10.1159/000082817; Sher L, 2005, EUR NEUROPSYCHOPHARM, V15, P203, DOI 10.1016/j.euroneuro.2004.09.009; Sher L, 2004, J AFFECT DISORDERS, V82, P53, DOI 10.1016/j.jad.2003.09.012; Sher L, 2004, QJM-INT J MED, V97, P677, DOI 10.1093/qjmed/hch106; Sher L, 2004, QJM-INT J MED, V97, P1, DOI 10.1093/qjmed/hch003; Sher L, 2003, FORSCH KOMP KLAS NAT, V10, P61, DOI 10.1159/000071664; SHER L, 2003, TXB MED PSYCHIAT, P701; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tarrier N, 2004, SOC PSYCH PSYCH EPID, V39, P927, DOI 10.1007/s00127-004-0828-3; Thompson C, 2001, BRIT J PSYCHIAT, V179, P450, DOI 10.1192/bjp.179.5.450; URSANO RJ, 2008, PSYCH TIMES, V25; Yehuda R, 2006, PSYCHOBIOLOGY POSTTR; Zivin K, 2007, AM J PUBLIC HEALTH, V97, P2193, DOI 10.2105/AJPH.2007.115477	48	25	25	0	10	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	AUG	2009	73	2					215	219		10.1016/j.mehy.2008.12.052			5	Medicine, Research & Experimental	Research & Experimental Medicine	462LN	WOS:000267354200029	19327892				2021-06-18	
J	Ouellet, MC; Morin, CM; Lavoie, A				Ouellet, Marie-Christine; Morin, Charles M.; Lavoie, Andre			Volunteer Work and Psychological Health Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						psychological adjustment; traumatic brain injury; volunteerism; work	QUALITY-OF-LIFE; MULTIDIMENSIONAL FATIGUE INVENTORY; COMMUNITY INTEGRATION; RETURN; DEPRESSION; VALIDATION; INSOMNIA; SATISFACTION; EMPLOYMENT; FREQUENCY	Objectives: To compare the long-term psychological functioning of 3 groups of survivors of traumatic brain injury (TBI): (1) those who report being regularly active either by working or studying, (2) those who are not competitively employed but are active volunteers, and (3) those who report neither working, studying, nor volunteering. Participants and Procedure: Two hundred eight participants aged 16 years and older with minor to severe TBI were classified as (1) Working/Studying (N = 78), (2) Volunteering (N = 54), or (3) Nonactive (N = 76). Main Outcome Measures: Measures of psychological distress (anxiety depression, cognitive disturbance, irritability/anger), fatigue, sleep disturbance, and perception of pain. Results: Survivors of TBI who report being active through work, studies, or volunteering demonstrate a significantly higher level of psychological adjustment than persons who report no activity. Even among participants who are unable to return to work and are declared on long-term disability leave, those who report engaging in volunteer activities present significantly better psychological functioning than participants who are nonactive. Conclusion: Volunteering is associated with enhanced psychological well-being and should be encouraged following TBI.	[Ouellet, Marie-Christine] CHA, Hop Enfants Jesus, CHAUQ, Ctr Rech, Quebec City, PQ G1J 1Z4, Canada; [Ouellet, Marie-Christine] McGill Univ, Dept Surg, Div Surg Res, Montreal, PQ H3A 2T5, Canada; [Morin, Charles M.] Univ Laval, Ecole Psychol, Quebec City, PQ, Canada	Ouellet, MC (corresponding author), CHA, Hop Enfants Jesus, CHAUQ, Ctr Rech, Pavillon Notre Dame,Local H-042 1401,18E Rue, Quebec City, PQ G1J 1Z4, Canada.	marie-christine.ouellet@mail.mcgill.ca	Morin, Charles/G-1021-2011; Morin, Charles M./A-4700-2008	Morin, Charles M./0000-0002-8649-8895; Ouellet, Marie-Christine/0000-0003-3477-1893	Fonds de Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec; Fondation de l'Hopital de I'Enfant-Jesus, Quebec, Canada	Collection of the data and preparation of this article was supported by fellowship's awarded to the first author by the Fonds de Recherche en Sante du Quebec and the Fondation de l'Hopital de I'Enfant-Jesus, Quebec, Canada (Dr Ouellet).	Audet N, 2001, ENQUETE SOCIALE SANT; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Blais FC, 1997, ENCEPHALE, V23, P447; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dyster-Aas J, 2007, J REHABIL MED, V39, P49, DOI 10.2340/16501977-0005; Fillion L, 2003, CANCER NURS, V26, P143, DOI 10.1097/00002820-200304000-00008; Gervais M, 1999, ETUDE EXPLORATOIRE B; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Holzner B, 2003, CANCER, V97, P1564, DOI 10.1002/cncr.11253; Holzner B, 2002, ANN ONCOL, V13, P965, DOI 10.1093/annonc/mdf122; ILFELD FW, 1976, PSYCHOL REP, V39, P1215, DOI 10.2466/pr0.1976.39.3f.1215; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; KINNEY WB, 1992, ARCH PHYS MED REHAB, V73, P863; Lindqvist KS, 1996, ACCIDENT ANAL PREV, V28, P209, DOI 10.1016/0001-4575(95)00065-8; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; MORIN CM, 1993, J CONSULT CLIN PSYCH, V61, P137, DOI 10.1037/0022-006X.61.1.137; Morrow-Howell Nancy, 2003, J Gerontol B Psychol Sci Soc Sci, V58, pS137; Musick MA, 1999, J GERONTOL B-PSYCHOL, V54, pS173, DOI 10.1093/geronb/54B.3.S173; Musick MA, 2003, SOC SCI MED, V56, P259, DOI 10.1016/S0277-9536(02)00025-4; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Preville M, 1992, DETRESSE PSYCHOL DET; ROBINSON N, 1995, DEV PSYCHOPATHOL, P162; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Szymanski EM, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P499, DOI 10.1037/10361-023; Thoits PA, 1995, J HLTH SOC BEHAV; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Van Willigen M, 2000, J GERONTOL B-PSYCHOL, V55, pS308, DOI 10.1093/geronb/55.5.S308; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	37	25	26	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2009	24	4					262	271		10.1097/HTR.0b013e3181a68b73			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	506SK	WOS:000270796000005	19625865				2021-06-18	
J	Matsushige, T; Nakaoka, M; Kiya, K; Takeda, T; Kurisu, K				Matsushige, Toshinori; Nakaoka, Mitsuo; Kiya, Katsuzo; Takeda, Tetsuji; Kurisu, Kaoru			Cerebral Sinovenous Thrombosis After Closed Head Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head injury; Sinus thrombosis; Cerebral venous infarction; Edema; Diffusion weighted imaging	DURAL SINUS THROMBOSIS; WEIGHTED MAGNETIC-RESONANCE; EMPTY DELTA SIGN; VENOUS THROMBOSIS; MR; PROGNOSIS; RECANALIZATION; THROMBOLYSIS; ANGIOPLASTY; HEMATOMA	Background: Cerebral sinovenous thrombosis (CSVT) after closed head injury is an uncommon but potentially serious complication. The aim of this study was to determine whether diffusion weighted imaging (DWI) provide predictive information regarding prognosis. Methods: We retrospectively reviewed a series of 11 patients with CSVT after closed head injury. Each patient underwent computed tomography and magnetic resonance imaging within 24 hours of onset of symptoms, including DWI, magnetic resonance venography, and conventional sequences. Apparent diffusion coefficient (ADC) values were measured in seven regions of interest in 7 of 11 patients using DWI. Follow-up imaging and clinical outcome were assessed 6 months or later after initial presentation. Results. The most affected sinus was the posterior portion of the superior sagittal sinus. There was a mean time interval of 4.1 days between subsequent venous stroke and the initial insult. Brain edema improved in 6 of 11 patients on follow-up imaging. Six of 11 patients recovered successfully, although high or mixed DWI intensity associated with moderately decreased ADC (0.53-0.57 x 10(-3) mm(2)/s). Two other patients with hematomas developed venous infarction, despite mixed DWI with heterogeneous ADC value (0.55-1.11 X 10(-3) nun/s). The other three patients, with high DWI and strongly decreased ADC values (0.26-0.27 X 10(-3) mm(2)/s), developed severe brain atrophy after superior sagittal sinus thrombosis.. Conclusions. The prospective cutoff point of ADC value may be higher in CSVT after head injury with traumatic hematoma. The territory of venous infarction was found to be larger in infants after treatment failure. In infants, CSVT can demonstrate initially cytotoxic brain edema, which is reversible with anticoagulation therapy.	[Matsushige, Toshinori; Kiya, Katsuzo] Hiroshima Univ, Grad Sch Biomed Sci, Dept Neurosurg, Minami Ku, Hiroshima 7348551, Japan; [Nakaoka, Mitsuo] Matsue Red Cross Hosp, Dept Neurosurg, Matsue, Shimane, Japan; [Kiya, Katsuzo] Hiroshima Prefectural Hosp, Dept Neurosurg, Minami Ku, Hiroshima, Japan; [Takeda, Tetsuji] Ehime Prefectural Cent Hosp, Dept Neurosurg, Matsuyama, Ehime, Japan	Matsushige, T (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Neurosurg, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	teruteru728@yahoo.co.jp					BOUSSER MG, 1985, STROKE, V16, P199, DOI 10.1161/01.STR.16.2.199; Canhao P, 2003, CEREBROVASC DIS, V15, P159, DOI 10.1159/000068833; Chahlavi A, 2004, J NEUROSURG, V101, P347, DOI 10.3171/jns.2004.101.2.0347; Chaloupka JC, 1999, NEUROSURGERY, V45, P650, DOI 10.1097/00006123-199909000-00045; Chu K, 2001, ARCH NEUROL-CHICAGO, V58, P1569, DOI 10.1001/archneur.58.10.1569; de Bruijn SFTM, 1999, STROKE, V30, P484, DOI 10.1161/01.STR.30.3.484; Ducreux D, 2001, AM J NEURORADIOL, V22, P261; Ferro JM, 2004, STROKE, V35, P664, DOI 10.1161/01.STR.0000117571.76197.26; Ferro JM, 2002, CEREBROVASC DIS, V13, P272, DOI 10.1159/000057855; Forbes KPN, 2001, AM J NEURORADIOL, V22, P450; HESSELBROCK R, 1985, NEUROSURGERY, V16, P825, DOI 10.1227/00006123-198506000-00017; Hinman JM, 2002, EUR J RADIOL, V41, P147, DOI 10.1016/S0720-048X(01)00365-5; Keller E, 1999, STROKE, V30, P1144, DOI 10.1161/01.STR.30.5.1144; Kim SY, 1997, AM J NEURORADIOL, V18, P639; Lee EJY, 2002, RADIOLOGY, V224, P788, DOI 10.1148/radiol.2243990978; Lovblad KO, 2000, NEURORADIOLOGY, V42, P728, DOI 10.1007/s002340000395; Lovblad KO, 2001, CEREBROVASC DIS, V11, P169, DOI 10.1159/000047634; Manzione J, 2000, AM J NEURORADIOL, V21, P68; Mullins ME, 2004, AM J NEURORADIOL, V25, P1666; Murphy KJ, 2000, NEUROSURGERY, V46, P497, DOI 10.1097/00006123-200002000-00048; Muthukumar N, 2004, J CLIN NEUROSCI, V11, P924, DOI 10.1016/j.jocn.2003.10.032; ONUMA T, 1995, J NEUROSURG, V82, P995, DOI 10.3171/jns.1995.82.6.0995; Owler BK, 2005, CHILD NERV SYST, V21, P262, DOI 10.1007/s00381-004-1014-3; Peeters E, 2001, AM J NEURORADIOL, V22, P1949; Rother J, 1996, J CEREBR BLOOD F MET, V16, P1353; Rottger C, 2005, NEUROSURGERY, V57, P573, DOI 10.1227/01.NEU.0000170438.13677.22; Stolz E, 2004, STROKE, V35, P544, DOI 10.1161/01.STR.0000112972.09096.65; Takitani K, 2002, PEDIATR INT, V44, P680, DOI 10.1046/j.1442-200X.2002.01620.x; TSAI FY, 1995, AM J NEURORADIOL, V16, P1021; VIRAPONGSE C, 1987, RADIOLOGY, V162, P779, DOI 10.1148/radiology.162.3.3809494; Wasay M, 2002, J NEUROIMAGING, V12, P267, DOI 10.1177/10528402012003009; Wasay M, 2001, STROKE, V32, P2310, DOI 10.1161/hs1001.096192; Yoshikawa T, 2002, NEURORADIOLOGY, V44, P481, DOI 10.1007/s00234-002-0772-4	33	25	30	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2009	66	6					1599	1604		10.1097/TA.0b013e3181a3a8e6			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	457PN	WOS:000266944500013	19509620				2021-06-18	
J	Xiong, Y; Chopp, M; Lee, CP				Xiong, Ye; Chopp, Michael; Lee, Chuan-Pu			Erythropoietin improves brain mitochondrial function in rats after traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						Erythropoietin; mitochondrion; rat; traumatic brain injury	CELL-DEATH; ENHANCES NEUROGENESIS; DYSFUNCTION; APOPTOSIS; RECEPTOR; DAMAGE; MECHANISMS; EXPRESSION; BCL-X(L); RECOVERY	Mitochondria play a central role in cellular energetics, calcium homeostasis and apoptosis. Our previous study demonstrates traumatic brain injury induces brain mitochondrial dysfunction after injury. Preservation and/or restoration of mitochondrial function may be one of the strategies for neuroprotection. Erythropoietin, a hormone for erythropoiesis, also provides tissue protection against traumatic brain injury and stroke. The present study was undertaken to evaluate the effect of erythropoietin on traumatic brain injury-induced brain mitochondrial dysfunction. Traumatic brain injury decreased rates of respiration at the active state ( state 3), increased that at the resting state ( state 4) and consequently decreased respiratory control index (state 3/state 4 ratio) and the efficiency of ATP synthesis ( the amount of ADP phosphorylated by inorganic phosphate divided by the amount of oxygen consumed during state 3 respiration). Erythropoietin administered intraperitoneally 30 minutes post-injury at 1000 U/kg partially improved mitochondrial function at day 1 post-injury. However, erythropoietin-induced improvement was not sustained at day 7 post-injury. Erythropoietin at 2000 or 5000 U/kg restored states 3 and 4 examined at day 1 post-injury to the sham levels. Consequently, the energy coupling capacities, such as respiratory control index and/or the efficiency of ATP synthesis, were also improved. The beneficial effect of erythropoietin at these doses persisted for at least 7 days post-injury. The beneficial effect of erythropoietin on brain mitochondrial function was observed with a wide therapeutic window from 5 minutes to 6 hours post-injury. Our data, for the first time, demonstrate that erythropoietin treatment restores brain mitochondrial function after traumatic brain injury, which will enhance cellular energy generation and reduce oxidative stress, strongly supporting erythropoietin as a promising agent for the therapeutic treatment of traumatic brain injury. [Neurol Res 2009; 31: 496-502]	[Xiong, Ye; Lee, Chuan-Pu] Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; [Xiong, Ye] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA	Lee, CP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	cplee@med.wayne.edu		Xiong, Ye/0000-0001-9770-6031	Johnson and Johnson Pharmaceutical Research and DevelopmentJohnson & JohnsonJohnson & Johnson USA	This study was supported in part by funds from Johnson and Johnson Pharmaceutical Research and Development. We would like to express our sincere thanks to Dr Donna Mildvan and Dr Francis Farrell for their advice and helpful discussion.	Bahcekapili N, 2007, LIFE SCI, V80, P1245, DOI 10.1016/j.lfs.2006.12.014; Bras M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P231, DOI 10.1007/s10541-005-0105-4; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chong ZZ, 2002, CIRCULATION, V106, P2973, DOI 10.1161/01.CIR.0000039103.58920.1F; Chtistophe M, 2006, CURR PHARM DESIGN, V12, P739; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Genc K, 2006, PHYSIOL RES, V55, P33; Genc S, 2004, RESTOR NEUROL NEUROS, V22, P105; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; Kumral A, 2006, BIOL NEONATE, V89, P205, DOI 10.1159/000089951; Lee C. P., 1993, V2, P41; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Liu J, 2006, GLIA, V53, P360, DOI 10.1002/glia.20289; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Mikati MA, 2007, EPILEPSIA, V48, P175, DOI 10.1111/j.1528-1167.2006.00900.x; Miro O, 2002, AM J KIDNEY DIS, V39, P1025, DOI 10.1053/ajkd.2002.32776; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Orrenius S, 2004, TOXICOL LETT, V149, P19, DOI 10.1016/j.toxlet.2003.12.017; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Radad K, 2006, NEUROCHEM INT, V49, P379, DOI 10.1016/j.neuint.2006.02.003; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang F, 2006, J NEUROSCI RES, V83, P1241, DOI 10.1002/jnr.20816; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036	49	25	26	1	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2009	31	5					496	502		10.1179/174313208X353703			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	468LF	WOS:000267819200009	19099671				2021-06-18	
J	Kim, J; Shin, SD; Im, TH; Lee, KJ; Ko, SB; Park, JO; Ahn, KO; Song, KJ				Kim, Jaiyong; Shin, Sang Do; Im, Tai Ho; Lee, Kug Jong; Ko, Sang Back; Park, Ju Ok; Ahn, Ki Ok; Song, Kyoung Jun			Development and Validation of the Excess Mortality Ratio-adjusted Injury Severity Score Using the International Classification of Diseases 10th Edition	ACADEMIC EMERGENCY MEDICINE			English	Article						Injury Severity Score; excess mortality; International Classification of Diseases; validation study	MYOCARDIAL-INFARCTION; ADMINISTRATIVE DATA; 9TH REVISION; TRAUMA; DIAGNOSIS; SYSTEM; PREDICTORS; ACCURACY; TRISS; DEATH	This study aimed to develop and validate a new method for measuring injury severity, the excess mortality ratio-adjusted Injury Severity Score (EMR-ISS), using the International Classification of Diseases 10th Edition (ICD-10). An injury severity grade similar to the Abbreviated Injury Scale (AIS) was converted from the ICD-10 codes on the basis of quintiles of the EMR for each ICD-10 code. Like the New Injury Severity Score (NISS), the EMR-ISS was calculated from three maximum severity grades using data from the Korean National Injury Database. The EMR-ISS was then validated using the Hosmer-Lemeshow goodness-of-fit chi-square (HL chi-square, with lower values preferable), the area under the receiver operating characteristic curve (AUC-ROC), and the Pearson correlation coefficient to compare it with the International Classification of Diseases 9th Edition-based Injury Severity Score (ICISS). Nationwide hospital discharge abstract data (DAD) from stratified-sample general hospitals (n = 150) in 2004 were used for an external validation. The total number of study subjects was 29,282,531, with five subgroups of particular interest identified for further study: traumatic brain injury (TBI, n = 3,768,670), traumatic chest injury (TCI, n = 1,169,828), poisoning (n = 251,565), burns (n = 869,020), and DAD (n = 26,374). The HL chi-square was lower for EMR-ISS than for ICISS in all groups: 42,410.8 versus 55,721.9 in total injury, 7,139.6 versus 20,653.9 in TBI, 6,603.3 versus 4,531.8 in TCI, 2,741.2 versus 9,112.0 in poisoning, 764.4 versus 4,532.1 in burns, and 28.1 versus 49.4 in DAD. The AUC-ROC for death was greater for EMR-ISS than for ICISS: 0.920 versus 0.728 in total injury, 0.907 versus 0.898 in TBI, 0.675 versus 0.799 in TCI, 0.857 versus 0.900 in poisoning, 0.735 versus 0.682 in burns, and 0.850 versus 0.876 in DAD. The Pearson correlation coefficient between the two scores was -0.68 in total injury, -0.76 in TBI, -0.86 in TCI, -0.69 in poisoning, -0.58 in burns, and -0.75 in DAD. The EMR-ISS showed better calibration and discrimination power for prediction of death than the ICISS in most injury groups. The EMR-ISS appears to be a feasible tool for passive injury surveillance of large data sets, such as insurance data sets or community injury registries containing diagnosis codes. Additional further studies for external validation on prospectively collected data sets should be considered.	[Shin, Sang Do] Seoul Natl Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Kim, Jaiyong] Hallym Univ, Dept Social & Prevent Med, Coll Med, Gangwon Do, South Korea; [Im, Tai Ho] Hanyang Univ, Coll Med, Dept Emergency Med, Seoul 133791, South Korea; [Lee, Kug Jong] Ajou Univ Hosp, Dept Emergency Med & Trauma Surg, Kyonggi Do, South Korea; [Ko, Sang Back] Yonsei Univ, Wonju Coll Med, Dept Prevent Med, Gangwon Do, South Korea; [Park, Ju Ok] Jeju Natl Univ, Coll Med, Dept Emergency Med, Jeju Do, South Korea; [Ahn, Ki Ok] Seoul Fire Serv Acad, EMS Educ & Training Ctr, Seoul, South Korea; [Song, Kyoung Jun] Seoul Natl Univ, Borame Hosp, Dept Emergency Med, Seoul, South Korea	Shin, SD (corresponding author), Seoul Natl Univ, Coll Med, Dept Emergency Med, Seoul, South Korea.	shinsangdo@snuh.org	Shin, Sang/J-5523-2012; 안, 기옥/L-5596-2019	안, 기옥/0000-0002-8446-3269	Korean Center for Disease Control and Prevention	This study was conducted by the Injury Statistics Working Group of Korea, which was composed on the basis of the convention for injury research among the Korean Society of Emergency Medicine, the Korean Society of Traumatology, the Korean Burn Society, and the Health Insurance Review Agency. This study was financially supported by the Korean Center for Disease Control and Prevention in 2006.	Ahn YS, 2004, INJURY PREV, V10, P199, DOI 10.1136/ip.2003.004895; Andel D, 2007, J BURN CARE RES, V28, P163, DOI 10.1097/BCR.0B013E31802C9E8F; *ASS ADV AUT MED, 1990, ABBR INJ SCAL 1990; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bilgin TE, 2005, TOXICOL IND HEALTH, V21, P141, DOI 10.1191/0748233705th222oa; Clark DE, 2006, INJURY PREV, V12, P111, DOI 10.1136/ip.2005.010058; Do Shin S, 2004, BURNS, V30, P820, DOI 10.1016/j.burns.2004.06.005; Ebrahim S, 2006, BMJ-BRIT MED J, V333, P22, DOI 10.1136/bmj.38855.610324.80; EICHELBERGER MR, 1989, ANN EMERG MED, V18, P939, DOI 10.1016/S0196-0644(89)80457-3; Gorelick MH, 2007, ACAD EMERG MED, V14, P646, DOI 10.1197/j.aem.2007.03.1357; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hannan EL, 1999, J TRAUMA, V47, P8, DOI 10.1097/00005373-199907000-00003; Harwood PJ, 2006, J TRAUMA, V60, P334, DOI 10.1097/01.ta.0000197148.86271.13; HAYS WL, 1998, STATISTICS, P484; Henderson T, 2006, MED CARE, V44, P1011, DOI 10.1097/01.mlr.0000228018.48783.34; Hosmer D, 1989, APPL LOGISTIC REGRES; Huang NC, 2006, CLIN TOXICOL, V44, P99, DOI 10.1080/15563650500514251; Hunt PA, 2006, INJURY, V37, P1, DOI 10.1016/j.injury.2005.02.014; Kim Y, 2003, J TRAUMA, V54, P775, DOI 10.1097/01.TA.0000028251.15629.1D; Kim Y, 2000, J TRAUMA, V48, P280, DOI 10.1097/00005373-200002000-00014; Lai DJ, 1996, AM J EPIDEMIOL, V143, P832; Langley J, 2006, INJURY PREV, V12, P58, DOI 10.1136/ip.2005.010173; Lavoie A, 2004, J TRAUMA, V56, P1312, DOI 10.1097/01.TA.0000075342.36072.EF; LeMier M, 2001, Inj Prev, V7, P334, DOI 10.1136/ip.7.4.334; Meinow B, 2004, J GERONTOL B-PSYCHOL, V59, pS181, DOI 10.1093/geronb/59.3.S181; Odongua N, 2007, YONSEI MED J, V48, P192, DOI 10.3349/ymj.2007.48.2.192; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Park HK, 2007, INT J CLIN PRACT, V61, P1086, DOI 10.1111/j.1742-1241.2007.01345.x; Park JH, 2008, INT J CARDIOL, V128, P392, DOI 10.1016/j.ijcard.2007.04.114; Quan H, 2004, MED CARE, V42, P801, DOI 10.1097/01.mlr.0000132391.59713.0d; Rutledge R, 1997, J TRAUMA, V42, P477, DOI 10.1097/00005373-199703000-00016; Shin SD, 2004, J KOREAN MED SCI, V19, P186, DOI 10.3346/jkms.2004.19.2.186; Song YM, 2003, AM J EPIDEMIOL, V158, P479, DOI 10.1093/aje/kwg173; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Sungurtekin H, 2006, CLIN TOXICOL, V44, P121, DOI 10.1080/15563650500514350; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Virnig BA, 2001, ANNU REV PUBL HEALTH, V22, P213, DOI 10.1146/annurev.publhealth.22.1.213; World Health Organization, INT STAT CLASS DIS R; DISCUSSION DOCUMENT	40	25	25	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	MAY	2009	16	5					454	464		10.1111/j.1553-2712.2009.00412.x			11	Emergency Medicine	Emergency Medicine	438IE	WOS:000265548300014	19388920	Bronze			2021-06-18	
J	Makdissi, M				Makdissi, M.			Is the simple versus complex classification of concussion a valid and useful differentiation?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; PROFESSIONAL FOOTBALL; AGREEMENT STATEMENT; AUSTRALIAN RULES; NCAA CONCUSSION; SOCCER PLAYERS; HEAD-INJURY	Background: At the Second International Conference on Concussion in Sport, concussion was classified as "simple" or "complex" based largely on duration of clinical features. The purpose of the classification system was to assist clinicians in identifying higher grades of injury severity and guide injury management. The aim of the current paper is to review the validity and clinical usefulness of the simple versus complex classification system. Study design: Qualitative review of the literature on concussion in sport, with a focus on time course of clinical recovery and prognostic factors. Intervention: Pubmed, Medline and Sport Discus databases were reviewed. Fifty journal articles were included in the review. Results: Prospective studies support the recovery of symptoms, balance deficits and cognitive impairment in the majority of concussed athletes within 10 days of injury. However, clinical factors that predict higher grades of injury severity or poor outcome following concussion remain unclear. At present, concussion severity can only be accurately determined in retrospect after all clinical features have resolved. Conclusion: It is recommended that concussion in sport be considered as a single entity. Clinical factors that have demonstrated to be associated with longer duration of symptoms (for example, post-traumatic amnesia) or poor outcome (for example, repetitive head injury) may serve as "modifying" factors to assist the treating practitioner in identifying potential for higher grades of injury severity or adverse outcomes.	[Makdissi, M.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia; [Makdissi, M.] Olymp Pk Sports Med Ctr, Melbourne, Vic, Australia	Makdissi, M (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia.	makdissi@unimelb.edu.au					*AM AC NEUR, 1997, 1997 AAN NAT PRESS C; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT., 1989, MILD HEAD INJURY, P257; Bland JM, 2002, BRIT MED J, V324, P606, DOI 10.1136/bmj.324.7337.606; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Giza CC, 2001, J ATHL TRAINING, V36, P228; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Porter MD, 2003, CLIN J SPORT MED, V13, P339, DOI 10.1097/00042752-200311000-00002; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; TEASDALE G, 1974, LANCET, V2, P81; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	50	25	25	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I23	I27		10.1136/bjsm.2009.058206			5	Sport Sciences	Sport Sciences	450YO	WOS:000266438100004	19433420				2021-06-18	
J	Briones, TL; Rogozinska, M; Woods, J				Briones, Teresita L.; Rogozinska, Magdalena; Woods, Julie			RETRACTED: Environmental Experience Modulates Ischemia-Induced Amyloidogenesis and Enhances Functional Recovery (Retracted article. See vol. 32, pg. 863, 2015)	JOURNAL OF NEUROTRAUMA			English	Article; Retracted Publication						A beta oligomers; beta-secretase amyloid cleaving enzyme (BACE); enriched environment; learning and memory; water maze	AMYLOID PRECURSOR PROTEIN; ENRICHMENT IMPROVES COGNITION; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; BETA PEPTIDE; SYNAPTIC PLASTICITY; HIPPOCAMPAL REGION; LEARNING-CAPACITY; DENDRITIC GROWTH; GENE-EXPRESSION	In this study, we examined whether ischemia-induced amyloidogenesis could be modulated by environmental "experience,'' and whether this modulation is associated with improved cognitive functioning. Rats were subjected to either global ischemia or sham surgery and then were randomly assigned to either enriched environment housing (EE) or socially paired housing (controls). After 14 days of differential environmental housing, the rats were tested in the water maze. Our results show decreased C-terminal fragments of the beta-amyloid precursor protein (beta APP) and decreased amyloid beta (A beta) load in the ischemic EE rats compared to the ischemic control animals. In addition, A beta oligomerization was significantly decreased in the ischemic EE animals compared to the ischemic control rats. Further, significantly increased levels of neprilysin, but not insulin-degrading enzyme, amyloid-degrading enzymes, were seen in the ischemic EE rats compared to the ischemic control animals. Behavioral analyses showed that ischemic EE rats performed significantly better on the memory task compared to the ischemic control group. These results suggest that use of multi-sensory environmental enrichment following cerebral ischemia may reduce the accumulation of A beta peptide in the more pathologic oligomeric form, and consequently may enhance functional recovery.	[Briones, Teresita L.; Rogozinska, Magdalena; Woods, Julie] Univ Illinois, Chicago, IL 60612 USA	Briones, TL (corresponding author), Univ Illinois, 845 S Damen Ave,Room 750,M-C 802, Chicago, IL 60612 USA.	tbriones@uic.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NINRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [RO1 NR007666]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR007666] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health, NINR grant no. RO1 NR007666. We are grateful for the assistance of Maggie Wadowska in animal handling and tissue imaging. We would also like to thank Mai Nguyen for assistance in the analysis of behavioral data.	Abramov AY, 2003, J NEUROSCI, V23, P5088; Apelt J, 1997, INT J DEV NEUROSCI, V15, P95, DOI 10.1016/S0736-5748(96)00073-1; Arendash GW, 2004, NEUROREPORT, V15, P1751, DOI 10.1097/01.wnr.0000137183.68847.4e; Badan I, 2004, EUR J NEUROSCI, V19, P2270, DOI 10.1111/j.0953-816X.2004.03323.x; BANATI RB, 1995, J CEREBR BLOOD F MET, V15, P647, DOI 10.1038/jcbfm.1995.80; BHATIA P, 1994, ANAL BIOCHEM, V216, P223, DOI 10.1006/abio.1994.1028; Bouet V, 2007, EXP NEUROL, V203, P555, DOI 10.1016/j.expneurol.2006.09.006; BOWES MP, 1994, EXP NEUROL, V129, P112, DOI 10.1006/exnr.1994.1152; Briones T L, 2000, Biol Res Nurs, V1, P299, DOI 10.1177/109980040000100406; Briones Teresita L, 2005, Biol Res Nurs, V6, P167, DOI 10.1177/1099800404271328; Briones TL, 2006, BEHAV BRAIN RES, V171, P17, DOI 10.1016/j.bbr.2006.03.011; Briones TL, 2006, EXP NEUROL, V198, P530, DOI 10.1016/j.expneurol.2005.12.032; Briones TL, 2006, BEHAV BRAIN RES, V168, P261, DOI 10.1016/j.bbr.2005.11.015; Briones TL, 2004, BRAIN RES, V1018, P130, DOI 10.1016/j.brainres.2004.06.001; Briones TL, 2004, BRAIN RES, V997, P137, DOI 10.1016/j.brainres.2003.10.030; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Costa DA, 2007, NEUROBIOL AGING, V28, P831, DOI 10.1016/j.neurobiolaging.2006.04.009; Davidson CM, 2000, BRAIN RES, V859, P96, DOI 10.1016/S0006-8993(00)01937-5; ESCORIHUELA RM, 1995, NEUROBIOL LEARN MEM, V64, P49, DOI 10.1006/nlme.1995.1043; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Fu WM, 2002, J NEUROSCI, V22, P10710; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Huber G, 1997, NEUROSCIENCE, V80, P313, DOI 10.1016/S0306-4522(97)00120-6; Ishimaru H, 1996, NEUROREPORT, V7, P3063, DOI 10.1097/00001756-199611250-00054; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; Jankowsky JL, 2003, J NEUROPATH EXP NEUR, V62, P1220, DOI 10.1093/jnen/62.12.1220; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KALARIA RN, 1993, ANN NY ACAD SCI, V695, P190, DOI 10.1111/j.1749-6632.1993.tb23050.x; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X; Kim HS, 1998, NEUROREPORT, V9, P533; Kirino T, 2000, NEUROPATHOLOGY, V20, pS95; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Kobayashi S, 2002, J NEUROSCI RES, V70, P340, DOI 10.1002/jnr.10442; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Marr RA, 2003, J NEUROSCI, V23, P1992; Mattson MP, 1997, PHYSIOL REV, V77, P1081; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Mouri A, 2006, BEHAV BRAIN RES, V168, P83, DOI 10.1016/j.bbr.2005.10.014; Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109; Paganelli RA, 2004, J NEUROSCI METH, V132, P9, DOI 10.1016/j.jneumeth.2003.08.012; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Perry G, 2002, FREE RADICAL BIO MED, V33, P1475, DOI 10.1016/S0891-5849(02)01113-9; Pham TM, 1999, NEUROSCIENCE, V94, P279, DOI 10.1016/S0306-4522(99)00316-4; Pluta R, 2002, ANN NY ACAD SCI, V977, P102, DOI 10.1111/j.1749-6632.2002.tb04803.x; Popa-Wagner A, 1998, STROKE, V29, P2196, DOI 10.1161/01.STR.29.10.2196; Puurunen K, 2001, EXP NEUROL, V167, P348, DOI 10.1006/exnr.2000.7563; Puurunen K, 1997, STROKE, V28, P623, DOI 10.1161/01.STR.28.3.623; Qiao XX, 2001, EUR J NEUROSCI, V14, P474, DOI 10.1046/j.0953-816x.2001.01666.x; Schrijver NCA, 2004, BEHAV BRAIN RES, V152, P307, DOI 10.1016/j.bbr.2003.10.016; SELKOE DJ, 1997, ANN NY ACAD SCI, V777, P57; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wahl AS, 2009, NEUROSCIENCE, V158, P344, DOI 10.1016/j.neuroscience.2008.06.018; Wang J, 2003, NEUROBIOL DIS, V14, P318, DOI 10.1016/j.nbd.2003.08.009; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; WEST RW, 1972, BEHAV BIOL, V7, P279, DOI 10.1016/S0091-6773(72)80207-4; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Yi JS, 2007, NEUROBIOL DIS, V26, P94, DOI 10.1016/j.nbd.2006.12.007	69	25	26	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					613	625		10.1089/neu.2008.0707			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300012	19271963	Green Published			2021-06-18	
J	Gawryszewski, VP; Coelho, HMM; Scarpelini, S; Zan, R; Jorge, MHPD; Rodrigues, EMS				Gawryszewski, Vilma Pinheiro; Mendes Coelho, Herlander Manoel; Scarpelini, Sandro; Zan, Renato; Prado de Mello Jorge, Maria Helena; Silveira Rodrigues, Eugenia Maria			Land transport injuries among emergency department visits in the state of Sao Paulo, in 2005	REVISTA DE SAUDE PUBLICA			Portuguese	Article						Traffic Accidents; Risk Factors; First Aid; Emergency Medical Care; External Causes	ROAD	OBJECTIVE: To analyze the characteristics of visits resulting from land transport injuries. METHODS: A total of 5,934 visits in four hospital emergency departments (ED) were analyzed, in the state of Sao Paulo, in 2005. A questionnaire based on the following three models was used to collect data: World Health Organization (WHO), Center for Disease Control and Prevention (CDC), and Pan American Health Organization (PAHO). Variables analyzed were as follows: type of road user (vehicle occupant, pedestrian, motorcyclist, and cyclist), sex, age group, and type of injury suffered. Logistic regression analysis was employed to test associations between variables. Odds ratios with their respective 95% confidence intervals were calculated. RESULTS: The majority of victims were males (74.2%) in the 20-to-29- year age group (35.0%). Vulnerable road users totaled 72.4% of all cases (29.8% were motorcyclists, 24.1% pedestrians, and 18.5% cyclists). Victims aged between zero and 14 years who had suffered injuries were mostly pedestrians and cyclists; motorcyclists predominated among those aged between 15 and 39 years; and pedestrians among those aged over 50 years. About half of the cases suffered minor injuries (strains, dislocations, contusions and cuts), while the other half was comprised by fractures, traumatic brain injuries and internal injuries. Extremities were the most affected body parts, particularly among motorcyclists. The majority of victims were discharged at triage (87.6%). Compared to women, men were 1.5 times more likely to be admitted or transferred, or to die. Pedestrians, vehicle occupants and motorcyclists were, respectively, 2.7, 2.4 and 1.9 times more likely to be admitted or transferred, or to die than cyclists. CONCLUSIONS: Measures aimed to protect vulnerable road users should be among the priorities to reduce land transport-related injuries.	[Gawryszewski, Vilma Pinheiro] SES SP, Ctr Vigilancia Epidemiol, Sao Paulo, Brazil; [Mendes Coelho, Herlander Manoel] Hosp Geral Grajau, SES SP, Sao Paulo, Brazil; [Scarpelini, Sandro] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, SP, Brazil; [Zan, Renato] Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil; [Prado de Mello Jorge, Maria Helena] Univ Sao Paulo, Fac Saude Publ, BR-09500900 Sao Paulo, Brazil; [Silveira Rodrigues, Eugenia Maria] Organizacao Pan Amer Saude, Washington, DC USA	Gawryszewski, VP (corresponding author), Av Dr Arnaldo,351 Sala 609 Cerqueira Cesar, BR-01246902 Sao Paulo, SP, Brazil.	gawry@uol.com.br	Scarpelini, Sandro/H-7063-2012	Scarpelini, Sandro/0000-0001-5727-3913			Ameratunga S, 2006, LANCET, V367, P1533, DOI 10.1016/S0140-6736(06)68654-6; Bastos Yara Gerber Lima, 2005, Cad. Saúde Pública, V21, P815, DOI 10.1590/S0102-311X2005000300015; Batista Sandra Elisa Adami, 2006, Rev. Col. Bras. Cir., V33, P6; Bunn F., 2003, COCHRANE DATABASE SY, DOI [10.1002/14651858.CD003110, DOI 10.1002/14651858.CD003110]; Diniz Eugênio Paceli Hatem, 2005, Ciênc. saúde coletiva, V10, P905, DOI 10.1590/S1413-81232005000400014; Gaspar Vera L. V., 2004, J. Pediatr. (Rio J.), V80, P447, DOI 10.1590/S0021-75572004000800005; Gawryszewski Vilma Pinheiro, 2006, Sao Paulo Med. J., V124, P208, DOI 10.1590/S1516-31802006000400007; Gawryszewski VP, 2008, CAD SAUDE PUBLICA, V24, P1121, DOI 10.1590/S0102-311X2008000500019; Haileyesus T, 2007, INJURY PREV, V13, P202, DOI 10.1136/ip.2006.014019; Holder Y, 2001, INJURY SURVEILLANCE; Jorge Maria Helena Prado de Mello, 2004, Rev. bras. epidemiol., V7, P228; Nicaj L, 2006, INJURY PREV, V12, P414, DOI 10.1136/ip.2005.010082; Peden M., 2004, WORLD REPORT ROAD TR; Queiroz Marcos S., 2003, Psicol. Soc., V15, P101, DOI 10.1590/S0102-71822003000200008; Scaringella RS., 2001, SAO PAULO PERSPECT, V15, P55, DOI DOI 10.1590/S0102-88392001000100007; Souza Edinilsa Ramos de, 2006, Ciênc. saúde coletiva, V11, P363, DOI 10.1590/S1413-81232006000200014; Veronese Andréa Márian, 2006, Cad. Saúde Pública, V22, P2717, DOI 10.1590/S0102-311X2006001200021; Vyrostek Sara B., 2004, Morbidity and Mortality Weekly Report, V53, P1	18	25	35	0	4	REVISTA DE SAUDE PUBLICA	SAO PAULO	FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO, BRAZIL	0034-8910	1518-8787		REV SAUDE PUBL	Rev. Saude Publica	APR	2009	43	2					275	282		10.1590/S0034-89102009000200008			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	419FC	WOS:000264203500008	19287873	DOAJ Gold, Green Published			2021-06-18	
J	Lloyd-Williams, M; Morton, J; Peters, S				Lloyd-Williams, Mari; Morton, Juliet; Peters, Sarah			The End-of-Life Care Experiences of Relatives of Brain Dead Intensive Care Patients	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Sudden death; organ donation; palliative care; intensive care	ORGAN DONATION; UNIT; PROFESSIONALS; BREAKING; NEWS	Brain death is a. traumatic and sudden event following a severe injury to the brain. Most patients with brain death spend the last days of life in at? intensive care unit (ICU), where some families will be approached to ask for organ donation, This qualitative study was carried out with relatives of patients who had died of brain death in an ICU; all relatives were interviewed six months after the death. Twenty ICUs were recruited for this study. The next of kin of 130 patients who died during the study period were approached, and 30 (22%) agreed to be interviewed; one later withdrew. This paper focuses on the perceived Palliative care needs of the 29 families. Participants valued the physical care their relatives had received, but communication, and breaking bad news was a cause for concern. The facilities on many ICUs, for examine, cramped relatives' rooms and little privacy to be with the patients at, to say the final goodbye, was a common theme to emerge. Bereavement follow-up did not routinely occur, and this was an identified factor noted by relatives. Families living through. the period of brain death in, a loved one may have particular needs in terms of end-of-life care and should be Offered the support of a palliative care team, through the last days of a. patients life, and into the period of bereavement. Staff training on how to communicate bad news also should be implemented as a matter Of urgency. J Pain Symptom Manage 2009;37:659-664. (C) 2009 U.S. Cancer Pain, Relief Committee. Published by Elsevier Inc. All rights reserved.	[Lloyd-Williams, Mari; Morton, Juliet] Univ Liverpool, Sch Populat Community & Behav Sci, Acad Palliat & Support Care Study Grp, Liverpool L69 3GB, Merseyside, England; [Peters, Sarah] Univ Manchester, Manchester, Lancs, England	Lloyd-Williams, M (corresponding author), Univ Liverpool, Sch Populat Community & Behav, Acad Palliat & Support Care Study Grp, Whelan Bldg, Liverpool L69 3GB, Merseyside, England.	mlw@liv.ac.uk					Byock I, 2006, CRIT CARE MED, V34, pS416, DOI 10.1097/01.CCM.0000237345.62823.82; Floden A, 2006, TRANSPLANT P, V38, P2619, DOI 10.1016/j.transproceed.2006.07.031; Gavrin JR, 2007, CRIT CARE MED, V35, pS85, DOI 10.1097/01.CCM.0000252909.52316.27; Kesselring A, 2007, AM J TRANSPLANT, V7, P211, DOI 10.1111/j.1600-6143.2006.01594.x; Lefebvre H, 2006, BRAIN INJURY, V20, P711, DOI 10.1080/02699050600744244; Levy MM, 2006, CRIT CARE MED, V34, pS306, DOI 10.1097/01.CCM.0000246096.18214.79; Murphy PG, 2007, BRIT J HOSP MED, V68, P298, DOI 10.12968/hmed.2007.68.6.23568; Parle M, 1997, SOC SCI MED, V44, P231, DOI 10.1016/S0277-9536(96)00148-7; Schildmann J, 2005, PALLIATIVE MED, V19, P93, DOI 10.1191/0269216305pm996oa; STRAUSS AC, 1998, BARRIERS QUALITATIVE; Wall RJ, 2007, CRIT CARE MED, V35, P1084, DOI 10.1097/01.CCM.0000259382.36414.06; White DB, 2007, ARCH INTERN MED, V167, P461, DOI 10.1001/archinte.167.5.461; Whitney CM, 2005, NEUROLOGIST, V11, P61, DOI 10.1097/01.nrl.0000149974.25259.6c; Williams G, 1997, BRIT MED J, V314, P1831, DOI 10.1136/bmj.314.7097.1831a	14	25	25	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	APR	2009	37	4					659	664		10.1016/j.jpainsymman.2008.04.013			6	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	433SH	WOS:000265225600006	18789640	Green Published, Bronze			2021-06-18	
J	Maisano, X; Carpentino, J; Becker, S; Lanza, R; Aaron, G; Grabel, L; Naegele, JR				Maisano, Xu; Carpentino, Joseph; Becker, Sandy; Lanza, Robert; Aaron, Gloster; Grabel, Laura; Naegele, Janice R.			Embryonic Stem Cell-Derived Neural Precursor Grafts for Treatment of Temporal Lobe Epilepsy	NEUROTHERAPEUTICS			English	Article; Proceedings Paper	4th Workshop on New Horizons in the Development of Antiepileptic Drugs	MAR 05-07, 2008	Dublin, IRELAND			Seizures; ES; cell therapy; hilus; hippocampus; GABA; interneuron; Sox1; GFP; sonic hedgehog	INDUCED STATUS EPILEPTICUS; PILOCARPINE-INDUCED SEIZURES; STABLE TRANSGENE EXPRESSION; MEDIAL GANGLIONIC EMINENCE; IN-VITRO DIFFERENTIATION; DENTATE GRANULE CELLS; DIRECTED DIFFERENTIATION; INHIBITORY INTERNEURONS; ADENOSINE KINASE; VENTRAL TELENCEPHALON	Complex partial seizures arising from mesial temporal lobe structures are a defining feature of mesial temporal lobe epilepsy (TLE). For many TLE patients, there is an initial traumatic head injury that is the precipitating cause of epilepsy. Severe TLE can be associated with neuropathological changes, including hippocampal sclerosis, neurodegeneration in the dentate gyrus, and extensive reorganization of hippocampal circuits. Learning disabilities and psychiatric conditions may also occur in patients with severe TLE for whom conventional anti-epileptic drugs are ineffective. Novel treatments are needed to limit or repair neuronal damage, particularly to hippocampus and related limbic regions in severe TLE and to suppress temporal lobe seizures. A promising therapeutic strategy may be to restore inhibition of dentate gyrus granule neurons by means of cell grafts of embryonic stem cell-derived GABAergic neuron precursors. "Proof-of-concept" studies show that human and mouse embryonic stem cell-derived neural precursors can survive, migrate, and integrate into the brains of rodents in different experimental models of TLE. In addition, studies have shown that hippocampal grafts of cell lines engineered to release GABA or other anticonvulsant molecules can suppress seizures. Furthermore, transplants of fetal GABAergic progenitors from the mouse or human brain have also been shown to suppress the development of seizures. Here, we review these relevant studies and highlight areas of future research directed toward producing embryonic stem cell-derived GABAergic interneurons for cell-based therapies for treating TLE.	[Naegele, Janice R.] Wesleyan Univ, Dept Biol, Hall Atwater Lab, Neurosci & Behav Program, Middletown, CT 06459 USA; [Carpentino, Joseph] Univ Florida, McKnight Brain Inst, Program Stem Cell Biol & Regenerat Med, Gainesville, FL 32610 USA; [Becker, Sandy; Lanza, Robert] Adv Cell Technol Inc, Worcester, MA 01605 USA	Naegele, JR (corresponding author), Wesleyan Univ, Dept Biol, Hall Atwater Lab, Neurosci & Behav Program, 52 Lawn Ave, Middletown, CT 06459 USA.	jnaegele@wesleyan.edu		Naegele, Janice/0000-0001-5151-0543; Lanza, Robert/0000-0002-3047-3074	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042826-01A1, R01 NS042826, NS42826] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042826] Funding Source: NIH RePORTER		Alvarez-Dolado M, 2006, J NEUROSCI, V26, P7380, DOI 10.1523/JNEUROSCI.1540-06.2006; Anderson SA, 2002, CEREB CORTEX, V12, P702, DOI 10.1093/cercor/12.7.702; Anderson SA, 2001, DEVELOPMENT, V128, P353; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; BEKENSTEIN JW, 1993, SCIENCE, V259, P97, DOI 10.1126/science.8093417; BENGZON J, 1993, EXP NEUROL, V122, P143, DOI 10.1006/exnr.1993.1115; Bernreuther C, 2006, J NEUROSCI, V26, P11532, DOI 10.1523/JNEUROSCI.2688-06.2006; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Boison D, 2008, PROG NEUROBIOL, V84, P249, DOI 10.1016/j.pneurobio.2007.12.002; Borges K, 2003, EXP NEUROL, V182, P21, DOI 10.1016/S0014-4886(03)00086-4; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Buckmaster PS, 2002, EPILEPSY RES, V48, P43, DOI 10.1016/S0920-1211(01)00318-7; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Buckmaster PS, 2002, J COMP NEUROL, V445, P360, DOI 10.1002/cne.10183; Bumanglag AV, 2008, J COMP NEUROL, V510, P561, DOI 10.1002/cne.21801; Butt SJB, 2007, J NEUROSCI, V27, P11847, DOI 10.1523/JNEUROSCI.3525-07.2007; Butt SJB, 2005, NEURON, V48, P591, DOI 10.1016/j.neuron.2005.09.034; BUZSAKI G, 1988, P NATL ACAD SCI USA, V85, P9327, DOI 10.1073/pnas.85.23.9327; Cai C, 2007, DEV DYNAM, V236, P3255, DOI 10.1002/dvdy.21306; Carpentino JE, 2008, J NEUROSCI RES, V86, P512, DOI 10.1002/jnr.21514; Casarosa S, 1999, DEVELOPMENT, V126, P525; Choi YS, 2007, J NEUROSCI, V27, P2999, DOI 10.1523/JNEUROSCI.4913-06.2007; Chu K, 2004, BRAIN RES, V1023, P213, DOI 10.1016/j.brainres.2004.07.045; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Denham M, 2006, AM J PHYSIOL-LUNG C, V290, pL1210, DOI 10.1152/ajplung.00427.2005; DETLEV B, 2007, CURR NEUROPHARMACOL, V5, P115; Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987; Dinocourt C, 2003, J COMP NEUROL, V459, P407, DOI 10.1002/cne.10622; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Eiges R, 2001, CURR BIOL, V11, P514, DOI 10.1016/S0960-9822(01)00144-0; Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002; Engel J, 1999, ARCH NEUROL-CHICAGO, V56, P1338, DOI 10.1001/archneur.56.11.1338; Englund U, 2002, P NATL ACAD SCI USA, V99, P17089, DOI 10.1073/pnas.252589099; Finley MFA, 1996, J NEUROSCI, V16, P1056; Flames N, 2007, J NEUROSCI, V27, P9682, DOI 10.1523/JNEUROSCI.2750-07.2007; FRAICHARD A, 1995, J CELL SCI, V108, P3181; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Fukuda H, 2006, STEM CELLS, V24, P763, DOI 10.1634/stemcells.2005-0137; Gabriel S, 2004, J NEUROSCI, V24, P10416, DOI 10.1523/JNEUROSCI.2074-04.2004; Gaspard N, 2008, NATURE, V455, P351, DOI 10.1038/nature07287; Gernert M, 2002, EXP NEUROL, V176, P183, DOI 10.1006/exnr.2002.7914; Giudice A, 2008, CELL STEM CELL, V2, P422, DOI 10.1016/j.stem.2008.04.003; Goetz AK, 2006, P NATL ACAD SCI USA, V103, P11063, DOI 10.1073/pnas.0510926103; Golarai G, 2001, J NEUROSCI, V21, P8523; Gropp M, 2006, METHOD ENZYMOL, V420, P64, DOI 10.1016/S0076-6879(06)20005-3; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Hamaguchi I, 2000, J VIROL, V74, P10778, DOI 10.1128/JVI.74.22.10778-10784.2000; Hattiangady B, 2004, NEUROBIOL DIS, V17, P473, DOI 10.1016/j.nbd.2004.08.008; HELLER AC, 2008, SURG NEUROL     0529; Jessberger S, 2005, EXP NEUROL, V196, P342, DOI 10.1016/j.expneurol.2005.08.010; Jiao YQ, 2007, EXP NEUROL, V205, P569, DOI 10.1016/j.expneurol.2007.03.025; Jutila L, 2001, AM J NEURORADIOL, V22, P1490; Kempermann G, 2006, NEURON, V52, P935, DOI 10.1016/j.neuron.2006.12.004; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Lauren HB, 2005, J NEUROCHEM, V94, P1384, DOI 10.1111/j.1471-4159.2005.03274.x; Leroy C, 2004, J PHYSIOL-LONDON, V557, P473, DOI 10.1113/jphysiol.2003.059246; Li H, 2008, P NATL ACAD SCI USA, V105, P9397, DOI 10.1073/pnas.0802876105; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Li TF, 2008, J CLIN INVEST, V118, P571, DOI 10.1172/JCI33737; Li TF, 2007, BRAIN, V130, P1276, DOI 10.1093/brain/awm057; Liew CG, 2007, STEM CELLS, V25, P1521, DOI 10.1634/stemcells.2006-0634; Loscher W, 2008, TRENDS NEUROSCI, V31, P62, DOI 10.1016/j.tins.2007.11.012; Longo BM, 1997, NEUROSCI LETT, V226, P163, DOI 10.1016/S0304-3940(97)00267-X; Loring DW, 2007, NEUROPSYCHOL REV, V17, P413, DOI 10.1007/s11065-007-9043-9; Loscher W, 1998, J NEUROSCI RES, V51, P196; Manabe T, 2007, CELL DEATH DIFFER, V14, P1080, DOI 10.1038/sj.cdd.4402106; Manabe T, 2005, J NEUROCHEM, V94, P723, DOI 10.1111/j.1471-4159.2005.03261.x; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; Marin O, 2000, J NEUROSCI, V20, P6063; MATHERN GW, 1995, J NEUROSURG, V82, P220, DOI 10.3171/jns.1995.82.2.0220; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Nishimura T, 2005, NEUROSCIENCE, V134, P691, DOI 10.1016/j.neuroscience.2005.04.013; Oka Masahiro, 2006, V329, P273; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Passier R, 2005, STEM CELLS, V23, P772, DOI 10.1634/stemcells.2004-0184; Pitkanen A, 1998, EPILEPSY RES, V32, P233, DOI 10.1016/S0920-1211(98)00055-2; Raedt R, 2007, SEIZURE-EUR J EPILEP, V16, P565, DOI 10.1016/j.seizure.2007.05.003; Ren G, 2007, EXP NEUROL, V208, P26, DOI 10.1016/j.expneurol.2007.07.016; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Ribak CE, 2000, J COMP NEUROL, V428, P240, DOI 10.1002/1096-9861(20001211)428:2<240::AID-CNE4>3.0.CO;2-Q; Ribak CE, 2002, PROG BRAIN RES, V136, P319; Ruschenschmidt T, 2005, EPILEPSIA, V46, P174, DOI 10.1111/j.1528-1167.2005.01028.x; Sartipy P, 2008, PHARMACOL RES, V58, P152, DOI 10.1016/j.phrs.2008.06.002; Scharfman HE, 2007, EPILEPSIA, V48, P33, DOI 10.1111/j.1528-1167.2007.01065.x; Scheffler B, 2006, BRAIN PATHOL, V16, P155, DOI 10.1111/j.1750-3639.2006.00010.x; Schinder AF, 2004, PHYSIOLOGY, V19, P253, DOI 10.1152/physiol.00012.2004; Schwartzkroin PA, 1997, EPILEPSIA, V38, P853, DOI 10.1111/j.1528-1157.1997.tb01250.x; Shetty AK, 1997, EXP NEUROL, V143, P231, DOI 10.1006/exnr.1996.6363; Shetty AK, 2007, HIPPOCAMPUS, V17, P943, DOI 10.1002/hipo.20311; Shetty AK, 2007, STEM CELLS, V25, P2396, DOI 10.1634/stemcells.2007-0313; Siemen Henrike, 2008, V423, P131, DOI 10.1007/978-1-59745-194-9_8; Sloviter RS, 2006, J COMP NEUROL, V494, P944, DOI 10.1002/cne.20850; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; Steiner B, 2008, NEUROSCIENCE, V154, P521, DOI 10.1016/j.neuroscience.2008.04.023; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; Takahashi T, 2003, CIRCULATION, V107, P1912, DOI 10.1161/01.CIR.0000064899.53876.A3; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Thompson KW, 2005, NEUROSCIENCE, V133, P1029, DOI 10.1016/j.neuroscience.2005.03.003; Thompson KW, 2004, EPILEPSIA, V45, P4, DOI 10.1111/j.0013-9580.2004.29503.x; Trinh HH, 2006, EUR J NEUROSCI, V24, P2967, DOI 10.1111/j.1460-9568.2006.05194.x; Vallier L, 2004, STEM CELLS, V22, P2, DOI 10.1634/stemcells.22-1-2; Vezzani A, 1999, TRENDS NEUROSCI, V22, P25, DOI 10.1016/S0166-2236(98)01284-3; Walter C, 2007, J NEUROSCI, V27, P7541, DOI 10.1523/JNEUROSCI.0431-07.2007; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402; Wernig M, 2004, J NEUROSCI, V24, P5258, DOI 10.1523/JNEUROSCI.0428-04.200; Westmoreland JJ, 2001, BIOCHEM BIOPH RES CO, V284, P674, DOI 10.1006/bbrc.2001.5031; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Wichterle H, 2001, DEVELOPMENT, V128, P3759; Wichterle H, 1999, NAT NEUROSCI, V2, P461, DOI 10.1038/8131; Wonders CP, 2008, DEV BIOL, V314, P127, DOI 10.1016/j.ydbio.2007.11.018; Yao S, 2006, P NATL ACAD SCI USA, V103, P6907, DOI 10.1073/pnas.0602280103; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Yun K, 2002, DEVELOPMENT, V129, P5029; Zeng JM, 2007, STEM CELLS, V25, P1055, DOI 10.1634/stemcells.2006-0616; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhang SC, 2006, BRAIN PATHOL, V16, P132, DOI 10.1111/j.1750-3639.2006.00008.x; Zhao Y, 2008, J COMP NEUROL, V510, P79, DOI 10.1002/cne.21772	120	25	30	1	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	APR	2009	6	2					263	277		10.1016/j.nurt.2009.01.011			15	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	425TL	WOS:000264659900008	19332319	Green Accepted, Green Published			2021-06-18	
J	Olivecrona, M; Zetterlund, B; Rodling-Wahlstrom, M; Naredi, S; Koskinen, LOD				Olivecrona, Magnus; Zetterlund, Bo; Rodling-Wahlstrom, Marie; Naredi, Silvana; Koskinen, Lars-Owe D.			Absence of electroencephalographic seizure activity in patients treated for head injury with an intracranial pressure-targeted therapy	JOURNAL OF NEUROSURGERY			English	Article						continuous EEG; head injury; seizure	TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; NONCONVULSIVE STATUS EPILEPTICUS; CONTINUOUS EEG; HEMORRHAGE; PRINCIPLES; EDEMA	Object. The authors prospectively studied the occurrence of clinical and nonclinical electroencephalographically verified seizures during treatment with an intracranial pressure (ICP)-targeted protocol in patients with traumatic brain injury (TBI). Methods. All patients treated for TBI at the Department of Neurosurgery, University Hospital Umea, Sweden, were eligible for the stud. The inclusion was consecutive and based on the availability of the electroencephalographic (EEG) monitoring equipment. Patients were included irrespective of pupil size, pupil reaction, or level of consciousness as long as their first measured cerebral perfusion pressure was > 10 mm Hg. The patients were treated in a protocol-guided manner with an ICP-targeted treatment based on the Lund concept. The patients were continuously sedated with midazolam, fentanyl, propofol, or thiopental, or combinations thereof. Five-lead continuous EEG monitoring was performed with the electrodes at F3, F4, P3, P4, and a midline reference. Sensitivity was set at 100 mu V per cm and filter settings 0.5-70 Hz. Amplitude-integrated EEG recording and relative band power trends were displayed. The trends were analyzed offline by trained clinical neurophysiologists. Results. Forty-seven patients (mean age 40 years) were studied. Their median Glasgow Coma Scale score at the time of sedation and intubation was 6 (range 3-15). In 8.5% of the patients clinical seizures were observed before sedation and intubation. Continuous EEG monitoring was performed for a total of 7334 hours. During this time neither EEG nor clinical seizures were observed. Conclusions. Our protocol-guided ICP targeted treatment seems to protect patients with severe TBI from clinical and subclinical seizures and thus reduces the risk of secondary brain injury. (DOI: 10.3171/2008.4.17538)	[Olivecrona, Magnus; Koskinen, Lars-Owe D.] Univ Hosp, Dept Neurosurg, SE-90185 Umea, Sweden; [Zetterlund, Bo] Univ Hosp, Dept Clin Neurophysiol, SE-90185 Umea, Sweden; [Rodling-Wahlstrom, Marie; Naredi, Silvana] Univ Hosp, Dept Anaesthesiol, SE-90185 Umea, Sweden	Olivecrona, M (corresponding author), Univ Hosp, Dept Neurosurg, SE-90185 Umea, Sweden.	magnus.olivecrona@vll.se	Koskinen, Lars-Owe/AAQ-8957-2020	Naredi, Silvana/0000-0002-4409-6089; Koskinen, Lars-Owe/0000-0003-3528-8502	Department of Neurosciences at Umea University; Umea University Hospital General Foundation; Capio Research Foundation; Tore Nilssons Foundation	This study was supported by grants from the Department of Neurosciences at Umea University, Umea University Hospital General Foundation, Capio Research Foundation, and Tore Nilssons Foundation.	ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen Jan, 2002, Curr Neurol Neurosci Rep, V2, P534, DOI 10.1007/s11910-002-0042-1; Grande P O, 1997, Acta Anaesthesiol Scand Suppl, V110, P36; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; GRANDMAISON F, 1991, ELECTROEN CLIN NEURO, V79, P264, DOI 10.1016/0013-4694(91)90121-J; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Kollevold T, 1976, J Oslo City Hosp, V26, P99; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; LABAR DR, 1991, ELECTROEN CLIN NEURO, V78, P325, DOI 10.1016/0013-4694(91)90094-K; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; LOWENSTEIN DH, 1992, NEUROLOGY, V42, P100, DOI 10.1212/WNL.42.1.100; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; PAYEN D, 1990, CRIT CARE MED, V18, P392, DOI 10.1097/00003246-199004000-00008; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Privitera Michael D., 1994, Emergency Medicine Clinics of North America, V12, P1089; Procaccio F, 2001, Curr Opin Crit Care, V7, P74, DOI 10.1097/00075198-200104000-00004; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Scheuer ML, 2002, EPILEPSIA, V43, P114, DOI 10.1046/j.1528-1157.43.s.3.7.x; Spencer E M, 1990, Intensive Care World, V7, P34; SYNEK VM, 1988, CLIN ELECTROENCEPHAL, V19, P160, DOI 10.1177/155005948801900310; Theilen HJ, 2000, CRIT CARE MED, V28, P3522, DOI 10.1097/00003246-200010000-00029; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Young GB, 1996, NEUROLOGY, V47, P83	39	25	26	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2009	110	2					300	305		10.3171/2008.4.17538			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	399GI	WOS:000262788000015	18759609				2021-06-18	
J	Adeleye, AO; Olowookere, KG; Olayemi, OO				Adeleye, A. O.; Olowookere, K. G.; Olayemi, O. O.			Clinicoepidemiological Profiles and Outcomes during First Hospital Admission of Head Injury Patients in Ikeja, Nigeria A Prospective Cohort Study	NEUROEPIDEMIOLOGY			English	Article						Head injury, Nigeria; Clinicoepidemiological profiles	TRAUMATIC BRAIN-INJURIES; CARE; PERSPECTIVE; HYPOTENSION; MANAGEMENT; PATTERN; IBADAN; KENYA	Background: Although head injury ( HI) is a major public health problem in Nigeria and other low and middle income countries of the world, there is a paucity of data from these societies. This is largely due to under-reporting. We carried out a prospective study of the clinicoepidemiological profiles and outcomes following the first hospitalization of a cohort of head-injured patients in Ikeja, Nigeria, a metropolitan African city. Methods: In an 8-month period from May until December 2005, data from all HI cases seen in our neurosurgical unit were prospectively recorded for subsequent analysis. These include demographics, mechanism of injury, pre-neurosurgical care received, severity of injury using the Glasgow Coma Scale, presence of hemodynamic instability, pupillary anomalies and associated systemic injuries, cranial computed tomography (CT) findings and the number of surgical interventions, as well as outcomes after the first hospital admission using the Glasgow Outcome Scale. Determinants of outcome were explored using the chi(2) test and the level of significance was put at p = 0.05. Results: There were 143 cases of HI, which is about one fifth of our total workload, including 122 males and 21 females aged 0.5-85 years (mean age 29.15). The majority (88%) were either school children or low income earners. Road accidents accounted for 75% of the cases; three quarter of the cases had some initial care in other health facilities before the arrival in our unit, at an average of 33 h. Mild, moderate and severe HI accounted for 60, 18 and 22%, respectively. About a quarter of the patients sustained other systemic injuries. Cranial CT scanning was obtainable in 40 patients (28%); 9 of these revealed surgical mass lesions, of whom 5 had life-saving operations. Many well-known determinants of a poor outcome of HI were prevalent in this study group and found to have a significantly adverse effect on patient outcome. Conclusions: HI is a major public health problem in Nigeria, taking up at least one fifth of the neurosurgical workload. The prehospital emergency medical service is poorly organized. Determinants of a poor outcome of HI are highly prevalent, including poor accessibility to cranial CT scanning, absence or inadequacy of logistics for neurocritical care and an inadequate number of neurosurgeons. Copyright (C) 2008 S. Karger AG, Basel	[Adeleye, A. O.] Univ Ibadan, Dept Surg, Div Neurosurg, Coll Med, Ibadan, Nigeria; [Adeleye, A. O.] Univ Coll Ibadan Hosp, Ibadan, Nigeria; [Olayemi, O. O.] Univ Ibadan, Coll Med, Dept Obstet & Gynecol, Ibadan, Nigeria; [Olowookere, K. G.] Lagos State Univ, Teaching Hosp, Dept Surg, Ikeja, Nigeria	Adeleye, AO (corresponding author), Univ Ibadan, Dept Surg, Div Neurosurg, Coll Med, PMB 5116, Ibadan, Nigeria.	femdoy@yahoo.com					ADELOYE A, 1976, INT SURG, V61, P478; Adeloye A, 1997, E AFR MED J, V74, P822; ADEOLU AA, 2005, INTERNET J EPIDEMIOL, V2, pN2; Akang EEU, 2002, MED SCI LAW, V42, P160, DOI 10.1177/002580240204200207; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Basso A, 2001, WORLD J SURG, V25, P1174; Broessner G, 2007, CRIT CARE MED, V35, P2025, DOI 10.1097/01.ccm.0000281449.07719.2b; CHI JH, 2003, SEMIN NEUROSURG, V23, P71; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Elesha S O, 2002, Niger Postgrad Med J, V9, P38; Huynh T, 2006, AM SURGEON, V72, P1162; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Igun GO, 2000, E AFR MED J, V77, P9; JENNETT B, 1973, LANCET, V1, P480; Joshipura MK, 2003, INJURY, V34, P686, DOI 10.1016/S0020-1383(03)00163-3; Liko O., 1996, Papua New Guinea Medical Journal, V39, P100; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MUHAMMAD I, 1990, E AFR MED J, V67, P447; Muyembe VM, 1998, E AFR MED J, V75, P364; NWAGOMBE NJ, 2001, E AFR MED J, V78, P238; Odebode TO, 2004, PEDIATR SURG INT, V20, P348, DOI 10.1007/s00383-004-1196-5; OHAEGBULAM SC, 1978, AFR J MED MED SCI, V7, P23; Otieno T, 2004, INJURY, V35, P1228, DOI 10.1016/j.injury.2004.03.013; Raja IA, 2001, WORLD J SURG, V25, P1230; Shokunbi T, 1994, West Afr J Med, V13, P38; SILVERSTON P, 1989, BRIT MED J, V298, P711, DOI 10.1136/bmj.298.6675.711; Solagberu B A, 2003, West Afr J Med, V22, P177; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; TEASDALE G, 1974, LANCET, V2, P81; Thanni L O A, 2006, Afr Health Sci, V6, P104; Tiesman H, 2007, J NEUROTRAUM, V24, P1189, DOI 10.1089/neu.2006.0196	31	25	25	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350	1423-0208		NEUROEPIDEMIOLOGY	Neuroepidemiology		2009	32	2					136	141		10.1159/000182821			6	Public, Environmental & Occupational Health; Clinical Neurology	Public, Environmental & Occupational Health; Neurosciences & Neurology	395UL	WOS:000262548900009	19088486				2021-06-18	
J	Bay, E; Sikorskii, A; Gao, FL				Bay, Esther; Sikorskii, Alla; Gao, Fuli			Functional Status, Chronic Stress, and Cortisol Response After Mild-to-Moderate Traumatic Brain Injury	BIOLOGICAL RESEARCH FOR NURSING			English	Article						chronic stress; functional status; traumatic brain injury; depressive symptoms; allostatic load	COMPETENCE RATING-SCALE; POSTCONCUSSIVE SYMPTOMS; RISK-FACTORS; HEAD-INJURY; DEPRESSION; RELIABILITY; DISABILITY; DISORDERS; AWARENESS; RECOVERY	It is well known that individuals experience difficulties with depressive symptoms and functional status after traumatic brain injury. However, it is unclear what the relationship is between these 2 phenomena and whether there is a biological explanation for. In this secondary analysis, we examined whether depressive symptoms explained postinjury functional status and whether chronic stress and salivary cortisol influenced this relationship. Participants included 75 persons within 24 months of their injury dates who were evaluated or treated in specialty clinics. All participants and a family member or significant other completed survey data, and 50 of the participants provided cortisol data. Results indicated that chronic stress, measured using Cohen's Perceived Stress Scale, completely mediated the relationship between depressive symptoms, measured using the Center for Epidemiological Studies Depression Scale, and psychological functioning, measured using the Patient Competency Rating Scale. Furthermore, those who provided cortisol data displayed hypocortisolemia in their 12-hr profile. Results froth this analysis suggest that interventions focused on addressing the chronic stress experience may be important in limiting depressive symptoms and improving psychological functioning. Longitudinal study of this phenomenon is required to understand the progression of chronic stress after traumatic brain injury.	[Bay, Esther; Sikorskii, Alla; Gao, Fuli] Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA	Bay, E (corresponding author), Michigan State Univ, Coll Nursing, A417 W Fee, E Lansing, MI 48824 USA.	baye@msu.edu					Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; Bay Esther, 2006, Care Manag J, V7, P3, DOI 10.1891/cmaj.7.1.3; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bay E, 2007, ARCH PSYCHIAT NURS, V21, P2, DOI 10.1016/j.apnu.2006.07.005; Bay Esther, 2005, J Neurosci Nurs, V37, P4; Bay Esther, 2004, Res Theory Nurs Pract, V18, P213, DOI 10.1891/088971804780957108; Bay Esther, 2007, J Neurosci Nurs, V39, P43; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; *CDCP, 2007, TRAUM BRAIN INJ FACT; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cohen S., 1995, MEASURING STRESS GUI; *COMBI, 2005, PCRS PROP; Conrad CD, 2004, NEUROSCIENCE, V125, P759, DOI 10.1016/j.neuroscience.2004.01.049; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dudley WN, 2004, NURS RES, V53, P59, DOI 10.1097/00006199-200401000-00009; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Flesher MR, 2001, BRAIN INJURY, V15, P879, DOI 10.1080/02699050110065682; Gaab J, 2005, PSYCHONEUROENDOCRINO, V30, P599, DOI 10.1016/j.psyneuen.2005.02.001; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Karlamangla AS, 2006, PSYCHOSOM MED, V68, P500, DOI 10.1097/01.psy.0000221270.93985.82; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; Kraemer HC, 2006, AM J GERIAT PSYCHIAT, V14, P325, DOI 10.1097/01.JGP.0000201816.26786.5b; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; MacKinnon D P, 2000, Prev Sci, V1, P173, DOI 10.1023/A:1026595011371; MAIO R, 2006, ACAD EMERG MED, V13, pS1; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; McBeth J, 2007, ARTHRITIS RHEUM-US, V56, P360, DOI 10.1002/art.22336; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; MCEWEN B, 2002, END STRESS WE KNOW I; McEwen BS, 2003, BIOL PSYCHIAT, V54, P200, DOI 10.1016/S0006-3223(03)00177-X; MCNAIR DM, 1964, J ABNORM SOC PSYCH, V69, P620, DOI 10.1037/h0040902; MCNAIR DM, 2002, PROFILE MOOD STATES; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Miller MM, 2006, ANN NY ACAD SCI, V1071, P294, DOI 10.1196/annals.1364.023; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Sapolsky R, 2003, SCI AM, V289, P86, DOI 10.1038/scientificamerican0903-86; *SAS SOFTW, 2002, SAS SYST WIND, V9; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Sherman EMS, 2000, BRAIN INJURY, V14, P621; SOBEL ME, 1990, PSYCHOMETRIKA, V55, P495, DOI 10.1007/BF02294763; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; TEASDALE G, 1974, LANCET, V2, P81; Tsigos C, 2002, J PSYCHOSOM RES, V53, P865, DOI 10.1016/S0022-3999(02)00429-4; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 2001, INT CLASS FUNCT ICF; Yang CH, 2004, J NEUROSCI, V24, P11029, DOI 10.1523/JNEUROSCI.3968-04.2004	69	25	25	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1099-8004	1552-4175		BIOL RES NURS	Biol. Res. Nurs.	JAN	2009	10	3					213	225		10.1177/1099800408326453			13	Nursing	Nursing	386UH	WOS:000261907600003	19015162				2021-06-18	
J	Emanuelson, I; Uvebrant, P				Emanuelson, I.; Uvebrant, P.			Occurrence of epilepsy during the first 10 years after traumatic brain injury acquired in childhood up to the age of 18 years in the south western Swedish population-based series	BRAIN INJURY			English	Article						Long-term onset epilepsy; traumatic brain injury; children	EARLY POSTTRAUMATIC SEIZURES; HEAD-INJURY; CHILDREN; REHABILITATION; ADOLESCENTS	Background: The risk of seizures is increased after a traumatic brain injury (TBI), but the impact and duration of this increased risk is not well characterized in children. Objective: To identify post-traumatic epilepsy (PTE) and post-concussion symptoms 10 years after a TBI during childhood. Research design: The study is a population-based retrospective follow-up study. Procedure: Ten years after brain injury all 165 survivors, who as children (18 years) in 1987-1991 as residents in the south western Swedish health care region had had a TBI, were invited to participate in a follow-up. A questionnaire regarding medical conditions and medication was filled out by the patients themselves or their parents as was a 21-item questionnaire (PCSQ) regarding post-concussion symptoms. Of the surviving 165 individuals, 109 participated (67%). Results: Eight of 109 developed immediate seizures. During the follow-up period 12/109 had developed active epilepsy. Of these 12, five had had immediate seizures. The incidence of developing PTE within 10 years after a TBI was thus in this series 11%. The relative risk to develop late onset post-traumatic epilepsy (epsilon 1 week after injury) for those who had had immediate seizures was 9.018 (p = 0.0003, 95% CI = 3.69-22.05). Conclusions: TBI is a relatively rare cause of epilepsy in childhood, although immediate seizures are associated with an increased risk of developing post-traumatic epilepsy.	[Emanuelson, I.; Uvebrant, P.] Gothenburg Univ, Inst Clin Sci, Dept Pediat, S-41124 Gothenburg, Sweden	Emanuelson, I (corresponding author), Reg Barn Och Ungdomshabiliteringen, PB 210 62, S-41804 Gothenburg, Sweden.	ingrid.emanuelson@vgregion.se			The Association for Cancer and Traffic Victims; The Swedish Road Administration; The Vastra Gotaland Region	This study was supported by grants from The Association for Cancer and Traffic Victims, The Swedish Road Administration and The Vastra Gotaland Region.	Andersson EE, 2006, J REHABIL MED, V38, P26, DOI 10.1080/16501970500310564; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Dalmady-Israel Christina, 1993, Brain Injury, V7, P263, DOI 10.3109/02699059309029679; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007; JENETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; Tomlin P, 2002, DEV MED CHILD NEUROL, V44, P828	17	25	25	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	7-8					612	616	PII 912689904	10.1080/02699050902973913			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600004	19557563				2021-06-18	
J	Fait, P; McFadyen, BJ; Swaine, B; Cantin, JF				Fait, P.; McFadyen, B. J.; Swaine, B.; Cantin, J. F.			Alterations to locomotor navigation in a complex environment at 7 and 30 days following a concussion in an elite athlete	BRAIN INJURY			English	Article						Attention; locomotion; multi-tasking; executive functioning; mild traumatic brain injury; sport	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; POSTURAL STABILITY; NCAA CONCUSSION; ATTENTION; GAIT; RECOVERY; DEFICITS	Primary objective: To compare the locomotor capacity during (1) unobstructed walking and (2) the circumvention of fixed obstacles with and without a simultaneous visual task in an elite athlete before and after a sports-related concussion. Research design: Case report. Methods and procedures: Gait analysis and clinical neuropsychological measures were taken pre- and at 7 and 30 days post-injury in an 18 year old male junior hockey player. The task consisted of walking along an unobstructed or obstructed path with or without a visual interference task. Measurements included dual tasks costs, response errors, maximal gait speed and minimal clearance with the obstacle. Main outcome and results: Although the athlete was symptom-free and neuropsychological test results returned to baseline relatively quickly, he showed continued errors in the interference task, abnormally small obstacle clearance distances and decreased maximal gait speed up to 30 days after the concussion. Conclusions: Concussion can result in persistent planning and attention deficits in ecologically valid, complex environments. This report suggests that functional assessment within an ecological context could be an innovative way to evaluate concussed athletes before sending them back to play, even in the absence of medically related symptoms or abnormal neuropsychological test results.	[Fait, P.; McFadyen, B. J.] Univ Laval, Fac Med, Dept Rehabil, Quebec City, PQ G1K 7P4, Canada; [Fait, P.; McFadyen, B. J.; Cantin, J. F.] Ctr Interdisciplinary Res Rehabil & Social Integr, Quebec City, PQ, Canada; [Swaine, B.] Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; [Cantin, J. F.] Quebec Rehabil Inst, Quebec City, PQ, Canada	McFadyen, BJ (corresponding author), CIRRIS IRDPQ, 525 Boul, Hamel, PQ G1M 2S8, Canada.	brad.mcfadyen@rea.ulaval.ca		McFadyen, Bradford/0000-0003-1992-4927; Fait, Philippe/0000-0002-2554-9273	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	This study was supported in part by the Canadian Institutes for Health Research and the Natural Sciences and Engineering Research Council of Canada (BJ McFadyen).	Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; *CDCP NAT CTR INJ, 2003, REP C MILD TRAUM BRA; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Gerin-Lajoie M, 2005, MOTOR CONTROL, V9, P242, DOI 10.1123/mcj.9.3.242; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Golden C., 1978, STROOP COLOR WORD TE; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; KEATLEY MA, 2000, SYMPTOM QUESTI UNPUB; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Miller EN, 1990, CALCAP CALIFORNIA CO; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Smith A., 1982, SYMBOL DIGIT MODALIT; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wai-Hang JL, 2002, ARE YOU LEFT HANDED; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	40	25	25	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	4					362	369	PII 909310678	10.1080/02699050902788485			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	425MY	WOS:000264643000012	19274521				2021-06-18	
J	Huizenga, HM; van Bers, BMCW; Plat, J; van den Wildenberg, WPM; van der Molen, MW				Huizenga, Hilde M.; van Bers, Bianca M. C. W.; Plat, Jacqueline; van den Wildenberg, Wery P. M.; van der Molen, Maurits W.			Task Complexity Enhances Response Inhibition Deficits in Childhood and Adolescent Attention-Deficit/Hyperactivity Disorder: A Meta-Regression Analysis	BIOLOGICAL PSYCHIATRY			English	Article						Attention-deficit/hyperactivity disorder; meta-regression; response inhibition; spatial compatibility of stimulus-response; mappings; stop-signal paradigm	EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; STOP-SIGNAL PARADIGM; HYPERACTIVITY DISORDER; WORKING-MEMORY; BEHAVIORAL-INHIBITION; EXECUTIVE FUNCTIONS; NEUROPSYCHOLOGICAL PROFILES; SELECTIVE-INHIBITION; READING-DISABILITY	Background: The ability to inhibit motor responses, as assessed by the stop-signal reaction time (SSRT), is impaired in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). However, the between-study variation in effect sizes is large. The aim of this study was to investigate whether this variability can be explained by between-study variation in Go task complexity. Method: Forty-one studies comparing children or adolescents diagnosed with ADHD to normal control subjects were incorporated in a random-effects meta-regression analysis. The independent variables were a global index of Go task complexity (i.e., mean reaction time in control subjects [RTc]) and a more specific index (i.e., spatial compatibility of the stimulus-response mapping). The dependent variable was the SSRT difference between ADHD and control subjects. Results: The SSRT difference increased significantly with increasing RTc. Moreover, the SSRT difference was significantly increased in studies that employed a noncompatible, that is, arbitrary, mapping compared with studies that incorporated a spatially compatible stimulus-response mapping. Conclusions: These results indicate that inhibitory dysfunction in children and adolescents with ADHD varies with task complexity: inhibitory dysfunction in ADHD is most pronounced for spatially noncompatible responses. Explanations in terms of inhibition and working memory deficits and a tentative neurobiological explanation are briefly discussed.	[Huizenga, Hilde M.; van den Wildenberg, Wery P. M.] Univ Amsterdam, Dept Psychol, Amsterdam Ctr Study Adapt Control Brain & Behav, NL-1018 WB Amsterdam, Netherlands	Huizenga, HM (corresponding author), Univ Amsterdam, Dept Psychol, Amsterdam Ctr Study Adapt Control Brain & Behav, Roetersstr 15, NL-1018 WB Amsterdam, Netherlands.	h.m.huizenga@uva.nl	van der Molen, Maurits W/B-7543-2014		VIDINetherlands Organization for Scientific Research (NWO); VENINetherlands Organization for Scientific Research (NWO); Netherlands Organization for Scientific ResearchNetherlands Organization for Scientific Research (NWO)	This research is supported by a VIDI grant (HMH) and a VENI grant (WPMudW) from the Netherlands Organization for Scientific Research.	Alderson RM, 2007, J ABNORM CHILD PSYCH, V35, P745, DOI 10.1007/s10802-007-9131-6; Aron AR, 2005, BIOL PSYCHIAT, V57, P1285, DOI 10.1016/j.biopsych.2004.10.026; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Band GPH, 2003, ACTA PSYCHOL, V112, P105, DOI 10.1016/S0001-6918(02)00079-3; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Bedard AC, 2003, J ABNORM CHILD PSYCH, V31, P315, DOI 10.1023/A:1023285614844; Bitsakou P, 2008, J NEURAL TRANSM, V115, P261, DOI 10.1007/s00702-007-0828-z; Bond CF, 2003, PSYCHOL METHODS, V8, P406, DOI 10.1037/1082-989X.8.4.406; Castellanos FX, 2002, NAT REV NEUROSCI, V3, P617, DOI 10.1038/nrn896; Chambers CD, 2006, J COGNITIVE NEUROSCI, V18, P444, DOI 10.1162/jocn.2006.18.3.444; Chambers CD, 2007, J NEUROPHYSIOL, V98, P3638, DOI 10.1152/jn.00685.2007; Chhabildas N, 2001, J ABNORM CHILD PSYCH, V29, P529, DOI 10.1023/A:1012281226028; Clark L, 2007, BIOL PSYCHIAT, V61, P1395, DOI 10.1016/j.biopsych.2006.07.020; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Crone EA, 2003, J CHILD PSYCHOL PSYC, V44, P214, DOI 10.1111/1469-7610.00115; DAUGHERTY TK, 1993, J GENET PSYCHOL, V154, P177, DOI 10.1080/00221325.1993.9914731; Dimoska A, 2003, BIOL PSYCHIAT, V54, P1345, DOI 10.1016/S0006-3223(03)00703-0; Fuggetta GP, 2006, CHILD NEUROPSYCHOL, V12, P1, DOI 10.1080/09297040500203418; Geurts HM, 2004, J CHILD PSYCHOL PSYC, V45, P836, DOI 10.1111/j.1469-7610.2004.00276.x; Hommel B, 1997, ADV PSYCHOL, V118, P281; Jennings JR, 1997, DEV PSYCHOL, V33, P308, DOI 10.1037/0012-1649.33.2.308; Johnstone SJ, 2007, INT J PSYCHOPHYSIOL, V66, P37, DOI 10.1016/j.ijpsycho.2007.05.011; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Konrad KN, 2000, BRAIN INJURY, V14, P859; KORNBLUM S, 1990, PSYCHOL REV, V97, P253, DOI 10.1037/0033-295X.97.2.253; KRAMER AF, 1994, PSYCHOL AGING, V9, P491, DOI 10.1037/0882-7974.9.4.491; Kuntsi J, 2001, J CHILD PSYCHOL PSYC, V42, P199, DOI 10.1111/1469-7610.00711; Lijffijt M, 2005, J ABNORM PSYCHOL, V114, P216, DOI 10.1037/0021-843X.114.2.216; Liotti M, 2007, PSYCHOPHYSIOLOGY, V44, P936, DOI 10.1111/j.1469-8986.2007.00568.x; Logan G.D., 1994, INHIBITORY PROCESSES; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Logan GD, 2000, PSYCHON B REV, V7, P107, DOI 10.3758/BF03210728; Manassis K, 2000, J AM ACAD CHILD PSY, V39, P1152, DOI 10.1097/00004583-200009000-00015; Martinussen R, 2005, J AM ACAD CHILD PSY, V44, P377, DOI 10.1097/01.chi.0000153228.72591.73; McInerney RJ, 2003, CHILD NEUROPSYCHOL, V9, P91, DOI 10.1076/chin.9.2.91.14506; Morein-Zamir S, 2006, Q J EXP PSYCHOL, V59, P2148, DOI 10.1080/17470210500416375; Nigg J, 2007, DEV PSYCHOPATHOL, V19, P767, DOI 10.1017/S0954579407000387; Nigg JT, 2005, BIOL PSYCHIAT, V57, P1424, DOI 10.1016/j.biopsych.2004.11.011; Nigg JT, 2002, J AM ACAD CHILD PSY, V41, P59, DOI 10.1097/00004583-200201000-00012; Nigg JT, 1999, J ABNORM CHILD PSYCH, V27, P393, DOI 10.1023/A:1021980002473; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.3.CO;2-G; Oosterlaan J, 1998, J ABNORM CHILD PSYCH, V26, P161, DOI 10.1023/A:1022650216978; Oosterlaan J, 1998, J CHILD PSYCHOL PSYC, V39, P411, DOI 10.1111/1469-7610.00336; Oosterlaan J, 1996, J ABNORM CHILD PSYCH, V24, P19, DOI 10.1007/BF01448371; Overtoom CCE, 2002, BIOL PSYCHIAT, V51, P668, DOI 10.1016/S0006-3223(01)01290-2; Pliszka SR, 1997, J DEV BEHAV PEDIATR, V18, P254; Pliszka SR, 2000, BIOL PSYCHIAT, V48, P238, DOI 10.1016/S0006-3223(00)00890-8; Pliszka SR, 2006, AM J PSYCHIAT, V163, P1052, DOI 10.1176/appi.ajp.163.6.1052; Purvis KL, 2000, J AM ACAD CHILD PSY, V39, P485, DOI 10.1097/00004583-200004000-00018; Ridderinkhof KR, 1999, ACTA PSYCHOL, V101, P315; Ridderinkhof KR, 2005, J ABNORM PSYCHOL, V114, P197, DOI 10.1037/0021-843X.114.2.197; Rubia K, 1998, BEHAV BRAIN RES, V94, P25, DOI 10.1016/S0166-4328(97)00166-6; Rubia K, 2005, AM J PSYCHIAT, V162, P1067, DOI 10.1176/appi.ajp.162.6.1067; Rubia K, 2001, BRIT J PSYCHIAT, V179, P138, DOI 10.1192/bjp.179.2.138; Rubia K, 2007, CHILD NEUROPSYCHOL, V13, P276, DOI 10.1080/09297040600770761; Rucklidge JJ, 2002, J CHILD PSYCHOL PSYC, V43, P988, DOI 10.1111/1469-7610.00227; Schachar R, 2000, J ABNORM CHILD PSYCH, V28, P227, DOI 10.1023/A:1005140103162; SCHACHAR R, 1995, J ABNORM CHILD PSYCH, V23, P411, DOI 10.1007/BF01447206; Schachar RJ, 2004, J ABNORM CHILD PSYCH, V32, P285, DOI 10.1023/B:JACP.0000026142.11217.f2; Schachar R, 2007, J ABNORM CHILD PSYCH, V35, P229, DOI 10.1007/s10802-006-9075-2; Scheres A, 2001, J CHILD PSYCHOL PSYC, V42, P347, DOI 10.1111/1469-7610.00728; SCHWARTZ SP, 1977, J EXPT PSYCHOL HUMAN, V3, P402; Sergeant JA, 2005, BIOL PSYCHIAT, V57, P1248, DOI 10.1016/j.biopsych.2004.09.010; Slusarek M, 2001, J AM ACAD CHILD PSY, V40, P355, DOI 10.1097/00004583-200103000-00016; Solanto MV, 2001, J ABNORM CHILD PSYCH, V29, P215, DOI 10.1023/A:1010329714819; Stevens J, 2002, DEV NEUROPSYCHOL, V21, P117, DOI 10.1207/S15326942DN2102_1; van den Wildenberg WPM, 2004, J EXP CHILD PSYCHOL, V87, P201, DOI 10.1016/j.jecp.2003.11.003; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; Verbruggen F, 2005, ACTA PSYCHOL, V120, P307, DOI 10.1016/j.actpsy.2005.05.003; Verbruggen F, 2004, ACTA PSYCHOL, V116, P21, DOI 10.1016/j.actpsy.2003.12.011; Viechtbauer W, 2006, MIMA S PLUS R FUNCTI; Walcott CM, 2004, J CLIN CHILD ADOLESC, V33, P772, DOI 10.1207/s15374424jccp3304_12; Willcutt EG, 2005, DEV NEUROPSYCHOL, V27, P35, DOI 10.1207/s15326942dn2701_3; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006	74	25	26	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	JAN 1	2009	65	1					39	45		10.1016/j.biopsych.2008.06.021			7	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	384DM	WOS:000261724500008	18723163				2021-06-18	
J	Jamous, MA; Aziz, HA; Al Kaisy, F; Eloqayli, H; Azab, M; Al-Jarrah, M				Jamous, Mohammad A.; Aziz, Hani Abdel; Al Kaisy, Farouk; Eloqayli, Haytham; Azab, Mohammed; Al-Jarrah, Muhammed			Conservative Management of Acute Epidural Hematoma in a Pediatric Age Group	PEDIATRIC NEUROSURGERY			English	Article						Acute epidural hematoma; Children; Head injury; Conservative treatment	EXTRADURAL HEMATOMAS; CHILDREN	Objective: Craniotomy and evacuation is the standard treatment of acute epidural hematoma (EDH). Here, the authors report their experience in nonoperative management of acute EDH in children with mild head injury. Methods: The authors retrospectively reviewed charts of patients with conservatively treated EDH at the Department of Neurosurgery, King Abdulla University Hospital, Irbid, Jordan, between August 2003 and October 2007. All patients had a Glasgow Coma Scale score of 14 or 15, and an initial computerized tomography (CT) scan demonstrating an EDH with or without skull fractures. Follow-up included neurological examination and brain CT. Results: Six children (3 boys, 3 girls) with acute EDH were successfully managed at our department without surgical intervention. The Glasgow Outcome Scale score of all patients was 5, with no posttraumatic sequelae. Follow-up brain CT showed complete resolution of the EDH within 2-3 months. Conclusions: Our results demonstrated that pediatric EDH can be managed nonoperatively. The pronounced increase in the number of CT examinations for patients with head injuries has resulted in a greater proportion of EDH detected in conscious patients. We recommend such treatment be performed in specialized pediatric neurosurgical centers under close neurological observation. Copyright (C) 2009 S. Karger AG, Basel	[Jamous, Mohammad A.] Jordan Univ Sci & Technol, Sch Med, Dept Neurosci, Irbid 22110, Jordan; [Al-Jarrah, Muhammed] Jordan Univ Sci & Technol, Fac Appl Med Sci, Dept Physiotherapy, Irbid 22110, Jordan; [Azab, Mohammed] Jordan Univ Sci & Technol, Fac Med, Dept Toxicol & Forens Sci, Irbid 22110, Jordan	Jamous, MA (corresponding author), Jordan Univ Sci & Technol, Sch Med, Dept Neurosci, POB 3030, Irbid 22110, Jordan.	mojamous@yahoo.com	Solebo, Colette N/B-6615-2008	Solebo, Colette N/0000-0001-9764-2541; Al-Jarrah, Muhammed/0000-0003-2948-6932; eloqayli, haytham/0000-0003-0021-0887			Bejjani GK, 1996, PEDIATR NEUROSURG, V25, P302, DOI 10.1159/000121144; Cayli S, 1998, NEUROSURG REV, V21, P226, DOI 10.1007/BF01105776; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; Cheung PSY, 2007, INJURY, V38, P76, DOI 10.1016/j.injury.2006.08.059; Ciurea AV, 2007, CHILD NERV SYST, V23, P335, DOI 10.1007/s00381-006-0230-4; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; McLaurin R, 1989, PEDIATRIC NEUROSURGE, P277; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; PILLAY R, 1995, S AFR MED J, V85, P672; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; Servadei F, 1988, Brain Inj, V2, P87, DOI 10.3109/02699058809150935	11	25	26	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.		2009	45	3					181	184		10.1159/000218200			4	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	459GX	WOS:000267090700003	19440005				2021-06-18	
J	Kaminski, TW; Groff, RM; Glutting, JJ				Kaminski, Thomas W.; Groff, Rachel M.; Glutting, Joseph J.			Examining the stability of Automated Neuropsychological Assessment Metric (ANAM) baseline test scores	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Sport-related concussion; Brain; Cognition; Mental; Memory	SAMPLE-SIZE; RELIABILITY; PERFORMANCE; CONCUSSION; MANAGEMENT	Computerized neuropsychological (NP) testing has evolved into an important tool for clinicians in the assessment of sport-related concussions. The importance of having a reliable baseline test score for comparison post concussion is critical; yet, the stability of these baseline measurements has not been well established. The purpose of this study was to examine the consistency of the measurements derived from the Automated Neuropsychological Assessment Metric (ANAM) test battery over a series of repeated trials, in an attempt to determine at what point the test scores stabilized. A cohort of 25 recreationally active collegiate students, free from mild head injury, volunteered for the study. Throughput score (measures of performance efficiency) stability was assessed for the computerized NP tests using intraclass correlation coefficients (ICCs). Average throughput scores for all five test trials were simple reaction time (SRT) = 235, matching to sample (MSP) = 41, continuous performance test (CPT) = 108, math processing (MTH) = 24, and Sternberg memory (STN) = 89, and these are within the range of those previously reported. Results show that all four of the ICCs were in the excellent range of agreement (i.e., >= .75), and more importantly, the statistical comparisons of the ICCs show that there was no significant difference between the ICCs. Consequently, results serve to show that two time periods are sufficient to obtain stable NP results, and thus clinicians can feel comfortable relying on a two-score baseline test for follow-up comparison.	[Kaminski, Thomas W.; Groff, Rachel M.] Univ Delaware, Dept Hlth Nutr & Exercise Sci, Athlet Training Res Lab, Newark, DE 19716 USA; [Glutting, Joseph J.] Univ Delaware, Sch Educ, Newark, DE 19716 USA	Kaminski, TW (corresponding author), Univ Delaware, Dept Hlth Nutr & Exercise Sci, Human Performance Lab, 159 Fred Rust Ice Arena,541 S Coll Ave, Newark, DE 19716 USA.	kaminski@udel.edu			University of Delaware Research Foundation; University of Delaware Undergraduate Science and Engineering Scholars Program; University of Delaware Alumni Enrichment Award	This study was generously supported by a grant from the University of Delaware Research Foundation, the University of Delaware Undergraduate Science and Engineering Scholars Program, and the University of Delaware Alumni Enrichment Award.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; BANDERET LE, 1988, 30 ANN M MIL TEST AS; BARTKO JJ, 1976, PSYCHOL BULL, V83, P762, DOI 10.1037/0033-2909.83.5.762; BITTNER AC, 1985, BEHAV RES METH INS C, V17, P217, DOI 10.3758/BF03214386; BLEIBERG J, 1994, M INT NEUR SOC CINC; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Cicchetti D, 2006, J NERV MENT DIS, V194, P557, DOI 10.1097/01.nmd.0000230392.83607.c5; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; Cohen J., 1983, APPL MULTIPLE REGRES; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; Fleiss J., 1986, DESIGN ANAL CLIN EXP; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Kane R., 1997, NEUROPSYCHOLOGY HDB; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; Kenny D. A., 2006, DYADIC DATA ANAL; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MARUFF P, 2001, COGSPORT COMPUTER SO; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Randolph C, 2005, J ATHL TRAINING, V40, P139; REEVES D, 2001, AUTOMATED NEUROPSYCH; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; REEVES DL, 1995, AUTOMATED NEUROPSYCH; Salthouse TA, 2002, J CLIN EXP NEUROPSYC, V24, P858, DOI 10.1076/jcen.24.7.858.8392; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sim J, 2005, PHYS THER, V85, P257; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.0.CO;2-E	34	25	25	1	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	6					689	697		10.1080/13803390802484771			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	482JV	WOS:000268883300006	19110989				2021-06-18	
J	Schwarz, L; Penna, S; Novack, T				Schwarz, Lauren; Penna, Suzanne; Novack, Thomas			Factors contributing to performance on the Rey Complex Figure Test in individuals with traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						Traumatic brain injury; Rey Complex Figure Test; Executive function	MEMORY; IMPACT; SCALE	When examining visual memory test results one must be aware of other variables that impact performance, particularly in individuals with traumatic brain injury who have broad cognitive deficits. The present investigation sought to determine the extent to which executive functioning, as operationally defined as perceptual organization, planning, and mental flexibility, impacted Rey Complex Figure Test (RCFT) performance. Results indicated that executive functioning measures accounted for between 11% and 16% of the variance in RCFT scores. ANCOVAs revealed that the relationship between degree of executive impairment and RCFT memory trials were non-significant when performance on the copy trial was controlled for. Furthermore, speed of processing and word reading were significantly related to RCFT performance. The predicted relationship with fine motor functioning was not supported. Implications and future research directions are discussed.	[Schwarz, Lauren] Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL USA; [Penna, Suzanne; Novack, Thomas] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA	Schwarz, L (corresponding author), 9324 Fredr Court, St Louis, MO 63144 USA.	larallo79@aol.com			National Institute on Disability and Rehabilitation Research, U. S. Department of EducationUS Department of Education [H133A020509]	Supported by the National Institute on Disability and Rehabilitation Research, U. S. Department of Education (grant no. H133A020509).	Ashton VL, 2005, J CLIN EXP NEUROPSYC, V27, P55, DOI 10.1080/138033990513636; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benton A, 1989, MULTILINGUAL APHASIA; Benton A., 1994, MULTILINGUAL APHASIA; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BENTON AL, 1946, VISUAL RETENTION TES; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1976, CORTEX, V10, P224; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Fujii DE, 2000, CLIN NEUROPSYCHOL, V14, P551, DOI 10.1076/clin.14.4.551.7206; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; Hooper, 1983, HOOPER VISUAL ORG TE; Kongs SK, 2000, WISCONSIN CARD SORTI; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P139, DOI 10.1076/1385-4046(200002)14:1;1-8;FT139; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Matthews C, 1964, INSTRUCTION MANUAL A; Meyers J., 1995, REY COMPLEX FIGURE T; Millis SR, 1999, J CLIN EXP NEUROPSYC, V21, P87, DOI 10.1076/jcen.21.1.87.937; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A., 1958, LEXAMEN CLINIQUE PSY; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Shum DHK, 2000, J CLIN EXP NEUROPSYC, V22, P25, DOI 10.1076/1380-3395(200002)22:1;1-8;FT025; Smith A., 1991, SYMBOL DIGIT MODALIT; Tabachnick B., 2001, USING MULTIVARIATE S; Temple RO, 2006, CLIN NEUROPSYCHOL, V20, P480, DOI 10.1080/13854040590967540; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Westervelt H, 2000, ARCH CLIN NEUROPSYCH, V15, P684, DOI 10.1016/S0887-6177(00)80060-8	31	25	25	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	2					255	267	PII 908190130	10.1080/13854040802220034			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	399LS	WOS:000262802000004	19172529				2021-06-18	
J	Srinivasan, L; Roberts, B; Bushnik, T; Englander, J; Spain, DA; Steinberg, GK; Ren, L; Sandel, ME; Al-Lawati, Z; Teraoka, J; Hoffman, AR; Katznelson, L				Srinivasan, Lakshmi; Roberts, Brian; Bushnik, Tamara; Englander, Jeffrey; Spain, David A.; Steinberg, Gary K.; Ren, Li; Sandel, M. Elizabeth; Al-Lawati, Zahraa; Teraoka, Jeffrey; Hoffman, Andrew R.; Katznelson, Laurence			The impact of hypopituitarism on function and performance in subjects with recent history of traumatic brain injury and aneurysmal subarachnoid haemorrhage	BRAIN INJURY			English	Article						Traumatic brain injury; hypopituitarism; growth hormone deficiency; Quality of Life; subarachnoid haemorrhage	GROWTH-HORMONE DEFICIENCY; QUALITY-OF-LIFE; ANTERIOR-PITUITARY FUNCTION; NEUROENDOCRINE DYSFUNCTION; LONG-TERM; HIGH-RISK; PREVALENCE; ADULTS; INSUFFICIENCY; ASSOCIATION	Primary objective: To correlate deficient pituitary function with life satisfaction and functional performance in subjects with a recent history of traumatic brain injury (TBI) and subarachnoid haemorrhage (SAH). Research design: Cross-sectional study. Methods and procedures: Eighteen subjects with TBI and 16 subjects with SAH underwent pituitary hormonal and functional assessments 5-12 months following the event. Adrenal reserve was assessed with a 1 mcg cosyntropin stimulation test and growth hormone deficiency (GHD) was diagnosed by insufficient GH response to GHRH-Arginine stimulation. Assessments of life satisfaction and performance-function included the Satisfaction with Life Scale (SWLS), Craig Handicap Assessment and Reporting Technique (CHART) and the Mayo Portland Adaptability Inventory-4 (MPAI-4). Results: Hypopituitarism was present in 20 (58.8%) subjects, including 50% with adrenal insufficiency. Hypothyroidism correlated with worse performance on SWLS and CHART measures. GHD was associated with poorer performance on CHART and MPAI-4 scale. Conclusions: In this series of subjects with history of TBI and SAH, hypothyroidism and GHD were associated with diminished life satisfaction and performance-function on multiple assessments. Further studies are necessary to determine the appropriate testing of adrenal reserve in this population and to determine the benefit of pituitary hormone replacement therapy on function following brain injury.	[Srinivasan, Lakshmi; Roberts, Brian; Ren, Li; Al-Lawati, Zahraa; Hoffman, Andrew R.; Katznelson, Laurence] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Bushnik, Tamara; Englander, Jeffrey] Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; [Spain, David A.] Stanford Univ, Dept Surg, Sch Med, Stanford, CA 94305 USA; [Steinberg, Gary K.; Katznelson, Laurence] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA; [Sandel, M. Elizabeth] Kaiser Fdn, Rehabil Ctr, Vallejo, CA USA; [Teraoka, Jeffrey] Stanford Univ, Dept Rehabil Med, Sch Med, Stanford, CA 94305 USA; [Teraoka, Jeffrey] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA	Katznelson, L (corresponding author), 875 Blake Wilbur Dr, Stanford, CA 94305 USA.	lkatznelson@stanford.edu		Bushnik, Tamara/0000-0003-3328-257X	Human Health Service grant [M01-RR00070]; General Clinical Research CentersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Rehabilitation Research and Development Service of the Department of Veterans AffairsUS Department of Veterans Affairs; GenentechRoche HoldingGenentech; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000070] Funding Source: NIH RePORTER	The investigation was supported by Human Health Service grant M01-RR00070, General Clinical Research Centers, National Center for Research Resources, National Institutes of Health, the Rehabilitation Research and Development Service of the Department of Veterans Affairs and fellowship stipend award from Genentech.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Alexander GM, 1998, HORM BEHAV, V33, P85, DOI 10.1006/hbeh.1998.1439; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Burmeister LA, 2001, THYROID, V11, P1177, DOI 10.1089/10507250152741037; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Corrigan J., 2000, SATISFACTION LIFE SC; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Kreitschmann-Andermahr I, 2007, CLIN ENDOCRINOL, V66, P833, DOI 10.1111/j.1365-2265.2007.02821.x; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Lieberman SA, 1996, J PEDIATR-US, V128, pS58, DOI 10.1016/S0022-3476(96)70013-6; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF., 2005, The Mayo-Portland Adaptability Inventory; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Mellick D., 2000, CRAIG HANDICAP ASSES; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Wright J, 2000, FIM TM; Wright J., 2000, DISABILITY RATING SC	45	25	25	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					639	648	PII 912683898	10.1080/02699050902970778			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600008	19557567				2021-06-18	
J	Wallace, D				Wallace, Duncan			Improvised explosive devices and traumatic brain injury: the military experience in Iraq and Afghanistan	AUSTRALASIAN PSYCHIATRY			English	Article						Afghanistan; blast injury; improvised explosive devices; Iraq; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; VIETNAM HEAD-INJURY; UNITED-STATES; BLAST INJURY; WAR; FREEDOM; BATTLEFIELD; CONCUSSION; CASUALTIES; SYMPTOMS	Objective: The current conflicts in Iraq and Afghanistan have seen frequent use of improvised explosive devices resulting in thousands of casualties, with traumatic brain injuries particularly common. The recent literature is reviewed to provide information to clinicians on the management of this condition. Method: A Medline search from 2001-2008, using the terms Afghanistan, blast injury, improvised explosive devices, Iraq and traumatic brain injury, was performed. Results: The United States military experience predominates in the literature. The use of body armour and other advances has led to improved survival rates among blast injury victims. Resultant neuropsychiatric injuries, in particular traumatic brain injuries, are discussed. There is debate about the prevalence of traumatic brain injuries. The diagnosis, management, relationship with posttraumatic stress disorder and prognosis of traumatic brain injury are reviewed. Conclusions: Traumatic brain injury has been described as the 'signature wound' of the current conflicts in Iraq and Afghanistan. While this term is highly debatable and probably unhelpful, clinicians need to know about this condition to provide the best management.	Prince Wales Hosp, Kiloh Ctr, Randwick, NSW 2031, Australia	Wallace, D (corresponding author), Prince Wales Hosp, Kiloh Ctr, Randwick, NSW 2031, Australia.	duncan.wallace@sesiahs.health.nsw.gov.au		Wallace, Duncan/0000-0002-2636-2814			Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Burnham G, 2006, LANCET, V368, P1421, DOI 10.1016/S0140-6736(06)69491-9; Cooke BB, 2008, PERSPECT PSYCHIATR C, V44, P54, DOI 10.1111/j.1744-6163.2008.00148.x; Crabtree J, 2006, J BURN CARE RES, V27, P576, DOI 10.1097/01.BCR.0000235459.60000.A5; Danis DM, 2005, J EMERG NURS, V31, P447, DOI 10.1016/j.jen.2005.08.005; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Eastridge BJ, 2006, J TRAUMA, V61, P1366, DOI 10.1097/01.ta.0000245894.78941.90; Fox CJ, 2005, J VASC SURG, V41, P638, DOI 10.1016/j.jvs.2005.01.010; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Hodgetts T, 2007, J R Army Med Corps, V153, P252; Holcomb JB, 2006, J TRAUMA, V60, P397, DOI 10.1097/01.ta.0000203581.75241.f1; *IR BOD COUNT, IR BOD COUNT; Jones E, 2002, BMJ-BRIT MED J, V324, P321, DOI 10.1136/bmj.324.7333.321; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; METZ T, 2008, US ARMY MIL NEW 0604; *MIN DEF, UN KINGD MIN DEF; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Montgomery SP, 2005, J AM COLL SURGEONS, V201, P7, DOI 10.1016/j.jamcollsurg.2005.03.038; Nelson TJ, 2008, J TRAUMA, V65, P212, DOI 10.1097/01.ta.0000196010.50246.9a; Neuhaus SJ, 2006, ANZ J SURG, V76, P637, DOI 10.1111/j.1445-2197.2006.03795.x; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Peake JB, 2005, NEW ENGL J MED, V352, P219, DOI 10.1056/NEJMp048312; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; *US DEP DEF, PERS MIL CAS STAT MI; *US DEP DEF, 2008, US MIL CAS OP IR FRE; Walters TJ, 2005, MIL MED, V170, P770, DOI 10.7205/MILMED.170.9.770; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wenke JC, 2005, MIL MED, V170, P776, DOI 10.7205/MILMED.170.9.776; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003	43	25	24	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1039-8562	1440-1665		AUSTRALAS PSYCHIATRY	Australas. Psychiatry		2009	17	3					218	224		10.1080/10398560902878679			7	Psychiatry	Psychiatry	467TP	WOS:000267766300007	19404818				2021-06-18	
J	Johnstone, B; Glass, BA				Johnstone, Brick; Glass, Bret A.			SUPPORT FOR A NEUROPSYCHOLOGICAL MODEL OF SPIRITUALITY IN PERSONS WITH TRAUMATIC BRAIN INJURY	ZYGON			English	Article						neuropsychology; spirituality; traumatic brain injury	TEMPORAL-LOBE EPILEPSY; CEREBRAL-BLOOD-FLOW; RELIGIOUS-EXPERIENCE; MEDITATION; ATTENTION; DISEASE; SPECT; TASK; MYTH	Recent research suggests that spiritual experiences are related to increased physiological activity of the frontal and temporal lobes and decreased activity of the right parietal lobe. The current study determined if similar relationships exist between self-reported spirituality and neuropsychological abilities associated with those cerebral structures for persons with traumatic brain injury (TBI). Participants included 26 adults with TBI referred for neuropsychological assessment. Measures included the Core Index of Spirituality (INSPIRIT); neuropsychological indices of cerebral structures: temporal lobes (Wechsler Memory Scale-III), right parietal lobe (Judgment of Line Orientation), and frontal lobes (Trail Making Test, Controlled Oral Word Association Test). As hypothesized, spirituality was significantly negatively correlated with a measure of right parietal lobe functioning and positively correlated (nonsignificantly) with measures of left temporal lobe functioning. Contrary to hypotheses, correlations between spirituality and measures of frontal lobe functioning were zero or negative (and nonsignificant). The data support a neuropsychological model that proposes that spiritual experiences are related to decreased activity of the right parietal lobe, which may be associated with decreased awareness of the self (transcendence) and increased activity of the left temporal lobe, which may be associated with the experience of specific religious archetypes (religious figures and symbols).	[Johnstone, Brick] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA; [Glass, Bret A.] Univ Missouri, Dept Educ Sch & Counseling Psychol, Columbia, MO 65212 USA	Johnstone, B (corresponding author), Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA.	johnstoneg@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			Aftanas LI, 2001, NEUROSCI LETT, V310, P57, DOI 10.1016/S0304-3940(01)02094-8; Azari NP, 2001, EUR J NEUROSCI, V13, P1649, DOI 10.1046/j.0953-816x.2001.01527.x; BEAR DM, 1979, CORTEX, V15, P357, DOI 10.1016/S0010-9452(79)80064-7; BEAR DM, 1977, ARCH NEUROL-CHICAGO, V34, P454, DOI 10.1001/archneur.1977.00500200014003; BENTON A, 1975, NEUROLOGY, V25, P907, DOI 10.1212/WNL.25.10.907; Benton A, 1989, MULTILINGUAL APHASIA; BENTON AL, 1970, NEUROLOGY, V20, P1084, DOI 10.1212/WNL.20.11.1084; Brozgold A Z, 1998, Appl Neuropsychol, V5, P15, DOI 10.1207/s15324826an0501_2; d'Aquili E. G., 1993, ZYGON J RELIG SCI, V33, P177; d'Aquili E. G., 1993, STUDIA LITURGICA, V23, P2; d'Aquili EG, 2000, ZYGON, V35, P39, DOI 10.1111/0591-2385.00258; d'Aquili EG, 1998, ZYGON, V33, P187, DOI 10.1111/0591-2385.00140; DAQUILI EG, 1978, ZYGON, V13, P257, DOI 10.1111/j.1467-9744.1978.tb00338.x; DAQUILI EG, 1986, ZYGON, V21, P141, DOI 10.1111/j.1467-9744.1986.tb00741.x; FENWICK P, 2003, SPIRITUALITY PSYCHIA, V13; HERZOG H, 1991, NEUROPSYCHOBIOLOGY, V23, P182, DOI 10.1159/000119450; Johnstone B., 1995, APPL NEUROPSYCHOL, V2, DOI [10.1207/s15324826an0201_4, DOI 10.1207/S15324826AN0201_4]; JOSEPH R, 1990, NEUROPSYCHOLOGY NEUR; KANDEL ER, 1993, PRINCIPLES NEURAL SC; KASS JD, 1991, J SCI STUD RELIG, V30, P203, DOI 10.2307/1387214; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Mesulam MM, 2000, PRINCIPLES BEHAV COG, P1; Newberg A, 2003, PERCEPT MOTOR SKILL, V97, P625, DOI 10.2466/PMS.97.6.625-630; Newberg A, 2001, PSYCHIAT RES-NEUROIM, V106, P113, DOI 10.1016/S0925-4927(01)00074-9; Newberg A, 1997, J NUCL MED, V38, P77; Newberg A. B., 1998, HDB RELIG MENTAL HLT, P76; Newberg AB, 2003, MED HYPOTHESES, V61, P282, DOI 10.1016/S0306-9877(03)00175-0; NEWBERG AB, 2005, FIELD ANAL NEUROSCIE; Newberg Andrew, 1994, ANTHR CONSCIOUSNESS, V5, P1; Newberg Andrew I., 2005, HDB PSYCHOL RELIG SP, P199; NOVELLY RA, 1984, ANN NEUROL, V15, P64, DOI 10.1002/ana.410150112; Portas CM, 1998, J NEUROSCI, V18, P8979; Puri BK, 2001, INT J PSYCHOPHYSIOL, V40, P143, DOI 10.1016/S0167-8760(00)00159-8; Reitan R. M., 1992, TRAIL MAKING TEST MA; Saver JL, 1997, J NEUROPSYCH CLIN N, V9, P498; Shimizu T, 2000, NEUROREPORT, V11, P3077, DOI 10.1097/00001756-200009280-00009; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; Tranel D., 2002, HDB MEMORY DISORDERS; Wechsler D, 1997, WMS 3 ADM SCORING MA; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wuerfel J, 2004, J NEUROL NEUROSUR PS, V75, P640, DOI 10.1136/jnnp.2003.06973	42	25	25	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0591-2385	1467-9744		ZYGON	Zygon	DEC	2008	43	4					861	874		10.1111/j.1467-9744.2008.00964.x			14	Social Issues; Religion	Social Issues; Religion	375JO	WOS:000261110200007					2021-06-18	
J	Lunsman, M; Edwards, JD; Andel, R; Small, BJ; Ball, KK; Roenker, DL				Lunsman, Melissa; Edwards, Jerri D.; Andel, Ross; Small, Brent J.; Ball, Karlene K.; Roenker, Daniel L.			What Predicts Changes in Useful Field of View Test Performance?	PSYCHOLOGY AND AGING			English	Article						UFOV; useful field of view; longitudinal; random effects; speed of processing	DIGIT-SYMBOL-SUBSTITUTION; COGNITIVE TRAINING TRIAL; TRAUMATIC BRAIN-INJURY; ADULT AGE-DIFFERENCES; OLDER-ADULTS; VISUAL-ATTENTION; DRIVING PERFORMANCE; EVERYDAY PERFORMANCE; PROCESSING SPEED; DRIVERS	The Useful Field of View Test (UFOV) has been used as ail examination of age-related changes in visual Processing and cognition and as an indicator of everyday performance outcomes, particularly driving, for over 20 years. How UFOV performance changes with age and what may impact such changes have not previously been investigated longitudinally. Predictors of change in UFOV performance over a 5-year period among control group participants (N = 690) from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) stud), were examined. Random effects models were estimated with 4-subtest-total UFOV as the outcome and with baseline age. education, gender. race, visual acuity. depressive symptoms. mental status, and self-rated health. as well as attrition, as predictors. UFOV performance generally followed a curvilinear pattern. improving and then declining over time. Only increased age was consistently related to greater declines in UFOV performance over time. UFOV and Digit Symbol Substitution subtest, a standard measure of cognitive speed, had similar trajectories of change. The implications of these results are discussed.	[Lunsman, Melissa; Edwards, Jerri D.; Andel, Ross; Small, Brent J.] Univ S Florida, Sch Aging Studies, Tampa, FL 33620 USA; [Ball, Karlene K.] Univ Alabama Birmingham, Edward R Roybal Ctr Translat Res Aging & Mobil, Dept Psychol, Birmingham, AL USA; [Roenker, Daniel L.] Western Kentucky Univ, Dept Psychol, Bowling Green, KY USA	Edwards, JD (corresponding author), Univ S Florida, Sch Aging Studies, 4202 E Fowler Ave,MHC 1326, Tampa, FL 33620 USA.	jedwards1@cas.usf.edu		Ball, Karlene/0000-0003-1811-9870; Andel, Ross/0000-0003-4083-4790; Edwards, Jerri/0000-0002-5117-3863; Small, Brent/0000-0002-7444-4689	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [5 P30 AG022838, U01 AG014282, U01 AG014260-04, R03 AG024082, U01 AG14260, U01 AG14263, U01 AG014260, P30 AG022838, U01 AG014276, U01 AG014263, U01 AG14289, U01 AG14282, U01 AG014289] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [U01 NR004507, U01 NR04508, U01 NR004508, U01 NR04507] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [U01NR004508, U01NR004507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG014289, U01AG014282, U01AG014276, U01AG014263, U01AG014260, P30AG022838, R03AG024082] Funding Source: NIH RePORTER		Anstey KJ, 2003, J EXP PSYCHOL GEN, V132, P470, DOI 10.1037/0096-3445.132.3.470; BALL K, 1990, CLIN VISION SCI, V5, P113; BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Ball K, 2007, J GERONTOL B-PSYCHOL, V62, P19, DOI 10.1093/geronb/62.special_issue_1.19; Ball KK, 2006, J AM GERIATR SOC, V54, P77, DOI 10.1111/j.1532-5415.2005.00568.x; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; BALL KK, 2008, MAINTAINING PR UNPUB; BERES CA, 1981, J GERONTOL, V36, P591, DOI 10.1093/geronj/36.5.591; BERGEN JR, 1983, NATURE, V303, P696, DOI 10.1038/303696a0; Broman AT, 2004, INVEST OPHTH VIS SCI, V45, P2955, DOI 10.1167/iovs.04-0219; Duchek JM, 1998, J GERONTOL B-PSYCHOL, V53, pP130, DOI 10.1093/geronb/53B.2.P130; Edwards JD, 2005, J CLIN EXP NEUROPSYC, V27, P529, DOI 10.1080/13803390490515432; Edwards JD, 2005, AGING MENT HEALTH, V9, P262, DOI 10.1080/13607860412331336788; Edwards JD, 2002, GERONTOLOGY, V48, P329, DOI 10.1159/000065259; Edwards JD, 2006, ARCH CLIN NEUROPSYCH, V21, P275, DOI 10.1016/j.acn.2006.03.001; Finkel D, 2007, PSYCHOL AGING, V22, P558, DOI 10.1037/0882-7974.22.3.558; Fisk GD, 2002, ARCH PHYS MED REHAB, V83, P469, DOI 10.1053/apmr.2002.31179; Fisk GD, 2002, J HEAD TRAUMA REHAB, V17, P16, DOI 10.1097/00001199-200202000-00004; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Goode KT, 1998, J CLIN PSYCHOL MED S, V5, P425, DOI 10.1023/A:1026206927686; Hinton-Bayre A, 2005, PSYCHOL ASSESSMENT, V17, P237, DOI 10.1037/1040-3590.17.2.237; Hoffman L, 2005, PSYCHOL AGING, V20, P610, DOI 10.1037/0882-7974.20.4.610; Hoyer WJ, 2004, PSYCHOL AGING, V19, P211, DOI 10.1037/0882-7974.19.1.211; Jobe JB, 2001, CONTROL CLIN TRIALS, V22, P453, DOI 10.1016/S0197-2456(01)00139-8; Lemke U, 2005, AGING NEUROPSYCHOL C, V12, P57, DOI 10.1080/13825580590925116; MacDonald SWS, 2003, J GERONTOL B-PSYCHOL, V58, pP187, DOI 10.1093/geronb/58.3.P187; Myers RS, 2000, PERCEPT MOTOR SKILL, V91, P279, DOI 10.2466/PMS.91.5.279-290; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; OWSLEY C, 1995, VISION RES, V35, P579, DOI 10.1016/0042-6989(94)00166-J; Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; Owsley C, 2004, J AM GERIATR SOC, V52, P1901, DOI 10.1111/j.1532-5415.2004.52516.x; Owsley C, 2002, GERONTOLOGY, V48, P254, DOI 10.1159/000058360; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; PLUDE DJ, 1981, J GERONTOL, V36, P598, DOI 10.1093/geronj/36.5.598; RABBITT P, 1965, J GERONTOL, V20, P233, DOI 10.1093/geronj/20.2.233; Rabbitt P, 2004, J GERONTOL B-PSYCHOL, V59, pP84, DOI 10.1093/geronb/59.2.P84; RABBITT P, 1965, BEHAV AGING NERVOUS; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Richards E, 2006, VISION RES, V46, P4217, DOI 10.1016/j.visres.2006.08.011; Riolo L., 2003, PHYS OCCUPATIONAL TH, V22, P15; Rizzo M, 1997, ARCH NEUROL-CHICAGO, V54, P545, DOI 10.1001/archneur.1997.00550170027011; Roenker DL, 2003, HUM FACTORS, V45, P218, DOI 10.1518/hfes.45.2.218.27241; SALTHOUSE TA, 1992, J GERONTOL, V47, pP121, DOI 10.1093/geronj/47.3.P121; SANDERS A F, 1970, Ergonomics, V13, P101, DOI 10.1080/00140137008931124; Scalf PE, 2007, J GERONTOL B-PSYCHOL, V62, P32, DOI 10.1093/geronb/62.special_issue_1.32; SCHAIE KW, 1989, PSYCHOL AGING, V4, P443, DOI 10.1037/0882-7974.4.4.443; SCIALFA CT, 1987, PSYCHOL AGING, V2, P14, DOI 10.1037/0882-7974.2.1.14; Seiple W, 1996, VISION RES, V36, P1859, DOI 10.1016/0042-6989(95)00288-X; Sekuler AB, 2000, EXP AGING RES, V26, P103, DOI 10.1080/036107300243588; SEKULER R, 1986, J OPT SOC AM A, V3, P864, DOI 10.1364/JOSAA.3.000864; Shawaryn MA, 2002, ARCH PHYS MED REHAB, V83, P1123, DOI 10.1053/apmr.2002.33730; Sims RV, 2001, J AGING HEALTH, V13, P430, DOI 10.1177/089826430101300306; Stalvey BT, 1999, J APPL GERONTOL, V18, P460, DOI 10.1177/073346489901800404; Uc EY, 2006, ANN NEUROL, V60, P407, DOI 10.1002/ana.20958; VERRIEST G, 1985, OCCUPATIONAL VISUAL, V2; Wechsler, 1981, WAIS R MANUAL; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Wolinsky FD, 2006, J GERONTOL A-BIOL, V61, P1324, DOI 10.1093/gerona/61.12.1324; Wolinsky FD, 2006, J GERONTOL B-PSYCHOL, V61, pS281, DOI 10.1093/geronb/61.5.S281; WOOD JM, 1995, OPTOMETRY VISION SCI, V72, P115, DOI 10.1097/00006324-199502000-00010; Wood KM, 2005, GERONTOLOGY, V51, P131, DOI 10.1159/000082199	64	25	25	0	26	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0882-7974	1939-1498		PSYCHOL AGING	Psychol. Aging	DEC	2008	23	4					917	927		10.1037/a0013466			11	Gerontology; Psychology, Developmental	Geriatrics & Gerontology; Psychology	387YR	WOS:000261988000022	19140660	Green Accepted			2021-06-18	
J	Vukovic, M; Vuksanovic, J; Vukovic, I				Vukovic, Mile; Vuksanovic, Jasmina; Vukovic, Irena			Comparison of the recovery patterns of language and cognitive functions in patients with post-traumatic language processing deficits and in patients with aphasia following a stroke	JOURNAL OF COMMUNICATION DISORDERS			English	Article							CLOSED HEAD-INJURY; CONDUCTION APHASIA; VERBAL IMPAIRMENT; MEMORY; REHABILITATION; INTELLIGENCE; PERFORMANCE; REPETITION; APRAXIA; TRAUMA	In this study we investigated the recovery patterns of language and cognitive functions in patients with post-traumatic language processing deficits and in patients with aphasia following a stroke. The correlation of specific language functions and cognitive functions was analyzed in the acute phase and 6 months later. Significant recovery of the tested functions was observed in both groups. However, in patients with post-traumatic language processing deficits the degree of recovery of most language functions and some cognitive functions was higher. A significantly greater correlation was revealed within language and cognitive functions, as well as between language functions and other aspects of cognition in patients with post-traumatic language processing deficits than in patients with aphasia following a stroke. Our results show that patients with post-traumatic language processing deficits have a different recovery pattern and a different pattern of correlation between language and cognitive functions compared to patients with aphasia following a stroke. Learning outcomes: (1) Better understanding of the differences in recovery of language and cognitive functions in patients who have suffered strokes and those who have experienced traumatic brain injury. (2) Better understanding of the relationship between language and cognitive functions in patients with post-traumatic language processing deficits and in patients with aphasia following a stroke. (3) Better understanding of the factors influencing recovery. (c) 2008 Elsevier Inc. All rights reserved.	[Vukovic, Mile] Univ Belgrade, Fac Special Educ & Rehabil, Belgrade 11000, Serbia; [Vuksanovic, Jasmina] Hlth Ctr Zemun, Belgrade 11000, Serbia; [Vukovic, Irena] Univ Belgrade, Ctr Multidisciplinary Studies, Belgrade 11000, Serbia	Vukovic, M (corresponding author), Univ Belgrade, Fac Special Educ & Rehabil, Belgrade 11000, Serbia.	mvukovic@yubc.net		Vukovic, Mile/0000-0003-3750-7991; Vukovic, Irena/0000-0001-8288-4222			Archibald Z. M., 1967, CORTEX, V3, P275; Baldo JV, 2005, BRAIN LANG, V92, P240, DOI 10.1016/j.bandl.2004.06.103; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Bartha L, 2004, BRAIN LANG, V88, P83, DOI 10.1016/S0093-934X(03)00281-5; Bartha L, 2003, BRAIN LANG, V85, P93, DOI 10.1016/S0093-934X(02)00502-3; BASSO A, 1981, BRAIN, V104, P721, DOI 10.1093/brain/104.4.721; BASSO A, 1979, ARCH NEUROL-CHICAGO, V36, P190, DOI 10.1001/archneur.1979.00500400044005; BASSO A, 1973, BRAIN, V96, P715, DOI 10.1093/brain/96.4.715; BASSO A, 1982, CORTEX, V18, P469, DOI 10.1016/S0010-9452(82)80044-0; Basso A., 2003, APHASIA ITS THERAPY; Berndt R. S., 1990, NEUROPSYCHOLOGICAL I, P115; BOROD JC, 1982, CORTEX, V18, P199, DOI 10.1016/S0010-9452(82)80003-8; Bryan J, 2000, J CLIN EXP NEUROPSYC, V22, P40, DOI 10.1076/1380-3395(200002)22:1;1-8;FT040; BUTFIELD E, 1946, J NEUROL NEUROSUR PS, V9, P75, DOI 10.1136/jnnp.9.2.75; Cappa S.F., 1998, HDB NEUROLINGUISTICS, P535; CARAMAZZA A, 1981, BRAIN LANG, V14, P235, DOI 10.1016/0093-934X(81)90078-X; Caspari I, 1998, BRAIN COGNITION, V37, P205, DOI 10.1006/brcg.1997.0970; Goodglass H., 1983, ASSESSMENT APHASIA R; Granacher R, 2003, TRAUMATIC BRAIN INJU; Hagan C., 1982, COGNITIVE REHABILITA, P131; HAGAN C, 1984, LANGUAGE DISORDERS A; HAMSHER K, 1991, ACQUIRED APHASIA, P339; Hartley L. L., 1995, COGNITIVE COMMUNICAT; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Helm-Estabrooks N, 2002, J COMMUN DISORD, V35, P171, DOI 10.1016/S0021-9924(02)00063-1; HJELMQUIST EKE, 1989, SCAND J PSYCHOL, V30, P243, DOI 10.1111/j.1467-9450.1989.tb01087.x; HULME C, 1991, J MEM LANG, V30, P685, DOI 10.1016/0749-596X(91)90032-F; Kaplan E., 1983, BOSTON NAMING TEST; KERTESZ A, 1977, BRAIN, V100, P1, DOI 10.1093/brain/100.1.1; KERTESZ A, 1975, BRAIN LANG, V2, P385; KOHLMEYER K, 1976, RECOVERY APHASICS; Laska AC, 2001, J INTERN MED, V249, P413, DOI 10.1046/j.1365-2796.2001.00812.x; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1976, NEUROPSYCHOLOGICAL A; Luria AR., 1970, TRAUMATIC APHASIA; MARKS M, 1957, NEUROLOGY, V7, P837, DOI 10.1212/WNL.7.12.837; MARSHALL RC, 1982, FOLIA PHONIATR, V34, P305, DOI 10.1159/000265671; Martin N, 2004, BRAIN LANG, V89, P464, DOI 10.1016/j.bandl.2003.12.004; Martin N, 1997, COGNITIVE NEUROPSYCH, V14, P641; Martin N, 1996, BRAIN LANG, V52, P83, DOI 10.1006/brln.1996.0005; Osterrieth P. A, 1944, ARCH PSYCHOL, V30, P286; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Raven J., 1960, GUIDE STANDARD PROGR; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rothi Leslie J. Gonzalez, 1997, P91; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1991, ACQUIRED APHASIA; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Spreen O, 2003, ASSESSMENT APHASIA; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; Vignolo L, 1964, CORTEX, V1, P344, DOI DOI 10.1016/S0010-9452(64)80008-3; Vukovic M, 1998, TRAUMATIC APHASIA; WEPMAN J, 1951, RECOVERY APHASIA	55	25	30	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924			J COMMUN DISORD	J. Commun. Disord.	NOV-DEC	2008	41	6					531	552		10.1016/j.jcomdis.2008.04.001			22	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	349MO	WOS:000259285100005	18571195				2021-06-18	
J	Stranjalis, G; Bouras, T; Korfias, S; Andrianakis, I; Pitaridis, M; Tsamandouraki, K; Alamanos, Y; Sakas, DE; Marmarou, A				Stranjalis, George; Bouras, Triantafyllos; Korfias, Stefanos; Andrianakis, Ilias; Pitaridis, Marinos; Tsamandouraki, Kiki; Alamanos, Yannis; Sakas, Damiabos E.; Marmarou, Anthony			Outcome in 1,000 Head Injury Hospital Admissions: The Athens Head Trauma Registry	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Clinical management of brain injury; Epidemiology; Head trauma; Outcome measures; Traumatic brain injury	BRAIN-INJURY; INTENSIVE-CARE; SUBDURAL HEMATOMAS; MANAGEMENT; EPIDEMIOLOGY; COMA; CONSORTIUM; PRESSURE	Background. The aim of this study was to establish a head trauma registry to (a) examine demographics, etiology, severity, clinical course, and outcome; (b) compare results with previous published series; (c) identify causes of bad outcomes; and (d) propose methods to improve therapy and prognosis. Methods: The following data were collected on 1,000 consecutive victims with head injury over 14 years of age admitted during a 4-year period: demographic characteristics, cause of injury, clinical variables, neuroimaging, therapy data, and outcome in 6 months. Results: Seventy-four percent were men, and mean age was 43 years. Seventy-one percent suffered injuries due to road crashes, 14% due to alcohol, and 2% due to substances. The secondary transfer rate was 49%. For severe injuries, the time intervals from incident to hospital and subsequently to neurosurgical unit were 35 minutes and 4 hours, respectively. In 65% and 72% of cases, there was no record of preresuscitation hypoxia or hypotension, respectively, whereas suspected or definite episodes of hypoxia and hypotension were 27% and 13%, respectively. Most cases were mild trauma (63%), the remaining were severe (26%) and moderate (11%) injuries. Severe systemic trauma coexisted in 18%. Cranial surgery rate was.19% and it increased to 39% in severe trauma. The 6-month overall good outcome was 71%, with lower rates in moderate (58%) and severe (24%) injuries. Conclusions: The organization of Greece's first head injury registry offered an important preliminary core data concerning brain trauma etiology, management, and long-term outcome.	[Stranjalis, George; Bouras, Triantafyllos; Korfias, Stefanos; Sakas, Damiabos E.] Univ Athens, Dept Neurosurg, Evangelismos Hosp, Athens, Greece; [Andrianakis, Ilias; Pitaridis, Marinos] Univ Athens, Dept Intens Care Med, Evangelismos Hosp, Athens, Greece; [Stranjalis, George; Bouras, Triantafyllos; Korfias, Stefanos; Sakas, Damiabos E.] Hellen Neurosurg Res Ctr Prof P Kokkalis, Athens, Greece; [Tsamandouraki, Kiki] Inst Social & Prevent Med, Athens, Greece; [Alamanos, Yannis] Univ Ioannina, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece; [Marmarou, Anthony] Amer Brain Injury Consortium, Richmond, VA USA	Stranjalis, G (corresponding author), 32 Skoufa St, Athens 10673, Greece.	stranjal@otenet.gr					Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Annoni J M, 1992, Disabil Rehabil, V14, P23; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Cruz J, 2001, NEUROSURGERY, V49, P864; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1979, Acta Neurochir Suppl (Wien), V28, P149; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Munch E, 2000, NEUROSURGERY, V47, P315; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; OBrien DP, 1996, IRISH MED J, V89, P216; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; QUATTROCCHI KB, 1991, SURG NEUROL, V35, P183, DOI 10.1016/0090-3019(91)90069-L; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; SERVADEI F, 1988, ITAL J NEUROL SCI, V9, P449, DOI 10.1007/BF02337162; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Servadei F, 2000, NEUROSURGERY, V46, P70; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Stranjalis G, 1996, SURG NEUROL, V45, P314, DOI 10.1016/0090-3019(95)00435-1; Stranjalis G, 1998, J NEUROSURG, V88, P782, DOI 10.3171/jns.1998.88.4.0782; Stranjalis G, 2000, HEADACHE, V40, P176, DOI 10.1046/j.1526-4610.2000.00024.x; STRANJALIS G, 2000, J RESTOR NEUROSCI NE, V6, P24; TALIAFERI T, 2006, ACTA NEUROCHIR WIEN, V148, P255; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, ACTA NEUROCHIR, V139, P797, DOI 10.1007/BF01411397; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049	44	25	25	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2008	65	4					789	793		10.1097/TA.0b013e3181469e26			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	361JS	WOS:000260124500009	18849792				2021-06-18	
J	Fisk, JE; Montgomery, C				Fisk, J. E.; Montgomery, C.			Real-world memory and executive processes in cannabis users and non-users	JOURNAL OF PSYCHOPHARMACOLOGY			English	Article						separable executive processes; everyday memory; prospective memory; cognitive failures; cannabis	COGNITIVE FAILURES QUESTIONNAIRE; TRAUMATIC BRAIN-INJURY; EVERYDAY MEMORY; RECREATIONAL USE; WORKING-MEMORY; MARIJUANA USE; ECSTASY MDMA; DEFICITS; IMPAIRMENT; ATTENTION	The relationships between executive processes, associative learning and different aspects of real world memory functioning were explored in a sample of cannabis users and nonusers. Measures of executive component processes, associative learning, everyday memory, prospective memory, and cognitive failures were administered. Relative to nonusers, cannabis users were found to be impaired in several aspects of real world memory functioning. No other group differences were apparent. The absence of cannabis related deficits in those executive component processes and aspects of learning that are believed to support real world memory processes is surprising given that cannabis related deficits were obtained in real world memory. The present results are discussed within the context of neuroimaging evidence which suggests that cannabis users may exhibit different patterns of neural activation when performing executive tasks while not always exhibiting deficits on these tasks.	[Fisk, J. E.] Univ Cent Lancashire, Dept Psychol, Preston PR1 2HE, Lancs, England; [Montgomery, C.] Liverpool John Moores Univ, Sch Psychol, Liverpool L3 5UX, Merseyside, England	Fisk, JE (corresponding author), Univ Cent Lancashire, Dept Psychol, Preston PR1 2HE, Lancs, England.	jfisk@uclan.ac.uk	Ballesteros, Soledad/F-5561-2015; Montgomery, Catharine/B-6096-2014; Aviles, Jose Manuel Reales/G-3929-2011	Ballesteros, Soledad/0000-0002-8391-9615; Montgomery, Catharine/0000-0003-2805-5807; 			Andersson M, 2005, J NEUROSCI, V25, P8432, DOI 10.1523/JNEUROSCI.1289-05.2005; BLOCK RI, 1993, PSYCHOPHARMACOLOGY, V110, P219, DOI 10.1007/BF02246977; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Collette F, 2006, NEUROSCIENCE, V139, P209, DOI 10.1016/j.neuroscience.2005.05.035; Cornish IM, 2000, BRIT J PSYCHOL, V91, P427, DOI 10.1348/000712600161916; Court JH, 1998, MANUAL RAVENS PROGR; Croft RJ, 2001, PSYCHOPHARMACOLOGY, V153, P373, DOI 10.1007/s002130000591; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Efklides A, 2002, EUR J PSYCHOL ASSESS, V18, P63, DOI 10.1027//1015-5759.18.1.63; FEHR KA, 1976, SCIENCE, V192, P1249, DOI 10.1126/science.1273591; Fisk JE, 2004, J CLIN EXP NEUROPSYC, V26, P874, DOI 10.1080/13803390490510680; GOLDSTEIN LH, 1992, CORTEX, V28, P189, DOI 10.1016/S0010-9452(13)80047-0; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hubert JP, 1998, DRUG DEVELOP RES, V45, P74, DOI 10.1002/(SICI)1098-2299(199810)45:2<74::AID-DDR4>3.0.CO;2-H; Jacobsen LK, 2007, BIOL PSYCHIAT, V61, P31, DOI 10.1016/j.biopsych.2006.02.014; Jager G, 2006, PSYCHOPHARMACOLOGY, V185, P358, DOI 10.1007/s00213-005-0298-7; Jager G, 2007, EUR NEUROPSYCHOPHARM, V17, P289, DOI 10.1016/j.euroneuro.2006.10.003; Jones GV, 2003, APPL COGNITIVE PSYCH, V17, P861, DOI 10.1002/acp.935; Kliegel M, 2005, J NEUROL NEUROSUR PS, V76, P1501, DOI 10.1136/jnnp.2004.051268; Knight RG, 2004, NEW ZEAL J PSYCHOL, V33, P163; KOLTAI DC, 1996, ASSESSMENT, V3, P443, DOI DOI 10.1177/107319119600300410; Lawston J, 2000, BRAIN RES, V877, P407, DOI 10.1016/S0006-8993(00)02739-6; Marsh RL, 1998, J EXP PSYCHOL LEARN, V24, P336, DOI 10.1037/0278-7393.24.2.336; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; Messinis L, 2006, NEUROLOGY, V66, P737, DOI 10.1212/01.wnl.0000201279.83203.c6; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Montgomery C, 2005, PSYCHOPHARMACOLOGY, V182, P262, DOI 10.1007/s00213-005-0065-9; Montgomery C, 2005, PSYCHOPHARMACOLOGY, V180, P141, DOI 10.1007/s00213-004-2131-0; Morgan MJ, 1998, NEUROPSYCHOPHARMACOL, V19, P252, DOI 10.1016/S0893-133X(98)00012-8; Morgan MJ, 1999, PSYCHOPHARMACOLOGY, V141, P30, DOI 10.1007/s002130050803; Nelson HE, 1982, NATL ADULT READING T; Olsson E, 2006, NEUROPSYCHOL REHABIL, V16, P257, DOI 10.1080/09602010500176328; Pope HG, 1997, PSYCHOTHER PSYCHOSOM, V66, P179; Rodgers J, 2000, PSYCHOPHARMACOLOGY, V151, P19, DOI 10.1007/s002130000467; Rodgers J, 2001, HUM PSYCHOPHARM CLIN, V16, P619, DOI 10.1002/hup.345; Sarne Y, 2004, MED HYPOTHESES, V63, P187, DOI 10.1016/j.mehy.2004.02.043; SARNE Y, 2005, INT ASS CANN MED IAC; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; SCHWARTZ RH, 1991, PSYCHIAT ANN, V21, P80, DOI 10.3928/0048-5713-19910201-07; Smith-Spark JH, 2004, MEMORY, V12, P174, DOI 10.1080/09658210244000450; Solowij N, 2002, JAMA-J AM MED ASSOC, V287, P1123, DOI 10.1001/jama.287.9.1123; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; VARMA VK, 1988, DRUG ALCOHOL DEPEN, V21, P147, DOI 10.1016/0376-8716(88)90061-0; Verdejo-Garcia A, 2006, ADDICT BEHAV, V31, P1373, DOI 10.1016/j.addbeh.2005.11.003; Verheul R, 2001, EUR PSYCHIAT, V16, P274, DOI 10.1016/S0924-9338(01)00578-8; Wallace JC, 2004, PERS INDIV DIFFER, V37, P307, DOI 10.1016/j.paid.2003.09.005; Wallace JC, 2002, J GEN PSYCHOL, V129, P238, DOI 10.1080/00221300209602098; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012	51	25	25	0	19	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-8811			J PSYCHOPHARMACOL	J. Psychopharmacol.	SEP	2008	22	7					727	736		10.1177/0269881107084000			10	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	341KK	WOS:000258713200004	18208908				2021-06-18	
J	Lemoyne, R; Coroian, C; Mastroianni, T; Grundfest, W				Lemoyne, Robert; Coroian, Cristian; Mastroianni, Timothy; Grundfest, Warren			VIRTUAL PROPRIOCEPTION	JOURNAL OF MECHANICS IN MEDICINE AND BIOLOGY			English	Article						Virtual proprioception; wireless accelerometers; gait analysis; gait rehabilitation; locomotion; proprioception; hemiparetic gait; traumatic brain injury	EVOKED MOTOR-RESPONSES; PHYSICAL-ACTIVITY; HUMAN WALKING; GAIT ANALYSIS; INTERLIMB COORDINATION; ENERGY-EXPENDITURE; OLDER-ADULTS; ACCELEROMETRY; TRUNK; ACCELERATIONS	Virtual proprioception represents a novel means of developing cortical reorganization of alternative strategies for hemiparetic gait. Fundamentals of the device are motor control plasticity, aftereffect, and visual-based biofeedback. Two wireless three-dimensional (3D) microelectromechanical systems (MEMS) accelerometers are placed on the femur ( upper leg) of both the affected and unaffected limbs above the lateral epicondyle next to the knee joint. The acceleration data from the two wireless 3D MEMS accelerometers are fed back to the user in real time by visual output from a portable laptop PC. Given the virtual proprioception feedback, the user can then adjust the original gait while walking to an improved alternative gait strategy. First, hemiparetic gait is comprehensively discussed. The inherent roles of proprioception with locomotion and issues with traumatic brain injury are considered. Then, the technology advance of accelerometers and gait analysis is detailed. Virtual proprioception is tested and evaluated, while demonstrating the capacity to improve disparities in hemiparetic gait during real time.	[Lemoyne, Robert; Grundfest, Warren] Univ Calif Los Angeles, Biomed Engn IDP, Los Angeles, CA 90095 USA; [Coroian, Cristian] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Mastroianni, Timothy] Cognit Engn, Pittsburgh, PA USA	Lemoyne, R (corresponding author), Univ Calif Los Angeles, Biomed Engn IDP, 5121 Engn 5,Box 951600, Los Angeles, CA 90095 USA.	rlemoyne@ucla.edu	LeMoyne, Robert/AAI-9686-2020	LeMoyne, Robert/0000-0003-3587-3250			Aiello E, 2005, P ANN INT IEEE EMBS, P7703, DOI 10.1109/IEMBS.2005.1616297; Aminian K, 1999, MED BIOL ENG COMPUT, V37, P304, DOI 10.1007/BF02513304; Auvinet B, 2002, GAIT POSTURE, V16, P124, DOI 10.1016/S0966-6362(01)00203-X; Besier TF, 2003, J BIOMECH, V36, P1159, DOI 10.1016/S0021-9290(03)00087-3; Brandt T, 1999, LANCET, V354, P746, DOI 10.1016/S0140-6736(99)03179-7; Brunnekreef JJ, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-17; Capaday C, 1999, J NEUROPHYSIOL, V81, P129; CAPADAY C, 1987, J PHYSIOL-LONDON, V392, P513, DOI 10.1113/jphysiol.1987.sp016794; Culhane KM, 2005, AGE AGEING, V34, P556, DOI 10.1093/ageing/afi192; DIETZ V, 1989, NEUROSCI LETT, V106, P350, DOI 10.1016/0304-3940(89)90189-4; DIETZ V, 1992, EXP BRAIN RES, V89, P229; DIETZ V, 1987, J PHYSIOL-LONDON, V386, P149, DOI 10.1113/jphysiol.1987.sp016527; Dietz V., 2001, Neural Plasticity, V8, P83, DOI 10.1155/NP.2001.83; Dietz V, 2001, NEUROREPORT, V12, P2743, DOI 10.1097/00001756-200108280-00030; DIETZ V, 1992, PHYSIOL REV, V72, P33; DIETZ V, 1989, J NEUROPHYSIOL, V62, P680; Dietz V, 2002, NAT REV NEUROSCI, V3, P781, DOI 10.1038/nrn939; Dobkin B.H., 2003, CLIN SCI NEUROLOGIC; Duysens J, 1996, J NEUROPHYSIOL, V76, P301; DUYSENS J, 1990, EXP BRAIN RES, V82, P351; Finney R. L., 1990, CALCULUS; Growney E, 1997, GAIT POSTURE, V6, P147, DOI 10.1016/S0966-6362(97)01114-4; HANSEN PD, 1988, EXP BRAIN RES, V73, P627, DOI 10.1007/BF00406622; Hester T, 2006, BSN 2006: International Workshop on Wearable and Implantable Body Sensor Networks, Proceedings, P5; Hoos MB, 2004, EUR J CLIN NUTR, V58, P1425, DOI 10.1038/sj.ejcn.1601991; Horak FB, 2001, J NEUROPHYSIOL, V86, P575; Huang H, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-11; Jafari R, 2005, PROCEEDINGS OF MOBIQUITOUS 2005, P479; JANKOWSKA E, 1981, TRENDS NEUROSCI, V4, P230, DOI 10.1016/0166-2236(81)90072-2; Jones KE, 2001, NEUROREPORT, V12, P4029, DOI 10.1097/00001756-200112210-00035; KADABA MP, 1989, J ORTHOPAED RES, V7, P849, DOI 10.1002/jor.1100070611; Kavanagh JJ, 2004, GAIT POSTURE, V20, P291, DOI 10.1016/j.gaitpost.2003.10.004; Kavanagh JJ, 2006, J BIOMECH, V39, P2863, DOI 10.1016/j.jbiomech.2005.09.012; Lackner JR, 2000, TRENDS COGN SCI, V4, P279, DOI 10.1016/S1364-6613(00)01493-5; LEE JA, 2007, C P IEEE ENG MED BIO, V1, P483; LEMOYNE R, 2007, 3 ANN THER STRAT NEU; LEMOYNE R, 2005, UCLA COMMUNICATION N; LEMOYNE R, 2007, UCLA BRAIN RES I NEU; LEMOYNE R, 2007, IGERT STUD RES S PIT; Lord SE, 2005, STROKE, V36, P1457, DOI 10.1161/01.STR.0000170698.20376.2e; Mansfield A, 2003, MED ENG PHYS, V25, P879, DOI 10.1016/S1350-4533(03)00116-4; Mayagoitia RE, 2002, J BIOMECH, V35, P537, DOI 10.1016/S0021-9290(01)00231-7; Menz HB, 2003, GAIT POSTURE, V18, P35, DOI 10.1016/S0966-6362(02)00159-5; Menz HB, 2003, AGE AGEING, V32, P137, DOI 10.1093/ageing/32.2.137; Moe-Nilssen R, 2005, GAIT POSTURE, V21, P164, DOI 10.1016/j.gaitpost.2004.01.013; Moe-Nilssen R, 2004, J BIOMECH, V37, P121, DOI 10.1016/S0021-9290(03)00233-1; Moe-Nilssen R, 1998, CLIN BIOMECH, V13, P328, DOI 10.1016/S0268-0033(98)00090-4; NAKAMURA S, 1996, NUMERICAL ANAL GRAPH; Pang MYC, 2000, J PHYSIOL-LONDON, V528, P389, DOI 10.1111/j.1469-7793.2000.00389.x; Pang MYC, 2001, J PHYSIOL-LONDON, V533, P617, DOI 10.1111/j.1469-7793.2001.0617a.x; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Perry J, 1992, GAIT ANAL NORMAL PAT; Saremi K, 2006, NEUROREHAB NEURAL RE, V20, P297, DOI 10.1177/1545968306287171; SAUNDERS JBDM, 1953, J BONE JOINT SURG AM, V35-A, P543, DOI 10.2106/00004623-195335030-00003; SCHOMBURG ED, 1990, NEUROSCI RES, V7, P265, DOI 10.1016/0168-0102(90)90008-3; Schubert M, 1997, EXP BRAIN RES, V115, P234, DOI 10.1007/PL00005693; Schubert M, 1999, EXP BRAIN RES, V126, P583, DOI 10.1007/s002210050767; SINKJAER T, 1994, BRAIN, V117, P355, DOI 10.1093/brain/117.2.355; Sinkjaer T, 1996, J NEUROPHYSIOL, V76, P1112; Takahashi CD, 2001, J NEUROPHYSIOL, V86, P1047; Vaillancourt DE, 2000, CLIN NEUROPHYSIOL, V111, P2046, DOI 10.1016/S1388-2457(00)00467-3; vandenBogert AJ, 1996, J BIOMECH, V29, P949, DOI 10.1016/0021-9290(95)00155-7; vanEmmerik REA, 1996, J BIOMECH, V29, P1175, DOI 10.1016/0021-9290(95)00128-X; Waters RL, 1999, GAIT POSTURE, V9, P207, DOI 10.1016/S0966-6362(99)00009-0; Yoshimura I, 2002, INT ORTHOP, V26, P303, DOI 10.1007/s00264-002-0379-8; Zhang K, 2004, MED SCI SPORT EXER, V36, P883, DOI 10.1249/01.MSS.0000126585.40962.22; Zhang K, 2003, OBES RES, V11, P33, DOI 10.1038/oby.2003.7; Zijlstra W, 2004, CLIN BIOMECH, V19, P819, DOI 10.1016/j.clinbiomech.2004.05.005; Zijlstra W, 2003, GAIT POSTURE, V18, P1, DOI 10.1016/S0966-6362(02)00190-X	69	25	25	0	5	WORLD SCIENTIFIC PUBL CO PTE LTD	SINGAPORE	5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE	0219-5194	1793-6810		J MECH MED BIOL	J. Mech. Med. Biol.	SEP	2008	8	3					317	338		10.1142/S0219519408002693			22	Biophysics; Engineering, Biomedical	Biophysics; Engineering	389LM	WOS:000262094100002					2021-06-18	
J	Rasmussen, IA; Xu, J; Antonsen, IK; Brunner, J; Skandsen, T; Axelson, DE; Berntsen, EM; Lydersen, S; Haberg, A				Rasmussen, Inge-Andre, Jr.; Xu, Jian; Antonsen, Ida Kristin; Brunner, Jan; Skandsen, Toril; Axelson, David E.; Berntsen, Erik M.; Lydersen, Stian; Haberg, Asta			Simple Dual Tasking Recruits Prefrontal Cortices in Chronic Severe Traumatic Brain Injury Patients, But Not in Controls	JOURNAL OF NEUROTRAUMA			English	Article						anterior cingulate cortex; attention; executive; MRI; white matter injury	SURFACE-BASED ANALYSIS; WORKING-MEMORY; DIVIDED ATTENTION; NEURAL BASIS; FUNCTIONAL NEUROANATOMY; SEARCH EFFICIENCY; EXECUTIVE CONTROL; VISUAL-SEARCH; HEAD-INJURY; TOP-DOWN	The ability to carry out two tasks simultaneously, dual tasking, is specifically impaired after traumatic brain injury (TBI). The aim of the present study was to investigate the neuronal correlates to this increased dual cost in chronic severe TBI patients (n = 10) compared to healthy controls (n = 11) using functional magnetic resonance imaging (fMRI) at 3 Tesla (T). The tasks were a visual search and a simple two-fingers button press motor task. Performance data demonstrated similar and significant dual task interference in both TBI patients and controls using a linear mixed model. However, principal component analysis showed that TBI patients and controls could be classified into different categories based on motor activity in the single compared to the dual task condition, thus reflecting the increased variability in the performance in the TBI group. Random effects between-group analysis demonstrated significantly reduced activation in the TBI group in both single task conditions in the occipital and posterior cingulate cortices, and for the visual task also in the thalami. This pattern was reversed in the dual task condition with significantly increased activation of a predominantly left lateralized prefrontal-anterior midline-parietal network in the TBI group compared to the controls. The increase in activation occurred within regions described to be engaged in healthy volunteers as dual task cost increases. This finding points to substitution, functional reorganization within the primary network subserving the task, following TBI, and demonstrates more effortful processing. Recruitment of these additional prefrontal resources may be connected to serial rather than parallel processing in low level dual tasking in TBI. Thus, in severe TBI, low level dual task performance depends on increased attentional and executive guidance.	[Rasmussen, Inge-Andre, Jr.; Xu, Jian; Berntsen, Erik M.; Haberg, Asta] NTNU, Dept Circulat & Med Imaging, N-7489 Trondheim, Norway; [Xu, Jian; Antonsen, Ida Kristin; Haberg, Asta] St Olavs Hosp, Dept Radiol, Trondheim, Norway; [Brunner, Jan; Skandsen, Toril] St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Skandsen, Toril] NTNU, Dept Neurosci, N-7489 Trondheim, Norway; [Lydersen, Stian] NTNU, Dept Canc Res & Mol Med, Unit Appl Clin Res, N-7489 Trondheim, Norway; [Axelson, David E.] MRI Consulting, Kingston, ON, Canada	Haberg, A (corresponding author), NTNU, Dept Circulat & Med Imaging, N-7489 Trondheim, Norway.	asta.haberg@ntnu.no	Berntsen, Erik Magnus/AAM-7134-2020; Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338; Brunner, Jan Ferenc/0000-0002-8576-678X			Adcock RA, 2000, P NATL ACAD SCI USA, V97, P3567, DOI 10.1073/pnas.060588897; Anderson EJ, 2007, EXP BRAIN RES, V180, P289, DOI 10.1007/s00221-007-0860-0; Arciniegas David B, 2004, Phys Med Rehabil Clin N Am, V15, P177, DOI 10.1016/S1047-9651(03)00104-9; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; BADDELEY AD, 1991, BRAIN, V114, P2521, DOI 10.1093/brain/114.6.2521; BADDELEY AD, 1974, RECENT ADV LEARNING, V8, P47, DOI DOI 10.1016/S0079-7421(08)60452-1; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Boynton GM, 1996, J NEUROSCI, V16, P4207, DOI 10.1523/jneurosci.16-13-04207.1996; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Brouwer W, 2001, BRAIN COGNITION, V46, P54, DOI 10.1016/S0278-2626(01)80033-6; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; Bunge SA, 2000, P NATL ACAD SCI USA, V97, P3573, DOI 10.1073/pnas.050583797; Buschman TJ, 2007, SCIENCE, V315, P1860, DOI 10.1126/science.1138071; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Collette F, 2005, COGNITIVE BRAIN RES, V24, P237, DOI 10.1016/j.cogbrainres.2005.01.023; CREPEAU F, 1993, J CLIN EXP NEUROPSYC, V15, P73; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Donner TH, 2002, NEUROIMAGE, V15, P16, DOI 10.1006/nimg.2001.0951; Dreher JC, 2003, CEREB CORTEX, V13, P329, DOI 10.1093/cercor/13.4.329; Erickson KI, 2005, NEUROIMAGE, V28, P967, DOI 10.1016/j.neuroimage.2005.06.047; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Goldberg TE, 1998, NEUROIMAGE, V7, P296, DOI 10.1006/nimg.1998.0338; Handford Martin, 1987, WALLY; Herath P, 2001, CEREB CORTEX, V11, P796, DOI 10.1093/cercor/11.9.796; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Kiebel SJ, 2000, NEUROIMAGE, V11, P656, DOI 10.1006/nimg.1999.0542; Klingberg T, 1998, CEREB CORTEX, V8, P593, DOI 10.1093/cercor/8.7.593; Klingberg T, 2000, PROG BRAIN RES, V126, P95; Knudsen EI, 2007, ANNU REV NEUROSCI, V30, P57, DOI 10.1146/annurev.neuro.30.051606.094256; Koechlin E, 1999, NATURE, V399, P148; Kriegeskorte N, 2001, NEUROIMAGE, V14, P329, DOI 10.1006/nimg.2001.0831; Kubler A, 2006, J COGNITIVE NEUROSCI, V18, P1331, DOI 10.1162/jocn.2006.18.8.1331; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leonards U, 2000, J COGNITIVE NEUROSCI, V12, P61, DOI 10.1162/089892900564073; LOGIE RH, 1990, ACTA PSYCHOL, V75, P55, DOI 10.1016/0001-6918(90)90066-O; Logie RH, 2004, NEUROPSYCHOLOGY, V18, P504, DOI 10.1037/0894-4105.18.3.504; Lotze M, 2006, NEUROREHAB NEURAL RE, V20, P14, DOI 10.1177/1545968305282919; Marois R, 2005, TRENDS COGN SCI, V9, P296, DOI 10.1016/j.tics.2005.04.010; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Moore T, 2001, P NATL ACAD SCI USA, V98, P1273, DOI 10.1073/pnas.021549498; Muller NG, 2003, NEUROIMAGE, V20, P1578, DOI 10.1016/S1053-8119(03)00416-6; Nobre AC, 2003, NEUROIMAGE, V18, P91, DOI 10.1006/nimg.2002.1329; NORMAN DA, 1986, ATTENTION ACTION WIL; Nunez A, 2007, ADV ANAT EMBRYOL CEL, V187, P1; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PASHLER H, 1994, J EXP PSYCHOL HUMAN, V20, P330, DOI 10.1037/0096-1523.20.2.330; Passingham RE, 1996, PHILOS T ROY SOC B, V351, P1473, DOI 10.1098/rstb.1996.0132; Perry RJ, 1999, BRAIN, V122, P383, DOI 10.1093/brain/122.3.383; Prigatano GP, 2004, BRAIN INJURY, V18, P661, DOI 10.1080/02699050310001646170; Rasmussen IA, 2006, ACTA NEUROPSYCHIATR, V18, P216, DOI 10.1111/j.1601-5215.2006.00145.x; Repovs G, 2006, NEUROSCIENCE, V139, P5, DOI 10.1016/j.neuroscience.2005.12.061; Sato T, 2001, NEURON, V30, P583, DOI 10.1016/S0896-6273(01)00304-X; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; SKANDSEN T, 2008, CLIN REHABI IN PRESS; Smith EE, 2001, P NATL ACAD SCI USA, V98, P2095, DOI 10.1073/pnas.98.4.2095; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stelzel C, 2006, PSYCHOL RES-PSYCH FO, V70, P514, DOI 10.1007/s00426-005-0013-7; Szameitat AJ, 2006, PSYCHOL RES-PSYCH FO, V70, P541, DOI 10.1007/s00426-005-0015-5; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Tomita H, 1999, NATURE, V401, P699, DOI 10.1038/44372; TREISMAN A, 1991, J EXP PSYCHOL HUMAN, V17, P652, DOI 10.1037/0096-1523.17.3.652; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wolfe JM, 1996, NATURE, V380, P587, DOI 10.1038/380587a0; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	71	25	26	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1057	1070		10.1089/neu.2008.0520			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900002	18729718				2021-06-18	
J	Gillette, Y; Depompei, R				Gillette, Yvonne; Depompei, Roberta			Do PDAs enhance the organization and memory skills of students with cognitive disabilities?	PSYCHOLOGY IN THE SCHOOLS			English	Article							TRAUMATIC BRAIN-INJURY; PORTABLE ELECTRONIC DEVICES; ASSISTIVE-TECHNOLOGY; REHABILITATION; AIDS; PEOPLE; IMPAIRMENT; COMPUTER	The project studied the on-time behavior of 35 Students with intellectual disabilities (ID) or traumatic brain injury (TBI) under three conditions - times and tasks list, paper planner, and two different personal data assistants (PDAs). Students participated for two 4-week periods, receiving one morning reminder during Period I and no reminders during Period 2. Students were on time more often using a PDA compared to a list (p <.024) or a planner (p <.002). Students were on time 50% more often in Period I with a single daily morning reminder as compared to no reminder across all conditions. When applying results, clinicians and researchers should note that only the alarm function prompting on-time behavior was studied, and the influence of the small sample size and short time frame. Future researchers will find a framework for studying PDAs and cell phones with larger samples. over longer time periods, and with a wider range of functions. (C) 2008 Wiley Periodicals, Inc.	[Gillette, Yvonne; Depompei, Roberta] Univ Akron, Akron, OH 44325 USA	Gillette, Y (corresponding author), Univ Akron, Polsky Bldg 188B, Akron, OH 44325 USA.	yg@uakron.edu					Bergman MM, 2002, J HEAD TRAUMA REHAB, V17, P431, DOI 10.1097/00001199-200210000-00005; BLOSSER JL, 2002, PEDIAT TRAUMATIC BRA; BRYEN DN, 2005, 6 ANN COL I C DENV C; CAREY A, 2005, MENT RETARD, V43, P32; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Constantinidou F., 2004, TRAUMATIC BRAIN INJU, P337; Davies DK, 2002, MENT RETARD, V40, P358, DOI 10.1352/0047-6765(2002)040<0358:EITMSO>2.0.CO;2; DePompei R, 2004, LEARNING COGNITIVE C; Derer K., 1996, Journal of Special Education Technology, V13, P62; DOWDS M, 2005, 6 ANN COL I C DENV C; Epstein J. N., 2001, Journal of Special Education Technology, V16, P19; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Flavell J.H., 2002, COGNITIVE DEV, V4th; Fuhrer MJ, 2001, AM J PHYS MED REHAB, V80, P528, DOI 10.1097/00002060-200107000-00013; Gillette Y, 2004, NEUROREHABILITATION, V19, P233; GILLETTE Y, 2005, TECHN PERS DIS CSUN; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Hart T, 2003, BRAIN INJURY, V17, P401, DOI 10.1080/0269905021000038438; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hilbe J. M., 2007, NEGATIVE BINOMIAL RE; Holme SA, 1997, AM J OCCUP THER, V51, P42, DOI 10.5014/ajot.51.1.42; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kirsch NL, 2004, J HEAD TRAUMA REHAB, V19, P366, DOI 10.1097/00001199-200409000-00002; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Bryen DN, 2007, INTELLECT DEV DISAB, V45, P1, DOI 10.1352/1934-9556(2007)45[1:CPUBAW]2.0.CO;2; PARENTE R, 2001, EXTERNAL AIDS UNPUB; PARENTE R, 1991, COGNITIVE REHABILITA, P147; Rothman K.J., 1998, MODERN EPIDEMIOLOGY, V2nd ed.; SCHERER MJ, 1990, J APPL REHABIL COUNS, V21, P36; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 2007, J MED SPEECH-LANG PA, V15, pXV; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Stickel MS, 2002, DISABIL REHABIL, V24, P115, DOI 10.1080/09638280110066794; Van Hulle A, 2006, BRAIN INJURY, V20, P101, DOI 10.1080/02699050500309684; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WEHMEYER ML, 1999, J SPECIAL ED TECHNOL, V14, P48; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Wilson B.A., 1991, NEUROPSYCHOL REHABIL, V1, P117, DOI [https://doi.org/10.1080/09602019108401386, DOI 10.1080/09602019108401386]; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P181	46	25	25	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0033-3085	1520-6807		PSYCHOL SCHOOLS	Psychol. Schools	AUG	2008	45	7					665	677		10.1002/pits.20316			13	Psychology, Educational	Psychology	334WM	WOS:000258252100007					2021-06-18	
J	Rowson, S; McNeely, DE; Brolinson, PG; Duma, SM				Rowson, Steven; McNeely, David E.; Brolinson, P. Gunnar; Duma, Stefan M.			Biomechanical analysis of football neck collars	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						stinger; neck collar; football; brachial plexus	PROFESSIONAL FOOTBALL; LATERAL FLEXION; HYPEREXTENSION; CONCUSSION; INJURIES; PLAYERS; IMPACTS	Objective: To determine the load-limiting capabilities of protective neck collars used in football through dynamic impact testing. Design: A 50th-percentile male Hybrid III dummy was used in 48 dynamic impact tests comparing the Cowboy Collar, Bullock Collar, and Kerr Collar. A control and each collar were tested at two velocities (5 m/s and 7 m/s), three impact locations (front, top, and side of the helmet), and two shoulder pad positions (normal and raised). Setting: Research laboratory. Patients: None. Interventions: None. Independent variables were the neck collars, impact velocity, and shoulder pad position. Main Outcome Measurements: In addition to range of motion, upper and lower neck forces and moments were measured. Results: With the top impact location, it was found that the Kerr Collar and Bullock Collar reduced head accelerations and force transmission through the neck. With the front impact location, all the collars reduced lower neck moment. The Kerr Collar was also capable of reducing the lower neck force and upper neck moment. With the side impact location, the Kerr Collar substantially reduced lower neck moment. Conclusions: These reductions in loads correlate with the degree to which each collar restricted the motion of the head and neck. By restricting the range of motion of the neck and,redistributing load to the shoulders, neck loads can be effectively lowered.	[Rowson, Steven; McNeely, David E.; Duma, Stefan M.] Virginia Tech, Wake Forest Ctr Injury Biomech, Blacksburg, VA 24061 USA; [Brolinson, P. Gunnar] Edward Via Coll Osteopath Med, Blacksburg, VA 24061 USA	Rowson, S (corresponding author), Virginia Tech, Wake Forest Ctr Injury Biomech, 100F Randolph Hall,MC 0238, Blacksburg, VA 24061 USA.	srowson@vt.edu	Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Rowson, Steven/0000-0002-3227-0596; 			Clancy W G Jr, 1977, Am J Sports Med, V5, P209, DOI 10.1177/036354657700500508; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Gorden JA, 2003, J ATHL TRAINING, V38, P209; HALL G, 1998, SOC AUTOMOTIVE ENG, V98, P1141; HERSHMAN EB, 1990, CLIN SPORT MED, V9, P311; HOVIS WD, 1994, MED SCI SPORT EXER, V26, P872; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; ROBERTSON WC, 1979, JAMA-J AM MED ASSOC, V241, P1480, DOI 10.1001/jama.241.14.1480; Rowson S, 2007, BIOMED SCI INSTRUM, V43, P200; SALLIS RE, 1992, PHYSICIAN SPORTSMED, V20, P47, DOI 10.1080/00913847.1992.11947521	11	25	25	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2008	18	4					316	321		10.1097/JSM.0b013e31817f016a			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	325DK	WOS:000257568300002	18614882				2021-06-18	
J	Wang, Y; Rubel, EW				Wang, Y.; Rubel, E. W.			Rapid regulation of microtubule-associated protein 2 in dendrites of nucleus laminaris of the chick following deprivation of afferent activity	NEUROSCIENCE			English	Article						deafferentation; dendritic plasticity; afferent regulation; cytoskeleton	STEM AUDITORY NUCLEI; ATROPHY FOLLOWING DEAFFERENTATION; INTERAURAL TIME DIFFERENCES; ACUTE HIPPOCAMPAL SLICES; TRAUMATIC BRAIN-INJURY; AVIAN COCHLEAR NUCLEUS; INTRACELLULAR CALCIUM; RAT HIPPOCAMPUS; N-LAMINARIS; MAP2	Differential innervation of segregated dendritic domains in the chick nucleus laminaris (NL), composed of third-order auditory neurons, provides a unique model to study synaptic regulation of dendritic structure. Altering the synaptic input to one dendritic domain affects the structure and length of the manipulated dendrites while leaving the other set of unmanipulated dendrites largely unchanged. Little is known about the effects of neuronal input on the cytoskeletal structure of NL dendrites and whether changes in the cytoskeleton are responsible for dendritic remodeling following manipulations of synaptic input. In this study, we investigate changes in the immunoreactivity of high-molecular weight microtubule associated protein 2 (MAP2) in NL dendrites following two different manipulations of their afferent input. Unilateral cochlea removal eliminates excitatory synaptic input to the ventral dendrites of the contralateral NL and the dorsal dendrites of the ipsilateral NL. This manipulation produced a dramatic decrease in MAP2 immunoreactivity in the deafferented dendrites. This decrease was detected as early as 3 h following the surgery, well before any degeneration of afferent axons. A similar decrease in MAP2 immunoreactivity in deafferented NL dendrites was detected following a midline transection that silences the excitatory synaptic input to the ventral dendrites on both sides of the brain. These changes were most distinct in the caudal portion of the nucleus where individual deafferented dendritic branches contained less immunoreactivity than intact dendrites. Our results suggest that the cytoskeletal protein MAP2, which is distributed in dendrites, perikarya, and postsynaptic densities, may play a role in deafferentation-induced dendritic remodeling. (c) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.	[Wang, Y.; Rubel, E. W.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Sch Med, Virginia Merrill Bloedel Hearing Res Ctr, Seattle, WA 98195 USA	Rubel, EW (corresponding author), Univ Washington, Dept Otolaryngol Head & Neck Surg, Sch Med, Virginia Merrill Bloedel Hearing Res Ctr, Box 357923, Seattle, WA 98195 USA.	rubel@u.washington.edu		Wang, Yuan/0000-0003-4347-7063	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01 DC003829-10, P30 DC004661-09, P30 DC004661-08, DC00018, P30 DC004661, DC04661, R01 DC003829-09, R01 DC003829-08, T32 DC000018, DC03829, R01 DC003829, P30 DC004661-07] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC003829, P30DC004661, T32DC000018] Funding Source: NIH RePORTER		Arias C, 1997, EXP BRAIN RES, V116, P467, DOI 10.1007/PL00005774; BENES FM, 1977, BRAIN RES, V122, P1, DOI 10.1016/0006-8993(77)90658-8; BIGOT D, 1991, EUR J NEUROSCI, V3, P551, DOI 10.1111/j.1460-9568.1991.tb00842.x; Bjorkblom B, 2005, J NEUROSCI, V25, P6350, DOI 10.1523/JNEUROSCI.1517-05.2005; BORN DE, 1991, BRAIN RES, V557, P37, DOI 10.1016/0006-8993(91)90113-A; BORN DE, 1985, J COMP NEUROL, V231, P435, DOI 10.1002/cne.902310403; BURGER RM, 2008, SENSES COMPREHENSIVE, P613; CARR CE, 1988, P NATL ACAD SCI USA, V85, P8311, DOI 10.1073/pnas.85.21.8311; CARR CE, 1990, J NEUROSCI, V10, P3227; DEITCH JS, 1984, J COMP NEUROL, V229, P66, DOI 10.1002/cne.902290106; DEITCH JS, 1989, J COMP NEUROL, V281, P234, DOI 10.1002/cne.902810207; Faddis BT, 1997, J NEUROSCI, V17, P951; FELIPO V, 1993, J NEUROCHEM, V60, P1626, DOI 10.1111/j.1471-4159.1993.tb13384.x; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; HENDRY SHC, 1992, VISUAL NEUROSCI, V9, P445, DOI 10.1017/S0952523800011251; Hoskison MM, 2007, NEUROSCIENCE, V145, P66, DOI 10.1016/j.neuroscience.2006.11.034; Hoskison MM, 2006, EXP NEUROL, V202, P302, DOI 10.1016/j.expneurol.2006.06.010; JOSEPH AW, 1993, J NEUROPHYSIOL, V69, P1197; Kelley MS, 1997, J COMP NEUROL, V389, P469; KOWALSKI RJ, 1993, J BIOL CHEM, V268, P9847; Ohkawa N, 2007, J CELL SCI, V120, P1447, DOI 10.1242/jcs.001461; OVERHOLT EM, 1992, J NEUROSCI, V12, P1698; PARKS TN, 1975, J COMP NEUROL, V164, P435, DOI 10.1002/cne.901640404; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Rubel EW, 2004, SPR HDB AUD, V23, P8; RUBEL EW, 1981, J COMP NEUROL, V202, P397, DOI 10.1002/cne.902020309; RUBEL EW, 1990, J NEUROBIOL, V21, P169, DOI 10.1002/neu.480210112; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SMITH DJ, 1979, J COMP NEUROL, V186, P213, DOI 10.1002/cne.901860207; SMITH ZDJ, 1981, J COMP NEUROL, V203, P309, DOI 10.1002/cne.902030302; Sorensen SA, 2006, J NEUROSCI, V26, P1539, DOI 10.1523/JNEUROSCI.3807-05.2006; Steward O, 1999, J NEUROSCI, V19, P7834; Swann JW, 2000, HIPPOCAMPUS, V10, P617, DOI 10.1002/1098-1063(2000)10:5<617::AID-HIPO13>3.0.CO;2-R; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Vaillant AR, 2002, NEURON, V34, P985, DOI 10.1016/S0896-6273(02)00717-1; YAMAUCHI PS, 1993, J NEUROCHEM, V60, P817, DOI 10.1111/j.1471-4159.1993.tb03225.x; ZIRPEL L, 1995, J NEUROPHYSIOL, V74, P1355; Zirpel L, 1996, J NEUROPHYSIOL, V76, P4127	42	25	26	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	JUN 12	2008	154	1					381	389		10.1016/j.neuroscience.2008.02.032			9	Neurosciences	Neurosciences & Neurology	315IP	WOS:000256872300034	18440716	Green Accepted			2021-06-18	
J	Kemp, CD; Cotton, BA; Johnson, JC; Ellzey, M; Pinson, CW				Kemp, Clinton D.; Cotton, Bryan A.; Johnson, J. Chad; Ellzey, Michelle; Pinson, C. Wright			Donor conversion and organ yield in traumatic brain injury patients: Missed opportunities and missed organs	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	World Transplant Congress	JUL 22-27, 2006	Boston, MA			organ yield; traumatic brain injury; donation; donor	SUBARACHNOID HEMORRHAGE; POTENTIAL DONOR; GUNSHOT WOUNDS; UNITED-STATES; DONATION; DEATH; MANAGEMENT; TRANSPLANTATION; CONSEQUENCES; PROCUREMENT	Background: The purpose of this study was to define donation patterns and lost donor opportunities in severe traumatic brain injury (TBI) patients. Methods: The trauma registry was queried for all deaths after severe TBI in 2004; this was cross matched with the regional organ procurement organization database and subjected to post hoc statistical analysis. Results: One hundred thirty-five patients met criteria for inclusion. Forty percent had isolated TBI. Forty-two patients (31%) were eligible for deceased donation. Seventeen eligible patients (40%) did not convert to donation, 15 from family declining. Twenty-five eligible patients (60%) donated 85 organs (yield 3.4 organs/donor). Yield was similar in both isolated TBI (3.2) and patients with head injuries (3.5). Ineligible patients had higher admission Glasgow Coma Scale scores, lower head Abbreviated Injury Scale scores, and were more likely to develop cardiovascular or pulmonary dysfunction (p < 0.05). Of the 25 donors, 48% did not donate hearts and 84% did not donate lungs, despite the absence of chest trauma in the majority of patients. Conclusion: Less than one-third of severe TBI patients were identified as eligible organ donors and only 40% actually donated. Half of all donors fail to donate hearts and over 80% fail to donate lungs. Within this population, opportunities may exist to improve both donor conversion and organ yield.	[Kemp, Clinton D.; Cotton, Bryan A.; Johnson, J. Chad] Vanderbilt Univ, Med Ctr, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Nashville, TN USA; [Pinson, C. Wright] Vanderbilt Univ, Med Ctr, Div Hepatobiliary Surg & Liver Transplantat, Nashville, TN USA; [Ellzey, Michelle] Tennessee Donor Serv, Nashville, TN USA	Cotton, BA (corresponding author), VUMC Trauma, Dept Surg, 1211 21st Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	bryan.cotton@vanderbilt.edu	Cotton, Bryan/A-7107-2009				Abadie A, 2006, J HEALTH ECON, V25, P599, DOI 10.1016/j.jhealeco.2006.01.003; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Ciccone AM, 2002, J THORAC CARDIOV SUR, V123, P429, DOI 10.1067/mtc.2002.120732; COTTON BA, 2005, EVALUATION MANAGEMEN; COTTON BA, 2005, DECLARATION BRAIN DE; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; *DEP HLTH HUM SERV, 2005 ANN REP US ORG; Dutton Richard P, 2003, Curr Opin Crit Care, V9, P503, DOI 10.1097/00075198-200312000-00007; ELLZEY M, 2007, VANDERBILT U MED CTR; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; Fiser SM, 2001, J THORAC CARDIOV SUR, V122, P1257, DOI 10.1067/mtc.2001.116464; Gortmaker SL, 1996, CRIT CARE MED, V24, P432, DOI 10.1097/00003246-199603000-00012; Howard RJ, 2005, TRANSPLANTATION, V80, P564, DOI 10.1097/01.tp.0000168156.79847.46; JACOBS DG, 1995, AM SURGEON, V61, P647; Karamlou T, 2005, J HEART LUNG TRANSPL, V24, P29, DOI 10.1016/j.healun.2003.10.009; Kemp CD, 2006, J AM COLL SURGEONS, V203, pS36, DOI 10.1016/j.jamcollsurg.2006.05.090; KENNEDY AP, 1992, J TRAUMA, V33, P516, DOI 10.1097/00005373-199210000-00005; Kompanje EJO, 2006, INTENS CARE MED, V32, P217, DOI 10.1007/s00134-005-0001-9; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; MACKENZIE DJ, 1993, AM SURGEON, V59, P764; MACKERSIE RC, 1991, ANN SURG, V213, P143, DOI 10.1097/00000658-199102000-00009; Macmillan CSA, 2002, INTENS CARE MED, V28, P1012, DOI 10.1007/s00134-002-1382-7; Malangoni MA, 1996, J TRAUMA, V40, P632, DOI 10.1097/00005373-199604000-00019; McLean KM, 2006, J AM COLL SURGEONS, V203, pS91, DOI 10.1016/j.jamcollsurg.2006.05.238; Parker M, 2002, CRIT CARE, V6, P399; Ranjan D, 2006, AM J TRANSPLANT, V6, P199, DOI 10.1111/j.1600-6143.2005.01150.x; Razek T, 2000, SURG CLIN N AM, V80, P1021, DOI 10.1016/S0039-6109(05)70111-0; ROSS S, 1989, J TRAUMA, V29, P1036; Salim A, 2001, ARCH SURG-CHICAGO, V136, P1377, DOI 10.1001/archsurg.136.12.1377; Sque M, 2005, TRANSPLANT P, V37, P543, DOI 10.1016/j.transproceed.2004.11.038; Williams MA, 2003, CRIT CARE MED, V31, P1568, DOI 10.1097/01.CCM.0000063090.21056.A6	33	25	27	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2008	64	6					1573	1580		10.1097/TA.0b013e318068fc2f			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	313MG	WOS:000256744100028	18545126				2021-06-18	
J	Reshef, A; Shirvan, A; Shohami, E; Grimberg, H; Levin, G; Cohen, A; Trembovler, V; Ziv, I				Reshef, Ayelet; Shirvan, Anat; Shohami, Esther; Grimberg, Hagit; Levin, Galit; Cohen, Avi; Trembovler, Victoria; Ziv, Ilan			Targeting cell death in vivo in experimental traumatic brain injury by a novel molecular probe	JOURNAL OF NEUROTRAUMA			English	Article						animal studies; apoptosis; molecular imaging; neuronal cell death; traumatic brain injury	CLOSED-HEAD INJURY; COGNITIVE DEFICITS; NEURONAL INJURY; MICE; MODEL; LIGAND	Traumatic brain injury (TBI) remains a frequent and major challenge in neurological and neurosurgical practice. Apoptosis may play a role in cerebral tissue damage induced by the traumatic insult, and thus its detection and inhibition may advance patient care. DDC (N, N'-didansyl-L-cystine) is a novel fluorescent probe for detection of apoptotic cells. We now report on the performance of DDC in experimental TBI. Closed head injury was induced in mice by weight-drop. DDC was administered intravenously in vivo. Two hours later, animals were sacrificed, and brain tissue was subjected to fluorescent microcopy, for assessment of DDC uptake, in correlation with histopathological assessment of apoptosis by TUNEL and caspase substrates, and also in correlation with the neurological deficits, as assessed by Neurological Severity Score (NSS). Selective uptake of DDC was observed at the primary site of injury, and also at remote sites. Uptake was at the cellular level, with accumulation of DDC in the cytoplasm. Cells manifesting DDC uptake were confirmed as apoptotic cells by detection of the characteristic apoptotic DNA fragmentation (positive TUNEL staining) and detection of activated caspases. The damaged region stained by DDC fluorescence correlated with the severity of neuronal deficits. Our study confirms the role of apoptosis in TBI, and proposes DDC as a useful tool for its selective targeting and detection in vivo. Such imaging of apoptosis, following future radiolabeling of DDC, may advance care for patients with head injury, by allowing real-time evaluation of the extent of tissue damage, assessment of novel therapeutic strategies, and optimization of treatment for the individual patient.	[Reshef, Ayelet; Shirvan, Anat; Grimberg, Hagit; Levin, Galit; Cohen, Avi; Ziv, Ilan] NST NeuroSurvival Technol Ltd, Petah Tiqwa, Israel; [Shohami, Esther; Trembovler, Victoria] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, Jerusalem, Israel; [Ziv, Ilan] Rabin Med Ctr, Dept Neurol, Petah Tiqwa, Israel	Reshef, A (corresponding author), NST, 5 Odem St,POB 7119, IL-49170 Petah Tiqwa, Israel.	ayelet@nst.co.il					Aloya R, 2006, APOPTOSIS, V11, P2089, DOI 10.1007/s10495-006-0282-7; Bacskai BJ, 2003, P NATL ACAD SCI USA, V100, P12462, DOI 10.1073/pnas.2034101100; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Boersma HH, 2005, J NUCL MED, V46, P2035; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cohen A, 2007, TECHNOL CANCER RES T, V6, P221, DOI 10.1177/153303460700600310; Damianovich M, 2006, EUR J NUCL MED MOL I, V33, P281, DOI 10.1007/s00259-005-1905-x; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Reshef A, 2007, BRAIN RES, V1144, P156, DOI 10.1016/j.brainres.2007.01.095; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Xu LJ, 2001, EXP NEUROL, V169, P416, DOI 10.1006/exnr.2001.7678; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	21	25	25	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					569	580		10.1089/neu.2007.0341			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900001	18447626				2021-06-18	
J	Schick, DM; Molloy, MG; Wiley, JP				Schick, D. M.; Molloy, M. G.; Wiley, J. P.			Injuries during the 2006 Women's Rugby World Cup	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PERFORMANCE PROJECT; UNION FOOTBALL; CLUB RUGBY; PLAYERS; EPIDEMIOLOGY; SURVEILLANCE; HEADGEAR; COHORT; FEMALE; SEASON	Background: Although there have been reports of injury rates in men's World Cup rugby, there has been no research into injury rates in women's international rugby. Objective: To determine the rate of injury at the 2006 Women's Rugby World Cup (WRWC). Methods: All participating teams in the 2006 WRWC were enrolled prospectively in this study. Healthcare workers for each team collected data on training and game exposure and information on injuries. Results: 55 players (16%) sustained at least one injury (10.0/1000 player hours); 4 players (1%) sustained two injuries. 45 injuries occurred during games (37.5/1000 player hours) and 14 injuries occurred during practice (12.5/1000 player hours), a statistically significant difference (RR = 12.5, 95% CI 6.9 to 22.8). The injury rate was 39.3/1000 player hours for the forwards and 42.2/1000 player hours for the backs (RR = 1.3, 95% CI 0.7 to 2.3). The front row had the highest injury rate (62.5/1000 player hours). 63.6% of injuries occurred during the tackle. Most injuries occurred to the neck, knee and head/face. The majority of injuries were sprains, muscle injuries and contusions. There were five fractures during the event and four reported concussions. Conclusion: Female players sustained a considerable rate of injury during the 2006 WRWC. Backs had a slightly higher rate of injury than forwards, but the players most often injured were in the front row. The neck/cervical spine and knee were the most commonly injured regions, followed by the head and face. This is the first study to examine injury rates in female rugby players at a World Cup and reports valuable data in this population.	[Wiley, J. P.] Univ Calgary, Sport Med Ctr, Calgary, AB T2N 1N4, Canada; [Schick, D. M.] Trinity Western Univ, Langley, BC, Canada; [Molloy, M. G.] Int Rugby Board, Dublin, Ireland	Wiley, JP (corresponding author), Univ Calgary, Sport Med Ctr, 2500 Univ Dr, Calgary, AB T2N 1N4, Canada.	wiley@ucalgary.ca					Alsop J C, 2000, J Sci Med Sport, V3, P97, DOI 10.1016/S1440-2440(00)80072-9; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; Carson JD, 1999, CLIN J SPORT MED, V9, P75, DOI 10.1097/00042752-199904000-00006; CLARK DR, 1990, S AFR MED J, V77, P559; Comstock R, 2002, PATTERNS INJURY FEMA; Comstock RD, 2005, J SCI MED SPORT, V8, P101, DOI 10.1016/S1440-2440(05)80030-1; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; GERRARD DF, 1994, BRIT J SPORT MED, V28, P229, DOI 10.1136/bjsm.28.4.229; HAVKINS SB, 1986, PHYSICIAN SPORTSMED, V14, P111, DOI 10.1080/00913847.1986.11709127; *INT RUGB BOARD, 2006, WOM RUGB WORLD CUP 2; Jakoet I, 1998, S AFR MED J, V88, P45; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Lee AJ, 2000, J SPORT SCI, V18, P91, DOI 10.1080/026404100365153; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; LEWIS ER, 1996, SPORTS EXERC INJURY, V2, P186; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; NATHAN M, 1983, S AFR MED J, V64, P132; Rotem T, 2001, INT SPORTMED J, V2, P1; ROUX CE, 1987, S AFR MED J, V71, P307; Stewart DR, 2004, BRIT J SPORT MED, V38, P457, DOI 10.1136/bjsm.2003.004861; Upton PAH, 1996, S AFR MED J, V86, P531; WALLER AE, 1994, BRIT J SPORT MED, V28, P223, DOI 10.1136/bjsm.28.4.223; Wekesa M, 1996, BRIT J SPORT MED, V30, P61, DOI 10.1136/bjsm.30.1.61; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9	31	25	25	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	JUN	2008	42	6					447	451		10.1136/bjsm.2008.046672			5	Sport Sciences	Sport Sciences	310HD	WOS:000256518600010	18424486				2021-06-18	
J	Tasky, KK; Rudrud, EH; Schulze, KA; Rapp, JT				Tasky, Kim K.; Rudrud, Epic H.; Schulze, Kimberly A.; Rapp, John T.			Using choice to increase on task behavior in individuals with trauaiatic brain injury	JOURNAL OF APPLIED BEHAVIOR ANALYSIS			English	Article						antecedent intervention; choice; motivating operations; traumatic brain injury	WORK PERFORMANCE; OPERATIONS	An ABA'B design was used to evaluate the effects of choice on task engagement for 3 adults who had been diagnosed with traumatic brain injury. A yoked-control condition, in which tasks that were selected by each participant were assigned subsequently to that participant by a trainer, was implemented to help distinguish between the effects of task preference and choice. The results for all 3 participants indicated that permitting individuals to choose from a list of tasks increased on-task behavior.	[Rapp, John T.] St Cloud State Univ, Educ Leadership & Community Psychol, St Cloud, MN 56301 USA	Rapp, JT (corresponding author), St Cloud State Univ, Educ Leadership & Community Psychol, 720 4th Ave S, St Cloud, MN 56301 USA.	j.trapp@stcloudstate.edu					BAMBARA LM, 1994, J APPL BEHAV ANAL, V27, P555, DOI 10.1901/jaba.1994.27-555; CHILDS KE, 1994, J APPL BEHAV ANAL, V27, P7, DOI 10.1901/jaba.1994.27-7; Cooper J. O., 2007, APPL BEHAV ANAL; Kern L., 2001, J POSIT BEHAV INTERV, V3, P3, DOI DOI 10.1177/109830070100300102; Laraway S, 2003, J APPL BEHAV ANAL, V36, P407, DOI 10.1901/jaba.2003.36-407; McComas J, 2000, J APPL BEHAV ANAL, V33, P479, DOI 10.1901/jaba.2000.33-479; PARSONS MB, 1990, J APPL BEHAV ANAL, V23, P253, DOI 10.1901/jaba.1990.23-253; Vaughn BJ, 1997, J APPL BEHAV ANAL, V30, P299, DOI 10.1901/jaba.1997.30-299	8	25	25	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-8855	1938-3703		J APPL BEHAV ANAL	J. Appl. Behav. Anal.	SUM	2008	41	2					261	265		10.1901/jaba.2008.41-261			5	Psychology, Clinical	Psychology	309LL	WOS:000256461800012	18595291	Green Published, Bronze			2021-06-18	
J	Thornton, KE; Carmody, DP				Thornton, Kirtley E.; Carmody, Dennis P.			Efficacy of traumatic brain injury rehabilitation: Interventions of QEEG-guided biofeedback, computers, strategies, and medications	APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK			English	Article						EEG biofeedback; traumatic brain injury; cognitive rehabilitation; neurocognitive rehabilitation; QEEG; activation QEEG; memory rehabilitation	CLINICAL-NEUROPHYSIOLOGY-SOCIETY; CLOSED-HEAD INJURY; OF-THE-LITERATURE; COGNITIVE REHABILITATION; AMERICAN-ACADEMY; NEUROPSYCHOLOGICAL TESTS; NEUROIMAGING TECHNIQUES; CONTROLLED-TRIAL; MEMORY; EEG	The onset of cognitive rehabilitation brought with it a hope for an effective treatment for the traumatic brain injured subject. This paper reviews the empirical reports of changes in cognitive functioning after treatment and compares the relative effectiveness of several treatments including computer interventions, cognitive strategies, EEG biofeedback, and medications. The cognitive functions that are reviewed include auditory memory, attention and problem solving. The significance of the change in cognitive function is assessed in two ways that include effect size and longevity of effect. These analyses complement the previously published meta-reviews by adding these two criteria and include reports of EEG biofeedback, which is shown to be an effective intervention for auditory memory.	[Thornton, Kirtley E.; Carmody, Dennis P.] Brain Fdn, S Plainfield, NJ 07080 USA; [Carmody, Dennis P.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Inst Study Child Dev, New Brunswick, NJ 08903 USA	Thornton, KE (corresponding author), Brain Fdn, Ste 2A,2509 Pk Ave, S Plainfield, NJ 07080 USA.	ket@chp-neurotherapy.com	Carmody, Dennis P./AAS-7734-2020	thornton, kirtley/0000-0002-3303-4747; Carmody, Dennis/0000-0002-1288-104X			ASHLEY MJ, 1990, J INSURANCE MED, V22, P156; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BENEDICT RHB, 1989, CLIN PSYCHOL REV, V9, P605; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; CHEREK L, 1995, NEUROREHABILITATION, V5, P87, DOI 10.3233/NRE-1995-5108; CHESTNUT RM, 1998, 2 AG HLTH CAR POL RE; Christensen AL., 1975, LURIAS NEUROPSYCHOLO; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Coe R., 2000, WHAT IS EFFECT SIZE; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cohen J., 1969, STAT POWER ANAL BEHA; Delis DC, 1987, CALIFORNIA VERBAL LE; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Glass GV., 1981, METAANALYSIS SOCIAL; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAMMOND C, 2004, J NEUROTHERAPY, V8, P5, DOI DOI 10.1300/J184V08N01_02; *HARC ASS INC, 1955, WECHSL AD INT SCAL; HARLEY JP, 1992, NEUROREHABILITATION, V2, P62; Hedges L. V., 1981, J EDUC STAT, V6, P107; Hedges L.V., 1985, STAT METHODS META AN; Hoffman DA, 1999, J NEUROPSYCH CLIN N, V11, P401, DOI 10.1176/jnp.11.3.401; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; *IVA, 1995, BRAIN TRAIN; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Keller I., 2001, J NEUROTHER, V5, P19, DOI DOI 10.1300/J184V05N01_03; KERNER MJ, 1985, COGNITIVE REHABI NOV, P26; Laatsch L, 2000, NEUROREHABILITATION, V15, P189; Leon-Carrion J, 2000, NEUROREHABILITATION, V14, P33; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; LUBAR JF, 1995, BIOFEEDBACK SELF-REG, V20, P83, DOI 10.1007/BF01712768; LUBAR JO, 1984, BIOFEEDBACK SELF-REG, V9, P1, DOI 10.1007/BF00998842; MARKER T, 1996, COGPACK; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McKinlay W W, 1992, Brain Inj, V6, P107, DOI 10.3109/02699059209029649; Milders M, 1998, MEMORY, V6, P21, DOI 10.1080/741941597; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; *NAN, 2002, COGN REH OFF POS NAT; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; Olejnik S, 2000, CONTEMP EDUC PSYCHOL, V25, P241, DOI 10.1006/ceps.2000.1040; OTHMER S, 1992, EEG BIOFEEDBACK TRAI; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; *PSYCH ASS RES, 1993, WISC CARD SCOR TEST; Quemada JI, 2003, J HEAD TRAUMA REHAB, V18, P532, DOI 10.1097/00001199-200311000-00007; REITAN R, 1993, H REITAN NEUROPSYCHO; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Ricker J H, 1998, Appl Neuropsychol, V5, P184, DOI 10.1207/s15324826an0504_3; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Schoenberger NE, 2001, J HEAD TRAUMA REHAB, V16, P260, DOI 10.1097/00001199-200106000-00005; SIEGMUND K, 1999, NEUROSOFT INTEGRIERT; STEPHENS J, 2006, EFFECTIVENESS EEG BI; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TANSEY MA, 1991, AUST J PSYCHOL, V43, P147, DOI 10.1080/00049539108260139; TANSEY MA, 1993, BIOFEEDBACK SELF-REG, V18, P33, DOI 10.1007/BF00999512; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; Thatcher RW, 1999, CLIN ELECTROENCEPHAL, V30, P94, DOI 10.1177/155005949903000304; Thornton K, 2000, J HEAD TRAUMA REHAB, V15, P1285, DOI 10.1097/00001199-200012000-00008; Thornton KE, 2005, CHILD ADOL PSYCH CL, V14, P137, DOI 10.1016/j.chc.2004.07.001; THORNTON KE, 2007, 20071 BRAIN FDN; THORNTON KE, 2001, Patent No. 6309361; THORNTON KE, 2002, CLIN NEUROPSYCHOLOGY, V17, P1, DOI DOI 10.1016/S0887-6177(00)00073-1; THORNTON KE, J NEUROTHER IN PRESS; Tinius T. P., 2000, J NEUROTHERAPY, V4, P27, DOI [10.1300/J184v04n02_05, DOI 10.1300/J184V04N02_05]; *TOVA CO, 1992, TEST VAR ATT; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WEHMAN P, 1989, J HEAD TRAUMA REHAB, V4, P66; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3	86	25	26	1	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1090-0586	1573-3270		APPL PSYCHOPHYS BIOF	Appl. Psychophysiol. Biofeedback	JUN	2008	33	2					101	124		10.1007/s10484-008-9056-z			24	Psychology, Clinical	Psychology	316CO	WOS:000256926700005	18551365				2021-06-18	
J	Corrigan, JA; Bogner, JA				Corrigan, John A.; Bogner, Jennifer A.			Neighborhood characteristics and outcomes after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; environment; rehabilitation; rehabilitation outcome	CRAIG HANDICAP ASSESSMENT; NEW-SOUTH-WALES; ENVIRONMENTAL-FACTORS; LIFE SATISFACTION; SYSTEMATIC BIAS; HEALTH; URBAN; REHABILITATION; VALIDITY; HEAD	Objective: To determine the extent to which characteristics of a person's neighborhood contribute to outcomes after traumatic brain injury (TBI). Design: Prospective cohort. Setting: A specialized brain injury unit providing acute rehabilitation care. Participants: A consecutive sample of participants (N=200) in the Traumatic Brain Injury Model Systems (TBIMS) longitudinal study: 100 participants were 2 years Postinjury, and 100 participants were 5 years postinjury. Interventions: Not applicable. Main Outcome Measures: U.S. Census Bureau block group descriptors of economic and social characteristics and initial and follow-up data from the TBIMS national dataset including the Glasgow Outcome Scale-Extended (GOS-E) and Satisfaction With Life Scale (SWLS). Results: Economic and social characteristics of a person's neighborhood accounted for additional variance in outcomes C beyond what Could be accounted for by individual characteristics, including demographic, premorbid, and injury-related measures; concurrent Measures of functioning; and the persons's perception of environmental influences. Individual characteristics predicted a substantial proportion of the variance in the GOS-E (69%): neighborhood characteristics contributed an additional 1.5%. Individual characteristics predicted 33.3% of the variance in SWLS, with neighborhood characteristics accounting for an additional 6.9%. Conclusions: For both outcomes. a small but important proportion of the variance accounted for by neighborhood indices was Unique to these environmental influences and was not accounted for by individual indices. including concurrent measures of functioning and the individual's perception of environmental influences. Further investigations of how neighborhood factors affect Outcomes after TBI are warranted.	[Corrigan, John A.; Bogner, Jennifer A.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Corrigan, JA (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu			National Institute on Disability and Rehabilitation Research [H133A020503]	Supported by the National Institute on Disability and Rehabilitation Research to the Ohio Regional Traumatic Brain Injury Model Sysiem (grant no. H133A020503).	Barnett R, 2005, SOC SCI MED, V60, P1515, DOI 10.1016/j.socscimed.2004.08.002; Baum F, 2002, HEALTH PROMOT INT, V17, P351, DOI 10.1093/heapro/17.4.351; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Breeze E, 2005, INT J EPIDEMIOL, V34, P276, DOI 10.1093/ije/dyh328; Collins CA, 1999, SOCIOL FORUM, V14, P495, DOI 10.1023/A:1021403820451; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Cote Isabelle, 2004, Can J Clin Pharmacol, V11, pe232; Culham LE, 2002, BRIT J OPHTHALMOL, V86, P743, DOI 10.1136/bjo.86.7.743; Cummins S, 2002, URBAN STUD, V39, P2115, DOI 10.1080/0042098022000011399; Cummins S, 2002, BRIT MED J, V325, P436, DOI 10.1136/bmj.325.7361.436; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Diez-Roux AV, 2000, ANNU REV PUBL HEALTH, V21, P171, DOI 10.1146/annurev.publhealth.21.1.171; Farmer JE, 2003, J HEAD TRAUMA REHAB, V18, P116, DOI 10.1097/00001199-200303000-00003; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Gill SC, 2007, PSYCHIAT RES, V152, P63, DOI 10.1016/j.psychres.2006.11.005; Gontkovsky ST, 2006, BRAIN INJURY, V20, P701, DOI 10.1080/02699050600744103; Grogan-Kaylor A, 2005, ARCH PEDIAT ADOL MED, V159, P938, DOI 10.1001/archpedi.159.10.938; Hall KM, 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; Harradine PG, 2004, MED J AUSTRALIA, V181, P130, DOI 10.5694/j.1326-5377.2004.tb06202.x; *I MED, 1997, EN AM ASS ROL REH SC; Jago R, 2006, AM J HEALTH PROMOT, V20, P422, DOI 10.4278/0890-1171-20.6.422; Johnstone B, 2003, NEUROREHABILITATION, V18, P197; Kawachi I., 2003, NEIGHBOURHOODS HLTH; King JT, 2005, J NEUROSURG, V102, P489, DOI 10.3171/jns.2005.102.3.0489; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Mason Michael, 2004, Subst Use Misuse, V39, P1751, DOI 10.1081/LSUM-200033222; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; Moss Margaret P, 2006, Int J Health Geogr, V5, P37, DOI 10.1186/1476-072X-5-37; Oliver M., 1990, POLITICS DISABLEMENT; OSHA, 2006, FED REG, V71; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pearce N, 2003, AM J PUBLIC HEALTH, V93, P122, DOI 10.2105/AJPH.93.1.122; Pickett KE, 2001, J EPIDEMIOL COMMUN H, V55, P111, DOI 10.1136/jech.55.2.111; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Romley JA, 2007, J STUD ALCOHOL DRUGS, V68, P48, DOI 10.15288/jsad.2007.68.48; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Schootman M, 1999, BRAIN INJURY, V13, P995; Schootman M, 1998, BIOM HLTH R, V21, P73; SEGAL ME, 1995, AM J PHYS MED REHAB, V74, P276, DOI 10.1097/00002060-199507000-00004; Sellstrom E, 2006, SCAND J PUBLIC HEALT, V34, P544, DOI 10.1080/14034940600551251; SIMPSON D, 1981, MED J AUSTRALIA, V2, P660, DOI 10.5694/j.1326-5377.1981.tb113043.x; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; United States Census Bureau, AM FACT FIND; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; Ware J., 1995, SCORE SF 12 PHYS MEN, V2 nd 2; Whiteneck GG, 2004, ARCH PHYS MED REHAB, V85, P1324, DOI 10.1016/j.apmr.2003.09.027; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whiteneck GG, 1992, CRAIG HANDICAP ASSES; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x; World Health Organization, 2001, INT CLASS FUNCT DIS; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Young AF, 2004, SOC SCI MED, V59, P2627, DOI 10.1016/j.socscimed.2004.05.001	60	25	25	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					912	921		10.1016/j.apmr.2007.12.027			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900018	18452741				2021-06-18	
J	Sell, SL; Avila, MA; Yu, GX; Vergara, L; Prough, DS; Grady, JJ; DeWitt, DS				Sell, Stacy L.; Avila, Marcela A.; Yu, Guangxiang; Vergara, Leoncio; Prough, Donald S.; Grady, James J.; DeWitt, Douglas S.			Hypertonic resuscitation improves neuronal and behavioral outcomes after traumatic brain injury plus hemorrhage	ANESTHESIOLOGY			English	Article							CEREBRAL-BLOOD-FLOW; CORTICAL IMPACT INJURY; ARGININE METHYL-ESTER; NITRIC-OXIDE; HEAD-INJURY; RATS; HYPOTENSION; SURVIVAL; SHOCK; AMINOGUANIDINE	Background: Resuscitation with hypertonic saline or hypertonic saline Plus L-arginine acutely improves cerebral blood How after traumatic brain injury (TBI) followed by hemorrhagic hypotension. The authors investigated whether hypertonic saline or hypertonic L-arginine would improve long-term neuronal survival and behavioral outcomes 15 days after TBI and hemorrhagic hypotension. Methods: Mean arterial pressure, arterial blood gases, pH, plasma glucose, hematocrit, and hemoglobin were measured in male Sprague-Dawley rats before and after moderate (2.0 atm) fluid percussion TBI. Rats were assigned to one of six groups: (1) sham TBI, (2) hemorrhage only, (3) TBI only, (4) TBI plus hemorrhage and resuscitation with 0.9% saline, (5) TBI plus hemorrhage and resuscitation with hypertonic saline (7.50/6), or (6) TBI plus hemorrhage and resuscitation with L-arginine (100 mg/kg) in hypertonic saline. On postinjury days 1-5, vestibulomotor function was assessed using beam balance and beam walking tasks. On postinjury days 11-15, spatial memory function was assessed using the Morris water maze. After behavioral testing, neuronal counting was performed bilaterally on specific hippocampal. regions. Results: Groups receiving hypertonic saline (P < 0.05, day 15 vs. day 11) or hypertonic L-arginine (P < 0.05, days 13-15 vs. day 11) showed improved performance over time on the Morris water maze, as well as significantly improved neuronal survival in the contralateral hippocampus (P < 0.05, hypertonic saline or hypertonic L-arginine vs. normal saline) compared with untreated TBI or normal saline-treated TBI plus hemorrhage groups. Conclusions: Hypertonic saline and hypertonic L-arginine were both effective at promoting long-term neuronal survival and behavioral recovery. The slightly earlier improvement in Morris water maze performance in the hypertonic L-arginine group warrants further studies to determine whether higher doses Of L-arginine provide additional improvement. This study supports the therapeutic benefits of hypertonic resuscitation after TBI plus hemorrhagic hypotension.	[Sell, Stacy L.; Prough, Donald S.; DeWitt, Douglas S.] Univ Texas Galveston, Med Branch, Dept Anesthesiol, Charles R Allen Res Labs, Galveston, TX 77555 USA; [Vergara, Leoncio] Univ Texas Galveston, Med Branch, Dept Neurosci & Cell Biol, Opt Imaging Lab, Galveston, TX 77555 USA; [Grady, James J.] Univ Texas Galveston, Med Branch, Dept Prevent Med & Community Hlth, Off Biostat, Galveston, TX 77555 USA	DeWitt, DS (corresponding author), Univ Texas Galveston, Med Branch, Dept Anesthesiol, Charles R Allen Res Labs, 610 Texas Ave, Galveston, TX 77555 USA.	ddewitt@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019355] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01NS019355-15] Funding Source: Medline		Angele MK, 1999, J TRAUMA, V46, P34, DOI 10.1097/00005373-199901000-00006; Atan MS, 2004, J NEUROSURG, V101, P138, DOI 10.3171/jns.2004.101.1.0138; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BICKEL PJ, 1992, STAT SINICA, V2, P1; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Daughters K, 1996, RESUSCITATION, V31, P141, DOI 10.1016/0300-9572(95)00922-1; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hartl R, 1997, ACT NEUR S, V70, P126; Hua TC, 1999, SHOCK, V11, P51, DOI 10.1097/00024382-199901000-00008; Huk I, 1997, CIRCULATION, V96, P667; Long JB, 1996, J NEUROTRAUM, V13, P149, DOI 10.1089/neu.1996.13.149; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; Mellander S, 1997, ACTA PHYSIOL SCAND, V160, P57, DOI 10.1046/j.1365-201X.1997.00117.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Prough DS, 2006, SHOCK, V26, P290, DOI 10.1097/01.shk.0000225405.66693.49; Todorovic Z, 2001, PHARMACOL RES, V43, P321, DOI 10.1006/phrs.2001.0805; VANGELDEREN EM, 1991, BRIT J PHARMACOL, V103, P1899; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wade CE, 2003, J TRAUMA, V54, pS144, DOI 10.1097/01.TA.0000047223.62617.AB; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	33	25	30	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2008	108	5					873	881		10.1097/ALN.0b013e31816c8a15			9	Anesthesiology	Anesthesiology	292YV	WOS:000255302900014	18431123	Bronze			2021-06-18	
J	Geeraerts, T; Friggeri, A; Mazoit, JX; Benhamou, D; Duranteau, J; Vigue, B				Geeraerts, Thomas; Friggeri, Arnaud; Mazoit, Jean-Xavier; Benhamou, Dan; Duranteau, Jacques; Vigue, Bernard			Posttraumatic brain vulnerability to hypoxia-hypotension: the importance of the delay between brain trauma and secondary insult	INTENSIVE CARE MEDICINE			English	Article						brain metabolism; hypoxia-hypotension; microdialysis; rat; secondary insult; traumatic brain injury	FREELY MOVING RATS; HEAD-INJURY; MICRODIALYSIS; EDEMA; MODEL; PERTURBATION; DYSFUNCTION; METABOLISM; HYPOXEMIA; ACID	Objective: To examine whether the effect of hypoxia-hypotension (HH) after traumatic brain injury (TBI) is affected by the delay between insults. Design: Thirty Sprague-Dawley rats were randomized into five groups: sham, TBI alone (trauma alone, impact-acceleration, 450 g weight drop from 1.8 m), HH alone (blood depletion, mean arterial pressure 40 mmHg, FIO2 = 10%, 15 min), TBI + early HH (TBI followed by HH, 45-min delay), and TBI + late HH (225-min delay). Cerebral perfusion pressure was continuously recorded. Brain microdialysis and PtiO(2) probes were inserted stereotaxically into the right thalamus. Measurements and results: After the HH period and for 60 min a significant increase in cerebral lactate-pyruvate ratio was observed in groups subjected to HH vs. TBI alone and sham groups (33.0 +/- 5.1 for HH alone and 51.9 +/- 6.7 for TBI + early HH vs. 16.7 +/- 2.4 for TBI alone at the same time, 27.6 +/- 4.4 for TBI + late HH vs. 13.1 v 1 for TBI alone at the same time). There was no significant difference in lactate-pyruvate ratio peaks between HH alone and TBI + late HH while it was higher in TBI + early HH. Similar results were obtained for cerebral glycerol. PtiO(2) during HH phase did not differ between HH alone, TBI + early HH and TBI + late HH (respectively, 4.2 +/- 3.1, 4.9 +/- 5.7, and 2.9 +/- 1.8 mmHg). Conclusions: A 45-min delay between HH and TBI has important metabolic consequences while a 225-min delay has a similar effect as HH in a noninjured brain. The posttraumatic brain vulnerability to HH depends on the delay between cerebral aggressions.	[Geeraerts, Thomas; Friggeri, Arnaud; Mazoit, Jean-Xavier; Benhamou, Dan; Duranteau, Jacques; Vigue, Bernard] Hop Bicetre, Dept Anethesie Reanimat, AP HP, F-94276 Le Kremlin Bicetre, France; [Geeraerts, Thomas; Friggeri, Arnaud; Mazoit, Jean-Xavier; Benhamou, Dan; Duranteau, Jacques; Vigue, Bernard] Univ Paris Sud, Lab Anesthesie, UPRES 3540, F-94276 Le Kremlin Bicetre, France	Geeraerts, T (corresponding author), Hop Bicetre, Dept Anethesie Reanimat, AP HP, F-94276 Le Kremlin Bicetre, France.	thgeeraerts@hotmail.com	Friggeri, Arnaud/AAE-7644-2020				Beaumont A, 2002, ACT NEUR S, V81, P217; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Carre E, 2004, J NEUROSCI METH, V140, P23, DOI 10.1016/j.jneumeth.2004.04.037; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; FELLOWS LK, 1992, J NEUROCHEM, V59, P2141; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Geeraerts T, 2006, J NEUROTRAUM, V23, P1059, DOI 10.1089/neu.2006.23.1059; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Holtzer S, 2001, CRIT CARE MED, V29, P1609, DOI 10.1097/00003246-200108000-00018; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KUHR WG, 1988, J CEREBR BLOOD F MET, V8, P130, DOI 10.1038/jcbfm.1988.17; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; MAGISTRETTI PJ, 2003, FUNDAMENTAL NEUROSCI, P339; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; PAXINOS J, 1982, RAT BRAIN STEREOTAXI; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Valtysson J, 1998, ACTA NEUROCHIR, V140, P387, DOI 10.1007/s007010050113; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487	31	25	27	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2008	34	3					551	560		10.1007/s00134-007-0863-0			10	Critical Care Medicine	General & Internal Medicine	263EQ	WOS:000253200800025	17938889				2021-06-18	
J	Votruba, KL; Rapport, LJ; Vangel, SJ; Hanks, RA; Lequerica, A; Whitman, RD; Langenecker, S				Votruba, Kristen Loeher; Rapport, Lisa J.; Vangel, Stephen J., Jr.; Hanks, Robin A.; Lequerica, Anthony; Whitman, R. Douglas; Langenecker, Scott			Impulsivity and traumatic brain injury: the relations among Behavioral observation, performance measures, and rating scales	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	35th Annual Meeting of the International-Neuropsychological-Society	FEB 07-10, 2007	Portland, OR	Int Neuropsychol Soc		behavioral observation; impulsivity; inhibition; neuropsycbological assessment; traumatic brain injury rehabilitation	CLOSED-HEAD-INJURY; INHIBITORY CONTROL; REACTION-TIME; PERSONALITY DESCRIPTION; DIMENSIONAL SYSTEM; AWARENESS; DEFICITS; REHABILITATION; PREDICTORS; RESPONSES	Objective: To assess the interrelations of neuropsychological tests and rating scales with in vivo behavioral observation of impulsive behavior, accounting for the mode of expression (verbal or motor). Design: Cross-sectional, correlational. Setting: An urban, inpatient rehabilitation facility in the Midwestern United States. Participants: Forty patients who were hospitalized in the traumatic brain injury unit. Main outcome measures: Impulsivity Rating Scale and Agitated Behavior Scale (completed by rehabilitation therapists), Barratt Impulsivity Scale (patient self-report), neuropsychological tests, and in vivo behavioral observation of impulsivity using a structured checklist during rehabilitation therapy. Results: Relations of impulsivity rating scales and performance tests to in vivo behavior dissociated. Verbal impulsivity was best assessed by rating scales and was largely unrelated to performance measures of impulsivity, whereas motor impulsivity was best assessed by performance tests and was unrelated to rating scales. Performance tests also had poor specificity, showing equally strong associations with tests of other neuropsychological domains. Conclusions: Impulsivity is a multidimensional construct that should be assessed in a variety of ways. Using either rating scales or neuropsychological tests alone will not likely yield a comprehensive representation of TBI patients' impulsive behaviors. In vivo observation in the clinical setting showed strong ability to identify impulsivity in the presence of global deficits.	[Votruba, Kristen Loeher; Rapport, Lisa J.; Lequerica, Anthony; Whitman, R. Douglas] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Vangel, Stephen J., Jr.; Hanks, Robin A.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48202 USA; [Langenecker, Scott] Univ Michigan, Med Ctr, Dept Psychiat, Neuropsychol Sect, Ann Arbor, MI 48109 USA	Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	rapport@wayne.edu	Langenecker, Scott/F-3548-2012	Langenecker, Scott/0000-0002-7932-5494			BARRATT ES, 1965, PSYCHOL REP, V16, P547, DOI 10.2466/pr0.1965.16.2.547; BARTKO JJ, 1976, PSYCHOL BULL, V83, P762, DOI 10.1037/0033-2909.83.5.762; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Benton AL, 1978, MULTILINGUAL APHASIA; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; CARRILLODELAPENA MT, 1993, PERCEPT MOTOR SKILL, V77, P567, DOI 10.2466/pms.1993.77.2.567; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; DELIS DC, 2000, CALIFORNIA VERBAL LE; Eastwood EA, 1999, NURS ECON, V17, P96; Evenden J, 1999, J PSYCHOPHARMACOL, V13, P180, DOI 10.1177/026988119901300211; EYSENCK SBG, 1977, BRIT J SOC CLIN PSYC, V16, P57, DOI 10.1111/j.2044-8260.1977.tb01003.x; EYSENCK SBG, 1978, PSYCHOL REP, V43, P1247, DOI 10.2466/pr0.1978.43.3f.1247; Flory JD, 2006, J PSYCHIATR RES, V40, P438, DOI 10.1016/j.jpsychires.2006.01.008; FOSTER SL, 1986, HDB BEHAV ASSESSMENT, P253; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; GERBING DW, 1987, MULTIVAR BEHAV RES, V22, P357, DOI 10.1207/s15327906mbr2203_6; Golden C., 1978, STROOP COLOR WORD TE; Greve KW, 2001, BRAIN INJURY, V15, P255; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; KAMINER Y, 1995, ADOLESCENCE, V30, P483; Konrad KN, 2000, BRAIN INJURY, V14, P859; Langenecker SA, 2005, J CLIN EXP NEUROPSYC, V27, P320, DOI 10.1080/13803390490490515720; Lecrubier Y, 1995, EUR PSYCHIAT, V10, P331, DOI 10.1016/0924-9338(96)80333-6; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; LUENGO MA, 1994, J PERS SOC PSYCHOL, V66, P542, DOI 10.1037/0022-3514.66.3.542; OLSON SL, 1989, J CLIN CHILD PSYCHOL, V18, P176, DOI 10.1207/s15374424jccp1802_9; PAULSEN K, 1980, J ABNORM CHILD PSYCH, V8, P269, DOI 10.1007/BF00919070; Peterson BS, 1999, BIOL PSYCHIAT, V45, P1237, DOI 10.1016/S0006-3223(99)00056-6; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; SAUNDERS JT, 1973, AM J ORTHOPSYCHIAT, V43, P789, DOI 10.1111/j.1939-0025.1973.tb00851.x; SCHLEENBAKER RE, 1994, ARCH PHYS MED REHAB, V75, P427, DOI 10.1016/0003-9993(94)90166-X; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; Stewart JAL, 1999, BRAIN COGNITION, V41, P411, DOI 10.1006/brcg.1999.1141; Tabachnick BG, 2007, USING MULTIVARIATE S, P5; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wingrove J, 1997, PERS INDIV DIFFER, V22, P333, DOI 10.1016/S0191-8869(96)00222-X	47	25	25	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2008	23	2					65	73		10.1097/01.HTR.0000314525.93381.69			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	280KW	WOS:000254426700001	18362760				2021-06-18	
J	Nakase-Richardson, R; Yablon, SA; Sherer, M; Evans, CC; Nick, TG				Nakase-Richardson, R.; Yablon, S. A.; Sherer, M.; Evans, C. C.; Nick, T. G.			Serial yes/no reliability after traumatic brain injury: implications regarding the operational criteria for emergence from the minimally conscious state	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							DIAGNOSTIC-CRITERIA; COGNITIVE TEST; DEFINITION; DELIRIUM	Background: Published guidelines for defining the "minimally conscious state'' (MCS) included behaviours that characterise emergence, specifically "reliable and consistent'' functional interactive communication (accurate yes/no responding) and functional use of objects. Guidelines were developed by consensus because of the lack of empirical data to guide definitions. Criticism emerged that individuals with severely impaired cognition would have difficulty achieving the requisite threshold of accuracy and consistency proposed to demonstrate emergence from MCS. Objective: To determine the utility of the operational threshold for emergence from post-traumatic MCS, by evaluating a measure of yes/no accuracy (Cognitive Test for Delirium, auditory processing subtest (CTD-AP).) Methods: Prospective, consecutive cohort of responsive patients recovering from traumatic brain injury (TBI), including a subset meeting criteria for MCS at neurorehabilitation admission who improved and were able to undergo the study protocol. Participants were evaluated at least weekly, and given the CTD-AP to assess yes/no responding. Results: Of the 1434 observations from 336 participants, 767 observations yielded inaccurate yes/no responses. 75 participants (22%) never attained consistently accurate yes/no responses at any time during their hospitalisation. Generalised estimating equations analysis revealed that confused participants were more likely to respond inaccurately to yes/no questions. Further, the subset of individuals who were in MCS on rehabilitation admission and improved, were also more likely to respond inaccurately to yes/no questions. Conclusions: Consistent yes/no accuracy is uncommon among responsive patients in early recovery from TBI. These results suggest that the operational threshold for yes/no response accuracy as a diagnostic criterion for emergence from MCS should be revisited.	[Nakase-Richardson, R.; Yablon, S. A.; Evans, C. C.] Methodist Rehabil Ctr, Dept Neurophysiol, Jackson, MS 39216 USA; [Nakase-Richardson, R.; Yablon, S. A.; Evans, C. C.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Sherer, M.] Baylor Coll Med, Houston, TX 77030 USA; [Sherer, M.] Mem Hermann TIRR, Houston, TX 77030 USA; [Nick, T. G.] Univ Cincinnati, Cincinnati, OH USA; [Nick, T. G.] Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA	Nakase-Richardson, R (corresponding author), Methodist Rehabil Ctr, Dept Neurophysiol, 1350 E Woodrow Wilson Dr, Jackson, MS 39216 USA.	Nakase@aol.com					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bernat JL, 2002, NEUROLOGY, V58, P337, DOI 10.1212/WNL.58.3.337; Coleman D, 2002, NEUROLOGY, V58, P506, DOI 10.1212/WNL.58.3.506; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; Kennedy RE, 2003, PSYCHOSOMATICS, V44, P283, DOI 10.1176/appi.psy.44.4.283; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542	11	25	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2008	79	2							216	10.1136/jnnp.2007.127795			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	261PG	WOS:000253091900030	18202213				2021-06-18	
J	Gutierrez, PM; Brenner, LA; Huggins, JA				Gutierrez, Peter M.; Brenner, Lisa A.; Huggins, Joseph A.			A Preliminary Investigation of Suicidality in Psychiatrically Hospitalized Veterans with Traumatic Brain Injury	ARCHIVES OF SUICIDE RESEARCH			English	Article						suicide; traumatic brain injury; veterans		The objective of this study was to explore suicidal behaviors documented at time of discharge from acute psychiatric hospitalization. Data from 114 acute psychiatric admissions were reviewed for 22 veterans with a history of traumatic brain injury (TBI). Information extracted included presence of suicidal ideation, nature of suicide attempts, and TBI characteristics. The Lethality of Suicide Attempt Rating Scale was used to classify veterans' non-lethal self-harm behavior. Post-TBI, 6 patients (27.3%) made a total of 14 suicide attempts. Half of those attempts required wounds being sutured, stomach lavage, or other medical attention. Clinicians and researchers are strongly encouraged to focus increased attention on suicide prevention in those with a history of TBI.	[Gutierrez, Peter M.; Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Psychiat,Dept Phys Med & Rehabil,Dept Neurol, Denver VA Med Ctr,MIRECC,VA VISN 19, Denver, CO 80220 USA; [Huggins, Joseph A.] Univ Colorado Denver, Sch Med, Dept Family Med, MIRECC,MSW,MSCIS VA VISN 19, Denver, CO 80220 USA	Gutierrez, PM (corresponding author), Univ Colorado Denver, Sch Med, Dept Psychiat,Dept Phys Med & Rehabil,Dept Neurol, Denver VA Med Ctr,MIRECC,VA VISN 19, 1055 Clermont St, Denver, CO 80220 USA.	peter.gutierrez@va.gov	Gutierrez, Peter/K-8905-2019; Brenner, Lisa A./AAG-2442-2019	Gutierrez, Peter/0000-0001-8981-8404; Huggins, Joe/0000-0001-8151-5062			American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Berman AL, 2003, SUICIDE LIFE-THREAT, V33, P261, DOI 10.1521/suli.33.3.261.23211; Brenner L. A., J HEAD TRAU IN PRESS; *DEP VET AFF, 2004, VETEESA138 SP DEP VE; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jennett B, 1981, MANAGEMENT HEAD INJU; Jollant F, 2005, AM J PSYCHIAT, V162, P304, DOI 10.1176/appi.ajp.162.2.304; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Powell KB, 2004, J CHILD NEUROL, V19, P785, DOI 10.1177/08830738040190100801; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; SMITH K, 1984, SUICIDE LIFE-THREAT, V14, P215; STUSS DT, 2007, HUMAN FRONTAL LOBES, P293; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436	23	25	25	0	1	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1381-1118			ARCH SUICIDE RES	Arch. Suicide Res.		2008	12	4					336	343		10.1080/13811110802324961			8	Psychiatry; Psychology; Psychology, Multidisciplinary	Psychiatry; Psychology	V11CR	WOS:000207510200005	18828036				2021-06-18	
J	Viano, DC				Viano, David C.			Seat Design Principles to Reduce Neck Injuries in Rear Impacts	TRAFFIC INJURY PREVENTION			English	Article; Proceedings Paper	World Congress on Neck Pain	JAN 20-22, 2008	Los Angeles, CA			Whiplash; Seats; Head restraints; Spinal cord injury; Rear crashes; Injury biomechanics		Objectives: In the 1990s, research was conducted at General Motors R&D Center on seat safety in rear impacts. It led to the development of high retention seats and an active head restraint to improve occupant safety. This article provides an overview of the design principles found from that research and focuses on seat characteristics that lower whiplash risks. Methods: Sled and quasistatic seat testing showed how occupants interact with the seat in rear impacts and what seat characteristics improve occupant retention, energy management, and support of the head-neck, lowering injury risks. Neck displacements, moments, and forces were used to assess whiplash and more severe injury risks. A QST test was developed to quasi-statically push a dummy rearward into the seat to determine seat stiffness (k), frame strength (j), and peak bending moment (M(Hpt)). These parameters were related to neck displacements associated with whiplash. Sled tests were run with in-position and out-of-position male and female Hybrid III dummies to assess performance. A high retention seat and active head restraint were developed and put into production in 1997. Results: High retention seats have 2.3 times greater moment, develop 2.2 times greater load, but have the same stiffness as earlier yielding seats. Seat stiffness was found to be a principle characteristic related to neck displacements associated with whiplash. The combination of a stronger frame, yielding seatback, and high-forward head restraint in the high retention seat provides early head support and low neck displacements in rear impacts. Larger reductions in neck displacement were obtained by adding an active head restraint that moves the head restraint forward and upward by occupant penetration into the seatback. This substantially reduces head contact time, neck displacements, and loads. Conclusions: Whiplash risks are related to seat stiffness, the position of the head restraint, and frame strength. Low seat stiffness allows the occupant to move into the seatback without high loads on the torso until the head-neck is supported by the head restraint. A strong seat frame reduces early seatback rotation that increases the gap to the head restraint and drops it in relation to the occupant's head. A high and forward head restraint provides support of the head and neck. Large forces can be applied to the occupant once the head, neck, and torso are supported by the seat and head restraint without adverse loading of the spine. The addition of an active head restraint closes the gap behind the head before significant load develops on the neck. The movement provides a more upward trajectory of the head restraint. Low- speed rear crashes are not just a matter of whiplash; older occupants, some with cervical stenosis, are at risk for paralyzing spinal cord injury.	ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA	Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					Anderson JO, 1961, R341295 RES LAB GEN; Blaisdell DM, 1993, 930340 SAE; Farmer Charles M, 2003, Traffic Inj Prev, V4, P83, DOI 10.1080/15389580309867; ONEILL B, 1972, AM J PUBLIC HEALTH N, V62, P399, DOI 10.2105/AJPH.62.3.399; Partyka S, 1992, SUMMARY SAFETY ISSUE; Prasad P, 1997, 973343 SAE; *RCAR IIWPG, 2007, SEAT HEAD RESTR EV P; SCHWIMMER S, 1962, LEADING CAUSES INJUR; Severy DM, 1976, 760810 SAE; SEVERY DM, 1968, 680079 SAE; Viano, 2002, R3171491 SAE; Viano D.C., 2002, 2002010030 SAE; Viano D. C., 2003, 2003010180 SAE; Viano David C, 2003, Traffic Inj Prev, V4, P214, DOI 10.1080/15389580309877; Viano David C, 2003, Traffic Inj Prev, V4, P228, DOI 10.1080/15389580309880; Viano David C, 2003, Traffic Inj Prev, V4, P324, DOI 10.1080/714040490; Viano DC, 2001, J TRAUMA, V51, P959, DOI 10.1097/00005373-200111000-00022; Viano DC, 1996, ACCIDENT ANAL PREV, V28, P665, DOI 10.1016/S0001-4575(96)00011-5; Viano DC, 2008, 2008011851 SAE; VIANO DC, 2007, 2007010708 SAE; Viano DC, 2003, 2003011351 SAE; Viano DC., 2008, 2008010188 SAE; Viano DC, 2003, DEBATE STIFF YIELDIN; Viano DC., 2003, 2003010173 SAE; Viano DC., 2008, 2008011485 SAE; VIANO DC, 2003, COMMUNICATION; WARNER C, 1991, OCCUPANT PROTECTION, V2	27	25	25	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1538-9588			TRAFFIC INJ PREV	Traffic Inj. Prev.		2008	9	6					552	560		10.1080/15389580802381939			9	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	387DN	WOS:000261932000008	19058102				2021-06-18	
J	Acerini, CL; Tasker, RC				Acerini, Carlo L.; Tasker, Robert C.			Traumatic brain injury induced hypothalamic-pituitary dysfunction: a paediatric perspective	PITUITARY			English	Article						traumatic brain injury; hypopituitarism; pituitary dysfunction; growth hormone deficiency	GROWTH-HORMONE DEFICIENCY; STRESS-DISORDER PERSISTS; SEVERE HEAD TRAUMA; LONG-TERM; POSTTRAUMATIC HYPOPITUITARISM; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; PRECOCIOUS PUBERTY; DIABETES-INSIPIDUS; STALK TRANSECTION	In survivors of traumatic brain injury (TBI), impairment in anterior pituitary hormone function may be an important cause of long-term morbidity. Histopathological evidence from post-mortem studies suggests that the hypothalamic-pituitary structures are vulnerable to damage following head injury. Pituitary dysfunction, present months or years after injury, is now well recognised in adults, however, little evidence is known about this potential complication in children and adolescents. This article reviews the available paediatric data, which shows that hypopituitarism may occur after both mild and severe TBI, with growth hormone and gonadotrophin deficiencies appearing to be most common abnormalities. Central precocious puberty has also been documented. There are, however, few published data within a population of children with TBI on the incidence or prevalence of hypopituitarism, nor on its natural history or response to hormone replacement, and prospective studies are needed. Given the critical role of anterior pituitary hormones in the regulation of growth, pubertal and neurocognitive development in childhood, early detection of hormone abnormalities following TBI is important. We propose that a multidisciplinary approach to follow-up and endocrine assessment is required for the long-term management and rehabilitation of children and adolescents who survive moderate to severe head injury.	[Acerini, Carlo L.; Tasker, Robert C.] Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England	Acerini, CL (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Level 8,Box 116, Cambridge CB2 2QQ, England.	cla22@cam.ac.uk	Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113; Acerini, Carlo/0000-0003-2121-5871			Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Barbeau C, 1998, ARCH PEDIATRIE, V5, P274, DOI 10.1016/S0929-693X(97)89368-2; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; BARZILAY Z, 1988, J MED, V19, P47; Benoit R, 2000, J TRAUMA, V49, P477, DOI 10.1097/00005373-200009000-00015; Benvenga S, 2004, AM J MED, V116, P767, DOI 10.1016/j.amjmed.2003.12.038; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BLENDONOHY P M, 1991, Brain Injury, V5, P63, DOI 10.3109/02699059108998513; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; CORTE FD, 1998, CRIT CARE MED, V26, P1419; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; DANIEL PM, 1959, LANCET, V2, P927; EDWARDS OM, 1986, MEDICINE, V65, P281; EICHLER I, 1998, J ENDOCRINOL INVEST, V33, P409; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; GIRARD J, 1977, J PEDIATR-US, V90, P241, DOI 10.1016/S0022-3476(77)80637-9; GROSSMAN WF, 1994, J REPROD MED, V39, P738; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; Holbrook TL, 2005, J TRAUMA, V58, P764, DOI 10.1097/01.TA.0000159247.48547.7D; Jacobs LM, 2005, J TRAUMA, V58, P769; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; LAFRANCHI SH, 1979, AM J DIS CHILD, V133, P739, DOI 10.1001/archpedi.1979.02130070075016; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mariani R, 1996, ARCH PEDIATRIE, V3, P796, DOI 10.1016/0929-693X(96)82164-6; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; MILLER WL, 1980, NEW ENGL J MED, V302, P724, DOI 10.1056/NEJM198003273021305; Mooney DP, 2004, J TRAUMA, V57, P1241, DOI 10.1097/01.TA.0000106694.75576.69; Nemergut EC, 2005, J NEUROSURG, V103, P448, DOI 10.3171/jns.2005.103.3.0448; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; PAXSON CL, 1976, PEDIATRICS, V57, P893; Popovic V, 2005, GROWTH HORM IGF RES, V15, P177, DOI 10.1016/j.ghir.2005.02.003; SHAUL PW, 1985, AM J DIS CHILD, V139, P467, DOI 10.1001/archpedi.1985.02140070041029; SOCKALOSKY JJ, 1987, J PEDIATR-US, V110, P373, DOI 10.1016/S0022-3476(87)80497-3; SURTEES R, 1987, HORM RES, V28, P5, DOI 10.1159/000180918; TANRIVERDI F, 2006, J CLIN ENDOCR METAB, V91, P2015; Tasker RC, 2006, EMERG MED J, V23, P519, DOI 10.1136/emj.2005.028779; VALENTA LJ, 1980, AM J MED, V68, P614, DOI 10.1016/0002-9343(80)90314-9; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; YAMANAKA C, 1993, EUR J PEDIATR, V152, P99, DOI 10.1007/BF02072482	53	25	28	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1386-341X	1573-7403		PITUITARY	Pituitary	DEC	2007	10	4					373	380		10.1007/s11102-007-0052-8			8	Endocrinology & Metabolism	Endocrinology & Metabolism	250ML	WOS:000252304100008	17570066				2021-06-18	
J	Takamiya, M; Fujita, S; Saigusa, K; Aoki, Y				Takamiya, Masataka; Fujita, Sachiko; Saigusa, Kiyoshi; Aoki, Yasuhiro			Simultaneous detections of 27 cytokines during cerebral wound healing by multiplexed bead-based immunoassay for wound age estimation	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; growth factors; head trauma; molecular biological approaches; traumatic brain injury	HUMAN BRAIN-INJURY; SUSPENSION ARRAY TECHNOLOGY; NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; GROWTH-FACTOR; RAT-BRAIN; EXPRESSION; MICROGLIA; INTERLEUKIN-1-BETA; ASTROCYTES	Quantification of 27 cytokines following cerebral wounding was performed for wound age estimation. The cytokines evaluated included interleukin (IL)-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12 p40, IL-12 p70, IL-15, IL-17, IL-18, basic fibroblast growth factor (bFGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), Interferon-gamma (IFN-gamma), keratinocyte derived cytokine (KC), leukemia inhibitory factor (LIF), macrophage-colony stimulating factor (M-CSF), monokine inducible by interferon gamma (MIG), macrophage inflammatory protein (MIP)-1 alpha, MIP 2, platelet-derived growth factor BB (PDGF BB), regulated upon activation, normal T-cell expressed, and secreted (Rantes), tumor necrosis factor -alpha (TNF-alpha), and vascular endothelial growth factor (VEGF). The proliferation of glial cells as well as the infiltration of inflammatory cells were also evaluated. Although astroglia proliferated from 72 hours post-injury, inflammatory cell dynamics were generally steady. Among cytokines analyzed in the present study, IL-1 beta, IL-5, IL-6, IL-12 p40, G-CSF, IFN-gamma, KC, LIF, MIP 2, and PDGF BB increased during the early phase of cerebral wound healing, and M-CSF increased during the middle phase, while IL-15, IL-18, and MIG increased during the late phase. In contrast, IL-1 alpha, IL-10, IL-12 p70, and TNF-alpha were suppressed throughout the cerebral wound healing process. Based on our findings, quantitative cytokine analyses at the cerebral wound site may be a useful tool for wound age estimation. Further, this study suggests that multiplex data gained from the same sample using a single methodology demonstrates highly accurate cytokine interactions during the process of cerebral wound healing.	[Takamiya, Masataka; Fujita, Sachiko; Aoki, Yasuhiro] Iwate Med Univ, Sch Med, Dept Legal Med, Morioka, Iwate 020, Japan; [Saigusa, Kiyoshi] Iwate Med Univ, Ctr Gen Educ, Dept Biol, Morioka, Iwate, Japan	Takamiya, M (corresponding author), Iwate Med Univ, Sch Med, Dept Legal Med, 19-1 Uchimaru, Morioka, Iwate 020, Japan.	mtakamiy@iwate-med.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18590642] Funding Source: KAKEN		Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Bonmann E, 1997, NEUROSCI LETT, V230, P109, DOI 10.1016/S0304-3940(97)00485-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bugga L, 1998, J NEUROBIOL, V36, P509, DOI 10.1002/(SICI)1097-4695(19980915)36:4<509::AID-NEU5>3.0.CO;2-#; Davies CA, 1999, J CEREBR BLOOD F MET, V19, P87, DOI 10.1097/00004647-199901000-00010; Di Prospero NA, 1998, J NEUROCYTOL, V27, P491, DOI 10.1023/A:1006995624754; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Grau V, 1997, GLIA, V19, P181, DOI 10.1002/(SICI)1098-1136(199703)19:3<181::AID-GLIA1>3.0.CO;2-2; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hausmann R, 2001, INT J LEGAL MED, V114, P338, DOI 10.1007/s004140000199; Hausmann Roland, 2002, Leg Med (Tokyo), V4, P79, DOI 10.1016/S1344-6223(02)00003-2; Kellar KL, 2002, EXP HEMATOL, V30, P1227, DOI 10.1016/S0301-472X(02)00922-0; Knight B., 2004, KNIGHTS FORENSIC PAT, P174; Krupinski J, 1997, STROKE, V28, P564, DOI 10.1161/01.STR.28.3.564; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Lund Frances E., 2005, V8, P25; Mandy FF, 2001, CLIN LAB MED, V21, P713; Nolan JP, 2001, CELL MOL BIOL, V47, P1241; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Orihara Y, 2002, INT J LEGAL MED, V116, P92, DOI 10.1007/s00414-001-0265-8; Orihara Yoshiyuki, 2003, Leg Med (Tokyo), V5 Suppl 1, pS278; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rasley A, 2004, J NEUROVIROL, V10, P171, DOI 10.1080/13550280490444119; SAWADA M, 1993, NEUROSCI LETT, V155, P175, DOI 10.1016/0304-3940(93)90701-L; Schaffer M, 1998, BRIT J SURG, V85, P444; Takamiya M, 2003, INT J LEGAL MED, V117, P46, DOI 10.1007/s00414-002-0354-3	30	25	28	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2007	24	12					1833	1844		10.1089/neu.2007.0336			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	245BR	WOS:000251910000006	18159995				2021-06-18	
J	Tontisirin, N; Armstead, W; Waitayawinyu, P; Moore, A; Udomphorn, Y; Zimmerman, JJ; Chesnut, R; Vavilala, MS				Tontisirin, Nuj; Armstead, William; Waitayawinyu, Pichaya; Moore, Anne; Udomphorn, Yuthana; Zimmerman, Jerry J.; Chesnut, Randall; Vavilala, Monica S.			Change in cerebral autoregulation as a function of time in children after severe traumatic brain injury: a case series	CHILDS NERVOUS SYSTEM			English	Article						pediatric traumatic brain injury; cerebral autoregulation; cerebral blood flow; pediatric trauma	HEAD-INJURY; BLOOD-FLOW; METABOLISM	Objective The objective of this study was to describe changes in cerebral autoregulation after severe pediatric traumatic brain injury (TBI). Materials and methods Two cerebral autoregulation tests were performed during the first 10 days after severe TBI in children < 16 years. Cerebral autoregulation was quantified using the mean autoregulatory index (mARI). Results Nine (five males/four females) children (10 +/- 5 years) with severe (admission Glasgow Coma Scale (GCS), 5 +/- 2) TBI were enrolled. Thirty (3/9) percent of initial exams revealed impaired cerebral autoregulation; all three had returned to intact cerebral autoregulation on second exam. However, in three of nine (33%) patients, cerebral autoregulation worsened on second exam. Of the factors examined, worsening mARI on second exam was associated with worsening head computed tomography (CT) lesion. Conclusions Cerebral autoregulation often changed and worsened during the first 9 days after severe pediatric TBI. Worsening cerebral autoregulation may mirror worsening TBI.	Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Dept Pediat, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Cerebrovasc Lab, Seattle, WA 98104 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Penn, Dept Anesthesiol, Philadelphia, PA 19104 USA	Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9th Ave,POB 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu		Chesnut, Randall/0000-0001-6377-3666	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23/HD044632] Funding Source: Medline		AINSLIE PN, 2006, AM J PHYSIOL-HEART C, V292, P976; Cremer OL, 2004, ANESTHESIOLOGY, V100, P1101, DOI 10.1097/00000542-200405000-00011; DOHMEN C, 2006, STROKE, V22, P1; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kaiser JR, 2005, PEDIATR RES, V58, P931, DOI 10.1203/01.pdr.0000182180.80645.0c; LAM AM, 1995, ANESTHESIOLOGY, V82, P1536, DOI 10.1097/00000542-199506000-00035; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NISHIZAMA H, 1993, ACTA ANAESTH SCAND, V40, P1149; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P162; Sahuquillo J, 1998, ACT NEUR S, V71, P233; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Sundgreen C, 2001, STROKE, V32, P128, DOI 10.1161/01.STR.32.1.128; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P233, DOI 10.1097/00008506-200107000-00009; VAVILALA MS, 2004, PEDIATR CRIT CARE ME, V5, P298; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X	21	25	25	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	OCT	2007	23	10					1163	1169		10.1007/s00381-007-0339-0			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	208CO	WOS:000249297600012	17429655				2021-06-18	
J	Haider, AH; Efron, DT; Haut, ER; Chang, DC; Paidas, CN; Cornwell, EE				Haider, Adil H.; Efron, David T.; Haut, Elliott R.; Chang, David C.; Paidas, Charles N.; Cornwell, Edward E., III			Mortality in adolescent girls vs boys - Following traumatic shock an analysis of the national pediatric trauma registry	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	78th Annual Meeting of the Pacific-Coast-Surgical-Association	FEB   18, 2007	Kohala Coast, HI	Pacific Coast Surg Assoc			INJURY SEVERITY SCORE; GENDER DIFFERENCES; IMMUNE-RESPONSES; FUNCTIONAL OUTCOMES; HEMORRHAGIC-SHOCK; BRAIN-INJURY; AGE; TESTOSTERONE; SURVIVAL; MALES	Hypothesis: Female sex imparts a survival benefit after traumatic injury in children. Design, Setting, and Patients: Review of patients (aged 0-17 years) included in the National Pediatric Trauma Registry between April 1994 and September 2001. Multiple logistic regression was used to analyze the effect of sex on mortality, adjusting for age, severity of injury (New Injury Severity Score and Pediatric Trauma Score), severity of head or extremity injury, injury mechanism, intent, and comorbidities. Subset analysis focused on severely injured children (New Injury Severity Score >= 16) with shock (systolic blood pressure <= 90 mm Hg, adjusted for age). Main Outcome Measure: Adjusted odds of mortality between sexes. Results: Of 46 859 children, 67% were boys. Girls had a higher crude mortality rate than boys (3.1% vs 2.7%, respectively; p<.05), but after adjustment, no significant difference was found in the odds of mortality between sexes (odds ratio, 1.16; 95% confidence interval, 0.89-1.37). Among children meeting the definition. of severe injury with shock (n = 697), mortality was 39%. On regression analysis, sex did not predict outcomes in prepubescent children (aged: <= 11 years; n=532; 95% confidence interval, 0.56-1.22). However, among adolescents (aged 12-17 years), girls demonstrated significantly decreased odds of death when compared with equivalently injured boys (odds ratio, 0.38; 95% confidence interval, 0. 14-0.90; n = 165). Conclusions: Adolescent girls exhibit lower mortality than boys following traumatic shock. This effect is not seen in prepubescent children. These findings suggest that hormonal differences may play a role in the sex-based outcome disparities following traumatic shock in children.	Johns Hopkins Sch Med, Dept Surg, Div Trauma & Crit Care, Baltimore, MD 21287 USA; Univ S Florida, Dept Surg, Tampa, FL 33620 USA	Haider, AH (corresponding author), Johns Hopkins Sch Med, Dept Surg, Div Trauma & Crit Care, 600 N Wolfe St,Blalock 688, Baltimore, MD 21287 USA.	ahaider1@jhmi.edu	Haut, Elliott R./J-3948-2019	Haut, Elliott/0000-0001-7075-771X			Angele Martin K., 2006, Clinics, V61, P479, DOI 10.1590/S1807-59322006000500017; Angele MK, 2005, LANGENBECK ARCH SURG, V390, P333, DOI 10.1007/s00423-005-0557-4; Angele MK, 1998, AM J PHYSIOL-CELL PH, V274, pC1530; Angele MK, 1998, J TRAUMA, V44, P78, DOI 10.1097/00005373-199801000-00007; Angele MK, 2000, SHOCK, V14, P81, DOI 10.1097/00024382-200014020-00001; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Chumlea WC, 2003, PEDIATRICS, V111, P110, DOI 10.1542/peds.111.1.110; Cornwell EE, 2003, ARCH SURG-CHICAGO, V138, P838, DOI 10.1001/archsurg.138.8.838; Cornwell EE, 1999, J GASTROINTEST SURG, V3, P648, DOI 10.1016/S1091-255X(99)80088-2; Diodato MD, 2001, CYTOKINE, V14, P162, DOI 10.1006/cyto.2001.0861; Gannon CJ, 2002, J AM COLL SURGEONS, V195, P11, DOI 10.1016/S1072-7515(02)01187-0; George RL, 2003, J TRAUMA, V54, P464, DOI 10.1097/01.TA.0000051939.95039.E6; George RL, 2003, SHOCK, V19, P28, DOI 10.1097/00024382-200301000-00006; Haider A, 2003, J AM COLL SURGEONS, V197, pS67; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Haider AH, 2004, J PEDIATR SURG, V39, P976, DOI 10.1016/j.jpedsurg.2004.02.028; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mostafa G, 2002, J TRAUMA, V53, P430, DOI 10.1097/00005373-200209000-00006; Napolitano LM, 2001, J TRAUMA, V50, P274, DOI 10.1097/00005373-200102000-00013; Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Samy TSA, 2001, ENDOCRINOLOGY, V142, P3519, DOI 10.1210/en.142.8.3519; Sullivan T, 2003, J TRAUMA, V55, P1083, DOI 10.1097/01.TA.0000102175.58306.2A; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Wichmann MW, 1997, SHOCK, V8, P242, DOI 10.1097/00024382-199710000-00002; Wichmann MW, 1996, CYTOKINE, V8, P853, DOI 10.1006/cyto.1996.0114; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7	28	25	25	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	SEP	2007	142	9					875	879		10.1001/archsurg.142.9.875			5	Surgery	Surgery	210KB	WOS:000249454000017	17875843	Bronze			2021-06-18	
J	Liu, D; McIlvain, HB; Fennell, M; Dunlop, J; Wood, A; Zaleska, MM; Graziani, EI; Pong, K				Liu, Danni; McIlvain, H. Beal; Fennell, Myles; Dunlop, John; Wood, Andrew; Zaleska, Margaret M.; Graziani, Edmund I.; Pong, Kevin			Screening of immunophilin ligands by quantitative analysis of neurofilament expression and neurite outgrowth in cultured neurons and cells	JOURNAL OF NEUROSCIENCE METHODS			English	Article						amyotrophic lateral sclerosis; immunophilin ligands; neurite outgrowth; neuronal survival; neuroregeneration; Parkinson's disease; spinal cord injury; stroke	TRAUMATIC BRAIN-INJURY; PEPTIDYL-PROLYL ISOMERASE; LONG-TERM POTENTIATION; CIS-TRANS ISOMERASE; SPINAL-CORD-INJURY; CYCLOSPORINE-A; IMMUNOSUPPRESSANT FK506; BINDING-PROTEIN; NONIMMUNOSUPPRESSIVE IMMUNOPHILIN; MITOCHONDRIAL DYSFUNCTION	Immunophilins are protein receptors for the immunosuppressant drugs FK506, cyclosporin A (CsA), and rapamycin. Two categories of immunophilins are the FK506-binding proteins (FKBPs), which bind to FK506, rapamycin, and CCI-779 and the cyclophilins, which bind to CsA. Reports have shown that immunophilins are expressed in the brain and spinal cord, are 10-100-fold higher in CNS tissue than immune tissue, and their expression is increased following nerve injury, suggesting that their chemical ligands may have therapeutic utility in the treatment of neurodegenerative diseases. In this study, we report the development and utility of a rapid neurofilament (NF) enzyme-linked immunosorbent assay (ELISA) to quantify neuronal survival and the Cellomics ArrayScan platform to quantify neurite outgrowth following treatment with immunophilin ligands. Cultured neurons or F-11 cells were treated with various immunophilin ligands for 72 or 96 h and their promotion of neuronal survival and neurite outgrowth were determined. The results showed that all immunophilin ligands, in a concentration-dependent manner, significantly increased neuronal survival and neurite outgrowth, when compared to control cultures. Taken together, these results demonstrate the potential utility of the neurofilament ELISA and Cellomics ArrayScan platform to efficiently quantify neurotrophic effects of immunophilin ligands on cultured neurons and cell lines. (c) 2007 Elsevier B.V. All rights reserved.	Wyeth Res, Neurosci Discovery Res, Princeton, NJ 08543 USA; Wyeth Res, Chem & Screening Sci, Pearl River, NY USA	Pong, K (corresponding author), Wyeth Res, Neurosci Discovery Res, CN 8000, Princeton, NJ 08543 USA.	pongk@wyeth.com		Graziani, Edmund/0000-0003-4742-3900			Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ARMISTEAD DM, 1992, Patent No. 9219593; Avramut M, 2001, DEV BRAIN RES, V132, P151, DOI 10.1016/S0165-3806(01)00307-8; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Birge RB, 2004, NEUROSCIENCE, V124, P351, DOI 10.1016/j.neuroscience.2003.10.013; Chen QS, 2002, NEUROBIOL LEARN MEM, V77, P354, DOI 10.1006/nlme.2001.4034; Choo YS, 2004, HUM MOL GENET, V13, P1407, DOI 10.1093/hmg/ddh162; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Costantini LC, 2001, EUR J NEUROSCI, V13, P1085, DOI 10.1046/j.0953-816x.2001.01473.x; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Dubowchik GM, 2001, ORG LETT, V3, P3987, DOI 10.1021/ol0166909; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRANCEL PC, 1987, J NEUROCHEM, V48, P1624, DOI 10.1111/j.1471-4159.1987.tb05711.x; Gold BG, 2004, J NEUROSCI RES, V77, P367, DOI 10.1002/jnr.20165; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; Kano Y, 2002, NEUROCHEM RES, V27, P1655, DOI 10.1023/A:1021639128120; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; KITAMURA Y, 1994, J NEUROIMMUNOL, V50, P221; Klettner A, 2001, MOL BRAIN RES, V97, P21, DOI 10.1016/S0169-328X(01)00286-8; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; Lench NJ, 1997, HUM GENET, V99, P547, DOI 10.1007/s004390050404; LIU D, 2004, SOC NEUROSCI ABSTR, V35; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; LYONS WE, 1995, J NEUROSCI, V15, P2985; McIlvain HB, 2006, BRAIN RES, V1077, P16, DOI 10.1016/j.brainres.2005.12.130; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; NIXON RA, 1998, BIOESSAYS, V98, P229; Ohuchi T, 2002, J NEUROSCI METH, V118, P1, DOI 10.1016/S0165-0270(02)00116-4; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Parker EM, 2000, NEUROPHARMACOLOGY, V39, P1913, DOI 10.1016/S0028-3908(00)00028-9; Pong K, 2001, EXP NEUROL, V171, P84, DOI 10.1006/exnr.2001.7747; Pong K, 2003, CNS NEUROL DISORD-DR, V2, P349, DOI 10.2174/1568007033482652; Price RD, 2005, EUR J PHARMACOL, V509, P11, DOI 10.1016/j.ejphar.2004.12.023; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Ravikumar B, 2003, HUM MOL GENET, V12, P985, DOI 10.1093/hmg/ddg109; Rosenstiel P, 2003, J NEUROTRAUM, V20, P297, DOI 10.1089/089771503321532888; Ross DT, 2001, NEUROSCI LETT, V297, P113, DOI 10.1016/S0304-3940(00)01683-9; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sauer H, 1999, BRAIN RES, V842, P109, DOI 10.1016/S0006-8993(99)01851-X; Schreyer DJ, 1997, J NEUROSCI METH, V72, P137, DOI 10.1016/S0165-0270(96)02171-1; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; Sharkey J, 1996, STROKE, V27, P2282, DOI 10.1161/01.STR.27.12.2282; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Simpson PB, 2001, ANAL BIOCHEM, V298, P163, DOI 10.1006/abio.2001.5346; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Skotnicki J. S., 1994, U.S. Pat, Patent No. [5,362,718, 5362718]; Small SL, 1996, ANN NEUROL, V40, P575, DOI 10.1002/ana.410400406; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Summers MY, 2006, J ANTIBIOT, V59, P184, DOI 10.1038/ja.2006.26; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Terashima A, 2000, NEUROPHARMACOLOGY, V39, P1920, DOI 10.1016/S0028-3908(00)00015-0; Wang M S, 1999, J Spinal Cord Med, V22, P287; WOOD A, 2004, SOC NEUROSCI ABSTR; Yabe T, 2002, J NEUROSCI RES, V68, P161, DOI 10.1002/jnr.10210; Young L, 1999, J NEUROSCI METH, V93, P81, DOI 10.1016/S0165-0270(99)00134-X; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhang CY, 2001, J NEUROSCI, V21; 1996, Patent No. 9640633	70	25	30	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUL 30	2007	163	2					310	320		10.1016/j.jneumeth.2007.03.018			11	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	188UW	WOS:000247945800013	17490751				2021-06-18	
J	Gao, JL; Coggeshall, RE; Chung, JM; Wang, JG; Wu, P				Gao, Junling; Coggeshall, Richard E.; Chung, Jin Mo; Wang, Jigong; Wu, Ping			Functional motoneurons develop from human neural stem cell transplants in adult rats	NEUROREPORT			English	Article						human neural stem cell; innervation; motoneuron disease; myelin; synapse; transplantation	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; MOTOR-NEURONS; NEUROTROPHIC FACTORS; CHOLINERGIC NEURONS; DIFFERENTIATION; RECOVERY; SPECIFICATION; SURVIVAL; GROWTH	We have shown previously that primed human fetal neural stem cells, after transplantation into rat spinal cords, differentiated into cholinergic motoneurons that sent axons to contact medial gastrocnemius myocytes. Here we demonstrate that (i) axons from the transplanted cells are cholinergic and myelinated, (ii) putative synapses form on transplanted somata and dendrites in the ventral horn, (iii) human fetal neural stem cells transplantation led to normal electromyograms from medial gastrocnemius muscles, and (iv) the gait of transplanted animals was much improved. Accumulatively, our data indicate that some transplanted human fetal neural stem cells in adult motoneuron-deficient ventral horns differentiate into relatively normal motoneurons that are integrated into spinal and peripheral circuitry These findings are steps towards the long-term goal of providing stem cell transplants for motoneuron loss.	Univ Texas, Med Branch, Dept Cell Biol & Neurosci, Galveston, TX 77555 USA	Wu, P (corresponding author), Univ Texas, Med Branch, Dept Cell Biol & Neurosci, Galveston, TX 77555 USA.	piwu@utmb.edu	wu, Ping/G-8958-2011		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS046025, NS10161, NS11255, NS31680] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS011255, R01NS046025, R01NS031680] Funding Source: NIH RePORTER		Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; Corti S, 2006, HUM MOL GENET, V15, P167, DOI 10.1093/hmg/ddi446; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Deshpande DM, 2006, ANN NEUROL, V60, P32, DOI 10.1002/ana.20901; Gao J, 2005, NEUROSCIENCE, V131, P257, DOI 10.1016/j.neuroscience.2004.10.033; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Hamada M, 2006, NEUROBIOL DIS, V22, P509, DOI 10.1016/j.nbd.2005.12.020; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kuo HC, 2003, BIOL REPROD, V68, P1727, DOI 10.1095/biolreprod.102.012195; Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Miles GB, 2004, J NEUROSCI, V24, P7848, DOI 10.1523/JNEUROSCI.1972-04.2004; NIETOSAMPEDRO M, 1987, ANN NY ACAD SCI, V495, P108, DOI 10.1111/j.1749-6632.1987.tb23670.x; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Renoncourt Y, 1998, MECH DEVELOP, V79, P185, DOI 10.1016/S0925-4773(98)00189-0; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shin S, 2005, STEM CELLS DEV, V14, P266, DOI 10.1089/scd.2005.14.266; Soundararajan P, 2006, J NEUROSCI, V26, P3256, DOI 10.1523/JNEUROSCI.5537-05.2006; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Tarasenko YI, 2004, J NEUROSCI RES, V78, P625, DOI 10.1002/jnr.20316; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Wu P, 2002, GENE THER, V9, P245, DOI 10.1038/sj.gt.3301646	25	25	28	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	APR 16	2007	18	6					565	569		10.1097/WNR.0b013e3280b10c2c			5	Neurosciences	Neurosciences & Neurology	155WM	WOS:000245609300008	17413658				2021-06-18	
J	Davis, DP; Kene, M; Vilke, GM; Sise, MJ; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB				Davis, Daniel P.; Kene, Mamata; Vilke, Gary M.; Sise, Michael J.; Kennedy, Frank; Eastman, A. Brent; Velky, Thomas; Hoyt, David B.			Head-injured patients who "talk and die": The San Diego perspective	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	64th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-24, 2005	Atlanta, GA	Amer Assoc Surg Trauma			COMA SCALE SCORE; ENDOTRACHEAL INTUBATION; TRAUMA PATIENTS; FIELD; MODERATE; HEPARIN; DEATHS; SYSTEM	Background: Head-injured patients who "talk and die" are potentially salvageable, making their early identification important. This study uses a large, comprehensive database to explore risk factors for head-injured patients who deteriorate after their initial presentation. Methods: Patients with a head Abbreviated Injury Score (AIS) score of 3+ and a preadmission verbal Glasgow Coma Scale (GCS) score of 3+ were identified from our county trauma registry during a 16-year period. Survivors and nonsurvivors were compared with regard to demographics, initial clinical presentation, and various risk factors. Logistic regression was used to explore the impact of multiple factors on outcome, including the significance of a change in GCS score from field to arrival. In addition, patients were stratified by injury severity and hospital day of death to further define the relationship between outcome and multiple clinical variables. Results: A total of 7,443 patients were identified with head AIS 3+ and verbal GCS score 3+. Overall mortality was 6.1%. About one-third of deaths occurred on the first hospital day, with more than one-third occurring after hospital day 5. Logistic regression revealed an association between mortality and older age, more violent mechanisms of injury (fall, gunshot wound, pedestrian versus automobile), greater injury severity (higher head AIS and Injury Severity Score), lower GCS score, and hypotension. In addition, mortality was associated with a decrease in GCS score from field to arrival, the use of anticoagulants, and a diagnosis of pulmonary embolus. Two important groups of "talk-and-die" patients were identified. Early deaths occurred in younger patients with more critical extracranial injuries. Anticoagulant use was also an independent risk factor in these early deaths. Later deaths occurred in older patients with less significant extracranial injuries. Pulmonary embolus also appeared to be an important contributor to late mortality. Conclusions: More severe injuries and use of anticoagulants are independent risk factors for early death in potentially salvageable traumatic brain injury patients, whereas older age and pulmonary embolus are associated with later deaths.	Univ Calif San Diego, Mercy Air Med Serv, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Mercy Air Med Serv, Dept Surg, San Diego, CA 92103 USA; Scripps Mercy Hosp, Dept Surg, San Diego, CA USA; Sharp Mem Hosp & Rehabil Ctr, Dept Surg, San Diego, CA 90034 USA; Scripps La Jolla Hosp, Dept Surg, San Diego, CA USA; Palomar Hosp, Dept Surg, San Diego, CA USA	Davis, DP (corresponding author), Univ Calif San Diego, Mercy Air Med Serv, Dept Emergency Med, 200 W Arbor Dr 8676, San Diego, CA 92103 USA.	davismd@cox.net					Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Demetriades D, 2005, J AM COLL SURGEONS, V201, P343, DOI 10.1016/j.jamcollsurg.2005.05.003; Dunn LT, 2003, J TRAUMA, V54, P497, DOI 10.1097/01.TA.0000030627.71453.CD; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Ginzburg E, 2003, BRIT J SURG, V90, P1338, DOI 10.1002/bjs.4309; Hadfield RJ, 2001, RESUSCITATION, V49, P279, DOI 10.1016/S0300-9572(00)00364-6; Kibayashi K, 2000, Leg Med (Tokyo), V2, P175, DOI 10.1016/S1344-6223(00)80021-8; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Meislin H, 1997, J TRAUMA, V43, P433, DOI 10.1097/00005373-199709000-00008; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; RAMADAN A, 1986, NEUROCHIRURGIE, V32, P423; REILLY PL, 1975, LANCET, V2, P375; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; WRIGHT PJ, 1989, ANAESTHESIA, V44, P219, DOI 10.1111/j.1365-2044.1989.tb11227.x	23	25	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2007	62	2					277	281		10.1097/TA.0b013e31802ef4a3			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	137ZY	WOS:000244333300001	17297312				2021-06-18	
J	Dohi, K; Satoh, K; Nakamachi, T; Yofu, S; Hiratsuka, K; Nakamura, S; Ohtaki, H; Yoshikawa, T; Shioda, S; Aruga, T				Dohi, Kenji; Satoh, Kazue; Nakamachi, Tomoya; Yofu, Sachiko; Hiratsuka, Keisuke; Nakamura, Shunsuke; Ohtaki, Hirokazu; Yoshikawa, Toshikazu; Shioda, Seiji; Aruga, Tohru			Does edaravone (MCI-186) act as an antioxidant and a neuroprotector in experimental traumatic brain injury?	ANTIOXIDANTS & REDOX SIGNALING			English	Article							LIPID-PEROXIDATION; OXIDATIVE STRESS; ISCHEMIA; DAMAGE; PROTECTS; INCREASE; EDEMA; RATS	Edaravone (MCI-186) is a novel synthetic free radical scavenger intended to have neuroprotective effect against ischemic insult. It is currently used on patients with cerebral infarction. Here, we note beneficial pharmaceutical effects of edaravone in rat experimental traumatic brain injury. Under specific experimental conditions, edaravone minimized traumatic brain injury by functioning as a synthetic antioxidant. Clinical trials testing the efficacy of edaravone are warranted.	Showa Univ, Sch Med, Dept Emergency & Crit Care Med, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Dept Anat, Tokyo 1428555, Japan; Kyoto Prefectural Univ Med, Dept Med 1, Kyoto, Japan	Dohi, K (corresponding author), Showa Univ, Sch Med, Dept Emergency & Crit Care Med, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	kdop@med.showa-u.ac.jp		dohi, kenji/0000-0002-4451-0382	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18591989] Funding Source: KAKEN		Araki Y, 2003, INT J MOL MED, V12, P125; Benedetti S, 2004, CLIN BIOCHEM, V37, P312, DOI 10.1016/j.clinbiochem.2003.12.001; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Chang EF, 2003, J NEUROSCI, V23, P3689; Dohi K, 2005, IN VIVO, V19, P855; Dohi K, 2003, ACT NEUR S, V86, P123; DOHI K, IN PRESS J NEUROTRAU; HOUKIN K, 2003, CEREBROVASC DIS, V15, P222; Huh PW, 2000, EUR J PHARMACOL, V389, P79, DOI 10.1016/S0014-2999(99)00768-2; Ikeda Y, 2000, ACT NEUR S, V76, P343; Ito K, 2005, FREE RADICAL BIO MED, V38, P369, DOI 10.1016/j.freeradbiomed.2004.10.029; Juurlink BHJ, 1999, NEUROTOX RES, V1, P119, DOI 10.1007/BF03033276; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; Khanna S, 2005, STROKE, V36, pE144, DOI 10.1161/01.STR.0000181082.70763.22; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mihara Y, 2004, HYPOTHERMIA FOR ACUTE BRAIN DAMAGE: PATHOMECHANISM AND PRACTICAL ASPECTS, P94; Nakamura H, 2003, ACT NEUR S, V86, P309; OGAWA T, 2004, NEUROTRAUMATOLOGY, V27, P149; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Satoh K, 2002, REDOX REP, V7, P219, DOI 10.1179/135100002125000587; Scholpp J, 2004, J NEUROTRAUM, V21, P667, DOI 10.1089/0897715041269632; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; WATANABE T, 1988, PROSTAG LEUKOTR ESS, V33, P81, DOI 10.1016/0952-3278(88)90127-5; WATANABE T, 1994, J PHARMACOL EXP THER, V268, P1597; Wen J, 2006, BIOL PHARM BULL, V29, P713, DOI 10.1248/bpb.29.713; WILLMORE LJ, 1984, EXP NEUROL, V83, P62, DOI 10.1016/0014-4886(84)90046-3; Yamato M, 2003, FREE RADICAL BIO MED, V35, P1619, DOI 10.1016/j.freeradbiomed.2003.09.013	30	25	26	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1523-0864	1557-7716		ANTIOXID REDOX SIGN	Antioxid. Redox Signal.	FEB	2007	9	2					281	287		10.1089/ars.2007.9.281			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	126GJ	WOS:000243500400012	17115943				2021-06-18	
J	Kamsler, A; Avital, A; Greenberger, V; Segal, M				Kamsler, Ariel; Avital, Avi; Greenberger, Varda; Segal, Menahem			Aged SOD overexpressing mice exhibit enhanced spatial memory while lacking hippocampal neurogenesis	ANTIOXIDANTS & REDOX SIGNALING			English	Article							LONG-TERM POTENTIATION; TRAUMATIC BRAIN-INJURY; RAT DENTATE GYRUS; ADULT-RAT; SUPEROXIDE DISMUTASE; ENVIRONMENTAL ENRICHMENT; SYNAPTIC PLASTICITY; AGING HIPPOCAMPUS; NEURONS; CELLS	The recent finding that hippocampal slices from aged mice overexpressing the gene for superoxide dismutase (SOD) exhibit long-term potentiation (LTP) of reactivity to afferent stimulation that is significantly larger than that produced in aged wild-type (wt) mice has encouraged the exploration of the effects of reactive oxygen species (ROS) on learning in aged mice. In addition, young-adult and aged wt and SOD transgenic mice were used in an attempt to correlate adult neurogenesis with spatial learning. Aged wt and SOD mice exhibited a 90% reduction in doublecortin-labeled new dentate gyrus neurons as compared to young mice, with no significant difference between genotypes. In addition, aged SOD mice exhibited better performance than wt controls in both reference and working memory tasks in a water maze. These findings provide a behavioral measure to demonstrate that excessive production of H2O2 is beneficial in aged mice.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Kamsler, A (corresponding author), MIT, Picower Ctr Learning & Memory, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	kamsler@mit.edu	SEGAL, MENAHEM/K-1577-2012; Avital, Avraham/I-2163-2016	Avital, Avraham/0000-0002-0691-153X; Kamlser, Ariel/0000-0002-6199-8906			Akman C, 2004, EPILEPSY BEHAV, V5, P446, DOI 10.1016/j.yebeh.2004.03.008; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Ambrogini P, 2000, NEUROSCI LETT, V286, P21, DOI 10.1016/S0304-3940(00)01074-0; BARNES CA, 1988, NEUROBIOL AGING, V9, P563, DOI 10.1016/S0197-4580(88)80114-3; Bondolfi L, 2004, NEUROBIOL AGING, V25, P333, DOI 10.1016/S0197-4580(03)00083-6; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Cui X, 2006, J NEUROSCI RES, V84, P647, DOI 10.1002/jnr.20899; Deisseroth K, 2004, NEURON, V42, P535, DOI 10.1016/S0896-6273(04)00266-1; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Driscoll I, 2006, NEUROSCIENCE, V139, P1173, DOI 10.1016/j.neuroscience.2006.01.040; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gahtan E, 1998, EUR J NEUROSCI, V10, P538, DOI 10.1046/j.1460-9568.1998.00058.x; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Hu DY, 2006, J NEUROSCI, V26, P3933, DOI 10.1523/JNEUROSCI.5566-05.2006; Jaako-Movits K, 2005, EUR J NEUROSCI, V22, P2871, DOI 10.1111/j.1460-9568.2005.04481.x; Kamsler A, 2003, J NEUROSCI, V23, P10359; Kawai T, 2004, J CEREBR BLOOD F MET, V24, P548, DOI 10.1097/00004647-200405000-00009; Kempermann G, 2002, EUR J NEUROSCI, V16, P129, DOI 10.1046/j.1460-9568.2002.02042.x; Kim H, 2006, BRAIN DEV-JPN, V28, P109, DOI 10.1016/j.braindev.2005.05.008; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Lee HH, 2006, BRAIN DEV-JPN, V28, P147, DOI 10.1016/j.braindev.2005.05.007; Levkovitz Y, 1999, J NEUROSCI, V19, P10977; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu L, 2003, EXP NEUROL, V183, P600, DOI 10.1016/S0014-4886(03)00248-6; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; McDonald HY, 2005, NEUROSCI LETT, V385, P70, DOI 10.1016/j.neulet.2005.05.022; Merrill DA, 2003, J COMP NEUROL, V459, P201, DOI 10.1002/cne.10616; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Pourie G, 2006, NEUROSCIENCE, V140, P1369, DOI 10.1016/j.neuroscience.2006.02.083; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Scerri C, 2006, PSYCHOPHARMACOLOGY, V184, P540, DOI 10.1007/s00213-005-0086-4; Serrano F, 2004, AGEING RES REV, V3, P431, DOI 10.1016/j.arr.2004.05.002; Shimazu K, 2006, LEARN MEMORY, V13, P307, DOI 10.1101/lm.76006; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; Ueda S, 2005, NEUROSCIENCE, V135, P395, DOI 10.1016/j.neuroscience.2005.06.065; Van Kampen JM, 2004, EUR J NEUROSCI, V19, P2377, DOI 10.1111/j.0953-816X.2004.03342.x; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Wang R, 2004, NEUROSCIENCE, V126, P305, DOI 10.1016/j.neuroscience.2004.03.048; Wati H, 2006, NEUROSCI LETT, V399, P171, DOI 10.1016/j.neulet.2006.01.056; Winocur G, 2006, HIPPOCAMPUS, V16, P296, DOI 10.1002/hipo.20163; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	50	25	25	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1523-0864	1557-7716		ANTIOXID REDOX SIGN	Antioxid. Redox Signal.	FEB	2007	9	2					181	189		10.1089/ars.2007.9.181			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	126GJ	WOS:000243500400003	17115939				2021-06-18	
J	Francisco, GE; Latorre, JM; Ivanhoe, CB				Francisco, Gerard E.; Latorre, Juan M.; Ivanhoe, Cindy B.			Intrathecal baclofen therapy for spastic hypertonia in chronic traumatic brain injury	BRAIN INJURY			English	Article						spastic hypertonia; baclofen; brain injuries		Objective: To describe the outcome of intrathecal baclofen ( ITB) therapy in treating spastic hypertonia and its sequelae in individuals with chronic (> 14 years) traumatic brain injuries ( TBI). Design: Case series. Setting: Free- standing rehabilitation hospital. Participants: Three adult males who received a TBI 14, 17.1, and 19.9 years prior to receiving ITB pump. Outcome measures: Modified Ashworth Scale ( MAS); Functional Independence Measure ( FIM)- mobility scores; and informal functional evaluation. Intervention: ITB therapy. Results: MAS scores of the five most hypertonic muscles in the affected lower limbs improved following of ITB therapy. FIM- mobility scores did not change from baseline, but certain functional domains improved, such as gait, transfers, and sitting; decreased assistance for activities of daily living ( ADL) and nursing care; decreased painful spasms; and increased community mobility and participation in recreational activities. Conclusion: ITB therapy is still beneficial even > 14 years after TBI onset. In spite of the absence of improvement in FIM scores, functional enhancements in areas not measured by traditional scales can still be achieved. This suggests that in this patient population consideration for ITB therapy should not be based solely on conventional assessment scales.	TIRR Hosp, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Houston, TX USA	Francisco, GE (corresponding author), TIRR Hosp, 1333 Moursund St, Houston, TX 77030 USA.	gerard.e.francisco@uth.tmc.edu					Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Meythaler JA, 2001, ARCH PHYS MED REHAB, V82, P1155, DOI 10.1053/apmr.2001.25141; Meythaler JM, 2004, J HEAD TRAUMA REHAB, V19, P101, DOI 10.1097/00001199-200403000-00003; Rawicki B, 1999, J NEUROSURG, V91, P733, DOI 10.3171/jns.1999.91.5.0733; Rifici C, 1994, Funct Neurol, V9, P29; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939	7	25	26	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	3					335	338		10.1080/02699050701311018			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IW	WOS:000246518400009	17453762				2021-06-18	
J	Vassallo, JL; Proctor-Weber, Z; Lebowitz, BK; Curtiss, G; Vanderploeg, RD				Vassallo, Jessica L.; Proctor-Weber, Zoe; Lebowitz, Brian K.; Curtiss, Glenn; Vanderploeg, Rodney D.			Psychiatric risk factors for traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; head injury; risk factors for TBI; psychiatric risk factors	DIAGNOSTIC INTERVIEW SCHEDULE; HEAD-INJURY; ALCOHOL-INTOXICATION; DRUG-USE; MILD; DISABILITY; ILLNESS	Objective: To examine the risk of sustaining a traumatic brain injury (TBI) associated with prior psychiatric conditions beyond that of fixed demographic variables. Design: Retrospective cohort study of non-referred community-dwelling male US veterans. Methods: Two-hundred and seventy-one individuals who sustained a TBI with altered consciousness were compared with 630 controls without a history of head injury, selected from a larger sample of 3766. Results: Hierarchical logistic regression analyses were used to model odds ratios and 95% confidence intervals for the unique association between pre- existing psychiatric disorders and the likelihood of incurring a TBI while adjusting for demographic characteristics and other known predictor variables. Mood (odds ratio 2.48, 95% confidence interval 1.23-5.01), anxiety (OR 1.64, 95% CI 1.01-2.68) and conduct disorders (OR 1.66, 95% CI 1.16 - 2.38) increased the risk of head injury. Conclusions: The pre-existence of psychiatric illness, particularly depression, anxiety and conduct disorder, increased the future risk of incurring a TBI. The implementation of early identification and treatment of psychiatric conditions may potentially lower risk and reduce yearly incidence rates of TBI.	James A Haley Vet Adm Med Ctr, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA; Def & Vet Brain Injury Ctr, Tampa, FL USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA	Vanderploeg, RD (corresponding author), James A Haley Vet Adm Med Ctr, Dept Mental Hlth & Behav Sci, 13000 N Bruce B Downs Blvd,116B, Tampa, FL 33612 USA.	rodney.vanderploeg@va.gov	Curtiss, Glenn/ABB-5566-2020	Lebowitz, Brian/0000-0001-8845-8136; Lebowitz, Barry/0000-0002-6467-646X			*AM PSYCH ASS, 1980, DIAGN STAT MAN MENT, P1; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P93; [Anonymous], 1988, JAMA, V259, P2701; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; *CDC, 1989, PSYCHOL NEUROPSYCHOL, V4; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; Dunn L, 2003, J NEUROL NEUROSUR PS, V74, P1060, DOI 10.1136/jnnp.74.8.1060; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; Gilson SF, 1996, AM J PUBLIC HEALTH, V86, P1613, DOI 10.2105/AJPH.86.11.1613; Hannay HJ, 2004, NEUROPSYCHOLOGICAL A, P718; HONKANEN R, 1991, INJURY, V22, P225, DOI 10.1016/0020-1383(91)90047-I; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; MONTAGUE E K, 1957, U S Armed Forces Med J, V8, P883; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; REYNOLDS HT, 1977, ANAL NOMINAL DATA, P1; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SHAFFER D, 1993, J AM ACAD CHILD PSY, V32, P643, DOI 10.1097/00004583-199305000-00023; Shih HC, 2003, AM J EMERG MED, V21, P91, DOI 10.1053/ajem.2003.50025; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sosin DM, 1996, BRAIN INJURY, V10, P47; *TBI, INC DISTR; Teasdale TW, 1997, BRIT MED J, V315, P569; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; *VET HLTH IN, TRAUM BRAIN INJ CONT; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5	33	25	25	1	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	6					567	573		10.1080/02699050701426832			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	192LU	WOS:000248204100003	17577707				2021-06-18	
J	Yeates, G; Henwood, K; Gracey, F; Evans, J				Yeates, Giles; Henwood, Karen; Gracey, Fergus; Evans, Jonathan			Awareness of disability after acquired brain injury and the family context	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							STAGE ALZHEIMERS-DISEASE; CLOSED HEAD-INJURY; SIGNIFICANT OTHERS; FOLLOW-UP; SELF; REHABILITATION; DEFICITS; INDIVIDUALS; ANOSOGNOSIA; UNAWARENESS	The dimension of family context for awareness of disability following acquired brain injury (ABI) is examined through a qualitative discourse analysis. Three participants with ABI, who were identified by clinicians and relatives as demonstrating difficulties with awareness of disability, and three relatives were interviewed. The findings highlight important contextual parameters influencing the emergence of families' accounts for disability after ABI: (1) availability of sense-making resources and use of pre-injury meanings, and (2) incongruity within family sense-making and resultant orientating, disputing and contesting of accounts within families. These findings are discussed in relation to pre-existing literature, and applications are suggested for family intervention following ABI.	Prince Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Ely CB6 1DN, Cambs, England; Cardiff Univ, Sch Social Sci, Cardiff, S Glam, Wales; Gartnavel Royal Hosp, Dept Psychol Med, Glasgow G12 0YN, Lanark, Scotland	Gracey, F (corresponding author), Prince Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Lynn Rd, Ely CB6 1DN, Cambs, England.	Fergus.Gracey@ozc.nhs.uk	Yeates, Giles/AAB-2875-2020	Gracey, Fergus/0000-0002-1416-7894; Yeates, Giles/0000-0002-0912-6027			BERGEN KJ, 1985, SOCIAL CONSTRUCTION; Bond J., 2002, DEMENTIA, V1, P313, DOI DOI 10.1177/147130120200100304; Bond M R, 1979, Acta Neurochir Suppl (Wien), V28, P124; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; Boscolo L., 1987, MILAN SYSTEMIC FAMIL; BRODAL A, 1973, BRAIN, V96, P675, DOI 10.1093/brain/96.4.675; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Burke W J, 1988, Alzheimer Dis Assoc Disord, V2, P356, DOI 10.1097/00002093-198802040-00004; Campbell D, 1999, CHILD PSYCHOL PSYCHI, V4, P76, DOI DOI 10.1017/S1360641799001896; CHARMAZ K, 1990, SOC SCI MED, V30, P1161, DOI 10.1016/0277-9536(90)90256-R; Clare L, 2004, BRIT J CLIN PSYCHOL, V43, P155, DOI 10.1348/014466504323088033; Clare L, 2003, SOC SCI MED, V57, P1017, DOI 10.1016/S0277-9536(02)00476-8; Clare L., 2002, DEMENTIA, V1, P295, DOI DOI 10.1177/147130120200100303; Cock J, 2003, BRAIN INJURY, V17, P561, DOI 10.1080/0269905031000088306; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DAVIES B, 1990, J THEOR SOC BEHAV, V20, P43, DOI 10.1111/j.1468-5914.1990.tb00174.x; Dirette D, 2002, BRAIN INJURY, V16, P861, DOI 10.1080/02699050210131902; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; ELLIOTT J, 1982, AUSTR REHABILITATION, V6, P50; Elliott R, 1999, BRIT J CLIN PSYCHOL, V38, P215, DOI 10.1348/014466599162782; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GAINOTTI G, 1975, PSYCHIAT CLIN, V8, P99, DOI 10.1159/000283622; GASQUOINE PG, 1992, NEUROPSYCHOLOGY, V3, P187; GASQUOINE PG, 1994, J HEAD TRAUMA REHAB, V9, P7; German W J, 1964, Clin Neurosurg, V12, P344; Gregory R J, 1998, J Psychosoc Nurs Ment Health Serv, V36, P28; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harr? R, 1992, AGEING SOC, V12, P443, DOI DOI 10.1017/S0144686X00005262; HAYES N, 2003, CLIN PSYCHOL, V21, P36; Holstein J. A., 1995, ACTIVE INTERVIEW; Hutchinson SA, 1997, SOC SCI MED, V45, P1399, DOI 10.1016/S0277-9536(97)00064-6; JAFFE J, 1958, ARCH NEURO PSYCHIATR, V80, P653, DOI 10.1001/archneurpsyc.1958.02340110123019; JOHNSON J, 1997, FAMILY THERAPY NEURO; Jones E., 1993, FAMILY SYSTEMS THERA; Kaplan-Solms K., 2000, CLIN STUDIES NEUROPS; Kinsella G, 1989, Int Disabil Stud, V11, P9; KREFTING L, 1990, SOC SCI MED, V30, P859, DOI 10.1016/0277-9536(90)90213-C; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LaBaw W L, 1968, Med Times, V96, P821; LaBaw W L, 1966, Med Times, V94, P407; LABAW WL, 1969, PSYCHIATR, V32, P174, DOI 10.1080/00332747.1969.11023582; LABAW WL, 1968, INJURED BRAINS MED M, P298; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; LEVINE J, 1975, J CONSULT CLIN PSYCH, V43, P751; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; Madill A, 2000, BRIT J PSYCHOL, V91, P1, DOI 10.1348/000712600161646; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MALIA K, 1997, J COGNITIVE REHABILI, V10, P10; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Marcel AJ, 2004, CORTEX, V40, P19, DOI 10.1016/S0010-9452(08)70919-5; McGlynn S.M., 1991, AWARENESS DEFICIT BR, P84; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCGLYNN SM, 1990, PSYCHOL BULL, V108, P420, DOI 10.1037/0033-2909.108.3.420; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; ODDY M, 1995, TRAUMATIC BRAIN INJU, P167; Ownsworth T, 2006, NEUROPSYCHOL REHABIL, V16, P415, DOI 10.1080/09602010500505641; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Potter J., 1987, DISCOURSE SOCIAL PSY; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Reisberg B., 1985, ALZHEIMERS DEMENT, P295; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; STEEL RT, 1997, ARCH PHYS MED REHAB, V78, P1254; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Taylor S., 2001, DISCOURSE DATA GUIDE, P311; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1987, BRAIN INJURY, V47, P260; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Turnbull O. H., 2002, NEUROPSYCHOANALYSIS, V4, P69; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; White M., 1990, NARRATIVE MEANS THER; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Yardley L, 2000, PSYCHOL HEALTH, V15, P215, DOI 10.1080/08870440008400302; YEATES GN, 2006, NEUROPSYCHOANALYSIS, V8, P175; YEATES GN, 2003, THESIS; ZIMOSTRAD SW, 1989, COGNITIVE REHABILITA, V7, P26	91	25	25	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2007	17	2					151	173		10.1080/09602010600696423			23	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	165IP	WOS:000246298400002	17454691				2021-06-18	
J	Li, SH; Kuroiwa, T; Ishibashi, S; Sun, LY; Endo, S; Ohno, K				Li, Shihong; Kuroiwa, Toshihiko; Ishibashi, Satoru; Sun, Liyuan; Endo, Shu; Ohno, Kikuo			Transient cognitive deficits are associated with the reversible accumulation of amyloid precursor protein after mild traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						axonal injury; microtubule-associated protein2; Mongolian gerbil; neuronal cytoskeleton	MICROTUBULE-ASSOCIATED PROTEIN-2; AXONAL DAMAGE; WHITE-MATTER; HEAD-INJURY; ISCHEMIA; RECOVERY; RAT	Mild traumatic brain injury (MTBI) may frequently cause transient behavioral abnormalities without observable morphological findings. In this study, we investigated neuropathological mechanisms underlying transient cognitive deficits after MTBI. Mongolian gerbils were subjected to experimental MTBI. At various time points after injury, behavioral changes were evaluated by the open-field test and T-maze test, and immunohistochemistry of microtubule-associated protein (MAP2) and amyloid precursor protein (APP) was performed to examine disruptions of the neuronal cytoskeleton and axonal transport, respectively. Transient cognitive deficits were observed after MTBI. Sustained MAP2 loss was found within the cortical impact site, but not the hippocampus. Transient APP accumulation at the same time as transient cognitive deficits occurred in the ipsilateral hemisphere, particularly in the subcortical white matter. These results suggest that the axonal dysfunction indicated by the reversible APP accumulation in the white matter, but not the sustained neuronal cytoskeletal damage reflected by the cortical MAP2 loss confined to the impact site, is responsible for the transient functional deficits after MTBI. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Tokyo Med & Dent Univ, Dept Neurosurg, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Anim Res Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Li, SH (corresponding author), Tokyo Med & Dent Univ, Dept Neurosurg, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138510, Japan.	lishihong.nsrg@tmd.ac.jp					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Briones TL, 2006, BEHAV BRAIN RES, V168, P261, DOI 10.1016/j.bbr.2005.11.015; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Flanagan S, 1999, MT SINAI J MED, V66, P152; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gerlai R, 1998, BEHAV BRAIN RES, V95, P91, DOI 10.1016/S0166-4328(97)00214-3; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GRONWALL D, 1974, LANCET, V2, P605; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Imai H, 2002, J CEREBR BLOOD F MET, V22, P1080, DOI 10.1097/00004647-200209000-00005; Ishibashi S, 2003, STROKE, V34, P1501, DOI 10.1161/01.STR.0000074034.32371.13; JOHNSON GVW, 1992, J NEUROSCI RES, V33, P505, DOI 10.1002/jnr.490330402; KUROIWA T, 1991, NEUROSCI LETT, V122, P141, DOI 10.1016/0304-3940(91)90842-H; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Qian L, 1996, ACTA NEUROCHIR, V138, P90, DOI 10.1007/BF01411731; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	28	25	25	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	DEC 6	2006	409	3					182	186		10.1016/j.neulet.2006.09.054			5	Neurosciences	Neurosciences & Neurology	111JW	WOS:000242448500005	17029784				2021-06-18	
J	Ariza, M; del Matarin, M; Junque, C; Mataro, M; Clemente, I; Moral, P; Poca, MA; Garnacho, A; Sahuquillo, J				Ariza, M; del Matarin, M; Junque, C; Mataro, M; Clemente, I; Moral, P; Poca, MA; Garnacho, A; Sahuquillo, J			Influence of angiotensin-converting enzyme polymorphism on neuropsychological subacute performance in moderate and severe traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; COGNITIVE DECLINE; IMPAIRMENT; GENE; VASOSPASM; PRESSURE; ISCHEMIA; RATS	Traumatic brain injury (TBI) frequently results in cerebrovascular lesions that may increase secondary damage and cause neuropsychological impairment. Previous studies suggest an association among the insertion/deletion. (I/D) polymorphism of the angiotensin-converting enzyme (ACE), cardiovascular disease, and cognitive performance. Clinical and experimental studies have demonstrated the beneficial effects of ACE inhibitor treatment on vascular injury, hypertension, brain ischemia, and cognitive functioning. In a sample of 73 moderate and severe TBI patients, the authors assessed whether cognitive sequelae differed in relation to the ACE I/D polymorphism. D allele carrier patients performed worse than those with I/I polymorphism on tests involving attention and processing speed. Findings suggest that the physiopathological changes associated with TBI may have greater consequences in ACE D allele carriers.	Univ Barcelona, Dept Psychiat & Clin Psychobiol, IDIBAPS, Barcelona 08036, Spain; Univ Barcelona, Dept Anim Biol, Barcelona, Spain; Univ Barcelona, Vall Hebron Hosp, Dept Neurosurg & Neurotraumatol Intens Care Unit, Barcelona, Spain	Ariza, M (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, IDIBAPS, C Casanova 143, Barcelona 08036, Spain.	marizago7@docd4.ub.edu	Garnacho, Angel/A-9309-2013; Mataro, Maria/B-4524-2011; Moral, Pedro/K-9587-2014; Sahuquillo, Juan/B-3577-2008; Clemente, I Concepcion/H-5399-2013; Matarin, Mar/F-1771-2016; Poca, Maria A./B-8475-2008; Junque, Carme/B-4400-2011	Mataro, Maria/0000-0002-9946-2656; Moral, Pedro/0000-0001-5072-5892; Sahuquillo, Juan/0000-0003-0713-5875; Clemente, I Concepcion/0000-0003-0728-0925; Matarin, Mar/0000-0002-4717-5735; Poca, Maria A./0000-0002-3831-0536; Junque, Carme/0000-0002-6381-3063; Ariza, Mar/0000-0003-1020-6945			Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Amenta F, 2002, J NEUROL SCI, V203, P147, DOI 10.1016/S0022-510X(02)00281-2; Amouyel P, 1996, NEUROSCI LETT, V217, P203, DOI 10.1016/0304-3940(96)13092-5; ANDREWS P, 1982, STROKE, V13, P480, DOI 10.1161/01.STR.13.4.480; Baranov D, 2003, ANESTHESIOLOGY, V99, P1118, DOI 10.1097/00000542-200311000-00018; Bartres-Faz D, 2000, NEUROSCI LETT, V290, P177, DOI 10.1016/S0304-3940(00)01349-5; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; FOGARTY DG, 1994, LANCET, V343, P851, DOI 10.1016/S0140-6736(94)92050-8; Gard PR, 2002, EUR J PHARMACOL, V438, P1, DOI 10.1016/S0014-2999(02)01283-9; Gerstein HC, 2000, LANCET, V355, P253; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; Mayer NJ, 2002, J CLIN PATHOL-MOL PA, V55, P29, DOI 10.1136/mp.55.1.29; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; PAULSON OB, 1985, J HYPERTENS, V3, pS487; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; POSTIGLIONE A, 1991, STROKE, V22, P1362, DOI 10.1161/01.STR.22.11.1363; Richard F, 2000, NEUROBIOL AGING, V21, P75, DOI 10.1016/S0197-4580(99)00102-5; Sahuquillo J, 2002, NEUROCIRUGIA, V13, P78; Stenman E, 2004, STROKE, V35, P970, DOI 10.1161/01.STR.0000121642.53822.58; TIRET L, 1992, AM J HUM GENET, V51, P197; Tzourio C, 2003, ARCH INTERN MED, V163, P1069; UNGER T, 1988, CIRCULATION, V77, P40; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WERNER C, 1991, STROKE, V22, P910, DOI 10.1161/01.STR.22.7.910; Zubkov AY, 1999, J NEUROTRAUM, V16, P763, DOI 10.1089/neu.1999.16.763	28	25	28	0	4	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2006	18	1					39	44		10.1176/appi.neuropsych.18.1.39			6	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	014YU	WOS:000235519900006	16525069				2021-06-18	
J	Coulthard, E; Singh-Curry, V; Husain, M				Coulthard, Elizabeth; Singh-Curry, Victoria; Husain, Masud			Treatment of attention deficits in neurological disorders	CURRENT OPINION IN NEUROLOGY			English	Article						cholinesterase inhibitor; guanfacine; inattention; methylphenidate; prism	TRAUMATIC BRAIN-INJURY; GABA(B) RECEPTOR ANTAGONIST; PRISM ADAPTATION; DOUBLE-BLIND; COGNITIVE PERFORMANCE; IMPROVES COGNITION; ALZHEIMERS-DISEASE; SPATIAL NEGLECT; RIVASTIGMINE; PLACEBO	Purpose of review Recent work has revealed the impact of deficits of attention on patients with neurological disorders. Here we discuss therapeutic interventions that have been used across a range of conditions, highlighting common themes both in the nature of the attention deficits and the strategies employed to treat them. Recent findings Cholinesterase inhibitors improve attention, as well as memory, in several conditions including cortical Lewy body disease, Parkinson's disease dementia, traumatic brain injury and Alzheimer's disease. Recent studies suggest that cholinergic stimulation may boost attention further if more specific nicotinic cholinergic agonists are used, or if cholinesterase inhibitors are combined with other agents. Monoaminergic drugs have been shown to improve attention in traumatic brain injury, attention-deficit hyperactivity disorder and hemispatial neglect following right-hemisphere stroke. New compounds targeting other neurotransmitter systems are currently being tested, while several types of behavioural intervention have shown promise, particularly in stroke patients. Summary Pharmacological and behavioural interventions can improve attention in neurological patients. In the future, optimum therapy may depend on careful delineation of the components of attention that are impaired as well as assessment of the potential for surviving brain regions to compensate for attention deficits.	UCL, Inst Cognit Neurosci, London, England	Coulthard, E (corresponding author), Inst Cognit Neurosci, 17 Queen Square,Alexandra House, London WC1N 3AR, England.	l.coulthard@ion.ucl.ac.uk	Husain, Masud/C-2074-2008	Husain, Masud/0000-0002-6850-9255; coulthard, elizabeth/0000-0002-0017-9595	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Almkvist O, 2004, EUR J NEUROL, V11, P253, DOI 10.1046/j.1468-1331.2003.00757.x; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Coull JT, 1998, PROG NEUROBIOL, V55, P343, DOI 10.1016/S0301-0082(98)00011-2; Czeisler CA, 2005, NEW ENGL J MED, V353, P476, DOI 10.1056/NEJMoa041292; de Tommaso M, 2004, MOVEMENT DISORD, V19, P1516, DOI 10.1002/mds.20235; Dijkerman HC, 2004, NEUROPSYCHOLOGIA, V42, P1697, DOI 10.1016/j.neuropsychologia.2004.04.004; Emre M, 2004, NEW ENGL J MED, V351, P2509, DOI 10.1056/NEJMoa041470; Farne A, 2002, NEUROPSYCHOLOGIA, V40, P718, DOI 10.1016/S0028-3932(01)00186-5; Foldi NS, 2005, INT J GERIATR PSYCH, V20, P485, DOI 10.1002/gps.1319; Franowicz JS, 1998, PSYCHOPHARMACOLOGY, V136, P8, DOI 10.1007/s002130050533; Froestl W, 2004, BIOCHEM PHARMACOL, V68, P1479, DOI 10.1016/j.bcp.2004.07.030; Gill M, 2006, ACAD EMERG MED, V13, P158, DOI 10.1197/j.aem.2005.08.013; Husain M, 2003, NAT REV NEUROSCI, V4, P26, DOI 10.1038/nrn1005; Jakala P, 1999, NEUROPSYCHOPHARMACOL, V20, P460, DOI 10.1016/S0893-133X(98)00127-4; Khateb A, 2005, EUR NEUROL, V54, P39, DOI 10.1159/000087718; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; KLEIN C, 2006, BIOL PSYCHIAT; Lawrence AD, 1998, BRAIN, V121, P1329, DOI 10.1093/brain/121.7.1329; Leclercq M, 2002, APPL NEUROPSYCHOLOGY; Leroi I, 2004, INT J GERIATR PSYCH, V19, P1, DOI 10.1002/gps.993; Malhotra PA, 2006, ANN NEUROL, V59, P186, DOI 10.1002/ana.20701; Maravita A, 2003, NEUROLOGY, V60, P1829, DOI 10.1212/WNL.60.11.1829; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; McKeith IG, 2004, DEMENT GERIATR COGN, V18, P94, DOI 10.1159/000077816; Michelson D, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.5.e83; Molloy S, 2005, J NEUROL NEUROSUR PS, V76, P1313; Morton AJ, 2005, EUR J NEUROSCI, V21, P855, DOI 10.1111/j.1460-9568.2005.03895.x; Perry RJ, 1999, BRAIN, V122, P383, DOI 10.1093/brain/122.3.383; Porrino LJ, 2005, PLOS BIOL, V3, P1639, DOI 10.1371/journal.pbio.0030299; Rossetti Y, 1998, NATURE, V395, P166, DOI 10.1038/25988; Rousseaux M, 2006, STROKE, V37, P542, DOI 10.1161/01.STR.0000198877.09270.e8; SAHAKIAN BJ, 1994, DRUG DEVELOP RES, V31, P80, DOI 10.1002/ddr.430310112; Saletu M, 2004, J NEUROL, V251, P1354, DOI 10.1007/s00415-004-0543-8; Scahill L, 2001, AM J PSYCHIAT, V158, P1067, DOI 10.1176/appi.ajp.158.7.1067; Schneider JS, 2003, J PHARMACOL EXP THER, V306, P401, DOI 10.1124/jpet.103.051912; Serino A, 2006, NEUROPSYCHOLOGIA, V44, P1068, DOI 10.1016/j.neuropsychologia.2005.10.024; Shindo K, 2006, J REHABIL MED, V38, P65, DOI 10.1080/16501970500441807; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Thimm M, 2006, NEUROPSYCHOLOGIA, V44, P1230, DOI 10.1016/j.neuropsychologia.2005.09.008; Tilikete C, 2001, CURR BIOL, V11, P524, DOI 10.1016/S0960-9822(01)00151-8; Tomlinson J, 2004, NEUROLOGY, V62, pA128; Tucha O, 2006, PSYCHOPHARMACOLOGY, V185, P315, DOI 10.1007/s00213-006-0318-2; Tzavara ET, 2006, MOL PSYCHIATR, V11, P187, DOI 10.1038/sj.mp.4001763; Vellas B, 2005, CURR MED RES OPIN, V21, P1423, DOI 10.1185/030079905X61884; Wesnes KA, 2005, NEUROLOGY, V65, P1654, DOI 10.1212/01.wnl.0000184517.69816.e9; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	48	25	25	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2006	19	6					613	618		10.1097/01.wco.0000247605.57567.9a			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	115XJ	WOS:000242766800017	17102702				2021-06-18	
J	Nakamura, N; Yamaura, A; Shigemori, M; Ogawa, T; Tokutomi, T; Ono, J; Kawamata, T; Sakamoto, T				Nakamura, Norio; Yamaura, Akira; Shigemori, Minoru; Ogawa, Takeki; Tokutomi, Takashi; Ono, Jun-ichi; Kawamata, Tatsurou; Sakamoto, Tetsuya			Final report of the Japan Neurotrauma Data Bank project 1998-2001: 1,002 cases of traumatic brain injury	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						severe brain injury; databank; epidemiology; trauma	COMA	A 4-year study (Japan Neurotrauma Data Bank) of the medical treatment of 1002 cases of traumatic brain injuries in Japan was conducted from 1998 to 2001 at 10 emergency medical centers. Patients with severe head injury were eligible for entry with a Glasgow Coma Scale score of 8 or less at admission. Patients who underwent craniotomy were also included. Children under 5 years old were excluded. An original data sheet with 392 items from multi-focal viewpoints, such as etiology of injury, pre-hospital care, initial treatment including neuro-intensive care unit, and surgical treatment, was created. The results show that the patient's age and mechanism of injury are the most important factors in the outcome.	Jikei Univ, Sch Med, Dept Emergency Med, Minato Ku, Tokyo 1058461, Japan; JNTDB Committee, Japan Soc Neurotraumatol, Japanese Council Traff Sci, Tokyo, Japan	Ogawa, T (corresponding author), Jikei Univ, Sch Med, Dept Emergency Med, Minato Ku, 3-25-8 Nishi Shimbashi, Tokyo 1058461, Japan.	dem@jikei.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18591617] Funding Source: KAKEN		KAWAMATA T, 2002, SHINKEI GAISHO, V25, P205; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; OGAWA T, 1998, SHINKEI GAISHO, V21, P125; OGAWA T, 2002, SHINKEI GAISHO, V25, P117; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; 2000, SHINKEI GAISHO, V23, P1	7	25	27	0	3	JAPAN NEUROSURGICAL SOC	TOKYO	5-25-16 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105	1349-8029		NEUROL MED-CHIR	Neurol. Med.-Chir.	DEC	2006	46	12					567	573		10.2176/nmc.46.567			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	117VM	WOS:000242901400001	17185881	Bronze			2021-06-18	
